<SEC-DOCUMENT>0001000694-23-000005.txt : 20230228
<SEC-HEADER>0001000694-23-000005.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228162700
ACCESSION NUMBER:		0001000694-23-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		23685905

	BUSINESS ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nvax-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:2e968d4d-f5d4-46a7-9a1c-6f56d63ea7b7,g:07ea8c72-99d3-4c76-b42c-1d6d27635d74,d:5fb43b2896e34be2b1f12f6c19f667b2--><html xmlns:nvax="http://www.novavax.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvax-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl8zLTEtMS0xLTcwMjAw_10cf82f1-a889-4bda-b99e-67223f31514a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl81LTEtMS0xLTcwMjAw_8706ead1-856a-4b21-a451-89faea8b7f29">2022</ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl82LTEtMS0xLTcwMjAw_0c617957-3ad7-45a1-b772-79a352bbb1f1">FY</ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl83LTEtMS0xLTcwMjAw_de46bf8f-f5a8-49d9-9730-40484e89b322">0001000694</ix:nonNumeric><ix:nonNumeric contextRef="i5778a549b12c4102a30a2bd1229fd57e_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcx_287a37ee-2b5f-45a2-a262-d63f80394c20">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="icfdf9690d60e4029a3ede7f1d4df8c62_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDE_cc59319b-f346-4179-ace9-8b072a6d76f3">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4">http://www.novavax.com/20221231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1">http://www.novavax.com/20221231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134">http://www.novavax.com/20221231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3">http://www.novavax.com/20221231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzExNTQ0ODcyMDkzMTQy_5f742c75-cbeb-4029-9948-e4253a87db5f">0.08</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i3fac9c0e3d6c4c58ae8c9f4c1844fb75_D20160101-20161231" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzExNTQ0ODcyMDkzNjU0_86489c66-a737-4423-b870-09a24872df43">0.02</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzMxMA_711981ca-b695-4ce4-b225-5273ad619031">.0073411</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8013133caa644857a213ff7c25f0f454_D20160101-20161231" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzQ4MA_b86eb62e-7810-4cb1-906d-5dbf72aede1c">.0089928</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzEzMDU_44088c8d-e2ff-4934-a440-4d094879ad8b">.05</ix:nonFraction><ix:nonNumeric contextRef="i52570d4cefef4923bc04161998db7004_D20150601-20150630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTc0_7315172c-cfb4-43c1-b403-98d1230d238a">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvax-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f9e1a5633fe44b2a624b7f0a93d8984_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id41865db09024993a1347220d7542819_I20230221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i39643791632e4e05a291fb0194ec9876_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if63b56ea82ae477cbdd1dde33c7982bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6887961a304cfc83b8882d4e95843b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i229e45ac7dd0484582dd508d0b410d09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2c1b3a8f554776b7ead7f9e8afc0be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608ca42330f04ed38d4a29292e36a8e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb291a2235b342fb88d2412401c2825b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dfc6b235bc64239a4750cc827d5e7be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42323458487a4a9c9100db83bbdf3ed4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba985ece231344b9884ac0673bdf1f76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77bd7520a4c413d82a3ee385fdabe20_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i276434eedddc41439edb0c1b98cc9b7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i478e92d6d04344fbaa0f10b3ab1efcba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c9aba10dd1499b9921e8f2fab79047_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee35c23efdb64a64bc904783db535a83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab79f65652ef4787919164353ded1194_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i939e909e3aee442cbe4c2ed5be1acf17_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284adc6f56cd47bb8227b04aeb8caefc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if69381417968421ab3aaeea9e7e8a831_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d79e2b326344dec97c2c4f1db0400d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79ae4732ce047b39cee388e3a7d5c42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic862fa293ea94c52be0807c27252da1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia042d64a00eb47ce9cb332d9341b3343_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a1a3f2ee4448078a0f2e6954fd5e5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f41fed49045497fbd18a61509fff1d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75daa84e516a43879509c48930e444f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i504579d4ccfc4230b080c69863a85566_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife9d9bbf7294424fa7bb5a43026e8d23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b104e574784fa7a1222f8870276e6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000db304d0ac493c91874d53eda30c3f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaecfb76823254dd19a4cf6ad1affdba6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4138df8c406d48159527133860ea5188_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8277fc63064ac59b415265922b2955_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i112cd4ea48f64fb4818bddbc7fbde54b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a2fe6a8df24324964c4a66ca6b445a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7bd4e1044a4bfdab99267a4bec8cec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461a71f67b2f48c69763adc332e28e74_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd03da035b34b17a46b6f7abfe523e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5673a51c537945239d7bb0e47db6afeb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ff09caaa96e4bde871b650ce7a243eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i643826e193814924924520e0e7696755_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0508fe92d74026bf85072a53f8d173_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb3b3ae8c2e49b6af7301fcc04bfce2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a2de06fc1f42a69276ce8a6224e6a0_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i673cb8037c324c8994caf3306884a92e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i807e3711af3b41989b73d47de7c77b65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5778a549b12c4102a30a2bd1229fd57e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78b588331a244138048f135d4c38cb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0708fc22c9854f0abba5629785850b62_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0df39d26bc0a425688c0db2d06381f38_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf56722506e4a18bd6e4b8223b6c740_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfAustraliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d86c3d5bfd54e03b15f74461ed5ae3a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8171acc620e44403a1acf786d872dcea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd7831a5ea8c46faaaeebc166d30480f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GaviVaccineAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae09a72a1ca3430c9be92032270e60ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i229f36f7f6ec4f50a926d184ce91f415_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac0cbe72c504988bee96db8bb6544d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia39f087502cf47ae90d1570eb534945f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d52b1aaa828491996f21dccbd34a922_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1404a3a6dc674929bfd21739b3442b4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8db9b8a25904abfbbb2438880a81408_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:SKBioscienceCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3c9b3cf2a747ce9a1576cadc4c0a46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d166751ab7a4c9c8c0655ff4da76514_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6203e4280b4a484f87366338bb51639b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic60027bdd04f4daa9e2d29cfb0744509_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>nvax:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i40a83ca620bd452aa6f58f72d2c85402_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icee78a963bab4b348f7582b0b78785d0_D20221001-20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a081a82e367415892816cf19c0e6996_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c53c7f16bb4d359be44c56e5a93d6d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32856f664ee8488999df14d37a8f364c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nvax:segment</xbrli:measure></xbrli:unit><xbrli:context id="i926dd27a465e4fdabe3cf710647081f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nvax:RevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d102737a020478786d531e426d6e856_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f5b877ba2042818de76d2a409905c8_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3abf6a1aebd248e584d82ca7df7e3fdf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd3d6a52163444b8ea692da78a4faf2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>nvax:dose</xbrli:measure></xbrli:unit><xbrli:context id="i0523638414324ebda053032feb1642dc_I20221118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39195769279040f9977e693d668d82a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5faf20068a344883a9f4f4c476b0ac54_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2706507e51524857a9ceffe04bbdfb19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ad425a20a9414db980cc6c772611e4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce1a3a4c4ef4e1d9f74c1e95e55e00c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec87e45039154115be91b56e82452836_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1626d37f2e4ef59d96daaad71fdbaa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368f367746e142668e6ba704011b5fc7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fc052561f64f5bb389212acc6492e1_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47baf28a107749f3b2ca7dc5b1b71532_I20201022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23178b856de1448ab841c7dd1fda4737_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id54b75d90c0445109878eb06ca06d922_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67162008d7604923adbbc7b516cc27be_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82199a3134c04ef69869eff76a4bd2cd_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9414495645c244dfa1f4271692735ef3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ec0fb5211549e2a256737805e4fce0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce0f3c1c39d4e28b5fe4043d6dc2ca5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2124dc03e6334482915d316bc6b47f65_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7742e770d4074f7c8483f51032cb198a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f39444854c467997b14a3f794dc641_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a790ed695ae48a7825f7db0794a528b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95983058bd8d4c6b889991a78b44a3a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0953f31b29d64b1c9efe84ff12aaf7c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d17441b7514d62aa6a4fb48ea6ec16_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb17db81cb4940059e2590656125cced_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8565eb181066484ab573f2f33ad705ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269b7fbf10f045c7b3eac59a9ee5c87d_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ac470da9ab41d39a8dd4ac58dde5eb_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28b320707a54cf7a261c50f50d34c04_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1458600dca343ad97871d021c6be059_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be0462e374b44418c24eeac2316d566_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:DoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:DoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04cb8aedaa04ea296920d2dafe47b45_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:DoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67595162b2e74d70acbd1d2e3fc54a75_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09f8465b2a5e4bfaa5c2543aadab3967_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e260c6f907f4344bad6fb4ab2321f9c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3000e1e12c2e4499ac858cd2ed3830ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4a1afee8bf4db08da83fe10dcf1648_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c853e8a4a7c4a54a237437e58933a8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1883dba2c86c4273926e697f5ab58bae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b9e55b23e44271b0b5d401791eb27a_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SKBioscienceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6179b85088426c91dd56a7ba42e5c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>nvax:installment</xbrli:measure></xbrli:unit><xbrli:context id="i3c0e43b772f0435c86af0d81656bac70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b7bd92fbd1475a82a5bfebeefa798f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb61b7126be74d498e8a47c4f03eac57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557fbd904011405793bff18a21cabb26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ac59f74cd740e6a0cadeca61d87f18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ac89c6ba624c228f64bcba1891a2a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07eb648508740f8a5d7ef32fc803047_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8240c1c9049f42469bde4e3f3fddf4b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ebb77a8ee864fc78eb779a17c09226a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia828d2bd46af4b7f8e4984cb14c9cafb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b47a43081534cda81d9835ec8a79235_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d72f7b153e4e8695661560c4fd46bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90676cb023842e180c00be05cf71a12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a7cf53ca85450590f17011e1295e6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0b6732392440598653904929954c98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f14050837d4c869dde5769d325bd7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50ad0f304ef5468ab90dfce6c1651bcc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac7cacc849b46c798d58117b7ff11d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23496a29b22d4426a67a18543af66bbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6271729b2154949abe04c08bdafe9ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ef3865c980492c8ddf20d9b5a9b4a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if419a9b5d1bc45b68cd3c42755335735_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07aa9a3ff734e88b8adaa9f439f1d27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8047cd560f6c44c382b2c1bf052d612c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c022c32626a40f9ba08a783a679df34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia128e17147ae46ebbeef34e5ce29d598_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8099f1e2bbdd4ec0970e209f1e0b270e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff83caef02b40f599cc74bcae40ff09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32cd12d82fc44bc780022e28d26cb8eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie83da57994934aae8def1bf0f382f5a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa7a2181db6a41c9b9b4919cafe3b1cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a45c212dfe4e53b8afb7e0ff8967f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8898a306024e42bfe586c67dd2d69f_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89587ae04de147c793c1b9499301a5d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2056ca33214fd9bb1ee8b7c7c6cca8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca80f7d1ad642bd978daca477579b19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a506862b80548d28dfcb14cd9a57994_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed14e6e12f045e6896127906a812d89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016b678121634f2ea331a88b589a7be0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03e9156a13034488a05b42b0e99c2e6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d108ce57a04b59a033717ce6e1e081_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia37923a559ac460cba463e92ab69d61b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8296c755f9446a59e2ee459a7b97bab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4056500d5930405896706052920574c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3ca7c3c6b834b43b446ee1616686ee3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74110891d1c4616a0230ee664e7675b_I20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6803c5d4d38740009777ad5eadf70727_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabda6dd0b85b41c5810ef5d88e33f6fb_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d86903b18c4a31908d43850afb1f79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18de67b571ba458cbba0933459b5975b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ada334c1e14256b42648cab21c02f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i201ad52388df4bebacf2bd74f56acfeb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i3094b6244ecc489b96c2559b7639a6b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i988682eb3b024cb688a6d71ca0cb108b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb89a63509c49b0b7381f32ace08d03_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd187e980034898b9aecf0c85fa92f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e0cb7900fe42bb90900d51daf494af_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfdf9690d60e4029a3ede7f1d4df8c62_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728c18080ef8448fb44592281f48f9b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7dd9ef2652406e95d1ff0060ae1b04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864f59e306a74cabbced7a3c1435512b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>nvax:day</xbrli:measure></xbrli:unit><xbrli:context id="i96a1add754d840f5946967a65b3f474e_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3956f36cdac340c886e2cbf2ea354b9f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i502585dd7e734b158fdf6a98bb9e12e1_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce452e9ba0b4f91b8ca4a6aa27cddc8_D20230201-20230201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied73af9ac932401ebc59933f068a2e4e_I20160125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ba24ef23674233a4a49398d78fe3b3_I20160125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e30c16b247446e89dea1ad6f8e71d44_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34bddce3a1514a0991451e1b87ccd098_I20160125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fac9c0e3d6c4c58ae8c9f4c1844fb75_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8013133caa644857a213ff7c25f0f454_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4f8a31db8143ffb528be60155adb66_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d0cb0853434fa2bfca424a22521ff9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6504e467cdf4ac9b1c7bb041d0d169a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb6c34ca0e6943a985fccfb3c3cd5034_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f4681005a149c69af0c9d36cd0c591_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic32ab2b881af4e00801939f78ec7d4d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a45e70dfcc4ed3a06e5a1a0ad85788_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09da20d245547229c7e424719065312_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb69e18ef584de69947a34bda69992f_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52295e266c04be6958801ee220a81e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708fc4297d3e486b988a67ddb519f244_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909d287d453b483eadef68a6db51c7ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c38f0119d96422898c0a8bea2f47c2c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied0bd77787a54028835f2babf0a109d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a915c3d5094ab9a4f33e9377b263ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5424c76f0f34f9abaf1051fa5d32862_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f0a3575acd74594903fd3f69ea74c2c_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0015ac21e2114e919dcd6b418ca0470e_I20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52570d4cefef4923bc04161998db7004_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4411c1dfac48628e521c4e1c62d82c_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833db54db4e5410a82b51d91507bc240_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75773c016ce41a0a9271d81feb47a62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b8e8541d10484db42a6e56bf4c319c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a884616d8f240c899d1ffded053d84f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e4f42ca7be4b18b06d0cb5a65f7f4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06256858a63a4f5e993fc634c6256da8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8deb5c81e1314ef6b0780d4f3a49ed98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78e81e12c2c645c891cd0ba8714b475c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba79020bba2422ea08fa0e1bc48a3eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57598acb9d345a0b294ceda6cce94ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ae9fcb872440ec9e5ebfc077767156_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7d25ca75ae343a48d6da2c1441b845e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37d9719b2524f6f8329cdee51688933_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46bf6d3912154f1792ce922416ae63c1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1266c70d6883487eb69de02a5cefcaa5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057ba2750d5b46caa17fd59064a93243_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3b6eafa7a2453eb9dc3916a75c7c1e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1af17faf5cc45288e504b60fca3980a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482ffe6e8ec14375b57c416c028deaec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73561b8b32cf4435ac835a50e53a576a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b07f0a42caf41428f69609a0b2b9990_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546bbc59bac14443b9fa7278f44f39a7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43cd1de147754aae88ac59750e8413d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4741524c2007402199ab8e23ba7c57fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3daeefe63f648a9aefa23c5a54e474f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e434d4808f2454da2b021293904e61e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde6dd916c874f429e3cc8fe6d0eabed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacf535e608c4110bfafdf3621b23f38_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:FirstThreePercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ab394f5b23492db52ba56a7cdec054_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:NextTwoPercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d0939ce4574bbca25cbd25ca1caa0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b46d3bb09db4518ba0e5b40ba4c579a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaae667010054892bbaeaa0a48298ea5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0fe342175f5492284e7a2703432374a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306c59f27cd9488b966d7683b0b6d3e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51d31dc3a62493c90d13cac0e14c304_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id751e3e489e44cc4a6c2e3c2d4ff8264_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f4ccb5e7cb74f8d88f8a5fed001536d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc1be450e664236a03f3377873ae30b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b0be8a4005f4b659c8142d8168d50eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i261ee1ff33254ce5ae3c71c1734f2118_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a2c21af45f4bb8b5b57fb18fbb2a36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134cfe86255d47f58e6942ddfddc42ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003cbd6d8fc147008d115dcbabd4f866_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0296343bcc7a45f7af04732eca6371c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie850cc1078634b628fb807996bac48ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba48e8ed9c64a64bc36603e29727b1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09d6c3cc8dd494997ad5e9e0699ba04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d589697b3448ef979612d981bcfa9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:SubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idccedc0b914042e9b04e606a7f40b047_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed100b1f229497699cf3a210f953003_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:SubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dadba2600544eb092b5aec9b95db726_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5882daa660420c9f6624c60e06285f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdf580566214e4581e43117da7df104_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>nvax:defendant</xbrli:measure></xbrli:unit><xbrli:context id="i38dbeaf8546447cc8d0775f85d2579d5_D20210823-20210823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1"></div><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTE3_90c9eda9-1235-4bcd-ad0a-30ed86e3d16c">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6OTAwMGQyYjgyNzI0NGZlODk5MDZkOWEzMjRkZjkwYzIvdGFibGVyYW5nZTo5MDAwZDJiODI3MjQ0ZmU4OTkwNmQ5YTMyNGRmOTBjMl8wLTAtMS0xLTcwMjAw_bfe1397c-8e7c-433c-a738-4042507eb123">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xNDg0MzQwNjk3ODU5NQ_d240afd7-5867-4ee3-a93d-a171e66a42f7"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xNDg0MzQwNjk3ODU5NQ_fe42eb2b-b13e-43fb-9b72-9466aab8189f">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6OGVmN2ExOTkxNTRhNDMzZWIwNTc3YWEyZmQ2YjQ4NTAvdGFibGVyYW5nZTo4ZWY3YTE5OTE1NGE0MzNlYjA1NzdhYTJmZDZiNDg1MF8wLTAtMS0xLTcwMjAw_c3e7e783-ba96-4983-a48b-6a1ed2fb4bd3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTE4_017344fd-064f-49e1-9c1b-85745c728257">000-26770</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTA5_832dacd2-ef35-4681-8f7e-6a46662af4ec">NOVAVAX,&#160;INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:28.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV8wLTAtMS0xLTcwMjAw_83071cc0-6081-42c5-960b-6d5c99926293">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV8wLTMtMS0xLTcwMjAw_b3d36fbf-53c1-410b-b848-1b6380b94401">22-2816046</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(State of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV8zLTAtMS0xLTcwMjAw_39c7ce9d-98b4-4317-8871-a3f595e6850f">21 Firstfield Road,</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV80LTAtMS0xLTcwMjAw_ede7d80e-4411-456c-acbc-e21f48e9520c">Gaithersburg,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV80LTEtMS0xLTcwMjAw_d0e85a61-0355-4ccd-98c0-de96d6c8af71">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV80LTMtMS0xLTcwMjAw_1ad5b140-4881-45ed-a22a-a5158d131f30">20878</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zMjU_82932bf4-8068-486d-9a5c-fb0cbc59cb7d">(240)</ix:nonNumeric> <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEw_7750ee8f-7559-4309-94c2-e72c5a162744">268-2000</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6ODU2ZDQ1M2ZhMjRlNDBiNWFlNWYzNjVhNzA1MGFhZTcvdGFibGVyYW5nZTo4NTZkNDUzZmEyNGU0MGI1YWU1ZjM2NWE3MDUwYWFlN18xLTAtMS0xLTcwMjAw_f6d97bc4-8b80-4dc5-acd1-825c14364125">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6ODU2ZDQ1M2ZhMjRlNDBiNWFlNWYzNjVhNzA1MGFhZTcvdGFibGVyYW5nZTo4NTZkNDUzZmEyNGU0MGI1YWU1ZjM2NWE3MDUwYWFlN18xLTEtMS0xLTcwMjAw_60916ad0-9319-4470-be34-9bf177fab6a1">NVAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6ODU2ZDQ1M2ZhMjRlNDBiNWFlNWYzNjVhNzA1MGFhZTcvdGFibGVyYW5nZTo4NTZkNDUzZmEyNGU0MGI1YWU1ZjM2NWE3MDUwYWFlN18xLTItMS0xLTcwMjAw_559ada54-9256-4749-9946-a9a45f25b2c4">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: Not Applicable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEx_7b1bed60-a714-40b4-b06f-5d6e580c773a">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act. Yes &#9744; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEy_5f48a4f5-60ed-4845-bf8a-8efa5d795d68">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTE1_ab5d7184-afd7-4805-8407-c54208a48e03">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTA3_b21bd43c-882c-4c76-a0e3-51b130e5bcd8">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K. &#9746;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6MGIwOWIyNTQ4NzgwNDdiMDkyNzE4Nzk3YjY5YWYxZGQvdGFibGVyYW5nZTowYjA5YjI1NDg3ODA0N2IwOTI3MTg3OTdiNjlhZjFkZF8wLTAtMS0xLTcwMjAw_9860821b-f478-4518-a6d0-f74fee465d94">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6MGIwOWIyNTQ4NzgwNDdiMDkyNzE4Nzk3YjY5YWYxZGQvdGFibGVyYW5nZTowYjA5YjI1NDg3ODA0N2IwOTI3MTg3OTdiNjlhZjFkZF8yLTMtMS0xLTcwMjAw_02bd667d-75ee-4a3c-b71b-4856224acd7f">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6MGIwOWIyNTQ4NzgwNDdiMDkyNzE4Nzk3YjY5YWYxZGQvdGFibGVyYW5nZTowYjA5YjI1NDg3ODA0N2IwOTI3MTg3OTdiNjlhZjFkZF80LTEtMS0xLTcwMjAw_3870c2af-6c02-43b6-b69b-ed8764efe9ca">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant had elected not to use the extended transition period for complying with any new or revised financial accounting standards provide pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xMTU0NDg3MjA5NTg2MA_449f9ed3-34b5-4613-9a5e-c690cdae42aa">&#9746;</ix:nonNumeric> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Exchange Act, indicate by check mark whether the financial</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9744;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEz_1315f2c4-d28a-4997-99d4-95350399d9ac">&#9744;</ix:nonNumeric> No &#9746;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant (based on the last reported sale price of Registrants common stock on June&#160;30, 2022 on the Nasdaq Global Select Market) was approximately $<ix:nonFraction unitRef="usd" contextRef="i4f9e1a5633fe44b2a624b7f0a93d8984_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xNDg0MzQwNjk3ODUzNQ_aed480bb-606b-4483-a34c-000709329367">4,010,000,000</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2023, there were <ix:nonFraction unitRef="shares" contextRef="id41865db09024993a1347220d7542819_I20230221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zMTA4_863079b4-2dcf-44c0-b1dc-ae5be72759fb">86,173,245</ix:nonFraction> shares of the Registrant&#8217;s common stock outstanding.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTA4_119c9cf8-45ee-4284-a757-308716d56c3f" escape="true">Documents incorporated by reference: Portions of the Registrant&#8217;s Definitive Proxy Statement to be filed no later than 120 days after the fiscal year ended December&#160;31, 2022 in connection with the Registrant&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent indicated herein.</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_7"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_13">BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_16">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_16">RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_16">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_19">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_19">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_19">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_22">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_22">PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_22">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_25">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_25">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_25">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_28">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_28">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_28">70</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_34">Item 5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_34">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_34">71</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_37">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_37">RESERVED</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_37">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_40">Item 7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_40">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_40">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_64">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_64">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_64">85</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_67">Item 8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_67">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_67">85</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_70">Item 9.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_70">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_70">85</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_73">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_73">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_73">85</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_76">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_76">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_76">86</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_79">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_79">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_79">86</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_85">Item 10.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_85">DIRECTORS, EXECUTIVE OFFICERS</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_85">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_85"> AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_85">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_88">Item 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_88">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_88">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_91">Item 12.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_91">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_91">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_94">Item 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_94">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_94">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_97">Item 14.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_97">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_97">87</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_103">Item 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_103">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_103">88</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 16.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">FORM 10-K SUMMARY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_106">95</a></span></div></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN DEFINITIONS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this Annual Report on Form 10-K to &#8220;Novavax,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Novavax, Inc. including its wholly-owned subsidiaries (unless the context otherwise indicates).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax&#8482;, Nuvaxovid&#8482;, Matrix-M&#8482;, Matrix&#8482;, Prepare&#8482;, Resolve&#8482;, and ResVax&#8482; are trademarks of Novavax. Any other trademarks referred to in this Annual Report on Form 10-K are the property of their owners. All rights reserved. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in these forward-looking statements. Please also see the disclaimer under the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks which are discussed more fully under the heading &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. These risks include, but are not limited to, the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and our future profitability is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to require significant funding to maintain our current level of operations and fund the further development of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our vaccine product development efforts depend on new and rapidly evolving technologies, we cannot be certain that our efforts will be successful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory and commercial success of our COVID-19 vaccine candidate, NVX-CoV2373, remains uncertain. While we have received provisional registration, conditional marketing authorization (&#8220;CMA&#8221;), or emergency use authorization (&#8220;EUA&#8221;) for NVX-CoV2373 in a number of jurisdictions, we may be unable to obtain full regulatory approvals in the United States (&#8220;U.S.&#8221;) or other jurisdictions or produce a successful vaccine in a timely manner, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The emergence and transmissibility of variants of the SARS-CoV-2 virus, and the demand for bivalent vaccines, may affect market acceptance or sales of NVX-CoV2373, and our strategy to develop versions of our COVID-19 vaccine to protect against certain variants may not be successful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a biotechnology company and face significant risk in developing, manufacturing, and commercializing our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we depend on third parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are highly dependent on the commercial success of NVX-CoV2373, and even though we have received provisional registration, CMA, or EUA in certain jurisdictions for NVX-CoV2373, and even if we have products licensed in additional markets, our vaccine products may not be initially or ever profitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic and associated governmental public health policies continue to evolve, which may have unpredictable effects on the prospects for commercial success of NVX-CoV2373.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is significant competition in the development of a vaccine against COVID-19, influenza, and respiratory syncytial virus (&#8220;RSV&#8221;) and we may never see returns on the significant resources we are devoting to our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not succeed in obtaining full U.S. Food and Drug Administration (&#8220;FDA&#8221;) licensure or foreign regulatory approvals necessary to sell our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products might fail to meet their primary endpoints in clinical trials, meaning that we will not have the clinical data required to support full regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory pathway for NVX-CoV2373 is continually evolving, and may result in unexpected or unforeseen challenges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, are conducting, and plan to conduct in the future, a number of clinical trials for NVX-CoV2373 at sites outside the U.S. and the FDA may not accept data from trials conducted in such locations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The later discovery of previously unknown problems with a product, manufacturer, or facility may result in restrictions, including withdrawal of a vaccine that had previously received regulatory approval in certain jurisdictions from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to maintain the proprietary nature of our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be adversely affected if we do not successfully execute our business development initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Given our current cash position and cash flow forecast, and significant uncertainties related to 2023 revenue, funding from the U.S. government, and our pending arbitration with Gavi, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that the financial statements included in this Annual Report were issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Servicing our 5.00% convertible senior unsecured notes due 2027 (the &#8220;Notes&#8221;) requires a significant amount of cash, and we may not have sufficient cash flow resources to pay our debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our stock price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation could have a material adverse impact on our results of operation and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or the third parties upon whom we depend may be adversely affected by natural or man-made disasters or public health emergencies, such as the COVID-19 pandemic.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_10"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_13"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1516"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc., together with our wholly owned subsidiaries, is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Our proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates are genetically engineered nanostructures of conformationally correct recombinant proteins that mimic those found on natural pathogens. This technology enables the immune system to recognize target proteins and develop broadly protective antibodies. We believe that our vaccine technology may lead to the induction of a differentiated immune response that may be more efficacious than naturally occurring immunity or other vaccine approaches. Our vaccine candidates also incorporate our proprietary saponin-based Matrix-M&#8482; adjuvant to enhance the immune response, stimulate higher levels of functional antibodies, and induce a cellular immune response.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and begun commercialization of a COVID-19 vaccine, NVX-CoV2373 (&#8220;Nuvaxovid&#8482;,&#8221; &#8220;Covovax&#8482;,&#8221; &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221;), that has received approval, interim authorization, provisional approval, conditional marketing authorization (&#8220;CMA&#8221;), and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications and are developing an influenza vaccine candidate, a COVID-19-Influenza Combination (&#8220;CIC&#8221;) vaccine candidate, and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition to COVID-19 and seasonal influenza, our other areas of focus include respiratory syncytial virus (&#8220;RSV&#8221;) and malaria.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1987 under the laws of the State of Delaware. Our principal executive offices are located at 21 Firstfield Road, Gaithersburg, Maryland, 20878, and our telephone number is (240) 268-2000. Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;NVAX.&#8221;</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1529"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technology Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recombinant nanoparticle vaccine technology, together with our proprietary Matrix-M&#8482; adjuvant, is well suited for the development and commercialization of vaccine candidates targeting a broad scope of respiratory and other emerging infectious diseases at scale.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant Nanoparticle Vaccine Technology</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a pathogenic threat has been identified, the genetic sequence encoding the antigen is selected for subsequent use in developing the vaccine construct. The genetic sequence may be optimized to enhance protein stability or confer resistance to degradation. This genetic construct is inserted into the baculovirus </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spodoptera frugiperda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;Sf-/BV&#8221;) insect cell-expression system, which enables efficient, large-scale expression of the optimized protein. The Sf-/BV system produces proteins that are properly folded and modified&#8212;which can be critical for functional, protective immunity&#8212;as the vaccine antigen. Protein antigens are purified and organized around a polysorbate-based nanoparticle core, in a configuration that resembles their native presentation. This results in a highly immunogenic nanoparticle that is ready to be formulated with Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;text-indent:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matrix-M&#8482; Adjuvant</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary Matrix-M&#8482; adjuvant has been a key differentiator within our platform. This adjuvant has demonstrated potent, well tolerated, and durable efficacy by stimulating the entry of antigen presenting cells (&#8220;APCs&#8221;) into the injection site and enhancing antigen presentation in local lymph nodes. This in turn activates APCs, T-cell and B-cell populations, and plasma cells, which promotes the production of high affinity antibodies, an immune boosting response. This potent mechanism of action enables a lower dose of antigen required to achieve the desired immune response, and we believe thereby contributes to increased vaccine supply and manufacturing capacity. These immune-boosting and dose-sparing capabilities contribute to the adjuvant&#8217;s highly unique profile.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate commercial opportunities for the use of our Matrix-M&#8482; adjuvant alongside vaccine antigens produced by other manufacturers. Matrix-M&#8482; adjuvant is being evaluated in combination with several partner-led malaria vaccine candidates, including in a Phase 3 trial for R21, a malaria vaccine candidate created by the Jenner Institute, University of Oxford. The University of Oxford has partnered with Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;) for commercial development of R21 and has granted SIIPL a license for R21. We expect to manufacture and supply the Matrix-M&#8482; adjuvant component of R21 to SIIPL, which represents a significant commercial opportunity for our adjuvant, pending possible licensure. We have commercial rights to sell and distribute the SIIPL-manufactured R21 in certain countries, primarily in the travelers&#8217; and military vaccine markets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also supplying Matrix-M&#8482; adjuvant for two Phase 1 vaccine trials led by National Institutes of Health teams, focused on Epstein-Barr virus and malaria transmission blocking.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1522"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NVX-CoV2373 Regulatory and Licensure</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made substantial progress in advancing NVX-CoV2373 toward regulatory approvals. We have received authorizations in over 40 countries globally within the adult population, aged 18 and older, and the adolescent population, aged 12 through 17, for primary series and both homologous and heterologous booster indications. To date, we have received approval, interim authorization, provisional approval, CMA, and EUA for both adult and adolescent populations. We are </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">working to continue to expand our label for heterologous boosting in adults, adolescents, and younger children, and achieve supportive policy recommendations enabling broad market access. We continue to work closely with governments, regulatory authorities, and non-governmental organizations in our commitment to facilitate equitable global access to our COVID-19 vaccine.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the territories in which our vaccine has gained authorization, NVX-CoV2373 is marketed under the brand names (i) Nuvaxovid&#8482; (SARS-CoV-2 rS Recombinant, adjuvanted), (ii) Covovax&#8482; (manufacturing and commercialization by SIIPL), or (iii) Novavax COVID-19 Vaccine, Adjuvanted.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of regulatory authorizations for NVX-CoV2373 through the date of filing this Annual Report on Form 10-K is presented below:</span></div><div style="margin-bottom:12pt"><img src="nvax-20221231_g1.jpg" alt="nvax-20221231_g1.jpg" style="height:640px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Regulatory approval received in partnership with SIIPL.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Regulatory manufacturing and marketing approval received by partner Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Regulatory approval received in partnership with SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;).</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below we highlight the fourth quarter 2022 and subsequent regulatory authorizations received through the date of this filing on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our partner SK bioscience received expanded manufacturing and marketing approval from Korean Ministry of Food and Drug Safety (&#8220;KMFDS&#8221;) for Nuvaxovid&#8482; for use as a booster in adults aged 18 and older.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, Health Canada approved a supplement to a New Drug Submission for Nuvaxovid&#8482; as a primary series of two doses in adolescents aged 12 to 17 years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the World Health Organization (&#8220;WHO&#8221;) issued an updated EUL for Nuvaxovid&#8482; as a primary series of two doses in adolescents aged 12 to 17 years and as a booster in adults aged 18 and older.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in November 2022, Health Canada granted expanded authorization for Nuvaxovid&#8482; as a homologous booster in adults aged 18 and older.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the same month, the Medicines and Healthcare products Regulatory Agency in the United Kingdom (&#8220;U.K.&#8221;) expanded CMA for Nuvaxovid&#8482; as a homologous and heterologous booster dose after the primary series of Nuvaxovid&#8482; or of an mRNA or adenoviral vector in adults aged 18 and older.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the U.S. FDA granted EUA to provide a first booster dose at least six months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to adults aged 18 and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to adults aged 18 and older who elect to receive NVX-CoV2373 because they would otherwise not receive a booster dose of a COVID-19 vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed additional regulatory submissions in major markets for both adult and adolescent populations for primary and booster indications, and we are in active discussions with regulatory authorities regarding several of those submissions. We remain focused on expanding our label in multiple countries for NVX-CoV2373.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we had several additional regulatory submissions. We submitted an application to the U.S. FDA for expanded EUA of NVX-CoV2373 as a booster in adolescents aged 12 to 17 years. The application for expanded EUA is supported by data from the pediatric arm of our Phase 3 PREVENT-19 trial conducted in the U.S. We submitted an application to the European Medicines Agency (&#8220;EMA&#8221;) for expanded CMA to include a booster in adolescents aged 12 to 17 years. We submitted an application to Taiwan&#8217;s Food and Drug Administration for EUA in adults aged 18 and older. We submitted an application to Singapore&#8217;s Health Sciences Authority for full BLA for primary series in adolescents aged 12 to 17 years and for a booster indication in adults aged 18 and older.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1573"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advance Purchase Agreements (&#8220;APA&#8221;)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into Advance Purchase Agreements (&#8220;APAs,&#8221; also referred to as &#8220;supply agreements&#8221; throughout this Annual Report on Form 10-K) with the EC and various countries globally. The APAs typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment. Such upfront payments generally become non-refundable upon our achievement of certain development milestones. We currently have $2.1 billion in committed APAs anticipated for future delivery.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with the EC, acting on behalf of various European Union member states to supply a minimum of 20 million and up to 100 million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100 million doses up to a maximum aggregate of 200 million doses in one or more tranches through 2023. In 2022, we were notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, we finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022 and are expected to be delivered in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373 and made an upfront payment to us. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#8220;Conditional Doses&#8221;) of NVX-CoV2373, with the number of Conditional Doses contingent on, and subject to reduction based on, our timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority does not purchase the Conditional Doses or the number of such Conditional Doses is reduced below 15&#160;million doses of NVX-CoV2373, we would have to repay up to $225&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not yet made a supportive recommendation with respect to NVX-CoV2373, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, our timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for us to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement, which is reflected in our consolidated balance sheet as Other current liabilities, with the remaining upfront payment balance of $112.5&#160;million reflected in current Deferred revenue.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of an APA dated May 5, 2021, by and between the Company and Gavi, the Vaccine Alliance (&#8220;Gavi&#8221; and &#8220;the Gavi APA&#8221;), we received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in the first quarter of 2022 related to our achieving EUL for NVX-CoV2373 by the WHO (the &#8220;Advance Payment Amount&#8221;). On November 18, 2022, we delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from us as required by the Gavi APA. As of November 18, 2022, we had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in our consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. Our response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while we believe that we are entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that we could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1536"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Product Pipeline</span></div><div style="margin-bottom:12pt;text-align:justify"><img src="nvax-20221231_g2.jpg" alt="nvax-20221231_g2.jpg" style="height:322px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax&#8482;; and Nuvaxovid&#8482;.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Ongoing Phase 3 strain change trial.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Ongoing Phase 3 trial for R21, a malaria candidate developed by the Jenner Institute, University of Oxford and formulated with Matrix-M&#8482; adjuvant.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)&#160;&#160;&#160;&#160;Clinical development conducted in older adults with previous construct through Phase 3 trial.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical pipeline encompasses vaccine candidates spanning multiple therapeutic areas, with our COVID-19 vaccine, NVX-CoV2373, as our lead product, which has received approval, interim authorization, provisional approval, CMA, or EUA for both adult and adolescent populations in over 40 countries. We advanced NVX-CoV2373 through two pivotal Phase 3 clinical trials that demonstrated high efficacy against both the original COVID-19 strain and commonly circulating COVID-19 variants, while maintaining a favorable safety profile. Beyond COVID-19, our clinical pipeline encompasses seasonal influenza and CIC vaccine, in addition to providing Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant for collaborations investigating the prevention of malaria.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing our quadrivalent nanoparticle influenza vaccine (&#8220;qNIV&#8221;) candidate, previously known as NanoFlu, which we advanced through a successful Phase 3 study published in September 2021, demonstrating the utility for a stand-alone influenza vaccine or for use in a combination vaccine. We have subsequently updated our qNIV for further development. We continue to progress in a Phase 2 trial our stand-alone influenza vaccine candidate, qNIV and our CIC vaccine candidate, which combines NVX-CoV2373 and our updated qNIV approach in a single formulation. In October 2022, we announced positive results from the Phase 1/2 CIC clinical trial demonstrating the CIC vaccine&#8217;s ability to generate both antibody and polyfunctional CD4+ T-cell (lymphocytes that help coordinate the immune response) responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and homologous and heterologous influenza strains. In December 2022, we initiated a Phase 2 CIC dose-refinement trial that also includes further stand-alone updated qNIV evaluation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to COVID-19 and seasonal influenza, we remain interested in continuing the development of both our RSV Program for respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate (&#8220;RSV F Vaccine&#8221;) and Matrix-M&#8482; adjuvant collaborations for malaria. An ongoing Phase 3 trial is being conducted for R21, a malaria candidate, by our partner, the Jenner Institute, University of Oxford, which is formulated with our Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain focused on expanding our NVX-CoV2373 vaccine label within the booster and adolescent market following global regulatory authorizations. We continue to evaluate vaccine efficacy through ongoing booster studies in our </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials and continued development of our COVID-19 variant strain containing monovalent or bivalent formulation. We expect to leverage these clinical insights to advance additional regulatory approvals of our COVID-19 vaccine for primary, booster, and pediatric indications globally, amidst the ongoing COVID-19 landscape.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our COVID-19, CIC, and influenza stand-alone vaccine candidates are our near-term priorities, our partner-led malaria candidates present strong opportunities for future development.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1543"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronavirus</span></div><div style="margin-bottom:12pt;text-indent:33pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NVX-CoV2373 Clinical Development</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NVX-CoV2373 has progressed through multiple clinical trials, including a Phase 3 Lot Consistency Study, two Phase 3 pivotal efficacy trials, one Phase 3 Omicron boosting trial, one Phase 2b trial, and one Phase 1/2 trial, along with numerous others. We have expanded our clinical trials to evaluate heterologous and homologous boosting for populations spanning adults, adolescents, and children. Through our clinical development program, we established a dose of 5 micrograms of recombinant spike protein plus 50 micrograms of Matrix-M&#8482; adjuvant. We continue to collect data that indicates a reassuring safety profile, and the induction robust cellular and humoral immune responses that were associated with high levels of efficacy in two independent Phase 3 studies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary and status of our clinical development of NVX-CoV2373 by trial is as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PREVENT-19 Phase 3 U.S. and Mexico</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PREVENT-19 was a randomized, placebo-controlled, observer-blinded Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 in 29,949 participants aged 18 years or older across 119 sites in the U.S. and Mexico. In the trial, NVX-CoV2373 achieved 90.4% efficacy overall, was generally well tolerated, and elicited a robust antibody response after the second dose. In December 2021, full results of the trial were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In December 2021, we also initiated a PREVENT-19 Phase 3 boosting study.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 at the World Vaccine Congress in Europe, we presented PREVENT-19 Phase 3 boosting data in both adults aged 18 years or older and adolescents aged 12 to 17 years, showing NVX-CoV2373 achieved its pre-specified immunologic endpoint.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 at IDWeek, we presented additional data from the PREVENT-19 booster study, including an evaluation of the effect of age (18 to 64 years, and &#8805; 65 years) and schedule on boosted immunologic response demonstrating significant boosting in all age groups. Booster doses were generally well tolerated, with mostly mild to moderate reactogenicity that was of short duration.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PREVENT-19 Phase 3 Pediatric Expansion</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PREVENT-19 Pediatric Expansion was a randomized, placebo-controlled, observer-blinded study to evaluate the safety, effectiveness (immunogenicity), and efficacy of NVX-CoV2373 in 2,247 adolescents aged 12 to 17 years in 73 locations in the U.S., with an emphasis on ensuring well-balanced racial and ethnic representation among participants. Participants randomly received either the vaccine candidate or placebo in two doses, administered 21 days apart.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 at the World Vaccine Congress in Europe, we presented PREVENT-19 Phase 3 pediatric expansion homologous boosting data, where a single boost dose was generally well tolerated and induced robust immune responses against prototype-strain as well as against Omicron BA.1, BA.2, and BA.5 subvariants. A third dose suggested benefit for the prevention of COVID-19 against contemporary variants such as Omicron. Additionally, booster doses were generally well tolerated, with mostly mild to moderate reactogenicity that was of short duration.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we announced initiation of PREVENT-19 Phase 3 booster study in adolescent trial participants with the booster dose administered at least 5 months after receipt of active vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced positive results from our Phase 3 PREVENT-19 pediatric expansion in adolescents. The results achieved their primary effectiveness endpoint and demonstrated 80% efficacy overall, with 82% clinical efficacy </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against the Delta variant. Immune responses were two-to-three-fold higher in adolescents than in adults against all variants studied. NVX-CoV2373 was well-tolerated with no safety signals identified.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2b/3 Hummingbird&#8482; Trial</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we initiated the Phase 2b/3 Hummingbird&#8482; Global Clinical Trial to evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of NVX-CoV2373 in younger children aged 6 months to 11 years, followed by a booster at 6 months after the primary vaccination series. The trial is an age de-escalation trial and age groups will be tested sequentially to assess NVX-CoV2373 in infants (6 through 23 months of age), toddlers (2 to 5 years), and children (6 to 11 years). Enrollment is ongoing, expanding into the cohort aged 2- to 5-years in January 2023. The trial seeks to enroll 3,600 total participants in the U.S. and other countries.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 Lot Consistency Study</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 at the World Vaccine Congress in Europe, we presented Lot Consistency data. The study achieved its primary endpoint showing that three lots of NVX-CoV2373 induced consistent immune responses in adults aged 18 to 49 years and demonstrated manufacturing consistency. Heterologous boosting responses for NVX-CoV2373 were consistent across participants who received primary vaccines from other approved U.S. FDA COVID-19 vaccines.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 U.K.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced an extended analysis from our pivotal Phase 3 U.K. trial showing that a high level of efficacy for NVX-CoV2373 was maintained over a 6-month period of surveillance. The analysis showed vaccine efficacy of 82.5% in protection against all COVID-19 infection, both symptomatic and asymptomatic. These data were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in October 2022 and build upon the final analysis of our Phase 3 U.K. trial, published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in June 2021, which highlighted the robust safety and efficacy data for NVX-CoV2373 and demonstrated a vaccine efficacy of 89.7%.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2b South Africa</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, results from our Phase 2b South Africa trial were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which highlighted safety and immunogenicity of two doses of NVX-CoV2373 in people living with and without HIV. The Phase 2b South Africa trial was a randomized, observer-blinded, placebo-controlled study that enrolled 4,419 participants. The results show that due to a lower observed antibody response in baseline SARS-CoV2 people living with HIV than compared to the HIV-negative participants, there is a need to investigate alternative dosing approaches, including potentially adding a third vaccine dose to the priming series.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 South Africa</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we initiated a Phase 2 South Africa trial evaluating the safety and immunogenicity of NVX-CoV2373 in adults aged 18 to 65 years, living with human immunodeficiency virus (&#8220;HIV&#8221;). The Phase 2 South Africa trial was a randomized, observer-blinded, placebo-controlled study that enrolled 360 participants living with HIV to evaluate different dosing regimens. Data are being evaluated to support extended primary vaccination schedules for immunocompromised adults.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NVX-CoV2373 Clinical Development Conducted by Partners</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2/3 India</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, immunogenicity and safety results from SIIPL and India Council of Medical Research Phase 2/3 trial were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in the preprint server for health sciences on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">medRxiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Phase 2/3 trial was expanded from </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adults to include a pediatric cohort. The trial was an observer-blind, randomized, controlled study in 920 total enrolled children aged 2 to 17 years and was found to be well tolerated and immunogenic.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1/2 Japan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, Takeda reported primary data analysis of a Phase 1/2 clinical trial of NVX-CoV2373 in Japan. This placebo-controlled trial evaluated the immunogenicity and safety of NVX-CoV2373 in 200 participants aged 20 years and older. Primary data analysis demonstrated acceptable safety results and induced robust immune responses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1/2 Boosting Study &#8211; Led by National Institute of Allergy and Infectious Diseases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced participation in an ongoing Phase 1/2 trial sponsored by the National Institute of Allergy and Infectious Diseases to evaluate safety, reactogenicity, and immunogenicity of delayed heterologous or homologous boosting regimens in participants who received a primary series of a COVID-19 vaccine which has received full approval or EUA from FDA. Participants will be given a third dose (greater than or equal to 12 weeks later) of either NVX-CoV2373 or one of three COVID-19 vaccines approved for use by the FDA. The full results are expected in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 United Arab Emirates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced participation in a Phase 3 study in the United Arab Emirates to evaluate the safety and immunogenicity of a single booster dose of NVX-CoV2373 in approximately 1,000 adults aged 18 or older who have already been immunized with Sinopharm&#8217;s inactive COVID-19 vaccine. Data from the head-to-head comparison is expected in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Com-COV3 Booster Trial &#8211; Led by University of Oxford</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022, we announced our participation in University of Oxford&#8217;s Phase 2 Com-COV3 vaccine trial where our COVID-19 vaccine, NVX-CoV2373 is one of two COVID-19 vaccines that are being studied as a third booster in approximately 380 adolescents aged 12 to 15 years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variant Strain-Containing Monovalent or Bivalent Vaccine Development</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our nanoparticle vaccine technology is purpose-built to rapidly address evolving infectious disease threats. As variants of COVID-19 emerge, we proactively evaluate NVX-CoV2373&#8217;s ability to protect against variant strains and evaluate the potential need for variant-specific monovalent or bivalent vaccine constructs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we participated in U.S. FDA Vaccine and Related Biological Products Advisory Committee&#8217;s meeting, which resulted in a unanimous vote harmonizing vaccine strain composition of primary series and booster doses. Within the meeting we shared data demonstrating NVX-CoV2373, when used as a booster induces broad functional immune responses, including against forward drift variants. We intend to deliver an updated vaccine following FDA guidance on strain change.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Phase 3 Omicron Variant Strain Vaccine </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced topline results from our Phase 3 boosting trial showing that our Omicron BA.1 vaccine candidate met the primary strain-change endpoint. We expect to advance group 2 of our Phase 3 Omicron boosting trial as part of our variant strategy to be ready for the fall season. Group 2 of the trial will build upon the first portion of our trial and will evaluate Omicron BA.5 vaccine in a monovalent and bivalent format in comparison to our monovalent prototype strain vaccine. These data will support regulatory filing authorization of a strain change. We expect to initiate part 2 of this study to evaluate our prototype vaccine compared to an Omicron BA.5 vaccine, as well as a bivalent containing prototype and Omicron BA.5 vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 U.S. and Australia Homologous Booster Study &#8211; Including Variant Results</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, exploratory analysis results of our Phase 2 homologous booster study were published within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was a randomized study to assess a single booster of NVX-CoV2373 in 1,282 healthy adults aged 18 to 84 years. Overall, a single booster dose of NVX-CoV2373 administered approximately 6 months after the primary </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">series induced substantial increases in humoral antibodies for both the prototype strain and all evaluated variants including Alpha, Delta, and Omicron (BA.1 and BA.2).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, immunogenicity data from a fourth homologous booster dose of NVX-CoV2373 was published as a letter in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January 2023. The study showed that a fourth dose of NVX-CoV2373 enhanced immunogenicity without increasing reactogenicity. Antigenic cartography mapping demonstrated a broad response against contemporary SARS-CoV-2 variants after a fourth dose of NVX-CoV2373, indicating that updates to the vaccine composition may not be warranted for the evaluated variants. Additional data are forthcoming.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Vaccine Funding</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have secured critical funding from the U.S. government to support the development of NVX-CoV2373 for the U.S. population, including $1.8&#160;billion from a partnership formerly known as Operation Warp Speed. In July 2020, we entered into a Project Agreement (the &#8220;Project Agreement&#8221;) with Advanced Technology International, Inc. (&#8220;ATI&#8221;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership. The partnership was among components of the U.S. Department of Health and Human Services and the U.S. Department of Defense working to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The Project Agreement relates to the Base Agreement we entered into with ATI in June 2020 (the &#8220;Base Agreement,&#8221; together with the Project Agreement, the &#8220;USG Agreement&#8221;). The original USG Agreement required us to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of NVX-CoV2373, and to manufacture and deliver to the U.S. government 100&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to us for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the U.S. government&#8217;s interest. If the Project Agreement is terminated prior to completion, we are entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. In July 2022, we entered into a modification to the USG Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373 and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100&#160;million doses of NVX-CoV2373 contemplated by the original USG Agreement (inclusive of the initial batch of approximately 3&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The 3&#160;million initial doses were delivered in July 2022. In February 2023, we entered into a modification to the USG Agreement that amended the terms of such agreement to provide for additional deliveries to the U.S. government of up to 1.5&#160;million doses of NVX-CoV2373. The performance period under the Project Agreement extends through 2023 to cover clinical trial activities, subject to early termination by the U.S. government or extension by mutual agreement of the parties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the USG Agreement, we were originally entitled to receive funding of up to $1.75&#160;billion to support certain activities related to the development of NVX-CoV2373 and the manufacture and delivery of the vaccine candidate to the U.S. government. In subsequent modifications, the USG Agreement was amended to increase the contract funding and ceiling to $1.8&#160;billion, which allows us to make expenditures or incur obligations of up to $1.8&#160;billion for support of the USG Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our funding agreement with the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;), under which CEPI has agreed to provide funding of up to $399.5&#160;million to us to support the development of NVX-CoV2373, provides up to $257.0&#160;million in CEPI Grant Funding and up to $142.5&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans in order to prepay certain manufacturing activities and are not subject to restrictive or financial covenants. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under our Gavi APA prior to its termination), and such sales cover our costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary and status of our historical COVID-19 funding developments follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding Partner</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Details</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$399.5 million</span></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Entitled to received up to $399.5 million of funding to support the development of NVX-CoV2373</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">To supply NVX-CoV2373 through the COVAX Facility </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Department of Defense (&#8220;DoD&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$45.7 million</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Entitled to received up to $45.7 million of funding to support the development of NVX-CoV2373</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">To manufacture and deliver up to 10 million doses of NVX-CoV2373 to the U.S. government</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Contract term ended in December 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Government through USG Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.8 billion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Allotted $1.8 billion to support the development of NVX-CoV2373</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">To manufacture and deliver up to 100 million doses of NVX-CoV2373 to the U.S. government</span></div></td></tr></table></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1550"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonal Influenza</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Influenza Program (Older Adults)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Influenza is a world-wide infectious disease with serious illness generally occurring in more susceptible populations such as children and older adults, but also occurring in the general population. According to a 2022 Fortune Business Insights research report forecast of influenza vaccines, the market for seasonal influenza vaccines is expected to grow from approximately $7.54 billion in 2022 to approximately $13.58 billion in 2029.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 at the World Vaccine Congress in Europe, we reviewed key findings from the Phase 3 stand-alone qNIV candidate, previously referred to as NanoFlu, which met its primary immunogenicity endpoints. The final analysis of these results was previously published in September 2021, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The results demonstrated non-inferior immunogenicity to Fluzone&#174; Quadrivalent against all four influenza virus strains included in the vaccine, while also showing both enhanced wild-type hemagglutination-inhibiting antibody responses against homologous strains (22-66% increased) and six heterologous A/H3N2 strains (34-46% increased) as compared to Fluzone&#174; Quadrivalent. Additionally, qNIV showed potent induction of polyfunctional antigen-specific CD4+ T-cells against A(H3N2) and B/Victoria strains, with a 126&#8211;189% increase in various post vaccination cell-mediated immunity markers as compared to Fluzone&#174; Quadrivalent.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Combination Vaccines</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Influenza Program team remains focused on advancing combination vaccine candidates. With the ongoing development of Influenza Program, NVX-CoV2373, and our RSV Program, a strong rationale exists for developing combination respiratory vaccines designed to protect susceptible populations against these diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID / Influenza Combination Vaccine</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Clinical Trial of COVID-19-Influenza Combination Vaccine</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we initiated a Phase 2 trial for CIC, which includes study arms for our stand-alone updated qNIV vaccine candidate. The dose-confirming trial will be conducted in two parts and will seek to enroll approximately 2,300 adults aged 50 to 80 years in Australia and New Zealand. The trial is randomized, observer-blinded with primary and secondary objectives of the study to assess the safety, tolerability, and immune responses to various formulations of the CIC and influenza vaccine candidates. As of January 2023, we completed enrollment of 1,500 participants. The initial results are expected mid-year 2023 with data informing the second part of the trial and future clinical development for both influenza stand-alone and CIC candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1/2 Clinical Trial of COVID-19-Influenza Combination Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 at the World Vaccine Congress in Europe, we announced additional positive results from Phase 1/2 CIC trial, which combines NVX-CoV2373 and our updated qNIV candidate. The results demonstrated CIC&#8217;s ability to generate immune responses, including both antibody and polyfunctional CD4+ T-cell (lymphocytes that help coordinate the immune </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">response) responses against an evolving SARS-CoV-2 virus, along with homologous and heterologous influenza strains. The CIC vaccine was well tolerated, and the safety and tolerability profile was consistent with the stand-alone NVX-CoV2373 prototype vaccine and quadrivalent influenza vaccine candidate reference formulations in the trial.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1557"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Respiratory Syncytial Virus (&#8220;RSV&#8221;)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there is no approved RSV vaccine available to combat the estimated 64 million RSV infections and 160 thousand deaths that occur globally each year. Older adults (60 years and older) are at increased risk for RSV disease due in part to immunosenescence, the age-related decline in the human immune system. RSV infection can also lead to exacerbation of underlying co-morbidities such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSV Program (Older Adults)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previous clinical development through a Phase 2 clinical trial demonstrated that our RSV Program for older adults with either aluminum phosphate or our proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant increased the magnitude, duration, and quality of the immune response versus the non-adjuvanted RSV F Vaccine. We continue to assess the preclinical development opportunities for our updated RSV vaccine for older adults.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1566"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Malaria</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaria is a life-threatening disease caused by a parasite that infects mosquitos subsequently transmitted to humans. According to the 2022 WHO World Malaria Report, in 2021, there were an estimated 247 million malaria cases and 619 thousand deaths worldwide in 2021. We believe malaria has the potential to be preventable through the R21 vaccine candidate, which is being developed through several partner-led trials and is formulated with our Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R21 - Malaria Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R21 is a malaria vaccine candidate created by the Jenner Institute, University of Oxford, and formulated with our Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. The University of Oxford has granted SIIPL a license for R21. SIIPL has committed to manufacture at least 200 million doses per year of R21 after licensure, if granted. Additionally, SIIPL has rights to use Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant in R21 in regions where the disease is endemic and will pay royalties to us on its market sales of the vaccine. We will have commercial rights to sell and distribute the SIIPL-manufactured R21 in certain countries, primarily in the travelers&#8217; and military vaccine markets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">R21 Clinical Development</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R21 is being evaluated in an ongoing Phase 3 trial being conducted by our partner, Jenner Institute, University of Oxford, for R21, a malaria candidate which is formulated using our Matrix-M&#8482; adjuvant. In September 2022, positive results from an ongoing Phase 1/2b study were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reporting safety, immunogenicity, and efficacy results at 12 months following administration of a booster vaccination in children aged 5 to 17 years in Nanoro, Burkina Faso. A total of 409 children received a booster dose of R21 formulated with our Matrix-M&#8482; adjuvant at 1 year following the primary three-dose regimen maintaining high efficacy against first and multiple episodes of clinical malaria, demonstrating 71% efficacy when formulated with 25 micrograms of Matrix-M&#8482; adjuvant and 80% efficacy when formulated with 50 micrograms of Matrix-M&#8482; adjuvant. The trial is continuing for a further 2 years to assess long-term follow-up of the participants and the value of further booster vaccinations.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1580"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to partnering globally in efforts to end the COVID-19 pandemic is demonstrated through our partnership with SIIPL to supply NVX-CoV2373 to India and low- and middle-income countries. We have also partnered with both Takeda in Japan and SK bioscience in South Korea to expand our manufacturing and supply capabilities.</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:36.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Licensee</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Marketed Under</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Territories</span></div></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:36.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Serum Institute of India Private Limited</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Covovax&#8482;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">India</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">COVAX Facility</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Philippines</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Indonesia</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">South Africa</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Bangladesh</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Takeda Pharmaceutical Company Limited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nuvaxovid&#8482;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Japan</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">South Korea</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SK bioscience Co., Ltd.</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nuvaxovid&#8482;</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">South Korea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;SK bioscience also has non-exclusive licenses in Thailand and Vietnam.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our license and collaboration agreements follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIIPL</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously granted exclusive and non-exclusive licenses to SIIPL under a supply and license agreement for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase our Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant and we granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#8217;s licensed territory solely for use in the manufacture of NVX-CoV2373. We equally split the revenue from SIIPL's sale of NVX-CoV2373 in its licensed territory, net of agreed costs. We granted to SIIPL (i) an exclusive license in India during the agreement, and (ii) a non-exclusive license (a) during the &#8220;Pandemic Period&#8221; (as declared by the World Health Organization), in all countries other than specified countries designated by the World Bank as upper-middle or high-income countries, with respect to which we retains rights, and (b) after the Pandemic Period, in only those countries designated as low or middle-income by the World Bank. Following the Pandemic Period, we may notify SIIPL of any bona fide opportunities for us to license NVX-CoV2373 to a third party in such low- and middle-income countries and SIIPL would have an opportunity to match or improve such third-party terms, failing which, we would have the discretion to remove one or more non-exclusive countries from SIIPL&#8217;s license. We also have a supply agreement with SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under which SIIPL and SLS will supply us with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to us using antigen drug substance and Matrix-M&#8482; adjuvant supplied by us. In May and August 2022, we expanded our license and supply arrangements with SIIPL to include our proprietary COVID-19 variant antigen candidate(s), our quadrivalent influenza vaccine candidate, and our CIC vaccine candidate, so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, a quadrivalent influenza vaccine, and CIC vaccine, and supply such vaccines to us. In March 2020, we granted SIIPL a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by us to develop, manufacture, and commercialize R21, a malaria candidate developed by the Jenner Institute, University of Oxford.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeda</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Takeda under which we granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from us to manufacture doses of NVX-CoV2373 and we are entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150 million doses of NVX-CoV2373. In February 2023, MHLW cancelled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether we will receive future payments from Takeda under the terms and conditions of our current collaboration and licensing agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SK bioscience</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with SK bioscience to manufacture and commercialize NVX-CoV2373 for sale to the governments of South Korea, Thailand, and Vietnam. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, we have a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the antigen component of NVX-CoV2373 to us for use in the final drug product globally, including product distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economies. In July 2022, we signed an additional agreement with SK bioscience for the technology transfer of our proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. We also have an agreement with SK bioscience, pursuant to which it supplies us with our COVID-19 vaccine in a prefilled syringe.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1589"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases and are exploring a number of combination vaccine candidates, including a CIC vaccine, directly and by leveraging our strategic global partnerships. In 2021 and 2020, we established a global supply chain and worldwide partnerships to support the commercialization of NVX-CoV2373. In 2022, we modified and continued to assess our manufacturing needs and our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for NVX-CoV2373.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our key manufacturing and supply arrangements follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Adjuvant</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our proprietary saponin-based Matrix-M&#8482; adjuvant at our Novavax AB facility in Uppsala, Sweden. We also have contract manufacturing arrangements with AGC Biologics and the Polypeptide Group to provide contract development and manufacturing services, supplying us with large-scale production of Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antigen Component of NVX-CoV2373</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the antigen component of NVX-CoV2373 at our Novavax CZ facility in the Czech Republic. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supply agreement with SIIPL and SLS, an affiliate of SIIPL, for the manufacture of the antigen component of NVX-CoV2373 and the co-formulation, fill, and finishing of the finished vaccine product. In May and August 2022, we expanded our license and supply arrangements with SIIPL to include our proprietary COVID-19 variant antigen candidate(s), our quadrivalent influenza vaccine candidate, and our CIC vaccine candidate, so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, a quadrivalent influenza vaccine, and CIC vaccine, and supply such vaccines to us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies us with the antigen component of NVX-CoV2373 for use in the final drug product globally. In July 2022, we signed an additional agreement with SK bioscience for the technology transfer of our proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a partnership with FUJIFILM Diosynth Biotechnologies through an agreement for long-term commercial manufacturing of NVX-CoV2373, under which it manufactures the antigen component of NVX-CoV2373 at its Billingham, UK site.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an arrangement with the National Research Council of Canada (&#8220;NRCC&#8221;) for the ongoing technology transfer for the production of NVX-CoV2373 at the NRCC&#8217;s Biologics Manufacturing Centre. Engineering runs are currently underway at the facility and, once complete, process performance qualification and large-scale GMP production can begin.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finished NVX-CoV2373</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the supply agreement with SIIPL and SLS for the co-formulation, fill, and finishing of the finished vaccine product, we have a contract development manufacture agreement with SLS, pursuant to which SLS will manufacture and supply finished vaccine product to us using antigen drug substance and Matrix-M&#8482; adjuvant supplied by us. We currently depend exclusively on SIIPL and SLS for co-formulation, filling, and finishing NVX-CoV2373. We also have an agreement with SK bioscience, pursuant to which it supplies us with our COVID-19 vaccine in a prefilled syringe.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1596"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition in COVID-19, Influenza, and RSV</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vaccine market is intensely competitive, characterized by rapid technological progress. Our technology is based upon utilizing the baculovirus expression system in insect cells to make recombinant vaccines. Our Matrix-M&#8482; adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response. We believe this baculovirus expression system with our nanoparticle configuration formulated with our Matrix-M&#8482; adjuvant offers many advantages such as enabling dose-sparing effects and refrigerator temperature storage when compared to other technologies creating a best-in-class vaccine, and is uniquely well suited for developing COVID-19, influenza, and RSV vaccines, as well as vaccines against a number of other infectious diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of vaccine manufacturers, research institutions, and other organizations are developing a vaccine for SARS-CoV-2, the virus that causes COVID-19. A variety of different vaccine technologies are being studied, including nucleic acid (RNA/DNA), viral vectors, live attenuated or inactivated, and protein-based vaccines. According to a coronavirus vaccine tracker published by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New York Times</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, updated as of August 31, 2022, there are 33 vaccines approved for limited or full use and 123 vaccines in clinical trials. Novavax is the first protein-based COVID-19 vaccine that received EUA by the FDA and a CMA by EMA in the European Union. As of February 2023, Novavax is one of four manufacturers that have a COVID-19 vaccine that has received EUA by the FDA, with the other manufacturers being Pfizer, Moderna, and Johnson &amp; Johnson. As of February 2023, Pfizer and Moderna have received BLA approval by the FDA in the U.S. for their monovalent COVID-19 vaccines and received EUA by the FDA in the U.S. for their bivalent COVID-19 vaccines. Novavax and Johnson &amp; Johnson have received EUA by the FDA in the U.S. for their monovalent vaccines. Based on NVX-CoV2373&#8217;s high efficacy against both the original and variant strains and its well-tolerated profile demonstrated in clinical trials, including two pivotal Phase 3 trials in the U.K. and U.S., we believe our vaccine candidate will continue to play an important role in addressing this global public health crisis.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies are selling vaccines for seasonal influenza employing both traditional (egg-based) and new vaccine technologies (cell-based). Many seasonal influenza vaccines are currently approved and marketed, and most of these are marketed by major pharmaceutical companies such as Sanofi, GSK, and Seqirus. Competition in the sale of seasonal influenza vaccines is intense. For the older adult segment in the U.S., the CDC preferentially recommends Fluzone-HD&#174; and Flublok&#174; manufactured by Sanofi and Fluad&#174; manufactured by Seqirus. Therefore, newly developed and approved products must be differentiated from existing vaccines in order to have commercial success. In order to show differentiation in the seasonal influenza market, a product may need to be more efficacious and/or be less expensive and quicker to manufacture, all while still showing a comparable or improved tolerability profile. Many of our competitors are working on new products and new generations of current products, some by adding an adjuvant that is used to increase the immunogenicity of that product, each of which is intended to be more efficacious than currently marketed products. Several competitors are working on developing seasonal influenza vaccines using different technologies than those in existing marketed vaccines, the most notable being mRNA from companies including Sanofi, Moderna, and Pfizer. Despite the significant competition and advancing technologies, based on our completed Phase 3 and Phase 1/2 trial results, we believe that our Influenza Program, our adjuvanted nanoparticle seasonal influenza product, could be as efficacious as, or more so than, current products or products being developed by our competitors.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we believe that our platform is well suited for combination vaccines, for example influenza and COVID-19. Following our Phase 1/2 trial results, we are currently in a Phase 2 trial for our CIC and influenza standalone vaccine candidates to evaluate the safety and effectiveness (immunogenicity) of different formulations in adults aged 50 through 80. Other manufacturers, most notably Moderna and Pfizer, are in Phase 1/2 and Phase 1 clinical trials with COVID-19-influenza combination candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is currently no approved RSV vaccine for sale in the world; however, a number of vaccine manufacturers, academic institutions, and other organizations currently have, or have had, programs to develop such a vaccine. These groups are developing products to prevent disease caused by RSV using a variety of technology platforms, including viral vectors, nucleic acid (&#8220;RNA/DNA&#8221;), live attenuated chimeric, antigens or monoclonal antibodies (&#8220;Mab&#8221;), and competitive recombinant technologies. We continue to believe that our updated RSV F Vaccine candidate, which is a recombinant F-protein nanoparticle, is likely to be as effective as other RSV vaccine candidates or other products in development by our competitors. At this time, there are a number of companies and other organizations with vaccine candidates in late-stage clinical trials. In older adults, GSK, Pfizer, and Moderna have announced data from their Phase 3 studies, with GSK and Pfizer completing regulatory submission to the FDA in the U.S. with Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) dates in May 2023 and Moderna planning regulatory submission to the FDA in the first half of 2023. Janssen and Bavarian Nordic currently are in </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 trials. In infants Pfizer announced Phase 3 data and completed regulatory submission to the FDA for their vaccine candidate via maternal immunization and have a PDUFA date in August 2023. Additionally, in infants, AstraZeneca / Sanofi partnered monoclonal antibody is approved in Europe and has a PDUFA date with the FDA in the U.S. in the third quarter of 2023, and Merck&#8217;s monoclonal antibody is in Phase 3 trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, competition among pharmaceutical products is based in part on product efficacy, safety, reliability, availability, price, and patent position. An important factor is the relative timing of the market introduction of our products and our competitors&#8217; products. Accordingly, the speed with which we can develop products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market is an important competitive factor. Our competitive position also may depend upon our ability to show differentiation with a product that is more efficacious and/or less expensive and quicker to manufacture. Other factors affecting our competitive position include our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the lengthy period between technological conception and commercial sale.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1603"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally seek patent protection for our technology and product candidates in the U.S. and abroad. The patent position of biotechnology and pharmaceutical firms generally is highly uncertain and involves complex legal and factual questions. Our success will depend, in part, on whether we can:</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">obtain patents to protect our own technologies and product candidates;</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">obtain licenses to use the technologies of third-parties, which may be protected by patents;</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">protect our trade secrets and know-how; and</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">operate without infringing the intellectual property and proprietary rights of others.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Rights; Licenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have intellectual property (patents, licenses, know-how) related to our vaccines, manufacturing processes, and other technologies. Currently, we have or have rights to over 550 U.S. and foreign patents and patent applications relating to vaccines and vaccine-related technologies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents related to our Virus-Like Particle (&#8220;VLP&#8221;) program include U.S. Patent No. 7,763,450, which covers, in part, the use of influenza gene sequences for high-yield production of consistent influenza VLP vaccines to protect against current and future seasonal and pandemic strains of influenza viruses. Corresponding European patent, European Patent No. 1644037 also covers this technology. U.S. Patent Nos. 8,080,255, 8,551,756, 8,506,967 and 8,592,197 are directed to methods of producing VLPs and inducing substantial immunity to an influenza virus infection by administering VLPs comprising HA and NA proteins, and our M1 protein derived from the avian influenza strain, A/Indonesia/5/05. Certain claims also encompass similar methods and compositions where the M1 protein is from a different strain of influenza virus than the influenza HA protein and the influenza NA protein. Related patent protection in Europe is provided by European Patent No. 2343084, which covers, in part, vaccine compositions containing VLPs that contain M1, HA, and NA proteins. Our VLP patent portfolio contains many other patents, including U.S. Patent Nos. 8,951,537, 8,992,939, 9,144,607, 9,050,290, 9,180,180, 9,381,239, 9,464,276, 9,474,799, and other patents in multiple ex-U.S. jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have been issued patents directed to other core programs, including our RSV and influenza programs. Issued patents directed to various aspects of the RSV program include U.S. Patent Nos. 8,715,692, 9,675,685, 9,731,000, 9,717,786, 10,022,437, 10,426,829, and 11,253,585. Additional patents in the family include EP237009 in Europe, as well as others throughout the world. Patents related to our rabies program include 9,724,405 and 10,086,065 in the U.S., and EP2635257 and EP3246019 in Europe. Related patents have been issued in other world markets. Issued patents in our influenza nanoparticle program include US Patent Nos. 11,364,294 and 11,278,612. In addition to our focus on vaccine programs, we also pursue patent protection for our Matrix Adjuvant program. Issued U.S. Patent Nos. 7,838,019, 9,205,147, 9,901,634, 8,821,881, and 10,729,764 provide examples of patents related to our Matrix Adjuvant program.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue patents related to our COVID-19 vaccine program, including to NVX-CoV2373, our COVID-19 vaccine candidate. Issued U.S. Patent Nos. 10,953,089, 11,253,586, 11,541,112 provide examples of patents related to our COVID-19 program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have four pending PCT applications directed to our COVID program (PCT/US2022/020974, PCT/US2022/080700, PCT/US2022/082331 and PCT/US2022/027465) and two pending PCT applications directed to our malaria program (PCT/US2022/078665 and PCT/US2022/080334).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to prepare, file, and prosecute patent applications to provide broad and strong protection of our proprietary rights, including our RSV Program, our influenza nanoparticle program, our COVID-19 program, and our adjuvant program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Technology Transfer Act of 1986 and related statutory guidance encourages the dissemination of science and technology innovation. While our expired contract with the U.S. Department of Health and Human Services (&#8220;DHHS&#8221;), Biomedical Advanced Research and Development Authority provided us with the right to retain ownership in our inventions that may have arisen during performance of that contract, with respect to certain other collaborative research efforts with the U.S. government, certain developments and results that may have commercial potential are to be freely published, not treated as confidential, and we may be required to negotiate a license to developments and results in order to commercialize products. There can be no assurance that we will be able to successfully obtain any such license at a reasonable cost, or that such development and results will not be made available to our competitors on an exclusive or non-exclusive basis.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely significantly on trade secret protection and confidentiality agreements to protect our interests. It is our policy to require employees, consultants, contractors, manufacturers, collaborators, and other advisors to execute confidentiality agreements upon the commencement of employment, consulting, or collaborative relationships with us. We also require confidentiality agreements from any entity that is to receive confidential information from us. With respect to employees, consultants, and contractors, the agreements generally provide that all inventions made by the individual while rendering services to us shall be assigned to us as our property.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1610"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, production, and marketing of biological products, which include the vaccine candidates being developed by Novavax or our collaborators, are subject to regulation for safety, efficacy, and quality by numerous governmental authorities in the U.S. and other countries. We focus on the U.S. regulatory process and the standards imposed by the FDA, the International Council for Harmonisation (&#8220;ICH&#8221;), and other agencies because we believe meeting U.S. and ICH standards generally allows us to also satisfy regulatory agencies&#8217; standards in other countries where we intend to do business. However, we are mindful that expectations in some venues, notably in the European Union and the United Kingdom (in relation to Great Britain), differ to some degree and we take proactive steps to address such differences by maintaining regular filings and correspondence and attending regular meetings with many other non-U.S. regulatory agencies. In the U.S., the development, manufacturing, and marketing of human pharmaceuticals and vaccines are subject to extensive regulation under the Federal Food, Drug, and Cosmetic Act, and biological products are subject to regulation under provisions of that act and the Public Health Service Act. The FDA not only assesses the safety and efficacy of these products but it also regulates, among other things, the testing, manufacture, labeling, storage, record-keeping, advertising, and promotion of such products. The process of obtaining FDA licensure for a new vaccine is costly and time-consuming.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine clinical development in most countries follows the same general regulatory pathway as drugs and other biologics. Before applying for FDA licensure to market any new vaccine candidate, we expect to first submit an investigational new drug application (&#8220;IND&#8221;) that explains to the FDA, among other things, the results of preclinical toxicology testing conducted in laboratory animals, the method of manufacture, quality control tests for release, the stability of the investigational product, and our proposed plans for human testing. At this stage, the FDA decides whether it is reasonably safe to move forward with testing the vaccine candidate in humans. We must then conduct Phase 1 clinical trials and larger-scale Phase 2 and 3 clinical trials that demonstrate the safety, immunogenicity, and efficacy of our vaccine candidate to the satisfaction of the FDA. Following successful completion of all three phases of clinical development, a BLA can be submitted to the FDA requesting licensure of the vaccine for marketing based on the vaccine&#8217;s safety and efficacy. Similar pathways exist in Europe and other geographies.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA will only approve a BLA if the vaccine is demonstrated to be safe, pure, and potent. During the FDA&#8217;s review of a BLA, the proposed manufacturing facility undergoes a pre-approval inspection during which the FDA examines in detail the production of the vaccine, the manufacturing facility, and the quality documentation related to the vaccine. Vaccine licensure also requires the provision of adequate product labeling to allow health care providers to understand the vaccine&#8217;s proper use, including its potential benefits and risks, to communicate with patients and parents, and to safely deliver the vaccine to the public. Until a vaccine is given to the general population, all potential adverse events cannot be anticipated. Thus, the FDA typically requires Phase 4 post-marketing clinical trials for vaccines after licensure to continue gathering safety, and sometimes effectiveness/efficacy data in the indicated and additional populations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Commissioner of the FDA may, following the issuance of an appropriate declaration by the Secretary of the DHHS, issue an EUA that would permit the use of an unapproved medical product or unapproved use of an approved medical product to diagnose, treat, or prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives. When issuing an EUA, the FDA imposes conditions of authorization, with which the EUA holder must comply. Such conditions include, but may not be limited to, compliance with labeling, distribution of materials designed to ensure proper use, reporting obligations, and restrictions on advertising and promotion. The EUA is only effective for the duration of the declaration issued by the Secretary of the DHHS that EUAs are appropriate. The FDA may also revise or revoke the EUA sooner if the criteria for issuance are no longer met or other circumstances make a revision or revocation appropriate to protect the public health or safety. For example, an EUA may be revoked when the FDA determines that the underlying public health threat no longer exists or warrants such authorization, or for reasons such as significant adverse inspectional findings, reports of adverse events linked to or suspected of being caused by the EUA product, or newly emerging data that may demonstrate the product may not be effective. An EUA is separate from and not dependent on the issuance of a public health emergency (&#8220;PHE&#8221;) by the Secretary of the DHHS. Therefore, although the Biden Administration has announced that it intends for the COVID-19 PHE, first declared in February 2020, to expire on May 11, 2023, that expiration will not terminate EUAs issued by the FDA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to ensure continuing safety, the FDA and most other non-U.S. based regulatory agencies continue to oversee the production of vaccines even after the vaccine and manufacturing processes are approved. For example, monitoring of the vaccine and of production activities, including periodic facility inspections, must continue as long as the manufacturer holds a license for the product. Manufacturers may also be required to submit the results of their own tests for potency, safety, and purity for each vaccine lot, if requested by the relevant regulatory agency. They may also be required to submit samples of each vaccine lot to the agency for testing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining FDA licensure for each product, each domestic manufacturing establishment must be registered with the FDA, is subject to FDA inspection, and must comply with current Good Manufacturing Practices (&#8220;GMP&#8221;) regulations. To supply products for use either in the U.S. or outside the U.S., including clinical trials, U.S. and foreign manufacturing establishments, including third-party facilities, must comply with GMP regulations and are subject to periodic inspection by the FDA or by corresponding regulatory agencies in their home country.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU and the U.K. similarly provide a faster means to achieve approval by offering CMA to fulfil unmet medical needs. CMAs are granted with the proviso of obtaining additional comprehensive data to confirm the benefit/risk so that the marketing authorization will eventually become unconditional. The benefit to public health of the immediate availability on the market of the medicinal product concerned should outweigh the risk inherent in the fact that additional data are still required.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has several programs designed to expedite the development and approval of drugs and biological products intended to treat serious or life-threatening diseases or conditions, including fast track designation, breakthrough therapy designation, priority review designation, and accelerated approval. First, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have more frequent interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. The FDA granted Fast Track Designation for NVX-CoV2373 in November 2020 and for NanoFlu, our recombinant quadrivalent seasonal influenza vaccine candidate, in January 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA may hold meetings with the sponsor throughout the development process, provide timely advice to the </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product sponsor regarding development and approval, involve more senior staff in the review process, assign a cross-disciplinary project lead for the review team, and take other steps to design the clinical trials in an efficient manner.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third, the FDA may designate a product for priority review if it is a product that treats a serious disease or life-threatening condition and, if approved, would provide a significant improvement in safety or effectiveness over available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and, for a drug product (including a vaccine), to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fourth, a product may be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to confirm efficacy using a clinically meaningful endpoint, thereby confirming efficacy observed pre-approval using a surrogate endpoint. In June 2019, we announced that the FDA acknowledged that the accelerated approval pathway is available for NanoFlu.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulatory approvals that must be obtained in the U.S., an investigational product is also subject to regulatory approval in other countries in which it is intended to be marketed. No such product can be marketed in a country until the regulatory authorities of that country have approved an appropriate marketing application. FDA licensure does not guarantee approval by other regulatory authorities. In addition, in many countries, the government is involved in the pricing of the product. In such cases, the pricing review period often begins after market approval is granted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, and other present and potential federal, state, or local regulations, including national and local regulations that govern our facility in Sweden. These and other laws govern our use, handling, and disposal of various biological and chemical substances used in, and waste generated by, our operations. Our research and development involves the controlled use of hazardous materials, chemicals, and viruses. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources. Additionally, for formulations containing controlled substances, we are subject to Drug Enforcement Act regulations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payers. Third-party payers include government authorities or programs, private health insurers (including managed care plans), and other organizations. These third-party payers are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the product is approved by the FDA or similar regulatory authorities outside the United States. Our product candidates may not be considered cost-effective at certain prices. Adequate third-party reimbursement may not be available in certain markets to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Third-party payors may also control access to, or manage utilization of, our products with various utilization management techniques. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payer to not cover our product candidates could reduce physician utilization of our products and have a material adverse effect on our sales, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S., if we obtain appropriate approval in the future to market any of our product candidates, those products could potentially be covered by various government health benefit programs as well as purchased by government agencies. The participation in such programs or the sale of products to such agencies is subject to regulation. In exchange for coverage, we may be obligated to provide rebates or offer discounts under government health programs or to government and private purchasers.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, health care, including initiatives to reduce the cost of healthcare. For example, in March 2010, the U.S. Congress enacted the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (&#8220;Healthcare Reform Act&#8221;) which includes changes to the coverage and reimbursement of drug products under government health care programs. Under the Trump administration, there were several efforts to modify or repeal all or certain provisions of the Healthcare Reform Act, and some modifications were implemented. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our net revenue and results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the Healthcare Reform Act was enacted. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 due to subsequent legislative amendments contained in the Coronavirus Aid, Relief, and Economic Security Act, commonly referred to as the &#8220;CARES Act.&#8221; In November 2020, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) issued an interim final rule that seeks to lower prescription drug costs by paying no more for certain Medicare Part B drugs than the lowest price paid for such drugs in certain other countries (the &#8220;Most Favored Nation Rule&#8221;). Under the rule, the lower payment rates for affected drugs would be phased in over a period of four years, beginning in 2021. The rule has been challenged by industry associations on a number of grounds. On December 28, 2020, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction in Biotechnology Innovation Organization v. Azar, No. 3:20-cv-08603, which preliminarily enjoins CMS from implementing the Most Favored Nation Rule. Given this preliminary injunction, the Most Favored Nation Rule was not implemented on January 1, 2021 and will not be implemented without further rule-making. However, this interim final rule or any similar type of reference pricing regulation could potentially harm our business if expanded to include our products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, there has been considerable public and government scrutiny in the U.S. of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals. There have also been several recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices or price increases. Adoption of new legislation at the federal or state level could affect demand for, or pricing of, our product candidates if approved for sale. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic. We cannot predict the ultimate content, timing, or effect of any federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, in many countries outside the U.S., pharmaceutical pricing is subject to regulatory control, particularly in countries where healthcare is provided mainly through government funding or government backed insurers. In such countries governmental organizations will generally determine firstly if a medicinal product might be reimbursed and secondly the maximum price payable.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S., we may be subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws, for activities related to future sales of any of our product candidates that may in the future receive regulatory and marketing approval. Anti-kickback laws generally prohibit a pharmaceutical manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase, prescription, or use of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations, guidance, or court decisions that apply the laws to particular industry practices. There is therefore a possibility that our practices might be challenged under such anti-kickback laws. False claims laws, including the federal False Claims Act (&#8220;FCA&#8221;), prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third party payers (including Medicare and Medicaid) that are false or fraudulent. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the FCA. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, the DHHS published a Final Rule entitled &#8220;Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection,&#8221; commonly referred to as the &#8220;Rebate Rule,&#8221; which amends the federal Anti-Kickback Statute discount safe harbor by eliminating protection for price concessions, including rebates, that are offered by pharmaceutical manufacturers to plan sponsors, or pharmacy benefit </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">managers under contract with them, under the Medicare Part D program and Medicare Advantage Plans, unless the price reduction is one required by law. Effective January 1, 2022, in advance of the calendar year 2022 Part D plan year, safe harbor protection will be eliminated for manufacturer rebates paid directly (or indirectly through a pharmacy benefit manager) to Part D prescription drug plans and Medicare Advantage prescription drug plans. Effective December 30, 2020, the Rebate Rule established two new safe harbors. The first new safe harbor protects price reductions paid by manufacturers to prescription drug plans (including prescription drug plans offered by Medicare Advantage organizations) and Medicaid managed care organizations, which are fully reflected at the point-of-sale. The second new safe harbor protects fair-market-value service fees paid to pharmacy benefit managers by manufacturers. This new rule could result in a change in incentives for health plans and pharmacy benefit managers in negotiating rebates and discounts with manufactures for preferred formulary placement. At this time we cannot predict how these changes may impact our business and operations if our products are commercialized in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the European Union and the United Kingdom, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of EU Member States and the United Kingdom, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits any U.S. individual or business from paying, offering, authorizing payment of, or offering anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Various laws, regulations, and executive orders also restrict the use and dissemination outside the U.S. or the sharing with certain non-U.S. nationals of information classified for national security purposes, as well as certain products and technical data relating to those products. As we expand our presence outside the U.S., it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs. We cannot guarantee that we, our employees, our consultants, or our third-party contractors are or will be in compliance with all federal, state, and foreign regulations regarding bribery and corruption. Moreover, our strategic collaborators and third-party contractors located outside the U.S. may have inadequate compliance programs or may fail to respect the laws and guidance of the territories in which they operate. The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission (&#8220;SEC&#8221;) also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, impose requirements regarding the privacy and security of individually identifiable health information, including mandatory contractual terms, for covered entities, or certain healthcare providers, health plans, and healthcare clearinghouses, and their business associates that provide services to the covered entity that involve individually identifiable health information and their subcontractors that use, disclose, or otherwise process individually identifiable health information. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA. While pharmaceutical </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and biotechnology companies are typically not directly regulated by HIPAA, our business may be indirectly impacted by HIPAA in our interactions with providers, payors, and others that have HIPAA compliance obligations. We are also subject to state and foreign laws governing the privacy and security of health or personal information such as the European Union General Data Protection Regulation (&#8220;GDPR&#8221;) and the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Physician Payments Sunshine Act imposes annual reporting requirements on certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, for payments made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information related to payments and other transfers of value provided in the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the European Union and the United Kingdom, payments made to physicians must be publicly disclosed. Moreover, agreements with physicians must in some countries be the subject of prior notification and approval by the physician&#8217;s employer, their competent professional organization, or the regulatory authorities of the individual country. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products. The laws and regulations generally limit financial interactions between manufacturers and health care providers and/or require disclosure to the government and public of such interactions. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Given the lack of clarity in laws and their implementation, any future activities (if we obtain approval and/or reimbursement from federal healthcare programs for our product candidates) could be subject to challenge.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant global impact of the COVID-19 pandemic, it is possible that one or more government entities may take actions, including the U.S. government under the Defense Production Act of 1950, as amended, which could directly or indirectly have the effect of diminishing some of our rights or opportunities with respect to NVX-CoV2373 and the economic value of a COVID-19 vaccine to us could be limited. In addition, during a global health crisis, such as the COVID-19 pandemic, where the spread of a disease needs to be controlled, closed or heavily regulated national borders will create challenges and potential delays in our development and production activities and may necessitate that we pursue strategies to develop and produce our vaccine candidates within self-contained national or international borders, at potentially much greater expense and with longer timeframes for public distribution.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and commercialization of our products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. In the United States, the Public Readiness and Emergency Preparedness Act (the &#8220;PREP Act&#8221;), when applicable, provides immunity for manufacturers from all claims under state or federal law for &#8220;loss&#8221; arising out of the administration or use of a &#8220;covered countermeasure.&#8221; However, injured persons may still bring a suit for &#8220;willful misconduct&#8221; against the manufacturer under some circumstances. &#8220;Covered countermeasures&#8221; include security countermeasures and &#8220;qualified pandemic or epidemic products,&#8221; including products intended to diagnose or treat pandemic or epidemic disease, such as pandemic vaccines, as well as treatments intended to address conditions caused by such products. For these immunities to apply, the Secretary of DHHS must invoke the PREP Act by issuing a declaration that a public health emergency or &#8220;credible risk&#8221; of a future public health emergency exists. On March 17, 2020, the Secretary of DHHS issued a declaration under the PREP Act and has issued subsequent amendments thereto since then to provide liability immunity for activities related to certain countermeasures against the ongoing COVID-19 pandemic. The current declaration will end on October 1, 2024, unless it is renewed. While we believe our products would be covered under the current PREP Act declaration, this cannot be assured.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there can be no assurance that the Secretary of the HHS will make other declarations in the future that cover any of our other product candidates or that the U.S. Congress will not act in the future to reduce coverage under the PREP Act or to repeal it altogether. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1617"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2023, we have 1,992 full-time employees, of whom approximately 9% hold M.D. or Ph.D. degrees and approximately 21% hold other advanced degrees. Of our total workforce, approximately 63% of employees are engaged primarily in research, development, and manufacturing activities and approximately 37% of employees are engaged primarily in executive, business development, commercial, finance and accounting, legal, and administrative functions. Except for certain employees located in Sweden, who are covered by collective agreements with trade unions pursuant to local law, none of our employees are represented by a labor union or works council and none of our employees have entered into a collective bargaining agreement with us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To nurture, grow, and treat our employees fairly is an integral part of our culture. We are proud to have been recognized in the 2021 Top Workplaces USA list based on employee surveys. We believe this award reflects our investment in an exceptional work culture.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Safety and Well-Being</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee safety is our highest priority. As we moved through the pandemic in 2022, we continued to encourage employees who were able to work from home to do so. We have continued to follow all CDC guidelines related to COVID-19 safety. In addition, we implemented our Ways of Working guidelines, which allow employees the flexibility to work remotely either full time or in a hybrid manner to provide employees with continued flexibility based on business needs. We provide employees with updated information on COVID-19 through our COVID-19 Resources page on our intranet. This resource provides employees with information on COVID-19 safety, both inside and outside of the workplace. Resources on this site include our COVID-19 Protocols and Guide, our policies on face coverings and social distancing, a list of infection control measures, and mental wellness support resources.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 700 Quince Orchard office space located in Gaithersburg, Maryland received WELL Platinum certification in 2022. WELL is the leading tool for advancing health and well-being in buildings globally. As one of 35 WELL certified buildings in North America, this building will meet rigorous standards for materials selection, indoor air quality, and acoustics. In addition, our operations and policies contribute to earning high marks in all of the 10 WELL Concepts: Air, Water, Nourishment, Light, Movement, Thermal Comfort, Sound, Materials, Mind, and Community.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation and Benefits; Health and Wellness</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards package is designed to attract, engage, motivate, and retain top talent. We strive to provide compensation, benefits, and services that help meet the varying needs of our employees. Our generous total rewards package includes competitive market pay and comprehensive benefits, including insurance to protect and maintain health; income protection through our short- and long-term disability programs; adoption assistance and paid parental leave programs; and services to assist in balancing work and personal life, such as backup child, adult, and elder care, and financial well-being programs, including monthly financial wellness seminars, one-on-one financial planning sessions, and debt and credit management support.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wellness initiatives include a monthly newsletter, which highlights organizations and partners, tools, and resources intended to help our employees lead healthier and happier lives. We offer several digital apps that allow our employees to connect to an online licensed therapist or to access activities that are designed to reduce stress and anxiety and increase mindfulness and emotional well-being. We have a robust employee assistance program for employees to access support for a variety of life events.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To assist employees with work/life balance, we offer a concierge service that helps employees with managing various personal tasks including finding and booking auto services; sourcing pet sitters and boarders; researching online and in-person tutors; suggesting community events; providing vacation ideas; finding and booking home cleaners, plumbers, HVAC, and </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">landscaping services; finding and booking yoga, personal training sessions, and spin classes; suggesting nutritional meals and recipes; and researching day care center availability and ratings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we offer every employee the benefit of equity ownership in the Company through equity grants or participation in our employee stock purchase plan. We believe that equity compensation has been, and will continue to be, a critical component of our compensation package because it develops a culture of ownership among our employees and aligns their interests with the interests of our stockholders.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recruitment, Development, and Training</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The attraction, development, and retention of employees is a critical factor for our success. We utilize a variety of recruitment vehicles to source top talent, including strategic partnerships with search firms, leveraging social media channels, and a robust employee referral program. In 2022, we held an Early Career Summit to engage, retain, and develop over 150 employees and college interns. The Summit provided a forum for this group to network, build relationships, and learn from Novavax leaders and one another.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support the growth and advancement of our employees, we offer tuition and continuing education reimbursement, and an array of training and professional development opportunities, including on-the-spot coaching with executive coaches and access to the LinkedIn Learning library of over 16,000 on-demand video tutorials that address skills, knowledge, and behaviors related to business, leadership, technology, and innovation. In the last 12 months, videos were viewed and completed over 50,000 times by our employees. In addition, approximately 200 employees have participated in spot coaching. We provide an Executive Development Program for employees identified as having high potential and for employees who have been identified as potential successors to leadership positions. Our Executive Development Program includes executive coaching engagements and leadership development programs designed to strengthen our leadership bench and accelerate and prepare our top talent for future growth. The 2023 Executive Development Program includes a diverse and global group of 34 employees. Professional development learning series are available to all employees and focus on self-awareness, collaboration, hybrid working, leadership, and business acumen.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Communications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ a variety of tools to facilitate open and direct communication, including global forums with executives, employee surveys, and engagement through forums and committees. Our executive leadership team recognizes the importance of increased employee engagement to the success of each individual&#8217;s career and to our success as a whole.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our culture of diversity, equity, and inclusion (&#8220;DEI&#8221;) helps us to create, develop, and leverage the strengths of our workforce to meet our growth objectives. We recently completed an evidence-based analysis of our current DEI state, resulting in a multi-year roadmap and strategy that will enable our mission, our people, and our best work. It is designed around three pillars:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Embed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> DEI into our people decisions and processes.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Enable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our employees, who we refer to as our SuperNovas, to live our values and thrive in a culture of inclusion.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equip </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our leaders and SuperNovas with the understanding, capability, education, tools, and resources on DEI.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We started implementing our roadmap in 2022 and are making progress. We hired a DEI and Employee Engagement Manager who will facilitate and help focus our actions to build an inclusive workforce. We began acknowledging global DEI-related observances and we are investing in training to build an inclusive culture and develop our leaders to access different perspectives when generating ideas and decision making. The second annual Novavax Women&#8217;s Leadership Forum was held and resulted in building networks, developing skills, sharing voices and ideas, and becoming agents of positive change for nearly 300 Novavax women. In 2022, we also made progress in increasing representation for women and minorities at the Executive level. We commenced and completed the reviews of three people processes, namely, Talent Acquisition, Promotion, and Performance Management. We also have intentionally incorporated DEI principles into our Novavax Leadership Model. We believe our multi-year DEI strategy and roadmap will enable us to continuously improve and excel.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Social, and Governance</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the DEI and human capital initiatives described above, we have several other Environmental, Social, and Governance (&#8220;ESG&#8221;) related initiatives that are underway. These initiatives are centered around four focus areas including environmental sustainability, innovating for vaccine access and improving global health, empowering our employees, and governing responsibility. We believe that our multi-stakeholder approach through these focus areas is critical to our long-term success and enhances value for our shareholders Examples of initiatives supportive of these focus areas include the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Sustainability</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Resource management and greenhouse gas (&#8220;GHG&#8221;) reduction strategy with tracking and reporting GHG emissions</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Procurement approach that incorporates sustainability metrics into vendor evaluation rubrics</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lease of approximately 170,000 square foot property in Gaithersburg, Maryland at 700 Quince Orchard Road that is designed with carbon-conscious initiatives in place such as a net zero parking structure</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conserving water and monitoring energy use across multi-use leased and owned facilities </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Award of WELL certifications at multiple leased facilities</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sustainable saponin sourcing with our partner Desert King, who is the key supplier of the Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">uillaja saponaria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Soapbark) tree found native to central Chile, used to produce our Matrix-M&#8482; adjuvant</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovating for Vaccine Access and Improving Global Health</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">R21 malaria vaccine candidate, developed by the Jenner Institute, University of Oxford, and formulated with our Matrix-M&#8482; adjuvant</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vaccine access through community partnerships such as collaboration with representatives from Hip Hop Public Health, Anthem, and the CDC Foundation to host a discussion entitled &#8220;The Last Mile: Coming Together to Make Vaccines Make a Difference&#8221; at Aspen Ideas: Health</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advocacy efforts to build a bureau of third-party organizations who are registered with the CDC to provide public commentary on behalf on Novavax, including National Health Council, Vaccinate your Families, and National Black Nurses Association</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efforts focused on clinical trial diversity</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Empowering our Employees</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Introduced an employee donation matching program to elevate Novavax&#8217; charitable contributions, collaborated with local community groups (Montgomery Country Community College, Fairfax Country SkillSource Center), and supported local non-profits</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Introduced a program to help build community and establish corporate values, and provide tuition and education reimbursement, access to professional coaching, and Executive Development programming for high-potential employees</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governing Responsibly</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 2021, we hired a Head of Global Quality Assurance and Quality Control to focus on building quality control and functions of global technical quality, clinical quality, control systems, and compliance operations</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Policy to comply with all government and regulatory agency requirements and industry standards with good laboratory practices (&#8220;GLP&#8221;), current good manufacturing practices (&#8220;cGMP&#8221;), and good distribution practices (&#8220;GDP&#8221;)</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hired a Chief Compliance Officer and published &#8220;The NovaCode,&#8221; a robust handbook of written standards and business ethics policies</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global hotline for reporting compliance concerns with established internal investigating protocols</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establishment of a Strategic Compliance Governance Committee to help our partners comply with U.S. regulations </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Company-wide business ethics training, guidance, and raw materials review</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Standard operating procedures drafted to guide decision-making </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Robust cybersecurity standards, meeting elevated government contracting requirements</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hired a Chief Safety Officer to build out a robust epidemiology benefit / risk group to better understand safety profiles of different vaccines</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ongoing employee training for updated Safety Policy and Standards</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1624"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Availability of Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.novavax.com. We make available, free of charge and through our website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and our other filings with the SEC, and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after filed with or furnished to the SEC. The SEC maintains an Internet site that contains reports, proxy, and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our website (www.novavax.com) as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures are included on our website (www.novavax.com) in the &#8220;Investors&#8221; or &#8220;News&#8221; sections. Accordingly, investors should monitor these portions of our website (www.novavax.com), in addition to following our press releases, SEC filings, and public conference calls and webcasts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also available on our website is information relating to corporate governance at Novavax and our Board of Directors, including our Code of Conduct. We intend to disclose on our website any future amendments to and waivers from this code that apply to our Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer and Controller, and persons performing similar functions, as promptly as practicable, as may be required under applicable SEC and Nasdaq rules.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We webcast our earnings calls and certain events we participate in or host with members of the investment community on the investor relations section of our website. Additionally, we provide notifications of news or announcements regarding press and earnings releases as part of the investor relations section of our website. The contents of our website are not part of this Annual Report on Form 10-K, or any other report we file with, or furnish to, the SEC.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_16"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the following risk factors in evaluating our business. A number of risks could cause our actual results to differ materially from those that are indicated by forward-looking statements. Some risks relate principally to our business and the industry in which we operate. Others relate principally to the securities market and ownership of our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us. Any of the following risks could result in material adverse impacts on our business, financial condition, or results of operations. You also should consider the other information included in this Annual Report on Form 10-K as well as our other filings with the SEC.</span></div><div style="padding-left:5.5pt;padding-right:5.45pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks. The following is a summary of the principal risk factors described in this section:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and our future profitability is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to require significant funding to maintain our current level of operations and fund the further development of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our vaccine product development efforts depend on new and rapidly evolving technologies, our efforts may not succeed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory and commercial success of our COVID-19 vaccine candidate, NVX-CoV2373, remains uncertain. While we have received provisional registration, conditional marketing authorization, or emergency use authorization for NVX-CoV2373 in a number of jurisdictions, we may be unable to obtain full regulatory approvals in the U.S. or other jurisdictions or produce a successful vaccine in a timely manner, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The emergence and transmissibility of variants of the SARS-CoV-2 virus, and the demand for bivalent vaccines, may affect market acceptance or sales of NVX-CoV2373, and our strategy to develop versions of our COVID-19 vaccine to protect against certain variants may not be successful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a biotechnology company and face significant risk in developing, manufacturing, and commercializing our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we depend on third parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are highly dependent on the commercial success of NVX-CoV2373, and even though we have received provisional registration, conditional marketing authorization, or emergency use authorization in certain jurisdictions for NVX-CoV2373, and even if we have products licensed in additional markets, our vaccine products may not be initially or ever profitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic and associated governmental public health policies continue to evolve, which may have unpredictable effects on the prospects for commercial success of NVX-CoV2373.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is significant competition in the development of a vaccine against COVID-19, influenza, and RSV and we may never see returns on the significant resources we are devoting to our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not succeed in obtaining full FDA licensure or foreign regulatory approvals necessary to sell our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products might fail to meet their primary endpoints in clinical trials, meaning that we will not have the clinical data required to support full regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory pathway for NVX-CoV2373 is continually evolving, and may result in unexpected or unforeseen challenges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, are conducting, and plan to conduct in the future, a number of clinical trials for NVX-CoV2373 at sites outside the U.S. and the FDA may not accept data from trials conducted in such locations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The later discovery of previously unknown problems with a product, manufacturer, or facility may result in restrictions, including withdrawal of a vaccine that had previously received regulatory approval in certain jurisdictions from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to maintain the proprietary nature of our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be adversely affected if we do not successfully execute our business development initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Given our current cash position and cash flow forecast, and significant uncertainties related to 2023 revenue, funding from the U.S. government, and our pending arbitration with Gavi, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that the financial statements included in this Annual Report were issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Servicing our 5.00% convertible senior unsecured notes due 2027 requires a significant amount of cash, and we may not have sufficient cash flow resources to pay our debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our stock price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation or regulatory investigations could have a material adverse impact on our results of operation and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or the third parties upon whom we depend may be adversely affected by natural or man-made disasters or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses and our future profitability is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses have exceeded our revenue since our formation in 1987, and our accumulated deficit at December&#160;31, 2022 was $4.3 billion. Our revenue and expenses fluctuate significantly from period to period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For most of our history our expenses have exceeded our revenue, which may occur during most periods in the foreseeable future. Our net losses for the last three fiscal years were $0.7 billion in 2022, $1.7 billion in 2021, and $0.4 billion in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our losses have resulted predominantly from research and development expenses for our vaccine candidates, manufacturing-related expenses, expenses associated with efforts to obtain regulatory approvals, costs related to protection of our intellectual property, and other general and administrative operating expenses, a significant portion of which have been noncash. Our expenses have exceeded our revenue since inception, and we believe our expenses will fluctuate over time, and may substantially increase in some years, as a result of continuing efforts to develop, test, manufacture, and make regulatory filings for our vaccine candidates, and commercialize NVX-CoV2373 and any other product candidates that receive requisite regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of fiscal year 2022, our investment in the development and manufacture of NVX-CoV2373 has been substantial, and we expect such levels of investment to continue for the rest of 2023 and beyond, although the precise magnitude of our total investment will depend on the duration of the COVID-19 pandemic, the competitive landscape, the timing and results of our applications for regulatory approvals, the availability of funding, and whether and what booster shot protocols are recommended by governments, regulatory authorities, and healthcare providers. If we are unable to timely </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize a vaccine against COVID-19 in sufficient jurisdictions, we likely would never recoup our investments. We expect to continue to incur significant operating expenses and anticipate significant losses over time as we seek to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">conduct additional clinical trials and continue to seek regulatory approvals for NVX-CoV2373 and other potential vaccine candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">conduct preclinical studies for other potential vaccine candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expand our global manufacturing and distribution capacity, and commercialize NVX-CoV2373; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">maintain, expand and protect our intellectual property portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we expect our cumulative operating losses to increase until such time, if ever, that product sales, licensing fees, royalties, milestones, contract research and other sources generate sufficient revenue to fully fund our operations. We may never achieve profitability and may not sustain profitability, if achieved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to require significant funding to maintain our current level of operations and fund the further development of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently generate sufficient revenue from product sales, licensing fees, royalties, milestones, contract research or other sources to fully fund our operations. We, therefore, will use our cash resources, and expect to require additional funds, to maintain our operations, continue our research and development programs, advance preclinical studies and clinical trials, seek regulatory approvals and manufacture and market NVX-CoV2373 and any other product candidates that are approved for commercialization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the sale of equity and debt securities, government funding and grant agreements, and supply agreements (also sometimes referred to as advance purchase agreements) for NVX-CoV2373. Although we have entered into supply agreements for NVX-CoV2373 that include prepayments from the purchasers, until we can generate sufficient product revenue from such agreements to fully fund our operations, which we may never do, we expect to finance our cash needs through a combination of additional public or private equity or debt financings, as well as existing cash, potential collaborations, strategic alliances and marketing, distribution or licensing arrangements, funding from governmental and non-governmental funding entities, and potentially other sources. While we may continue to apply for contracts or grants from academic institutions, non-profit organizations and governmental entities, we may not be successful. Adequate additional funding may not be available to us on favorable terms, or at all. Furthermore, negative interpretations of clinical trial data or setbacks, or perceived setbacks, with respect to manufacturing ability and/or capacity or regulatory filing timelines for NVX-CoV2373 or our other vaccine candidates, as well as the competitive landscape posed by other COVID-19 vaccines, may impair our ability to raise additional financing on favorable terms, or at all. Additionally, under certain supply agreements, if we do not timely achieve requisite regulatory milestones for NVX-CoV2373 in the relevant jurisdictions, obtain supportive recommendations from governmental advisory committees, and/or achieve product volume or delivery timing obligations, purchasers may seek to terminate such agreements, reduce their purchase commitments, require us to refund all or some prepayments we have received, or renegotiate such agreements. If we cannot raise the additional funds required for our anticipated operations, we may be required to delay significantly, reduce the scope of or eliminate one or more of our research or development programs, downsize our organization, or seek alternative measures to avoid insolvency, including arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies or vaccine candidates. If we raise additional funds through future offerings of shares of our common stock or other securities, such offerings would cause dilution of current stockholders&#8217; percentage ownership in the Company, which could be substantial. Future offerings also could have a material and adverse effect on the price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Economic and political uncertainty may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, worldwide economic conditions remain uncertain, particularly due to the COVID-19 pandemic, the impact of increased interest rates, and inflation. In addition, our operations and performance may be affected by political or civil unrest or military action, including the ongoing conflict between Russia and Ukraine. Access to capital markets is </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">critical to our ability to operate. Traditionally, biotechnology companies have funded their research and development expenditures by raising capital in the equity markets. Declines and uncertainties in these markets in the past have severely restricted raising new capital and have affected companies&#8217; ability to continue to expand or fund existing development, manufacturing, regulatory and commercialization efforts. We require significant capital for our current and expected operations. The general economic and capital market conditions, both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected our access to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, our future cost of equity or debt capital and access to the capital markets could be adversely affected. In addition, if we are unable to access the capital markets on favorable terms, our ability to execute our business plan as contemplated would be compromised. Moreover, we rely and intend to rely on third parties, including clinical research organizations, contract manufacturing organizations and other important vendors and consultants. Global economic conditions may result in a disruption or delay in the performance of our third-party contractors and suppliers. If such third parties are unable to adequately satisfy their contractual commitments to us in a timely manner, our business could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing funding and supply agreements do not assure success of our vaccine candidates or that we will be able to fully fund our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our funding agreements with the U.S. government (&#8220;USG&#8221;) and CEPI each reimburse a portion of the expenses associated with the development and commercialization of NVX-CoV2373. To the extent funding commitments in such agreements are conditioned on our meeting certain milestones or conditions, we may not ultimately receive the full amount of committed funds and may require additional funding to support our NVX-CoV2373 development and commercialization activities, and we may be unable to timely obtain additional funding. For example, in July 2021, in connection with funding from the USG partnership formerly known as Operation Warp Speed, the USG instructed us to prioritize alignment with the FDA on our analytic methods before conducting additional U.S. manufacturing, and the USG indicated that it would not fund additional U.S. manufacturing until such alignment was reached, which did not occur until June 2022. In February 2023, in connection with the execution of Modification 17 to the USG Agreement, the U.S. government indicated to us that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as we had previously expected, then we may not receive all of the remaining $416&#160;million in funding we had previously anticipated pursuant to the USG Agreement. The USG Agreement also includes provisions giving the USG termination rights based on a determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the USG&#8217;s interest. Such a determination would result in the loss of funding under that agreement and could result in other actions by the USG. The CEPI funding agreement, meanwhile, provides CEPI certain &#8220;march-in&#8221; rights in the event of certain breaches of that agreement. Additionally, we have entered into, and plan to continue entering into, supply agreements (also sometimes referred to as advance purchase agreements) for NVX-CoV2373 that include prepayments from the purchasers to help fund our development and manufacture of the vaccine. Under certain supply agreements, if we do not timely achieve requisite regulatory milestones for NVX-CoV2373 in the relevant jurisdictions, obtain supportive recommendations from governmental advisory committees, and/or achieve product volume or delivery timing obligations, purchasers may seek to terminate such agreements, reduce their purchase commitments, require us to refund all or some prepayments we have received, or renegotiate such agreements, each of which could have a material and adverse effect on our financial condition. In July 2022, following a delay in obtaining regulatory approval in the United Kingdom, for example, we entered into the Amended and Restated UK Supply Agreement, which amended and restated in its entirety the Original UK Supply Agreement, which reduced the volume of vaccine doses that the Authority is committed to purchase as compared to the Original UK Supply Agreement. As of November 30, 2022, the United Kingdom&#8217;s Joint Committee on Vaccination and Immunisation had not yet made a supportive recommendation with respect to NVX-CoV2373, triggering, under the terms of the Amended and Restated UK Supply Agreement, a further reduction of the volume of vaccine doses that the Authority is committed to purchase, as well as an obligation of the Company to repay $112.5 million of an upfront payment previously received from the Authority. Additionally, following our notice to Gavi of termination of the Gavi APA, Gavi responded by providing us with its own purported termination of the Gavi APA, claiming that we are obligated to refund $697.4&#160;million in advance payments previously received from Gavi. On January 31, 2023, Novavax received a Request for Arbitration from Gavi in respect of the dispute. Arbitration is inherently uncertain, and, while we believe that we are entitled to retain the advance payments received from Gavi, it is possible that we could be required to refund all or a portion of the advance payments from Gavi. As a result, our existing funding and supply agreements do not assure success of our vaccine candidates and may be insufficient to fully fund the development and commercialization of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development and Commercialization</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our vaccine product development efforts depend on new and rapidly evolving technologies, our efforts may not succeed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine development efforts depend on new, rapidly evolving technologies and on the marketability and profitability of our products. Our development efforts and, if those are successful, commercialization of NVX-CoV2373 and our other vaccines could fail for a variety of reasons, including if:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our recombinant nanoparticle vaccine technologies, any or all of the products based on such technologies or our proprietary manufacturing process prove ineffective or unsafe; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">new strains of COVID-19 evolve, with respect to which NVX-CoV2373 proves less effective;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our third-party manufacturer facilities fail to reproducibly scale-up and maintain manufacturing with sufficiently high yields at reasonable cost and on projected timelines, or such manufacturing fails to generate product that consistently satisfies purity, potency, quality, stability, and shelf-life standards necessary for obtaining regulatory approvals or achieving commercial viability;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the products are uneconomical to market or manufacture;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">some or all of the products that we or our third-party partners have manufactured may be determined to be unsalable based on criteria imposed by regulators as they complete regulatory approvals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our in-house or third-party manufacturing facilities fail regulatory inspections;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">proprietary rights of third-parties prevent us or our collaborators from exploiting technologies, and manufacturing or marketing products; or</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">third-party competitors achieve and maintain greater market share due to earlier approvals or superior marketing capabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory and commercial success of our COVID-19 vaccine candidate, NVX-CoV2373, remains uncertain. While we have received provisional registration, conditional marketing authorization or emergency use authorization for NVX-CoV2373 in a number of jurisdictions, we may be unable to obtain full regulatory approvals in the U.S. or other jurisdictions or produce a successful vaccine in a timely manner, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the outbreak of COVID-19, we are pursuing the development and manufacture of our vaccine candidate, NVX-CoV2373. Even though we have reported positive data from Phase 1, 2 and 3 clinical trials, and we and our partners have received provisional registration, conditional marketing authorization, or emergency use authorization from the World Health Organization and in the U.S., Canada, Australia, New Zealand, the European Union (&#8220;E.U.&#8221;), the United Kingdom, India, Indonesia, the Philippines, and Singapore, as well as full approval in South Korea, such results may not be sufficient to support regulatory submissions, authorizations and approvals, accelerated or otherwise, in any other relevant jurisdictions on our projected timelines, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, even though NVX-CoV2373 has received regulatory authorizations in certain jurisdictions and may receive further regulatory approval in others, successful commercialization depends on our ability to effectively scale up and maintain manufacturing capabilities at our own locations and those of our manufacturing partners and contractors. In May 2020, we acquired Novavax CZ (formerly Praha Vaccines, a.s.) including its vaccine manufacturing facility in Bohumil, Czech Republic and approximately 150 of its employees but we have yet to produce commercial batches or receive regulatory approval at this site. We also are actively entering into agreements with third parties to manufacture the antigen component of NVX-CoV2373 and our proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjuvant, as well as to distribute NVX-CoV2373. Because of contractual restraints and the limited number of third-party manufacturers with the relevant expertise, required regulatory approvals and facilities to manufacture NVX-CoV2373 and its components at commercial scale, replacement of a </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer may be expensive and time-consuming and may cause interruptions in production. Manufacturing of NVX-CoV2373 and its components involves a complicated process that will require significant investments of time and financial resources to implement, and our efforts to establish and maintain manufacturing capabilities may not meet expectations as to timing, scale-up, reproducibility, yields, purity, cost, potency or quality. Shortages of raw materials and supplies also negatively impact our manufacturing efforts. We may not be able to timely and effectively produce or receive regulatory approvals for NVX-CoV2373 in adequate quantities to address global demand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience with the commercial launch of vaccine products, and doing so in a pandemic environment with an urgent, critical global need creates additional challenges. In addition to scaling up our manufacturing capabilities, we need to develop global distribution channels and form partnerships with third parties worldwide, as well as hire, train and integrate additional management, administrative and sales and marketing personnel. Rapid and significant growth may strain our administrative and operational infrastructure, imposing significant additional responsibilities on our organization, and our efforts to establish and maintain these capabilities may not meet expectations as to timing, scale-up, reproducibility, yields, purity, cost, potency or quality. If we fail to successfully manage our growth and the increased complexity of our operations, our business, financial position, results of operations and prospects may be materially and adversely affected.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The emergence and transmissibility of variants of the SARS-CoV-2 virus, and the demand for bivalent vaccines, may affect market acceptance or sales of NVX-CoV2373, and our strategy to develop versions of our COVID-19 vaccine to protect against certain variants may not be successful.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prototype COVID-19 vaccine, NVX-CoV2373, was a monovalent vaccine developed based upon the genetic sequence of the SARS-CoV-2 virus that was first discovered in December 2019. As the SARS-CoV-2 virus continues to evolve, new strains of the virus, or those that are already in circulation, may prove more transmissible or cause more severe forms of COVID-19 disease than the predominant strains to date. For example, the Omicron and Delta variants have been observed to be more transmissible, or contagious, than previous variants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NVX-CoV2373 may not be as effective in protecting against these or other future variant strains. Additionally, we expect the demand for bivalent vaccines to continue to increase, which may negatively impact the demand, particularly in the U.S., for NVX-CoV2373 and would likely require significant expenditures by the Company to successfully market a bivalent formulation, particularly in the U.S. NVX-CoV2373 may fail to achieve market acceptance or significant sales, despite gaining regulatory approval, provisional registration, conditional marketing authorization or emergency use authorization in a number of jurisdictions, including emergency use authorization the U.S., as demand for variant-specific or bivalent vaccines increases. We have several variant-specific vaccine candidates in development, including for Omicron subvariants, and bivalent formulations with NVX-CoV2373, and may develop others in the future. However, if these efforts are unsuccessful, these candidates do not receive regulatory approvals expeditiously, we are slower to develop variant-specific or bivalent vaccines than competitors, these vaccine candidates prove less effective than competitors&#8217; vaccines, or we are unable to successfully manufacture, distribute or market such vaccine candidates once approved, these shortcomings may lead to reputational harm, loss of market share, and adverse financial results.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 revenue depends on our ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. We experienced delays in early 2023 in manufacturing our BA.5 clinical trial materials, which has the potential to delay regulatory approval from the FDA for our vaccine candidate for the fall 2023 COVID vaccine season. In addition, in January 2023, the U.S. Vaccines and Related Biologics Products Advisory Committee (&#8220;VRBPAC&#8221;) announced its intent to provide the industry with its strain protocol guidance in the second quarter of 2023 for the fall 2023 COVID vaccine season. To meet potential demand for fall 2023, we intend to begin manufacturing an updated COVID-19 variant strain-containing formulation prior to the availability of strain protocol guidance. If we begin manufacturing a formulation that is not consistent with the strain protocol guidance, we will not be able to deliver the appropriate vaccine to our customers in sufficient quantities for the fall 2023 COVID vaccine season and we will have incurred significant costs for a formulation that we will be unable to sell.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, counterparties to certain of our existing supply agreements may request variant-specific vaccines in place of NVX-CoV2373 and, depending on when we are able to offer variant-specific vaccines, if at all, such counterparties may seek to delay, reduce or otherwise renegotiate their purchase commitments, which may adversely impact our ability to realize the full financial benefit of such supply agreements. In addition, we may expend significant resources adapting NVX-CoV2373 </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or conducting clinical trials to protect against variants of the SARS-CoV-2 virus, but a market for this adapted vaccine may not develop and demand may not align with our projections or cost expenditures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our research and development activities on vaccines, an area in which we believe we have particular strengths and a technology that appears promising. The outcome of any research and development program is highly uncertain. Only a small fraction of biopharmaceutical development programs ultimately result in commercial products or even product candidates and a number of events could delay our development efforts and negatively impact our ability to make regulatory submissions or obtain regulatory approval for, and to manufacture, market and sell, NVX-CoV2373 or any other vaccine on our projected timelines, if at all. Vaccine candidates that initially appear promising often fail to yield successful products, and we may not ultimately be able to demonstrate the safety, potency, purity, stability and efficacy necessary to obtain or maintain regulatory authorization to market our product candidates. In many cases, preclinical studies or clinical trials will show that a product candidate is not efficacious or that it raises safety concerns or has other side effects that outweigh its intended benefit. Success in preclinical or early clinical trials may not translate into success in large-scale clinical trials. Further, success in clinical trials often leads to increased investment, accelerating cumulative losses. Even if clinical trial results appear positive, regulatory approval may not be obtained if the FDA, or a foreign equivalent, does not agree with our interpretation of the results, and we may face challenges when scaling-up the production process to commercial levels. Even after a product is approved and launched, general usage or post-marketing clinical trials may identify safety or other previously unknown problems with the product, or manufacturing issues may emerge, either of which may result in regulatory approvals being suspended, limited to narrow the scope of the approval, or revoked, which may otherwise prevent successful commercialization. Intense competition in the vaccine industry could also limit the successful commercialization of any products for which we receive commercial approval.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require approval from the FDA of any name we intend to use for our products regardless of whether we have secured a trademark registration from the USPTO. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. The FDA may object to any product name we submit if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product names, we may be required to adopt an alternative name for our proposed products. If we adopt an alternative name, we would lose the benefit of any existing trademark applications for such developmental candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our products, if approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we depend on third parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on third-party organizations to conduct some of our laboratory testing and clinical trials and a significant amount of our vaccine manufacturing activities and distribution. If we are unable to obtain any necessary services on acceptable terms, we may not complete our product development or commercialization efforts in a timely manner. We may lose control over these activities or become too dependent upon these parties. These third parties may not complete testing, manufacturing or distribution activities on schedule, or in satisfaction of regulatory or commercial requirements. In particular, we currently depend exclusively on SIIPL and SLS for co-formulation, filling, and finishing NVX-CoV2373. If SLS is unable to provide sufficient co-formulation, fill, and finish services to us, fails to meet regulatory requirements, or otherwise defaults on its obligations to us, we may not be able to obtain alternative co-formulation, fill, and finish services from other providers on acceptable terms in a timely manner or at all, which could prevent or delay delivery of customer orders, or otherwise negatively affect our business. Certain of our facilities are also contracted for defined time frames and through association with USG and CEPI, and we may not be able to access those facilities for sufficient periods of time to provide adequate supply. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for confirming that each of our clinical trials is conducted in accordance with its general investigational plan and protocol. Moreover, the FDA and foreign regulatory agencies require us to comply with regulations and standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, safety and welfare of clinical trial </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participants are adequately protected. The FDA and foreign regulatory agencies also require us to comply with good manufacturing practices. Our reliance on third parties does not relieve us of these responsibilities and requirements. These third parties may not successfully carry out their contractual duties or regulatory obligations. Furthermore, if a third-party manufacturer is producing materials or products for themselves or other companies, that manufacturer is exposed to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of the third-party manufacturer&#8217;s facility, which could impact its ability to produce our materials and products. Any of our third-party service providers may need to be replaced, the quality or accuracy of the data they obtain may be compromised, the services provided to us may be delayed, or the product they manufacture may be contaminated and unusable due to the failure to adhere to our clinical and manufacturing protocols, regulatory requirements or for other reasons. In any such event, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval of, or successfully commercially manufacture on a timely basis, our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results from the Prepare trial, including that ResVax failed to meet the primary endpoint of the trial, will likely create challenges, some of which may be significant, around further development of that vaccine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Prepare results suggest that ResVax, the project name for the RSV vaccine candidate, is safe and is likely efficacious in more serious manifestations of RSV disease, the trial failed to achieve its primary clinical endpoint. Not achieving the primary clinical endpoint has been viewed negatively by our investors. Although the failure to achieve the primary endpoint in the trial is not evidence that the vaccine is ineffective, it means that regulatory agencies like the FDA and European Medicines Agency (&#8220;EMA&#8221;) are likely to require additional clinical trial data prior to licensure. This development may be viewed negatively by our potential collaborators and partners, which may make future development of ResVax, and our other RSV F Vaccine candidates, more challenging.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have product liability exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The administration of drugs or vaccines to humans, whether in clinical trials or after marketing approval, can result in product liability claims. We maintain product liability insurance coverage for our current clinical programs, including our NVX-CoV2373 trials, and for commercialization of NVX-CoV2373. However, we may not be able to obtain additional insurance coverage or maintain insurance coverage on commercially reasonable terms, at a reasonable cost or in sufficient amounts to protect us against losses due to liability. Furthermore, such insurance coverage and our resources may not be sufficient to satisfy all liabilities that result from product liability claims. A successful claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable terms, if at all. Even if a claim is not successful, defending such a claim would be time- consuming and expensive, may damage our reputation in the marketplace and would likely divert management&#8217;s attention.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are developing NVX-CoV2373 in response to the outbreak of COVID-19, a global pandemic, we have received provisional registration, conditional marketing authorization or emergency use authorization from the World Health Organization and in the U.S., Canada, Australia, New Zealand, the E.U., the United Kingdom, India, Indonesia, the Philippines, and Singapore, as well as full authorization in South Korea, and we have a widely used vaccine as an investigational vaccine or a product authorized for temporary or emergency use prior to our receipt of marketing approval in other jurisdictions as well. Unexpected safety issues in these circumstances could lead to product liability claims and our existing insurance may not be adequate for such claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">decreased demand for our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of regulatory authorizations and approvals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">voluntary or mandatory recalls of our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">necessity for additional nonclinical or clinical studies, changes in labeling, or changes to manufacturing processes, specifications and/or facilities;</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">impairment of our business reputation and negative media attention;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of clinical trial participants;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs of related litigation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">substantial monetary awards to participants or other claimants;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">loss of revenue; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to commercialize our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the PREP Act, when applicable, provides immunity for manufacturers from all claims under state or federal law for &#8220;loss&#8221; arising out of the administration or use of a &#8220;covered countermeasure.&#8221; However, injured persons may still bring a suit for &#8220;willful misconduct&#8221; against the manufacturer under some circumstances. &#8220;Covered countermeasures&#8221; include security countermeasures and &#8220;qualified pandemic or epidemic products&#8221;, including products intended to diagnose or treat pandemic or epidemic disease, such as pandemic vaccines, as well as treatments intended to address conditions caused by such products. For these immunities to apply, the Secretary of DHHS must invoke the PREP Act by issuing a declaration that a public health emergency or &#8220;credible risk&#8221; of a future public health emergency exists. Such a PREP Act declaration is separate from other declarations such as a PHE or EUA declaration and, among other things, defines the scope and duration of the PREP Act immunities. On March 17, 2020, the Secretary of DHHS issued a declaration under the PREP Act and has issued subsequent amendments thereto to provide liability immunity for activities related to certain countermeasures against the ongoing COVID-19 pandemic. The current declaration will end on October 1, 2024, unless it is renewed. While we believe our products are covered under the current PREP Act declaration, this cannot be assured. Also, the Secretary of the HHS may not make other declarations in the future that cover any of our other product candidates, and the U.S. Congress may reduce coverage under the PREP Act or repeal it altogether. Product liability lawsuits may result in substantial liabilities and may require us to limit commercialization of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to effectively manufacture our vaccines in sufficient quantities, at sufficient yields or are unable to obtain regulatory approvals for a manufacturing facility for our vaccines, we may experience delays or an adverse impact on product development, clinical trials, regulatory approvals and commercial distribution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to pursue the manufacture, distribution and clinical testing of NVX-CoV2373, which is currently our only commercial product and source of product revenues. Completion of our clinical trials and commercialization of NVX-CoV2373 and our other vaccine candidates requires access to, or development of, facilities to effectively manufacture NVX-CoV2373 and our other vaccine candidates at sufficient yields and at commercial-scale. We have limited experience manufacturing any of our vaccine candidates in the volumes necessary to support commercial sales. While we have increased our global manufacturing capacity for NVX-CoV2373, our efforts to establish and maintain manufacturing capabilities may not meet expectations as to timing, scale-up, reproducibility, yields, purity, cost, potency or quality. For example, we experienced delays in early 2023 in manufacturing our BA.5 clinical trial materials, which has the potential to delay regulatory approval from the FDA for our vaccine candidate for the fall 2023 COVID vaccine season. We are highly dependent on third-party organizations to conduct a significant amount of our vaccine manufacturing activities. We do not have sufficient internal manufacturing infrastructure to support global commercialization of NVX-CoV2373 and we have entered into third-party agreements for the components, as well as for commercial fill-finish manufacturing, for NVX-CoV2373. The antigen component of NVX-CoV2373 is currently being manufactured at Novavax CZ, as well as partnered manufacturing sites, including SIIPL in India and SK bioscience in Korea, and the Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant component of NVX-CoV2373 is currently being manufactured at Novavax AB, as well as other partnered manufacturing sites, including AGC Biologics in Europe. Challenges in manufacturing either the antigen component or the adjuvant, or issues in later manufacturing stages, could compromise production of NVX-CoV2373. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we currently depend exclusively on SIIPL and SLS for co-formulation, filling, and finishing NVX-CoV2373 and the loss of this supplier could prevent or delay the delivery of customer orders.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to ensure adequate inventory supply and manage our operations, we forecast anticipated manufacturing requirements and customer demand to predict inventory needs and place orders with our third-party </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers based on such predictions. Our ability to accurately forecast demand for NVX-CoV2373 could be negatively affected by many factors, including challenges in managing our commercial strategy, unanticipated changes in general market conditions or regulatory matters, and market demand for variant-specific COVID-19 vaccines, among others. If we underestimate our third-party manufacturing requirements, we may not be able to timely meet obligations under our customer supply agreements. Conversely, if we overestimate our third-party manufacturing requirements, we may end up with inventory levels in excess of customer demand that result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs, or we may need to cancel previously forecasted batches of product from our third-party manufacturers, which may result in material cancellation fees. In September 2022, for example, we entered into a Confidential Settlement Agreement and Release with FUJIFILM under which we are responsible for up to $185 million to FUJIFILM in connection with the termination of manufacturing activity. Additionally, in December 2022, we agreed to approximately $95 million in fees owed to AGC Biologics in connection with the cancellation of batches in 2022. If we are unable to accurately forecast demand for NVX-CoV2373 and the required services from third-party manufacturers, our results of operations could be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing NVX-CoV2373 and our other vaccine candidates involves a complicated process with which we have limited experience. If we and our third-party manufacturers are unable to manufacture NVX-CoV2373 and our other vaccine candidates in clinical quantities or, if and when necessary, in commercial quantities and at sufficient yields and at required specifications, then clinical trials and commercialization will be delayed, and we will need to identify and reach supply arrangements with additional third parties. Third-party manufacturers also must receive FDA or equivalent foreign regulatory body approval before they can produce clinical material or commercial product which could cause delays and alter our production schedule. Our vaccines are in competition with other products for access to these third-party facilities and may be subject to delays in manufacture if third parties prioritize other products. We may not be able to enter into any necessary additional third-party manufacturing arrangements on acceptable terms, or on a timely basis. In addition, we have to enter into technical transfer agreements and share our know-how with the third-party manufacturers, which can be time-consuming and may result in delays.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of contractual restraints and the limited number of third-party manufacturers with the expertise, required regulatory approvals and facilities to manufacture bulk vaccines at commercial-scale, replacement of a manufacturer may be expensive and time-consuming and may cause interruptions in the production of our vaccine and negatively impact our ability to timely meet obligations under our customer supply agreements. We and our third-party manufacturers may also encounter production challenges related to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs, scale up, and yields;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shortages of raw materials and supplies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shipment delays or other supply chain disruptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">quality control and assurance;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">contamination, lot consistency, potency, and purity;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shortages of qualified personnel and other capacity constraints;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with strictly enforced and evolving federal, state and foreign regulations that vary in each country where products might be sold including nationalization or other territory restrictions placed on our owned and third-party manufacturing sites; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">capital funding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays or interruptions could have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must identify vaccines for development with our technologies and establish successful third-party relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The near and long-term viability of our vaccine candidates depend in part on our ability to successfully establish new strategic collaborations with pharmaceutical and biotechnology companies, non-profit organizations and government agencies. Establishing strategic collaborations and obtaining government funding is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property position or based on their internal pipelines; government agencies may reject contract or grant applications based on their assessment of public need, the public interest, our products&#8217; ability to address these areas, or other reasons beyond our expectations or control. Collaborators also may seek to modify or terminate relationships.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past success in establishing strategic collaborations with pharmaceutical and biotechnology companies, non-profit organizations and government agencies in the past is no guarantee of future success in entering into new relationships or in performing under existing relationships. If we fail to establish a sufficient number of collaborations or government relationships on acceptable terms, or fail to perform under collaborations or relationships to the satisfaction of counter-parties, we may not be able to commercialize our vaccine candidates or generate sufficient revenue to fund further research and development efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaborations we have established or may establish may not result in the successful development or commercialization of any vaccine candidates for several reasons, including the fact that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not have the ability to control the activities of our partners and cannot provide assurance that they will fulfill their obligations to us, including with respect to the license, development and commercialization of vaccine candidates, in a timely manner or at all;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">such partners may not devote sufficient resources to our vaccine candidates or properly maintain or defend our intellectual property rights;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners could independently develop, or develop with third parties, products that compete directly or indirectly with our vaccine candidates if such partners believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any failure on the part of our partners to perform or satisfy their obligations to us could lead to delays in the development or commercialization of our vaccine candidates and affect our ability to realize product revenue; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disagreements, including disputes over the ownership of technology developed with such collaborators, could result in litigation, which would be time consuming and expensive, and may delay or terminate research and development efforts, regulatory approvals and commercialization activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators fail to maintain our existing agreements or in the event we fail to establish agreements as necessary, we could be required to undertake research, development, manufacturing and commercialization activities solely at our own expense. These activities would significantly increase our capital requirements and, given our lack of sales, marketing and distribution capabilities, significantly delay the commercialization of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the commercial success of NVX-CoV2373, and even though we have received provisional registration, conditional marketing authorization or emergency use authorization in certain jurisdictions for NVX-CoV2373, and even if we have products licensed in additional markets, our vaccine products may not be initially or ever profitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the commercial success of NVX-CoV2373, which is currently our only commercial product and source of product revenues. Whether we make a profit from the sale of our vaccine products is dependent on a number of variables, including the costs we incur manufacturing, testing and releasing, packaging and shipping such vaccine product. Additionally, the CEPI funding agreement necessitates that we allocate a certain number of doses of NVX-CoV2373 to certain middle and lower income countries, and the Grant Agreement with the Bill and Melinda Gates Foundation necessitates that we commit to a specific amount of sales in certain specified middle and lower income countries, which may </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact negatively our ability to generate profit. We cannot predict when, if at all, our approved vaccine products will be profitable to the Company, and, ultimately, we may never generate sufficient revenues from our products to reach or maintain profitability or sustain our anticipated levels of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we successfully commercialize any of our vaccine candidates, either alone or in collaboration, we face uncertainty with respect to pricing, third-party reimbursement and healthcare reform, all of which could be subject to change and could adversely affect any commercial success of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to collect revenue from the commercial sale of our vaccines may depend on our ability, and that of any current or potential future collaboration partners or customers, to obtain and if obtained, maintain adequate levels of approval, coverage and reimbursement for such products from third-party payers such as:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">government health administration authorities such as the Advisory Committee for Immunization Practices of the Centers for Disease Control and Prevention;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">private health insurers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">managed care organizations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">pharmacy benefit management companies; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">other healthcare related organizations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the prices charged for medical products and may deny coverage or offer inadequate levels of reimbursement if they determine that a prescribed product has not received appropriate clearances from the FDA, or foreign equivalent, or other government regulators; is not used in accordance with cost-effective treatment methods as determined by the third-party payer; or is experimental, unnecessary or inappropriate. Prices could also be driven down by managed care organizations that control or significantly influence utilization of healthcare products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals and initiatives to change the health care system in ways that could affect our ability to sell vaccines and could adversely affect the prices that we receive for our vaccine candidates, if approved. Some of these proposed and implemented reforms could result in reduced pharmaceutical pricing or reimbursement rates for medical products, and while we have no current vaccines available for commercial sale other than subject to provisional registration, conditional marketing authorization or emergency use authorization in certain foreign jurisdictions, the impact of such reform could nevertheless adversely affect our business strategy, operations and financial results. For example, the Affordable Care Act (&#8220;ACA&#8221;) contained several cost containment measures that could adversely affect our future revenue, including, for example, increased drug rebates under Medicaid for brand name prescription drugs, extension of Medicaid rebates to Medicaid managed care organizations, and extension of so-called 340B discounted pricing on pharmaceuticals sold to certain healthcare providers. Additional provisions of the healthcare reform laws that may negatively affect our future revenue and prospects for profitability include the assessment of an annual fee based on our proportionate share of sales of brand name prescription drugs to certain government programs, including Medicare and Medicaid. The ACA also established a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable branded on drugs (including vaccines) to eligible beneficiaries during their coverage gap period (the so-called &#8220;donut hole&#8221;), as condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Other aspects of healthcare reform, such as expanded government enforcement authority and heightened standards that could increase compliance-related costs, could also affect our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we face uncertainties because of occasional political, legislative, and administrative efforts to substantially modify or invalidate some or all of the provisions of the ACA. For example, in 2017, the Trump administration withheld the cost-sharing subsidies paid to ACA health insurance exchange plans serving low-income enrollees. The Tax Cut and Jobs Act (&#8220;TCJA&#8221;) was also enacted at the end of 2017 and included provisions that affected healthcare insurance coverage and payment, such as the elimination of the tax penalty for individuals who do not maintain sufficient health insurance coverage beginning in 2019 (the so-called &#8220;individual mandate&#8221;). </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the American Rescue Plan Act of 2021, the Biden Administration increased subsidies for coverage purchased through ACA health insurance exchanges and extended eligibility for subsidies to higher income levels. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the case, and oral arguments were heard on November 10, 2020. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Separately, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On April 5, 2022, the Biden administration issued an Executive Order directing agencies &#8220;with responsibilities related to Americans&#8217; access to health coverage&#8221; to &#8220;review agency actions to identify ways to continue to expand the availability of affordable health coverage.&#8221; It is also unclear how these and other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA, will impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and, due to subsequent legislative amendments, will stay in effect through 2030 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our products and, accordingly, the results of our financial operations. Additionally, the pharmaceutical industry has also been the subject of significant publicity in recent years regarding the pricing of pharmaceutical products, including publicity and pressure resulting from prices charged by pharmaceutical companies for new products as well as price increases by pharmaceutical companies on older products that some people have deemed excessive. As a result, pharmaceutical product prices have been the focus of increased scrutiny by the USG, including certain state attorneys general, members of congress, presidential candidates and the United States Department of Justice. If reforms in the health care industry make reimbursement for our potential products less likely, the market for our potential products will be reduced, and we could lose potential sources of revenue. The existence or threat of cost control measures could cause our corporate collaborators to be less willing or able to pursue research and development programs related to our vaccine candidates. Further, it is also possible that additional governmental action is taken in response to the COVID-19 pandemic. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive regulatory approvals for our vaccine candidates, including NVX-CoV2373, coverage and reimbursement may be subject to unique and changing regulatory policies. For example, under the ACA preventive care mandate, non-grandfathered group health plans and health insurance coverage offered in the individual or group market typically have at least one year before they must provide first-dollar coverage for a newly issued preventive care requirement or guideline. However, pursuant to the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;), non-grandfathered group health plans and health insurance coverage offered in the individual or group market must cover any qualifying coronavirus preventive service 15 business days after the United States Preventive Services Task Force, or Advisory Committee on Immunization Practices (&#8220;ACIP&#8221;) designates such service as preventive. Further, third-party reimbursement for providers administering COVID-19 vaccines may affect market acceptance of NVX-CoV2373, if we receive regulatory approval. Currently, the CARES Act and its implementing regulations state that (i) providers that participate in the U.S. Centers for Disease Control and Prevention&#8217;s COVID-19 Vaccination Program must administer a COVID-19 immunization regardless of an individual&#8217;s ability to pay or health insurance coverage status, (ii) providers may not seek any reimbursement, including through balance billing, from an immunization recipient, (iii) coverage is required, without cost-sharing, for the administration of the immunization even if a third party, such as the federal government, pays for the cost of the immunization, and (iv) for the duration of the COVID-19 public health emergency (the &#8220;PHE&#8221;), private health insurance plans must cover COVID-19 immunizations and their administration even when provided by out-of-network </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers. Even if we receive regulatory approvals for NVX-CoV2373, there is no guarantee that all payors will provide coverage and reimbursement for our product after the termination of the PHE, planned for May 11, 2023, nor can we guarantee that even if coverage is provided, the reimbursement amount will be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. We cannot predict continued prevalence of COVID-19, whether herd immunity will be achieved (which would affect the need for future administration of COVID-19 vaccines), or whether NVX-CoV2373 will be effective against continuing mutations or variants of the SARS-CoV-2 virus.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the COVID-19 pandemic, the U.S. federal government has been the predominant purchaser of COVID-19 vaccines, making it possible for population-wide access to vaccinations. This population-wide access may change as the pandemic moves past the crisis phase, the PHE expires, and the market transitions to a third&#8208;party reimbursement model. This transition to a more traditional third&#8208;party reimbursement model is not tied to the ending of the PHE and in part reflects the fact that the U.S. federal government has not received additional funds from Congress to continue to purchase more vaccines. As federal funding declines for COVID-19 vaccines, the USG will most likely transition to standard commercial purchasing through different health care system channels, including commercial insurers and pharmacy benefit managers, and consequently shift the cost of COVID-19 vaccines to insurers and patients (in the form of premiums and out-of-network costs). With respect to the government health care programs and commercial insurance, there may no longer be blanket coverage of COVID-19 vaccines without, in certain instances, accompanying conditions of reimbursement, such as the institution of prior authorization protocols. Medicare (including traditional Medicare and Medicare Advantage) will continue to pay for vaccinations in full; starting January 1, 2023, all Medicare Part D plans are required to cover all adult vaccines recommended by the ACIP, with no cost-sharing, even if the beneficiary is in the deductible phase of the benefit. Provisions in the ARPA and IRA require Medicaid (specifically, with respect to enrollees who receive coverage under traditional Medicaid and all Medicaid medically needy enrollees in specified states) and CHIP programs to cover all ACIP&#8208;recommended vaccines, including COVID&#8208;19 vaccines/boosters with no cost sharing even when the emergency declarations expire and there is no longer any supply of federally purchased vaccines. Under the ACA, people enrolled in non&#8208;grandfathered plans (i.e., the vast majority of people with private insurance) will continue to pay nothing for</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACIP&#8208;recommended COVID&#8208;19 vaccines and associated appointments, so long as the enrollee receives this care from an in&#8208;network provider. Even if consumers are guaranteed free access or protected against some costs, they could face access challenges to our product if sufficient amounts of our product are not available compared to that of our competitors or not procured by pharmacies or other providers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited marketing capabilities, and if we are unable to enter into collaborations with marketing partners or develop our own sales and marketing capability, we may not be successful in commercializing any approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have initiated commercialization of NVX-CoV2373, we currently have limited dedicated sales, marketing or distribution capabilities. As a result, we depend on collaborations with third parties that have established distribution systems and sales forces, including our collaboration with SIIPL, among others. To the extent that we enter into co-promotion or other licensing arrangements, our revenue will depend upon the efforts of third parties, over which we may have little or no control. If we are unable to reach and maintain agreements with one or more pharmaceutical companies or collaborators, we may be required to market our products directly. Developing a marketing and sales force is expensive and time-consuming and could delay a product launch. We may not be able to attract and retain qualified sales personnel or otherwise develop this capability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our vaccine candidates may never achieve market acceptance even if we obtain full regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive full regulatory approvals for the commercial sale of our vaccine candidates, the commercial success of these vaccine candidates will depend on, among other things, their acceptance by physicians, patients and third-party payers, such as health insurance companies and other members of the medical community, as a vaccine and cost-effective alternative to competing products. If our vaccine candidates fail to gain market acceptance, we may be unable to earn sufficient revenue to continue our business. Market acceptance of, and demand for, any product that we may develop and commercialize will depend on many factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to provide acceptable evidence of safety and efficacy (including against emerging COVID-19 variants);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the prevalence and severity of adverse side effects;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">whether our vaccines are differentiated from other vaccines;</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">availability, relative cost and relative efficacy of alternative and competing treatments;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effectiveness of our marketing and distribution strategy;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">publicity concerning our products or competing products and treatments; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain sufficient third party insurance coverage or reimbursement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our vaccine candidates do not become widely accepted by physicians, patients, third-party payers and other members of the medical community as well as the relevant public health authorities responsible for scheduling immunizations, our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to secure sufficient supplies of a key component of our adjuvant technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because an important component of our adjuvant technology is extracted from a species of soap-bark tree (Quillaja saponaria) grown in Chile, we need long term access to quillaja extract with a consistent and sufficiently high quality. We need a secure supply of raw material, as well as back-up suppliers, or our adjuvant products may be delayed and we may not be able to meet our obligations under our various collaboration and supply agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current or future regional relationships may hinder our ability to engage in larger transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into regional collaborations to develop, manufacture and distribute our vaccine candidates in certain parts of the world, and we anticipate entering into additional regional collaborations. Our relationships with SIIPL, Takeda, and SK bioscience are examples of these regional relationships. These relationships often involve the licensing of our technology to our partner or entering into a distribution agreement, frequently on an exclusive basis. Generally, exclusive agreements are restricted to certain territories. Because we have entered into exclusive license and distribution agreements, larger companies may not be interested, or able, to enter into collaborations with us on a worldwide-scale. Also, these regional relationships may make us an unattractive target for an acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are sensitive to shipping and storage conditions, which could subject our vaccine candidates to risk of loss or damage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates are sensitive to storage and handling conditions. Loss in vaccine candidates could occur if the product or product intermediates are not stored or handled properly. It is possible that our vaccine candidates could be lost due to expiration prior to use. If we do not effectively maintain our supply logistics, then we may experience an unusual number of returned or out of date products. Failure to effectively maintain our supply logistics, by us or third parties, could lead to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or otherwise.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our vaccine candidates could become subject to a product recall which could harm our reputation, business, and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar foreign governmental authorities have the authority to require the recall of certain vaccine candidates. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us or our strategic collaborators could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our vaccine candidates would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry and Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to intense competition and rapid and significant technological change. We have many potential competitors, including major pharmaceutical companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. Many of our competitors have significantly greater financial and technical resources, experience and expertise in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical testing;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">designing and implementing clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory processes and approvals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">production and manufacturing; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales and marketing of approved products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal competitive factors in our industry include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the quality and breadth of an organization&#8217;s technology;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">management of the organization and the execution of the organization&#8217;s strategy;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the skill and experience of an organization&#8217;s employees and its ability to recruit and retain skilled and experienced employees;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an organization&#8217;s intellectual property portfolio;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the range of capabilities, from target identification and validation to drug discovery and development to manufacturing and marketing; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of substantial capital resources to fund discovery, development and commercialization activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large and established companies, such as Merck &amp; Co., Inc., GlaxoSmithKline plc, CSL Ltd., Sanofi Pasteur, SA, Pfizer Inc., Johnson &amp; Johnson, AstraZeneca, and Moderna, among others, compete in the vaccine market. In particular, these companies have greater experience and expertise in securing government contracts and grants to support their research and development efforts, conducting testing and clinical trials, obtaining regulatory approvals to market products, manufacturing such products on a broad scale and marketing approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the disease, smaller or early-stage companies and research institutions also may prove to be significant competitors, particularly through collaborative arrangements with large and established pharmaceutical companies. As these companies develop their technologies, they may develop proprietary positions, which may prevent or limit our product development and commercialization efforts. We will also face competition from these parties in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and participant registration for clinical trials and in acquiring and in-licensing technologies and products complementary to our programs or potentially advantageous to our business. If any of our competitors succeed in obtaining approval from the FDA or other regulatory authorities for their products sooner than we do or for products that are more effective or less costly than ours, our commercial opportunity could be significantly reduced.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to effectively compete, we will have to make substantial investments in development, testing, manufacturing and sales and marketing or partner with one or more established companies. We may not be successful in </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gaining significant market share for any vaccine. Our technologies and vaccines also may be rendered obsolete or non-competitive as a result of products introduced by our competitors to the marketplace more rapidly and at a lower cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is significant competition in the development of a vaccine against COVID-19, influenza, and RSV and we may never see returns on the significant resources we are devoting to our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine has moved rapidly through the regulatory review and authorization processes in the U.S. and other jurisdictions. The speed at which COVID-19 vaccines and therapeutics are being created and tested is atypical, and evolving or changing plans or priorities within the FDA or other regulatory authorities, including changes based on new knowledge of COVID-19 and how the disease, and new variants of the virus, affect the human body, may significantly affect our ability to establish a competitive market share for our COVID-19 vaccine. A large number of vaccine manufacturers, academic institutions and other organizations have developed COVID-19 vaccines or are developing COVID-19 vaccine candidates. In particular, Moderna, and Pfizer/BioNTech have received full regulatory approvals for their COVID-19 vaccines and, along with Johnson &amp; Johnson have received emergency use authorizations for their COVID-19 vaccines in the U.S. and other countries. Many other companies, including AstraZeneca, Sinovac Biotech, and Sinopharm are in various stages of developing and obtaining marketing authorization for COVID-19 vaccine candidates. All of these companies have obtained the relevant Emergency Use Licenses (&#8220;EULs&#8221;) from the World Health Organization for their respective vaccines to be supplied to the countries or international coalition partners, including the relevant United Nations agencies, which rely upon the World Health Organization&#8217;s EULs to support the local immunization programs. Despite funding provided to us to date, many of our competitors pursuing vaccine candidates have significantly greater product candidate development, manufacturing and marketing resources than we do. Larger pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products and may have the resources to heavily invest to accelerate discovery and development of their vaccine candidates. The success of our COVID-19 vaccine will depend, in part, on its relative safety, efficacy (including against emerging variant strains), side effect profile, convenience, and cost. COVID-19 vaccines approved prior to our vaccine satisfy a portion of the demand for initial vaccinations, and we no longer have access to that opportunity. In addition, COVID-19 vaccines approved prior to our vaccine may develop broad market acceptance that we are challenged to overcome. For example, in the U.S., the FDA granted a Biologics License Application (&#8220;BLA&#8221;) in August 2021 to the Pfizer/BioNTech vaccine as a two-dose primary series for the prevention of COVID-19 in individuals 12 years of age and older, and in January 2022 to the Moderna vaccine as a two-dose primary series for the prevention of COVID-19 in individuals 18 years of age and older. The FDA amended the Pfizer-BioNTech emergency use authorization on September 22, 2021, and the Moderna emergency use authorization and Johnson &amp; Johnson emergency use authorization on October 20, 2021, to authorize the use of a single booster dose for certain populations after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine. The FDA then amended both of the Pfizer-BioNTech emergency use authorization and the Moderna emergency use authorization again on November 19, 2021, to authorize the use of such a single booster dose for all patients 18 years and older. The FDA has since amended the Pfizer-BioNTech emergency use authorization to authorize the use of the single booster dose for individuals 5 years and older and the Moderna emergency use authorization to authorize the use of the single booster dose for individuals 6 years and older and for individuals 6 months to 5 years who have received the primary Moderna vaccine series. The FDA has also approved Gilead&#8217;s Veklury (remdesivir) for treatment of COVID-19 in both adult and pediatric populations, as well as Eli Lilly&#8217;s Olumiant (baricitinib) and Genentech&#8217;s Actemra (tocilizumab) for treatment of COVID-19 in certain hospitalized adults. Furthermore, if any competitors are successful in producing a more efficacious vaccine or other treatment for COVID-19 (including against emerging variant strains), or if any competitors are able to manufacture and distribute any such vaccines or treatments with greater efficiency there may be a diversion of potential governmental and other funding away from us and toward such other parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are allocating significant financial and personnel resources to the development and commercialization of NVX-CoV2373, which may cause delays in or otherwise negatively impact our other development programs. Our business could be negatively impacted by our allocation of significant resources to combating a global health threat that is unpredictable or against which our vaccine may ultimately prove unsuccessful or unprofitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many seasonal influenza vaccines are currently approved and marketed. Competition in the sale of these seasonal influenza vaccines is intense. Therefore, newly developed and approved products must be differentiated from existing vaccines in order to have commercial success. In order to show differentiation in the seasonal influenza market, a product may need to be more efficacious, particularly in older adults, and/or be less expensive or quicker to manufacture. Many competitors are working on new products and new generations of current products, intended to be more efficacious than those currently marketed. Our nanoparticle seasonal influenza vaccine candidate may not prove to be more efficacious than current </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products or products under development by our competitors. Further, our in-house or third-party manufacturing arrangements may not provide enough savings of time or money to provide the required differentiation for commercial success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware that there are multiple companies with active RSV vaccine programs at various stages of development. Thus, while there is no RSV vaccine currently on the market, there is likely to be significant and consistent competition as these active programs mature. Different RSV vaccines may work better for different segments of the population, so it may be difficult for a single RSV vaccine manufacturer to provide vaccines that are marketable to multiple population segments. Geographic markets are also likely to vary significantly, which may make it difficult to market a single RSV vaccine worldwide. Even if a manufacturer brings an RSV vaccine to license, it is likely that competitors will continue to work on new products that could be more efficacious and/or less expensive. Even if our RSV vaccine candidate is developed in the future and receives regulatory approval, it may not achieve significant sales if other, more effective vaccines under development by our competitors are also approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory and Compliance Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not succeed in obtaining full FDA licensure or foreign regulatory approvals necessary to sell our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and marketing of our pharmaceutical and biological products are subject to government regulation by the FDA and regulatory authorities in other jurisdictions, including the EMA, the Czech Republic&#8217;s State Institute for Drug Control (SUKL) with respect to our manufacturing facility in the Czech Republic and the Swedish Medical Products Agency (L&#228;kemedelsverket, LV) with respect to our adjuvant product being developed in Sweden, as well as other country authorities into which active pharmaceutical ingredients and excipients are imported and/or manufactured by us or our sub-contracted manufacturers. In the U.S. and most foreign countries, we must complete rigorous preclinical testing and extensive clinical trials that demonstrate the safety and efficacy of a product in order to apply for regulatory approval to market the product. Additionally, we must demonstrate that our manufacturing facilities, processes and controls are adequate with respect to such product to assure safety, purity and potency and comply with applicable good manufacturing practice requirements. None of our vaccine candidates has yet gained full regulatory approval in the U.S., although NVX-CoV2373 has received provisional registration, conditional marketing authorization or emergency use authorization in the U.S., Canada, Australia, New Zealand, the E.U., the United Kingdom, India, Indonesia, the Philippines, and Singapore, and South Korea as well as EUL from the World Health Organization. We also have vaccine candidates in clinical trials and preclinical laboratory or animal studies. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products might fail to meet their primary endpoints in clinical trials, meaning that we will not have the clinical data required to support regulatory approvals.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps generally required by the FDA before our proposed investigational products may be marketed in the U.S. include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of preclinical (animal and laboratory) tests;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submission to the FDA of an IND, which must become effective before clinical trials may commence;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of adequate and well controlled clinical trials to establish the safety and efficacy of the investigational product in the intended target population;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of a consistent and reproducible manufacturing process at commercial scale capable of passing FDA inspection;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submission to the FDA of a BLA or a NDA; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">FDA approval of the BLA or NDA before any commercial sale or shipment of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials that we undertake in other countries will be subject to similar or equivalent processes and requirements, In Europe, as well as an authorization for the trial itself, it is necessary to obtain the consent of a local ethics committee for each trial site and to provide for publication specific information about the trial and its outcome. If endpoints are not met, this information will be made publicly available and could be damaging to the reputation of the Company.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These processes are expensive and can take many years to complete, and we may not be able to demonstrate the safety, purity, potency and efficacy of our vaccine candidates to the satisfaction of regulatory authorities. The start of clinical trials can be delayed or take longer than anticipated for many and varied reasons, many of which are out of our control. Safety concerns may emerge that could lengthen the ongoing clinical trials or require additional clinical trials to be conducted. Promising results in early clinical trials may not be replicated in subsequent clinical trials. Regulatory authorities may also require additional testing, and we may be required to demonstrate that our proposed products represent an improved form of treatment over existing therapies, which we may be unable to do without conducting further clinical trials. Moreover, if a regulatory authority grants regulatory approval of a product, the approval may be limited to specific indications or limited with respect to its distribution. Expanded or additional indications for approved products may not be approved, which could limit our revenue. Foreign regulatory authorities may apply similar limitations or may refuse to grant any approval. Consequently, even if we believe that preclinical and clinical data are sufficient to support regulatory approval for our vaccine candidates, the FDA and foreign regulatory authorities ultimately may not grant approval for commercial sale in their applicable jurisdiction, or may impose regulatory requirements that make further pursuit of approval uneconomical in one or more jurisdictions. If our vaccine candidates are not approved, our ability to generate revenue will be limited, and our business will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to obtain regulatory approval for our products on a timely basis or comply with our continuing regulatory obligations after approval is obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in obtaining regulatory approval can be extremely costly in terms of lost sales opportunities, loss of any potential marketing advantage of being early to market and increased clinical trial costs. For example, certain of our APAs and supply agreements may be terminated by the counterparty if we do not timely achieve requisite regulatory approval for NVX-CoV2373 in the relevant jurisdictions under such agreements. The speed with which we begin and complete the preclinical studies necessary to begin clinical trials, the clinical trials themselves and our applications for marketing approval will depend on several factors, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to scale-up and maintain manufacturing capability that reproducibly generates consistent yields of product with required purity,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potency and quality; that such scale-up occurs on a timely basis; and that we have access to sufficient quantities of materials for use in necessary preclinical studies and clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authority review and approval of proposed clinical trial protocols;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">approval of clinical trials protocols and informed consent forms by institutional review boards responsible for overseeing the ethical conduct of the trial;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the rate of participant enrollment and retention, which is a function of many factors, including the size of the participant population, the proximity of participants to clinical sites, the eligibility criteria for the clinical trial and the nature of the protocol;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">unfavorable test results or side effects experienced by clinical trial participants;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">analysis of data obtained from preclinical and clinical activities, which are susceptible to varying interpretations and which interpretations could delay, limit, result in the suspension or termination of, or prevent further conduct of clinical studies or regulatory approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of skilled and experienced staff to conduct and monitor clinical trials and to prepare the appropriate regulatory applications; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the policies of regulatory authorities for drug or vaccine approval during the period of product development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have somewhat limited experience in conducting and managing the preclinical studies and clinical trials necessary to obtain regulatory marketing approvals. We may not be permitted to continue or commence additional clinical trials. We also face the risk that the results of our clinical trials may be inconsistent with the results obtained in preclinical studies or clinical trials of similar products or that the results obtained in later phases of clinical trials may be inconsistent with those obtained in earlier phases. A number of companies in the biotechnology and product development industry have suffered significant setbacks in advanced clinical trials, even after experiencing promising results in early animal and human testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory agencies may require us or our collaborators to delay, restrict or discontinue clinical trials on various grounds, including a finding that the participants are being exposed to an unacceptable health risk. In addition, we or our collaborators may be unable to submit applications to regulatory agencies within the time frame we currently expect. Once submitted, applications must be approved by various regulatory agencies before we or our collaborators can commercialize the product described in the application. All statutes and regulations governing the conduct of clinical trials are subject to change in the future, which could affect the cost of such clinical trials. Any unanticipated costs or delays in our clinical trials or regulatory submissions could delay our ability to generate revenue and harm our financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our products internationally.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to have our vaccine candidates marketed outside the U.S. In furtherance of this objective, we have entered into supply agreements with various foreign governments and international distribution agreements with commercial entities. In order to market our products in the European Union, United Kingdom, India, Asia and many other non-U.S. jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing and data review. The time required to obtain foreign regulatory approval may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. Additionally, regulatory authorities outside the U.S. might not accept data from trials conducted in other countries. Although NVX-CoV2373 has received provisional registration, conditional marketing authorization or emergency use authorization in a number of jurisdictions, we may not obtain regulatory approvals in other relevant jurisdictions on a timely basis, if at all. Approval by one regulatory agency does not ensure approval by regulatory agencies in other jurisdictions. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in other jurisdictions, including approval by the FDA. The failure to obtain regulatory approval in foreign jurisdictions could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory pathway for NVX-CoV2373 is continually evolving and may result in unexpected or unforeseen challenges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory pathway for NVX-CoV2373 is evolving and failure by us to comply with any laws, rules and standards, some of which may not exist yet or are subject to interpretation and may be subject to change, could result in a variety of adverse consequences, including penalties, fines and delays in vaccine licensure. Efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention to regulatory compliance activities. For example, the rules, regulations and standards governing the USG Agreement are uncertain and may evolve as the program progresses. Such rules or standards may adversely affect our plans to develop NVX-CoV2373 and failure by us to comply with any laws, rules or standards, some of which may not exist yet or may change, could result in a range of adverse consequences, such as penalties, fines or failure to receive funding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The speed at which multiple stakeholders are moving to create, test and approve vaccines for COVID-19 is highly unusual and may increase the risks associated with traditional vaccine development, which typically takes between eight and ten years. Given this accelerated timeline, we and regulators, such as the FDA, the EMA, and the UK&#8217;s Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) may make decisions more rapidly than is typical. Evolving or changing plans or priorities at the FDA or other regulatory bodies to whom we wish to apply for authorization, including based on new knowledge of COVID-19 and how the disease affects the human body, and new variants of the virus, may significantly affect </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the regulatory pathway for NVX-CoV2373. Results from clinical testing may raise new questions and require us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. In addition, the FDA&#8217;s or other regulatory authorities&#8217; analysis of clinical data may differ from our interpretation, or regulators&#8217; requirements and expectations for vaccine authorization or approval may change over time, with the result that the FDA or other regulators may require that we conduct additional clinical trials or non-clinical studies. The evolving regulatory pathway may impede the development, commercialization and/or licensure of NVX-CoV2373.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because the path to licensure of any vaccine against COVID-19 is unclear, we may have a widely used vaccine in circulation in certain countries as an investigational vaccine or a product authorized for temporary or emergency use prior to our receipt of full marketing approval. Unexpected safety issues in these circumstances could lead to significant reputational damage for Novavax and our technology platform going forward and other issues, including delays in our other programs, the need for re-design of our clinical trials and the need for significant additional financial resources. For example, although we currently operate under an emergency use authorization provided by the FDA for NVX-CoV2373, the FDA may revoke such authorization if it determines that the underlying health emergency no longer exists or warrants such authorization, and we cannot predict how long such authorization will remain in place. Such revocation could adversely impact our business in a variety of ways.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, continue to conduct and plan to conduct in the future, a number of clinical trials for NVX-CoV2373 at sites outside the U.S. and the FDA may not accept data from trials conducted in such locations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and are currently conducting several clinical trials of NVX-CoV2373 at sites outside the U.S., including a Phase 3 trial partially in Mexico, a Phase 3 trial in the U.K., a Phase 2b trial in South Africa, a Phase 1/2 trial partially in Australia, a Phase 2/3 trial in India, and a Phase 1/2 trial in Japan. Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. Other regulatory authorities impose equivalent requirements for their countries. In addition, while these clinical trials are subject to the applicable local laws, where the data is to be used to support our BLA, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the U.S., it could result in delay pending completion of our trials conducted in the U.S. or result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development and commercialization of NVX-CoV2373.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions, including withdrawal of a vaccine that had previously received regulatory approval in certain jurisdictions from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a product gains regulatory approval, the product and the manufacturer of the product will be subject to continuing regulatory review, including adverse event reporting requirements and prohibitions against promoting products for unapproved uses. Failure to comply with any post-approval requirements can, among other things, result in warning letters, product seizures, recalls, substantial fines, injunctions, suspensions or revocations of marketing authorizations or licenses, operating restrictions and criminal prosecutions. Any such enforcement actions, any unanticipated changes in existing regulatory requirements or the adoption of new requirements, or any safety issues that arise with any approved products, could adversely affect our ability to market products and generate revenue and thus adversely affect our ability to continue our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be restricted or prohibited from marketing or manufacturing a product, even after obtaining product approval, if previously unknown problems with the product or its manufacture are subsequently discovered. We cannot provide assurance that newly discovered or developed safety issues will not arise following regulatory approval. With the use of any vaccine by a wide patient population, serious adverse events may occur from time to time that did not arise in the clinical trials of the product or that initially appeared to be unrelated to the vaccine itself and only with the collection of subsequent information were found to be causally related to the product. Any such safety issues could cause us to suspend or cease marketing of our approved products, possibly subject us to substantial liabilities, and adversely affect our ability to generate revenue and our financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to produce a successful vaccine may be curtailed by one or more government actions or interventions, which may be more likely during a global health crisis such as COVID-19.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant global impact of the COVID-19 pandemic, it is possible that one or more government entities may take actions, including under the USG under the Defense Production Act of 1950, as amended, that directly or indirectly have the effect of diminishing some of our rights or opportunities with respect to NVX-CoV2373, and the economic value of a COVID-19 vaccine to us could be limited. In addition, during a global health crisis, such as the COVID-19 pandemic, where the spread of a disease needs to be controlled, closed or heavily regulated national borders create challenges and delays in our development, production and distribution activities and may necessitate that we pursue strategies to develop, produce and distribute our vaccine candidates within self-contained national or international borders or with additional safety measures or checks in place, at potentially much greater expense and with longer timeframes for public distribution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, or otherwise perform their normal functions on which the operation of our business may rely, which could negatively impact our ability to develop or commercialize new products or services, access capital markets, or otherwise operate our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and other regulatory authorities to review and approve new product applications is affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. For example, average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the USG has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough employees and stop or slow the pace of critical activities. Equally, the move of the EMA to the Netherlands from London caused a significant loss of experienced staff and the UK&#8217;s MHRA&#8217;s loss of funding from the E.U. has caused a loss of funding and consequently of staff. If a prolonged government shutdown or slowdown of the relevant regulatory authority occurs, it could significantly impact the ability of that Authority to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track Designation by the FDA, the issue of conditional marketing authorizations by the EMA or MHRA, or other regulatory acceleration options may not actually lead to a faster development or regulatory review or approval process and does not assure approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address an unmet medical need for this condition, the drug sponsor may apply for FDA Fast Track Designation or similar fast track processes with other regulatory agencies. In the EU and the UK, rolling review procedure was relied upon for conditional marketing authorizations to be granted. However, Fast Track Designation or conditional authorizations do not ensure that the drug sponsor will receive marketing approval or that approval will be granted within any particular timeframe. The FDA granted Fast Track Designation for NVX-CoV2373 in November 2020 and for NanoFlu, our recombinant quadrivalent seasonal influenza vaccine candidate, in January 2020. We may also seek Fast Track Designation for more of our other vaccine candidates. If we do seek Fast Track Designation for our other vaccine candidates, we may not receive it, and even if we receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining a Fast Track Designation does not change the standards for product approval, but may expedite the development or approval process. Even though the FDA has granted such designation for NVX-CoV2373 and NanoFlu, it may not actually result in faster clinical development or regulatory review or approval. Furthermore, such a designation does not increase the likelihood that NVX-CoV2373 or NanoFlu will receive marketing approval in the U.S.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are subject to environmental, health and safety laws, we may be unable to conduct our business in the most advantageous manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with our research, including infectious disease agents. We also cannot accurately predict the extent of regulations that might result from any future legislative or administrative action. Any of these laws or regulations could cause us to incur additional expense or restrict our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in Maryland are subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including chemicals, microorganisms and various hazardous compounds used in connection with our research and development activities. In the U.S., these laws include the Occupational Safety and Health Act, the Toxic Test Substances Control Act and the Resource Conservation and Recovery Act. Similar national and local regulations govern our facilities in Sweden and the Czech Republic. We cannot eliminate the risk of accidental contamination or discharge or injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. We could be subject to civil damages in the event of an improper or unauthorized release of, or exposure of individuals to, these hazardous materials. In addition, claimants may sue us for injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development or production efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have general liability insurance, these policies contain exclusions from insurance against claims arising from pollution from chemicals or pollution from conditions arising from our operations. Our collaborators are working with these types of hazardous materials in connection with our collaborations. In the event of a lawsuit or investigation, we could be held responsible for any injury we or our collaborators cause to persons or property by exposure to, or release of, any hazardous materials. However, we believe that we are currently in compliance with all material applicable environmental and occupational health and safety regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For our product candidates, we will be subject to additional healthcare laws and our failure to comply with those laws could have a material adverse effect on our results of operations and financial conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. (and within foreign countries), if we obtain full approval for any of our product candidates and begin commercializing them, our operations may be directly, or indirectly through our arrangements with third-party payors and customers, subject to additional healthcare regulation and enforcement by the federal and state governments (or the regulatory bodies or governments of foreign countries), which may constrain the business or financial arrangements and relationships through which we sell, market and distribute our products. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The applicable U.S. federal and state healthcare laws and regulations (which may be comparable to foreign laws existing in foreign countries) that may affect our ability to operate include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the Federal Food, Drug and Cosmetic Act, which among other things, strictly regulates drug product marketing and promotion and prohibits manufacturers from marketing such products for unapproved uses;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving or providing remuneration, directly or indirectly, to induce the referral for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">federal false claims laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, information or claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims; the FCA also permits a private individual acting as whistleblower to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">the federal Physician Payment Sunshine Act and its implementing regulations, which require manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the DHHS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; similar reporting requirements have also been enacted on the state level in the U.S., and an increasing number of countries worldwide either have adopted or are considering similar laws requiring disclosure of interactions with health care professionals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal law known as HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">state law equivalents of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state gift ban and transparency laws, many of which state laws differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">state laws restricting interactions with healthcare providers and other members of the healthcare community or requiring pharmaceutical manufacturers to implement certain compliance standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to, on a corporate or individual basis, penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and even imprisonment, any of which could materially adversely affect our ability to operate our business and our financial results. In addition, the cost of implementing sufficient systems, controls, and processes to ensure compliance with all of the aforementioned laws could be significant. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of the company&#8217;s business. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights those actions, our business may be impaired. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are also subject to anti-bribery and anti-corruption laws, including the FCPA, the UK Bribery Act, and other similar worldwide anti-bribery laws, as well as various trade laws and regulations (including economic sanctions, export laws, and customs laws), and our failure to comply with those laws could have a material adverse effect on our results of operations and financial conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA and similar worldwide anti-bribery and anti-corruption laws prohibit companies and their intermediaries from corruptly providing any payments or other benefits to foreign government officials for the purpose of obtaining or retaining business. The U.S. Departments of Justice, Securities &amp; Exchange Commission, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of the FCPA, economic sanctions laws, export control laws, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, the U.K. Bribery Act of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public sectors. An organization that fails to prevent bribery by anyone associated with the organization can be charged under the Bribery Act unless the organization can establish the defense of having implemented adequate procedures to prevent bribery.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, U.S. and similar worldwide trade laws, including economic sanctions, export laws, and customs laws, regulate our ability to conduct business with certain jurisdictions and counterparties, and regulate the ways in which we may export and import products around the world. In connection with these laws, various government agencies may require us to obtain export licenses, and may impose modifications to business practices, including requiring the cessation of business activities in or with countries, entities, and individuals targeted with sanctions. The breadth and dynamic nature of these laws and regulations may increase compliance costs, and may subject us to fines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax has received a number of regulatory approvals in ex-U.S. jurisdictions and has commenced commercial operations in these international locations, including partnering with third-parties in certain higher-risk jurisdictions. Further, a portion of our business with respect to our manufacturing is conducted outside of the U.S. in higher-risk jurisdictions. We expect our international activities to increase in the future. Though we maintain policies, internal controls and other measures reasonably designed to promote compliance with applicable anti-corruption and trade laws and regulations, our employees or agents may nevertheless engage in improper conduct for which we might be held responsible. Any violations of these anti-corruption or trade laws, or even allegations of such violations, can lead to an investigation and/or enforcement action, which could disrupt our operations, involve significant management distraction, and lead to significant costs and expenses, including legal fees. If we, or our employees or agents acting on our behalf, are found to have engaged in practices that violate these laws and regulations, we could be subject to criminal and civil enforcement action, suffer severe fines and penalties, profit disgorgement, injunctions on future conduct, securities litigation, bans on transacting government business, delisting from securities exchanges and other consequences that may have a material adverse effect on our business, financial condition and results of operations. In addition, our reputation, our revenue or our stock price could be adversely affected if we become the subject of any negative publicity related to actual or potential violations of anti-corruption or trade laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to maintain the proprietary nature of our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success in large part depends on our ability to maintain the proprietary nature of our technology and other trade secrets. To do so, we must prosecute and maintain existing patents, obtain new patents and pursue trade secret and other intellectual property protection. We also must operate without infringing the proprietary rights of third-parties or allowing third-parties to infringe our rights. We currently have or have rights to over 560 U.S. and foreign patents and patent applications covering our technologies. However, patent issues relating to pharmaceuticals and biologics involve complex legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth of biotechnology patent claims that are granted by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) or enforced by the federal courts. Therefore, we do not know whether any particular patent applications will result in the issuance of patents, or that any patents issued to us will provide us with any competitive advantage. We also cannot be sure that we will develop additional proprietary products that are patentable. Furthermore, there is a risk that others will independently develop or duplicate similar technology or products or circumvent the patents issued to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our patent filings include claims covering various features of our vaccine candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection against the development of competing products. Some of our know-how and technology is not patentable. To protect our proprietary rights in unpatentable intellectual property and trade secrets, we require employees, consultants, advisors and collaborators to enter into confidentiality agreements. These agreements may not provide meaningful protection for our trade secrets, know-how or other proprietary information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain trademark registrations for proposed product names/brands, in the U.S. or abroad, may adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark registration to protect the trademarks for our proposed products will require approval from the USPTO in the U.S. and in trademark offices throughout the world in our key markets. The USPTO or a trademark office in a key international jurisdiction may refuse registration of any of our trademarks on a variety of potential grounds. If registration is not granted to one of our trademarks in the U.S. or in another key international jurisdiction, we may be required to adopt an alternative name for that proposed product. If we adopt an alternative name, we would lose the benefit of any existing trademark applications for such developmental candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA and other regulatory authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may claim we infringe their intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and commercialization activities, including any vaccine candidates resulting from these activities, may be found to infringe patents or trademarks owned by third-parties and to which we do not hold licenses or other rights. There may be rights we are not aware of, including applications that have been filed, but not published that, when issued, could be asserted against us. These third-parties could bring claims against us, and that may cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent or trademark infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of patent or trademark infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non- exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent or trademark infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been substantial litigation and other proceedings regarding patent, trademark, and other intellectual property rights in the pharmaceutical and biotechnology industries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in litigation to defend or enforce our intellectual property or the intellectual property of our collaborators or licensors, which could be expensive and time-consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our collaborators or licensors. As a result, we may be required to file patent infringement suits to prevent unauthorized uses. This can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. An adverse determination of any litigation or defense proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at the risk of not issuing. Competitors may infringe our trademarks or the trademarks of collaborators or licensors. As a result, we may be required to file suit to counter infringement for unauthorized use of an identical or confusingly similar trademark. This can be expensive and time-consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful, litigation may result in substantial costs and distraction to our management. Even with a broad portfolio, we may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The scope, validity, and ownership of our patent claims may be challenged in various venues and, if we do not prevail, our ability to exclude competitors may be harmed, potentially reducing our ability to succeed commercially.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to a variety of challenges from third parties that relate to the scope of the claims or to their validity. Such challenges can be mounted in post-grant review, ex parte re-examination, and inter partes review proceedings before the USPTO, or similar adversarial proceedings in other jurisdictions. If we are unsuccessful in any such challenge, the scope of our claims could be narrowed or could be invalidated. Any such outcome could impair our ability to exclude competitors from the market in those countries, potentially impacting our commercial success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents may be subject to various challenges related to ownership and inventorship, including interference or derivation proceedings. Third parties may assert that they are inventors on our patents or that they are owners of the patents. While we perform inventorship analyses to insure that the correct inventors are listed on our patents, we cannot be certain that a court of competent jurisdiction would arrive at the same conclusions we do. If we are unsuccessful in defending against ownership or inventorship challenges, a court may require us to list additional inventors, may invalidate the patent, or may transfer ownership of the patent to a third party. Any of these outcomes may harm our ability to exclude competitors and potentially impact our commercial success. Further, if ownership is transferred to a third party we may be required to seek a license to those rights to preserve our exclusive ability to practice the invention. Such a license may not be available on commercially reasonable terms, or at all. If we are unable to obtain a license, we may be required to expend time, effort, and other resources to design around the patent. Any such license may be non-exclusive and if a competitor is able to obtain a license from the third party, our ability to exclude that competitor from the market may be negatively impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are ultimately successful, defending any such challenges may cause us to incur substantial expenses and may require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The scope, validity, and ownership of our trademark rights/registrations may be challenged in various venues in the U.S. and abroad and, if we do not prevail, our ability to exclude competitors from using and registering confusingly similar trademarks may be harmed, potentially reducing our ability to succeed commercially.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to a variety of challenges from third parties that relate to the validity of our trademark registrations in the U.S. and internationally. Such challenges can be mounted in trademark cancellation and opposition proceedings before the USPTO, or similar adversarial proceedings in other jurisdictions. If we are unsuccessful in any such challenge, our trademark registrations could be narrowed or could be refused or canceled. Any such outcome could impair our ability to exclude competitors from using a confusingly similar mark, potentially impacting our commercial success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark registrations may be subject to various challenges related to likelihood of confusion, use of a trademark in commerce, or other grounds in the U.S. and internationally. Third parties may assert that our trademarks infringe on their prior rights or that we are not using a trademark in a particular jurisdiction in connection with the goods/services identified in the trademark registration. While we perform trademark clearance searches and analysis to determine that we are not infringing upon the trademark rights of others, we cannot be certain that a court of competent jurisdiction would arrive at the same conclusions we do. If we are unsuccessful in defending against such challenges, a court may cancel our trademark registration and/or issue an injunction requiring that we cease use of the trademark. We may also not be able to rely on common law rights that we may have in any trademark. Any of these outcomes may potentially impact our commercial success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are ultimately successful, defending any such challenges may cause us to incur substantial expenses and may require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties and, if our right to use the intellectual property we license is affected, our ability to develop and commercialize our vaccine candidates may be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past, and we expect in the future to license intellectual property from third parties and that these licenses will be material to our business. We will not own the patents or patent applications that underlie these licenses, and we may not control either the prosecution or the enforcement of the patents. Under such circumstances, we may be forced to rely upon our licensors to properly prosecute and file those patent applications and prevent infringement of those patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many of the licenses under which we have rights provide us with rights in specified fields, the scope of our rights under these and other licenses may be subject to dispute by our licensors or third parties. In addition, our rights to use these technologies and practice the inventions claimed in the licensed patents and patent applications are subject to our licensors abiding by the terms of those licenses and not terminating them. Any of our licenses may be terminated by the licensor if we are in breach of a term or condition of the license agreement, or in certain other circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any disputes regarding obligations in licenses may require us to take expensive and time-consuming legal action to resolve, and, even if we are successful, may delay our ability to commercialize products and generate revenue. Further, if we are unable to resolve license issues that arise we may lose rights to practice intellectual property that is required to make, use, or sell products. Any such loss could compromise our development and commercialization efforts for current or future product candidates and/or may require additional effort and expense to design around.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates and potential vaccine candidates will require several components that may each be the subject of a license agreement. The cumulative license fees and royalties for these components may make the commercialization of these vaccine candidates uneconomical.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize our discoveries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biopharmaceutical products and processes in the U.S. and other important markets outside the U.S., such as Europe and Japan. In addition, foreign markets may not provide the same level of patent protection as provided under the U.S. patent system. Litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to do one or more of the following: cease selling or using any of our products that incorporate the challenged intellectual property, which would adversely affect our revenue; obtain a license from the holder of the intellectual property right alleged to have been infringed, which license may not be available on reasonable terms, if at all; and redesign our products to avoid infringing the intellectual property rights of third parties, which may be time-consuming or impossible to do. In addition, changes in, or different interpretations of, patent laws in the U.S. and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products. We cannot provide assurance that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection. In Europe, a new unitary patent system, which takes effect on June 1, 2023, may significantly impact European patents, including those granted before the introduction of the new system. Under the new system, applicants can, upon grant of a patent, opt for that patent to become a Unitary Patent which will be subject to the jurisdiction of a new Unitary Patent Court (&#8220;UPC&#8221;). Patents </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted before the implementation of the new system can be opted out of UPC jurisdiction, remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be challenged in a single UPC-based revocation proceeding that, if successful, could invalidate the patent in all countries who are signatories to the UPC. Further, because the UPC is a new court system and there is no precedent for the court&#8217;s laws, there is increased uncertainty regarding the outcome of any patent litigation. We are unable to predict what impact the new patent regime may have on our ability to exclude competitors in the European market. In addition to changes in patents laws, geopolitical dynamics, including Russia&#8217;s incursion into Ukraine, may also impact our ability to obtain and enforce patents in particular jurisdictions. If we are unable to obtain and enforce patents as needed in particular markets, our ability to exclude competitors in those markets may be reduced.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and/or patent term adjustment in the U.S. under the Hatch- Waxman Act and similar extensions in foreign countries, our ability to exclude competitors may be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the patent term is 20 years from the earliest U.S. non-provisional filing date. Extensions of patent term may be available under certain circumstances. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of one patent that covers a marketed product under the Drug Price Competition and Patent Term Restoration Act of 1984, (the &#8220;Hatch-Waxman Amendments&#8221;) and similar legislation in the European Union and the United Kingdom.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Amendments permit patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. We may not receive any extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term covering our products may also be extended for time spent during the prosecution of the patent application in the USPTO. This extension is referred to as Patent Term Adjustment (&#8220;PTA&#8221;). The laws and regulations governing how the USPTO calculates the PTA is subject to change and changes in the law can reduce or increase any such PTA. Further, the PTA granted by the USPTO may be challenged by a third party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, shortening the patent term, which may negatively impact our ability to exclude competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Growth and Information Technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute our business development initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate growing through both internal development projects, as well as external opportunities, which include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. The availability of high quality opportunities is limited, and we may fail to identify candidates that we and our stockholders consider suitable or complete transactions on terms that prove advantageous. In order to pursue such opportunities, we may require significant additional financing, which may not be available to us on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions, like our business combinations with Novavax CZ (formerly Praha Vaccines) and Novavax AB, strategic transactions involve many risks, including, among others, those related to diversion of management&#8217;s attention from other business concerns, unanticipated expenses and liabilities, and increased complexity of our operations, which could prevent us from effectively exploiting acquired facilities, successfully integrating the acquired business and personnel, or fully realizing expected synergies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To effectively manage our current and future potential growth, we will need to continue to enhance our operational, financial and management processes and to effectively expand, train and manage our employee base. Supporting our growth initiatives will require significant expenditures and management resources, including investments in research and development, manufacturing in-house and through third-party manufacturers and other areas of our business. If we do not successfully manage our growth and do not successfully execute our growth initiatives, then our business and financial results may be adversely impacted, and we may incur asset impairment or restructuring charges.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Given our current cash position and cash flow forecast, and significant uncertainties related to 2023 revenue, funding from the U.S. government, and our pending arbitration with Gavi, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that the financial statements included in this Annual Report were issued.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. At December 31, 2022, we had $1.3 billion in cash and cash equivalents and restricted cash, of which $236.2 million was raised in December 2022 through concurrent sales of our common stock and issuance of our convertible senior unsecured notes that will mature on December 15, 2027 (the &#8220;2027 Notes&#8221;). On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on our convertible senior unsecured notes that matured on&#160;February&#160;1, 2023&#160;(the &#8220;2023 Notes&#8221;). During 2022, we incurred a net loss of $657.9 million and had net cash flows used in operating activities of $415.9&#160;million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our current cash flow forecast for the one-year going concern look forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">2023 Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our 2023 revenue depends on our ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approvals. We experienced delays in early 2023 in manufacturing our BA.5 clinical trial materials, which has the potential to delay regulatory approval from the FDA for our vaccine candidate for the fall 2023 COVID vaccine season. In addition, in January 2023, VRBPAC announced its intent to provide the industry with its strain protocol guidance in the second quarter of 2023 for the fall 2023 COVID vaccine season. To meet potential demand for fall 2023, we intend to begin manufacturing an updated COVID-19 variant strain-containing formulation prior to the availability of strain protocol guidance. If we begin manufacturing a formulation that is not consistent with the strain protocol guidance, we will not be able to deliver the appropriate vaccine to our customers in sufficient quantities for the fall 2023 COVID vaccine season and we will have incurred significant costs for a formulation that we will be unable to sell.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt;text-decoration:underline">Funding from the U.S. Government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our USG Agreement will expire by its terms in December 2023. We had anticipated that the U.S. government would extend the USG Agreement until the full $1.8&#160;billion authorized amount had been realized. In February 2023, in connection with the execution of Modification 17 to the USG Agreement, the U.S. government indicated to us that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as we had previously expected, then we may not receive all of the remaining $416&#160;million in funding we had previously anticipated pursuant to the USG Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Pending Arbitration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration regarding an alleged material breach by us of the Gavi APA. The outcome of that arbitration is inherently uncertain, and it is possible we could be required to refund all or a portion of the remaining advance payments of $697.4&#160;million. See Note 3 and Note 18 to our consolidated financial statements in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221; of this Annual Report on Form 10-K for additional information related to the arbitration with Gavi.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the significance of these uncertainties, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to fund Company operations is dependent upon revenue related to vaccine sales for our products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters, including whether, when, and how the dispute with Gavi is resolved; and management&#8217;s plans, which include resolving the dispute with Gavi and may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to us on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require us to give up some or all of our rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of NVX-CoV2373 and our other vaccine candidates, including an influenza vaccine candidate, CIC vaccine candidate, or a COVID-19 variant strain-containing monovalent or bivalent formulation, remains uncertain. If we are </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate some or all of our operations, or downsize our organization, any of which may have a material adverse effect on our business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other disruptions to our information technology systems or those of the vendors on whom we rely could compromise our information and expose us to liability, reputational damage, or other costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and many of our current and future strategic partners, vendors, contractors, and consultants collect and store sensitive data, including intellectual property, our proprietary business information and data about our clinical participants, suppliers and business partners and personally identifiable information. The secure maintenance of this information is critical to our operations and business strategy. Some of this information represents an attractive target of criminal attack by malicious third parties with a wide range of motives and expertise, including nation-states, organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees and others. Our ongoing operating activities also depend on functioning information technology systems. Cyber attacks are of ever-increasing levels of sophistication, and, despite our security measures, our information technology systems and infrastructure and those of our vendors and partners are not immune to such attacks or breaches. In 2020, several domestic and foreign security agencies announced that government actors or government-affiliated actors were specifically targeting organizations engaging in COVID-19 vaccine development and research. Our profile as a recipient of funding under the USG Agreement and our development of NVX-CoV2373 may result in greater risk of cyber attack. Any such attack could result in a material compromise of our networks, and the information stored there could be accessed, publicly disclosed, lost, rendered, permanently or temporarily, inaccessible. Furthermore, we may not promptly discover a system intrusion. Like other companies in our industry, we have and third parties with connections to our systems or with data relevant to our business have experienced attacks to our data and systems, including malware and computer viruses. Additionally, we partner with sites that store our clinical trial data. Attacks could have a material impact on our business, operations or financial results. Any access, disclosure or other loss of information, whether stored by us or our partners, or other cyberattack causing disruption to our business, including ransomware, could result in reputational, business, and competitive harms, significant costs related to remediation and strengthening our cyber defenses, legal claims or proceedings, government investigations, liability including under laws that protect the privacy of personal information, and increased insurance premium, all of which could adversely affect our business. We also may need to pay a ransom if a &#8220;ransomware&#8221; infection prevents access or use of our systems and we may face reputational and other harms in addition to the cost of the ransom if an attacker steals certain critical data in the course of such an attack.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and our failure to comply with data protection laws and regulations could lead to government enforcement actions, which would cause our business and reputation to suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolving state, federal and foreign laws, regulations and industry standards regarding privacy and security apply to our collection, use, retention, protection, disclosure, transfer and other processing of personal data. Privacy and data protection laws may be interpreted and applied differently from country to country and may create inconsistent or conflicting requirements, which increases the costs incurred by us in complying with such laws, which may be substantial. For example, the GDPR, which became effective in May 2018, imposes a broad array of requirements for processing personal data, including elevated disclosure requirements regarding collection and use of such data, requirements that companies allow individuals to obtain copies or demand deletion of personal data held by those companies, limitations on retention of information, and public disclosure of significant data breaches, among other things. The GDPR provides for substantial penalties for non-compliance of up to the greater of &#8364;20 million or 4% of global annual revenue for the preceding financial year. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1, 2021 the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GDPR</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been retained</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in U.K., as it forms part of the law of England and Wales, Scotland and Northern Ireland by virtue of section 3 of the European Union (Withdrawal) Act 2018, as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (SI 2019/419) (&#8220;UK GDPR&#8221;), alongside the U.K.&#8217;s Data Protection Act 2018. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to comply with GDPR, the UK GDPR and other privacy and data protection laws impose significant costs and challenges that are likely to increase over time, and we are exposed to substantial penalties or litigation related to violations of existing or future data privacy laws and regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the GDPR and UK GDPR impose strict restrictions surrounding the transfer of personal data to countries outside the EEA and the U.K., including to the U.S. In 2016, the EU and U.S. agreed to a transfer framework for data transferred from the European Union to the U.S., called the EU-US Privacy Shield. On July 16, 2020, however, the Court of Justice of the European Union issued a decision that declared the Privacy Shield framework invalid and raised </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">questions about whether the European Commission&#8217;s Standard Contractual Clauses (&#8220;SCCs&#8221;), an alternative to the Privacy Shield, can lawfully be used for cross-border data transfers. On June 4, 2021, the European Commission adopted new SCCs under the GDPR for personal data transfers outside of the EEA. Under this legal mechanism, we may have obligations to conduct transfer impact assessments for such cross-border data transfers and implement additional security measures. As we incorporate the new SCCs into our contractual arrangements, we may be required to expend significant resources to update our contractual arrangements and to comply with the new obligations. If we are unable to implement a valid compliance mechanism for cross-border personal information transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal information from Europe to the U.S. An inability to import personal information from Europe to the U.S. may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trials in Europe&#894; limiting our ability to collaborate with contract research organizations, service providers, contractors and other companies subject to the GDPR; or requiring us to increase our data processing capabilities in Europe at significant expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy laws and regulations are also expanding in the U.S. The CCPA, which became effective January 1, 2020, substantially expands privacy obligations of many businesses, requiring new disclosures to California consumers, imposing new rules for collecting or using information about minors and affording consumers new abilities, such as the right to know whether their data is sold or disclosed and to whom, the right to request that a company delete their personal information, the right to opt-out of the sale of personal information and the right to non-discrimination in terms of price or service when a consumer exercises a privacy right. Like the GDPR, the CCPA establishes potentially significant penalties for violation. The CCPA also provides a private right of action along with statutory damages for certain data breaches, which is expected to increase risks related to data breach litigation. The California Privacy Rights Act (&#8220;CPRA&#8221;), which will become operational in 2023, expands on the CCPA, creating new consumer rights and protections, including the right to correct personal information, the right to opt out of the use of personal information in automated decision making, the right to opt out of &#8220;sharing&#8221; consumer&#8217;s personal information for cross-context behavioral advertising, and the right to restrict use of and disclosure of sensitive personal information, including geolocation data to third parties. Similar restrictions are also included in the Virginia Consumer Data Protection Act (&#8220;VCDPA&#8221;) and the Colorado Privacy Act (&#8220;CPA&#8221;), the first comprehensive state privacy statutes to follow the CCPA. We will need to evaluate and potentially update our privacy program to seek to comply with the CPRA, VCDPA, CPA and other US privacy laws, and we expect to incur additional expense in our effort to comply.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a likelihood that other states will follow California, Colorado and Virginia in enacting more comprehensive privacy laws. Such legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, and may require additional investment of resources in compliance programs, impact strategies, reduce the availability of previously useful data and result in increased compliance costs and/or changes in business practices and policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborations and contracts of our wholly owned subsidiaries Novavax AB and Novavax CZ, with regional partners, such as SIIPL, Takeda and SK bioscience, as well as with international providers, expose us to additional risks associated with doing business outside the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swedish-based Novavax AB and Czech Republic-based Novavax CZ are wholly owned subsidiaries of Novavax, Inc. We also have entered into a supply and license agreement with SIIPL, collaboration and license agreements with each of Takeda and SK bioscience and other agreements and arrangements with foreign governments and companies in other countries. We plan to continue to enter into collaborations or partnerships with companies, non-profit organizations and local governments in various parts of the world. Risks of conducting business outside the U.S. include negative consequences of:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs associated with seeking to comply with multiple regulatory requirements that govern our ability to develop, manufacture and sell products in local markets;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to comply with anti-bribery laws such as the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws in other jurisdictions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">new or changes in interpretations of existing trade measures, including tariffs, embargoes, sanctions, import restrictions, and export licensing requirements;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulties in and costs of staffing, managing and operating our international operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in environmental, health and safety laws;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fluctuations in foreign currency exchange rates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">new or changes in interpretations of existing tax laws;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">political instability and actual or anticipated military or potential conflicts (including, without limitation, the ongoing conflict between Russia and Ukraine, and a wider European or global conflict);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">economic instability, inflation, recession and interest rate fluctuations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">minimal or diminished protection of intellectual property in many jurisdictions; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">possible nationalization and expropriation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks, individually or in the aggregate, could have a material adverse effect on our business, financial conditions, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to attract or retain key management or other personnel, our business, operating results and financial condition could be materially adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our senior executive officers, as well as key scientific and other personnel. The loss of these individuals or our failure to implement an appropriate succession plan could harm our business and significantly delay or prevent the achievement of research, development or business objectives. Turnover in key executive positions resulting in lack of management continuity and long-term history with our Company could result in operational and administrative inefficiencies and added costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract qualified individuals for key positions on terms acceptable to us. Competition for qualified employees is intense among pharmaceutical and biotechnology companies, and the loss of qualified employees, or an inability to attract, retain and motivate additional highly skilled employees could hinder our ability to complete clinical trials successfully and otherwise develop marketable products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely from time to time on outside advisors who assist us in formulating our research and development and clinical strategy. We may not be able to attract and retain these individuals on acceptable terms, which could delay our development efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Convertible Senior Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our 5.00% convertible senior unsecured notes due 2027 requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we issued $175.3 million aggregate principal amount of Notes. Our ability to make scheduled payments of the principal of, to pay interest on, or to refinance our indebtedness, including the Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We do not expect our business to be able to generate cash flow from operations sufficient to service our debt and make necessary capital expenditures and may therefore be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness, which matures in 2027, unless earlier converted, redeemed, or repurchased, will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, and limit our flexibility in planning for and reacting to changes in our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to repurchase the Notes as required upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes will have the right to require us to repurchase their Notes for cash upon the occurrence of a fundamental change at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any. A fundamental change may also constitute an event of default or prepayment under, and result in the acceleration of the maturity of, our then-existing indebtedness. We cannot assure that we will have sufficient financial resources, or will be able to arrange financing, to pay the fundamental change repurchase price in cash with respect to any Notes surrendered by holders for repurchase upon a fundamental change. In addition, restrictions in our then existing credit facilities or other indebtedness, if any, may not allow us to repurchase the Notes upon a fundamental change. Our failure to repurchase the Notes upon a fundamental change when required would result in an event of default pursuant to the indenture governing the Notes which could, in turn, constitute a default under the terms of our other indebtedness, if any. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our stock price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been highly volatile. From January 1, 2022 through December 31, 2022, the closing sale price of our common stock has been as low as $8.86 per share and as high as $142.90 per share. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. For example, the trading prices of biopharmaceutical companies in particular have been highly volatile as a result of the COVID-19 pandemic, inflation and increased interest rates. These broad market fluctuations may cause the market price of our common stock to be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, given the global focus on the COVID-19 pandemic and our investment in developing a COVID-19 vaccine, information in the public arena on this topic, whether or not accurate, has had and will likely continue to have an outsized impact (positive or negative) on our stock price. Information related to our development, manufacturing, regulatory and commercialization efforts with respect to NVX-CoV2373, or information regarding such efforts by competitors with respect to their COVID-19 vaccines and vaccine candidates, may meaningfully impact our stock price. As a result of this volatility, you may not be able to sell your common stock at or above your initial purchase price. The market price of our common stock may be influenced by many other factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">future announcements about us or our collaborators or competitors, including the results of testing, technological innovations or new commercial products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">clinical trial results;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in making regulatory submissions; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">depletion of our cash reserves;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sale of equity securities or issuance of additional debt;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcement by us of significant strategic partnerships, collaborations, joint ventures, capital commitments or acquisitions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in government regulations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">impact of competitor successes and in particular development success of vaccine candidates that compete with our own vaccine candidates;</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments in our relationships with our collaboration and funding partners;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements relating to health care reform and reimbursement levels for new vaccines and other matters affecting our business and results, regardless of accuracy;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of substantial amounts of our stock by us or existing stockholders (including stock by insiders or 5% stockholders);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">development, spread or new announcements related to pandemic diseases;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">litigation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">public concern as to the safety of our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant set-backs or concerns with the industry or the market as a whole;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory inquiries, reviews and potential action, including from the FDA or the SEC;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">demand for bivalent vaccines;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">recommendations by securities analysts or changes in earnings estimates; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the other factors described in this Risk Factors section.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, and results of operations, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders or require us to relinquish rights to our technologies or vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to partner with a third-party to advance the development of one or more of our vaccine candidates, we will need to raise money through additional debt or equity financings. To the extent that we raise additional capital by issuing equity securities, our stockholders will experience immediate dilution, which may be significant. There is also a risk that such equity issuances may cause an ownership change under the Internal Revenue Code of 1986, as amended, and similar state provisions, thus limiting our ability to use our net operating loss carryforwards and credits. To the extent that we raise additional capital through licensing arrangements or arrangements with collaborative partners, we may be required to relinquish, on terms that may not be favorable to us, rights to some of our technologies or vaccine candidates that we would otherwise seek to develop or commercialize ourselves. In addition, economic conditions may also negatively affect the desire or ability of potential collaborators to enter into transactions with us. They may also have to delay or cancel research and development projects or reduce their overall budgets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our Second Amended and Restated Certificate of Incorporation and Amended and Restated By-Laws and Delaware law could delay or prevent the acquisition of the Company, even if such acquisition would be beneficial to stockholders, and could impede changes in our Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our organizational documents could hamper a third party&#8217;s attempt to acquire, or discourage a third-party from attempting to acquire control of, the Company. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Our organizational documents also could limit the price investors are willing to pay in the future for our securities and make it more difficult to change the composition of our Board in any one year. For example, our </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizational documents provide for a staggered board with three classes of directors serving staggered three-year terms and advance notice requirements for stockholders to nominate directors and make proposals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a Delaware corporation, we are also afforded the protections of Section 203 of the Delaware General Corporation Law, which will prevent us from engaging in a business combination with a person who acquires at least 15% of our common stock for a period of three years from the date such person acquired such common stock, unless advance board or stockholder approval was obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or prevention of a change of control transaction or changes in our Board or management could deter potential acquirers or prevent the completion of a transaction in which our stockholders could receive a substantial premium over the then current market price for their shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid dividends on our capital stock, and we do not anticipate paying any such dividends in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock. We currently anticipate that we will retain all of our earnings for use in the development of our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stock would be the only source of gain for stockholders until dividends are paid, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or regulatory investigations could have a material adverse impact on our results of operation and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to intellectual property litigation, from time to time, we may be subject to other litigation or regulatory investigations. Regardless of the merits of any claims that may be brought against us, litigation or regulatory investigations could result in a diversion of management&#8217;s attention and resources and we may be required to incur significant expenses defending against these claims. If we are unable to prevail in litigation or regulatory investigations, we could incur substantial liabilities. Where we can make a reasonable estimate of the liability relating to pending litigation and determine that it is probable, we record a related liability. As additional information becomes available, we assess the potential liability and revise estimates as appropriate. However, because of uncertainties relating to litigation, the amount of our estimates could be wrong.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon whom we depend may be adversely affected by natural or man-made disasters or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our clinical research organizations, contract manufacturing organizations, vendors of materials needed in manufacturing, collaboration partners, distributors and other third parties upon whom we depend, could be subject to fires, extreme weather conditions, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, war, political unrest, sabotage or terrorism and other natural or man-made disasters, as well as public health emergencies, such as the COVID-19 pandemic. The occurrence of any of these business disruptions could prevent us from using all or a significant portion of our facilities and it may be difficult or impossible for us to continue certain activities for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event and we may incur substantial expenses and delays as a result. Our ability to manufacture our product candidates and obtain necessary clinical supplies for our product candidates could be disrupted if the operations of our contract manufacturing organizations or suppliers are affected by a natural or man-made disaster, or a public health emergency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of COVID-19 may materially and adversely affect our business and our financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present substantial global economic and public health challenges, which may materially and adversely impact our business, financial condition and results of operations. In response to COVID-19, various aspects of our business operations have been, and could continue to be, disrupted. We have implemented our Ways of Working guidelines, which allow employees the flexibility to work remotely either full time or in a hybrid manner to provide </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees with continued flexibility based on business needs. Working remotely could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations. Travel restrictions and other governmental measures may also result in a disruption or delay in the performance of our third-party contractors and suppliers. If such third parties are unable to adequately satisfy their contractual commitments to us in a timely manner, our business could be adversely affected. Furthermore, while some jurisdictions have phased out restrictions imposed on commercial activities at varying degrees, a resurgence of COVID-19, coupled with a potential surge in variant strains of COVID-19, in certain geographies could result in restrictions being reinstated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials, whether planned or ongoing, may be affected by the COVID-19 pandemic. Study procedures (particularly any procedures that may be deemed non-essential), site initiation, participant recruitment and enrollment, participant dosing, shipment of our product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis may be paused or delayed due to changes in hospital or research institution policies, federal, state or local regulations, prioritization of hospital and other medical resources toward efforts to treat or prevent COVID-19, or other reasons related to the pandemic. In addition, there could be a potential effect of COVID-19 to the operations of the FDA or other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates. Any prolongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading prices for our common stock and that of other biopharmaceutical companies have been highly volatile due to the COVID-19 pandemic, especially as a result of investor concerns and uncertainty related to the impact of the outbreak on the economies of countries worldwide. These broad market and industry fluctuations, as well as general economic, political and market conditions, may negatively impact the market price of shares of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the emergence of variant strains, the duration of the pandemic, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in the UK and/or Europe and impose additional challenges in securing regulatory approval of our product candidates in the UK and/or Europe.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s exit from the European Union as of January 31, 2020, with a transitional period up to December 31, 2020, commonly referred to as &#8220;Brexit&#8221;, has caused political and economic uncertainty, including in the regulatory framework applicable to our operations and vaccine candidates in the United Kingdom and the European Union, and this uncertainty may persist for years. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the European Union, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. As one of the Brexit consequences, the EMA has relocated from the United Kingdom to the Netherlands. This has led to a significant reduction of the EMA workforce, which has resulted and could further result in significant disruption and delays in its administrative procedures, such as granting clinical trial authorization or opinions for marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations. As the European Union granted conditional marketing authorization for NVX-CoV2373 after January 1, 2021, it is not grandfathered in the UK. We therefore must seek to obtain a separate marketing authorization for Great Britain or &#8220;GB&#8221; (England, Scotland and Wales while the European Union conditional marketing authorization continues to be applicable in Northern Ireland), increasing our regulatory burden. The GB product license for Nuvaxovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted on February 3, 2022, following a rigorous review of the safety, quality and effectiveness of this vaccine by the UK Medicines and Healthcare products Regulatory Agency and expert advice from the UK&#8217;s independent scientific advisory body, the Commission on Human Medicines.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2022, the Department for Business, Energy &amp; Industry Strategy published the Retained EU law (Revocation and Reform) Bill 2022 (the &#8220;Bill&#8221;) and introduced it to the UK Parliament. The Bill seeks to provide a domestic law basis for amending or revoking over 2,400 well-established retained EU laws that operate across 21 sectors of the UK </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economy, including those concerning the life sciences industry, by December 31, 2023. The Bill will add further uncertainty to the future of medicines regulation and the potential regulatory burden that may arise in the U.K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom. It is possible that there will be increased regulatory complexities, which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenues and achieve and sustain profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the European Union. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the European Union will have, how such withdrawal will affect us, and the full extent to which our business could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are increasingly a target for public scrutiny, and our business may be impacted by unfavorable publicity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that COVID-19 represents an unprecedented urgent public health crisis, that we are developing NVX-CoV2373 as a COVID-19 vaccine candidate, and that we have received significant funding from the U.S. and foreign governments and other sources to support the development and potential commercialization of NVX-CoV2373, we have observed and are likely to continue to face significant public attention and scrutiny over the complex decisions we have made and will be making regarding the development, testing, manufacturing, allocation and pricing of NVX-CoV2373. If we are unable to successfully manage these risks, we could face significant reputational harm, which could negatively affect our stock price. The intense public interest, including speculation by the media, in the development of NVX-CoV2373 has caused significant volatility in our stock price, which we expect to continue as data and other information from our ongoing clinical trials become publicly available. If concerns should arise about the actual or anticipated efficacy or safety of any of our product candidates, such concerns could adversely affect the market&#8217;s perception of these candidates, which could lead to a decline in investors&#8217; expectations and a decline in the price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about pharmaceutical companies&#8217; research, product candidates, and the diseases such product candidates are being developed to prevent. Social media practices in the pharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, subjects may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such events occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social media or networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur reputational or other harm to our business.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_19"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_22"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. PROPERTIES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we leased approximately 53,000 square feet of office space in Gaithersburg, Maryland that serves as our corporate headquarters, and approximately 170,000 square feet of office space in Gaithersburg, Maryland (&#8220;700QO&#8221;) that we currently use for office space and intend to also use for manufacturing and research and development. The term of the 700QO lease agreement is approximately 15 years, and we have the option to extend the Lease Agreement for two successive five-year terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we lease and own approximately 369,000 square feet of office and other space in the U.S., including our corporate headquarters and 700QO, and approximately 242,000 square feet of office and other space in various foreign locations. We use this space for our services and support, commercial, research and development, manufacturing, and administrative personnel. Although we believe that our facilities are suitable and adequate for our present needs, the Company&#8217;s management continues to review and assess real property requirements that may be necessary to address our current business plan.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_25"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sothinathan Sinnathurai v. Novavax, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the NVX-CoV2373&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Sinnathurai Action was filed, seven derivative lawsuits were filed: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Robert E. Meyer v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shui Shing Yung v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">William Kirst, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:22-cv-00024-TDC (the &#8220;Kirst Action&#8221;), (iv) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amy Snyder v. Stanley C. Erck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charles R. Blackburn, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diego J. Mesa v. Stanley C. Erck, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Mesa Action&#8221;), and (vii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sean Acosta v. Stanley C. Erck, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Acosta Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. On December 6, 2022, the parties to the Kirst Action filed a stipulated schedule pursuant to which the plaintiffs were expected to file an amended complaint on December 22, 2022, and either (i) the parties would file a stipulated stay of the Kirst Action or (ii) the defendants would file a motion to stay the case by January 23, 2023. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On February 24, 2023, the Court entered an order staying the Kirst Action until a final judgment in the Second Consolidated Derivative Action. The Company takes no position on whether the broader stay entered by the Court in the Kirst Action is likely to be modified to align with the parties&#8217; stipulation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, the court entered an order granting the parties&#8217; request to set a briefing schedule in connection with a motion to stay that defendants intended to file. Pursuant to the order, defendants filed a motion to stay on January 18, 2023. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted Defendants&#8217; motion to stay.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta action. The financial impact of this claim, as well as the claims discussed above, is not estimable.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2021, a Company stockholder named Thomas Golubinski filed a derivative complaint against members of the Company&#8217;s board of directors and members of senior management in the Delaware Court, captioned Thomas Golubinski v. Richard H. Douglas, et al., No. 2021-0172-JRS. The Company is deemed a nominal defendant. Golubinski challenged equity awards made in April 2020 and in June 2020 on the ground that they were &#8220;spring-loaded,&#8221; that is, made at a time when such board members or members of senior management allegedly possessed undisclosed positive material information concerning the Company. The complaint asserted claims for breach of fiduciary duty, waste, and unjust enrichment. The plaintiff sought an award of damages to the Company, an order rescinding both awards or requiring disgorgement, and an award of attorneys&#8217; fees incurred in connection with the litigation. On May 10, 2021, the defendants moved to dismiss the complaint in its entirety. On June 17, 2021, the Company&#8217;s stockholders voted FOR ratification of the April 2020 awards and ratification of the June 2020 awards. Details of the ratification proposals are set forth in the Company&#8217;s Definitive Proxy Statement filed on May 3, 2021. The results of the vote were disclosed in the Company&#8217;s Current Report on Form 8-K filed on June 24, 2021. Thereafter, the plaintiff stipulated that, as a result of the outcome of the June 17, 2021 vote, the plaintiff no longer intends to pursue the lawsuit or any claim arising from the April 2020 and June 2020 awards. On August 23, 2021, the plaintiff filed a motion seeking an award of attorneys&#8217; fees and expenses, to which the defendants filed an opposition. On October 18, 2022, the Delaware Court denied the plaintiff&#8217;s fee application in its entirety. Under a prior Delaware Court order, the case was automatically dismissed with prejudice upon denial of the plaintiff&#8217;s fee application. On November 14, 2022, Golubinski filed a Notice of Appeal in the Supreme Court of the State of Delaware. The plaintiff / appellant filed his opening appellate brief on December 30, 2022. The Company filed its responsive brief on January 30, 2023 and the appellant filed his reply brief on February 14, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2022, Par Sterile Products, LLC (&#8220;Par&#8221;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (the &#8220;Par MSA&#8221;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. The parties are engaged in discovery and arbitration is scheduled for July 2023. While the Company maintains that no breach of the Par MSA has occurred and intends to vigorously defend the matter, if the final resolution of the matter is adverse to the Company, it could have a material impact on the Company&#8217;s financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December 31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#8217;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while we believe that we are entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that we could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on our financial position, results of operations, or cash flows.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_28"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_31"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_34"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;NVAX.&#8221; Our common stock was held by approximately 137 stockholders of record as of February&#160;21, 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one of which is Cede &amp; Co., a nominee for Depository Trust Company (&#8220;DTC&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the shares of common stock held by brokerage firms, banks, and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC, and are therefore considered to be held of record by Cede &amp; Co. as one stockholder. We do not anticipate declaring or paying any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under our Equity Compensation Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our equity compensation plans, including both stockholder approved plans and non-stockholder approved plans, is included in Part III, Item 12 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below matches Novavax, Inc.'s cumulative 5-Year total shareholder return on common stock with the cumulative total returns of the Nasdaq Composite Index and the Russell 2000 Growth Biotechnology Index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from December 31, 2017 to December 31, 2022.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPARISON OF 5 YEAR CUMULATIVE RETURN*</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among Novavax Inc., the NASDAQ Composite index, </span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Russell2000 Growth Biotechnology Index</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="nvax-20221231_g3.jpg" alt="nvax-20221231_g3.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*$100 invested on 12/31/17 in stock or index, including reinvestment of dividends. </span></div><div style="padding-left:72pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal year ending December 31.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value of $100 invested on December 31, 2017 in stock or index, including reinvestment of dividends, for fiscal years ended:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novavax, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">449.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Composite</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 2000 Growth Biotechnology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This graph is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC, and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_37"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_40"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any statements in the discussion below and elsewhere in this Annual Report on Form 10-K about expectations, beliefs, plans, objectives, assumptions, or future events or performance of Novavax, Inc. (&#8220;Novavax,&#8221; together with its wholly owned subsidiaries, the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;) are not historical facts and are forward-looking statements. Such forward-looking statements include, without limitation, statements about our capabilities, goals, expectations regarding future revenue and expense levels, and capital raising activities; our operating plans and prospects, including our ability to continue as a going concern through one year from the date of Novavax&#8217; audited financial statements for the year ended December 31, 2022; potential market sizes and demand for our product candidates; the efficacy, safety, and intended utilization of our product candidates; the development of our clinical-stage product candidates and our recombinant vaccine and adjuvant technologies; the development of our preclinical product candidates; our expectations related to enrollment in our clinical trials; the conduct, timing, and potential results from clinical trials and other preclinical studies; plans for and potential timing of regulatory filings; our expectation of manufacturing capacity, timing, production, distribution, and delivery for NVX-CoV2373 by us and our partners; our estimate of the number of individuals who may potentially be reached by NVX-CoV2373; our expectations with respect to the anticipated ongoing development and commercialization or licensure of NVX-CoV2373, ongoing development of  COVID-19 variant strain-containing monovalent or bivalent formulation, efforts to expand the NVX-CoV2373 label worldwide as a booster, and to various age groups and geographic locations, and our seasonal quadrivalent influenza vaccine, previously known as NanoFlu; the expected timing, content, and outcomes of regulatory actions; funding from the U.S. government partnership formerly known as Operation Warp Speed under the USG Agreement, the U.S. Department of Defense (&#8220;DoD&#8221;), and CEPI; funding under our APAs and supply agreements and amendments to, termination of, or legal disputes relating to any such agreement; our available cash resources and usage and the availability of financing generally; plans regarding partnering activities and business development initiatives; and other matters referenced herein. Generally, forward-looking statements can be identified through the use of words or phrases such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;possible,&#8221; &#8220;can,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;consider,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; or &#8220;assume,&#8221; the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs and expectations about the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities, such as the FDA, the WHO, United Kingdom (&#8220;UK&#8221;) Medicines and Healthcare Products Regulatory Agency, the European Medicines Agency, the Republic of Korea&#8217;s Ministry of Food and Drug Safety, or Japan&#8217;s Ministry of Health, Labour and Welfare; unanticipated challenges or delays in conducting clinical trials; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capacity, constraints on the ability of Novavax to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and other risks and uncertainties identified in Part I, Item 1A &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K, which may be detailed and modified or updated in other documents filed with the SEC from time to time, and are available at www.sec.gov and at www.novavax.com. You are encouraged to read these filings as they are made.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee future results, events, level of activity, performance, or achievement. Any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate or materially different from actual results. Further, any forward-looking statement speaks only as of the date when it is made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information in this Annual Report on Form 10-K, includes a financial measure that was not prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), which we refer to as adjusted cost of sales. We are presenting this non-GAAP financial measure to assist an understanding of our business and its performance. Adjusted cost of sales includes an estimate of standard manufacturing costs that were previously expensed to research and development prior to regulatory approvals for NVX-CoV2373 that would otherwise have been capitalized to inventory. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by GAAP, have no standardized meaning prescribed by GAAP, and may not be comparable to the calculation of similar measures of other companies.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_43"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Our proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates are genetically engineered nanostructures of conformationally correct recombinant proteins that mimic those found on natural pathogens. This technology enables the immune system to recognize the right target proteins from different angles and develop protective antibodies. We believe that our vaccine technology may lead to the induction of a differentiated immune response that may be more efficacious than naturally occurring immunity or other vaccine approaches. Our vaccine candidates also incorporate our proprietary saponin-based Matrix-M&#8482; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a COVID-19 vaccine NVX-CoV2373 (&#8220;Nuvaxovid&#8482;,&#8221; &#8220;Covovax&#8482;,&#8221; &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221;) and are developing an influenza vaccine candidate, a COVID-19-Influenza Combination (&#8220;CIC&#8221;) vaccine candidate, and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (&#8220;CMA&#8221;), and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. In addition to COVID-19 and seasonal influenza, our other areas of focus include respiratory syncytial virus (&#8220;RSV&#8221;) and malaria.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_46"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter 2022 and Recent Highlights</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">COVID-19 Vaccine Orders and Plans for the 2023 Fall Vaccination Season </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delivered over 100 million doses of Nuvaxovid, Novavax&#8217;s COVID-19 vaccine, globally to date</span></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Modified agreement with the U.S. government for up to 1.5 million additional doses of Novavax&#8217;s COVID-19 vaccine for delivery in 2023</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Agreement maintains the U.S. public&#8217;s access to Novavax&#8217;s COVID-19 vaccine and supports the development of smaller dose vials, strain selection in line with U.S. Food and Drug Administration (FDA) recommendations and a smooth transition to the commercial market</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reaffirmed intent to deliver an updated mono- or bivalent strain vaccine for the 2023 fall vaccination season, consistent with public health recommendations</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Secured European Medicines Agency (EMA) and FDA approval of Nuvaxovid five-dose vial variation and EMA approval of the Company&#8217;s Czech Republic facility to manufacture antigen and supply Nuvaxovid to the E.U.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">COVID-19 Vaccine Clinical Development Program and Expanded Authorizations</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Presented data to the U.S. FDA Vaccine and Related Biological Products Advisory Committee demonstrating that when used as a booster, Novavax&#8217;s COVID-19 vaccine induces broad functional immune responses, including for contemporary variants</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Announced topline results from Phase 3 COVID-19 Omicron BA.1 vaccine candidate, achieving the primary strain-change endpoint</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Part 2 to evaluate our prototype vaccine compared to an Omicron BA.5 vaccine, as well as a bivalent containing prototype and Omicron BA.5 vaccine</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Expanded Nuvaxovid label in adult booster and adolescent primary series to enable broader uptake in the long-term commercial market</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">COVID-19-Influenza Combination (CIC) Vaccine Candidate Clinical Development</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Initiated Phase 2 dose-confirming trial to evaluate safety and immunogenicity of different formulations of CIC and influenza stand-alone vaccine candidates in adults aged 50 to 80 years, with topline results expected by mid-year 2023</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">CIC Phase 2 trial includes additional study arms exploring alternate influenza stand-alone formulations</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_49"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we completed a public offering of 7,475,000 shares of our common stock, including 975,000 shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $10.00 per share, resulting in net proceeds of $69.8 million. Concurrently with this public offering, we issued $175.3 million aggregate principal amount of 5.00% convertible senior unsecured notes due 2027 (the &#8220;2027 Notes&#8221;), including $25.3 million that was issued upon the exercise of the full option to purchase additional notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The 2027 Notes will mature on December 15, 2027, unless earlier converted, redeemed, or repurchased. We received $166.4 million in net proceeds from the issuance of the 2027 Notes after deducting the initial purchasers&#8217; fees and our offering expenses. See Note 11 to our consolidated financial statements in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221; of this Annual Report on Form 10-K for additional information related to the 2027 Notes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into an At Market Issuance Sales Agreement (the &#8220;June 2021 Sales Agreement&#8221;), which allows us to issue and sell up to $500 million in gross proceeds of shares of our common stock, and terminated our then-existing At Market Issuance Sales Agreement. As of December&#160;31, 2022, the remaining balance under the June 2021 Sales Agreement was approximately $318&#160;million. During the years ended December&#160;31, 2022 and 2021, we sold 2.2 million and 2.6 million, respectively, of shares of our common stock resulting in net proceeds of approximately $179&#160;million and $565&#160;million, respectively, under our various At Market Issuance Sales Agreements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_52"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, and equity and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates, particularly estimates relating to accounting for grant revenue, lease accounting, pre-launch inventory, inventory valuation, and research and development expenses have a material impact on our consolidated financial statements and are discussed in detail throughout our analysis of the results of operations discussed below. We base our estimates on historical experience and various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity that are not readily apparent from other sources. Actual results and outcomes could differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For an in-depth discussion of each of our significant accounting policies, including our critical accounting policies and further information regarding estimates and assumptions involved in their application, see Note 2 to the accompanying consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our grant revenue primarily consists of funding under U.S. government contracts including the USG Agreement and the DoD Contract and was $382.9&#160;million in 2022. We measure progress toward satisfaction of our grant performance obligations using an Estimate-at-Completion (&#8220;EAC&#8221;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of our performance obligation. Under this process, we consider the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of our performance obligation under a contract is subjective and requires us to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on our contracts. For our cost-reimbursable-plus-fixed-fee contracts, we recognize the fixed fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. Changes in estimates related to the EAC process are recognized in the period when such changes are made on a cumulative catch-up basis. We have not experienced any material difference as a result of change in estimate arising from the EAC process.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into manufacturing supply agreements with CMOs and contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to manufacture our vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by us and for which we obtain substantially all the output and may qualify as an embedded lease. The evaluation of leases that are embedded in our CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset, which generally is the use of a portion of the manufacturing facility; whether we have the right to direct the use of, and obtain substantially all of the benefit from, the identified asset; the term of the lease; and the fixed lease payments under the contract. Determining the lease commencement date may require judgment because the lease commencement date may be different than the inception date of the contract. We determine the non-cancellable lease term of our embedded leases based on the impact of certain expected milestones on our option to terminate the lease where we are reasonably certain to not exercise that option. For leases that have a lease term of more than 12 months at the lease commencement date, we recognize lease liabilities and corresponding right-of-use (&#8220;ROU&#8221;) assets based on the present value of the fixed future payments over the lease term. We calculate the present value of future payments using the discount rate implicit in the lease, if available, or our incremental borrowing rate. In determining the lease period, we evaluate facts and circumstances that could affect the period over which we are reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which we have the right to use the underlying asset and any option period to extend or terminate the lease if we are reasonably certain to exercise the option. We use significant assumptions and judgment in evaluating our lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease, whether a change in the terms and conditions of a lease contract represent a new or modified lease, whether </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a lease represents an operating or finance lease, the discount rate used to determine the present value of lease obligations, and the term of embedded leases in our manufacturing supply agreements. As of December&#160;31, 2022, we had total noncurrent ROU assets of $106.2&#160;million, current lease liabilities of $44.1&#160;million, and noncurrent lease liabilities of $81.3&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Launch Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize raw materials and production costs as inventory when we determine that commercialization of a product is probable and have a present right to the economic benefit associated with the product. Our estimate of when commercialization is probable is based primarily on our experience with obtaining regulatory approval of comparable products. We began to capitalize inventory in 2022 and, as of December&#160;31, 2022, we had approximately $30.6&#160;million of commercial inventory that was expensed prior to approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory Realizability</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically analyze our inventories for excess amounts or obsolescence and write down obsolete or otherwise unmarketable inventory to its estimated net realizable value. We estimate excess or obsolete inventory and losses on firm purchase commitments of inventory quarterly based on multiple factors, including assumptions about expected future demand and market conditions, current sales orders, and product expiry dates. Our assumptions about expected future demand are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory write down that we report in a particular period. We began to capitalize inventory in 2022. Subsequently, we recorded inventory write-downs of $447.6&#160;million and losses on firm purchase commitments of inventory of $155.9&#160;million to the extent the cost cannot be recovered based on estimates about future demand.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our prepaid and accrued expenses related to our research and development activities using a process that involves reviewing contracts and purchase orders, communicating with our project managers and service providers to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or for which we have been invoiced in advance of the service. This estimation process includes a review of:</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) that conduct our clinical trials and third party consultants; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of developing and manufacturing vaccine components under third-party CMOs and CDMOs agreements, including expenses incurred for the procurement of raw materials, laboratory supplies and equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses on our estimates of the services provided and efforts expended pursuant to contracts, statements of work and related change orders with the service provider, and discussion with internal personnel and external service providers as to the progress of the services and the agreed-upon fee to be paid for such services. The financial terms of these agreements are based on negotiated terms, vary from contract to contract, and may result in an uneven level of activity over time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Additionally, invoicing from third-party service providers may not coincide with actual work performed and can result in a prepaid or an accrual position at the end of the period. The estimation process requires us to make significant judgments and estimates in determining the services incurred as of the balance sheet date, which may result in either a prepaid or an accrual balance. As actual costs become known, we adjust our estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from the related estimates and could result in us reporting amounts that are too high or too low in a particular period. Our prepaid and accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from CROs, CMOs, CDMOs, and third-party service providers. Due to the nature of the estimation process, there may be a difference between estimated costs and actual costs incurred. Historically, we have not experienced any material differences in prior periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 2&#8213;Summary of Significant Accounting Policies&#8221; included in our Notes to Consolidated Financial Statements (under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_55"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for Fiscal Years 2022 and 2021</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with the consolidated financial statements and notes thereto set forth in this Annual Report on Form 10-K. Additional information concerning factors that could cause actual results to differ materially from those in our forward-looking statements is described under Part&#160;I,&#160;Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our discussion of the year ended December&#160;31, 2021, compared to the year ended December&#160;31, 2020, please read Item 7.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;located in Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,554,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(565,788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(153,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product sales for 2022 were $1.6 billion as compared to no product sales for 2021. Product sales for 2022 related to revenue from commercial sales of NVX-CoV2373, which commenced in 2022. The geographic distribution of product sales in 2022 was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized grant revenue as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,709&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565,788)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Grant revenue for 2022 was $382.9 million compared to $948.7 million for 2021, a decrease of $565.8 million. Grant revenue for 2022 primarily comprised revenue for services performed under the USG Agreement and grant revenue for 2021 primarily comprised revenue for services performed under the USG Agreement and the CEPI funding agreement. The decrease in revenue was primarily due to decreased development activities under the USG Agreement and our funding agreement with CEPI.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalties and other revenue for 2022 was $44.0 million as compared to $197.6 million for 2021, a decrease of $153.6 million. Royalties and other revenue primarily related to royalties under our licensing arrangements, and the decrease in revenue was due to lower sales-based royalties from our license partners.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Expenses:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,299,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,832,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206,258)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $902.6 million, or 58% of product sales, for 2022, including expense of $603.5&#160;million related to excess or obsolete inventory and losses on firm purchase commitments. Prior to receiving regulatory approval, we expensed manufacturing costs as research and development expenses. After receiving regulatory approval, we capitalize the costs of production for a particular supply chain when we determine that we have a present right to the economic benefit associated with the product. While we tracked the quantities of our manufactured vaccine product and components, we did not track pre-approval manufacturing costs and therefore the manufacturing cost of our pre-launch inventory produced prior to approval is not reasonably determinable. However, based on our expectations for future manufacturing costs to produce our vaccine product and components inventory, we estimate at December&#160;31, 2022 we had approximately $30.6&#160;million of commercial inventory that was expensed prior to approval. We expect to utilize the majority of our reduced-cost inventory through 2023. If inventory and pre-launch inventory sold in 2022 was valued at expected standard cost, including expenses related to excess and obsolete inventory and losses on firm purchase commitments, adjusted cost of sales for the period would have been approximately $1,067.4&#160;million, or 69% of product sales, an adjustment of $164.8&#160;million as compared to cost of sales recognized. The cost of sales as a percentage of product sales may fluctuate in the future as a result of changes to our customer pricing mix or standard costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased to approximately $1.2 billion for 2022 as compared to $2.5 billion for 2021, a decrease of $1.3&#160;billion. The decrease was primarily due to a decrease in development activities relating to coronavirus vaccines, including NVX-CoV2373, an Omicron BA.1 vaccine candidate, bivalent formulations, and CIC, as summarized in the table below (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and Development Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronavirus vaccines</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Influenza vaccine</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other vaccine development programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct external research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534,508&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for coronavirus vaccines for 2022 and 2021 included a benefit of $201.4 million, inclusive of a $98.3 million benefit pursuant to the Fujifilm Settlement Agreement (see Note 4 to our consolidated financial statements in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221; of this Annual Report on Form 10-K), and an </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense of $239.2 million, respectively, related to previously accelerated manufacturing costs for leases that we determined were embedded in multiple manufacturing supply agreements with CMOs and CDMOs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide forward-looking estimates of costs and time to complete our research programs due to the many uncertainties associated with vaccine development. As we obtain data from preclinical studies and clinical trials, we may elect to discontinue or delay clinical trials in order to focus our resources on more promising vaccine candidates. Completion of clinical trials may take several years or more, but the length of time can vary substantially depending upon the phase, size of clinical trial, primary and secondary endpoints, and the intended use of the vaccine candidate. The cost of clinical trials may vary significantly over the life of a project as a result of a variety of factors, including:</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of participants who participate in the clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of sites included in the clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if clinical trial locations are domestic, international, or both;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time to enroll participants;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of treatment and follow-up;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy profile of the vaccine candidate; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of, and the ability to secure, regulatory approvals.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these uncertainties, we are unable to determine the duration and completion costs of our research and development projects or when, and to what extent, we will generate future cash flows from our research projects.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023, we expect research and development expenses to decrease as compared to 2022 as we continue to assess our manufacturing needs and modify our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, NVX-CoV2373 and as additional manufacturing activities that were previously recognized as research and development expenses begin to meet the criteria for capitalization as inventory. We are gating funding for our potential Phase 3 research and development expenses related to our influenza and CIC vaccine candidates based on the assessment of our Phase 2 clinical trial results anticipated for mid 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general, and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased to $488.7&#160;million for 2022 from $298.4&#160;million for 2021, an increase of $190.3&#160;million. The increase in selling, general, and administrative expenses is primarily due to a $149.5 million increase in expenses related to the commencement of our commercial sales operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For 2023, our expected selling, general, and administrative expenses levels may vary depending on our ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season. Due to this uncertainty, we have announced our intention to reduce and control our operating spend to focus on key priorities and we will continue to evaluate our level of investment as the year progresses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Expense, Net:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Expense, Net (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,911)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,960)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total net other expense of $8.9&#160;million for 2022 compared to total net other expense of $28.0&#160;million for 2021, a decrease of $19.0&#160;million. During 2022 and 2021, other income (expense) was primarily related to foreign exchange rate activity.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, we recognized $4.3&#160;million and $29.2 million, respectively, of income tax expense related to federal and state income taxes and foreign withholding tax on royalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss (in thousands, except per share information):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,743,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,085,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for 2022 was $0.7 billion, or $8.42 per share, as compared to $1.7 billion, or $23.44 per share, for 2021, a decrease of $1.1&#160;billion. The decrease in net loss was primarily due the commencement of commercial sales of NVX-CoV2373 in 2022 and a decrease in research and development expense, partially offset by the write-down of excess or obsolete inventory and losses on firm purchase commitments and decreased revenue under the USG Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in weighted average shares outstanding for 2022 is primarily a result of sales of our common stock and common stock issued under our incentive programs.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_58"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity Matters and Capital Resources</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our future capital requirements depend on numerous factors including, but not limited to, revenue from our product sales and royalties under licensing arrangements with our strategic partners; funding and repayments under our grant agreements; our projected activities related to the development and commercial support of NVX-CoV2373 and variant candidates, including significant commitments under various CRO, CMO, and CDMO agreements; the progress of preclinical studies and clinical trials; the time and costs involved in obtaining regulatory approvals; the costs of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights; and other manufacturing, sales, and distribution costs. We plan to continue developing other vaccines and product candidates, such as our influenza vaccine candidate and potential combination vaccines candidates, which are in various stages of development.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into supply agreements, sometimes referred to as APAs, with the EC and various countries globally. We also have grant and license agreements. As of December&#160;31, 2022, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties under the licensing agreements, was approximately $3&#160;billion, which excludes amounts related to the Gavi APA and the reduction in doses related to the Amended and Restated UK Supply Agreement, as defined below. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under our APAs may require us to refund portions of upfront payments or result in reduced future payments, which could adversely impact our ability to realize revenue from our unsatisfied performance obligations. The timing to fulfill performance obligations related to grant agreements will depend on the results of our research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to supply agreements will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 vaccine under certain of our APAs. The supply agreements typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment, and are applied to billings upon delivery of NVX-CoV2373. Such upfront payments generally become non-refundable upon our achievement of certain development, regulatory, and commercial milestones.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continue to assess our manufacturing needs and modify our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and, as a result, significant costs may be incurred. Pursuant to the Fujifilm Settlement Agreement (see Note 4 to our consolidated financial statements in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221; of this this Annual Report on Form 10-K), we are responsible for a Settlement Payment of up to $185.0&#160;million to Fujifilm in connection with cancellation of manufacturing activity at FDBT </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Fujifilm CSA, of which $47.8&#160;million, constituting the initial reservation fee under the Fujifilm CSA, was credited against the Settlement Payment on September 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with the EC, acting on behalf of various European Union member states to supply a minimum of 20 million and up to 100 million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100 million doses up to a maximum aggregate of 200 million doses in one or more tranches through 2023. In 2022, we were notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, we finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022 and are expected to be delivered in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373 and made an upfront payment to us. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#8220;Conditional Doses&#8221;) of NVX-CoV2373, with the number of Conditional Doses contingent on, and subject to reduction based on, our timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority does not purchase the Conditional Doses or the number of such Conditional Doses is reduced below 15&#160;million doses of NVX-CoV2373, we would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not yet made a supportive recommendation with respect to NVX-CoV2373, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, our timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for us to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement, which is reflected in our consolidated balance sheet as Other current liabilities, with the remaining upfront payment balance of $112.5&#160;million reflected in current Deferred revenue.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gavi APA, we received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in the first quarter of 2022 related to our achieving EUL for NVX-CoV2373 by the WHO (the &#8220;Advance Payment Amount&#8221;). On November 18, 2022, we delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from us as required by the Gavi APA. As of November 18, 2022, we had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in our consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. Our response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while we believe that we are entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that we could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into a modification to the USG Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3 million doses of NVX-CoV2373 and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100 million doses of NVX-CoV2373 contemplated by the original USG Agreement (inclusive of the initial batch of approximately 3 million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. Additionally, in July 2022, we entered into a modification to our existing agreement with the DoD that amended the terms of such agreement to provide for the initial delivery of 0.2 million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining 9.8 million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding. In February 2023, in connection with the execution of Modification 17 to the USG Agreement, the U.S. government indicated to us that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as we had previously expected, then we may not receive all of the remaining $416&#160;million in funding we had previously anticipated pursuant to the USG Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our funding agreements currently include funding from CEPI in the form of one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the CMO network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under our Gavi APA prior to its termination), and such sales cover our costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $1.3&#160;billion in cash and cash equivalents and restricted cash as compared to $1.5&#160;billion as of December&#160;31, 2021. On January 31, 2023, we funded the outstanding principal amount of $325.0 million on the 2023 Notes, due February 1, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded our operations in 2022 with cash and cash equivalents, upfront payments under APAs, revenue from product sales, royalties under licensing arrangements with our strategic partners, and proceeds from the sale of common stock, together with revenue under the USG Agreement that support our NVX-CoV2373 vaccine development activities. We anticipate our future operations to be funded primarily by revenue from product sales, revenue under our USG Agreement, our cash and cash equivalents, and other potential funding sources.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash flows for 2022 and 2021:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(415,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">322,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(738,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92,985)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(193,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">324,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">461,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(136,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect on exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,414)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">879,521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,058,935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,528,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">648,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">879,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,348,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,528,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,414)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $415.9&#160;million for 2022, as compared to cash provided by operating activities of $322.9 million in 2021. The decrease in cash from operating activities is primarily due to a decrease in upfront payments received under our APAs, timing of payments to vendors, and an increase in inventory production, partially offset by a reduction in our net loss.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities primarily consisted of capital expenditures and, in 2021, $159.8&#160;million in proceeds from maturities and sale of marketable securities, net of purchases. Capital expenditures for the years ended December&#160;31, 2022 and 2021 were $89.1&#160;million and $54.5&#160;million, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities consisted primarily of sales of our common stock, issuance of our 2027 Notes, payments of finance lease liabilities, and exercises of stock-based awards. In 2022, we received net proceeds of approximately $179 million and $70 million from the sale of shares of common stock through our At Market Issuance Sales Agreements and a public offering at $10.00 per share, respectively. In addition, we received net proceeds of $166.4 million during 2022 through the issuance of our 2027 Notes (see Note 11 to the accompanying consolidated financial statements). In 2021, we received net proceeds of approximately $565 million from the sale of shares of common stock through our At Market Issuance Sales Agreements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221; of this Annual Report on Form 10-K have been prepared assuming that we will continue as a going concern within one year after the date that the financial statements are issued. At December 31, 2022, we had $1.3 billion in cash and cash equivalents and restricted cash, of which $236.2 million was raised in December 2022 through concurrent sales of our common stock and issuance of our 2027 Notes. On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on the 2023 Notes. During 2022, we incurred a net loss of $657.9 million and had net cash flows used in operating activities of $415.9&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our current cash flow forecast for the one-year going concern look forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration. Our 2023 revenue depends on our ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. See &#8220;Risk Factors&#8212;Risks Related to Product Development and Commercialization&#8212;The emergence and transmissibility of variants of the SARS-CoV-2 virus, and the demand for bivalent vaccines, may affect market acceptance or sales of NVX-CoV2373, and our strategy to develop versions of our COVID-19 vaccine to protect against certain variants may not be successful.&#8221; In February 2023, in connection with the execution of Modification 17 to the USG Agreement, the U.S. government indicated to us that the award may not be extended past its current period of performance, which may result in us not receiving all of the remaining $416&#160;million in funding we had previously anticipated. See &#8220;Risk Factors&#8212;Risks Related to Our Financial Condition and Capital Requirements&#8212;Our existing funding and supply agreements do not assure success of our vaccine candidates or that we will be able to fully fund our vaccine candidates.&#8221; On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration regarding an alleged material breach by us of the Gavi APA. The outcome of that arbitration is inherently uncertain, and it is possible we could be required to refund all or a portion of the remaining Advance payment Amount of $697.4&#160;million. See Note 3 and Note 18 to our consolidated financial statements in Part II, Item 8, </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Financial Statements and Supplementary Data,&#8221; of this Annual Report on Form 10-K for additional information related to the arbitration with Gavi. Management believes that, given the significance of these uncertainties, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to fund Company operations is dependent upon revenue related to vaccine sales for our products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters, including whether, when, and how the dispute with Gavi is resolved; and management&#8217;s plans, which include resolving the dispute with Gavi and may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to us on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require us to give up some or all of our rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of NVX-CoV2373 and our other vaccine candidates, including an influenza vaccine candidate, CIC vaccine candidate, or a COVID-19 variant strain-containing monovalent or bivalent formulation, remains uncertain. If we are unable to obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate some or all of our operations, or downsize our organization, any of which may have a material adverse effect on our business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_61"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of December&#160;31, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual&#160;Obligations:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less&#160;than&#160;<br/>One&#160;Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1&#160;&#8211;&#160;3<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3&#160;&#8211;&#160;5<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More&#160;than<br/>5&#160;Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations recognized as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,034&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities lease agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total contractual obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;We had $325.0 million of 3.75% convertible senior unsecured notes due February 1, 2023, which we repaid in full. In 2022, we issued $175.3 million of 5.00% convertible senior unsecured notes due in 2027. See &#8220;Note 11&#8212;Long-term Debt&#8221; included in our Notes to Consolidated Financial Statements for additional information related to our convertible notes.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;This amount primarily represents our non-cancelable fixed payment obligations under certain CMO, CDMO, and lab supply agreements that we are not contractually able to terminate for convenience. Certain agreements provide for termination rights subject to termination fees. Under such agreements, we are contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses incurred. As of December&#160;31, 2022, these agreements are active ongoing arrangements and we expect to receive value from these arrangements in the future. The amount of such obligations is dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. Our current obligations under non-cancelable purchase agreements are reflected in our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;This relates to the lease of floor space at 700 Quince Orchard that had not commenced as of December&#160;31, 2022 (see Note 10 to the consolidated financial statements).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally allow us the option to cancel, reschedule, or adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. It is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_64"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flows, and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rate movements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are headquartered in the U.S. our results of operations, including our foreign subsidiaries&#8217; operations, are subject to foreign currency exchange rate fluctuations, primarily the U.S. dollar against the Euro, Pound Sterling, Swedish Krona, and Czech Koruna. This exchange exposure may have a material effect on our cash and cash equivalents, cash flows, and results of operations, particularly in cases of revenue generated under APAs that include provisions that impact our and our counterparty&#8217;s currency exchange exposure. To date, we have not entered into any foreign currency hedging contracts, although we may do so in the future.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face foreign currency exchange exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. While the financial results of our global activities are reported in U.S. dollars, the functional currency for our foreign subsidiaries is generally their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. A 10% decline in the foreign exchange rates (primarily against the U.S. dollar) relating to our foreign subsidiaries would result in a decline of stockholders&#8217; equity (deficit) of approximately $18.2 million as of December&#160;31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Interest Rate Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is preservation of capital, with the secondary objective of maximizing income.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to interest rate risk is primarily confined to our investment portfolio, which historically has been classified as available-for-sale. We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our investment portfolio. Changes in interest rates may affect the investment income we earn on our marketable securities when they mature and the proceeds are reinvested into new marketable securities and, therefore, could impact our cash flows and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income is recorded when earned and included in investment income. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in investment income. The specific identification method is used in computing realized gains and losses on the sale of our securities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our convertible senior unsecured notes have a fixed interest rate and we have no additional material debt. As such, we do not believe that we are exposed to any material interest rate risk as a result of our borrowing activities.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_67"></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is set forth on pages&#160;F-1 to F-40.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_70"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_73"></div><div style="margin-bottom:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;disclosure controls and procedures&#8221; (defined in SEC Rule&#160;13a-15(e)) refers to the controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized, and reported, within time periods specified in the rules&#160;and forms of the Securities and Exchange Commission. &#8220;Disclosure controls and </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures&#8221; include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the chief executive officer and the chief financial officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K (the &#8220;Evaluation Date&#8221;). Based on that evaluation, the Company&#8217;s chief executive officer and chief financial officer have concluded that, as of the Evaluation Date, such controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;promulgated under the Exchange Act, as a process designed by, or under the supervision of, the Company&#8217;s principal executive officer and principal financial officer and effected by the Company&#8217;s board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Such internal control includes those policies and procedures that:</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of an unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. In making this assessment, our management used the criteria set forth in the 2013 Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its assessment, our management has determined that, as of December&#160;31, 2022, our internal controls over financial reporting are effective based on those criteria.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young LLP has issued a report on our internal control over financial reporting. This report is included in the Reports of Independent Registered Public Accounting Firm in Item 15(a)(1).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our chief executive officer and chief financial officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended December&#160;31, 2022 and has concluded that there was no change that occurred during the quarterly period ended December&#160;31, 2022 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_76"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_79"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_82"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_85"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement for our 2023 Annual Meeting of Stockholders scheduled to be held in June&#160;2023 (the &#8220;2023 Proxy Statement&#8221;). We expect to file the 2023 Proxy Statement within 120 days after the close of the fiscal year ended December&#160;31, 2022.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_88"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the information required by this item concerning executive compensation to be contained in the 2023 Proxy Statement.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_91"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the information required by this item concerning security ownership of certain beneficial owners and management and related stockholder matters to be contained in the 2023 Proxy Statement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides our equity compensation plan information as of December&#160;31, 2022. Under these plans, our common stock may be issued upon the exercise or vesting of equity awards and purchases under our Employee Stock Purchase Plan (&#8220;ESPP&#8221;). See also the information regarding our equity awards and ESPP in Note 14 to the consolidated financial statements included herewith.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities<br/>to be Issued<br/>Upon Exercise of<br/>Outstanding Options,<br/>Warrants and Rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise Price of<br/>Outstanding<br/>Options, Warrants<br/>and Rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities<br/>Remaining Available for<br/>Future Issuance Under<br/>Equity Compensation<br/>Plans (Excluding<br/>Securities Reflected in<br/>Column (a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151,589</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$47.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501,492</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes our 2015 Stock Incentive Plan, 2005 Stock Incentive Plan, and ESPP. The weighted-average exercise price in column (b)&#160;excludes restricted stock units, which are not subject to an exercise price.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_94"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We incorporate herein by reference the information required by this item concerning certain relationships and related transactions and director independence to be contained in the 2023 Proxy Statement.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_97"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the information required by this item concerning principal accountant fees and services to be contained in the 2023 Proxy Statement.</span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_100"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_103"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:10pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">The following documents are filed as part of the Annual Report on Form 10-K:</span></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Index to Financial Statements</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_115">Reports of Independent Registered Public Accounting Firm (PCAOB ID:42)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_121">Consolidated Statements of Operations and Statements of Comprehensive Loss for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_118">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124">Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the years ended December&#160;31, 2022, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124"> and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_127">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124">022, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124"> and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 9</span></td></tr></table></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statement Schedules</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules are omitted because they are not applicable, not required under the instructions or all the information required is set forth in the financial statements or notes thereto.</span></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits marked with a single asterisk (*) are filed herewith.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Exhibits marked with a double plus sign (&#8224;&#8224;) refer to management contracts, compensatory plans, or arrangements.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Confidential treatment has been granted for portions of exhibits marked with a double asterisk (**).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confidential information contained in exhibits marked with a caret (&#94;) has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other exhibits listed have previously been filed with the SEC and are incorporated herein by reference.</span></div><div><span><br/></span></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form&#160;8-K filed on May&#160;9, 2019 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000110465921085180/tm2120584d1_ex3-1.htm">Amended and Restated By-Laws of the Company (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on June 24, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920075307/tm2023024d1_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000110465919077299/tv535518_ex4-1.htm">Specimen stock certificate for shares of common stock of the Company, par value $.01 per share (Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-3, filed on December 31, 2019 (File No. 333-235761))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">Indenture (including form of Notes) with respect to the Company's </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">00</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">% Convertible Senior Notes due 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">December 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">22</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (Incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">December 21, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm"> (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000110465920075307/tm2023024d1_ex4-1.htm">Form of Series A Convertible Preferred Stock Certificate of the Company (Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20221231xex44.htm">Description of the Company's Securities</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.1&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex10-2.htm">The Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2012, filed on March&#160;12, 2013 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.2&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420414026440/v376628_def14a.htm">Amendment to Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Appendix 1 of the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420414026440/v376628_def14a.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420414026440/v376628_def14a.htm">s Definitive Proxy Statement filed on April&#160;30, 2014 in connection with the Annual Meeting held on June&#160;12, 2014 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.3&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415012379/v401319_ex10-4.htm">Form&#160;of Non-Statutory Stock Option Award Agreement granted under the Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2014, filed on February&#160;27, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.4&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415012379/v401319_ex10-5.htm">Form&#160;of Incentive Stock Option Award Agreement granted under the Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2014, filed on February&#160;27, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.5&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Amended and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Novavax, I</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">c.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">013 Employee Stock Purchase Plan (Incorporated by reference to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Appendix D </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">of the C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">mpany</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">s Definitive Proxy Statement filed on May 2, 2022 in connection with the A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">nual Meeting held on June 16, 2022 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">(File No. 000-26770)) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.6&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Amended and Restated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm"> Novavax, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm"> 2015 Stock Incentive Plan (Incorporated by reference to Appendix </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Appendix </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">C </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">of the Company&#8217;s Definitive Proxy Statement filed on May 2, 2022 in connection with the Annual Meeting held on June 16, 2022 (File No. 000-26770)) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.7&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-3.htm">Form&#160;of Non-Statutory Stock Option Award Agreement granted under the</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-3.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-3.htm">Amended and Restated Novavax, Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-3.htm">2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.8&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-4.htm">Form&#160;of Incentive Stock Option Award Agreement granted under the</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-4.htm"> Amended and Restated Novavax, I</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-4.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-4.htm">c.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-4.htm"> 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.9&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417011334/v459518_ex10-9.htm">Form&#160;of Incentive Stock Option Award Agreement granted under the</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417011334/v459518_ex10-9.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417011334/v459518_ex10-9.htm">Amended and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417011334/v459518_ex10-9.htm">Novavax, Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417011334/v459518_ex10-9.htm">2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.9 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2016, filed on February&#160;27, 2017 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.10&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416134953/v453291_ex10-1.htm">Form&#160;of Incentive Stock Option Agreement granted under the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416134953/v453291_ex10-1.htm">Amended and Restated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416134953/v453291_ex10-1.htm"> Novavax, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416134953/v453291_ex10-1.htm"> 2015 Stock Incentive Plan (Performance- and Time-Based Vesting) (Incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on November&#160;16, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.11&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-5.htm">Form&#160;of Restricted Stock Award Agreement granted under the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-5.htm">Amended and Restated Novavax, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-5.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-5.htm">2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.5 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-5.htm">&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.12&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm">Form&#160;of Restricted Stock Unit Agreement granted under the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm">Amended and Restated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm"> Novavax, I</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm">nc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm"> 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.12 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019, filed on March&#160;18, 2019 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.13&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465919061157/tm1919566d1_ex10-1.htm">Form&#160;of Stock Appreciation Right Award Agreement granted under the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465919061157/tm1919566d1_ex10-1.htm">Amended and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465919061157/tm1919566d1_ex10-1.htm">Novavax, Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465919061157/tm1919566d1_ex10-1.htm">2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2019, filed on November&#160;7, 2019&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465919061157/tm1919566d1_ex10-1.htm">(File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.14&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416084770/v431853_ex10-10.htm">Form&#160;of Director Deferred Fee Agreement (Incorporated by reference to Exhibit&#160;10.10 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015, filed on February&#160;29, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.15&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-1.htm">Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.16&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-2.htm">Form of Non-Statutory Stock Option Agreement under the Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-3.htm">Form of Restricted Stock Unit Award Agreement under the Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8224;&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex1018.htm">Employment Agreement between the Company and John C. Jacobs, dated as of January 5, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.19&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420411044872/v231158_ex10-2.htm">Employment Agreement between the Company and Stanley C. Erck, dated as of June&#160;22, 2011 (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2011, filed on August&#160;9, 2011 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.20&#8224;&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nvax-20221231xex1020.htm">Consulting and Advisory Agreement between the Company and Stanley C. Erck, dated as of January 5, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.21&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420410036677/v189965_ex10-1.htm">Employment Agreement between the Company and Gregory M. Glenn dated July&#160;1, 2010 (Incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on July&#160;6, 2010 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.22&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416099046/v435593_ex10-2.htm">Employment Agreement between the Company and John A. Herrmann dated April&#160;1, 2012 (Incorporated by reference to Exhibit&#160;10.2 to the Company's Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2016, filed on May&#160;5, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.23&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416099046/v435593_ex10-3.htm">E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416099046/v435593_ex10-3.htm">mployment Agreement between the Company and John J. Trizzino dated March&#160;3, 2014 (Incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2016, filed on May&#160;5, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.24&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex101.htm">Employment Agreement between the Company and James P. Kelly dated July 12, 2021 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.25&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm">Offer letter to James P. Kelly dated July 12, 2021 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm">Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.26&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex102.htm">Form of Amendment to Employment Agreement, dated June 17, 2021, between the Company and each of Stanley C. Erck, Gregory M. Glenn, John J. Trizzino and John A. Herrmann, III (Incorporated by reference to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex102.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex102.htm">Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.27&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex104.htm">Company Amended and Restated Change in Control Severance Benefit Plan (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.28&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420410013614/v176992_ex10-19.htm">Form&#160;of Indemnification Agreement entered into between the Company and its directors and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420410013614/v176992_ex10-19.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420410013614/v176992_ex10-19.htm">officers&#160;(Incorporated by reference to Exhibit&#160;10.19 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2009, filed on March&#160;16, 2010 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420412014910/v304706_ex10-25.htm">Lease Agreement for space at 22 Firstfield Road between ARE-20/22/1300 Firstfield Quince Orchard, LLC and the Company, dated as of November&#160;18, 2011 (Incorporated by reference to Exhibit&#160;10.25 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2011, filed on March&#160;14, 2012 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415051329/v418551_ex10-1.htm">Deed of Lease for space at 21 Firstfield Road between Firstfield Holdco, LLC and the Company, dated as of February&#160;4, 2015 (Incorporated by reference to Exhibit&#160;10.1 to the Company's Current Report on Form&#160;8-K, filed on August&#160;21, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415051329/v418551_ex10-2.htm">First Amendment to Deed of Lease for space at 21 Firstfield Road between Firstfield Holdco, LLC and the Company, dated as of August&#160;17, 2015 (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Current Report on Form&#160;8-K, filed on August&#160;21, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417025227/v465353_ex10-2.htm">Second Amendment to Deed of Lease for space at 21 Firstfield Road between BMR-Firstfield LLC (formerly Firstfield Holdco, LLC) and the Company, dated as of March&#160;31, 2017 (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2017, filed on May&#160;8, 2017 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1027.htm">Deed of Lease for space at 700 Quince Orchard Road between ARE-MARYLAND NO. 51, LLC and the Company, dated October 22, 2020 (Incorporated by reference to Exhibit 10.27 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">Amendment to Deed of Lease for space at 700 Quince Orchard Road between ARE-MARYLAND NO. 51, LLC and the Company, dated June 22, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">(Incorporated by reference to Exhibit 10.33 to the C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">mpany</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">s Annual Report on F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">rm 10-K for the year ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm"> 31, 2021, filed on March 1, 2022 (F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">il</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">e No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.35&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex104.htm">Amended and Restated Supply and License Agreement, dated July 1, 2021, between the Company and Serum Institute of India Private Limited (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex104.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.36&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1037.htm">Supply Agreement between the Company, Serum Institute of India Private Limited and Serum Life Sciences Limited, executed as of October 26, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1037.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1037.htm">(Incorporated by reference to Exhibit 10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1037.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1037.htm"> to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.37&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">Contract Development Manufacture Agreement, dated October 21, 2021,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm"> between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">Serum Life Sciences Limited</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm"> (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">10.3 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">to the Company&#8217;s Quarterly Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">10-Q for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">June </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">30, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">2022,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm"> filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">August 8, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm"> (File No.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.38&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex104.htm">Amendment No. 1 to the Contract Development Manufacture Agreement, executed as of April 29, 2022, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 8, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.39&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex105.htm">Statement of Work No. 1 to the Contract Development Manufacture Agreement, effective as of April 29, 2022, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 8, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.40&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000008/nvax-20210331xex101.htm">Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of February 12, 2021 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed on May 10, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.41&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1039.htm">Amendment to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1039.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1039.htm">(Incorporated by reference to Exhibit 10.39 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.42&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1040.htm">Statement of Work No. 1 to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1040.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1040.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1040.htm">40</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1040.htm"> to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.43&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000009/nvax-20220331xex102.htm">Change Order No. 1 to Statement of Work No. 1 to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of March 31, 2022 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed on May 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.44&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000008/nvax-20210331xex102.htm">Collaboration and Exclusive License Agreement between the Company and Takeda Pharmaceutical Company Limited, dated as of February 24, 2021 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed on May 10, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.45**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415063483/v422902_ex10-2.htm">Global Access Commitments Agreement between Bill &amp; Melinda Gates Foundation and the Company, dated as of September 25, 2015 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 9, 2015 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.46&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419038206/tv526077_ex10-3.htm">Asset Purchase Agreement between Company and Paragon Bioservices, Inc., dated June 26, 2019 (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, filed on August 7, 2019 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.47&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">Amended and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">SARS-CoV-2 Vaccine Supply Agreement, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">July 1, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">, between the Company and The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm"> to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm"> Report on Form 10-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm"> for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">uarter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm"> ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">September 30, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">, filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">N</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">vember 9, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.48&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex102.htm">Letter of Amendment to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of September 26, 2022, between the Company and The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.49&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1036.htm">Advance</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1036.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1036.htm"> Purchase Agreement, effective as of December 31, 2020, between the Company and the Commonwealth of Australia as represented by the Department of Health (Incorporated by reference to Exhibit 10.36 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.50&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm">Amendment to Advance</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm"> Purchase Agreement between</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm">the Company, and the Commonwealth of Australia as represented by the Department of Health, dated as of December 23, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm">(Incorporated by reference to Exhibit 10.47 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.51&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1037.htm">Advance</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1037.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1037.htm"> Purchase Agreement, effective as of January 19, 2021, between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1037.htm">the Company and Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (Incorporated by reference to Exhibit 10.37 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.52&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex108.htm">Advance Purchase Agreement, dated August 16, 2021, between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex108.htm">the Company, Novavax CZ and the European Commission (Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.53&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d1.htm">Base Agreement between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d1.htm">the Company and Advanced Technology International, dated June 25, 2020 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.54&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000009/nvax-20220331xex101.htm">Modification No. 01 to Base Agreement between the Company and Advanced Technology International, dated as of March 23, 2022 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed on May 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.55&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex103.htm">Modification No. 02 to Base Agreement between the Company and Advanced Technology International, dated as of August 2, 2022 (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.56&#94;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex1056.htm">Modification No. 03 to Base Agreement between the Company and Advanced Technology International, dated as of November 30, 2022</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.57&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d2.htm">Undefinitized Project Agreement No. 1 between the Company and Advanced Technology International, dated July 6, 2020 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.58&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d3.htm">Modification No. 01 to Undefinitized Project Agreement No. 1 between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d3.htm">the Company and Advanced Technology International, dated July 9, 2020 (Incorporated by reference to Exhibit 10.3 to the</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d3.htm"> Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.59&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1041.htm">Modification No. 02 to Undefinitized Project Agreement No. 01, entered into September 10, 2020, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.41 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.60&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1042.htm">Modification No. 03 to Undefinitized Project Agreement No. 01, entered into September 18, 2020, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.42 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.61&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1043.htm">Modification No. 04 to Undefinitized Project Agreement No. 01, entered into December 23, 2020, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.43 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.62&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1044.htm">Modification No. 05 to Undefinitized Project Agreement No. 01, dated January 12, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.44 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.63&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1045.htm">Modification No. 06 to Undefinitized Project Agreement No. 01, entered into January 19, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.45 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.64&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex106.htm">Modification No. 07 to Undefinitized Project Agreement No. 01, dated April 23, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.65&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex107.htm">Modification No. 08 to Undefinitized Project Agreement No. 01, dated June 4, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.66&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex105.htm">Modification No. 09 to Undefinitized Project Agreement No. 01, dated July 16, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.67&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex106.htm">Modification No. 10 to Undefinitized Project Agreement No. 01, dated August 6, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.68&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex107.htm">Modification No. 11 to Undefinitized Project Agreement No. 01, dated August 26, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.69&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1064.htm">Modification No. 12 to Undefinitized Project Agreement No. 01, dated December 20, 2021, between the Company and Advanced Technology International</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1064.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1064.htm">(Incorporated by reference to Exhibit 10.64 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.70&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1065.htm">Modification No. 13 to Undefinitized Project Agreement No. 01, dated February 1, 2022, between the Company and Advanced Technology International</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1065.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1065.htm">(Incorporated by reference to Exhibit 10.65 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.71&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex104.htm">Modification No. 14 to Undefinitized Project Agreement No. 01, dated July 1, 2022, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.72&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex105.htm">Modification No. 15 to Undefinitized Project Agreement No. 01, dated August 9, 2022, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.73&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex106.htm">Modification No. 16 to Undefinitized Project Agreement No. 01, dated September 9, 2022, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.74&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20200930xex107.htm">Amendment of Solicitation/Modification of Contract, Modification No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20200930xex107.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20200930xex107.htm">, dated as of July 29, 2022, between the Company and the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920075307/tm2023024d1_ex10-1.htm">Series A Convertible Preferred Subscription Agreement, dated June 15, 2020, between the Company and RA Capital Healthcare Fund, L.P. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.76</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920092782/nvax-20200630xex10d1.htm">Restated Funding Agreement, entered into on May 11, 2020, between the Company and the Coalition for Epidemic Preparedness Innovations (Incorporated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920092782/nvax-20200630xex10d1.htm">by</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920092782/nvax-20200630xex10d1.htm"> reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1056.htm">Amendment Number 1 to the iPDP and Budget of the Outbreak Response Funding Agreement (Step 2), entered into on November 2, 2020, between the Company and the Coalition for Epidemic Preparedness Innovations (Incorporated by reference to Exhibit 10.56 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.78&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex108.htm">Settlement Agreement, dated September 30, 2022, between the Company and FUJIFILM Diosynth Biotechnologies UK Limited, FUJIFILM Diosynth Biotechnologies Texas, LLC, and FUJIFILM Diosynth Biotechnologies USA, Inc. (Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm">Code of Conduct</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm"> (Incorporated by reference to Exhibit 14 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm">s Annual Report on Form 10-K for the year ended December 31, 2021, filed on M</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm">arch 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex21.htm">Subsidiaries of the Company</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex231.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20221231xex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from our Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets as of December 31, 2022 and 2021, (ii) the Consolidated Statements of Operations for the three years in the period ended December 31, 2022, (iii) the Consolidated Statements of Comprehensive Loss for the three years in the period ended December 31, 2022, (iv) the Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the three years in the period ended December 31, 2022, (v) the Consolidated Statements of Cash Flows for the three years in the period ended December 31, 2022, and (vi) the Notes to Consolidated Financial Statements.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_106"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_109"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ John C. Jacobs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John C. Jacobs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;28, 2023 </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ John C. Jacobs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John C. Jacobs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ James P. Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Executive Vice President, Chief Financial Officer, and Treasurer (Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James P. Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ James F. Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James F. Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Gregg H. Alton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gregg H. Alton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard H. Douglas</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard H. Douglas</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Rachel K. King</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rachel K. King</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Margaret G. McGlynn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Margaret G. McGlynn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David M. Mott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David M. Mott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard J. Rodgers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard J. Rodgers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_112"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2022, 2021, and 2020</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_115">Reports of Independent Registered Public Accounting Firm </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(PCAOB ID:<ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTIvZnJhZzpkNmE5MzU0MzlhNmM0NGE1OThhZTgzMTgwMjFmNmY5My90YWJsZTo4NjA5MjBjNWY2NjU0OTY2YmQ4Y2I1OTM2OGFjNTVlMS90YWJsZXJhbmdlOjg2MDkyMGM1ZjY2NTQ5NjZiZDhjYjU5MzY4YWM1NWUxXzAtMC0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplOTJiNTdiZmU5Yjk0ZDYwOTBiODlhNGRlMDVhNjg1Zl83MQ_4d1393d9-1bc5-482d-b316-dbb4b6fe0f44">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_115">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_121">Consolidated Statements of Operations and Statements of Comprehensive Loss for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_121">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_118">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_118">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_124">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_127">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_127">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_130">9</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 1</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_115"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax,&#160;Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Novavax,&#160;Inc. (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;28, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s Ability to Continue as a Going Concern</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosures to which it relates. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.694%"><tr><td style="width:1.0%"></td><td style="width:12.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inventory Excess and Obsolescence Reserve<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $36.7&#160;million of inventory. As disclosed in Note 2, inventories are stated at the lower of cost or net realizable value. The Company assesses its inventory levels each reporting period and writes down inventory that is either expected to be at risk of expiration prior to sale, or for which there are inventory quantities in excess of expected requirements. For the year ended December&#160;31, 2022, inventory write-downs were $447.6&#160;million and losses on firm purchase commitments were $155.9&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management's estimates for excess and obsolete inventory involved subjective auditor judgment because the estimates rely on a number of factors that are affected by market and economic conditions outside the Company's control. In particular, the obsolete and excess inventory calculations are sensitive to significant assumptions, including the expected demand for the Company&#8217;s products, assumptions about the vaccine&#8217;s life cycle, the effect on demand of competitive products and the Company's purchase commitments.</span></div><div style="text-align:justify"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the Company's excess and obsolete inventory reserve process including management&#8217;s review of the significant assumptions described above and controls over the completeness and accuracy of the information used to develop the estimate.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our substantive audit procedures included, among others, evaluating methodologies, assumptions and data utilized in the analysis for inventory expected to be at risk for expiration or excess. We evaluated purchase commitments or alternative uses, compared forecasted demand to historical trends, compared actual inventory levels to forecasted demand requirements and evaluated the sensitivity of sales forecast assumptions on the amount of inventory reserves recorded.</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODc_033d45d9-9287-4e66-bc57-98ff79892c0d">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2014.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODg_30981a92-b8d7-4144-bb9a-95b64c2ca1da">Tysons, Virginia</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2023</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax,&#160;Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Novavax, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Novavax,&#160;Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes and our report dated February&#160;28, 2023 expressed an unqualified opinion that included an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 9A. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODk_5c8ecd2e-b45d-4362-a34e-f8b7b83d4725">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODY_400caa96-3a51-47df-8cbf-0bfdbbf11ebe">Tysons, Virginia</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2023</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 4</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_121"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share information)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39643791632e4e05a291fb0194ec9876_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzMtMS0xLTEtNzAyMDA_fcc6d592-859f-41a6-a99a-11444413ebaf">1,554,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63b56ea82ae477cbdd1dde33c7982bf_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzMtMy0xLTEtNzAyMDA_0a664a45-cd3a-4925-ac58-28764b4cc3fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6887961a304cfc83b8882d4e95843b_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzMtNS0xLTEtNzAyMDA_31cf2d41-b8e4-4538-aa7c-ef95fb7cedb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229e45ac7dd0484582dd508d0b410d09_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzQtMS0xLTEtNzAyMDA_38eee527-c4da-4b59-b052-6fb454311d2d">382,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2c1b3a8f554776b7ead7f9e8afc0be_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzQtMy0xLTEtNzAyMDA_76cee181-b6f2-49cd-a06b-ec6ffbcd61f9">948,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608ca42330f04ed38d4a29292e36a8e2_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzQtNS0xLTEtNzAyMDA_2373da09-6d59-4c58-a8c1-2df9c4e05d50">453,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb291a2235b342fb88d2412401c2825b_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMS0xLTEtOTY2OTA_4d21a157-596f-4c44-a387-5e68f3424e28">43,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dfc6b235bc64239a4750cc827d5e7be_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMy0xLTEtOTY2NzQ_f96ddc88-7b38-4807-918a-a6e3527e213e">197,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42323458487a4a9c9100db83bbdf3ed4_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtNS0xLTEtOTY2NzQ_e2203802-eb0d-47d6-bb19-e21efa0b76d2">22,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMS0xLTEtNzAyMDA_532359a7-bcde-4d1f-9a8d-61ee065942d0">1,981,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMy0xLTEtNzAyMDA_9c5dd588-5e3f-40b3-979d-2b6b29cce22f">1,146,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtNS0xLTEtNzAyMDA_00a2908f-a5a4-489a-81de-026e5dfaf5e3">475,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzktMS0xLTEtOTk0Njg_e3f2c51a-c344-4d4d-b367-af8392deed9c">902,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzktMy0xLTEtOTk0NzU_1bd4de17-7029-4068-ba43-e73610690184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzktNS0xLTEtOTk0ODI_01ba8a70-94b1-4053-b2d8-92275d3dc863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzgtMS0xLTEtNzAyMDA_12bf16b3-99a3-4eb4-9ba8-c72a4b57ee4b">1,235,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzgtMy0xLTEtNzAyMDA_28df42ea-e820-46a5-8306-73b78bfe7ed7">2,534,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzgtNS0xLTEtNzAyMDA_5f2feab4-4bd1-400f-b049-526059425d01">747,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEwLTEtMS0xLTcwMjAw_94bbb78e-4102-4503-8ccf-6c2983940f0e">488,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEwLTMtMS0xLTcwMjAw_c0fbb8c9-e927-476e-ab75-7d4084476614">298,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEwLTUtMS0xLTcwMjAw_ef07b393-e75c-4364-92f7-d281d4885da0">145,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzExLTEtMS0xLTcwMjAw_bcb20372-ceb9-40b1-a021-30b27b3c9e19">2,626,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzExLTMtMS0xLTcwMjAw_dcb4301c-766a-4587-b2bc-571160dc5bf2">2,832,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzExLTUtMS0xLTcwMjAw_5dd75b39-a788-41ed-90ea-e072a1171452">892,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEyLTEtMS0xLTcwMjAw_5147951e-d55c-45bb-8a90-4918477ef042">644,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEyLTMtMS0xLTcwMjAw_6c745ee5-395c-492e-9d05-1b7af5cbd6b6">1,686,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEyLTUtMS0xLTcwMjAw_663a4741-4b2e-4a5e-962d-83ec9423d6cf">416,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE1LTEtMS0xLTcwMjAw_b28dffac-1688-498b-851a-c74835e920da">19,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE1LTMtMS0xLTcwMjAw_7ce6cfbe-fc58-4034-abad-625fe2169135">21,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE1LTUtMS0xLTcwMjAw_964db1cc-e4e1-4643-a0c9-6a443d859149">15,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE2LTEtMS0xLTcwMjAw_ec1fbd6e-9e80-4c0f-9e06-0fc59f6aea93">10,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE2LTMtMS0xLTcwMjAw_199c8b92-c61f-476a-b5bd-a01eaa1ae2ac">6,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE2LTUtMS0xLTcwMjAw_af70b387-6c2b-4229-ba62-39c603edf976">13,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE3LTEtMS0xLTcwMjAw_4acea058-1e3d-4283-9d8f-68e3e4db5b2e">653,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE3LTMtMS0xLTcwMjAw_52ef65b6-a759-441b-a346-a746f96ecf08">1,714,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE3LTUtMS0xLTcwMjAw_c76e27a0-b54f-479b-bad8-df7fd919ba07">418,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE4LTEtMS0xLTcwMjAw_da1ca305-7dd8-4ec8-8fb4-3d98a7ead94a">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE4LTMtMS0xLTcwMjAw_95793e84-8743-4a7a-bc6f-ee4ff55b211d">29,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE4LTUtMS0xLTcwMjAw_1db3ecfa-d514-4ebf-a9ff-a271cc0e3ff2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE5LTEtMS0xLTcwMjAw_1856259a-2ef1-4ab9-9162-bfae9629d0bd">657,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE5LTMtMS0xLTcwMjAw_e3d4fc2b-85bc-46e5-9818-00e668b4af32">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE5LTUtMS0xLTcwMjAw_3e062e01-3580-44a5-903d-a3e66ca622c4">418,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTEtMS0xLTcwMjAw_04bcb035-1bf5-4ac0-bdbb-717ccd37699c"><ix:nonFraction unitRef="usdPerShare" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTEtMS0xLTcwMjAw_d95a2c67-4af8-4c9a-96d0-ae596525c23f">8.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTMtMS0xLTcwMjAw_c4182bcf-abcb-43b9-b2f5-a8b8d49c92e5"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTMtMS0xLTcwMjAw_d0f8e238-a3da-4b1b-8f52-7bdc3177b99a">23.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTUtMS0xLTcwMjAw_263d52f0-98ab-459e-bcb7-6edb54b8cb4b"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTUtMS0xLTcwMjAw_98205ac3-e696-4989-b620-ec99ba87ae2c">7.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTEtMS0xLTcwMjAw_2e7b6b2f-4a3c-482c-9ab8-34c275f49af1"><ix:nonFraction unitRef="shares" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTEtMS0xLTcwMjAw_a13cb166-7553-4be7-ab26-e44a01502cc4">78,183</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTMtMS0xLTcwMjAw_4218a06a-4e68-440c-a7e8-ba951bc77a58"><ix:nonFraction unitRef="shares" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTMtMS0xLTcwMjAw_fb90b521-5431-43d2-8644-e1063e89abeb">74,400</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTUtMS0xLTcwMjAw_8f7d5c0c-f2b1-4f0d-a387-88333c6aeba7"><ix:nonFraction unitRef="shares" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTUtMS0xLTcwMjAw_ee70ea05-68c2-4471-a015-c537b0128df8">57,554</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:30pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzItMS0xLTEtNzAyMDA_943f10b4-eefa-45de-9421-3d08efc9cbc0">657,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzItMy0xLTEtNzAyMDA_ac9ad98d-61be-457a-b50e-5cad66f042ba">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzItNS0xLTEtNzAyMDA_6dce43f2-6315-4293-a84d-e18872f18e8c">418,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzQtMS0xLTEtNzAyMDA_7dbf0a8f-27e7-452b-b257-4d19f3b4b926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzQtMy0xLTEtNzAyMDA_5c0e2a6a-14b0-4a2e-b87b-15cd0c8143aa">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzQtNS0xLTEtNzAyMDA_d1d4a0b4-b857-4dfe-88ea-00588a475e6a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzUtMS0xLTEtNzAyMDA_5e9013cd-0299-4f32-8312-7b9854ab3a67">5,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzUtMy0xLTEtNzAyMDA_9185ef63-daab-48fc-8844-169d81e6be10">8,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzUtNS0xLTEtNzAyMDA_9bf2f05a-1243-4a81-81ac-2e546540dbd0">19,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzYtMS0xLTEtNzAyMDA_361f114c-7367-4f55-ab59-b6a2dcb2265b">5,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzYtMy0xLTEtNzAyMDA_60f986bc-a152-4197-a84f-248a88184483">8,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzYtNS0xLTEtNzAyMDA_14bf129b-26a1-471c-8bde-6999e17947da">19,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzctMS0xLTEtNzAyMDA_1027c8ca-038c-45eb-bfb9-ad01a3fd898c">662,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzctMy0xLTEtNzAyMDA_7617a853-615c-4639-895d-25631d8dd31c">1,752,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzctNS0xLTEtNzAyMDA_72c0fe25-d73a-46be-bf47-627fe743134e">398,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 5</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_118"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share information)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQtMS0xLTEtNzAyMDA_67f60d10-3792-48ce-87bf-71885014b1db">1,336,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQtMy0xLTEtNzAyMDA_85cf10cd-4176-4bc7-bd72-f93e155072b9">1,515,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzYtMS0xLTEtNzAyMDA_7da308f5-8363-4888-975e-2291da6dab8a">10,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzYtMy0xLTEtNzAyMDA_ee894795-dd6a-47fa-830a-6d2c4d7fa234">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMS0xLTEtNzAyMDA_573efe11-4dbb-45f7-a6c4-d837aa0835a7">82,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMy0xLTEtNzAyMDA_b5610319-4e6f-4b8e-89c5-239614d2504e">454,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMS0xLTEtOTk5Mjk_04b84ee7-66d3-4bda-9f97-79b0f71c0a47">36,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMy0xLTEtOTk5MjI_1d7a8988-70da-4be0-baae-c2b2a3cf79f4">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzgtMS0xLTEtNzAyMDA_24eadd4e-73a1-4665-b222-07b532691043">237,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzgtMy0xLTEtNzAyMDA_3677b5f8-4ed5-4ee6-8692-0b70a98b2890">164,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzktMS0xLTEtNzAyMDA_66c9260a-34a9-4aad-8cd3-7a6a53e342b7">1,703,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzktMy0xLTEtNzAyMDA_273d8ed9-3731-490a-be30-2eebcff1ebcb">2,155,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEwLTEtMS0xLTcwMjAw_55aa55d4-0469-4e81-b990-7e96f775d6f3">294,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEwLTMtMS0xLTcwMjAw_29dfdbbe-882a-4fa5-bcf2-202afde62c59">225,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzExLTEtMS0xLTk5OTc1_859973ee-9751-4f58-81a3-64d42a11731f">106,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzExLTMtMS0xLTk5OTc1_a09e4df4-82ca-4c8b-8d63-a3685a65072c">40,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEyLTEtMS0xLTcwMjAw_0e295127-5c0b-42c6-9797-ba3d8d2fd1b9">126,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEyLTMtMS0xLTcwMjAw_bb3b2a07-7a82-4ab0-9569-faa657013e95">131,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEzLTEtMS0xLTcwMjAw_8c2deb53-e371-4f8c-99f0-8dabcfce4ecd">28,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEzLTMtMS0xLTcwMjAw_b4bea2ef-c761-4402-a003-a33ad677a150">24,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE0LTEtMS0xLTcwMjAw_0fa0792b-e3b5-43d8-8402-e9efd09f3d5b">2,258,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE0LTMtMS0xLTcwMjAw_e5b691d3-59c6-40f6-86d0-bbba59acb565">2,576,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE3LTEtMS0xLTcwMjAw_e41a84c4-4ff4-47e3-962e-3b9314159534">216,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE3LTMtMS0xLTcwMjAw_f407249f-da52-472e-9c8f-7ebef94cfed1">127,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE4LTEtMS0xLTcwMjAw_61d13b1b-64c2-45a0-a0e1-bd461cd1b350">591,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE4LTMtMS0xLTcwMjAw_2bf00dff-7970-403f-8c22-30346cc89ba7">673,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE5LTEtMS0xLTcwMjAw_3ba02bb0-4096-4c72-b4a3-1bda0f357acb">370,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE5LTMtMS0xLTcwMjAw_4aeacd12-9434-46dd-a3ab-a3410f633830">1,422,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIwLTEtMS0xLTcwMjAw_373e29ec-cf9d-4d3a-8564-b91695d66580">27,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIwLTMtMS0xLTcwMjAw_78ee88c6-7a4c-49ed-89fe-e38ce0311edb">130,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTEtMS0xLTEwMTI0NQ_c987aa58-824d-43b3-bbd5-bbaf4fb39097">324,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTMtMS0xLTEwMTI1Mw_3e9caebf-c486-492d-8712-c537ba029238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTEtMS0xLTcwMjAw_350c952b-8ced-45cd-a0a3-48cf2841fdb7">930,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTMtMS0xLTcwMjAw_778df95e-0889-4418-87a7-9e6246003a98">36,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIyLTEtMS0xLTcwMjAw_3b0a0e44-e19f-4f52-b186-4ceaf9a691b2">2,459,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIyLTMtMS0xLTcwMjAw_6ecfb34e-83c1-4635-9a37-245f500cdc51">2,390,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIzLTEtMS0xLTcwMjAw_39f0f158-703f-4ac4-9717-0e114bc25eb3">179,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIzLTMtMS0xLTcwMjAw_ba8cce8e-8acd-40b8-be52-6ed74bcece97">172,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI0LTEtMS0xLTcwMjAw_0cf93431-578b-4918-a529-903c3b3ff6a0">166,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI0LTMtMS0xLTcwMjAw_1b385082-0318-43e6-84ac-dde23ef040ab">323,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTEtMS0xLTEyNDI4MQ_50d90b8e-39d8-4a91-85ac-1c346515d2d2">31,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTMtMS0xLTEyNDI4MQ_b8d13615-1737-41ae-aa0c-558c2e86c390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTEtMS0xLTcwMjAw_ea954d22-9e02-40ad-9b4a-0d17f7708c0d">55,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTMtMS0xLTcwMjAw_5da4a467-b928-45d0-8e8d-0f59f9306f5c">42,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI3LTEtMS0xLTcwMjAw_ebdc7cfc-b750-4546-aff9-6ad4c35416bf">2,892,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI3LTMtMS0xLTcwMjAw_9218d44f-3884-4c3a-ac5f-448e97dcc3bd">2,928,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 18)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI5LTEtMS0xLTcwMjAw_2decc3ab-3dc2-49e7-b06b-cd5dfb795f91"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI5LTMtMS0xLTcwMjAw_f907b4a2-ac68-4fbd-8153-b22b164c8f91"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMjI_4a78bce0-b47c-4625-b306-6291154b5d64"><ix:nonFraction unitRef="usdPerShare" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMjI_5a488198-f1dd-4b7f-9cd4-6cb011039759">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMzY_2e1f5f6c-4d53-4d17-b70d-9f3e881b5094"><ix:nonFraction unitRef="shares" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMzY_d1c479a7-0029-48c1-9d2e-7a297bcc4ff8">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_7a2c7654-bfff-47ce-99de-9e9db5a397ec"><ix:nonFraction unitRef="shares" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_82dea189-29e7-4b18-8840-9b52decddf4f"><ix:nonFraction unitRef="shares" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_ccc1cce5-c98b-4ce2-836d-4053b63e9aac"><ix:nonFraction unitRef="shares" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_daaf177c-378a-4d3e-a7f9-29c9606fdaff">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTEtMS0xLTcwMjAw_3e0e3335-6d8f-4a47-b521-b3bb863058cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTMtMS0xLTcwMjAw_22cc859d-0093-44d1-bbad-463127002538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTg_59ffc122-f25b-4092-8a45-41dbc09ed109"><ix:nonFraction unitRef="usdPerShare" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTg_844490c9-e0be-478c-b7d2-e9898426dbf0">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMzI_81384262-5bc8-4789-a14e-21f3a40618e6"><ix:nonFraction unitRef="shares" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMzI_be60f325-3b17-4adf-8d26-67abd098010a">600,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2022 and 2021; and <ix:nonFraction unitRef="shares" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfNzE_4a9e7a5e-00cf-4cf5-9c94-2b593a6ffaab">86,806,554</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfOTI_8f73ab06-19b1-42f0-9272-7b5cfe12f439">86,039,923</ix:nonFraction> shares outstanding at December&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTI0_f60448ba-5f41-4303-9638-86e54287a737">76,433,151</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTQ1_28b8f7a7-5395-422c-8b6e-0c1177675508">75,841,171</ix:nonFraction> shares outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTEtMS0xLTcwMjAw_5aa8c578-ff40-4288-a239-0262579efd5c">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTMtMS0xLTcwMjAw_bd320b7d-80ab-4ec0-8dc0-0b9402ab66d9">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM1LTEtMS0xLTcwMjAw_f95ef58f-db0a-4a5e-ad6d-f0be9620c21f">3,737,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM1LTMtMS0xLTcwMjAw_73f63a81-1b4d-48b8-9f0e-5d4d8ce4408f">3,351,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM2LTEtMS0xLTcwMjAw_80da236f-07a0-45df-83b0-57b70fd8add3">4,275,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM2LTMtMS0xLTcwMjAw_d3562459-dad3-4bca-bbb8-71b10ed42698">3,617,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, <ix:nonFraction unitRef="shares" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZDU4ODVkYjBiNzE2NDBiNGE5ZmUyNmM1MDIzNjFhZDFfMjA_c670c571-b357-4a14-a52a-72e9be97b5e9">766,631</ix:nonFraction> shares, cost basis at December&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZDU4ODVkYjBiNzE2NDBiNGE5ZmUyNmM1MDIzNjFhZDFfNTI_46a7e3a6-001f-4095-91fc-ccb92165cad1">591,980</ix:nonFraction> shares, cost basis at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTEtMS0xLTcwMjAw_21ac5b7f-9ee3-4068-9bdd-298945d95f0e">90,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTMtMS0xLTcwMjAw_b2eb464f-fc5b-438d-9c7a-ef96ea262816">85,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM4LTEtMS0xLTcwMjAw_3cb4877f-a5cd-4232-90e4-2b2d5b9a634f">6,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM4LTMtMS0xLTcwMjAw_d3095558-7613-4648-a9a7-b6c3fcfee23e">1,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM5LTEtMS0xLTcwMjAw_e69c1775-a4fa-4b6e-87c0-5b738380f76e">634,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM5LTMtMS0xLTcwMjAw_73be1edd-372d-4fde-bdd1-1579f3b771ac">351,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQwLTEtMS0xLTcwMjAw_c1f81a16-eb60-4113-95e4-ed750c806c10">2,258,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQwLTMtMS0xLTcwMjAw_c7193a8a-6789-43a2-9df1-28e84bd9fa3f">2,576,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 6</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_124"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share information)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.298%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib77bd7520a4c413d82a3ee385fdabe20_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMS0xLTEtNzAyMDA_6cedb5dc-51ed-4525-970e-7e6ce39273f8">32,399,352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77bd7520a4c413d82a3ee385fdabe20_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMy0xLTEtNzAyMDA_06ddff85-9b7d-4c5f-86e5-516ba86f86fc">324</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i276434eedddc41439edb0c1b98cc9b7b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItNS0xLTEtNzAyMDA_fcabcceb-bba9-4ce5-948b-f553da095090">1,260,551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i478e92d6d04344fbaa0f10b3ab1efcba_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItNy0xLTEtNzAyMDA_2ab1045d-2716-4069-93fa-47257e8e03f0">1,431,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0c9aba10dd1499b9921e8f2fab79047_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItOS0xLTEtNzAyMDA_3b5038e7-1d2a-4538-97e9-4bb1ce92310b">2,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee35c23efdb64a64bc904783db535a83_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMTEtMS0xLTcwMjAw_cb14cacd-d8d4-45da-ad9a-68b94633ed3a">12,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab79f65652ef4787919164353ded1194_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMTMtMS0xLTcwMjAw_7ff6923a-7f8d-4edd-b690-fe6a786d2152">186,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Preferred stock beneficial conversion feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231" decimals="-3" name="nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtNS0xLTEtOTcxMDM_d78ab371-1839-4aae-bc1f-223a3b165ae3">24,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939e909e3aee442cbe4c2ed5be1acf17_D20200101-20201231" decimals="-3" sign="-" name="nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtNy0xLTEtOTcxMDM_26886e79-f84d-4e63-8c31-fe9cff532db8">24,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMTMtMS0xLTk3MTAz_ecec973e-24e8-4bbb-a75b-667f8c1653eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Conversion of preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMS0xLTEtNzAyMDA_d18e8e98-5387-4d09-9934-a97d92770437">4,388,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMy0xLTEtNzAyMDA_7ce0c106-3e5e-486e-ac57-6ece64ab2d61">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtNS0xLTEtNzAyMDA_1b562ae5-630c-4d6d-a7fb-f74963e584ce">199,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMTMtMS0xLTcwMjAw_f2fcf2b7-c761-4a6a-a0ec-37709b28cb7a">199,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzQtNS0xLTEtNzAyMDA_4517eadb-3eae-415c-9a65-e521edb586bd">128,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzQtMTMtMS0xLTcwMjAw_f863876c-54f8-43e6-94db-cb846728b4e7">128,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtMS0xLTEtNzAyMDA_e789c29a-2b75-4532-8481-a4d0bcb9e3cc">2,168,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtMy0xLTEtNzAyMDA_21a1160a-d4de-4279-936e-944ee025daf9">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtNS0xLTEtNzAyMDA_1fe92393-cf1c-43c5-9490-4f8f82563d27">44,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i284adc6f56cd47bb8227b04aeb8caefc_D20200101-20201231" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtOS0xLTEtNzAyMDA_fc775698-688a-4d33-bdbd-e0005cc56ae0">39,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtMTMtMS0xLTcwMjAw_43a9189c-0cad-4141-a72f-0b886a28b8d9">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMC0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxNjEzYzQ1ZmJmMTg0OGI3YmJkMGEwYTc2N2JlYmQxNl8xNDg0MzQwNjk3NTA0NQ_cc2f33e8-dbd0-4815-b973-82188e43a7be">11,416</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMS0xLTEtNzAyMDA_fbaa56ec-8fbc-459c-ab89-035d7cc9665b">32,393,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMy0xLTEtNzAyMDA_e3ef6974-5c05-4d15-bdd6-98accbf45d5a">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtNS0xLTEtNzAyMDA_8b379e62-01d9-4542-aa73-7bb1ae3c5af5">878,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMTMtMS0xLTcwMjAw_19792b5b-7003-427b-8b0f-e9df9896234a">878,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69381417968421ab3aaeea9e7e8a831_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzctMTEtMS0xLTcwMjAw_a45711e9-1c1e-4b99-b10b-345812a846c6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzctMTMtMS0xLTcwMjAw_98f43434-fc82-47ed-8e3f-ed7b34dd1801">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69381417968421ab3aaeea9e7e8a831_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzgtMTEtMS0xLTcwMjAw_6a17cf05-3344-45c7-bb09-08fcffd36a71">19,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzgtMTMtMS0xLTcwMjAw_1995a41d-fbf8-4691-b830-537bfe211ece">19,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939e909e3aee442cbe4c2ed5be1acf17_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzktNy0xLTEtNzAyMDA_8dcd56a8-797f-4695-afca-fb828755bdf2">418,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzktMTMtMS0xLTcwMjAw_acbd9260-4b44-4b9c-8f1c-747f52e20e0e">418,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d79e2b326344dec97c2c4f1db0400d9_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTEtMS0xLTcwMjAw_84636cd4-f722-404e-9031-e0e5f788be09">71,350,365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d79e2b326344dec97c2c4f1db0400d9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTMtMS0xLTcwMjAw_28d5e646-366b-4736-a945-6cb3a93c2e6a">714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79ae4732ce047b39cee388e3a7d5c42_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTUtMS0xLTcwMjAw_a512e63d-f470-4874-b208-b41bdb3a7083">2,535,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic862fa293ea94c52be0807c27252da1a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTctMS0xLTcwMjAw_209c0f8e-5446-4680-9c69-8a3dea3e87a7">1,874,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia042d64a00eb47ce9cb332d9341b3343_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTktMS0xLTcwMjAw_a84addc4-0343-4904-a936-670c9731e207">41,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a1a3f2ee4448078a0f2e6954fd5e5f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTExLTEtMS03MDIwMA_4f920ab7-9af4-4ae7-ad2b-033a9806a7c2">7,024</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTEzLTEtMS03MDIwMA_e3691661-361b-4a25-8a88-e9178fd83354">627,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75daa84e516a43879509c48930e444f6_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzExLTUtMS0xLTcwMjAw_56b11a48-dae8-4e41-9e2b-766395f50417">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzExLTEzLTEtMS03MDIwMA_9f60e659-f40a-4430-b681-9694c4adf702">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTEtMS0xLTcwMjAw_ad11e148-15f5-4e5c-ac70-b461de82fbc7">2,503,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTMtMS0xLTcwMjAw_a8330647-a9a2-4711-a386-d9c42a1833a5">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75daa84e516a43879509c48930e444f6_D20210101-20211231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTUtMS0xLTcwMjAw_858423ea-2615-47db-9477-28b6212aceda">68,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife9d9bbf7294424fa7bb5a43026e8d23_D20210101-20211231" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTktMS0xLTcwMjAw_1412aef0-831c-4485-8926-e0f8f9a3de66">43,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTEzLTEtMS03MDIwMA_53bf0f7f-665a-4dee-b37b-5d30eddd41d6">24,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTAtMS0xLTcwMjAwL3RleHRyZWdpb246NDE5NzMxZGI2ODM4NGMzZGFjM2E0Y2RlNTliMGMzOGRfMTQ4NDM0MDY5NzUwNDM_c006f6f7-856f-447b-b5b9-8aaf264c7323">7,292</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTEtMS0xLTcwMjAw_a1db9e91-728b-4012-a660-998eb3c9a4b7">2,578,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTMtMS0xLTcwMjAw_eef5c376-f604-4777-8c6c-cbd19c5fff8e">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75daa84e516a43879509c48930e444f6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTUtMS0xLTcwMjAw_bb52f8da-361d-4e62-8b65-98cdaac665ef">564,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTEzLTEtMS03MDIwMA_9cf1095f-02f6-4a90-891f-5d16e8a6af38">564,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47b104e574784fa7a1222f8870276e6a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE0LTExLTEtMS03MDIwMA_92740c36-e2b6-455e-8cc9-047f92b5eb68">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE0LTEzLTEtMS03MDIwMA_4a3fee2a-de68-4899-a876-a49f0bf5e0ce">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47b104e574784fa7a1222f8870276e6a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE1LTExLTEtMS03MDIwMA_fa412264-c121-4245-8ba4-e67ea9db5c8f">8,368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE1LTEzLTEtMS03MDIwMA_e2c3f24a-7d6c-4b1b-8545-1e30a36bc929">8,368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000db304d0ac493c91874d53eda30c3f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE2LTctMS0xLTcwMjAw_8b148efe-0bee-42af-b39d-60ae04ffa603">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE2LTEzLTEtMS03MDIwMA_5c29e5a1-5a63-4be3-afe9-9659a1d65433">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaecfb76823254dd19a4cf6ad1affdba6_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTEtMS0xLTcwMjAw_60692afc-c535-47c8-9806-d01eafade209">76,433,151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecfb76823254dd19a4cf6ad1affdba6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTMtMS0xLTcwMjAw_86460e9f-73c3-4ebb-8ded-1858c85d5384">764</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4138df8c406d48159527133860ea5188_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTUtMS0xLTcwMjAw_6d50c417-70be-41ab-969c-7b3b1058ff3c">3,351,967</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice8277fc63064ac59b415265922b2955_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTctMS0xLTcwMjAw_4caf7f56-2308-4b90-82af-9e856b31f275">3,617,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i112cd4ea48f64fb4818bddbc7fbde54b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTktMS0xLTcwMjAw_930b60c8-2be6-4a02-98b9-da3d98ab5e6f">85,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1a2fe6a8df24324964c4a66ca6b445a_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTExLTEtMS03MDIwMA_ecec22fa-b133-415c-839c-2856aadb60d6">1,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTEzLTEtMS03MDIwMA_22a34020-82f6-4a8a-ae2f-7a010092835a">351,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIwLTUtMS0xLTcwMjAw_0a237d52-7a92-4936-943f-1a415d07d826">131,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIwLTEzLTEtMS03MDIwMA_a9315305-8872-4ee3-86dd-33119bed5792">131,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTEtMS0xLTcwMjAw_40b7675e-a643-4739-8912-2e202805d7bc">701,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTMtMS0xLTcwMjAw_e7e7e957-0746-40d4-bd73-88eefebb6388">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTUtMS0xLTcwMjAw_22be9607-e626-4797-8ed5-451c6a0a141d">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e7bd4e1044a4bfdab99267a4bec8cec_D20220101-20221231" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTktMS0xLTcwMjAw_8851971b-6544-4d6a-b9a0-75261a1b09e1">5,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTEzLTEtMS03MDIwMA_9fe697ef-b638-411e-abe5-edeb06581e3e">639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZDNkZjg4OTJmMzQyNDI5MWEwNTVmZTFjNGNjNDRlNDNfMTQ4NDM0MDY5NzUwMzU_3d1711d9-40a2-4370-bc2b-239aa4aa6abf">7,216</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTEtMS0xLTcwMjAw_cfa195dd-7d0b-4e13-bd3d-c540775a5bb3">9,672,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTMtMS0xLTcwMjAw_cb277b56-7640-4e36-95fe-b2419d6a6c5f">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTUtMS0xLTcwMjAw_0acd9f34-4f30-419c-9a66-7c6009acea96">249,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTEzLTEtMS03MDIwMA_587dc7e8-6429-4f3d-91b4-a532020e5cb9">249,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a71f67b2f48c69763adc332e28e74_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI0LTExLTEtMS03MDIwMA_e4ee5c38-958b-4ae7-b536-878ee7ca5735">5,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI0LTEzLTEtMS03MDIwMA_418de912-2636-4bd1-8c54-0307e300f591">5,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd03da035b34b17a46b6f7abfe523e2_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI1LTctMS0xLTcwMjAw_dc5261f1-ed45-4e1a-aa64-9c9ba64dac76">657,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI1LTEzLTEtMS03MDIwMA_ab3b3a73-1613-415b-8c14-7a803849748a">657,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5673a51c537945239d7bb0e47db6afeb_I20221231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTEtMS0xLTcwMjAw_2b5010d6-a60f-4fa3-8be5-2810204d7d85">86,806,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5673a51c537945239d7bb0e47db6afeb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTMtMS0xLTcwMjAw_d7d8923e-974b-4501-a910-90d8a08bff4a">868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff09caaa96e4bde871b650ce7a243eb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTUtMS0xLTcwMjAw_ea0992b3-4234-4048-9523-b17a338bc22a">3,737,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i643826e193814924924520e0e7696755_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTctMS0xLTcwMjAw_84073351-e41e-4ade-8a5d-bee86aed306a">4,275,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e0508fe92d74026bf85072a53f8d173_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTktMS0xLTcwMjAw_f6273ee5-4a2d-472d-9207-d969cb81f87d">90,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb3b3ae8c2e49b6af7301fcc04bfce2_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTExLTEtMS03MDIwMA_2d013f0b-1646-4582-b5e8-1bc8ed8015f9">6,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTEzLTEtMS03MDIwMA_a21a9f6c-db5f-4be8-afd6-2973905dd2b5">634,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 7</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_127"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMtMS0xLTEtNzAyMDA_ff599ee3-5dff-4433-b2a2-2ba01827e5ae">657,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMtMy0xLTEtNzAyMDA_2fec0502-9678-47c3-8113-3e9264aa556d">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMtNS0xLTEtNzAyMDA_217877e7-2672-440a-a2f9-5389df890e54">418,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzUtMS0xLTEtNzAyMDA_a9ce4cce-845b-411a-b13f-0eb6ee9253e6">29,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzUtMy0xLTEtNzAyMDA_86a6a8ec-4352-4c03-8cfd-f377552c316b">12,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzUtNS0xLTEtNzAyMDA_332307a8-b371-4fcb-82b6-d2a318ba5d63">4,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets expensed, net of credits received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzctMS0xLTEtNzAyMDA_34aff6a7-b90d-4843-80a1-ca7c0df214c5">18,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzctMy0xLTEtNzAyMDA_70d952ed-cdaf-45a3-9050-1c9be27383b4">144,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzctNS0xLTEtNzAyMDA_28dca50c-30ac-434f-9dc3-f392fdb51c04">245,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMS0xLTEtNzAyMDA_cb2dd159-44e9-4946-ad7f-e464879e529f">130,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMy0xLTEtNzAyMDA_5f0f1455-d759-4fa8-afd4-f897c134f944">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtNS0xLTEtNzAyMDA_d9df1eee-a1ae-4111-ad39-822509225c22">128,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for excess and obsolete inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMS0xLTEtMTAxMjc1_92425b3f-f8e5-47c1-9de7-622e6601c645">447,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMy0xLTEtMTAxMjgy_fbe74f28-59bc-46d5-83d0-a2dd1087d9ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtNS0xLTEtMTAxMjg5_dc87e68d-97a2-45c5-9af2-8ed894290fa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzktMS0xLTEtNzAyMDA_911cf833-f5de-420f-ae85-17de0cd63858">21,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzktMy0xLTEtNzAyMDA_180b78e1-ee43-4809-9ec0-e15c66188dcf">7,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzktNS0xLTEtNzAyMDA_c8df6a82-284c-491d-8c8f-13e19826fbbd">15,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTEtMS0xLTExNDI1Mg_49384831-7d3a-4b73-8940-3b947f23b046">477,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTMtMS0xLTExNDQ5NQ_c04ce03a-8ff2-4156-bdbf-af19ebf8c8ec">8,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTUtMS0xLTExNDQ5NQ_f40ee7b4-f71c-40e0-9565-5f2cf6461c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses, and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTEtMS0xLTcwMjAw_5adcff76-07fb-4981-868f-0de0f1eed6c1">249,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTMtMS0xLTcwMjAw_ebc5a76b-8a7a-4d35-8636-1f859b092b94">183,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTUtMS0xLTcwMjAw_18c0abda-032b-46e0-8551-6dbda459ca9e">422,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEyLTEtMS0xLTcwMjAw_bc6c6cb0-b3c7-4a29-9fb2-b0857352447f">913,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEyLTMtMS0xLTcwMjAw_fe38a5af-8ea1-47cc-af25-1e7faed9d3a3">600,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEyLTUtMS0xLTcwMjAw_ae2552a5-6334-42b0-b5a2-97f2e99e7c47">163,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEzLTEtMS0xLTcwMjAw_62225873-3158-4168-9de4-c425368f2907">1,045,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEzLTMtMS0xLTcwMjAw_791aa00d-a96b-4751-8bdc-b9ad328ddb50">1,325,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEzLTUtMS0xLTcwMjAw_0889cec6-306a-45e0-ac3f-8369402b1152">271,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE0LTEtMS0xLTcwMjAw_c59325dd-a0a3-4d69-b45d-ecda32e61afd">415,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE0LTMtMS0xLTcwMjAw_1ce161dc-d709-480b-a82c-cc3ab813afec">322,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE0LTUtMS0xLTcwMjAw_ea5c53a6-b6a9-45de-a2ec-d3e4e7cf9ee5">42,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE2LTEtMS0xLTcwMjAw_f733f189-ea1f-4584-b857-5b3055e88dad">89,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE2LTMtMS0xLTcwMjAw_bf3cc4c4-4c04-4b07-be05-4110ef53a09f">54,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE2LTUtMS0xLTcwMjAw_265ddacf-b8b2-4998-adf6-2cdd9a89cfdd">54,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTEtMS0xLTEwMTMwNw_8ddffb9b-98c2-43c3-857b-e5c0448c882e">3,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTMtMS0xLTEwMTMxNw_8c4dd714-0419-4c81-be93-2a535453d7bc">2,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTUtMS0xLTEwMTMyNA_a998e350-be17-4c58-82be-e5752a70a641">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Novavax CZ, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTEtMS0xLTcwMjAw_b6a94713-74eb-478a-a71f-c310dbfd0ec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTMtMS0xLTcwMjAw_96a6d384-061d-4de2-9a58-8c5a380fbd27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTUtMS0xLTcwMjAw_2bb24980-d104-419b-8bb0-67798726a163">165,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE5LTEtMS0xLTcwMjAw_26e4c205-aa3e-4f88-8801-c862c0f84577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE5LTMtMS0xLTcwMjAw_41d163f4-aaee-40b3-b7be-72d26b8f620f">2,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE5LTUtMS0xLTcwMjAw_e9b2798f-45a2-4f55-bb4c-fa7a52ceb8d9">363,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIwLTEtMS0xLTcwMjAw_f9b56228-cbf6-4a59-901f-203994fdea5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIwLTMtMS0xLTcwMjAw_10d43bf3-a147-4393-b647-0085a14b4936">159,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIwLTUtMS0xLTcwMjAw_ba7e2f6b-3689-41cd-ae69-913ba6fdef53">205,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIxLTEtMS0xLTcwMjAw_8afbf2b8-41c1-4b65-9652-8383ebd2cf6d">92,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIxLTMtMS0xLTcwMjAw_613f9b69-5704-4e4f-98e1-554793c7219f">100,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIxLTUtMS0xLTcwMjAw_bed595e4-bdfd-4dbd-b363-7f263024e650">377,778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from sale of preferred stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIzLTEtMS0xLTcwMjAw_266dcc52-556d-4294-9883-e10a2f0cf524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIzLTMtMS0xLTcwMjAw_50a796b8-3625-4838-a4df-71fc4c4abf0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIzLTUtMS0xLTcwMjAw_cf55bbb6-71a5-4602-b678-02cd43714a7a">199,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from sales of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI0LTEtMS0xLTcwMjAw_8c8f2ccb-0947-4e87-8185-f53007a2f90a">249,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI0LTMtMS0xLTcwMjAw_7a38c485-ffa9-47f2-a91f-fa17d7807d67">564,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI0LTUtMS0xLTcwMjAw_9266b922-5b57-47d1-b9e3-5c2c4c07c251">875,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTEtMS0xLTEwNjA0NQ_39fcfbd8-af3c-459b-af76-9d11cc91e9e1">175,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTMtMS0xLTEwNjA0NQ_a87b28a6-f070-43cc-8bb1-1e3ea8b873ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTUtMS0xLTEwNjA0NQ_b5d13fdb-0cb4-4af5-a987-34a896380d4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of costs related to issuance of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTEtMS0xLTEwNjA0OQ_1351afdd-0ace-4b5e-a6a9-9860f9388bc2">5,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTMtMS0xLTEwNjA0OQ_ae13867a-6258-4280-81fd-63bb89e57e6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTUtMS0xLTEwNjA0OQ_529b22aa-ecc3-45f6-9ff5-1f4d0843a97f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from the exercise of stock-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTEtMS0xLTcwMjAw_ce226fee-74c8-4888-b1d6-0f99d1005fea">639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTMtMS0xLTcwMjAw_fa911ce5-0084-407f-8c70-6d1b98063d45">24,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTUtMS0xLTcwMjAw_f06c5dfa-5ca5-4324-a25f-acd61c89994f">5,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTEtMS0xLTcwMjAw_e3cf1ce3-bba5-4870-8acd-fab00b30760a">93,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTMtMS0xLTcwMjAw_338e02f3-a327-4b38-b871-ee4b2703d3d9">127,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTUtMS0xLTcwMjAw_2294d8b4-f5be-4e41-b266-677809186b4b">96,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI3LTEtMS0xLTcwMjAw_0fe4b1dd-15a8-420a-8531-5bd36ef8df33">324,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI3LTMtMS0xLTcwMjAw_1005559b-0f5c-4545-80ca-33f3b6810a62">461,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI3LTUtMS0xLTcwMjAw_288aac7c-8add-4ea9-a663-2c7d2508759e">984,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI4LTEtMS0xLTcwMjAw_0e99e2f1-9753-4aca-a02a-a8c584490a8a">4,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI4LTMtMS0xLTcwMjAw_9e93b933-5391-4e20-a91a-1efae7c10902">5,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI4LTUtMS0xLTcwMjAw_8965892f-cb13-4cde-a4fc-2c9c6f694f48">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI5LTEtMS0xLTcwMjAw_23f68080-83db-4f1d-9624-215790c51ea9">179,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI5LTMtMS0xLTcwMjAw_c8824ea0-ee7a-44d3-80d1-095431d54ea4">879,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI5LTUtMS0xLTcwMjAw_8981c42c-f3ca-4eb3-aa3c-4e92294fb65f">566,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMwLTEtMS0xLTcwMjAw_7b98862b-0511-4b5e-b9a2-8fd591a98b76">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMwLTMtMS0xLTcwMjAw_ac43094e-6550-4112-9136-9016d9adcb0c">648,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab79f65652ef4787919164353ded1194_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMwLTUtMS0xLTcwMjAw_160743ad-2d63-49f7-999b-f71a02cf0c69">82,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMxLTEtMS0xLTcwMjAw_ecd49807-a28d-42a8-bddc-ab138e15f0fc">1,348,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMxLTMtMS0xLTcwMjAw_4322b060-7671-4bda-8e30-8817ff651a6d">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMxLTUtMS0xLTcwMjAw_bbbc6f13-af4e-4a42-99c8-58e073c00c2e">648,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of common stock under the Sales Agreement not settled at year-end</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMzLTEtMS0xLTcwMjAw_04d6de7c-2d1c-4372-985b-64c1a47ad565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMzLTMtMS0xLTcwMjAw_13e7115f-1bbe-402c-9025-bef2ec6b0956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMzLTUtMS0xLTcwMjAw_f855b6cb-d25c-4b4b-8efa-05c646631f52">3,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM0LTEtMS0xLTcwMjAw_d88a0ecd-e1b6-4e7b-bd40-25bbb1d42ecf">17,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM0LTMtMS0xLTcwMjAw_526f959e-8efa-4091-a234-5725672e49b7">10,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM0LTUtMS0xLTcwMjAw_e7308425-6ef9-417c-9d9a-f8a882e3a930">9,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets from new lease agreements</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM1LTEtMS0xLTcwMjAw_63d5b79e-4687-4dda-9593-985d2ae4af46">91,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM1LTMtMS0xLTcwMjAw_6eaa6119-d9bf-4572-bb78-9f6da2b424aa">179,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM1LTUtMS0xLTcwMjAw_c91afee8-067e-448c-9a10-1152fd0d43ba">247,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest payments, net of amounts capitalized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM3LTEtMS0xLTcwMjAw_b91007c7-9984-48e0-9d1a-93f20e6d3f4a">18,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM3LTMtMS0xLTcwMjAw_09aaa123-c1ce-4034-ab0b-b590df858b51">19,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM3LTUtMS0xLTcwMjAw_3ca4a886-cdef-4918-8a4a-83a201c19b7d">13,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM4LTEtMS0xLTcwMjAw_d60d9375-1fc0-4a55-8446-3c937f38aea9">17,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM4LTMtMS0xLTcwMjAw_bbb447b4-f595-40d1-8805-e41b65939483">12,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM4LTUtMS0xLTcwMjAw_a54dc54b-8048-4762-ba03-955f76ba982f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:103.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 8</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_130"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_133"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzMvZnJhZzoxN2Y5YWMzMjZlOWQ0Y2Q4YjgzY2Y0NTJlNzYwMzhjZC90ZXh0cmVnaW9uOjE3ZjlhYzMyNmU5ZDRjZDhiODNjZjQ1MmU3NjAzOGNkXzIxNjE_1cb32208-4a7f-4c69-9022-028b94142a49" continuedAt="i724e08689df74efc93de5487bb92f4aa" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i724e08689df74efc93de5487bb92f4aa"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The Company&#8217;s COVID-19 vaccine NVX-CoV2373 (&#8220;Nuvaxovid&#8482;,&#8221; &#8220;Covovax&#8482;,&#8221; &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221;); influenza vaccine candidate; COVID-19-Influenza Combination (&#8220;CIC&#8221;) vaccine candidate; and additional vaccine candidates, including for Omicron subvariants and bivalent formulations with prototype vaccine (&#8220;NVX-CoV2373&#8221;), are genetically engineered nanostructures of conformationally correct recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or other vaccine approaches. NVX-CoV2373 and the Company&#8217;s other vaccine candidates incorporate the Company's proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response. The Company has announced data from its ongoing PREVENT-19 study supporting the use of NVX-CoV2373 for homologous boosting in adults and adolescents aged 12 through 17. Additional findings in Phase 3 COVID-19 Omicron (study 311) trial showed utility of the prototype vaccine as a heterologous booster, inducing broad immune responses against contemporary Omicron variants.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for NVX-CoV2373 for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commenced commercial shipments of NVX-CoV2373 doses under the name &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221; and the brand name &#8220;Nuvaxovid&#8482;&#8221; in 2022.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_136"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzA3_da6c4a64-7718-4101-9253-ba6244c8fecd" continuedAt="if904443bb3ff43748c3fb6a25bebe355" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if904443bb3ff43748c3fb6a25bebe355" continuedAt="ifb05fc59c8014a33886034c6a9292fd0"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg3_11ea9253-8db8-4b98-bab2-1f5d50cfa02c" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:LiquidityAndGoingConcernPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjE4MDE4_491900af-b3ba-499d-85ed-511feae0a857" continuedAt="ie2cd817a7b9749cdb1e3d08b4e47d247" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. At December 31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MTExNDQ_328df23e-405b-4106-98fd-c19a2c44d3d4">1.3</ix:nonFraction> billion in cash and cash equivalents and restricted cash, of which $<ix:nonFraction unitRef="usd" contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231" decimals="-5" name="nvax:ProceedsFromIssuanceCommonStockAndDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDAyNjE_e70e10f6-b1e7-4974-a19d-12686b2057c4">236.2</ix:nonFraction> million was raised in December 2022 through concurrent sales of common stock and issuance of the Company&#8217;s convertible senior unsecured notes that will mature on December 15, 2027 (see Notes 11 and 13). On January 31, 2023, the Company funded the outstanding principal amount of $<ix:nonFraction unitRef="usd" contextRef="i63a2de06fc1f42a69276ce8a6224e6a0_D20230131-20230131" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDA0NTQ_3fdb8611-4041-4504-b91b-325c3df443c4">325.0</ix:nonFraction> million on the Company&#8217;s convertible senior unsecured notes that matured on&#160;February&#160;1, 2023. During 2022, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MTExNTM_45749e6e-fb6f-4bb3-94ea-0ee0d7a95205">657.9</ix:nonFraction> million and had net cash flows used in operating activities of $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDA1NzU_a7cd5577-b003-4f86-b5c7-fcc2e24d64fe">415.9</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company&#8217;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration. The Company&#8217;s 2023 revenue depends on its ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. In February 2023, in connection with the execution of Modification 17 to the USG Agreement (as defined in Note 3), the U.S. government indicated to the Company that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as the Company&#8217;s management had previously expected, then the Company may not receive all of the remaining $<ix:nonFraction unitRef="usd" contextRef="i673cb8037c324c8994caf3306884a92e_I20221231" decimals="-6" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MjA3OTc_885de22a-675c-49dc-9f3c-2a9fcec2aa75">416</ix:nonFraction>&#160;million in funding that was previously anticipated pursuant to the USG Agreement. On January 24, 2023, Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;) filed a demand for arbitration with the International Court of Arbitration regarding an alleged material breach by the Company of the Company&#8217;s advance purchase agreement with Gavi (&#8220;the Gavi APA&#8221;). The outcome of that arbitration is inherently uncertain, and it is possible the Company could be required to refund all or a portion of the remaining advance payments of $<ix:nonFraction unitRef="usd" contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDYzNjY_8f556068-c6cf-4287-82bf-ab17568f8af7">697.4</ix:nonFraction>&#160;million (see Note 3 and Note 18). </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="ifb05fc59c8014a33886034c6a9292fd0" continuedAt="iaf77aed13fb248e18c83d48ef6bb0e32"><ix:continuation id="ie2cd817a7b9749cdb1e3d08b4e47d247"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the significance of these uncertainties, substantial doubt exists regarding the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to fund Company operations is dependent upon revenue related to vaccine sales for its products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters, including whether, when, and how the dispute with Gavi is resolved; and management&#8217;s plans, which include resolving the dispute with Gavi and may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of NVX-CoV2373 and the Company&#8217;s other vaccine candidates, including an influenza vaccine candidate, CIC vaccine candidate, or a COVID-19 variant strain-containing monovalent or bivalent formulation, remains uncertain. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.</span></div></ix:continuation><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg4_597f753c-d62f-4bb9-aac1-03f6f1038a21" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODQ4_b6ad244d-7833-4fca-9dfc-2938704deef7" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, revenue recognition, inventory, research and development expenses, stock-based compensation, useful lives of long-lived assets, leases, and income taxes. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODQ5_88550cb5-93df-4ce5-b463-936892113da9" continuedAt="ie9cbbd728df04c45bf3d6d69bb9eec53" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), or are contributions subject to the guidance in ASC Topic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities &#8211; Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 958-605&#8221;). The Company recognizes revenue from arrangements within the scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are associated with the Company&#8217;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="iaf77aed13fb248e18c83d48ef6bb0e32" continuedAt="ie09d49224ddd4347ab7847878f788f80"><ix:continuation id="ie9cbbd728df04c45bf3d6d69bb9eec53" continuedAt="idb1223d0dff54eb5b161087b0ece2543"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of NVX-CoV2373.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of NVX-CoV2373 to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#8220;EAC&#8221;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#8217;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#8217;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other funding agreements currently include funding from CEPI in the form of a grant (&#8220;CEPI Grant Funding&#8221;) and one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Under the Company&#8217;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of NVX-CoV2373. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#8217;s Gavi APA prior to its termination), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 730&#8221;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#8217;s policy of presenting such amounts as revenue. In reaching this determination, the </span></div></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="ie09d49224ddd4347ab7847878f788f80" continuedAt="i8d9b727b11e443a7914409987d2ca256"><ix:continuation id="idb1223d0dff54eb5b161087b0ece2543"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#8217;s core operations. The Company will record revenue as it performs the contractual research and development services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#8217;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.</span></div></ix:continuation><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUw_5d07722c-ce4c-416d-a97f-98652a0a09dc" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#8220;Inventory.&#8221;</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUx_ca885670-d026-419b-983a-6ee030f8400a" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#8220;CROs&#8221;), CMOs, and contract development and manufacturing organizations (&#8220;CDMOs&#8221;); and other expenses associated with the Company&#8217;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUy_43f4e593-d055-48f3-bac3-13291e250405" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#8217;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i8d9b727b11e443a7914409987d2ca256" continuedAt="ic7280efeed0c4649a51da39599853781"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcw_df8c70e7-5f64-422a-a9cf-2e16757cee02" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The Company had advertising costs of $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzM4NjI_7cbc6131-b6e0-4b0e-b992-0269ef0ec810">84.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzM4NzA_0c9e2e90-5b12-4af8-8f1a-adf893862c43">8.9</ix:nonFraction>&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUz_36d1fd3f-e5c0-49af-b4a3-ca672504091d" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock awards (&#8220;RSUs&#8221;), and purchases under the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcx_287a37ee-2b5f-45a2-a262-d63f80394c20">one</span> to <ix:nonNumeric contextRef="id78b588331a244138048f135d4c38cb8_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTgy_a6808dab-ad8d-4770-85ac-7cfb3cf3eaf0">four years</ix:nonNumeric>. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#8217;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk1_2f38f38b-9e98-4e90-ac72-c2f93bd0f9dd" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzEy_8271be5a-1074-4a35-9578-a083e68dbc4c" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzAy_b86b9289-42f1-4022-b5f1-b6ccb403e3d3" continuedAt="i2c81497f082b4fa39b96f7c198294c98" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2c81497f082b4fa39b96f7c198294c98">The Company&#8217;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements.</ix:continuation> As of December&#160;31, 2022 and 2021, the restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements.</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk4_972fb959-9216-4bd3-ac4f-9624844aebfb" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. The Company evaluates outstanding receivables to assess collectability, with consideration given to economic conditions, the aging of receivables, and customer-specific risks.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="ic7280efeed0c4649a51da39599853781" continuedAt="i03dbeaf70c5242f1961c85860e6e4cb2"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk3_852ea386-105a-48f2-8b7a-e11eabcdb577" continuedAt="i2fb310856dd8403280a9a6a8b6975377" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#8217;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzA4_27a8d811-40af-49ef-90c7-80ef852cb3cb" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenue<br/>&#160;for Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Accounts Receivable as of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0708fc22c9854f0abba5629785850b62_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItMS0xLTEtMTExMjgz_45265c30-7946-47fa-9b79-c7469ddefb74">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0df39d26bc0a425688c0db2d06381f38_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItNy0xLTEtMTExMzAx_c7a77984-2d06-4a6f-87e3-67459c72f185">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacf56722506e4a18bd6e4b8223b6c740_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzMtMS0xLTEtMTExNDEz_1b1abf98-e173-4bd8-bce4-0e78f1480d20">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d86c3d5bfd54e03b15f74461ed5ae3a_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzQtMS0xLTEtMTE4ODUy_c239047b-2350-4322-9725-d373ec387788">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8171acc620e44403a1acf786d872dcea_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzQtNy0xLTEtMTE4NDI3_0d877880-5e8e-4dbf-bad5-bc3e3f933615">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gavi, the Vaccine Alliance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd7831a5ea8c46faaaeebc166d30480f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzUtOS0xLTEtMTE4Mzgz_602df0e2-7951-4a29-a4f7-7b15788ee93a">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae09a72a1ca3430c9be92032270e60ab_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItMS0xLTEtNzAyMDA_0c45d528-6a99-44a8-8d53-8db73aa2d591">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i229f36f7f6ec4f50a926d184ce91f415_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItMy0xLTEtNzAyMDA_49431de5-6e92-4852-b54c-b9fb162f2da0">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ac0cbe72c504988bee96db8bb6544d7_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItNS0xLTEtNzAyMDA_aef1320f-b77c-47ef-986e-45d76c03a4db">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia39f087502cf47ae90d1570eb534945f_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItNy0xLTEtNzAyMDA_062b9f8e-e9a2-410b-b289-0d87870634a1">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d52b1aaa828491996f21dccbd34a922_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzMtMy0xLTEtNzAyMDA_5cdd01ef-b4f4-4ec0-90c4-7d98197574e8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1404a3a6dc674929bfd21739b3442b4c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzMtNS0xLTEtNzAyMDA_f0eb1211-53d3-4e4a-a5a1-39379d4a87b2">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SK bioscience, Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8db9b8a25904abfbbb2438880a81408_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzUtMy0xLTEtNzAyMDA_76431849-6bd5-48e2-8076-d92dafcf44de">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Amounts represent less than 10%</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and Department of Defense.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2fb310856dd8403280a9a6a8b6975377">The Company currently depends exclusively on a single supplier for co-formulation, filling, and finishing NVX-CoV2373. The loss of this supplier could prevent or delay the Company&#8217;s delivery of customer orders.</ix:continuation></span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg5_92070919-0e12-4228-8808-3463fde4d786" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i03dbeaf70c5242f1961c85860e6e4cb2" continuedAt="i2f09c485de254e9980ab6f1083064234"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjkw_0bb3c4cf-235e-47ea-97b0-62daa42281d6" continuedAt="i5c64740704a34deebf77dc1215ef3cf4" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c64740704a34deebf77dc1215ef3cf4">Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred.</ix:continuation> <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg1_3f4eaa90-32d1-433b-9b92-673d8ba7c49d" continuedAt="i731487c7cea346ffae4285817b92934b" escape="true">The estimated useful lives of property and equipment are described below:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i731487c7cea346ffae4285817b92934b" continuedAt="ia55b1c1ff42b48bc8041a36909c4b3fb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b3c9b3cf2a747ce9a1576cadc4c0a46_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzEtMS0xLTEtNzAyMDA_80e39476-f932-420a-8e01-b1a092001cec">25</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d166751ab7a4c9c8c0655ff4da76514_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiYWVjYzg5YjI1ZjQ0ZjViYjk1Mjg5Mjc4NWUzZWIwNl80_68cc1687-f80a-439d-9ae0-eb0454352400">5</ix:nonNumeric> - <ix:nonNumeric contextRef="i6203e4280b4a484f87366338bb51639b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiYWVjYzg5YjI1ZjQ0ZjViYjk1Mjg5Mjc4NWUzZWIwNl85_a1406bf0-f5ae-4daa-8ea4-60abaa3d2bf5">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic60027bdd04f4daa9e2d29cfb0744509_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzMtMS0xLTEtNzAyMDA_5806bed1-2e3f-4621-8cfa-0e73b38bd75f">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzAz_3a987e41-fc8b-46a1-ba20-90842f3e9a29" continuedAt="id4d1f55f9ee14c4381848ce580bc6639" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#8217;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#8217;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#8220;ROU&#8221;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#8217;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#8220;short-term&#8221; leases), the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i2f09c485de254e9980ab6f1083064234" continuedAt="if0d54dbb2c214cb2b540aeb38dccaa23"><ix:continuation id="id4d1f55f9ee14c4381848ce580bc6639"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#8217;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.</span></div></ix:continuation><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjkx_0cd7fbbf-b9ef-487e-9c1a-90d0e08fdcef" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company calculates the estimated fair value of a long-lived asset or asset group using the income approach. Impairment losses are recognized when the sum of expected future cash flows is less than the asset&#8217;s or asset group&#8217;s carrying value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzA0_70df8c20-87b1-43b0-bf88-983e765a2146" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development of recombinant vaccines, it operates as a single operating segment and has <ix:nonFraction unitRef="reporting_unit" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTk5_5ce377e5-7b16-461b-87c1-3842359acef2">one</ix:nonFraction> reporting unit. The Company primarily utilizes the market approach and, if considered necessary, the income approach to determine if it has an impairment of its goodwill. The market approach is based on market value of invested capital. To ensure that the Company&#8217;s capital stock is the appropriate measurement of fair value, the Company considers factors such as its trading volume, diversity of investors, and analyst coverage. If considered necessary, the income approach is used to corroborate the results of the market approach. Goodwill impairment may exist if the carrying value of the reporting unit exceeds its estimated fair value. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#8217;s goodwill over its implied fair value, should such a circumstance arise.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October 1, 2022 and 2021, the fair value of the Company&#8217;s single reporting unit was substantially higher than its carrying value, resulting in <ix:nonFraction unitRef="usd" contextRef="i40a83ca620bd452aa6f58f72d2c85402_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMjA5_056e6ea1-9ea3-40bb-b955-413672ab3be4"><ix:nonFraction unitRef="usd" contextRef="icee78a963bab4b348f7582b0b78785d0_D20221001-20221001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMjA5_f471d1ed-95e3-4931-8602-9ea540f61fcd">no</ix:nonFraction></ix:nonFraction> impairment to goodwill as of October 1, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzEz_0c0870d0-a1d8-48f3-9490-15f16f6adc7c" continuedAt="ia7bcf7c3894c4280b990dcd3305c2d2d" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="if0d54dbb2c214cb2b540aeb38dccaa23" continuedAt="ia66740b4f3d148aba8623e46359de0b1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia7bcf7c3894c4280b990dcd3305c2d2d">in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.</ix:continuation></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDYyMDg3_e9268816-9b18-439d-b491-790e47e89a81">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDYyMDk2_a92bdca8-fef6-4e1f-8e02-469a12a3a015">29.2</ix:nonFraction> million, respectively, primarily in income tax expense related to foreign withholding tax on royalties. During the year ended December&#160;31, 2020, the Company recognized <ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDY0MDY1_5e85bdb4-9786-4c5e-9fdf-18a0abad04e0">no</ix:nonFraction> income tax expense.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjkz_88daf1da-ae6f-4acf-a82e-cdd0264a4e35" continuedAt="i3dcf7118739e4815a4353ae6df14aa1b" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3dcf7118739e4815a4353ae6df14aa1b">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period, primarily convertible notes, stock options, SARs, and unvested RSUs.</ix:continuation> As of December&#160;31, 2022, the Company's 2027 Notes and 2023 Notes (see Note 11) would have been convertible into approximately <ix:nonFraction unitRef="shares" contextRef="i7a081a82e367415892816cf19c0e6996_D20220101-20221231" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzIwNTQ_1ab69c7a-7f02-4306-aa2a-26a3bd23e4a8"><ix:nonFraction unitRef="shares" contextRef="i42c53c7f16bb4d359be44c56e5a93d6d_D20220101-20221231" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzIwNTQ_e8c97b0c-b83e-4b1a-8a3d-6adc070ab118">16.4</ix:nonFraction></ix:nonFraction> million shares of the Company's common stock assuming the common stock price is equal to or greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg1NjM1_08ca07ae-4d21-4b13-b6b5-def4a1e1322b">12.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg5MDE2_ea0846b5-19dc-4003-bc50-1c2ded5bf7ad">136.20</ix:nonFraction>, respectively. These shares, after giving effect to the add back of interest expense and unamortized discounts and debt issuance costs on the Notes and any shares due to the Company upon settlement of its capped call transactions, are excluded from the computation, as their effect is antidilutive under the if-converted method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzAw_796123fe-66c8-4de8-8a6a-c0ef984a3762" continuedAt="i97b124693eb049cfbbfe1ecf27c2a770" escape="true">Foreign Currency</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i97b124693eb049cfbbfe1ecf27c2a770">The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#8217;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets.</ix:continuation> The foreign currency translation adjustment balance included in accumulated other comprehensive income (loss) was $(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg1MTQ3_c738f9de-699d-4cd7-8c10-e28cf30726e1">6.4</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg5MDIz_6411a1ca-fedc-4795-8e0c-4000d7eaf604">1.4</ix:nonFraction>) million at December&#160;31, 2022 and 2021, respectively. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were $(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzU0OTc1NTgyNTU0MTM_26956e1a-5170-42ca-9e74-5d4db873a39d">2.5</ix:nonFraction>)&#160;million, $(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzU0OTc1NTgyNTU0MTg_3707efa0-ad83-4c89-8adb-3440089933d9">5.3</ix:nonFraction>)&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-5" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxNDQwNDc2ODY4MDE2_772c07ae-51bc-45bd-9505-37594233c6c2">9.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021, and 2020 respectively, which are reflected in Other income (expense).</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjky_103cc875-25b3-499b-8e56-1e84e3a9e576" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business as <ix:nonFraction unitRef="segment" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMjIw_b091fd9b-918e-4210-adac-1b6f1b01addc">one</ix:nonFraction> operating segment: the development of recombinant vaccines. The Company does not operate separate lines of business with respect to its vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk5_45a77ee4-c1a5-4a50-aa61-1377dbe0fc39" continuedAt="i908d10dd22d24e64b21622a1a5bd0c26" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management has evaluated the effect of the guidance and its implementation will not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="ia66740b4f3d148aba8623e46359de0b1"><ix:continuation id="i908d10dd22d24e64b21622a1a5bd0c26"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#8217;s consolidated financial statements.</span></ix:continuation></ix:continuation></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_169"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIwNzQ3_b1d2e63c-22dc-4c05-92d1-c6f577207ca8" continuedAt="id9c14af5b799487fa84e701762de3287" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="id9c14af5b799487fa84e701762de3287" continuedAt="i33a8653053a44df7a18facb69a11542b"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-5" name="us-gaap:BilledContractReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzM1Mw_30dc2164-0fd6-4f46-b1e3-8d6f5e819a6e">53.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-5" name="us-gaap:BilledContractReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzM2MA_21a6ad58-63a6-4a6c-9733-d6cd8b897f09">419.7</ix:nonFraction> million related to amounts that were billed to customers and $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY4NzQ_844effbc-53b2-4955-915d-68881c503c30">28.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY4ODA_f43f2716-5aec-44a7-b8c9-9d56919201c7">35.3</ix:nonFraction> million related to amounts which had not yet been billed to customers as of December&#160;31, 2022 and 2021, respectively. <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIwNzQ2_075ffd7b-2d57-44c9-86a1-297b77f88834" continuedAt="if4e947ee3e8e489ab8cd64d5072c7935" escape="true">During the years ended December&#160;31, 2022 and 2021, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="if4e947ee3e8e489ab8cd64d5072c7935"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItMS0xLTEtMTE3OTky_e9bdc4f9-0481-45c2-9cc7-45e6dbcf6cde">454,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItMy0xLTEtMTE3OTky_6c6aa1b3-8c75-44db-b86b-8048769eed41">1,768,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItNS0xLTEtMTE3OTky_5301900e-2a2a-414a-9492-a339e42adf1c">2,127,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItNy0xLTEtMTE3OTky_756b20d1-1e38-4616-b8ad-7734d4bbd176">96,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtMS0xLTEtMTE3OTg1_bab79258-b0a8-420b-97c2-015c9d1bcb08">262,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtMy0xLTEtMTE3OTg1_a18b0e94-774a-47a5-8c51-7cc62fbe2c7d">2,432,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtNS0xLTEtMTE3OTg1_79f07618-3832-4f64-abad-f632d438ba64">2,239,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtNy0xLTEtMTE3OTg1_e228758d-024f-4308-a94b-dcdd39052c33">454,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtMS0xLTEtMTE4MTky_672e8f2a-726c-4040-bc6d-4e63acdbb6f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtMy0xLTEtMTE4MTkyL3RleHRyZWdpb246Zjc5YzYyMDQzYWYzNGVmYWEzYWQyYTliNjk3YWVhZThfMjE5OTAyMzI1NTU1OA_6e3380df-b12b-4e25-a298-bad335ebec1b">13,835</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtNS0xLTEtMTE4MTky_2ed45e3f-835e-4f96-816f-4989a8e483f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtNy0xLTEtMTE4MTky_38e04477-9162-44f3-8c92-2599bb8cb364">13,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMS0xLTEtMTE4MTky_f2e9073a-6b05-4bdb-8151-2281667bb15b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMy0xLTEtMTE4MTky_a9eb8fb8-80c4-4f8b-ae9e-04bdab1e2c40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNS0xLTEtMTE4MTky_4b0f48e4-b0f3-4eec-a2e0-d563eb5c9dd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNy0xLTEtMTE4MTky_4537ffcf-be10-40c9-806d-e6ef9c319c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtMi0xLTEtNzAyMDA_75ea6427-cef4-41db-ac2c-91f1a6dfcc12">1,595,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtNC0xLTEtNzAyMDA_d247d655-1dcb-4554-8d94-7c97a443e0ce">46,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtNi0xLTEtNzAyMDAvdGV4dHJlZ2lvbjowNWJmMzBkYzllYTQ0NzJkOGFhYjcxZTE2ODU4ZTk4Ml8yNzQ4Nzc5MDY5NDQ2_eca4ed9a-9401-4e48-9c15-dff0c13defdf">1,092,829</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtOC0xLTEtNzAyMDA_404c4235-9c3f-4258-b713-5b1f1e01ef8c">549,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMS0xLTEtMTE4MDEz_a1f05211-352c-448d-be03-06e6244ada92">273,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMy0xLTEtMTE4MDEz_caffa725-ce42-43a1-9b8f-a49af5341720">1,598,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="nvax:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNS0xLTEtMTE4MDEz_5b1acca1-26f9-4880-be82-de1f882192e2">275,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNy0xLTEtMTE4MDEz_120739e5-44d4-4183-b225-8e55c65b7dee">1,595,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Bad debt expense was $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU0MjM_b9940843-4ad8-4b48-b9a8-91a8c6f64ff0">13.8</ix:nonFraction>&#160;million in the year ended December&#160;31, 2022 and there was <ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="INF" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU2MzI_07427bd5-65ca-4492-9fc2-f9f0249cbe7b"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="INF" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU2MzI_46ec886f-c4f8-45b5-bb7a-ad3a35ef0775">no</ix:nonFraction></ix:nonFraction> bad debt expense in the years ended December&#160;31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Amount is comprised of $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5NTI_37016902-3ddc-45b4-869e-3ecfaabcdb86">0.4</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5NDc_a7fba182-5397-4c12-b8cd-ec5a85fd4ecc">1.4</ix:nonFraction>&#160;billion, and $<ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMDc0Mjg_2acb582e-554b-408d-8c51-60acd2e3d59a">0.3</ix:nonFraction>&#160;billion current Deferred revenue and $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5Njk_70e2414d-5d9e-487e-9fe0-66ff3f1350f8">179.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5ODQ_e2fdaf76-c6d2-4a51-a492-157fe16f3b56">172.5</ix:nonFraction>&#160;million, and <ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMDc0NDQ_6cb71919-d3ac-4392-a110-ae71853510c9">no</ix:nonFraction> non-current Deferred revenue as of December&#160;31, 2022, 2021, and 2020 respectively.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Deductions from Deferred revenue include the following: $<ix:nonFraction unitRef="usd" contextRef="i926dd27a465e4fdabe3cf710647081f8_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxNDY1Mzk_0d4543a6-91ed-4957-a019-74f89f0e0688">273.8</ix:nonFraction>&#160;million that was realized in Revenue and $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTAzMjE_d9b07708-0aa1-4064-8f50-a9786ebda584">819.0</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTAzMzk_8f556068-c6cf-4287-82bf-ab17568f8af7">697.4</ix:nonFraction>&#160;million related to the Advance Payment Amount (as described below) at issue in the Gavi arbitration and $<ix:nonFraction unitRef="usd" contextRef="i7d102737a020478786d531e426d6e856_I20221231" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTA0OTY_0190c551-b3f4-4ccc-ba54-43e59458a385">112.5</ix:nonFraction>&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below. In the fourth quarter of 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i46f5b877ba2042818de76d2a409905c8_D20221001-20221231" decimals="-5" name="nvax:RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDI1NjQ_cf75ed8a-08df-4de1-9621-45b5b8db21e2">41.9</ix:nonFraction>&#160;million related to a change in estimate attributed to changes in constraint of variable consideration.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $<ix:nonFraction unitRef="usd" contextRef="i3abf6a1aebd248e584d82ca7df7e3fdf_I20221231" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzEwNjU_7bbc1fd6-5d88-42b0-beb5-f62c84b351bb">3</ix:nonFraction>&#160;billion as of December&#160;31, 2022, which excludes amounts related to the Company&#8217;s APA (&#8220;the Gavi APA&#8221;) with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;) and the reduction in doses related to the Amended and Restated UK Supply Agreement, as defined below. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 vaccine under certain of the Company&#8217;s APAs. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than <ix:nonNumeric contextRef="i3abf6a1aebd248e584d82ca7df7e3fdf_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzE1NDI_026c8455-3295-43d3-b9ca-b3f6313e3263">one year</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gavi APA and a separate purchase agreement between Gavi and Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;), <ix:nonFraction unitRef="dose" contextRef="i6cd3d6a52163444b8ea692da78a4faf2_I20221231" decimals="-8" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODE3MDM_95baee15-5e43-4ac6-a82a-c57cbefd26a3">1.1</ix:nonFraction> billion doses of NVX-CoV2373 were to be made available to countries participating in the COVAX Facility. The Company expected to manufacture and distribute <ix:nonFraction unitRef="dose" contextRef="i0523638414324ebda053032feb1642dc_I20221118" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODE4NTM_de75fba7-dfc1-47d2-81c2-2c433a3d7710">350</ix:nonFraction>&#160;million doses of NVX-CoV2373 to countries participating under the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i33a8653053a44df7a18facb69a11542b" continuedAt="i32f0818feb9048c881f88a2d6dcd1800"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the balance of the <ix:nonFraction unitRef="dose" contextRef="i6cd3d6a52163444b8ea692da78a4faf2_I20221231" decimals="-8" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODIwNDI_95baee15-5e43-4ac6-a82a-c57cbefd26a3">1.1</ix:nonFraction> billion doses of NVX-CoV2373 for low- and middle-income countries participating in the COVAX Facility. The Company expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under the Company's funding agreement with CEPI, with initial doses supplied by SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under a supply agreement. The Company expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, the Company could provide additional doses of NVX-CoV2373, to the extent available from CEPI funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i39195769279040f9977e693d668d82a1_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODI5NTA_c814f9fb-b891-4a0c-9777-48de3e9461ea">350.0</ix:nonFraction>&#160;million from Gavi in 2021 and an additional payment of $<ix:nonFraction unitRef="usd" contextRef="i5faf20068a344883a9f4f4c476b0ac54_I20220331" decimals="-5" name="nvax:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODMwMzU_1686d733-764c-4cc5-88cd-ea89882389cf">350.0</ix:nonFraction>&#160;million in the first quarter of 2022 related to the Company&#8217;s achieving EUL for NVX-CoV2373 by the WHO (the &#8220;Advance Payment Amount&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of <ix:nonFraction unitRef="dose" contextRef="i0523638414324ebda053032feb1642dc_I20221118" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTQ2MTg_de75fba7-dfc1-47d2-81c2-2c433a3d7710">350</ix:nonFraction>&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately <ix:nonFraction unitRef="dose" contextRef="i0523638414324ebda053032feb1642dc_I20221118" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTQ3NzQ_7e71e3b9-d280-4b67-80c0-708e81d4dfa1">2</ix:nonFraction>&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2022, the remaining Gavi Advance Payment Amount of $<ix:nonFraction unitRef="usd" contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDQyNTA_8f556068-c6cf-4287-82bf-ab17568f8af7">697.4</ix:nonFraction>&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#8217;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that it could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzExNTQ0ODcyMTc4NjA1_c801c4fd-cfc6-4c6b-b570-9bd5066bfce0" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2706507e51524857a9ceffe04bbdfb19_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzEtMS0xLTEtMTE1Njgy_48be2fe4-a9aa-49d8-9ad0-95723087e732">194,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad425a20a9414db980cc6c772611e4_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzItMS0xLTEtMTE1Njgy_938c3452-1b3e-4f9a-b712-a851b8c60b62">823,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce1a3a4c4ef4e1d9f74c1e95e55e00c_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzMtMS0xLTEtMTE1Njgy_c31d3773-23ac-4211-9b93-5996b0eb213b">536,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39643791632e4e05a291fb0194ec9876_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzQtMS0xLTEtMTE1OTUz_96a243e2-40fd-42e1-8d69-2385f05cb06c">1,554,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of <ix:nonFraction unitRef="dose" contextRef="iec87e45039154115be91b56e82452836_I20221231" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc2Njk_7ac7295e-79c8-46b1-9d0e-a1000f2d5742">20</ix:nonFraction>&#160;million and up to <ix:nonFraction unitRef="dose" contextRef="ice1626d37f2e4ef59d96daaad71fdbaa_I20221231" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc2ODM_d6e5400d-cf7f-4b2a-b680-09128a3cb2a5">100</ix:nonFraction>&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional <ix:nonFraction unitRef="dose" contextRef="i368f367746e142668e6ba704011b5fc7_I20221231" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc3NzA_038e92e8-ecbe-411a-8ebb-40fe3bc07b13">100</ix:nonFraction>&#160;million doses up to a maximum aggregate of <ix:nonFraction unitRef="dose" contextRef="i368f367746e142668e6ba704011b5fc7_I20221231" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc4MDk_0f487956-7d11-4f27-9b51-485f5b8d24bf">200</ix:nonFraction>&#160;million doses in one or more tranches, through 2023. Under the terms of the APA, the Company agreed to manufacture the vaccine in facilities located in the European Union and ensure continued efficacy of the vaccine against variants of the SARS-CoV-2 virus. Pursuant to the terms of the APA, the Company is prohibited from supplying NVX-CoV2373 to any third party if such delivery would impede or limit the fulfillment of the Company&#8217;s obligations to the European Commission under the APA, except with respect to the Company&#8217;s obligations under the Gavi APA. In 2022, the Company was notified by the EC that it was cancelling approximately <ix:nonFraction unitRef="dose" contextRef="i368f367746e142668e6ba704011b5fc7_I20221231" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesCancelled" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDg1MjM_f4b3eff9-1ffe-44aa-9e0b-c7d9334318da">7</ix:nonFraction>&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately <ix:nonFraction unitRef="dose" contextRef="i368f367746e142668e6ba704011b5fc7_I20221231" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDg3MDM_7ecbc6c1-9ae9-431e-926c-7fb6998ca80a">63</ix:nonFraction>&#160;million doses. In January 2023, the Company finalized a revised delivery schedule for the remaining <ix:nonFraction unitRef="dose" contextRef="i36fc052561f64f5bb389212acc6492e1_D20230101-20230131" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNjI1Mjk_dd57aa8b-78c8-4b4c-85bd-76c85667aa54">20</ix:nonFraction>&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022 and are expected to be delivered in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase <ix:nonFraction unitRef="dose" contextRef="i47baf28a107749f3b2ca7dc5b1b71532_I20201022" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NTg_bcd11cfd-3e59-4be2-bc6f-f9c4d3a80ecc">60</ix:nonFraction>&#160;million doses of NVX-CoV2373 and made an </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i32f0818feb9048c881f88a2d6dcd1800" continuedAt="i21a2a796b32c4c779f75e5457dc729e4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment to the Company. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of <ix:nonFraction unitRef="dose" contextRef="i23178b856de1448ab841c7dd1fda4737_I20220731" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NjY_1c419937-9247-40fd-ae1c-4832a5370d0d">1</ix:nonFraction>&#160;million doses and up to an additional <ix:nonFraction unitRef="dose" contextRef="id54b75d90c0445109878eb06ca06d922_I20220731" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NzA_e40f6d19-90c2-4840-8590-ceec10a5e50e">15</ix:nonFraction>&#160;million doses (the &#8220;Conditional Doses&#8221;) of NVX-CoV2373, with the number of Conditional Doses contingent on, and subject to reduction based on, the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority does not purchase the Conditional Doses or the number of such Conditional Doses is reduced below <ix:nonFraction unitRef="dose" contextRef="id54b75d90c0445109878eb06ca06d922_I20220731" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NzM_e40f6d19-90c2-4840-8590-ceec10a5e50e">15</ix:nonFraction>&#160;million doses of NVX-CoV2373, the Company would have to repay up to $<ix:nonFraction unitRef="usd" contextRef="i67162008d7604923adbbc7b516cc27be_I20220731" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwMjU_2d00da02-a996-482d-b3c9-8d84b77869f7">225.0</ix:nonFraction>&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional <ix:nonFraction unitRef="dose" contextRef="i67162008d7604923adbbc7b516cc27be_I20220731" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5OTU_dcbf0f83-84bc-4565-97f3-7b0229046fe8">44</ix:nonFraction>&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not yet made a supportive recommendation with respect to NVX-CoV2373, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from <ix:nonFraction unitRef="dose" contextRef="id54b75d90c0445109878eb06ca06d922_I20220731" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwMzc_e40f6d19-90c2-4840-8590-ceec10a5e50e">15</ix:nonFraction>&#160;million doses to <ix:nonFraction unitRef="dose" contextRef="i82199a3134c04ef69869eff76a4bd2cd_I20221130" decimals="-5" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwNDE_b4eef17f-6af1-420d-b96a-3eb9daa7b474">7.5</ix:nonFraction>&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, the Company&#8217;s timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation of the Company to repay $<ix:nonFraction unitRef="usd" contextRef="i7d102737a020478786d531e426d6e856_I20221231" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwNTU_0190c551-b3f4-4ccc-ba54-43e59458a385">112.5</ix:nonFraction>&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement, which is reflected in Other current liabilities, with the remaining upfront payment balance of $<ix:nonFraction unitRef="usd" contextRef="i7d102737a020478786d531e426d6e856_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwNjk_2c917a47-5d3d-4728-b7fe-71dda5fc82ce">112.5</ix:nonFraction>&#160;million reflected in current Deferred revenue.</span></div><div style="margin-bottom:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIwNzQ4_4b5e1f14-e758-4784-a8e5-7f575917c49e" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9414495645c244dfa1f4271692735ef3_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzItMS0xLTEtOTk1MjQ_379a2590-ccf1-4b98-9ac0-3926dba15b68">380,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ec0fb5211549e2a256737805e4fce0_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzItMi0xLTEtNzAyMDA_1a45f277-9dd0-4150-98b2-84e38333f924">788,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce0f3c1c39d4e28b5fe4043d6dc2ca5_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzItNC0xLTEtNzAyMDA_5eb3ab8e-f260-46e5-aee1-e5675c36e53b">204,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2124dc03e6334482915d316bc6b47f65_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzMtMS0xLTEtOTk1MjQ_0e69b7ed-32e6-49a7-bc9f-e5955667959d">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7742e770d4074f7c8483f51032cb198a_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzMtMi0xLTEtNzAyMDA_520d795c-4f5f-4446-9a33-7702f9451a78">21,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f39444854c467997b14a3f794dc641_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzMtNC0xLTEtNzAyMDA_cc9e2f5e-8b96-46c8-a0b6-d5bf3643798c">12,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a790ed695ae48a7825f7db0794a528b_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzQtMS0xLTEtOTk1MjQ_162ab43c-8431-4001-a1a4-4add914b3102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95983058bd8d4c6b889991a78b44a3a1_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzQtMi0xLTEtNzAyMDA_cd91fffc-fb24-464a-b3dd-03adb9f80dad">135,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0953f31b29d64b1c9efe84ff12aaf7c3_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzQtNC0xLTEtNzAyMDA_f4e0a9f4-eac9-4a26-80bb-5d3442b36e32">223,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d17441b7514d62aa6a4fb48ea6ec16_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzUtMS0xLTEtOTk1MjQ_07c0b426-0816-44e4-8aee-b040660c985b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb17db81cb4940059e2590656125cced_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzUtMi0xLTEtNzAyMDA_b3caf261-1ae7-48a2-86e3-fde54b7bff51">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8565eb181066484ab573f2f33ad705ba_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzUtNC0xLTEtNzAyMDA_15d5e3ef-7825-49f3-95c5-4e85b139959f">12,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229e45ac7dd0484582dd508d0b410d09_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzYtMS0xLTEtOTk1MjQ_df812200-72ee-4580-a06c-4ba0f2c4db33">382,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2c1b3a8f554776b7ead7f9e8afc0be_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzYtMi0xLTEtNzAyMDA_ae2840ba-4436-4b54-987f-852ebb4b6ff5">948,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608ca42330f04ed38d4a29292e36a8e2_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzYtNC0xLTEtNzAyMDA_83a55efb-d00a-42be-96e7-62b03f8c4a5d">453,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Government</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a Project Agreement (the &#8220;Project Agreement&#8221;) with Advanced Technology International, Inc. (&#8220;ATI&#8221;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed. Operation Warp Speed was a partnership among components of the U.S. Department of Health and Human Services and the U.S. Department of Defense working to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The Project Agreement relates to the Base Agreement the Company entered into with ATI in June 2020 (the &#8220;Base Agreement,&#8221; together with the Project Agreement, the &#8220;USG Agreement&#8221;). The original USG Agreement required the Company to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of NVX-CoV2373, and to manufacture and deliver to the U.S. government <ix:nonFraction unitRef="dose" contextRef="i269b7fbf10f045c7b3eac59a9ee5c87d_D20200701-20200731" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzMzNjk_fc671df1-7a61-46ce-a140-a11cf3a93ad5">100</ix:nonFraction>&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to the Company for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the U.S. government&#8217;s interest. If the Project Agreement is terminated prior to completion, the Company is entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. In July 2022, the Company entered into a modification to the USG Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately <ix:nonFraction unitRef="dose" contextRef="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwODI_476911bc-4657-4e81-94f8-218940d90a44">3</ix:nonFraction>&#160;million doses of NVX-CoV2373 and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of <ix:nonFraction unitRef="dose" contextRef="i269b7fbf10f045c7b3eac59a9ee5c87d_D20200701-20200731" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMDM_fc671df1-7a61-46ce-a140-a11cf3a93ad5">100</ix:nonFraction>&#160;million doses of NVX-CoV2373 contemplated by the original USG Agreement (inclusive of the initial batch of </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i21a2a796b32c4c779f75e5457dc729e4" continuedAt="if2b20429966446b68b9746df75c6633d"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately <ix:nonFraction unitRef="dose" contextRef="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwOTI_476911bc-4657-4e81-94f8-218940d90a44">3</ix:nonFraction>&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The <ix:nonFraction unitRef="dose" contextRef="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMDc_476911bc-4657-4e81-94f8-218940d90a44">3</ix:nonFraction>&#160;million initial doses were delivered in July 2022. The performance period under the Project Agreement extends through 2023 to cover clinical trial activities, subject to early termination by the U.S. government or extension by mutual agreement of the parties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the USG Agreement, the Company was originally entitled to funding of up to $<ix:nonFraction unitRef="usd" contextRef="id7ac470da9ab41d39a8dd4ac58dde5eb_D20200701-20200731" decimals="-7" name="nvax:RevenueFromContractWithCustomerCommitment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzU0NTY_6efb6fc7-1827-4712-8152-ad5d26edb761">1.75</ix:nonFraction>&#160;billion to support certain activities related to the development of NVX-CoV2373 and the manufacture and delivery of the vaccine candidate to the U.S. government. In subsequent modifications, the Company's USG Agreement was amended to increase the contract funding and ceiling to $<ix:nonFraction unitRef="usd" contextRef="ib28b320707a54cf7a261c50f50d34c04_I20200731" decimals="-8" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzU4NDM_5d2b24dc-1eac-44a7-b5c9-664495d261e0">1.8</ix:nonFraction>&#160;billion, which allows the Company to make expenditures or incur obligations of up to $<ix:nonFraction unitRef="usd" contextRef="ib28b320707a54cf7a261c50f50d34c04_I20200731" decimals="-8" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTM2MjE_5d2b24dc-1eac-44a7-b5c9-664495d261e0">1.8</ix:nonFraction>&#160;billion for support of the USG Agreement. As of December&#160;31, 2022, the Company had recognized $<ix:nonFraction unitRef="usd" contextRef="ia1458600dca343ad97871d021c6be059_D20220101-20221231" decimals="-8" name="nvax:RevenueFromContractWithCustomerCommitment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzYxMTM_501f2bbf-afa9-43c8-b98d-d8304126942f">1.4</ix:nonFraction>&#160;billion in revenue related to the USG Agreement since the inception of the contract, leaving $<ix:nonFraction unitRef="usd" contextRef="i673cb8037c324c8994caf3306884a92e_I20221231" decimals="-8" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzYyMDE_4660742b-a64f-497d-a71d-a5b3a0605fda">0.4</ix:nonFraction>&#160;billion remaining to spend.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Department of Defense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a letter contract that was later amended in January 2021 (the &#8220;DoD Contract&#8221;) with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (&#8220;JPEO-CRBND-EB&#8221;), under which JPEO-CRBND-EB agreed to provide funding of up to $<ix:nonFraction unitRef="usd" contextRef="i7be0462e374b44418c24eeac2316d566_D20200601-20200630" decimals="-5" name="nvax:RevenueFromContractWithCustomerCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzY3OTA_4e44192d-3262-4293-80b4-587d29717170">45.7</ix:nonFraction>&#160;million to the Company to support the manufacture of NVX-CoV2373. The Company is authorized to make expenditures or incur obligations up to the full amount of the funding.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the DoD Contract, the Company originally expected to deliver <ix:nonFraction unitRef="dose" contextRef="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzcwNDE_802a0d81-9a11-47a5-83c4-0412a3dd25e4">10</ix:nonFraction>&#160;million doses of NVX-CoV2373 to the DoD. The <ix:nonFraction unitRef="dose" contextRef="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzcwODE_802a0d81-9a11-47a5-83c4-0412a3dd25e4">10</ix:nonFraction>&#160;million doses of NVX-CoV2373 could be used in Phase 2/3 clinical trials or under an EUA, if approved by the FDA. Pursuant to the DoD Contract, after NVX-CoV2373 is approved by the FDA, the DoD is entitled to most-favored customer status for a period of <ix:nonNumeric contextRef="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630" name="nvax:RevenueRemainingPerformanceObligationCustomerStatusPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzExNTQ0ODcyMTYzMzc0_31c024db-b529-4abc-9b74-6b989d230be0">five years</ix:nonNumeric> from the award of the DoD Contract, meaning that the Company cannot give any comparable commercial client in the United States more favorable pricing than the DoD under similar transactional circumstances. In July 2022, the Company modified its existing agreement with the DoD and delivered <ix:nonFraction unitRef="dose" contextRef="if04cb8aedaa04ea296920d2dafe47b45_I20220731" decimals="-5" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMjE_e614077d-230e-44b8-bac1-01055b06a9c2">0.2</ix:nonFraction>&#160;million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining <ix:nonFraction unitRef="dose" contextRef="if04cb8aedaa04ea296920d2dafe47b45_I20220731" decimals="-5" name="nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMzE_d1fbaf9b-fb9f-45a4-85e5-7cebadafef02">9.8</ix:nonFraction>&#160;million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding. The term of the DoD Contract expired in December 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into a restated funding agreement which was amended in November 2020 with CEPI, under which CEPI agreed to provide funding of up to $<ix:nonFraction unitRef="usd" contextRef="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531" decimals="-5" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2Xzc3ODY_6a868c39-04d9-4a85-be57-aa84b60d5fea">399.5</ix:nonFraction>&#160;million to the Company to support the development of NVX-CoV2373. The agreement provides up to $<ix:nonFraction unitRef="usd" contextRef="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531" decimals="-5" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2Xzc4ODk_5e4d4a64-8221-4e45-9380-cc180411838d">257.0</ix:nonFraction>&#160;million in CEPI Grant Funding and up to $<ix:nonFraction unitRef="usd" contextRef="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531" decimals="-5" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2Xzc5MTk_33e82be7-b94c-4d9f-80b4-23e7456de222">142.5</ix:nonFraction>&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans in order to prepay certain manufacturing activities and are not subject to restrictive or financial covenants. As of December&#160;31, 2022 and 2021, the Company had recognized total revenue related to CEPI of $<ix:nonFraction unitRef="usd" contextRef="i67595162b2e74d70acbd1d2e3fc54a75_D20220101-20221231" decimals="-5" name="nvax:RevenueFromContractWithCustomerCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDM0NDQ_214d47b8-39cc-4b39-b090-7666e3b27813"><ix:nonFraction unitRef="usd" contextRef="i09f8465b2a5e4bfaa5c2543aadab3967_D20210101-20211231" decimals="-5" name="nvax:RevenueFromContractWithCustomerCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDM0NDQ_c81345bf-157f-43b9-9252-4c7f6a185edb">358.6</ix:nonFraction></ix:nonFraction>&#160;million, with the unused amounts primarily related to CEPI Forgivable Loan Funding. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the CMO network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#8217;s Gavi APA prior to its termination), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6e260c6f907f4344bad6fb4ab2321f9c_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMTkwNTg_a3530d3a-8d4d-4188-b97b-1c32c6b4c063">9.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3000e1e12c2e4499ac858cd2ed3830ce_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzEyNDI1_b8342972-143e-40af-b5f1-539452f449bf">178.6</ix:nonFraction>&#160;million, respectively, in revenue related to sales-based royalties, which is reflected in Royalties and other revenue. For the years ended December&#160;31, 2022 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ide4a1afee8bf4db08da83fe10dcf1648_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMTkzOTg_33476ed6-6a9b-4ad1-b3d8-0b3e42dcb1fe">20.0</ix:nonFraction>&#160;million upon the sale of NVX-CoV2373 in Japan and $<ix:nonFraction unitRef="usd" contextRef="i0c853e8a4a7c4a54a237437e58933a8e_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzEyNTE5_17099232-e0ec-4b82-a968-0a7c0a8c506e">20.0</ix:nonFraction>&#160;million related to a development milestone payment, respectively.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1480"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8211; <ix:continuation id="if2b20429966446b68b9746df75c6633d" continuedAt="iaf5a5144e9f249b7984a6d40edd682cd">Collaboration and License Agreements</ix:continuation></span></div><ix:continuation id="iaf5a5144e9f249b7984a6d40edd682cd" continuedAt="i97e011b78b4f472d9b6cc5cd394094aa"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serum Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company's Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i97e011b78b4f472d9b6cc5cd394094aa" continuedAt="ieb6f9e631ee24eafae9fc5e47698d774"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#8217;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company granted to SIIPL (i) an exclusive license in India during the agreement and (ii) a non-exclusive license (a) during the &#8220;Pandemic Period&#8221; (as declared by the WHO) in all countries other than specified countries designated by the World Bank as upper-middle or high-income countries, with respect to which the Company retains rights, and (b) after the Pandemic Period, in only those countries designated as low or middle-income by the World Bank. Following the Pandemic Period, the Company may notify SIIPL of any bona fide opportunities for the Company to license NVX-CoV2373 to a third party in such low and middle-income countries and SIIPL would have an opportunity to match or improve such third-party terms, failing which, the Company would have the discretion to remove one or more non-exclusive countries from SIIPL&#8217;s license. The Company also has a supply agreement with SIIPL and SLS under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. In May and August 2022, the Company expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s), its quadrivalent influenza vaccine candidate, and its CIC vaccine candidate, so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, a quadrivalent influenza vaccine, and CIC vaccine, and supply such vaccines to the Company. In March 2020, the Company granted SIIPL a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21, a malaria candidate developed by the Jenner Institute, University of Oxford.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of <ix:nonFraction unitRef="dose" contextRef="i1883dba2c86c4273926e697f5ab58bae_I20210930" decimals="INF" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEyODMyNA_d2bd2aa0-346e-49e7-9f7f-bcddc1016498">150</ix:nonFraction>&#160;million doses of NVX-CoV2373. In February 2023, MHLW cancelled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the years ended December&#160;31, 2022 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ide4a1afee8bf4db08da83fe10dcf1648_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8yNzQ4Nzc5MDkyMTE1_33476ed6-6a9b-4ad1-b3d8-0b3e42dcb1fe">20.0</ix:nonFraction>&#160;million upon the sale of NVX-CoV2373 in Japan and $<ix:nonFraction unitRef="usd" contextRef="i0c853e8a4a7c4a54a237437e58933a8e_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8yNzQ4Nzc5MDkyMTYx_17099232-e0ec-4b82-a968-0a7c0a8c506e">20.0</ix:nonFraction>&#160;million related to a development and commercial milestone payment, respectively, which are included in Royalties and other revenue on the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SK bioscience, Co., Ltd.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of South Korea, Thailand, and Vietnam. SK bioscience finalized an APA with the Korean government to supply <ix:nonFraction unitRef="dose" contextRef="i96b9e55b23e44271b0b5d401791eb27a_I20210228" decimals="INF" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8yMTk5MDIzMjc5MTky_b4530183-93cf-43c9-af1c-fa59fc3cd35d">40</ix:nonFraction>&#160;million doses of NVX-CoV2373 to the Republic of Korea beginning in 2021. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. The companies also signed an agreement to manufacture and supply NVX-CoV2373 in a prefilled syringe.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Fujifilm Settlement Agreement&#8221;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#8220;Fujifilm CSA&#8221;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#8220;Fujifilm MSA&#8221;) by and between the Company and Fujifilm. The Fujifilm MSA </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="ieb6f9e631ee24eafae9fc5e47698d774"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Fujifilm CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to NVX-CoV2373 under the associated statements of work.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Fujifilm Settlement Agreement, the Company is responsible for payment of up to $<ix:nonFraction unitRef="usd" contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjMyNw_7c1ea22e-f0fb-40e2-9307-1fb084025e36">185.0</ix:nonFraction>&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT under the Fujifilm CSA, of which (i) $<ix:nonFraction unitRef="usd" contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231" decimals="-5" name="nvax:SettlementAgreementInitialReservationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjM0Mw_21cb5641-7aa3-4669-acf9-d89bff88d56b">47.8</ix:nonFraction>&#160;million, constituting the initial reservation fee under the Fujifilm CSA, was credited against the Settlement Payment on September 30, 2022 and (ii) the remaining balance is to be paid in <ix:nonFraction unitRef="installment" contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjM1Nw_f76627c6-6701-4dad-8481-a9b1e5d78f09">four</ix:nonFraction> equal quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231" decimals="-5" name="nvax:SettlementAgreementQuarterlyInstallmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjM4Mg_f038cb54-01c2-409c-9093-b262aa434aa0">34.3</ix:nonFraction>&#160;million each beginning March 31, 2023. As of December&#160;31, 2022, the remaining payment of $<ix:nonFraction unitRef="usd" contextRef="i3c0e43b772f0435c86af0d81656bac70_I20221231" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV81NDk3NTU4MTcwOTk0_0fa9ffe1-277b-4cfe-ab33-2dfad8ef16d5">137.2</ix:nonFraction>&#160;million was reflected in Accrued expenses. Under the Fujifilm Settlement Agreement, Fujifilm is required to use commercially reasonable efforts to mitigate the losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the Fujifilm CSA, and the final two quarterly installments will be mitigated by any replacement revenue achieved by Fujifilm between July 1, 2023 and December 31, 2023. The Settlement Payment is less than amounts previously recognized as embedded lease expense and reflected in Research and development expense from FDBT manufacturing activity under the Fujifilm CSA prior to the Fujifilm Settlement Agreement and accordingly, during the year ended December&#160;31, 2022, the Company recorded a benefit of $<ix:nonFraction unitRef="usd" contextRef="ic6b7bd92fbd1475a82a5bfebeefa798f_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjQxMQ_939e98e4-08e1-4e47-a323-70d997c07507">98.3</ix:nonFraction>&#160;million as Research and development expense (see Note 10).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except with respect to certain limited activities agreed upon by the parties, the Fujifilm MSA terminated with respect to all activities in FDBU and FDBT on October 21, 2022 and the impact of the termination was determined in accordance with the provisions of the Fujifilm MSA. The terms and conditions of the Fujifilm MSA and Fujifilm CSA will remain in full force and effect with respect to the ongoing activities at FDBK. In addition, the Company and Fujifilm mutually released all claims relating to (i) the cancellation of batches to be manufactured at FDBT under the Fujifilm MSA or Fujifilm CSA, (ii) FDBT facility idle time in 2022, (iii) failure to complete product performance qualification testing of batches manufactured by Fujifilm by December 2021, and (iv) any obligation by Fujifilm to reserve capacity or manufacture batches at FDBT for the benefit of the Company under the Fujifilm MSA or Fujifilm CSA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and, as a result, significant costs may be incurred.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_139"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90ZXh0cmVnaW9uOjEyZDExMTQ1NTQzYjRkZTk4YWM4NzVjN2ZmZWRjY2VhXzMxNA_5aee8a65-d388-41a8-aece-09b687385736" continuedAt="ieeef13f32af04b88898059b7fb6a9498" escape="true">Cash, Cash Equivalents, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="ieeef13f32af04b88898059b7fb6a9498" continuedAt="idd87a8a8c8c945a59f57f5313acd7399"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90ZXh0cmVnaW9uOjEyZDExMTQ1NTQzYjRkZTk4YWM4NzVjN2ZmZWRjY2VhXzExNTQ0ODcyMDkzMTA3_2f75bb0f-ee4a-45f0-add1-907ba3ced180" continuedAt="ie03f25dcb4344809ac69a913bec8cdfe" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzItMS0xLTEtNzIwNDI_d9e1835a-c68b-40c0-9023-4b220d0026df">1,336,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzItMy0xLTEtNzIwNDI_2ed5a1ae-005e-45bf-b795-a08c837dbd4d">1,515,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzItNS0xLTEtMTEyMTU5_290bb21f-917c-4dfd-b60f-26df17d30d60">553,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzMtMS0xLTEtNzIwNDI_5f55cd79-f200-4af4-a930-8d5e48cb0635">10,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzMtMy0xLTEtNzIwNDI_e89bfa9f-91d4-4ffe-9c66-c3a7f3bddb96">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzMtNS0xLTEtMTEyMTU5_93db602c-10c3-4efb-9962-301b94e26d8f">93,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzQtMS0xLTEtNzIwNDI_123166cb-aca8-4692-ae38-f197200cfae8">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzQtMy0xLTEtNzIwNDI_bdff6638-38db-455b-a3ec-4d2096a749fa">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzQtNS0xLTEtMTEyMTU5_6a4b6ad2-75dd-4554-9635-49cca9c61120">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzUtMS0xLTEtNzIwNDI_e13e4d53-de7f-460c-8a99-025b7f4a068f">1,348,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzUtMy0xLTEtNzIwNDI_fe8ba67e-02f8-4205-868d-368192145cd2">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzUtNS0xLTEtMTEyMTY3_df7638d9-fece-4a45-ab74-2f7e5151e8ef">648,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd87a8a8c8c945a59f57f5313acd7399"><ix:continuation id="ie03f25dcb4344809ac69a913bec8cdfe">(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2022 and 2021</ix:continuation></ix:continuation>.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 23</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_142"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90ZXh0cmVnaW9uOjhkYjQ0YzFlNDBiMTQ5ODFhNDZmMDQzM2NmMjVlYmI0XzEzMDA_473631fb-312d-460b-ac16-253496fd712a" continuedAt="if1ad99a14c4d4838ad9c428fcbd7ea8d" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="if1ad99a14c4d4838ad9c428fcbd7ea8d"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90ZXh0cmVnaW9uOjhkYjQ0YzFlNDBiMTQ5ODFhNDZmMDQzM2NmMjVlYmI0XzEyOTk_11a7ce7b-d8d3-40cb-9786-1fc4bc5ae8bd" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the estimated fair value of the Company&#8217;s financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb61b7126be74d498e8a47c4f03eac57_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItMS0xLTEtNzAyMDA_738f14a8-d9bf-4d33-873e-065ff1b90f9a">398,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557fbd904011405793bff18a21cabb26_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItMy0xLTEtNzAyMDA_bebe4039-a6e8-428f-8982-ae4e17f4b3f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ac59f74cd740e6a0cadeca61d87f18_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItNS0xLTEtNzAyMDA_9122e9fc-b468-4c6d-88da-f8a098b1b833">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ac89c6ba624c228f64bcba1891a2a0_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItNy0xLTEtNzAyMDA_8b92b068-7a02-43be-bed5-1406103de3f2">361,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07eb648508740f8a5d7ef32fc803047_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItOS0xLTEtNzAyMDA_7427b4b1-dab6-4749-bfb8-b83b2cf6c1d6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8240c1c9049f42469bde4e3f3fddf4b8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItMTEtMS0xLTcwMjAw_5441bb26-d92e-4b7a-87b8-eebe682ae7bd">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ebb77a8ee864fc78eb779a17c09226a_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtMS0xLTEtNzAyMDA_d8cf0867-2fca-425b-b8a0-e0fcd3fa6ff7">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia828d2bd46af4b7f8e4984cb14c9cafb_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtMy0xLTEtNzAyMDA_7febdc2e-f2d7-4d9b-aa76-17093715cfc6">296,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b47a43081534cda81d9835ec8a79235_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtNS0xLTEtNzAyMDA_bf4223b8-46ec-4198-a1ff-7cc41516d5a6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d72f7b153e4e8695661560c4fd46bc_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtNy0xLTEtNzAyMDA_2b895ff7-3168-4444-8f58-5fc3daa5f3e9">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90676cb023842e180c00be05cf71a12_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtOS0xLTEtNzAyMDA_5d1efb9f-53fc-4108-b22b-f8d08ac7e9ef">266,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a7cf53ca85450590f17011e1295e6d_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtMTEtMS0xLTcwMjAw_ada27edc-ec67-494e-8c55-d08379e7cc5c">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b6732392440598653904929954c98_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtMS0xLTEtNzAyMDA_2c154c02-7d31-4de5-aff7-837a93a1a322">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f14050837d4c869dde5769d325bd7f_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtMy0xLTEtNzAyMDA_8d453fd4-c508-4a2c-98ac-12c5fd2c0fd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ad0f304ef5468ab90dfce6c1651bcc_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtNS0xLTEtNzAyMDA_bb466daf-633a-4126-84ac-14d5b80cc0e4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac7cacc849b46c798d58117b7ff11d0_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtNy0xLTEtNzAyMDA_47370b90-5061-487d-9fe7-7c9f771ce835">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23496a29b22d4426a67a18543af66bbc_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtOS0xLTEtNzAyMDA_868d5b92-1777-4824-afd6-74a55e777a92">790,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6271729b2154949abe04c08bdafe9ac_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtMTEtMS0xLTcwMjAw_43b39fef-693a-46f3-a5b7-505e274cb073">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ef3865c980492c8ddf20d9b5a9b4a0_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtMS0xLTEtNzAyMDA_768cdde9-0c04-4061-85aa-014548a96241">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if419a9b5d1bc45b68cd3c42755335735_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtMy0xLTEtNzAyMDA_07092e28-bfdc-4eb1-bea0-aeacd1e5809b">104,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07aa9a3ff734e88b8adaa9f439f1d27_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtNS0xLTEtNzAyMDA_b1ae265f-c494-4228-b3db-38c4a745dc01">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8047cd560f6c44c382b2c1bf052d612c_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtNy0xLTEtNzAyMDA_9df2e713-bf06-414e-b916-2fe12a13d6ce">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c022c32626a40f9ba08a783a679df34_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtOS0xLTEtNzAyMDA_3957c993-f921-4b66-8474-6823d2f8b21a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia128e17147ae46ebbeef34e5ce29d598_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtMTEtMS0xLTcwMjAw_f13515d2-3ac8-462b-a905-ab8a2558d829">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8099f1e2bbdd4ec0970e209f1e0b270e_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctMS0xLTEtNzAyMDA_b68acf1a-b92e-478e-9fce-deeeaf2d0e3d">398,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff83caef02b40f599cc74bcae40ff09_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctMy0xLTEtNzAyMDA_4afda8f6-8d59-4eff-83b6-560f08cca335">400,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cd12d82fc44bc780022e28d26cb8eb_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctNS0xLTEtNzAyMDA_f2d40c34-936b-45e4-bb40-25526fd207c8">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83da57994934aae8def1bf0f382f5a8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctNy0xLTEtNzAyMDA_101cb93b-50e7-477f-a21f-9bd3e8456202">361,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa7a2181db6a41c9b9b4919cafe3b1cd_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctOS0xLTEtNzAyMDA_45fd2803-a4fd-468f-8d8c-287bdf29dc0d">1,056,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a45c212dfe4e53b8afb7e0ff8967f5_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctMTEtMS0xLTcwMjAw_cd17846f-7770-4b37-9ff2-58b060b3e074">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTAtMS0xLTEwNjA4Ni90ZXh0cmVnaW9uOjg3MmMxOWMyNjUyNjQwMzI5ZGJmODBiMDRlYzQzMjRkXzIxOTkwMjMyNTU1OTQ_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f">3.75</ix:nonFraction>% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89587ae04de147c793c1b9499301a5d8_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTEtMS0xLTEwNTAzOA_ff89310e-c787-477f-9183-725c55dec701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2056ca33214fd9bb1ee8b7c7c6cca8_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTMtMS0xLTEwNTAzOA_ed9d7447-46ea-43ba-bd45-b38e6c458000">322,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca80f7d1ad642bd978daca477579b19_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTUtMS0xLTEwNTAzOA_65dd7962-c86a-47d7-8022-442714fa2a42">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a506862b80548d28dfcb14cd9a57994_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTctMS0xLTEwNTAzOA_e5c03117-19b3-441e-8397-1acd9d03c144">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed14e6e12f045e6896127906a812d89_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTktMS0xLTEwNTAzOA_4767a3d1-e9d3-4999-9831-c040a3266e2a">447,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016b678121634f2ea331a88b589a7be0_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTExLTEtMS0xMDUwMzg_b993730a-1b44-4ecb-9c4f-a5672c529e53">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTAtMS0xLTEwNjA4NC90ZXh0cmVnaW9uOjYwNjM1N2UwNTU0NDQ4YTBhZWIyNTUwNDZjZDk2ZTFhXzIxOTkwMjMyNTU1OTQ_33fa4bef-21c4-415d-8233-3d518d1dee7b">5.00</ix:nonFraction>% Convertible notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e9156a13034488a05b42b0e99c2e6a_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTEtMS0xLTEwNjA4MA_e9cc824f-a0b4-442d-8225-361a5a8b7851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d108ce57a04b59a033717ce6e1e081_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTMtMS0xLTEwNjA4MA_c9190c3e-92be-4d9e-ab43-8fe728fa90f4">172,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia37923a559ac460cba463e92ab69d61b_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTUtMS0xLTEwNjA4MA_d6b2e605-f634-4d5f-8d42-714ffb257473">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8296c755f9446a59e2ee459a7b97bab_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTctMS0xLTEwNjA4MA_7a462c0a-5247-4323-843b-8b634a37b7d5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4056500d5930405896706052920574c9_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTktMS0xLTEwNjA4MA_db937b15-4f84-4089-b04c-4f35c4efd6d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3ca7c3c6b834b43b446ee1616686ee3_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTExLTEtMS0xMDYwODA_7e418a21-676c-453d-b3d6-c43832ab62a1">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8099f1e2bbdd4ec0970e209f1e0b270e_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktMS0xLTEtNzAyMDA_91e0a466-fb90-4132-9d19-f1f24952fe68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff83caef02b40f599cc74bcae40ff09_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktMy0xLTEtNzAyMDA_7935d931-c468-4ee4-b0f3-fb06fa69c06b">494,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cd12d82fc44bc780022e28d26cb8eb_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktNS0xLTEtNzAyMDA_48041c2d-e474-48ef-9c29-96dad17527cb">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83da57994934aae8def1bf0f382f5a8_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktNy0xLTEtNzAyMDA_310c40e4-e6a9-445c-8138-a1ccbfa4031e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa7a2181db6a41c9b9b4919cafe3b1cd_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktOS0xLTEtNzAyMDA_2089e749-7ae8-4e62-92db-1b7b510f9d60">447,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a45c212dfe4e53b8afb7e0ff8967f5_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktMTEtMS0xLTcwMjAw_90538d23-504b-4901-87e5-273679509301">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as Cash and cash equivalents as of December&#160;31, 2022 and 2021, on the consolidated balance sheets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#8217;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics.&#160;Pricing of the Company&#8217;s convertible notes has been estimated using observable inputs, including the price of the Company&#8217;s common stock, implied volatility, interest rates, and credit spreads.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company did not have any transfers between Levels.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount in the Company&#8217;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_1496"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7&#160;&#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5MTcyOQ_39e0c986-1284-4b58-b4a4-29862c6f35a6" continuedAt="i89b805675b214b91a83d964e64b1245a" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i89b805675b214b91a83d964e64b1245a" continuedAt="ib89cb3413a9b4d71b47d6cc85cdd4b03"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5MTczMA_b42c21cb-f857-4119-887e-442504e4f87e" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8xLTEtMS0xLTcyMzUx_3453f93f-66e0-4340-8a73-5830f3dba693">13,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8xLTMtMS0xLTcyMzUx_55071f01-9533-4986-812b-e3093099ee05">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8yLTEtMS0xLTcyMzUx_eb2403e4-1bd3-4f64-a196-25b5178b9bdf">21,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8yLTMtMS0xLTcyMzUx_efae9569-ef9b-44db-9935-10dfbdaec6c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8zLTEtMS0xLTcyMzUx_686e3c54-7a30-4249-8ca2-0f71d90d5fa0">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8zLTMtMS0xLTcyMzUx_7b3a6dbe-31f7-4fca-b63f-5983728b9c8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl81LTEtMS0xLTk2NTEy_568be4cd-2af0-4b5f-bd8b-232382f4e0c3">36,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl81LTMtMS0xLTk2NTEy_ba0bc3f1-bc88-44d2-bb7a-6db0a7172f25">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of Cost of sales in the consolidated statements of operations. For the year ended December&#160;31, 2022, inventory write-downs were $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="nvax:InventoryReserveChargedToCostsOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8yMTQ0MDQ3Njc0NDU2Nw_fcb939b3-fe80-4bf3-94fd-3e2a1b57850c">447.6</ix:nonFraction>&#160;million and losses on firm purchase commitments were $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8yMTQ0MDQ3Njc0NDUyNQ_7f8e3fad-460b-44d6-8cd6-e9536bb5b098">155.9</ix:nonFraction>&#160;million. There were <ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="INF" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_02bb9278-c56c-4dd5-b899-8e51010f69cb"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_17d3f222-5bba-46a3-8a26-83d21bfce2a2"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_8947e7dd-cc39-48fd-a6ea-c11e29aa8125"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="INF" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_b0a85781-8f15-4ca2-8f8c-6428cda0dfe6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> inventory write-downs or losses on firm purchase commitments during 2021 or 2020. Inventory </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="ib89cb3413a9b4d71b47d6cc85cdd4b03"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reserves for write-downs are relieved when the inventory is disposed of through scrap or sale. <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:ScheduleOfInventoryReserveTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5NDg3OA_34ec3576-5b51-4816-aeb9-a97535aa8bb4" continuedAt="i149b1df185b34e5199cc5bc24a65cd32" escape="true">Activity in the reserve for excess and obsolete inventory was as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i149b1df185b34e5199cc5bc24a65cd32"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8xLTEtMS0xLTExNDUyNw_11564c00-9313-4a55-9e49-39879771933b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Cost of sales, including impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:InventoryReserveChargedToCostsOfSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8yLTEtMS0xLTExNDUyNw_19994269-6817-4d07-987a-91ae2b87d915">447,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other additions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="nvax:InventoryReserveOtherAdditions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8zLTEtMS0xLTEyODQ3MQ_10dd4214-3cd0-4fac-b9a4-a380239450b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8zLTEtMS0xLTExNDUyNw_d4e9b059-cdb5-4ebf-a32c-4ec231c858c0">79,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl80LTEtMS0xLTExNDUyNw_b8933371-c594-464e-b62c-176da83bbfc4">368,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_145"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:GoodwillDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90ZXh0cmVnaW9uOjJiOTFjOTNhZWMyYzRkZjg4YTNjYThmYjVmNjgyOTg0XzQ5Mw_4c31a3c5-b1d1-4464-8de0-af2ee5385692" continuedAt="icd7d3064ba4a4cdf85f49ad26c29b7b9" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="icd7d3064ba4a4cdf85f49ad26c29b7b9"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90ZXh0cmVnaW9uOjJiOTFjOTNhZWMyYzRkZjg4YTNjYThmYjVmNjgyOTg0XzQ5Ng_e126095a-9e73-480a-94af-2beaf21f198d" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amounts of goodwill was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzMtMS0xLTEtNzAyMDA_198b969a-54ae-4aa4-9f41-c2fe8aa01152">131,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzMtMy0xLTEtNzAyMDA_f8e61f67-f5ed-4e42-9ee1-a1241aad45c7">135,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzUtMS0xLTEtNzAyMDA_7b14bbd2-03f3-40b7-a334-584d0ecc92d7">5,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzUtMy0xLTEtNzAyMDA_752ce8ac-4ab0-4d4a-9827-01918fdee582">3,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzYtMS0xLTEtNzAyMDA_6f6cdc9e-7826-48cb-a3a8-93fce42265a2">126,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzYtMy0xLTEtNzAyMDA_06e944a6-60dc-4421-9301-ef640aa14b1b">131,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_148"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzUyNjI_920a7767-f36e-49dd-9b6d-102538a38810" continuedAt="i7e816331f0b3464d9e968529b5b48c46" escape="true">Acquisition of Novavax CZ</ix:nonNumeric></span></div><ix:continuation id="i7e816331f0b3464d9e968529b5b48c46" continuedAt="icf5f925d25a345afbcd27bf9ae67190d"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 27, 2020 (the &#8220;Acquisition Date&#8221;), the Company entered into a Share Purchase Agreement (the &#8220;Deed&#8221;) by and among Novavax AB, the Company&#8217;s wholly-owned Swedish subsidiary (the &#8220;Buyer&#8221;), and De Bilt Holdings B.V., Poonawalla Science Park B.V., and Bilthoven Biologicals B.V. and, solely as guarantors, each of Serum International B.V. and the Company. Pursuant to the terms and conditions of the Deed, the Buyer acquired all the issued and outstanding shares of Novavax CZ (formerly, Praha Vaccines a.s.), a vaccine manufacturing company (the &#8220;Acquisition&#8221;). The assets of Novavax CZ acquired as part of the Acquisition include a biologics manufacturing facility and associated assets in Bohumil, Czech Republic and will be used by the Company to expand its manufacturing capacity.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allocation of Purchase Price to Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has accounted for the Acquisition as a business combination using the acquisition method of accounting, with the Company as the acquirer. The acquisition method requires the Company to record the assets acquired and liabilities assumed at fair value. The amount by which the purchase price exceeds the fair value of net assets acquired is recorded as goodwill. The Company completed the appraisal process necessary to assess the fair values of the assets acquired and liabilities assumed to determine the amount of goodwill to be recognized as of the Acquisition Date. The final determination of the fair value of all assets and liabilities was completed in 2020 and is presented in the table below.</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzUyNjM_eebe5338-331b-41b0-bc31-97f9b0509b4f" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes the final allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">May 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzEtMS0xLTEtNzAyMDA_51f839b1-ab88-4f6e-9056-76837cd400b2">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzItMS0xLTEtNzAyMDA_329fb619-57f0-43a8-a49e-3079e71b7a3c">96,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzMtMS0xLTEtNzAyMDA_c2204ef6-f01b-4f11-ba02-7d47a11864d6">70,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzQtMS0xLTEtNzAyMDA_e550866e-0602-4e73-bca4-ac885adf5d24">1,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-3" name="nvax:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzUtMS0xLTEtNzAyMDA_b8c41e00-36a2-401e-b938-60ac9e877292">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzYtMS0xLTEtNzAyMDA_f8d118fe-e52d-4f4a-a9dc-dc8bbbd29f49">813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchase price, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzctMS0xLTEtNzAyMDA_7a2e3d10-8c55-492f-a146-516580c2cf77">165,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the assets acquired and liabilities assumed was determined using market and cost valuation methodologies. The fair value measurements were based on significant unobservable inputs that were developed by the </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="icf5f925d25a345afbcd27bf9ae67190d"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company using publicly available information, market participant assumptions, and cost and development assumptions. Because of the use of significant unobservable inputs, the fair value measurements represent a Level 3 measurement as defined in ASC 820. The market approach is a valuation technique that uses prices and other relevant information generated by market transactions involving identical or comparable assets, liabilities, or a group of assets or liabilities. The cost approach estimates value by determining the current cost of replacing an asset with another of equivalent utility. The cost to replace a given asset reflects the estimated reproduction or replacement cost for the property, less an allowance for loss in value due to depreciation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost approach was the primary approach used to value fixed assets, including the real property. Fixed assets are depreciated on a straight-line basis over their expected remaining useful lives, ranging from <ix:nonNumeric contextRef="i6803c5d4d38740009777ad5eadf70727_D20200527-20200527" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzMwMDY_16bc801c-b60e-49cb-b5e9-a3e9becae255">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="iabda6dd0b85b41c5810ef5d88e33f6fb_D20200527-20200527" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzMwMTI_bc7cbedd-ba0f-47d9-a409-3cba2be4854d">25</ix:nonNumeric> years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded $<ix:nonFraction unitRef="usd" contextRef="if74110891d1c4616a0230ee664e7675b_I20200527" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzMwMzk_8174ac9a-3232-49c9-a8ed-9214f1102781">70.7</ix:nonFraction>&#160;million in goodwill related to the Acquisition representing the purchase price that was in excess of the fair value of the assets acquired and liabilities assumed. The goodwill generated from the Acquisition is not expected to be deductible for U.S. federal income tax purposes. The goodwill recognized is attributable to intangible assets that do not qualify for separate recognition, such as the assembled workforce of Novavax CZ.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current assets and current liabilities were recorded at their contractual or historical acquisition amounts, which approximate their fair value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impact to Financial Results for the Year Ended December 31, 2020</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of operations from Novavax CZ have been included in the consolidated financial statements since the Acquisition Date. As a result, the consolidated financial results for the year ended December 31, 2020 does not reflect a full twelve months of Novavax CZ results. From the Acquisition Date through December 31, 2020, Novavax CZ did not recognize any revenue and recorded a net loss from operations of $<ix:nonFraction unitRef="usd" contextRef="i98d86903b18c4a31908d43850afb1f79_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzQwOTM_4a467c0b-dfcb-4536-882a-7f80867723d8">11.3</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i98d86903b18c4a31908d43850afb1f79_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzQxMzM_aeb0836e-686f-47c2-830f-c8b60bfb56fb">2.7</ix:nonFraction>&#160;million of costs related to the Acquisition in the year ended December 31, 2020, which are included within general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supplemental Pro Forma Financial Information (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unaudited pro forma financial information below gives effect to the Acquisition as if it had occurred as of January 1, 2019. The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved had the Acquisition been consummated as of that time. <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzUyNjE_dd891cfa-1e44-42cf-b476-c06a71c1b6fc" continuedAt="i15bc9044efe4406c8617e73d2e32871b" escape="true">The unaudited pro forma financial information combines the historical results of operations of the Company and Novavax CZ and reflects the application of certain pro forma adjustments (in thousands, except per share amounts):</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i15bc9044efe4406c8617e73d2e32871b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzItMS0xLTEtNzAyMDA_9014e6ea-9d75-4390-8eea-a3aa424a61fb">475,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzMtMS0xLTEtNzAyMDA_c31ab273-025d-4737-b03f-709e699031d5">419,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzQtMS0xLTEtNzAyMDA_391228ef-3b8f-4ea5-888b-0332fc9c046b"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzQtMS0xLTEtNzAyMDA_7444f8c0-73ca-4565-91df-1b160ad5ee8c">7.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pro forma adjustments include the recognition of depreciation expense based on the Acquisition Date fair value and remaining useful lives of Novavax CZ fixed assets (net of historical depreciation expense) and the elimination of costs related to the Acquisition, which are non-recurring in nature.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_151"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTc_812623c1-0ebb-4a34-ab99-6b4788eb4367" continuedAt="i631d439d7f74416abf3bc356c5389818" escape="true"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTc_fbe860ed-3a12-4c57-8e0a-15284ae73d77" continuedAt="i2e52b94a6ba140ab9ff6af3a9750c764" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i631d439d7f74416abf3bc356c5389818" continuedAt="i69cf20e5934f48cb8b3acbe4fc88a29c"><ix:continuation id="i2e52b94a6ba140ab9ff6af3a9750c764" continuedAt="ia33fd86f37954c14938e5c25d97ad213"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CDMOs to manufacture NVX-CoV2373, as well as operating leases for its research and development and manufacturing facilities, corporate headquarters and offices, and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2022, the Company recognized ROU assets and a corresponding long-term operating lease liability on the remeasurement of modified supply agreements. During the </span></div></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i69cf20e5934f48cb8b3acbe4fc88a29c" continuedAt="ia87ac65f1c3a4a558f63f1d8e5356cdd"><ix:continuation id="ia33fd86f37954c14938e5c25d97ad213" continuedAt="i061f48f035fe42ea9793c63e2a424688"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2021, for leases that were previously determined to represent short-term embedded leases, modifications did not result in a change in lease classification.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, of $<ix:nonFraction unitRef="usd" contextRef="i18de67b571ba458cbba0933459b5975b_D20220101-20221231" decimals="-5" name="nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzIxOTkwMjMyNjMyMDY_0f16937c-be13-48fa-844d-134641a29955">18.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i94ada334c1e14256b42648cab21c02f2_D20210101-20211231" decimals="-5" name="nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzIxOTkwMjMyNjMyMDI_3dba1092-0a34-4cb0-9a88-c2cc62d751e9">144.4</ix:nonFraction>&#160;million, respectively, for its finance leases and long-term operating leases embedded in CMO and CDMO manufacturing supply agreements. The Company expensed the ROU assets since they related to research and development activities for the development of NVX-CoV2373 for which the Company did not have an alternative future use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company entered into and extended various facility lease agreements related to research and development facilities and office space. During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately <ix:nonFraction unitRef="sqft" contextRef="i201ad52388df4bebacf2bd74f56acfeb_D20200101-20201231" decimals="INF" name="nvax:FacilityNumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzI0Njg_fb04c48f-1937-4115-a429-acbb3c473704">170,000</ix:nonFraction> square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is <ix:nonNumeric contextRef="i3094b6244ecc489b96c2559b7639a6b9_I20201231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzI2MDc_debbf180-c92a-4c21-b184-21d234b6d9a3">15</ix:nonNumeric> years with options to extend the lease that have not been recognized in the ROU asset. The lease provides for an annual base rent of $<ix:nonFraction unitRef="usd" contextRef="i201ad52388df4bebacf2bd74f56acfeb_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzI2OTA_f0f4e16e-1608-4177-9591-b76cee56001a">5.8</ix:nonFraction>&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December&#160;31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $<ix:nonFraction unitRef="usd" contextRef="i988682eb3b024cb688a6d71ca0cb108b_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzExNTQ0ODcyMDk2OTIw_77045a1a-1c3d-463f-bc81-f28ce0f2fe42"><ix:nonFraction unitRef="usd" contextRef="i988682eb3b024cb688a6d71ca0cb108b_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzExNTQ0ODcyMDk2OTIw_cd5d8066-acd5-4488-b1a2-e51c57533d54">73.2</ix:nonFraction></ix:nonFraction>&#160;million as lease commencement for accounting purposes had occurred. As of December 31, 2022 and 2021, the Company had incurred $<ix:nonFraction unitRef="usd" contextRef="i9bb89a63509c49b0b7381f32ace08d03_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForTenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzE5MjQxNDUzNTAxNjQ1_e6c695af-89dd-4909-9447-54824efabe94">49.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7bd187e980034898b9aecf0c85fa92f4_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForTenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzE5MjQxNDUzNTAxMTg2_cc696af1-c199-43b3-8c83-23748cde6b61">36.4</ix:nonFraction>&#160;million, respectively, related to tenant improvement costs to be recognized as a ROU asset. The Company anticipates that it will incur additional tenant improvement costs, net of a landlord contribution of $<ix:nonFraction unitRef="usd" contextRef="if0e0cb7900fe42bb90900d51daf494af_D20230101-20231231" decimals="-5" name="us-gaap:PaymentsForTenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzE5MjQxNDUzNTAxNjMw_686edaa7-98b7-493c-a854-a804b850253b">9.8</ix:nonFraction>&#160;million, through 2023 to bring the remainder of the building to the condition necessary for its intended use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, facility leases, excluding the 700QO lease, have expirations that range from approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDE_cc59319b-f346-4179-ace9-8b072a6d76f3">three</span> to <ix:nonNumeric contextRef="i728c18080ef8448fb44592281f48f9b5_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDc_f9093a9e-6ea0-4b80-90b7-4e0900370280">nine years</ix:nonNumeric>, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTg_d3b392c2-d80a-491e-bc27-9e721c88acdd" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtNC0xLTEtNzAyMDA_830ed373-b85c-4572-9d23-74428e71d907">36,384</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtNi0xLTEtNzAyMDA_cbfdaeab-da80-47a6-b2fc-414091fc274e">40,123</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtNC0xLTEtMTA5NjUy_971f9bf4-c2b9-4d85-9b2e-ef11c43ec8a7">69,857</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtNi0xLTEtMTA5NjYw_def1351b-77ad-413e-8717-ee5476432ac9">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzUtNC0xLTEtMTE0NTU5_055b9c85-34e6-4984-89f9-cee7368c30c9">106,241</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzUtNi0xLTEtMTE0NTU5_b97789ff-3b0b-442c-9d04-ea6bf0ce0549">40,123</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtNC0xLTEtNzAyMDA_0527d295-1378-4a19-8a71-7146d115463e">16,867</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtNi0xLTEtNzAyMDA_58ad3fc4-47d7-44bc-9bbc-40ea9129284e">30,983</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzctNC0xLTEtNzAyMDA_bc5da765-cf76-44c3-897d-66e7569b3e5d">27,196</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzctNi0xLTEtNzAyMDA_97f0cd5c-e22b-4b3b-bb20-84bf0bd0b1e8">130,533</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzgtNC0xLTEtNzAyMDA_521526b4-410b-4f66-90ab-b5d14d35affe">44,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzgtNi0xLTEtNzAyMDA_fe8a0be4-70f0-43bc-a797-2154c960dd67">161,516</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTQtMS0xLTcwMjAw_1db3e104-d618-4b8c-ae9b-a57b4e6b5827">50,085</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTYtMS0xLTcwMjAw_cddfa991-5141-4f95-be9c-166cb9b754ea">39,116</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzExLTQtMS0xLTcwMjAw_f4f463b4-2816-419f-823a-1c4d910911e9">31,238</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzExLTYtMS0xLTcwMjAw_e89beb8c-a9d3-472f-a7c2-8b8cbeb86d20">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:LeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEyLTQtMS0xLTcwMjAw_61f359f0-10cc-474e-992a-5b9c6a299408">81,323</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:LeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEyLTYtMS0xLTcwMjAw_e3d7f88a-154f-4cf2-abd9-3e2aa0a82c54">39,116</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE1LTQtMS0xLTcwMjAw_d85efe00-5a10-4a47-89d5-04996593828c">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE1LTYtMS0xLTcwMjAw_0213f0e2-24ba-4a05-be28-6b0d3a936d6c">5.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE2LTQtMS0xLTcwMjAw_3494e916-a880-4c11-82cb-7ac7d0dbbb97">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE2LTYtMS0xLTcwMjAw_3d335418-a6ce-492b-a245-98142c50b2f1">3.7</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE5LTQtMS0xLTcwMjAw_d9f0f180-c91c-44f7-8326-47f8d87b0004">6.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE5LTYtMS0xLTcwMjAw_b97258a8-1256-4dbf-a1cc-a32e6b03f322">6.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzIwLTQtMS0xLTcwMjAw_fbf69dd1-5916-475e-a64e-2dba3b0231df">5.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzIwLTYtMS0xLTcwMjAw_3e0debd4-fc78-410d-9a2f-9a966476ca26">5.2</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="ia87ac65f1c3a4a558f63f1d8e5356cdd"><ix:continuation id="i061f48f035fe42ea9793c63e2a424688"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTk_d55be6ae-e9f3-462c-a76d-46bab068b11c" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzItMS0xLTEtNzAyMDA_9371e4be-4327-4e28-b7c2-5be68566d4c5">6,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzItMy0xLTEtNzAyMDA_c3bffea1-91a8-4615-b790-8d443dea50b9">37,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzItNS0xLTEtOTc0OTU_cf6cee46-0ecd-4bf5-81a8-9c18ea8ff340">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzMtMS0xLTEtNzAyMDA_bec3ad99-4e8a-4097-91b6-0e55a34cf070">94,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzMtMy0xLTEtNzAyMDA_b36b95ff-fe94-4fb6-9456-7d5d48f0fe4f">468,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzMtNS0xLTEtOTc0OTU_0de37b0a-c8cf-4b34-9eb2-0f85f38e619b">66,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzQtMS0xLTEtNzAyMDA_cdd257c5-92cc-4ce9-861b-ffc9815cb7d4">6,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzQtMy0xLTEtNzAyMDA_de57a734-09ef-4175-8919-c9fd103b1d2c">116,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzQtNS0xLTEtOTc0OTU_9bdef47b-8641-404c-b896-1fd839c465c5">4,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzYtMS0xLTEtNzAyMDA_f496a364-7646-40bd-b4fc-9ffc7e26ad3a">7,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzYtMy0xLTEtNzAyMDA_0a9c1a94-c5b6-476e-8612-b0b6a52c4f5c">112,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzYtNS0xLTEtOTc1MDY_b1f2176a-9792-470a-ad43-1c00e98d679d">242,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzctMS0xLTEtNzAyMDA_9020deed-c334-4467-b4e2-f75efd8ec717">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzctMy0xLTEtNzAyMDA_37ad2df2-71a9-4578-b82b-5f8bbbb784f9">7,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzctNS0xLTEtOTc1MDY_3dc660e1-97f9-46c2-8597-dee97c0c1780">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzgtMS0xLTEtNzAyMDA_9858d4cf-d8bc-4ff2-b026-db3d9548f1a8">9,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzgtMy0xLTEtNzAyMDA_2f0c3053-cb18-49c7-a8a6-400b5dc2c13a">119,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzgtNS0xLTEtOTk3MjA_25510f26-42dd-4ff7-9fc0-90baeb82dd9f">245,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTU_ed31e87b-445d-48f4-808b-5d79123cca36" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzMtMS0xLTEtNzAyMDA_93dfa6b0-f0e9-4097-8302-5c04d8e3fee8">190,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzMtMy0xLTEtNzAyMDA_92adb522-d152-4b3a-8d2e-2820dd4b7194">203,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzMtNS0xLTEtOTc2MzE_a531b13e-3dac-4956-b06c-d7d04ad75dee">63,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzQtMS0xLTEtNzAyMDA_eef80516-beab-47fa-bc00-3f85d5347c22">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzQtMy0xLTEtNzAyMDA_57c6f77e-b3e7-4b54-b365-d7a15a63be99">7,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzQtNS0xLTEtOTc2MzE_b3b9d6c2-161f-49b6-b6ab-3bb611f142f4">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzUtMS0xLTEtNzAyMDA_20580ac7-30b4-4fd7-959d-c27e7851b05b">93,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzUtMy0xLTEtNzAyMDA_90c59ea8-5586-4b11-b1c6-f35e9cc8a3ec">127,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzUtNS0xLTEtOTc2MzE_c716f843-b4f5-4621-b83d-447b089063a3">96,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzctMS0xLTEtNzAyMDA_7ac3b0a7-71ad-4f78-9793-2487c0b772af">30,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzctMy0xLTEtNzAyMDA_02bcf4a7-7984-4105-a33e-5c4f03104083">66,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzctNS0xLTEtOTc2MzE_bdab1142-397b-49e0-8df8-f69139ad4f78">5,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzgtMS0xLTEtNzAyMDA_5f7a1440-7aea-4d6c-b8d8-4642f211e039">73,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzgtMy0xLTEtNzAyMDA_6c2cf617-5825-415f-a887-60afcb417d55">112,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzgtNS0xLTEtOTc2MzE_560bd452-94fb-44e0-b118-f54cf04b28ae">242,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTY_8bd8f6dc-3709-4d87-a1af-d697fca8cca5" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzEtMi0xLTEtNzAyMDA_32f4b63f-9165-4d5e-9c24-7ca823b799be">47,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzItMi0xLTEtNzAyMDA_fba4abab-db2f-4cdf-8139-4fb8fd459b87">24,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzMtMi0xLTEtNzAyMDA_e1dcfe80-b72d-4c14-8041-6f0e078b4871">10,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzQtMi0xLTEtNzAyMDA_b276c1ab-ff01-4053-a3b5-e4128f19953d">10,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzUtMi0xLTEtNzAyMDA_085c9c96-989e-4ca5-9447-63102cb0d00e">10,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzYtMi0xLTEtNzAyMDA_a3ee6e41-c4e3-47a2-bb03-babe139504ab">46,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzctMi0xLTEtNzAyMDA_1e71c4ba-a5c4-4a6e-9592-d9dafb049a2f">149,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzgtMi0xLTEtNzAyMDA_77057c24-35df-4e08-82ee-5c1d3d0fe38e">24,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzktMi0xLTEtNzAyMDA_12c3cde7-fdb2-4f6e-ac39-c12b93178082">125,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 28</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_154"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzUyMzM_c74751f9-a2cf-4afe-be42-89a8fad9a632" continuedAt="i18033e4d1eb84ef18fc61ef88180eb1b" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="i18033e4d1eb84ef18fc61ef88180eb1b" continuedAt="i6e4a76f706364cbda9b892f0660fecda"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTEyODgx_eb8e1000-21af-4196-845e-3be549765b1b" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzMtMC0xLTEtMTEzNTcwL3RleHRyZWdpb246MGE5YWNlMzRjMzJjNGY2NWE0OTgyZDhiZDk0YTI5YThfMjE5OTAyMzI1NTU5NA_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f">3.75</ix:nonFraction>% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231" decimals="-3" name="nvax:DebtInstrumentFaceAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzMtMS0xLTEtMTA4MDcz_4fb14d7d-ad5b-411f-8051-f9378387eff8">325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied7dd9ef2652406e95d1ff0060ae1b04_I20211231" decimals="-3" name="nvax:DebtInstrumentFaceAmountCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzMtMy0xLTEtMTA4MDcz_2ed1775e-8774-48fd-a070-0f97be662c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzQtMS0xLTEtMTA4MDcz_48d33fae-f752-4881-81d7-2737e3d9eea2">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzQtMy0xLTEtMTA4MDcz_ac7876bc-64b7-4495-b24d-1798af02c2ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current convertible notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzUtMS0xLTEtMTA4Mzcw_6d153b2c-7cb4-423c-b72d-6a31268f03a8">324,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzUtMy0xLTEtMTA4Mzcw_84d8f45e-8cd2-435c-a2d8-8a818eeeacae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzctMC0xLTEtMTEzNTY3L3RleHRyZWdpb246ODU2NjA0ZDFlZDkzNGRjMDhlZWRmYWFlZTE3YzA4NDhfMjE5OTAyMzI1NTU5Mg_33fa4bef-21c4-415d-8233-3d518d1dee7b">5.00</ix:nonFraction>% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzctMS0xLTEtMTA4MDcz_86d5b8ad-0484-4169-bde6-ea8b47847262">175,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864f59e306a74cabbced7a3c1435512b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzctMy0xLTEtMTA4MDcz_2cb7dc40-709c-42af-a344-0da3e0025b91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzgtMC0xLTEtMTEzNTcyL3RleHRyZWdpb246OWFiYmZhMDZmMTUyNGYwNzljNWU3NzMzNDBmN2ZlMmVfMjE5OTAyMzI1NTU5NA_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f">3.75</ix:nonFraction>% Convertible notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzgtMS0xLTEtMTA4MDcz_200434e2-cb65-41cd-a844-f67e16333473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied7dd9ef2652406e95d1ff0060ae1b04_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzgtMy0xLTEtMTA4MDcz_cc03b522-5cf0-4282-9dfc-7e8abdb2bb0f">325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzktMS0xLTEtMTA4MDcz_4f4d4967-20d1-476e-9841-6e359450fb2f">8,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzktMy0xLTEtMTA4MDcz_a8c3168b-d11f-4c7d-8ffa-e37744c53707">1,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzEwLTEtMS0xLTEwODM3Mg_f07643ae-b0b6-40a4-9c5b-6702f8a81fa2">166,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzEwLTMtMS0xLTEwODM3Mg_905cb591-6395-42fb-8c70-c1df515cdbe3">323,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTEyODgy_87ffd7a1-cf53-479f-8565-6ec37d1b13d3" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzItMS0xLTEtMTA4MDcz_a53709ed-95ef-46be-be48-90a090870330">12,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzItMy0xLTEtMTA4MDcz_f1aa78f1-3e66-495e-9bc7-5a13915643d9">12,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzItNS0xLTEtMTA4MDcz_595ebaf2-d7a5-431b-a9e6-f196576dbf82">12,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzMtMS0xLTEtMTA4MDcz_068ae510-d800-4cd1-8597-a534e4663b93">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzMtMy0xLTEtMTA4MDcz_22205fca-a29d-4817-b52d-9e5cd8a16a75">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzMtNS0xLTEtMTA4MDcz_22611755-79d0-4110-a168-5ef1627e26b8">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzQtMS0xLTEtMTA4Mzc1_82f07895-7ff0-4f9f-a0d9-b461b8baa83e">14,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzQtMy0xLTEtMTA4Mzc1_723a6a30-1b68-4b90-a4f9-f3c6d355f31e">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzQtNS0xLTEtMTA4Mzc1_d7e3938e-2650-4ac5-b324-80a4c57501b8">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2027 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwODYx_349e3722-8398-4fc2-a731-78357c0ea774">175.3</ix:nonFraction> million aggregate principal amount of convertible senior unsecured notes that will mature on December 15, 2027 (the &#8220;2027 Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2027 Notes were issued in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and pursuant to an indenture dated December 20, 2022 (the &#8220;2027 Indenture&#8221;) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Concurrently with the issuance of the 2027 Notes, the Company completed a public offering of shares of its common stock (see Note 13). The Company received $<ix:nonFraction unitRef="usd" contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwODgx_dc93b80a-ccd6-4244-8e56-08e9b0592445">166.4</ix:nonFraction> million in net proceeds from the issuance of the 2027 Notes after deducting the initial purchasers&#8217; fees and the Company&#8217;s offering expenses. The 2027 Notes bear cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwODk0_33fa4bef-21c4-415d-8233-3d518d1dee7b">5.00</ix:nonFraction>% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding September 15, 2027, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least <ix:nonFraction unitRef="day" contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTI4_65e8f74f-4771-4717-b0c8-ad2c0451a960">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTIw_477d3af9-34e3-4b55-83b3-cb569aa92faf">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTM3_34cd3ddb-e410-42f2-b634-9082fd9148f6">130</ix:nonFraction>% of the conversion price for the 2027 Notes on each applicable trading day; (2) during the <ix:nonFraction unitRef="day" contextRef="i96a1add754d840f5946967a65b3f474e_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTQy_789c02b6-8d10-4994-bc90-3e0de743e5da">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="i96a1add754d840f5946967a65b3f474e_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTUy_b9897d27-97d6-4aa6-9b20-ade7f790ac35">ten</ix:nonFraction> consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2027 Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i96a1add754d840f5946967a65b3f474e_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTYz_6eed38f7-3bb5-45af-9a8c-bf8550e0a527">98</ix:nonFraction>% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate for the 2027 Notes on each such trading day; (3) if the Company calls such 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2027 Notes called (or deemed called) for redemption; and (4) upon the occurrence of specified corporate events as set forth in the 2027 Indenture. On or after September 15, 2027, until the close of business on the business day immediately preceding the maturity date (December 15, 2027), holders of the 2027 Notes may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing conditions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of the Company&#8217;s common stock, or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s election, in the manner and subject to the terms and conditions provided in the 2027 Indenture.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i6e4a76f706364cbda9b892f0660fecda" continuedAt="i7f1e3cfa747c480da681b09ff28175f0"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion rate for the 2027 Notes will initially be 80.0000 shares of the Company&#8217;s common stock per $1,000 principal amount of 2027 Notes, which is equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwOTEy_08ca07ae-4d21-4b13-b6b5-def4a1e1322b">12.50</ix:nonFraction> per share of common stock. The initial conversion price of the 2027 Notes represents a conversion premium of <ix:nonFraction unitRef="number" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="2" name="nvax:ConversionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwOTE4_8fd03ac1-ef53-4455-99e2-e3b82d2999a9">25</ix:nonFraction>% of the public offering price in the Company&#8217;s concurrent common stock offering that closed on December 20, 2022 (see Note 13). The conversion rate for the 2027 Notes is subject to adjustment under certain circumstances in accordance with the terms of the 2027 Indenture. In addition, following certain corporate events that occur prior to the maturity date of the 2027 Notes or if the Company delivers a notice of redemption in respect of the 2027 Notes, the Company will, under certain circumstances, increase the conversion rate of the 2027 Notes for a holder who elects to convert its 2027 Notes (or any portion thereof) in connection with such a corporate event or convert its 2027 Notes called (or deemed called) for redemption during the related redemption period (as defined in the 2027 Indenture), as the case may be.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes prior to December 22, 2025. The Company may redeem for cash all or any portion of the 2027 Notes, at its option, on or after December 22, 2025, if the last reported sale price of the common stock has been at least <ix:nonFraction unitRef="number" contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTY4_d4d316ae-9c33-4131-a70e-a219730f95af">130</ix:nonFraction>% of the conversion price for the 2027 Notes then in effect for at least <ix:nonFraction unitRef="day" contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTc0_19d312ef-d0b7-4b67-b826-cafb58dfe4ab">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="day" contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTgy_885676be-7ba5-49e1-91e7-ce145477d448">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTkw_d1fba93e-4f88-4409-bb58-4b5112a082c1">100</ix:nonFraction>% of the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, to, but excluding, the redemption date. If the Company redeems less than all the outstanding 2027 Notes, at least $<ix:nonFraction unitRef="usd" contextRef="i3956f36cdac340c886e2cbf2ea354b9f_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTk2_eeef87fe-9d9c-497f-ba2c-089ddbe8b813">50</ix:nonFraction>&#160;million aggregate principal amount of 2027 Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for the 2027 Notes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a Fundamental Change (as defined in the 2027 Indenture), holders may require, subject to certain conditions and exceptions as set forth in the 2027 Indenture, the Company to repurchase for cash all or any portion of their 2027 Notes at a Fundamental Change repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231" decimals="INF" name="nvax:DebtInstrumentRepurchaseOfPrincipalAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQzOTgwNDY1NDIyNjg_a1cbe598-5ebe-4536-9c23-4eaabeac2a13">100</ix:nonFraction>% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the Fundamental Change repurchase date. If a holder of the 2027 Notes converted upon a Make-Whole Fundamental Change (as described in the 2027 Indenture), they may be eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 20.0000 shares per $1,000 principal amount of 2027 Notes (subject to other adjustments as described in the 2027 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the 2027 Notes, the Company determined that the scope exceptions provided under ASC 815-40,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 815-40&#8221;) apply to all but one of the conversion features embedded in the 2027 Notes. This remaining conversion feature, which is associated with a Fundamental Change of the Company, was determined to have a de minimis value as of December 31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchasers&#8217; fees and the Company&#8217;s issuance costs related to the 2027 Notes totaled $<ix:nonFraction unitRef="usd" contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzIxOTkwMjMyNzc3NTk_b727d662-315e-4649-b7fb-26510c8eccfe">8.8</ix:nonFraction> million, which were recorded as a reduction to the 2027 Notes on the consolidated balance sheet. The $<ix:nonFraction unitRef="usd" contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzIxOTkwMjMyNzc3Njk_b727d662-315e-4649-b7fb-26510c8eccfe">8.8</ix:nonFraction> million of debt issuance costs is being amortized and recognized as additional interest expense over the <ix:nonNumeric contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MjA4_ab33d674-57e8-4262-8c15-f6d67101658f">five-year</ix:nonNumeric> contractual term of the 2027 Notes using an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i32856f664ee8488999df14d37a8f364c_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE0ODQzNDA2OTk2Mjg2_7269cd16-8ab0-4b42-a818-fd12fff81fa4">6.2</ix:nonFraction>%.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i502585dd7e734b158fdf6a98bb9e12e1_I20161231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzc1_2d868b9d-441a-45a8-92e0-e631fdfbe0eb"><ix:nonFraction unitRef="usd" contextRef="i5ce452e9ba0b4f91b8ca4a6aa27cddc8_D20230201-20230201" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzc1_3d5168c2-c138-4d81-bbdb-2220f8768550">325</ix:nonFraction></ix:nonFraction> million&#160;aggregate principal amount of convertible senior unsecured notes that matured on&#160;February&#160;1, 2023&#160;(the &#8220;2023 Notes&#8221;).&#160;The 2023 Notes were senior unsecured debt obligations and were issued at par. The Company repaid the outstanding principal amount of $<ix:nonFraction unitRef="usd" contextRef="i502585dd7e734b158fdf6a98bb9e12e1_I20161231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE0ODQzNDA2OTk2NDUz_2d868b9d-441a-45a8-92e0-e631fdfbe0eb"><ix:nonFraction unitRef="usd" contextRef="i5ce452e9ba0b4f91b8ca4a6aa27cddc8_D20230201-20230201" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE0ODQzNDA2OTk2NDUz_3d5168c2-c138-4d81-bbdb-2220f8768550">325</ix:nonFraction></ix:nonFraction> million together with accrued but unpaid interest on the maturity date. The repayment was funded by the issuance of the 2027 Notes and the concurrent common stock offering, as well as cash on hand.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes were issued pursuant to an indenture dated January&#160;29, 2016 (the &#8220;2023 Indenture&#8221;) between the Company and the trustee.&#160;The Company received $<ix:nonFraction unitRef="usd" contextRef="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQxMw_494ca1a6-f2de-490b-8d9d-e25853714c39">315.0</ix:nonFraction> million in net proceeds from the offering after deducting underwriting fees and offering expenses. The 2023 Notes bore cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzU0OQ_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f">3.75</ix:nonFraction>%, payable on&#160;February&#160;1&#160;and&#160;August&#160;1&#160;of each year. The 2023 Notes were not redeemable prior to maturity and were convertible into shares of&#160;the Company&#8217;s&#160;common stock. As a result of the Company&#8217;s one-for-twenty reverse stock split in 2019 and pursuant to Section&#160;14.04(a)&#160;of the 2023 Indenture, the 2023 Notes were initially convertible into approximately <ix:nonFraction unitRef="shares" contextRef="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzkxOQ_91a259a6-39d1-49f2-97d9-ebe1a28ce238">2,385,800</ix:nonFraction> shares of the Company&#8217;s common stock based on the initial conversion rate of 7.3411 shares of the Company&#8217;s common stock per&#160;$1,000&#160;principal amount of the 2023 Notes. This represents an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ied73af9ac932401ebc59933f068a2e4e_I20160125" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNDI_8faa5c17-4e4b-4798-ba84-fe8b9e7185f0">136.20</ix:nonFraction>&#160;per share of the Company&#8217;s common stock,&#160;representing an approximate <ix:nonFraction unitRef="number" contextRef="ied73af9ac932401ebc59933f068a2e4e_I20160125" decimals="3" name="nvax:ConversionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzEyMTQ_f91c07d2-b654-45b4-9588-863ae7fcbcd5">22.5</ix:nonFraction>% conversion premium based on the last reported sale price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0ba24ef23674233a4a49398d78fe3b3_I20160125" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzEzMDc_b07e64ed-436b-4b84-adbb-2cbb753200df">111.20</ix:nonFraction> per share on January&#160;25, 2016. In addition, the holders of the 2023 Notes may have required the Company to repurchase the 2023 </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i7f1e3cfa747c480da681b09ff28175f0"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes at par value plus accrued and unpaid interest following the occurrence of a Fundamental Change (as described in the 2023 Indenture). If a holder of the 2023 Notes converted upon a Make-Whole Adjustment Event (as described in the 2023 Indenture), they may have been eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 8.9928 shares per $1,000 principal amount of 2023 Notes (subject to other adjustments as described in the 2023 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes are accounted for in accordance with ASC 470-20,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 470-20&#8221;) and ASC 815-40.&#160;Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded) the instrument (or embedded feature) must be both (1)&#160;indexed to the issuer&#8217;s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company&#8217;s analysis, it was determined the 2023 Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20,&#160;the proceeds received from the issuance of the convertible debt were recorded as a liability on the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes,&#160;the Company&#160;also paid $<ix:nonFraction unitRef="usd" contextRef="i3e30c16b247446e89dea1ad6f8e71d44_D20160101-20161231" decimals="-5" name="nvax:PaymentForCappedCallTransactions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzI5Nzg_1ac2f0a0-a0db-4eb5-bffb-26a1390e7289">38.5</ix:nonFraction> million, including expenses, to enter into privately negotiated capped call transactions with certain financial institutions (the &#8220;capped call transactions&#8221;). The capped call transactions expired by their terms on January 27, 2023. The capped call transactions were generally expected to reduce the potential dilution upon conversion of the 2023 Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, was greater than the strike price of the capped call transactions, which initially corresponded to the conversion price of the 2023 Notes, and was subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2023 Notes. The cap price of the capped call transactions was initially $<ix:nonFraction unitRef="usdPerShare" contextRef="i34bddce3a1514a0991451e1b87ccd098_I20160125" decimals="2" name="nvax:DebtCapPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzM2OTg_cf37f42e-5e6d-43b7-adda-a75281a65474">194.60</ix:nonFraction> per share, which represented a premium of approximately <ix:nonFraction unitRef="number" contextRef="i34bddce3a1514a0991451e1b87ccd098_I20160125" decimals="2" name="nvax:ConversionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzM3NTc_0125f0cb-3e3a-49a7-a397-c73fe2153973">75</ix:nonFraction>% based on the last reported sale price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0ba24ef23674233a4a49398d78fe3b3_I20160125" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzM4MzE_b07e64ed-436b-4b84-adbb-2cbb753200df">111.20</ix:nonFraction> per share on January&#160;25, 2016, and was subject to certain adjustments under the terms of the capped call transactions. If, however, the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, exceeded the cap price, there would nevertheless have been dilution upon conversion of the 2023 Notes to the extent that such market price exceeded the cap price. The Company evaluated the capped call transactions under ASC 815-10,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8211; Overall</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and determined that they should be accounted for as a separate transaction and that the capped call transactions would be classified as an equity instrument.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQ1MjY_609861a7-d643-4a75-8058-e9f3b14becb2">10.0</ix:nonFraction> million of debt issuance costs in 2016 relating to the issuance of the 2023 Notes, which were recorded as a reduction to the 2023 Notes on the consolidated balance sheet. The $<ix:nonFraction unitRef="usd" contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQ2ODY_609861a7-d643-4a75-8058-e9f3b14becb2">10.0</ix:nonFraction> million of debt issuance costs was amortized and recognized as additional interest expense over the <ix:nonNumeric contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzUyMzQ_9fc05759-1fe6-4f72-97bf-e40046dfbe87">seven-year</ix:nonNumeric> contractual term of the 2023 Notes on a straight-line basis, which approximated the effective interest rate method. The Company also incurred $<ix:nonFraction unitRef="usd" contextRef="i3e30c16b247446e89dea1ad6f8e71d44_D20160101-20161231" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQ5MzE_37820b98-e730-4b43-bc83-ac0dafb4822f">0.9</ix:nonFraction> million of expenses related to the capped call transactions, which were recorded as a reduction to additional paid-in-capital.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_160"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:PreferredStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzk2NQ_b1117366-7867-4933-a480-38f32b5f7fed" continuedAt="i6caf301a16724b8098d46cc532e5ac47" escape="true">Preferred Stock</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6caf301a16724b8098d46cc532e5ac47">In June 2020, the Company entered into a redeemable Series A Convertible Preferred Stock Subscription Agreement, pursuant to which the Company agreed to issue and sell in a private placement <ix:nonFraction unitRef="shares" contextRef="i9a4f8a31db8143ffb528be60155adb66_I20200630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzIyMg_f5fbd397-dbb5-47ee-a368-3f4d04e3ceb0">438,885</ix:nonFraction> shares of its newly designated redeemable Series A Convertible Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="id6d0cb0853434fa2bfca424a22521ff9_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzMxNQ_294fe4b4-7ead-4a99-85b4-3446972fcfd5"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6504e467cdf4ac9b1c7bb041d0d169a_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzMxNQ_81a0d369-d5ab-4c6a-96db-5f2471736f35">0.01</ix:nonFraction></ix:nonFraction> per share (&#8220;Preferred Stock&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb6c34ca0e6943a985fccfb3c3cd5034_I20200630" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzM3Mg_8c0b5d94-6a01-4612-8927-16f62b775b91">455.70</ix:nonFraction> per share, for total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib3f4681005a149c69af0c9d36cd0c591_D20200601-20200630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzQxNA_0d48e36a-6c14-4763-a5b5-ca006cd88c39">200.0</ix:nonFraction>&#160;million. During the fourth quarter of 2020, all outstanding shares of Preferred Stock were converted and the Company issued <ix:nonFraction unitRef="shares" contextRef="ic32ab2b881af4e00801939f78ec7d4d9_I20201231" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzUzMw_464049c2-079b-4f54-b285-c2a283507a26">4,388,850</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="id6d0cb0853434fa2bfca424a22521ff9_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzU3MA_294fe4b4-7ead-4a99-85b4-3446972fcfd5"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6504e467cdf4ac9b1c7bb041d0d169a_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzU3MA_81a0d369-d5ab-4c6a-96db-5f2471736f35">0.01</ix:nonFraction></ix:nonFraction> per share, and reclassified $<ix:nonFraction unitRef="usd" contextRef="i72a45e70dfcc4ed3a06e5a1a0ad85788_D20201001-20201231" decimals="-5" name="nvax:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzYwMQ_89becf98-5425-41ed-a623-83294ddf59bb">199.8</ix:nonFraction> million from Preferred stock to Additional paid-in capital. The Company recognized a beneficial conversion feature of approximately $<ix:nonFraction unitRef="usd" contextRef="i72a45e70dfcc4ed3a06e5a1a0ad85788_D20201001-20201231" decimals="-5" name="nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzcyOA_4b18354d-8c1d-4835-a0dd-390371a32d9d">24.1</ix:nonFraction> million at the time of issuance of the Preferred Stock that was recorded in Additional paid-in capital and Accumulated deficit as the Preferred Stock issuance was contingently redeemable and convertible at any time at the option of the holder.</ix:continuation></span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_163"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzYwNA_fa656432-2241-42ee-a7df-5793959a0706" continuedAt="i8639a6ddebed48a9bf3e690702824ed9" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8639a6ddebed48a9bf3e690702824ed9" continuedAt="ieef66657e64d4351ae9d9d7208000155">In December 2022, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="id09da20d245547229c7e424719065312_D20221201-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzU4_73a331d7-eee5-4804-b257-f46601297caf">7,475,000</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="ifcb69e18ef584de69947a34bda69992f_D20221201-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzcw_23957e65-4ac6-4381-abe1-480c65d8a5b8">975,000</ix:nonFraction> shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id52295e266c04be6958801ee220a81e6_I20221231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzc4_b0d38b9b-b320-494a-9d07-1f5a46c8ee43">10.00</ix:nonFraction> per share resulting in net proceeds, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="ifcb69e18ef584de69947a34bda69992f_D20221201-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzkz_c1d7c2cf-c43f-4de8-bfd9-64dd5fae494e">4.9</ix:nonFraction> million, of approximately $<ix:nonFraction unitRef="usd" contextRef="id09da20d245547229c7e424719065312_D20221201-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxNDEx_7643f5a2-a65c-4062-bbef-fde9c92f55a6">70</ix:nonFraction> million. The Company completed this public offering concurrent with the issuance of the 2027 Notes (see Note 11).</ix:continuation></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieef66657e64d4351ae9d9d7208000155">In June 2021, the Company entered into an At Market Issuance Sales Agreement (the "June 2021 Sales Agreement"), which allows it to issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="i708fc4297d3e486b988a67ddb519f244_D20210601-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NjU3_5b4bcb71-a1ce-4fab-bebb-dc0a044ccf6c">500</ix:nonFraction>&#160;million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales Agreement. As of December&#160;31, 2022, the remaining balance available under the June 2021 Sales Agreement was approximately $<ix:nonFraction unitRef="usd" contextRef="i909d287d453b483eadef68a6db51c7ba_I20221231" decimals="-6" name="nvax:ShelfRegistrationStatementRemainingUnissuedCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NjY1_26ef624b-e639-4eab-85ee-a2bcf724c26a">318</ix:nonFraction>&#160;million. During the years ended December&#160;31, 2022, 2021, and 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i4c38f0119d96422898c0a8bea2f47c2c_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3Njc0_fc000a3f-8802-4548-9370-0d3323761a74">2.2</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="ied0bd77787a54028835f2babf0a109d4_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3Njgy_0afe45df-6294-40f2-8dba-b0235fde118a">2.6</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i71a915c3d5094ab9a4f33e9377b263ee_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3Njkw_491cc527-6f0f-41c0-815e-ba379a34ade4">32.4</ix:nonFraction> million, respectively, of shares of its common stock resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i4c38f0119d96422898c0a8bea2f47c2c_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NzI0_faded10a-edb0-43a9-925a-333572c14805">179</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ied0bd77787a54028835f2babf0a109d4_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NzMy_d6fbfef3-27d9-403f-9abf-77a874e09ca9">565</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i71a915c3d5094ab9a4f33e9377b263ee_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NzQw_3c546ca6-396a-4e3d-8935-e9f3350bf5cf">877</ix:nonFraction>&#160;million, respectively, under its various At Market Issuance Sales Agreements.</ix:continuation></span></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_172"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTg_1f803b47-d00d-4a2e-87f0-920d4f8a8e99" continuedAt="i19df9df6fde4484ebceb794f87403265" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i19df9df6fde4484ebceb794f87403265" continuedAt="i65d7a6bf28b042d59a53533a0c122553"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzQwMg_9f2b78b1-05fe-49b1-baed-e9f885a8835e">14.8</ix:nonFraction> million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of <ix:nonFraction unitRef="shares" contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwNw_b627fee0-00d4-4818-9ad5-425182ca3cbd">2.4</ix:nonFraction> million shares approved for issuance under the 2015 Plan at the Company&#8217;s 2022 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;4, 2025. As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIxOTkwMjMyNjQ3MDE_fab54ff1-95c2-446a-ba65-29f4329208cd">3.8</ix:nonFraction> million shares available for issuance under the 2015 Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, SARs, and RSUs. In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of <ix:nonNumeric contextRef="i2f0a3575acd74594903fd3f69ea74c2c_D20150601-20150630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTU5_ec10ace5-1471-4df3-a581-dc59a005d0ec">10</ix:nonNumeric> years and may be or were granted with an exercise price that is no less than <ix:nonFraction unitRef="number" contextRef="i0015ac21e2114e919dcd6b418ca0470e_I20150630" decimals="2" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAxMDA0_b68389af-1e18-4ca1-9209-de842f3d89bb">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTc0_7315172c-cfb4-43c1-b403-98d1230d238a">one</span> to <ix:nonNumeric contextRef="i0d4411c1dfac48628e521c4e1c62d82c_D20150601-20150630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTg2_38080a9f-6ec6-4bf7-90d8-5a7ecab1d5b5">four years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTk_064d5981-d4ac-4c2d-a910-86a8bdeabba3" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833db54db4e5410a82b51d91507bc240_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMS0xLTEtMTAxNjMz_a1f63832-a01f-4362-b726-a59c60562d8b">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75773c016ce41a0a9271d81feb47a62_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMy0xLTEtMTAxNjMz_d01647f1-803c-428a-9737-4305e927297d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b8e8541d10484db42a6e56bf4c319c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItNS0xLTEtMTAxNjMz_43189cf7-9394-4310-ac94-46d41db18f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a884616d8f240c899d1ffded053d84f_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMS0xLTEtNzAyMDA_d10c0461-23fe-4051-a689-7d130fef9cd4">66,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e4f42ca7be4b18b06d0cb5a65f7f4f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMy0xLTEtNzAyMDA_b53d41a7-2d66-49f5-b849-8114893532c7">86,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06256858a63a4f5e993fc634c6256da8_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItNS0xLTEtNzAyMDA_9b7f4a3f-fdad-4210-b941-0016b400331f">55,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8deb5c81e1314ef6b0780d4f3a49ed98_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzMtMS0xLTEtNzAyMDA_eb09d510-7e78-42d0-8793-72708d0ff726">62,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e81e12c2c645c891cd0ba8714b475c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzMtMy0xLTEtNzAyMDA_e82b697f-0705-4369-a294-e21ed578d436">96,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba79020bba2422ea08fa0e1bc48a3eb_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzMtNS0xLTEtNzAyMDA_a24e0ae6-e001-4244-88ec-a3cfae011af5">72,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzQtMS0xLTEtNzAyMDA_566911b8-c793-4767-a221-ebeeae54abe0">130,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzQtMy0xLTEtNzAyMDA_b7ec3988-34f4-4859-b0b2-8744606c8665">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzQtNS0xLTEtNzAyMDA_4b0df8ac-e831-4d73-817f-37446e305d58">128,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation capitalized and included in inventory as of December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIxOTkwMjMyNjQ2Nzk_cb5c8190-ba87-4c8e-91b9-aa7414d5fdfb">1.7</ix:nonFraction> million. There was <ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIxOTkwMjMyNjQ2OTI_01a17f47-d8c2-4529-8ea9-8f6039e78bd9">no</ix:nonFraction> stock-based compensation capitalized and included in inventory as of December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzE3MzM_7c5d5412-d808-4b27-b1dd-f40b900dad1c">171</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIwMzg_1a67a6ff-313f-442f-9adf-b4345c9d1e43">1.1</ix:nonNumeric> years and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option and SARs holders exercised their stock options and SARs on December&#160;31, 2022. This amount is subject to change based on changes to the closing price of the Company&#8217;s common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the years ending December&#160;31, 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzMwMTU_19767a04-5c02-4267-8c14-67d4071122e2">21.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzMwMTk_2850d07f-dbc0-453a-8517-ff82a1b1163a">453.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzMwMjc_4a4b3b1a-ab6a-412b-9585-c7412df1920b">187.3</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i65d7a6bf28b042d59a53533a0c122553" continuedAt="i5a078cfb0e584ec49296603a8d847d42"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMjA_2f739bff-3065-4be4-91bb-5d52909f9b6b" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2005 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic57598acb9d345a0b294ceda6cce94ab_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItMS0xLTEtNzAyMDA_38b647cb-55f1-422c-a6b5-6f2c91afe3f5">3,635,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic57598acb9d345a0b294ceda6cce94ab_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItMy0xLTEtNzAyMDA_b601e668-1a22-498a-8996-44dd56ac3a56">42.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07ae9fcb872440ec9e5ebfc077767156_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItNS0xLTEtNzAyMDA_dd592270-b3ba-4042-84d3-fd7e6564921e">68,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07ae9fcb872440ec9e5ebfc077767156_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItNy0xLTEtNzAyMDA_02485e4c-228a-495d-82fd-d061b7c10cf4">109.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtMS0xLTEtNzAyMDA_a38ce6d8-6317-4bcc-b70c-c4f09763d663">633,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtMy0xLTEtNzAyMDA_7b93ac2d-9c4d-4063-86e2-87b177df7366">65.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtNS0xLTEtNzAyMDA_1d9bf7aa-e139-4c0d-b59c-ea370f56bdc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtNy0xLTEtNzAyMDA_be22508d-6f7c-487e-a399-f1c58643e955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtMS0xLTEtNzAyMDA_e6f97472-0a30-49c8-8940-dcb35c7d9ff0">134,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtMy0xLTEtNzAyMDA_4988b74a-6998-4fcc-9c71-332260ae9275">15.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtNS0xLTEtNzAyMDA_0f72879d-fb92-469e-82f5-7f8aa3ee8bde">3,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtNy0xLTEtNzAyMDA_bdbf643f-14e8-4d6c-b41c-1f757eb38171">31.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtMS0xLTEtNzAyMDA_d44f02e4-3270-477a-98f6-ba684e28f9d4">81,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtMy0xLTEtNzAyMDA_4ada0a78-486f-406f-9bf5-7df6690af555">90.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtNS0xLTEtNzAyMDA_53c6d8dc-90c7-48bc-873c-bb39f3fc6879">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtNy0xLTEtNzAyMDA_8b885f2c-9e4f-465a-a190-73d506e8d00b">121.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtMS0xLTEtNzAyMDA_0d188a80-3a6a-47f3-aa81-851dadeb81b1">4,053,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtMy0xLTEtNzAyMDA_06ab6ca6-f165-449a-b733-62f6ac2127ff">46.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtNS0xLTEtNzAyMDA_6d8c8d71-1196-43e9-bfb8-0d3bde66fcc6">63,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtNy0xLTEtNzAyMDA_05c78405-74bc-4dd0-bf4b-d89d7cc0321a">112.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctMS0xLTEtNzAyMDA_535f3d79-e76c-4dec-9af5-732e79133f9b">2,892,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctMy0xLTEtNzAyMDA_61a562f0-45df-4345-a17f-db5e40918693">39.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctNS0xLTEtNzAyMDA_11cf792a-c6e6-4eb1-b07f-7d2a8082aee8">63,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctNy0xLTEtNzAyMDA_1362b064-9bf1-4e5f-988d-ad2b7c13eeb9">112.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTU_965cdd3c-94d7-488b-ac1a-1194dae90d32" continuedAt="ia795b64575934af79a3a2fae63deef50" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2015 Plan was estimated at the date of grant or the date upon which the 2015 Plan was approved by the Company&#8217;s stockholders for certain stock options granted in 2020 and 2019 using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average Black-Scholes fair value of stock<br/>options and SARs granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzItMS0xLTEtNzAyMDA_5a8b8a95-6501-42f1-af78-0d47d6b2cf94">55.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzItMy0xLTEtNzAyMDA_cc31dbcc-4344-4f8c-a6c9-82d470849a59">158.02</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzItNS0xLTEtNzAyMDA_7a1fc50a-49ba-4c00-a158-80ff248f08d6">80.48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjMjk2NGI2MzVmZjc0YWI3YjNlYjNmMTFlMzQzNDU1YV80_bc98c5d7-f478-4932-bb8d-f8ba7b54c4e2">1.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjMjk2NGI2MzVmZjc0YWI3YjNlYjNmMTFlMzQzNDU1YV83_f8335201-932a-400c-a7cc-0b9029b72299">4.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo3NWFjN2NmNDk5YjA0ZmQxYWJjZjgwNmM2MGRhYTMwY180_4db9dfd8-63cc-44cf-97ad-2c7613205d4a">0.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo3NWFjN2NmNDk5YjA0ZmQxYWJjZjgwNmM2MGRhYTMwY183_f4a2d9b3-d7b3-4fa7-9917-381bf40f9c1a">1.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiMTZkYmFhNDE0N2Q0MzUzODQ0ZjYwZDU1MDk5ZjJmZF80_4ae3e7aa-9925-4d5a-980f-5349e9763e65">0.2</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiMTZkYmFhNDE0N2Q0MzUzODQ0ZjYwZDU1MDk5ZjJmZF83_3d7ef630-e404-43c8-bc71-bdf1d9c5ef05">1.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzQtMS0xLTEtNzAyMDA_8256e2da-b83f-42af-a535-9e1d032cd444">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzQtMy0xLTEtNzAyMDA_7059aab0-2ac2-42a2-87bb-8f57ba8239a9">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzQtNS0xLTEtNzAyMDA_3ed167c6-2917-4bb4-888e-1af0038cc6ed">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozOWQ5YjYzMDkwNjA0NTE2OGQzNzg1Nzk0MmVlN2NhZl80_9b763b93-102e-464d-8b71-ad8e9936abb7">120.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozOWQ5YjYzMDkwNjA0NTE2OGQzNzg1Nzk0MmVlN2NhZl83_94d4f3e0-562e-417b-a3be-eb0ba8091be5">140.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphNDQ2YjQ3NGI3OTc0YWZkYjRmYzZhZDViZDM1YWViNl80_dbeac9a7-fdf6-42e1-9112-defb40c7c046">124.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphNDQ2YjQ3NGI3OTc0YWZkYjRmYzZhZDViZDM1YWViNl83_0b2d6024-a580-4193-8dc5-323c341d3f38">142.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo4ZTY5OGNhNmQ3NzI0NDBkODU0Mjg3MzZiNjUwYWFkMl80_6936c653-7a7b-453f-b6d5-62e631b1df48">116.0</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo4ZTY5OGNhNmQ3NzI0NDBkODU0Mjg3MzZiNjUwYWFkMl83_fad2094c-ed21-49ae-8f8e-2f8e1db2198e">152.2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if37d9719b2524f6f8329cdee51688933_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjE0MGI3N2Y2MDQ0MDNjYmU0NDc5NTVhYWJlY2FjM180_e714c802-0e6e-4c99-ad0d-14e479586af8">4.0</ix:nonNumeric>-<ix:nonNumeric contextRef="i46bf6d3912154f1792ce922416ae63c1_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjE0MGI3N2Y2MDQ0MDNjYmU0NDc5NTVhYWJlY2FjM183_8f11790b-8006-47d1-92f6-98fe6d9f403f">6.3</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1266c70d6883487eb69de02a5cefcaa5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjM2YmRkZjQwMzk0MDk4ODJlZGM1ZjUwZGNjODBiM180_5b1b7eec-0f5a-4961-8d07-044d695a7237">4.1</ix:nonNumeric>-<ix:nonNumeric contextRef="i057ba2750d5b46caa17fd59064a93243_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjM2YmRkZjQwMzk0MDk4ODJlZGM1ZjUwZGNjODBiM183_310e0681-f934-485a-b3f6-3359957b0503">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc3b6eafa7a2453eb9dc3916a75c7c1e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplMDBmNjA4MjAyMzM0ZTQ5YmIxMTBkYWViZGMzNGUwNl80_3ad1b891-1ede-4e64-aae7-ab1f4549ebbc">3.9</ix:nonNumeric>-<ix:nonNumeric contextRef="ie1af17faf5cc45288e504b60fca3980a_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplMDBmNjA4MjAyMzM0ZTQ5YmIxMTBkYWViZGMzNGUwNl83_7e8debbf-afc5-46ab-8174-daa3bc5e0c45">7.6</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2015 Plan and 2005 Plan as of December&#160;31, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM3NDU_3aa2c7e2-e823-46d7-937b-0addb5c3f5bd">3</ix:nonFraction> million and <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM3NTI_585c07ea-8471-42a5-aaac-c5328b09f3f0">7.1</ix:nonNumeric> years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2015 Plan and 2005 Plan as of December&#160;31, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM5NzQ_208ef92d-fe0f-4057-b7a4-128f841718f9">2</ix:nonFraction> million and <ix:nonNumeric contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM5ODE_100810f6-1a2d-4ab9-b5f6-c0eb46c2d245">6.6</ix:nonNumeric> years, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTY_4fb5e061-1ecf-484d-ad03-2a04a7ee6637" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the year ended December&#160;31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i482ffe6e8ec14375b57c416c028deaec_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzEtMS0xLTEtNzAyMDA_7b882ad3-8da9-4d7c-b10a-2d4056b680fb">819,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i482ffe6e8ec14375b57c416c028deaec_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzEtMy0xLTEtNzAyMDA_c83754e7-35ff-4828-a451-27d448308ea6">116.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzItMS0xLTEtNzAyMDA_77b3543b-9d05-4f12-bd87-e4e267252974">1,882,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzItMy0xLTEtNzAyMDA_8e588347-69b4-4f75-90fa-1be1ae5658b3">48.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzMtMS0xLTEtNzAyMDA_264528df-e5d9-49e5-be71-3d1a24e732a8">505,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzMtMy0xLTEtNzAyMDA_f2899bed-884e-438e-9e4f-cdc699428f7b">89.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzQtMS0xLTEtNzAyMDA_1fdb2e8e-f61d-4856-9c22-443a72bf3b8d">163,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzQtMy0xLTEtNzAyMDA_64d5df84-0994-4301-b726-c333eadca1a5">99.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73561b8b32cf4435ac835a50e53a576a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzUtMS0xLTEtNzAyMDA_966fe225-be4c-4bc5-857b-47dedaf89a79">2,034,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73561b8b32cf4435ac835a50e53a576a_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzUtMy0xLTEtNzAyMDA_14611241-23d9-4570-8738-598ed380f4b1">61.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i5a078cfb0e584ec49296603a8d847d42"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of <ix:nonFraction unitRef="shares" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzQyNjg_8bd6ce10-3216-4a6a-9257-c23547517849">1.1</ix:nonFraction> million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase <ix:nonFraction unitRef="number" contextRef="i4b07f0a42caf41428f69609a0b2b9990_I20221231" decimals="INF" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMDk3MDU1_ddeb7b6a-6fe2-463c-b006-71e1e94e8679">5</ix:nonFraction>% on each anniversary of its adoption up to a maximum of <ix:nonFraction unitRef="shares" contextRef="i4b07f0a42caf41428f69609a0b2b9990_I20221231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzE1MzkzMTYyNzk0MjUy_f4ebe456-90d5-459e-a2a1-8bd9c18ebe63">1.65</ix:nonFraction> million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of <ix:nonFraction unitRef="number" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="2" name="nvax:MaximumContributionOfEmployeesAsPayrollDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAxMDE1_4e4ceb32-c22e-48dc-ad4e-9cbffe425f09">15</ix:nonFraction>% of their compensation, at <ix:nonFraction unitRef="number" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="2" name="nvax:PercentageOfMarketPriceForStockPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAxMDEw_cb26f02e-7ad7-4598-a50d-46ab0620c337">85</ix:nonFraction>% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). At December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i4b07f0a42caf41428f69609a0b2b9990_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzQ3NDU_399fcaf3-13e9-45a9-9b98-d8423a5b6c1b">0.7</ix:nonFraction> million shares available for issuance under the ESPP.</span></div><ix:continuation id="ia795b64575934af79a3a2fae63deef50"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of Black-Scholes fair values of ESPP<br/>shares granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i546bbc59bac14443b9fa7278f44f39a7_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo1ZjRkMGY1MDQ0OTI0N2I1YTliMzMzYWUwNmM1N2NmMF80_ce374fc6-1ddf-49bb-be38-5011bd384707">23.59</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i43cd1de147754aae88ac59750e8413d4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo1ZjRkMGY1MDQ0OTI0N2I1YTliMzMzYWUwNmM1N2NmMF83_5c166301-aa6c-4fb2-a7f8-20bbb9066c82">79.74</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4741524c2007402199ab8e23ba7c57fc_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjY2JjYjMyNWE1OTU0MGRiYjQ1NjIyOGVmNWE5MWJjYV80_ac4cc70f-be8c-44eb-b437-445bb4629cd4">83.47</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ib3daeefe63f648a9aefa23c5a54e474f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjY2JjYjMyNWE1OTU0MGRiYjQ1NjIyOGVmNWE5MWJjYV83_39eaebb6-ac23-45c6-bcc8-1e5e8b6566b3">238.85</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4e434d4808f2454da2b021293904e61e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo5ZWY0ZTAxNmNiY2Q0MGZlYmU1MmQ5NTQwM2E2ZDdhMF80_79da707c-36f7-4a66-82e2-c26882a5582a">2.57</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="idde6dd916c874f429e3cc8fe6d0eabed_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo5ZWY0ZTAxNmNiY2Q0MGZlYmU1MmQ5NTQwM2E2ZDdhMF83_c03c9790-87ec-4c43-a92e-a91048bb6212">92.67</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyMzU2MjgwNGQxY2U0ZTA3YTFmNGM5YWRlOGQ5MzFkY180_bfa5f52d-6cb8-4d3b-8413-60e2acd7d124">0.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyMzU2MjgwNGQxY2U0ZTA3YTFmNGM5YWRlOGQ5MzFkY183_f3f133cf-c745-4437-9f5f-bec57eeb5171">3.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpkNGVhOTlmM2EyNTQ0Njg0YWZhNmM3M2FhN2Y5ODI0M180_167112e7-0987-483d-b0ca-2196f87f41ad">0.1</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpkNGVhOTlmM2EyNTQ0Njg0YWZhNmM3M2FhN2Y5ODI0M183_5ba66416-b33d-47d0-8448-eda8f7fb3028">0.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjNWUzZjg3ZmNhNWY0MGFkYWQ4NWU3ZDFiZTVmNTNlNF80_f0351990-be40-4af8-90e4-f3a630359840">0.2</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjNWUzZjg3ZmNhNWY0MGFkYWQ4NWU3ZDFiZTVmNTNlNF83_8fa4595f-c0c6-442a-9846-b050b9ee4467">2.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzQtMS0xLTEtNzAyMDA_0058f251-bbac-4a67-8042-c0bb1f1987d3">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzQtMy0xLTEtNzAyMDA_dd01cdde-970e-43cf-b0d3-99c3784cd2c3">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzQtNS0xLTEtNzAyMDA_af677455-2018-4f02-8df9-dd5edffd7d9b">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplNDk5ZjI2ZDFmZGM0NmJlOWFlNjdiNDViZDJlOTNiNF80_71ada6f6-9f97-4dc0-bcab-d5187a365636">103.0</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplNDk5ZjI2ZDFmZGM0NmJlOWFlNjdiNDViZDJlOTNiNF83_cdda34fc-aaf3-47ae-9826-594d095be90c">142.9</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyNzNkMzc0YTQyZDM0NWFmOWEzNzg0MGQyYWM3OGYyYl80_175cb2b7-d5e2-4b2b-9c3a-420db5f03fb6">114.9</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyNzNkMzc0YTQyZDM0NWFmOWEzNzg0MGQyYWM3OGYyYl83_d449951f-e294-4c1d-9534-66086d25e440">159.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozMDg5YTVlY2M0ZDA0M2UyYTViZDkyZWEyMzNlOTk0ZF80_ca011fc1-5d57-4968-855b-0456cb835976">66.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozMDg5YTVlY2M0ZDA0M2UyYTViZDkyZWEyMzNlOTk0ZF83_3daa10a5-92b9-44e7-9816-84df26896580">189.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i546bbc59bac14443b9fa7278f44f39a7_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyY2JjYmJhYTNkZWI0ODJmYWQ3YzI3MmYyOGEwN2RjZV80_bb7d6a98-7651-4387-8588-02c72f4df1b6">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="i43cd1de147754aae88ac59750e8413d4_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyY2JjYmJhYTNkZWI0ODJmYWQ3YzI3MmYyOGEwN2RjZV83_8be7ae9c-884d-42a9-b11d-ff1f37dcaf03">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4741524c2007402199ab8e23ba7c57fc_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphYjc5YzlhN2IzODA0MTkyODJjOGE3MGUyNjM2NDkxZl80_40e9e497-3f63-459b-97d3-06745347dd73">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="ib3daeefe63f648a9aefa23c5a54e474f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphYjc5YzlhN2IzODA0MTkyODJjOGE3MGUyNjM2NDkxZl83_c8bac955-9028-47ad-b605-80ab992cdd07">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e434d4808f2454da2b021293904e61e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjowZDNkMjAyOTUyZDg0ZDg4OGE1ZTJkNmFkYzVjYmQxMl80_0cd9f470-32e6-4390-8143-5844d63becb4">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="idde6dd916c874f429e3cc8fe6d0eabed_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjowZDNkMjAyOTUyZDg0ZDg4OGE1ZTJkNmFkYzVjYmQxMl83_f1413132-628b-4f4d-8853-0697b9935e7c">2.0</ix:nonNumeric></span></div></td></tr></table></div></ix:continuation></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_175"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzg3Nw_7d0801c0-d345-4196-932c-072c895e2fd9" continuedAt="i29a8caabc4a94bc0b898cf14a3dc9542" escape="true">Employee Benefits</ix:nonNumeric></span></div><ix:continuation id="i29a8caabc4a94bc0b898cf14a3dc9542"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution 401(k)&#160;retirement plan, pursuant to which employees may elect to contribute up to <ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzE2MA_078bfc31-b4c7-4a53-a8d0-b0f674bf31b2">100</ix:nonFraction>% of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code of 1986, as amended. The Company matches <ix:nonFraction unitRef="number" contextRef="icacf535e608c4110bfafdf3621b23f38_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzMxNA_cbae2c8a-886f-4a16-8678-8a0a24514592">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="icacf535e608c4110bfafdf3621b23f38_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzMzMA_5a74fb7b-59a2-402e-8300-8cbff9015f45">3</ix:nonFraction>% of the participants&#8217; deferral, and <ix:nonFraction unitRef="number" contextRef="ie8ab394f5b23492db52ba56a7cdec054_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzM2OA_9f7e39d6-833f-4c0b-8203-65490030bcda">50</ix:nonFraction>% on the next <ix:nonFraction unitRef="number" contextRef="ie8ab394f5b23492db52ba56a7cdec054_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzM4Mw_fc42ecf9-d76f-4c89-9012-177b7e4061ce">2</ix:nonFraction>% of the participants&#8217; deferral, up to a potential <ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzQzNQ_edd7b3d6-ef3a-475f-971b-de013907896b">4</ix:nonFraction>% Company match. The Company&#8217;s matching contributions to the 401(k)&#160;plan vest immediately. Under its 401(k)&#160;plan, the Company has recorded expense of $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzU4Ng_532b1f36-803c-4fd8-808d-5a39e60b8189">6.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzU5MA_295012eb-3e3f-413f-9f15-549d3603c1a7">3.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzU5OA_32d3400a-50ba-48f5-84a6-2cb790747739">0.9</ix:nonFraction> million in 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries have pension plans under local tax and labor laws and are obligated to make contributions to the plan. Contributions and other expenses related to this plan were $<ix:nonFraction unitRef="usd" contextRef="i07d0939ce4574bbca25cbd25ca1caa0a_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzgzMQ_aa3aefcb-521f-481f-b2b7-1fcf47f54b14">2.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0b46d3bb09db4518ba0e5b40ba4c579a_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzgzNQ_40162f35-ab6f-4bae-b792-74c6871e7174">1.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ieaae667010054892bbaeaa0a48298ea5_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzg0Mw_69ac9103-21bc-410b-b71d-1e587ec7ceae">1.0</ix:nonFraction> million in 2022, 2021, and 2020, respectively.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_166"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzU1Mw_cb99f716-ba2d-47f5-a3d2-f0e7545bc652" continuedAt="i4fac20fb5e6e401c87d2bb4f55cd583d" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="i4fac20fb5e6e401c87d2bb4f55cd583d" continuedAt="i17c6b0380ca846f18882f06945b5ffd2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzU1NA_576eafc0-ab55-46b6-8fc4-92c1199792ee" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzItMS0xLTEtNzAyMDA_f014a4ea-1b14-44e7-b595-0595fa711705">160,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzItMy0xLTEtNzAyMDA_18f5adb8-39b8-4ab4-8321-70d5189c03b0">120,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzMtMS0xLTEtNzAyMDA_b39b9c10-50fd-493a-8978-381d152cec55">76,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzMtMy0xLTEtNzAyMDA_53200372-0349-436e-8615-a58073bd93dc">44,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzQtMS0xLTEtNzAyMDA_2e387e8e-e383-470c-b254-cbf776235dac">237,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzQtMy0xLTEtNzAyMDA_473efbd6-29c0-4a37-a0cd-21663253b329">164,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i17c6b0380ca846f18882f06945b5ffd2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><ix:continuation id="ia55b1c1ff42b48bc8041a36909c4b3fb"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0fe342175f5492284e7a2703432374a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzItMS0xLTEtNzAyMDA_a46ecbba-10d7-4599-88d7-7ba141035e44">101,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306c59f27cd9488b966d7683b0b6d3e1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzItMy0xLTEtNzAyMDA_6a58b336-8eeb-40d8-a0f1-6313b567f9e8">83,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51d31dc3a62493c90d13cac0e14c304_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzMtMS0xLTEtNzAyMDA_ad782bd6-b6e1-41aa-b3f6-faa8592ec071">134,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id751e3e489e44cc4a6c2e3c2d4ff8264_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzMtMy0xLTEtNzAyMDA_824042f6-1419-47e9-9995-52b8d82a0798">119,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f4ccb5e7cb74f8d88f8a5fed001536d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzQtMS0xLTEtNzAyMDA_963103a0-7438-4f55-8c11-30d854e60a52">18,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc1be450e664236a03f3377873ae30b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzQtMy0xLTEtNzAyMDA_48d70f17-1e96-43cc-8254-1c7f2fb83198">10,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0be8a4005f4b659c8142d8168d50eb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzUtMS0xLTEtNzAyMDA_192230ec-a971-419f-ae06-ca7f0da5a255">4,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i261ee1ff33254ce5ae3c71c1734f2118_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzUtMy0xLTEtNzAyMDA_536ba18e-e0af-41ac-976a-23941dfb7800">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a2c21af45f4bb8b5b57fb18fbb2a36_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzYtMS0xLTEtNzAyMDA_764abcfd-e865-404e-b5cd-23d5962db91e">81,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134cfe86255d47f58e6942ddfddc42ee_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzYtMy0xLTEtNzAyMDA_b358863c-2f38-4a8c-8381-f27e6e1659ae">35,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzctMS0xLTEtNzAyMDA_14fadaf1-f42e-4a38-837e-3bdc69b24b35">341,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzctMy0xLTEtNzAyMDA_c988e99b-4758-4ff5-be65-1a1d1bb8ca80">251,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzgtMS0xLTEtNzAyMDA_88fc70fe-b68e-4df5-b5e4-43dfd2b8437b">47,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzgtMy0xLTEtNzAyMDA_52d5d08e-4f34-4ba7-9d8e-7aafc835afe8">25,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzktMS0xLTEtNzAyMDA_0b1d6405-ea73-4eba-81c7-8a8777fdf60e">294,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzktMy0xLTEtNzAyMDA_e1816db3-9572-4568-9864-2f8efc647868">225,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="i003cbd6d8fc147008d115dcbabd4f866_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzI5NQ_da553977-0d44-4db4-a49e-79f5490b3d65">170.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0296343bcc7a45f7af04732eca6371c5_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzExNTQ0ODcyMDkyMzAw_e5b2faad-2173-43be-9e03-51e11ced827b">164.0</ix:nonFraction>&#160;million, respectively, of net assets used in operations were located in the Czech Republic. Depreciation expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzQwNg_216f58c5-2908-4490-8acc-bd0cf1d2f24d">29.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzQxMA_626e018b-9141-47e4-96f7-e51f02667d90">12.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzQxOA_628224b3-46a4-4286-a3cc-c59fd52b747a">4.3</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzU1Ng_ff18f9c3-2cb6-4174-810f-3588ae5d9915" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits and compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzItMS0xLTEtNzAyMDA_6e4579e3-cf60-48c3-badf-0734d509ad20">52,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzItMy0xLTEtNzAyMDA_d0a4619a-07e1-4356-9a50-37b84fef18fa">38,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:ResearchAndDevelopmentAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzMtMS0xLTEtNzAyMDA_41b26346-0d9f-427f-b694-6be37e6d5433">468,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:ResearchAndDevelopmentAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzMtMy0xLTEtNzAyMDA_2cc02b90-b42b-4e57-9ae3-6432d82c0a37">577,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzQtMS0xLTEtNzAyMDA_2ed66550-4b31-4c31-b92b-cd93a8da15f3">70,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzQtMy0xLTEtNzAyMDA_0474b600-c2da-498b-8907-07a500219ca4">58,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzUtMS0xLTEtNzAyMDA_77d37b47-267b-4418-b7cf-bc0b4d2a923f">591,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzUtMy0xLTEtNzAyMDA_98829248-19b0-45ba-8b03-6ff98aac4846">673,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzExNTQ0ODcyMDkyNjUx_7d39cc71-cb0a-423b-9c51-a463bd8880c5" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds to customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzItMS0xLTEtMTExNjEz_f381da22-2428-4abf-b795-ed10b8211d18">210,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzItMy0xLTEtMTExNjEz_a060b082-3374-402b-a551-45433b036ce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liability related to Gavi (see Note 3 and Note 18)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzMtMS0xLTEtMTIxNTA3_4bdf9a00-1541-4a3d-8adb-41c039718ce3">697,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzMtMy0xLTEtMTIxNTA3_d7c49da7-109f-46dc-a51a-7281ed1dc679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzQtMS0xLTEtMTExNjEz_a92b1d9b-89fc-4f04-81fc-252e20bf853b">22,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzQtMy0xLTEtMTExNjEz_1e2b588f-ec29-42c9-9cf0-f695546aa866">36,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzUtMS0xLTEtMTExNjEz_33831310-1772-4fdf-b05d-05a659c557bb">930,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzUtMy0xLTEtMTExNjEz_1aafdf3c-f938-4663-991b-74f73369d4e8">36,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 35</span></div></div></div><div id="i5fb43b2896e34be2b1f12f6c19f667b2_178"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjQ_6b57b039-d7b2-4bb1-9682-721cd27eefb9" continuedAt="ia4c8c2c8455440c990cc1efcc345918a" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ia4c8c2c8455440c990cc1efcc345918a" continuedAt="i5d85e7ca9e6b48e0863a82aaa8c9fa96"><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjM_2c9cf6f2-d60b-4760-aef5-4ab23a9b3ce2" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income (loss) from operations before income tax provision (benefit) by jurisdiction for the years ended December&#160;31 are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzItMS0xLTEtNzAyMDA_2d5932fa-9c11-4882-8ced-c1d00e34327f">712,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzItMy0xLTEtNzAyMDA_22bad0b9-49a0-4e48-a7c0-b4948514501d">1,633,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzItNS0xLTEtNzAyMDA_0a12645d-4d8a-4eed-866d-2a9963e4c3d1">455,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzMtMS0xLTEtNzAyMDA_8c795f3b-d2be-4819-abf9-f5c4a2817293">58,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzMtMy0xLTEtNzAyMDA_0cd7cb8d-5df8-4ad6-8c09-d7350b66f075">81,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzMtNS0xLTEtNzAyMDA_7a5ef1ad-e370-4a5d-a6ce-2c28fbd2e3bd">36,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzQtMS0xLTEtNzAyMDA_4225490c-7051-499a-bdef-847eaa13c201">653,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzQtMy0xLTEtNzAyMDA_1f54dc3d-d88c-4a26-a5dd-f6b6f6310195">1,714,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzQtNS0xLTEtNzAyMDA_8e221e3f-1b8e-441a-b1f8-152c0d0a4801">418,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzExNTQ0ODcyMTA1NzA2_5a34df0c-ef89-4fbe-b6b1-5ade16aa407a" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the current income tax provision (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzItMS0xLTEtMTI0Njc1_a85b5b87-bb63-499c-9c61-e7690ab55411">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzItMy0xLTEtMTI0Njc1_3d89b341-029e-449b-a479-e3ef1fc44fe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzItNS0xLTEtMTI0Njc1_d44875bb-2a77-491a-a385-98eaaef8a4f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzMtMS0xLTEtMTI0Njc1_4d1e1ab4-4778-41b6-beab-7d2df66a8613">503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzMtMy0xLTEtMTI0Njc1_ac627fcb-0320-420f-aebb-d0d2d5b43b18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzMtNS0xLTEtMTI0Njc1_2e9a4a75-5645-4709-8f8a-ea7ac0f5eb70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzQtMS0xLTEtMTI0Njc1_636b5f7d-d07b-42b1-8e10-d0b1556229cb">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzQtMy0xLTEtMTI0Njc1_5dbeb1a0-a4e9-4505-b69a-66d8f7e00fe7">29,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzQtNS0xLTEtMTI0Njc1_60ba866b-a70f-4a08-b4f9-3c1ce8e65fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzUtMS0xLTEtMTI1MzA0_7b4c43b7-c441-4953-aafb-e81fe4ce2365">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzUtMy0xLTEtMTI1MzA0_29380e39-52a1-4f84-bc16-6a95e8b5972c">29,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzUtNS0xLTEtMTI1MzA0_eed0a412-51cb-4c5a-b272-fd8cb5e56f96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjg2MTU_395f7d4b-5cb9-4fc9-8209-f4b533ec6538">4.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjg2MjQ_9887b32e-6444-4326-9f93-aadc51a1fd72">29.2</ix:nonFraction>&#160;million, and <ix:nonFraction unitRef="usd" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjg2MzM_d003f47a-8264-4dfb-a8c0-fe037963772f">no</ix:nonFraction> federal, state, and foreign current income tax expense. The foreign income tax expense is primarily related to foreign withholding tax on royalties. The Company recognized no deferred income tax expense during the years listed above due to a full valuation allowance.</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjI_2aa393da-c8f6-4f3b-8710-24d5fcc2d836" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the provision for income tax to the amount computed by applying the U.S. federal statutory tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzItMS0xLTEtNzAyMDA_af53646e-bc76-48f6-81dd-51eeb9e1d697">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzItMy0xLTEtNzAyMDA_e57c20e2-5e2a-48a5-b7b8-de8580cdb2ba">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzItNS0xLTEtNzAyMDA_6e2917fe-2c20-49b2-8121-b8bd56c318e6">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzMtMS0xLTEtNzAyMDA_d4100031-4ed0-4ac1-868a-5ec6bd0473c2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzMtMy0xLTEtNzAyMDA_8d1bc9fd-9b1d-4959-9d2a-73971209d466">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzMtNS0xLTEtNzAyMDA_8726f80b-47d0-47c8-b847-2d31b8c73ec4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzQtMS0xLTEtNzAyMDA_ba989de5-e2b4-4040-92c4-17c50660146b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzQtMy0xLTEtNzAyMDA_9ce50911-b012-4483-aeca-7516e582418b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzQtNS0xLTEtNzAyMDA_b1b6c6b3-e431-4bf0-8263-f6e8b2ba1344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzUtMS0xLTEtNzAyMDA_119113e0-abef-4056-837b-fa6a5f6a2aed">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzUtMy0xLTEtNzAyMDA_34ce9cfb-b688-4b9c-ac7c-4c501f215d52">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzUtNS0xLTEtNzAyMDA_78a8c1de-2e30-493d-9bd9-d6f9df67dbf1">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzYtMS0xLTEtNzAyMDA_e4f25502-cf48-4bf3-9d7e-32042d941d26">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzYtMy0xLTEtNzAyMDA_95ea7dfb-1bee-4af8-b503-bb82643f33d1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzYtNS0xLTEtNzAyMDA_5048ab07-aad3-4d44-8b0d-f1145247921a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" sign="-" name="nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzctMS0xLTEtNzAyMDA_89f2eecd-cfd8-4ea7-92b0-a3c96ceb3bee">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" name="nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzctMy0xLTEtNzAyMDA_737d5147-8c4e-4b45-b6fe-3b4649cf52c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" name="nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzctNS0xLTEtNzAyMDA_6a3ff147-c56b-432f-8fcf-e3a83f417b2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMS0xLTEtMTI1MTMy_4c26ac77-f4c2-4ab1-837c-72dee0a9ca23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMy0xLTEtMTI1MTMy_d4947158-6225-47a4-afbe-7a388c5ce749">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtNS0xLTEtMTI1MTMy_f9f74d14-35e2-4f2f-af28-a4ebfd36ca18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMS0xLTEtNzAyMDA_aa466bde-b7df-467b-8f2b-294130fce48d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMy0xLTEtNzAyMDA_1910e6ce-50b9-4569-959b-8d515d5f1be5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtNS0xLTEtNzAyMDA_d6d74d60-86cd-4859-b44d-4cabdd76ff0a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzktMS0xLTEtNzAyMDA_32789578-d73a-4cb7-b409-db310a6fb592">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzktMy0xLTEtNzAyMDA_13d06c63-f814-4249-b977-e79c9be50912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzktNS0xLTEtNzAyMDA_6c04a4e5-ee87-4701-8619-0f77fa403046">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzEwLTEtMS0xLTcwMjAw_9c29a8e7-45b2-43b9-a854-149bf2951fdb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzEwLTMtMS0xLTcwMjAw_0dfae5c0-6aeb-4043-9037-3c96753963f2">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzEwLTUtMS0xLTcwMjAw_e36b34cd-3638-48e2-98d9-140da5d09102">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzExLTEtMS0xLTcwMjAw_8c6fc661-8c3b-4323-ad5d-d11b28b3b543">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzExLTMtMS0xLTcwMjAw_970e82f2-ab19-4eb5-ac0b-e5f28331683d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzExLTUtMS0xLTcwMjAw_c41956f1-290c-45c1-914d-3ad58d28a74a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has available federal, state, and foreign net operating losses of $<ix:nonFraction unitRef="usd" contextRef="ie850cc1078634b628fb807996bac48ec_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzYzNQ_d473f32a-58bc-422e-89bd-4673994a923a">2.0</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="ibba48e8ed9c64a64bc36603e29727b1b_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzYzOQ_28184b81-c09a-44d7-99ce-6b805b67ceb6">0.9</ix:nonFraction>&#160;billion, and $<ix:nonFraction unitRef="usd" contextRef="ie09d6c3cc8dd494997ad5e9e0699ba04_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzY0Nw_da096268-fdac-48e3-a90d-e14a5c948e71">29.1</ix:nonFraction>&#160;million, respectively, that may be applied against future taxable income in the respective jurisdiction. The federal net operating losses of $<ix:nonFraction unitRef="usd" contextRef="ie850cc1078634b628fb807996bac48ec_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzU0OTc1NTgxNDM3OTU_d473f32a-58bc-422e-89bd-4673994a923a">2.0</ix:nonFraction>&#160;billion can be carried forward indefinitely, although limited to 80% of annual taxable income. State net operating losses of $<ix:nonFraction unitRef="usd" contextRef="i18d589697b3448ef979612d981bcfa9b_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNjkw_d58c31f4-d2dc-4204-b7e0-cffe1f2751be">0.4</ix:nonFraction>&#160;billion have various expiration dates between 2028 and 2042. The remaining state net operating losses of $<ix:nonFraction unitRef="usd" contextRef="idccedc0b914042e9b04e606a7f40b047_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNjk4_b1abdc50-39f0-4f3b-a21f-9c5884cc0714">0.5</ix:nonFraction>&#160;billion can be carried forward indefinitely. Approximately $<ix:nonFraction unitRef="usd" contextRef="i4ed100b1f229497699cf3a210f953003_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNzA1_bd91149f-3d75-46a9-ada8-f6626ad67f4b">15.1</ix:nonFraction>&#160;million of the foreign net operating losses will begin to expire in 2024 through 2027. The remaining $<ix:nonFraction unitRef="usd" contextRef="i0dadba2600544eb092b5aec9b95db726_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzExNTQ0ODcyMDk4MzUy_1b5d7f2d-ea6a-4e32-84b9-eb8e308c67f3">14.0</ix:nonFraction>&#160;million of foreign net operating losses can be carried forward indefinitely. The Company also has research tax credits of $<ix:nonFraction unitRef="usd" contextRef="i9b5882daa660420c9f6624c60e06285f_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNzE1_0c42e667-daaa-46fc-9968-78cfedcf61d4">46.0</ix:nonFraction>&#160;million that will begin to expire in 2030 through 2052. Utilization of the domestic net operating loss carryforwards and research tax credits may be subject to an annual limitation due to potential ownership changes of the Company. As of December&#160;31, 2022, the Company does not expect such limitation, if any, to impact the use of these domestic net operating losses and research tax credits.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i5d85e7ca9e6b48e0863a82aaa8c9fa96" continuedAt="i76c7365fc2d14fdbb520c27fbfb8d736"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and in various states, as well as in foreign jurisdictions such as Sweden and the Czech Republic. The Company has U.S. federal and state net operating losses and credit carryforwards that are subject to examination from 2002 through 2022. The returns in Sweden are subject to examination from 2016 through 2022 and the returns for the Czech Republic are subject to examination from 2019 through 2022.</span></div><ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjA_69c4fe31-d195-4e07-a6a3-64e022671893" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzMtMS0xLTEtNzAyMDA_7ed2cb99-e218-451d-9a72-17f045f4708a">479,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzMtMy0xLTEtNzAyMDA_2f7059b2-4075-41cd-b75c-d308b958b317">845,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzQtMS0xLTEtNzAyMDA_c9f0563a-7544-4e00-b935-eed419a9f332">5,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzQtMy0xLTEtNzAyMDA_1d4326e9-693c-4178-8f65-6e43f029abb7">25,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzUtMS0xLTEtNzAyMDA_db4f5377-33e8-4e08-9594-983033985d67">45,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzUtMy0xLTEtNzAyMDA_16d0afcc-5cda-402e-9b92-2e5df22bad4d">44,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:DeferredTaxAssetLeasingLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzYtMS0xLTEtNzAyMDA_5436b98b-11cf-4e04-b8b1-aa8a7c5b685b">27,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:DeferredTaxAssetLeasingLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzYtMy0xLTEtNzAyMDA_513948d4-46fd-46e2-ad2c-fda2da59978b">52,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMS0xLTEtMTI1MDI1_c8db2cf6-2f00-4596-b542-6f9d199cbf24">195,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMy0xLTEtMTI1MDI1_43ac6381-8aed-423f-9831-d69a79b6391a">20,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMS0xLTEtNzAyMDA_13a318b6-8eb1-48d6-950e-cdb931fb13c1">213,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMy0xLTEtNzAyMDA_a5e2e62b-8ec9-40d5-99c7-b5d6e31ffc56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzktMS0xLTEtNzAyMDA_e7dc230a-8dbc-48c6-9f9d-3164ab6a80cb">27,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzktMy0xLTEtNzAyMDA_ffb76d69-6dc5-4386-bb66-3903075aae70">24,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Original discount interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="nvax:DeferredTaxAssetsOriginalDiscountInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEwLTEtMS0xLTcwMjAw_79b65f1b-fe79-4dee-8af6-f85da9bf79ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="nvax:DeferredTaxAssetsOriginalDiscountInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEwLTMtMS0xLTcwMjAw_b2a975af-3214-4a3f-80ec-535ba963810f">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTEtMS0xLTEyNDk1NA_478d2b33-1a2a-4ef9-8a73-29478aed5cec">49,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTMtMS0xLTEyNDk1NA_9c86da83-a6f2-4253-9881-7e13dc77063f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTEtMS0xLTEyNTAxNg_e6ff90d5-93a9-4876-a3e0-404cda15a4b2">13,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTMtMS0xLTEyNDk2Mg_c4c2315c-b94e-409d-a2d4-8bbb2e2160b0">11,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTEtMS0xLTcwMjAw_3fe1b6ca-5d36-4bd2-a0de-c2def009298d">1,056,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTMtMS0xLTcwMjAw_455a5de9-f617-4183-bfb1-07ef7e8068e8">1,027,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTEtMS0xLTcwMjAw_fdefc3bb-e597-47a4-8ef2-eaec6f5fd300">1,020,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTMtMS0xLTcwMjAw_d6e2821e-750c-41ae-97bf-4732da77e883">1,015,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEzLTEtMS0xLTcwMjAw_7d59e095-9b70-4827-a264-c4e9413025c8">36,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEzLTMtMS0xLTcwMjAw_1082c7b8-3604-4245-8b2d-c0b6f37cbd2a">11,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE1LTEtMS0xLTcwMjAw_d00989d9-d4ea-40af-a9f4-33a4ef3d1351">23,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE1LTMtMS0xLTcwMjAw_b7a034f3-300b-4c2c-8be6-4cd2577bfa1b">10,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTEtMS0xLTEyNTA3NQ_058338b3-ccd3-4ea2-8deb-1a6bc5d5bc63">11,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTMtMS0xLTEyNTA3NQ_a8d1185c-7902-42c7-b7d7-629acaa7cc9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE2LTEtMS0xLTcwMjAw_4ddddd5a-5d6d-463b-9b0e-2ecb48de1c84">1,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE2LTMtMS0xLTcwMjAw_ff6257d2-60ca-4150-bd8a-a0af273047c2">1,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE3LTEtMS0xLTcwMjAw_287af014-1234-4461-842f-d3520ac16447">704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE3LTMtMS0xLTcwMjAw_78c2587d-b41c-4402-9216-729df7858e86">878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTEtMS0xLTcwMjAw_ad43c8d1-bb8f-4be9-8db1-8b9535462a87">36,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTMtMS0xLTcwMjAw_121ff5ab-3766-4268-9127-0094c13010f9">11,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE5LTEtMS0xLTcwMjAw_d4794054-f33f-4670-919d-ad4453f6331b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE5LTMtMS0xLTcwMjAw_98d09eb5-0e11-4446-a547-f7fc27da9e27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realization of its deferred tax assets, including its history of significant losses in every year since inception and, in accordance with U.S GAAP, has fully reserved the net deferred tax asset. The Company concluded that realization of its net deferred tax assets is not more-likely-than-not to be realized as of December&#160;31, 2022 and 2021. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIyOTk_14b64819-f4ac-4b47-ad2d-02ac431dbaac">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIzMDY_e0e133f6-7221-4e39-8852-fde541b383d2">510.5</ix:nonFraction> million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets, weighing positive and negative evidence to assess the recoverability. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including its cumulative losses over the three years ended December&#160;31, 2022 and the substantial doubt about the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued, and positive evidence, including its regulatory authorizations for and commercial sales of NVX-CoV2373. After assessing both the negative and positive evidence, the Company concluded that it should maintain the valuation allowance on its net operating losses, credits, and its other deferred tax assets as of December&#160;31, 2022. The release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, the Company's level of profitability, revenue growth, clinical program progression, and expectations regarding future profitability. The Company's total net deferred tax asset balance subject to the valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-8" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjk3NzM_d80815a7-42ec-4fe3-8ef5-c4bd6f25cc99">1.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-8" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjk3ODU_0b72665e-c11e-4bf1-bb9e-64530c2f47f5">1.0</ix:nonFraction>&#160;billion as of December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i76c7365fc2d14fdbb520c27fbfb8d736"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of an income tax position when it is more likely than not, based on the technical merits, that the income tax position will be sustained upon examination. <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjE_e43d4874-088c-4ab6-9ceb-dce4831e384a" continuedAt="id297434ff902472799edb6238fea9540" escape="true">A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2022, 2021, and 2020 is as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="id297434ff902472799edb6238fea9540"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzItMS0xLTEtNzAyMDA_5ca7a277-b3d0-4910-95d7-481eded87f58">11,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzItMy0xLTEtNzAyMDA_c7a771fa-69c4-4488-b410-04d4b9a20e15">8,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab79f65652ef4787919164353ded1194_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzItNS0xLTEtNzAyMDA_8388aff4-6115-4fcf-adcd-4544da59d9ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzMtMS0xLTEtNzAyMDA_d56be037-6e65-4769-a8ec-75d3b07f3741">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzMtMy0xLTEtNzAyMDA_76fa040a-7df1-463d-8361-eda4fa3c7bd0">4,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzMtNS0xLTEtNzAyMDA_01cbe1ce-fe43-478c-8006-11c0c6c0c3b3">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzQtMS0xLTEtNzAyMDA_ec26477a-74c8-4230-b2cc-610a3e99d4ce">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzQtMy0xLTEtNzAyMDA_300e4df7-f8bf-47e9-95bf-2c9de545414f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzQtNS0xLTEtNzAyMDA_3f8c12af-ba79-461a-a512-5467f0542900">7,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions for tax positions of prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzUtMS0xLTEtNzAyMDA_648cbb24-3224-4581-8f29-555544bb87a3">8,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzUtMy0xLTEtNzAyMDA_cc04581e-a74e-4801-b1a6-c6a354707b99">1,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzUtNS0xLTEtNzAyMDA_8048b65e-da8e-40ce-b529-7044986ea6b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzYtMS0xLTEtNzAyMDA_5c414170-d467-4cc3-b85b-08c1f6ec563d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzYtMy0xLTEtNzAyMDA_acb0affc-772e-45a2-b3db-4036d81b1a03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzYtNS0xLTEtNzAyMDA_36236635-4e5c-424c-9d31-a4c682ac968e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzctMS0xLTEtNzAyMDA_0ce3ca73-2d03-4225-ab65-292ff32d5d33">5,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzctMy0xLTEtNzAyMDA_b7cc39ce-9e8a-461a-a93b-1d40fbefe972">11,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzctNS0xLTEtNzAyMDA_90d280ee-e180-4444-a9fe-c2d23b86c201">8,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2022 and 2021, the Company had no accruals for interest or penalties related to income tax matters. The total amount of unrecognized tax benefits that, if recognized, could affect the effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMTg_ac53d425-57af-4b38-8415-5bbf84e277fa">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzExNTQ0ODcyMDk2Mjc3_bc471721-0133-4477-adbc-fa861daf61e5">11.2</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively. However, the Company maintains a full valuation allowance as of December&#160;31, 2022 and 2021 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact. As of December&#160;31, 2022, the Company does not expect a significant change in the recorded unrecognized tax benefits reserve balance during the next twelve months. The unrecognized tax benefits are presented in the financial statements as a reduction to the deferred tax assets for all periods.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_184"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzY1NTA_ff072e58-b961-4ac6-bd60-aacacfeeb612" continuedAt="ifbd2d0f52e934279a81d31d9c51e525b" escape="true">Commitment and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ifbd2d0f52e934279a81d31d9c51e525b" continuedAt="ifcd035d7dba44b98aa359cd778d0e54a"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sothinathan Sinnathurai v. Novavax, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the NVX-CoV2373&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against <ix:nonFraction unitRef="defendant" contextRef="i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzQzOTgwNDY1ODY5ODU_0f86f796-7fb2-4930-b6f7-1f864f621028">two</ix:nonFraction> individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within <ix:nonNumeric contextRef="i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212" name="nvax:LossContingencyPeriodToAnswer" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzQzOTgwNDY1ODcwMDY_48cd793e-9dea-406e-9b65-4412801f30f9">fourteen days</ix:nonNumeric>. On December 27, 2022, the Company filed its answer and affirmative defenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Sinnathurai Action was filed, seven derivative lawsuits were filed: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Robert E. Meyer v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shui Shing Yung v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">William Kirst, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:22-cv-00024-TDC (the &#8220;Kirst Action&#8221;), (iv) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amy Snyder v. Stanley C. Erck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charles R. Blackburn, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diego J. Mesa v. Stanley C. Erck, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Mesa Action&#8221;), and (vii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sean Acosta v. Stanley C. Erck, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Acosta Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="ifcd035d7dba44b98aa359cd778d0e54a" continuedAt="i2afcb8dd91b940e4bf6f856956583249"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. On December 6, 2022, the parties to the Kirst Action filed a stipulated schedule pursuant to which the plaintiffs were expected to file an amended complaint on December 22, 2022, and either (i) the parties would file a stipulated stay of the Kirst Action or (ii) the defendants would file a motion to stay the case by January 23, 2023. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On February 24, 2023, the Court entered an order staying the Kirst Action until a final judgment in the Second Consolidated Derivative Action. The Company takes no position on whether the broader stay entered by the Court in the Kirst Action is likely to be modified to align with the parties&#8217; stipulation.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, the court entered an order granting the parties&#8217; request to set a briefing schedule in connection with a motion to stay that defendants intended to file. Pursuant to the order, defendants filed a motion to stay on January 18, 2023. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted Defendants&#8217; motion to stay.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta action. The financial impact of this claim, as well as the claims discussed above, is not estimable.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2021, a Company stockholder named Thomas Golubinski filed a derivative complaint against members of the Company&#8217;s board of directors and members of senior management in the Delaware Court, captioned Thomas Golubinski v. Richard H. Douglas, et al., No. 2021-0172-JRS. The Company is deemed a nominal defendant. Golubinski challenged equity awards made in April 2020 and in June 2020 on the ground that they were &#8220;spring-loaded,&#8221; that is, made at a time when such board members or members of senior management allegedly possessed undisclosed positive material information concerning the Company. The complaint asserted claims for breach of fiduciary duty, waste, and unjust enrichment. The plaintiff sought an award of damages to the Company, an order rescinding both awards or requiring disgorgement, and an award of attorneys&#8217; fees incurred in connection with the litigation. On May 10, 2021, the defendants moved to dismiss the complaint in its entirety. On June 17, 2021, the Company&#8217;s stockholders voted FOR ratification of the April 2020 awards and ratification of the June 2020 awards. Details of the ratification proposals are set forth in the Company&#8217;s Definitive Proxy Statement filed on May 3, 2021. The results of the vote were disclosed in the Company&#8217;s Current Report on Form 8-K filed on June 24, 2021. Thereafter, the plaintiff stipulated that, as a result of the outcome of the June 17, 2021 vote, the plaintiff no longer intends to pursue the lawsuit or any claim arising from the April 2020 and June 2020 awards. On August 23, 2021, the plaintiff filed a motion seeking an award of attorneys&#8217; fees and expenses for $<ix:nonFraction unitRef="usd" contextRef="i38dbeaf8546447cc8d0775f85d2579d5_D20210823-20210823" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzg3OTYwOTMwOTgwNTY_69a009a2-5b80-485e-b5c2-df9297291beb">1.5</ix:nonFraction>&#160;million, to which the defendants filed an opposition. On October 18, 2022, the Delaware Court denied the plaintiff&#8217;s fee application in its entirety. Under a prior Delaware Court order, the case was automatically dismissed with prejudice upon denial of the plaintiff&#8217;s fee application. On November 14, 2022, Golubinski filed a Notice of Appeal in the Supreme Court of the State of Delaware. The plaintiff / appellant filed his opening appellate brief on December 30, 2022. The Company filed its responsive brief on January 30, 2023 and the appellant filed his reply brief on February 14, 2023. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2022, Par Sterile Products, LLC (&#8220;Par&#8221;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (the &#8220;Par MSA&#8221;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. The parties are engaged in discovery and arbitration is scheduled for July 2023. While the Company maintains that no breach of the Par MSA has occurred and intends to vigorously defend the matter, if the final resolution of the </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5fb43b2896e34be2b1f12f6c19f667b2_7">Table of Contents</a></span></div></div><ix:continuation id="i2afcb8dd91b940e4bf6f856956583249"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matter is adverse to the Company, it could have a material impact on the Company&#8217;s financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#8217;s failure to procure the purchase of <ix:nonFraction unitRef="dose" contextRef="i0523638414324ebda053032feb1642dc_I20221118" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzIxOTkwMjMzMTcxNTU_de75fba7-dfc1-47d2-81c2-2c433a3d7710">350</ix:nonFraction>&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately <ix:nonFraction unitRef="dose" contextRef="i0523638414324ebda053032feb1642dc_I20221118" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzIxOTkwMjMzMjc5MzI_7e71e3b9-d280-4b67-80c0-708e81d4dfa1">2</ix:nonFraction>&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December 31, 2022, the remaining Gavi Advance Payment Amount of $<ix:nonFraction unitRef="usd" contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzIxOTkwMjMzMjk1NTU_8f556068-c6cf-4287-82bf-ab17568f8af7">697.4</ix:nonFraction>&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#8217;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that the Company could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on the Company's financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements in the normal course of business with CMOs and CDMOs supplying the Company with production capabilities, and with vendors for preclinical studies, clinical trials, and other goods or services. A number of these arrangements are within the scope of lease accounting (see Note 10). Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Company is contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses. The exact amount of such obligations are dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. As of December&#160;31, 2022, most of these agreements were active ongoing arrangements and the Company expects to receive value from these arrangements in the future. The Company recognizes fees related to obligations for terminated contracts where such fees are reasonably estimable. The Company did not accrue obligations that were not reasonably estimable. As of December&#160;31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231" decimals="INF" name="us-gaap:PurchaseObligation" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzY1NTI_fc9415d1-a567-4d4e-a3c5-d317f761f3e3">no</ix:nonFraction> non-cancelable purchase commitments with a remaining term of more than one year.</span></div></ix:continuation><div id="i5fb43b2896e34be2b1f12f6c19f667b2_187"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19 &#8211; <ix:nonNumeric contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODcvZnJhZzo3ODBlM2I5MTdkZjE0OTNjYmNmMmVjNTQ1MjgxYmE0Yy90ZXh0cmVnaW9uOjc4MGUzYjkxN2RmMTQ5M2NiY2YyZWM1NDUyODFiYTRjXzc3NA_821decdf-6393-4601-acc8-4ccbfa5510b1" continuedAt="i903fb32777cf4e97922b8e7a45c3b3af" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i903fb32777cf4e97922b8e7a45c3b3af"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2023, the Board of Directors of the Company approved the appointment of John C. Jacobs, as President and Chief Executive Officer and a member of the Board, effective as of January 23, 2023. Mr. Jacobs succeeded Stanley C. Erck, who provided the Board with notice on January 5, 2023 of his decision to retire as President and Chief Executive Officer and as a member of the Board, in each case effective as of January 23, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on claims stemming from the Gavi APA. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that it could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi (see Note 3 and Note 18).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the Company funded the outstanding principal amount of $<ix:nonFraction unitRef="usd" contextRef="i63a2de06fc1f42a69276ce8a6224e6a0_D20230131-20230131" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODcvZnJhZzo3ODBlM2I5MTdkZjE0OTNjYmNmMmVjNTQ1MjgxYmE0Yy90ZXh0cmVnaW9uOjc4MGUzYjkxN2RmMTQ5M2NiY2YyZWM1NDUyODFiYTRjXzIxOTkwMjMyNjY2MTA_3fdb8611-4041-4504-b91b-325c3df443c4">325.0</ix:nonFraction> million on the 2023 Notes, due February 1, 2023 and the indenture governing the 2023 Notes was subsequently satisfied and discharged in accordance with its terms. The Company&#8217;s related &#8220;capped call transactions&#8221; expired by their terms on January 27, 2023.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>nvax-20221231xex44.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i48e3280bfcee43f0820a4dfa2e54430e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 4.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of December 31, 2022, Novavax, Inc. (the &#8220;Company&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Description of Common Stock</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following description of the Company&#8217;s Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company&#8217;s Second Amended and Restated Certificate of Incorporation, as amended, (the &#8220;Certificate of Incorporation&#8221;), Certificate of Designation of Series A Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;) and Amended and Restated By-Laws (the &#8220;By-Laws&#8221;), each of which is incorporated by reference as an exhibit to this Annual Report on Form 10-K. The Company encourages you to read the Certificate of Incorporation, the Certificate of Designation, the By-Laws, and the applicable provisions of the Delaware General Corporation Law for additional information. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authorized Capital Shares</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Certificate of Incorporation authorizes the issuance of 600,000,000 shares of common stock, $0.01 par value per share (&#8220;Common Stock&#8221;), and 2,000,000 shares of preferred stock, $0.01 par value per share (&#8220;Preferred Stock&#8221;), of which 438,885 shares of Preferred Stock have been designated as Series A Convertible Preferred Stock, par value $0.01 per share, pursuant to the Certificate of Designation (&#8220;Series A Convertible Preferred Stock&#8221;). The outstanding shares of Common Stock are fully paid and nonassessable. As of December 31, 2022, there are no shares of Preferred Stock outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Preferred Stock </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Authorized but Unissued Preferred Stock </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Board of Directors (the &#8220;Board&#8221;), without further stockholder approval, has the power to issue Preferred Stock in one or more series and determine certain terms relative to any Preferred Stock to be issued, such as the power to establish different series and to set voting rights, the dividend rights and dates, conversion rights, redemption privileges and liquidation preferences. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Each share of Series A Convertible Preferred Stock is convertible into ten shares of Common Stock, subject to mandatory conversion upon the earlier of (1) the tenth anniversary of the issuance date or (2) immediately prior to the effectiveness of certain change of control transactions. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Holders of Series A Convertible Preferred Stock are not entitled to vote on matters submitted to the holders of Common Stock and do not have the right to cumulative dividends. In the event that the Company declares a dividend upon Common Stock, a holder of the Series A Convertible Preferred Stock is entitled to receive the amount of dividends per share of Series A Convertible Preferred Stock that such holder would have been entitled to receive if it had converted such Series A Convertible Preferred Stock into Common Stock immediately prior to such declaration of a dividend. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of a liquidation, dissolution or winding up of the Company that does not constitute a change of control transaction triggering mandatory conversion of the Series A Convertible Preferred Stock, any holder of Series A Convertible Preferred Stock will be entitled to receive, in preference to the holders of Common Stock and any junior Preferred Stock, an amount per share equal to the greater of (1) the sum of the purchase price plus an amount equal to any declared and unpaid dividends on the Series A Convertible Preferred Stock, or (2) the amount that such shares of Series A Convertible Preferred Stock would have been entitled to receive if they had converted into Common Stock immediately prior to such liquidation, dissolution or winding up.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 4.4</font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of December 31, 2022, there are no shares of the Series A Convertible Preferred Stock outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Common Stock </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Dividend Rights</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the rights of holders of outstanding shares of Preferred Stock, if any, the holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Board in its discretion out of funds legally available for the payment of dividends. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Voting Rights</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The holders of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors, and do not have cumulative voting rights.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Classified Board</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The members of the Board are divided into three classes, designated as Class I, Class II, and Class III, each serving staggered three-year terms, with no one class having more than one more director than any other class. The By-Laws provide for directors in director elections to be elected by a plurality of the votes entitled to vote.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Liquidation Rights</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to any preferential rights of outstanding shares of Preferred Stock, holders of Common Stock will share ratably in all assets legally available for distribution to the Company&#8217;s stockholders in the event of dissolution.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Rights and Preferences</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Common Stock has no redemption provisions or preemptive, conversion or exchange rights. No shares of any class of the Company&#8217;s capital stock are subject to any sinking fund provisions, restrictions on the alienability of securities to be registered, calls, assessments by, or liabilities of the Company. Holders of Common Stock may act by written consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Certain Provisions of the Certificate of Incorporation, By-laws, and Delaware Law </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain provisions of the Certificate of Incorporation and By-Laws may be deemed to have an anti-takeover effect and may prevent, delay, or defer a tender offer or takeover attempt, including&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Classified Board, Removal of Directors, and Charter Amendments relating to the Board </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Certificate of Incorporation and the By-Laws provide for the division of members of the Board into three classes, with no one class having more than one more director than any other class, serving staggered three-year terms. The Certificate of Incorporation provides that any amendments to the charter relating to the number, classes, election, term, removal, vacancies, and related provisions with respect to the Board may only be made by the affirmative vote of the holders of at least 75% of the shares of capital stock issued and outstanding and entitled to vote. These provisions may have the effect of making it more difficult for a third party to acquire control of the Company, or of discouraging a third party from attempting to acquire control of the Company. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Authorized but Unissued Shares </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The authorized but unissued shares of Common Stock and Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the Nasdaq Stock Market. These additional shares may be utilized for a variety of corporate purposes. In particular, the Board could issue shares of Preferred Stock that could, depending on the terms of the series, impede the completion of a takeover effort. The Board may determine that the issuance of such shares of Preferred Stock is in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 4.4</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">best interest of the Company and its stockholders. Such issuance could discourage a potential acquiror from making an unsolicited acquisition attempt through which such acquiror may be able to change the composition of the Board, including a tender offer or other transaction a majority of the Company&#8217;s stockholders might believe to be in their best interest or in which stockholders might receive a substantial premium for their stock over the then-current market price. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Advance Notice Requirements for Stockholder Proposals and Director Nominations </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The By-Laws provide that a stockholder seeking to bring business before an annual meeting of stockholders, or to nominate candidates for election as directors, must provide timely notice of such stockholder&#8217;s intention in writing. To be timely, a stockholder nominating individuals for election to the Board or proposing business must provide advanced notice to the Company not less than 60&#160;days nor more than 90&#160;days prior to the anniversary date of the prior year&#8217;s annual meeting of stockholders or, in the case of any special meeting, not less than 60&#160;days nor more than 90&#160;days prior to the special meeting, unless, in the case of annual meeting, such meeting occurs more than 30&#160;days before or after such anniversary date, or, in the case of a special meeting, such meeting occurs less than 100&#160;days after notice or public disclosure of the date of the special meeting is given or made, in which cases notice will be timely if received not later than the close of business on the tenth day after the day on which notice or public announcement of the date of such meeting was made. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Limits on Ability of Stockholders to Act by Written Consent </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Certificate of Incorporation provides that the stockholders may not act by written consent. In addition, the Certificate of Incorporation requires that special meetings of stockholders be called only by the Board, the Company&#8217;s chief executive officer, or the Company&#8217;s president if there is no chief executive officer. Further, business transacted at any special meeting of stockholders is limited to matters relating to the purpose or purposes stated in the notice of meeting. This limit on the ability of the Company&#8217;s stockholders to act by written consent or to call a special meeting may lengthen the amount of time required to take stockholder proposed actions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Section&#160;203 of the General Corporation Law of the State of Delaware </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is subject to Section&#160;203 of the Delaware General Corporation Law. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with an interested stockholder for three&#160;years following the date that the stockholder became an interested stockholder, unless&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59; </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">upon completion of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers, and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is any person who, together with such person&#8217;s affiliates and associates (1) owns 15% or more of a corporation&#8217;s voting securities or (2) is an affiliate or associate of a corporation and was the owner of 15% or more of the corporation&#8217;s voting securities at any time within the three year period immediately preceding a business combination </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 4.4</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">governed by Section 203. The existence of this provision may have an anti-takeover effect with respect to transactions the Board does not approve.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Listing</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company&#8217;s Common Stock is traded on The Nasdaq Global Select Market under the trading symbol &#8220;NVAX.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>nvax-20221231xex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id4ce0b24a69d467186f1053bc7577247_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.18</font></div></div><div style="padding-right:22pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Employment Agreement (this &#8220;Agreement&#8221;) is dated as of&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">January 5, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, between&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (&#8220;Novavax&#8221; or the &#8220;Company&#8221;) a Delaware corporation having its principal office at 21 Firstfield Road, Gaithersburg, MD 20878, and&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">John C. Jacobs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an individual (&#8220;Executive&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive will commence employment with the Company on or about January 23, 2023 (the date Executive actually commences employment, the &#8220;Effective Date&#8221;), now therefore the Company and Executive hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company hereby employs Executive and Executive hereby accepts employment as&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">President and Chief Executive Officer&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon the terms and conditions hereinafter set forth, effective as of the Effective Date. As used throughout this Agreement, &#8220;Company&#8221; shall mean and include any and all of its present and future subsidiaries and any and all subsidiaries of a subsidiary. Executive warrants and represents that he is free to enter into and perform this Agreement and is not subject to any employment, confidentiality, non-competition or other agreement which prohibits, restricts, or would be breached by either his acceptance or his performance of this Agreement.  The Board of Directors of the Company (the &#8220;Board of Directors&#8221;) shall appoint Executive to serve on the Board of Directors from the Effective Date until the next annual meeting of the Company&#8217;s shareholders at which his term as a member of the Board of Directors expires (based on his designated director class), and shall nominate him for election to serve on the Board of Directors at each subsequent applicable annual meeting of shareholders (based on his director class) during the Term (as hereinafter defined) (with removal of Executive as a member of the Board of Directors during the Term only in accordance with the Company&#8217;s by-laws, as in effect from time to time).  Concurrent with any termination of Executive&#8217;s employment with the Company, Executive shall resign (or shall be deemed to have resigned) from the Board of Directors and from any other positions that he then holds with the Company and its affiliates.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Term (as hereinafter defined), Executive shall devote his full business time to the performance of services as President and Chief Executive Officer of Novavax, performing such services and assuming such duties and responsibilities as prescribed by the Board of Directors and reporting to the Board of Directors. During the Term, Executive&#8217;s services shall be completely exclusive to the Company and he shall devote his entire business time, attention and energies to the business of the Company and the duties which the Company shall assign to him from time to time. Executive agrees to perform his services faithfully and to the best of his ability and to carry out the policies and directives of the Company. Notwithstanding the foregoing, it shall not be a violation of this Agreement for Executive to serve as a director of any company whose products do not compete with those of the Company and to serve as a director, trustee, officer, or consultant to a charitable or non-profit entity&#59; provided that such service does not adversely affect Executive&#8217;s ability to perform his obligations hereunder. Executive agrees not to take any action that is in bad faith and prejudicial to the interests of the Company during his employment hereunder. Executive shall be based primarily at the Company&#8217;s headquarters, currently in Gaithersburg, Maryland, and he also may be required from time to time to perform duties hereunder for reasonably short periods of time outside of said area.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The &#8220;Term&#8221; of this Agreement shall be the period of time beginning on the Effective Date and shall continue for so long as Executive shall be an at-will employee of the Company hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.8pt">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For all Executive&#8217;s services and covenants under this Agreement, during the Term, the Company shall pay Executive an annual base salary, which is&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$700,000&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the Effective Date.  Executive&#8217;s base salary shall be subject to review (but not reduction, other than an across-the-board reduction, not in excess of 10% of Executive&#8217;s annual base salary, applicable to all similarly situated executives of the Company) by the Board of Directors or the Compensation Committee thereof (the &#8220;Compensation Committee&#8221;) in its discretion, with the first such review occurring in the first quarter of 2024.  Executive&#8217;s base salary shall be payable in accordance with the Company&#8217;s payroll policy as constituted from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.18pt">Bonus Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive shall be eligible to receive a performance and incentive bonus in respect of Executive&#8217;s employment with the Company during each year of the Term in an amount determined by the Board of Directors or the Compensation Committee to be appropriate based upon the achievement of certain specified goals for such year.  Executive&#8217;s target bonus shall be&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">75%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of Executive&#8217;s base salary during the year to which the bonus relates. The bonus shall be paid out in cash, unless otherwise agreed to by Executive. Notwithstanding the foregoing, for calendar year 2023, if the Effective Date is on or after March 1, 2023 any bonus shall be prorated for the portion of the calendar year during which Executive was employed hereunder.  In order to receive any bonus hereunder, Executive must be employed through the first business day that immediately follows the last day of the calendar year performance period to which the bonus relates.  Any annual bonus payable under this paragraph shall be paid no later than March 15 of the year following the calendar year performance period to which the bonus relates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.8pt">Initial Equity Award Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As soon as reasonably practicable following the Effective Date, subject to the approval of the Board of Directors or the Compensation Committee, as a material inducement for the Executive to commence employment with the Company and in accordance with Nasdaq Listing Rule 5635(c)(4), Executive will receive an equity grant (the &#8220;Initial Grant&#8221;) with an aggregate target value equal to approximately $6,000,000, with approximately one-half (1&#47;2) of the Initial Grant to be in the form of restricted stock units (the &#8220;Inducement Restricted Stock Units&#8221;), and the remaining portion of the Initial Grant to be in the form of stock options (the &#8220;Inducement Stock Options&#8221;), in each case as determined by the Board of Directors or the Compensation Committee in accordance with customary practice. The Inducement Restricted Stock Units will vest as to one-third (1&#47;3) of the shares underlying the Inducement Restricted Stock Units on each of the first three (3) anniversaries of the date of grant, in each case subject to Executive&#8217;s continued employment with the Company through the applicable vesting date, except as provided in Section 8(a) of this Agreement, and the Inducement Stock Options will vest as to one-quarter (1&#47;4) of the shares underlying the Inducement Stock Options on the first anniversary of the date of grant and as to the remaining shares in equal monthly installments for thirty-six (36) months thereafter, in each case subject to Executive&#8217;s continued employment with the Company through the applicable vesting date, except as provided in Section 8(a) of this Agreement.  Each of the Inducement Restricted Stock Units and Inducement Stock Options will be granted under and subject to the terms of the Company&#8217;s inducement equity plan and an agreement in substantially the form of a restricted stock unit agreement or the form of a stock option award agreement, as applicable, previously approved by the Board of Directors or the Compensation Committee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.18pt">Annual Equity Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Beginning in 2024, Executive will be eligible for additional annual equity awards based upon performance and subject to the approval of the Board of Directors or the Compensation Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.8pt">10b5-1 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall permit Executive to establish a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, with respect to the sale of the Company&#8217;s common stock to the extent that such plan does not violate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company&#8217;s insider trading policy, share ownership guidelines, or applicable law, each as may be in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.02pt">Make Whole Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Executive&#8217;s obligations in the immediately following sentence, if Executive fails to be paid an annual bonus by Executive&#8217;s prior employer in respect of the 2022 calendar performance year of at least $430,000 (the &#8220;2022 Bonus Value&#8221;), then on the first regular payroll date of the Company following the date annual bonuses are paid by Executive&#8217;s prior employer, the Company shall pay to Executive a single sum cash payment (the &#8220;Make Whole Payment&#8221;) not to exceed the lesser of (i) $250,000, and (ii) the product of (A) the 2022 Bonus Value reduced by the amount of annual bonus paid to Executive by Executive&#8217;s prior employer in respect of the 2022 calendar performance year, if any, and (B) seventy-five percent (75%).  Executive shall use his good faith best efforts to obtain the 2022 bonus described herein from his prior employer. If, prior to the one (1)-year anniversary of the Effective Date, the Company terminates Executive&#8217;s employment for Cause or Executive voluntarily terminates Executive&#8217;s employment without Good Reason, Executive agrees to repay the Make Whole Payment, if any, in full upon receipt of notice from the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Reimbursable Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive shall be entitled to reimbursement for reasonable expenses incurred by him in connection with the performance of his duties hereunder in accordance with such procedures and policies for executive officers as the Company has heretofore or may hereafter establish.  Executive&#8217;s right to payment or reimbursement for expenses under this Agreement will be subject to the following additional rules&#58; (i) the amount of expenses eligible for reimbursement during any calendar year shall not affect the expenses eligible for reimbursement in any other calendar year, (ii) the reimbursement of an eligible expense shall be made as soon as practicable after Executive submits the request for reimbursement, but not later than December 31 of the calendar year following the calendar year in which the expense was incurred and (iii) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.  The Company shall also reimburse Executive for all reasonable legal fees actually incurred by Executive in the negotiation and review of this Agreement, in an amount not to exceed $40,000 in the aggregate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive shall be entitled to five (5) weeks of paid vacation time per year, calculated and administered in accordance with Company policies for executive officers in effect from time to time. Executive shall be entitled to all other benefits associated with normal full-time employment in accordance with Company policies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be eligible to participate in the Company&#8217;s Amended and Restated Change in Control Severance Benefit Plan adopted on June 17, 2021 (as may be further amended from time to time, the &#8220;Change in Control Severance Benefit Plan&#8221;), subject to the terms and conditions of the Change in Control Severance Benefit Plan, but shall only receive severance payments and benefits under the Change in Control Severance Benefit Plan in connection with a Qualifying Termination (as defined in the Change in Control Severance Benefit Plan), and in the event of any other termination of Executive&#8217;s employment, Executive shall be entitled to receive only the severance payments and benefits, if any, set forth in this Agreement (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, there shall be no duplication of severance payments and benefits). The Company shall not amend or modify the Change in Control Severance Benefit Plan, as in effect on the date hereof, in such a way that diminishes or otherwise adversely affects the rights or benefits of Executive without the written consent of Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">During the Term, the Company will pay or reimburse Executive for all reasonable and customary housing and commuting expenses actually incurred by Executive, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an amount not to exceed $100,000 per year in the aggregate, in accordance with such procedures and policies for substantiation of expenses and reimbursement as the Company may establish.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding any other provision of this Agreement, Executive&#8217;s employment may be terminated, without such action constituting a breach of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.63pt">By the Company, for &#8220;Cause,&#8221; as defined in Section 7(b) below&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.58pt">By the Company, without Cause&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">By the Company, upon thirty (30) days&#8217; notice to Executive, if he should be prevented by illness, accident or other disability (mental or physical) from discharging his duties hereunder for one or more periods totaling three (3) consecutive months during any twelve (12)-month period&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.13pt">By Executive with &#8220;Good Reason&#8221;, as defined in Section 7(c) below, within thirty (30) days of the occurrence or commencement of such Good Reason&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">By Executive without Good Reason upon thirty (30) days prior written notice&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.13pt">By the event of Executive&#8217;s death during the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;Cause&#8221; shall mean (i) Executive&#8217;s failure or refusal to perform in all material respects the services required of him hereby, (ii) Executive&#8217;s refusal to carry out any proper and material direction by the Board of Directors with respect to the services to be rendered by him hereunder or the manner of rendering such services, (iii) Executive&#8217;s material misconduct in the performance of his duties hereunder, (iv) Executive&#8217;s commission of an act of fraud, embezzlement or theft or a felony involving moral turpitude, (v) Executive&#8217;s engagement in any activity prohibited by Section 10 of this Agreement, other than the use of confidential information for the benefit of the Company in the course of rendering services to the Company, or (vi) Executive&#8217;s engagement in any activity prohibited by Section 11 or 12 of this Agreement.  For purposes of this Section 7, the Company shall be required to provide Executive a specific written warning with regard to any occurrence of subsections (b)(i), (ii) and (iii) above, which warning shall include a statement of corrective actions and a thirty (30)-day period for Executive to respond to and implement such actions, prior to any termination of employment by the Company pursuant to Section 7(a)(i) above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;Good Reason&#8221; shall mean the Company&#8217;s (i) material reduction or diminution of Executive&#8217;s responsibilities and authority, other than for Cause, without his consent&#59; or (ii) material breach of this Agreement.  In order to terminate his employment for Good Reason hereunder, (x) Executive must provide written notice to the Company, setting forth in reasonable detail the nature of the condition giving rise to Good Reason, within thirty (30) days of the initial existence of such condition, (y) the condition remains uncured by the Company for a period of thirty (30) days following such notice and (z) Executive terminates his employment, if at all, not later than thirty (30) days after the expiration of such cure period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">Separation Pay&#59; Final Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subject to Executive&#8217;s execution and delivery to the Company of the Company&#8217;s standard form of Separation and Release Agreement, Executive&#8217;s Initial Grant, to the extent not vested, shall become fully vested and exercisable (and any then-outstanding </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Inducement Stock Options shall remain exercisable for no less than ninety (90) days from Executive&#8217;s termination date (or, if earlier, the expiration of the original term of such options)) and the Company shall pay or provide Executive with the Separation Pay as defined herein, in each case upon the occurrence of the applicable Separation Event, as defined below. The Separation Pay shall be paid in a single lump sum as soon as administratively practicable following the date the Separation and Release Agreement becomes effective, but not later than the date that is sixty (60) days following the Separation Event. &#8220;Separation Pay&#8221; shall mean (i) an amount equal to eighteen (18) months of Executive&#8217;s then effective base salary and (ii) an amount equal to one hundred percent (100%) of the monthly COBRA premiums, including the two percent (2%) administration fee, as in effect as of the date of termination for the Company&#8217;s group medical, dental, vision and hospitalization insurance benefits in which Executive is enrolled as of the date of termination for Executive and his eligible dependents for eighteen (18) months, subject to Executive&#8217;s timely and proper election of coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Section 8(a) above shall not apply should Executive receive severance benefits under the Change in Control Severance Benefit Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;Separation Event&#8221; shall mean&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.63pt">the Company&#8217;s termination of Executive&#8217;s employment by the Company without Cause&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.58pt">the termination of Executive&#8217;s employment by Executive for Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">If, at the time of Executive&#8217;s separation from service, Executive is a &#8220;specified employee,&#8221; as hereinafter defined, any and all amounts payable under this Section 8 in connection with such separation from service that constitute deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the treasury regulations thereunder (collectively, &#8220;Section 409A&#8221;), as determined by the Company in its sole discretion, and that would (but for this sentence) be payable within six (6) months following such separation from service, shall instead be paid on the date that follows the date of such separation from service by six (6) months. For purposes of the preceding sentence, &#8220;separation from service&#8221; shall be determined in a manner consistent with Section 409A(a)(2)(A)(i) of the Code and the term &#8220;specified employee&#8221; shall mean an individual determined by the Company to be a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">In the event of termination of Executive&#8217;s employment with the Company, howsoever occurring, the Company shall pay Executive (i) his base salary for the final payroll period of his employment, through the date his employment terminates&#59; and (ii) reimbursement, in accordance with Section 5 or 6(c) hereof, for expenses incurred by Executive but not yet paid to Executive as of the date his employment terminates, provided that the Executive submits all expenses and supporting documentation required within sixty (60) days of the date his employment terminates, and provided further that such expenses are reimbursable under Company policies then in effect (all of the foregoing, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Except as otherwise provided in Section 8(e)(ii), Final Compensation will be paid to Executive within thirty (30) days following the date of termination or such shorter period required by law.  Other than as provided in Section 8(a) hereof, in the event of a Separation Event, or under the Change in Control Severance Benefit Plan, or as provided in this subsection (e), Executive shall have no rights to any separation or termination-related payments or benefits upon his termination of employment with the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.75pt">All Business to be Property of the Company&#59; Assignment of Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive agrees that any and all presently existing business of the Company and all business developed by him or any other employee of the Company including without limitation all contracts, fees, commissions, compensation, records, customer or client lists, agreements and any other incident of any business developed, earned or carried on by Executive for the Company is and shall be the exclusive property of the Company, and (where applicable) shall be payable directly to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive hereby acknowledges that any plan, method, data, know-how, research, information, procedure, development, invention, improvement, modification, discovery, design, process, software and work of authorship, documentation, formula, technique, trade secret or intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor (herein sometimes collectively referred to as &#8220;Intellectual Property&#8221;) made, conceived, created, invested, developed, reduced to practice and&#47;or acquired by Executive solely or jointly with others during the Term is the sole and exclusive property of the Company, as work for hire, and that he has no personal right in any such Intellectual Property. Executive hereby grants to the Company (without any separate remuneration or compensation other than that received by him from time to time in the course of his employment) his entire right, title and interest throughout the world in and to, all Intellectual Property, which is made, conceived, created, invested, developed, reduced to practice and&#47;or acquired by him solely or jointly with others during the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive shall cooperate fully with the Company, both during and after his employment with or engagement by the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Intellectual Property. Without limiting the foregoing, Executive agrees that to the extent copyrightable, any such original works of authorship shall be deemed to be &#8220;works for hire&#8221; and that the Company shall be deemed the author thereof under the U.S. Copyright Act, as amended, provided that in the event and to the extent such works are determined not to constitute &#8220;works for hire&#8221; as a matter of law, Executive hereby irrevocably assigns and transfers to the Company all right, title and interest in such works, including but not limited to copyrights thereof. Executive shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Intellectual Property (at the Company&#8217;s expense) and agrees that these obligations are binding upon his assigns, executors, administrators and other legal representatives. To that end, Executive shall provide current contact information to the Company including, but not limited to, home address, telephone number and email address, and shall update his contact information whenever necessary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive acknowledges his obligation of confidentiality with respect to all proprietary, confidential and non-public information of the Company, including all Intellectual Property. By way of illustration, but not limitation, confidential and proprietary information shall be deemed to include any plan, method, data, know-how, research, information, procedure, development, invention, improvement, modification, discovery, process, work of authorship, documentation, formula, technique, product, idea, concept, design, drawing, specification, technique, trade secret or intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor, personnel data, records, marketing techniques and materials, marketing and development plans, customer names and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information related to customers, including prospective customers and contacts at customers, price lists, pricing policies and supplier lists of the Company, in each case coming into Executive&#8217;s possession, or which Executive learns, or to which Executive has access, or which Executive may discover or develop (whether or not related to the business of the Company at the time this Agreement is signed or any information Executive originates, discovers or develops, in whole or in part) as a result of Executive&#8217;s employment by (either full-time or part-time), or retention as a consultant of, the Company. Executive shall not either during the Term or thereafter use for any purpose other than the furtherance of the Company&#8217;s business, or disclose to any person other than a person with a need to know such confidential, proprietary or non-public information for the furtherance of the Company&#8217;s business who is obligated to maintain the confidentiality of such information, any information concerning any Intellectual Property, or other confidential, proprietary or non-public information of the Company, whether Executive has such information in his memory or such information is embodied in writing, electronic or other tangible form.  For the avoidance of doubt, (i) nothing contained in this Agreement limits, restricts or in any other way affects Executive&#8217;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity and (ii) Executive will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (y) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (z) in a complaint or other document filed under seal in a lawsuit or other proceeding&#59; provided, however, that notwithstanding this immunity from liability, Executive may be held liable if he unlawfully accesses trade secrets by unauthorized means.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All originals and copies of any of the foregoing, however and whenever produced, shall be the sole property of the Company. All files, letters, memoranda, reports, records, data, sketches, drawings, program listings, or other written, photographic, or other tangible or electronic material containing confidential or proprietary information or Intellectual Property, whether created by Executive or others, which shall come into Executive&#8217;s custody or possession, shall be and are the exclusive property of the Company to be used by Executive only in the performance of his duties for the Company. All electronic material containing confidential or proprietary information or Intellectual Property will be stored on a computer supplied to Executive by the Company and, under no circumstances, will it be transferred to a personal computer. Executive will promptly deliver to the Company and&#47;or a person or entity identified by the Company all such materials or copies of such materials and all tangible property of the Company in Executive&#8217;s custody or possession, upon the earlier of (i) a request by the Company or (ii) termination of employment or engagement by the Company. After such delivery, Executive will not retain any such materials or copies or any such tangible property or any summaries or memoranda regarding same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Non-Competition Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As Executive has been or will be granted equity-based awards with respect to the Company&#8217;s common stock and as such has a financial interest in the success of the Company&#8217;s business and as Executive recognizes that the Company would be substantially injured by Executive competing with the Company, Executive agrees and warrants that within the United States, he will not, unless acting with the Company&#8217;s express prior written consent, directly or indirectly, while an employee of the Company and during the Non-Competition Period, as defined below, engage in the development, production, marketing or sale of products that compete (or, upon commercialization, would compete) with products or candidate products that, as of the date of Executive&#8217;s termination or any date during the following six (6) months, are in clinical development, awaiting regulatory licensure or being actively marketed or sold by the Company&#59; provided, however, that Executive may own, and exercise rights with respect to, less than one percent of the equity of a publicly traded company. The &#8220;Non-Competition Period&#8221; shall be a period of&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">eighteen (18)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months following termination of employment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive and the Company are of the belief that the period of time and the area herein specified are reasonable in view of the nature of the business in which the Company is engaged and proposes to engage, the state of its business development and Executive&#8217;s knowledge of this business&#59; however, if such period or such area should be adjudged unreasonable in any judicial proceeding, then the period of time shall be reduced by such number of months or such area shall be reduced by elimination of such portion of such area, or both, as are deemed unreasonable, so that this covenant may be enforced in such area and during such period of time as is adjudged to be reasonable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Non-Solicitation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive agrees and covenants that he will not, unless acting with the Company&#8217;s express written consent, directly or indirectly, during the Term or during the Non-Competition Period (as defined in Section 11 above) solicit, entice or attempt to entice away or interfere in any manner with the Company&#8217;s relationships or proposed relationships with any customer, officer, employee, consultant, proposed customer, vendor, supplier, proposed vendor or supplier or person or entity or person providing or proposed to provide research and&#47;or development services to, on behalf of or with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">The intent of the parties is that payments and benefits under this Agreement comply with Section 409A, to the extent subject thereto, and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance therewith. Without limiting the foregoing, to the extent required in order to avoid accelerated taxation and&#47;or tax penalties under Section 409A, Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement and no payment shall be due to Executive under this Agreement until Executive would be considered to have incurred a &#8220;separation from service&#8221; within the meaning of Section 409A. Each amount to be paid or benefit to be provided to Executive pursuant to this Agreement that constitutes deferred compensation subject to Section 409A shall be treated as a separate payment for purposes of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices and other communications hereunder shall be in writing and shall be deemed to have been given on actual receipt after having been delivered by hand, mailed by first class mail, postage prepaid, or sent by Federal Express or similar overnight delivery services, as follows&#58; (a) if to Executive, at his most recent address on file with the Company, and, if to the Company, to the Company&#8217;s Executive Vice President, General Counsel and Corporate Secretary, 21 Firstfield Road, Gaithersburg, MD 20878 or to such other person(s) or address(es) as the Company shall have furnished to Executive in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of a Change in Control (as defined in the Change in Control Severance Benefit Plan), the terms of this Agreement shall inure to the benefit of, and be assumed by, the successor to the Company or the acquiring person in such Change in Control. This Agreement shall not be assignable by Executive, but it shall be binding upon, and to the extent provided in Section 8 shall inure to the benefit of, his heirs, executors, administrators and legal representatives.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement along with the Non-Disclosure, Proprietary Information and Invention Assignment Agreement entered into between Executive and the Company contain the entire agreement between the Company and Executive with respect to the subject matter hereof and there have been no oral or other prior agreements of any kind </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whatsoever as a condition precedent or inducement to the signing of this Agreement or otherwise concerning this Agreement or the subject matter hereof. Notwithstanding the foregoing, Executive acknowledges that he is required as a condition to continued employment, to comply at all times, with the Company&#8217;s policies affecting employees, including the Company&#8217;s published Code of Business Ethics, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive recognizes and agrees that the Company&#8217;s remedy at law for any breach of the provisions of Sections 9, 10, 11 or 12 hereof would be inadequate, and he agrees that for breach of such provisions, the Company shall, in addition to such other remedies as may be available to it at law or in equity or as provided in this Agreement, be entitled to injunctive relief and to enforce its rights by an action for specific performance. Should Executive engage in any activities prohibited by this Agreement, he agrees to pay over to the Company all compensation, remuneration or monies or property of any sort received in connection with such activities&#59; such payment shall not impair any rights or remedies of the Company or obligations or liabilities of Executive which such parties may have under this Agreement or applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may not be amended, nor shall any change, waiver, modification, consent or discharge be effected except by written instrument executed by the Company and Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any part of any term or provision of this Agreement shall be held or deemed to be invalid, inoperative or unenforceable to any extent by a court of competent jurisdiction, such circumstances shall in no way affect any other term or provision of this Agreement, the application of such term or provision in any other circumstances, or the validity or enforceability of this Agreement. Executive agrees that the restrictions set forth in Sections 9, 10, 11 and 12 above (including, but not limited to, the geographical scope and time period of restrictions) are fair and reasonable and are reasonably required for the protection of the interests of the Company and its affiliates. In the event that any provision of Section 9, 10, 11 or 12 relating to time period and&#47;or areas of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period or areas such court deems reasonable and enforceable, said time period and&#47;or areas of restriction shall be deemed to become and thereafter be the maximum time period and&#47;or areas which such court deems reasonable and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Paragraph Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The paragraph headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Governing Law.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by and construed and enforced in accordance with the law of the State of Maryland, without regard to the principles of conflict of laws thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Resolution of Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. With the exception of proceedings for equitable relief brought pursuant to Section 17 of this Agreement, any disputes arising under or in connection with this Agreement including, without limitation, any assertion by any party hereto that the other party has breached any provision of this Agreement, shall be resolved by arbitration, to be conducted in Baltimore, Maryland, in accordance with the rules and procedures of the American Arbitration Association. The parties shall bear equally the cost of such arbitration, excluding attorneys&#8217; fees and disbursements which shall be borne solely by the party incurring the same&#59; provided, however, that if the arbitrator rules in favor of Executive on at least one material component of the dispute, Company shall be solely responsible for the payment of all costs, fees and expenses (including without limitation Executive&#8217;s reasonable attorneys&#8217; fees and disbursements) of such arbitration. The Company shall reimburse Executive for any such fees and expenses incurred by Executive in any calendar year within a reasonable time following </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#8217;s submission of a request for such reimbursement, which in no case shall be later than the end of the calendar year following the calendar year in which such expenses were incurred. Executive shall submit any such reimbursement request no later than the June 30th&#160;next following the calendar year in which the fees and expenses are incurred. In the event the arbitrator rules against Executive, Executive shall repay the Company the amount of such reimbursed expenses no later than 180 days following the date as of which such arbitrator&#8217;s decision becomes final. The provisions of this Section 22 shall survive the termination for any reason of the Term (whether such termination is by the Company or by Executive).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Excess Parachute Payments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary herein, if any payment or benefit that Executive may receive, whether or not payable or provided under this Agreement (&#8220;Payment&#8221;), would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;Excise Tax&#8221;), then such Payment shall be reduced to the Reduced Amount. The &#8220;Reduced Amount&#8221; shall be either (A) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (B) the largest portion, up to and including the total amount, of the Payment, whichever of the amounts determined under (A) and (B), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order&#58; reduction of cash payments&#894; reduction of employee benefits&#894; and cancellation of accelerated vesting of outstanding equity awards. In the event that acceleration of vesting of outstanding equity awards is to be reduced, such acceleration of vesting shall be undertaken in the reverse order of the date of grant of Executive&#8217;s outstanding equity awards. All calculations and determinations made pursuant this Section 23 will be made by an independent accounting or consulting firm or independent tax counsel appointed by the Company (the &#8220;Tax Counsel&#8221;) whose determinations shall be conclusive and binding on the Company and Executive for all purposes. For purposes of making the calculations and determinations required by this Section 23, the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G of the Code and Section 4999 of the Code. The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification&#59; Insurance.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall be entitled to liability and expense indemnification and reimbursement to the fullest extent permitted by the Company&#8217;s current Amended and Restated By-laws and Second Amended and Restated Certificate of Incorporation, as in effect from time to time. During the Term, the Company will use commercially reasonable efforts to maintain in effect directors&#8217; and officers&#8217; liability insurance no less favorable to Executive than that in effect as of the date of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.25pt">Survival.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sections 8 through 25 shall survive termination of this Agreement for the period and to the extent specified therein.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id4ce0b24a69d467186f1053bc7577247_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed or caused to be executed under seal this Agreement as of the date first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOVAVAX, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SEAL&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John A. Herrmann III</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John A. Herrmann III</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President &#38; Chief Legal Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTIVE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John C. Jacobs</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John C. Jacobs</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>4
<FILENAME>nvax-20221231xex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i52540ea0d17f405188ff18740822ed42_1"></div><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.20</font></div><div><font><br></font></div></div><div style="margin-top:8.45pt;padding-left:100.82pt;padding-right:100.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTING AND ADVISORY AGREEMENT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This CONSULTING AND ADVISORY AGREEMENT (this &#8220;Agreement&#8221;) is entered into as of January 5, 2023 by and between Novavax, Inc., a Delaware corporation having its principal office at 21 Firstfield Road, Gaithersburg, MD 20878 (&#8220;Novavax&#8221; or the &#8220;Company&#8221;), and Stanley C. Erck, an individual (&#8220;Executive&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:10.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive is retiring from his employment with the Company as its Chief Executive Officer (&#8220;Retirement&#8221;) effective as of January 23, 2023 (the &#8220;Effective Date&#8221;)&#59;</font></div><div style="margin-top:11.9pt;padding-left:5.95pt;padding-right:10.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive has agreed to act as an advisor to the Company following his Retirement&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:10.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company and Executive desire to enter into this Agreement setting forth the terms of Executive&#8217;s consulting and advisory relationship with the Company and certain other matters relating to his transition to an advisor role.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereto agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:10.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.05pt">Consulting Services. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees to advise the Company&#8217;s Chief Executive Officer and the Board of Directors of the Company (the &#8220;Board of Directors&#8221;) regarding certain transition-related matters, including with respect to the Company&#8217;s management and key partnerships, as well as to provide certain other consulting and advisory services to the Company&#8217;s Chief Executive Officer and the Board of Directors relating to the Company&#8217;s business as reasonably requested by the Company&#8217;s Chief Executive Officer or the Board of Directors from time to time (collectively, the &#8220;Services&#8221;). The term of this Agreement will commence on the Effective Date and end on April 30, 2024, unless earlier terminated as provided herein (the &#8220;Consulting Period&#8221;). Executive agrees to devote that amount of time as is reasonably required by the Company for him to perform the Services, taking into account his other business obligations as in effect from time to time&#59; it being understood that the current expectation is that Executive will generally provide services on average at the level of two (2) days per week for the first six (6) months of the Consulting Period and thereafter for one (1) day per week. Executive acknowledges and agrees that the current expectation is that, once a month for the first three (3) months of the Consulting Period, he will travel internationally on behalf of the Company and thereafter the expectation is that he will make such a trip once per quarter.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Independent Contractor. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#8217;s relationship with the Company will be that of an independent contractor and not that of an employee. Executive will be solely responsible for determining the method, details and means of performing the Services. Executive will have no authority to enter into contracts that bind the Company or create obligations on the part of the Company without the prior written authorization of the Company. Executive acknowledges and agrees that he will not be eligible for any benefits available to employees of the Company. All of the Services to be performed by Executive will be as agreed between Executive and the Board of Directors and&#47;or the Company&#8217;s Chief Executive Officer, and Executive will be required to report only to the Board of Directors concerning the Services performed under this Agreement. The nature and frequency of these reports will be left to the discretion of the Board of Directors and&#47;or the Chief Executive Officer. Executive will have full responsibility for applicable withholding taxes for all compensation paid to Executive under this Agreement and will have full responsibility for compliance with all applicable labor and employment requirements with respect to Executive&#8217;s self-employment. Executive agrees to indemnify, defend and hold the Company harmless from any liability for, or assessment of, any claims or penalties with respect to such withholding taxes, labor or employment requirements, including any liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to Executive in his capacity as a non-employee of the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:78pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Compensation and Other Benefits.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt">Consulting Fee. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As compensation for the Services provided hereunder, during the Consulting Period, the Company will pay to Executive a consulting fee (the &#8220;Consulting Fee&#8221;) of (i) $50,000 per month for the first six (6) months of the Consulting Period beginning on the Effective Date and (ii) $25,000 per month for the remaining nine (9) months of the Consulting Period. The Consulting Fee will be paid to Executive on the first business day of each month during the Consulting Period, in arrears, and will be pro-rated for partial service.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.07pt">Office Space, etc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Consulting Period, the Company will provide Executive with reasonable levels of administrative support and office access to support his provision of the Services hereunder.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt">Equity Awards. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is a schedule of all outstanding stock options previously granted (and not yet exercised) to Executive by the Company as of the Effective Date (the &#8220;Stock Options&#8221;), all outstanding stock appreciation rights previously granted (and not yet exercised) to Executive by the Company as of the Effective Date (the &#8220;SARs&#8221;) and all outstanding and unvested restricted stock unit awards previously granted to Executive by the Company as of the Effective Date (the &#8220;RSUs&#8221;, and together with the Stock Options and the SARs, the &#8220;Equity Awards&#8221;). The Equity Awards will remain outstanding and each of the Equity Awards that is unvested as of the Effective Date will continue to vest during the Consulting Period, in each case, except as modified herein, in accordance with the terms of the applicable equity plan and the equity award agreement between Executive and the Company (&#8220;Equity Documents&#8221;) and subject to the provisions of this Agreement. With respect to any Stock Options and SARs that remain outstanding and unexercised as of the last day of the Consulting Period, such Stock Options and SARs shall remain exercisable by Executive until the earlier of (i) the one-year period following the last day of the Consulting Period and (ii) the stated expiration date of such Stock Options or SARs.  In the event of a Change in Control during the Consulting Period, as defined in the Company&#8217;s Amended and Restated Change in Control Severance Benefit Plan (the &#8220;Change in Control Severance Benefit Plan&#8221;), Executive shall be entitled to accelerated vesting of 100% of all outstanding Equity Awards.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:6pt;padding-right:15.3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.02pt">Reimbursable Expenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall be entitled to reimbursement for reasonable expenses incurred by him in connection with the performance of the Services in accordance with the applicable policies and procedures of the Company as in effect from time to time. The Company shall also reimburse Executive for reasonable attorneys&#8217; fees actually incurred in connection with the review, revision and negotiation of this Agreement.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i52540ea0d17f405188ff18740822ed42_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5.95pt;padding-right:10.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.05pt">Termination. </font></div><div style="margin-top:3.9pt;padding-left:6pt;padding-right:10.75pt;text-align:justify;text-indent:75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.7pt">The Company may terminate this Agreement without Cause, and Executive may voluntarily terminate this Agreement without Good Reason, in each case prior to the expiration of the Consulting Period, upon giving thirty (30) days&#8217; advance written notice of such termination to the other party.  </font></div><div style="margin-top:3.9pt;padding-left:6pt;padding-right:10.75pt;text-align:justify;text-indent:75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt">The Company may terminate this Agreement for Cause, and Executive may terminate this Agreement with Good Reason, in each case prior to the expiration of the Consulting Period, solely under the circumstances set forth below.</font></div><div style="margin-top:3.9pt;padding-left:4.5pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;Cause&#8221; shall be limited to Executive&#8217;s willful refusal or failure to perform his material obligations hereunder (other than due to illness, death or disability) that is not cured within thirty (30) days of Executive&#8217;s receipt of written notice from the Company containing reasonable specificity of such refusal or failure and a statement of corrective actions.</font></div><div style="margin-top:3.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;Good Reason&#8221; shall be limited to the Company&#8217;s material breach of this Agreement that is not cured within thirty (30) days of the Company&#8217;s receipt of written notice from Executive identifying such breach with reasonable specificity.   </font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:78pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Effect of Termination</font></div><div style="margin-top:4.5pt;padding-left:6pt;text-align:justify;text-indent:70.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">If this Agreement is terminated by the Company for Cause or by Executive voluntarily without Good Reason, in each case prior to the expiration of the Consulting Period, the Company&#8217;s only obligation under this Agreement will be to pay Executive any earned but unpaid Consulting Fee as of the termination date.  Executive&#8217;s Equity Awards shall be treated as provided in the Equity Documents (without giving effect to any modifications hereunder).</font></div><div style="margin-top:4.5pt;padding-left:6pt;text-align:justify;text-indent:70.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">If this Agreement is terminated for any reason other than those set forth in Section 5(a) above prior to the expiration of the Consulting Period, the Company shall continue to pay the Consulting Fee through April 30, 2024, on the same schedule as provided in Section 3(a) above, and the  Equity Awards shall continue to vest and be subject to the same post-termination exercise periods and other terms as if Executive had remained providing the Services through April 30, 2024 as set forth in Section 3(c) above. </font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:78pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Restrictive Covenants.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt">Continuing Obligations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive acknowledges and agrees that he remains bound by his obligations under the Employment Agreement between the Company and Executive dated April 19, 2011, as amended (the &#8220;Employment Agreement&#8221;), which survive the termination of his employment by the terms thereof, including without limitation his obligations under Sections 9-12 of the Employment Agreement (such obligations, hereinafter referred to as the &#8220;Continuing Obligations&#8221;).  Notwithstanding the foregoing, nothing in this Agreement or the Employment Agreement shall prevent or preclude Executive from engaging in or pursuing business or other commercial activities that do not violate the terms of the Continuing Obligations. </font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.07pt">Confidentiality. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive hereby reaffirms and agrees to comply with the policies and procedures of the Company and its affiliates for protecting Confidential Information (as defined in the Employment Agreement) and will never disclose to any person (except as required by applicable law or for the proper performance of his duties and responsibilities to the Company and its affiliates), or use for his own benefit or gain, any Confidential Information obtained by Executive incident to his employment or other association with the Company or any of its affiliates. Executive understands that this restriction will continue to apply after the termination of this Agreement, regardless of the reason for such termination. For the avoidance of doubt, (i) nothing contained in this Agreement limits, restricts or in any other way affects Executive&#8217;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity and (ii) Executive will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (y) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (z) in a complaint or </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other document filed under seal in a lawsuit or other proceeding&#59; provided, however, that notwithstanding this immunity from liability, Executive may be held liable if he unlawfully accesses trade secrets by unauthorized means.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt">Non-Compete and Non-Solicit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the generality of subsection (a) above, Executive acknowledges and agrees that he continues to be bound by each of his undertakings under Sections 11 and 12 of the Employment Agreement, with the post-employment portion of the Non-Competition Period, as defined in the Employment Agreement, commencing on the Effective Date.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:10.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.07pt">Remedies&#59; Enforceability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Executive commits a breach, or threatens to commit a breach, of any of the provisions of this Section 6, the Company shall have the right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages may not provide an adequate remedy to the Company. Executive therefore agrees that the Company, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by Executive of any of the provisions of this Section 6, without having to post bond. If any of the covenants contained in this Section 6, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions. If any of the covenants contained in this Section 6, or any part thereof, is held to be unenforceable because of the duration or scope of such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to reduce the duration and&#47;or area of such provision and, in its reduced form, such provision shall then be enforceable. In the event that the courts of any one or more of such states shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other states within the geographical scope of such other covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.7pt">Securities Trading</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive further agrees that he will not buy, sell or otherwise trade any securities of Novavax based on any material Confidential Information learned as a consultant of Novavax, or tip others to do so. If Executive is ever unsure about Executive&#8217;s compliance with this Section 6(e), Executive shall contact the Company&#8217;s Executive Vice President, General Counsel and Corporate Secretary.  </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Section 409A of the Code. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is intended to comply with, or be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and shall be construed consistent with such intent. To the extent required to comply with Section 409A of the Code, as it relates to Section 3(c) of this Agreement, a Change in Control shall also be required to meet the requirements under Section 409A of the Code. Notwithstanding the foregoing, in no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code. Executive&#8217;s right to payment or reimbursement for expenses under this Agreement will be subject to the following additional rules&#58; (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made promptly, and in all events not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Miscellaneous.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.7pt">No Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive acknowledges and agrees that except as expressly provided in this Agreement, he is not eligible for any severance benefits in connection with or </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following his Retirement, including but not limited to under the Change in Control Severance Benefit Plan. For the avoidance of doubt, however, nothing in this Agreement shall impact Executive&#8217;s right to his 2022 annual bonus under the Employment Agreement, and Executive shall be entitled to payment of such annual bonus at the same time that bonuses are paid to the Company&#8217;s executive officers, with the amount of such incentive compensation determined by applying the same corporate funding factor as is applicable to the Company&#8217;s executive officers for 2022.</font></div><div><font><br></font></div><div style="margin-top:3.9pt;padding-left:6pt;padding-right:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.02pt">Entire Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement constitutes the sole agreement of the parties and supersedes all oral negotiations and prior writings with respect to the subject matter hereof&#59; it being understood that the Continuing Obligations and the plans and agreements governing the Equity Awards will remain outstanding and will survive in accordance with their terms.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:10.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.7pt">Amendments and Waivers. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any term of this Agreement may be amended or waived only with the written consent of the parties.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.02pt">Choice of Law, Attorneys&#8217; Fees. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, interpretation, construction and performance of this Agreement will be governed by the laws of the State of Maryland, without giving effect to the principles of conflict of laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.7pt">Severability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If one or more provisions of this Agreement are held to be unenforceable under applicable law, such portion will be deemed to be modified or altered to the extent necessary to conform thereto or, if that is not possible, to be omitted from this Agreement. The invalidity of any such portion will not affect the force, effect, and validity of the remaining portion hereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:10.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:10.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.02pt">Successors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is personal to Executive and, without the prior written consent of the Company, will not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement will inure to the benefit of and be enforceable by Executive&#8217;s legal representatives. This Agreement will inure to the benefit of and be binding upon the Company and its successors and assigns. As used in this Agreement, &#8220;the Company&#8221; will mean both the Company as defined above and any such successor assign to or of the Company.  The Company shall require that any successor or assign agree to perform this Agreement in the same manner as the Company. </font></div><div style="margin-top:4.5pt;padding-right:10.7pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.02pt">No Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither the Company nor Executive shall directly or indirectly cause or permit any use of the other party&#8217;s name or trademarks, without the other party&#8217;s prior written consent, save and except as such disclosure is required by law or any securities exchange or governmental body to which either party is subject or submits, wherever situated, including (without limitation) the Securities and Exchange Commission, The NASDAQ OMX Group, or the Food and Drug Administration whether or not the requirement has the force of law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:10.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.69pt">Sunshine Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the Company and Executive acknowledge that certain state or federal laws now or in the future may require Novavax to disclose information regarding compensation, funding, gifts, payments or other remuneration (&#8220;Remuneration&#8221;) provided to physicians and other members of the health care community. Novavax may report information about Remuneration provided under this Agreement as required by applicable law. Once reported, such information will be publicly accessible.</font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="margin-top:3.9pt;padding-left:5.95pt;padding-right:20.3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.74pt">Advice of Counsel. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EACH PARTY ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5.95pt;padding-right:20.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.85pt;padding-left:150.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of page intentionally left blank.&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:6pt;padding-right:15.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement has been executed as a sealed instrument by the Company, by its duly authorized representative, and by Executive.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.85pt;padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOVAVAX, INC.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John A. Herrmann III&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; John A. Herrmann III</font></div><div style="margin-top:4.5pt;padding-left:288pt;text-indent:-30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Executive Vice President &#38; Chief Legal Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">STANLEY C. ERCK</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Stanley C. Erck&#160;&#160;&#160;&#160;</font></div><div style="padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8.55pt;padding-left:100.9pt;padding-right:100.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:100.95pt;padding-right:100.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule of Executive Equity Awards as of Effective Date</font></div><div style="margin-top:0.05pt"><img alt="image_01.jpg" src="image_01.jpg" style="height:468px;margin-bottom:5pt;vertical-align:text-bottom;width:493px"></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.56
<SEQUENCE>5
<FILENAME>nvax-20221231xex1056.htm
<DESCRIPTION>EX-10.56
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6011b0f4cc6242e5aca0d32851092630_1"></div><div style="min-height:113.04pt;width:100%"><div style="padding-right:59.5pt;text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.56</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="text-align:center"><font><br></font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:736px"></div><div style="margin-top:5.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">November 30, 2022</font></div><div style="margin-top:5.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novavax, Inc.</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21 Firstfield Road</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gaithersburg, MD 20878</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:3pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;&#160;&#160;&#160;&#160;&#91;***&#93;, Senior Vice President</font></div><div style="padding-left:5pt;padding-right:3pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject&#58;&#160;&#160;&#160;&#160;Modification No. 03</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:297.6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%">Reference&#58;&#160;&#160;&#160;&#160;MCDC Base Agreement No. 2020-530</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:297.6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%">Dear &#91;***&#93;&#58;</font></div><div style="padding-left:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 03 hereby amends the Base Agreement as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:200pt;padding-right:200pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF MODIFICATION</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1) Article XXI, General Provisions, Section 21.15, Follow-On Production, of the MCDC Base Agreement is hereby amended to read as indicated in bold italics below&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:23pt;text-align:justify"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 21.15 Follow-On Production</font></div><div><font><br></font></div><div style="padding-left:23pt;padding-right:6.65pt;text-align:justify"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10 U.S.C. &#167; 4022(f) authorizes the use of a follow-on production contract (FAR) or transaction (OTA). In order to be eligible for follow-on production, the following criteria is required&#58; (1) the follow-on shall be awarded to the same participants named in the PA&#59; (2) competitive procedures were used to award the PA in question&#59; and (3) the PA was successfully completed. This MCDC Base Agreement was the result of competitive procedures, and competitive procedures are used to award individual projects under this MCDC Base Agreement. The AO shall be responsible for documenting whether or not a PA was successfully completed. Follow-on production efforts shall be strictly limited to the scope of the successfully completed prototype. This MCDC Base Agreement will not be used to award follow-on production efforts&#59; Government customers will be responsible for working with their contracting personnel.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:23pt;padding-right:6.95pt;text-align:justify"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Furthermore, successful completion can occur prior to the conclusion of a prototype project, in order to allow the Government to transition any aspects of the prototype project determined to provide utility, into production, while other aspects of the prototype project have yet to be completed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:23pt;text-align:justify"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All PAs shall include the following statement&#58;</font></div><div><font><br></font></div><div style="padding-left:23pt;padding-right:6.7pt;text-align:justify"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;In accordance with 10 U.S.C. &#167; 4022(f), and upon a determination that this competitively awarded prototype project has been successfully completed, this prototype project may result in the award of a follow-on production contract or transaction without the use of competitive procedures.&#34;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6011b0f4cc6242e5aca0d32851092630_4"></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-top:4.2pt;padding-left:5pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as provided herein, all Terms and Conditions of the referenced MCDC Base Agreement and preceding modifications remain unchanged and in full force and effect.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:21.5pt;text-align:justify"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%">This modification is issued unilaterally. The Project Agreement Holder is not required to sign to finalize this action. Advanced Technology International</font></div><div style="padding-left:5pt;padding-right:328.3pt;text-align:justify"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%">By&#58;&#91;</font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%;text-decoration:underline">***&#93;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%"> Name&#58;&#91;</font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%;text-decoration:underline">***&#93;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%"> Title&#58; </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%;text-decoration:underline">Subcontracts Administrator II&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%"> Date&#58; </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:232%;text-decoration:underline">Nov 30 2022&#160;&#160;&#160;&#160;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>6
<FILENAME>nvax-20221231xex21.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibe9b557f03c74a4b9a80eb4ea8e373bb_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">LIST OF SUBSIDIARIES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> The following is a list of subsidiaries of the Company as of December 31, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Name of Subsidiary&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Jurisdiction of Incorporation or Organization</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Novavax AB&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sweden</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Novavax CZ (formerly Praha Vaccines a.s.)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;              The Czech Republic</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Novavax NL B.V.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Netherlands</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Novavax CH GmbH&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Switzerland</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>nvax-20221231xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic8484764b8b84f2b8d6eb185181f38cc_1"></div><div style="min-height:82.8pt;width:100%"><div style="text-align:right"><img alt="image_02.jpg" src="image_02.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:56px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                                                                                                                               Exhibit 23.1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.535%"><tr><td style="width:1.0%"></td><td style="width:37.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.867%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No.333-269309) pertaining to the Novavax, Inc. 2023 inducement plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-266681) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-258517) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-243758) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-3 No. 333-237094) pertaining to Novavax, Inc. common stock, preferred stock, warrants and units,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-233133) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-226498) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-219829) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-213069) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-206354) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-198121) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-190600) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-190599) pertaining to the Novavax, Inc. 2013 employee stock purchase plan, </font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-183113) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-145298) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(16)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-130990) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(17)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-110401) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(18)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-97931) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(19)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-46000) pertaining to the Novavax, Inc. stock incentive plan, </font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(20)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-77611) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(21)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-03384) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(22)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 33-80279) pertaining to the Novavax, Inc. stock incentive plan, and</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(23)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 33-80277) pertaining to the Novavax, Inc. stock incentive plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of our reports dated February 28, 2023, with respect to the consolidated financial statements of Novavax, Inc., and the effectiveness of internal control over financial reporting of Novavax, Inc., included in this Annual Report (Form 10-K) of Novavax, Inc. for the year ended December 31, 2022.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div style="text-align:right"><img alt="image_02.jpg" src="image_02.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:56px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                                                                                                                               Exhibit 23.1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.535%"><tr><td style="width:1.0%"></td><td style="width:37.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.867%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tysons, Virginia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 28, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>nvax-20221231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i738e895af9e94f3d8088d026aa6f8351_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, John C. Jacobs, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">I have reviewed this Annual Report on Form 10-K of Novavax, Inc.&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2023&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John C. Jacobs</font></div><div style="padding-left:234pt;text-indent:-234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;John C. Jacobs</font></div><div style="padding-left:234pt;text-indent:-234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>nvax-20221231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id636c32a047943f583b59eab00fa4c50_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 31.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, James P. Kelly, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">I have reviewed this Annual Report on Form 10-K of Novavax, Inc.&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2023&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; James P. Kelly</font></div><div style="padding-left:229.5pt;text-indent:-229.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;James P. Kelly</font></div><div style="padding-left:229.5pt;text-indent:-229.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Executive Vice President, Chief Financial Officer and Treasurer</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>nvax-20221231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6692da2959254be78bbc81fd1de1867c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO 18 UNITED STATES CODE &#167;1350<br>(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with the Annual Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John C. Jacobs, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2023&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; John C. Jacobs</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;John C. Jacobs</font></div><div style="padding-left:261pt;text-indent:-261pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>nvax-20221231xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i38d33e232da6422db7a7bd144da4d84a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 UNITED STATES CODE &#167;1350<br>(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with the Annual Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James P. Kelly, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2023&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James P. Kelly</font></div><div style="padding-left:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James P. Kelly</font></div><div style="padding-left:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer and Treasurer</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>nvax-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2e968d4d-f5d4-46a7-9a1c-6f56d63ea7b7,g:07ea8c72-99d3-4c76-b42c-1d6d27635d74-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvax="http://www.novavax.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novavax.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.novavax.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.novavax.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.novavax.com/role/Organization">
        <link:definition>0000010 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.novavax.com/role/Revenue">
        <link:definition>0000012 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.novavax.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000013 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>0000014 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.novavax.com/role/FairValueMeasurements">
        <link:definition>0000015 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.novavax.com/role/Inventory">
        <link:definition>0000016 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.novavax.com/role/Goodwill">
        <link:definition>0000017 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofNovavaxCZ" roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZ">
        <link:definition>0000018 - Disclosure - Acquisition of Novavax CZ</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.novavax.com/role/Leases">
        <link:definition>0000019 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.novavax.com/role/LongTermDebt">
        <link:definition>0000020 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStock" roleURI="http://www.novavax.com/role/PreferredStock">
        <link:definition>0000021 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.novavax.com/role/StockholdersEquity">
        <link:definition>0000022 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.novavax.com/role/StockBasedCompensation">
        <link:definition>0000023 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://www.novavax.com/role/EmployeeBenefits">
        <link:definition>0000024 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.novavax.com/role/OtherFinancialInformation">
        <link:definition>0000025 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.novavax.com/role/IncomeTaxes">
        <link:definition>0000026 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.novavax.com/role/CommitmentandContingencies">
        <link:definition>0000027 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.novavax.com/role/SubsequentEvents">
        <link:definition>0000028 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.novavax.com/role/RevenueTables">
        <link:definition>0000031 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>0000032 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.novavax.com/role/FairValueMeasurementsTables">
        <link:definition>0000033 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.novavax.com/role/InventoryTables">
        <link:definition>0000034 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.novavax.com/role/GoodwillTables">
        <link:definition>0000035 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofNovavaxCZTables" roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZTables">
        <link:definition>0000036 - Disclosure - Acquisition of Novavax CZ (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.novavax.com/role/LeasesTables">
        <link:definition>0000037 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.novavax.com/role/LongTermDebtTables">
        <link:definition>0000038 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.novavax.com/role/StockBasedCompensationTables">
        <link:definition>0000039 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.novavax.com/role/OtherFinancialInformationTables">
        <link:definition>0000040 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.novavax.com/role/IncomeTaxesTables">
        <link:definition>0000041 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000042 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails">
        <link:definition>0000043 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>0000044 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails" roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails">
        <link:definition>0000045 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails_1" roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1">
        <link:definition>0000045 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" roleURI="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails">
        <link:definition>0000046 - Disclosure - Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofProductRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails">
        <link:definition>0000047 - Disclosure - Revenue - Schedule of Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofGrantRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails">
        <link:definition>0000048 - Disclosure - Revenue - Schedule of Grant Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>0000049 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000050 - Disclosure - Cash, Cash Equivalents, and Restricted Cash - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails">
        <link:definition>0000051 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryDetails" roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryDetails">
        <link:definition>0000052 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryAdditionalInformationDetails" roleURI="http://www.novavax.com/role/InventoryAdditionalInformationDetails">
        <link:definition>0000053 - Disclosure - Inventory - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryReservesDetails" roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails">
        <link:definition>0000054 - Disclosure - Inventory - Schedule of Inventory Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.novavax.com/role/GoodwillDetails">
        <link:definition>0000055 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000056 - Disclosure - Acquisition of Novavax CZ - Schedule of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofNovavaxCZAdditionalInformationDetails" roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails">
        <link:definition>0000057 - Disclosure - Acquisition of Novavax CZ - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails" roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails">
        <link:definition>0000058 - Disclosure - Acquisition of Novavax CZ - Schedule of Business Acquisition, Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.novavax.com/role/LeasesAdditionalInformationDetails">
        <link:definition>0000059 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails">
        <link:definition>0000060 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseExpensesDetails" roleURI="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails">
        <link:definition>0000061 - Disclosure - Leases - Schedule of Operating Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails" roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails">
        <link:definition>0000062 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000063 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000063 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofNotesPayableDetails" roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails">
        <link:definition>0000064 - Disclosure - Long-Term Debt - Schedule of Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofInterestExpenseDetails" roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails">
        <link:definition>0000065 - Disclosure - Long-Term Debt - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>0000066 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStockDetails" roleURI="http://www.novavax.com/role/PreferredStockDetails">
        <link:definition>0000067 - Disclosure - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.novavax.com/role/StockholdersEquityDetails">
        <link:definition>0000068 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>0000069 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>0000070 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails">
        <link:definition>0000071 - Disclosure - Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails">
        <link:definition>0000072 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails">
        <link:definition>0000073 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsDetails" roleURI="http://www.novavax.com/role/EmployeeBenefitsDetails">
        <link:definition>0000074 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>0000075 - Disclosure - Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails">
        <link:definition>0000076 - Disclosure - Other Financial Information - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAdditionalInformationDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails">
        <link:definition>0000077 - Disclosure - Other Financial Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedExpensesDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails">
        <link:definition>0000078 - Disclosure - Other Financial Information - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationOtherCurrentLiabilitiesDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails">
        <link:definition>0000079 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails">
        <link:definition>0000080 - Disclosure - Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails">
        <link:definition>0000081 - Disclosure - Income Taxes - Schedule of Components of Current Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000082 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofTaxRateDifferencesDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails">
        <link:definition>0000083 - Disclosure - Income Taxes - Schedule of Tax Rate Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000084 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails">
        <link:definition>0000085 - Disclosure - Income Taxes - Schedule of Unrecognized Tac Benefits Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails">
        <link:definition>0000086 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.novavax.com/role/SubsequentEventsDetails">
        <link:definition>0000087 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nvax_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nvax_SKBioscienceCoLtdMember" abstract="true" name="SKBioscienceCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" abstract="true" name="JointCommitteeOnVaccinationAndImmunizationJCVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_InventoryReserveRollForward" abstract="true" name="InventoryReserveRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_LossContingencyPeriodToAnswer" abstract="false" name="LossContingencyPeriodToAnswer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_ProceedsFromIssuanceCommonStockAndDebt" abstract="false" name="ProceedsFromIssuanceCommonStockAndDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" abstract="false" name="ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_GrantsUSGovernmentContractAndJointVentureAbstract" abstract="true" name="GrantsUSGovernmentContractAndJointVentureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_OtherGrantRevenueMember" abstract="true" name="OtherGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DeferredRevenueIncreaseDecreaseAbstract" abstract="true" name="DeferredRevenueIncreaseDecreaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_USGovernmentMember" abstract="true" name="USGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" abstract="false" name="NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" abstract="false" name="ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" abstract="false" name="StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" abstract="true" name="CashFlowOperatingAndFinancingActivitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_RevenueFromContractWithCustomerCommitment" abstract="false" name="RevenueFromContractWithCustomerCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_InventoryReserveOtherAdditions" abstract="false" name="InventoryReserveOtherAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_EuropeanCommissionsECMember" abstract="true" name="EuropeanCommissionsECMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" abstract="false" name="AccountsReceivableBeforeAllowanceForCreditLossAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AmendedAndRestatedUKSupplyAgreementMember" abstract="true" name="AmendedAndRestatedUKSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" abstract="false" name="ProceedsFromIssuanceOrSaleOfEquityNotSettled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_June2021SalesAgreementMember" abstract="true" name="June2021SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" abstract="false" name="OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" abstract="true" name="ThreePointSeventyFiveConvertibleNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_FacilityLeaseAgreementMember" abstract="true" name="FacilityLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ConvertibleDebtConversionRate" abstract="false" name="ConvertibleDebtConversionRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nvax_SalesBasedRoyaltiesMember" abstract="true" name="SalesBasedRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_USGovernmentAgreementMember" abstract="true" name="USGovernmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" abstract="false" name="EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_DeferredTaxAssetLeasingLiability" abstract="false" name="DeferredTaxAssetLeasingLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FirstThreePercentOfParticipantsDeferralMemberMember" abstract="true" name="FirstThreePercentOfParticipantsDeferralMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_OperatingAndFinanceLeaseWriteOff" abstract="false" name="OperatingAndFinanceLeaseWriteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ConvertibleNotesPayableCurrentAbstract" abstract="true" name="ConvertibleNotesPayableCurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_FivePointZeroConvertibleNotesDue2027Member" abstract="true" name="FivePointZeroConvertibleNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_DeferredTaxAssetsOriginalDiscountInterest" abstract="false" name="DeferredTaxAssetsOriginalDiscountInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_TakedaArrangementMember" abstract="true" name="TakedaArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_GovernmentOfAustraliaMember" abstract="true" name="GovernmentOfAustraliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfDosesCancelled" abstract="false" name="PurchaseAgreementNumberOfDosesCancelled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_SettlementPayment" abstract="false" name="SettlementPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DebtCapPrice" abstract="false" name="DebtCapPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nvax_PercentageOfMarketPriceForStockPurchase" abstract="false" name="PercentageOfMarketPriceForStockPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" abstract="false" name="DebtInstrumentRepurchaseOfPrincipalAmountPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_GaviVaccineAllianceMember" abstract="true" name="GaviVaccineAllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_RestOfTheWorldMember" abstract="true" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_RoyaltiesAndOtherMember" abstract="true" name="RoyaltiesAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" abstract="false" name="AccountsReceivableBeforeAllowanceForCreditLossDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_SettlementAgreementQuarterlyInstallmentAmount" abstract="false" name="SettlementAgreementQuarterlyInstallmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod" abstract="false" name="RevenueRemainingPerformanceObligationCustomerStatusPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_CMOAndCMDAgreementsMember" abstract="true" name="CMOAndCMDAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ConvertibleNotesPayableNoncurrentAbstract" abstract="true" name="ConvertibleNotesPayableNoncurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_CollaborationAgreementUpfrontPaymentAmount" abstract="false" name="CollaborationAgreementUpfrontPaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DebtInstrumentFaceAmountCurrent" abstract="false" name="DebtInstrumentFaceAmountCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_UnderwriterMember" abstract="true" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_AccountsReceivableAllowanceForCreditLossAdditions" abstract="false" name="AccountsReceivableAllowanceForCreditLossAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_NextTwoPercentOfParticipantsDeferralMemberMember" abstract="true" name="NextTwoPercentOfParticipantsDeferralMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentAccruals" abstract="false" name="ResearchAndDevelopmentAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_GovernmentOfCanadaMember" abstract="true" name="GovernmentOfCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_GovernmentOfIsraelMember" abstract="true" name="GovernmentOfIsraelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_InventoryReserveChargedToCostsOfSales" abstract="false" name="InventoryReserveChargedToCostsOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_TwoThousandFiveStockIncentivePlanMember" abstract="true" name="TwoThousandFiveStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_USDepartmentOfDefenseDoDContractMember" abstract="true" name="USDepartmentOfDefenseDoDContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SubjectToExpirationMember" abstract="true" name="SubjectToExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" abstract="false" name="NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_ScheduleOfInventoryReserveTableTextBlock" abstract="false" name="ScheduleOfInventoryReserveTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NumberOfQuarterlyInstallmentPayments" abstract="false" name="NumberOfQuarterlyInstallmentPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_SKBioscienceAgreementMember" abstract="true" name="SKBioscienceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NumberOfDosesOfVaccineCandidate" abstract="false" name="NumberOfDosesOfVaccineCandidate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_AccountsReceivableAllowanceForCreditLossDeductions" abstract="false" name="AccountsReceivableAllowanceForCreditLossDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ProvisionForExcessAndObsoleteInventory" abstract="false" name="ProvisionForExcessAndObsoleteInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FacilityNumberOfSquareFeet" abstract="false" name="FacilityNumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="nvax_NumberOfDosesToBeDistributed" abstract="false" name="NumberOfDosesToBeDistributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" abstract="false" name="RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DoDContractMember" abstract="true" name="DoDContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_TwoThousandFifteenStockIncentivePlanMember" abstract="true" name="TwoThousandFifteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_GaviAdvancePurchaseAgreementSIIPLMember" abstract="true" name="GaviAdvancePurchaseAgreementSIIPLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" abstract="false" name="RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" abstract="false" name="AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_CollaborativeArrangementAbstract" abstract="true" name="CollaborativeArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ShelfRegistrationStatementRemainingUnissuedCapital" abstract="false" name="ShelfRegistrationStatementRemainingUnissuedCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" abstract="true" name="FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NovavaxCZFormerlyPrahaVaccinesASMember" abstract="true" name="NovavaxCZFormerlyPrahaVaccinesASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_LeaseLiabilityNoncurrent" abstract="false" name="LeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_RevenueMember" abstract="true" name="RevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CoalitionForEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ComputerSoftwareAndHardwareMemberMember" abstract="true" name="ComputerSoftwareAndHardwareMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" abstract="true" name="GaviAdvancePurchaseAgreementCOVAXFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" abstract="true" name="AccountsReceivableBeforeAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" abstract="false" name="ShareBasedCompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CEPIGrantFundingMember" abstract="true" name="CEPIGrantFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SettlementAgreementMember" abstract="true" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" abstract="false" name="InterestExpenseRelatedToConvertibleNotesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ConversionPremiumPercentage" abstract="false" name="ConversionPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_MaximumContributionOfEmployeesAsPayrollDeductions" abstract="false" name="MaximumContributionOfEmployeesAsPayrollDeductions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_A700QuinceOrchardRoadAgreementMember" abstract="true" name="A700QuinceOrchardRoadAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_PaymentForCappedCallTransactions" abstract="false" name="PaymentForCappedCallTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_NetProceedsFromTheExerciseOfStockBasedAwards" abstract="false" name="NetProceedsFromTheExerciseOfStockBasedAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_SettlementAgreementInitialReservationFee" abstract="false" name="SettlementAgreementInitialReservationFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_LiquidityAndGoingConcernPolicyTextBlock" abstract="false" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_CompensationStockIssuedUnderIncentiveProgram" abstract="false" name="CompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_EuropeanCommissionMember" abstract="true" name="EuropeanCommissionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfVaccineDoses" abstract="false" name="PurchaseAgreementNumberOfVaccineDoses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>nvax-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2e968d4d-f5d4-46a7-9a1c-6f56d63ea7b7,g:07ea8c72-99d3-4c76-b42c-1d6d27635d74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_193c4284-0994-411e-b953-57064e5fafcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4fd523b7-288c-47be-8553-12a405c56850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_193c4284-0994-411e-b953-57064e5fafcc" xlink:to="loc_us-gaap_InterestExpense_4fd523b7-288c-47be-8553-12a405c56850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f805f351-6abf-440f-b3f7-f6c501022973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_193c4284-0994-411e-b953-57064e5fafcc" xlink:to="loc_us-gaap_OperatingIncomeLoss_f805f351-6abf-440f-b3f7-f6c501022973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1f1e3d09-a0dd-4f6c-b905-5161dbec577b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_193c4284-0994-411e-b953-57064e5fafcc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1f1e3d09-a0dd-4f6c-b905-5161dbec577b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1a3bb549-6f9a-490f-b26b-0197ae3e0e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a6b3f2fd-0d22-429a-ac93-a107659290cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1a3bb549-6f9a-490f-b26b-0197ae3e0e9d" xlink:to="loc_us-gaap_CostOfRevenue_a6b3f2fd-0d22-429a-ac93-a107659290cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_12e12cac-c51b-422b-bf61-eb4ba230169f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1a3bb549-6f9a-490f-b26b-0197ae3e0e9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_12e12cac-c51b-422b-bf61-eb4ba230169f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cd463193-26b4-4a7e-9dec-5d6788f72c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1a3bb549-6f9a-490f-b26b-0197ae3e0e9d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cd463193-26b4-4a7e-9dec-5d6788f72c32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b89a6900-4946-4107-a5bc-ed6b47aae61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0763c219-7ade-453b-a872-494365940726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b89a6900-4946-4107-a5bc-ed6b47aae61c" xlink:to="loc_us-gaap_Revenues_0763c219-7ade-453b-a872-494365940726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_18ac6681-0c59-4fdd-b519-ebcc4e1141a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b89a6900-4946-4107-a5bc-ed6b47aae61c" xlink:to="loc_us-gaap_CostsAndExpenses_18ac6681-0c59-4fdd-b519-ebcc4e1141a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e5c73f1-4823-40e0-be17-37cc4c7c10bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_030e349e-3826-4496-8dcb-5ac09a74d43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e5c73f1-4823-40e0-be17-37cc4c7c10bc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_030e349e-3826-4496-8dcb-5ac09a74d43a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_704746ba-212a-4722-86ff-baaea71a1bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e5c73f1-4823-40e0-be17-37cc4c7c10bc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_704746ba-212a-4722-86ff-baaea71a1bb4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d3fb7024-c940-4155-ad6d-d4b27d49b7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bb85f8d0-94e3-4b51-a2ec-b704e041edc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d3fb7024-c940-4155-ad6d-d4b27d49b7ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bb85f8d0-94e3-4b51-a2ec-b704e041edc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f56b862a-f81a-44ce-ac58-9884cd99154e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d3fb7024-c940-4155-ad6d-d4b27d49b7ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f56b862a-f81a-44ce-ac58-9884cd99154e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe60bff9-f5f2-4f9a-b7fc-39375250e740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_19c62fd0-ecca-46c8-9dae-02fa9e496301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe60bff9-f5f2-4f9a-b7fc-39375250e740" xlink:to="loc_us-gaap_NetIncomeLoss_19c62fd0-ecca-46c8-9dae-02fa9e496301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f06d44cc-e955-449b-9fef-4f44215a8771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe60bff9-f5f2-4f9a-b7fc-39375250e740" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f06d44cc-e955-449b-9fef-4f44215a8771" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8631a08f-bf02-4ee0-ab29-8c72db7b3cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d5f19f-a763-445c-b378-f049903bb589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8631a08f-bf02-4ee0-ab29-8c72db7b3cdb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d5f19f-a763-445c-b378-f049903bb589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4cf97681-774d-4fe0-9c79-6d5bdb689251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8631a08f-bf02-4ee0-ab29-8c72db7b3cdb" xlink:to="loc_us-gaap_InventoryNet_4cf97681-774d-4fe0-9c79-6d5bdb689251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_1c874f09-b8f9-4448-8e62-4009f0fd18d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8631a08f-bf02-4ee0-ab29-8c72db7b3cdb" xlink:to="loc_us-gaap_AccountsReceivableNet_1c874f09-b8f9-4448-8e62-4009f0fd18d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3f2c5d0-df4b-4d8d-880d-0031555a4c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8631a08f-bf02-4ee0-ab29-8c72db7b3cdb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3f2c5d0-df4b-4d8d-880d-0031555a4c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_9d827b58-fb77-4628-b120-9882c8c0d18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8631a08f-bf02-4ee0-ab29-8c72db7b3cdb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_9d827b58-fb77-4628-b120-9882c8c0d18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_40f64aa7-d00f-4d7a-a7ff-536534632fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_66d5dfc0-6d92-474c-a2e8-76b368a48b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40f64aa7-d00f-4d7a-a7ff-536534632fd3" xlink:to="loc_us-gaap_AssetsCurrent_66d5dfc0-6d92-474c-a2e8-76b368a48b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1d128a5d-b331-4839-87f9-799b74b504b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40f64aa7-d00f-4d7a-a7ff-536534632fd3" xlink:to="loc_us-gaap_Goodwill_1d128a5d-b331-4839-87f9-799b74b504b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3df7a0b8-93ce-4692-9c14-0bafe84ed6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40f64aa7-d00f-4d7a-a7ff-536534632fd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3df7a0b8-93ce-4692-9c14-0bafe84ed6fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_941fd92b-0fdb-492f-b26e-90adb54500db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40f64aa7-d00f-4d7a-a7ff-536534632fd3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_941fd92b-0fdb-492f-b26e-90adb54500db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_3c1eb3ef-0bda-4e70-9f84-57b03e420443" xlink:href="nvax-20221231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40f64aa7-d00f-4d7a-a7ff-536534632fd3" xlink:to="loc_nvax_LeaseRightOfUseAsset_3c1eb3ef-0bda-4e70-9f84-57b03e420443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_85b2341c-9fae-4de9-932f-0381f28eac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0994e470-bd8c-4f8d-b3ee-97ec8727ba19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_85b2341c-9fae-4de9-932f-0381f28eac5e" xlink:to="loc_us-gaap_PreferredStockValue_0994e470-bd8c-4f8d-b3ee-97ec8727ba19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bd43cdde-b685-4c5a-aee0-11e0a1d3b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_85b2341c-9fae-4de9-932f-0381f28eac5e" xlink:to="loc_us-gaap_CommonStockValue_bd43cdde-b685-4c5a-aee0-11e0a1d3b68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3a7aa821-e52c-467a-900d-da42428f4c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_85b2341c-9fae-4de9-932f-0381f28eac5e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3a7aa821-e52c-467a-900d-da42428f4c6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4cecfa16-8033-41c5-95bf-95b9a9105149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_85b2341c-9fae-4de9-932f-0381f28eac5e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4cecfa16-8033-41c5-95bf-95b9a9105149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4237d07b-3eee-474e-bf2f-a9d56daeed02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_85b2341c-9fae-4de9-932f-0381f28eac5e" xlink:to="loc_us-gaap_TreasuryStockValue_4237d07b-3eee-474e-bf2f-a9d56daeed02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f219ae63-374a-482d-ac85-af32deb85901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_85b2341c-9fae-4de9-932f-0381f28eac5e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f219ae63-374a-482d-ac85-af32deb85901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e3b610fa-ce37-4e43-b9af-6ac7eac63534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1f0d8144-7fb8-4d62-8848-9eb69ef8f806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e3b610fa-ce37-4e43-b9af-6ac7eac63534" xlink:to="loc_us-gaap_Liabilities_1f0d8144-7fb8-4d62-8848-9eb69ef8f806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_58b671ce-8102-4c88-b32e-16ff08fd8f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e3b610fa-ce37-4e43-b9af-6ac7eac63534" xlink:to="loc_us-gaap_CommitmentsAndContingencies_58b671ce-8102-4c88-b32e-16ff08fd8f74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff75693d-a4b4-43fc-926d-d4f6a2bd5b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e3b610fa-ce37-4e43-b9af-6ac7eac63534" xlink:to="loc_us-gaap_StockholdersEquity_ff75693d-a4b4-43fc-926d-d4f6a2bd5b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ae52dd1c-906a-4ff6-aa5c-0908344caa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2d658dcd-1114-4d11-85c5-e40a6cad9432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ae52dd1c-906a-4ff6-aa5c-0908344caa64" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2d658dcd-1114-4d11-85c5-e40a6cad9432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4fee08f2-3956-4d65-a824-92718588d384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ae52dd1c-906a-4ff6-aa5c-0908344caa64" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4fee08f2-3956-4d65-a824-92718588d384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_725ca20c-bb70-45f2-af90-4cf33df4a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ae52dd1c-906a-4ff6-aa5c-0908344caa64" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_725ca20c-bb70-45f2-af90-4cf33df4a362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3fda515c-2d1d-4a5d-b695-5d80220ad26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ae52dd1c-906a-4ff6-aa5c-0908344caa64" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3fda515c-2d1d-4a5d-b695-5d80220ad26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ad9578a1-20c5-43ee-a08a-174f2490d772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ae52dd1c-906a-4ff6-aa5c-0908344caa64" xlink:to="loc_us-gaap_LiabilitiesCurrent_ad9578a1-20c5-43ee-a08a-174f2490d772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9fa30037-5e95-4dfd-a572-a25aa6f53649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ee35f406-7c52-4a05-a5ec-f9328de2bb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9fa30037-5e95-4dfd-a572-a25aa6f53649" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ee35f406-7c52-4a05-a5ec-f9328de2bb8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_dc3de135-4856-4f0e-817a-2c16647d9e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9fa30037-5e95-4dfd-a572-a25aa6f53649" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_dc3de135-4856-4f0e-817a-2c16647d9e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e1065d80-cd87-4466-81fa-2fa9917baac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9fa30037-5e95-4dfd-a572-a25aa6f53649" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e1065d80-cd87-4466-81fa-2fa9917baac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_1ab6a11f-2de7-452c-96b9-f9cf3af8ef01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9fa30037-5e95-4dfd-a572-a25aa6f53649" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_1ab6a11f-2de7-452c-96b9-f9cf3af8ef01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a52e0073-402a-404e-a90a-82ff7184bc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9fa30037-5e95-4dfd-a572-a25aa6f53649" xlink:to="loc_us-gaap_AccountsPayableCurrent_a52e0073-402a-404e-a90a-82ff7184bc74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4807efef-be12-4398-abcd-618c1f5a640a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9fa30037-5e95-4dfd-a572-a25aa6f53649" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4807efef-be12-4398-abcd-618c1f5a640a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10d7205e-1c34-4e1a-a734-3dfa134b3c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_ebbcac1e-18d3-4dbe-a9ce-d6313fe302e2" xlink:href="nvax-20221231.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10d7205e-1c34-4e1a-a734-3dfa134b3c22" xlink:to="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_ebbcac1e-18d3-4dbe-a9ce-d6313fe302e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_f8f45052-c599-411b-96fc-5b337e91f715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10d7205e-1c34-4e1a-a734-3dfa134b3c22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_f8f45052-c599-411b-96fc-5b337e91f715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bb12895d-92a1-4e04-9a51-95f6e35df66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10d7205e-1c34-4e1a-a734-3dfa134b3c22" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bb12895d-92a1-4e04-9a51-95f6e35df66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0ebdf294-09ab-4069-9f04-1b642d9dbea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10d7205e-1c34-4e1a-a734-3dfa134b3c22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0ebdf294-09ab-4069-9f04-1b642d9dbea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_8652d433-130e-4e2c-abb2-83050c109cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10d7205e-1c34-4e1a-a734-3dfa134b3c22" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_8652d433-130e-4e2c-abb2-83050c109cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_2a36f0f8-2585-4f8b-b6f9-2f65b20359f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10d7205e-1c34-4e1a-a734-3dfa134b3c22" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_2a36f0f8-2585-4f8b-b6f9-2f65b20359f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f8e6cef-770e-4de7-a981-01da83590bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8932126f-159c-4bff-8060-3296df2cd8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f8e6cef-770e-4de7-a981-01da83590bf1" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8932126f-159c-4bff-8060-3296df2cd8f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ee8f55ea-9540-4e4c-b192-21abce8d4686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f8e6cef-770e-4de7-a981-01da83590bf1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ee8f55ea-9540-4e4c-b192-21abce8d4686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_4e7669c6-8951-4066-a09e-4957641a26b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f8e6cef-770e-4de7-a981-01da83590bf1" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_4e7669c6-8951-4066-a09e-4957641a26b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e3cc5238-e210-4642-8036-4b5ebe1fa51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f8e6cef-770e-4de7-a981-01da83590bf1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e3cc5238-e210-4642-8036-4b5ebe1fa51a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_828094fc-6210-4c24-bd9a-71e667fc3635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f8e6cef-770e-4de7-a981-01da83590bf1" xlink:to="loc_us-gaap_PaymentsForSoftware_828094fc-6210-4c24-bd9a-71e667fc3635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da3c70e1-02aa-4398-82d2-a82b8f659af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_87ab7fbc-0e55-4b7d-bab5-f03ad504782b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da3c70e1-02aa-4398-82d2-a82b8f659af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_87ab7fbc-0e55-4b7d-bab5-f03ad504782b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7eaf6a5d-150a-4579-8498-5d8d38597218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da3c70e1-02aa-4398-82d2-a82b8f659af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7eaf6a5d-150a-4579-8498-5d8d38597218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bf57500-21dd-492d-9f70-5911f225541f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da3c70e1-02aa-4398-82d2-a82b8f659af7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bf57500-21dd-492d-9f70-5911f225541f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66b6daf7-7b98-487a-b7eb-5ec72f6b3b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da3c70e1-02aa-4398-82d2-a82b8f659af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66b6daf7-7b98-487a-b7eb-5ec72f6b3b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7e81348c-bd16-4985-81ce-43c8846254f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7e81348c-bd16-4985-81ce-43c8846254f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_34586adf-dec9-4dab-84fc-200b4448078a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_34586adf-dec9-4dab-84fc-200b4448078a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e481098e-71d1-405f-828d-37b29b8e7dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_DepreciationAndAmortization_e481098e-71d1-405f-828d-37b29b8e7dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_22bc851e-8634-4bd0-b2db-d5b75a8919dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_ShareBasedCompensation_22bc851e-8634-4bd0-b2db-d5b75a8919dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory_628aabe1-005e-4b4e-abfd-b2a47f217da6" xlink:href="nvax-20221231.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_nvax_ProvisionForExcessAndObsoleteInventory_628aabe1-005e-4b4e-abfd-b2a47f217da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b81c49d7-d97d-40de-b83f-3bf093ad47fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_NetIncomeLoss_b81c49d7-d97d-40de-b83f-3bf093ad47fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d26521f1-a24a-484c-ab7e-30191465e07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d26521f1-a24a-484c-ab7e-30191465e07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff_b17e7535-0680-4053-9441-6b0bf36ae98f" xlink:href="nvax-20221231.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_nvax_OperatingAndFinanceLeaseWriteOff_b17e7535-0680-4053-9441-6b0bf36ae98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_4d0a7aaf-5939-4321-a86b-87720c5134d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_4d0a7aaf-5939-4321-a86b-87720c5134d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6c8fdb30-5627-460d-baa2-827aaa2b47fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b84f69ed-f4ed-49a2-a434-b82819a83630" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6c8fdb30-5627-460d-baa2-827aaa2b47fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20953d69-3d10-42e8-bba5-dd7fe019585d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_05839a15-9bea-4d8a-bc68-81fad04f80de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20953d69-3d10-42e8-bba5-dd7fe019585d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_05839a15-9bea-4d8a-bc68-81fad04f80de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_405141d6-7227-4506-8743-b29933e52912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20953d69-3d10-42e8-bba5-dd7fe019585d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_405141d6-7227-4506-8743-b29933e52912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d15841e0-142f-4c9a-9389-9ae8f6e8beec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20953d69-3d10-42e8-bba5-dd7fe019585d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d15841e0-142f-4c9a-9389-9ae8f6e8beec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#InventoryScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9c402ed9-b506-4cf0-acb6-c3400c71cc75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_b396b48c-2317-4f9f-8379-c651e41b6d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9c402ed9-b506-4cf0-acb6-c3400c71cc75" xlink:to="loc_us-gaap_InventoryRawMaterials_b396b48c-2317-4f9f-8379-c651e41b6d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_7c19cb29-54c7-4d1b-91ee-2011e8b3abde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9c402ed9-b506-4cf0-acb6-c3400c71cc75" xlink:to="loc_us-gaap_InventoryWorkInProcess_7c19cb29-54c7-4d1b-91ee-2011e8b3abde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_02b046fa-6758-470f-91aa-3eb1ea1eac82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9c402ed9-b506-4cf0-acb6-c3400c71cc75" xlink:to="loc_us-gaap_InventoryFinishedGoods_02b046fa-6758-470f-91aa-3eb1ea1eac82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_141ad83d-c0df-4988-b05e-310f1049d50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b9dab7c8-05ca-4600-b461-16d96150d7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_141ad83d-c0df-4988-b05e-310f1049d50a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b9dab7c8-05ca-4600-b461-16d96150d7f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_85caeb9c-5f0a-4c83-bd10-798bc8285470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_141ad83d-c0df-4988-b05e-310f1049d50a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_85caeb9c-5f0a-4c83-bd10-798bc8285470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1f42dc66-a8b5-424f-a99a-185fe9eab6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_141ad83d-c0df-4988-b05e-310f1049d50a" xlink:to="loc_us-gaap_Goodwill_1f42dc66-a8b5-424f-a99a-185fe9eab6ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_9615e9bd-f5bc-4dee-acf2-1a14545dd7cc" xlink:href="nvax-20221231.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_141ad83d-c0df-4988-b05e-310f1049d50a" xlink:to="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_9615e9bd-f5bc-4dee-acf2-1a14545dd7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_86c75851-2582-43db-8d96-dd85d96d2d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_141ad83d-c0df-4988-b05e-310f1049d50a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_86c75851-2582-43db-8d96-dd85d96d2d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_479b86ca-03b8-4c55-9f4e-51a6981f557e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_141ad83d-c0df-4988-b05e-310f1049d50a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_479b86ca-03b8-4c55-9f4e-51a6981f557e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_1bced078-d67c-44ab-a347-443652e332ab" xlink:href="nvax-20221231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_cae1b1e5-1934-4d0c-9683-7d6861cc424f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseRightOfUseAsset_1bced078-d67c-44ab-a347-443652e332ab" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_cae1b1e5-1934-4d0c-9683-7d6861cc424f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6d0f3602-f42e-4dee-a7f8-fb66159cc648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseRightOfUseAsset_1bced078-d67c-44ab-a347-443652e332ab" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6d0f3602-f42e-4dee-a7f8-fb66159cc648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityNoncurrent_c299bcf7-4a0b-4abe-b8df-bdfb1a1353eb" xlink:href="nvax-20221231.xsd#nvax_LeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_24c9a19d-39ad-4103-b3fe-3502c42671e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityNoncurrent_c299bcf7-4a0b-4abe-b8df-bdfb1a1353eb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_24c9a19d-39ad-4103-b3fe-3502c42671e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc308f22-7238-43d2-b666-ef751c546138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityNoncurrent_c299bcf7-4a0b-4abe-b8df-bdfb1a1353eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc308f22-7238-43d2-b666-ef751c546138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityCurrent_adb65fed-9944-4886-9ec1-90c2153edf31" xlink:href="nvax-20221231.xsd#nvax_LeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2bfb389-6139-4eeb-bd95-09a716b35979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityCurrent_adb65fed-9944-4886-9ec1-90c2153edf31" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2bfb389-6139-4eeb-bd95-09a716b35979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_28844a6b-2319-4be2-850d-0d1eaf4b854e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityCurrent_adb65fed-9944-4886-9ec1-90c2153edf31" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_28844a6b-2319-4be2-850d-0d1eaf4b854e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesScheduleofOperatingLeaseExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_908aea41-0b5d-4df6-9b9c-7880f3facff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7ea6855a-a164-4a1f-9b6e-b808613c550f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_908aea41-0b5d-4df6-9b9c-7880f3facff0" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7ea6855a-a164-4a1f-9b6e-b808613c550f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_747e5074-c04d-4488-8641-57c7d30ad35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_908aea41-0b5d-4df6-9b9c-7880f3facff0" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_747e5074-c04d-4488-8641-57c7d30ad35b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2ba2227-3a51-4e29-a968-945dd50b4ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_af1ba708-fa2c-4436-9691-0dfbab9aee0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2ba2227-3a51-4e29-a968-945dd50b4ad9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_af1ba708-fa2c-4436-9691-0dfbab9aee0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bb41b5a2-02b4-49ce-8f93-105116b5eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2ba2227-3a51-4e29-a968-945dd50b4ad9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bb41b5a2-02b4-49ce-8f93-105116b5eb2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d890ad37-e1fe-4772-a56a-f1e0aee4407b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2ba2227-3a51-4e29-a968-945dd50b4ad9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d890ad37-e1fe-4772-a56a-f1e0aee4407b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_44b041e5-eead-4bda-8f7b-953fd44bbb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2ba2227-3a51-4e29-a968-945dd50b4ad9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_44b041e5-eead-4bda-8f7b-953fd44bbb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_483084be-4457-4697-a08f-988849dd960a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2ba2227-3a51-4e29-a968-945dd50b4ad9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_483084be-4457-4697-a08f-988849dd960a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4a7b9f42-7659-408b-8ba9-65f3cd5f98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2ba2227-3a51-4e29-a968-945dd50b4ad9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4a7b9f42-7659-408b-8ba9-65f3cd5f98f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c019fd97-5daa-48b5-85a6-580838eb679b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0b7a59da-c1f1-4c51-a89c-0a71408350f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c019fd97-5daa-48b5-85a6-580838eb679b" xlink:to="loc_us-gaap_OperatingLeaseLiability_0b7a59da-c1f1-4c51-a89c-0a71408350f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27aa8947-dce6-49a2-8eb1-15fa066ff00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c019fd97-5daa-48b5-85a6-580838eb679b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27aa8947-dce6-49a2-8eb1-15fa066ff00a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtScheduleofNotesPayableDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_b72f6e35-61b4-45a1-8959-44ef108bd150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent_87967b56-a893-4898-9067-a0aa56e919dd" xlink:href="nvax-20221231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent_b72f6e35-61b4-45a1-8959-44ef108bd150" xlink:to="loc_nvax_DebtInstrumentFaceAmountCurrent_87967b56-a893-4898-9067-a0aa56e919dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_f82cae2a-6aa9-451f-93ad-b80e6029ce10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent_b72f6e35-61b4-45a1-8959-44ef108bd150" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_f82cae2a-6aa9-451f-93ad-b80e6029ce10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_51703168-3716-4c93-9a08-4606abb02828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2eb6f3ac-9d00-4d5f-8d2e-b2d6726bdc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_51703168-3716-4c93-9a08-4606abb02828" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2eb6f3ac-9d00-4d5f-8d2e-b2d6726bdc26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3ec47961-08fd-492b-9520-5eacda6a4f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_51703168-3716-4c93-9a08-4606abb02828" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3ec47961-08fd-492b-9520-5eacda6a4f66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f417cf3b-5428-45ea-b53d-eefa3654ccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ba3b6f32-01c0-4c34-a436-d4d0091936eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_f417cf3b-5428-45ea-b53d-eefa3654ccb1" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ba3b6f32-01c0-4c34-a436-d4d0091936eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a6f82d67-21d5-403b-9283-5243de9ec749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_f417cf3b-5428-45ea-b53d-eefa3654ccb1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a6f82d67-21d5-403b-9283-5243de9ec749" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7c5ab5e3-cffa-4bc1-823e-571263d70cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4bb904f9-6aa8-4b3f-bdfc-d64289f80169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7c5ab5e3-cffa-4bc1-823e-571263d70cc3" xlink:to="loc_us-gaap_OtherAssetsCurrent_4bb904f9-6aa8-4b3f-bdfc-d64289f80169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_fbeed298-d630-477a-8b52-371d59844176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7c5ab5e3-cffa-4bc1-823e-571263d70cc3" xlink:to="loc_us-gaap_Supplies_fbeed298-d630-477a-8b52-371d59844176" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c229159b-f28e-49d9-abde-abac51bdbe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_49fe4fda-b6de-4434-9872-9b914325dac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c229159b-f28e-49d9-abde-abac51bdbe2b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_49fe4fda-b6de-4434-9872-9b914325dac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_558ba0b3-cda8-4812-bfbe-da0ba047ba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c229159b-f28e-49d9-abde-abac51bdbe2b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_558ba0b3-cda8-4812-bfbe-da0ba047ba0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_83a11a5c-4c61-442a-ae6a-433900fc1e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d3229115-cf8f-4135-aed7-6f10dd5d827a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83a11a5c-4c61-442a-ae6a-433900fc1e18" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d3229115-cf8f-4135-aed7-6f10dd5d827a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_285519df-3e55-44d7-b579-f094a16f8367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83a11a5c-4c61-442a-ae6a-433900fc1e18" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_285519df-3e55-44d7-b579-f094a16f8367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentAccruals_a684adfa-4ba6-478b-b831-f38c653d56d8" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentAccruals"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83a11a5c-4c61-442a-ae6a-433900fc1e18" xlink:to="loc_nvax_ResearchAndDevelopmentAccruals_a684adfa-4ba6-478b-b831-f38c653d56d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_58227a09-e3ad-481c-9f8b-88fac26df1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_b7319539-5e42-4dd8-a79a-9ef5da568948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_58227a09-e3ad-481c-9f8b-88fac26df1e5" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_b7319539-5e42-4dd8-a79a-9ef5da568948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_4872ee8a-6e7d-48e9-8a69-1a9d4f135180" xlink:href="nvax-20221231.xsd#nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_58227a09-e3ad-481c-9f8b-88fac26df1e5" xlink:to="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_4872ee8a-6e7d-48e9-8a69-1a9d4f135180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_e106d574-9ef1-4a4a-96cc-234e17cdbb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_58227a09-e3ad-481c-9f8b-88fac26df1e5" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_e106d574-9ef1-4a4a-96cc-234e17cdbb7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_723ac7bb-04fb-4a05-b5ea-5d48ecb059ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5ad6d302-3837-47b1-a2e4-65bb8d157f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_723ac7bb-04fb-4a05-b5ea-5d48ecb059ef" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5ad6d302-3837-47b1-a2e4-65bb8d157f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_991e8cdd-ea0f-4b3a-ada1-513fdc58de2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_723ac7bb-04fb-4a05-b5ea-5d48ecb059ef" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_991e8cdd-ea0f-4b3a-ada1-513fdc58de2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ef24797a-0548-43d4-a278-f9a1c8385c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c176e64a-1a83-4f8b-9fec-1b8e1cf297a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ef24797a-0548-43d4-a278-f9a1c8385c68" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c176e64a-1a83-4f8b-9fec-1b8e1cf297a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_536c9043-4e1f-467f-95e3-538a1fcc0c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ef24797a-0548-43d4-a278-f9a1c8385c68" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_536c9043-4e1f-467f-95e3-538a1fcc0c06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c2ae80b7-ecd5-487e-8dba-2d82f8f2b147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ef24797a-0548-43d4-a278-f9a1c8385c68" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c2ae80b7-ecd5-487e-8dba-2d82f8f2b147" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofTaxRateDifferencesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b8312eea-ba85-4669-9084-677a0d0f9a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b8312eea-ba85-4669-9084-677a0d0f9a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_386d7ec4-1afb-44fa-9e55-93a4f952b8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_386d7ec4-1afb-44fa-9e55-93a4f952b8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cc77e5f0-5e36-4da6-863b-96878e47ab24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cc77e5f0-5e36-4da6-863b-96878e47ab24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d3f28ffa-ca51-42f3-8e26-b0ae0ae25b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d3f28ffa-ca51-42f3-8e26-b0ae0ae25b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5a74c83e-baee-422a-bad4-9c49d1ac4b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5a74c83e-baee-422a-bad4-9c49d1ac4b31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b7cb1a58-e03b-4b78-be45-eedc2e66c229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b7cb1a58-e03b-4b78-be45-eedc2e66c229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3462a9bf-f8cf-4383-bbfb-d2bfa179e88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3462a9bf-f8cf-4383-bbfb-d2bfa179e88c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_87bee612-c405-4101-823b-690ab0701241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_87bee612-c405-4101-823b-690ab0701241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_85de3468-3b91-4272-aa30-269bf3d8a72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_85de3468-3b91-4272-aa30-269bf3d8a72e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_a092588a-bd01-4242-8fd4-a6c422cae85b" xlink:href="nvax-20221231.xsd#nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2d1149c-14b6-448d-b699-fd807fc9cf07" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_a092588a-bd01-4242-8fd4-a6c422cae85b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4563e862-d41a-4d93-8c8e-dace8f850f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_74fdfc2e-7bd2-494e-8063-f8bec07066be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4563e862-d41a-4d93-8c8e-dace8f850f76" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_74fdfc2e-7bd2-494e-8063-f8bec07066be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7e6be797-407c-4564-bce0-6029924a2995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4563e862-d41a-4d93-8c8e-dace8f850f76" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7e6be797-407c-4564-bce0-6029924a2995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_81bdfab2-775e-47d3-9ae1-2c3cf2eff8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_81bdfab2-775e-47d3-9ae1-2c3cf2eff8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_83065bc3-0411-4be3-b281-0a95ca69851d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_83065bc3-0411-4be3-b281-0a95ca69851d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_a1085a5e-f492-4220-89a4-3bc3a686aedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_a1085a5e-f492-4220-89a4-3bc3a686aedf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetsOriginalDiscountInterest_cac94ea0-5111-4203-af2b-c7db17aecbee" xlink:href="nvax-20221231.xsd#nvax_DeferredTaxAssetsOriginalDiscountInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_nvax_DeferredTaxAssetsOriginalDiscountInterest_cac94ea0-5111-4203-af2b-c7db17aecbee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c2091f3c-9bc6-4d4b-8164-914ae071d01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c2091f3c-9bc6-4d4b-8164-914ae071d01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_389ce79a-f828-41d7-8b62-7da4efea0092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_389ce79a-f828-41d7-8b62-7da4efea0092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetLeasingLiability_9b926483-70d2-4794-9479-506d4bdb1d21" xlink:href="nvax-20221231.xsd#nvax_DeferredTaxAssetLeasingLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_nvax_DeferredTaxAssetLeasingLiability_9b926483-70d2-4794-9479-506d4bdb1d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7847ea17-fadf-44ee-9e0c-3845cc307cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7847ea17-fadf-44ee-9e0c-3845cc307cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_04bcf9da-e9bd-4de7-aed2-bf86a303b4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_04bcf9da-e9bd-4de7-aed2-bf86a303b4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_dcf13746-7c5d-44db-b2cb-917f6cd3904c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5036db93-21a0-401d-8c43-a00733c12c21" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_dcf13746-7c5d-44db-b2cb-917f6cd3904c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5730285b-2c32-40aa-962a-2681e3a32f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1cf41d5f-7695-4d26-aa52-5a8a1e75def7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5730285b-2c32-40aa-962a-2681e3a32f09" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1cf41d5f-7695-4d26-aa52-5a8a1e75def7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5e98c5b9-ed48-4621-ab86-ccd8a76e4c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5730285b-2c32-40aa-962a-2681e3a32f09" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5e98c5b9-ed48-4621-ab86-ccd8a76e4c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_11e7ad31-41e6-4fcc-9d40-ca994dd8ce72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_49acf25f-cc37-4f0a-a578-26fc2102db33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_11e7ad31-41e6-4fcc-9d40-ca994dd8ce72" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_49acf25f-cc37-4f0a-a578-26fc2102db33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4ad0bbfc-fb6e-4b22-be2d-4dd1e5e87f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_11e7ad31-41e6-4fcc-9d40-ca994dd8ce72" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4ad0bbfc-fb6e-4b22-be2d-4dd1e5e87f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ea906baf-683d-41fe-869c-1602727b3d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_11e7ad31-41e6-4fcc-9d40-ca994dd8ce72" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ea906baf-683d-41fe-869c-1602727b3d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_45e81f90-0b52-40cc-b47f-0f20345d8bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_11e7ad31-41e6-4fcc-9d40-ca994dd8ce72" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_45e81f90-0b52-40cc-b47f-0f20345d8bde" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>nvax-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2e968d4d-f5d4-46a7-9a1c-6f56d63ea7b7,g:07ea8c72-99d3-4c76-b42c-1d6d27635d74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ie3fed4b90b4643a2ac0195c34e6e1bfc_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0d5fea7b-9a2a-47c5-a801-c5814a4e1a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_RevenuesAbstract_0d5fea7b-9a2a-47c5-a801-c5814a4e1a88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_41a2f5ac-f89b-4e6a-8899-a903b721ee49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0d5fea7b-9a2a-47c5-a801-c5814a4e1a88" xlink:to="loc_us-gaap_Revenues_41a2f5ac-f89b-4e6a-8899-a903b721ee49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c38924d3-1d9e-41fa-b264-fddfd06f6e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_CostOfRevenue_c38924d3-1d9e-41fa-b264-fddfd06f6e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_368206df-edb1-457c-b58c-48fd3e7c4150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_368206df-edb1-457c-b58c-48fd3e7c4150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_48edbce0-e15f-4abd-aaa9-1f394b3a47aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_48edbce0-e15f-4abd-aaa9-1f394b3a47aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_61e36387-88f5-42a5-b2d7-89cc9563c9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_CostsAndExpenses_61e36387-88f5-42a5-b2d7-89cc9563c9e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_00e74fd8-98c5-4afe-b2ec-be3c8a066a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_OperatingIncomeLoss_00e74fd8-98c5-4afe-b2ec-be3c8a066a48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ea56d2e1-c706-4182-a198-4913efe94ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:to="loc_us-gaap_InterestExpense_ea56d2e1-c706-4182-a198-4913efe94ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_123b0783-2265-4303-8ac5-24d2a224aab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_123b0783-2265-4303-8ac5-24d2a224aab3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52513a56-aeb6-4b87-8382-09d9e92d3cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52513a56-aeb6-4b87-8382-09d9e92d3cae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b47dfea3-bc18-4c0a-abf9-9773cded1732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b47dfea3-bc18-4c0a-abf9-9773cded1732" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b694129d-17a9-4871-b472-59bac2b7e191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_NetIncomeLoss_b694129d-17a9-4871-b472-59bac2b7e191" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_15881c3f-0561-494a-a5e8-851c28e3a481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:to="loc_us-gaap_EarningsPerShareBasic_15881c3f-0561-494a-a5e8-851c28e3a481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3168d39a-ff43-4211-a99f-cb5b59b2d241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3168d39a-ff43-4211-a99f-cb5b59b2d241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12d52a5f-81bd-47dd-beb6-54b290423d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12d52a5f-81bd-47dd-beb6-54b290423d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb330a9f-31c4-4da4-82b5-70d1f2b555bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb330a9f-31c4-4da4-82b5-70d1f2b555bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_76a5a768-327d-4857-8225-430af61f20e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_StatementTable_76a5a768-327d-4857-8225-430af61f20e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75a34f12-f17c-49f8-9dca-effa35ac5fbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_76a5a768-327d-4857-8225-430af61f20e2" xlink:to="loc_srt_ProductOrServiceAxis_75a34f12-f17c-49f8-9dca-effa35ac5fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_75a34f12-f17c-49f8-9dca-effa35ac5fbe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_75a34f12-f17c-49f8-9dca-effa35ac5fbe" xlink:to="loc_srt_ProductsAndServicesDomain_75a34f12-f17c-49f8-9dca-effa35ac5fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_75a34f12-f17c-49f8-9dca-effa35ac5fbe" xlink:to="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5f14b76a-2e6a-40e5-a1d9-84da4f6a5995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:to="loc_us-gaap_ProductMember_5f14b76a-2e6a-40e5-a1d9-84da4f6a5995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_c2810c48-b2b7-43d8-809d-4d6dc4c0071b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:to="loc_us-gaap_GrantMember_c2810c48-b2b7-43d8-809d-4d6dc4c0071b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember_524b4dea-3461-42fe-8c85-a87151602d1e" xlink:href="nvax-20221231.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:to="loc_nvax_RoyaltiesAndOtherMember_524b4dea-3461-42fe-8c85-a87151602d1e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="ia5db9a2a12684ef4bb050f2e266e4f1f_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e109e26-759b-48c7-a30c-876d849fdfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e109e26-759b-48c7-a30c-876d849fdfcb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_38d58f4c-666f-4c14-8ef2-317f072b1e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_SharesIssued_38d58f4c-666f-4c14-8ef2-317f072b1e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff435fca-fe33-418c-b34d-422baca7caad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockholdersEquity_ff435fca-fe33-418c-b34d-422baca7caad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_65921686-1146-45da-8b3a-260efcda70a8" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_65921686-1146-45da-8b3a-260efcda70a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2e591334-526c-4227-a4da-f5abe7238d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2e591334-526c-4227-a4da-f5abe7238d1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_aba63d37-78e7-42dd-a870-a77d2370f8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_aba63d37-78e7-42dd-a870-a77d2370f8ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b1a0966-5c50-4db2-9b07-f5c03f998f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b1a0966-5c50-4db2-9b07-f5c03f998f2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_21e917cd-c925-4ece-8800-7c0d6d3ea124" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_21e917cd-c925-4ece-8800-7c0d6d3ea124" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_83484424-5e65-4af9-a2ca-25c9d0e459ca" xlink:href="nvax-20221231.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_83484424-5e65-4af9-a2ca-25c9d0e459ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83af7bd2-ce04-45a8-a6fe-d34ed5f36826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83af7bd2-ce04-45a8-a6fe-d34ed5f36826" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8198bbae-6a11-46bf-8a67-c0b270ae0d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8198bbae-6a11-46bf-8a67-c0b270ae0d64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_88ab2ea3-acf4-4bc1-a8b6-a46cacae222e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_88ab2ea3-acf4-4bc1-a8b6-a46cacae222e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e8e284f9-1797-4a0e-bcb5-a5855ad6ae21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e8e284f9-1797-4a0e-bcb5-a5855ad6ae21" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0c0b0ec-eb1b-43f5-bf19-224a46d96e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_NetIncomeLoss_d0c0b0ec-eb1b-43f5-bf19-224a46d96e0c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_424a5d71-d1ad-4008-bdf4-b4f7d7cad256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_12623bd8-d241-4d96-842e-254cfce5d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5b70b7d4-d49b-4f4f-b8b9-159d29739488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7e109e26-759b-48c7-a30c-876d849fdfcb" xlink:to="loc_us-gaap_StatementTable_5b70b7d4-d49b-4f4f-b8b9-159d29739488" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c681ac38-3a34-4578-9937-a3e05172f204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5b70b7d4-d49b-4f4f-b8b9-159d29739488" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c681ac38-3a34-4578-9937-a3e05172f204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c681ac38-3a34-4578-9937-a3e05172f204_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c681ac38-3a34-4578-9937-a3e05172f204" xlink:to="loc_us-gaap_EquityComponentDomain_c681ac38-3a34-4578-9937-a3e05172f204_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c681ac38-3a34-4578-9937-a3e05172f204" xlink:to="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4ffca24-6d17-4d1c-9485-923b611eac39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_CommonStockMember_b4ffca24-6d17-4d1c-9485-923b611eac39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ae09a97b-e512-4b36-ab06-49387a2e4ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ae09a97b-e512-4b36-ab06-49387a2e4ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d5a9c9af-ebaa-4d95-a43d-0dbd7562b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_RetainedEarningsMember_d5a9c9af-ebaa-4d95-a43d-0dbd7562b1b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_c5193b0d-a8ab-49ca-9145-9fda62a4226c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_TreasuryStockMember_c5193b0d-a8ab-49ca-9145-9fda62a4226c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_959f243c-a1df-4fa4-b793-07f8d6c7c013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_959f243c-a1df-4fa4-b793-07f8d6c7c013" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="idac4244103a04d67945ad2df72a5e565_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:href="nvax-20221231.xsd#nvax_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3c3a3d2-594c-4abb-a395-dddc0904cd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3c3a3d2-594c-4abb-a395-dddc0904cd13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromIssuanceCommonStockAndDebt_fdffa47b-dbed-4e61-b742-68977d7f1acc" xlink:href="nvax-20221231.xsd#nvax_ProceedsFromIssuanceCommonStockAndDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_nvax_ProceedsFromIssuanceCommonStockAndDebt_fdffa47b-dbed-4e61-b742-68977d7f1acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_8acd9122-e71d-41c1-8535-2b9c32d3d447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_RepaymentsOfDebt_8acd9122-e71d-41c1-8535-2b9c32d3d447" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76da2837-ae37-405a-84fb-3263607f33d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NetIncomeLoss_76da2837-ae37-405a-84fb-3263607f33d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f644376-2605-4f8d-ba55-ba32345d4411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f644376-2605-4f8d-ba55-ba32345d4411" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_ddcc7b29-1d3e-4fdf-8e17-5703b1304902" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_ddcc7b29-1d3e-4fdf-8e17-5703b1304902" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_187f6dbc-3387-4fe1-a8d2-f17affca2c99" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_187f6dbc-3387-4fe1-a8d2-f17affca2c99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_401d571d-a00b-4d1b-973b-491c8baf50c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_AdvertisingExpense_401d571d-a00b-4d1b-973b-491c8baf50c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f768b5c3-251e-4411-9b60-ed7cb05d1b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f768b5c3-251e-4411-9b60-ed7cb05d1b47" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_8276374e-86a8-4e24-ad0e-8d9573a17ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NumberOfReportingUnits_8276374e-86a8-4e24-ad0e-8d9573a17ec9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d778ef06-d0b8-4eb7-b644-12e44fc052e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d778ef06-d0b8-4eb7-b644-12e44fc052e7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_33f63e7b-3c45-432c-8b6f-64ef4051d365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_33f63e7b-3c45-432c-8b6f-64ef4051d365" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_76a4db48-1587-460e-a236-5f2c0b9a9aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_76a4db48-1587-460e-a236-5f2c0b9a9aea" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_16fb262d-95e9-4811-8cf2-b4781340f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_16fb262d-95e9-4811-8cf2-b4781340f55d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_5f1d4461-7d24-478e-9d59-d200d77ebb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_5f1d4461-7d24-478e-9d59-d200d77ebb6e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_f034821d-3e61-4d83-87b5-3a612a1ca2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_f034821d-3e61-4d83-87b5-3a612a1ca2e4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d63a2000-1591-4855-bfbf-e4ad2746699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d63a2000-1591-4855-bfbf-e4ad2746699b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:href="nvax-20221231.xsd#nvax_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3c55360-9f99-4742-a16e-8a1af3983628" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_srt_RangeAxis_c3c55360-9f99-4742-a16e-8a1af3983628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3c55360-9f99-4742-a16e-8a1af3983628_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c3c55360-9f99-4742-a16e-8a1af3983628" xlink:to="loc_srt_RangeMember_c3c55360-9f99-4742-a16e-8a1af3983628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c3c55360-9f99-4742-a16e-8a1af3983628" xlink:to="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f145c3da-21bf-4e17-8859-36500f0dc34d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:to="loc_srt_MinimumMember_f145c3da-21bf-4e17-8859-36500f0dc34d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_453467d4-a82d-458e-b173-21af1bcc292c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:to="loc_srt_MaximumMember_453467d4-a82d-458e-b173-21af1bcc292c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a50590ab-6b99-4ef6-b148-9c1c25f6a796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_DebtInstrumentAxis_a50590ab-6b99-4ef6-b148-9c1c25f6a796" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a50590ab-6b99-4ef6-b148-9c1c25f6a796_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a50590ab-6b99-4ef6-b148-9c1c25f6a796" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a50590ab-6b99-4ef6-b148-9c1c25f6a796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a50590ab-6b99-4ef6-b148-9c1c25f6a796" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_581b8890-fe6f-418a-8368-322ab2b0d131" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_581b8890-fe6f-418a-8368-322ab2b0d131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_19c65be0-b7d9-4302-bda8-11769b19c0c1" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_19c65be0-b7d9-4302-bda8-11769b19c0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3a019552-54ba-4da4-806d-66c3a589699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3a019552-54ba-4da4-806d-66c3a589699b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a019552-54ba-4da4-806d-66c3a589699b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3a019552-54ba-4da4-806d-66c3a589699b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a019552-54ba-4da4-806d-66c3a589699b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0fb9574e-7704-4521-a460-d7e9026fc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3a019552-54ba-4da4-806d-66c3a589699b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0fb9574e-7704-4521-a460-d7e9026fc72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_729c5d9b-70f7-4305-a0a8-160807b8f025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fb9574e-7704-4521-a460-d7e9026fc72e" xlink:to="loc_us-gaap_UnsecuredDebtMember_729c5d9b-70f7-4305-a0a8-160807b8f025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d034443-6631-4001-aa1c-6071e55727d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_srt_ProductOrServiceAxis_5d034443-6631-4001-aa1c-6071e55727d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d034443-6631-4001-aa1c-6071e55727d3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5d034443-6631-4001-aa1c-6071e55727d3" xlink:to="loc_srt_ProductsAndServicesDomain_5d034443-6631-4001-aa1c-6071e55727d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35e8620b-3398-4d6b-ab10-733a7fd60862" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5d034443-6631-4001-aa1c-6071e55727d3" xlink:to="loc_srt_ProductsAndServicesDomain_35e8620b-3398-4d6b-ab10-733a7fd60862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_d6ff4ad2-352c-4de4-9ead-109bcc88972c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35e8620b-3398-4d6b-ab10-733a7fd60862" xlink:to="loc_us-gaap_GovernmentContractMember_d6ff4ad2-352c-4de4-9ead-109bcc88972c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d3313c6e-4461-4505-a260-bab66788fe8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d3313c6e-4461-4505-a260-bab66788fe8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3313c6e-4461-4505-a260-bab66788fe8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3313c6e-4461-4505-a260-bab66788fe8c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3313c6e-4461-4505-a260-bab66788fe8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3313c6e-4461-4505-a260-bab66788fe8c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_78f49f81-6dde-4be1-88df-46d75f108a8f" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:to="loc_nvax_USGovernmentAgreementMember_78f49f81-6dde-4be1-88df-46d75f108a8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_c7ad3e6f-8f8a-43c8-88cf-c4fcf6107e0e" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_c7ad3e6f-8f8a-43c8-88cf-c4fcf6107e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_022ef835-db7c-4077-b63e-761dd52f7748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_022ef835-db7c-4077-b63e-761dd52f7748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d45281db-f079-4f19-8655-c2200d4f4cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_022ef835-db7c-4077-b63e-761dd52f7748" xlink:to="loc_us-gaap_SubsequentEventMember_d45281db-f079-4f19-8655-c2200d4f4cfd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended" id="idb9471779b3549bcb1fe9d09dd61c72f_SummaryofSignificantAccountingPoliciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_220d3eee-e154-4fed-ba2a-0d84197f3121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0d878317-f405-466c-85f6-8ba049698aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_220d3eee-e154-4fed-ba2a-0d84197f3121" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0d878317-f405-466c-85f6-8ba049698aac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_220d3eee-e154-4fed-ba2a-0d84197f3121" xlink:to="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5738b323-d0b3-4c89-99f0-ac2715980ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5738b323-d0b3-4c89-99f0-ac2715980ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5738b323-d0b3-4c89-99f0-ac2715980ba4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5738b323-d0b3-4c89-99f0-ac2715980ba4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5738b323-d0b3-4c89-99f0-ac2715980ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f5ccc0e7-f96f-4c39-9e87-716070ea2f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5738b323-d0b3-4c89-99f0-ac2715980ba4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f5ccc0e7-f96f-4c39-9e87-716070ea2f15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2fc7454f-ac5c-4b18-b8bd-03ea132e60b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f5ccc0e7-f96f-4c39-9e87-716070ea2f15" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2fc7454f-ac5c-4b18-b8bd-03ea132e60b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9d81f9d-8c65-4448-b534-cd02580d5b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9d81f9d-8c65-4448-b534-cd02580d5b57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c9d81f9d-8c65-4448-b534-cd02580d5b57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9d81f9d-8c65-4448-b534-cd02580d5b57" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c9d81f9d-8c65-4448-b534-cd02580d5b57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9d81f9d-8c65-4448-b534-cd02580d5b57" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d05d9032-18d6-4325-861f-ba63894c1e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:to="loc_us-gaap_SalesRevenueNetMember_d05d9032-18d6-4325-861f-ba63894c1e9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_74406342-328e-4391-a6f0-2cc9ecbb6171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:to="loc_us-gaap_AccountsReceivableMember_74406342-328e-4391-a6f0-2cc9ecbb6171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5da10c1b-7bdf-4401-a667-0fe1e919a1b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:to="loc_srt_MajorCustomersAxis_5da10c1b-7bdf-4401-a667-0fe1e919a1b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5da10c1b-7bdf-4401-a667-0fe1e919a1b8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5da10c1b-7bdf-4401-a667-0fe1e919a1b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_5da10c1b-7bdf-4401-a667-0fe1e919a1b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5da10c1b-7bdf-4401-a667-0fe1e919a1b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionMember_787903ac-090b-46eb-9344-cb66c7cd5755" xlink:href="nvax-20221231.xsd#nvax_EuropeanCommissionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_EuropeanCommissionMember_787903ac-090b-46eb-9344-cb66c7cd5755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfAustraliaMember_dba310d0-2c52-4d45-8db7-192edabf2dfe" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfAustraliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GovernmentOfAustraliaMember_dba310d0-2c52-4d45-8db7-192edabf2dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfCanadaMember_3f1ca358-be63-4126-8435-687adc2377c6" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GovernmentOfCanadaMember_3f1ca358-be63-4126-8435-687adc2377c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfIsraelMember_7bcc9f85-90c0-440d-b5be-63b0341f02e5" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfIsraelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GovernmentOfIsraelMember_7bcc9f85-90c0-440d-b5be-63b0341f02e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviVaccineAllianceMember_0637c53a-e873-4618-8bcb-3f174b7b23e7" xlink:href="nvax-20221231.xsd#nvax_GaviVaccineAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GaviVaccineAllianceMember_0637c53a-e873-4618-8bcb-3f174b7b23e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentMember_ea628de1-e861-4cb1-8242-ccf384df0df8" xlink:href="nvax-20221231.xsd#nvax_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_USGovernmentMember_ea628de1-e861-4cb1-8242-ccf384df0df8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f22cb920-075b-4729-8e6f-354739dfc294" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f22cb920-075b-4729-8e6f-354739dfc294" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceCoLtdMember_9ee0641d-f1c5-44f7-b13c-3e9c6d7d0790" xlink:href="nvax-20221231.xsd#nvax_SKBioscienceCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_SKBioscienceCoLtdMember_9ee0641d-f1c5-44f7-b13c-3e9c6d7d0790" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="i78cf2e88bd244373b4c8ee35ad2b78ae_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d593ba0-749c-4c91-809f-aa9e58f91cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b871f59c-926c-4fc8-953b-c67d9e658f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d593ba0-749c-4c91-809f-aa9e58f91cde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b871f59c-926c-4fc8-953b-c67d9e658f72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d593ba0-749c-4c91-809f-aa9e58f91cde" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b9bc2786-5057-4636-a575-1e17ae2fa0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b9bc2786-5057-4636-a575-1e17ae2fa0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9bc2786-5057-4636-a575-1e17ae2fa0b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b9bc2786-5057-4636-a575-1e17ae2fa0b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9bc2786-5057-4636-a575-1e17ae2fa0b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b9bc2786-5057-4636-a575-1e17ae2fa0b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_28b05e3d-4dd4-4b7d-9e37-97abe6ae49c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:to="loc_us-gaap_BuildingMember_28b05e3d-4dd4-4b7d-9e37-97abe6ae49c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_bc557c09-4fe2-4956-b749-12144eca1732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_bc557c09-4fe2-4956-b749-12144eca1732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b0a0d1aa-3363-479a-8bf3-eadabc689294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:to="loc_us-gaap_ComputerEquipmentMember_b0a0d1aa-3363-479a-8bf3-eadabc689294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43d99cc1-4e77-45b2-b933-2c1519ccba81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:to="loc_srt_RangeAxis_43d99cc1-4e77-45b2-b933-2c1519ccba81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43d99cc1-4e77-45b2-b933-2c1519ccba81_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_43d99cc1-4e77-45b2-b933-2c1519ccba81" xlink:to="loc_srt_RangeMember_43d99cc1-4e77-45b2-b933-2c1519ccba81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_43d99cc1-4e77-45b2-b933-2c1519ccba81" xlink:to="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_031c05d2-5238-4b0f-93ae-a9dda5023d50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:to="loc_srt_MinimumMember_031c05d2-5238-4b0f-93ae-a9dda5023d50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40cab3e7-2979-4b09-9dab-c14fb82b0449" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:to="loc_srt_MaximumMember_40cab3e7-2979-4b09-9dab-c14fb82b0449" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended" id="ie15abe05903b445dad434ae459db6b0f_RevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_d0444b6a-9bec-4be9-9b83-47e1fc24a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_BilledContractReceivables_d0444b6a-9bec-4be9-9b83-47e1fc24a00a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_dc252221-80c6-4a09-968e-08081b72690c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_UnbilledContractsReceivable_dc252221-80c6-4a09-968e-08081b72690c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0d83f0ae-c481-4be9-ab46-f0c81e26e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0d83f0ae-c481-4be9-ab46-f0c81e26e45a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_852613e5-089f-48d2-8c78-ca3c821a5bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_852613e5-089f-48d2-8c78-ca3c821a5bca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_e53ad198-b051-4016-bafb-9aaeeb5f2807" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_e53ad198-b051-4016-bafb-9aaeeb5f2807" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3fb7eff5-c959-448b-aa4c-be1964e65c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3fb7eff5-c959-448b-aa4c-be1964e65c58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_461b6d0d-b90b-4c31-9803-c4769bd1e314" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_461b6d0d-b90b-4c31-9803-c4769bd1e314" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_db43e052-5ebe-46a6-b4ee-076a40feaecf" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_db43e052-5ebe-46a6-b4ee-076a40feaecf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_4866b47b-c7be-4d62-9ead-5346a49e13f7" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_4866b47b-c7be-4d62-9ead-5346a49e13f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_e6860a54-98f0-49f9-8e5a-7314872619be" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_e6860a54-98f0-49f9-8e5a-7314872619be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_a89eacd9-9953-4690-835f-86abc5963873" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_a89eacd9-9953-4690-835f-86abc5963873" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate_22842e3a-8274-4344-8fa1-167c7286d456" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidate_22842e3a-8274-4344-8fa1-167c7286d456" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment_0d270f50-38b7-463e-bc30-1f70a50ee60e" xlink:href="nvax-20221231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueFromContractWithCustomerCommitment_0d270f50-38b7-463e-bc30-1f70a50ee60e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_bce64962-0792-4ee8-a3b6-8c68d3d357ef" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_bce64962-0792-4ee8-a3b6-8c68d3d357ef" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_686922c5-b190-4220-bfe2-3846f069c0a9" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_686922c5-b190-4220-bfe2-3846f069c0a9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_0941c0aa-25cd-4938-8539-9fee82f19f29" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_0941c0aa-25cd-4938-8539-9fee82f19f29" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_35ffdcf8-cfb3-4948-94c5-358d827c5284" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_35ffdcf8-cfb3-4948-94c5-358d827c5284" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_bf1951cc-ff8f-47a1-8cc3-e30b08923e1e" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_bf1951cc-ff8f-47a1-8cc3-e30b08923e1e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_fcec57e2-ecc9-40d6-bfd8-9761798cca08" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_fcec57e2-ecc9-40d6-bfd8-9761798cca08" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bac09eb7-d6b9-43ea-90f2-f5e703134226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_Revenues_bac09eb7-d6b9-43ea-90f2-f5e703134226" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00860300-cb4b-410d-836a-f4db6a60f2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00860300-cb4b-410d-836a-f4db6a60f2c6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_21828965-d18b-4b8c-a519-820abb4ef00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_21828965-d18b-4b8c-a519-820abb4ef00d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_786fbb6c-4f8d-48bd-8302-240c67012792_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_786fbb6c-4f8d-48bd-8302-240c67012792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_2cdffa0f-1e96-4f42-91b7-7cfcfad261ef" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_2cdffa0f-1e96-4f42-91b7-7cfcfad261ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_6fb02db0-22c6-44ad-a8a6-6c52e94ef1a4" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_6fb02db0-22c6-44ad-a8a6-6c52e94ef1a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_c16412e0-e49f-45aa-947f-1d37c9948808" xlink:href="nvax-20221231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_c16412e0-e49f-45aa-947f-1d37c9948808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_bf2dba7a-ae20-4bf9-b15c-91f368c15692" xlink:href="nvax-20221231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_EuropeanCommissionsECMember_bf2dba7a-ae20-4bf9-b15c-91f368c15692" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_5246c4ef-0b8f-4edb-b801-296e0fb9f02a" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_USGovernmentAgreementMember_5246c4ef-0b8f-4edb-b801-296e0fb9f02a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DoDContractMember_7c717c6d-d605-41ef-aefb-640d39494fb1" xlink:href="nvax-20221231.xsd#nvax_DoDContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_DoDContractMember_7c717c6d-d605-41ef-aefb-640d39494fb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_ab2b6452-6fa2-4372-bd04-6b137b74089f" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_ab2b6452-6fa2-4372-bd04-6b137b74089f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember_1a2c2ddf-2afb-4018-9927-6d3f5dc762b3" xlink:href="nvax-20221231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_CEPIGrantFundingMember_1a2c2ddf-2afb-4018-9927-6d3f5dc762b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_61388200-5a94-4dc0-9494-5c2a345758c8" xlink:href="nvax-20221231.xsd#nvax_TakedaArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_TakedaArrangementMember_61388200-5a94-4dc0-9494-5c2a345758c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_adbb26c9-ba35-4a88-ab55-ae7956ff126c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_adbb26c9-ba35-4a88-ab55-ae7956ff126c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_22e3dfd6-f7ed-4ff5-9393-8d107f9f51ba" xlink:href="nvax-20221231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_22e3dfd6-f7ed-4ff5-9393-8d107f9f51ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaad5764-1774-4a60-af86-e84dc41d25c0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:to="loc_srt_RangeMember_eaad5764-1774-4a60-af86-e84dc41d25c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:to="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4067f4e0-af87-4d54-9467-729e6ef81e40" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:to="loc_srt_MinimumMember_4067f4e0-af87-4d54-9467-729e6ef81e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5daa1ba5-e3b8-4dc2-848e-4c90812e0332" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:to="loc_srt_MaximumMember_5daa1ba5-e3b8-4dc2-848e-4c90812e0332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd7f4f02-badb-4daa-a46e-2501fecddd1b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:to="loc_srt_ProductsAndServicesDomain_bd7f4f02-badb-4daa-a46e-2501fecddd1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:to="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_35093a4d-74bf-4095-8ec4-58b8f7e64611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:to="loc_us-gaap_GovernmentContractMember_35093a4d-74bf-4095-8ec4-58b8f7e64611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_6c891466-3f20-49ae-8439-490b7fdbde11" xlink:href="nvax-20221231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_6c891466-3f20-49ae-8439-490b7fdbde11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_adbdc4bf-eb48-4467-83d7-797861195bd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_adbdc4bf-eb48-4467-83d7-797861195bd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ab9cf0b7-09f8-47b4-8120-2f724de6a63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:to="loc_us-gaap_SubsequentEventMember_ab9cf0b7-09f8-47b4-8120-2f724de6a63d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended" id="ib819cf09b37c43ba91b47038739c1c20_RevenueAdditionalInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_d0444b6a-9bec-4be9-9b83-47e1fc24a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_BilledContractReceivables_d0444b6a-9bec-4be9-9b83-47e1fc24a00a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_dc252221-80c6-4a09-968e-08081b72690c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_UnbilledContractsReceivable_dc252221-80c6-4a09-968e-08081b72690c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0d83f0ae-c481-4be9-ab46-f0c81e26e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0d83f0ae-c481-4be9-ab46-f0c81e26e45a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_852613e5-089f-48d2-8c78-ca3c821a5bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_852613e5-089f-48d2-8c78-ca3c821a5bca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_e53ad198-b051-4016-bafb-9aaeeb5f2807" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_e53ad198-b051-4016-bafb-9aaeeb5f2807" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3fb7eff5-c959-448b-aa4c-be1964e65c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3fb7eff5-c959-448b-aa4c-be1964e65c58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_461b6d0d-b90b-4c31-9803-c4769bd1e314" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_461b6d0d-b90b-4c31-9803-c4769bd1e314" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_db43e052-5ebe-46a6-b4ee-076a40feaecf" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_db43e052-5ebe-46a6-b4ee-076a40feaecf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_4866b47b-c7be-4d62-9ead-5346a49e13f7" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_4866b47b-c7be-4d62-9ead-5346a49e13f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_e6860a54-98f0-49f9-8e5a-7314872619be" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_e6860a54-98f0-49f9-8e5a-7314872619be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_a89eacd9-9953-4690-835f-86abc5963873" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_a89eacd9-9953-4690-835f-86abc5963873" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate_22842e3a-8274-4344-8fa1-167c7286d456" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidate_22842e3a-8274-4344-8fa1-167c7286d456" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment_0d270f50-38b7-463e-bc30-1f70a50ee60e" xlink:href="nvax-20221231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueFromContractWithCustomerCommitment_0d270f50-38b7-463e-bc30-1f70a50ee60e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_bce64962-0792-4ee8-a3b6-8c68d3d357ef" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_bce64962-0792-4ee8-a3b6-8c68d3d357ef" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_686922c5-b190-4220-bfe2-3846f069c0a9" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_686922c5-b190-4220-bfe2-3846f069c0a9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_0941c0aa-25cd-4938-8539-9fee82f19f29" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_0941c0aa-25cd-4938-8539-9fee82f19f29" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_35ffdcf8-cfb3-4948-94c5-358d827c5284" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_35ffdcf8-cfb3-4948-94c5-358d827c5284" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_bf1951cc-ff8f-47a1-8cc3-e30b08923e1e" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_bf1951cc-ff8f-47a1-8cc3-e30b08923e1e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_fcec57e2-ecc9-40d6-bfd8-9761798cca08" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_fcec57e2-ecc9-40d6-bfd8-9761798cca08" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bac09eb7-d6b9-43ea-90f2-f5e703134226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_Revenues_bac09eb7-d6b9-43ea-90f2-f5e703134226" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00860300-cb4b-410d-836a-f4db6a60f2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00860300-cb4b-410d-836a-f4db6a60f2c6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_786fbb6c-4f8d-48bd-8302-240c67012792_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_786fbb6c-4f8d-48bd-8302-240c67012792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_2cdffa0f-1e96-4f42-91b7-7cfcfad261ef" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_2cdffa0f-1e96-4f42-91b7-7cfcfad261ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_6fb02db0-22c6-44ad-a8a6-6c52e94ef1a4" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_6fb02db0-22c6-44ad-a8a6-6c52e94ef1a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_c16412e0-e49f-45aa-947f-1d37c9948808" xlink:href="nvax-20221231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_c16412e0-e49f-45aa-947f-1d37c9948808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_bf2dba7a-ae20-4bf9-b15c-91f368c15692" xlink:href="nvax-20221231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_EuropeanCommissionsECMember_bf2dba7a-ae20-4bf9-b15c-91f368c15692" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_5246c4ef-0b8f-4edb-b801-296e0fb9f02a" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_USGovernmentAgreementMember_5246c4ef-0b8f-4edb-b801-296e0fb9f02a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DoDContractMember_7c717c6d-d605-41ef-aefb-640d39494fb1" xlink:href="nvax-20221231.xsd#nvax_DoDContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_DoDContractMember_7c717c6d-d605-41ef-aefb-640d39494fb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_ab2b6452-6fa2-4372-bd04-6b137b74089f" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_ab2b6452-6fa2-4372-bd04-6b137b74089f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember_1a2c2ddf-2afb-4018-9927-6d3f5dc762b3" xlink:href="nvax-20221231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_CEPIGrantFundingMember_1a2c2ddf-2afb-4018-9927-6d3f5dc762b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_61388200-5a94-4dc0-9494-5c2a345758c8" xlink:href="nvax-20221231.xsd#nvax_TakedaArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_TakedaArrangementMember_61388200-5a94-4dc0-9494-5c2a345758c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_adbb26c9-ba35-4a88-ab55-ae7956ff126c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_adbb26c9-ba35-4a88-ab55-ae7956ff126c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_22e3dfd6-f7ed-4ff5-9393-8d107f9f51ba" xlink:href="nvax-20221231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_22e3dfd6-f7ed-4ff5-9393-8d107f9f51ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaad5764-1774-4a60-af86-e84dc41d25c0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:to="loc_srt_RangeMember_eaad5764-1774-4a60-af86-e84dc41d25c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:to="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4067f4e0-af87-4d54-9467-729e6ef81e40" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:to="loc_srt_MinimumMember_4067f4e0-af87-4d54-9467-729e6ef81e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5daa1ba5-e3b8-4dc2-848e-4c90812e0332" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:to="loc_srt_MaximumMember_5daa1ba5-e3b8-4dc2-848e-4c90812e0332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd7f4f02-badb-4daa-a46e-2501fecddd1b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:to="loc_srt_ProductsAndServicesDomain_bd7f4f02-badb-4daa-a46e-2501fecddd1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:to="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_35093a4d-74bf-4095-8ec4-58b8f7e64611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:to="loc_us-gaap_GovernmentContractMember_35093a4d-74bf-4095-8ec4-58b8f7e64611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_6c891466-3f20-49ae-8439-490b7fdbde11" xlink:href="nvax-20221231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_6c891466-3f20-49ae-8439-490b7fdbde11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_adbdc4bf-eb48-4467-83d7-797861195bd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_adbdc4bf-eb48-4467-83d7-797861195bd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ab9cf0b7-09f8-47b4-8120-2f724de6a63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:to="loc_us-gaap_SubsequentEventMember_ab9cf0b7-09f8-47b4-8120-2f724de6a63d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="extended" id="ifbdd51dad1c04ced8af6696aea6254d3_RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_73e4653f-19b7-4466-8b05-dcaf454d53f2" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_73e4653f-19b7-4466-8b05-dcaf454d53f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73241689-d1cf-4424-b6fd-6f70c45eca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73241689-d1cf-4424-b6fd-6f70c45eca30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_de09d900-3ba3-47ba-820e-5cc66f3a6ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_de09d900-3ba3-47ba-820e-5cc66f3a6ee5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eb26644a-dbc2-4a1f-9641-ded650c1d9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eb26644a-dbc2-4a1f-9641-ded650c1d9d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_b05d0f3a-8243-400d-b6b6-1d213720a167" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_b05d0f3a-8243-400d-b6b6-1d213720a167" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount_2864934c-9abc-45ba-b3ee-98722d701a54" xlink:href="nvax-20221231.xsd#nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount_2864934c-9abc-45ba-b3ee-98722d701a54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c2dec62-cd92-48a5-b660-46a57d09aef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c2dec62-cd92-48a5-b660-46a57d09aef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c2dec62-cd92-48a5-b660-46a57d09aef0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c2dec62-cd92-48a5-b660-46a57d09aef0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c2dec62-cd92-48a5-b660-46a57d09aef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c2dec62-cd92-48a5-b660-46a57d09aef0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_403170fb-9642-4c44-a56c-971964635387" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_403170fb-9642-4c44-a56c-971964635387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_242b0598-6868-4ad6-a99c-7eea5014d9a7" xlink:href="nvax-20221231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_242b0598-6868-4ad6-a99c-7eea5014d9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09d89cf5-039f-4322-99cd-52a1db9e6e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09d89cf5-039f-4322-99cd-52a1db9e6e77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_09d89cf5-039f-4322-99cd-52a1db9e6e77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09d89cf5-039f-4322-99cd-52a1db9e6e77" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_09d89cf5-039f-4322-99cd-52a1db9e6e77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dc6ddeea-c972-480d-92e1-c209c4f4917d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09d89cf5-039f-4322-99cd-52a1db9e6e77" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dc6ddeea-c972-480d-92e1-c209c4f4917d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueMember_4c10e259-dc71-4961-92a4-71906e1a5613" xlink:href="nvax-20221231.xsd#nvax_RevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dc6ddeea-c972-480d-92e1-c209c4f4917d" xlink:to="loc_nvax_RevenueMember_4c10e259-dc71-4961-92a4-71906e1a5613" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueScheduleofProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="extended" id="i15531bbe34a749759b6edba44f5f18b0_RevenueScheduleofProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_17457ba8-a080-49f6-bd46-76ceb99447bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f2464c6d-5018-46d5-8fa2-cf7b02a84bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_17457ba8-a080-49f6-bd46-76ceb99447bd" xlink:to="loc_us-gaap_Revenues_f2464c6d-5018-46d5-8fa2-cf7b02a84bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_17457ba8-a080-49f6-bd46-76ceb99447bd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68781f40-3e27-41a8-b2f0-9b80e5450f25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:to="loc_srt_ProductOrServiceAxis_68781f40-3e27-41a8-b2f0-9b80e5450f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68781f40-3e27-41a8-b2f0-9b80e5450f25_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_68781f40-3e27-41a8-b2f0-9b80e5450f25" xlink:to="loc_srt_ProductsAndServicesDomain_68781f40-3e27-41a8-b2f0-9b80e5450f25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b817f0d-010d-40c5-bc0b-25cbadf5aa1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_68781f40-3e27-41a8-b2f0-9b80e5450f25" xlink:to="loc_srt_ProductsAndServicesDomain_8b817f0d-010d-40c5-bc0b-25cbadf5aa1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5daa2def-691b-4b7d-927e-2f7c5563f3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b817f0d-010d-40c5-bc0b-25cbadf5aa1f" xlink:to="loc_us-gaap_ProductMember_5daa2def-691b-4b7d-927e-2f7c5563f3bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e86f43fa-a4fa-4e72-9400-a84af0953a11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:to="loc_srt_StatementGeographicalAxis_e86f43fa-a4fa-4e72-9400-a84af0953a11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e86f43fa-a4fa-4e72-9400-a84af0953a11_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e86f43fa-a4fa-4e72-9400-a84af0953a11" xlink:to="loc_srt_SegmentGeographicalDomain_e86f43fa-a4fa-4e72-9400-a84af0953a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e86f43fa-a4fa-4e72-9400-a84af0953a11" xlink:to="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_8148e584-63c3-43fc-9c9f-fbcf871fa684" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:to="loc_srt_NorthAmericaMember_8148e584-63c3-43fc-9c9f-fbcf871fa684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_e567073c-f467-49d1-b9cb-10e78e4e9687" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:to="loc_srt_EuropeMember_e567073c-f467-49d1-b9cb-10e78e4e9687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember_018ebbd6-81d4-4f32-9903-fbf7ba49fbf6" xlink:href="nvax-20221231.xsd#nvax_RestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:to="loc_nvax_RestOfTheWorldMember_018ebbd6-81d4-4f32-9903-fbf7ba49fbf6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueScheduleofGrantRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="extended" id="if50e8ff6ca0f495dba174682c93decbe_RevenueScheduleofGrantRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ff9ddeb-eca7-459e-9e4c-1f2c3c15094e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b9c6fdff-8ae0-4a4c-933b-a7b481f3082f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ff9ddeb-eca7-459e-9e4c-1f2c3c15094e" xlink:to="loc_us-gaap_Revenues_b9c6fdff-8ae0-4a4c-933b-a7b481f3082f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ff9ddeb-eca7-459e-9e4c-1f2c3c15094e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9329d37a-cbdd-4e05-822a-cc422d0354c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:to="loc_srt_ProductOrServiceAxis_9329d37a-cbdd-4e05-822a-cc422d0354c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9329d37a-cbdd-4e05-822a-cc422d0354c2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9329d37a-cbdd-4e05-822a-cc422d0354c2" xlink:to="loc_srt_ProductsAndServicesDomain_9329d37a-cbdd-4e05-822a-cc422d0354c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_662aeb2c-c425-44d8-a32b-297f4312a0a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9329d37a-cbdd-4e05-822a-cc422d0354c2" xlink:to="loc_srt_ProductsAndServicesDomain_662aeb2c-c425-44d8-a32b-297f4312a0a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_8c357484-4fa2-4248-ac3c-eaf3d2e38a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_662aeb2c-c425-44d8-a32b-297f4312a0a4" xlink:to="loc_us-gaap_GrantMember_8c357484-4fa2-4248-ac3c-eaf3d2e38a17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3bd5f009-51ca-4eec-b39a-2834bf58de3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3bd5f009-51ca-4eec-b39a-2834bf58de3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3bd5f009-51ca-4eec-b39a-2834bf58de3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3bd5f009-51ca-4eec-b39a-2834bf58de3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3bd5f009-51ca-4eec-b39a-2834bf58de3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3bd5f009-51ca-4eec-b39a-2834bf58de3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_b7a55477-c36f-412d-8372-cc16c6588f11" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_USGovernmentAgreementMember_b7a55477-c36f-412d-8372-cc16c6588f11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember_7d18dbd2-be31-4a70-ba08-65ca0b91bae0" xlink:href="nvax-20221231.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_USDepartmentOfDefenseDoDContractMember_7d18dbd2-be31-4a70-ba08-65ca0b91bae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_5606e31f-e450-4bd2-a18f-f2da7a172ad8" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_5606e31f-e450-4bd2-a18f-f2da7a172ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherGrantRevenueMember_68277269-3c91-4e94-9fa8-7f00a8c6217f" xlink:href="nvax-20221231.xsd#nvax_OtherGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_OtherGrantRevenueMember_68277269-3c91-4e94-9fa8-7f00a8c6217f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended" id="i5530dc6e568a4c4692d3678edf34a48c_CollaborationandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_5b433e6e-2224-4b06-ba42-b32c475980bf" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_5b433e6e-2224-4b06-ba42-b32c475980bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1853e760-d30b-420b-b637-2ded4096676b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1853e760-d30b-420b-b637-2ded4096676b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_c9a11b5b-c4d9-42a5-95a9-75dfbb0010ba" xlink:href="nvax-20221231.xsd#nvax_SettlementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_SettlementPayment_c9a11b5b-c4d9-42a5-95a9-75dfbb0010ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementInitialReservationFee_ca5b04a1-5878-4327-ac81-4aa1c5e960d5" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementInitialReservationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_SettlementAgreementInitialReservationFee_ca5b04a1-5878-4327-ac81-4aa1c5e960d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_8044c1f5-e8fa-4ebf-8664-77398da6e39e" xlink:href="nvax-20221231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_8044c1f5-e8fa-4ebf-8664-77398da6e39e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_61913082-176b-446a-995d-e776fdaf648d" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_61913082-176b-446a-995d-e776fdaf648d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9f2cf255-e36e-41ca-8236-d37ee21d5cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9f2cf255-e36e-41ca-8236-d37ee21d5cf7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e0a677d-4fda-4539-a3a2-d242d6fa9b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e0a677d-4fda-4539-a3a2-d242d6fa9b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e0a677d-4fda-4539-a3a2-d242d6fa9b28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e0a677d-4fda-4539-a3a2-d242d6fa9b28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e0a677d-4fda-4539-a3a2-d242d6fa9b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e0a677d-4fda-4539-a3a2-d242d6fa9b28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_23b2b99c-d188-4453-bf7f-81ee90269dd8" xlink:href="nvax-20221231.xsd#nvax_TakedaArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:to="loc_nvax_TakedaArrangementMember_23b2b99c-d188-4453-bf7f-81ee90269dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceAgreementMember_e717a309-a504-4681-9fca-4b79815159a2" xlink:href="nvax-20221231.xsd#nvax_SKBioscienceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:to="loc_nvax_SKBioscienceAgreementMember_e717a309-a504-4681-9fca-4b79815159a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_77cc7aee-9ef0-4569-ba71-2bb754e8a699" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:to="loc_nvax_SettlementAgreementMember_77cc7aee-9ef0-4569-ba71-2bb754e8a699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_682aa330-0aab-4de1-8c42-a95f8c999121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_682aa330-0aab-4de1-8c42-a95f8c999121" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_682aa330-0aab-4de1-8c42-a95f8c999121_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_682aa330-0aab-4de1-8c42-a95f8c999121" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_682aa330-0aab-4de1-8c42-a95f8c999121_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d0096a01-7cbe-415a-bc65-269f4852a41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_682aa330-0aab-4de1-8c42-a95f8c999121" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d0096a01-7cbe-415a-bc65-269f4852a41d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_6a1a1620-8588-466b-bc31-91241981e2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d0096a01-7cbe-415a-bc65-269f4852a41d" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_6a1a1620-8588-466b-bc31-91241981e2bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="id03043c1ff4042368d9e7bbd5fadefbb_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ab28660b-0267-4787-8aca-cf0ef00b74b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ab28660b-0267-4787-8aca-cf0ef00b74b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5ac219b3-a8be-40ae-b4d0-56094765278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ab28660b-0267-4787-8aca-cf0ef00b74b0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5ac219b3-a8be-40ae-b4d0-56094765278d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4fbc9d8f-4a96-4765-9c84-f2a2d2601162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4fbc9d8f-4a96-4765-9c84-f2a2d2601162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a0f00918-52fc-404e-ba64-dfd7e9e881dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4fbc9d8f-4a96-4765-9c84-f2a2d2601162" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a0f00918-52fc-404e-ba64-dfd7e9e881dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_cf114802-9753-44c5-b33f-f15793a0252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_cf114802-9753-44c5-b33f-f15793a0252f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf302360-1898-4335-abc4-ff1e83a3a22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf302360-1898-4335-abc4-ff1e83a3a22f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf302360-1898-4335-abc4-ff1e83a3a22f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf302360-1898-4335-abc4-ff1e83a3a22f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf302360-1898-4335-abc4-ff1e83a3a22f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf302360-1898-4335-abc4-ff1e83a3a22f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_84a485c1-d882-4cf5-8964-206196896415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_84a485c1-d882-4cf5-8964-206196896415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_175af9e6-93ba-44ec-b4d7-ba4d4579a997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_175af9e6-93ba-44ec-b4d7-ba4d4579a997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_33710145-a4e1-4893-88d9-f35f2223cbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_33710145-a4e1-4893-88d9-f35f2223cbf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b042aedd-2c8d-4c8b-a682-867827608a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b042aedd-2c8d-4c8b-a682-867827608a38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_feca6c8e-50ba-4813-97e9-47a39b7094ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_feca6c8e-50ba-4813-97e9-47a39b7094ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9df80e2f-cbf0-44bc-93f8-c1498f4074a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9df80e2f-cbf0-44bc-93f8-c1498f4074a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_0a891796-a274-4ea1-bd02-d469c1b643dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_AgencySecuritiesMember_0a891796-a274-4ea1-bd02-d469c1b643dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0a29c942-28bd-4c60-9efd-79c5b4ba1c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_0a29c942-28bd-4c60-9efd-79c5b4ba1c36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0a29c942-28bd-4c60-9efd-79c5b4ba1c36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0a29c942-28bd-4c60-9efd-79c5b4ba1c36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0a29c942-28bd-4c60-9efd-79c5b4ba1c36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0a29c942-28bd-4c60-9efd-79c5b4ba1c36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07e121c1-ac3e-47c4-9c0d-5dd7e1275929" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07e121c1-ac3e-47c4-9c0d-5dd7e1275929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_443284fa-6d3b-4841-970f-92146375ee8e" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_443284fa-6d3b-4841-970f-92146375ee8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_092fbe36-06ef-4c71-973c-76b5d88be4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_092fbe36-06ef-4c71-973c-76b5d88be4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_d78da311-6a48-4efc-a4c7-0ab1685e3bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_092fbe36-06ef-4c71-973c-76b5d88be4de" xlink:to="loc_us-gaap_UnsecuredDebtMember_d78da311-6a48-4efc-a4c7-0ab1685e3bef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i5411e429c692467abf1276e3bb6b21b2_AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b808eaa7-1cbd-4e1c-ae3c-201ada90f0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b808eaa7-1cbd-4e1c-ae3c-201ada90f0da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f2e89d21-82fb-462c-811e-17ff0039b975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f2e89d21-82fb-462c-811e-17ff0039b975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bdbb9143-b44f-4302-9c31-f353629d55e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_Goodwill_bdbb9143-b44f-4302-9c31-f353629d55e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_970541ef-e655-4e97-82a3-99ab1f755b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_970541ef-e655-4e97-82a3-99ab1f755b88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_846c2d3c-69a1-4705-84b4-f8cf0dbce0f8" xlink:href="nvax-20221231.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_846c2d3c-69a1-4705-84b4-f8cf0dbce0f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e4599a91-0c0e-4ece-ae3d-0ad6e5255feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e4599a91-0c0e-4ece-ae3d-0ad6e5255feb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_82e7a300-1dc0-439b-8cb0-77b12c7b1783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_82e7a300-1dc0-439b-8cb0-77b12c7b1783" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_bf1f7f17-2c9f-4cd4-8396-9673e6aadbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_bf1f7f17-2c9f-4cd4-8396-9673e6aadbab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7142183-3856-4f7a-a982-8bfd2f7848e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_bf1f7f17-2c9f-4cd4-8396-9673e6aadbab" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7142183-3856-4f7a-a982-8bfd2f7848e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7142183-3856-4f7a-a982-8bfd2f7848e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7142183-3856-4f7a-a982-8bfd2f7848e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7142183-3856-4f7a-a982-8bfd2f7848e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4691a5d-baf3-4f07-b1e1-c747406e1fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7142183-3856-4f7a-a982-8bfd2f7848e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4691a5d-baf3-4f07-b1e1-c747406e1fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_9908c3be-07c4-4643-a8c9-ccc8d651ec7c" xlink:href="nvax-20221231.xsd#nvax_NovavaxCZFormerlyPrahaVaccinesASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4691a5d-baf3-4f07-b1e1-c747406e1fb5" xlink:to="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_9908c3be-07c4-4643-a8c9-ccc8d651ec7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails" xlink:type="extended" id="i128a1f02bcaf4cfaad31d7d29d8edde8_AcquisitionofNovavaxCZAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_acc0e76e-7ef0-4574-a5ae-ff40e2ec634f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_acc0e76e-7ef0-4574-a5ae-ff40e2ec634f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0123cb10-c4fa-4bd7-8fd9-1a93610ca0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_Goodwill_0123cb10-c4fa-4bd7-8fd9-1a93610ca0c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d8c9cebe-8157-4f39-87f2-0dfff17a3f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d8c9cebe-8157-4f39-87f2-0dfff17a3f7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b769ddb4-0daf-4f79-a877-2ffd1f85d8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b769ddb4-0daf-4f79-a877-2ffd1f85d8e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3cf2b5bb-9af2-4938-9793-b994b2c16404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3cf2b5bb-9af2-4938-9793-b994b2c16404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cf2b5bb-9af2-4938-9793-b994b2c16404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cf2b5bb-9af2-4938-9793-b994b2c16404" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cf2b5bb-9af2-4938-9793-b994b2c16404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_160ad86d-7396-48e2-9ceb-31f344030f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cf2b5bb-9af2-4938-9793-b994b2c16404" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_160ad86d-7396-48e2-9ceb-31f344030f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_a7937c95-08ce-4e31-8a7b-dff2732c26a6" xlink:href="nvax-20221231.xsd#nvax_NovavaxCZFormerlyPrahaVaccinesASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_160ad86d-7396-48e2-9ceb-31f344030f4c" xlink:to="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_a7937c95-08ce-4e31-8a7b-dff2732c26a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:to="loc_srt_RangeAxis_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d" xlink:to="loc_srt_RangeMember_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d" xlink:to="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_109c0f16-8dce-48fe-a663-48ffc08126af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:to="loc_srt_MinimumMember_109c0f16-8dce-48fe-a663-48ffc08126af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_abb2f7e6-cf7d-41b1-babe-15c5319d0625" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:to="loc_srt_MaximumMember_abb2f7e6-cf7d-41b1-babe-15c5319d0625" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i1e42ea2087084b698907ad0ba76d50d7_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_e673ff97-dd43-4505-833b-8d62a78bab12" xlink:href="nvax-20221231.xsd#nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_e673ff97-dd43-4505-833b-8d62a78bab12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet_146448e9-a3c2-4847-b498-17775a4588ce" xlink:href="nvax-20221231.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_nvax_FacilityNumberOfSquareFeet_146448e9-a3c2-4847-b498-17775a4588ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_aef97e78-b23e-4ff4-ad0b-09f2d09719ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_aef97e78-b23e-4ff4-ad0b-09f2d09719ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f90cf011-8c04-4fd7-8bc0-b070ef395cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_OperatingLeaseExpense_f90cf011-8c04-4fd7-8bc0-b070ef395cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d27d27ad-9e0d-47f3-bfed-bd677820e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d27d27ad-9e0d-47f3-bfed-bd677820e6fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f5a16dea-d8f1-4b64-93ee-91c80fc5ebd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f5a16dea-d8f1-4b64-93ee-91c80fc5ebd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_bc6063c0-5934-4f57-9cbb-e6d6b724f210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_bc6063c0-5934-4f57-9cbb-e6d6b724f210" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3b90804-2c88-40e0-958e-29783edd3777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:to="loc_srt_CounterpartyNameAxis_c3b90804-2c88-40e0-958e-29783edd3777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3b90804-2c88-40e0-958e-29783edd3777_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c3b90804-2c88-40e0-958e-29783edd3777" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3b90804-2c88-40e0-958e-29783edd3777_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c3b90804-2c88-40e0-958e-29783edd3777" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAndCMDAgreementsMember_2f91d110-4e08-4a59-8e91-140d9f346ed6" xlink:href="nvax-20221231.xsd#nvax_CMOAndCMDAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:to="loc_nvax_CMOAndCMDAgreementsMember_2f91d110-4e08-4a59-8e91-140d9f346ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700QuinceOrchardRoadAgreementMember_b407cbd3-b610-415a-88db-db1347cb6b5b" xlink:href="nvax-20221231.xsd#nvax_A700QuinceOrchardRoadAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:to="loc_nvax_A700QuinceOrchardRoadAgreementMember_b407cbd3-b610-415a-88db-db1347cb6b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityLeaseAgreementMember_d946b3aa-b9b1-4cac-8408-58d95561f269" xlink:href="nvax-20221231.xsd#nvax_FacilityLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:to="loc_nvax_FacilityLeaseAgreementMember_d946b3aa-b9b1-4cac-8408-58d95561f269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdda37fd-cc1c-41b9-8d30-bafd0518e98f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:to="loc_srt_RangeAxis_fdda37fd-cc1c-41b9-8d30-bafd0518e98f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdda37fd-cc1c-41b9-8d30-bafd0518e98f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdda37fd-cc1c-41b9-8d30-bafd0518e98f" xlink:to="loc_srt_RangeMember_fdda37fd-cc1c-41b9-8d30-bafd0518e98f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdda37fd-cc1c-41b9-8d30-bafd0518e98f" xlink:to="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a06e8a07-6590-44eb-8840-38d897b98aa2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:to="loc_srt_MinimumMember_a06e8a07-6590-44eb-8840-38d897b98aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38355cc5-2a63-49ca-a146-0173d4f7ea33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:to="loc_srt_MaximumMember_38355cc5-2a63-49ca-a146-0173d4f7ea33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_feffd25b-8ea5-4e64-9913-c89e96098746" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:to="loc_srt_StatementScenarioAxis_feffd25b-8ea5-4e64-9913-c89e96098746" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_feffd25b-8ea5-4e64-9913-c89e96098746_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_feffd25b-8ea5-4e64-9913-c89e96098746" xlink:to="loc_srt_ScenarioUnspecifiedDomain_feffd25b-8ea5-4e64-9913-c89e96098746_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_93327a22-6c96-4066-b220-adc129d34a04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_feffd25b-8ea5-4e64-9913-c89e96098746" xlink:to="loc_srt_ScenarioUnspecifiedDomain_93327a22-6c96-4066-b220-adc129d34a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_46decd8d-f253-4ea6-8ba3-a31057f36bbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_93327a22-6c96-4066-b220-adc129d34a04" xlink:to="loc_srt_ScenarioForecastMember_46decd8d-f253-4ea6-8ba3-a31057f36bbf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtScheduleofNotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="extended" id="i30417f2b4c5f4e8da19b421c3b21e150_LongTermDebtScheduleofNotesPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:href="nvax-20221231.xsd#nvax_ConvertibleNotesPayableCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:to="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent_b9635773-3e15-43c2-ba76-1fc8b2f9e576" xlink:href="nvax-20221231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:to="loc_nvax_DebtInstrumentFaceAmountCurrent_b9635773-3e15-43c2-ba76-1fc8b2f9e576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_340245a1-ad9d-48c1-94de-1cef07768ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_340245a1-ad9d-48c1-94de-1cef07768ee0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_496c9698-8cbd-45b5-96a7-56680d8c6140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_496c9698-8cbd-45b5-96a7-56680d8c6140" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:href="nvax-20221231.xsd#nvax_ConvertibleNotesPayableNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:to="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f6fa5c73-d853-4fd1-a95c-418a821ed958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f6fa5c73-d853-4fd1-a95c-418a821ed958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_94d3c013-a2f0-4adf-9925-60a1fe1eded2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_94d3c013-a2f0-4adf-9925-60a1fe1eded2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_93cd0eeb-3c9d-4c22-90c1-17d8ba449970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_93cd0eeb-3c9d-4c22-90c1-17d8ba449970" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:to="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea249842-97bf-43e6-a14f-33067bc101ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea249842-97bf-43e6-a14f-33067bc101ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea249842-97bf-43e6-a14f-33067bc101ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea249842-97bf-43e6-a14f-33067bc101ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea249842-97bf-43e6-a14f-33067bc101ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea249842-97bf-43e6-a14f-33067bc101ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_defaae60-9c58-4b3f-983d-df9cf074b234" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_defaae60-9c58-4b3f-983d-df9cf074b234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ce8b1b0c-2034-46c6-bb21-8c73b5dbf3bb" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ce8b1b0c-2034-46c6-bb21-8c73b5dbf3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7bd31a68-bfc2-4491-8ed8-a99c1f694186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7bd31a68-bfc2-4491-8ed8-a99c1f694186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4f8cb2fe-089b-4a7d-ab10-cd4820f55c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7bd31a68-bfc2-4491-8ed8-a99c1f694186" xlink:to="loc_us-gaap_UnsecuredDebtMember_4f8cb2fe-089b-4a7d-ab10-cd4820f55c42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended" id="icc2c970051f2470a89c6558ace2b9b8d_LongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4bef30d3-144f-4b23-815a-257b99983f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4bef30d3-144f-4b23-815a-257b99983f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_8e9fad77-0a55-4ab2-b95b-9872a18aceec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_8e9fad77-0a55-4ab2-b95b-9872a18aceec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_3441b342-45c5-466a-ba0b-2e90b0e56587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_3441b342-45c5-466a-ba0b-2e90b0e56587" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_61845f04-9e9d-4f94-b854-dc584f5d436a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_61845f04-9e9d-4f94-b854-dc584f5d436a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_55fd30af-c29d-47b0-b2c7-ced2f28ec816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_55fd30af-c29d-47b0-b2c7-ced2f28ec816" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_15265041-b1ab-4a87-b4ee-6c9fb1baac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_15265041-b1ab-4a87-b4ee-6c9fb1baac3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_41597e61-4485-4716-a436-6e22fc34a9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_41597e61-4485-4716-a436-6e22fc34a9ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleDebtConversionRate_79c7dfbe-e6c9-4d02-a3f6-2cf91d37956a" xlink:href="nvax-20221231.xsd#nvax_ConvertibleDebtConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_ConvertibleDebtConversionRate_79c7dfbe-e6c9-4d02-a3f6-2cf91d37956a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5a9d799-d7c4-48e0-a1b9-7acb905d0fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5a9d799-d7c4-48e0-a1b9-7acb905d0fa3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConversionPremiumPercentage_04a05fc9-dd52-4a62-a274-20a7bec761e6" xlink:href="nvax-20221231.xsd#nvax_ConversionPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_ConversionPremiumPercentage_04a05fc9-dd52-4a62-a274-20a7bec761e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e511add7-04df-4965-ba8c-c0e57f30afbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e511add7-04df-4965-ba8c-c0e57f30afbe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_a20983ec-e176-4ae4-b250-06009cb18c60" xlink:href="nvax-20221231.xsd#nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_a20983ec-e176-4ae4-b250-06009cb18c60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_9be2a98c-fc43-4d1a-ac50-8c288eff8a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_9be2a98c-fc43-4d1a-ac50-8c288eff8a72" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cb21d9a1-1313-4e43-a7e1-9eb6ef54082b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentTerm_cb21d9a1-1313-4e43-a7e1-9eb6ef54082b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3bc51cdc-4e80-4c30-a607-9800ea3153e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3bc51cdc-4e80-4c30-a607-9800ea3153e8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_fa858fae-2191-4769-a052-c6d64b5c8734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_RepaymentsOfDebt_fa858fae-2191-4769-a052-c6d64b5c8734" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8b514e67-7345-4066-a843-8e3875e102eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8b514e67-7345-4066-a843-8e3875e102eb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_73a2f2ee-6369-41a9-93f7-3dde33032065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_73a2f2ee-6369-41a9-93f7-3dde33032065" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dc3abbc4-7e3b-4c7f-a7a4-0254653806f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dc3abbc4-7e3b-4c7f-a7a4-0254653806f0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentForCappedCallTransactions_d2db513a-00f8-4e2a-af30-238542729a8c" xlink:href="nvax-20221231.xsd#nvax_PaymentForCappedCallTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_PaymentForCappedCallTransactions_d2db513a-00f8-4e2a-af30-238542729a8c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtCapPrice_891f7a6f-263f-41b4-9d62-81c20870a9b1" xlink:href="nvax-20221231.xsd#nvax_DebtCapPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_DebtCapPrice_891f7a6f-263f-41b4-9d62-81c20870a9b1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_933f5e7d-2ae8-4111-a88a-1c278325e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_933f5e7d-2ae8-4111-a88a-1c278325e1aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_933f5e7d-2ae8-4111-a88a-1c278325e1aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_933f5e7d-2ae8-4111-a88a-1c278325e1aa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_933f5e7d-2ae8-4111-a88a-1c278325e1aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d6b08539-24d1-4ee3-bff9-0ae954daa2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_933f5e7d-2ae8-4111-a88a-1c278325e1aa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d6b08539-24d1-4ee3-bff9-0ae954daa2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_b26b7f9e-aef7-4b26-b4cf-398fed5f016c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d6b08539-24d1-4ee3-bff9-0ae954daa2b4" xlink:to="loc_us-gaap_UnsecuredDebtMember_b26b7f9e-aef7-4b26-b4cf-398fed5f016c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9cd8c611-30fc-483f-ac9f-daf0b062ea02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_DebtInstrumentAxis_9cd8c611-30fc-483f-ac9f-daf0b062ea02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9cd8c611-30fc-483f-ac9f-daf0b062ea02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9cd8c611-30fc-483f-ac9f-daf0b062ea02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9cd8c611-30fc-483f-ac9f-daf0b062ea02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9cd8c611-30fc-483f-ac9f-daf0b062ea02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_d870a8cb-955d-4b30-9dab-39875ecc0f92" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_d870a8cb-955d-4b30-9dab-39875ecc0f92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_82299256-15d4-43ae-be0e-4218f5a03480" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_d870a8cb-955d-4b30-9dab-39875ecc0f92" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_82299256-15d4-43ae-be0e-4218f5a03480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_11cb3583-3361-4c96-aa6a-d00389b47bba" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_11cb3583-3361-4c96-aa6a-d00389b47bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_19a7c3bd-22cd-48f4-81e4-a9a80db9699c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_19a7c3bd-22cd-48f4-81e4-a9a80db9699c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_19a7c3bd-22cd-48f4-81e4-a9a80db9699c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_19a7c3bd-22cd-48f4-81e4-a9a80db9699c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_19a7c3bd-22cd-48f4-81e4-a9a80db9699c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_41ad83a6-bfb2-4e24-bb94-3234d5f25de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_19a7c3bd-22cd-48f4-81e4-a9a80db9699c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_41ad83a6-bfb2-4e24-bb94-3234d5f25de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_8b4d49e8-578b-4c47-bb2b-e885f147097c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_41ad83a6-bfb2-4e24-bb94-3234d5f25de8" xlink:to="loc_us-gaap_CallOptionMember_8b4d49e8-578b-4c47-bb2b-e885f147097c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b9c47af-5f2f-4346-953d-d8ccfb33af05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_srt_RangeAxis_0b9c47af-5f2f-4346-953d-d8ccfb33af05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b9c47af-5f2f-4346-953d-d8ccfb33af05_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0b9c47af-5f2f-4346-953d-d8ccfb33af05" xlink:to="loc_srt_RangeMember_0b9c47af-5f2f-4346-953d-d8ccfb33af05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fac45c99-fb42-405a-a861-efe18034a24f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0b9c47af-5f2f-4346-953d-d8ccfb33af05" xlink:to="loc_srt_RangeMember_fac45c99-fb42-405a-a861-efe18034a24f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc376c33-8b23-4a40-920c-c7b244896d22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fac45c99-fb42-405a-a861-efe18034a24f" xlink:to="loc_srt_MaximumMember_bc376c33-8b23-4a40-920c-c7b244896d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_877ff16e-e6b0-4649-a360-d7efb58590b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_877ff16e-e6b0-4649-a360-d7efb58590b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_877ff16e-e6b0-4649-a360-d7efb58590b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_877ff16e-e6b0-4649-a360-d7efb58590b7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_877ff16e-e6b0-4649-a360-d7efb58590b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_877ff16e-e6b0-4649-a360-d7efb58590b7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b21d4489-9927-4709-8c4b-9b0ccd4e0397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b21d4489-9927-4709-8c4b-9b0ccd4e0397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b8c70070-f653-4807-8d9f-aa9175fce296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b8c70070-f653-4807-8d9f-aa9175fce296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_67bf9c4d-c961-411a-a1a2-4e500a29a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_67bf9c4d-c961-411a-a1a2-4e500a29a6c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_67bf9c4d-c961-411a-a1a2-4e500a29a6c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_67bf9c4d-c961-411a-a1a2-4e500a29a6c9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_67bf9c4d-c961-411a-a1a2-4e500a29a6c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9b240f39-e102-48a3-a1a7-a874ff5c2d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_67bf9c4d-c961-411a-a1a2-4e500a29a6c9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9b240f39-e102-48a3-a1a7-a874ff5c2d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6b52b11d-88d4-4a83-97ef-b29c3a124ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9b240f39-e102-48a3-a1a7-a874ff5c2d70" xlink:to="loc_us-gaap_SubsequentEventMember_6b52b11d-88d4-4a83-97ef-b29c3a124ca0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#PreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/PreferredStockDetails" xlink:type="extended" id="i7c68ffa50a224a1bbc21297522ede72a_PreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f5d12f49-badb-4322-8935-0ff15dadc2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f5d12f49-badb-4322-8935-0ff15dadc2d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec99a905-6c57-41c0-b82b-0c834b314a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec99a905-6c57-41c0-b82b-0c834b314a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2e602794-ab9d-480e-b9fe-917737632ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_2e602794-ab9d-480e-b9fe-917737632ed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_e9fa38d0-4279-4762-87f9-c81b4d9c609f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_e9fa38d0-4279-4762-87f9-c81b4d9c609f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_68b2f38a-c7db-4cbd-99cf-8fbf9a5f205a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_68b2f38a-c7db-4cbd-99cf-8fbf9a5f205a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_56bef112-503a-41f2-ac07-3a3b1ac5d200" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_56bef112-503a-41f2-ac07-3a3b1ac5d200" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_7f9d4a30-04d4-4468-9a0c-aa61d16c566a" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_7f9d4a30-04d4-4468-9a0c-aa61d16c566a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e96e18e7-4439-456b-a263-dc026e78b831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e96e18e7-4439-456b-a263-dc026e78b831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e96e18e7-4439-456b-a263-dc026e78b831_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e96e18e7-4439-456b-a263-dc026e78b831" xlink:to="loc_us-gaap_ClassOfStockDomain_e96e18e7-4439-456b-a263-dc026e78b831_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e96e18e7-4439-456b-a263-dc026e78b831" xlink:to="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_314e02c7-f267-4fc3-801e-801b62653cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_314e02c7-f267-4fc3-801e-801b62653cb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e3341675-72af-4899-acba-3cc290bd3fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e3341675-72af-4899-acba-3cc290bd3fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9c32e6c2-f35b-4e5b-b583-ca10f0917023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9c32e6c2-f35b-4e5b-b583-ca10f0917023" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c32e6c2-f35b-4e5b-b583-ca10f0917023_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9c32e6c2-f35b-4e5b-b583-ca10f0917023" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c32e6c2-f35b-4e5b-b583-ca10f0917023_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_923279d7-f4bf-49ef-b121-bd5d1cd60e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9c32e6c2-f35b-4e5b-b583-ca10f0917023" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_923279d7-f4bf-49ef-b121-bd5d1cd60e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ba18ad51-848e-49ba-82ad-4cb0cba95a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_923279d7-f4bf-49ef-b121-bd5d1cd60e65" xlink:to="loc_us-gaap_PrivatePlacementMember_ba18ad51-848e-49ba-82ad-4cb0cba95a21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a6774590-f922-4b78-ab6b-fcdd69fbe726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a6774590-f922-4b78-ab6b-fcdd69fbe726" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6774590-f922-4b78-ab6b-fcdd69fbe726_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6774590-f922-4b78-ab6b-fcdd69fbe726" xlink:to="loc_us-gaap_EquityComponentDomain_a6774590-f922-4b78-ab6b-fcdd69fbe726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87ca3dc7-42bc-46de-8bef-3d164f458033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6774590-f922-4b78-ab6b-fcdd69fbe726" xlink:to="loc_us-gaap_EquityComponentDomain_87ca3dc7-42bc-46de-8bef-3d164f458033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_36b8e1bf-ce21-42ff-814b-9eeb940fd76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87ca3dc7-42bc-46de-8bef-3d164f458033" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_36b8e1bf-ce21-42ff-814b-9eeb940fd76e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockholdersEquityDetails" xlink:type="extended" id="iff764b9332214e31a108e12febcc5bc9_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d015ea1-e6cf-464a-a2d3-1e93c328aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d015ea1-e6cf-464a-a2d3-1e93c328aaf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_aa129c58-63d1-422c-bc4b-4d617b3f1820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_aa129c58-63d1-422c-bc4b-4d617b3f1820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f37690cb-239f-462c-a44c-26f38598c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f37690cb-239f-462c-a44c-26f38598c0f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_98184cbd-68ca-4020-9c74-c651f2ab4614" xlink:href="nvax-20221231.xsd#nvax_ShelfRegistrationStatementRemainingUnissuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_98184cbd-68ca-4020-9c74-c651f2ab4614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7c2ef435-edd0-4a17-87a1-e2535aa0eb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7c2ef435-edd0-4a17-87a1-e2535aa0eb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c2ef435-edd0-4a17-87a1-e2535aa0eb59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c2ef435-edd0-4a17-87a1-e2535aa0eb59" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c2ef435-edd0-4a17-87a1-e2535aa0eb59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c2ef435-edd0-4a17-87a1-e2535aa0eb59" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PublicOfferingMember_1c21489c-3c5c-4a1b-a829-1f50287165fc" xlink:href="nvax-20221231.xsd#nvax_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:to="loc_nvax_PublicOfferingMember_1c21489c-3c5c-4a1b-a829-1f50287165fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_UnderwriterMember_663d089e-6efd-47b2-a77a-78a9721d10cf" xlink:href="nvax-20221231.xsd#nvax_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:to="loc_nvax_UnderwriterMember_663d089e-6efd-47b2-a77a-78a9721d10cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember_12b719fe-4e5b-43ec-8358-f74dd0aba74f" xlink:href="nvax-20221231.xsd#nvax_June2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:to="loc_nvax_June2021SalesAgreementMember_12b719fe-4e5b-43ec-8358-f74dd0aba74f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81b9f514-2786-49d7-8f43-12b363718ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81b9f514-2786-49d7-8f43-12b363718ec1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_81b9f514-2786-49d7-8f43-12b363718ec1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81b9f514-2786-49d7-8f43-12b363718ec1" xlink:to="loc_us-gaap_EquityComponentDomain_81b9f514-2786-49d7-8f43-12b363718ec1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1230068-8109-41d2-a28c-42b4b8aedf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81b9f514-2786-49d7-8f43-12b363718ec1" xlink:to="loc_us-gaap_EquityComponentDomain_e1230068-8109-41d2-a28c-42b4b8aedf8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e0d889b3-7d11-4974-a050-f0e57d73dcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1230068-8109-41d2-a28c-42b4b8aedf8a" xlink:to="loc_us-gaap_CommonStockMember_e0d889b3-7d11-4974-a050-f0e57d73dcf9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i89dd3d84ba1144abb59f04ee0c7b2bb0_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0ab68a7a-95ff-47cc-85d6-43886e0575f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0ab68a7a-95ff-47cc-85d6-43886e0575f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3e7e66db-1824-4adc-90cb-2b26769083be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3e7e66db-1824-4adc-90cb-2b26769083be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_99386b89-7d03-4108-9d36-8b390ad37ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_99386b89-7d03-4108-9d36-8b390ad37ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc90da10-dd3f-45bf-852c-53e2600eb5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc90da10-dd3f-45bf-852c-53e2600eb5c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_e37b2fa9-3df0-4b6e-bfb0-b1ef0f6a920d" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_e37b2fa9-3df0-4b6e-bfb0-b1ef0f6a920d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9db36532-eb2d-4ad0-96b0-8f1124530cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9db36532-eb2d-4ad0-96b0-8f1124530cda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68e6ec0e-8180-4d7f-842a-d071e47f93a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68e6ec0e-8180-4d7f-842a-d071e47f93a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c81b51f6-3418-4482-aaa2-f5a05740e057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c81b51f6-3418-4482-aaa2-f5a05740e057" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bd0598a-d326-4005-9a3d-cb47f480a183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bd0598a-d326-4005-9a3d-cb47f480a183" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f1780a19-4d35-4674-bf98-59954d6040ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f1780a19-4d35-4674-bf98-59954d6040ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c36f28cd-b27a-44d8-91df-d5881fc826be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c36f28cd-b27a-44d8-91df-d5881fc826be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3cd63ac-2088-44c3-a3cd-4d23f81e1ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3cd63ac-2088-44c3-a3cd-4d23f81e1ba4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4d781cdf-6d52-452e-9db9-69525cb4e1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4d781cdf-6d52-452e-9db9-69525cb4e1f5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_71e59e2c-c3ef-46e5-b926-b6bd15c11bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_71e59e2c-c3ef-46e5-b926-b6bd15c11bad" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_88462d7a-6117-4735-bc5c-eb276c7c6287" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_88462d7a-6117-4735-bc5c-eb276c7c6287" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_3bdec9ca-1363-4f1f-a6b1-c9c214ccdf00" xlink:href="nvax-20221231.xsd#nvax_MaximumContributionOfEmployeesAsPayrollDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_3bdec9ca-1363-4f1f-a6b1-c9c214ccdf00" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentageOfMarketPriceForStockPurchase_4c7bbb1c-8844-45ed-9fcb-c9ac011f5cf0" xlink:href="nvax-20221231.xsd#nvax_PercentageOfMarketPriceForStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_PercentageOfMarketPriceForStockPurchase_4c7bbb1c-8844-45ed-9fcb-c9ac011f5cf0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2811e688-e5aa-4621-b992-e5de2697ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:to="loc_us-gaap_PlanNameAxis_2811e688-e5aa-4621-b992-e5de2697ee5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2811e688-e5aa-4621-b992-e5de2697ee5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2811e688-e5aa-4621-b992-e5de2697ee5e" xlink:to="loc_us-gaap_PlanNameDomain_2811e688-e5aa-4621-b992-e5de2697ee5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9e9efc2-a1e4-4bce-8b90-1de05204f770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2811e688-e5aa-4621-b992-e5de2697ee5e" xlink:to="loc_us-gaap_PlanNameDomain_d9e9efc2-a1e4-4bce-8b90-1de05204f770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_2f6da2d9-4326-444d-97e1-2c50db7f4bad" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d9e9efc2-a1e4-4bce-8b90-1de05204f770" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_2f6da2d9-4326-444d-97e1-2c50db7f4bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:to="loc_srt_RangeAxis_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b" xlink:to="loc_srt_RangeMember_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b" xlink:to="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ea43d62-f7f0-4a31-90b1-4278e0e2c90c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:to="loc_srt_MinimumMember_6ea43d62-f7f0-4a31-90b1-4278e0e2c90c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5324d1a-a625-46bb-9bce-0cdd5cd2a646" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:to="loc_srt_MaximumMember_e5324d1a-a625-46bb-9bce-0cdd5cd2a646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f905f90-5c73-4aa5-a9ec-876ad9f53482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:to="loc_us-gaap_AwardTypeAxis_2f905f90-5c73-4aa5-a9ec-876ad9f53482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f905f90-5c73-4aa5-a9ec-876ad9f53482_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2f905f90-5c73-4aa5-a9ec-876ad9f53482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f905f90-5c73-4aa5-a9ec-876ad9f53482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47dadb27-4a94-4a91-b261-7e47eb1ea6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2f905f90-5c73-4aa5-a9ec-876ad9f53482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47dadb27-4a94-4a91-b261-7e47eb1ea6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e4c7cb99-e952-4f68-b68f-88351d7fa689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47dadb27-4a94-4a91-b261-7e47eb1ea6fb" xlink:to="loc_us-gaap_EmployeeStockMember_e4c7cb99-e952-4f68-b68f-88351d7fa689" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended" id="ia7b2af7b39d44339bbcf1850d4b43319_StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dc3208e-9b4a-4632-a212-d374e9a9680d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9c49de3-537f-466b-bccf-06329384f90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dc3208e-9b4a-4632-a212-d374e9a9680d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9c49de3-537f-466b-bccf-06329384f90a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab1f0bf2-84f9-4e54-8ffc-f5deda6d16c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dc3208e-9b4a-4632-a212-d374e9a9680d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab1f0bf2-84f9-4e54-8ffc-f5deda6d16c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab1f0bf2-84f9-4e54-8ffc-f5deda6d16c8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bd4fe314-5162-4348-bd42-cc34c2296a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:to="loc_us-gaap_CostOfSalesMember_bd4fe314-5162-4348-bd42-cc34c2296a1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_350c41ee-a876-443d-93a2-ee61b1d9cbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_350c41ee-a876-443d-93a2-ee61b1d9cbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cca4a0a5-4872-49c0-9c8b-5d8623beb176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cca4a0a5-4872-49c0-9c8b-5d8623beb176" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="extended" id="id44820a227f54975b9612e2df4f614f9_StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9d1ac39-8905-4fd7-8e8c-7dff14591cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9d1ac39-8905-4fd7-8e8c-7dff14591cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11b57002-e5fd-4c56-a177-2af0282cefa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11b57002-e5fd-4c56-a177-2af0282cefa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_def943b1-8e8e-4c82-beae-b967de697abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_def943b1-8e8e-4c82-beae-b967de697abc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d6493bb8-0335-4418-8026-8f52d28ead4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d6493bb8-0335-4418-8026-8f52d28ead4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c76ebe60-9066-470e-b204-9362c4e6de42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3133063a-3d78-455c-82ef-421c2fc1adf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3133063a-3d78-455c-82ef-421c2fc1adf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_464f7833-b9b2-4904-832f-dcf2f1008fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_464f7833-b9b2-4904-832f-dcf2f1008fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0538ff27-d3cb-4813-8ddf-42124fb32d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0538ff27-d3cb-4813-8ddf-42124fb32d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7ef57bf-585b-4f71-89a3-86dd022485ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7ef57bf-585b-4f71-89a3-86dd022485ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4dab7b3b-d1d0-4253-ad79-e7a48d0c676c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4dab7b3b-d1d0-4253-ad79-e7a48d0c676c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8c12bd7-57c1-4d6a-b9c8-70097f9fef93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0a73da06-332c-4cfc-bd6f-f3da1d98dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0a73da06-332c-4cfc-bd6f-f3da1d98dbce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0f362b3-fb2e-4234-97b1-d6edaa612396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0f362b3-fb2e-4234-97b1-d6edaa612396" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fe9efa76-3783-4107-9e80-d4898931acfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0f362b3-fb2e-4234-97b1-d6edaa612396" xlink:to="loc_us-gaap_PlanNameAxis_fe9efa76-3783-4107-9e80-d4898931acfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fe9efa76-3783-4107-9e80-d4898931acfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fe9efa76-3783-4107-9e80-d4898931acfe" xlink:to="loc_us-gaap_PlanNameDomain_fe9efa76-3783-4107-9e80-d4898931acfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fe9efa76-3783-4107-9e80-d4898931acfe" xlink:to="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_eb823bb9-5cd2-4650-8a1c-f870518c388f" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_eb823bb9-5cd2-4650-8a1c-f870518c388f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_c23c6bbb-a78a-47b1-ab58-4e0870514950" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_c23c6bbb-a78a-47b1-ab58-4e0870514950" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="extended" id="i315b72b6e6ba4ee690094463a7b851a9_StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ee6ea990-d2d2-4d7e-9e08-9b4c9efa0691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ee6ea990-d2d2-4d7e-9e08-9b4c9efa0691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f697c660-c115-41ee-8def-71ecbcd32324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f697c660-c115-41ee-8def-71ecbcd32324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_59b4515e-3481-43e6-9014-dc0cad2cd9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_59b4515e-3481-43e6-9014-dc0cad2cd9aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7ff38400-964b-485b-8ebd-96a8b5dd8ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7ff38400-964b-485b-8ebd-96a8b5dd8ea5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_765a32a6-1622-4340-84ce-7357162c287c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_765a32a6-1622-4340-84ce-7357162c287c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f0f314a8-93e5-476b-b8b4-c7c44c050dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f0f314a8-93e5-476b-b8b4-c7c44c050dfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71bcf185-3f59-4ccf-94e7-8b2485c385b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71bcf185-3f59-4ccf-94e7-8b2485c385b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8254ab6-4d1c-4497-880c-964b36158aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:to="loc_us-gaap_AwardTypeAxis_e8254ab6-4d1c-4497-880c-964b36158aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8254ab6-4d1c-4497-880c-964b36158aaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e8254ab6-4d1c-4497-880c-964b36158aaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8254ab6-4d1c-4497-880c-964b36158aaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e8254ab6-4d1c-4497-880c-964b36158aaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_901e64cf-648d-4295-bcd0-95a46db129bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_901e64cf-648d-4295-bcd0-95a46db129bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_836b6002-f3ba-4b2f-886f-08a6aff782a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:to="loc_us-gaap_EmployeeStockMember_836b6002-f3ba-4b2f-886f-08a6aff782a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2b571d9-6627-4088-aed4-d77fb9eced28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:to="loc_srt_RangeAxis_d2b571d9-6627-4088-aed4-d77fb9eced28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2b571d9-6627-4088-aed4-d77fb9eced28_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d2b571d9-6627-4088-aed4-d77fb9eced28" xlink:to="loc_srt_RangeMember_d2b571d9-6627-4088-aed4-d77fb9eced28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d2b571d9-6627-4088-aed4-d77fb9eced28" xlink:to="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b91ac32-b2c1-4352-80a0-cb9a4db9ddfe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:to="loc_srt_MinimumMember_9b91ac32-b2c1-4352-80a0-cb9a4db9ddfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d86de9ca-34ab-4a4b-b3e6-ee77890e3275" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:to="loc_srt_MaximumMember_d86de9ca-34ab-4a4b-b3e6-ee77890e3275" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i9175e33abeaf4f6595c5360cc6f1c85f_StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9709106b-3b1e-45b6-9aae-11b8a65e8e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9709106b-3b1e-45b6-9aae-11b8a65e8e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bda1f64b-4e54-46a0-acdc-0c5ab06b596c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bda1f64b-4e54-46a0-acdc-0c5ab06b596c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1415599f-fedf-4735-a4df-290b50a1fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1415599f-fedf-4735-a4df-290b50a1fc73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f8cbbdd4-9ece-486e-9747-85ec184b4ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f8cbbdd4-9ece-486e-9747-85ec184b4ceb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e4e39b0-4cb0-47aa-b543-4fbf4816325f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c1aa122-7bc0-4fba-8c59-6f69c213b588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c1aa122-7bc0-4fba-8c59-6f69c213b588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0663775a-6224-4f02-9665-212eee4eb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0663775a-6224-4f02-9665-212eee4eb555" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_527230fc-e048-4228-9c2f-df91b18618b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_527230fc-e048-4228-9c2f-df91b18618b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bf7cdc58-46de-47bd-8b4a-e3d8d2d0e381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bf7cdc58-46de-47bd-8b4a-e3d8d2d0e381" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15e80019-79b7-4ff7-ba5d-f9fe89ffdbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a37fb1-1b69-4642-bdc6-f59667c9da87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a37fb1-1b69-4642-bdc6-f59667c9da87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_665c8701-dc4c-4f96-91a1-80521eec6b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a37fb1-1b69-4642-bdc6-f59667c9da87" xlink:to="loc_us-gaap_AwardTypeAxis_665c8701-dc4c-4f96-91a1-80521eec6b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_665c8701-dc4c-4f96-91a1-80521eec6b1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_665c8701-dc4c-4f96-91a1-80521eec6b1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_665c8701-dc4c-4f96-91a1-80521eec6b1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cff8faab-642c-4925-bd00-50afa68d72ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_665c8701-dc4c-4f96-91a1-80521eec6b1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cff8faab-642c-4925-bd00-50afa68d72ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc4fc8f-e8cd-497e-99ea-ef624f38aac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cff8faab-642c-4925-bd00-50afa68d72ca" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc4fc8f-e8cd-497e-99ea-ef624f38aac3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#EmployeeBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="extended" id="ib27bd675ff7e432baa212a32e2301bd5_EmployeeBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ace57eda-de8b-44af-9702-1b7e1b1fcfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ace57eda-de8b-44af-9702-1b7e1b1fcfec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9ae4336d-bbd7-4d38-bc13-3ccafbfd5bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9ae4336d-bbd7-4d38-bc13-3ccafbfd5bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_130d5e82-25cc-48ea-8e18-c69e270e615e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_130d5e82-25cc-48ea-8e18-c69e270e615e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_ee9b3eed-ac61-4fd7-bb59-beabe6ac01bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_ee9b3eed-ac61-4fd7-bb59-beabe6ac01bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMultiemployerPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementAxis_a499df15-15c8-4c90-ab7b-bd9cb4690775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:to="loc_us-gaap_CollectiveBargainingArrangementAxis_a499df15-15c8-4c90-ab7b-bd9cb4690775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain_a499df15-15c8-4c90-ab7b-bd9cb4690775_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis_a499df15-15c8-4c90-ab7b-bd9cb4690775" xlink:to="loc_us-gaap_CollectiveBargainingArrangementDomain_a499df15-15c8-4c90-ab7b-bd9cb4690775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis_a499df15-15c8-4c90-ab7b-bd9cb4690775" xlink:to="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_ea187bb4-18da-4111-a932-7ba648e82eab" xlink:href="nvax-20221231.xsd#nvax_FirstThreePercentOfParticipantsDeferralMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:to="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_ea187bb4-18da-4111-a932-7ba648e82eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_110f32e2-8252-4983-9e7c-f17d84cd11f4" xlink:href="nvax-20221231.xsd#nvax_NextTwoPercentOfParticipantsDeferralMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:to="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_110f32e2-8252-4983-9e7c-f17d84cd11f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bc3c2769-2469-4838-afec-2f39a34ff06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bc3c2769-2469-4838-afec-2f39a34ff06a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_bc3c2769-2469-4838-afec-2f39a34ff06a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bc3c2769-2469-4838-afec-2f39a34ff06a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_bc3c2769-2469-4838-afec-2f39a34ff06a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0d5b2308-bded-4b4b-b397-7819f67ebff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bc3c2769-2469-4838-afec-2f39a34ff06a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0d5b2308-bded-4b4b-b397-7819f67ebff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f97321dc-fbdf-4785-b0a6-88d629a25173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0d5b2308-bded-4b4b-b397-7819f67ebff7" xlink:to="loc_us-gaap_ForeignPlanMember_f97321dc-fbdf-4785-b0a6-88d629a25173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_434439a8-33ea-40f0-84d6-556510cc1b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_434439a8-33ea-40f0-84d6-556510cc1b2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_434439a8-33ea-40f0-84d6-556510cc1b2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_434439a8-33ea-40f0-84d6-556510cc1b2e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_434439a8-33ea-40f0-84d6-556510cc1b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0d1a1cb9-3d6d-427e-bd5b-aaa7f2042be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_434439a8-33ea-40f0-84d6-556510cc1b2e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0d1a1cb9-3d6d-427e-bd5b-aaa7f2042be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_961cfb35-8eef-46b8-bd21-55fe5491c2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0d1a1cb9-3d6d-427e-bd5b-aaa7f2042be0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_961cfb35-8eef-46b8-bd21-55fe5491c2f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="ib74110cd356f41de9048ef86046cc347_OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_10e6d47c-0065-4060-8ba8-46800a988642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_10e6d47c-0065-4060-8ba8-46800a988642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff8348c-a199-4118-813f-feaf34f89bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff8348c-a199-4118-813f-feaf34f89bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ffbae9ca-97b3-4a0c-8966-8e7121f845f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ffbae9ca-97b3-4a0c-8966-8e7121f845f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b45707ea-bf4f-4f96-8b93-7272fae95124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b45707ea-bf4f-4f96-8b93-7272fae95124" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33fdd3dd-2f64-475e-8df7-1041cff9b65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b45707ea-bf4f-4f96-8b93-7272fae95124" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33fdd3dd-2f64-475e-8df7-1041cff9b65d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33fdd3dd-2f64-475e-8df7-1041cff9b65d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33fdd3dd-2f64-475e-8df7-1041cff9b65d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33fdd3dd-2f64-475e-8df7-1041cff9b65d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33fdd3dd-2f64-475e-8df7-1041cff9b65d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_06fce64e-a7c1-47e1-b867-b39bc6b87bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_06fce64e-a7c1-47e1-b867-b39bc6b87bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_2413c9b6-3c8f-4700-b001-9dd781f42ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_2413c9b6-3c8f-4700-b001-9dd781f42ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_76d3420c-9595-4374-a73f-69d5163c9921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_76d3420c-9595-4374-a73f-69d5163c9921" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ComputerSoftwareAndHardwareMemberMember_e9800f87-6398-4c69-8f8b-3e7f8a24206d" xlink:href="nvax-20221231.xsd#nvax_ComputerSoftwareAndHardwareMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_nvax_ComputerSoftwareAndHardwareMemberMember_e9800f87-6398-4c69-8f8b-3e7f8a24206d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c566c6cf-56d1-43b0-aacd-fea096ecf938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_ConstructionInProgressMember_c566c6cf-56d1-43b0-aacd-fea096ecf938" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="extended" id="i6a8342eaf3cb4cea878bf5377081f74c_OtherFinancialInformationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49e74497-c47f-4453-8b97-99470eaca86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49e74497-c47f-4453-8b97-99470eaca86d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6088cf7f-ed64-4dc2-a47d-f4a4a6f67ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6088cf7f-ed64-4dc2-a47d-f4a4a6f67ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f99ffa4a-bef0-45fe-928a-fc9a79a5a471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f99ffa4a-bef0-45fe-928a-fc9a79a5a471" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_779c7bde-9ec2-4159-99f4-640f78cacd82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f99ffa4a-bef0-45fe-928a-fc9a79a5a471" xlink:to="loc_srt_StatementGeographicalAxis_779c7bde-9ec2-4159-99f4-640f78cacd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_779c7bde-9ec2-4159-99f4-640f78cacd82_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_779c7bde-9ec2-4159-99f4-640f78cacd82" xlink:to="loc_srt_SegmentGeographicalDomain_779c7bde-9ec2-4159-99f4-640f78cacd82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_409c49c1-02a6-4f59-b6c5-2c938dd03423" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_779c7bde-9ec2-4159-99f4-640f78cacd82" xlink:to="loc_srt_SegmentGeographicalDomain_409c49c1-02a6-4f59-b6c5-2c938dd03423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CZ_1ddef1ba-71b7-449f-8773-3f50a3e0db19" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CZ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_409c49c1-02a6-4f59-b6c5-2c938dd03423" xlink:to="loc_country_CZ_1ddef1ba-71b7-449f-8773-3f50a3e0db19" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i814530db38674717b670c502ed557cae_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29d54489-0dfe-442c-89b9-34e3bd18efa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29d54489-0dfe-442c-89b9-34e3bd18efa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f26555d1-4201-4363-8a6d-1cb074e89e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f26555d1-4201-4363-8a6d-1cb074e89e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6c9cd134-e68a-4159-8191-4721265a4f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6c9cd134-e68a-4159-8191-4721265a4f39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e35242b9-d737-4c56-8a48-a200a5bbf845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e35242b9-d737-4c56-8a48-a200a5bbf845" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_08b5a945-05d8-485a-85a8-6efe9d8befa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_08b5a945-05d8-485a-85a8-6efe9d8befa5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9329bdf0-a8eb-4f94-b74e-9f0060dcfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9329bdf0-a8eb-4f94-b74e-9f0060dcfb59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c6c595af-7dbb-4897-a2ec-728de47436b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c6c595af-7dbb-4897-a2ec-728de47436b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c6c595af-7dbb-4897-a2ec-728de47436b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c6c595af-7dbb-4897-a2ec-728de47436b4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c6c595af-7dbb-4897-a2ec-728de47436b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c6c595af-7dbb-4897-a2ec-728de47436b4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5692ed37-566a-4ffc-bb92-f7d18b528225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:to="loc_us-gaap_DomesticCountryMember_5692ed37-566a-4ffc-bb92-f7d18b528225" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4413b292-d494-4a2d-85d0-b3aeef456f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4413b292-d494-4a2d-85d0-b3aeef456f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_7cb91891-5cb8-4bb8-b905-d42edfde88d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:to="loc_us-gaap_ForeignCountryMember_7cb91891-5cb8-4bb8-b905-d42edfde88d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1fa2bc7c-52e9-4d4d-ac29-a2215188530d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1fa2bc7c-52e9-4d4d-ac29-a2215188530d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1fa2bc7c-52e9-4d4d-ac29-a2215188530d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1fa2bc7c-52e9-4d4d-ac29-a2215188530d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1fa2bc7c-52e9-4d4d-ac29-a2215188530d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_a001c807-c512-4292-a80e-b35d5745d664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1fa2bc7c-52e9-4d4d-ac29-a2215188530d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_a001c807-c512-4292-a80e-b35d5745d664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_a7ea0acb-6301-41ad-8c56-dcd8e7287629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_a001c807-c512-4292-a80e-b35d5745d664" xlink:to="loc_us-gaap_ResearchMember_a7ea0acb-6301-41ad-8c56-dcd8e7287629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_896fc992-7683-4619-9956-bb8ff755b66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:to="loc_us-gaap_TaxPeriodAxis_896fc992-7683-4619-9956-bb8ff755b66d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_896fc992-7683-4619-9956-bb8ff755b66d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_896fc992-7683-4619-9956-bb8ff755b66d" xlink:to="loc_us-gaap_TaxPeriodDomain_896fc992-7683-4619-9956-bb8ff755b66d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_896fc992-7683-4619-9956-bb8ff755b66d" xlink:to="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SubjectToExpirationMember_5a3acadf-9575-4a34-af1b-4e9c65bcdf58" xlink:href="nvax-20221231.xsd#nvax_SubjectToExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:to="loc_nvax_SubjectToExpirationMember_5a3acadf-9575-4a34-af1b-4e9c65bcdf58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NoExpirationMember_8c859143-495c-4017-bfd2-bfc09b37b02e" xlink:href="nvax-20221231.xsd#nvax_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:to="loc_nvax_NoExpirationMember_8c859143-495c-4017-bfd2-bfc09b37b02e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="extended" id="i5637ed100a764e1f827aaa6e74d70822_CommitmentandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_38488f02-5948-4dfa-a331-066ee477b339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_38488f02-5948-4dfa-a331-066ee477b339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer_25638aad-46aa-442d-b54d-39262a01ed35" xlink:href="nvax-20221231.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_LossContingencyPeriodToAnswer_25638aad-46aa-442d-b54d-39262a01ed35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_5411a017-74e1-4c62-baf8-13f02996704e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_5411a017-74e1-4c62-baf8-13f02996704e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_a6113740-57ba-4516-8674-2e1ccfccfd13" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_a6113740-57ba-4516-8674-2e1ccfccfd13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_52835ea7-6341-4583-8b93-4e12beb87b05" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_52835ea7-6341-4583-8b93-4e12beb87b05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_3645cd22-f48f-43da-953e-4be6265ffea4" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_3645cd22-f48f-43da-953e-4be6265ffea4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_02a3787c-bb98-48bf-a876-c88a5d3f44e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_us-gaap_PurchaseObligation_02a3787c-bb98-48bf-a876-c88a5d3f44e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d30d253d-31a3-489e-a1ce-125860988df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_us-gaap_LossContingenciesTable_d30d253d-31a3-489e-a1ce-125860988df7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_414e5b4f-f543-4d96-96f3-1626eafecba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d30d253d-31a3-489e-a1ce-125860988df7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_414e5b4f-f543-4d96-96f3-1626eafecba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_414e5b4f-f543-4d96-96f3-1626eafecba5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_414e5b4f-f543-4d96-96f3-1626eafecba5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_414e5b4f-f543-4d96-96f3-1626eafecba5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b831f85-9013-479a-96ce-b8def2f42dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_414e5b4f-f543-4d96-96f3-1626eafecba5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b831f85-9013-479a-96ce-b8def2f42dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_20ec04bb-627c-43cd-9f34-c191f62e0601" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b831f85-9013-479a-96ce-b8def2f42dee" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_20ec04bb-627c-43cd-9f34-c191f62e0601" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="extended" id="ife9961817ee84c01aae4457ddd44efac_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b75997dd-32f4-4631-b43e-5765a2269bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ab59211e-2b25-4459-9695-9d8c00506957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b75997dd-32f4-4631-b43e-5765a2269bc1" xlink:to="loc_us-gaap_RepaymentsOfDebt_ab59211e-2b25-4459-9695-9d8c00506957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b75997dd-32f4-4631-b43e-5765a2269bc1" xlink:to="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa5483bf-43f2-4dfd-ab38-90581abdba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa5483bf-43f2-4dfd-ab38-90581abdba5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa5483bf-43f2-4dfd-ab38-90581abdba5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa5483bf-43f2-4dfd-ab38-90581abdba5b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa5483bf-43f2-4dfd-ab38-90581abdba5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ddb19466-0c48-4c1f-a1e3-f247be6b8904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa5483bf-43f2-4dfd-ab38-90581abdba5b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ddb19466-0c48-4c1f-a1e3-f247be6b8904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07b5d137-8209-4b70-942d-1f7315016458" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ddb19466-0c48-4c1f-a1e3-f247be6b8904" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07b5d137-8209-4b70-942d-1f7315016458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58d31ec7-bb55-4475-bed1-433f02fcbc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58d31ec7-bb55-4475-bed1-433f02fcbc83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_58d31ec7-bb55-4475-bed1-433f02fcbc83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58d31ec7-bb55-4475-bed1-433f02fcbc83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_58d31ec7-bb55-4475-bed1-433f02fcbc83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f1498cc-7f8a-4548-8ca3-759a3c95a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58d31ec7-bb55-4475-bed1-433f02fcbc83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f1498cc-7f8a-4548-8ca3-759a3c95a07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2263e8e4-9852-430e-bd9a-475f9f6d6bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6f1498cc-7f8a-4548-8ca3-759a3c95a07a" xlink:to="loc_us-gaap_UnsecuredDebtMember_2263e8e4-9852-430e-bd9a-475f9f6d6bf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_99b82e61-d5f1-4787-89dd-e3c6a0cc8722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_99b82e61-d5f1-4787-89dd-e3c6a0cc8722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_99b82e61-d5f1-4787-89dd-e3c6a0cc8722_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_99b82e61-d5f1-4787-89dd-e3c6a0cc8722" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_99b82e61-d5f1-4787-89dd-e3c6a0cc8722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b8160526-4c39-4072-a3bc-e46eda386856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_99b82e61-d5f1-4787-89dd-e3c6a0cc8722" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b8160526-4c39-4072-a3bc-e46eda386856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5d097f63-e25c-421a-8b0c-145434f87769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b8160526-4c39-4072-a3bc-e46eda386856" xlink:to="loc_us-gaap_SubsequentEventMember_5d097f63-e25c-421a-8b0c-145434f87769" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_6b6bffff-f71b-4c49-b167-1b94f5f28ec6" xlink:href="nvax-20221231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_nvax_LeaseRightOfUseAsset_6b6bffff-f71b-4c49-b167-1b94f5f28ec6" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>nvax-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2e968d4d-f5d4-46a7-9a1c-6f56d63ea7b7,g:07ea8c72-99d3-4c76-b42c-1d6d27635d74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_24ebd39e-c674-4b8f-ab17-e132446b30e3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_de26a575-66d1-4992-8625-391389b1be81_terseLabel_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_label_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility [Member]</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_documentation_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:to="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8f1f7700-931a-4659-bcd0-a7471c4ad78d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_52f48104-c554-4165-a1b9-b7c9bf734544_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_143f9efc-41a1-4277-90ff-0e208522acc9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_51867c90-4393-4f5b-a991-a596612f1b4e_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_18eabf61-5653-49b0-bc9a-70c0904e0c38_terseLabel_en-US" xlink:label="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liability related to Gavi (see Note 3 and Note 18)</link:label>
    <link:label id="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_label_en-US" xlink:label="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liability Related To Advance Purchase Agreements</link:label>
    <link:label id="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_documentation_en-US" xlink:label="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liability Related To Advance Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:href="nvax-20221231.xsd#nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:to="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FacilityLeaseAgreementMember_66c8820b-c60d-4341-b5e4-f47fa451b114_terseLabel_en-US" xlink:label="lab_nvax_FacilityLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Lease Agreement</link:label>
    <link:label id="lab_nvax_FacilityLeaseAgreementMember_label_en-US" xlink:label="lab_nvax_FacilityLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Lease Agreement [Member]</link:label>
    <link:label id="lab_nvax_FacilityLeaseAgreementMember_documentation_en-US" xlink:label="lab_nvax_FacilityLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityLeaseAgreementMember" xlink:href="nvax-20221231.xsd#nvax_FacilityLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FacilityLeaseAgreementMember" xlink:to="lab_nvax_FacilityLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_106ee33f-ba37-44e2-901b-f649066e9cec_terseLabel_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC")</link:label>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_label_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC") [Member]</link:label>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_documentation_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember" xlink:href="nvax-20221231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EuropeanCommissionsECMember" xlink:to="lab_nvax_EuropeanCommissionsECMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_660cc8f0-106e-4e7b-b3a5-cce5dae287d2_terseLabel_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional purchase option, number of doses</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_label_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate, Additional Purchase Option</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_documentation_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate, Additional Purchase Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:to="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_78044bb5-3ed6-4d02-9587-d70b40dbab47_terseLabel_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from the exercise of stock-based awards</link:label>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_label_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From The Exercise Of Stock-Based Awards</link:label>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_documentation_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From The Exercise Of Stock-Based Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:href="nvax-20221231.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:to="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b7829365-a039-4ecb-9c00-96e5e5512860_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_c113f1c1-0478-49b0-aefc-d9f2c78c6b64_terseLabel_en-US" xlink:label="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Three Percent Of Participants Deferral</link:label>
    <link:label id="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_label_en-US" xlink:label="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Three Percent Of Participants Deferral Member [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:href="nvax-20221231.xsd#nvax_FirstThreePercentOfParticipantsDeferralMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:to="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_0f4054aa-5e6c-420f-a9ea-723b9fd101e0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets, finance, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0c0482a1-e649-4f71-9b3e-73cf97d11f88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f740b441-b3a8-4b89-95c0-011383879eee_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d9c035b7-56a8-4ec1-93a3-ad221d41575d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_71549e6c-3a09-446b-9571-7b49a1918d33_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_77ffbc02-203e-4387-adf1-88dcb59ff887_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d2812a2c-780e-4768-8c12-cfdadc4da646_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_f3de0b3c-2475-4f3e-ae95-36357502b187_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_450b3617-540d-4933-aa75-dce1f70114b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_bae5c515-6a7b-483b-a9ef-3bd478d13556_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f53e5f14-e47c-4261-8df1-a1a880823ccc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_d846e0c9-f3e6-43f0-b8e1-4d9d78073e32_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction (losses) gain</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryReserveRollForward_49955449-386a-467e-91aa-bf9b116711d9_terseLabel_en-US" xlink:label="lab_nvax_InventoryReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve [Roll Forward]</link:label>
    <link:label id="lab_nvax_InventoryReserveRollForward_label_en-US" xlink:label="lab_nvax_InventoryReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve [Roll Forward]</link:label>
    <link:label id="lab_nvax_InventoryReserveRollForward_documentation_en-US" xlink:label="lab_nvax_InventoryReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveRollForward" xlink:href="nvax-20221231.xsd#nvax_InventoryReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryReserveRollForward" xlink:to="lab_nvax_InventoryReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_f2d0e518-eecf-4064-95b1-d41f4df24135_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_185cc2fb-6d57-4c98-9cb5-74438cdc334c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8d980ee3-7fa2-4da6-a5bd-3a4ce4092256_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18fd204c-b03f-4b75-80b7-3b1a84ef6558_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0e22ab53-70fe-4c6d-aab8-61e690476f41_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_44ebbcd6-aaba-4a2a-b19e-368937fada3a_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryReserveOtherAdditions_55681445-9208-4ecf-9014-1a385267bcbf_terseLabel_en-US" xlink:label="lab_nvax_InventoryReserveOtherAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other additions</link:label>
    <link:label id="lab_nvax_InventoryReserveOtherAdditions_label_en-US" xlink:label="lab_nvax_InventoryReserveOtherAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Other Additions</link:label>
    <link:label id="lab_nvax_InventoryReserveOtherAdditions_documentation_en-US" xlink:label="lab_nvax_InventoryReserveOtherAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Other Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveOtherAdditions" xlink:href="nvax-20221231.xsd#nvax_InventoryReserveOtherAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryReserveOtherAdditions" xlink:to="lab_nvax_InventoryReserveOtherAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6df77599-61c0-48a3-9628-40af325b7273_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_74019cb1-7461-40ad-8dab-2106438c9c07_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency securities</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_176e1f4d-58ad-46f7-9f08-a02fbcc0a61c_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_53bcfc7c-59d5-4bd9-ac6a-b44178eb59a9_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0be0048-642b-400d-9f27-3eb7cd0c29a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0483838e-4616-44d2-a658-81890b978489_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_51f78651-6070-46cf-a64a-5f14968f0aea_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_7661af9e-7b03-4d77-95fa-5f91cc8ba40b_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_907b5c4b-35be-43bd-8a1f-87d4419ff9b2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_48ef500e-ad05-464a-ac07-e23dddd45e7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_00e25d2f-4c5b-4b8d-857e-ec8b093e980b_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_d159cbcc-b33d-4d19-a3bc-e1c29b368274_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c3d7f054-88e7-42a5-8476-7432d9d1b051_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_cbe96fdb-4748-4ee6-8546-72941e92b434_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4b6586c1-c9df-4f42-a50d-dc6289dfa01b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_cbe6ca20-1f1c-4597-a9ad-80a9bfb7774a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_cb26511a-a0d0-43e7-8ac8-db2f296a1b6e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_a2e6d3b2-9644-4f91-9c83-b2c15ef18f71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_26f52a7f-d5a9-49b0-a854-f930fa6269fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_ab4abf06-c105-4384-ae5e-168400182efd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f2c0b22c-2451-42ab-a898-2afe897364d0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_1e6f0a53-21c0-488e-be87-4a60156923f2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2a403110-2421-41aa-9b90-3445ceafa4b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_c4cd8057-d853-4fdb-b72b-028f4f7d62b4_verboseLabel_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets expensed, net of credits received</link:label>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_label_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease, Write-off</link:label>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_documentation_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease, Write-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff" xlink:href="nvax-20221231.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_OperatingAndFinanceLeaseWriteOff" xlink:to="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c576fe55-b61b-46b9-80f4-a8fe422c38ed_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentOfAustraliaMember_2dad7e6c-4e7d-427b-9a47-b3d4b2e9a919_terseLabel_en-US" xlink:label="lab_nvax_GovernmentOfAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Australia</link:label>
    <link:label id="lab_nvax_GovernmentOfAustraliaMember_label_en-US" xlink:label="lab_nvax_GovernmentOfAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Australia [Member]</link:label>
    <link:label id="lab_nvax_GovernmentOfAustraliaMember_documentation_en-US" xlink:label="lab_nvax_GovernmentOfAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Australia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfAustraliaMember" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfAustraliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentOfAustraliaMember" xlink:to="lab_nvax_GovernmentOfAustraliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e148d522-cb01-4290-a619-86a02bd8a38b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_fc6454fa-948d-4406-9d40-5ea9a1f49c45_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_8838df21-75ef-4280-8266-1a7d7e0f4079_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f1f47287-d71e-48d8-8da3-12ae2f982935_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_faa729b8-0957-4ea0-8fb7-ddf792c127fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5c561347-cdb8-4634-be31-02f804c5a929_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets expensed</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f200a289-b972-42df-902c-1ef7ff359106_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_61000ab4-1cdd-4a28-b863-9c40ef239646_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4c89026a-591f-4c99-9e42-2e7a0dc9ee7a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_19b1528b-1ec8-484d-9d23-be3837fb7254_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EuropeanCommissionMember_a0ada2e1-ee6a-4bcb-8e34-fc93e4cbb6c5_terseLabel_en-US" xlink:label="lab_nvax_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission</link:label>
    <link:label id="lab_nvax_EuropeanCommissionMember_label_en-US" xlink:label="lab_nvax_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission [Member]</link:label>
    <link:label id="lab_nvax_EuropeanCommissionMember_documentation_en-US" xlink:label="lab_nvax_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionMember" xlink:href="nvax-20221231.xsd#nvax_EuropeanCommissionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EuropeanCommissionMember" xlink:to="lab_nvax_EuropeanCommissionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_651b91d1-1f90-4163-896e-af325509a715_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0c9bfc41-3b8a-4976-a7d6-323f827c6fb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_26b50e16-1966-4a63-a1ae-82041b89791e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72a9733c-6d60-436e-b87f-bb0c0c4233db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_58e4dab5-97cf-4608-9c43-56af68e2115c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_1b939af2-acef-4a9e-9079-47c9f0adc975_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for tenant improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_4ee08c04-c68d-41d7-a60a-183ea40de6d7_terseLabel_en-US" xlink:label="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock beneficial conversion feature</link:label>
    <link:label id="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_8ee895dd-84e7-4913-9ffe-7f6f2e970a4f_verboseLabel_en-US" xlink:label="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial conversion feature</link:label>
    <link:label id="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_label_en-US" xlink:label="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease</link:label>
    <link:label id="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_documentation_en-US" xlink:label="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" xlink:to="lab_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e2d2d6e0-1b26-48d1-9fbd-5ef1074398dd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_83de09f7-56ac-4bb4-a2ff-ca1ca4bb6e4f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_68591beb-e32f-4ddf-88b0-78f7783a7858_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_70ecd596-fea3-4e7a-9f9e-74b22e37287c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7d9da882-7012-4dd9-acaf-682fcc3647db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c2d0e037-acfd-43a8-b218-8a951222d75f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_8190544c-d664-4379-be4d-302b482f5a99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_7c6a61b8-51dc-49f9-af99-339d354a406b_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase of shares each anniversary</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_da2a3ba9-33df-4d62-b76a-36e252aba934_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a6b1fab-3312-48cc-84d4-ae9e732513bf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term of stock options and stock appreciation rights outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_b3092344-4928-486e-8d00-8c099198fea7_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1c25d900-df74-4410-9bb7-3a155945d0f3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b5633ccb-1eff-491b-bb4c-958f646fb7cd_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_9df28bf2-4bfe-4c51-bc37-97b72440711b_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2005 Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Five Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6614f9d4-9a99-4d57-80ec-c0a206abfe6a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e1eb58b0-db2c-4543-bd70-84b68a1eb7f8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c4e6449-9d75-4822-94eb-787bd56f55b2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9a7e21ec-2dd2-42e2-9cd6-402c5f114d0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50022b16-60dd-4d25-b8b0-9145869ac06b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_2d082740-dd47-4fa2-ad7f-9ce7032c0798_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ee1acd24-625b-4377-81aa-37e30e421c5b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3d66db24-d1e4-45bf-9f2d-743824394d72_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0df8e568-ca36-4c4a-aac6-a1a8334cf850_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution, percentage of compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_07e1b7ba-df32-4f2a-98b7-0c7d5132824e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_fb098cf1-b242-45c5-89a4-364efe2ed66c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8d1db714-01bc-48cf-b25e-07fc5094001a_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USGovernmentMember_97927886-9ade-4bfa-8edf-28e6011dc4c8_terseLabel_en-US" xlink:label="lab_nvax_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government</link:label>
    <link:label id="lab_nvax_USGovernmentMember_label_en-US" xlink:label="lab_nvax_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government [Member]</link:label>
    <link:label id="lab_nvax_USGovernmentMember_documentation_en-US" xlink:label="lab_nvax_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentMember" xlink:href="nvax-20221231.xsd#nvax_USGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USGovernmentMember" xlink:to="lab_nvax_USGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_0b7a9c92-7a2d-4360-8f43-4066e281bdc5_terseLabel_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture</link:label>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_label_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:href="nvax-20221231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:to="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems_0259a4da-325c-4288-8555-835744fa50b3_terseLabel_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nvax-20221231.xsd#nvax_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_f1b73fee-2b53-44df-8018-a3aef9f756ee_terseLabel_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under incentive programs</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Stock Issued Under Incentive Program</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Stock Issued Under Incentive Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20221231.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_504c94fb-94ce-4a7c-8c01-8ec177b0a353_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_d2bc6c07-d205-4a1f-b820-b8ad2fe948bb_terseLabel_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxation of foreign operations</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_label_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_documentation_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:href="nvax-20221231.xsd#nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:to="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6ee29a53-c3d8-49a3-adc1-0d23ecf4117a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062f48fe-64b6-46df-8574-69702b075fe8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b9e66d54-bade-44b7-a37b-ede2908961ec_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_437cd768-324b-4670-b31e-93c80946a064_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_f5a11b7f-a01d-470c-965c-baf15423b62f_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement, contract ceiling</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Contract Ceiling</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Contract Ceiling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_742531dd-821d-432d-bfdf-33e854675d07_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_be0c84a8-76dc-42f4-a87f-8f9b6af9dd1e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_70122de7-7a9e-42d2-a5be-a28e5d2b2af7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements of tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_74a89c81-4782-4b60-84d2-5f8a8d36c356_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PercentageOfMarketPriceForStockPurchase_2c940431-a526-448e-bcb3-e13835ff4d38_terseLabel_en-US" xlink:label="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of market price for stock purchase</link:label>
    <link:label id="lab_nvax_PercentageOfMarketPriceForStockPurchase_label_en-US" xlink:label="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Market Price For Stock Purchase</link:label>
    <link:label id="lab_nvax_PercentageOfMarketPriceForStockPurchase_documentation_en-US" xlink:label="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of market price for stock purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentageOfMarketPriceForStockPurchase" xlink:href="nvax-20221231.xsd#nvax_PercentageOfMarketPriceForStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PercentageOfMarketPriceForStockPurchase" xlink:to="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0230f4ec-9b66-421b-ab09-e86dfe90aa00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_eb55b1db-c1d6-45d2-92d0-3e3fffc8b853_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_363bd847-592f-4c87-aac8-9e15395e4b36_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_84837a5c-da10-4ad9-af63-73dbe272e8e3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfb1888d-4af5-4bb2-83e8-deebd69d264c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_dcc95819-669b-4a89-90a0-9f1ece4738fb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52dc50de-8219-413c-8ad7-160e4bc39dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_680f24f6-f930-4e94-9a81-47df1f4e5419_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ComputerSoftwareAndHardwareMemberMember_9a4fd560-c413-444d-818f-618373d44b85_terseLabel_en-US" xlink:label="lab_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_nvax_ComputerSoftwareAndHardwareMemberMember_label_en-US" xlink:label="lab_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software And Hardware Member [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:href="nvax-20221231.xsd#nvax_ComputerSoftwareAndHardwareMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:to="lab_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_2fc1ac3d-615c-4269-90ce-4b2356ad726a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_496cd49e-83b7-43e2-967d-457b879b505e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_699fbc87-a077-46ec-be7f-df5d2b506a4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4b906b1f-9157-4be4-bade-df6678b1b383_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_be12373f-a0d7-4064-85b4-c0318297cf5a_terseLabel_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installment payments</link:label>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_label_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Quarterly Installment Payments</link:label>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_documentation_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Quarterly Installment Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments" xlink:href="nvax-20221231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfQuarterlyInstallmentPayments" xlink:to="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_627c096c-07e3-49c0-a8ea-328491f8c39e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fdd4e762-a28c-488b-966c-8eb6efc41e09_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_3191c324-3448-47a0-9ece-b1731cd43a1c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_070ea88f-7e8a-42a7-b8e6-63c33a7d9255_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_c7cb84de-0c68-403f-af5f-574f9a8ff987_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_da8bd6f1-0f23-4b52-ae25-d054482a9904_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dc178a38-6af9-4cee-86a5-a0181f69224b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_034e1900-d76f-445b-b915-f3e6485b0e15_terseLabel_en-US" xlink:label="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Operating and Financing Activities Lessee [Abstract]</link:label>
    <link:label id="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_documentation_en-US" xlink:label="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Operating and Financing Activities Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:href="nvax-20221231.xsd#nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_2de08299-32db-4b2a-9d4c-34f7c3de9c61_terseLabel_en-US" xlink:label="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement remaining unissued capital</link:label>
    <link:label id="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_label_en-US" xlink:label="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement Remaining Unissued Capital</link:label>
    <link:label id="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_documentation_en-US" xlink:label="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement Remaining Unissued Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:href="nvax-20221231.xsd#nvax_ShelfRegistrationStatementRemainingUnissuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:to="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f4d4256d-2655-43a1-9e4b-6b2e2e30a3a8_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_dd8cdf57-324c-4b5d-8871-485ee15eb825_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b5aa8e2a-abe7-4793-aa38-acfbc279b0a5_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f2bf2d33-2c02-4c3a-9909-484380e39355_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b4b1c0e1-8bd9-4cf1-8854-b8de1e3abee6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a684bf12-0866-470b-b086-e0a02728cf51_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2de9a597-be3b-4c94-ae77-383cca247410_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_35c8bfce-e095-44c7-a8c9-4ddfa9fb7f27_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable:</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b22e4b91-a8fb-4ddf-9cdc-3332860f2caf_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_df1868f0-ccca-42ec-adde-26c1df34c3d7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_e58e7c9b-4c75-47cd-96d0-529d790d43b6_verboseLabel_en-US" xlink:label="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Information Related to Lease [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balance sheet information related to lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:to="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_46c174fa-8273-4f04-9175-73ed447f18ec_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:to="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_36f1af1e-f8ae-44f6-b19b-d0300ed301e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_86e5f404-e1b3-45af-9c3b-2dc9a95105e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_2331a8c3-a637-4442-bd65-6b02606df0a1_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1273491f-990d-4505-9eb0-525f0044153e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_2501259a-21be-4e32-b367-0595456419aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_30b065d3-0de9-4bd4-bd74-9c8e28866a2c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_e9ba8786-3da6-4bcf-ac6a-925b122412b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_8328b8c2-5f6a-4a3a-8aa6-f02ab63f6b52_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2bdcb5d7-6b0c-42e5-b5ac-0a7630413490_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_137a9fbb-fca5-4c35-8cca-c64ddba48f76_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_4705c701-5f72-4c76-a063-3097b3a826b1_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3d16b479-4d74-4b5b-baab-5d26b6c4ffc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d27658a6-dcba-4e4a-ba64-c832d9102a53_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e226ce7-b5d7-4e9f-a4a8-d2a645b558ca_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount_7c743eb7-ba14-4f78-a45d-fc601199d395_terseLabel_en-US" xlink:label="lab_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation satisfied at previous quarter</link:label>
    <link:label id="lab_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount_label_en-US" xlink:label="lab_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation Satisfied at Point in Time, Amount</link:label>
    <link:label id="lab_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount_documentation_en-US" xlink:label="lab_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation Satisfied at Point in Time, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" xlink:href="nvax-20221231.xsd#nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" xlink:to="lab_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6efea3d0-c5c6-4831-bb9a-3dfdb8886aba_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_164bc49e-3877-4d2b-b683-5e7391451a3e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f1a06c48-6e1e-4fad-9f22-c02f3fbb32e2_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense on convertible notes payable</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_641a5583-d0fe-40da-8532-d77ebd92c109_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits and compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_574bf368-98ef-4049-b67a-007c5761d90a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_0894f512-2494-4490-9c9c-f24dc6488ab1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentOfIsraelMember_becb7736-ae39-4891-aac1-cd60e884902d_terseLabel_en-US" xlink:label="lab_nvax_GovernmentOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Israel</link:label>
    <link:label id="lab_nvax_GovernmentOfIsraelMember_label_en-US" xlink:label="lab_nvax_GovernmentOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Israel [Member]</link:label>
    <link:label id="lab_nvax_GovernmentOfIsraelMember_documentation_en-US" xlink:label="lab_nvax_GovernmentOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Israel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfIsraelMember" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfIsraelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentOfIsraelMember" xlink:to="lab_nvax_GovernmentOfIsraelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_414fb10d-5890-4752-9716-c743b7d9893c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2b643f64-5f5e-4890-afbd-551591c34229_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06c37fcb-c4c8-44f3-b074-2a5dc0b11592_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4ee11f5b-97d2-40c2-beda-f3d7657e6cae_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5a066bb1-add4-406e-b9eb-7378f1937a8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AuditInformationAbstract_label_en-US" xlink:label="lab_nvax_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_nvax_AuditInformationAbstract_documentation_en-US" xlink:label="lab_nvax_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AuditInformationAbstract" xlink:href="nvax-20221231.xsd#nvax_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AuditInformationAbstract" xlink:to="lab_nvax_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d9bf73c3-1175-4202-bf02-318595e0ffee_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_2c01e6ad-544d-454a-944a-741ee153af46_terseLabel_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets from new lease agreements</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:href="nvax-20221231.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:to="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_32742a51-58b5-415e-ae74-ed64d803eff6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_eb3a89ce-50ec-4854-9d57-2cebc94b9e96_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0222bd80-7235-4b1a-87e9-b79e1ef9eb50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used in Estimation of Fair Value of Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_672dff79-67fd-4846-8a8e-f0ebce01b5bc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseLiabilityNoncurrent_36024c61-8b8b-4b01-8db7-afef6b4045a8_totalLabel_en-US" xlink:label="lab_nvax_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current lease liabilities</link:label>
    <link:label id="lab_nvax_LeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_nvax_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Noncurrent</link:label>
    <link:label id="lab_nvax_LeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_nvax_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityNoncurrent" xlink:href="nvax-20221231.xsd#nvax_LeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseLiabilityNoncurrent" xlink:to="lab_nvax_LeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_73ebd45a-6d2e-4dbc-bcb9-0359c1d046d4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6bbe966e-dffe-4389-8cfc-44df1ecbcb22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Current Income Tax Provision (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1969212-08e8-49e6-8bad-86f183bfe278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90f80797-0d31-4b8a-9271-6a7a62d14b10_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_UnderwriterMember_4faee5f5-a598-40e9-8dd4-f05554b45189_terseLabel_en-US" xlink:label="lab_nvax_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter</link:label>
    <link:label id="lab_nvax_UnderwriterMember_label_en-US" xlink:label="lab_nvax_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter [Member]</link:label>
    <link:label id="lab_nvax_UnderwriterMember_documentation_en-US" xlink:label="lab_nvax_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_UnderwriterMember" xlink:href="nvax-20221231.xsd#nvax_UnderwriterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_UnderwriterMember" xlink:to="lab_nvax_UnderwriterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b039e6e3-4830-4c8a-9831-bcc03eb37e84_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_66908a04-5472-43ea-a332-5513abbf0ff2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term of stock options and stock appreciation rights exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_c0a3fe69-25d3-4ec4-93be-185a4ea17863_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_ede05181-9831-435c-a0b1-eebaeae18995_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ab08d08f-3be6-440a-9d50-2e96885c8f0a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7acbeb59-97d2-4fa2-9ec0-0187e802d621_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_afe8aeb0-7d1c-4f3d-8613-59a9f24577ea_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_19a518d8-e8f9-4150-9a3b-58d7505ae4bc_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_12965b5e-b650-475a-bd95-413530690f30_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f2d82e0b-9eee-4f2a-b2c4-65b0fc58e22b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SubjectToExpirationMember_b1603b7f-7ff6-450c-85fd-123416b19d62_terseLabel_en-US" xlink:label="lab_nvax_SubjectToExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subject to Expiration</link:label>
    <link:label id="lab_nvax_SubjectToExpirationMember_label_en-US" xlink:label="lab_nvax_SubjectToExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subject to Expiration [Member]</link:label>
    <link:label id="lab_nvax_SubjectToExpirationMember_documentation_en-US" xlink:label="lab_nvax_SubjectToExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SubjectToExpirationMember" xlink:href="nvax-20221231.xsd#nvax_SubjectToExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SubjectToExpirationMember" xlink:to="lab_nvax_SubjectToExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3927dc7b-bbdd-4614-b363-68d60beb22bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_31c5d30f-196e-4cef-879f-5660e469c37d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_d4b4e68f-ec25-4f09-8631-cf2b588d4231_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under incentive programs (in shares)</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Stock Issued Under Incentive Program</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Stock Issued Under Incentive Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_fa72a7ac-baf0-4a3e-a4a3-54b34a9b0d4a_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others funding</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Funding</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8e323332-550c-45fe-9217-29e8445fc290_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_840a3105-9f71-4a17-8d4f-74b591cd5937_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CZ_bdf17ac5-252e-43e8-885c-ae602a721392_terseLabel_en-US" xlink:label="lab_country_CZ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Czech Republic</link:label>
    <link:label id="lab_country_CZ_label_en-US" xlink:label="lab_country_CZ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CZECHIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CZ" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CZ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CZ" xlink:to="lab_country_CZ" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_d6fd3c9f-8faa-4131-a769-2dbd148ad8f4_terseLabel_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period to answer</link:label>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_label_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Period To Answer</link:label>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_documentation_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Period To Answer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer" xlink:href="nvax-20221231.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LossContingencyPeriodToAnswer" xlink:to="lab_nvax_LossContingencyPeriodToAnswer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6f64d9a1-f52a-479e-8ffc-eab9fbb6c685_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredTaxAssetLeasingLiability_393b17ff-0293-4ae0-905d-0ed0a9109c92_terseLabel_en-US" xlink:label="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_nvax_DeferredTaxAssetLeasingLiability_label_en-US" xlink:label="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Leasing Liability</link:label>
    <link:label id="lab_nvax_DeferredTaxAssetLeasingLiability_documentation_en-US" xlink:label="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Leasing Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetLeasingLiability" xlink:href="nvax-20221231.xsd#nvax_DeferredTaxAssetLeasingLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredTaxAssetLeasingLiability" xlink:to="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b6aa79e2-5593-401f-80b7-5b0d08fa9525_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4f3bc157-33d5-4aad-a1eb-89e74e46bbfa_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USGovernmentAgreementMember_b4acc93f-9a7f-4bd7-a62d-78e3ce0229bb_terseLabel_en-US" xlink:label="lab_nvax_USGovernmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USG Agreement</link:label>
    <link:label id="lab_nvax_USGovernmentAgreementMember_label_en-US" xlink:label="lab_nvax_USGovernmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agreement [Member]</link:label>
    <link:label id="lab_nvax_USGovernmentAgreementMember_documentation_en-US" xlink:label="lab_nvax_USGovernmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USGovernmentAgreementMember" xlink:to="lab_nvax_USGovernmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4e1486d5-2322-4ca6-b4ae-ee169ff77ae4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e7981fed-45c0-42fa-8554-a07f0ce5c35c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_07853383-dfc8-4796-81f6-52ee13411391_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9fa7f533-def6-46e3-baa8-c83adb999e1c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_label_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Abstract]</link:label>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_documentation_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract" xlink:href="nvax-20221231.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborativeArrangementAbstract" xlink:to="lab_nvax_CollaborativeArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d86f6e43-8e62-4416-959d-29226d1474c4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_fe96fd8c-714e-41ea-9eb5-6bc3b4a61360_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for excess and obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_3c3f9f14-55f9-4c16-9084-efd7da90fddc_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_816861fd-b2be-4d3f-a12f-dfdc159317e3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_9541fa16-99b4-468c-9d58-716c05f1efe9_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_9f6f61ba-6dd1-43c9-b8b5-043fbefdbd68_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_99682267-f42e-48f6-9d65-9d048aba576d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_68c28561-5dbc-4cd9-a43e-0693a0f1152a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_7b30647b-1b6c-4548-b7e0-6583664d6514_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1c2ce04d-37ee-45d1-87a4-b8b02e1d9e76_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_20e4e4a2-16a7-4551-b403-273fc9da1be7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_be5996d2-c0ab-40ec-81b8-f1b26b546eb6_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentOfCanadaMember_9bf60ab6-41f6-4a39-80a3-676f924a8863_terseLabel_en-US" xlink:label="lab_nvax_GovernmentOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Canada</link:label>
    <link:label id="lab_nvax_GovernmentOfCanadaMember_label_en-US" xlink:label="lab_nvax_GovernmentOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Canada [Member]</link:label>
    <link:label id="lab_nvax_GovernmentOfCanadaMember_documentation_en-US" xlink:label="lab_nvax_GovernmentOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfCanadaMember" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentOfCanadaMember" xlink:to="lab_nvax_GovernmentOfCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_639d70eb-ad1c-4d4b-93a1-93415a77c83d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e76d4aeb-358a-4bd8-a7b5-f72d952b085e_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6272822e-6201-4630-8650-7c458a887917_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_68b5b834-e373-4454-98ea-24891cda8548_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_892f14fb-419d-4f94-8fec-976bddfe8ff1_negatedTerseLabel_en-US" xlink:label="lab_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_label_en-US" xlink:label="lab_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses</link:label>
    <link:label id="lab_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_documentation_en-US" xlink:label="lab_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:href="nvax-20221231.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:to="lab_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_5eafdf3e-1a7f-4116-9525-cca8610cbe54_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_60c43f85-0b5f-40d0-b593-afc703a6eff5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c07fcdae-7d47-46de-a877-814852dd60d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7d0c3db2-d094-4d2d-8b14-2ce552135991_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40c90c3b-a57b-46a8-92a3-b569af4de933_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_94d19d8f-2cf8-4b35-97e6-a7c3e9cd3bfb_verboseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4fa44251-e345-4d94-894b-8cd7e6c3836e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_WeightedAverageRemainingLeaseTermAbstract_51c5cd5c-8da1-4f48-9234-8108801359dc_terseLabel_en-US" xlink:label="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years):</link:label>
    <link:label id="lab_nvax_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_nvax_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:href="nvax-20221231.xsd#nvax_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_e5ae30ed-9aa7-44c4-b9fc-164e228666d3_terseLabel_en-US" xlink:label="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Expenses</link:label>
    <link:label id="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Expenses, Policy [Policy Text Block]</link:label>
    <link:label id="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for accrued research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:href="nvax-20221231.xsd#nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:to="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_64f124cf-7a77-4b0f-a5e8-679d1cdd2c0d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_37c85be2-414c-413c-9411-a408679d61fa_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DoDContractMember_bae7b343-3305-4212-a488-e570821bd8b7_terseLabel_en-US" xlink:label="lab_nvax_DoDContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD Contract</link:label>
    <link:label id="lab_nvax_DoDContractMember_label_en-US" xlink:label="lab_nvax_DoDContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD Contract [Member]</link:label>
    <link:label id="lab_nvax_DoDContractMember_documentation_en-US" xlink:label="lab_nvax_DoDContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DoDContractMember" xlink:href="nvax-20221231.xsd#nvax_DoDContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DoDContractMember" xlink:to="lab_nvax_DoDContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_5fd637ee-967e-4655-992a-87e7357e1cfe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_OtherGrantRevenueMember_34b495ba-63c6-4820-bc6a-6aff90176d7f_terseLabel_en-US" xlink:label="lab_nvax_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue</link:label>
    <link:label id="lab_nvax_OtherGrantRevenueMember_label_en-US" xlink:label="lab_nvax_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Revenue [Member]</link:label>
    <link:label id="lab_nvax_OtherGrantRevenueMember_documentation_en-US" xlink:label="lab_nvax_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherGrantRevenueMember" xlink:href="nvax-20221231.xsd#nvax_OtherGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_OtherGrantRevenueMember" xlink:to="lab_nvax_OtherGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e0e72928-4b19-499d-9d22-2e2f7d4b5c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_cedad4b1-6ef8-48de-bd87-a4ed88c777e6_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_76b73eb7-5e5e-4701-a837-4cdc2f19713a_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e08a4457-a5fe-4621-8032-273c2a4d835e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposal to increase authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4d6e458b-146b-4d4b-93cd-687766137e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_87571010-90ba-4289-bf35-4787466c523b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b7e9d9a9-a5f2-4f11-ac2a-b0cca5c6ee94_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_81b7bca2-eaed-4b41-9a85-044df75ebdce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f5608736-8298-4aa2-aee8-c3b73999cc2e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_76fd88fa-6602-4406-90f3-ed581f125b88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_181047c7-7a0c-4698-8b12-952870354061_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest payments, net of amounts capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_165a9fac-e97e-45a6-95ea-d8b805040b2d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66860b9d-d095-4c81-b679-0231453ed798_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_7dfd5193-aed9-485e-afe8-ad61f21f34fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_e321e5e3-e3af-4eda-a0f5-35a42976a6bc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2141814e-1345-4146-a70a-1bc7dc2f1df2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_1ae7088a-c6fb-4680-8cee-6176f05b9464_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement, contract to perform for others, contract remaining</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Contract Remaining</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Contract Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_67dda9c9-c152-460e-b433-12e23a4ce10d_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and buildings</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_bbda1aec-f20f-4d99-bcd9-91dba6aaf408_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_69da01b7-4da2-4df0-8480-18b38b40c307_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_57a6b202-5934-4a4a-acbe-d125db680f86_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_7ffad604-2ce0-40f8-8c56-6590ee1ef211_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of costs related to issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0cecb8c4-51b3-495f-ba54-37d35582a5da_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_2aeae0fd-a530-403e-bdc4-25f86283499d_negatedTerseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions" xlink:href="nvax-20221231.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityDeductions" xlink:to="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d399283f-cf52-4d5d-a9a1-3363c1dafdcd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_e7daffd2-f4fa-4196-a705-a962e37d5a31_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4daea934-7661-4b61-8d9a-50cecff216c1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2d63c9ca-31e2-427e-a6b5-049c2fa10e84_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_76483f41-5182-443b-8a93-9ed12c210f33_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1605414d-edd4-4054-8416-572caeed42ae_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_416f07fd-4109-4ea0-9321-9e62c13336fd_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_090d7595-f42b-43bb-9401-b92987648f32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b2122bae-942f-4cc2-a6dd-e458ec0bd763_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_81e55b67-2282-4a1a-a557-6ab080a3d68f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1c775cc0-14f9-455a-b1c3-906daa7a6ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_66db05bd-30a6-404f-99ae-12289c50d8ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementDomain_662ea5e9-70aa-4a0b-851c-607183409c94_terseLabel_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective Bargaining Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementDomain_label_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective-Bargaining Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain" xlink:to="lab_us-gaap_CollectiveBargainingArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9e5a83cf-ac69-4bfc-86cb-3aabfa890853_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_19f04f1a-9190-4f6d-935b-9a42c74f8eb5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_9ebf35fc-62b5-4083-9e04-ffef5e959493_terseLabel_en-US" xlink:label="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution of employees as payroll deductions</link:label>
    <link:label id="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_label_en-US" xlink:label="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Contribution Of Employees As Payroll Deductions</link:label>
    <link:label id="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_documentation_en-US" xlink:label="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution of employees as payroll deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:href="nvax-20221231.xsd#nvax_MaximumContributionOfEmployeesAsPayrollDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:to="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_fe1a44b7-f1b2-4b80-b04d-9af3963fc87b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4a71dce9-9010-45c4-a406-41adb79e8efe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_27a15a23-b70c-4a34-b794-f6b4d65620ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5162ed9e-839a-4c1d-aefd-0cb4ec9b746c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6d4e0494-bef5-4c50-8002-11460b67e4df_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ee74f308-0f82-4a79-ac75-eac8ff4214aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_830d86ba-124d-4077-96a8-47653e6d02c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_b2beec11-4ef0-427a-ac60-ca894a7a948b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3609ae65-c7d0-4dad-a41e-065d144f26ff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d460edcd-634b-447b-8e15-aa902efe1f20_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_a6ef0fb8-979e-4a13-8955-6101735c453b_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5be51350-5b55-4cc5-9191-4e8f9bdbb67f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_99f4dc62-dad1-4501-b999-a4552a0ac60c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_a47a20b8-99fd-4b3a-9590-204ff185a280_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_077f32fa-8544-418d-92b9-253f9b1dc233_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2803a39c-8d2d-4ddf-829e-e7db2c6beda5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2b51d022-78d7-4e79-bb83-6ec5cf57c662_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_91cc7b8e-27e1-4ddd-a635-1a17076c2233_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_03c1d3f3-80ce-4faa-871b-1878b3b0d8a6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e4e15d92-a978-417f-a44f-510cdde53548_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_d2245ef4-82b2-4dd6-87d1-94cb3903b55c_negatedTerseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_62bff33d-cf60-416e-80e8-2845ab9d27c7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_81d85698-933f-4212-8c30-a9e87f09acea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b5fbba00-179e-45be-8db5-6fecfb6c0a05_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_7f3b3844-81c4-4e7d-b974-cd09519dc666_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion (shares issued)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_c42666a0-5686-4587-bde4-b7dbdf64dfb3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_a76a4cee-3099-4af6-ba37-0567354b965a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f6ec05a8-b936-444a-a9cd-81e9f5d6fa35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_128a3887-c803-4423-8c30-a74bed5a5316_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1424bf1f-76f5-4957-98c8-72d5a221fe39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercisable at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_eccc9b5d-f56d-4932-bdf9-fc3142bb3776_terseLabel_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_52e7c6ff-89b7-48b7-b51d-8cc6c2a693af_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_e751f3cb-e24a-4856-abf8-ba426b2da08c_terseLabel_en-US" xlink:label="lab_nvax_NovavaxCZFormerlyPrahaVaccinesASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novavax CZ</link:label>
    <link:label id="lab_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_label_en-US" xlink:label="lab_nvax_NovavaxCZFormerlyPrahaVaccinesASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novavax CZ (Formerly Praha Vaccines A.S) [Member]</link:label>
    <link:label id="lab_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_documentation_en-US" xlink:label="lab_nvax_NovavaxCZFormerlyPrahaVaccinesASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novavax CZ (Formerly Praha Vaccines A.S)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember" xlink:href="nvax-20221231.xsd#nvax_NovavaxCZFormerlyPrahaVaccinesASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember" xlink:to="lab_nvax_NovavaxCZFormerlyPrahaVaccinesASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_c92bd240-fea2-4535-aeb1-765c2a801c50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f75cd65e-6ffd-4b18-8969-b54f4e08fb51_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_5e293303-984e-4878-9f0c-6b99916725da_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_ecd1ca2a-b63f-4b0f-a8ab-546693c88d83_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementInitialReservationFee_51b20b58-bd17-4ad0-b2ad-2f3389ef19ff_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementInitialReservationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial reservation fee</link:label>
    <link:label id="lab_nvax_SettlementAgreementInitialReservationFee_label_en-US" xlink:label="lab_nvax_SettlementAgreementInitialReservationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Initial Reservation Fee</link:label>
    <link:label id="lab_nvax_SettlementAgreementInitialReservationFee_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementInitialReservationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Initial Reservation Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementInitialReservationFee" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementInitialReservationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementInitialReservationFee" xlink:to="lab_nvax_SettlementAgreementInitialReservationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c860fa72-0aec-49c9-9a91-05d442705ba1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_771475a8-fa3a-43ea-a8c1-82b1a804a7db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractMember_9e55cdc9-7dca-4b81-bc8b-ebf74f7d7cc4_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contract</link:label>
    <link:label id="lab_us-gaap_GovernmentContractMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractMember" xlink:to="lab_us-gaap_GovernmentContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_d8a0b760-f3ff-41b1-a81e-62a06fc4b3c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_b777ba8f-d70a-47b0-a7b0-2ce935b2c069_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows used in finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_f1c300a0-5a7c-40c9-86af-12b06a89c6f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Capital Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCapitalImprovements" xlink:to="lab_us-gaap_PaymentsForCapitalImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_da6e019c-2669-4591-b15f-16ff6f8a3da9_terseLabel_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties</link:label>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_label_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties [Member]</link:label>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_documentation_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember" xlink:href="nvax-20221231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SalesBasedRoyaltiesMember" xlink:to="lab_nvax_SalesBasedRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_5519f045-d0dc-4eff-884f-e9311005632e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19fc17d8-8b3c-40c0-8104-fda23975f2b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ad9f951-9b98-4ae6-a833-5b86f5a38219_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfInventoryReserveTableTextBlock_be960565-72e0-4221-869b-422f2b27b771_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserve</link:label>
    <link:label id="lab_nvax_ScheduleOfInventoryReserveTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserve [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfInventoryReserveTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfInventoryReserveTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:to="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a270fece-e827-4e91-a56d-71cb578ef1c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_7f9c7843-0bbb-4a29-8f3c-fbfe8ad78262_terseLabel_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Notes, Make-Whole Fundamental Change</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_label_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change [Member]</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_documentation_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:to="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9aed7a77-c066-4fdd-91c5-84c3ae4a6ae8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_e0ea0447-986d-4250-bba7-20830440591c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_b563b133-7b6f-4a05-ae70-9f89f9bbef79_terseLabel_en-US" xlink:label="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase percentage of principal amount</link:label>
    <link:label id="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_label_en-US" xlink:label="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Of Principal Amount, Percentage</link:label>
    <link:label id="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_documentation_en-US" xlink:label="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Of Principal Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:href="nvax-20221231.xsd#nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:to="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_5290f147-e928-441d-b1c4-0cf756e501ea_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_80ad5507-710a-49d9-8e03-79192db36feb_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_2b9c3d61-b534-4e73-8ff3-9f1b70a7eddd_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal, state, and foreign current income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6657d548-8aa6-4666-bf79-11eacb4dbb1b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3d31846b-3faa-4a8a-beb3-1e1f765a9915_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets, operating, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_7a8b00f7-b55c-4604-8969-369a62fafa55_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_129c4d1f-6d3c-4173-9c1c-9276884ebf61_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7c5cb86f-7af4-4340-9058-1766e5c70bf8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_6945c25a-dbcf-4e69-9d68-793f4669554d_terseLabel_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, number of square feet</link:label>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_label_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Number of Square Feet</link:label>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_documentation_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet" xlink:href="nvax-20221231.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FacilityNumberOfSquareFeet" xlink:to="lab_nvax_FacilityNumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_43327366-edf5-4276-ab03-601689f38d9a_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4294cc06-8d87-4081-ac5a-2488307f74d3_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_4e56a347-e8e2-4f45-93cb-e25855a6c33c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PublicOfferingMember_50cfde7c-d282-4984-aaef-37b598d804fe_terseLabel_en-US" xlink:label="lab_nvax_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_nvax_PublicOfferingMember_label_en-US" xlink:label="lab_nvax_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_nvax_PublicOfferingMember_documentation_en-US" xlink:label="lab_nvax_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PublicOfferingMember" xlink:href="nvax-20221231.xsd#nvax_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PublicOfferingMember" xlink:to="lab_nvax_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_2ac92e61-efcf-4c50-a391-492f22c6ad9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2748d87c-7f1f-48f1-b896-d222437bca01_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_4d43cd58-742b-4998-ad87-58b1ccc0a84d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_2a9aa568-9ae8-4a2b-977c-43f0abfc9d1a_terseLabel_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Convertible notes due 2027</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_e4126cfe-82d3-4be6-915d-ef364563a038_verboseLabel_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Notes</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_label_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027 [Member]</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_documentation_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:to="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesTable_f2c5f0ca-334f-4a0e-b26d-811c321ba449_terseLabel_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:href="nvax-20221231.xsd#nvax_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d1d68738-2ad7-4e66-851a-bea6be961971_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_80119ff5-4752-418e-bb3c-97297f41af73_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8fbbfe9f-bbae-487b-8b0c-efe88a97551c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option and Appreciation Rights Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ec473897-a000-499e-927b-efe85f531cc9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_5004bc3f-47d4-4a4d-8492-3e3b54c43661_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8318dfe0-8861-4cda-8160-d6423c95b75f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_b16e81fc-2017-4edd-aa94-f78106a6dd61_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_302654b7-b9fe-43f7-8dae-2295efe09f74_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7f1a08f0-6fd6-4b20-9c1f-47468280cf90_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f1230afb-cc09-4b17-ba2e-9d475427e406_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for debt converted (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4f26952e-9c40-4b8f-9192-b29916f8f3d5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseLiabilityCurrent_57f520de-b8b7-4282-9f0e-0c5e9897c429_totalLabel_en-US" xlink:label="lab_nvax_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current lease liabilities</link:label>
    <link:label id="lab_nvax_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_nvax_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Current</link:label>
    <link:label id="lab_nvax_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_nvax_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityCurrent" xlink:href="nvax-20221231.xsd#nvax_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseLiabilityCurrent" xlink:to="lab_nvax_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_149daef7-0b5a-468c-abc0-7308d9a3e8c2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, prepaid expenses, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_ab588e54-b45f-45e1-9d50-14e4af571b4c_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_840c8500-45ba-4b90-af5f-fde322b5e886_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementMember_4756179a-1450-47aa-a9fb-5b6a4474432b_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement</link:label>
    <link:label id="lab_nvax_SettlementAgreementMember_label_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement [Member]</link:label>
    <link:label id="lab_nvax_SettlementAgreementMember_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementMember" xlink:to="lab_nvax_SettlementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d8aa8ad1-c99c-4c8d-81b0-5607167ac942_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_78539415-6f7d-4308-b9cf-f061d965b7e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_04bc6bfd-5ea2-43d2-863a-aabf289a124f_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_5446e2ae-b1bf-4fb5-85a9-1d8a35a097fb_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_a35a1ee1-a040-4ace-b2c8-d541459f34d5_terseLabel_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current ROU assets</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_3cecf5f4-2e83-4a90-91a5-41c7844ee7f6_totalLabel_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current ROU assets</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset" xlink:href="nvax-20221231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseRightOfUseAsset" xlink:to="lab_nvax_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_b2becdc2-d279-487f-954e-3440cc021daf_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3701ee31-dbe6-4b64-bde2-f8d5a8f51369_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a62de4cd-10cc-4bd7-855a-625af06e819e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0740dcd3-5ac6-445a-989a-0077be6a5060_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b3ae3174-9197-4dc9-92c5-7b42c1dae444_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_045ce3fd-8e8e-443c-8d10-6d06fb5ec000_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4c3ddf7e-9092-4132-bb2a-54e44625acbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8c40ad81-debb-4d29-9aec-ecf1dc745b4d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5406c10-d031-4043-8bd5-d72ed984bd1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_381e5679-4226-4c49-970f-a0e74c149c4f_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1090788a-d97a-4fb5-a643-6439ca66d143_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par or stated value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e0682376-163e-45bf-bed4-5e4be7af682c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e060e675-0871-40d0-b9ee-b8ed0872580b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01caa15b-369f-4bd1-af89-6f5f5ae4cb26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_04125387-7c9c-4e98-a2fc-9efc2eda0afd_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase agreement, number of vaccine doses</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Vaccine Doses</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Vaccine Doses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:to="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_e592add1-587d-44b6-8699-490c06973d7b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4a2bdada-d7ae-408f-9e86-47eeaac182e2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4f09a405-32f8-43db-b42f-5cf50d589d06_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cff53108-b40c-4fd3-8f1e-d2c4cde4e7b4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_7060a0f3-9a25-4499-a67b-0db4abac632f_terseLabel_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation, customer status, period</link:label>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_label_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Customer Status, Period</link:label>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_documentation_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Customer Status, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod" xlink:to="lab_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ea764d12-2f69-46e5-b0f8-6bb0fd43f5f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options and stock appreciation rights exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TakedaArrangementMember_da7e95dd-7585-454d-8c02-814977417cf7_terseLabel_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_label_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement [Member]</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_documentation_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember" xlink:href="nvax-20221231.xsd#nvax_TakedaArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TakedaArrangementMember" xlink:to="lab_nvax_TakedaArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7bd057c7-b6dc-422d-acc7-719e9d6c6a99_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c5861526-1db9-4c52-932b-247a66cf26c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c9525fc3-7298-47b4-bb0e-d4d473294698_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e4e59a3a-1546-4b1b-9370-7442226576bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_7ad3298a-ff16-4c18-8735-bb557bd2219f_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed contracts receivable</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b0eee444-6ccc-4ca1-9bce-e2f1a012e11e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_93b3e6c3-da51-430f-bb2b-089802252c16_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c60f827f-6c61-4a67-8f69-ca24e59e561a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_62c31fab-64e4-469d-b862-28822956daf2_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts:</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_7ec04305-077d-4d77-9567-bc095e5a46fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_96da0d2d-1b61-4ca6-b4d4-becf0cf70cca_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_92a18e7d-2515-4cd3-a9b1-b7eb164e2083_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 600,000,000 shares authorized at December&#160;31, 2022 and 2021; and 86,806,554 shares issued and 86,039,923 shares outstanding at December&#160;31, 2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_bcfc8dc2-714c-49d5-a802-75284819b2e3_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses, cancelled</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Cancelled</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:to="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5d9ebfbe-7bb9-4ae2-b076-bf67db104891_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8468269b-eb1c-49f2-8949-296e2f2c8118_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_11e9e2e8-89aa-4b39-b561-e4f5b546028d_terseLabel_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement</link:label>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_label_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement [Member]</link:label>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_documentation_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:href="nvax-20221231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:to="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_47b3554e-1f71-4521-abff-0eef6341c67a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_8f093e8e-4315-4040-b4f9-9a56c2a8fb33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_3d1c88ec-9e6f-4231-9773-5cb4b3ccbeae_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others grant</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Grant</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentAccruals_6c2e5f63-e9cf-44a1-815e-a0fe576198bf_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development accruals</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentAccruals_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Accruals</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentAccruals_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Accruals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentAccruals" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentAccruals" xlink:to="lab_nvax_ResearchAndDevelopmentAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c5ccd0d3-28d0-4117-a614-168c540a41c4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options and stock appreciation rights exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_9c2bb8a0-7348-4bbd-989c-a742b0e98ea8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_51cd7eec-3458-4d14-a45a-0fd0583e7cf2_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5418c217-8b2d-4959-9982-e17c725e853f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_940c0910-69a7-411b-80e4-200611d95435_terseLabel_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock under the Sales Agreement not settled at year-end</link:label>
    <link:label id="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_label_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Or Sale Of Equity Not Settled</link:label>
    <link:label id="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_documentation_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of proceeds from issuance or sale of equity not settled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:href="nvax-20221231.xsd#nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:to="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9b4f86c1-7bdd-4b3e-b2a3-3ef10bdfc7b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_351cdc79-0e35-4915-9004-7b37558fa9e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b3c6aae-51c4-411a-82eb-c677222d8217_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_734e4265-c1ba-49ab-aedf-94078f46a3f0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_714e4817-4760-448d-b0ca-53f1db5bde6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_c3453fba-afcf-49ef-af45-e5d1543d2080_verboseLabel_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_label_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Related to Convertible Notes [Table Text Block]</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_documentation_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of interest expense related to convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:href="nvax-20221231.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:to="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_55c94a58-0d81-4fdb-a3b3-ecb565968eb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5dfcb851-902e-4377-baa9-c5d766c8251b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_f10f23fa-e675-4f5c-b31e-68ca46c5ae2b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_171cccd2-6815-479a-a4b8-016a5b291340_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_b61cf272-ad91-42b5-950f-6ebca497a360_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3651d0e3-b84b-454e-b87d-4c8839711604_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4013bb99-29dd-4194-9412-377e72776112_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_604cfac4-baa9-444b-9172-a94b0261592b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_62ebff3f-9ca8-43c5-a5ed-7459452fd4f4_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_afe63683-5b50-4b1a-8a5b-9d9fadcfd525_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_db00bdbf-f06e-47f2-90c0-c706b4412d42_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidate_78330140-fcb9-4872-8e2a-5d7b219d2223_terseLabel_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidate_label_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidate_documentation_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfDosesOfVaccineCandidate" xlink:to="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f5873f51-5b0e-4fee-aaf4-dcc61e2e26dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_390689ee-cdd4-46c1-bd2b-fb38edc9402a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_87ff26f6-49c7-491a-bac1-42d25a6d95da_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_0dee7d17-1144-4cf6-88f1-0f6f7e2bd6dd_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_06f568f3-31a3-44ed-84c5-920be19b03ae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224fbc75-dc17-4383-9e2a-fcbe00c4c161_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredTaxAssetsOriginalDiscountInterest_5b1061a4-821f-4100-bbd1-ad150363d3d2_verboseLabel_en-US" xlink:label="lab_nvax_DeferredTaxAssetsOriginalDiscountInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original discount interest</link:label>
    <link:label id="lab_nvax_DeferredTaxAssetsOriginalDiscountInterest_label_en-US" xlink:label="lab_nvax_DeferredTaxAssetsOriginalDiscountInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Original Discount Interest</link:label>
    <link:label id="lab_nvax_DeferredTaxAssetsOriginalDiscountInterest_documentation_en-US" xlink:label="lab_nvax_DeferredTaxAssetsOriginalDiscountInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from original discount interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetsOriginalDiscountInterest" xlink:href="nvax-20221231.xsd#nvax_DeferredTaxAssetsOriginalDiscountInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredTaxAssetsOriginalDiscountInterest" xlink:to="lab_nvax_DeferredTaxAssetsOriginalDiscountInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7a01aff5-34e0-43f8-89c3-ac1377ddcce9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryReserveChargedToCostsOfSales_afab8d7f-ebf0-49d9-8a8f-83134c4239f8_verboseLabel_en-US" xlink:label="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_nvax_InventoryReserveChargedToCostsOfSales_8e8b3c76-cbe7-44db-b6d1-27afd26523a3_terseLabel_en-US" xlink:label="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to Cost of sales, including impairments</link:label>
    <link:label id="lab_nvax_InventoryReserveChargedToCostsOfSales_label_en-US" xlink:label="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Charged to Costs of sales</link:label>
    <link:label id="lab_nvax_InventoryReserveChargedToCostsOfSales_documentation_en-US" xlink:label="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Charged to Costs of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveChargedToCostsOfSales" xlink:href="nvax-20221231.xsd#nvax_InventoryReserveChargedToCostsOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryReserveChargedToCostsOfSales" xlink:to="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_9c44baff-cc01-4ad3-a54a-dd30cf7a640f_terseLabel_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_label_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL [Member]</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_documentation_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:to="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c1790db-4225-40c0-aead-0886e4acbd62_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d1c6d675-995a-4624-b168-162a734d78e8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_52053c07-3742-4293-bf2e-53c88a8c6601_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_042ccbb3-9fea-4632-9984-ef4f844fe2be_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_A700QuinceOrchardRoadAgreementMember_e44a5e2f-57f4-4db6-bb73-d4cefc0af134_terseLabel_en-US" xlink:label="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700 Quince Orchard Road Agreement</link:label>
    <link:label id="lab_nvax_A700QuinceOrchardRoadAgreementMember_label_en-US" xlink:label="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700 Quince Orchard Road Agreement [Member]</link:label>
    <link:label id="lab_nvax_A700QuinceOrchardRoadAgreementMember_documentation_en-US" xlink:label="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700 Quince Orchard Road Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700QuinceOrchardRoadAgreementMember" xlink:href="nvax-20221231.xsd#nvax_A700QuinceOrchardRoadAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_A700QuinceOrchardRoadAgreementMember" xlink:to="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_59681664-36f6-4218-bf9a-d59593b50a65_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_0dcb44d8-b08d-4689-bf74-2c964475ef82_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Novavax CZ</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_56dd7f64-1507-4c10-a0f3-17a95e30ad28_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_96486fd4-27a4-40a6-979d-4a14d68f2398_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0e3f6c6c-544b-426c-bc53-fabd061578fa_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b9fba98-c680-4943-b8d8-24a6ae14b16c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e4ace76b-701b-43ae-8a9b-a60815a4c04a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_b776021f-4da8-4a3e-8c0e-6d2b32f01a89_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_61024379-36ad-476b-9998-2be96d80ca5c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60cf57e8-81d7-4061-b2d3-39a050dd9923_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercisable at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_592c14e5-b435-4b66-bd16-7ed6a1c449ef_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_92c7286a-16f8-4c56-b884-e4099cf3b2f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6e572e7f-0dd6-490a-990a-f25e447d3c00_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory federal tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_800d2e4d-d8b6-425d-ba17-ece7903795c4_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expiration</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_170ebce2-17a9-4eb2-bcfc-0b86d6dc6b93_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ea2fff1a-a5e2-4440-b8d5-5535c62f5f1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_cd82f8ac-5ad5-430e-8ca9-fa3aaeadfb79_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ef7254d-30e7-4652-a073-c1954f11d827_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e0e1ed79-0df5-4f61-a141-9ba2d6ed6607_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0c6ad301-11b1-46f3-8279-261e5028a9d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8b28ad46-eb0f-45b3-ad0b-b5dc2d9ef0b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_09e80387-ec44-49c4-b898-6566c0e5ed7f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b1dce1f3-24c5-4df5-900d-08a832328682_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0019c08-4c58-4ec5-9656-70c5fa0ac740_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3df1eac5-7301-43fd-94bf-b5c1d275bfd7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ed0c313-eb57-4065-9066-6b18a66ecb7f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a7bc4df6-4de9-4986-9399-39bc4222d664_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c3658165-b802-4ab5-8d53-cd3f37095d6c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9a71a0fe-3651-44d1-91f9-3524a87197b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_35fe4394-d001-42cc-be9e-738d73518dc8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_9027fd35-535a-426c-b6c6-2280b1da6aef_verboseLabel_en-US" xlink:label="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information of Leases</link:label>
    <link:label id="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow information of Lease [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental cash flow information of lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:to="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_a2d1ff02-1583-45c6-ba97-1ff2df7dd861_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, 766,631 shares, cost basis at December&#160;31, 2022 and 591,980 shares, cost basis at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConvertibleNotesPayableCurrentAbstract_160eabb5-74ca-4571-88f1-a324d59c4fdf_terseLabel_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableCurrentAbstract_label_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current [Abstract]</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableCurrentAbstract_documentation_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:href="nvax-20221231.xsd#nvax_ConvertibleNotesPayableCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:to="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_33a079f5-fa40-46ad-9f53-39e511e547a6_terseLabel_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_label_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations Award [Member]</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_documentation_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:to="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_ec128ec8-55f2-40b2-adba-c365da2c2392_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cf5b21a3-ee13-4f7e-8903-8f9c95795c8d_negatedNetLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_aeefab22-18a5-4097-af7c-e6684ef012f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7110fd46-8361-4fba-8c26-b5a192981410_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_7412abb7-4ecd-4088-a5d5-ce6fef3441d9_terseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions" xlink:href="nvax-20221231.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityAdditions" xlink:to="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_4fdd6e43-c61d-4010-9207-0384ecf1286a_terseLabel_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses to be distributed</link:label>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_label_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses, To Be Distributed</link:label>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_documentation_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses, To Be Distributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfDosesToBeDistributed" xlink:to="lab_nvax_NumberOfDosesToBeDistributed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9a6f7c7a-08fa-4b91-b022-65a932053fa4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a01e3362-3fc7-482e-be87-8ad39334949d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_aa50d0ab-2892-474b-bd15-4121e3947e19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Segment Allocation [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Segment Allocation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_June2021SalesAgreementMember_6dc6396b-6781-49b9-88d0-a4bfbbd0ac6e_terseLabel_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 Sales Agreement</link:label>
    <link:label id="lab_nvax_June2021SalesAgreementMember_label_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 Sales Agreement [Member]</link:label>
    <link:label id="lab_nvax_June2021SalesAgreementMember_documentation_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember" xlink:href="nvax-20221231.xsd#nvax_June2021SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_June2021SalesAgreementMember" xlink:to="lab_nvax_June2021SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1da0844f-2a33-4206-9832-57d19919565e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6bbad9d9-5252-4605-b127-1452519f4a99_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_73866ed1-222b-4cc4-b1f9-5085b26e48c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DebtCapPrice_88ca928b-71bf-4d07-9a01-4add567376f7_terseLabel_en-US" xlink:label="lab_nvax_DebtCapPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt cap price (in usd per share)</link:label>
    <link:label id="lab_nvax_DebtCapPrice_label_en-US" xlink:label="lab_nvax_DebtCapPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Cap Price</link:label>
    <link:label id="lab_nvax_DebtCapPrice_documentation_en-US" xlink:label="lab_nvax_DebtCapPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cap rate on a debt . A payment or receipt is triggered if the market rate exceeds the cap rate on the debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtCapPrice" xlink:href="nvax-20221231.xsd#nvax_DebtCapPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DebtCapPrice" xlink:to="lab_nvax_DebtCapPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_c6a0953e-fe51-4b51-b9c0-e3ce79a90951_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7823155e-7b77-4483-b844-8a98b78a3134_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1f95f083-205f-444f-8ab4-35e8aaefa3f9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_42e0cbec-652d-4d11-b3a7-4af60c3640d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_2c0d3748-1a9c-42d8-aa88-a244f9182e99_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Semi-finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c67be3d9-2691-4f21-b858-53a23380b53b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_WeightedAverageDiscountRateAbstract_abcec16b-e5e4-4d6b-a829-aefb383f5aaa_terseLabel_en-US" xlink:label="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate:</link:label>
    <link:label id="lab_nvax_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_nvax_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageDiscountRateAbstract" xlink:href="nvax-20221231.xsd#nvax_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_WeightedAverageDiscountRateAbstract" xlink:to="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_752222de-7eec-4746-93cf-fe9d289ee4f2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConversionPremiumPercentage_37197e92-fce3-4199-8bd4-992131edb1ac_terseLabel_en-US" xlink:label="lab_nvax_ConversionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium percentage</link:label>
    <link:label id="lab_nvax_ConversionPremiumPercentage_label_en-US" xlink:label="lab_nvax_ConversionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Premium Percentage</link:label>
    <link:label id="lab_nvax_ConversionPremiumPercentage_documentation_en-US" xlink:label="lab_nvax_ConversionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the rate of premium based on the last reported sales price of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConversionPremiumPercentage" xlink:href="nvax-20221231.xsd#nvax_ConversionPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConversionPremiumPercentage" xlink:to="lab_nvax_ConversionPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f4f751c8-ab90-45d2-b3b2-a1412e2f258f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_69a59b38-ff34-445b-90d4-3909ba89c25d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_339c988f-2473-4987-9a3f-333251b0b723_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_826ed07f-9dea-4fe3-a48b-27c99e3f7b1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_86762056-886d-469c-9baf-66c75ae3b7db_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CEPIGrantFundingMember_e3a39a8b-e40c-4d09-b2b7-601a4f0fd432_terseLabel_en-US" xlink:label="lab_nvax_CEPIGrantFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI Grant Funding</link:label>
    <link:label id="lab_nvax_CEPIGrantFundingMember_label_en-US" xlink:label="lab_nvax_CEPIGrantFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI Grant Funding [Member]</link:label>
    <link:label id="lab_nvax_CEPIGrantFundingMember_documentation_en-US" xlink:label="lab_nvax_CEPIGrantFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember" xlink:href="nvax-20221231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CEPIGrantFundingMember" xlink:to="lab_nvax_CEPIGrantFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_dd6e6f28-6a87-4eb6-96f7-bb079fe70f3b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_44bf5aca-166e-470b-9249-a2e41823ee05_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_877d4dcc-a603-4435-978f-dad40c2ca46f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2f511e56-6d9b-4ed5-a32e-2cf1cd9cf559_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_9dab95dc-d1c5-4c1c-8a9a-b9ccd63437c2_terseLabel_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_documentation_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:href="nvax-20221231.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:to="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMultiemployerPlansTable_79062a40-817b-4148-877d-d234277f47b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiemployer Plan [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMultiemployerPlansTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiemployer Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMultiemployerPlansTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:to="lab_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f1aa7bf8-f3cf-4607-819d-01788890821f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_a4a6f7c5-03f1-4ff4-ae34-6220109cdf64_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm purchase commitment loss</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_36db2585-53f5-42cc-8ef0-9359f57034cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8147a714-6d42-4309-9fed-578b976be800_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_ca70b25b-07c9-4509-88fd-f0192a5b13f2_terseLabel_en-US" xlink:label="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability and right of use assets recognized</link:label>
    <link:label id="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_label_en-US" xlink:label="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability</link:label>
    <link:label id="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_documentation_en-US" xlink:label="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:href="nvax-20221231.xsd#nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:to="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ef7118e5-3018-41ad-91f3-f1e62a32a167_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options and stock appreciation rights outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb32f45a-4500-41c4-b694-c90fe502683d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5d033b6c-e2d3-4968-a955-336907f22d0d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_7ad134c1-ec39-4164-a9f1-303a370d1e90_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_7c275995-6c13-438f-9f59-9657fb55cad0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_7bd60ee7-4b40-4dd5-984e-8a935e3f5364_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement upfront payment amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_label_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:to="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d55502ba-3f80-4253-a5e3-1fbc4030c1f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_dd15d13e-138a-457c-a294-59ddbdaf415e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_120b2cd9-b119-4167-a991-78cf76483fde_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c9c1483b-7c88-47b9-817c-0daba1391fe2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_26ba5289-c214-4a3f-99fb-42ea5b0bd443_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_654b0e9b-4757-4740-aa52-3e82f9975956_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0900e060-abe2-454b-ae86-effedcac167f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9d14728c-e255-4788-8436-2a7fc62c65c0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract_8c72e8bc-9ee1-49f5-b443-b8e89e520111_terseLabel_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract_label_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent [Abstract]</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract_documentation_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:href="nvax-20221231.xsd#nvax_ConvertibleNotesPayableNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:to="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c9c76a9-f210-48ce-bc6d-c781a1eee7c0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_fe29c206-01a8-498e-94e0-7e62096d6646_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others forgivable no interest term loans</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1ce65279-ea85-4321-bec0-28947cb5b862_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_eb9cdf3e-7d72-435e-a9a2-27670272ca75_terseLabel_en-US" xlink:label="lab_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from preferred stock to additional paid in capital</link:label>
    <link:label id="lab_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued as a result of the exercise of stock options and employee stock purchase plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="lab_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab7adc8f-c5ce-4c2a-bad5-1abc5f1cc5dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_00294716-11d5-4485-a86b-7312d3382b4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2887c91e-e386-4230-8e3e-6662c9f96d5a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_81197875-1e54-49a3-b58b-307c1ae040f8_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_220cb123-4fd5-423c-8965-537fe10255ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_dacfc098-40c4-4288-ac46-8b8f47003508_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_c21be055-ed49-46b2-9ae2-7ce331d68867_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c04ac22f-8aa3-4e40-a5a9-fa5f0e62b9dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of stock price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConvertibleDebtConversionRate_84af80af-d8f4-49fa-9847-d295a846a669_terseLabel_en-US" xlink:label="lab_nvax_ConvertibleDebtConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt conversion rate</link:label>
    <link:label id="lab_nvax_ConvertibleDebtConversionRate_label_en-US" xlink:label="lab_nvax_ConvertibleDebtConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Conversion Rate</link:label>
    <link:label id="lab_nvax_ConvertibleDebtConversionRate_documentation_en-US" xlink:label="lab_nvax_ConvertibleDebtConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleDebtConversionRate" xlink:href="nvax-20221231.xsd#nvax_ConvertibleDebtConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConvertibleDebtConversionRate" xlink:to="lab_nvax_ConvertibleDebtConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_327bab21-3feb-4c80-84e1-8046e16f4a00_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_4a691f8b-54aa-4852-8c05-e7194a6538ae_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a5282d6e-6b38-4fb7-9144-a4d3973287e2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_e5323624-7084-4a2f-ba4d-091f1c7e5fe6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sales of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_496b8176-e98d-4deb-94ee-99d8b62c8c64_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_7841bc61-e47d-4d59-9243-11fe9b2b0f9f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a9861893-245e-491f-9bea-b37cb67282e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on acquiree since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SKBioscienceCoLtdMember_3504b966-4196-4f14-9dd6-34080d67496a_terseLabel_en-US" xlink:label="lab_nvax_SKBioscienceCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK bioscience, Co., Ltd.</link:label>
    <link:label id="lab_nvax_SKBioscienceCoLtdMember_label_en-US" xlink:label="lab_nvax_SKBioscienceCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK Bioscience, Co. Ltd [Member]</link:label>
    <link:label id="lab_nvax_SKBioscienceCoLtdMember_documentation_en-US" xlink:label="lab_nvax_SKBioscienceCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK Bioscience, Co. Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceCoLtdMember" xlink:href="nvax-20221231.xsd#nvax_SKBioscienceCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SKBioscienceCoLtdMember" xlink:to="lab_nvax_SKBioscienceCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_d2c18b1f-fcf7-43ba-93b1-562ec75fa325_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5685569a-5cac-4d7e-8af2-64307b1db6e5_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d0dc2aa4-4aa6-4a43-acc1-514b95a922b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_939ff8ba-84b9-448a-8c6b-41b27e8b2c04_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b90280ff-14a2-4602-ba11-88689913a8f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ed4ab27d-bb70-4960-850e-d026823faedd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenueFromContractWithCustomerCommitment_06307625-a778-40b6-b5ff-9d0ca818dee5_terseLabel_en-US" xlink:label="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_nvax_RevenueFromContractWithCustomerCommitment_label_en-US" xlink:label="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Commitment</link:label>
    <link:label id="lab_nvax_RevenueFromContractWithCustomerCommitment_documentation_en-US" xlink:label="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment" xlink:href="nvax-20221231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenueFromContractWithCustomerCommitment" xlink:to="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SKBioscienceAgreementMember_cad6b6aa-9f7c-41c5-a790-91ed3e73d780_terseLabel_en-US" xlink:label="lab_nvax_SKBioscienceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK Bioscience Agreement</link:label>
    <link:label id="lab_nvax_SKBioscienceAgreementMember_label_en-US" xlink:label="lab_nvax_SKBioscienceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK Bioscience Agreement [Member]</link:label>
    <link:label id="lab_nvax_SKBioscienceAgreementMember_documentation_en-US" xlink:label="lab_nvax_SKBioscienceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK Bioscience Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceAgreementMember" xlink:href="nvax-20221231.xsd#nvax_SKBioscienceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SKBioscienceAgreementMember" xlink:to="lab_nvax_SKBioscienceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_78213fa5-47f1-4da6-802f-697ac380b6ad_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_85afffdb-a8eb-43fa-98f1-c4de6f0b3f95_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 2,000,000 shares authorized at December&#160;31, 2022 and 2021; no shares issued and outstanding at December&#160;31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NoExpirationMember_9b5b47f6-3f78-439b-990f-2cdafb2ac073_terseLabel_en-US" xlink:label="lab_nvax_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration</link:label>
    <link:label id="lab_nvax_NoExpirationMember_label_en-US" xlink:label="lab_nvax_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration [Member]</link:label>
    <link:label id="lab_nvax_NoExpirationMember_documentation_en-US" xlink:label="lab_nvax_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NoExpirationMember" xlink:href="nvax-20221231.xsd#nvax_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NoExpirationMember" xlink:to="lab_nvax_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_25352ef0-8ca3-4999-a70a-4dfbdb8dcbf5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7ffffbb5-3f2e-4ae4-ad81-6e8ffbd41353_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_fa737c5c-caee-466b-90e5-7f8167d0d7ea_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f2a25a6b-3198-4f2c-bcbc-91e0d5696532_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a997273d-af7b-4fdc-8bc3-aefc3e90e193_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5cf1077a-876b-414b-9e82-cfab721ed956_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_0493db7e-344b-4bc7-b088-5c10141e5e45_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer matching contribution, percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_56d95fd1-0f3c-43b8-8a10-7227efd25483_negatedTerseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_label_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:to="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a118073d-6d4b-40a7-be7d-91bc9da770cf_terseLabel_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, variable consideration amount</link:label>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_1fded30d-5420-46e2-97f5-f125eba610e3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8c6ffac1-7047-45be-a256-17ec6d5d57f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8c9cc959-9ea4-43a5-b280-a280084c8753_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Accounting</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e2a325f5-ca16-4653-a099-8533388bfa9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_951dd8a8-ea3d-45f9-a0ba-37db874055bc_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_4bba6dde-3d24-4874-8414-3e8bcb44a65b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_af972d1e-5cf8-441b-a6dc-8982bfbcae72_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dab0eed4-5404-43c9-8da8-f89cfb2cca89_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7393457c-6edf-44e3-86a3-b8690f8a666a_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_164c72fc-6752-4f6b-a8b4-5c738c1d3ca6_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, end balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_daf9d0bb-753c-469c-8bea-26f300813175_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_089ecfdc-4c1e-4982-a6d8-cc449d601e07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_d091c8c9-7981-493a-9c33-2cfa41682408_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CallOptionMember_fee61452-fe8f-4bff-910e-c8c03624b4b2_terseLabel_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option</link:label>
    <link:label id="lab_us-gaap_CallOptionMember_label_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CallOptionMember" xlink:to="lab_us-gaap_CallOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_626a95c9-9954-4ddf-a1dd-64cc0eabc3bc_terseLabel_en-US" xlink:label="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Two Percent Of Participants Deferral</link:label>
    <link:label id="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_label_en-US" xlink:label="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Two Percent Of Participants Deferral Member [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:href="nvax-20221231.xsd#nvax_NextTwoPercentOfParticipantsDeferralMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:to="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7e1c8181-1e2a-4fa6-a35a-a2a5171e7322_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ec6f7b4d-38d7-44e2-9572-c94819235d6d_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenueMember_3556fe20-91d2-47fc-b916-25f16afdcca1_terseLabel_en-US" xlink:label="lab_nvax_RevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_nvax_RevenueMember_label_en-US" xlink:label="lab_nvax_RevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Member]</link:label>
    <link:label id="lab_nvax_RevenueMember_documentation_en-US" xlink:label="lab_nvax_RevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueMember" xlink:href="nvax-20221231.xsd#nvax_RevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenueMember" xlink:to="lab_nvax_RevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_fffb6205-04d3-4f8c-8762-696ccf92b24f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e3a909f4-f54f-436a-92c3-5c0cdd81ee25_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_c98a9e68-5949-404b-9a3f-b75515287d92_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_fc75b700-0feb-425b-8624-e6859201fad5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_30cee88b-ef56-43a3-9cc5-49187d179b73_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_8381ce65-14b3-4e21-8528-afb88b0f319c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_be333b89-b7bd-420c-b0b1-11d93114c875_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_0dfef5f6-82f0-411b-8b02-aa910bcab413_negatedLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_2ee70664-b77f-4525-864e-14aca4f8de7e_verboseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_label_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:to="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af95d4ee-a75b-4165-8be3-792bdf3108e3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_cce505c2-cec3-4e9f-8cd2-1803cd61efe7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4f33a12b-f4aa-4ac1-a3ab-38a8765edae0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9b86077c-8a7e-430c-88ab-38785da130e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Novavax CZ, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e53c4402-911f-4af8-bcf7-1cbe9367a2db_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_637997f9-2c22-4483-b6b7-851e002133ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_59853783-0452-44c3-a07c-886c2efc0442_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2e3bdb2e-27dd-4d5c-b2e6-f1e75843ca14_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27570890-f595-4ed0-b32f-2a3b92c8f7d9_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7fbe2c26-9b33-4d80-9ed7-3f821145ece2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_58b2906a-4002-45e7-b0a8-f921ad7fae52_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_aee3819e-dd2b-4a84-99d4-0476958c47fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_355431b0-5f43-40e3-8e5d-0eaaeb3ff1dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33ef11c9-6dbb-40a3-9aac-1c1c343101f0_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_76ad7238-d067-4c53-a5e0-ae7ca2111904_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c1060825-78b8-4f6a-9885-008444123a55_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_91153166-aa77-4df4-a477-836f06a96cdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProceedsFromIssuanceCommonStockAndDebt_7afe6c53-fa5b-4a08-88f0-830383bf97de_terseLabel_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceCommonStockAndDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and issuance debt</link:label>
    <link:label id="lab_nvax_ProceedsFromIssuanceCommonStockAndDebt_label_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceCommonStockAndDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Common Stock and Debt</link:label>
    <link:label id="lab_nvax_ProceedsFromIssuanceCommonStockAndDebt_documentation_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceCommonStockAndDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Common Stock and Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromIssuanceCommonStockAndDebt" xlink:href="nvax-20221231.xsd#nvax_ProceedsFromIssuanceCommonStockAndDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProceedsFromIssuanceCommonStockAndDebt" xlink:to="lab_nvax_ProceedsFromIssuanceCommonStockAndDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_2c136342-f39e-4b94-9c99-eab384b0d341_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3828a573-c540-4e68-9782-7815c8cdbe21_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CMOAndCMDAgreementsMember_25eb2546-e5f2-4a8c-81ad-f4047c039f22_terseLabel_en-US" xlink:label="lab_nvax_CMOAndCMDAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO and CMD Agreements</link:label>
    <link:label id="lab_nvax_CMOAndCMDAgreementsMember_label_en-US" xlink:label="lab_nvax_CMOAndCMDAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO and CMD Agreements [Member]</link:label>
    <link:label id="lab_nvax_CMOAndCMDAgreementsMember_documentation_en-US" xlink:label="lab_nvax_CMOAndCMDAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO and CMD Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAndCMDAgreementsMember" xlink:href="nvax-20221231.xsd#nvax_CMOAndCMDAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CMOAndCMDAgreementsMember" xlink:to="lab_nvax_CMOAndCMDAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_ff866c70-d2b7-4d62-af30-82b500e232f5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_2962ffa8-e58c-4812-931c-669d98fbe36c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4e3c9c18-b07d-4b08-ada6-72d7e451518c_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits balance at January 1,</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b8fdc522-74a6-4209-81b9-9e1849770cbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits balance at December 31,</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_381c8966-09b4-48c5-9cbf-70ade7b8ac3d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_3fa17c1b-edda-4d5d-a0be-f9ea8e355024_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f0bff044-a5ea-4b63-bdd5-9daed7960090_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4b9c702e-4685-4e56-950f-538ff4feb522_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_89572aad-77f1-4b22-95ff-f76c62dac12b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation to be satisfied</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember_ea6ce59b-81e3-4dc7-b02d-2b64064e92aa_terseLabel_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1c862d2f-e87a-41b9-ae41-fe7c872e9e0b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award, terms of award</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PaymentForCappedCallTransactions_09506d15-9346-417e-9411-ddab9df0df65_terseLabel_en-US" xlink:label="lab_nvax_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for capped call transactions</link:label>
    <link:label id="lab_nvax_PaymentForCappedCallTransactions_label_en-US" xlink:label="lab_nvax_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PaymentForCappedCallTransactions</link:label>
    <link:label id="lab_nvax_PaymentForCappedCallTransactions_documentation_en-US" xlink:label="lab_nvax_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of payment which is made for entering into privately negotiated capped call transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentForCappedCallTransactions" xlink:href="nvax-20221231.xsd#nvax_PaymentForCappedCallTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PaymentForCappedCallTransactions" xlink:to="lab_nvax_PaymentForCappedCallTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a11fd523-dc5e-4fbb-8a9f-dbb9469d5b80_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d284f825-79c5-4402-8353-a49092356424_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4ab33c2e-c7af-487f-9c2c-8ce461c92b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_5732cc2e-b836-4080-a4dc-3792a48b24ea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6901d82b-fae6-450d-86bd-50d4d353a7c3_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_b4eeb6cc-92a0-4294-a5f3-2148d972e6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Grant Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7dfcf144-ab7b-4f91-a157-a4da1f57ba6f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a4bf3b04-db2f-4236-8f3b-8c822b0af4d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_939e80f4-afd7-4fed-9855-9445d6b47d7e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_18ee3eb7-f0d8-45e9-a792-96b8920db5ff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RestOfTheWorldMember_bf4f8f60-ede5-410c-96fc-c9704c42c38e_terseLabel_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the world</link:label>
    <link:label id="lab_nvax_RestOfTheWorldMember_label_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World [Member]</link:label>
    <link:label id="lab_nvax_RestOfTheWorldMember_documentation_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember" xlink:href="nvax-20221231.xsd#nvax_RestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RestOfTheWorldMember" xlink:to="lab_nvax_RestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9c5f3305-ab95-4daf-9d7e-db5f8c263dc3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1c729904-319d-4e40-942d-31f03c61fab3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ab154fd9-61c8-403d-8a1c-3638c07f6bef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_44a7a2a0-9642-4e76-adcf-773122b582ad_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_32c3e804-abb7-4fe5-95e2-6ec363649151_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_fe659dd5-2aac-4bbc-bcce-42635e3c138d_terseLabel_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other</link:label>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_label_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and Other [Member]</link:label>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_documentation_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember" xlink:href="nvax-20221231.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RoyaltiesAndOtherMember" xlink:to="lab_nvax_RoyaltiesAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_655f10cf-3c08-4af6-bdff-c9ec91bffb2c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_510d7147-5daa-4873-a561-7c8d87f74086_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_f68299db-10b1-467e-b1e5-442fca016e0b_terseLabel_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations ("CEPI")</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_label_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations (CEPI) Agreement [Member]</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_documentation_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations (CEPI) Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:to="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_01c2b1ae-4132-42ec-81ac-5edfd5b271d3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, deferred tax asset, amount increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_d89c2877-cd5e-4596-89d2-3a3b2e4d8603_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_774c854f-2d6c-426c-a03a-0bae53499385_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c2810185-af0d-423d-9253-43f67549b7d3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_46386269-98cd-49e9-85a8-527dc6244372_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_cf4a1006-5e43-4cc5-bd79-28c7a1f0e1c4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_26b78482-0fb1-46f1-924b-45cfeca6885e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b293cfdf-ea2e-4faa-a465-68f88aff0978_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_b0a2b733-0d79-42c2-b6d4-0b2587448634_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_71394a16-81d2-4925-a136-595176407828_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_4c8907f2-65d3-45cf-a571-462bbcef778c_terseLabel_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_label_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI) [Member]</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_documentation_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:href="nvax-20221231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:to="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_cb53f2cb-e438-42af-a4c7-0e866b405808_periodStartLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1, 2022</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_18f9bf6a-2aad-4cf5-8ef7-ab7f06b4cbfe_periodEndLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0f30c6cd-27d4-47d9-b043-d9f989b0f737_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_00ee7bd1-bfe2-4806-9c20-2898f539ef20_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GaviVaccineAllianceMember_221be303-d770-4938-9d6b-1b035df4a1ab_terseLabel_en-US" xlink:label="lab_nvax_GaviVaccineAllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi, the Vaccine Alliance</link:label>
    <link:label id="lab_nvax_GaviVaccineAllianceMember_label_en-US" xlink:label="lab_nvax_GaviVaccineAllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Vaccine Alliance [Member]</link:label>
    <link:label id="lab_nvax_GaviVaccineAllianceMember_documentation_en-US" xlink:label="lab_nvax_GaviVaccineAllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Vaccine Alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviVaccineAllianceMember" xlink:href="nvax-20221231.xsd#nvax_GaviVaccineAllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviVaccineAllianceMember" xlink:to="lab_nvax_GaviVaccineAllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_f2dd8b0f-a195-456d-979f-f1c735654622_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4e1ea6f2-bcfd-4bd3-a5df-de9a98f8f395_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3cdbd355-3141-4e59-a22a-b9b41e218071_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6382f8c8-c4bb-416c-9519-566fffade9ae_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_505d99a7-f7a7-49ed-9408-8f830c616909_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ebc7732d-5f77-481a-a0d6-b45e4f31805b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_3f510d9f-096a-454b-83dd-b11e064b1b96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_89fbf979-9ceb-44cd-9cde-436f7634e2dd_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_b4b1fa60-9680-46e5-ab3c-11996ebabbd2_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_59b15815-8815-4f40-b108-cfe51395db9d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_4e0eac8c-5dd9-403f-b3d1-f4dabd93e5c1_terseLabel_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. DoD</link:label>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_label_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Defense ("DoD Contract") [Member]</link:label>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_documentation_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Defense ("DoD Contract")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember" xlink:href="nvax-20221231.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USDepartmentOfDefenseDoDContractMember" xlink:to="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementAxis_e65e3057-b02e-46fd-a4ac-1a4e6908df3d_terseLabel_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective Bargaining Arrangement [Axis]</link:label>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementAxis_label_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective-Bargaining Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis" xlink:to="lab_us-gaap_CollectiveBargainingArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_3c1b5647-c77b-4c60-b39e-7673aa2d173e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8e438f48-c3d4-449c-b57a-6c3fe4c86089_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tax Rate Differences</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementPayment_45f669c9-ebb2-4b59-aff3-2108edf46e60_terseLabel_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_nvax_SettlementPayment_label_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment</link:label>
    <link:label id="lab_nvax_SettlementPayment_documentation_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment" xlink:href="nvax-20221231.xsd#nvax_SettlementPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementPayment" xlink:to="lab_nvax_SettlementPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_608de640-30a0-4625-9c4f-1de5284d4327_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_9413e586-0d5f-4712-a659-5567773d48a5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_06ac74c5-c024-4a0a-a1b9-783cc51c4872_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum grant price, percent of common stock fair value</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c971695c-50a1-4002-923b-244024915e83_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5509f48c-f85d-4834-b844-ba8f44587753_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c162a76-f2a3-4079-a50c-7c21e226db73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Share Weighted-Average Grant-Date Fair Value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DebtInstrumentFaceAmountCurrent_f1ede1d6-c69c-4b77-925d-0eee89cc8223_terseLabel_en-US" xlink:label="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Current</link:label>
    <link:label id="lab_nvax_DebtInstrumentFaceAmountCurrent_label_en-US" xlink:label="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Current</link:label>
    <link:label id="lab_nvax_DebtInstrumentFaceAmountCurrent_documentation_en-US" xlink:label="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent" xlink:href="nvax-20221231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DebtInstrumentFaceAmountCurrent" xlink:to="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acef602f-4ba6-441a-9927-3e3739a45d79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_936533ac-0d90-4dc8-b4bf-a4af5c764f59_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2a1b2206-cb31-4286-81fe-2aebcba363ae_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a7061094-c814-4c0f-89ac-ef49d8de89d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_0dc33d41-56e1-428a-9a8c-c73f8fd6da94_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_665f873f-5204-40e1-8470-5210311fdfee_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fbe6d237-1939-46b5-acea-56433a9c2570_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bfe520f8-fa52-418e-adb0-3093845d7e0b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a736e3ec-502a-4c56-b74f-01477fe1cb09_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_80903a78-b492-4ac0-b27b-3f93b4c1b460_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_470fcd57-3e79-497e-b197-82ad6d04e1a5_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_e5468ca8-16eb-4e83-8dc2-5e5714d17998_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2da17a61-51bd-45cd-a5b8-0e0011c53c81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6c3bd8f5-f0e7-48b0-84fd-436b7d5550a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_e1eb7cf1-a68e-4def-a6e3-22e1377b56cc_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_fd3f0045-1b37-4f4f-912e-80c9e9f08b4f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4ba2e3c-e60d-402a-8e58-c47a09fc10d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_aeca44ee-a5a7-4b3b-8a4a-79af9f984a62_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_874a7382-a534-449a-8d1c-00bacda7dc55_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total convertible notes payable</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0f73db4c-2e75-4bd9-addb-71edbac6d309_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_42849066-037d-4a0d-9140-e2762a68fde4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7b33801-cc3e-4952-af6c-cadeaee0e2a5_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5e4e2e25-e256-4abf-8206-0e6671a975d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_76ae080f-075d-44f6-b2c8-bd427ffa8f11_terseLabel_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="nvax-20221231.xsd#nvax_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a36fa7b6-111e-4d06-bbe0-9fffea64de03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_fa90fe0b-9259-47d2-9b6b-f4731da8bdfc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_13c9e2ab-1dda-4746-b3dc-3b44581a98a3_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_9defc536-aacd-422d-a887-bedb89361f78_verboseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_63db2b07-9789-4269-b481-65a7b0abfe5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3e984de6-db51-4c92-9951-8729bba54eb7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_5a309247-806c-4da0-a8ca-a6455f2eb039_terseLabel_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for excess and obsolete inventory</link:label>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_label_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Excess And Obsolete Inventory</link:label>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_documentation_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Excess And Obsolete Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory" xlink:href="nvax-20221231.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProvisionForExcessAndObsoleteInventory" xlink:to="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab6f1492-f6bd-41fc-bb9a-937370ee970e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_3478ba99-504a-4c0e-87e3-c2db3b9166e8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount_11928efa-6195-42b9-ab3b-a387dc99e592_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement, quarterly installment amount</link:label>
    <link:label id="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount_label_en-US" xlink:label="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Quarterly Installment Amount</link:label>
    <link:label id="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Quarterly Installment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:to="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_2cd4bd50-ed55-4f16-8b6b-8c7ae5ddb119_terseLabel_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Convertible notes due 2023</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_9af81e8c-000b-43ce-8f75-37b49383c45c_verboseLabel_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Notes</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_label_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seventy Five Convertible Notes Due 2023 [Member]</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_documentation_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seventy Five Convertible Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:to="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4b97ed59-d9b3-46a1-8527-8913a75b9461_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_83dbec3d-de02-4467-8283-c07abbd3442e_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation, Restricted Stock Awards, Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:to="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_7f3f44b7-94fc-4cf0-bc78-8e38a2930ba0_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>nvax-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2e968d4d-f5d4-46a7-9a1c-6f56d63ea7b7,g:07ea8c72-99d3-4c76-b42c-1d6d27635d74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CoverPage" xlink:type="simple" xlink:href="nvax-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0a4c965e-a6d3-40a1-8147-9e447e4f9ae0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_DocumentType_0a4c965e-a6d3-40a1-8147-9e447e4f9ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_35b7a57c-e646-46fc-a37f-409ec1543eaf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_DocumentAnnualReport_35b7a57c-e646-46fc-a37f-409ec1543eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0921fc66-82ca-46f3-a1ec-65597626cc79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_DocumentPeriodEndDate_0921fc66-82ca-46f3-a1ec-65597626cc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_29339569-8ba8-4f90-a74e-f903e91ca39a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_CurrentFiscalYearEndDate_29339569-8ba8-4f90-a74e-f903e91ca39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9834c1cb-3dfb-44d3-b030-c936061db78f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_DocumentTransitionReport_9834c1cb-3dfb-44d3-b030-c936061db78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bd6f733d-65b5-4c71-b21b-8c927d10fbc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityFileNumber_bd6f733d-65b5-4c71-b21b-8c927d10fbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c1963057-4e3d-43ec-812f-c7e5495778bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityRegistrantName_c1963057-4e3d-43ec-812f-c7e5495778bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_212f1632-42cd-4ca6-8951-8c3c4d4c2fd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_212f1632-42cd-4ca6-8951-8c3c4d4c2fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fc22170d-6d9e-4e0a-962b-7ed689fade52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityTaxIdentificationNumber_fc22170d-6d9e-4e0a-962b-7ed689fade52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d3e55cdc-1bd0-48d3-84f9-519fcfdcb1b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityAddressAddressLine1_d3e55cdc-1bd0-48d3-84f9-519fcfdcb1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ce1d06af-76a1-48c5-a244-e00975869bd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityAddressCityOrTown_ce1d06af-76a1-48c5-a244-e00975869bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1cf11b52-ce8a-4084-9388-ecb256822f1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityAddressStateOrProvince_1cf11b52-ce8a-4084-9388-ecb256822f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7cbc2ce4-3077-4d7f-83b7-365a846cdd66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityAddressPostalZipCode_7cbc2ce4-3077-4d7f-83b7-365a846cdd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_680cb963-fbb9-4e95-b578-251774453bac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_CityAreaCode_680cb963-fbb9-4e95-b578-251774453bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c9fb3986-0f07-471b-b1fb-af9dddb99f53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_LocalPhoneNumber_c9fb3986-0f07-471b-b1fb-af9dddb99f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ec39c125-1d42-4355-9d73-552935256a3f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_Security12bTitle_ec39c125-1d42-4355-9d73-552935256a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0df7b7d5-cf67-436b-b302-883c17040f6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_TradingSymbol_0df7b7d5-cf67-436b-b302-883c17040f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f83434cf-a1ff-497e-9853-087adeeff744" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_SecurityExchangeName_f83434cf-a1ff-497e-9853-087adeeff744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c5ec2f52-7d7d-401e-ac22-e310c2b84e38" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c5ec2f52-7d7d-401e-ac22-e310c2b84e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_bbdc37fc-e46b-4054-8d86-0a72b48e0e49" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityVoluntaryFilers_bbdc37fc-e46b-4054-8d86-0a72b48e0e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4df8dbeb-1fce-4423-bc57-cf6f2e6f4941" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityCurrentReportingStatus_4df8dbeb-1fce-4423-bc57-cf6f2e6f4941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ae33446d-bfa9-48f5-aca4-68f8e89dc4f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityInteractiveDataCurrent_ae33446d-bfa9-48f5-aca4-68f8e89dc4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a31a162e-6fb7-4729-b8a1-0f8dd38e6edd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityFilerCategory_a31a162e-6fb7-4729-b8a1-0f8dd38e6edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_21c2dec5-6039-4bde-a9cd-13bf2192d5ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityEmergingGrowthCompany_21c2dec5-6039-4bde-a9cd-13bf2192d5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_82d99eff-ee24-4c8a-be37-9ee707333ae8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntitySmallBusiness_82d99eff-ee24-4c8a-be37-9ee707333ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_00a29031-b4f9-4bec-8d57-966d83de0903" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_00a29031-b4f9-4bec-8d57-966d83de0903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5beea7e7-0b61-438b-abcc-2cc125059b27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityShellCompany_5beea7e7-0b61-438b-abcc-2cc125059b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_dca66e7e-a7ec-4cd6-981f-c4ccdcdf5cbb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityPublicFloat_dca66e7e-a7ec-4cd6-981f-c4ccdcdf5cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_693d474e-f1d8-40c3-8372-981b070ac5c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_693d474e-f1d8-40c3-8372-981b070ac5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f34724f7-774a-422e-881f-fa569589f138" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f34724f7-774a-422e-881f-fa569589f138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_28e39586-0f02-4a73-9718-82f11e658879" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_AmendmentFlag_28e39586-0f02-4a73-9718-82f11e658879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6ed1095c-4bfc-4bd8-bbc1-c035a4a3268b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_DocumentFiscalYearFocus_6ed1095c-4bfc-4bd8-bbc1-c035a4a3268b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_33df2716-bc1d-41cf-bfa2-b531f4236e0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_33df2716-bc1d-41cf-bfa2-b531f4236e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9aaa3b83-abc0-41ab-83c2-2e7836a639f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b575a9a-9619-4fb9-aece-c0be4982e4d3" xlink:to="loc_dei_EntityCentralIndexKey_9aaa3b83-abc0-41ab-83c2-2e7836a639f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AuditInformation" xlink:type="simple" xlink:href="nvax-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AuditInformationAbstract_0201f237-1f73-48c9-9e11-c8e9642d964c" xlink:href="nvax-20221231.xsd#nvax_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_4ae2e240-3658-40b1-a768-ff7f8188eefd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AuditInformationAbstract_0201f237-1f73-48c9-9e11-c8e9642d964c" xlink:to="loc_dei_AuditorName_4ae2e240-3658-40b1-a768-ff7f8188eefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_54b4c62f-4562-45e7-9b15-b3580f802458" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AuditInformationAbstract_0201f237-1f73-48c9-9e11-c8e9642d964c" xlink:to="loc_dei_AuditorLocation_54b4c62f-4562-45e7-9b15-b3580f802458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_f671b474-2532-4c96-bb5e-ca1154ec9154" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AuditInformationAbstract_0201f237-1f73-48c9-9e11-c8e9642d964c" xlink:to="loc_dei_AuditorFirmId_f671b474-2532-4c96-bb5e-ca1154ec9154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_645691a7-b0ab-4230-99a1-0d9fe3b6c924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_76a5a768-327d-4857-8225-430af61f20e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_645691a7-b0ab-4230-99a1-0d9fe3b6c924" xlink:to="loc_us-gaap_StatementTable_76a5a768-327d-4857-8225-430af61f20e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75a34f12-f17c-49f8-9dca-effa35ac5fbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_76a5a768-327d-4857-8225-430af61f20e2" xlink:to="loc_srt_ProductOrServiceAxis_75a34f12-f17c-49f8-9dca-effa35ac5fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_75a34f12-f17c-49f8-9dca-effa35ac5fbe" xlink:to="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5f14b76a-2e6a-40e5-a1d9-84da4f6a5995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:to="loc_us-gaap_ProductMember_5f14b76a-2e6a-40e5-a1d9-84da4f6a5995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_c2810c48-b2b7-43d8-809d-4d6dc4c0071b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:to="loc_us-gaap_GrantMember_c2810c48-b2b7-43d8-809d-4d6dc4c0071b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember_524b4dea-3461-42fe-8c85-a87151602d1e" xlink:href="nvax-20221231.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bc08efc-95fd-4f89-9e37-2e9ca534d832" xlink:to="loc_nvax_RoyaltiesAndOtherMember_524b4dea-3461-42fe-8c85-a87151602d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_76a5a768-327d-4857-8225-430af61f20e2" xlink:to="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0d5fea7b-9a2a-47c5-a801-c5814a4e1a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_RevenuesAbstract_0d5fea7b-9a2a-47c5-a801-c5814a4e1a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_41a2f5ac-f89b-4e6a-8899-a903b721ee49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0d5fea7b-9a2a-47c5-a801-c5814a4e1a88" xlink:to="loc_us-gaap_Revenues_41a2f5ac-f89b-4e6a-8899-a903b721ee49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c38924d3-1d9e-41fa-b264-fddfd06f6e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_CostOfRevenue_c38924d3-1d9e-41fa-b264-fddfd06f6e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_368206df-edb1-457c-b58c-48fd3e7c4150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_368206df-edb1-457c-b58c-48fd3e7c4150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_48edbce0-e15f-4abd-aaa9-1f394b3a47aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_48edbce0-e15f-4abd-aaa9-1f394b3a47aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_61e36387-88f5-42a5-b2d7-89cc9563c9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1e6f2a14-2f58-42cd-89fe-fb3f98136b4e" xlink:to="loc_us-gaap_CostsAndExpenses_61e36387-88f5-42a5-b2d7-89cc9563c9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_00e74fd8-98c5-4afe-b2ec-be3c8a066a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_OperatingIncomeLoss_00e74fd8-98c5-4afe-b2ec-be3c8a066a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ea56d2e1-c706-4182-a198-4913efe94ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:to="loc_us-gaap_InterestExpense_ea56d2e1-c706-4182-a198-4913efe94ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_123b0783-2265-4303-8ac5-24d2a224aab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9019bb9b-89b8-4c78-bcaf-d9cec1c3a7e8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_123b0783-2265-4303-8ac5-24d2a224aab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52513a56-aeb6-4b87-8382-09d9e92d3cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52513a56-aeb6-4b87-8382-09d9e92d3cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b47dfea3-bc18-4c0a-abf9-9773cded1732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b47dfea3-bc18-4c0a-abf9-9773cded1732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b694129d-17a9-4871-b472-59bac2b7e191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_NetIncomeLoss_b694129d-17a9-4871-b472-59bac2b7e191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_15881c3f-0561-494a-a5e8-851c28e3a481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:to="loc_us-gaap_EarningsPerShareBasic_15881c3f-0561-494a-a5e8-851c28e3a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3168d39a-ff43-4211-a99f-cb5b59b2d241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5437825e-33c5-4116-b6ac-ded5c7adffee" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3168d39a-ff43-4211-a99f-cb5b59b2d241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b65d04d-64c6-4e2e-8976-786203258e8b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12d52a5f-81bd-47dd-beb6-54b290423d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12d52a5f-81bd-47dd-beb6-54b290423d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb330a9f-31c4-4da4-82b5-70d1f2b555bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9230e1b5-11e3-4529-a641-b03e2c3341da" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb330a9f-31c4-4da4-82b5-70d1f2b555bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7ff5337b-b79e-4f18-ad3f-81966a1789d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_897247bc-beb4-4b84-ae24-824f0861f4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7ff5337b-b79e-4f18-ad3f-81966a1789d4" xlink:to="loc_us-gaap_NetIncomeLoss_897247bc-beb4-4b84-ae24-824f0861f4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_308ea9d2-ff61-46f1-abd0-81532d4e8d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7ff5337b-b79e-4f18-ad3f-81966a1789d4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_308ea9d2-ff61-46f1-abd0-81532d4e8d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7e409c56-7b35-4308-bac2-e8efbbf01922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_308ea9d2-ff61-46f1-abd0-81532d4e8d7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7e409c56-7b35-4308-bac2-e8efbbf01922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e1ce9317-b86e-45d5-b709-5688880ffdef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_308ea9d2-ff61-46f1-abd0-81532d4e8d7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e1ce9317-b86e-45d5-b709-5688880ffdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_38be0f9d-53d4-49e7-b902-9f7f3761e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_308ea9d2-ff61-46f1-abd0-81532d4e8d7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_38be0f9d-53d4-49e7-b902-9f7f3761e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_22a2a32c-dab9-43a0-9cb4-59941fe70174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7ff5337b-b79e-4f18-ad3f-81966a1789d4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_22a2a32c-dab9-43a0-9cb4-59941fe70174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c997e909-6c73-4a6f-95a9-35f53a72e9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c997e909-6c73-4a6f-95a9-35f53a72e9cd" xlink:to="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0739eb37-3698-4959-8a6b-4ab2d1b697ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0739eb37-3698-4959-8a6b-4ab2d1b697ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_763827d9-52c7-4d72-9674-72c346edf753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_763827d9-52c7-4d72-9674-72c346edf753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d55c8e07-78c8-4618-a382-88f1d9fc95b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:to="loc_us-gaap_AccountsReceivableNet_d55c8e07-78c8-4618-a382-88f1d9fc95b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b097ec10-fe5f-427c-a50f-64371c27b219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:to="loc_us-gaap_InventoryNet_b097ec10-fe5f-427c-a50f-64371c27b219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6d30532c-9e65-42f3-b6c4-af71389690f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6d30532c-9e65-42f3-b6c4-af71389690f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3f28843e-cba4-48a4-9d6b-e9465b58be1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46426d79-00d2-49d7-81c3-e36ff8e9105a" xlink:to="loc_us-gaap_AssetsCurrent_3f28843e-cba4-48a4-9d6b-e9465b58be1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b8b8a6d0-ae46-4434-8fa7-8e8a302a900e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b8b8a6d0-ae46-4434-8fa7-8e8a302a900e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_1b3a6ff5-23bb-4294-bb5d-b1c3030f9831" xlink:href="nvax-20221231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:to="loc_nvax_LeaseRightOfUseAsset_1b3a6ff5-23bb-4294-bb5d-b1c3030f9831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b648acde-a84b-4d25-a084-33e5e08b5f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:to="loc_us-gaap_Goodwill_b648acde-a84b-4d25-a084-33e5e08b5f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_73c00d35-724e-47c6-84b9-e0d3843e83ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_73c00d35-724e-47c6-84b9-e0d3843e83ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e72d586a-bafb-4ad8-a43b-8da678501d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69c1b67c-7247-4e8c-be13-88b8eedbbed0" xlink:to="loc_us-gaap_Assets_e72d586a-bafb-4ad8-a43b-8da678501d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c997e909-6c73-4a6f-95a9-35f53a72e9cd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5245b88c-28c6-4562-95ea-ecf6965223c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:to="loc_us-gaap_AccountsPayableCurrent_5245b88c-28c6-4562-95ea-ecf6965223c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2660d298-4a73-4127-ac94-d63e5b9ad5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2660d298-4a73-4127-ac94-d63e5b9ad5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_96e20c7e-dce7-4449-8c53-bb812a3efe21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_96e20c7e-dce7-4449-8c53-bb812a3efe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_95916713-978a-4f04-a3c1-270e3fa13832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_95916713-978a-4f04-a3c1-270e3fa13832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_b595c895-d2bf-4078-84a9-a63ed616378a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_b595c895-d2bf-4078-84a9-a63ed616378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5d0f77de-2015-4609-8a70-1e7f5efb1eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5d0f77de-2015-4609-8a70-1e7f5efb1eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f71a25a-9fd9-4691-9883-ae96516917eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_468bc6fe-a087-41d6-80a3-52632a34ac5c" xlink:to="loc_us-gaap_LiabilitiesCurrent_9f71a25a-9fd9-4691-9883-ae96516917eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3194d2e8-04a0-437a-a0e2-f0a6d72a4595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3194d2e8-04a0-437a-a0e2-f0a6d72a4595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_5742f164-99d9-4c61-8b4c-fa991a40308e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_5742f164-99d9-4c61-8b4c-fa991a40308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f398e431-e5d8-43ef-a9f0-84b2e98e033f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f398e431-e5d8-43ef-a9f0-84b2e98e033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3ad5d063-9fbc-4fc7-8868-0581ea375868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3ad5d063-9fbc-4fc7-8868-0581ea375868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_031ab00a-a8cd-4798-abda-3bd2ce3e0e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_Liabilities_031ab00a-a8cd-4798-abda-3bd2ce3e0e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26062eff-d736-4120-b7c3-f8b9d0b382c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26062eff-d736-4120-b7c3-f8b9d0b382c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_23ae0510-e16a-4ccd-b1dc-05934a5798d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_PreferredStockValue_23ae0510-e16a-4ccd-b1dc-05934a5798d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7680927c-b44b-4371-8a7d-2b0aae419922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:to="loc_us-gaap_CommonStockValue_7680927c-b44b-4371-8a7d-2b0aae419922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a8a29ac8-8253-41fe-a2ee-d225c368af7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a8a29ac8-8253-41fe-a2ee-d225c368af7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d7395697-f1b4-4f39-bcce-471d3e20805c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d7395697-f1b4-4f39-bcce-471d3e20805c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a41d922b-0874-4a12-bf67-df77bd9dabb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:to="loc_us-gaap_TreasuryStockValue_a41d922b-0874-4a12-bf67-df77bd9dabb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb23d01e-303c-4da3-acfd-e6ce19e66f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb23d01e-303c-4da3-acfd-e6ce19e66f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_46c8fb52-c41b-471d-98fc-d0a343ff8518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13e3208d-8881-4717-9ec9-3665140d7c4b" xlink:to="loc_us-gaap_StockholdersEquity_46c8fb52-c41b-471d-98fc-d0a343ff8518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_23321f8c-a948-417d-abe3-232260502d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_03a96bff-7dcb-43c1-94b8-b5ffc2407a6e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_23321f8c-a948-417d-abe3-232260502d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_30cdfeb5-fc21-4322-bf40-58bf918cf885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_30cdfeb5-fc21-4322-bf40-58bf918cf885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b24d54a7-2914-4e6f-ad82-01a277ba299a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b24d54a7-2914-4e6f-ad82-01a277ba299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a166a60b-a2d2-45f3-80b5-f8480c63ce30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a166a60b-a2d2-45f3-80b5-f8480c63ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7f7dfed4-f4bd-4c9f-bf5a-0deee6e77c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7f7dfed4-f4bd-4c9f-bf5a-0deee6e77c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b30eff3d-98ce-4fdf-9d8d-b90a00461ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b30eff3d-98ce-4fdf-9d8d-b90a00461ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bdc56ebf-6c20-4e37-9e94-f0f43e92b816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bdc56ebf-6c20-4e37-9e94-f0f43e92b816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d93fe745-96a8-4236-b020-1e95a0ce44a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_CommonStockSharesIssued_d93fe745-96a8-4236-b020-1e95a0ce44a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e09e0825-c611-4984-bf59-c92b084800ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e09e0825-c611-4984-bf59-c92b084800ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_d789b35f-fc04-455f-90c0-30c2421d6935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f8c4903-cb99-416f-9b30-9ffc1795d0a6" xlink:to="loc_us-gaap_TreasuryStockShares_d789b35f-fc04-455f-90c0-30c2421d6935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_915b2da2-6eef-48ca-b31f-50a65f2505bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5b70b7d4-d49b-4f4f-b8b9-159d29739488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_915b2da2-6eef-48ca-b31f-50a65f2505bd" xlink:to="loc_us-gaap_StatementTable_5b70b7d4-d49b-4f4f-b8b9-159d29739488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c681ac38-3a34-4578-9937-a3e05172f204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5b70b7d4-d49b-4f4f-b8b9-159d29739488" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c681ac38-3a34-4578-9937-a3e05172f204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c681ac38-3a34-4578-9937-a3e05172f204" xlink:to="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4ffca24-6d17-4d1c-9485-923b611eac39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_CommonStockMember_b4ffca24-6d17-4d1c-9485-923b611eac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ae09a97b-e512-4b36-ab06-49387a2e4ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ae09a97b-e512-4b36-ab06-49387a2e4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d5a9c9af-ebaa-4d95-a43d-0dbd7562b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_RetainedEarningsMember_d5a9c9af-ebaa-4d95-a43d-0dbd7562b1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_c5193b0d-a8ab-49ca-9145-9fda62a4226c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_TreasuryStockMember_c5193b0d-a8ab-49ca-9145-9fda62a4226c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_959f243c-a1df-4fa4-b793-07f8d6c7c013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219bc32e-9141-4d77-ad8b-34c573536831" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_959f243c-a1df-4fa4-b793-07f8d6c7c013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e109e26-759b-48c7-a30c-876d849fdfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5b70b7d4-d49b-4f4f-b8b9-159d29739488" xlink:to="loc_us-gaap_StatementLineItems_7e109e26-759b-48c7-a30c-876d849fdfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e109e26-759b-48c7-a30c-876d849fdfcb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_38d58f4c-666f-4c14-8ef2-317f072b1e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_SharesIssued_38d58f4c-666f-4c14-8ef2-317f072b1e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff435fca-fe33-418c-b34d-422baca7caad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockholdersEquity_ff435fca-fe33-418c-b34d-422baca7caad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_65921686-1146-45da-8b3a-260efcda70a8" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_65921686-1146-45da-8b3a-260efcda70a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2e591334-526c-4227-a4da-f5abe7238d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2e591334-526c-4227-a4da-f5abe7238d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_aba63d37-78e7-42dd-a870-a77d2370f8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_aba63d37-78e7-42dd-a870-a77d2370f8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b1a0966-5c50-4db2-9b07-f5c03f998f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b1a0966-5c50-4db2-9b07-f5c03f998f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_21e917cd-c925-4ece-8800-7c0d6d3ea124" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_21e917cd-c925-4ece-8800-7c0d6d3ea124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_83484424-5e65-4af9-a2ca-25c9d0e459ca" xlink:href="nvax-20221231.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_83484424-5e65-4af9-a2ca-25c9d0e459ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83af7bd2-ce04-45a8-a6fe-d34ed5f36826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83af7bd2-ce04-45a8-a6fe-d34ed5f36826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8198bbae-6a11-46bf-8a67-c0b270ae0d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8198bbae-6a11-46bf-8a67-c0b270ae0d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_88ab2ea3-acf4-4bc1-a8b6-a46cacae222e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_88ab2ea3-acf4-4bc1-a8b6-a46cacae222e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e8e284f9-1797-4a0e-bcb5-a5855ad6ae21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e8e284f9-1797-4a0e-bcb5-a5855ad6ae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0c0b0ec-eb1b-43f5-bf19-224a46d96e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_NetIncomeLoss_d0c0b0ec-eb1b-43f5-bf19-224a46d96e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_424a5d71-d1ad-4008-bdf4-b4f7d7cad256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_SharesIssued_424a5d71-d1ad-4008-bdf4-b4f7d7cad256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_12623bd8-d241-4d96-842e-254cfce5d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca954cf8-ce9c-48a0-87c9-107bdcaaf50a" xlink:to="loc_us-gaap_StockholdersEquity_12623bd8-d241-4d96-842e-254cfce5d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6cd72ae8-c5c4-4197-8698-b6b7d262fe65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5408d409-2cbe-4531-813e-f940bc655acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6cd72ae8-c5c4-4197-8698-b6b7d262fe65" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5408d409-2cbe-4531-813e-f940bc655acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24a1bbe4-178f-483c-9647-761910bd9638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24a1bbe4-178f-483c-9647-761910bd9638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d293847e-0730-477a-8d45-0b3a053523bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24a1bbe4-178f-483c-9647-761910bd9638" xlink:to="loc_us-gaap_NetIncomeLoss_d293847e-0730-477a-8d45-0b3a053523bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24a1bbe4-178f-483c-9647-761910bd9638" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c9beb4d0-847b-4027-9df4-da59a119f061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:to="loc_us-gaap_DepreciationAndAmortization_c9beb4d0-847b-4027-9df4-da59a119f061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff_c9a6f11b-b887-423b-97bc-4adcf88d7f2b" xlink:href="nvax-20221231.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:to="loc_nvax_OperatingAndFinanceLeaseWriteOff_c9a6f11b-b887-423b-97bc-4adcf88d7f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c8133d12-dc50-4a07-a22f-051b8a268dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:to="loc_us-gaap_ShareBasedCompensation_c8133d12-dc50-4a07-a22f-051b8a268dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory_ce5bba9a-da08-4ec2-a321-e005194e9853" xlink:href="nvax-20221231.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:to="loc_nvax_ProvisionForExcessAndObsoleteInventory_ce5bba9a-da08-4ec2-a321-e005194e9853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9bc047b3-239e-4961-9112-1cd43a6e67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9bc047b3-239e-4961-9112-1cd43a6e67fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac3d2436-c8c9-4824-9ec1-9e6f9c91db25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea72c976-e11c-4bf6-b5fb-7b39a11de517" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac3d2436-c8c9-4824-9ec1-9e6f9c91db25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_78238b87-ffc5-4873-9a41-f43e120550a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac3d2436-c8c9-4824-9ec1-9e6f9c91db25" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_78238b87-ffc5-4873-9a41-f43e120550a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_89dbc235-ba8d-466f-a53b-6f110658d082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac3d2436-c8c9-4824-9ec1-9e6f9c91db25" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_89dbc235-ba8d-466f-a53b-6f110658d082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5ac4422e-549b-433f-a098-1dbc450ec84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac3d2436-c8c9-4824-9ec1-9e6f9c91db25" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5ac4422e-549b-433f-a098-1dbc450ec84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6ecdff66-2a75-4e1e-a0b4-4a9e2c7daec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac3d2436-c8c9-4824-9ec1-9e6f9c91db25" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6ecdff66-2a75-4e1e-a0b4-4a9e2c7daec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b6277f8-a0bb-497e-aaae-ff6fc19009a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24a1bbe4-178f-483c-9647-761910bd9638" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b6277f8-a0bb-497e-aaae-ff6fc19009a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_9240f3da-a3b8-4e51-8612-1554c3ea9442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_9240f3da-a3b8-4e51-8612-1554c3ea9442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_7e453d05-c459-4fb2-86ce-d955457aa2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:to="loc_us-gaap_PaymentsForSoftware_7e453d05-c459-4fb2-86ce-d955457aa2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e4becaba-1f4a-4522-8bdf-5571b377eaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e4becaba-1f4a-4522-8bdf-5571b377eaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4d2b2b91-6316-4721-86a9-73d6a994b269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4d2b2b91-6316-4721-86a9-73d6a994b269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4a837ca-8802-4936-b743-8017a5d3e853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4a837ca-8802-4936-b743-8017a5d3e853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f128d40-838c-4f23-96ea-550f77f607f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5eec875a-f8a7-4acb-acbf-b2bede3e325b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f128d40-838c-4f23-96ea-550f77f607f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_83d30f0c-7b6f-49b3-8e47-cd1db44c8214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_83d30f0c-7b6f-49b3-8e47-cd1db44c8214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ac4a70e1-472c-443e-a0bb-0a091d0aa8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ac4a70e1-472c-443e-a0bb-0a091d0aa8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_9f7a32be-7b6b-46f5-8ef5-6b64f9086be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_9f7a32be-7b6b-46f5-8ef5-6b64f9086be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_a04a802b-1a37-4dd6-ac99-5fda2091d314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_a04a802b-1a37-4dd6-ac99-5fda2091d314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_2d370bab-83e2-4318-8bf7-0252aacbd2c4" xlink:href="nvax-20221231.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:to="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_2d370bab-83e2-4318-8bf7-0252aacbd2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_7b112365-148f-4e65-b68c-2ac580a91fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_7b112365-148f-4e65-b68c-2ac580a91fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09aef46a-33b6-4d4b-aea5-9ae79813ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31a8e39a-a24a-420d-bbf7-003ba5abd175" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09aef46a-33b6-4d4b-aea5-9ae79813ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0e24136-8c03-4ccc-a5d5-de6dae92d15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0e24136-8c03-4ccc-a5d5-de6dae92d15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c73dfca9-bd7b-4fe2-87c3-aad0ea4e9300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c73dfca9-bd7b-4fe2-87c3-aad0ea4e9300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d2e4d88-ef53-41a0-b314-ac9268d4c740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d2e4d88-ef53-41a0-b314-ac9268d4c740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e359566d-1fe2-45ed-93d7-d8959067971a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e359566d-1fe2-45ed-93d7-d8959067971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d8baf909-b3ac-4c3e-b030-b932afc40c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d8baf909-b3ac-4c3e-b030-b932afc40c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_1a179bc4-ea42-41ab-b84a-2dcd826fb9e8" xlink:href="nvax-20221231.xsd#nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d8baf909-b3ac-4c3e-b030-b932afc40c7d" xlink:to="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_1a179bc4-ea42-41ab-b84a-2dcd826fb9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6de5dce0-7a61-4fdf-ab07-0388e3bcb26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d8baf909-b3ac-4c3e-b030-b932afc40c7d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6de5dce0-7a61-4fdf-ab07-0388e3bcb26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_3b891ed9-87d6-4d6d-ab02-66a212a772a8" xlink:href="nvax-20221231.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d8baf909-b3ac-4c3e-b030-b932afc40c7d" xlink:to="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_3b891ed9-87d6-4d6d-ab02-66a212a772a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1631c95b-fdc3-4d84-9380-17fe1144e18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34e8827d-8737-45cf-b8c3-1291c34c5a54" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1631c95b-fdc3-4d84-9380-17fe1144e18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_9e59c28b-b94f-441e-b8ae-efd0d960e410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1631c95b-fdc3-4d84-9380-17fe1144e18f" xlink:to="loc_us-gaap_InterestPaidNet_9e59c28b-b94f-441e-b8ae-efd0d960e410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_29520721-bec1-4607-82ad-d2e5adce69ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1631c95b-fdc3-4d84-9380-17fe1144e18f" xlink:to="loc_us-gaap_IncomeTaxesPaid_29520721-bec1-4607-82ad-d2e5adce69ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Organization" xlink:type="simple" xlink:href="nvax-20221231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e1005e8-c534-4361-9a51-17a3aaf6afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_462708fc-6ce2-4bd7-b498-a6d56422e806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e1005e8-c534-4361-9a51-17a3aaf6afc9" xlink:to="loc_us-gaap_NatureOfOperations_462708fc-6ce2-4bd7-b498-a6d56422e806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b330bfe4-6ddb-44f1-8221-0862d0ccc4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d20d6625-dce8-4593-a239-9a1ffbed28cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b330bfe4-6ddb-44f1-8221-0862d0ccc4ea" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d20d6625-dce8-4593-a239-9a1ffbed28cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Revenue" xlink:type="simple" xlink:href="nvax-20221231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_33bbbcc5-5ae7-473a-bf36-e6c05a5f153e" xlink:href="nvax-20221231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d38d8e8e-f012-4546-82f7-4a3af407f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_33bbbcc5-5ae7-473a-bf36-e6c05a5f153e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d38d8e8e-f012-4546-82f7-4a3af407f1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="nvax-20221231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_d837204f-698e-4e77-a149-c6ae2172dc9c" xlink:href="nvax-20221231.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_95368c11-3d59-4059-9caf-b77dd86a1b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_d837204f-698e-4e77-a149-c6ae2172dc9c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_95368c11-3d59-4059-9caf-b77dd86a1b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nvax-20221231.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_08885736-334e-47b6-9adb-5c78fa1027f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_abfdfe95-c19d-45c6-93b0-eb997c04ee50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_08885736-334e-47b6-9adb-5c78fa1027f0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_abfdfe95-c19d-45c6-93b0-eb997c04ee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nvax-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_871d3dd2-ab09-4fb0-8e52-07b7a6bf6c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5d515079-9f56-458f-b9c3-bc56af98194f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_871d3dd2-ab09-4fb0-8e52-07b7a6bf6c3e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5d515079-9f56-458f-b9c3-bc56af98194f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Inventory" xlink:type="simple" xlink:href="nvax-20221231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9cc8a873-c185-45ba-b7ef-3c14b0c84672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_c98ffe3c-3932-472c-911c-3ba472410e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9cc8a873-c185-45ba-b7ef-3c14b0c84672" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_c98ffe3c-3932-472c-911c-3ba472410e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Goodwill" xlink:type="simple" xlink:href="nvax-20221231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c73d05f-6af1-467e-ac88-1d32f8783f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_da6638c9-3d66-43ca-88f9-2e49cfb43daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c73d05f-6af1-467e-ac88-1d32f8783f04" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_da6638c9-3d66-43ca-88f9-2e49cfb43daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZ" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZ"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZ" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f7581ff7-a891-4f7d-ad5c-171255d1d639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_746d593b-bc4f-4a88-9a19-577e5cf5d1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f7581ff7-a891-4f7d-ad5c-171255d1d639" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_746d593b-bc4f-4a88-9a19-577e5cf5d1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Leases" xlink:type="simple" xlink:href="nvax-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_caa03e3d-6f32-4a89-9b0a-48ac45a85120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fbe1657d-c9b7-4680-8838-5dd606fc7f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_caa03e3d-6f32-4a89-9b0a-48ac45a85120" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fbe1657d-c9b7-4680-8838-5dd606fc7f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_1740ad5a-ae90-4d3e-92fe-a3d30a32ecbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_caa03e3d-6f32-4a89-9b0a-48ac45a85120" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_1740ad5a-ae90-4d3e-92fe-a3d30a32ecbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebt" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a29b2e96-5090-454d-9c62-a6b51101c936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_517248ff-35cf-4abe-b79b-b345ae64479e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a29b2e96-5090-454d-9c62-a6b51101c936" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_517248ff-35cf-4abe-b79b-b345ae64479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/PreferredStock" xlink:type="simple" xlink:href="nvax-20221231.xsd#PreferredStock"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/PreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f61c1c69-7ee0-47f6-848b-bfc678f0c281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock_e7c885d7-96f3-4b58-880b-d5182308b57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f61c1c69-7ee0-47f6-848b-bfc678f0c281" xlink:to="loc_us-gaap_PreferredStockTextBlock_e7c885d7-96f3-4b58-880b-d5182308b57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquity" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0bd3049b-a95e-45e4-9cd1-5799374e411d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_546441ef-e2c3-46ff-9488-5038ece98881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0bd3049b-a95e-45e4-9cd1-5799374e411d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_546441ef-e2c3-46ff-9488-5038ece98881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f28b3acf-91a6-4a4d-b0d5-6fd22d83fef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_910fae46-0a43-41d4-a2a7-84f22f626bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f28b3acf-91a6-4a4d-b0d5-6fd22d83fef3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_910fae46-0a43-41d4-a2a7-84f22f626bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="nvax-20221231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_d5d422e7-d347-4eb5-9437-1914b51fbe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_28b26dfe-563b-41a0-82cd-16d27006c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_d5d422e7-d347-4eb5-9437-1914b51fbe7c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_28b26dfe-563b-41a0-82cd-16d27006c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23ecdc72-3c86-402d-b7cc-556ae149df99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_c1b17033-f274-48e8-b1e1-29767ad2d15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23ecdc72-3c86-402d-b7cc-556ae149df99" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_c1b17033-f274-48e8-b1e1-29767ad2d15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4678bc46-fa61-4a15-baec-a920c7f0ebe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_03f92d99-1beb-469a-98d1-91f1692e69c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4678bc46-fa61-4a15-baec-a920c7f0ebe8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_03f92d99-1beb-469a-98d1-91f1692e69c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="nvax-20221231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bffd50d8-7fee-49e2-9890-7d4c4f955000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e38d9553-57ca-4714-8cc6-e08899ae73b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bffd50d8-7fee-49e2-9890-7d4c4f955000" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e38d9553-57ca-4714-8cc6-e08899ae73b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEvents" xlink:type="simple" xlink:href="nvax-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d79df9ca-eb10-4172-8b88-052cc8cb5a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3f529ae6-d325-4b73-a8d3-f33ecc5a7484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d79df9ca-eb10-4172-8b88-052cc8cb5a2f" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3f529ae6-d325-4b73-a8d3-f33ecc5a7484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_982db548-6010-419c-b15b-819e346e2d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_982db548-6010-419c-b15b-819e346e2d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock_086add83-632e-49d2-bc2e-678fe7448248" xlink:href="nvax-20221231.xsd#nvax_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock_086add83-632e-49d2-bc2e-678fe7448248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_7f5e45a9-8fb1-4346-a9d2-cadbe2e5ed65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_7f5e45a9-8fb1-4346-a9d2-cadbe2e5ed65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b6b26075-6d4f-4879-9dc6-c330ef7db3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_UseOfEstimates_b6b26075-6d4f-4879-9dc6-c330ef7db3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0e4511c5-b528-4c55-9291-f3e8a3f38c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0e4511c5-b528-4c55-9291-f3e8a3f38c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_2fabc191-f918-44a7-a164-01ba51638a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_2fabc191-f918-44a7-a164-01ba51638a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2409fe52-45a2-4b79-9b1e-8107650656ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2409fe52-45a2-4b79-9b1e-8107650656ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_558c6856-d80d-493d-b082-f8018b041b83" xlink:href="nvax-20221231.xsd#nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_558c6856-d80d-493d-b082-f8018b041b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_c7c73152-d8c1-4c22-b8d4-cb776ba19229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_c7c73152-d8c1-4c22-b8d4-cb776ba19229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_188d8fbd-0591-4a15-a84a-dae1d844f964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_188d8fbd-0591-4a15-a84a-dae1d844f964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ee26fe18-cd73-4c45-997d-61866889b4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ee26fe18-cd73-4c45-997d-61866889b4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_620a4199-2288-48bc-b38a-e9bda8b92e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_620a4199-2288-48bc-b38a-e9bda8b92e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_bd9020ed-56e4-493d-92a6-fd6024468b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_bd9020ed-56e4-493d-92a6-fd6024468b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c60b49ff-85f6-41a6-be94-cdfa48749ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c60b49ff-85f6-41a6-be94-cdfa48749ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b4a5b757-86a7-4bbf-909e-e63736762cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b4a5b757-86a7-4bbf-909e-e63736762cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_b611298d-d049-4fe5-b5e2-00cd7093867e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_b611298d-d049-4fe5-b5e2-00cd7093867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_19ef121b-71b0-4566-8abd-a6c03849d4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_19ef121b-71b0-4566-8abd-a6c03849d4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5a6c8dc1-16b2-4739-8111-d176dbd1b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5a6c8dc1-16b2-4739-8111-d176dbd1b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02cdbd26-90a9-43d4-a8ad-cdd8d329ca23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02cdbd26-90a9-43d4-a8ad-cdd8d329ca23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_98c7b02d-9893-48bf-9abe-34286ba72114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_98c7b02d-9893-48bf-9abe-34286ba72114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9677b161-e7e8-43aa-b557-6aa856775022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9677b161-e7e8-43aa-b557-6aa856775022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_266ec750-c646-4791-97af-0d11d150fd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_266ec750-c646-4791-97af-0d11d150fd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_05bc9d9e-5a83-4f39-a3d6-57a350099dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_05bc9d9e-5a83-4f39-a3d6-57a350099dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_038cd784-2a1c-41af-b539-ab64dbb6f525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_038cd784-2a1c-41af-b539-ab64dbb6f525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c4c917d4-bed8-4a52-a407-39bc0b0bbd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ab9225c-217d-4fae-ac24-a1f834e134c9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c4c917d4-bed8-4a52-a407-39bc0b0bbd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_839526fa-94bb-4722-88cb-2c09a16cc982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e210197c-622a-4d96-b072-6c2fc75cafc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_839526fa-94bb-4722-88cb-2c09a16cc982" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e210197c-622a-4d96-b072-6c2fc75cafc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d8357871-74e2-4f54-a106-b7ac9ec067b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_839526fa-94bb-4722-88cb-2c09a16cc982" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d8357871-74e2-4f54-a106-b7ac9ec067b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_2c23f9d5-a107-4d3c-accc-8737f8ade268" xlink:href="nvax-20221231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_576c4029-e57f-4db8-995e-74479a0e3cef" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_2c23f9d5-a107-4d3c-accc-8737f8ade268" xlink:to="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_576c4029-e57f-4db8-995e-74479a0e3cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_490c0f44-05d7-4016-91b5-7eaebe558755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_2c23f9d5-a107-4d3c-accc-8737f8ade268" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_490c0f44-05d7-4016-91b5-7eaebe558755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_ff87efee-ddb3-435b-889f-e510fd2a2938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_2c23f9d5-a107-4d3c-accc-8737f8ade268" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_ff87efee-ddb3-435b-889f-e510fd2a2938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_fd38359b-e839-4e8c-af4a-f45bfd16a5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2a7978d7-876e-415f-9e08-3239bad445a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fd38359b-e839-4e8c-af4a-f45bfd16a5d0" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2a7978d7-876e-415f-9e08-3239bad445a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d2714c2a-36b0-469d-aa3d-d54628067f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_6cc4022f-d346-4ef3-9428-746eb59c94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d2714c2a-36b0-469d-aa3d-d54628067f24" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_6cc4022f-d346-4ef3-9428-746eb59c94f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_959834b7-419c-4255-ae17-a8ac015751db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_97ec08d9-23c9-4a59-912e-7163c7b9313c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_959834b7-419c-4255-ae17-a8ac015751db" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_97ec08d9-23c9-4a59-912e-7163c7b9313c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfInventoryReserveTableTextBlock_b8ae34a2-0df0-4f06-aa9c-27a07db0e17d" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfInventoryReserveTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_959834b7-419c-4255-ae17-a8ac015751db" xlink:to="loc_nvax_ScheduleOfInventoryReserveTableTextBlock_b8ae34a2-0df0-4f06-aa9c-27a07db0e17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81d9dcaf-751d-4d37-9e4f-067a12e4fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_cd44099d-9e80-4b13-997f-6a1315c11313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81d9dcaf-751d-4d37-9e4f-067a12e4fc33" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_cd44099d-9e80-4b13-997f-6a1315c11313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6324fc2c-3dc7-449e-8d15-6b7903597998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_860bd267-7085-4373-a722-97d838e3837f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6324fc2c-3dc7-449e-8d15-6b7903597998" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_860bd267-7085-4373-a722-97d838e3837f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e3dc3c82-2a11-420e-8d8e-c91e56c5d39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6324fc2c-3dc7-449e-8d15-6b7903597998" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e3dc3c82-2a11-420e-8d8e-c91e56c5d39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_df980a6e-345e-4dc7-88fa-14b6aadbeec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_1db55002-dcdc-49ca-a3cf-cbeebb099686" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df980a6e-345e-4dc7-88fa-14b6aadbeec7" xlink:to="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_1db55002-dcdc-49ca-a3cf-cbeebb099686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_54eef1a1-95f5-406b-ac77-2c9c4607a7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df980a6e-345e-4dc7-88fa-14b6aadbeec7" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_54eef1a1-95f5-406b-ac77-2c9c4607a7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_2677ca1e-7b83-4b78-82c3-8b9b397a090a" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df980a6e-345e-4dc7-88fa-14b6aadbeec7" xlink:to="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_2677ca1e-7b83-4b78-82c3-8b9b397a090a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9b8a0497-454f-4978-9f3c-ca69e7f2de16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df980a6e-345e-4dc7-88fa-14b6aadbeec7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9b8a0497-454f-4978-9f3c-ca69e7f2de16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0a713f6b-e25e-4022-b726-12d6f6cf0585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_4dfdbae5-cb63-4e60-b20c-59ac972bacd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0a713f6b-e25e-4022-b726-12d6f6cf0585" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_4dfdbae5-cb63-4e60-b20c-59ac972bacd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_13e5ce70-0c41-451c-85a9-2030ff115a9f" xlink:href="nvax-20221231.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0a713f6b-e25e-4022-b726-12d6f6cf0585" xlink:to="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_13e5ce70-0c41-451c-85a9-2030ff115a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb1d8459-a313-4af4-825f-9aec33891e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8fa718ec-a267-41c7-8a61-d5994771d0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb1d8459-a313-4af4-825f-9aec33891e09" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8fa718ec-a267-41c7-8a61-d5994771d0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_94f60fe5-ad08-446b-a89b-19f4c395a029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb1d8459-a313-4af4-825f-9aec33891e09" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_94f60fe5-ad08-446b-a89b-19f4c395a029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7d4aa4b5-6344-4301-a520-84503383d8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb1d8459-a313-4af4-825f-9aec33891e09" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7d4aa4b5-6344-4301-a520-84503383d8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_b02adba8-00a6-4cd5-ba3f-9d032eada276" xlink:href="nvax-20221231.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb1d8459-a313-4af4-825f-9aec33891e09" xlink:to="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_b02adba8-00a6-4cd5-ba3f-9d032eada276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd263316-e809-44b2-ace9-ec04958fe375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0b96be6f-7404-49ad-b1ee-65efc6b3227f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd263316-e809-44b2-ace9-ec04958fe375" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0b96be6f-7404-49ad-b1ee-65efc6b3227f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b64643c5-77b0-4fbe-9316-3d7aa7597118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd263316-e809-44b2-ace9-ec04958fe375" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b64643c5-77b0-4fbe-9316-3d7aa7597118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9e8c7e53-7a71-4895-a4d3-d6a5ceabf173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd263316-e809-44b2-ace9-ec04958fe375" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9e8c7e53-7a71-4895-a4d3-d6a5ceabf173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_5853a976-0898-4a38-a519-2aa969b6e6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd263316-e809-44b2-ace9-ec04958fe375" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_5853a976-0898-4a38-a519-2aa969b6e6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7f3021c7-f61d-4317-8523-93121e02f94d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_9fa3a191-c96b-47a2-9310-861ebd223ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f3021c7-f61d-4317-8523-93121e02f94d" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_9fa3a191-c96b-47a2-9310-861ebd223ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bbf776b4-81ea-4e55-bc40-6effa88c09a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f3021c7-f61d-4317-8523-93121e02f94d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bbf776b4-81ea-4e55-bc40-6effa88c09a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_77dddf49-a29d-4a55-a1a4-38ec858cd8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f3021c7-f61d-4317-8523-93121e02f94d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_77dddf49-a29d-4a55-a1a4-38ec858cd8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b7841c4b-93f8-4ab8-ab63-948034c876b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f3021c7-f61d-4317-8523-93121e02f94d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b7841c4b-93f8-4ab8-ab63-948034c876b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a1bc6941-c83f-4614-9790-b6d152c5caaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f3021c7-f61d-4317-8523-93121e02f94d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a1bc6941-c83f-4614-9790-b6d152c5caaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f25cbffb-3054-405c-b856-eb9dbdc5408e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:href="nvax-20221231.xsd#nvax_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f25cbffb-3054-405c-b856-eb9dbdc5408e" xlink:to="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3c55360-9f99-4742-a16e-8a1af3983628" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_srt_RangeAxis_c3c55360-9f99-4742-a16e-8a1af3983628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c3c55360-9f99-4742-a16e-8a1af3983628" xlink:to="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f145c3da-21bf-4e17-8859-36500f0dc34d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:to="loc_srt_MinimumMember_f145c3da-21bf-4e17-8859-36500f0dc34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_453467d4-a82d-458e-b173-21af1bcc292c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2268c588-4200-4394-8cc6-78e59bb9a759" xlink:to="loc_srt_MaximumMember_453467d4-a82d-458e-b173-21af1bcc292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a50590ab-6b99-4ef6-b148-9c1c25f6a796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_DebtInstrumentAxis_a50590ab-6b99-4ef6-b148-9c1c25f6a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a50590ab-6b99-4ef6-b148-9c1c25f6a796" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_581b8890-fe6f-418a-8368-322ab2b0d131" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_581b8890-fe6f-418a-8368-322ab2b0d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_19c65be0-b7d9-4302-bda8-11769b19c0c1" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b7e7645-7b70-4f97-bd11-9372a224b5da" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_19c65be0-b7d9-4302-bda8-11769b19c0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3a019552-54ba-4da4-806d-66c3a589699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3a019552-54ba-4da4-806d-66c3a589699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0fb9574e-7704-4521-a460-d7e9026fc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3a019552-54ba-4da4-806d-66c3a589699b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0fb9574e-7704-4521-a460-d7e9026fc72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_729c5d9b-70f7-4305-a0a8-160807b8f025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fb9574e-7704-4521-a460-d7e9026fc72e" xlink:to="loc_us-gaap_UnsecuredDebtMember_729c5d9b-70f7-4305-a0a8-160807b8f025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d034443-6631-4001-aa1c-6071e55727d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_srt_ProductOrServiceAxis_5d034443-6631-4001-aa1c-6071e55727d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35e8620b-3398-4d6b-ab10-733a7fd60862" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5d034443-6631-4001-aa1c-6071e55727d3" xlink:to="loc_srt_ProductsAndServicesDomain_35e8620b-3398-4d6b-ab10-733a7fd60862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_d6ff4ad2-352c-4de4-9ead-109bcc88972c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35e8620b-3398-4d6b-ab10-733a7fd60862" xlink:to="loc_us-gaap_GovernmentContractMember_d6ff4ad2-352c-4de4-9ead-109bcc88972c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d3313c6e-4461-4505-a260-bab66788fe8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d3313c6e-4461-4505-a260-bab66788fe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3313c6e-4461-4505-a260-bab66788fe8c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_78f49f81-6dde-4be1-88df-46d75f108a8f" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:to="loc_nvax_USGovernmentAgreementMember_78f49f81-6dde-4be1-88df-46d75f108a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_c7ad3e6f-8f8a-43c8-88cf-c4fcf6107e0e" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4edd34e0-62fb-4d00-b0bf-181ca5256a6e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_c7ad3e6f-8f8a-43c8-88cf-c4fcf6107e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_022ef835-db7c-4077-b63e-761dd52f7748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5fc7f3b0-db7c-45c8-b29c-2bf7a36c7c6d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_022ef835-db7c-4077-b63e-761dd52f7748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d45281db-f079-4f19-8655-c2200d4f4cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_022ef835-db7c-4077-b63e-761dd52f7748" xlink:to="loc_us-gaap_SubsequentEventMember_d45281db-f079-4f19-8655-c2200d4f4cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:href="nvax-20221231.xsd#nvax_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_dd10be97-113d-4d14-8f64-d7262c264828" xlink:to="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3c3a3d2-594c-4abb-a395-dddc0904cd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3c3a3d2-594c-4abb-a395-dddc0904cd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromIssuanceCommonStockAndDebt_fdffa47b-dbed-4e61-b742-68977d7f1acc" xlink:href="nvax-20221231.xsd#nvax_ProceedsFromIssuanceCommonStockAndDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_nvax_ProceedsFromIssuanceCommonStockAndDebt_fdffa47b-dbed-4e61-b742-68977d7f1acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_8acd9122-e71d-41c1-8535-2b9c32d3d447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_RepaymentsOfDebt_8acd9122-e71d-41c1-8535-2b9c32d3d447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76da2837-ae37-405a-84fb-3263607f33d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NetIncomeLoss_76da2837-ae37-405a-84fb-3263607f33d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f644376-2605-4f8d-ba55-ba32345d4411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f644376-2605-4f8d-ba55-ba32345d4411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_ddcc7b29-1d3e-4fdf-8e17-5703b1304902" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_ddcc7b29-1d3e-4fdf-8e17-5703b1304902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_187f6dbc-3387-4fe1-a8d2-f17affca2c99" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_187f6dbc-3387-4fe1-a8d2-f17affca2c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_401d571d-a00b-4d1b-973b-491c8baf50c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_AdvertisingExpense_401d571d-a00b-4d1b-973b-491c8baf50c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f768b5c3-251e-4411-9b60-ed7cb05d1b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f768b5c3-251e-4411-9b60-ed7cb05d1b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_8276374e-86a8-4e24-ad0e-8d9573a17ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NumberOfReportingUnits_8276374e-86a8-4e24-ad0e-8d9573a17ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d778ef06-d0b8-4eb7-b644-12e44fc052e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d778ef06-d0b8-4eb7-b644-12e44fc052e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_33f63e7b-3c45-432c-8b6f-64ef4051d365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_33f63e7b-3c45-432c-8b6f-64ef4051d365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_76a4db48-1587-460e-a236-5f2c0b9a9aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_76a4db48-1587-460e-a236-5f2c0b9a9aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_16fb262d-95e9-4811-8cf2-b4781340f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_16fb262d-95e9-4811-8cf2-b4781340f55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_5f1d4461-7d24-478e-9d59-d200d77ebb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_5f1d4461-7d24-478e-9d59-d200d77ebb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_f034821d-3e61-4d83-87b5-3a612a1ca2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_f034821d-3e61-4d83-87b5-3a612a1ca2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d63a2000-1591-4855-bfbf-e4ad2746699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_e1903930-f33d-475a-bebb-2e61ecd36e68" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d63a2000-1591-4855-bfbf-e4ad2746699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_300a7a08-662d-49e5-b43c-1d93a31269a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300a7a08-662d-49e5-b43c-1d93a31269a4" xlink:to="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5738b323-d0b3-4c89-99f0-ac2715980ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5738b323-d0b3-4c89-99f0-ac2715980ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f5ccc0e7-f96f-4c39-9e87-716070ea2f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5738b323-d0b3-4c89-99f0-ac2715980ba4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f5ccc0e7-f96f-4c39-9e87-716070ea2f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2fc7454f-ac5c-4b18-b8bd-03ea132e60b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f5ccc0e7-f96f-4c39-9e87-716070ea2f15" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2fc7454f-ac5c-4b18-b8bd-03ea132e60b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9d81f9d-8c65-4448-b534-cd02580d5b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9d81f9d-8c65-4448-b534-cd02580d5b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9d81f9d-8c65-4448-b534-cd02580d5b57" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d05d9032-18d6-4325-861f-ba63894c1e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:to="loc_us-gaap_SalesRevenueNetMember_d05d9032-18d6-4325-861f-ba63894c1e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_74406342-328e-4391-a6f0-2cc9ecbb6171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9245e86-79f6-4606-a924-dc05a4d30857" xlink:to="loc_us-gaap_AccountsReceivableMember_74406342-328e-4391-a6f0-2cc9ecbb6171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5da10c1b-7bdf-4401-a667-0fe1e919a1b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:to="loc_srt_MajorCustomersAxis_5da10c1b-7bdf-4401-a667-0fe1e919a1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5da10c1b-7bdf-4401-a667-0fe1e919a1b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionMember_787903ac-090b-46eb-9344-cb66c7cd5755" xlink:href="nvax-20221231.xsd#nvax_EuropeanCommissionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_EuropeanCommissionMember_787903ac-090b-46eb-9344-cb66c7cd5755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfAustraliaMember_dba310d0-2c52-4d45-8db7-192edabf2dfe" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfAustraliaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GovernmentOfAustraliaMember_dba310d0-2c52-4d45-8db7-192edabf2dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfCanadaMember_3f1ca358-be63-4126-8435-687adc2377c6" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfCanadaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GovernmentOfCanadaMember_3f1ca358-be63-4126-8435-687adc2377c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfIsraelMember_7bcc9f85-90c0-440d-b5be-63b0341f02e5" xlink:href="nvax-20221231.xsd#nvax_GovernmentOfIsraelMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GovernmentOfIsraelMember_7bcc9f85-90c0-440d-b5be-63b0341f02e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviVaccineAllianceMember_0637c53a-e873-4618-8bcb-3f174b7b23e7" xlink:href="nvax-20221231.xsd#nvax_GaviVaccineAllianceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_GaviVaccineAllianceMember_0637c53a-e873-4618-8bcb-3f174b7b23e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentMember_ea628de1-e861-4cb1-8242-ccf384df0df8" xlink:href="nvax-20221231.xsd#nvax_USGovernmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_USGovernmentMember_ea628de1-e861-4cb1-8242-ccf384df0df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f22cb920-075b-4729-8e6f-354739dfc294" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f22cb920-075b-4729-8e6f-354739dfc294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceCoLtdMember_9ee0641d-f1c5-44f7-b13c-3e9c6d7d0790" xlink:href="nvax-20221231.xsd#nvax_SKBioscienceCoLtdMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fa0458c-2a08-47bf-841f-a69030da9d57" xlink:to="loc_nvax_SKBioscienceCoLtdMember_9ee0641d-f1c5-44f7-b13c-3e9c6d7d0790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_220d3eee-e154-4fed-ba2a-0d84197f3121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_343e4a90-a934-4fa5-95db-c2aec150a0c9" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_220d3eee-e154-4fed-ba2a-0d84197f3121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0d878317-f405-466c-85f6-8ba049698aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_220d3eee-e154-4fed-ba2a-0d84197f3121" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0d878317-f405-466c-85f6-8ba049698aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9275465f-aaf5-4bf4-bc31-20a2fc641e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9275465f-aaf5-4bf4-bc31-20a2fc641e2a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b9bc2786-5057-4636-a575-1e17ae2fa0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b9bc2786-5057-4636-a575-1e17ae2fa0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b9bc2786-5057-4636-a575-1e17ae2fa0b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_28b05e3d-4dd4-4b7d-9e37-97abe6ae49c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:to="loc_us-gaap_BuildingMember_28b05e3d-4dd4-4b7d-9e37-97abe6ae49c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_bc557c09-4fe2-4956-b749-12144eca1732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_bc557c09-4fe2-4956-b749-12144eca1732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b0a0d1aa-3363-479a-8bf3-eadabc689294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8ba646e-57a7-46e6-8b89-298b4f52c5a5" xlink:to="loc_us-gaap_ComputerEquipmentMember_b0a0d1aa-3363-479a-8bf3-eadabc689294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43d99cc1-4e77-45b2-b933-2c1519ccba81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:to="loc_srt_RangeAxis_43d99cc1-4e77-45b2-b933-2c1519ccba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_43d99cc1-4e77-45b2-b933-2c1519ccba81" xlink:to="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_031c05d2-5238-4b0f-93ae-a9dda5023d50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:to="loc_srt_MinimumMember_031c05d2-5238-4b0f-93ae-a9dda5023d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40cab3e7-2979-4b09-9dab-c14fb82b0449" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c8bdca9-16a7-402a-a2f7-49fb2ea53e42" xlink:to="loc_srt_MaximumMember_40cab3e7-2979-4b09-9dab-c14fb82b0449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d593ba0-749c-4c91-809f-aa9e58f91cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae9aa67-2576-44f6-ac63-8a0fc28ad206" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d593ba0-749c-4c91-809f-aa9e58f91cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b871f59c-926c-4fc8-953b-c67d9e658f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d593ba0-749c-4c91-809f-aa9e58f91cde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b871f59c-926c-4fc8-953b-c67d9e658f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_f55c176d-0f3c-43b1-9255-a3a2e7a65208" xlink:href="nvax-20221231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_f55c176d-0f3c-43b1-9255-a3a2e7a65208" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_21828965-d18b-4b8c-a519-820abb4ef00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_21828965-d18b-4b8c-a519-820abb4ef00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_786fbb6c-4f8d-48bd-8302-240c67012792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_2cdffa0f-1e96-4f42-91b7-7cfcfad261ef" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_2cdffa0f-1e96-4f42-91b7-7cfcfad261ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_6fb02db0-22c6-44ad-a8a6-6c52e94ef1a4" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_6fb02db0-22c6-44ad-a8a6-6c52e94ef1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_c16412e0-e49f-45aa-947f-1d37c9948808" xlink:href="nvax-20221231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_c16412e0-e49f-45aa-947f-1d37c9948808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_bf2dba7a-ae20-4bf9-b15c-91f368c15692" xlink:href="nvax-20221231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_EuropeanCommissionsECMember_bf2dba7a-ae20-4bf9-b15c-91f368c15692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_5246c4ef-0b8f-4edb-b801-296e0fb9f02a" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_USGovernmentAgreementMember_5246c4ef-0b8f-4edb-b801-296e0fb9f02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DoDContractMember_7c717c6d-d605-41ef-aefb-640d39494fb1" xlink:href="nvax-20221231.xsd#nvax_DoDContractMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_DoDContractMember_7c717c6d-d605-41ef-aefb-640d39494fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_ab2b6452-6fa2-4372-bd04-6b137b74089f" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_ab2b6452-6fa2-4372-bd04-6b137b74089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember_1a2c2ddf-2afb-4018-9927-6d3f5dc762b3" xlink:href="nvax-20221231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_CEPIGrantFundingMember_1a2c2ddf-2afb-4018-9927-6d3f5dc762b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_61388200-5a94-4dc0-9494-5c2a345758c8" xlink:href="nvax-20221231.xsd#nvax_TakedaArrangementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f7c7748-06ae-4d39-a766-e0a5b35d9119" xlink:to="loc_nvax_TakedaArrangementMember_61388200-5a94-4dc0-9494-5c2a345758c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_adbb26c9-ba35-4a88-ab55-ae7956ff126c" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_22e3dfd6-f7ed-4ff5-9393-8d107f9f51ba" xlink:href="nvax-20221231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_fd75185b-5e09-433e-b5a9-593cfff047f4" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_22e3dfd6-f7ed-4ff5-9393-8d107f9f51ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eaad5764-1774-4a60-af86-e84dc41d25c0" xlink:to="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4067f4e0-af87-4d54-9467-729e6ef81e40" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:to="loc_srt_MinimumMember_4067f4e0-af87-4d54-9467-729e6ef81e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5daa1ba5-e3b8-4dc2-848e-4c90812e0332" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef51c273-a3d2-41a1-8345-77bdf0a18de7" xlink:to="loc_srt_MaximumMember_5daa1ba5-e3b8-4dc2-848e-4c90812e0332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bd7f4f02-badb-4daa-a46e-2501fecddd1b" xlink:to="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_35093a4d-74bf-4095-8ec4-58b8f7e64611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:to="loc_us-gaap_GovernmentContractMember_35093a4d-74bf-4095-8ec4-58b8f7e64611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_6c891466-3f20-49ae-8439-490b7fdbde11" xlink:href="nvax-20221231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_073f29b0-99bb-4d1d-8e29-ee8346f274a1" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_6c891466-3f20-49ae-8439-490b7fdbde11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_adbdc4bf-eb48-4467-83d7-797861195bd1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ab9cf0b7-09f8-47b4-8120-2f724de6a63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_494e9a32-109e-4acb-be4c-1132ec16c726" xlink:to="loc_us-gaap_SubsequentEventMember_ab9cf0b7-09f8-47b4-8120-2f724de6a63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27632916-334d-4891-a6e5-10f86296f224" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_d0444b6a-9bec-4be9-9b83-47e1fc24a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_BilledContractReceivables_d0444b6a-9bec-4be9-9b83-47e1fc24a00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_dc252221-80c6-4a09-968e-08081b72690c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_UnbilledContractsReceivable_dc252221-80c6-4a09-968e-08081b72690c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0d83f0ae-c481-4be9-ab46-f0c81e26e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0d83f0ae-c481-4be9-ab46-f0c81e26e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_852613e5-089f-48d2-8c78-ca3c821a5bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_852613e5-089f-48d2-8c78-ca3c821a5bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_e53ad198-b051-4016-bafb-9aaeeb5f2807" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_e53ad198-b051-4016-bafb-9aaeeb5f2807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3fb7eff5-c959-448b-aa4c-be1964e65c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3fb7eff5-c959-448b-aa4c-be1964e65c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_461b6d0d-b90b-4c31-9803-c4769bd1e314" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_461b6d0d-b90b-4c31-9803-c4769bd1e314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_db43e052-5ebe-46a6-b4ee-076a40feaecf" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_db43e052-5ebe-46a6-b4ee-076a40feaecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_4866b47b-c7be-4d62-9ead-5346a49e13f7" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_4866b47b-c7be-4d62-9ead-5346a49e13f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_e6860a54-98f0-49f9-8e5a-7314872619be" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_e6860a54-98f0-49f9-8e5a-7314872619be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_a89eacd9-9953-4690-835f-86abc5963873" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_a89eacd9-9953-4690-835f-86abc5963873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate_22842e3a-8274-4344-8fa1-167c7286d456" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidate_22842e3a-8274-4344-8fa1-167c7286d456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment_0d270f50-38b7-463e-bc30-1f70a50ee60e" xlink:href="nvax-20221231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueFromContractWithCustomerCommitment_0d270f50-38b7-463e-bc30-1f70a50ee60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_bce64962-0792-4ee8-a3b6-8c68d3d357ef" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling_bce64962-0792-4ee8-a3b6-8c68d3d357ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_686922c5-b190-4220-bfe2-3846f069c0a9" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining_686922c5-b190-4220-bfe2-3846f069c0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_0941c0aa-25cd-4938-8539-9fee82f19f29" xlink:href="nvax-20221231.xsd#nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod_0941c0aa-25cd-4938-8539-9fee82f19f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_35ffdcf8-cfb3-4948-94c5-358d827c5284" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_35ffdcf8-cfb3-4948-94c5-358d827c5284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_bf1951cc-ff8f-47a1-8cc3-e30b08923e1e" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_bf1951cc-ff8f-47a1-8cc3-e30b08923e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_fcec57e2-ecc9-40d6-bfd8-9761798cca08" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_fcec57e2-ecc9-40d6-bfd8-9761798cca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bac09eb7-d6b9-43ea-90f2-f5e703134226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_Revenues_bac09eb7-d6b9-43ea-90f2-f5e703134226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00860300-cb4b-410d-836a-f4db6a60f2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ae1a98d-a3e2-4fbc-82d0-d500b2c0011a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00860300-cb4b-410d-836a-f4db6a60f2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_0996b1f5-004e-49d7-bad5-61fc81dfe8d9" xlink:href="nvax-20221231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_af44bc4e-30d4-4215-a370-aeea12d41a13" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_0996b1f5-004e-49d7-bad5-61fc81dfe8d9" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_af44bc4e-30d4-4215-a370-aeea12d41a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_b24bb8d9-ac3b-4914-b681-62045591f71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_af44bc4e-30d4-4215-a370-aeea12d41a13" xlink:to="loc_us-gaap_AccountsReceivableGross_b24bb8d9-ac3b-4914-b681-62045591f71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_e72085e5-ad20-4bf2-ade6-bdd28dd3b9af" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_af44bc4e-30d4-4215-a370-aeea12d41a13" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_e72085e5-ad20-4bf2-ade6-bdd28dd3b9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_895494f9-6ee0-40fc-b99c-e3ce6d2200e5" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_af44bc4e-30d4-4215-a370-aeea12d41a13" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_895494f9-6ee0-40fc-b99c-e3ce6d2200e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_635f9ee3-428c-4c5a-9a36-32709e9f9d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_af44bc4e-30d4-4215-a370-aeea12d41a13" xlink:to="loc_us-gaap_AccountsReceivableGross_635f9ee3-428c-4c5a-9a36-32709e9f9d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_959e5d05-af85-4a02-8b0d-9bc34a0ad3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_0996b1f5-004e-49d7-bad5-61fc81dfe8d9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_959e5d05-af85-4a02-8b0d-9bc34a0ad3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_a2a35519-35dc-4490-a0f5-8b2f6d641acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_959e5d05-af85-4a02-8b0d-9bc34a0ad3e7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_a2a35519-35dc-4490-a0f5-8b2f6d641acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_02d6cd5e-1e47-4ee1-84d6-90a43196d690" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_959e5d05-af85-4a02-8b0d-9bc34a0ad3e7" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_02d6cd5e-1e47-4ee1-84d6-90a43196d690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_020abcc0-3d3a-4eb6-b1b9-9ffced27a5b5" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_959e5d05-af85-4a02-8b0d-9bc34a0ad3e7" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_020abcc0-3d3a-4eb6-b1b9-9ffced27a5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c081a6e8-bda3-405d-91a7-e0652b0a442d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_959e5d05-af85-4a02-8b0d-9bc34a0ad3e7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c081a6e8-bda3-405d-91a7-e0652b0a442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_479ba3f9-f602-4b24-8447-20fe6fe05f04" xlink:href="nvax-20221231.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_0996b1f5-004e-49d7-bad5-61fc81dfe8d9" xlink:to="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_479ba3f9-f602-4b24-8447-20fe6fe05f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cbda7656-995c-4648-a68c-ecd2bf2fd595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_479ba3f9-f602-4b24-8447-20fe6fe05f04" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cbda7656-995c-4648-a68c-ecd2bf2fd595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions_b7441bd8-06ea-4cbb-8bf5-ab0535821715" xlink:href="nvax-20221231.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_479ba3f9-f602-4b24-8447-20fe6fe05f04" xlink:to="loc_nvax_ContractWithCustomerLiabilityAdditions_b7441bd8-06ea-4cbb-8bf5-ab0535821715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions_2d3ca7b0-3581-4436-9710-2afc9c111541" xlink:href="nvax-20221231.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_479ba3f9-f602-4b24-8447-20fe6fe05f04" xlink:to="loc_nvax_ContractWithCustomerLiabilityDeductions_2d3ca7b0-3581-4436-9710-2afc9c111541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9cc55cd0-1ffd-4e5d-a0a2-0bc6e6c22b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_479ba3f9-f602-4b24-8447-20fe6fe05f04" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9cc55cd0-1ffd-4e5d-a0a2-0bc6e6c22b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_0996b1f5-004e-49d7-bad5-61fc81dfe8d9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c2dec62-cd92-48a5-b660-46a57d09aef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c2dec62-cd92-48a5-b660-46a57d09aef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c2dec62-cd92-48a5-b660-46a57d09aef0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_403170fb-9642-4c44-a56c-971964635387" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_403170fb-9642-4c44-a56c-971964635387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_242b0598-6868-4ad6-a99c-7eea5014d9a7" xlink:href="nvax-20221231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99c984e-3598-4523-b5c3-cd75be8a16e8" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_242b0598-6868-4ad6-a99c-7eea5014d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09d89cf5-039f-4322-99cd-52a1db9e6e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09d89cf5-039f-4322-99cd-52a1db9e6e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dc6ddeea-c972-480d-92e1-c209c4f4917d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09d89cf5-039f-4322-99cd-52a1db9e6e77" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dc6ddeea-c972-480d-92e1-c209c4f4917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueMember_4c10e259-dc71-4961-92a4-71906e1a5613" xlink:href="nvax-20221231.xsd#nvax_RevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dc6ddeea-c972-480d-92e1-c209c4f4917d" xlink:to="loc_nvax_RevenueMember_4c10e259-dc71-4961-92a4-71906e1a5613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6d41d85d-7f07-4a9b-a766-0a8d66c26f99" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_73e4653f-19b7-4466-8b05-dcaf454d53f2" xlink:href="nvax-20221231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_73e4653f-19b7-4466-8b05-dcaf454d53f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73241689-d1cf-4424-b6fd-6f70c45eca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73241689-d1cf-4424-b6fd-6f70c45eca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_de09d900-3ba3-47ba-820e-5cc66f3a6ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_de09d900-3ba3-47ba-820e-5cc66f3a6ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eb26644a-dbc2-4a1f-9641-ded650c1d9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eb26644a-dbc2-4a1f-9641-ded650c1d9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_b05d0f3a-8243-400d-b6b6-1d213720a167" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_b05d0f3a-8243-400d-b6b6-1d213720a167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount_2864934c-9abc-45ba-b3ee-98722d701a54" xlink:href="nvax-20221231.xsd#nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0c40576-2b4a-4b6e-aec7-338521bf3325" xlink:to="loc_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount_2864934c-9abc-45ba-b3ee-98722d701a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueScheduleofProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_bdc1d760-c18e-4a6b-bc64-d9e4d07dd3fb" xlink:href="nvax-20221231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_bdc1d760-c18e-4a6b-bc64-d9e4d07dd3fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68781f40-3e27-41a8-b2f0-9b80e5450f25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:to="loc_srt_ProductOrServiceAxis_68781f40-3e27-41a8-b2f0-9b80e5450f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b817f0d-010d-40c5-bc0b-25cbadf5aa1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_68781f40-3e27-41a8-b2f0-9b80e5450f25" xlink:to="loc_srt_ProductsAndServicesDomain_8b817f0d-010d-40c5-bc0b-25cbadf5aa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5daa2def-691b-4b7d-927e-2f7c5563f3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b817f0d-010d-40c5-bc0b-25cbadf5aa1f" xlink:to="loc_us-gaap_ProductMember_5daa2def-691b-4b7d-927e-2f7c5563f3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e86f43fa-a4fa-4e72-9400-a84af0953a11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:to="loc_srt_StatementGeographicalAxis_e86f43fa-a4fa-4e72-9400-a84af0953a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e86f43fa-a4fa-4e72-9400-a84af0953a11" xlink:to="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_8148e584-63c3-43fc-9c9f-fbcf871fa684" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:to="loc_srt_NorthAmericaMember_8148e584-63c3-43fc-9c9f-fbcf871fa684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_e567073c-f467-49d1-b9cb-10e78e4e9687" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:to="loc_srt_EuropeMember_e567073c-f467-49d1-b9cb-10e78e4e9687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember_018ebbd6-81d4-4f32-9903-fbf7ba49fbf6" xlink:href="nvax-20221231.xsd#nvax_RestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_42a4af63-397c-4057-8f48-681cfdffcef5" xlink:to="loc_nvax_RestOfTheWorldMember_018ebbd6-81d4-4f32-9903-fbf7ba49fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_17457ba8-a080-49f6-bd46-76ceb99447bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc85c39c-24f2-4870-b400-c391f0c069a5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_17457ba8-a080-49f6-bd46-76ceb99447bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f2464c6d-5018-46d5-8fa2-cf7b02a84bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_17457ba8-a080-49f6-bd46-76ceb99447bd" xlink:to="loc_us-gaap_Revenues_f2464c6d-5018-46d5-8fa2-cf7b02a84bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#RevenueScheduleofGrantRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_f7cc3971-63fd-45b7-bae7-a25e06422e84" xlink:href="nvax-20221231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_f7cc3971-63fd-45b7-bae7-a25e06422e84" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9329d37a-cbdd-4e05-822a-cc422d0354c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:to="loc_srt_ProductOrServiceAxis_9329d37a-cbdd-4e05-822a-cc422d0354c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_662aeb2c-c425-44d8-a32b-297f4312a0a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9329d37a-cbdd-4e05-822a-cc422d0354c2" xlink:to="loc_srt_ProductsAndServicesDomain_662aeb2c-c425-44d8-a32b-297f4312a0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_8c357484-4fa2-4248-ac3c-eaf3d2e38a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_662aeb2c-c425-44d8-a32b-297f4312a0a4" xlink:to="loc_us-gaap_GrantMember_8c357484-4fa2-4248-ac3c-eaf3d2e38a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3bd5f009-51ca-4eec-b39a-2834bf58de3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3bd5f009-51ca-4eec-b39a-2834bf58de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3bd5f009-51ca-4eec-b39a-2834bf58de3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_b7a55477-c36f-412d-8372-cc16c6588f11" xlink:href="nvax-20221231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_USGovernmentAgreementMember_b7a55477-c36f-412d-8372-cc16c6588f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember_7d18dbd2-be31-4a70-ba08-65ca0b91bae0" xlink:href="nvax-20221231.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_USDepartmentOfDefenseDoDContractMember_7d18dbd2-be31-4a70-ba08-65ca0b91bae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_5606e31f-e450-4bd2-a18f-f2da7a172ad8" xlink:href="nvax-20221231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_5606e31f-e450-4bd2-a18f-f2da7a172ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherGrantRevenueMember_68277269-3c91-4e94-9fa8-7f00a8c6217f" xlink:href="nvax-20221231.xsd#nvax_OtherGrantRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6247dccc-5672-429b-84e5-91a37c761334" xlink:to="loc_nvax_OtherGrantRevenueMember_68277269-3c91-4e94-9fa8-7f00a8c6217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ff9ddeb-eca7-459e-9e4c-1f2c3c15094e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd2c31ed-52bc-440a-bc7b-ee47c0114308" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ff9ddeb-eca7-459e-9e4c-1f2c3c15094e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b9c6fdff-8ae0-4a4c-933b-a7b481f3082f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ff9ddeb-eca7-459e-9e4c-1f2c3c15094e" xlink:to="loc_us-gaap_Revenues_b9c6fdff-8ae0-4a4c-933b-a7b481f3082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_2695f60f-393e-430f-b514-d93d73d883f4" xlink:href="nvax-20221231.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_2695f60f-393e-430f-b514-d93d73d883f4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e0a677d-4fda-4539-a3a2-d242d6fa9b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e0a677d-4fda-4539-a3a2-d242d6fa9b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e0a677d-4fda-4539-a3a2-d242d6fa9b28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_23b2b99c-d188-4453-bf7f-81ee90269dd8" xlink:href="nvax-20221231.xsd#nvax_TakedaArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:to="loc_nvax_TakedaArrangementMember_23b2b99c-d188-4453-bf7f-81ee90269dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceAgreementMember_e717a309-a504-4681-9fca-4b79815159a2" xlink:href="nvax-20221231.xsd#nvax_SKBioscienceAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:to="loc_nvax_SKBioscienceAgreementMember_e717a309-a504-4681-9fca-4b79815159a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_77cc7aee-9ef0-4569-ba71-2bb754e8a699" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d4765eb-3343-45b6-bed6-848161caa23b" xlink:to="loc_nvax_SettlementAgreementMember_77cc7aee-9ef0-4569-ba71-2bb754e8a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_682aa330-0aab-4de1-8c42-a95f8c999121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_682aa330-0aab-4de1-8c42-a95f8c999121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d0096a01-7cbe-415a-bc65-269f4852a41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_682aa330-0aab-4de1-8c42-a95f8c999121" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d0096a01-7cbe-415a-bc65-269f4852a41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_6a1a1620-8588-466b-bc31-91241981e2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d0096a01-7cbe-415a-bc65-269f4852a41d" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_6a1a1620-8588-466b-bc31-91241981e2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_af290031-47d1-49f4-a8d1-6494492c3b75" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_5b433e6e-2224-4b06-ba42-b32c475980bf" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_5b433e6e-2224-4b06-ba42-b32c475980bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1853e760-d30b-420b-b637-2ded4096676b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1853e760-d30b-420b-b637-2ded4096676b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_c9a11b5b-c4d9-42a5-95a9-75dfbb0010ba" xlink:href="nvax-20221231.xsd#nvax_SettlementPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_SettlementPayment_c9a11b5b-c4d9-42a5-95a9-75dfbb0010ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementInitialReservationFee_ca5b04a1-5878-4327-ac81-4aa1c5e960d5" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementInitialReservationFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_SettlementAgreementInitialReservationFee_ca5b04a1-5878-4327-ac81-4aa1c5e960d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_8044c1f5-e8fa-4ebf-8664-77398da6e39e" xlink:href="nvax-20221231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_8044c1f5-e8fa-4ebf-8664-77398da6e39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_61913082-176b-446a-995d-e776fdaf648d" xlink:href="nvax-20221231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_61913082-176b-446a-995d-e776fdaf648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9f2cf255-e36e-41ca-8236-d37ee21d5cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a5328b2-b297-460c-9cb1-85833789328f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9f2cf255-e36e-41ca-8236-d37ee21d5cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_fbcbc36a-b218-4d31-91d9-ae539174af2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08ac6e52-30f2-49ef-a918-8ff377a3fdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fbcbc36a-b218-4d31-91d9-ae539174af2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08ac6e52-30f2-49ef-a918-8ff377a3fdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_c4519e03-65a5-4425-bb83-08142f3af459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fbcbc36a-b218-4d31-91d9-ae539174af2c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_c4519e03-65a5-4425-bb83-08142f3af459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_470fc94f-c05e-4354-832c-049e3a34e75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fbcbc36a-b218-4d31-91d9-ae539174af2c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_470fc94f-c05e-4354-832c-049e3a34e75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ed360ba-9604-4f36-93fb-763b834525c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fbcbc36a-b218-4d31-91d9-ae539174af2c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ed360ba-9604-4f36-93fb-763b834525c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d66f4a30-8156-4283-ad90-e0796c2da85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d66f4a30-8156-4283-ad90-e0796c2da85e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf302360-1898-4335-abc4-ff1e83a3a22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf302360-1898-4335-abc4-ff1e83a3a22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf302360-1898-4335-abc4-ff1e83a3a22f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_84a485c1-d882-4cf5-8964-206196896415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_84a485c1-d882-4cf5-8964-206196896415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_175af9e6-93ba-44ec-b4d7-ba4d4579a997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_175af9e6-93ba-44ec-b4d7-ba4d4579a997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_33710145-a4e1-4893-88d9-f35f2223cbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2893f39-51f8-4828-87aa-0deec6b66b42" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_33710145-a4e1-4893-88d9-f35f2223cbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f9e406d1-1ed5-429f-b7a6-c4ee4a4907ea" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b042aedd-2c8d-4c8b-a682-867827608a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b042aedd-2c8d-4c8b-a682-867827608a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_feca6c8e-50ba-4813-97e9-47a39b7094ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_feca6c8e-50ba-4813-97e9-47a39b7094ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9df80e2f-cbf0-44bc-93f8-c1498f4074a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9df80e2f-cbf0-44bc-93f8-c1498f4074a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_0a891796-a274-4ea1-bd02-d469c1b643dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12545554-edbf-4752-9b0d-81b8350c5711" xlink:to="loc_us-gaap_AgencySecuritiesMember_0a891796-a274-4ea1-bd02-d469c1b643dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0a29c942-28bd-4c60-9efd-79c5b4ba1c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_0a29c942-28bd-4c60-9efd-79c5b4ba1c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0a29c942-28bd-4c60-9efd-79c5b4ba1c36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07e121c1-ac3e-47c4-9c0d-5dd7e1275929" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07e121c1-ac3e-47c4-9c0d-5dd7e1275929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_443284fa-6d3b-4841-970f-92146375ee8e" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f0b666d-ee79-4d65-b046-cd545536f70e" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_443284fa-6d3b-4841-970f-92146375ee8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_092fbe36-06ef-4c71-973c-76b5d88be4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b3d6cfd4-cd87-40f4-87e4-35abeb5e0d2f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_092fbe36-06ef-4c71-973c-76b5d88be4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_d78da311-6a48-4efc-a4c7-0ab1685e3bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_092fbe36-06ef-4c71-973c-76b5d88be4de" xlink:to="loc_us-gaap_UnsecuredDebtMember_d78da311-6a48-4efc-a4c7-0ab1685e3bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0eff596d-5250-4cc7-9fed-7de2affc89fe" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ab28660b-0267-4787-8aca-cf0ef00b74b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ab28660b-0267-4787-8aca-cf0ef00b74b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5ac219b3-a8be-40ae-b4d0-56094765278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ab28660b-0267-4787-8aca-cf0ef00b74b0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5ac219b3-a8be-40ae-b4d0-56094765278d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4fbc9d8f-4a96-4765-9c84-f2a2d2601162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4fbc9d8f-4a96-4765-9c84-f2a2d2601162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a0f00918-52fc-404e-ba64-dfd7e9e881dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4fbc9d8f-4a96-4765-9c84-f2a2d2601162" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a0f00918-52fc-404e-ba64-dfd7e9e881dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_cf114802-9753-44c5-b33f-f15793a0252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a578e492-1bc6-4f76-8e39-a4c5a8bce311" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_cf114802-9753-44c5-b33f-f15793a0252f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#InventoryScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b6cb4ddb-f9d4-448d-a2fc-12b860e6b3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ceca1d94-3082-4cb7-824b-0ce3c3a8bdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b6cb4ddb-f9d4-448d-a2fc-12b860e6b3e9" xlink:to="loc_us-gaap_InventoryRawMaterials_ceca1d94-3082-4cb7-824b-0ce3c3a8bdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_3fa149f9-69d5-4546-9134-0f7b7dbd24ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b6cb4ddb-f9d4-448d-a2fc-12b860e6b3e9" xlink:to="loc_us-gaap_InventoryWorkInProcess_3fa149f9-69d5-4546-9134-0f7b7dbd24ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_c3faffa7-0874-414b-8d3c-af51b16be56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b6cb4ddb-f9d4-448d-a2fc-12b860e6b3e9" xlink:to="loc_us-gaap_InventoryFinishedGoods_c3faffa7-0874-414b-8d3c-af51b16be56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_50fead44-9837-4aa1-8bb1-8640eeee11f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b6cb4ddb-f9d4-448d-a2fc-12b860e6b3e9" xlink:to="loc_us-gaap_InventoryNet_50fead44-9837-4aa1-8bb1-8640eeee11f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#InventoryAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f6be7c6b-3d2c-43a4-994a-f888e6fbefeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveChargedToCostsOfSales_7f685cde-e3c1-4f8e-8ea5-f93276597f38" xlink:href="nvax-20221231.xsd#nvax_InventoryReserveChargedToCostsOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f6be7c6b-3d2c-43a4-994a-f888e6fbefeb" xlink:to="loc_nvax_InventoryReserveChargedToCostsOfSales_7f685cde-e3c1-4f8e-8ea5-f93276597f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_d9dc228d-ace2-4eb1-b34f-7dda0ce895cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f6be7c6b-3d2c-43a4-994a-f888e6fbefeb" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_d9dc228d-ace2-4eb1-b34f-7dda0ce895cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_55e1fa6a-0dd4-47fd-a643-6d27a0cfff24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f6be7c6b-3d2c-43a4-994a-f888e6fbefeb" xlink:to="loc_us-gaap_InventoryWriteDown_55e1fa6a-0dd4-47fd-a643-6d27a0cfff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#InventoryScheduleofInventoryReservesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c13d9efc-236f-48c5-ad8a-ca88df3bd636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveRollForward_f81d1077-1b2f-45b2-aa74-61f7c86c5d8f" xlink:href="nvax-20221231.xsd#nvax_InventoryReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c13d9efc-236f-48c5-ad8a-ca88df3bd636" xlink:to="loc_nvax_InventoryReserveRollForward_f81d1077-1b2f-45b2-aa74-61f7c86c5d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_dc873028-fd3e-4025-98e8-cb6b460134ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_f81d1077-1b2f-45b2-aa74-61f7c86c5d8f" xlink:to="loc_us-gaap_InventoryValuationReserves_dc873028-fd3e-4025-98e8-cb6b460134ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveChargedToCostsOfSales_cf15d125-e334-4e79-97ec-3a9f95a9109d" xlink:href="nvax-20221231.xsd#nvax_InventoryReserveChargedToCostsOfSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_f81d1077-1b2f-45b2-aa74-61f7c86c5d8f" xlink:to="loc_nvax_InventoryReserveChargedToCostsOfSales_cf15d125-e334-4e79-97ec-3a9f95a9109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveOtherAdditions_7f7c6820-4830-42c1-ab56-070d2f4f9702" xlink:href="nvax-20221231.xsd#nvax_InventoryReserveOtherAdditions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_f81d1077-1b2f-45b2-aa74-61f7c86c5d8f" xlink:to="loc_nvax_InventoryReserveOtherAdditions_7f7c6820-4830-42c1-ab56-070d2f4f9702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ec34b19e-8512-4364-a0e9-2e1c6082990d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_f81d1077-1b2f-45b2-aa74-61f7c86c5d8f" xlink:to="loc_us-gaap_InventoryWriteDown_ec34b19e-8512-4364-a0e9-2e1c6082990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_10ba5f98-d740-4916-8ab6-f1b2ecca68bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_f81d1077-1b2f-45b2-aa74-61f7c86c5d8f" xlink:to="loc_us-gaap_InventoryValuationReserves_10ba5f98-d740-4916-8ab6-f1b2ecca68bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2aa658e9-928a-4a41-a1d3-b5505f8f642a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_342e1b29-e92a-4b10-932b-adff037bb4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2aa658e9-928a-4a41-a1d3-b5505f8f642a" xlink:to="loc_us-gaap_GoodwillRollForward_342e1b29-e92a-4b10-932b-adff037bb4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_350ae12b-765c-4f84-846a-e5fd2f7338f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_342e1b29-e92a-4b10-932b-adff037bb4cb" xlink:to="loc_us-gaap_Goodwill_350ae12b-765c-4f84-846a-e5fd2f7338f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_3c52736c-9b06-4001-ae7e-679b8e04a069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_342e1b29-e92a-4b10-932b-adff037bb4cb" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_3c52736c-9b06-4001-ae7e-679b8e04a069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c2587973-aca9-4d53-9c92-bab10e0a5b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_342e1b29-e92a-4b10-932b-adff037bb4cb" xlink:to="loc_us-gaap_Goodwill_c2587973-aca9-4d53-9c92-bab10e0a5b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5b60f817-8655-4e2b-a571-cf21f37d2fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_bf1f7f17-2c9f-4cd4-8396-9673e6aadbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5b60f817-8655-4e2b-a571-cf21f37d2fa7" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_bf1f7f17-2c9f-4cd4-8396-9673e6aadbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7142183-3856-4f7a-a982-8bfd2f7848e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_bf1f7f17-2c9f-4cd4-8396-9673e6aadbab" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7142183-3856-4f7a-a982-8bfd2f7848e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4691a5d-baf3-4f07-b1e1-c747406e1fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7142183-3856-4f7a-a982-8bfd2f7848e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4691a5d-baf3-4f07-b1e1-c747406e1fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_9908c3be-07c4-4643-a8c9-ccc8d651ec7c" xlink:href="nvax-20221231.xsd#nvax_NovavaxCZFormerlyPrahaVaccinesASMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4691a5d-baf3-4f07-b1e1-c747406e1fb5" xlink:to="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_9908c3be-07c4-4643-a8c9-ccc8d651ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_bf1f7f17-2c9f-4cd4-8396-9673e6aadbab" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b808eaa7-1cbd-4e1c-ae3c-201ada90f0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b808eaa7-1cbd-4e1c-ae3c-201ada90f0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f2e89d21-82fb-462c-811e-17ff0039b975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f2e89d21-82fb-462c-811e-17ff0039b975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bdbb9143-b44f-4302-9c31-f353629d55e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_Goodwill_bdbb9143-b44f-4302-9c31-f353629d55e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_970541ef-e655-4e97-82a3-99ab1f755b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_970541ef-e655-4e97-82a3-99ab1f755b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_846c2d3c-69a1-4705-84b4-f8cf0dbce0f8" xlink:href="nvax-20221231.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_846c2d3c-69a1-4705-84b4-f8cf0dbce0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e4599a91-0c0e-4ece-ae3d-0ad6e5255feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e4599a91-0c0e-4ece-ae3d-0ad6e5255feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_82e7a300-1dc0-439b-8cb0-77b12c7b1783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_f3485e12-cd45-41cd-bf4e-b4ee980b4acc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_82e7a300-1dc0-439b-8cb0-77b12c7b1783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0957c193-7d00-44e6-9858-6cda8c77cb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0957c193-7d00-44e6-9858-6cda8c77cb33" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3cf2b5bb-9af2-4938-9793-b994b2c16404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3cf2b5bb-9af2-4938-9793-b994b2c16404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_160ad86d-7396-48e2-9ceb-31f344030f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cf2b5bb-9af2-4938-9793-b994b2c16404" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_160ad86d-7396-48e2-9ceb-31f344030f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_a7937c95-08ce-4e31-8a7b-dff2732c26a6" xlink:href="nvax-20221231.xsd#nvax_NovavaxCZFormerlyPrahaVaccinesASMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_160ad86d-7396-48e2-9ceb-31f344030f4c" xlink:to="loc_nvax_NovavaxCZFormerlyPrahaVaccinesASMember_a7937c95-08ce-4e31-8a7b-dff2732c26a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:to="loc_srt_RangeAxis_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f11ae542-c6c0-4554-9dfe-5ddbeaf0489d" xlink:to="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_109c0f16-8dce-48fe-a663-48ffc08126af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:to="loc_srt_MinimumMember_109c0f16-8dce-48fe-a663-48ffc08126af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_abb2f7e6-cf7d-41b1-babe-15c5319d0625" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1057da2b-2c28-4065-8630-87dcfeb9a362" xlink:to="loc_srt_MaximumMember_abb2f7e6-cf7d-41b1-babe-15c5319d0625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_5400648a-221f-4d5a-83c6-c41479ea2d71" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_acc0e76e-7ef0-4574-a5ae-ff40e2ec634f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_acc0e76e-7ef0-4574-a5ae-ff40e2ec634f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0123cb10-c4fa-4bd7-8fd9-1a93610ca0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_Goodwill_0123cb10-c4fa-4bd7-8fd9-1a93610ca0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d8c9cebe-8157-4f39-87f2-0dfff17a3f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d8c9cebe-8157-4f39-87f2-0dfff17a3f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b769ddb4-0daf-4f79-a877-2ffd1f85d8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_00f70f9b-2658-452e-8f54-80dc959cd1ef" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b769ddb4-0daf-4f79-a877-2ffd1f85d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47c3b0c9-bcdf-435e-91d7-13bb5c87c886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1f697fd4-d723-42f5-aab1-c9bcf31afca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47c3b0c9-bcdf-435e-91d7-13bb5c87c886" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1f697fd4-d723-42f5-aab1-c9bcf31afca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_19b49f4b-c09e-4374-9e14-55a27af47b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47c3b0c9-bcdf-435e-91d7-13bb5c87c886" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_19b49f4b-c09e-4374-9e14-55a27af47b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_7cb08fca-1f53-442c-b763-53cb600a2568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47c3b0c9-bcdf-435e-91d7-13bb5c87c886" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_7cb08fca-1f53-442c-b763-53cb600a2568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_efae17f2-a5db-4685-97e5-1bdadcc09ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47c3b0c9-bcdf-435e-91d7-13bb5c87c886" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_efae17f2-a5db-4685-97e5-1bdadcc09ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_234076f2-8749-4b1f-ab18-cf25f4290050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_234076f2-8749-4b1f-ab18-cf25f4290050" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3b90804-2c88-40e0-958e-29783edd3777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:to="loc_srt_CounterpartyNameAxis_c3b90804-2c88-40e0-958e-29783edd3777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c3b90804-2c88-40e0-958e-29783edd3777" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAndCMDAgreementsMember_2f91d110-4e08-4a59-8e91-140d9f346ed6" xlink:href="nvax-20221231.xsd#nvax_CMOAndCMDAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:to="loc_nvax_CMOAndCMDAgreementsMember_2f91d110-4e08-4a59-8e91-140d9f346ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700QuinceOrchardRoadAgreementMember_b407cbd3-b610-415a-88db-db1347cb6b5b" xlink:href="nvax-20221231.xsd#nvax_A700QuinceOrchardRoadAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:to="loc_nvax_A700QuinceOrchardRoadAgreementMember_b407cbd3-b610-415a-88db-db1347cb6b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityLeaseAgreementMember_d946b3aa-b9b1-4cac-8408-58d95561f269" xlink:href="nvax-20221231.xsd#nvax_FacilityLeaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b48d6640-1286-4537-8012-702c81050e39" xlink:to="loc_nvax_FacilityLeaseAgreementMember_d946b3aa-b9b1-4cac-8408-58d95561f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdda37fd-cc1c-41b9-8d30-bafd0518e98f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:to="loc_srt_RangeAxis_fdda37fd-cc1c-41b9-8d30-bafd0518e98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdda37fd-cc1c-41b9-8d30-bafd0518e98f" xlink:to="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a06e8a07-6590-44eb-8840-38d897b98aa2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:to="loc_srt_MinimumMember_a06e8a07-6590-44eb-8840-38d897b98aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38355cc5-2a63-49ca-a146-0173d4f7ea33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8539b3db-1fbb-4a4e-9621-1f197d2b04f3" xlink:to="loc_srt_MaximumMember_38355cc5-2a63-49ca-a146-0173d4f7ea33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_feffd25b-8ea5-4e64-9913-c89e96098746" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:to="loc_srt_StatementScenarioAxis_feffd25b-8ea5-4e64-9913-c89e96098746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_93327a22-6c96-4066-b220-adc129d34a04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_feffd25b-8ea5-4e64-9913-c89e96098746" xlink:to="loc_srt_ScenarioUnspecifiedDomain_93327a22-6c96-4066-b220-adc129d34a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_46decd8d-f253-4ea6-8ba3-a31057f36bbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_93327a22-6c96-4066-b220-adc129d34a04" xlink:to="loc_srt_ScenarioForecastMember_46decd8d-f253-4ea6-8ba3-a31057f36bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8606e2ce-6f12-44c9-a589-5b629a719a16" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_e673ff97-dd43-4505-833b-8d62a78bab12" xlink:href="nvax-20221231.xsd#nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_e673ff97-dd43-4505-833b-8d62a78bab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet_146448e9-a3c2-4847-b498-17775a4588ce" xlink:href="nvax-20221231.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_nvax_FacilityNumberOfSquareFeet_146448e9-a3c2-4847-b498-17775a4588ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_aef97e78-b23e-4ff4-ad0b-09f2d09719ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_aef97e78-b23e-4ff4-ad0b-09f2d09719ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f90cf011-8c04-4fd7-8bc0-b070ef395cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_OperatingLeaseExpense_f90cf011-8c04-4fd7-8bc0-b070ef395cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d27d27ad-9e0d-47f3-bfed-bd677820e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d27d27ad-9e0d-47f3-bfed-bd677820e6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f5a16dea-d8f1-4b64-93ee-91c80fc5ebd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f5a16dea-d8f1-4b64-93ee-91c80fc5ebd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_bc6063c0-5934-4f57-9cbb-e6d6b724f210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_118c3b88-1f2a-4352-ba41-105e68885d1e" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_bc6063c0-5934-4f57-9cbb-e6d6b724f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3f8c28d1-173b-41f3-ab0f-0ce5a4e9ebb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3f8c28d1-173b-41f3-ab0f-0ce5a4e9ebb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_68b16e15-4217-4cd4-95b7-2cbce3f40718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_3f8c28d1-173b-41f3-ab0f-0ce5a4e9ebb6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_68b16e15-4217-4cd4-95b7-2cbce3f40718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_9a0f1cd2-1e43-44bc-89c3-7d7d02bbfcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_9a0f1cd2-1e43-44bc-89c3-7d7d02bbfcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b3419ed0-9b1d-440c-9063-227ded9d5b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_9a0f1cd2-1e43-44bc-89c3-7d7d02bbfcbe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b3419ed0-9b1d-440c-9063-227ded9d5b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_dd51a929-1543-43a9-b8a1-96a0aad720dc" xlink:href="nvax-20221231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_nvax_LeaseRightOfUseAsset_dd51a929-1543-43a9-b8a1-96a0aad720dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9013b05d-854e-4c54-a371-795db3988c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9013b05d-854e-4c54-a371-795db3988c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_68703fad-562e-4842-b804-67b1c0ace73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_9013b05d-854e-4c54-a371-795db3988c4a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_68703fad-562e-4842-b804-67b1c0ace73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6d0b2587-551d-47b2-9a51-1519830ce197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6d0b2587-551d-47b2-9a51-1519830ce197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityCurrent_e239bb1a-5fb9-4c2e-ba62-5fd2957b6dc7" xlink:href="nvax-20221231.xsd#nvax_LeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_nvax_LeaseLiabilityCurrent_e239bb1a-5fb9-4c2e-ba62-5fd2957b6dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c33d345e-22b1-4a5d-b8ba-5e403a691e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c33d345e-22b1-4a5d-b8ba-5e403a691e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ba615540-18f4-4920-84f0-cb3af33ecf29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c33d345e-22b1-4a5d-b8ba-5e403a691e6f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ba615540-18f4-4920-84f0-cb3af33ecf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_54665959-db8b-4a3d-8260-517cb81e8d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_54665959-db8b-4a3d-8260-517cb81e8d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityNoncurrent_d447a39b-34bc-46c1-ac9c-f71195f372ca" xlink:href="nvax-20221231.xsd#nvax_LeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_nvax_LeaseLiabilityNoncurrent_d447a39b-34bc-46c1-ac9c-f71195f372ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_4a0c8dd6-6f22-40d5-99f5-3852933a95c2" xlink:href="nvax-20221231.xsd#nvax_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_4a0c8dd6-6f22-40d5-99f5-3852933a95c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d45b9f9a-bffb-4dfc-9adf-19e66e8af57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_4a0c8dd6-6f22-40d5-99f5-3852933a95c2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d45b9f9a-bffb-4dfc-9adf-19e66e8af57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0bb8e5b3-ae47-46e7-a1a5-2ff55d763185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_4a0c8dd6-6f22-40d5-99f5-3852933a95c2" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0bb8e5b3-ae47-46e7-a1a5-2ff55d763185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageDiscountRateAbstract_50341664-82c9-486c-a606-9fdaa9e3a072" xlink:href="nvax-20221231.xsd#nvax_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79267dea-7b8d-491c-ae9e-c9606de8ba89" xlink:to="loc_nvax_WeightedAverageDiscountRateAbstract_50341664-82c9-486c-a606-9fdaa9e3a072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fbcc507d-c82a-4dcc-a6f6-d6d037738eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageDiscountRateAbstract_50341664-82c9-486c-a606-9fdaa9e3a072" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fbcc507d-c82a-4dcc-a6f6-d6d037738eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bd8579d3-48b7-4275-b812-95642290f090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageDiscountRateAbstract_50341664-82c9-486c-a606-9fdaa9e3a072" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bd8579d3-48b7-4275-b812-95642290f090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesScheduleofOperatingLeaseExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e6fe1cbe-59d5-414a-a744-6606b095dbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_101ed64b-d132-4cef-9095-43ca66115d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6fe1cbe-59d5-414a-a744-6606b095dbbc" xlink:to="loc_us-gaap_OperatingLeaseCost_101ed64b-d132-4cef-9095-43ca66115d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_661f2bf1-70df-4cb1-aac3-064b6b51baf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6fe1cbe-59d5-414a-a744-6606b095dbbc" xlink:to="loc_us-gaap_ShortTermLeaseCost_661f2bf1-70df-4cb1-aac3-064b6b51baf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b44ea54a-574d-42a7-ac6d-289aa4264588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6fe1cbe-59d5-414a-a744-6606b095dbbc" xlink:to="loc_us-gaap_VariableLeaseCost_b44ea54a-574d-42a7-ac6d-289aa4264588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_d1b185b2-72be-4a87-8902-54c73d7f2623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6fe1cbe-59d5-414a-a744-6606b095dbbc" xlink:to="loc_us-gaap_LeaseCostAbstract_d1b185b2-72be-4a87-8902-54c73d7f2623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a3083fcd-af84-45a3-9945-d790d918c962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d1b185b2-72be-4a87-8902-54c73d7f2623" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a3083fcd-af84-45a3-9945-d790d918c962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_b86cd69c-0515-4641-8ef3-f4c6f0a12a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d1b185b2-72be-4a87-8902-54c73d7f2623" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_b86cd69c-0515-4641-8ef3-f4c6f0a12a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e9ec9417-5772-4002-a72e-d030cc1753c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6fe1cbe-59d5-414a-a744-6606b095dbbc" xlink:to="loc_us-gaap_LeaseCost_e9ec9417-5772-4002-a72e-d030cc1753c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3f458d08-5d9d-42e7-9daf-cf56e450b27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_371c75bc-2765-4bb1-86db-1f74961f4323" xlink:href="nvax-20221231.xsd#nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f458d08-5d9d-42e7-9daf-cf56e450b27a" xlink:to="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_371c75bc-2765-4bb1-86db-1f74961f4323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4384cac7-edc7-419e-8366-3de73c7b515c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_371c75bc-2765-4bb1-86db-1f74961f4323" xlink:to="loc_us-gaap_OperatingLeasePayments_4384cac7-edc7-419e-8366-3de73c7b515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_a75bc8e3-bd53-49e8-9dfe-4d0479942c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_371c75bc-2765-4bb1-86db-1f74961f4323" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_a75bc8e3-bd53-49e8-9dfe-4d0479942c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4976d522-3192-4bd1-ae4e-476de7818ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_371c75bc-2765-4bb1-86db-1f74961f4323" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4976d522-3192-4bd1-ae4e-476de7818ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_06603596-8057-410b-8c0c-a640dd3eafeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f458d08-5d9d-42e7-9daf-cf56e450b27a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_06603596-8057-410b-8c0c-a640dd3eafeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6d76e31e-1f93-46c1-a803-6545d7063659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f458d08-5d9d-42e7-9daf-cf56e450b27a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6d76e31e-1f93-46c1-a803-6545d7063659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_800be5e1-938a-409c-9226-b40df3fa150c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_800be5e1-938a-409c-9226-b40df3fa150c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_450fc072-fd26-4c24-926c-7a43c65f708b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_450fc072-fd26-4c24-926c-7a43c65f708b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_79328460-492c-4293-9ea3-0a6c01d93890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_79328460-492c-4293-9ea3-0a6c01d93890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bf35684a-81cc-412c-a1c4-1e7d91f7e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bf35684a-81cc-412c-a1c4-1e7d91f7e56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18043670-390d-43ce-902f-02ece3d3b518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18043670-390d-43ce-902f-02ece3d3b518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7396ab21-a20c-43d6-981b-5db4e2eb042f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7396ab21-a20c-43d6-981b-5db4e2eb042f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a546afda-d172-4f3d-b896-df2062bd5de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a546afda-d172-4f3d-b896-df2062bd5de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_64ca0287-8321-4a32-906b-07e18aeba4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_64ca0287-8321-4a32-906b-07e18aeba4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1df0073a-8253-42bf-b792-464b64e7a2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87337467-d8b4-406e-86f8-8a9c145b62b6" xlink:to="loc_us-gaap_OperatingLeaseLiability_1df0073a-8253-42bf-b792-464b64e7a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nvax-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtScheduleofNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c06b05f0-3ac7-44b3-b06c-227c11d44511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c06b05f0-3ac7-44b3-b06c-227c11d44511" xlink:to="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea249842-97bf-43e6-a14f-33067bc101ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea249842-97bf-43e6-a14f-33067bc101ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea249842-97bf-43e6-a14f-33067bc101ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_defaae60-9c58-4b3f-983d-df9cf074b234" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_defaae60-9c58-4b3f-983d-df9cf074b234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ce8b1b0c-2034-46c6-bb21-8c73b5dbf3bb" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26227644-6917-4b2d-aaf7-a5102be4c562" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ce8b1b0c-2034-46c6-bb21-8c73b5dbf3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7bd31a68-bfc2-4491-8ed8-a99c1f694186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0bcdc863-f988-4b1d-b83f-ff8cb11bda9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7bd31a68-bfc2-4491-8ed8-a99c1f694186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4f8cb2fe-089b-4a7d-ab10-cd4820f55c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7bd31a68-bfc2-4491-8ed8-a99c1f694186" xlink:to="loc_us-gaap_UnsecuredDebtMember_4f8cb2fe-089b-4a7d-ab10-cd4820f55c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8177dcc2-8337-47e2-8054-559419031d94" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:href="nvax-20221231.xsd#nvax_ConvertibleNotesPayableCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:to="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent_b9635773-3e15-43c2-ba76-1fc8b2f9e576" xlink:href="nvax-20221231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:to="loc_nvax_DebtInstrumentFaceAmountCurrent_b9635773-3e15-43c2-ba76-1fc8b2f9e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_340245a1-ad9d-48c1-94de-1cef07768ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_340245a1-ad9d-48c1-94de-1cef07768ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_496c9698-8cbd-45b5-96a7-56680d8c6140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_ac69b084-e288-4b1c-a320-e5b4ce2db64f" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_496c9698-8cbd-45b5-96a7-56680d8c6140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:href="nvax-20221231.xsd#nvax_ConvertibleNotesPayableNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e0ea0eb-5e60-4900-8762-9fac86b41f39" xlink:to="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f6fa5c73-d853-4fd1-a95c-418a821ed958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f6fa5c73-d853-4fd1-a95c-418a821ed958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_94d3c013-a2f0-4adf-9925-60a1fe1eded2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_94d3c013-a2f0-4adf-9925-60a1fe1eded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_93cd0eeb-3c9d-4c22-90c1-17d8ba449970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_97faf94c-0993-4d89-bb56-e6f74d4c641a" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_93cd0eeb-3c9d-4c22-90c1-17d8ba449970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_67b5717e-f186-4feb-8fa9-06599c83e980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_777e92e8-c2c5-407a-b785-9c036a6d0ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67b5717e-f186-4feb-8fa9-06599c83e980" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_777e92e8-c2c5-407a-b785-9c036a6d0ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5b4b4493-8fdb-4584-b2f1-e70f9ad09b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67b5717e-f186-4feb-8fa9-06599c83e980" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5b4b4493-8fdb-4584-b2f1-e70f9ad09b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9e23fb94-d6e8-4085-8926-d3270d3be717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67b5717e-f186-4feb-8fa9-06599c83e980" xlink:to="loc_us-gaap_InterestExpenseDebt_9e23fb94-d6e8-4085-8926-d3270d3be717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e18c3211-164c-40cb-a072-4a58a78afedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c3211-164c-40cb-a072-4a58a78afedb" xlink:to="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_933f5e7d-2ae8-4111-a88a-1c278325e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_933f5e7d-2ae8-4111-a88a-1c278325e1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d6b08539-24d1-4ee3-bff9-0ae954daa2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_933f5e7d-2ae8-4111-a88a-1c278325e1aa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d6b08539-24d1-4ee3-bff9-0ae954daa2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_b26b7f9e-aef7-4b26-b4cf-398fed5f016c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d6b08539-24d1-4ee3-bff9-0ae954daa2b4" xlink:to="loc_us-gaap_UnsecuredDebtMember_b26b7f9e-aef7-4b26-b4cf-398fed5f016c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9cd8c611-30fc-483f-ac9f-daf0b062ea02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_DebtInstrumentAxis_9cd8c611-30fc-483f-ac9f-daf0b062ea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9cd8c611-30fc-483f-ac9f-daf0b062ea02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_d870a8cb-955d-4b30-9dab-39875ecc0f92" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_d870a8cb-955d-4b30-9dab-39875ecc0f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_82299256-15d4-43ae-be0e-4218f5a03480" xlink:href="nvax-20221231.xsd#nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_d870a8cb-955d-4b30-9dab-39875ecc0f92" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_82299256-15d4-43ae-be0e-4218f5a03480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_11cb3583-3361-4c96-aa6a-d00389b47bba" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_814b973c-f52c-4515-b52e-8e10ebcd6943" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_11cb3583-3361-4c96-aa6a-d00389b47bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_19a7c3bd-22cd-48f4-81e4-a9a80db9699c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_19a7c3bd-22cd-48f4-81e4-a9a80db9699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_41ad83a6-bfb2-4e24-bb94-3234d5f25de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_19a7c3bd-22cd-48f4-81e4-a9a80db9699c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_41ad83a6-bfb2-4e24-bb94-3234d5f25de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_8b4d49e8-578b-4c47-bb2b-e885f147097c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_41ad83a6-bfb2-4e24-bb94-3234d5f25de8" xlink:to="loc_us-gaap_CallOptionMember_8b4d49e8-578b-4c47-bb2b-e885f147097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b9c47af-5f2f-4346-953d-d8ccfb33af05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_srt_RangeAxis_0b9c47af-5f2f-4346-953d-d8ccfb33af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fac45c99-fb42-405a-a861-efe18034a24f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0b9c47af-5f2f-4346-953d-d8ccfb33af05" xlink:to="loc_srt_RangeMember_fac45c99-fb42-405a-a861-efe18034a24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc376c33-8b23-4a40-920c-c7b244896d22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fac45c99-fb42-405a-a861-efe18034a24f" xlink:to="loc_srt_MaximumMember_bc376c33-8b23-4a40-920c-c7b244896d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_877ff16e-e6b0-4649-a360-d7efb58590b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_877ff16e-e6b0-4649-a360-d7efb58590b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_877ff16e-e6b0-4649-a360-d7efb58590b7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b21d4489-9927-4709-8c4b-9b0ccd4e0397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b21d4489-9927-4709-8c4b-9b0ccd4e0397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b8c70070-f653-4807-8d9f-aa9175fce296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7a1ea313-47b6-4667-845c-69d5f5109550" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b8c70070-f653-4807-8d9f-aa9175fce296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_67bf9c4d-c961-411a-a1a2-4e500a29a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_67bf9c4d-c961-411a-a1a2-4e500a29a6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9b240f39-e102-48a3-a1a7-a874ff5c2d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_67bf9c4d-c961-411a-a1a2-4e500a29a6c9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9b240f39-e102-48a3-a1a7-a874ff5c2d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6b52b11d-88d4-4a83-97ef-b29c3a124ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9b240f39-e102-48a3-a1a7-a874ff5c2d70" xlink:to="loc_us-gaap_SubsequentEventMember_6b52b11d-88d4-4a83-97ef-b29c3a124ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93cfc73c-1dc4-4ead-8b16-4d1d5754e73b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4bef30d3-144f-4b23-815a-257b99983f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4bef30d3-144f-4b23-815a-257b99983f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_8e9fad77-0a55-4ab2-b95b-9872a18aceec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_8e9fad77-0a55-4ab2-b95b-9872a18aceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_3441b342-45c5-466a-ba0b-2e90b0e56587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_3441b342-45c5-466a-ba0b-2e90b0e56587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_61845f04-9e9d-4f94-b854-dc584f5d436a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_61845f04-9e9d-4f94-b854-dc584f5d436a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_55fd30af-c29d-47b0-b2c7-ced2f28ec816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_55fd30af-c29d-47b0-b2c7-ced2f28ec816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_15265041-b1ab-4a87-b4ee-6c9fb1baac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_15265041-b1ab-4a87-b4ee-6c9fb1baac3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_41597e61-4485-4716-a436-6e22fc34a9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_41597e61-4485-4716-a436-6e22fc34a9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleDebtConversionRate_79c7dfbe-e6c9-4d02-a3f6-2cf91d37956a" xlink:href="nvax-20221231.xsd#nvax_ConvertibleDebtConversionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_ConvertibleDebtConversionRate_79c7dfbe-e6c9-4d02-a3f6-2cf91d37956a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5a9d799-d7c4-48e0-a1b9-7acb905d0fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5a9d799-d7c4-48e0-a1b9-7acb905d0fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConversionPremiumPercentage_04a05fc9-dd52-4a62-a274-20a7bec761e6" xlink:href="nvax-20221231.xsd#nvax_ConversionPremiumPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_ConversionPremiumPercentage_04a05fc9-dd52-4a62-a274-20a7bec761e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e511add7-04df-4965-ba8c-c0e57f30afbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e511add7-04df-4965-ba8c-c0e57f30afbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_a20983ec-e176-4ae4-b250-06009cb18c60" xlink:href="nvax-20221231.xsd#nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_a20983ec-e176-4ae4-b250-06009cb18c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_9be2a98c-fc43-4d1a-ac50-8c288eff8a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_9be2a98c-fc43-4d1a-ac50-8c288eff8a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cb21d9a1-1313-4e43-a7e1-9eb6ef54082b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentTerm_cb21d9a1-1313-4e43-a7e1-9eb6ef54082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3bc51cdc-4e80-4c30-a607-9800ea3153e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3bc51cdc-4e80-4c30-a607-9800ea3153e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_fa858fae-2191-4769-a052-c6d64b5c8734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_RepaymentsOfDebt_fa858fae-2191-4769-a052-c6d64b5c8734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8b514e67-7345-4066-a843-8e3875e102eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8b514e67-7345-4066-a843-8e3875e102eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_73a2f2ee-6369-41a9-93f7-3dde33032065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_73a2f2ee-6369-41a9-93f7-3dde33032065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dc3abbc4-7e3b-4c7f-a7a4-0254653806f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dc3abbc4-7e3b-4c7f-a7a4-0254653806f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentForCappedCallTransactions_d2db513a-00f8-4e2a-af30-238542729a8c" xlink:href="nvax-20221231.xsd#nvax_PaymentForCappedCallTransactions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_PaymentForCappedCallTransactions_d2db513a-00f8-4e2a-af30-238542729a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtCapPrice_891f7a6f-263f-41b4-9d62-81c20870a9b1" xlink:href="nvax-20221231.xsd#nvax_DebtCapPrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f77dd5-4263-47d4-ace8-d131e3402029" xlink:to="loc_nvax_DebtCapPrice_891f7a6f-263f-41b4-9d62-81c20870a9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#PreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/PreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_627bdd9f-f3a1-487b-acce-dbfa922cee62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_627bdd9f-f3a1-487b-acce-dbfa922cee62" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e96e18e7-4439-456b-a263-dc026e78b831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e96e18e7-4439-456b-a263-dc026e78b831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e96e18e7-4439-456b-a263-dc026e78b831" xlink:to="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_314e02c7-f267-4fc3-801e-801b62653cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_314e02c7-f267-4fc3-801e-801b62653cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e3341675-72af-4899-acba-3cc290bd3fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bfd43d5b-2e3d-496a-8725-f4f9ce287c13" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e3341675-72af-4899-acba-3cc290bd3fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9c32e6c2-f35b-4e5b-b583-ca10f0917023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9c32e6c2-f35b-4e5b-b583-ca10f0917023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_923279d7-f4bf-49ef-b121-bd5d1cd60e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9c32e6c2-f35b-4e5b-b583-ca10f0917023" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_923279d7-f4bf-49ef-b121-bd5d1cd60e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ba18ad51-848e-49ba-82ad-4cb0cba95a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_923279d7-f4bf-49ef-b121-bd5d1cd60e65" xlink:to="loc_us-gaap_PrivatePlacementMember_ba18ad51-848e-49ba-82ad-4cb0cba95a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a6774590-f922-4b78-ab6b-fcdd69fbe726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a6774590-f922-4b78-ab6b-fcdd69fbe726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87ca3dc7-42bc-46de-8bef-3d164f458033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6774590-f922-4b78-ab6b-fcdd69fbe726" xlink:to="loc_us-gaap_EquityComponentDomain_87ca3dc7-42bc-46de-8bef-3d164f458033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_36b8e1bf-ce21-42ff-814b-9eeb940fd76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87ca3dc7-42bc-46de-8bef-3d164f458033" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_36b8e1bf-ce21-42ff-814b-9eeb940fd76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86b34f7c-fbad-4e1e-a2a1-d29a888d7591" xlink:to="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f5d12f49-badb-4322-8935-0ff15dadc2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f5d12f49-badb-4322-8935-0ff15dadc2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec99a905-6c57-41c0-b82b-0c834b314a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec99a905-6c57-41c0-b82b-0c834b314a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2e602794-ab9d-480e-b9fe-917737632ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_2e602794-ab9d-480e-b9fe-917737632ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_e9fa38d0-4279-4762-87f9-c81b4d9c609f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_e9fa38d0-4279-4762-87f9-c81b4d9c609f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_68b2f38a-c7db-4cbd-99cf-8fbf9a5f205a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_68b2f38a-c7db-4cbd-99cf-8fbf9a5f205a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_56bef112-503a-41f2-ac07-3a3b1ac5d200" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_56bef112-503a-41f2-ac07-3a3b1ac5d200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_7f9d4a30-04d4-4468-9a0c-aa61d16c566a" xlink:href="nvax-20221231.xsd#nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_151b9a69-680e-4fff-9f67-e6c118e9d553" xlink:to="loc_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease_7f9d4a30-04d4-4468-9a0c-aa61d16c566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d70dd2ea-552c-484c-853a-fd0533e84e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d70dd2ea-552c-484c-853a-fd0533e84e19" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7c2ef435-edd0-4a17-87a1-e2535aa0eb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7c2ef435-edd0-4a17-87a1-e2535aa0eb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c2ef435-edd0-4a17-87a1-e2535aa0eb59" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PublicOfferingMember_1c21489c-3c5c-4a1b-a829-1f50287165fc" xlink:href="nvax-20221231.xsd#nvax_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:to="loc_nvax_PublicOfferingMember_1c21489c-3c5c-4a1b-a829-1f50287165fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_UnderwriterMember_663d089e-6efd-47b2-a77a-78a9721d10cf" xlink:href="nvax-20221231.xsd#nvax_UnderwriterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:to="loc_nvax_UnderwriterMember_663d089e-6efd-47b2-a77a-78a9721d10cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember_12b719fe-4e5b-43ec-8358-f74dd0aba74f" xlink:href="nvax-20221231.xsd#nvax_June2021SalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e2f7d1-fa83-4e77-a8a6-b51f36decd29" xlink:to="loc_nvax_June2021SalesAgreementMember_12b719fe-4e5b-43ec-8358-f74dd0aba74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81b9f514-2786-49d7-8f43-12b363718ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81b9f514-2786-49d7-8f43-12b363718ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1230068-8109-41d2-a28c-42b4b8aedf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81b9f514-2786-49d7-8f43-12b363718ec1" xlink:to="loc_us-gaap_EquityComponentDomain_e1230068-8109-41d2-a28c-42b4b8aedf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e0d889b3-7d11-4974-a050-f0e57d73dcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1230068-8109-41d2-a28c-42b4b8aedf8a" xlink:to="loc_us-gaap_CommonStockMember_e0d889b3-7d11-4974-a050-f0e57d73dcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_887b97e1-6da5-48fb-877b-c0866835dad9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d015ea1-e6cf-464a-a2d3-1e93c328aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d015ea1-e6cf-464a-a2d3-1e93c328aaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_aa129c58-63d1-422c-bc4b-4d617b3f1820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_aa129c58-63d1-422c-bc4b-4d617b3f1820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f37690cb-239f-462c-a44c-26f38598c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f37690cb-239f-462c-a44c-26f38598c0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_98184cbd-68ca-4020-9c74-c651f2ab4614" xlink:href="nvax-20221231.xsd#nvax_ShelfRegistrationStatementRemainingUnissuedCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_495ffa8a-3eb1-49f8-9666-3f9f062f82a2" xlink:to="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_98184cbd-68ca-4020-9c74-c651f2ab4614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a83d4f2-f77f-4294-80bb-40d61d99ca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a83d4f2-f77f-4294-80bb-40d61d99ca5b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2811e688-e5aa-4621-b992-e5de2697ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:to="loc_us-gaap_PlanNameAxis_2811e688-e5aa-4621-b992-e5de2697ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9e9efc2-a1e4-4bce-8b90-1de05204f770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2811e688-e5aa-4621-b992-e5de2697ee5e" xlink:to="loc_us-gaap_PlanNameDomain_d9e9efc2-a1e4-4bce-8b90-1de05204f770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_2f6da2d9-4326-444d-97e1-2c50db7f4bad" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d9e9efc2-a1e4-4bce-8b90-1de05204f770" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_2f6da2d9-4326-444d-97e1-2c50db7f4bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:to="loc_srt_RangeAxis_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d4dbc1ea-18fa-4a01-9596-9fa6a8f3141b" xlink:to="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ea43d62-f7f0-4a31-90b1-4278e0e2c90c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:to="loc_srt_MinimumMember_6ea43d62-f7f0-4a31-90b1-4278e0e2c90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5324d1a-a625-46bb-9bce-0cdd5cd2a646" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_165df813-7220-4bfd-b635-dc7bf2a3a1a6" xlink:to="loc_srt_MaximumMember_e5324d1a-a625-46bb-9bce-0cdd5cd2a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f905f90-5c73-4aa5-a9ec-876ad9f53482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:to="loc_us-gaap_AwardTypeAxis_2f905f90-5c73-4aa5-a9ec-876ad9f53482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47dadb27-4a94-4a91-b261-7e47eb1ea6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2f905f90-5c73-4aa5-a9ec-876ad9f53482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47dadb27-4a94-4a91-b261-7e47eb1ea6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e4c7cb99-e952-4f68-b68f-88351d7fa689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47dadb27-4a94-4a91-b261-7e47eb1ea6fb" xlink:to="loc_us-gaap_EmployeeStockMember_e4c7cb99-e952-4f68-b68f-88351d7fa689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be4f1f08-eed0-49a2-aba8-b6f3e0663616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0ab68a7a-95ff-47cc-85d6-43886e0575f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0ab68a7a-95ff-47cc-85d6-43886e0575f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3e7e66db-1824-4adc-90cb-2b26769083be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3e7e66db-1824-4adc-90cb-2b26769083be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_99386b89-7d03-4108-9d36-8b390ad37ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_99386b89-7d03-4108-9d36-8b390ad37ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc90da10-dd3f-45bf-852c-53e2600eb5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc90da10-dd3f-45bf-852c-53e2600eb5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_e37b2fa9-3df0-4b6e-bfb0-b1ef0f6a920d" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_e37b2fa9-3df0-4b6e-bfb0-b1ef0f6a920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9db36532-eb2d-4ad0-96b0-8f1124530cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9db36532-eb2d-4ad0-96b0-8f1124530cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68e6ec0e-8180-4d7f-842a-d071e47f93a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68e6ec0e-8180-4d7f-842a-d071e47f93a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c81b51f6-3418-4482-aaa2-f5a05740e057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c81b51f6-3418-4482-aaa2-f5a05740e057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bd0598a-d326-4005-9a3d-cb47f480a183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bd0598a-d326-4005-9a3d-cb47f480a183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f1780a19-4d35-4674-bf98-59954d6040ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f1780a19-4d35-4674-bf98-59954d6040ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c36f28cd-b27a-44d8-91df-d5881fc826be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c36f28cd-b27a-44d8-91df-d5881fc826be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3cd63ac-2088-44c3-a3cd-4d23f81e1ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3cd63ac-2088-44c3-a3cd-4d23f81e1ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4d781cdf-6d52-452e-9db9-69525cb4e1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4d781cdf-6d52-452e-9db9-69525cb4e1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_71e59e2c-c3ef-46e5-b926-b6bd15c11bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_71e59e2c-c3ef-46e5-b926-b6bd15c11bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_88462d7a-6117-4735-bc5c-eb276c7c6287" xlink:href="nvax-20221231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_88462d7a-6117-4735-bc5c-eb276c7c6287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_3bdec9ca-1363-4f1f-a6b1-c9c214ccdf00" xlink:href="nvax-20221231.xsd#nvax_MaximumContributionOfEmployeesAsPayrollDeductions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_3bdec9ca-1363-4f1f-a6b1-c9c214ccdf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentageOfMarketPriceForStockPurchase_4c7bbb1c-8844-45ed-9fcb-c9ac011f5cf0" xlink:href="nvax-20221231.xsd#nvax_PercentageOfMarketPriceForStockPurchase"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6af1e5-5298-40fa-ba66-0de617f80c29" xlink:to="loc_nvax_PercentageOfMarketPriceForStockPurchase_4c7bbb1c-8844-45ed-9fcb-c9ac011f5cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_389e31d0-d886-431e-bc2f-6fb4a8f5616d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab1f0bf2-84f9-4e54-8ffc-f5deda6d16c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_389e31d0-d886-431e-bc2f-6fb4a8f5616d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab1f0bf2-84f9-4e54-8ffc-f5deda6d16c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab1f0bf2-84f9-4e54-8ffc-f5deda6d16c8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_deaf4aa1-b4a9-4f8c-8ef1-f7a238a4bbac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bd4fe314-5162-4348-bd42-cc34c2296a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:to="loc_us-gaap_CostOfSalesMember_bd4fe314-5162-4348-bd42-cc34c2296a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_350c41ee-a876-443d-93a2-ee61b1d9cbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_350c41ee-a876-443d-93a2-ee61b1d9cbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cca4a0a5-4872-49c0-9c8b-5d8623beb176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08b8c96c-1b6f-4082-99fd-eef0b6002a2f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cca4a0a5-4872-49c0-9c8b-5d8623beb176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dc3208e-9b4a-4632-a212-d374e9a9680d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab1f0bf2-84f9-4e54-8ffc-f5deda6d16c8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dc3208e-9b4a-4632-a212-d374e9a9680d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9c49de3-537f-466b-bccf-06329384f90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dc3208e-9b4a-4632-a212-d374e9a9680d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9c49de3-537f-466b-bccf-06329384f90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b9dcc31-2a1c-49c1-a8cd-22040fcc456c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0f362b3-fb2e-4234-97b1-d6edaa612396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b9dcc31-2a1c-49c1-a8cd-22040fcc456c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0f362b3-fb2e-4234-97b1-d6edaa612396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fe9efa76-3783-4107-9e80-d4898931acfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0f362b3-fb2e-4234-97b1-d6edaa612396" xlink:to="loc_us-gaap_PlanNameAxis_fe9efa76-3783-4107-9e80-d4898931acfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fe9efa76-3783-4107-9e80-d4898931acfe" xlink:to="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_eb823bb9-5cd2-4650-8a1c-f870518c388f" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_eb823bb9-5cd2-4650-8a1c-f870518c388f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_c23c6bbb-a78a-47b1-ab58-4e0870514950" xlink:href="nvax-20221231.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_756758a9-a844-474d-bdd4-44c5afcbd4ca" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_c23c6bbb-a78a-47b1-ab58-4e0870514950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0f362b3-fb2e-4234-97b1-d6edaa612396" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9d1ac39-8905-4fd7-8e8c-7dff14591cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9d1ac39-8905-4fd7-8e8c-7dff14591cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11b57002-e5fd-4c56-a177-2af0282cefa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11b57002-e5fd-4c56-a177-2af0282cefa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_def943b1-8e8e-4c82-beae-b967de697abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_def943b1-8e8e-4c82-beae-b967de697abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d6493bb8-0335-4418-8026-8f52d28ead4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d6493bb8-0335-4418-8026-8f52d28ead4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c76ebe60-9066-470e-b204-9362c4e6de42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf22f4b1-b631-4516-97a4-d407bd3cf7ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c76ebe60-9066-470e-b204-9362c4e6de42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3133063a-3d78-455c-82ef-421c2fc1adf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3133063a-3d78-455c-82ef-421c2fc1adf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_464f7833-b9b2-4904-832f-dcf2f1008fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_464f7833-b9b2-4904-832f-dcf2f1008fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0538ff27-d3cb-4813-8ddf-42124fb32d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0538ff27-d3cb-4813-8ddf-42124fb32d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7ef57bf-585b-4f71-89a3-86dd022485ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7ef57bf-585b-4f71-89a3-86dd022485ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4dab7b3b-d1d0-4253-ad79-e7a48d0c676c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4dab7b3b-d1d0-4253-ad79-e7a48d0c676c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8c12bd7-57c1-4d6a-b9c8-70097f9fef93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08f38e8f-5c70-48be-a375-2a235ed511ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8c12bd7-57c1-4d6a-b9c8-70097f9fef93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0a73da06-332c-4cfc-bd6f-f3da1d98dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4274ef3-0952-45a1-9cf0-8ed8de5ff818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0a73da06-332c-4cfc-bd6f-f3da1d98dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90482108-6632-434c-b985-915672e4c120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90482108-6632-434c-b985-915672e4c120" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8254ab6-4d1c-4497-880c-964b36158aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:to="loc_us-gaap_AwardTypeAxis_e8254ab6-4d1c-4497-880c-964b36158aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e8254ab6-4d1c-4497-880c-964b36158aaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_901e64cf-648d-4295-bcd0-95a46db129bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_901e64cf-648d-4295-bcd0-95a46db129bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_836b6002-f3ba-4b2f-886f-08a6aff782a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88d1844-f67b-49c0-8ade-7a9ef9e5798c" xlink:to="loc_us-gaap_EmployeeStockMember_836b6002-f3ba-4b2f-886f-08a6aff782a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2b571d9-6627-4088-aed4-d77fb9eced28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:to="loc_srt_RangeAxis_d2b571d9-6627-4088-aed4-d77fb9eced28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d2b571d9-6627-4088-aed4-d77fb9eced28" xlink:to="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b91ac32-b2c1-4352-80a0-cb9a4db9ddfe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:to="loc_srt_MinimumMember_9b91ac32-b2c1-4352-80a0-cb9a4db9ddfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d86de9ca-34ab-4a4b-b3e6-ee77890e3275" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c23b3e1-19e5-4634-8c53-a9744c2ce0be" xlink:to="loc_srt_MaximumMember_d86de9ca-34ab-4a4b-b3e6-ee77890e3275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e0e9a0b-8bc6-4961-b46c-edf873c71c7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ee6ea990-d2d2-4d7e-9e08-9b4c9efa0691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ee6ea990-d2d2-4d7e-9e08-9b4c9efa0691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f697c660-c115-41ee-8def-71ecbcd32324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f697c660-c115-41ee-8def-71ecbcd32324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_59b4515e-3481-43e6-9014-dc0cad2cd9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_59b4515e-3481-43e6-9014-dc0cad2cd9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7ff38400-964b-485b-8ebd-96a8b5dd8ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7ff38400-964b-485b-8ebd-96a8b5dd8ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_765a32a6-1622-4340-84ce-7357162c287c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_765a32a6-1622-4340-84ce-7357162c287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f0f314a8-93e5-476b-b8b4-c7c44c050dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f0f314a8-93e5-476b-b8b4-c7c44c050dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71bcf185-3f59-4ccf-94e7-8b2485c385b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_152653b7-976b-4acf-88de-2741b1ea5541" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71bcf185-3f59-4ccf-94e7-8b2485c385b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9461642-18be-47c5-9fc4-d3aab7d34d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a37fb1-1b69-4642-bdc6-f59667c9da87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9461642-18be-47c5-9fc4-d3aab7d34d79" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a37fb1-1b69-4642-bdc6-f59667c9da87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_665c8701-dc4c-4f96-91a1-80521eec6b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a37fb1-1b69-4642-bdc6-f59667c9da87" xlink:to="loc_us-gaap_AwardTypeAxis_665c8701-dc4c-4f96-91a1-80521eec6b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cff8faab-642c-4925-bd00-50afa68d72ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_665c8701-dc4c-4f96-91a1-80521eec6b1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cff8faab-642c-4925-bd00-50afa68d72ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc4fc8f-e8cd-497e-99ea-ef624f38aac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cff8faab-642c-4925-bd00-50afa68d72ca" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc4fc8f-e8cd-497e-99ea-ef624f38aac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a37fb1-1b69-4642-bdc6-f59667c9da87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9709106b-3b1e-45b6-9aae-11b8a65e8e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9709106b-3b1e-45b6-9aae-11b8a65e8e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bda1f64b-4e54-46a0-acdc-0c5ab06b596c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bda1f64b-4e54-46a0-acdc-0c5ab06b596c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1415599f-fedf-4735-a4df-290b50a1fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1415599f-fedf-4735-a4df-290b50a1fc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f8cbbdd4-9ece-486e-9747-85ec184b4ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f8cbbdd4-9ece-486e-9747-85ec184b4ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e4e39b0-4cb0-47aa-b543-4fbf4816325f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f4d38d-b50f-458b-a141-bc342315ef56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e4e39b0-4cb0-47aa-b543-4fbf4816325f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16da0eb5-1afb-4fef-8a96-0bbf4f65c3cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c1aa122-7bc0-4fba-8c59-6f69c213b588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c1aa122-7bc0-4fba-8c59-6f69c213b588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0663775a-6224-4f02-9665-212eee4eb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0663775a-6224-4f02-9665-212eee4eb555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_527230fc-e048-4228-9c2f-df91b18618b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_527230fc-e048-4228-9c2f-df91b18618b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bf7cdc58-46de-47bd-8b4a-e3d8d2d0e381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bf7cdc58-46de-47bd-8b4a-e3d8d2d0e381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15e80019-79b7-4ff7-ba5d-f9fe89ffdbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6c90c343-3c77-466f-b4f5-71c656a2a2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15e80019-79b7-4ff7-ba5d-f9fe89ffdbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#EmployeeBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_cc2c933a-0b9a-4f9a-b223-b6dcdbe490cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMultiemployerPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_cc2c933a-0b9a-4f9a-b223-b6dcdbe490cb" xlink:to="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementAxis_a499df15-15c8-4c90-ab7b-bd9cb4690775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:to="loc_us-gaap_CollectiveBargainingArrangementAxis_a499df15-15c8-4c90-ab7b-bd9cb4690775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis_a499df15-15c8-4c90-ab7b-bd9cb4690775" xlink:to="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_ea187bb4-18da-4111-a932-7ba648e82eab" xlink:href="nvax-20221231.xsd#nvax_FirstThreePercentOfParticipantsDeferralMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:to="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_ea187bb4-18da-4111-a932-7ba648e82eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_110f32e2-8252-4983-9e7c-f17d84cd11f4" xlink:href="nvax-20221231.xsd#nvax_NextTwoPercentOfParticipantsDeferralMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_d736dec0-f448-41cb-94a5-20b36e8290dc" xlink:to="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_110f32e2-8252-4983-9e7c-f17d84cd11f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bc3c2769-2469-4838-afec-2f39a34ff06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bc3c2769-2469-4838-afec-2f39a34ff06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0d5b2308-bded-4b4b-b397-7819f67ebff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bc3c2769-2469-4838-afec-2f39a34ff06a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0d5b2308-bded-4b4b-b397-7819f67ebff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f97321dc-fbdf-4785-b0a6-88d629a25173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0d5b2308-bded-4b4b-b397-7819f67ebff7" xlink:to="loc_us-gaap_ForeignPlanMember_f97321dc-fbdf-4785-b0a6-88d629a25173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_434439a8-33ea-40f0-84d6-556510cc1b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_434439a8-33ea-40f0-84d6-556510cc1b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0d1a1cb9-3d6d-427e-bd5b-aaa7f2042be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_434439a8-33ea-40f0-84d6-556510cc1b2e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0d1a1cb9-3d6d-427e-bd5b-aaa7f2042be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_961cfb35-8eef-46b8-bd21-55fe5491c2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0d1a1cb9-3d6d-427e-bd5b-aaa7f2042be0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_961cfb35-8eef-46b8-bd21-55fe5491c2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_e37d201f-ae4b-4564-ad70-b6f4d506442f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ace57eda-de8b-44af-9702-1b7e1b1fcfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ace57eda-de8b-44af-9702-1b7e1b1fcfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9ae4336d-bbd7-4d38-bc13-3ccafbfd5bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9ae4336d-bbd7-4d38-bc13-3ccafbfd5bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_130d5e82-25cc-48ea-8e18-c69e270e615e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_130d5e82-25cc-48ea-8e18-c69e270e615e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_ee9b3eed-ac61-4fd7-bb59-beabe6ac01bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_608a492f-236f-40bd-bb00-d94b797a4a29" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_ee9b3eed-ac61-4fd7-bb59-beabe6ac01bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aecd7f8-6e23-4943-9fed-c0e0c46abbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_1b104aa1-d52d-43fb-8678-4bfd9e317f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aecd7f8-6e23-4943-9fed-c0e0c46abbfb" xlink:to="loc_us-gaap_Supplies_1b104aa1-d52d-43fb-8678-4bfd9e317f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_fef332bd-ae8b-4977-b4ef-c4e716308fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aecd7f8-6e23-4943-9fed-c0e0c46abbfb" xlink:to="loc_us-gaap_OtherAssetsCurrent_fef332bd-ae8b-4977-b4ef-c4e716308fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a1b795f-d1c1-4484-a6c0-0251c9c101b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aecd7f8-6e23-4943-9fed-c0e0c46abbfb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a1b795f-d1c1-4484-a6c0-0251c9c101b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f3a5bde-524d-48ab-b410-6c356849589f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b45707ea-bf4f-4f96-8b93-7272fae95124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f3a5bde-524d-48ab-b410-6c356849589f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b45707ea-bf4f-4f96-8b93-7272fae95124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33fdd3dd-2f64-475e-8df7-1041cff9b65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b45707ea-bf4f-4f96-8b93-7272fae95124" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33fdd3dd-2f64-475e-8df7-1041cff9b65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33fdd3dd-2f64-475e-8df7-1041cff9b65d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_06fce64e-a7c1-47e1-b867-b39bc6b87bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_06fce64e-a7c1-47e1-b867-b39bc6b87bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_2413c9b6-3c8f-4700-b001-9dd781f42ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_2413c9b6-3c8f-4700-b001-9dd781f42ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_76d3420c-9595-4374-a73f-69d5163c9921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_76d3420c-9595-4374-a73f-69d5163c9921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ComputerSoftwareAndHardwareMemberMember_e9800f87-6398-4c69-8f8b-3e7f8a24206d" xlink:href="nvax-20221231.xsd#nvax_ComputerSoftwareAndHardwareMemberMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_nvax_ComputerSoftwareAndHardwareMemberMember_e9800f87-6398-4c69-8f8b-3e7f8a24206d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c566c6cf-56d1-43b0-aacd-fea096ecf938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_930c4d1e-7d23-4895-8411-5160a58770ee" xlink:to="loc_us-gaap_ConstructionInProgressMember_c566c6cf-56d1-43b0-aacd-fea096ecf938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b45707ea-bf4f-4f96-8b93-7272fae95124" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_10e6d47c-0065-4060-8ba8-46800a988642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_10e6d47c-0065-4060-8ba8-46800a988642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff8348c-a199-4118-813f-feaf34f89bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff8348c-a199-4118-813f-feaf34f89bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ffbae9ca-97b3-4a0c-8966-8e7121f845f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_84f84917-eb7e-4283-810e-19c87cfd689d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ffbae9ca-97b3-4a0c-8966-8e7121f845f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400da149-b15a-4a3c-a136-711ab270f29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f99ffa4a-bef0-45fe-928a-fc9a79a5a471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400da149-b15a-4a3c-a136-711ab270f29a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f99ffa4a-bef0-45fe-928a-fc9a79a5a471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_779c7bde-9ec2-4159-99f4-640f78cacd82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f99ffa4a-bef0-45fe-928a-fc9a79a5a471" xlink:to="loc_srt_StatementGeographicalAxis_779c7bde-9ec2-4159-99f4-640f78cacd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_409c49c1-02a6-4f59-b6c5-2c938dd03423" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_779c7bde-9ec2-4159-99f4-640f78cacd82" xlink:to="loc_srt_SegmentGeographicalDomain_409c49c1-02a6-4f59-b6c5-2c938dd03423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CZ_1ddef1ba-71b7-449f-8773-3f50a3e0db19" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CZ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_409c49c1-02a6-4f59-b6c5-2c938dd03423" xlink:to="loc_country_CZ_1ddef1ba-71b7-449f-8773-3f50a3e0db19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f99ffa4a-bef0-45fe-928a-fc9a79a5a471" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49e74497-c47f-4453-8b97-99470eaca86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49e74497-c47f-4453-8b97-99470eaca86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6088cf7f-ed64-4dc2-a47d-f4a4a6f67ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0a5fb788-450c-4e28-aec9-13725d845dec" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6088cf7f-ed64-4dc2-a47d-f4a4a6f67ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97e1840a-b57b-4276-a1ca-6f882633550a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_71dbfb15-3e26-4890-93ea-b6795b8df8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97e1840a-b57b-4276-a1ca-6f882633550a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_71dbfb15-3e26-4890-93ea-b6795b8df8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentAccruals_56e33159-963b-4459-9a36-651daacccbf8" xlink:href="nvax-20221231.xsd#nvax_ResearchAndDevelopmentAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97e1840a-b57b-4276-a1ca-6f882633550a" xlink:to="loc_nvax_ResearchAndDevelopmentAccruals_56e33159-963b-4459-9a36-651daacccbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_412ed792-3ac0-47fd-9af1-d61d6fda3b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97e1840a-b57b-4276-a1ca-6f882633550a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_412ed792-3ac0-47fd-9af1-d61d6fda3b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_35ee3bb8-ba49-4770-af14-67e49b21084f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97e1840a-b57b-4276-a1ca-6f882633550a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_35ee3bb8-ba49-4770-af14-67e49b21084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_415379da-c290-4571-8717-30f52e1d977b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_7af88b54-79e1-480f-8eb3-8f91ed8ad9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_415379da-c290-4571-8717-30f52e1d977b" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_7af88b54-79e1-480f-8eb3-8f91ed8ad9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_67714fc3-3fdc-4479-9de8-429ca55f115f" xlink:href="nvax-20221231.xsd#nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_415379da-c290-4571-8717-30f52e1d977b" xlink:to="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_67714fc3-3fdc-4479-9de8-429ca55f115f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_1b9223bc-7a39-40f3-a4a4-48d9a6d8842a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_415379da-c290-4571-8717-30f52e1d977b" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_1b9223bc-7a39-40f3-a4a4-48d9a6d8842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_64b2bfb6-9a1f-425b-8471-6b59b8b3ea26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_415379da-c290-4571-8717-30f52e1d977b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_64b2bfb6-9a1f-425b-8471-6b59b8b3ea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ee320511-64e5-4055-9824-04e15ffc0525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_95bf810d-19a6-4f78-8e7d-0ce280b81331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee320511-64e5-4055-9824-04e15ffc0525" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_95bf810d-19a6-4f78-8e7d-0ce280b81331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d3eb8c80-3697-41cd-b71e-b818b1dc829e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee320511-64e5-4055-9824-04e15ffc0525" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d3eb8c80-3697-41cd-b71e-b818b1dc829e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7eb5c38-aaba-45c0-a7ea-312f9c46366d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee320511-64e5-4055-9824-04e15ffc0525" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7eb5c38-aaba-45c0-a7ea-312f9c46366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c6f56e6a-861a-4b4e-ac9a-d8af18d05d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ebea137c-7cfc-43f3-96ba-9b353a2750e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6f56e6a-861a-4b4e-ac9a-d8af18d05d82" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ebea137c-7cfc-43f3-96ba-9b353a2750e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fe60a5b2-5661-49a5-920c-fbe75775600a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6f56e6a-861a-4b4e-ac9a-d8af18d05d82" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fe60a5b2-5661-49a5-920c-fbe75775600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6aae2152-6ffe-4651-b849-a18b26ee8d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6f56e6a-861a-4b4e-ac9a-d8af18d05d82" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6aae2152-6ffe-4651-b849-a18b26ee8d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2f629e59-87f1-45b9-9c57-2767d79777e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6f56e6a-861a-4b4e-ac9a-d8af18d05d82" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2f629e59-87f1-45b9-9c57-2767d79777e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_23c8c118-68c2-4f43-824d-63f2046eb1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_23c8c118-68c2-4f43-824d-63f2046eb1eb" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c6c595af-7dbb-4897-a2ec-728de47436b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c6c595af-7dbb-4897-a2ec-728de47436b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c6c595af-7dbb-4897-a2ec-728de47436b4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5692ed37-566a-4ffc-bb92-f7d18b528225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:to="loc_us-gaap_DomesticCountryMember_5692ed37-566a-4ffc-bb92-f7d18b528225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4413b292-d494-4a2d-85d0-b3aeef456f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4413b292-d494-4a2d-85d0-b3aeef456f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_7cb91891-5cb8-4bb8-b905-d42edfde88d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5d3d536-0f35-4659-8e5a-ddda4391c9bd" xlink:to="loc_us-gaap_ForeignCountryMember_7cb91891-5cb8-4bb8-b905-d42edfde88d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1fa2bc7c-52e9-4d4d-ac29-a2215188530d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1fa2bc7c-52e9-4d4d-ac29-a2215188530d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_a001c807-c512-4292-a80e-b35d5745d664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1fa2bc7c-52e9-4d4d-ac29-a2215188530d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_a001c807-c512-4292-a80e-b35d5745d664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_a7ea0acb-6301-41ad-8c56-dcd8e7287629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_a001c807-c512-4292-a80e-b35d5745d664" xlink:to="loc_us-gaap_ResearchMember_a7ea0acb-6301-41ad-8c56-dcd8e7287629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_896fc992-7683-4619-9956-bb8ff755b66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:to="loc_us-gaap_TaxPeriodAxis_896fc992-7683-4619-9956-bb8ff755b66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_896fc992-7683-4619-9956-bb8ff755b66d" xlink:to="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SubjectToExpirationMember_5a3acadf-9575-4a34-af1b-4e9c65bcdf58" xlink:href="nvax-20221231.xsd#nvax_SubjectToExpirationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:to="loc_nvax_SubjectToExpirationMember_5a3acadf-9575-4a34-af1b-4e9c65bcdf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NoExpirationMember_8c859143-495c-4017-bfd2-bfc09b37b02e" xlink:href="nvax-20221231.xsd#nvax_NoExpirationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_00149ec1-655a-4daf-9478-ab8e7c2515f6" xlink:to="loc_nvax_NoExpirationMember_8c859143-495c-4017-bfd2-bfc09b37b02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d0f457b6-e837-4fff-bdd3-65bb62fb4bf1" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29d54489-0dfe-442c-89b9-34e3bd18efa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29d54489-0dfe-442c-89b9-34e3bd18efa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f26555d1-4201-4363-8a6d-1cb074e89e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f26555d1-4201-4363-8a6d-1cb074e89e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6c9cd134-e68a-4159-8191-4721265a4f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6c9cd134-e68a-4159-8191-4721265a4f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e35242b9-d737-4c56-8a48-a200a5bbf845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e35242b9-d737-4c56-8a48-a200a5bbf845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_08b5a945-05d8-485a-85a8-6efe9d8befa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_08b5a945-05d8-485a-85a8-6efe9d8befa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9329bdf0-a8eb-4f94-b74e-9f0060dcfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_936f8200-f09c-4121-823f-5fdb23944651" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9329bdf0-a8eb-4f94-b74e-9f0060dcfb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofTaxRateDifferencesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8a644494-b545-4e52-876f-2097ffe3aa44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8a644494-b545-4e52-876f-2097ffe3aa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_57d747b7-d9f4-4ddb-bcb6-f2d63b61efe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_57d747b7-d9f4-4ddb-bcb6-f2d63b61efe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ca9fb575-540b-40a7-9ae1-bfd096952551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ca9fb575-540b-40a7-9ae1-bfd096952551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2f17f3db-57ce-4702-8433-95c4ecef7072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2f17f3db-57ce-4702-8433-95c4ecef7072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_592d1cd4-315f-4b87-bf6f-3b6f5648ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_592d1cd4-315f-4b87-bf6f-3b6f5648ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_e13a6dd0-5c3f-48d5-8b08-c393f0013c9e" xlink:href="nvax-20221231.xsd#nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_e13a6dd0-5c3f-48d5-8b08-c393f0013c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_264c88e3-b2f1-47a5-80af-a24816fa0ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_264c88e3-b2f1-47a5-80af-a24816fa0ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4a9a4573-29d9-42ec-a121-57587b34bd00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4a9a4573-29d9-42ec-a121-57587b34bd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_10fec8ab-c0ba-4256-b44b-4a60067bf792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_10fec8ab-c0ba-4256-b44b-4a60067bf792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_78c08bf6-5671-4a58-a285-dd5b28b9d8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_78c08bf6-5671-4a58-a285-dd5b28b9d8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_60eefc87-1ddd-402f-803b-fd4c6f072ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c95abb9d-bab7-4c55-a39c-d85ecc1e0ec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_60eefc87-1ddd-402f-803b-fd4c6f072ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_00c5d487-739a-4910-bf08-d821574646bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00c5d487-739a-4910-bf08-d821574646bd" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d0ccbb94-7807-46c7-a840-bc7a5b038e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d0ccbb94-7807-46c7-a840-bc7a5b038e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_3ed6a6e7-122d-4092-888c-d0228e3a130f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_3ed6a6e7-122d-4092-888c-d0228e3a130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84825142-0a6d-46a3-b16d-1281b9cd7422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84825142-0a6d-46a3-b16d-1281b9cd7422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetLeasingLiability_68bef26a-d5fa-487b-bd9c-9fb57420afe8" xlink:href="nvax-20221231.xsd#nvax_DeferredTaxAssetLeasingLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_nvax_DeferredTaxAssetLeasingLiability_68bef26a-d5fa-487b-bd9c-9fb57420afe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_762c7993-ba25-43d4-965b-15cc6a8d2f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_762c7993-ba25-43d4-965b-15cc6a8d2f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_378e3267-c931-409d-97be-9955fb5c816e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_378e3267-c931-409d-97be-9955fb5c816e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_42f3503f-280d-4314-bf57-042a6c3c530d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_42f3503f-280d-4314-bf57-042a6c3c530d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetsOriginalDiscountInterest_f210962d-186c-41f8-8ee0-af72dda3e458" xlink:href="nvax-20221231.xsd#nvax_DeferredTaxAssetsOriginalDiscountInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_nvax_DeferredTaxAssetsOriginalDiscountInterest_f210962d-186c-41f8-8ee0-af72dda3e458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e7ca94a1-e29e-4233-94dd-9b087db3ce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e7ca94a1-e29e-4233-94dd-9b087db3ce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_70d502ab-a069-4107-90d6-5043b25dc830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_70d502ab-a069-4107-90d6-5043b25dc830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0f09efd0-c39a-407b-a860-bac877cbd19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0f09efd0-c39a-407b-a860-bac877cbd19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dae17929-cae1-47ae-bf9f-fb8f0f561c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dae17929-cae1-47ae-bf9f-fb8f0f561c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ae1e0755-b324-4b86-80ef-1e8a0c83df4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8ba29384-2346-43fe-8cbf-aa8ce6823dca" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ae1e0755-b324-4b86-80ef-1e8a0c83df4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_10fcd293-2ddb-49e2-839b-67d2d1bd2729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00c5d487-739a-4910-bf08-d821574646bd" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_10fcd293-2ddb-49e2-839b-67d2d1bd2729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b9631932-968b-45e9-a486-d1710c24d395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_10fcd293-2ddb-49e2-839b-67d2d1bd2729" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b9631932-968b-45e9-a486-d1710c24d395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7592c300-18b0-4466-a5d2-e9caa000c69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_10fcd293-2ddb-49e2-839b-67d2d1bd2729" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7592c300-18b0-4466-a5d2-e9caa000c69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a66bbbe1-5c08-4063-8407-3bc92ea7258e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_10fcd293-2ddb-49e2-839b-67d2d1bd2729" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a66bbbe1-5c08-4063-8407-3bc92ea7258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_525687d6-1f7a-4259-894b-e48fdb4e5653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_10fcd293-2ddb-49e2-839b-67d2d1bd2729" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_525687d6-1f7a-4259-894b-e48fdb4e5653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_343f4c5a-a29c-4c3a-98d6-b46fdf02d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_10fcd293-2ddb-49e2-839b-67d2d1bd2729" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_343f4c5a-a29c-4c3a-98d6-b46fdf02d26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b3462c33-7ff5-4305-831a-b47673046857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00c5d487-739a-4910-bf08-d821574646bd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b3462c33-7ff5-4305-831a-b47673046857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6e0d8ff2-15d3-4e69-9a8b-9f477cbb7412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e0d8ff2-15d3-4e69-9a8b-9f477cbb7412" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a07ace8c-a8de-46bf-9872-2d272ad78aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a07ace8c-a8de-46bf-9872-2d272ad78aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1e76280e-4e99-4e2a-ab8d-d6fc3274b981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1e76280e-4e99-4e2a-ab8d-d6fc3274b981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4fefcb8b-a53d-4405-94c3-bcd3bba755fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4fefcb8b-a53d-4405-94c3-bcd3bba755fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0ec8f7d1-74e9-4b8a-a264-db82ed225fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0ec8f7d1-74e9-4b8a-a264-db82ed225fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_0794b62d-4f63-4592-a5d4-23e12360abc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_0794b62d-4f63-4592-a5d4-23e12360abc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b3993434-02a1-44a5-b7ba-6718b448cf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_46f57617-509c-41a1-bae9-d1930185c892" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b3993434-02a1-44a5-b7ba-6718b448cf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7036952-d73d-4abd-9208-81de105777b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d30d253d-31a3-489e-a1ce-125860988df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7036952-d73d-4abd-9208-81de105777b3" xlink:to="loc_us-gaap_LossContingenciesTable_d30d253d-31a3-489e-a1ce-125860988df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_414e5b4f-f543-4d96-96f3-1626eafecba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d30d253d-31a3-489e-a1ce-125860988df7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_414e5b4f-f543-4d96-96f3-1626eafecba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b831f85-9013-479a-96ce-b8def2f42dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_414e5b4f-f543-4d96-96f3-1626eafecba5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b831f85-9013-479a-96ce-b8def2f42dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_20ec04bb-627c-43cd-9f34-c191f62e0601" xlink:href="nvax-20221231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b831f85-9013-479a-96ce-b8def2f42dee" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_20ec04bb-627c-43cd-9f34-c191f62e0601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d30d253d-31a3-489e-a1ce-125860988df7" xlink:to="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_38488f02-5948-4dfa-a331-066ee477b339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_38488f02-5948-4dfa-a331-066ee477b339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer_25638aad-46aa-442d-b54d-39262a01ed35" xlink:href="nvax-20221231.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_LossContingencyPeriodToAnswer_25638aad-46aa-442d-b54d-39262a01ed35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_5411a017-74e1-4c62-baf8-13f02996704e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_5411a017-74e1-4c62-baf8-13f02996704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_a6113740-57ba-4516-8674-2e1ccfccfd13" xlink:href="nvax-20221231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_a6113740-57ba-4516-8674-2e1ccfccfd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_52835ea7-6341-4583-8b93-4e12beb87b05" xlink:href="nvax-20221231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_52835ea7-6341-4583-8b93-4e12beb87b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_3645cd22-f48f-43da-953e-4be6265ffea4" xlink:href="nvax-20221231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_3645cd22-f48f-43da-953e-4be6265ffea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_02a3787c-bb98-48bf-a876-c88a5d3f44e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50bfb18a-e609-4ed1-95a3-f1a9ef4a242c" xlink:to="loc_us-gaap_PurchaseObligation_02a3787c-bb98-48bf-a876-c88a5d3f44e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nvax-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_19de2f7b-869f-4005-b6b0-46a724057561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_19de2f7b-869f-4005-b6b0-46a724057561" xlink:to="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa5483bf-43f2-4dfd-ab38-90581abdba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa5483bf-43f2-4dfd-ab38-90581abdba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ddb19466-0c48-4c1f-a1e3-f247be6b8904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa5483bf-43f2-4dfd-ab38-90581abdba5b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ddb19466-0c48-4c1f-a1e3-f247be6b8904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07b5d137-8209-4b70-942d-1f7315016458" xlink:href="nvax-20221231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ddb19466-0c48-4c1f-a1e3-f247be6b8904" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_07b5d137-8209-4b70-942d-1f7315016458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58d31ec7-bb55-4475-bed1-433f02fcbc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58d31ec7-bb55-4475-bed1-433f02fcbc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f1498cc-7f8a-4548-8ca3-759a3c95a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58d31ec7-bb55-4475-bed1-433f02fcbc83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f1498cc-7f8a-4548-8ca3-759a3c95a07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2263e8e4-9852-430e-bd9a-475f9f6d6bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6f1498cc-7f8a-4548-8ca3-759a3c95a07a" xlink:to="loc_us-gaap_UnsecuredDebtMember_2263e8e4-9852-430e-bd9a-475f9f6d6bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_99b82e61-d5f1-4787-89dd-e3c6a0cc8722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_99b82e61-d5f1-4787-89dd-e3c6a0cc8722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b8160526-4c39-4072-a3bc-e46eda386856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_99b82e61-d5f1-4787-89dd-e3c6a0cc8722" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b8160526-4c39-4072-a3bc-e46eda386856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5d097f63-e25c-421a-8b0c-145434f87769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b8160526-4c39-4072-a3bc-e46eda386856" xlink:to="loc_us-gaap_SubsequentEventMember_5d097f63-e25c-421a-8b0c-145434f87769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b75997dd-32f4-4631-b43e-5765a2269bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e5ddcf6b-0c45-4b80-be72-c9bb701d87f1" xlink:to="loc_us-gaap_SubsequentEventLineItems_b75997dd-32f4-4631-b43e-5765a2269bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ab59211e-2b25-4459-9695-9d8c00506957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b75997dd-32f4-4631-b43e-5765a2269bc1" xlink:to="loc_us-gaap_RepaymentsOfDebt_ab59211e-2b25-4459-9695-9d8c00506957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M]:/,']ZOP8_X2'5/^@C=_P#?]O\ &C_A(-4_Z"-Y_P!_V_QK?_5V7_/S\/\
M@E?5O,_>?S!_>H\P?WJ_!C_A(-4_Z"5W_P!_V_QH_P"$@U3_ *"-Y_W_ &_Q
MH_U=E_S\_#_@A]6\S]Y]Z^M 8=CDU^#'_"0:I_T$KO\ [_M_C7U%^RK)-\,/
MA_XR^-VOSS7$>E0MIF@V]S(Q6XO9!@L >H4,!]"_]VN:OD;H0Y_:7>R5MV^F
MY,J'*KW/U%WC^\*-X_O"OPAU'Q?K>K:A<WMUJUY-=7,K32R-,V6=B2QZ]R35
M?^W]4_Z"-W_W_;_&NC_5V7_/S\/^"/ZOYG[S!@V<4O;-?#/_  3@^%UW#HNK
M?$G7)YG%R&LM-^T2$JL2G,TO)QRP"@]MC^M?6%U\6-$MIY(XUO[YT!P+&T>=
MG/HJ+EF/T&._3FOF<3AUAZSI1ES6\NIS2CRRY46_&J^)YH7C\/K"FV%I-TD@
M1I'&<1@X.W. ,X[]>*H:+\5-!E\/Z;=7%U/!--"ID@N(6\^-\899 !PP((/Z
M9&#7%>.OB-J&L0I9)IU]H41&9+>]").^>1N",P (P<9SSR >!Q%G9R7UY:VZ
MLJ2W4RP1&5PH>1LX4$]S@\=\5SVMI;4@]FNO'VK^(KJ6R\':(]YY9"RZSJFZ
MVLHB0#\@(\R9@#T50O8N*YR\^%?B.^U0S3:A#*=^?/>5B<?EG/M5N3X$NZQ3
M6?C?Q5H-X$"R+I.H*ML6'?R9$=,]LXR<#-9^L:'X^^'\*7[_ !&N?$.FJWEO
M::AH]JLW*G#>=$$Q@@=4.:UY826C2?SN5HT>NZ39R6&FVUM+.US)$@1IGZL1
MWJWPM?,DGBC5Y)C,VI77F$YW"9LC\<UN:!H>H_%G59;?5_&7B:QLH+<8L-'O
M5LXY,-AB\B()B3N'_+0=#644GN[(1ZW-\0M%M]6?3IKSR9T8HS.I"!AU&>WU
M/%=&KAU#*0RD9!!X->:W'P+T6VTVWM-'EN+ 0*0#<3R71?)))9Y&+DY)Y+'Z
M5V_AO2'T+1;6P>X-TT*E?-(QGDG&/09Q^%)VOIL(UJ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE;KXE>&]/\ &5MX
M5GU6./7[A0\5FR/R""1\^W:"0IP"<GCU%=+)(D,;.[!$4$LS'  [DFOB_7+W
MQ3KEKK'Q(L_#,DEG_;D>K6NNM>1 QV]N6B2+R3\S+SR>G'3@T ?:M%?*'C3Q
MU_;_ ,0?%@;Q_JGAO1O[&M]2TV*VO3")93;JZ(O/&=Y)5<%C]!52/QOK&O:M
MX M_$?C74O"MCJ?AYGO+N"Z^S[V$TOEOD_*K,$3Y\9(/7F@#Z1\4?$#3_".O
M>'=)O(;F2XUR=K:V:!%*(R[<ER6! ^8= :O>%?%VD^-M*_M+1;O[;9>8\/F>
M6\?SJ<,,, >#[5\M^&?$6K>)IOA%<:M>SZDT/B*\M[>]N,EYX5\G:Q)Y/)89
M//'M69-\2?%?_"O_  Q"=;U-UU#6=02ZN1JPLYF6,1>7']JER(E^=SSQQ0!]
MI5S'AWQU8>)_$7B'1K2&Y2YT.6.&Y>95".SJ2-A#$D<'.0*^;_\ A-/%2> _
M#FG:OXGETK3KWQ$]I+KEIJT-W/%:A$94>ZA8C<"SY)P< <!1BNZ_9K^S_P#"
M7?$I;36)?$%LMW:K'J<T@D>X4)( Q<<,>,;N^,T =9>?M+?#C3[R>UN?$?ES
MP2-%(GV&Y.UE.",B/'45Z)INI6^L:;:W]I)YMK=1)/#)M*[D8!E.#@C((ZUY
M)XO_ .3I/ G_ &"KK_T&6O)?B5X]\877Q,\4VMIK=UIDFFW"Q6,7_"06^F6T
M:C!!>&;'G[ASP1U],"@#["KEO!_C[3O&EYKUM817,4FBW\FG7'VA%4-(AP2F
M&.5X.,X/M7@\_BV\U_QUX@'B?X@WG@B?2H;)K&QLYL0SL\:M(Q13^_!)Z*3P
MP(.!7*ZE;ZOH]A\6O%FD^)-4TBXTGQ/)LL[.79!.7N@A,@_BX88!XX/'- 'V
M717RWXKU+Q!XJ\:?$R:U\5:WHMGHNCV^K6MG8W;*GF?8TDV'T4G=D+C).3TJ
M'_A/+WQKJWABP\1^-K[P5I3>&HKX7=I="U:\NL[68R8 .2I.WV(')S0!] ^)
M/'VG>%_$_AS0KN"Y>[UZ26.U>%5,:&,*6WDL"/OC& ?PKJ:^0M&\4:YKUS\'
M=0U*6;4[R.^U9+:ZF4[[N-!%L8]SDY7/7CUJOI/CK5Y-&\,^);;X@:EJ7C+4
M-96"Z\,?:,P!#(1L%N/NC 7GI\V!@B@#[%K$\.>+M)\76]Y-I%U]LBM+I[.9
MO+=-DR8W+\P&<9'(X]Z^7='U3Q#\0?B$\*^-=1L4?7I8I?*\11VD?V57($<-
MIGS=YX .TJ<^N33-4^)'BJS^&NIF'5]0<W'C2XL)+PWWE2Q0"-&6))WR(03G
M!Z#![9H ^P**^0[?Q-XQ?X=ZG!)XM6RB_MBV2TFF\3V]Q<O$T4S26YO8LK&Q
MV*P:0*."!GH?9/A%XBNO%WP5DELKS4+O4XX[NVCN;Z8/.907*?O </@,@#\9
MQG H V9/CIX$B\2#06\1VXU0S"W\L1R%/,SC:9 NP'/'WJ[^OG+X!^,/ 6D_
M"G3])U>XT^VU9;MH[RQO(PT\MP9CY;>606; *@$#Y<=L5Y]X1^(?CK7/&EI?
MQ:Q.U\^L>5)8W7B*UAMFB,@4PK8.5?/. P))[#/- 'V=6?'K&GSZI-IL=];O
MJ$*"26S693-&AZ,R9R <]2*^4_$FK>*6TCXG>)H/&6MVC^&_$3P6=C%=-Y!1
MKD)M8'JH##"]!CIS6O"MO8_'KQ%J;>(M2L[U]+BU*RLY+\ 7<SJ'6U*XS)&"
M<",<X'M0!]2T5\??!OQSXRUOQIX=NWUV>[6\N634+>^\26LB21G/^JLB5DC*
M]>,DXX %>F?LMQZQKGA1/$^K>)M7U::<2V8L[RX,D$85P0X!Y+\$;B>AQVH
M]UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSUKU_P"$_C2YUAGTN^D:>2./?%*QRQ (!4GOU[^_M6#M?38@].HHHH ****
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M#&Z,6M%;&U\4WFI6#:3#$6C=;QD\[[4)(B"RQK;G]Y&N'P=X]A\87FK>'_"
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M\OY>N3Z'X]^ _@[XF:A<WVN6NJ)<W=H+&\.DZ[?Z8M[;C?MBN%M9XUG4>9(
M) V!(X'#',?BK]GOX?\ C"^T>ZO_  ^('TG3VT>WCTN\N-/B?3R4)LIH[>2-
M)[;]VO[B4/'C<-N&8$ ^=?@S\5OB=\9+7X$Z=<>/[G0V\4>!M1US7-1L=*L7
MNY[B&ZLTC>'S(6BA;]\0<Q.A1G&P.4DC?X+^+'Q0M_!7PP\<:WX\;5AJGCK_
M (0J^T:/1K2"TN[9;ZZT_P"TN0IF6Z:2%9RT<B0C[@@QEC])>#_@?X)\ S>&
MIM!T0:?)X;TN?1=**W,SBVLYI(Y)(L,Y#9:&,[FRPVX! )!2'X'^"(/#NC:
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M^%?A/XM2U^W2:#^SWJVJK:C_ );&";390GX[,?C7V[=?#7PW>:]H.L2:6O\
M:&A6-SIVFR1RNBV]O<"(31A%8*0P@A&2"1LX(R<Y/A?X'^"?!KZ"VDZ$MO\
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M%$RVY\RW&9%81S$KG!%>_P#Q&^!OA+XK:WH.L>(+?5?[4T'S_P"S;S2]=O\
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MW-S))*ZHN0JERJY.T#)R =E1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !116/XHFU:VT"^ET*TM[S6%B;[);WDIBA>3^'>P!(7N<#/%"U=
M@/!OVP_VIK3X#>%SIFD21W'C75(S]DAX86L9X-Q(/S"@]2/0&OR?U+4;K6-0
MN;Z^N);N\N9&FFGF8L\CL<LS$\DDG.:^P?&_[!OQQ^(GBK4?$.O:KX?O]5OY
M3+-,]])CV51Y7"@8  X  %8?_#M?XM?\_/AS_P #I/\ XU7WV7U,#@:5O:)R
M>[_KH>C3=.FMSY2 R0!R:^W/@[\-Y/V3/ASI_P 5=?\ "LOBGQYJTODZ/X;$
MHADM;989+BXF)*MB46T,SXQP %X+G'9?LQ_\$_;_ ,#^.4\2?$1]-U"/3BLF
MGZ?9RM-&\W:27<J\+@$+SDX)Z8/T;\3/@0GQ8^)6A:UK6K7UKH&B:;<P6=II
M-_/97)N[AE665Y8F4E/)0(%SSYCY[5Y^;9I&I'V&'=T]W^AE6JW]V)0^,O[4
M?A;X8^!]3U2QFEUW6%\/2>(;*QLK*XN8V@\MC#)<20QL((I&&T/(5!PV#\IQ
MUL7QL\(?V/!?2ZI@/JKZ&T,=M,\HOT5FD@$80L2%1VSC!4;@2""?GY?V2?B'
MX;\$^)_"7A[Q'X?NM+\1>&O^$4FN=82X:>SLX'NTLFCV?ZQA;W2QN&( :(."
MV2M=OXD_9@U?4_B'XD\0Z7XK;1;?4-#F6PC@C/F6&O2V@LFU)2".1;I&H P<
MESG)KY$XSHKKX_?"I[+4-2U0SV$EK<6D%S!J_AV[M[W?=,4M2()(!*XD*,JL
M%()4C.1BF_\ "\/A.=$L=3CC:=KR[N+&+3(/#US)J7GP &X1K-83.IC!4L60
M !E)/S+GS7P9^R+XBTO7AK%Y+X;T:1K[P[=26FD275P)/[.NKB:5Y)I_GDDE
M$PPQ QC!SC<>G;X >,O"GQ*U+Q]X4U/0[K6;C4]4E&GZN)DMWL[R*Q!!DC!9
M)4DL5;(4AE<C@X(KF?<#K[7XO?"^;Q#9:5#Y7GW4T-LEW_8TRVD=Q+&LL5O)
M<F(1QS,C*1$[!_F4$ D"J?A?]HSP_P#$OXJ:1X1\/03:IHFHZ-?ZF^J7.GW$
M$$P@FMHD^SO+&J7$3^>_SQEA\@YPPSP"?LEZLWB[5KG4+?POK6FZYJW]M7E]
M<R7L=W8SR*AG6WA#F)\2*7B=R"F5#!]N3T_P=^"?CKPCXN\%7GBC4_#MSI?@
M_P ,7'ABQ&D1SK/=(SVFR>4/\J'9: %%R 2<,0<!.3>X$7Q"\;>,/"/Q-T'P
MKIOPU\%:C;^(7O!IE[=ZW);MLMX1*YG06+A"02 %9^G)%;&E_'7X37>EW-Y>
M2V.G1VNGG4GN+C2IHK:Y@5TC>6SEDA4748DD1 T0;<9(\#YUSTOQ&^%4OCWQ
M[X*UHWB6]AHD6IPW4/(EE6ZMO)&PC@%>3S7@^A_L8ZWI_A6ST,CPG:WF@VMJ
MFC>)(A>SW4\UK<VT\!G@D?RXHW^RH)5C9MW52N *KFEW [V\_:L\'>%?&&DZ
M6FEZG8Z)>Z9J%].5\.W\=]%/;26H*FT$'F;/+N"YD*X 0<UU>H?M1?#73]3M
M[!_$,DSS1V,YN+;3[F:VABO #:RRSI&8XDDW*%9V R1573?ASXTU_P ?67B[
MQ;<:#:W5OH.I:*++1C/)&HN9;1T8O(%+$?9Y,_*OWU !P2>$T7]D_6M+^%GB
M3PJVN6+W6JZ%X>TF.X$;[(WTZ%(Y'(ZX<H2N.F>:@#T+Q%\?_ DUUJ^B1S_V
MEJEG]LCA2ZTZ<6-S>6L3R2VT=RT?DO*@1]R*Q8;7XRK8P_#/QW^&VH:7X776
M+:UT_5]5L-,N;N.#2I9K/3Y[V)'@AGN5B,4+.7 02,I.5_O#//7'[-?BV\MK
M3PM-J^C+X(TG7-3\0:=<(DW]HRRW(NVC@F&-BI')>R$R*275%&U<DU0L_P!E
M?QAI?A:]\$VVMZ')X3\0#1Y=:NY8YA?6\EG;6EO,MLH&QUE6RCVLY4QEV.'X
M%-2:V8'<7OQ^^#VFW]];7$J+':?;0UZ/#]RUG*;1'>[$5P(3'*8ECDW!&.-I
M'4&O3-%\6>'[S7I_#NDW<#WMG8P:C);6L9\N.WG:01/N V?.8Y"!G.%SC!!K
MY7\ > ?$C?%/P3X,DM;C5? 7@V\UQY)[[PQ?6#&WGAN(422XGQ#<DFX*C[.&
MWJ"Y*]#ZI^QW\,[_ .'_ ,+?M>M"^_MG5I]^-5B\J[@L(%%OI\$JGE62VBB+
M \AWDSR30Y-[@3Z3^TI%I.J>.5\<V5GX<TW0?$</AJRN-/FN-0FU"YEMX[B,
M"%+<,I9)HP -V6W#L"TL/[5W@_4/&'A#1-/AU:^M_$4.H-]L32KP-936DT,,
MD,\7D[HF#RG=OV^6%!; =36#8_ #Q==^,]9U75-0T2*TNO'MGXP@2S,S2"*&
MT%J87W*!N*Q1,".,LXZ $PS?LW^)+#QC_;>G:II-S'=:MK[WEM=>;&18:H;8
MN8W4']]']E& 1M;>>1BD!VW_  U)\-8]/O[^XU^:RT^TMEOOMUYIMU#!<VQF
M2'[1;NT8$\0DEC4O&64;U).&!,-U^U9\-+2\CM9M:O8I"MO)*S:+?*EI'.YC
M@DN&,($".RD!I"HZ<X.:\BT/]C?6]/\ !Z>&Y8O"<)T^RM+"S\0V[7KWMS'#
M>6LV7BD8QP;TM1N5"X+[2"JC%>E_$3]G_4?&K?%OR-4M(!XTL-,M+82HQ^SM
M:[]Q?'4-O&,>E %[QY\:_ .DWFM6NIZ?J$^KZ;:WL\,=UH=Y"E^UK"TLL5M<
M-#LF8*C'$;-P"0" :R?!?[2O@Z71;+5W@B\+Z%/X>AUR>.ZM+N&]1Y)8XE18
M6MU\Y2\JHCH29'("*P.:XW_ADWQ/JWQ,&N:UJNCW5O'J6LW/]M,]U-JMQ;7M
MK=010%7/E0I MRBA(_E81 _(<@N_X9=\;ZKI?AZ74M:\/VNN^&M%TW3=.:U2
M>6VFFT^^@NH))E8*P600;7522N_(+8Y /4IOVG/A[;Z?;3RZEJ"7,]_)I::7
M_8MZ=1^UI#YS0&T$/G*_E$. 4&5((R#4E]^TKX L/#^E:^VI:A+H&I6WVQ-6
MMM%O9K2WAWE"UQ*L)6WPX96$I4J5.X#!KD?#/P#\3R?%S3_B/XCU+2HM9;6)
M=0O-.TOS7MXX1IC6,,4;NJL[<EV=E7.< #:,^9>,/V*?&/B#PK>>'4UK0=4T
MZZTJ^L81JSW?EZ5//?7=R;FWAC(221TN8T9GP5,"D%@2M 'TK\,?B%/X]N/&
M<<]FEH- \0W.BQF-RWFI%'$XD.>A/F$8]J\S\<>"[WP]JT["%GL9&+13*,KM
M[ GL17I'PK^'=UX E\9/=7<-U_;OB&XUF+R@1Y:21PH$;/4@Q$\<<BN_H \2
M^$_A.[FUR'5)XGAM+?)5F&/,8C  ]>N?PKU;4O$^F:1=0V]Y>1P32G"(QY)]
M/KR./<5KUP_BKP/<:[J]M=QSA1;R>:B[RJE]\#XD ^^O[@<'^]_L@T =K'(L
MB!T8,K#(8'((I]5[*W^RV<$&[?Y4:INQC.!C-6* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\W\1?M!?#_PCX8\8^(-9\1QZ?I'@^^33==N);>;-G</Y
M)1"@3<V[[1#AD#*=_!X./2*^7/BQ^SWK?CCX^>3_ &3'??"_Q8+*^\4R2318
M2YL8+R.)!&S;G,QEL.0K!19G/WA0![)XI^./@CP7XJL?#>LZZMGK%Z+1H8?L
MTTB8NIS;VQ>1$*())59%WL,E3Z&EN/CEX%M;[Q]:2^(H([CP%;Q7?B6-HY/^
M)=%) TZ,QVX;,:,WR;CP1UXKYY\'_LZ^/O$WP-^)5OXWL[>S^(>IV%AI6D3K
M/'*#_95O&;&Y+*Q"^9>K-<;2P*B10P!!K$N_V<_B-XD;2K^\\.6]I<?$.ZN8
M?B);O=V[/8V)U:.[MXMP<B8+9BXM/DW\SAL;<X /H[4/VE/AOH_@;Q#XQO\
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MU#7EUR+4XIK8^;;V\#>58V*0,GDR,$6W^82%R[$G !](T444 %%%% !1110
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M?V5XN_Z'F^_[]?\ V= 'O=%>"?V3XM_Z'B^_[]?_ &=']D^+3_S/%]_WZ_\
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M3_OA_P#X[0![)17C?_"L_%/_ $435/\ OA__ ([2?\*U\5?]%$U3_OA__CM
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MRT5XY_PK3Q3_ -%$U3_OA_\ X[2?\*S\4_\ 11-4_P"^'_\ CM 'LE%>-_\
M"L_%/_11-4_[X?\ ^.TG_"M?%7_11-4_[X?_ ..T >RT5XU_PK7Q5_T435/^
M^'_^.T+\,_%/_11-4_[X?_X[0![+17C1^&?BGC_BXFJ?]\/_ /':7_A6?BG_
M **)JG_?#_\ QV@#V2BO'/\ A6GBG_HHFJ?]\/\ _':;_P *U\5?]%$U3_OA
M_P#X[0![+17C7_"M?%7_ $435/\ OA__ ([2_P#"L_%.W_DHFJ?]\/\ _':
M/9**\=C^%7BFX;8?B-JB^X63_P"/5-_PIOQ/_P!%)U?\I?\ X]0!ZY17D?\
MPIOQ/_T4G5_RE_\ CU'_  IOQ/\ ]%)U?\I?_CU 'KE%>1_\*;\4?]%*U?\
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6%++\0]4N47.8V$F#\I'>8_6B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '9 ?(# 2(  A$! Q$!_\0
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MI:*/JU'^1?<@]K4_F?WG-?\ "L_!_P#T*FA_^"Z'_P")H_X5GX/_ .A4T/\
M\%T/_P 372T4?5J/\B^Y![6I_,_O.:_X5GX/_P"A4T/_ ,%T/_Q-'_"L_!__
M $*FA_\ @NA_^)KI:*/JU'^1?<@]K4_F?WG-?\*S\'_]"IH?_@NA_P#B:/\
MA6?@_P#Z%30__!=#_P#$UTM%'U:C_(ON0>UJ?S/[SFO^%9^#_P#H5-#_ /!=
M#_\ $T?\*S\'_P#0J:'_ ."Z'_XFNEHH^K4?Y%]R#VM3^9_><U_PK/P?_P!"
MIH?_ (+H?_B:/^%9^#_^A4T/_P %T/\ \372T4?5J/\ (ON0>UJ?S/[SFO\
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M_P#Z%30__!=#_P#$UTM%'U:C_(ON0>UJ?S/[SFO^%9^#_P#H5-#_ /!=#_\
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M17J?5J/\B^Y'%[6I_,_O.:_X5GX/_P"A4T/_ ,%T/_Q-'_"L_!__ $*FA_\
M@NA_^)KI:*/JU'^1?<@]K4_F?WG-?\*S\'_]"IH?_@NA_P#B:/\ A6?@_P#Z
M%30__!=#_P#$UTM%'U:C_(ON0>UJ?S/[S]+O^&3O@A_T1OX?_P#A+V/_ ,:H
MKU6BOP0_2S\K/C+_ ,E?\<_]AV^_]*'KCZ]:U;P#<?$S]I3Q3X?M[A;+[1KN
MHM+=NFY8(UFD9G(R,X ]1SBL;Q_\%M<\&>+M9T:TCEUVWTVT34&O[6$A&M64
M$2D9.%Y(ZGH:_<:&)HPC3HRE:7*G\MO0_.IT:DW*<5=7M\_Z_3N>?45TL/PV
M\4W%UIUM'H-\\^HVIO;1!"?WT &3(O\ LXYS]/6IM1^%/C#2?#2>(+WPWJ-K
MHS ,+R6!E0*>C'N <C!/!R*ZW7I)I.:U\U_71F*I5'M%_=\_U1RE%===_"+Q
MK8K9F?POJ<?VR=;:V!MFS-(4WA5'?Y>?P/H:Z#QU\%+SX??#31]>UB.\L-:O
M-1ELYM.N8PHC15W*P/4Y_*LWBZ"<8\Z;D[*SN4J%1W?+LKGF-%%%=9@%%%%
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M?B-X_P#%FIR?'/7H/B!?^#)/ARJ)I&C6T=J;:ZVV45T);E9(F>19GD:(!64
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MBCQ!8^'_ !%/%=>(/#%J]N+'5IHT1 \I:$RIN6*-76*1 X49')S[4JA%"@8
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M9.04).P 86M%R.6FUO\ Y+?;7;MZ:HSGS+;^MMM]/O\ 569]94445D6%%%%
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MSVBJF4*P!#)N;M_K%QZ\UKZCJ-KH^GW-]?7,5G96T;33W$[A(XD499F8\
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M:L2LC?9OG^\P%1BG4C&]T[Z^DDM/D_-^5KM9*3<'*2L[+3U5_P!.MEYWM?\
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M[GO4M% $4=M#%+)(D2)))C>ZJ 6QTR>]+';10O(\<21O(=SLJ@%CZGUJ2B@
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MXKU:*&VN]<UOR%F:"(N8H42"..-$4R.<*F26))->BT44V[BM8****0PHHHH
MXCXK?"JR^*VD:;;S:GJ&A:EI-^FIZ9J^EF/[19W**RAU$J/&WRNZE71@0QX[
MUREC^SJ^G^&/$UI#\0/$Z>)?$MQ'/J_BL1V!OKD)&(EB$9MC;H@C 7"Q ]\Y
M.:]BHJ;)IQ>S_P"!_DK][:E<SNGV_P"#_F_O/#_!7P$\0_#71OA]X2T/Q[K=
M[X4\.W?GSRZD]NMR]K%;^5!8 001JT18AV9\M^[QD[OE3X<_LQ77PU\37NJV
M7Q6\:W\&H7\VHW^GW_\ 9SQWDL@(/F2"T$Q"C:%Q(-H10, 8KW&BM')RDY-Z
MO?SV_P E^>Y%K+E6W_#_ .;/'=%_9OM_^$EM=9\7^-?$?Q%?3XIX=,M?$'V1
M8;)9HS%*P%O!$9':,E-TA8@$XP224^&O[-&F_#O7=&OYO%?B+Q1:^'K>2S\.
MZ;K4MNT&CPNH0B(QPH\C; (P\K.P7(!Y)/L=%)-K;^M_\WKOJ^X-7W_K^NP4
M444AA1110 5QWQ6^'UQ\3_!]UX?A\4:OX4ANPT=S=:,ELTTT+(R/$?M$,JA6
M#=54-P,$<UV-%3**DK2V*C)Q=T>%VW[+ T_PYX1M++XC^++;7_"<<MKH_B/R
M]/:Z@M)$C1K5HS:^2\>V).6C+Y7.ZM+PS\$=1\#:MX3L]!\0Z@FAVFH7VN>(
M+RZN%-WKE[.I 69418]A:1I#M"@&*,*N"<>Q45IS/FYGO_7ZZON]7<S44HJ"
MV7]?DVEV3LCAO"'PDT_P7I/BRVL-3U(W_B;4+K4K[5WD3[6)IAM4HP3:!$BH
MD8*G C7.><\MH/[->GKJM]JGC/Q5KOQ)U&XTRXT6*;Q"+6-;:RGV^?$D=M#"
MN7V+N=@6.T $"O8J*BRV\K?*UK?=IZ:%W=[^=_G>_P">OJ>1_#3]G:S^'WB+
M3]9O?%OB+QC<:18OIFB)KTEN5TNU?9O2/R88R[$1QJ9)2[X7&>3GURBBK<G+
M?^OZ>I*26P4445(PHHHH ***\$^$WQE\7?%#XG>)+);[PGIVD:%JMUIE[X5F
MCF&NP1Q,RQ7;/YFW9+A'5?) V.")"1@B]Z7*NU_Z^] ](\WR_/\ R9[W17@7
MAC]HO5]:_:2U+P7<Z19P>!I3<Z9H^N*S>==:K:)%)=PMSMV!96"X .ZWFSGC
M'">)?VJO''AWXB>.T5_!MYX>\-^)[+P[!X;V3QZ[?B=+5C+%)YS(Y7[2Q""'
MD1GYAR:J$7/EM]I77I=)?>VOOOL$O=YK]';YVO\ A9W\TUN?7%%%%2 4444
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MFC&]EDRS8V@#G4UOX]^*%^(OP@MM+T'3$\#>.)?+.I7=RSWC[M/FNU$4285
MOEJI9V8G) 4##41BY.R\OQNT_G9V$VDK^3?W6O\ ==??ZGO5%?,7B_\ :1\9
MZ/=>-_%%C;>'5\">"M?CT+4M+NDF.JW:GR!)<1RB01Q;?/RL9C?>$^\NX8^G
M 0P!'0\U*UBI='^J37WII_\ !"ZYG'M^CL_N:L+1110,**** "BBB@ HKYV^
M*WQ3\67_ ,;K7X=^&M:\/>$+JPM[36HG\0RR(WB ,\JO:P!2/D0HGF,-[#>O
MR]S6\>_';Q5I_P"T _@#3_&WPU\()%8Z?<16/BN&:2^U*2=IA(ML5NX00HB
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M.QETZWN&D8B*"1T>0*F=H+&-,MC.% SBM>6T@G;=)#'(W3+(":;DY6;[MO\
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M _Q5TKQ[;W&I:(K9OK;[/JLEQ<W<L7WDC:(,XD/RD2J 3N%>G:[\:O WA_\
M:6TSQQK7B?3]/\&W/A>^T&SUN_D^SVD6H6^H+]JMO,?"^80H^7J?);&<5]//
M9PN\K^6J2R)L:5!A\?[W6LOPUX,T;PCX9L- TRQCATJR0+# ^9.<Y+,S9+,6
M)8L22222<FDG:W=-OYRCR/Y)+3S\A2BI771V7W2YE^._EYL^)O@1XCTOX(>,
M_"?B?XA:C!X4\+:WX>UK^Q;[6S]D@@\[6I+M("SX"O);R0,$.&(C. <'%?\
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M6H_M >.O#5GXL\)7<FC:EXTT[Q3I?AJQUY;*2&R9=02.2.>:W\PG=$KL&19
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ&/,E\M&.Y]H4L"OIVBZ]\0O#EOX$\+P^"O#VEW4BW0OK;3+R>?3=-L8(BL
MCG,$?SM(T*["GW=Y&=I-6]8R[NWR=KNW>VVF]F_6-5;Y_==VOZ[Z[72ZNV;X
M4^)_Q'TCXX6_@/QI;^&]5&J:#<ZY:OX:AN(6L/)EBC\B9IG82!S+\L@$>2C?
M(.VI\$OBOXO\=^)?B9I'BK0M,TF]\,:C;VUM9Z7<O.3'+:1W"K)*X56?]X 2
MJJH/'(&X\M\!O!/Q@\+>+]9UKQWX>\'7FJZYN?4?$&G^(;J:?"!OLUK# ]FB
MQ0)G&T.3\S.=S,<W/@GX.^*WAGXH_$3Q!XJ\/^%++3?%=Q#?J-*\07%U+;RP
MVL5ND6U[*,,K>7N+Y!7.-K=:%:UG_*_OYKKYJ.FN]K[O5Z7?JOR2^Z^OE?R.
M@^!?Q4\6>/\ Q7\2-%\6Z-I>B77AG4[:T@MM,N'N,12VL<X\R5@H=QY@!VJJ
MCD#=C<?7Z\#^!O@SXI>&_BO\0=?\7Z#X6T_2/%EU!?DZ1K]Q>36LD-K%;K'L
M>SB#AO++%MPQG&#UKWRA[1]%]]M?QN#M=V"BBBI **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW^]V^]6;\WTV&G[TK;:6^Y7_ !N@HHHJ2@HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR22>@%<_X4^)7A'QWI5WJ?AOQ3HWB#3;1VCN;S3-0BN(867E@[HQ"D#DY->
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MZ#_\M*/^&GM2_P"B+_$#_P "=!_^6E144?4J?=_U\@^NU.R_KYDO_#3VI?\
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MQGHFF^&'N;C3=&TQ?#EO9PW,Z['N-B:D/W@0R*"./WKD@G!'?T4+!4T[IO\
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M2?$*]MH/#O@"TUR/4_#%T+:'4-0E#G[2[ ?/%^[&(S\IW'([5R^W7*Y6VO\
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M^NM/FY=?^&_R0OJMU;FT_P"'_P W]Y_1_P#V!JG_ $#;O_OPW^%']@:I_P!
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@ V[_ ._#?X5_.!15?7I?RD?4H]S^JBBOY5Z*\P](_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_02.jpg
<TEXT>
begin 644 image_02.jpg
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MLB^]M<]Z$% LD7W9K?W6@X!BFNP+;NV]'@04H;(OM77.>A!0A,B^S-9YZT%
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HG$9 '40X<1H!=1"AQ&D$%%#6OP$OTS8IZ(MGC@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>nvax-20221231_g1.jpg
<TEXT>
begin 644 nvax-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" UX#F(# 2(  A$! Q$!_\0
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M_P#0Q7'_ (%2T?V+XI_Z&*X_\"I:ZRBC^S<-V_$/K%3N<G_8OBG_ *&*X_\
M J6C^Q?%/_0Q7'_@5+7644?V;ANWXA]8J=SD_P"Q?%/_ $,5Q_X%2T?V+XI_
MZ&*X_P# J6NLHH_LW#=OQ#ZQ4[G)_P!B^*?^ABN/_ J6C^Q?%/\ T,5Q_P"!
M4M=911_9N&[?B'UBIW.3_L7Q3_T,5Q_X%2T?V+XI_P"ABN/_  *EKK**/[-P
MW;\0^L5.YR?]B^*?^ABN/_ J6C^Q?%/_ $,5Q_X%2UUE%']FX;M^(?6*G<Y/
M^Q?%/_0Q7'_@5+1_8OBG_H8KC_P*EKK**/[-PW;\0^L5.YR?]B^*?^ABN/\
MP*EH_L7Q3_T,5Q_X%2UUE%']FX;M^(?6*G<Y/^Q?%/\ T,5Q_P"!4M']B^*?
M^ABN/_ J6NLHH_LW#=OQ#ZQ4[G)_V+XI_P"ABN/_  *EH_L7Q3_T,5Q_X%2U
MUE%']FX;M^(?6*G<Y/\ L7Q3_P!#%<?^!4M']B^*?^ABN/\ P*EKK**/[-PW
M;\0^L5.YR?\ 8OBG_H8KC_P*EH_L7Q3_ -#%<?\ @5+7644?V;ANWXA]8J=S
MD_[%\4_]#%<?^!4M']B^*?\ H8KC_P "I:ZRBC^S<-V_$/K%3N<G_8OBG_H8
MKC_P*EH_L7Q3_P!#%<?^!4M=911_9N&[?B'UBIW.3_L7Q3_T,5Q_X%2T?V+X
MI_Z&*X_\"I:ZRBC^S<-V_$/K%3N<G_8OBG_H8KC_ ,"I:/[%\4_]#%<?^!4M
M=911_9N&[?B'UBIW.3_L7Q3_ -#%<?\ @5+1_8OBG_H8KC_P*EKK**/[-PW;
M\0^L5.YR?]B^*?\ H8KC_P "I:/[%\4_]#%<?^!4M=911_9N&[?B'UBIW.3_
M +%\4_\ 0Q7'_@5+1_8OBG_H8KC_ ,"I:ZRBC^S<-V_$/K%3N<G_ &+XI_Z&
M*X_\"I:/[%\4_P#0Q7'_ (%2UUE%']FX;M^(?6*G<Y/^Q?%/_0Q7'_@5+1_8
MOBG_ *&*X_\  J6NLHH_LW#=OQ#ZQ4[G)_V+XI_Z&*X_\"I:/[%\4_\ 0Q7'
M_@5+7644?V;ANWXA]8J=SD_[%\4_]#%<?^!4M']B^*?^ABN/_ J6NLHH_LW#
M=OQ#ZQ4[G)_V+XI_Z&*X_P# J6C^Q?%/_0Q7'_@5+7644?V;ANWXA]8J=SD_
M[%\4_P#0Q7'_ (%2T?V+XI_Z&*X_\"I:ZRBC^S<-V_$/K%3N<G_8OBG_ *&*
MX_\  J6C^Q?%/_0Q7'_@5+7644?V;ANWXA]8J=SD_P"Q?%/_ $,5Q_X%2T?V
M+XI_Z&*X_P# J6NLHH_LW#=OQ#ZQ4[G)_P!B^*?^ABN/_ J6C^Q?%/\ T,5Q
M_P"!4M=911_9N&[?B'UBIW.3_L7Q3_T,5Q_X%2T?V+XI_P"ABN/_  *EKK**
M/[-PW;\0^L5.YR?]B^*?^ABN/_ J6C^Q?%/_ $,5Q_X%2UUE%']FX;M^(?6*
MG<Y/^Q?%/_0Q7'_@5+1_8OBG_H8KC_P*EKK**/[-PW;\0^L5.YR?]B^*?^AB
MN/\ P*EH_L7Q3_T,5Q_X%2UUE%']FX;M^(?6*G<Y/^Q?%/\ T,5Q_P"!4M']
MB^*?^ABN/_ J6NLHH_LW#=OQ#ZQ4[G)_V+XI_P"ABN/_  *EH_L7Q3_T,5Q_
MX%2UUE%']FX;M^(?6*G<Y/\ L7Q3_P!#%<?^!4M']B^*?^ABN/\ P*EKK**/
M[-PW;\0^L5.YR?\ 8OBG_H8KC_P*EH_L7Q3_ -#%<?\ @5+7644?V;ANWXA]
M8J=SD_[%\4_]#%<?^!4M']B^*?\ H8KC_P "I:ZRBC^S<-V_$/K%3N<G_8OB
MG_H8KC_P*EH_L7Q3_P!#%<?^!4M=911_9N&[?B'UBIW.3_L7Q3_T,5Q_X%2T
M?V+XI_Z&*X_\"I:ZRBC^S<-V_$/K%3N<G_8OBG_H8KC_ ,"I:/[%\4_]#%<?
M^!4M=911_9N&[?B'UBIW.3_L7Q3_ -#%<?\ @5+1_8OBG_H8KC_P*EKK**/[
M-PW;\0^L5.YR?]B^*?\ H8KC_P "I:/[%\4_]#%<?^!4M=911_9N&[?B'UBI
MW.3_ +%\4_\ 0Q7'_@5+1_8OBG_H8KC_ ,"I:ZRBC^S<-V_$/K%3N<G_ &+X
MI_Z&*X_\"I:/[%\4_P#0Q7'_ (%2UUE%']FX;M^(?6*G<Y/^Q?%/_0Q7'_@5
M+1_8OBG_ *&*X_\  J6NLHH_LW#=OQ#ZQ4[G)_V+XI_Z&*X_\"I:/[%\4_\
M0Q7'_@5+7644?V;ANWXA]8J=SD_[%\4_]#%<?^!4M']B^*?^ABN/_ J6NLHH
M_LW#=OQ#ZQ4[G)_V+XI_Z&*X_P# J6C^Q?%/_0Q7'_@5+7644?V;ANWXA]8J
M=SD_[%\4_P#0Q7'_ (%2T?V+XI_Z&*X_\"I:ZRBC^S<-V_$/K%3N<G_8OBG_
M *&*X_\  J6C^Q?%/_0Q7'_@5+7644?V;ANWXA]8J=SD_P"Q?%/_ $,5Q_X%
M2T?V+XI_Z&*X_P# J6NLHH_LW#=OQ#ZQ4[G)_P!B^*?^ABN/_ J6C^Q?%/\
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MQ3_T,5Q_X%2UUE%']FX;M^(?6*G<Y/\ L7Q3_P!#%<?^!4M']B^*?^ABN/\
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M.YR?]B^*?^ABN/\ P*EH_L7Q3_T,5Q_X%2UUE%']FX;M^(?6*G<Y/^Q?%/\
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M?^ABN/\ P*EKK**/[-PW;\0^L5.YR?\ 8OBG_H8KC_P*EH_L7Q3_ -#%<?\
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MBG_H8KC_ ,"I:/[%\4_]#%<?^!4M=911_9N&[?B'UBIW.3_L7Q3_ -#%<?\
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M/YJ-6_Y+?XV_["5]_P"E!K<K#U;_ )+?XV_["5]_Z4&MROK\K_W?YL\G$_Q
MHHHKUCE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **GL;&YU*\AM+.WEN[J9@D4$"%W=CT"J.2?85[-HO[%/QQU^T6YM?A
MMK,<; ,!>*EJV#_LRLK=O2HE4A#XG8I1<MD>)45VGQ ^"_COX5L@\7>$M6T!
M'("3WEJRPN3V63&TGV!KBZJ,E)7B[B::W"BBBF(**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG]](F<E6Z9Z5F^/OA!XP^&'CD>#O$FBR67B9O*VZ=#+'<NYEQY84Q,P8MD8
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MT^7RKFTFQN1L CD<$$$$$$@@@@D&DJD7)P3U0^5VO8Q****LD**** "BBB@
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MUINE'18+^U*);6DKJ%=0,[BRJSDOU\P=^6KL6-J2JNC"%VC+V,5%3<C\WYO
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M%=-V(C0;FX,_':+X:>+Y_"[>)8_"FMR>'%!+:PNG3&T&.N9MNS]:_2?X-?\
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M%YJ]V]P8]VX1)TCC!]$0*H]E%%#$NO4G&*]V/4)T^2*;>K.1HHHKN, HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OTJ_X),?"'[-I?BKXE7L&)+EAHVFLPY\M=LD[#V+>4N?\
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M\J,$\+\I*ID*H4DG.YCY3X;_ ."M?@G4O$<-IK'@W5]&TB238=22XCN&C!.
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M[#FNNA*'UNI[MG;>_H934O91U/G_ $[3;O6+Z&SL+6:]O)CMCM[>,R2.?15
MR3]*ZS7/@C\1?"^GO?ZSX!\4:38(I=KJ^T:YAB51C)+,@&.1S[U^O/PS^$_P
MO_81^$,VM:M/:V]S#"HU;Q)/"6N;N4_\LXP,L%+<+&OIDY.6KD/!W_!4#X.^
M+/%$6CW,6N^'K>>011:IJUK$MMD\ N8Y79 3W(P!R2O.%]?J3;=&G>*ZA[",
M=)RLS\@*T='\-ZOXB,HTK2[W4S#CS/L=N\NS.<9V@XS@_E7Z6?\ !0S]C?P]
M>^!M2^*7@K38-+UC30+G5K2R3;#>VY(#3!!\JR)G<2,;EW$Y(&>6_P""/_\
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M*&#(VT="6]<#Y!KV:-55J:J1ZG)*+A)Q84445J0%%%% !1110 4444 %%%%
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M_CC&3C<V&8@<^&Q-6L[3IV5KW-*E.,%[LKGC-%%%>B<X4444 %%%% !1110
M4444 %%%% !1110 58^!/_)Y'P@_['#0_P#TMAJO5CX$_P#)Y'P@_P"QPT/_
M -+8:\?-?X"]?\SKPOQG]&=%%%?)'JG\U&K?\EO\;?\ 82OO_2@UN5AZM_R6
M_P ;?]A*^_\ 2@UN5]?E?^[_ #9Y.)_B!1117K'*%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7VQ_P2E\=VOA[XY:WX=NI%B;Q!
MI3"V+-C?-"XD" =R8S*?^ U\3UK>$_%6J>!_$VF>(-$NWL-6TVX2ZM;F/JDB
MG(.#P1Z@\$9!K"O2]M2E3[EPER24C[R_X*P?!G4H_%'A_P")EE;23Z3-9KI.
MH21C(MYD=FB9O0.'*YZ9C ZD9_/>OV:_9U_;-^'?[3GA%- \2OIND^*+F'[-
M?^'=4*^1>Y&&,&_B1&Y^0Y8<@@@;C4\3?\$S?@AXBU*2[M],U;0@[;FM],U%
MA%GV$@? ]@0.>*\:AC?JL?8XB+31V3H^T?/3>Y^0OA7PIK'CCQ#8Z%H&G7&K
M:O?2"*WL[5-SR,?Y #))/  )/ J#7-#U#PUK%YI6JV<VG:E9RM!<6MPA22*1
M3@JP/0@U^V_A?X7_  0_8Q\.76M0PZ9X4C9-L^L:G<&6[G _@5G)<YX_=QCD
MX^7-?EY^VM^T!X:_:'^+)USPQX=CTJRM8OLIU1U*76J8P%DE7. % VJ,;MOW
MC]U5[L/C'B:C4(>[W,:E%4XZO4_4']JH7-]^QWXU/A7<5DT!7@\G))M,(9 -
MO8P[_P *_#ROU"_8'_;6\.ZYX'TWX8^/]2M]+UC3819:;?:@ZI;W]L!M2%F;
MY1(JX0 _>4+C)S7INO?\$T_@CXB\32:TFGZIIT$SF5M,TV^\NS)//RKM+*/9
M6 &> !BO.P]99>Y4JR>]T^YO4@ZZ4H,Y'_@D[#J<?P#\0O=+(NFR>()#9>8#
M@X@A$A7/\.X <=PW?-?//@^^LK?_ (*K3RV3A+<^)[Z)B""#*T$J2#\9"P_&
MOKC]H+]J;X=?L@_#7_A%/!PTR7Q):P-:Z5X<TYE=+-N?WEQM/R $EB&.]R?=
MF'Y*^"_B-J_@GXE:3XWMYC<ZUI^I)J9DF)/G2"3>P<]PW(/^\:UPU.==U:UK
M*2LB:DE!1AV/T6_X*[6DC_#[X?704^3'JEQ&S8Z,T0('Y(WY5\Z_\$OX9)?V
MIK1D1F6/2+QG('W1A1D_B0/QK]%;74OA1^W-\'5M7D@UO1[H1SS6(F$=]ILX
MSC<%.Z-U.X9Z,"<;E;FM\)_V<OA)^Q[IFK^(K&;^RS)!Y=YKVOWJEQ"#N\L,
M0JJ"0#A0"VT9S@5QPQ2IX:6&DGS:K[S:5-RJ*HGH?'?_  5VND;X@?#ZW!_>
M1Z9<2,/9I5 _]!-?4W_!.+_DT'P7_P!=;_\ ]+9J_-3]M+X_V_[1/QNO=>TS
M</#]A NF:69%*M)"C,QE*GD%W=V /(!4'D5^E?\ P3B_Y-!\%_\ 76__ /2V
M:ML53=/ TX2WO_F12DI5I-'X^?$+49=8\?>);^:4SS76IW,[RMU=FE9BQ^I-
M?LO^Q'(TG[''@0NQ8_V=<+DGL)Y@!^0K\6O$W_(R:K_U]R_^AFOVC_8?_P"3
M-_ G_8/N?_2B:NC-/X$/7]&9X7XV?DU^RW_R<G\+O^QET_\ ]*$K]%?^"LW_
M ";GX<_[&NV_]([ROSJ_9;_Y.3^%W_8RZ?\ ^E"5^BO_  5F_P"3<_#G_8UV
MW_I'>56*_P!\I"I_P9&E_P $KO\ DV6Z_P"Q@N__ $5!7YD_M$3/<?M ?$R2
M1B[MXFU,EC_U]25^FW_!*[_DV6Z_[&"[_P#14%?F-^T%_P EZ^)/_8RZE_Z5
M2483_>ZP5?X4#V[_ ()N_&3_ (5C^T+9Z-=S^5HWBR,:7,&.%%QG=;/]=^8Q
M_P!=C7VK^T_^QM'\;?VB_AGXM2V1M&5S;^)>!\\,&98<COYGS0D]@4]./R%L
M;Z?3;VWO+65K>ZMY%EBEC.&1U(*L#Z@@&OWV^#WQ*_X3[X)^%_'&J1_V9]OT
MB+4+OSAL6,^7F1O]S(9@?[I!K',%*A45>GN]/Z_KH7A[3BX2/D[_ (*H?&X>
M%?A[I'PUTR?R[_Q PN[]8V *643?*A'4!Y0,>T+#O7Y9UZ=^TI\8I_CM\:?$
MOB^1F^QW5P8M/B<8,=I'\D*D=CM 8_[3-7F->I@Z/U>BH]>IS59^TFV%?='_
M  2G^%*ZY\3/$'Q"OXPMCX;M#;6LLG"BYG!#,#_LQ!P?^NHKX7K].-1_XQ%_
MX)LQVP_T+Q5XPAVM_"_GWJY;W#1VJ[?9D%9XZ3]FJ4=Y.W^95%>]S/9'PO\
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MR@_X)Q?\G?>"_P#KE?\ _I%-7T+_ ,%A/^:2?]Q?_P!LJ^>O^"<7_)WW@O\
MZY7_ /Z135]"_P#!83_FDG_<7_\ ;*NZK_R,:?I_F81_W>7K_D>__P#!-F6S
MD_9'\++;%?.CNKY;K'_/3[5(1G_@!CK\BOBC#JMO\2_%D>N^9_;2ZM="]\W.
MXS>:V\G//WL]:^G/^"?G[8%E\!-;O?"/BZ9XO!FM3B=+P L-/NL!3(P'/ENH
M4-C.-BG&-U?='Q2_8W^#/[3^H0^,Y-YN[Q59M9\,WT:K>J  "YVNCG QN W8
MXSP,8JI]1Q,Y5%[LNI?+[:G%1>J/B;_@E'#J;?M#:S+:K)_9J>'YA>M@[.9H
M?+![;MPXSV#8[U[M^UY)9M^WM^STD>/[062V,W//EF\;R_U$E>WVZ?!/]@GX
M=WBQS6VA1RCSWB>83ZGJCC(4 $[I,9('1%R3\HR:_.?P;\:=3_: _;Q\%>,]
M2B%K]L\164=K9JVY;:W215CC![D#DGC+,QP,XJ8MXFM/$15HI->N@W:G%4V]
M;GV!_P %:)G7]G_PQ&&(1_$T)9?7%K<X_G7Y05^KG_!6K_D@OA7_ +&6+_TE
MN:_*.NW+/]W7JS'$_P 0_:G]G'Q9IW[7'[(-OI^O2"ZN+K3Y?#VLD_,ZSHFS
MS?\ ?*F.8>A8>E9/[$WP%'[*OP6\0:IXO\FPUNZGN+W5KAB-L%K;[UC&[NNQ
M7E_[:^U?+/\ P2=^)5]I/Q2\1^!S'+/I>L6!U ;1E8)H"!N/H&60J3ZA!7O'
M_!43XW_\(-\([/P)I\^S5O%4G^DA>J6,1!?GL7?8ONHD%>34HSC7>%A\,FG_
M %_70ZHR3@JKW1^:_P =OBO>_&[XM>)?&=[YB_VE=,UO#(<F"W7Y88O3Y4"@
MXZG)[UP5%%?4QBHI16R/,;N[LFL[.?4;R"TM8FGN9Y%BBBC&6=V. H'J217[
MY_ 'X60?!?X-^%?!L(42Z;9*MS)'C#W+9>9Q]9&<CVQ7Y4?\$Y_A#_PM#]H[
M2]0NH/-TGPNG]L3EERIE4@6ZY]?,(?Z1M7U;_P %-/VE=>^%]OX4\'>#M=N]
M"UR\9M4OKK3YC%,ENN8XDR.<.QD)_P"N0]:\/'\V(K0PT/5G;0M3@ZC.DO/^
M"6WPRU#79]:G\7>.GU6:Y:\DN_[0M!(9BV\OD6O7<<YKZ0^,'PQMOBU\)/$G
M@J^E\Q=4T][9+B8 E9@,Q2D  9614?@=J_%7_AK3XS_]%/\ %'_@SE_QK[C_
M ."9?[3'B/XC:QXL\&>-/$-[K^IB)-4TZXU&<RR;%(CFC#-S@9B8#W<US8G"
MXF$/:SG?E-*=2G)\J5KGYG:MI5WH.K7NFW\#6U]9SO;W$#_>CD1BK*?<$$?A
M7[7_ +6 ?6_V+_&<L!\XR>'X[C<!U4>6Y/Y FOSY_P""EGPA_P"%<_M"SZ]:
M0>7I/BV#^TD*KA1<J0EPON2VV0_]=J^TOV(OVE/"OQW^#.F>!_$-Y9-XKT^P
M&DWVDWY4?VC;JA19$5C^]#1@!P.0V[(P5)Z,9)U:=+$Q5TM7_7R,Z*Y92IOJ
M?E!\+X9+CXF>$8HD:2635[1411DL3,@ %?K+_P %.+I+?]E/4T<X:;4[*-/K
MYF[^2FMWP!^P'\&_A7XZB\9Z?IE[)=V,OVNTAU&^,MM9.O(=00"=O4%V;! /
M49KY+_X*9_M1:%\1Y-*^''A+4(=6T_2[O[=JE_:MOA:Y562.)''#!0[EB,C)
M4=5-2ZRQN)INDG:.K'RNC3ES=3)_X)*_\EZ\5?\ 8M2_^E5M5;_@K-_R<9X<
M_P"Q4MO_ $LO*L_\$E?^2]>*O^Q:E_\ 2JVJM_P5F_Y.,\.?]BI;?^EEY6__
M #,?D1_S#_,^S?\ @G%_R:#X+_ZZW_\ Z6S5^/?Q OY-4\>>)+V60S2W.I7,
MS2,22Y:5B2<^N:_83_@G%_R:#X+_ .NM_P#^ELU?C=XF_P"1DU7_ *^Y?_0S
M1@?]XK^OZL=;^' _:7]B.1I/V./ A=BQ_LZX7)/83S #\A7P=_P2LELX_P!I
MF\6Y*^=)X>NEM<_\]/-@)Q_P 25]W_L/_P#)F_@3_L'W/_I1-7X]?"+XGZO\
M&?B1H/C+1&7^T-*N!*(W.$F0@K)$W^RZ,RG_ 'N.:Y\/3=7ZS!=7_F74ERJF
MW_6Q]F_\%=8=5_X3_P  2R^8=#_LR=;?KL%QYH,OMG;Y/OQ7P5I\5U/?6T=D
MDKWKRJL"P F0R$@*%QSNSC&.<U^UFB^*O@W^WM\+8K&[%MJ@($\VD33"+4=,
MG QN&#N4C) =<JPR.1D5F_#7]AGX+?L^ZV/&7ESW%SIQ,\5_XEOD:&R.<B0?
M*B KV9LD=0<\TZ&.CAZ7LJD7S+H$Z+J2YXO1FQ^V>RP_L<>.O[<*F?\ LF%9
M>>#<&6(+C_MIMIG[#<C0_L=^ I$.'6PN6!]"+B:OB[_@H=^V9I/Q>C@^'G@>
MZ%]X:L[D7&HZM'G9>S)D)'%_>B4DG=T9@I'"@M]G_L/_ /)F_@3_ +!]S_Z4
M35Q5*,J6$CSJS<K_ (&T9*59VZ(_$MF+,68DDG))K]M/V9/^3(?"O_8LS?\
MH,E?B57[:_LR?\F0^%?^Q9F_]!DKU,T_AP]3EPOQ/T/SB_X)Q?\ )WW@O_KE
M?_\ I%-7T+_P6$_YI)_W%_\ VRKYZ_X)Q?\ )WW@O_KE?_\ I%-7T+_P6$_Y
MI)_W%_\ VRHJ_P#(QI^G^81_W>7K_D>'?\$W?C)_PK']H6ST:[G\K1O%D8TN
M8,<*+C.ZV?Z[\QC_ *[&OM7]I_\ 8VC^-O[1?PS\6I;(VC*YM_$O ^>&#,L.
M1W\SYH2>P*>G'Y"V-]/IM[;WEK*UO=6\BRQ2QG#(ZD%6!]00#7[[?![XE?\
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M^_\ 2:2O<_\ @L!_R$OA7_URU/\ ]"M:\,_X)K_\G;^&/^O2^_\ 2:2O<_\
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MBL_,+Q=XLU7P+\?O$'B'1+MK'5],\1W5U:W"<E)%N'(X/!'8@\$$@\&OTU^
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MS)_::MC,L48,UL,=P)Q@CTD-?BAI]_<:7?VU[:3-;W=M*LT,R'#(ZD%6'N"
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MGW @Z[/M'F#S?;.SRO>OS]K]M?#WC7X-_MY?"Y--O!:ZH' GGT2YF$>H:;.
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MNU4$]!Y<)P/Q)_.OC[X)M:K_ ,%+W-YM\G_A,M8"[L8\S=<^7^._;CWKZ_\
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MRKW'_@L!_P A+X5_]<M3_P#0K6O#/^":_P#R=OX8_P"O2^_])I*]S_X+ ?\
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MHK\Z?VZ/^3]K#_KKH_\ [3I8>I[;&3G:UU_D%2/)24?,^Q/^"F7_ ":?K?\
MV$++_P!'"K'_  36:S;]DGPR+5E,XO+X70':7[2^ ?\ @'E_G5?_ (*9?\FG
MZW_V$++_ -'"OC'_ ()__MA67P"UB]\(^+9&C\%ZS<"=;Q06_L^ZP%,A Y,;
M*%#8!(VJ1WK"E1E6P+4-U*_X&DI*%97['S1\6EU5?BGXP&NB0:S_ &O=_;/.
MSN\WSFW9SSUS7)U^UGQ6_8_^#7[55Q#XP>1C>7B+G7O"]]&/M:A0%+':\;D
M ;MN< #. !53PO\ LD_ ']F?PSK&IZQ9V,ME<6S07>I^+YXYR8NZ*&4*"?\
M84,>!SQ7?',Z:@EROF['.\-*^^A^27P2DM8?C-X!DOMOV)=?L&GW_=\L7,>[
M/MC-?JY_P4RAU2;]E/5_[.$C6Z:C9O?B,$_Z.).^.WF>5UK\K?C=>>!)/BGK
M4WPPM[^Q\(+/_H/VV4LYQU=,C<J$_=#DL!C)SP/U._9)_:M\)?M/?#.+P?XO
MGLF\8"S^P:GI.HE=NJQ[=IEC#<2!UR64<J<\8P28Y23IXE1TCNAT;6E3;W/Q
MSK]H_P#@G+!J=O\ LE>$AJ0D56FO'M%D!!$!N)"O7L3N([8(KFYO^"9OP+TC
M7I?$-W_;,.EP,;B33+G4U6P10=Q#,4$@0#CF3H.M?2'PO\6^$_&7@VTNO!%S
M:W7AFU9M/M)+%-MN%@/E%8N "BE=H(X('&1@UQ8[&0Q%-1II[FU&BZ<KR9^+
M?P3_ .3R/!O_ &.UO_Z6"OOK_@K-_P FY^'/^QKMO_2.\KX%^"?_ ">1X-_[
M':W_ /2P5]]?\%9O^3<_#G_8UVW_ *1WE=F(_P![HF-/^%,YO_@D5_R3GQ__
M -A6#_T2:\PTV6SA_P""M#M?%1"=:F5=W_/0Z>PC_P#'RE>G_P#!(K_DG/C_
M /["L'_HDU\A_M?^(=0\(_MH>-=<TFY:SU33=9AN[6X3K'+''$R-^! J81]I
MBZT.Z_R&WRTH/S/L#_@KE#JK_#3P))!YAT5-6F%WMSM\XQ?N2>WW?.QGUK\N
MJ_:'X.?'_P"&'[;GPM;PWXCAT]M7NH1'JGA>^D"R>8N#YL'(9ER-RNAW+QG!
MJCX2_P""<?P1\ ^(E\12V6H:JEH_VE+76KY9+.+;SEE"KN4=<.6'KD5GA\9'
M!T_8U8M-%5*+JRYXO1G6>!8[FP_8=TY?%@97C\"G[:L^0XB%D>'W<A@F <]\
MU\J?\$?_ /D)?%3_ *Y:9_Z%=5I_\%"/VV?#VJ>#[[X7^ -3AUF:_(CUG5K-
MP]O%""&\B)P<.S$ ,1E0N5Y).W,_X(__ /(2^*G_ %RTS_T*ZK+V<XX.K4FK
M<S3M\RN9.K&*Z'C7_!3C49;[]JS5(9)3(MGIEE!&I_@4Q^9M'XR$_P# J^@O
M^"0<C'PQ\2T+$HMY8L%SP"4FR?T'Y5\W_P#!2C_D[?Q/_P!>EC_Z31U]'?\
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MK>[\07<<D=D1SYB!4100.C,"1U!!YKY&_P""C7[8&D_%'[/\./!-^FHZ!97
MN=4U2W?=#=S*"$BC8</&F2Q;HS;<<+DN=7Z]B*?LEI'5L%'V-.7-NSVG_@DG
M<*WP/\76X^_'XB9S]&MH /\ T$U\%_MB63Z?^U%\38I%96;6YY0&&#ASO!^F
M&%>Q_P#!.+]IS1_@CXXU;PSXKNTT_P .>)#%LU"4@16ETA(4R'^&-U8@L> 5
M0G R1]Y_&#]B_P"$W[1OB2T\8ZO!<F_FBCWWVBW@C2^C4?)O.&#?+@;EPV !
MG %.53ZGBYSJ+20E'VU)*.Z.:_X)GQLG[)N@EE*A[^^921U'GL,C\0?RKX _
M9?F2X_;O\.RQMNCD\27CJP[@B8@U^B7QZ^-W@/\ 8N^"(\.^'GL[36+:R:TT
M#P_#)YDHD8'$L@R6V!F+LS'YCD9)-?F=^P\Q;]K+X<,Q))U%B2?^N,E+#)SA
M7KVLI7M^(5+)PAV/LS_@KK_R3GP!_P!A6?\ ]$BOH+X+^???L2^%T\-DC46\
M$QQVAB'/VH6FWC'?S<^^?>OGW_@KK_R3GP!_V%9__1(KE/\ @G+^V1HGAGP_
M%\+/'.IQ:5%#*SZ'JEXX2#:[%FMI'/"'<69">#N*Y!"@\_LI5,%"4%?E;9IS
M*-9I]3\ZY%9)&5P5=3A@PP0?>OT7_P""0=OJ0N?B;/B0:.R6";F!V-.#.?E/
M3(4\_P"\OM7T%\4/^"=OP?\ BSXNN/$\T.JZ'>7LGVBZ30KJ.*"Y<G+.4>-P
M"V<DIMR>>I)/IGP-L_A?X#BU+X;?#B6Q5O#RQS:E:V4AF>.24LH:>7G=*WE-
MD$[@%48 VBML5CX5Z#A!.[W\B:5"4)W;/RY_X*4?\G;^)_\ KTL?_2:.OT4U
M+_E'S=_]DO?_ --)K\Z_^"E'_)V_B?\ Z]+'_P!)HZ_134O^4?-W_P!DO?\
M]-)I8C^!A_E^@4_CF? O_!+G_DZ)/^P)>?SCKO\ _@KK_P E&\ ?]@J?_P!'
M"N _X)<_\G1)_P!@2\_G'7?_ /!77_DHW@#_ +!4_P#Z.%=4O^1C'T_S,E_N
M[]3[(_:Z%S>?L?>.3X8#,KZ(CPBW&?\ 1,QF3&WMY._VQ[5^'M?J-^P1^VIX
M<\1>!=,^&7C[4K?3-;TV$6.G7FH.%M]0M@-L<3.WRB11\FT_>4+C)R*])US_
M ()H_!#7O$SZRFG:II\$S^8VEZ??^79DDY.!M+J/97 &> .*YL/667N5*LGO
M=/N:5(.NE.#.5_X)/PZG'^SYKKW8D73I/$,QLO,!Y @@#E,_P[ACCC<'[YKY
M[^&LEG)_P5:NVL<>1_PD>K9VGCS/LMQYG_C^ZOJ_]H;]JCX>?LB_#4^$O!G]
MFR>)K:W:UTKP]IY#QV+?\]+C!^0 DMM8[G/U9A^??[!=]/J7[9G@2\NI6N+J
MXN;V6660Y9W:SN"S$^I))IT8RJ*OB&K*2=@DU%PI]4SZL_X*\:C/'X*^'-@L
MA%K/J%W/)'G@ND<:J?P$C_G7S5_P35F>/]K7PXJL562SOE<#N/L[G'Y@?E7T
M9_P5\_Y%OX9?]?=__P"@05\X_P#!-?\ Y.W\,?\ 7I??^DTE;8?_ )%[]'^I
M%3_>%\CVK_@KY_R,GPR_Z]+_ /\ 0X*_/2OT+_X*^?\ (R?#+_KTO_\ T."O
MSTKLR_\ W:']=3+$?Q&%%%%>@<X4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'KG
M[)'A4^-/VF/AOI>SS$_MJ"ZD3LT<!\]P?;;&:^_?^"LWBO\ LWX)^%]!1MLF
MJZV)F&?O1PPOD8_WI(S^%?,O_!+?PJ->_::.ILF5T31KJ\5\<!W*0 ?4K,_Y
M&NW_ ."N7BHWGQ,\"^' ^5T_29;\J.S3S;.??%L*\6M^\Q\(]E?^OP.R/NT)
M/N?6WPGU*V_:X_8IM;*_F66]U?0Y-(O)9.3'>Q*8_-/OYB)*/J*F\030_L=?
ML4R1PM'%J'A[05MXF0\/J,WR[QZ@W$I;Z9KYG_X)(_%+;+XS^'=S-PP36[&,
MGN-L4X'_ ) /X&M/_@K9\5/LNB>#OAW:RXDNY6UJ^13@B--T4 /J&9IC]8Q7
MG.A+ZU]7^S>_]?D='.O9>TZVL;7_  2/\5MJ'PT\=^'WD+O8:O%?X8Y(%Q#L
M_G;G]:\,N_#%MX*_X*G1V5XJQV\_BM+^/=C:7N4$\>,]]\H'UZ<UI?\ !)7Q
M1_9_QF\6Z"S[8]3T3[0H[-)!,@ ^NV9S^!JI_P %/M.O/ _[4'A[Q7I<K6=W
M=:5:WL-U'PR7,$TBAA[J$B-=JC;&U*?\R,;_ +F,NS/H3_@K)!J<GP&\.26N
M\Z9'K\9O @/!,$PC+8_ASD<]ROM7Y05^U7P+_:!^'?[:7PJ?P_KT.GS:Q<VP
MBUKPM>-ABRX)DB&=S1[@&5U.4.,D,*Y*R_X)R? 7X;ZK+XLUF;49M(L3]H>U
MU_4HAIT(']\[%)7..'<@XP<C(.6%Q<<)!T:L7=%5*3JOGB]#O_V<8-4MOV*?
M"T>L"1;T>&)"%E!#"$QN81S_ -,O+KY@_P""/?\ S5O_ +A'_M[7W.WB[1O'
MGP?OM>\/7"W>B7NEW#VDZH462,(ZA@I (!QQD#BOAC_@CW_S5O\ [A'_ +>U
MR1;EAZ[:MJOS-7I."]?R/G[_ (*17$DW[7?BY';*PV]@B#T'V2)L?FQ_.O7O
M^"17_)1O'_\ V"H/_1QKQW_@H[_R=]XT_P"N5A_Z10U[%_P2*_Y*-X__ .P5
M!_Z.->M6_P"1>O1?H<L?X_S9^@^D^.O!S?%S7_"=N]O:^-ELK:^NHW0++=VQ
M#+&RMU=4.X$?PELX^;)_,/\ X*8?#_XB:/\ &9O$OB>[?5_"FH?N=#NH4*P6
MD8Y^RE<G;(.6)/\ K.6'0JNA_P %$_&>M?#W]LJP\1^'M0FTO6=.TJRGMKJ$
MX*L#)P1T*D9!4\$$@@@U]B? WXT^!OV\_@KJ7AKQ/8VXUD6ZQ:UHN[#(W\-U
M;D\A=V&5NJ-P<\%O/I0E@U#$I7BUKY?U_P  Z)-5;TWHT?F=^QBUJG[4WPT-
MYM$/]KQA=^,>80PCZ]]^W'O7ZY_M+?%;X;_"?PSI5_\ $W1UU;1KJ\\BW\W2
MTOHXY]C,,JP.TE0^#[&OR7_:+_9[\6?LB_%2T GF>P6Y%]H&OQ+@2^6X92>R
MRH=NY?7!'!%?I#\(OCQ\+OVY_A/_ ,(IXLCL1KMQ$JZEX;N9O*E\Y<'S[4Y#
M%<C(*G<N<-[[XZ*J.&(6L.MC.BW%.GLSS[_ALW]DG_H3[+_PDH?_ (FNA7_@
MHM^SW;^'9-"M/[2L=*:![<6=MHICB1&!!4(I  Y/ ]:;HO\ P2K^#VEZXM]<
MZAXGU:S1PZZ==7L2Q, <E6:.)7(/3A@<=SUKY\_X*$:'^SKX3L8M-\%Z99V_
MQ$5TC>+PU,L=I:Q+C)N4 ,9<C@*NUR3N8X&&PA#"UIJ$.9_H7*56$7)V1RG_
M  2N_P"3FKK_ +%^[_\ 1L%=;_P5R_Y*OX'_ .P(_P#Z/>N2_P""5W_)S5U_
MV+]W_P"C8*ZW_@KE_P E7\#_ /8$?_T>]=TO^1BO0Q7^[OU/M+]CF[L;?]D'
MP#<00FYM8M&9I(8$#M(ZL_FJ%[L7#C'K7A__  V;^R3_ -"?9?\ A)0__$UY
M'_P3K_;,T;X::>_PT\=7Z:;HDMPT^D:M<-B&U=SEX93T1&;+!CP&9MQP01]'
M_$;_ ()Q_!SXP>(I/%=C=:KH1U)_M,R^'KN'[)<%CN:1%>-PI;/\!"_[->=.
MG"C7FL1=)ZIHZ%*4X+DMH87AW]OS]F;P?<2W&@Z3)HD\R>7)+IWAU+=G7.=I
M* $C/:O!_$'QJ\"_'3_@H;\*?%/AB6>32F^QVD[WMOY#&[62<)PW7[T.#Z\#
MD5]"_$3]FO\ 9<_9[^$-W8^,]-M$MGW2I?7EP7UFZEP=H@9=KYXQM4!.,L.I
MK\HWUR+1/&/]L>%S=Z7%9WWVO3#<3+)<6X23=$6=54,ZX7D*!D=*[<+1HU>:
M=+FV:N_,QJSG&RE8_47_ (*R0:G)\!O#DEKO.F1Z_&;P(#P3!,(RV/X<Y'/<
MK[5^4%?M5\"_V@?AW^VE\*G\/Z]#I\VL7-L(M:\+7C88LN"9(AG<T>X!E=3E
M#C)#"N2LO^"<GP%^&^JR^+-9FU&;2+$_:'M=?U*(:="!_?.Q25SCAW(.,'(R
M#EA<7'"0=&K%W152DZKYXO0[_P#9Q@U2V_8I\+1ZP)%O1X8D(64$,(3&YA'/
M_3+RZ_$.OZ!&\7:-X\^#]]KWAZX6[T2]TNX>TG5"BR1A'4,%(! ..,@<5_/W
M6V6-RE5;5M?\R,3HHH*^S/\ @EW\(?\ A-_CC=>+[R#S--\)VWFQLPRINY@R
M1#WPGFM[%5-?&=?L_P#L(_#2U^!?[+>G:GK&RQNM6BD\1:G-*,>5$R QACU
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ME"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_=CT\S>-10@XK=F%1117>8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7]
M)U[4]!E:73-1N].D;J]I.T1/XJ1ZU0HH N:IK%_KEQ]HU&^N;^XQCS;J9I&Q
M]6)-4Z** "BBB@ HHHH **** -31_%6M>'XY(]+U>_TU)#N=;.Y>(,1T)"D9
MJC>7EQJ%P]Q=3R7,[G+2S.79OJ3R:AHHLMP"BBB@ HHHH **** "I;6[GL+F
M.XMII+>XC;<DL3%74^H(Y!J*B@"_JWB#5/$$B2:IJ5YJ4B#"M=SO*5'H"Q.*
MH444 %%%% !1110!-9WUQIMU%=6D\MK<Q-NCFA<HZ'U!'(-7=6\4:SKZHNJ:
MO?:DJ'*K=W+R@?3<369119;@%%%% !1110 5KZ;XOU[1[(V=AK>HV-HQ)-O;
M7<D<9)ZG:"!S6111:^X#Y9GGD>25VDD<[F=CDDGN33*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M58JP9200<@BM/5/%6M:Y#'#J6L7^H0Q_<CNKEY57Z!B<5ET4 %%%% #X)Y+6
M9)89&BE0[EDC8JRD="".AK8U#QSXDU:U>VO?$&J7EL_WH;B]D=&^H+8-8E%*
MR8!1113 T='\1ZMX?:1M+U2\TUI!AS9W#Q%OKM(S3-6UW4M>F6;4]0NM1F48
M62[G:5@/0%B:HT4K*]P"BBBF 4444 %%%% #HY&BD5T8HZG*LIP0?45M7GCK
MQ+J5H]K=^(=5NK60;7AFO971AZ%2V"*PZ*+)@%%%% !1110 4444 %%%% !6
MK%XLUN#2SIL6LZA'IV,?8UNG$.,YQLSCK[5E446ON 4444 %%%% &CH_B/5O
M#[2-I>J7FFM(,.;.X>(M]=I&:9JVNZEKTRS:GJ%UJ,RC"R7<[2L!Z L35&BE
M97N 4JL58,I((.01244P-35/%6M:Y#'#J6L7^H0Q_<CNKEY57Z!B<5ET44;;
M %%%% !1110 J.T;JZ,593D,IP0?6M?4O&6OZU;?9]0US4K^W_YY7-W)(GY,
M2*QZ*+( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#:G\;>(KJQ^Q3:]J<MEM"?9Y+R1H]H& -I;&*Q:**+);
M?9O_  2C_P"3D]6_[%JZ_P#2BVK2_P""M7_)>O"O_8M1?^E5S7QUX3\;>(O
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M-_XT\0:K:?9;W7=2O+7_ )XW%Y(Z=,?=)QTK&HHHLEL 4444 %%%% !1110
M4444 %%%% !1110 4444 %6/@3_R>1\(/^QPT/\ ]+8:KU8^!/\ R>1\(/\
ML<-#_P#2V&O'S7^ O7_,Z\+\9_1G1117R1ZI_-1JW_);_&W_ &$K[_TH-;E:
M7P:_9?\ $7[2W[0/B[P+H6L:?I6IV!OKV2ZU R>4ZQ7*QL!L4MDF0'D=C7T=
M_P .8_BI_P!#YX4_[[NO_C5>UA,=]7I\G)?YG%5HJ<KWL?+]%?4'_#F/XJ?]
M#YX4_P"^[K_XU1_PYC^*G_0^>%/^^[K_ .-5V?VK_P!._P ?^ 8_5E_,?+]%
M?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_BI_T/GA3_ +[NO_C5']J_]._Q_P"
M'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:
MO_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\ 0^>%/^^[K_XU1_PYC^*G_0^>%/\
MONZ_^-4?VK_T[_'_ ( ?5E_,?+]%?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_B
MI_T/GA3_ +[NO_C5']J_]._Q_P" 'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO
M_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\
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M17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\
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MYX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\
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M?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_BI_T/GA3_ +[NO_C5']J_]._Q_P"
M'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:
MO_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\ 0^>%/^^[K_XU1_PYC^*G_0^>%/\
MONZ_^-4?VK_T[_'_ ( ?5E_,?+]%?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_B
MI_T/GA3_ +[NO_C5']J_]._Q_P" 'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO
M_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\
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M17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\
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MYX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\
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M?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_BI_T/GA3_ +[NO_C5']J_]._Q_P"
M'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:
MO_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\ 0^>%/^^[K_XU1_PYC^*G_0^>%/\
MONZ_^-4?VK_T[_'_ ( ?5E_,?+]%?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_B
MI_T/GA3_ +[NO_C5']J_]._Q_P" 'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO
M_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\
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M17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\
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MYX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\
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M?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_BI_T/GA3_ +[NO_C5']J_]._Q_P"
M'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:
MO_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\ 0^>%/^^[K_XU1_PYC^*G_0^>%/\
MONZ_^-4?VK_T[_'_ ( ?5E_,?+]%?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_B
MI_T/GA3_ +[NO_C5']J_]._Q_P" 'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO
M_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\
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M17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\
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MYX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\
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M?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_BI_T/GA3_ +[NO_C5']J_]._Q_P"
M'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:
MO_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\ 0^>%/^^[K_XU1_PYC^*G_0^>%/\
MONZ_^-4?VK_T[_'_ ( ?5E_,?+]%?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_B
MI_T/GA3_ +[NO_C5']J_]._Q_P" 'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO
M_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\ #F/XJ?\
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M17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\
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MYX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:O_3O\?\ @!]67\Q\OT5]0?\
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M?4'_  YC^*G_ $/GA3_ONZ_^-4?\.8_BI_T/GA3_ +[NO_C5']J_]._Q_P"
M'U9?S'R_17U!_P .8_BI_P!#YX4_[[NO_C5'_#F/XJ?]#YX4_P"^[K_XU1_:
MO_3O\?\ @!]67\Q\OU8^!/\ R>1\(/\ L<-#_P#2V&OIC_AS'\5/^A\\*?\
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M8RN6_']:F_D7R^9^@5%?G9\,OVFOC9^R[\?O#OPF_:(O+/Q+H7B1E@TCQ7;
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M_P#1\%?KM7Y$_M7?\I</AU_V,/A?_P!'P5G/8TAN?LC1116!N?C9_P $R?\
MD_SXE_\ 8.UC_P!.%O7Z\5^0_P#P3)_Y/\^)?_8.UC_TX6]?KQ6\-C">X444
M5H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GE^U%<16G_!4_X 33
MRI#$FC(6DD8*H_>WW4FOO#4/'OAG2;?S[[Q%I-G!G'F7%]$BYP3C);T!_*OS
ME_;T^&.C_&;_ (*(?!GP5K[7*:/K&@1P7+6<@CE"B>];Y6((!RH[&O6K?_@D
M#\!X9D=YO%<ZJ<F.35(PK>QQ"#^1J-;NQH[65SQS]N'XG:%^UA^TK\%_A=\,
MKN'Q1?:/JK7-_J^F2"6" .\)<)*O!$<<+2.RDC[H'((KV;_@IM^T)XT_9]TG
MX9:AX2U^YT."^U:9-36VABD:X@18V*?O%/8MTQUZU]"? W]EOX9?LY6L\?@3
MPQ;Z5=W*".YU&5WGNYU!SM:5R6"YP=JX7(''%?'7_!933_[6\._""Q^;_2=:
MN8?E&3\R1#@>O-)W2;!6;2-GP_X._:=_;&MK;XDP?$R3X+>#=0<3:#X<TY7-
MP]B6&V:9E*[F=/F!8L#G(5%(KM/BY\9/'/@O_@H)\%/AKIWB:['A#5M#\W4K
M&2.)OMDJB\'F.VS<&/DQD[2!\O2OL32]-M=%TVTT^Q@2VLK2%+>"",86.-%"
MJH'H  /PKX*_:(_Y2O? #_L -_/4*>PEJSLO^"FGQW\9? 7P-X!U3P?XAF\/
M->Z]]GOYH88Y#);B)F*D.K>F>.:X^PU;]I/]N3[1XG\%>+$^"'PEDE>/1G\D
MMJFIQJQ47#;<,%8YX#JO0 /C><[_ (+-VKWWPG^'%M&,R3>(FC7ZF!P*^^O"
MWANQ\'^&=)T'3(5@T[3+2*RMHE  6.- BCCV HW;#9'YX3?%[X]?L#_%+PO8
M?&'Q9%\3/A1XCNELAKTH/GV+9&YRQ&]64'>48NK*K;2&!QVEYX]^//[;VL:M
M-\'_ !';_"OX/V-U)8VWBF:(O?:V\;%7E@&W<L8(XP4Z8+$[E6?_ (+%6<=S
M^RKI4S ;[?Q1:2(<<\V]RI_1J^HOV<?"=GX'^ /P[T*QB6&WL]!LE(4 ;G,*
MM(YQW9RS$]RQI=;#OI<^%O&7B[]I'_@GQXBT/Q+XX\<-\8/A3J-ZEGJ+W 9K
MFV9LG(WY:-MH8KAV1BN& )4U^DVF:E;:SIMIJ%E*MQ9W4*3PS+T=&4,K#V((
M-?*__!4J".;]BCQL[HKM%<:<Z$CE6^VPKD>^&(_$UZ[^RG?/J/[,/PDN).9'
M\)Z7N)[D6D8)_'&::T=A/57/&/VQOVT=8^%/BS2?A3\*=#7Q?\7M<5?)M=OF
M1:>C\J[J"-SE0S $A54;W.W ;S73_P!D?]K[Q;:MK7B3]I"30-=FQ+_9>F&0
MVT9SG:?*$<:XXR%1A[D<FE_P3ITV#XB_M3?M(_$G6E%QXBMM9.GVGF_,UK#+
M/<;E&>GRV\,8(Z!&'>OT2H^+5@_=T1^;'CS]J']H+]DKPOXF\'_&@PZJ=2T>
M\C\)?$;18%9?MZP,88Y0$"D[@/OH&!Y.]26'T!^R[\7/%WCO]@"T\?:]K4NH
M^+WT?6KEM4>.-7,D-Q=I$VU5"_*L:#I_#SFNK_;P\!:;\0?V2_B7;:E;PS'3
M='GUBUDE',,]LC3*RGLQ"LON'(Z$BO)?V+_^47-C_P!@#Q%_Z5WU&J8:6/GK
M]FO]I#]H_P#:\\&I\.?"7B4Z9K-I-+>>)/B#?PH&M;5R%M[: 1H ';;(<@!C
M@X90K,?6/CCX'_:$_9;_ &7;SQ78?&?6/&?B31-:6^U"2X@26)],8+'LVRJ[
MY5]KL=V K/Z9.E_P1Q\.VNF_LSZ[JR0A;W4O$<XEFVX9HXX(51<]P"9"/=FK
M[?\ $OAW3_%WAW5-"U:V6\TO4[66RN[=_NR12(4=3]5)%)*Z&W9G/?!GXH:9
M\:OA7X7\<:00+'6[&.Z$8;<89",21$]V1PZ'W4URG[67QPA_9Y^ /BSQIO0:
MC;6QM],C< ^9>2_)",=P&.\C^ZC5\M_\$Y?$FH_!'XJ?%#]F?Q-<N]SX?OI-
M4T*68\SVS%=^WL R-!,%'_/20]C5;]LB23]JS]L;X:?L^6#M+X;T!QX@\5&,
M_*!M#;&(^Z1"0JG^]=C/2G?05M3Z3_8CD^(.I_L[^'->^)FO76O>*->4ZINN
MHHXS;6\@'D1!451_JPKG(SF0CL*]XID,,=M#'##&L44:A$C10%50,  #H *?
M5$A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OB3Q%IWA'P[J>N
M:O=)9:5IMM)>7=S)]V**-2SL?8 $UI5\"_\ !6GXY7GA_P"&^A_"/PXDMYXD
M\;3*UQ:VB&2?[''(NU%1?F+2R[5&.HCD'>DW97&E=V/,OV2O@S'^WA\0_C5\
M9?B%:R'1M;2X\/Z'%(N3:[XPHDCSQN@A\E01P6=SU%>@_P#!+KXC:IX%U3Q]
M^SGXPD$.O^#[Z>XTV-\C? 9"MPJ9ZJ)"LJ^HG8]!7GWP(_;<\>? 3X1^&O >
MC_LI^+I[71[41/=&XN8VN9B2TLQ4:><%W9FQDXSC)Q7B_P 7/VF/&5K^U-X3
M_:"_X4YXB^&3:>T%IJZWHFEAU)!NC<&1[>$!V@)CP<_<0C&VLKI:FMF]#]KZ
M^0/VQ/VUM7^%GC#2OA-\)]#7Q?\ %W6@H2U*F2+3E<91G4$;I"N7 )"JHWO\
MN ?J[PWXAT_Q=X>TS7-)N4O=*U*UCO+2YC^[+#(H=&'L5(-?G_\ \$Z=+@^(
MG[4G[2'Q*UI!<>(K?63IUIYOS-:PR3W&Y1GIA8(8P?1&'>M'V1FN[+MG^R/^
MU[XKM6UKQ#^TB^A:[-B7^S-,,OV9&SG:?+$:+CC.U".O4<G@/CE\=OC?\!?A
M;XX^%G[0-K;^)-*\2Z#>6/A[QYI,0V2W)A.R&8*J]>F617!Y.]267]0Z\#_;
MP\ Z9\0OV2_B5;:E;PS'3=(GUFUDE',,]M&TRLI[,0K+QU#D="12:TT&GKJ8
M7_!-?_DR7X9_]<;W_P!+[BN1_8]^-GC?XC?M1?M&^&/$>OS:IH/AG6#;:19R
M11JMI']JN4VJ54$_*B#YB>E==_P37_Y,E^&?_7&]_P#2^XKQ?]@UO)_;9_:R
M@=2LCZVT@_W?MEU_\4*.P=S] :^,/VBOCCXY\&_MZ?!'P)HWB":Q\):];(^I
M:8D4;)<,9IU)+,I8<(HX(Z5]GU^>_P"U<C2?\%.OV<PH+'[$AX]!/<D_I3EL
M*)I_\%FO^37_  O_ -CC:_\ I%?5]BZAINL:U\(+G3_#NIKHOB"[T)H-.U)T
M#BTN6MRL4Q4@Y".5;&.<5\=?\%FO^37_  O_ -CC:_\ I%?5]P^%?^17T?\
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M"#@'!P0""!^F7Q(^(F@_";P+K/B_Q/?+IVAZ3 ;BYG;DXR JJ/XF9BJJO=F
M[U\'ZYX!TSP/_P %CO!MSIEO#:CQ#H-QK-S'", SM:7L+L1V9C!N/J6)ZDFM
MG_@L%KFI/\)? 'A&RN/LMIXB\1*EU)G"L(T.Q6/]W=(&QZH#VI+1,;U:./\
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M?#G@K0+/P]HT3%Q;6BGYW.,N[$EG8X'S,2>!SQ2U>X]%L?&O_!9K_DU_PO\
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MU[]FW]LKX=?M(>#["^TS7;'3/$1C1;_P]>7"QW-M.1\RJK8,B9SM=<@CK@Y
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M3@4*][L':UD%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/W7[4EW\#%TC4QXAMK :@VHD1_9"AA67:/FWYPX'W>HKVROR)T[]LCX66_\
MP4BU3XNOK=R/ L^BK91WWV";S#*+6./'E;=_WE(SBOT#F_;3^%%O\$[?XLOK
MET/!$]\=.COO[/GWF<,R[?*V[\94\XQ4J13B>YT5\U_&7_@H5\&?@@VDP:SK
M5WJ6HZC:0WR:=H]KYT\,$J!XWE#%5C+*RD*QW8(.W'->Z^ ?&EC\1O!.A^*=
M+BNH--UBTCO;9+Z PS".10R[D/0D$'\>*JY-F;]%?,WQD_X*+_ _X*:Y-HFI
M>)9M=UJW<QW-EX?M_M9MV'!5Y,K&&!R"N\L".0*9\'?^"C?P.^-&O0:'IWB.
M?0=8N'$=M9^(+?[)Y['@*DF6CW$X 4L"20 #2NAV9].5X1\0/VJK7P'^U)X$
M^"\GAV:\NO%5B;Y-86[");@?:/E,>PEO^/<\[A][VKK_  S^T)X(\7_&+Q)\
M+],U*:;QEX>MA=ZA9M:R(D<9\KD2%=K?ZZ/@'O[&ODC]HC_E*]\ /^P W\]0
MH;!+N?3?[6G[14?[+GP;OO'+:#-XCDBN8;.&RCE\E-\A(#22;6V(,'G!R=H[
MYK;_ &<OC1#^T+\%_#7Q @TB?0DUB*1CI]P_F-$R2O$P#[5WJ2A(; R".!6G
M\:O''@_X<?#'7?$7CY(I/"-G'&+]9K,W:%7D2-08@K;@6=>,&M/X;^)] \:>
M = U[PL$'AS4;**YT\1P&!?(904Q&0-HQCC Q3ZBZ'1T5YQ\:?VB/AY^SWHL
M>I>/?$]KH:3Y^S6S;I;FY(Z^7"@+L < L!M&1DBOG72?^"N'P"U+5([2>Y\1
M:9 [[3?7>E9A49QN(C=WQ]%)HN@LV?:-%>-^.OVOOA1\/_A]H'CC4/%4-WX7
MUVZ%E8:CI<3WB2S%6;81&"5("MD, 01@X->A?$3X@:+\*_!.L>+/$=P]IH>D
MP&XNYXXFE9$! R%4$GJ.@H Z*BO&=4_; ^$N@_"'1_B9JGBV'3?"FL*YTZ6Y
MAD6XNRCLC+'!M\QB"ISA>."<#FO'/#G_  5D^ .OZ]%ILVHZYHL4K[!J.I:8
M1; YP"3&SLH/J5P.^*+H=F?9-%5=+U2SUO3;74-.NX+^PNHEFM[JVD$D4L;#
M*NK X92""".#5JF2>.?M._M3>%/V4/"6E>(O%VGZSJ-EJ5]]@BCT6&*619/+
M:3+"26,!<(>A)SCBOFW_ (?-?!3_ *%?Q[_X+[+_ .3*^[;W3K34HU2[M8;I
M%.X+-&' /K@BOSH_X*L:/8:?XZ_9T6UL;:V637KD.(854./-L>#@<]3^=1*Z
MU+C9Z'IOPY_X*P?"/XG>/_#GA#2_#OC6WU+7=0@TVVEO+&T6%))9 BERMTQ"
M@L,D G'8UZM\+/VL;3XG?M)?$+X11>&YM/N?"$+2R:J]V)$N</&F!'L!7_69
M^\>E>UP^&](MYDEBTJRBE0AE=+= RD="#C@U\ ?LMWUMIG_!2S]I2\O+B*TM
M+?3YI9KB=PD<:+-;EF9CP  "23THU0:,_1"BOC[QM_P58^ /@W7)=-@U?5O$
MIA)5[O1-/\RWW X(#R,F\?[2Y4]C7O/P/_:)\ ?M%^')=9\!^((=7AMV"75L
MR-%<VK$<++$P#+G!PV-K8."<55T39GI%%%?/GQT_;Q^#7[/>KR:+XD\2M>>(
M(AF72-&@-W<1>TA&$C;I\KL&Y!QB@#Z#HKY'^'__  5*^ /CS6HM,DU[4/"\
MTS!(IM?L3! S'UE1G5![N5'O7UG:W4-]:PW-M-'<6\R"2.:)@R.I&0RD<$$'
M.11=/8+-$M%>5ZI^T[\.M$^,%U\,]0UW[#XJM;!M3N([B!X[>*V6(RM(TY'E
MJ @).6XQ7G/PZ_X*(?"+XL_&"S^'7A.?6]:U6\EDBM[Z#36^QR;$+LVXD.$
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MVOJK.-&U>'[-<R*.K1C)63 Y(1B0.2!3NMA6>Y[Y1113$%>?^//CIX2^&_Q
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M^AZE17CGA/\ :\^%7C'P[XSUZU\41V>C>$+G[)K-[J4,EK';RY8!07 WDE2
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MP;?,8@J<X7C@G YH ]FHKXV\.?\ !63X Z_KT6FS:CKFBQ2OL&HZEIA%L#G
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M&!W=_6@#UJBL+QMX[\._#;PW=^(/%.M66@:+:C,U[?S"*-<]!D]6/0*,DG@
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M<@>.53W!'<'((Z@@@X(HNGL%FMS7HJ.XN(K2WEGGD2&")2\DDC!510,DDGH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >,Z-^RIX3TK]
MI#5?C;/J&LZMXOOK0V44.H30M9V,>Q(_]'18E9#L0KDNW$CYR6S7LU%%(844
M44Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% ')_%;XF:-\&_A_K'C+Q#]H&BZ2B2W36L?F2*C
M2*FX+D9QN!..< X!/%;N@:_IWBK0[#6-'O8-2TJ_A2YM;RV</'-&P!5E(Z@@
MUX3_ ,%!/^3-?BE_V#5_]'QU\&?L"_M4>(_V75\(^$_B<LL'PH\;1O>>'M:F
M;=#I\OFM')ANT1D!$B'[A97X#$M#E9V+4;JY^O%>3_M+?M*>&?V6? %KXO\
M%=CJVH:;<:A'IJQ:-#%+,)'CD<$B22,;<1-SG.2./3U:.19HU=&5T8!E93D$
M'H0:^%O^"QW_ ":OHW_8UVG_ *37=-Z(2W/N#1]4BUK2;'48%=(+N!+B-9
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M![UW% !7RE_PWE:_\-J?\*"_X0R]"[_LW]N_:#N\[[-]HS]G\O\ U6WC?O\
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MY_Z*MZ6M[7*TM>QZ5\3OVSF^%?[+NA?&'6/ 6I6TVI3Q6\GAJZN?L]S:L[2
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MRA^C5]^TX["EN? '[6W_ "DE_9J_ZXG_ -'2UJ_\%:K>Z_X53\/;Z]M+J_\
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M@^5&".%7' !;)R:WOCQ^QS\+?V@/"]WIFN>&+"PU*12;;7--MD@O;:3'#AU
MWC/5'RI],X(]IM;J&]MXKBWE2>WF021RQ,&5U(R&!'!!'.14E596L3=[GY8_
M\$W=!\5^%/V[/BOH7C>_?5?$^D^'9-/NKYWWFX$-S9QQ/NZL#&B$$_,0<MSF
MO3_VB/\ E*]\ /\ L -_/4*S_P!ECQEI7C[_ (*E?'S6-%DCFTXZ(UHLL1!2
M1[>2PMY&4C@@O$Y!'7.:T/VB/^4KWP _[ #?SU"LUL:=3V;_ (*4?\F2_$S_
M *XV7_I?;UI?LZ^-K'X:_L(^"/%FI!FL-#\$PZC.JG#,D5MO*CW.W ]R*S?^
M"E'_ "9+\3/^N-E_Z7V]<SH?A&_\=?\ !+>QT+2XWGU&[^'B"WAB!+2R+;!U
MC '4L5VX]ZOJ3T/%/V)OV>/^&OO$&L?M&?&Z!/%#:G>R0:%H=VI:Q2*)BA8Q
MGAHT8-&B'(RCLP9B#7W[JGPA\"ZWHPTC4/!GA^\TL*4%G/ID#1*#U 4K@?A7
MSK_P2V\>Z5XP_8_\+Z98RQ_VAX=FNM.O[=2,QR&>29&QUPT<J'/<[AVKZWHC
ML$F[GXQ_\%$/V7#^S+KF@KX,N[F#X5^)M46]70I9S(EAJ<2E3LW9;:T4AP<D
M_*0V=J5^D/[>7_)GOQ5_[ [_ /H:U\U_\%D/&6E6_P ._AOX3:2-M<N_$*ZI
M'&""Z6\,,D3$^@9ITQZ[#Z&OI3]O+_DSWXJ_]@=__0UJ=KC['R1_P3)_97TW
MXF?#_2/BI\2XAXJALC)IGA+1]2 EL[&VBE8O,(S\I8SF4 $<%2W)8%?O3XK?
M KP1\9_ U[X4\3^'[&\TV>!H8G%N@EM#@[9(&QF-U))!'OU!(/E?_!..".W_
M &*_ABD:A%-K=.0/5KR=B?Q))KZ2JHK0F3U/A?\ X)/>)M7M_AI\0/AOK%R]
MW+X&\1RV5N[?\LXG+9C4=@)8IF_[:&ONBO@'_@F.Q_X7%^U.,\?\)6AQ_P!O
M%_7W]1'8);A7YU_\%8_^1\_9O_[#]U_Z-L:_12OSK_X*Q_\ (^?LW_\ 8?NO
M_1MC2EL$=S]%*_':X^#NK?M _P#!2KXJ^ (-7O-(\+ZC>RW/B9K%PDD^GPF)
M_*SZ/-Y*^@+!B#MQ7[$U^>7[)\$;?\%0/VBIBH,J6,J*W< W%J2/_'1^5$N@
MXZ7/M_P3\(O!7PW\,1>'?#/A;2M&T6./R_LEO:J%<=<N2"7)/)9B23R237PC
MXX\#Z;^R?_P4J^%^J>"K5-#\-?$6"33]1T>S41VQF9C&VQ!PJ[S;2;1T96QP
M<5^CE? /[>S%?VT?V2L''_$^ _\ )RTIRV".Y[1_P4(_:'O?V<?V<M3U?1I'
MA\2:U.NBZ7<1GFVEE1V:?ZI'&Y'^ULKS;]C;]FKX,_!SP'I>O>+M4\+^)?B7
MJT"WFJZEK-]!<O;2R8=H8P[$*5)PSCYF.XDX( YO_@LIX<OK[X(^"M<BA:YT
MO2=?VWL(8@8EA8(S8Z#*%<]C(/6NU\(_\$U_V8?''A;2?$.C>&[R]TK5+6.\
MM;B/7+IE>-U#*<^9Z&IZCZ'I_P :/AG^S_\ 'KPK<:'XJN/"<F]"L&HV=[:P
MWMHW4-#,#E2#S@Y4]&!'%?/G_!.;XA:I\.?BM\1?V;]9UY?$UCX:W:EX<U2.
M998VL]R;D5@2 "LT,@0$A291VKTK_AU;^SG_ -"E?_\ @ZN__CE7OV;_ -G/
M]F[X;_%[79_A9<1-XY\.K)I^IV<>M3W$ELKA=ZO$[D$9P-P! 8$9# @/6]Q:
M6/C[]J;X4R?'#_@J;8>!&N[BST[6;2R34FMI#&SV4=KYTZ9']Y(B!G(R1P:_
M4?P?\-?"GP_TVPL/#?AS3-$M+&'R+9+*U2,QH<9 8#)S@$DG)(R<FOA:2%9?
M^"RT3$G,?AS>,>OV C^IK]#:(]0ET/S-\1Z#J'_!1?\ ;8\2^$]7O[J#X-_#
M"=H+BQM9"@N[D.8F!8?Q2R1RX;M%$0N&8D_?WAOX*^ /!^@+HFB^"M!T[20@
M0VD&G1!' _O#;\QZG+9)))-?$?\ P3MU"'X:_M3?M(?#/6S]D\0W.L?VE9K-
M\K74$<TY+#/)REQ#(/578]J_1"B/<)=C\Z?^"AG[&ND^"?A]XB^+7PFMD\':
MO;V<EKXBTS2\0VFHZ=,OES'R0-BL,JQ  ! +8WJ"???^":__ "9+\,_^N-[_
M .E]Q71_MT>,M*\$?LE?%"ZU:2-8[W1+C2[='(S)<7*&&(*.Y#.&XZ!2>U<Y
M_P $U_\ DR7X9_\ 7&]_]+[BC[07]T_/_P#95_9UO?VG_P!H_P"*WAK6]2NX
M/A=I'B.?5M=TVUG,1O[GS[A+6(D<]/..>P#8P6!'ZS^&?@QX"\&Z(FD:)X,T
M+3=-6-8C;P:?$%=0,#?\N7..[9)[U\,?\$N_&6E6_P ;/VBO"LCQQ:U<ZZ^H
MP*?O30QW%Q&^/78TB?\ ?ROT9HCL$MS\[/V[/V4;3X'V=O\ M!_!*WC\%>)_
M"]Q'<ZE8:5&([6> N%,JPK\HP6 =  KHS$C(.[ZU\%_M&:3XE_9=M?C/<6YA
MTT>'I-;N[2%MQ1H8V::%2>I#QN@]<"N4_P""@GCS2O /[(OQ$EU2:-'U73WT
M>SA<C=-<7 V*JCN5!9_8(3VKQWX>_"_Q O\ P2/;PQ'#,NM7/A2^U&*#D2/'
M+/->(@&,Y:)PH'^UBC9Z!NM3RO\ 8Q^'/@[]I/Q)K_[0'QXUG1M9UG4]2D31
M/#^LW\?V>TAC; 8Q.WS(IS&B,-H$98ABP(^Z=<@^"/B3P_+H6J?\()?:-(NQ
MK&9[-HL>RYP",\$<CM7PK^P7^Q?\ ?VCOV=='\1Z[H<]_P"++>XN++6/L^KW
M$>V596,>45P%S"T1X&.37T1_PZM_9S_Z%*__ /!U=_\ QRE&]ANUSYX\*IHW
M[!_[:WA+2/ GB9=9^$7Q+D6QFTN+4$NA87;2"-,D,>(WDB(=OF,<CJ2Q7<?5
M/^"QW_)J^C?]C7:?^DUW6F?V'_V2_AS\5/#&@3(-'\<73+J&D:?<>(+E9IFB
MD&UD!DP3N'"]6VM@':<2?\%<]%DU7]D2:Z2-G73==LKN1@/N*?,AR?QF _&B
MVC#JC[ \*_\ (KZ/_P!></\ Z *P/C5_R1OQY_V +_\ ])Y*M?"G6H/$GPO\
M(:K:S"XMK[1[2YCE# [U>%&!R/K6-^T1J\&@_ +XDZC<R)%#;>&]1D+2' XM
MI,#ZDX '<FK(/G7_ ()*_P#)GVG?]AF^_P#0UKRG_@J1X-\/Z#XE^ "Z9H6F
MZ<MSXCE2=;2TCB$J[[7AMH&X<G@^IKV3_@E-I,^F_L:^')ID9%OM0O[F/<,9
M7SVCR/;,9KS3_@J__P C/^SO_P!C++_Z':U#^$O[1]YZ)X1T+PS)*^CZ+IVE
M/* LC6-I'"7 Z E0,U\+?\$<O^2-_$3_ +&N3_TGAK[_ *^ /^".7_)&_B)_
MV-<G_I/#5=42MF<OXLTN^_X*+?ME>(O!6H:C<6WP7^&,QBO;.SE:)K^[RT9R
M?[S2)*H;^&.)MI#.2?O7P-\&_ OPST6+2O"WA'1]#L8XQ%Y=I9HK.N,?.V-S
MD]RQ)/<FOA[_ ()PZO;_  ^_:8_:,^&NN,MMXHGUIK^W\SAKN&*><.P)Y(VS
M1.!W61CV-?HG2CW'+L?,/[2W[ ?@+X\+;:QHD</P[\>V=S'<VWB;0[41R%E<
M,3+&A02-QD/D.I"X;&0?H_0-/N-(T/3[&[U&?5[JVMXX9=0NE19;EU4 R.$
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M/AYX^TS]H'X(Z9XGT*<)9>)-)+1G=DV\CH4>-B/XHWW*?=33CV%+N? OP-\
MC_@I-^T1XO\ BG\0&N+WX5^%;PZ;X>\/F1DAG(.Y5<#MLV22#@LTJ#.U=M?H
M=:?"/P+8Z"NB6_@SP_!HRKM&GQZ7 ( ,8QLV[>GM7Q7_ ,$?/$MMIOPM\??#
MF_46/BSP_P"(YKF\L)1ME"21119(/)*R6\BMZ?+GJ*_0&B.UPEO8_*'_ (*4
M?LDVGP&\':CXY^%^_P />$/$<\.G^*?#=M)BT+"59K>:.,\*HE3&T?=+#: K
M,*_0S]E7_DU_X/\ _8G:/_Z10UX3_P %8?&6E>'?V0=:T>]DC_M'Q!?V5I81
M$C>7CG2X=@.N D+ GMO [BO=OV5?^37_ (/_ /8G:/\ ^D4-"TD#^$_,#]B/
M]GN+]H[]HKXC:=XHGGNOASX9UR;6+W0U<K!?WS32QVRR@8RH59CUZ KT=J_5
M;Q!\!_AUXH\&R^$]1\$:#-X>DA, L$T^*..-2, Q[5'EL.S+@@\@@U\:?\$H
M;1$\0_M"W0^_)XGCC/T5[DC_ -#-?H-1%:!)ZGXV_LP_!G6_B1\?_%_[,^JZ
MY>2_"#P?XAU#6]2T]'*-?_9YEMHHF<8(5V\MBHQT=AA@"/U<7X(_#V/PFWA=
M? _A]?#K1>2=,&F0B KC&-NW&<=^M?&'[$-JC?M\_M2W)^_'?R1CCLUW(3_Z
M"*_06B.P2>I^=?[!.D_\*)_;6^._P3TJXN'\*V]NNL65O<2%_)VO %ZCKY=V
MBENK>6O7%=3_ ,%CO^35]&_[&NT_])KNL#X,_P#*8+XS?]BTO_HG3*W_ /@L
M=_R:OHW_ &-=I_Z37=+[+']I'KG[9'_)BWCW_L6D_E'7RY_P3)_97TWXF?#_
M $CXJ?$N(>*H;(R:9X2T?4@);.QMHI6+S",_*6,YE !'!4MR6!7ZC_;(_P"3
M%O'O_8M)_*.F?\$XX([?]BOX8I&H13:W3D#U:\G8G\22:?VA7]T]4^*WP*\$
M?&?P->^%/$_A^QO--G@:&)Q;H);0X.V2!L9C=2201[]02#\J_P#!)[Q-J]O\
M-/B!\-]8N7NY? WB.6RMW;_EG$Y;,:CL!+%,W_;0U]T5\ _\$QV/_"XOVIQG
MC_A*T./^WB_I]4"V8G@/_E,5\1_^Q4B_])K"L?\ :(UKPSX)_P""F_@C7?B]
M!$? \WAY(-!OM2C#6%K=AW >3=E1MD9LL?N&2)S@ -6QX#_Y3%?$?_L5(O\
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M;7357R[@VZ-<22!<&:23&YI&R<M[X&!Q7Q'^UE>>(?VQOVQ-)_9NTC5+C2/
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M]@H<?CI]??U..PI;A1115$A1110 4444 %%%% !1110 4444 %%%% !1110
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MXI>$-0D\+:3"3EQ',TB[U/4^1Y=QAN@Q /XA7W/^PE\ /^&=?V<?#N@WEO\
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MX,^,OAN;5_"FEV?@SXF:6OVK1->T=!9M]I0[XUF\L ,I8 ;R"R9RIZ@_/_\
MP1SNM2OH_C=<ZR6.L3:Q:27I=0K>>?M)DR!P#NSTXK]%]2U&UT?3[J_OKB.T
MLK6)IY[B9@J11J"S,Q/0  DGVK\_/^"3OB*T\7^)/VA=>T^/R;#5/$D-];Q[
M=NV.1[IU&.V PXHZH$_=9<^!O_*7KXZ?]BHG\M)K[_KX ^!O_*7KXZ?]BHG\
MM)K[_IQ%(*_$#]BW]L'QE^RG\(?%M[I7PQF\7>%YM6BDO=<:XDAM[.9HU1(G
M98V +<8R1]X"OV_K\U/^"0WA+2/'G[.GQ3\.Z_80ZIHNIZN+:[LYURDD;6R
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M/_311W%$M@B]3Z.^"NDV.N?L]?#NRU*RM]0LY/#>F%[>ZB66-L6T1&58$'!
M/X5\7^!_!?AZ7_@KE\0M(?0M,?28_"\4B6+6<9@5OLUB=PCV[0<D\X[FOMOX
M ?\ )!_AO_V+6F_^DL=?'O@/_E,5\1_^Q4B_])K"CL"ZGHW_  4QT>PT']AC
MQQ9Z;8VVG6B3Z>5M[6)8HU)OX"2%4 #)KN?AE\1K'X0_L'^"/&FHIYMIH7P]
MTV^:$-M,S)I\16,'L7;:H]V%<C_P5&_Y,E\=_P#7;3O_ $O@K(\=>%+_ ,:?
M\$J=/TK3(VFO3\-]*N4BCY9Q#:6\S*!W)6,@#OG%'4.AX_\ L._LPQ_M075[
M^T9\<8U\7:GKE[(^BZ3>'?9QPQ.T9=X3D% RE(XF^4*F2&W C[M\0? WX=^*
MO#IT'5O WAZ]T?RVB2SDTV$)&I&#Y>%^0^ZX(Z@UXY_P3=\;:1XR_8]\")I;
MQB72(9-+OH$QF&XCD8G</5E9)/<2"OING'84GJ?F'8^';W_@FS^VAX7TG1[^
MZE^#'Q*F%JMC=3&3[)-N2,DD_P 4,DL3;\9,4A4Y89KV;_@KM_R:,_\ V'[+
M^4M<1_P4UN8/'_QK_9Y^&ND!;KQ1<:Y]L=(^7MH'EA0,Q[*=DC'VA)[5V_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\]?\ !03_ ),U^*7_ &#5_P#1\=>1_L\_
ML[^&/VFO^"<'P^\(>)8MF^RN)K#4HT!FL+D74X29/SP5SAE)'?(]<_X*"?\
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MOCS2OBA\,?"_BO1)HYM+U;3X;J'RB,)E1NC([,C94CL5([5UM4DK";=S\?\
MP#\(_$'P#_X*:?##X?:KK%QK6A:/YY\-W%TX9TTR6&[DCC. .5D:93T&X,0
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M=@YMPHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ K\B?VKO\ E+A\.O\
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MM56;^&=*\ V_P$\*WP:'4=>U2Z,NH+$>JQ#Y'!*Y'RQC)_C2OO>BERCYO(^
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ML<;<%>#TG]K?]K'PI FB>*/V9;CQ!KT8\LZEI%TT=K(<C#'8LR<@'.) ,G.
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M?2E%%&P;F-XR\(Z7X^\):SX:UNV6\TC5K26RNX&_CCD4JP!['!X/8X-?)?\
MP3O^%_Q2_9]'CSX9>--$NO\ A$+'49+SPWKS2Q-#<(7*2*%5RR!P(Y0I P6D
MS@U]FT46ZA?2Q\1?M+?L9^.=+^,'_"\_V>M6AT3Q^W.JZ%<.L=MJV<;B"WR;
MGPN]'PK$!PRN,G*LOVQ/VJ8;<:1>?LMW5QXB4>6VH0W4D=B7P?F *LNW./\
MEMV///'WE12MV'S=S\O?CU^Q=\>_V@?AKXD^(?Q-FCUGXEJEO;^&? N@SQK:
M:5$US%]H)8OL+&,/P';.,EV(4+^@7[/?AW4O!_P"^&F@ZQ:M8ZOI?AG3+&\M
M78,89HK6-)$)!()#*1P2.*] HH2L#=]#XX_X)X?!/QO\'=0^,DGC'0)M#36_
M$/VS3S-+&_VB',OSC8QP/F7K@\U]CT44UH)NY\<?LG_!/QO\/_VN?VA?%OB#
M0)M-\.^)+XRZ3?22QLMTOVB1L@*Q8?*P/S =:^QZ**$K!N?&'PO^!WCG0O\
M@I=\4/B3?^'YK?P1JVA+:V6KM+&4FE\NP&T*&WCF&3JH^[]*V/\ @IO\&_&7
MQQ_9[TOP_P"!M#F\0:Q#XAMKQ[6&2.-A"L%PK/EV48!=1USS7UO12MI8=];G
MA_[3G@+7_''[)/C#PGH6G/J'B&]T);6WL4=5:24;,J"Q"]CU/:E_8F\!Z_\
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M]3XX^"OP3\;^&/\ @HC\8_B%J>@36G@W6]'6VT_56EC*7$F;+Y0H8L/]5)U
M^[]*^QZ**-@"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1X,^)Z6L+>$7A_M#Q! =N'OK78+=2O\ $)<Q9&",029^\,_;=%%%K!<^./\
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MYD9X56+#A3U Z5]CT4!<\)_:^_9/T+]K#X=QZ-?7)TCQ#ILC7.C:TB;FM92
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M%5)X!..]='I6E66@Z79Z9IEG;Z=IUG"EO;6=K$L4,$2*%2-$4 *JJ  H&
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M'1410%4#T J74M-L]:TVZT_4+2"_L+N)X+BUN8Q)%-&P*LCJP(92"001@@T
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MKD- ^#O@'PKXFN?$>B>!_#>C^(;DR&?5M/TFW@NY3(=TA:5$#MN/)R>3UHU
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MC-._9<^%Q\;:IH]UK=J+V&R^RV<BQOND#8;+<8&W]:U_V=?C79?M$_!SP_\
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M3I=G&(K:QL8%A@A0=%1% 50/0"I=2TVSUK3;K3]0M(+^PNXG@N+6YC$D4T;
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MB@ HHHH **** /%_VR_ ^N?$K]F'X@>&?#6GOJNNZE8K%:6<;JK2L)4; +$
M< ]3VJ#]B;P'K_PP_9;\ ^%_%&G/I.O:=:S1W5E(ZNT3&XE< E20?E8'@]Z]
MOHI6UN.^E@KX]_X*"_L-VO[3GA(^)/#%O#:_$O2(<6SDA%U.$9/V:1CP&Y)1
MSP"2#@-E?L*BAJX)V,?P;93Z;X0T.TN8S%<V]C!%+&2"598U!''H17P9X_\
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M>'_#MGH&G:?;VFBV=LMG!8QQCRHX54(L87IM"C&*^(?AK\ ?B-^QW^UA?O\
M#OP[=>)/@7XR=9;^QMIX@VBREB RH[J2(R>-H):)MIW,@-?>%%.PKGSA^V9^
MQ[9?M0>'-+OM*U/_ (1CXA^'I/M&AZ\A9=C AO*D*_,$+!6#+\R,-PSEE;P?
M1/VC/VR?@]9IH'C/X&?\+&N+9?*AUS1I"6N5' DD,'F*2<$_<C/(R <U^@]%
M*W4=S\X=9^#_ .TU^WAJ^G6'Q9LK?X0_"BWF6XGT>R<?:[W:<@%"SL7!'!EV
M(N=P1B*_0;P?X1TCP#X5TKPYH%C'INBZ7;):6EK%G;'&@P!D\D^I/).2>36Q
M10E8&[E36-(L_$&DWNEZC;1WFGWT#VUS;2C*2Q.I5T8=P02#]:^.OV!OV'Y?
MV7_&'Q+US6 MS>76H/I>A7#%6<Z6K"02DCHTI*!E[&#WK[0HIV%<*^.+;X)^
M-X_^"FEW\2VT"8>!W\/"S76/-C\LS?9U79MW;\Y!'W<5]CT4!<\A_:@_9I\-
M?M3?#&Y\)Z^6L[E'^TZ;JT*!I;&X (#@$C<I!*LA/S ]00&'R=X+\??M?_LH
M6,?A#7_AFOQM\-:>%@TW6=)NV-RT(P K.H9\!>!YD6X?WF %?H?12L._0^ ]
M<7]JO]LRW'AC5?"]O\ _AM>+LU>ZDN/.U.\A(^>%1D. P.,%(P<D,S#*UK_L
M _LO^)?V<OC9\;TN_#]WI/@R\N8K?P[>75Q'*UW;137&QCM8G.QD)W ?>Z=J
M^Y:*+=0YM+!1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7Y$_M7?\I</AU_V,/A?_P!'P5^NU?D3^U=_REP^'7_8P^%__1\%9SV-
M(;G[(T445@;GXV?\$R?^3_/B7_V#M8_].%O7Z\5^0_\ P3)_Y/\ /B7_ -@[
M6/\ TX6]?KQ6\-C">X4445H9A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?D3^U=_REP^'7_8P^%__ $?!
M7Z[5^1/[5W_*7#X=?]C#X7_]'P5G/8TAN?LC1116!N?C9_P3)_Y/\^)?_8.U
MC_TX6]?KQ7Y#_P#!,G_D_P ^)?\ V#M8_P#3A;U^O%;PV,)[A1116AF%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM_P4B^*WQ>OKM_@9\!-4\2Z!!*T*ZUJJ2LDC#!((BQ'&V/X?-8\CZ5K^"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7Y$_M7?\I</AU_V,/A?_P!'P5^NU?D3^U=_REP^
M'7_8P^%__1\%9SV-(;G[(T445@;GXV?\$R?^3_/B7_V#M8_].%O7Z\5^0_\
MP3)_Y/\ /B7_ -@[6/\ TX6]?KQ6\-C">X4445H9A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?G5_P5XTN]US4/@-IVG7K:;J%YKUQ;VUZC,K6\KFU
M5) 5Y!4D'(YXKF/&O_!-?]I'Q=X?N=.U']HBY\2VTJD-IVM:MJ3VTG'1@S.,
M?\!-=[_P5*_Y'S]FO_L:V_\ 1MI7W_6=KMFE[)'YJ?L<_%K5OV+_ (A:9^SY
M\6/ FE^$&UJ8/IOBS3&8QZE.YVHT\A+"3<<(&!78=JL@!)'J_P#P5@^+6J?#
MW]F^#P]HDLL.H>,=2329)(20_P!E",\J@CGYR$C([J[BO+O^"J&O:=X_^)WP
M6^&_AB87OQ$CUCSP+,>9+8I*T2Q[L="S*'P>@BW' ()]-_X*Q?#75_%W[/&F
M^*=#BDFO?!FKQZK,L:[BML59)' '/R,8F/HJL3THZ-!U3/?_ -F+]G?P]^S3
M\)](\*:+:PB]6%)-5U(1J);^Z(R\CL.2 20H).U0 *]-UG1=/\1:3=Z7JMC;
MZEIMW&T-Q9W<2RQ3(1@JZ,"&!'8UP_[/_P ;-"_:$^%.A>-=!N(I(KZ!?M5L
MCY>SN0!YL#CJ&5L]>HPPX(->@7%S%9V\MQ<2I!!$I>261@JHH&2Q)X  [U?H
M0?F_^R[I,O[)O_!1#QE\%=*NIY? WBBQ;4]-LY22()!%]H0C)_@19X<]6"H3
MTJS^VW;W'[37[;WPH_9_GN[FU\(VT!UC5DMV*F5RDLK]\9$,(16/W3._![O_
M &?=:'[5'_!2;Q;\5]"1YO W@O3&TJQU, ^7<R&,P+M/</ON9!C^$+GK4G[8
M&I2?LS_M\_"GXX:E#*?!6JV9T35+I5++;OMEB<M@=HY8Y .K>4^,XXSZ>1IU
M/T"\-^&M)\':#8Z)H6G6VD:18Q"&VL;.(1Q0H.BJHX KBOV@/@1X9_:+^&6K
M>#O$MK&\5U$QM+[R@\UA<8^2>(GD,IZX(W#*G@FN_P!.U&TUC3[:^L;F&]LK
MF-9H+FW</'*C#*LK#@@@@@CK7*?&+XL^'_@?\.=;\9^)KM+72],@:3:S //)
MCY(8P>KNV% ]3Z9K0S/DG_@DS\1];UCX3^+_ (=Z_-)<7O@/5_L4+2$DQV\F
M_;%D\X62*;'H"!T%>=?"'XP+_P $]_V@OB3X(^+&F7EEX0\9ZY)K>C>+X86F
MB97=O]9@%F&UE#!<LC Y4APP]%_X)/\ @G6HOAOX\^)FNVS6ESX^UQKV"-@1
MOAC,A\T9YVF2:8#U"9[U]@^-/ WA'XQ>$[K0_$NDZ;XIT&X9HY+>Y19HQ(C%
M"5/\+JP8;E(92#R"*A+1%MJ[+_A?7M \9:;:^(_#]]8:S8WT*^3JEA(DJ31@
MD@"1<Y );C/!)KQ/_@H)_P F:_%+_L&K_P"CXZ^;O@#X8?\ 9)_X*'7OP;\'
MZG=WWP[\5Z,^K_V3<3&4:9,(Y'4Y/\0\DH&/)25-VXJ&KZ1_X*"?\F:_%+_L
M&K_Z/CJKW0K69:_8-_Y,]^%7_8'3_P!#:O@[]K#XY>"?$?\ P41MK3XM7%Q/
M\,_A[&L=MIEM;&=;JZ,,<K!T!Z&9E#9X9+=5(Y-?>/[!O_)GOPJ_[ Z?^AM7
MRIJEQIO[,?\ P5*U;4?&,4<?@_XF:<([*_O$5K>*XD,(RY;@$30,A/\ "LRD
MX!S4O9#6[/5X_P#@K-^SW#&D<=]KL<: *JKH[  #H ,]*\$_;2_;+_9K_:>^
M#.K:.AU1O&%G"UQH.HS:0R/!<+@^7YF<B.3&QATY!QE01^FO_"*Z(>1H^G_^
M R?X5Y;^T?\ &#X=_LR?#6[\7>)]-L)-I$-EIL,,0N+^<](XP1Z<D]%4$TW>
MVK$K7T/*_P!FKXNZE\:?^">-UKFM7'VO6[7P[JFEWEPQRTK012QH['NS1B-F
M/<DFO(_^",?PRT_3OA3XQ\?/!&^L:IJO]DQS,H+1VT$<<A53V#/,<@=?+3/0
M8^N-4\6:?X]_97UWQ/I6C76@:?K/A:\OX;"^MT@GC22U<KO1"0"1@\$\$5X-
M_P $AU5?V1P0H!;7[TG ZG;$/Z"CJ@Z,^V****L@**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJ"^OK?2[&XO+N9+:TMXVFFFE;:L:*"68GL  30!\#_\
M%=/V@CX(^%6E_#'2KQ(=7\7/YM_AL-%I\;#@^@DD 7/=8Y!WKK_@!^UI^S%\
M!?@YX6\!Z;\4--EATBT$<TXL;L?:)V)>:7'D_P <C.V.P(':O#_V9/A[IO\
MP4"_:B^)GQE\=Z(-6^'NGG^R=$TV^W")R !$" >J1#S&7/W[@&OL7_A@W]G[
M_HE6@_\ ?M__ (JL]6[HTT6C/A?]C_XV^"/@K^WAXI\'^"?$<.L?"KX@3JNF
MRPJ\<5K=MF2"/:Z@C:SRVXXYWQDGBOU9U;4H=&TN\U"Y)%O:0O/(1UVJI8_H
M*^ /V]?V%?!7AOX#WGC7X4>%+?POXH\)SIJ[R:3O1YK5/];WZQC$H/4"-O6O
MJ#]F7XP6'[4W[-^A^))]OVC5+%]/UBWC(_=72@Q3KC^$,?G4'^%UIQTT%+74
M^2O^":?P_C^/OCSX@_M)>.(8]5\17FM266D1W WK8$(CN\8.<;4DBB0]55''
M>OT>K\ZO^"8/CI/@WXF^(G[.7C"1--\6:3K4U]IZS':+U2B)(L>>ORQQRJ.K
M+*2.%-?HK1'8);GYU_\ !7O]GC0]6^%]M\6M/LX[+Q'H]U#9ZC/#&%^VVLK!
M$,I'5D?8%8]G8?W<?9O[-?\ R;G\*_\ L5-*_P#2.*ODO_@KQ\=-%\,_ M/A
MI#>QS^)?$MU;S362-EH+.&02F5\=-TD<:J#U^8C[IKZT_9K_ .3<_A7_ -BI
MI7_I'%1]H'LCY'_X(Y?\D;^(G_8UR?\ I/#7W_7Y[_\ !+S5K;P#X^^.WPDU
M*9+7Q#I?B.6\BM&;!FB5FAD=!W"E(CD=I%-?H13CL*6Y^>VC_P#*9/7/^Q:7
M_P!(8:M?\%*/^3C/V0_^QKE_]+-+JI\!=3M/B_\ \%4_BSXOT.2.^\/^']$7
M3?MT1W(]PJV\! /0Y:.XP1P0F>]6_P#@I1_R<9^R'_V-<O\ Z6:74]&7U1]_
MU\ >&_\ E,5XJ_[%1/\ TFMJ^_Z^ /#?_*8KQ5_V*B?^DUM52Z$+J>W_ /!0
M;X+^(/CM^S#XA\/>%HFN]=MYX-2M[%6VF[\I\M$/5BI8J.[*H[USG[(O[>'@
M7XR:/I/@W7)5\$?$FQA2PN?#^J+]G$\T:A&^SEL Y(_U1PZ\C! W'ZMNKRWL
M41[F>.W5Y%B5I7"AG8A549ZDD@ =R:^<_P!KW]C7X<?M">#M;U?5].M]%\7V
MEE)-:^*+4"*:-HT++YY'$L8VX(?)"YVE3S0[[H%;9GT99V<&GVL5M:P1VUM$
MH2.&% B(HZ  < 5-7RO_ ,$T_BUXE^,'[+.D:CXKN9M0U/3;VXTI=0N#NENH
M8MIC=V_B8!]A8\GR\G)))^J*:$]- HHHIB"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5^1/[5W_ "EP^'7_ &,/A?\ ]'P5^NU?D3^U=_REP^'7_8P^%_\
MT?!6<]C2&Y^R-%%%8&Y^-G_!,G_D_P ^)?\ V#M8_P#3A;U^O%?@O^S)^U1I
M7[,O[4'C7Q[J>AWFM6FH1ZA9+9VDJ)(C2W<<H8EN, 1D?C7V5_P^K\%?]$WU
M[_P-@_PK:,DD8RBVS]'J*_.'_A]7X*_Z)OKW_@;!_A1_P^K\%?\ 1-]>_P#
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M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
MP-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!
MRL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_
M.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O
M^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_
MX&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J
M_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-
M]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_
MPHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1
MZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A
M]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z
M]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?
MX4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_
M $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\
M#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD
M'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOS
MA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*
M_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&
MP?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\
M/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?
M7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\
M*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]
M'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?
M5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B
M;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4
M?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!
M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
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M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
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M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
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M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
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M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
MP-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!
MRL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_
M.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O
M^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_
MX&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J
M_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-
M]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_
MPHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1
MZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A
M]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z
M]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?
MX4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_
M $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\
M#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD
M'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOS
MA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*
M_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&
MP?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\
M/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?
M7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\
M*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]
M'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?
M5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B
M;Z]_X&P?X4?\/J_!7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4
M?\/J_!7_ $3?7O\ P-@_PHYD'*S]'J*_.'_A]7X*_P"B;Z]_X&P?X4?\/J_!
M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
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M7_1-]>_\#8/\*.9!RL_1ZBOSA_X?5^"O^B;Z]_X&P?X4?\/J_!7_ $3?7O\
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M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
MA+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/
M_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :
MKU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B
M@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK
M_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[
MX(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]
M$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'
M_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X
M2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_
M /&J/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J
M/^&3O@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3
MO@A_T1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_
MT1OX?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX
M?_\ A+V/_P :KU6B@#RK_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\
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M\9?#?]M;X/\ PITF+2V\,>*[=)=0>YMV>Y!,LR'RW#@+Q&O53WKZVH ****
M"BBB@ HHJEK6M:?X;TB\U75KZWTS3+*)I[F\NY5BBAC499W=B J@#))H NT5
M^=OQ&_X*J:MXQ\977@W]G/X:WOQ)U6-]BZQ<P3-;-@\NMO&%D,?^V[QXP3C'
M-5V^)/\ P44>%M6'PS\)I"0?^)6)+/<%QNWX-[O]MN[=_L]Z /T:HK\[_ 7_
M  54U7P1XO@\)_M&?#'4?AGJ,H&W5;6VF\CK@N8) 7\OC[\;2_3O7Z >'_$&
MF>+-$LM8T74+;5=)OHEGMKVSE66*:-AD,K X(/M0!H4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !17&?&KQ3?\ @;X-^//$FEM&FIZ/H%_J%JTJ
M;T$T5O)(A*]QN4<5Y=^P;\:O$W[07[-/A_QMXNEMIM=O;F\BF>T@$,96.X=%
MPHZ?*HH ^A**** "BBB@ HHKYR_;X_:4U7]EG]GV[\5Z#:076OWM]#I.GM=*
M6B@ED5W,K+_%M2)\#.-VW.1D$ ^C:*^/?V6?#_[7%KXRT+6OBWXS\-^(? ^K
M6+W-QIMG!%'>6,KQ[HE.RVC'!(!P[CKUZU]A4 %%<G\7/&%S\/?A3XT\4V4,
M5S>:'HM[J<,,^?+D>&!Y%5L$':2H!P<XK\\OA]_P4 _:S^*WA6W\2>$?@+H^
MOZ%<,Z17UI%<&-V1BK 9G[,"/PH _3FBOS<F_P""D'[0W@"W%]X]_9=UB'28
MDW7%Y:PWMK'&.<L9'AE5?7!/;KSFOI7]EO\ ;R^&'[5073]!O9M%\6K$99?#
MFJ@)<;5'S-$P^651R?E.X 9*K0!]'4444 %%%% !1110 4444 %%%% !1110
M 445\T:O^VQX?TG]M32_@,R0,+K3"TVI^9@PZDP\V*U/.,-",^NZ2-1WH ^E
MZ*** "BBB@ HKY(_X*4?M)^-/V7_ (-^'?$G@:>SM]3OM?CT^9KZV$Z&$V\\
MA 4G@[HUY^M?6] !1110 4444 %%%?%G[>GQ&_::\$^/OAU;? S0KO4]$NRW
M]H/9:6E\LEQYB@17+,A\B'80?,W)G<WS#8#0!]IT5%:M,UM$;A52<H#(L9RH
M;'(!],U+0 4444 %%?$_[(/Q'_:?\5?M(_$?2OBSH%QI_P /[3[0;&6YTQ;:
M"&83JL*6DX13<QM'O)8E_N@Y4G#?;% !117*_%?Q->>"_A;XQ\0Z>(VO])T:
M\O[<3*60R10.Z[@",C*C(S0!U5%?.?[ _P ?O$W[2G[/=IXU\6QV$>L2ZC=6
MK+IL+11;(V 7Y69CGGUKZ,H **** "BBB@ HHKY)^//[4GC+X;_MK?!_X4Z3
M%I;>&/%=NDNH/<V[/<@F69#Y;AP%XC7JI[T ?6U%>=_M#:OXVT'X(^,]1^'%
MD-1\;VVG22:7;^6)"THQRJ$$.X7<50@[F '>O+_V!?&'QI\;?!*6_P#CCIMU
MI_B1=2EBLFU'3UL+R:T")AYH J[3O,B@E5)"@X/WF /I2BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\=OVO/^4O'P[_
M .Q@\+?^CX*_8FOQV_:\_P"4O'P[_P"Q@\+?^CX* /V)HHHH _'7_@ES_P I
M OB9_P!@S6/_ $XV]?L57XZ_\$N?^4@7Q,_[!FL?^G&WK]BJ "BBB@ HHHH
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MO$-L;N_U^ZO&B_L^)9'5F\L(=^ F<9!/2O'?VCO^4MG[/?\ V+[?SU&O/?\
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M5MI=M;-<+=W9BCE8.@XP9G4-GADMU4]:^I(O^"NG[.T,:1QW^O1QH JHNC,
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MIX"_90\)1:OXONY9K^\W+IVBV(#W=ZRXSM4D!4&1N=B ,@<D@'VBOS*_9O\
M!]K^V=^WS\6_B9XTA35_#WP_O5TO0M*NEWP!EEECMWV'((402RE?^>DJMVH
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MLQ#!]@V\LPZ'[M??_P#P3+_Y,<^&'_7&^_\ 2^YKPK]KC_E*-^S;_P!>4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3U*ZT[]EW_@JKK.H>-(88_!?Q0TY8['4+Q%:WBN)#",NS#"D3P.A_NK.K'
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M^#/%O_!-GQ5\-_&VH^*_V;/BK>?#!]1??=>'KO?)8$Y/W2-V4&3M22-\9.&
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M)G_!(;_DS;3O^PU?_P#H:UY\RJW_  6D4E02OAG()'0_8,9'X$_G7U+^QO\
MLXW/[*_P4MO =UKL7B*6&^N+O[=#;&!2)&!V["S=,=<USO\ PR/=_P##;_\
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M0O\ @F7_ ,F.?##_ *XWW_I?<UX5^UQ_RE&_9M_Z\H__ $HN:^P/V6_@K/\
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MRE^R==_LW^-_B[K]SXDAUU/'6L+JD<$5H839@2W+["2[;S_I &0!]WWKZ-H
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M>.U 'T]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'GWQ$_:"^&GPEU>WTOQIXYT+PO
MJ5Q +F*UU2^2"1XBS*' 8\KN5AGU!KG+/]LKX$7TWE1_&#P4K8SF;7+>)?\
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M1U/<5BZ%^T-\+?$]G:W6D_$?PI?P74WV:!H-9MV\R7C]VHWY+_,OR]?F'J*
M/0:**;)(D,;22,J(H+,S'  '4DT .HK&\+^-/#_CBQEO?#FNZ9X@LXI/)DN-
M+O([F-' !*%D8@-@@XZX(K9H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *S=0\2:3I.K:5I=[J5K:ZEJKR1V%I-*JRW31H9)!&I.6*H"QQT S6E7
MXM?MP?M/>,/&7[74_C;P#%=7/AKX+7,-N+R')MTG-P(YWD/3;-+^XX^\D8]3
M0!^TM%<Q\,?B%I/Q8^'OAWQEH4AETG6[&*^M]WWE5U!*-Z,IRI'8@UT] !14
M=Q<16=O+//*D$$2EY))&"JB@9))/  '>O+W_ &K?@M'K/]E-\6O!*ZAG;Y)U
M^USNSC9GS,;L_P .<^U '2?%CXN>$_@?X)O/%_C;5?[%\.VCQQS7GV::XV-(
MX1!LB1G.68#@=^:W?#/B33O&7AO2=?T>X^V:3JMI#?6=QL9/-AE0/&^U@&7*
ML#@@$9Y KY._X*KW,-Y^P[XJGMY4G@EN]->.6-@RNINXB""."".]>\_LR_\
M)MOPH_[%+2?_ $CBH ]+HK&\,^-/#_C:UGN?#NNZ9KUO!)Y,LVF7D=RD;X!V
M,48@-@@X//-;- !7GGQ-_: \!?!WQ)X.T#Q?KW]D:MXONS8Z);_8[B?[7,'B
M0INBC94^:>(9<J/FZ\''4KXV\.OXH?PVNO:6WB)(_-;2!>1F[5,!MQAW;\8(
M.<=#7P?_ ,%-/^3DOV._^QME_P#2S2Z /T*KA;?XX^!KKXM77PQB\00OX[MK
M47LVC>5)YB0E58/NV[,;74_>SS75:]XATKPKI,^J:WJ=GH^F6^WSKV_G2"&/
M<P5=SN0HRS #)Y) [U^;WAWXH^#(O^"NGBCQ(_B[0D\.R>%TA35FU*$6C/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F-_P %>_$3^#_B
M_P#LWZ]'92:D^EZA=WRV4)P]P8KBQ<1KP>6VX'!Z]*Z3_A[;K?\ T;EXP_\
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M#.*]+H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .%^/'C&X^'GP0^(/BFS?9>Z+X?O]0MVQ_P M8K=W3_QY17QW_P $:?A_
M::+^SKKWC%HV?6/$FMR)-<N<EX+=0L:_@[SGZM7VM\4_!H^(WPQ\7^$VD\E=
M>T>\TLR'^'SX'BS^&^OAG_@CS\1%M/AWXW^$.M+]@\6>$]:FG>PE.)!#(0D@
MQGDQS1R!L=-Z>M 'Z'4444 %?-W[>7[5$G[*OP5;5])ACO/&&M7']F:);2#<
MHF92S3,G5EC49QW9D!X-?2-?G-_P5 CBA_:,_93O-;8KX4C\1,MX[G$2#[78
MF0L>@R@[]E/I0!)\!/\ @E_9?$/3U^(/[2&K:QXT\<ZZJ7D^E2WTL*688;A%
M*Z$.S@$ JI5$^ZH. :V_C5_P28\"2:.VM_!2\U+X<>.]-/VG37CU.>6"211D
M(7D=I(F)Z2*_RYY!K[ZHH ^/O^"=O[6&O_'CPKXA\%_$*![3XG^"9A9ZIYL8
MC>ZCW,@E91P)%9&1P.,[2,;L#R+XEX_8G_X*/:'XYCQ9?#GXN(;'5?X8;>]+
M('D/8$2F*8L>TTV,"I?V:88KC_@K=\?[G0SNT:+17CNW0Y3[27L/,4XXW>:L
MWO\ *WO7T=^WU^SU_P -'_LU^(M"L[;[1XDTP?VOHN/O&ZA5OW8_ZZ1F2/'3
M+@]J /HNOSA\.C_AMC_@I5?:TW^F?#GX-*(;7G,4^H+(0K#'4F=7<$<%;5/6
MKNB_\%!O)_X)LS>.Y=0S\1;./_A$?G8&5]4V;8[CW/D_Z0>,95AVKW7_ ()V
M_L^-^SY^S3H5IJ%NT/B?Q!_Q.]8\P?O$EE4;(F[CRXPBD?WMY[T 6_V\OVJ)
M/V5?@JVKZ3#'>>,-:N/[,T2VD&Y1,REFF9.K+&HSCNS(#P:^>_@)_P $O[+X
MAZ>OQ!_:0U;6/&GCG752\GTJ6^EA2S##<(I70AV< @%5*HGW5!P#4?\ P5 C
MBA_:,_93O-;8KX4C\1,MX[G$2#[78F0L>@R@[]E/I7Z,T ? OQJ_X),>!)-'
M;6_@I>:E\./'>FG[3IKQZG/+!)(HR$+R.TD3$])%?Y<\@UW/_!.W]K#7_CQX
M5\0^"_B% ]I\3_!,PL]4\V,1O=1[F02LHX$BLC(X'&=I&-V!]@U^<W[-,,5Q
M_P %;OC_ '.AG=HT6BO'=NARGVDO8>8IQQN\U9O?Y6]Z (OB7C]B?_@H]H?C
MF/%E\.?BXAL=5_AAM[TL@>0]@1*8IBQ[338P*_1ZOG3]OK]GK_AH_P#9K\1:
M%9VWVCQ)I@_M?1<?>-U"K?NQ_P!=(S)'CIEP>U?/.B_\%!O)_P"";,WCN74,
M_$6SC_X1'YV!E?5-FV.X]SY/^D'C&58=J *7AT?\-L?\%*K[6F_TSX<_!I1#
M:\YBGU!9"%88ZDSJ[@C@K:IZU])?MW?M4#]E#X'W&OV$,5WXJU2?^S=%MYAE
M!.RLQF<=TC52V.YV+QNS6?\ \$[?V?&_9\_9IT*TU"W:'Q/X@_XG>L>8/WB2
MRJ-D3=QY<812/[V\]Z\%_P""J30V7QF_99U'62!X4MO$TIU%I/\ 5*OVFP9M
M^>.8UDQGLK4 2?L__P#!,:R^(EBGQ%_:4U#5_&WCO7D^U7&CSW\L$5FKC*QR
M/&5D,BY^ZC*B?="D#-=E\4/^"5/PYDMQKGP=O-2^%/CZPD^UZ;J5EJ-Q- LP
MSA6#NSH#TW1L-N>C#Y3]P44 ?DK^P9XX\:>/O^"DGBO4/B)9+8>-[7PQ-I>K
M1*FS=/:BTMVD('&7\H,=ORDME>"*]Q_X*!? KQ'\.?&&D_M1?"6+R/&7A<J_
MB&RB0E=1LE&TRNHY8*F4D[F,@Y'EY.#\+6TUO^"RWQ1.FE67_A&@+@H05\\6
M]AOQCOGK_M;J^\_B1XV\/?#?P'KOB;Q7=0V7AW3+1Y[V6<!E\L#!7:?O%B0H
M7JQ8 <F@#Y2^+W_!2+PEHO[)FE?$GP?)'>^+/%"MI^C:"Y$DUOJ  $RS(.2L
M)8$\?/NB P) :W?^"??[*%Y\!_ ]]XQ\;&2_^+'C-OMVMWET=\ULKMY@MMQ_
MBW'?(>[G'(137YC? N\T/X4_M$>$/CUXG^&USI7P/UKQ->QZ&TQ,D.FN&/E2
M #[_ )!((R.?)DV9:/C]YK*]M]2LX+NTGCNK6XC66&>%PZ2(PRK*PX(((((]
M: /B?_@L+_R9^_\ V,%C_*6OI_\ 9[_Y(%\-/^Q9TS_TECK=\>_#GPO\4M!_
ML3Q?H&G^)-(\U9_L6I0+-%YBYVMM88R,GGWK9TO2[30]+L].T^VCL["SA2WM
M[>%0J11HH544#H   ![4 ?G5^W%_RD@_9>_Z[6O_ *7&N,_X*A>&_$W[-GQZ
M\)_M#_#Z<Z7?:Q;3:+J%TB;E2[%NT:.PZ$O 2!Z&V!ZU^DOB3X2^"_&'BW1O
M%&M^%]+U7Q'HQ4Z=JEU;+)<6A#;QY;D97#<\=ZM^._AYX8^*'A]]#\7:#I_B
M/1WD64V.I6ZS1;U.5;:PQD>OO0!\'_LG? %_@Y_P3;^)GB#5(2OB;QOX5U36
MKMY.9%MS93?94)Z_<8R<\@S,*[W_ ()#?\F;:=_V&K__ -#6OL;4M!TW5]!N
MM%O;&WN=(NK9K.:QDC!AD@92C1E>FTJ2,=,5F>!/AYX9^%_A]-#\):%8>'-'
M21I5L=-@6&(.W+-M7C)H Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_';]KS_E+Q\._^Q@\+?^CX*_8FOQV_:\_Y2\?#O_L8/"W_ */@H _8
MFBBB@#\=?^"7/_*0+XF?]@S6/_3C;U^Q5?CK_P $N?\ E(%\3/\ L&:Q_P"G
M&WK]BJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOB?XZ?"K]IO7OVV_!/B3P1XEN++X2VWV,WL<>J+#:0Q*^;J*>T+YG>0 [6"'
M[R#*[<C[8KY0^+W[3OC#P/\ MW_"CX/Z=%IC>$_$^E->WSSV[-="0&[^XX<!
M1^X3JI[^M 'U?17R=_P4(_:B\6_LN^$? VJ^%%TLOK&N#3[QM5@:1%A\LL2N
M'7:>.IKA?$'[7GQJ_:-\5:KH_P"R_P"#]-N?">E7!M+KQ_XD^6TN)E/S+;*2
M R].<.Q# [4R"0#[KHK\Y=4_:R_::_8_US2;K]H7PQH_BKX>:A<+:R^)/#:*
M)+5SN/&S:,XR=CQKNVX5L@U^ANBZU8^(]'L-6TRZCOM-O[>.ZM;J%MR31.H9
M'4]P5((^M %VO#/VWOBEXB^"O[+GCGQIX3NX['Q!I<5JUK<2PI,J%[N&-LHX
M*GY78<CO7N=?+_\ P4T_Y,<^)_\ UQL?_2^VH ^9_AKXV_X* ?$7P'HGC;0=
M0\*:QHVL6J7=I!<0V4,CQOT)&U,$=<;OSKTS]G']O3QY_P +NMO@M^T)X+@\
M%>-[X :7J%BK+;W3G.Q&7>ZG?M8+)&Y4L-N :]R_8?N8;/\ 8W^%$]Q*D$,?
MAZW9Y)&"JHQU)/05\;_M6>,-'_:B_P""@/P)\)_#.XAU^^\'7T=[K.M:<PE@
MA1+F*=U\Q<@^4L).0<;Y@F=V10!^H5%%?#W[1G_!0K6M,^*4OPA^ ?@]?B3\
M1H6:.\N'#/96+K]],*R[RN<.Q=$0X!+'( !]PT5^>G]L?\%#O#:C7)M(\%>(
MXA^\?P^AM@RJ%R5!5XR<^TI.1QQUYCXK?\%7=9M?A'IDV@:#;^#OBQ8^(8=(
M\1>%?$EM)(T,+0S,TL(RC%=Z(#N&4)P1RK, ?IE17F7[3/Q%U7X1_ 'QYXST
M-;=]7T32IKVU6[0O$9%'&Y002/Q%?'7@S_@HW\0/BI\./!'AOX9>#;/X@_&[
M5[&2\UA8$:'2-%3SW1&G)D&"5$9VF10-Z_,2P6@#]$J*_.OQ9\1OV\/@;I,_
MC;Q)HW@[QQX;LD-SJ.D:6BF6W@53O8; C\#DE3)C&2"H-?8?[-O[0?AW]ISX
M2Z7XZ\-B2W@N6:"[L)F#2V5RF/,A<C@D95@>,JRG SB@#U&BO#/VL?VN_!_[
M)'@F#6/$*RZGK.H%XM)T&S8">]D4#)W'(2-<KN<@XW# 8D _+^C_ !*_;V^-
M5LGB/P[X3\+_  YT&8B:ST_6(T6XECP2 ZREY!NX&2L?4$ #F@#]$Z*^"M&_
M;J^*/P-U;_A$_P!I;P+:^$;V^AE31?&>E?O-*NIU0E$FP[!=Q R0PQN&Y$&6
M'K?_  3W_:*\5?M/? >X\8>,(]/BU:/6;BP"Z9 T,7EI'$R_*S,<Y=N<^E '
M _L6_&+QI\0/VL/VF?#?B+Q%>:MH7AS6FM])L;A@8[./[7=)M3 X&U$'_ 17
MVQ7YZ_\ !/W_ )/9_:\_[&!O_2V\K[D^)/Q(\._"/P/J_B[Q7J4>E:#I<)GN
M;F3G Z!5 Y9F)"JHY)( ZT =-17YO:7^V'^U'^UI?7UW\ ?A[IOACP)#(\,/
MB'Q&$:29ER,[G;RR>F4C23:>"YK2NOVGOVL/V6)(]7^.?P^TSQI\/5E6.]U[
MPKY?VBT4\>80C!0O_72- 3@;UR* /T/HKXV_9M_;6U#]H3]L#Q[X)T:\TG5/
MAII_A^'5]&OK6W=;F1G6SW"1BW4-/*I7:"I7!Y!KZ%^/7QY\)?LX_#>_\:>,
MKUK;3K8B.&WA :XO)VSLAA4D;G;![@  DD $@ ]$HK\W_#O[17[9_P"U1;'Q
M%\*_!&@_#SP/<'.GW^M[));A-V-V^7/F#@_,D(7&0"36SIW[9GQ__9AUS38/
MVF_A_:R>"M0G^SKXR\,JLBVKD@ RK&[*5[[2L;D9*AR-M '7_L"_&+QI\3/C
MM^T_H_BCQ%>:WIGAOQ)'::1:W3 I90FZU%"B8' VQ1C_ ( *^V*_.O\ X);:
MK9Z[\?OVM]2TZZBO=/O/$UO<6UU X>.:)[K5&1U8<%2""".H-?9'[0W[07A/
M]F?X9WOC3Q?<NEG$P@MK2W :>]N&!*0Q G!8A6.20 %)) % 'IE%?G%X?^.W
M[;G[3-J/$?PZ\%^'_AMX-NB3I\VMJIFFCR"KDS9:0$'AUA52.F>M6C^VU^T%
M^RQX@TVW_:5^'5G<^#+^<0)XM\,*&$+-S\VQV1L -^[(C<@$C=C! /T3HK-\
M-^)-,\8>'M-UW1;V'4M(U*WCN[2\@.4FB=0R.I]""#7PIXP_:G_:!_:(^+'C
M/PA^S=HFBZ?X;\'W3:?J'BO7@I^T72DADC#@J!N5P $<D ,2H8"@#[]KXG_:
M^^,7C3P+^V1^S?X6T#Q%>:7X?\0WXBU73X& CNU^TQ+AQC^ZQ'XUT7[*?Q\^
M/&M_$K5/AG\;OAC)IFJV-I]NB\6:.@&G2QDX57;>49F.0#$V<@@HNUFKQG_@
MHAXDTOP;^VM^S!KNMWT.F:/IMVUW=WEPV(X8DN8F9V/H #0!^CE%? G_  TM
M^TY^U--<ZE\ /!>D^$?ATLCQ67BKQ@ L^H[25,D49) 3(/2-QD8+9RHI^%OV
MTOC7^SA\4O#_ (+_ &H/#6EPZ#X@F^SZ?XTT7:L"/E5S)M.PH"1N&U'4-NPP
MP* /T'KY"_8UN!\4?V@?VC_BM,@D5_$2>#M,D8?ZJVT^,*^P]ED9XW(]17U[
M7Q[_ ,$L%63]F.\O&_X^;WQ1JMQ<;OO>890IW'N<*M 'H?[;GPK\(>._V=?B
M+K7B+PWINM:MH'A/6+G2KR]MUDDL91:.^^(G[C;HT.1W0>E;_P"QW_R:A\'O
M^Q2TO_TECJW^UC_R:S\9/^Q,UG_TAFJI^QW_ ,FH?![_ +%+2_\ TECH \;_
M &U(QX-_:,_9:^(%M^YNT\6MX7GD!QOAOT$>&/HH$A';YC7V)7Q[_P %,OW/
MP[^$=U&=M];_ !-T22U;_IIB?&?;&?R%?85 !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?F?\ \%<=3N?#/Q:_9T\2Q:7=ZK!H
M=_=ZA-#:1EF98KBQDVYQ@$A"!FMO_A\AHG_1&_&'_?:?_$U^BM% 'PM\*/\
M@JEI'Q4^)7AGP?#\*_%&E2ZYJ$-@M]=.AB@,C!=[87H,U]"_M=?L_P /[37P
M#\2^!?.CM-2N8UN=,NIB0D-Y$=T1; )VD@HW!(5V(&<5[)10!^8WP$_X*$:E
M^R;X=TOX0?M$>!O$.A:CX=A&GZ?K5I;B5+FVC.R/<K,N]54!1+$7# +P.2:W
M[1'[>FK?MD:1<?!;]G7PGK>JW/B)!::MKEY!Y"P6K, ZJ Q\N-AE7EE*@*6
M4E@1^F>LZ!IGB*U^RZMIMIJ=MG/DWD"S)_WRP([5'H/A?1O"MI]ET72;'1[;
MC]S86R0)QT^5 !0!YG^SI\(=+_93_9UT'PE->))!H%A)=:GJ"ABDDQ+37$H&
M,[=Q?:,9VA17QQ^PAX5U;]IS]K'XD?M*^+=*N;/3[.X;3?#-K?(5,)*! 0#W
MCM]JDC@M<,1ST_2:B@ J.>".ZADAFC66&12CQR*&5E(P00>H(J2B@#\U_P!E
MG3+[]BO]O#QK\&I8+A?AYXW5=1T"X9',4,F'>!-V,#CSH">K-''[5^E%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?GG^TYIMW/_P %6/V?+J.UFDM8]&0/,L9**?-O
M^"V,#J/SK]#*** "OSS_ ."N6FW>H?\ "BOLMK-<^7XED9_)C+[1^YY.!Q7Z
M&44 %?G[^T5IMW-_P5@_9_NX[69[6/0&#SK&2BG.H\%L8'4?G7Z!44 ?G[_P
M6 TV[U'P'\)EM+6:Z9/%:LPAC+E1Y3<G X%?H%110!\.?\%A;"ZU+]DVTBM+
M::ZE_P"$ELV\N%"[8\JXYP*^Q/A^I3P%X;5@58:9; @]1^Z6M^B@#Y0_X*D6
M<]_^Q'X\@MH)+B9IM-VQQ(68XOX"< 5ZE^R##);_ +*OPABEC:*5/"FF*R."
M&4BVCR"#T->NT4 ?GY^UE^SO\2?@G\?D_:6^!%@=9U*2/R_%'A6)69KV/:JN
MZQKS(KJBEE7YPZ+(H8YVZ/AG_@L9\'+K1BWB?1?%'A?7H1MN=*:R6XVR#.52
M0,N>1CYU0^PK[RK)O_".A:KJ"7U[HNGWE]'PES<6L;R+QCAB,CCB@#\P_P!I
M#XI?%G]OKX2^++KPKX3U+X?_  .\.Z=<:W/J&L1D7GB&:WB:6&%(U."A=5.%
M+*"NXL6"I7O7[%MC<VO_  2VL;6:WEBN?[ \1#R9$*ODW=]@;3SSD?G7VQ10
M!\3_ /!(:QN=._9%2&[MY;67^W[T^7,A1L8BYP:^V*** /@C_@KKX%2U^$OA
M/XM:3J<>A^,O ^M0-87@8++*LKK\D?'S.DB1R@'@*DO')KO_ /@F1\#;CX1_
MLWV6NZTCMXM\<3?\)!J4T^3+LD'^CHQ/)_=GS"#R&F>O'OVRY9/VMOVU/AI^
MSS82--X7\-L/$'BORR=H^4.4?'0B$JBGLUY7Z+0PQV\,<44:Q11J%2-  JJ!
M@  =!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)/VK/C4?V?_
M (#^*O&5O;O>ZM;V_D:7:QQES+>2?)""HZJK'>W^RC5ZW10!\4_\$KOV?[OX
M7_ VX\<^(X)O^$S\>S_VG<S7>3.MH"WD*Q/.7W/,?7S5SR*^UJ** . ^/?P>
MTKX^?"#Q1X#U@*MKK-FT,<Y7<;><8:&8#U214;WVX[U\I?\ !*OXCZ_:^ _%
M'P5\9VL]EXD^'^H2V]NMPC#S+5I7#*K$?,(Y@XS_ '9(P.!7W910!^:WQ4^%
MOQ-_8!^/WB+XQ_";P_+XS^%?BB0S^(_"]J&+V;%B[,%0$JJLSM'*%(C#NC +
M@MWUE_P6.^!EQH0NY[#Q;;ZGM^;2?[-C>4OQE5<2[#ST)8=.@Z5]UUD_\(CH
M7]K?VI_8NG_VGU^V_98_.ZY^_C=UYZ]: /R*_;8U[XU?M=?"'4/B7JWA2\^'
M_P )_#D\#:#X>O$=K[5[B:58?M,B8!PJ.Q#;=H#87?N9Z_4/]FF)X?V<OA5'
M(C1R)X4TI61A@J19Q9!'K7I%% 'YC^-)/'G_  37_:8\<^/]-\*7OC'X(>/+
MEM0U!=-4[M-G+/(<XR(V1I)-N[".C ;@R_+WGB3_ (+*?"5=%/\ PBGAGQ7X
MC\1S )::5+:1VZO(3@*\@D<C_@"N>1Q7WTZK(K*RAE88*L,@CTK*L/".A:5?
M/>V6BZ=9WDA!>XM[2-)&P"!E@,G@D?C0!\9_\$]O@7X__P"$V\??M ?%NQ?2
M?&WCG]U::5-&8Y;2S+*^&1B6C!\N%%1OF581NZU@?\%*M-N[[]HW]D*2WM9K
MB.'Q7*TKQ1EA&/MFE\L0.!P>OH:_0*B@ K\_?#>FW:_\%CO%=X;686C>%$47
M'EGRR?LMMQNQC-?H%10!X=^UY\8/B%\#OAC#XJ^'_@9/'<EG>QOJUJ9&#P6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$T[P1X<T?Q!>
MZ[8:!I=EKE\I6ZU.WLHX[FX!()$DH7<PRJGDGH/2MNBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OQV_:\_Y2\?#O\ [&#PM_Z/@K]B:_';]KS_
M )2\?#O_ +&#PM_Z/@H _8FBBB@#\=?^"7/_ "D"^)G_ &#-8_\ 3C;U^Q5?
MCK_P2Y_Y2!?$S_L&:Q_Z<;>OV*H **** "BBB@ HHHH **** "BBB@ HHHH
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MVJ#C,K#YB> *]GNK6&^MI;>XACN+>9#')#*H9'4C!4@\$$<8-2T4 ?#7C_\
MX)4^%9/&5SXI^$GC_P 1_!?5;DDR1Z$[/;(2<_NU62.1!NP=HDVC "A14_@G
M_@EQX?F\46/B#XP?$GQ5\;+ZQ(:"UU^XD6TS@??1Y)789 .WS IZ,&%?;U%
M'B7@+]E'PS\._P!HWQ=\8-+U"^75?$>F1:5+I.V);*VAC6W5?*54## M4X)Q
MR>.E>M>)O#.D^,M O]#UW3K;5M'OX6@NK&\C$D4T9ZJRG@BM.B@#X'UK_@E!
M9>&_$5]JOP<^,GC#X1)>-NDL["62>-/]E72:&0J 2 '9SSUKM/A'_P $T/!?
M@_QM;>-?B'XJ\0?&3Q;:N'MKKQ1.7MX65MROY3,[.P.?ONRY.=H/-?8E% 'B
M?P"_95\/_L]^._B?XIT;5]3U*\\?ZDNIWT-\8_+MW66XDVQ;5!VYNG'S$G"K
M[UZCXT\%Z'\1/"NI>&_$NEV^LZ%J4)@N[&Z7<DJ']00<$$8((!!! -;=% 'P
M)J7_  2AC\*ZQ=7?P@^-_C7X5VMPYD-E:RR3HC' (5HIH&(V@#YBQX&6-=!\
M*_\ @E7X!\->,+;Q7\1O%&N_%_7K=@T7_"0/BTR#E2\19VDP<G:TA0Y.5-?;
M=% $,]G;W5G):301RVLD9B>"1 R,A&"I4\$$<8KX8\8_\$J]+MO&6HZ[\)/B
MKXG^#L&I/NN]+T9I'M]I^\D92:)E4@M\K%P-V ,86ONVB@#Y^_93_8M\%?LI
M6NJ76D7%[XA\6:Q_R$_$FK,&N)UW;MB@<(F[YB.2QP69L+C5^,'[*OA_XR?&
M3X;_ !&U/5]3LM4\#7'VBRM;0Q^1.WF+)B7<I;&4 ^4CK7ME% !7F/[1_P !
M=(_:6^$^I^ ==U"^TO3;^6"5[G3]GG*8I5D4#>K#DJ >*].HH P/ '@^V^'O
M@3PWX5LII;FST/3;;3(9I\>9(D,2QJS8 &XA03@8S6_110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P#
MV>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/
M^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_
M / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./
M^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>
M@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>
M>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #
M9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B
M:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^
MBOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_
MZ)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_
MX?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__
M ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BO
MR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFG
MA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]Y
MXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\
M#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\
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M /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR
M_P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX
M?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>
M./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9
MZ /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X
M?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\
M\#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z
M)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z
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M]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\
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MWGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\
M V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\
MHFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U
M_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>.
M/^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z
M/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?
M_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_H
MK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)
MIX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?
M>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\
M_ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_
M (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA_
M_P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX
M_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH
M _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]
MYXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P
M-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HF
MGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _
M7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC
M_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C
M_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA
M_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\
M@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:
M>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'W
MGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P#
MV>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/
M^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_
M / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./
M^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>
M@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>
M>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #
M9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B
M:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^
MBOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_
MZ)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_
MX?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__
M ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BO
MR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFG
MA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]Y
MXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\
M#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\
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M /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR
M_P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX
M?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>
M./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9
MZ /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X
M?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\
M\#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z
M)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z
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M]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\
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MWGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\
M V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\
MHFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U
M_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>.
M/^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z
M/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?
M_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_H
MK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)
MIX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?
M>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\
M_ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_
M (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA_
M_P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX
M_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH
M _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]
MYXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P
M-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HF
MGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _
M7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC
M_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C
M_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA
M_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\
M@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:
M>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'W
MGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P#
MV>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/
M^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_
M / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./
M^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>
M@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>
M>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #
M9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B
M:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^
MBOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_
MZ)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_
MX?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__
M ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BO
MR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFG
MA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]Y
MXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\
M#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\
MA]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__
M  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_
M *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#
M]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WG
MCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V
M>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>
M'_\ P-GH _7^BOR _P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?
MZ*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^
MB:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^
M'WGCC_HFGA__ ,#9Z /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_
M /P-GH _7^BOR _X?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR
M_P"'WGCC_HFGA_\ \#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX
M?_\  V>C_A]YXX_Z)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>
M./\ HFGA_P#\#9Z /U_HK\@/^'WGCC_HFGA__P #9Z/^'WGCC_HFGA__ ,#9
MZ /U_HK\@/\ A]YXX_Z)IX?_ / V>C_A]YXX_P"B:>'_ /P-GH _7^BOR _X
M?>>./^B:>'__  -GH_X?>>./^B:>'_\ P-GH _7^BOR _P"'WGCC_HFGA_\
M\#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z*_(#_A]YXX_Z)IX?_\  V>C_A]YXX_Z
M)IX?_P# V>@#]?Z*_(#_ (?>>./^B:>'_P#P-GH_X?>>./\ HFGA_P#\#9Z
M/U_K\=OVO/\ E+Q\._\ L8/"W_H^"K7_  ^\\<?]$T\/_P#@;/7@>F_M":C^
MT_\ \% OA3X]U32;71+NZ\5^'[=K.SD9XU$5W @(+<\XH _?NBBB@#\;/^"9
M/_)_GQ+_ .P=K'_IPMZ_7BOR'_X)D_\ )_GQ+_[!VL?^G"WK]>*WAL83W"BB
MBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK!1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !117QQ^R?\;/&_Q
M_:Y_:%\)>(-?FU+P[X;OC%I-C)%&JVJ_:)%P"JAC\J@?,3TI7&?8]%%%,044
M44 %%<W\1_B%H7PH\"ZUXO\ $MX+#0](MVN;J?&3M' 51_$S,0JKW+ =Z^&/
M^'EGQ4\;6\WB+X=?LX:_K_@6&1\:K,9W:XC3.XCRH61",<@&3&#S4MI%)-GZ
M%T5XI^RK^U=X3_:P\#3:WX?2;3=4L'6'5M$NCNFLI6!*_,  Z-M;:X SM.0"
M"![73$%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7Y$_M7?\ *7#X=?\ 8P^%_P#T?!7Z[5^1/[5W_*7#
MX=?]C#X7_P#1\%9SV-(;G[(T445@;GXV?\$R?^3_ #XE_P#8.UC_ -.%O7Z\
M5^0__!,G_D_SXE_]@[6/_3A;U^O%;PV,)[A1116AF%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^"_#NFZ#HEC#INCZ;;I:VEI N$BB0 *H_ 4]V+9'P==?M,?M4_LOR1ZM\;_
M.F^,OA^LJQWFO>%]GVBU4\>80C !?^ND: G WKD5C?L=^.M#^)G_  4M^-'B
MGPW?QZGH>J^&8[FTNH\@.A.G]0>0P((*GD$$'D5^B]Y9V^I6<]I=P1W-K/&T
M4L,RADD1AAE8'@@@D$'UK\V?V(/A18?!'_@I#\;?!FE1M#I6GZ%))9Q.VXQP
M33V4\:9[[4E4<\\<\TGHT&EF?0O[9O[2_B[X"?$+X(Z+X:BTV2S\9:XVG:D;
M^W:1Q$);5/W9#KM.)WY.>U?4]?G]_P %/'$/Q>_9:E?Y8T\52%FQP/\ 2+ _
MTK] :I;L3V1Y#^UM\5-:^"/[.OC3QOX>2U?6='MXI;9;V,R0DM/'&=R@@GAS
MW%7OV8/B1JWQ@^ '@?QGKJVZ:OK.GK=7*VD92(.68?*I)(''J:X#_@HM_P F
M6_$__KSM_P#TKAK4_8-_Y,]^%7_8'3_T-J.H?9/G'_@B[_R0?QQ_V,I_])8*
M?_P4BO?V@QX#^)L%M8>%C\$?L]IFZ=C_ &GLS;E^-^,_:-P'R_=Q]:9_P1=_
MY(/XX_[&4_\ I+!7O7_!1;_DRWXG_P#7G;_^E<-3]DK[1XC^PG?_ +31\%_"
MF&YTWP>/@]]AC N$9O[1^Q[&V'&_&_=MS\OK73_'#]J3XN^-OCWJGP9_9[T+
M3)]6T&!)M?\ $NM#,%HS $(@)VC&Y020[,2P"X0L?9OV'_\ DT;X3_\ 8 M_
MY5\M?%[_ (3[]@_]J3QG\9]+\+S>-?A/XV$<FNK99\_39%QEV./EPY=E9OD8
M2%"5;#4;)"W9Z1\!?CE^TEX<^,FE?#3XU_#I-5M]5BDEM/%_AU%$$2QC+/,R
MMY>W.!C]VX+#"MN K[-KS#X"_M*?#_\ :2\--K'@;7([_P D+]KT^8>5>6;-
MG"RQ$Y7.#AAE6P<,<5Z?5HEA1113$%?$?_!4[XVWGA+X1Z9\+_#8EN/%_P 0
MKE=/CM[;_6_9 ZB11CO*[1Q ?Q!Y/2OMF::.VADFFD6**-2[R.0%50,DDGH
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MEF)]6I[NPME<^%M>^/7[:W[-EBWB;XC>"M#\>^#;8AM0FTP1"6"/J6S 0T8
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MC[J$CA@3]XUXG^R?^U)X4_:F^&T&N:!LT[5;-5AU706<&6PEQP.,;HVP2C@
M$#'!#*/9(=0M;BZN+6*YAEN;;;Y\*2 O%N&5W*.5R.1GK5+8E[EBBBBJ)"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]HCX?6'BSPEJ$=U;3HOVFS+@SV,Q +0S*/NN#^!'(R"#7:V>EA-#@TV_E.K
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M_!03XCR_"+_@H)\'O&$&AW7B272?#\<ZZ59L1+<9N+U=JD*W/S9Z'I7<P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_(G]J[_E+A\.
MO^QA\+_^CX*_7:OR)_:N_P"4N'PZ_P"QA\+_ /H^"LY[&D-S]D:***P-S\;/
M^"9/_)_GQ+_[!VL?^G"WK]>*_(?_ ()D_P#)_GQ+_P"P=K'_ *<+>OUXK>&Q
MA/<****T,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*"1T)QUKO* "BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\^_BA^V9\5?VA?BUJ7PL_9?LK5H-+8IJOCB[17@B()!,;.&1(\A@&*NTA!*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX*I? 2&U\):;\>O"4?\ 9'C;PI>VK7VH6IV/-;^8$AD/]Z2*4Q 'KL8@DA5
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M]O\ \:1QZ]<?$GP?X)F?,D6@300/Y&['R/LM)E(QG&9'(([=:RO&W[='QB^
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M?)Z $X%3S%\I^B=>)?MJ_%+6/@O^R[X^\7^'YUM-:L;2**TN&4-Y,DUQ% )
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M%O8:=X]\,W]]<N(H+6UUBWDEE<G 555R6)/85\>_\%FO^37_  O_ -CC:_\
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M$F\<_P!A?%[P3:$&_P#[-C7?;Q=6??'!%*@_Z:,CJO<8J>8?*?I!17F_[/\
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M/V>_VCOAK^TYH>G2ZGHVF*NC^(K> <K$?,0,<]/,CF= QX5XX\\L*^V?A?\
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M^WE^SEH>H0K<:??26D5S"XRLD7V_+H?8J"/QK]*Z_/;]L?\ Y2._LT?]L_\
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MZ[9^']&MQ\US>2!=S8)"(O5W.#A5!8]A3Z;B^1\#_L+Z+\2M'_;&^('B._\
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MNY+[85MHH%9(8(=JC"*K8YR3M&>E>FT(&%%%%,04444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,1\^_MW?'8?L_P#[-/BC7+>;RM<U"/\ L?2><-]IG5EWCWC022?]L\=ZI?\
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M8'J%D'5>^Q@RYYQFO,_@C_P36^"WP-\5VGB73]/U/Q'K5D_FV=QXBNDN!;2
MY5TC2-$W+_"Q4D8!'/-?5%%%EN%V%%%%,04444 %%%% !1110 4444 %%%%
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MQ_Z<+>OUXK>&QA/<****T,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF9F^'/#>E>#]"L=%T/3K;2=(L8A#;65G$(HH4'154< 5YM_PS'X/_P"&BO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"R( [<]F<J>X.:^U:*7*A\S(;&RM]-LX+.SMXK6TMXUBA@@0)'&BC"JJC@
M  #IBIJ**HDXB;X->%)_C%;_ !/?3@?&$&D-HJ7F>!;F3S/N_P!\'(W==K$=
M*[>BBD,.O!KX_P#BW_P2]^$?Q&\33>)-"EUCX=ZY,[2O)X:G6*W:0YR_E,I"
M<]HR@]N]?8%%%KA=H^*O /\ P2C^%6@^(H=<\8:SXB^)%]$=PAUVZ MF(.06
M1 ';GLSE3W!S7V?8V5OIMG!9V=O%:VEO&L4,$"!(XT48554<     =,5-119
M+8&VPKB)O@UX4G^,5O\ $]].!\80:0VBI>9X%N9/,^[_ 'P<C=UVL1TKMZ*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^1/[5W_*7#X=?]C#X7_]'P5^NU?D3^U=_P I</AU_P!C#X7_ /1\%9SV-(;G
M[(T445@;GXV?\$R?^3_/B7_V#M8_].%O7Z\5^0__  3)_P"3_/B7_P!@[6/_
M $X6]?KQ6\-C">X4445H9A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN-)5YKN[E:665M[<L[$DGW)KV^@ HHHIB"BBB@ HHHH **** "BBB@ HHHH
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MZ'1113$%%%?"'_!17Q#JNB_M!_LGV^GZG>6-O>>*)8[F*VG>-9U^UZ:-KA2
MPPS<'U/K2;L-*Y]WT45\,>'_ !EK\G_!6;Q-X=?7-2?P_'X829-):[D-HK_9
MK<[A%G:#DDYQGDT-A8^YZ***8@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[X"\$Z1\-O!>B^%M!M([+2-(M([2VAC7 "J,9/J2<DD\DDD\FMZGRBYCP/\
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MF?$;XBW7Q'UB:]:6"\G3"P08 5 6&\DG+'<Q R .A)]AHHJB HHHIB"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5^1/[5W_*7#X=?]C#X7_]'P5^NU?D
M3^U=_P I</AU_P!C#X7_ /1\%9SV-(;G[(T445@;GXV?\$R?^3_/B7_V#M8_
M].%O7Z\5^0__  3)_P"3_/B7_P!@[6/_ $X6]?KQ6\-C">X4445H9A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_(G]J[_E+A\.O^QA
M\+_^CX*_7:OR)_:N_P"4N'PZ_P"QA\+_ /H^"LY[&D-S]D:***P-S\;/^"9/
M_)_GQ+_[!VL?^G"WK]>*_(?_ ()D_P#)_GQ+_P"P=K'_ *<+>OUXK>&QA/<*
M***T,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OR)_:N_Y2X?#K_L8?"__H^"OUVK\B?VKO\ E+A\.O\
ML8?"_P#Z/@K.>QI#<_9&BBBL#<_G=^!WQ)^+WP]_:&\7ZW\*/#][KWC.<7T-
MW96>C2:A(D#7*-*QA0$J ZQC=CC..]?3?_#7/[>'_1+/$/\ X0%W_P#&Z9_P
M2Y_Y2!?$S_L&:Q_Z<;>OV*IW8K(_'C_AKG]O#_HEGB'_ ,("[_\ C='_  US
M^WA_T2SQ#_X0%W_\;K]AZ*?,^XN5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
MHEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;
MP_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N
M?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_
M (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C
M\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]P
MY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF
M?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'H
MHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z
M_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_
M ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%
MW_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/
M_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2S
MQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]
M$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>
M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
MHEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;
MP_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N
M?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_
M (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C
M\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]P
MY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF
M?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'H
MHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z
M_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_
M ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%
MW_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/
M_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2S
MQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]
M$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>
M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
MHEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;
MP_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N
M?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_
M (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C
M\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]P
MY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF
M?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'H
MHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z
M_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_
M ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>'_1+/$/_ (0%
MW_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\ #7/[>'_1+/$/
M_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='_#7/[>'_ $2S
MQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\ ^-T?\-<_MX?]
M$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[_P#C='_#7/[>
M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
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M'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\ P@+O_P"-T?\
M#7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9XA_\ " N__C='
M_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\ HEGB'_P@+O\
M^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;P_Z)9XA_\("[
M_P#C='_#7/[>'_1+/$/_ (0%W_\ &Z_8>BCF?<.5=C\>/^&N?V\/^B6>(?\
MP@+O_P"-T?\ #7/[>'_1+/$/_A 7?_QNOV'HHYGW#E78_'C_ (:Y_;P_Z)9X
MA_\ " N__C='_#7/[>'_ $2SQ#_X0%W_ /&Z_8>BCF?<.5=C\>/^&N?V\/\
MHEGB'_P@+O\ ^-T?\-<_MX?]$L\0_P#A 7?_ ,;K]AZ*.9]PY5V/QX_X:Y_;
MP_Z)9XA_\("[_P#C=>$Z3XW^(_Q"_P""@'PIUGXK:-=:#XQD\5^'TGLKS3'T
M^18UNX!&3"X!&5QSCFOW]K\=OVO/^4O'P[_[&#PM_P"CX*5V.R1^Q-%%%(9^
M.O\ P2Y_Y2!?$S_L&:Q_Z<;>OV*K\=?^"7/_ "D"^)G_ &#-8_\ 3C;U^Q5
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7X[?M>?\I>/AW_V,'A;_P!'P5^Q-?CM^UY_REX^'?\
MV,'A;_T?!0!^Q-%%% 'XZ_\ !+G_ )2!?$S_ +!FL?\ IQMZ_8JOQU_X)<_\
MI OB9_V#-8_].-O7[%4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?CM^UY_REX^'?\ V,'A;_T?
M!7[$U^.W[7G_ "EX^'?_ &,'A;_T?!0!^Q-%%% 'XZ_\$N?^4@7Q,_[!FL?^
MG&WK]BJ_'7_@ES_RD"^)G_8,UC_TXV]?L50 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\R/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !17QW_P4B_:5U;]F?PY\*M>T:607!\6QW%Y:1OM^VV,5O,+B!NQ#"5.
MO1@IZ@5]7>$O%6F>./"^D>(M%NEO=(U6TBO;2X3I)%(H9&_(B@#6HHKR/]JS
MX]67[-OP(\4>.;DQO>VD'D:;;2=+B]D^6%,=QN.YL=%5CVH ]<HKP7]A/XBW
M_P 5OV2_ASXEU:^EU+5;BQD@N[N=MTDLL,\D+,Q[DF//XU[U0 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\U?VR_%FC>!O\
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M#L6IW6BRZOH+:>NI6+;9[0RVYC$T9R,.F[<#GJ!7QG_P6K_Y-9\+?]CG:_\
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M<7&A_&'Q;8>,=5M;QXM-O[8.\[6:\(9Y6 ,CM@D97< ?F9B?E^.[/3_VA?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX8:_-\,_AWHNGVVGZOXZN\G4=5U!((_/\I@=X^<D_(4..6?+!![3_P %;/\
MDRWQ!_V$]/\ _1XKW#]DOP;IO@']F7X8Z-I44,5M'X>LIW:!0%EFEA6667W+
MR.[9_P!J@#Y&U3_@GK^T)X%M6UOP%^U-XCU;Q+$/,-EK;7,5M=.,GYBUQ,O/
MH\;#)Y(KTS]B7]M+7OBOXHUSX1_%O25\-?&'PX&$\(01QZC&F [JH^59!E6(
M4E65@Z?+D+]CU^<?[;NEVW@?_@HE^S#XOT55@US7-1ATN_\ *&&DA%S'!O;'
M4F*ZE3/H@'0"@#[#_:@_:)T+]EWX/ZKXYUR-KQH66VL-.C<(][=/GRX@3T&
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M &/_ (A^(/#6K7>AZW9Q69MM0L93%-$6O8$;:PY&59A]":S_  +\=-0\ ?\
M!/W0?BIKLLWB'5['P9#JDSWDI:2\N3"-OF/U^9RH+=>2:K?\%-/^3'/B?_UQ
ML?\ TOMJT?V<? &D_%3]@GP#X/UV-Y-(USP7;6%R(VVN$>W"[E/9AG(/8@4
M?+?PP_9;_:"_:J^&NE_%K7_VD/$'A/7=>C_M+2M'TDS+8VL).8AMBGC5"P ^
MZI(&-Q8Y%?87[(^G_&W1OAW=Z9\<KG2M1U^QO7MK#4=/D#RWEJH 668J N6.
M<<*Q7&\!LY^._#?C3X[_ /!,>$>'O%V@2?%7X#6TS?8]=TI3]JTN%G)PV?\
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MC-W;KC\I7_.@#]!Z*** "O@K_@L]_P FH:)_V-MG_P"DMW7WK7P5_P %GO\
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M?N >:[W_ (65_P % !P/A-\+P/\ KZ?_ .6%'_"R_P#@H#_T2?X7_P#@6_\
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MX6^+WA,8U*PV>4EW$&"F9$).UE)0.!E?G1E.&PO$?\++_P""@/\ T2?X7_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^,W[(_PB_: F:Z\<^!].U;4B@C_M2/?;7F!]T&:)E=@.P8D>U>(P_P#!(_\
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MW_!7G_DS;4?^PU8?^AM7U[X3\'Z'X#\/V>A>'-(LM"T:S79!8Z? L,,8]E4
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MGTWQG8Z#=V<\L4FF^)+B/3[HJA.)521OF0KAL@G&<-M((KY<^$?B+P_\8/\
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MPK@ E@#]*3? GP)-\7(?B>_AZ$^/(;?[(FLB642>5L*;2H;8?E8CE?Y"N]H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!YAX=_9M\!^%_C5KWQ8L],GD\=:U;_9;K4KJ\EF
M BQ&-L:,Q5!B)%^4# &.A->GT44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP/*QC'\5>T:3JUEKVEV>IZ;=PW^G7D*7%M=6[AXYHV 975AP5((((]:^%?\
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M 4444 %?CM^UY_REX^'?_8P>%O\ T?!7[$U^.W[7G_*7CX=_]C!X6_\ 1\%
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M#86YF8,YCBC5%W$ 9.%&3BM:BB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ()P^!/!?BZP6_T;4M.N$;H)(9!=S[)8V_AD0X(/MSD$@]]_P4._Y,M^*O\
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M\:^;/^"7/PI\7?!S]FFZT'QKH-WX<UAM?NKD6=XH#F)HX0K\$\$JWY5]?44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5'7-:LO#>BZAJ^IW"6>FV%O)=7-Q)PL42*6=S[!03^%7J^$?^"KGQJO]%^&
MN@?!SPHSW'C+XB7D=G]EMS^\^Q^8JE?;S93'&.Q42CM0!\U?LG_MRZQK/[>V
ML>*?$ N['P3\4+S^Q+1+@-Y,#0E4L #]TLFY(WQP#<LQZU^P=?GA^UI^PG:>
M'OV!_#NA^&4:;Q9\,;<ZQ%>6H(DNG;Y]0*GK\QS*O<>2BBOIK]B?]H"/]I/]
MG7POXMEE#ZW'%_9VLIQE;V$!9&('3>"LH'82"@#W6BN;^)'Q T;X4^ ]>\8>
M(9S;:+HMG)>W4BC<VQ!G:H[L3A0.Y(%?F]X%^'?QC_X*BSWWC'QOXMU#X<?!
M%KEX-+\.:02&U!$?!.#\KXY!FD##>&"(!G !^GMKJ%K?>8+:YAN#&VU_*D#;
M6]#CH:L5\!7G_!'_ ,$>%X8]2^&GQ)\<>"O%]JO^BZLUY%*NX<Y=8HXGY('W
M7 XZ&OF[7/BE\7;[]M_X!_#[XMH(_%WA#7H+.?5K&0I!K5M+/&T-QM 53D*1
MN &>A56#"@#]CJ;)(D,;22,J(H+,S'  '4DUYQ^T5\<-&_9S^#OB+Q[K0\Z'
M3(/]'LPX5KNY8[885/\ M.1DX.%W-C -?!?PQ_9!^)W[?VD6_P 3?C]X^UK1
M/#&L#[5HGA+0RL*QVQ.8Y0KAHXU*GY24=W4JS-Z@'Z:V>H6NI0^;:7,-U%G;
MYD+AUSZ9%6*_.WQM_P $G5^'-G)XD_9^^(WB;PCXWLU$D$-_J"^1=;3GRS)$
MB,F?]K>IZ$ $FO9?V#/VK];^/>@^(_!_Q!LUTGXK^"KG[#K5KL$?VE02@G"#
MA6WHRNJ_*"%(P'"@ ^K:BN+F&SA>:>5((4&6DD8*H^I-?F)_P5(^*U[\&?VJ
M/@7XMMXI[^/1K=M0;38[AHENFCN00C$9X) &<'KTKOO#_P#P3[\4?M26L7CG
M]ICQSX@EUO40+JU\':%<);6.BQL#MAPRR#>%(SM ((.YI"2: /O^&:.XA26)
MUEB<!E=""K ]"".HI]?E;\8O@YXE_P""6/B+PW\2_A?XKUK6_A=?:I'8^(/"
MVK3+(,.-V?E54.Y4=5DVAD8*"7#$5^HUKJ]E>Z1#JD5S&VGS0+<I<E@$,17<
M'R>@QSF@"Y5<:A:F\-H+F$W87>8-XW[?7;UQ7YJW'Q$^+G_!3#XF>(-#^&WB
MBZ^&WP'T"Y%I=ZY:"2*\U4D<@$$,Q8 D19551U,FYBH/<VO_  1C^#-OIY7_
M (2?QP=4SO74EU"V5T?@@A1;XQD=^>3ST( /OFBOA#X,_#O]I#]D_P".7ASP
M5_:FH?&?X+:QNB%_=.JW.AJ,9=WD;*!,\('974-L4/\ +3/^"HWA/Q#X)L?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY!_:Z_X
M)W^'_P!H3Q!%X[\(ZU-\//BA:XDCUJP!6*[D3!C:8(0ZR+@ 3(=P'4/A0/KZ
MB@#\Z](G_P""AWPE1-)CTCP?\5[:W_=QZA>7-N"Z@$#+--:R-VY<%B1R3S46
ML?#O]O+]HRW?1?%6N>&_@YX=N%*WBZ/.GGR(2<JK0/-(3CC'FH"#R37Z,T4
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M$DJJ[821%Y48((' !H ]@HJGK-K+?Z/?6T#B.>:"2.-V) 5BI .1TY-?'/[
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M96(+ $YR0#5/X\>"M:^)'P7\:^%O#E]%IFO:QI5Q96-Y/,\20S.A579T5F4
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M,*>QJ#]D'X3ZW\#?V;_!/@;Q&]J^M:/;RQ7+6,ADA+-/)(-K%03PX["O8J*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+]O;]EO3KN-9K6:_MO-B<95T%_&Q4CT(&/QK])J_.K]N;_E(9^RM_P!?L/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7X[?M>?\I>/AW_V,'A;_P!'P5^Q-?CM^UY_REX^'?\ V,'A;_T?
M!0!^Q-%%% 'XZ_\ !+G_ )2!?$S_ +!FL?\ IQMZ_8JOQU_X)<_\I OB9_V#
M-8_].-O7[%4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 86L> _#/B+6;#5]6\.Z3J>K:
M>5:SO[RQBFGMBK;E,<C*60AN1@C!YK=HHH *AO+.WU&SGM+N".ZM9XVBE@F0
M.DB,,,K*>"""00>N:FHH \U\>>$=8\"_"'Q':_!?1?#VA>*$C:[TZQ-@D-E<
M7 VEE=(R@W.J[ Q(P=I/ Q7S;^S+_P %%/!?Q7T.X\%_&N33? 'Q'LI7LM3T
MS7HOLEC=,&(^4S$JC= T<A!W?=R.GVY7D?QD_9-^$GQ^D-QXY\#Z;K&H;-G]
MI(&M[S & #/$5<@=@20/2@#(NOC!^SG\'+*XUZ/Q-\//#BN#(]QI<UFL\V[J
M56'+R$[?X02=OM7RI\%=5O/V[_V[;/XT:?I-[I_PH^'=BVGZ1=7T)3^TKLB3
M! /1MT[2$ DJ(H@V"^*]R\/_ /!+O]FWP_?QW@^'YU&6-U=%U#5;R:,$9ZQF
M7:X/<,".*^F_#_AW2O">CVND:)IEGH^E6J>7;V-A L$$*]<(B@*H^@H T:Y+
MQ_\ "/P1\5K6.V\9>$=%\4Q1?ZH:M817!CYS\A=25_#%=;10!YKX)_9I^$_P
MWU9=5\,?#CPOH>J(04OK/2H4G3']U]NY?P(KTJBB@#%U;P3X=U[6=/U?4]!T
MO4=6T\[K._N[..6>V(.08Y&4LG//RD<UM444 9OB'PUI'B[2Y-,UW2K'6M-D
M*L]GJ%ND\+%3E24<$'! (X[5;L;&VTNQM[*RMXK2SMXUAAMX$"1Q(H 5%4<!
M0   . !4]% %+6-%T_Q#IL^G:K86VIZ?<+MFM+R%98I%]&1@01]17E'_  QK
M\"/MGVG_ (5!X+,N_?@Z);[,YS]S9MQ[8Q7LE% %32=)L=!T^"PTRRM].L8%
MVQ6MI$L44:^BJH  ^E6Z** /SE^+2_\ #9G_  4B\+_#^,?;/ 'PGB.IZP.L
M4UX&1VC/8YD^SPE3SA)\=Z_1JN!^&OP'\!?!_6/$>J^$/#D&CZGXBN!=:M>+
M++++=R!G;<[2,Q^](YXP,L:[Z@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?%7C[PQX$CM
MI/$OB/2?#R7)98&U6^BM1*5QN"F1ANQD9QZBL?3?CA\.-8NTM;#X@>%[ZZ<X
M6&VUFVD=N<<*')/6OAS_ (*[:':>)O$/[.^CZA&9;#4/$DUI<1JQ4M'(]HC
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M^(AX?;Q=H2Z\7\H:6=2A%UO&?E\K=NSP>,=J .GHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQV_:\_P"4
MO'P[_P"Q@\+?^CX*_8FOQV_:\_Y2\?#O_L8/"W_H^"@#]B:*** /QU_X)<_\
MI OB9_V#-8_].-O7[%5^.O\ P2Y_Y2!?$S_L&:Q_Z<;>OV*H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'A?[:G[047[-/[._B;Q='(HUN2/^SM&C;^
M.]F!$9QW" -(1W$9%?/O["G[%^G?\,5Z_IGC:T)UKXJ6K7NHS3+NGA@92;/D
M_P :9\\9Y#R'/2O$OV[)/&'[<_[6UI\$OAG+:7%IX%LYKF]EO9=EH+S*^>\A
M"MG9F*$ J<.9!T)KTN#X6_\ !1.UACAA^*G@V*&-0B1QV=@JJH&  !I_  H
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_';]KS_E+Q\._^Q@\+?\
MH^"OV)K\=OVO/^4O'P[_ .Q@\+?^CX* /V)HHHH _'7_ ()<_P#*0+XF?]@S
M6/\ TXV]?L57XZ_\$N?^4@7Q,_[!FL?^G&WK]BJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR9^G_8P7W\HJ^W9(UEC9'4.C##*PR"/0U%9V-MIT/DVEO%:Q9SY<*!%SZX%
M$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,FV_"C_ +%+2?\ TCBKT6[L[?4(##=01W,+<F.9 RG'3@T^*)(8TCC18XT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQV_:\_
MY2\?#O\ [&#PM_Z/@K]B:_';]KS_ )2\?#O_ +&#PM_Z/@H _8FBBB@#\=?^
M"7/_ "D"^)G_ &#-8_\ 3C;U^Q5?CK_P2Y_Y2!?$S_L&:Q_Z<;>OV*H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%)JG_P C4?\ #KW]J+_HK6@_^%)JG_R-7ZW44<B#G9^2/_#KW]J+_HK6@_\
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MUH/_ (4FJ?\ R-1_PZ]_:B_Z*UH/_A2:I_\ (U?K=11R(.=GY(_\.O?VHO\
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M]J+_ **UH/\ X4FJ?_(U'_#KW]J+_HK6@_\ A2:I_P#(U?K=11R(.=GY(_\
M#KW]J+_HK6@_^%)JG_R-1_PZ]_:B_P"BM:#_ .%)JG_R-7ZW44<B#G9^2/\
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MC5^MU%'(@YV?DC_PZ]_:B_Z*UH/_ (4FJ?\ R-1_PZ]_:B_Z*UH/_A2:I_\
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MFJ?_ "-7ZW44<B#G9^2/_#KW]J+_ **UH/\ X4FJ?_(U'_#KW]J+_HK6@_\
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MUH/_ (4FJ?\ R-7ZW44<B#G9^2/_  Z]_:B_Z*UH/_A2:I_\C4?\.O?VHO\
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M]J+_ **UH/\ X4FJ?_(U?K=11R(.=GY(_P##KW]J+_HK6@_^%)JG_P C4?\
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M1_PZ]_:B_P"BM:#_ .%)JG_R-7ZW44<B#G9^2/\ PZ]_:B_Z*UH/_A2:I_\
M(U'_  Z]_:B_Z*UH/_A2:I_\C5^MU%'(@YV?DC_PZ]_:B_Z*UH/_ (4FJ?\
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M)JG_ ,C4?\.O?VHO^BM:#_X4FJ?_ "-7ZW44<B#G9^2/_#KW]J+_ **UH/\
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M5^MU%'(@YV?DC_PZ]_:B_P"BM:#_ .%)JG_R-1_PZ]_:B_Z*UH/_ (4FJ?\
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M)JG_ ,C5^MU%'(@YV?DC_P .O?VHO^BM:#_X4FJ?_(U'_#KW]J+_ **UH/\
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M%)JG_P C4?\ #KW]J+_HK6@_^%)JG_R-7ZW44<B#G9^2/_#KW]J+_HK6@_\
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MUH/_ (4FJ?\ R-1_PZ]_:B_Z*UH/_A2:I_\ (U?K=11R(.=GY(_\.O?VHO\
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M]J+_ **UH/\ X4FJ?_(U'_#KW]J+_HK6@_\ A2:I_P#(U?K=11R(.=GY(_\
M#KW]J+_HK6@_^%)JG_R-1_PZ]_:B_P"BM:#_ .%)JG_R-7ZW44<B#G9^2/\
MPZ]_:B_Z*UH/_A2:I_\ (U'_  Z]_:B_Z*UH/_A2:I_\C5^MU%'(@YV?DC_P
MZ]_:B_Z*UH/_ (4FJ?\ R-7A6D?!_P 8? S]O_X4^$_'6MVWB#Q#;^*_#\TM
M]:W<URC(]W R /,B.< XY'':OWCK\B?VKO\ E+A\.O\ L8?"_P#Z/@J9126A
M49-L_9&BBBLC4_&S_@F3_P G^?$O_L':Q_Z<+>OUXK\A_P#@F3_R?Y\2_P#L
M':Q_Z<+>OUXK>&QA/<****T,PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BN:\3?$[P=X)O8[/Q%XLT/0;N2/SDM]3U*&VD="2 P5V!(R",],@UDQ_
M'OX932*B?$7PF[L=JJNN6I))Z #S*0SNZ*KZ?J%KJUG%=V-S#>6DPW1SV\@D
MC<>H8'!%6*8@HHKRSQ5^T_\ #'P3\6M'^&>M>*K>R\:ZMY8M--:&5MS2-MB1
MI%4HC.?NJS GCU&4,]3HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCX>.U2-<<*I"LI^4<JH &3D?'ZUAL?\ @JI^SU;6T*6]O#X=,<4,2A411_:
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M ^F0:L5X9^Q3\"%_9W_9T\+>%YX!#K<T7]I:N<?,;R8!G4^NP;(\^D8KW.@
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M0Q6>A6-ND8& H2W10,?A7R?_ ,%@O^33K3_L9;/_ -%7%?8/P_\ ^1#\-_\
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MVM6<BYTY#A4"K_>+'.7VH<;=V6R$MM1N]]#YD/B7]H+_ ()NK;1^))/^%O\
MP(MY8[==03(O=*A+!4')+1XX 5B\7W5#(6%?H5X(\9Z1\1/!^C>)]!NUOM&U
M>TCO+2X48W1NH89'8C."#R""#R*_/[]IC_@HU\/?C9\&=8^'7PQTC7?&/C'Q
MA:MI<&G_ -F.I@\SAB1R7<#)4(&YP<C%?8O[*?PMU#X*_L[^!/!>K.K:KI>G
MA;P(^]4F=FED0-W"LY4$<8'%"WL@EM=GJ]%%%60%%%% !1110 4444 %%%%
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-):VL%C L%M#';PKG;'$H51DY. />I:* *&N:!I?B;3Y+#6--M-5L9/OVM]
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MR?9_LV?,\_;YGG^=QLS[8V_-2&?8%%%%,0445\D?LF_M">-_BM^TM^T%X/\
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MQJ,LS$]  *_,7P)\"-+_ &?O^"N7AW1-!B-MH&J6-[K-A:XPMO'-970:)/\
M861) OH,#G&3ZC_P5*\1:SXPU'X/_ [1KMK%/'FMHE_.O3RUFABB5@.J!YC(
M1ZPK1=V=PMKH1ZI_P4B\>?%KQ->Z3^SO\'-0\=:=8R^5+X@U19([9SG^XNT1
M@\$>9(&(/*+@U8T__@H9\3?A#J]I%^T)\$[_ ,&>'[N<0#Q)HX>6W@8YP&4E
MU?U^63=@'"MTK[-^&/PS\._!_P "Z3X1\*Z?'INBZ9"L,,2 ;G('S2.<?,['
MEF/)))K7\2^&M*\9:!?Z)KFGV^JZ1?Q-!=6=U&'CE0]58&BS[A==CX!_9K\0
M:;XL_P""KOQEUK1KV'4M*O\ P=#<VMY;N&CFC9-)*LI[@@U]_>)/$>E^#]!U
M#6]:OX-,TC3X'N;J\N7"1PQJ,LS'T K\SOV"_A##\!?^"D/Q=\"VLLL]CI/A
MNY%I)/\ ZPV\EUI\T(8]R(Y$!/<C/%>B_P#!4C7=8\<^(/@U\#-'O6L8O'&M
M*=1D7./+$L446['WD#2R2$>L2GM23LKC:N[":E_P4B\>_%SQ->Z5^SQ\&]0\
M<:=92^5+KVJ+(ENYX_A7:L8/4>9(&(.2BX-6=/\ ^"AGQ+^$>K6L7[0GP3U#
MP9H%U.+<>(]'626W@8YP&4EU?U^63=@'"MTK[/\ AI\-O#WPB\#Z3X2\+:='
MIFB:9"(888P,MCJ[G^)V.69CR22:U/$WAG2O&7A^_P!#US3[?5=(OX6@NK.Z
M0/'*AZ@@_P"1UJK/N*Z['@'PA_;#M_B_^U%XS^%VE:99W&@:)HL&LV7B2TO3
M*+Y)$M67";< 8N>H8_=]^/I*OS"_8 ^$D7P)_P""A7QE\"VTLL]EI&A3):R3
M_P"L-N]S9RP[CW/ER)D]^N!TK]/:(MO<4M] HHHJB0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!("8Y_+V='*J,9_BKD_&'CO0?AE_P5<\1>*/$^I0Z1H6F>#O/NKR<G:BBV0
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M>^$O@@NG?"75KU(H]>UZ9XK@VG):YX8  J,J CJ3A0YR#7B'_!0GP!:?%/\
MX*&? [PIJ"&33M4T^P@NT4X+0?;[DR@?5 PK]0+6VALK>*WMXD@MX4$<<42A
M510,!0!P !Q@4:MAHDCY[\!_M577C/\ ;)\?? ]_#L-K:^&-(74TUI;LL]P2
M+,[#%L 4?Z6>=Q^X/7CC?B;^U!^T#X3^(&O:/X<_9PO?$^A65V\-GK$>IF-;
MN,=) OEG&?3->=? W_E+U\=/^Q43^6DU]_\ 3DTU=AL?GO\ $;_@HC\</A'X
M<.O>,OV<'\.Z.)E@^UWVM%4,C9VH/W623@G [ GM7UG^S+\4O%'QJ^$.D>-?
M%/A:'P?/K -Q9:;'<M._V4X\N5RR+@N,L !]TJ<\X'Q5XDFD_P""D7[8T?A^
MV=I_@;\-)?,O9D)\K5+G=@@$<$2,A13_ ,\HY&!!?%?;W[1GQ&D^"O[/_CCQ
M;IT4:76BZ1-)91[1L6;;LARO3:'9./08I+N#['BG[2__  4)T'X-^,U^'O@C
MPW??$_XE.WEMHVDEC';.1G9(R*[-)CGRT4D '<5KS?\ X;"_:V\,PQZSXD_9
MJ2[T!5,DT.EO*+H(.2<!Y64@>L==/_P2U^!NG^%?@A%\3]33^T?&_C>6>\N=
M4NOWDZ6_G,JQASS\Y4RL>K%QG.T8^V*-7J&BT/ACQG_P5,\+1_"SPIXN\%Z&
M-:O=2UE-&U30]3NOLMSI<C1EPS!5;>IP=K#AL'H0RCZ,_:0^)_C_ .%GA73-
M0^'OPYF^)6IW%[Y%QI\%SY!@AV,WFYVG/S!5Q_M5\ _\%6_V?]$\&_$[P!\3
M-"M$L)?$.HBQU>&",)%)<H5>.?C^-U+AO7RP>I)/ZLT*^J!VLFC\=_V7?CM\
M7_!W[1'QWUSPQ\%KKQ9XAUO5#-K6AQWWEMH\GVB=O+9MAW?,SKG ^Y7V[^TM
M^V1XC_9O_9X\#?$'5? 49\0:[=6]G?>'KJ^,7V"1[>65U\P(=Q4Q;>@ZUY7^
MP/\ \GH?M:_]A]O_ $MNZ/\ @L]_R;GX/_[&N+_TCNJ2NHW'N['W_7Q%\:?^
M"E-OIOC^Y^'GP4\$WWQ;\96[/'/+8AVLX63[^P1JSS!3PQ&Q!V<UZ#_P4>^+
MFH_![]E#Q1?://)::MJ[Q:+;7,9PT/GD^:P(Y#>4LH!'()![5?\ V#?V=]#^
M ?[/OAD6EG'_ ,)'KUC!JNL:A)$!/)-+&K^26Z[(@VQ5Z<%L L:I[V1*M:[/
MG[5OV\/VE/A)"FN_$[]G;R/"2()+F[TEY4-NA(&]Y-TRIC/W7"Y/&17V'\ /
MVA_!?[2G@6+Q3X,OVN+<-Y5U97"A+JREQGRY4!.#CD$$J1R":](FACN(7BE1
M98I%*NC@%6!&""#U%?FS8>&8?V-?^"G.@Z-X45K/P+\3K+=/I42[8()9&E 2
M->@V3QJRX'RI,R#BEJAZ,^H?VNOVK+K]F.Y^'D5OX=AUY?%6K?V;(TUV8/LP
MS&-XPC;OO]..E>:^._V^O$WC'QCJGA3]G?X977Q6N-+D\F]\1R2&+2HI <%$
M?@/VPQD0'!*AA\U>8_\ !9ZPFU7PG\);*W7=/<ZO=0QJ>[-'$!^IK[I^"WPC
MT'X%_#+0?!7AVVCM[#2[=8VD5-K7,V!YD[^KNV6/UP. !1JW8-$KGR'H_P#P
M4.\?_"7QQI.@?M&_":3X?:=JTGE6_B+3I6EM(SG!W#+JX&06*2%E'.TYK[PA
MF2XB26)UDC=0RNAR&!Y!![BOFG_@I!X-T_QC^QUX^^W0I)-I4,6J6DK#+0S1
M2K\R^A*%T^CFNK_8D\17/BG]DOX5W]W(9;C^PX+9G/5A"#""?4XC'/>FM[">
MUSVZBBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **^>_P!N#X%>.?VA/A!8^&OA]K]IX;UN'6(;
MZ2[O+V>U1H5BF1DWPH[$EI$.,8X// KN?V;?A[XA^%/P-\(^$O%6I0ZOXATN
MU,-Y?6\\D\<KF1VR'D57;A@.0.E+J/H>ET5A>/-%O?$?@?Q%I.G3K:ZA?Z=<
M6MM.[LBQRO$RHQ902 "0<@$C%?,G[ O[+OQ0_9K_ .$Z_P"%D>++#Q1_;7V#
M[!]AU*ZN_(\G[1YN[SXDV[O-CQMSG:<XP,@=#ZXHHKXJNOV0_BY-^W0OQ;3Q
MGIJ_#P:BEU_8?]J7GG^4+41%?(\KRL[P3C?C'/7B@#[5HHKY-_;X_9A^)O[2
M5GX)B^&_BJP\,/H\EXU\;[4;JT\X2B$1[?(B?=CRW^]C&X8SDT,$?65%87@/
M1;WPYX'\.Z3J,ZW6H6&G6]K<SH[.LDJ1*KL&8 D$@G) )S7(_M)?#WQ#\5O@
M;XN\)>%=2ATCQ#JEJ(;.^N)Y((XG$B-DO&K.O"D< ]: /2Z*^=?V&/@+X\_9
MW^$NK>'/B'XAL_$NM76N3:A#=V5[<7:);M;V\:H7FC1@0T4AP!CY@<Y)Q]%4
M %%?%7[.O[(?Q<^%O[5GB?XB>*/&>FZMX-U%]2:UTNWU2\FEB$\V^',4D2QC
M:O!PQQVS7VK0@845\8?MC?LD?%KXZ?'#PAXL\#>,=.T#P]I5C;V]Y8W>J7=M
M)-(ES)*[!(HG5@4=1DD'C'3FOL^@ HKP;]M+X*^-?CY\%V\+> M=M?#VO'48
M+K[9>7D]JGE('W+OA1VR=PXQCBMW]D_X6^*/@O\ L_\ A;P;XSU:WUSQ+IOV
MK[7?VMS+<1R^9=S2IB255=L)(B\J,$$#@ T=0Z'KE%5-8M9;[2;VV@<1S30/
M&CDD!6*D Y'N:^0?V#?V3?BO^S?XB\6WOQ&\8:=XGM=4M8(;..QU.[NS$Z.Q
M8D3Q(%R".F>E 'V3117QAXZ_9(^+7B+]N/3_ (LZ=XQTZV^'L%]8W$FB/JEV
MD[1PV\<<J^0L1B)9D8@%\'.3@T C[/HHKY8_;R_9K^)/[2'AWPE9?#GQ18^&
M+K2[J>:\DOM0N;02HZ*% ,$;EL$'KCK0P/J>BN1^#_A?5/ _PE\$^'-<NX[_
M %K1]#L=/OKN*1Y$FN(K=(Y'5W 9@S*Q!8 G.2 :J?'3P9K/Q$^#?C/PQX=O
MHM-UW5M*N+.RO)I7B2&9T(5V= 64 GJH)]J .YHKYD_81_9U^(G[.?@?Q)I/
MQ%\2V7B;4-0U%;JVGLK^XNUCB$2J5+3QH0<@G !%?3= !17QA\)/V2/BUX)_
M;0\1_%+6O&.G7W@/4+[4[BVT:+5+N2>..X+F%3"\0B!7<,@.0,<9K[/H0!17
MQ7^W=^R'\7/VC/''AO5OAUXSTWPSI^GZ<UK<P7NJ7EHTDIE9@P6")P1@@9)!
MK[4H **\8_:^^$?BWXX? G6?"/@C6;;0?$5W/;207UU=36T:+',CN"\2,XRJ
MD<#G/-0_L=?!_P 8? OX&Z=X2\<ZU;:_XAM[JYFEOK2ZFN8V1Y"R /*B.< X
MY'%'4.A[;117QA^P[^R1\6OV>?B)XKUOX@^,=.\2:7J=C]GM+>SU2[NFBD\X
M/N*S1(JC:",@DT ?9]%%?%?QF_9#^+GCS]LSPU\4-"\9Z;I_@33]1TFZNM'F
MU2\BFDBMI(VG40I$8B6", "X!SSBA@C[4HHKYJ_;L_9[^(/[1?P[T#1/AWXD
ML_#6J6.J_;+BXO;ZXM%DA\F1-@:"-V)W,IP0!QUH ^E:*X#X ^!]<^&OP7\'
M>%O$M_%JFO:3IT5K>WD$SS)-*HY8.ZJS ^K &M?XJ>&]2\9?#'Q?H&CW266K
MZKH]Y8V=U+(T:PS2P.D;EE!90&8'(!(QP#0!U%%?+'[!O[-?Q)_9O\.^+;+X
MC>*+'Q/=:I=036<ECJ%S=B)$1@P)GC0KDD=,]*^IZ 845\5^#?V0_BYH/[=%
MQ\6[_P 9Z;<?#R34;^Z70TU2\:<136LT42^08A%E7D0D;\ #(R0!7VI0@845
M\>?MZ_LI?%7]I#5O!US\./%VG^&(=)@NH[U+[4[NT,S2-&4*B")]V C?>QC/
M%?67ANPN-*\.Z7974BS75M:Q0RR*Q8,ZH Q!/)R0>M &C17E/[4WPS\3?&+X
M"^*_!_@_5(-%\2:FD"VE]<W$MO'$4N(I&S)$K.N41APIZXZ5SG[%OP5\:_ /
MX+KX6\>Z[:^(=>&HSW7VRSO)[I/*<)M7?,B-D;3QC'-'4.A[S117Q7^QY^R'
M\7/@9\?/%?C'QSXSTW7_  WJ>G7=K:6%IJEY<R12R74$J,8Y8D10$C=<AB06
M '!)H ^U***^*OVGOV0_BY\7?VG/"_CWPCXSTW1O"6FI8+=Z;<ZI>02RF&X:
M27$4<31G<I &6&<8.!0P1]JT45\]_MP? KQS^T)\(+'PU\/M?M/#>MPZQ#?2
M7=Y>SVJ-"L4R,F^%'8DM(AQC'!YX% 'T)17FG[-OP]\0_"GX&^$?"7BK4H=7
M\0Z7:F&\OK>>2>.5S([9#R*KMPP'('2NN\>:+>^(_ _B+2=.G6UU"_TZXM;:
M=W9%CE>)E1BR@D $@Y )&* -VBOD?]@7]EWXH?LU_P#"=?\ "R/%EAXH_MK[
M!]@^PZE=7?D>3]H\W=Y\2;=WFQXVYSM.<8&?KBA PHKXJNOV0_BY-^W0OQ;3
MQGIJ_#P:BEU_8?\ :EYY_E"U$17R/*\K.\$XWXQSUXK[5H **^3?V^/V8?B;
M^TE9^"8OAOXJL/##Z/)>-?&^U&ZM/.$HA$>WR(GW8\M_O8QN&,Y-?2O@/1;W
MPYX'\.Z3J,ZW6H6&G6]K<SH[.LDJ1*KL&8 D$@G) )S1U W:*\T_:2^'OB'X
MK? WQ=X2\*ZE#I'B'5+40V=]<3R01Q.)$;)>-6=>%(X!ZUP'[#'P%\>?L[_"
M75O#GQ#\0V?B76KK7)M0AN[*]N+M$MVM[>-4+S1HP(:*0X Q\P.<DX.H=#Z*
MHHKXJ_9U_9#^+GPM_:L\3_$3Q1XSTW5O!NHOJ36NEV^J7DTL0GFWPYBDB6,;
M5X.&..V: /M6BBOC#]L;]DCXM?'3XX>$/%G@;QCIV@>'M*L;>WO+&[U2[MI)
MI$N9)78)%$ZL"CJ,D@\8Z<T,$?9]%%>#?MI?!7QK\?/@NWA;P%KMKX>UXZC!
M=?;+R\GM4\I ^Y=\*.V3N'&,<4 >\T5Y'^R?\+?%'P7_ &?_  MX-\9ZM;ZY
MXETW[5]KO[6YEN(Y?,NYI4Q)*JNV$D1>5&""!P :]1UBUEOM)O;:!Q'-- \:
M.20%8J0#D>YH MT5\;?L&_LF_%?]F_Q%XMO?B-XPT[Q/:ZI:P0V<=CJ=W=F)
MT=BQ(GB0+D$=,]*^R:$#"BOC#QU^R1\6O$7[<>G_ !9T[QCIUM\/8+ZQN)-$
M?5+M)VCAMXXY5\A8C$2S(Q +X.<G!K[/H **^6/V\OV:_B3^TAX=\)67PY\4
M6/ABZTNZGFO)+[4+FT$J.BA0#!&Y;!!ZXZU[S\'_  OJG@?X2^"?#FN7<=_K
M6CZ'8Z??7<4CR)-<16Z1R.KN S!F5B"P!.<D T=0Z'745PWQT\&:S\1/@WXS
M\,>';Z+3==U;2KBSLKR:5XDAF="%=G0%E )ZJ"?:O'?V$?V=?B)^SGX'\2:3
M\1?$MEXFU#4-16ZMI[*_N+M8XA$JE2T\:$'()P 10'0^FZ**^,/A)^R1\6O!
M/[:'B/XI:UXQTZ^\!ZA?:G<6VC1:I=R3QQW!<PJ87B$0*[AD!R!CC- 'V?11
M7Q7^W=^R'\7/VC/''AO5OAUXSTWPSI^GZ<UK<P7NJ7EHTDIE9@P6")P1@@9)
M!H8(^U***\8_:^^$?BWXX? G6?"/@C6;;0?$5W/;207UU=36T:+',CN"\2,X
MRJD<#G/- 'L]%>)?L=?!_P 8? OX&Z=X2\<ZU;:_XAM[JYFEOK2ZFN8V1Y"R
M /*B.< XY'%>VT %%?&'[#O[)'Q:_9Y^(GBO6_B#XQT[Q)I>IV/V>TM[/5+N
MZ:*3S@^XK-$BJ-H(R"37V?0@845\5_&;]D/XN>//VS/#7Q0T+QGING^!-/U'
M2;JZT>;5+R*:2*VDC:=1"D1B)8(P +@'/.*^U* "BOFK]NS]GOX@_M%_#O0-
M$^'?B2S\-:I8ZK]LN+B]OKBT62'R9$V!H(W8G<RG! ''6O5O@#X'USX:_!?P
M=X6\2W\6J:]I.G16M[>03/,DTJCE@[JK,#ZL :.H=#OZ*Y?XJ>&]2\9?#'Q?
MH&CW266KZKH]Y8V=U+(T:PS2P.D;EE!90&8'(!(QP#7@'[!O[-?Q)_9O\.^+
M;+XC>*+'Q/=:I=036<ECJ%S=B)$1@P)GC0KDD=,]* Z'U/117Q7X-_9#^+F@
M_MT7'Q;O_&>FW'P\DU&_NET--4O&G$4UK-%$OD&(195Y$)&_  R,D 4 ?:E%
M%?'G[>O[*7Q5_:0U;P=<_#CQ=I_AB'28+J.]2^U.[M#,TC1E"H@B?=@(WWL8
MSQ0P1]AT5G>&["XTKP[I=E=2+-=6UK%#+(K%@SJ@#$$\G)!ZUYU^U-\,_$WQ
MB^ OBOP?X/U2#1?$FII MI?7-Q+;QQ%+B*1LR1*SKE$8<*>N.E 'JU%>#?L6
M_!7QK\ _@NOA;Q[KMKXAUX:C/=?;+.\GND\IPFU=\R(V1M/&,<U[S0 45\5_
ML>?LA_%SX&?'SQ7XQ\<^,]-U_P -ZGIUW:VEA::I>7,D4LEU!*C&.6)$4!(W
M7(8D%@!P2:^U*$#"BOBK]I[]D/XN?%W]ISPOX]\(^,]-T;PEIJ6"W>FW.J7D
M$LIAN&DEQ%'$T9W*0!EAG&#@5]JT %%?/?[<'P*\<_M"?""Q\-?#[7[3PWK<
M.L0WTEW>7L]JC0K%,C)OA1V)+2(<8QP>>!7<_LV_#WQ#\*?@;X1\)>*M2AU?
MQ#I=J8;R^MYY)XY7,CMD/(JNW# <@=*.H=#TNBL+QYHM[XC\#^(M)TZ=;74+
M_3KBUMIW=D6.5XF5&+*"0 2#D D8KYD_8%_9=^*'[-?_  G7_"R/%EAXH_MK
M[!]@^PZE=7?D>3]H\W=Y\2;=WFQXVYSM.<8&0.A]<445\577[(?Q<F_;H7XM
MIXSTU?AX-12Z_L/^U+SS_*%J(BOD>5Y6=X)QOQCGKQ0!]JT45\F_M\?LP_$W
M]I*S\$Q?#?Q58>&'T>2\:^-]J-U:><)1"(]OD1/NQY;_ 'L8W#&<FA@CZRHK
M"\!Z+>^'/ _AW2=1G6ZU"PTZWM;F='9UDE2)5=@S $@D$Y(!.:Y']I+X>^(?
MBM\#?%WA+PKJ4.D>(=4M1#9WUQ/)!'$XD1LEXU9UX4C@'K0!Z717SK^PQ\!?
M'G[._P )=6\.?$/Q#9^)=:NM<FU"&[LKVXNT2W:WMXU0O-&C AHI#@#'S YR
M3CZ*H **^*OV=?V0_BY\+?VK/$_Q$\4>,]-U;P;J+ZDUKI=OJEY-+$)YM\.8
MI(EC&U>#ACCMFOM6A PHKXP_;&_9(^+7QT^.'A#Q9X&\8Z=H'A[2K&WM[RQN
M]4N[:2:1+F25V"11.K HZC)(/&.G-?9] !17@W[:7P5\:_'SX+MX6\!:[:^'
MM>.HP77VR\O)[5/*0/N7?"CMD[AQC'%;O[)_PM\4?!?]G_PMX-\9ZM;ZYXET
MW[5]KO[6YEN(Y?,NYI4Q)*JNV$D1>5&""!P :.H=#URBJFL6LM]I-[;0.(YI
MH'C1R2 K%2 <CW-?(/[!O[)OQ7_9O\1>+;WXC>,-.\3VNJ6L$-G'8ZG=W9B=
M'8L2)XD"Y!'3/2@#[)HHKXP\=?LD?%KQ%^W'I_Q9T[QCIUM\/8+ZQN)-$?5+
MM)VCAMXXY5\A8C$2S(Q +X.<G!H!'V?117RQ^WE^S7\2?VD/#OA*R^'/BBQ\
M,76EW4\UY)?:A<V@E1T4* 8(W+8(/7'6A@?4]%<C\'_"^J>!_A+X)\.:Y=QW
M^M:/H=CI]]=Q2/(DUQ%;I'(ZNX#,&96(+ $YR0#53XZ>#-9^(GP;\9^&/#M]
M%INNZMI5Q9V5Y-*\20S.A"NSH"R@$]5!/M0!W-%?,G["/[.OQ$_9S\#^)-)^
M(OB6R\3:AJ&HK=6T]E?W%VL<0B52I:>-"#D$X (KZ;H **^,/A)^R1\6O!/[
M:'B/XI:UXQTZ^\!ZA?:G<6VC1:I=R3QQW!<PJ87B$0*[AD!R!CC-?9]" **^
M*_V[OV0_BY^T9XX\-ZM\.O&>F^&=/T_3FM;F"]U2\M&DE,K,&"P1.",$#)(-
M?:E !17C'[7WPC\6_'#X$ZSX1\$:S;:#XBNY[:2"^NKJ:VC18YD=P7B1G&54
MC@<YYJ']CKX/^,/@7\#=.\)>.=:MM?\ $-O=7,TM]:74US&R/(60!Y41S@''
M(XHZAT/;:**^,/V'?V2/BU^SS\1/%>M_$'QCIWB32]3L?L]I;V>J7=TT4GG!
M]Q6:)%4;01D$F@#[/HHKXK^,W[(?Q<\>?MF>&OBAH7C/3=/\":?J.DW5UH\V
MJ7D4TD5M)&TZB%(C$2P1@ 7 .><4,$?:E%%?-7[=G[/?Q!_:+^'>@:)\._$E
MGX:U2QU7[9<7%[?7%HLD/DR)L#01NQ.YE." ..M 'TK17 ? 'P/KGPU^"_@[
MPMXEOXM4U[2=.BM;V\@F>9)I5'+!W568'U8 UK_%3PWJ7C+X8^+] T>Z2RU?
M5='O+&SNI9&C6&:6!TC<LH+* S Y )&. : .HHKY8_8-_9K^)/[-_AWQ;9?$
M;Q18^)[K5+J":SDL=0N;L1(B,&!,\:%<DCIGI7U/0#"BOBOP;^R'\7-!_;HN
M/BW?^,]-N/AY)J-_=+H::I>-.(IK6:*)?(,0BRKR(2-^ !D9( K[4H0,**^/
M/V]?V4OBK^TAJW@ZY^''B[3_  Q#I,%U'>I?:G=VAF:1HRA401/NP$;[V,9X
MKZR\-V%QI7AW2[*ZD6:ZMK6*&616+!G5 &()Y.2#UH T:*\I_:F^&?B;XQ?
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M%5=1=#[6KYR^%O[6-W\1/VM?B+\&I/#<-C;>%+)KM-76[+O<D/;KM,>P!?\
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MM$?%;XF3>)(=4@\;3/+'IT=H8VM-TQDP7+D/UQT%-[HE=3BO^"KW_)FNO_\
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M49+,QX %?"][_P $Y_'OP?\ $FHZK^SM\9+[P+IU](9)/#NK*T]JA/?=\P?
MX7?$6 'WSUJ_#^P/\4?C)J%HW[0?QPO_ !AX?MY1,_AG08C:6MRP;<-[*$4
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MM?7]?TWPKHM[K&L7UOIFEV,33W-Y=2".*&-1DLS'@ 5\,WO_  3I\?\ P?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@BOB*S_X)]_%[X&ZI>?\*"^.MUX<\/7,OFKH7B"#SXH#D$D?+)&Y_P!KRE)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$I/0%W( _.LWPS\2O"/C:XEM_#OBG1=>GB7=)%IFHPW+(/4A&) IB.CHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?D3^U=_P I</AU_P!C#X7_ /1\%?KM7Y$_M7?\I</AU_V,/A?_ -'P5G/8
MTAN?LC1116!N?C9_P3)_Y/\ /B7_ -@[6/\ TX6]?KQ7Y#_\$R?^3_/B7_V#
MM8_].%O7Z\5O#8PGN%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^""C=JX;)V/I?X$_L[^!OV;_  S>:#X$TIM-L;RZ:\G::9II9)" HR[$L0H
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M^%I?(UO5[,G=J;!V7L1O#E7\N,G;M0R,"<+7KEO_ ,$D?@##H:V+V?B">[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7Y$_M7?\ *7#X=?\ 8P^%_P#T?!7Z[5^1
M/[5W_*7#X=?]C#X7_P#1\%9SV-(;G[(T445@;GXV?\$R?^3_ #XE_P#8.UC_
M -.%O7Z\5^0__!,G_D_SXE_]@[6/_3A;U^O%;PV,)[A1116AF%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:I_\BT?\.J?VI/\ HK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\
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M'5/[4G_16?#W_A2:I_\ (M'_  ZI_:D_Z*SX>_\ "DU3_P"1:_8&B@#\?O\
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MT?\ #JG]J3_HK/A[_P *35/_ )%K]@:* /Q^_P"'5/[4G_16?#W_ (4FJ?\
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MFJ?_ "+1_P .J?VI/^BL^'O_  I-4_\ D6OV!HH _'[_ (=4_M2?]%9\/?\
MA2:I_P#(M'_#JG]J3_HK/A[_ ,*35/\ Y%K]@:* /Q^_X=4_M2?]%9\/?^%)
MJG_R+1_PZI_:D_Z*SX>_\*35/_D6OV!HH _'[_AU3^U)_P!%9\/?^%)JG_R+
M1_PZI_:D_P"BL^'O_"DU3_Y%K]@:* /Q^_X=4_M2?]%9\/?^%)JG_P BT?\
M#JG]J3_HK/A[_P *35/_ )%K]@:* /Q^_P"'5/[4G_16?#W_ (4FJ?\ R+1_
MPZI_:D_Z*SX>_P#"DU3_ .1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\BT?\.J?
MVI/^BL^'O_"DU3_Y%K]@:* /Q^_X=4_M2?\ 16?#W_A2:I_\BT?\.J?VI/\
MHK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\ (M'_  ZI_:D_Z*SX
M>_\ "DU3_P"1:_8&B@#\?O\ AU3^U)_T5GP]_P"%)JG_ ,BT?\.J?VI/^BL^
M'O\ PI-4_P#D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_(M'_#JG]J3_HK/A[_P
MI-4_^1:_8&B@#\?O^'5/[4G_ $5GP]_X4FJ?_(M'_#JG]J3_ **SX>_\*35/
M_D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_ "+1_P .J?VI/^BL^'O_  I-4_\
MD6OV!HH _'[_ (=4_M2?]%9\/?\ A2:I_P#(M'_#JG]J3_HK/A[_ ,*35/\
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M[_PI-4_^1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\ (M'_  ZI_:D_Z*SX>_\
M"DU3_P"1:_8&B@#\?O\ AU3^U)_T5GP]_P"%)JG_ ,BT?\.J?VI/^BL^'O\
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M/[4G_16?#W_A2:I_\BT?\.J?VI/^BL^'O_"DU3_Y%K]@:* /Q^_X=4_M2?\
M16?#W_A2:I_\BT?\.J?VI/\ HK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_16?#W
M_A2:I_\ (M'_  ZI_:D_Z*SX>_\ "DU3_P"1:_8&B@#\?O\ AU3^U)_T5GP]
M_P"%)JG_ ,BT?\.J?VI/^BL^'O\ PI-4_P#D6OV!HH _'[_AU3^U)_T5GP]_
MX4FJ?_(M'_#JG]J3_HK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_ $5GP]_X4FJ?
M_(M'_#JG]J3_ **SX>_\*35/_D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_ "+1
M_P .J?VI/^BL^'O_  I-4_\ D6OV!HH _'[_ (=4_M2?]%9\/?\ A2:I_P#(
MM'_#JG]J3_HK/A[_ ,*35/\ Y%K]@:* /Q^_X=4_M2?]%9\/?^%)JG_R+1_P
MZI_:D_Z*SX>_\*35/_D6OV!HH _'[_AU3^U)_P!%9\/?^%)JG_R+1_PZI_:D
M_P"BL^'O_"DU3_Y%K]@:* /Q^_X=4_M2?]%9\/?^%)JG_P BT?\ #JG]J3_H
MK/A[_P *35/_ )%K]@:* /Q^_P"'5/[4G_16?#W_ (4FJ?\ R+1_PZI_:D_Z
M*SX>_P#"DU3_ .1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\BT?\.J?VI/^BL^'
MO_"DU3_Y%K]@:* /Q^_X=4_M2?\ 16?#W_A2:I_\BT?\.J?VI/\ HK/A[_PI
M-4_^1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\ (M'_  ZI_:D_Z*SX>_\ "DU3
M_P"1:_8&B@#\?O\ AU3^U)_T5GP]_P"%)JG_ ,BT?\.J?VI/^BL^'O\ PI-4
M_P#D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_(M'_#JG]J3_HK/A[_PI-4_^1:_
M8&B@#\?O^'5/[4G_ $5GP]_X4FJ?_(M'_#JG]J3_ **SX>_\*35/_D6OV!HH
M _'[_AU3^U)_T5GP]_X4FJ?_ "+1_P .J?VI/^BL^'O_  I-4_\ D6OV!HH
M_'[_ (=4_M2?]%9\/?\ A2:I_P#(M'_#JG]J3_HK/A[_ ,*35/\ Y%K]@:*
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M:I_\BT?\.J?VI/\ HK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\
M(M'_  ZI_:D_Z*SX>_\ "DU3_P"1:_8&B@#\?O\ AU3^U)_T5GP]_P"%)JG_
M ,BT?\.J?VI/^BL^'O\ PI-4_P#D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_(M
M'_#JG]J3_HK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_ $5GP]_X4FJ?_(M'_#JG
M]J3_ **SX>_\*35/_D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_ "+1_P .J?VI
M/^BL^'O_  I-4_\ D6OV!HH _'[_ (=4_M2?]%9\/?\ A2:I_P#(M'_#JG]J
M3_HK/A[_ ,*35/\ Y%K]@:* /Q^_X=4_M2?]%9\/?^%)JG_R+1_PZI_:D_Z*
MSX>_\*35/_D6OV!HH _'[_AU3^U)_P!%9\/?^%)JG_R+1_PZI_:D_P"BL^'O
M_"DU3_Y%K]@:* /Q^_X=4_M2?]%9\/?^%)JG_P BT?\ #JG]J3_HK/A[_P *
M35/_ )%K]@:* /Q^_P"'5/[4G_16?#W_ (4FJ?\ R+1_PZI_:D_Z*SX>_P#"
MDU3_ .1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\BT?\.J?VI/^BL^'O_"DU3_Y
M%K]@:* /Q^_X=4_M2?\ 16?#W_A2:I_\BT?\.J?VI/\ HK/A[_PI-4_^1:_8
M&B@#\?O^'5/[4G_16?#W_A2:I_\ (M'_  ZI_:D_Z*SX>_\ "DU3_P"1:_8&
MB@#\?O\ AU3^U)_T5GP]_P"%)JG_ ,BT?\.J?VI/^BL^'O\ PI-4_P#D6OV!
MHH _'[_AU3^U)_T5GP]_X4FJ?_(M'_#JG]J3_HK/A[_PI-4_^1:_8&B@#\?O
M^'5/[4G_ $5GP]_X4FJ?_(M'_#JG]J3_ **SX>_\*35/_D6OV!HH _'[_AU3
M^U)_T5GP]_X4FJ?_ "+1_P .J?VI/^BL^'O_  I-4_\ D6OV!HH _'[_ (=4
M_M2?]%9\/?\ A2:I_P#(M'_#JG]J3_HK/A[_ ,*35/\ Y%K]@:* /Q^_X=4_
MM2?]%9\/?^%)JG_R+1_PZI_:D_Z*SX>_\*35/_D6OV!HH _'[_AU3^U)_P!%
M9\/?^%)JG_R+1_PZI_:D_P"BL^'O_"DU3_Y%K]@:* /Q^_X=4_M2?]%9\/?^
M%)JG_P BT?\ #JG]J3_HK/A[_P *35/_ )%K]@:* /Q^_P"'5/[4G_16?#W_
M (4FJ?\ R+1_PZI_:D_Z*SX>_P#"DU3_ .1:_8&B@#\?O^'5/[4G_16?#W_A
M2:I_\BT?\.J?VI/^BL^'O_"DU3_Y%K]@:* /Q^_X=4_M2?\ 16?#W_A2:I_\
MBT?\.J?VI/\ HK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\ (M'_
M  ZI_:D_Z*SX>_\ "DU3_P"1:_8&B@#\?O\ AU3^U)_T5GP]_P"%)JG_ ,BT
M?\.J?VI/^BL^'O\ PI-4_P#D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_(M'_#J
MG]J3_HK/A[_PI-4_^1:_8&B@#\?O^'5/[4G_ $5GP]_X4FJ?_(M'_#JG]J3_
M **SX>_\*35/_D6OV!HH _'[_AU3^U)_T5GP]_X4FJ?_ "+1_P .J?VI/^BL
M^'O_  I-4_\ D6OV!HH _'[_ (=4_M2?]%9\/?\ A2:I_P#(M'_#JG]J3_HK
M/A[_ ,*35/\ Y%K]@:* /Q^_X=4_M2?]%9\/?^%)JG_R+1_PZI_:D_Z*SX>_
M\*35/_D6OV!HH _'[_AU3^U)_P!%9\/?^%)JG_R+1_PZI_:D_P"BL^'O_"DU
M3_Y%K]@:* /Q^_X=4_M2?]%9\/?^%)JG_P BT?\ #JG]J3_HK/A[_P *35/_
M )%K]@:* /Q^_P"'5/[4G_16?#W_ (4FJ?\ R+1_PZI_:D_Z*SX>_P#"DU3_
M .1:_8&B@#\?O^'5/[4G_16?#W_A2:I_\BUX+IOP9\8_ 7_@H%\*?"'CO6K7
MQ!XBM_%?A^:6^L[N:YC9)+N!D >9$<X!QR..U?OW7X[?M>?\I>/AW_V,'A;_
M -'P4 ?L31110!^.O_!+G_E(%\3/^P9K'_IQMZ_8JOQU_P""7/\ RD"^)G_8
M,UC_ -.-O7[%4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %?CM^UY_REX^'?_8P>%O\ T?!7[$U^
M.W[7G_*7CX=_]C!X6_\ 1\% '[$T444 ?CK_ ,$N?^4@7Q,_[!FL?^G&WK]B
MJ_'7_@ES_P I OB9_P!@S6/_ $XV]?L50 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M._X*<>.M>_:6^+6N?#CP>_G^%_A3HMUX@U^=23&;I4&\''!**R1CN&>;LIH
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M!&_;L^/7[-?B;2+?]I?X6Z?IW@_4YA;Q^)O#!WB!R"<N%FE1R #^[_=OM5F
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M$W_!4#4/ /QO^*_@75_"=OK$^@7?]E^%M+T9)C?ZS>M,L<<3'+ #!))5<\
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MOV\I_P!F7]ICP7X)U:QTQ/ VI:,=6U359DE:[@ :Y7;$%8*2?(0 $$DMCTH
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M\._%.MV0C-YINE75[ )5W)YD<+.NX9&1E1GFNCKBOC=_R1?Q]_V+^H?^DTE
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M&_V_/B#X;^-&C_";]H_X>P^ O$6MND.E:QII/V.>1CM16S)(K!WPOF1R, Q
M*@9(UOB1^VQ\3?B-XZUKP;^S'\.(/B ^ASFTU3Q=JT@CTJ*<'#Q1,9(E<KUW
M>9SU5&7!(!]M4GTZU^>7A7_@H%\7?@?\5M"\$_M0?#[3O"MAKDGE67B31VQ
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M?)A@ 8A 3YD@+E0"Q5BN6P.E>B4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%1SSQVL,DTTBQ0QJ7>21@JJH&2
M23T % 'RQ^W5^VW:_LBP^!((+2'4]4US54>[M9 28]+C8?:9%P1B0[E5,\9W
M'G;BOI_1M8LO$.CV.JZ;<QWNG7T$=U;7,)RDL3J&1U/<%2"/K7Y(:/\ "B?_
M (*E?M&_&7QI/?3VO@SP_IKZ-X6G.Y8_M&'%H3ZID23R*.<RJ.AKZ1_X)/\
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MU)/[P,N7Q@#SD&.,GF/^"JOQ\N/AK\"8? >@2R/XO\?S'2H+>V!:;['D"X(
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MX+>#-4LOOR:78W*&YC7G[@6^8D].!O/(XZU['^R3^W7X>_:9U'4_"NJ:)=^
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M[VS;D_W<T ?3U%<G\5/BGX8^"_@35/&'B_4X])T'38]\T[@LS$G"HBCEG8D
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M"7/_ "D"^)G_ &#-8_\ 3C;U^Q5 !1110 4444 %%%% !1110 4444 %%%%
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M_MD:?^U=XG\?P>'?"]_:^%?#=XMK9>)9I!Y&I9!Z(0K(QP7V_-A&0MM+!:\
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MJ21@&N^\,_\ !5KX+^#?#VFZ%H?PN^).EZ/IUNEK:6=OH5HL<,2 !54?:^@
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M9RR@^*_\$;?^31[S_L9KW_T5;T ?=5<5\;O^2+^/O^Q?U#_TFDKM:XKXW?\
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MK0!K5^;7[5>@C]J3_@I)\-?@]K;/)X'\-:;_ &M?V.XA;ARC3R X[.J6\7J
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M &+]Q_*O._\ @G_X9A\:?\$Z_!OAZXE>"WU;2M5L))8_O(LMW=(6'N U1?\
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M/,Q/?YY&Q[ #M7S!_P %1O\ DM'[*'_8VR?^E.GU]J? ]0OP6\  # 'A_3P
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MOV+_ -O?XM?#/QC,-'\/?$"Y35- U6\<1V['S)I($W' ^83RQ;L_ZR$+CD8
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M!(V,?[KM7M7[(_[!OP\^&OP!\+:9X[^'GA?Q+XRG@^W:K=ZWHUM>31S2_-Y
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M>*.'3[=?M5S&F&O+H@>=.YZEG;)YZ#:HX4 >BR1K+&R.H=&&&5AD$>AKQO\
M9/\ VE?#W[4'PATCQ1I-[;G6%@CBUK3%<>;8W>W#JR9R$9@S(W\2X/7('KNI
M:E::/I]S?W]U#8V-M&TT]S<R".*)%&69F) 4 <DG@4 ?EWX5^!>C_ /_ (+$
M>&=,\/6WV'0]:TV]UVTLU "0":RNUD1 .B"6*3:.P(':O8/^"OOQ*U?PS^S[
MH?@W1'>.Z\::S'83F,X9[>-=[1CO\TGD@^VX'K7B'P[_ &@M,_:._P""O?AG
M7]!D^T>&],T^]T;3+K!'VF&*QNV:4#^ZTLDI7_9VYP<BOH?_ (*O_"'6OB)^
MSG:>)?#D$ESK'@G5$UIHX5+.;4(RS,H'79F.0^BQM0!](_ 'X(^'_P!GGX4Z
M%X'\.6Z16NGPCS[C:!)=W! ,L\A[LS9/L, 8  KOKNT@U"UFM;J&.YMID:.6
M&9 R2(1@JP/!!!((->5_LP_M%^&_VG/A/I/B[0;N%KIXDCU33E<>;878'[R)
MUSD#()4G[RD$=:]+UW7M-\+Z/>:MK%_;:7I=E$T]S>7DJQ0PQJ,EG9B  !W-
M 'YN_LTZ'_PR?_P4U\:_"'06DB\#>,-..HV5C(?EB983<Q[?:/%S$.Y7&>16
MY^T5_P I@?@'_P!BRO\ Z'JM4_V2]0N/VM/^"@7C[X\Z?:S1^ ?#=D=#T:\E
MC9/M$AC$2XSUS&9I2.JB6,$#-7/VBO\ E,#\ _\ L65_]#U6@#WS_@H]\5=2
M^$7[(?C;4]&NC9:OJ"PZ1;7"_>3SY524KZ-Y/FX(Y!P>U?'7[&?[=7P;_9<^
M!FB^%8OAY\0KK7IE^V:UJECHELR7ET_)*NUT"R(,(F0/E4' )-?:G_!0+X+Z
MA\=OV5?&7A_1H7N==M8X]5T^WC&6FEMW#F,#NSH)%4?WF6L/_@G3^T9H?QR_
M9S\,:9%>1IXK\*V$&C:MILLH-PI@18TGV]2DBA3NQC=N7JIH \[_ .'OWPL_
MZ)[\4/\ P26O_P EU\]_LV_'+P_>?\%)K77OACX:\0>%/ GCVU>RUK2]8TY+
M54N_*DD#QI'(Z &6*)MV0<RRC !Y_6J>>.UADFFD6*&-2[R2,%55 R22>@ K
MYP^#7[;6A?'G]HGQ;\.?!NA76M>'?#UFLLOC2UG5K)YMVUHP"!E2QVHREMY1
MR!L&Z@#S#_@H-\-O'WA_XB?##]H'X=Z(WBN_\ M*FIZ&BL\DMHYR715RQ #2
MJQ4$J&5L$*<>P?LQ_MQ?#']J:S2#P]J9TGQ2B;KCPSJI6*\3 ^8QC.)D']Y"
M<#&X*3BO;IO%&CV_B*W\/R:K91Z[<6[W<.F-<(+F2%6"M*L>=Q0%@"V,9-?G
M]_P5/^!?@CP#\/+?XV^%UA\$?$W2]9M6M]2THBVDU&5WYW*N TJ@&3?][","
M2.@![_\ \%%OB]J7P8_9*\9:OHL[6FL7ZQ:1:W,;E7A-PX1W4CD,(_,((Y!
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MS$?,4< \DJ223]F44 ?GK>_\$VOB]\2E72OBC^TWXB\0>%0W[W2[..4?:%'
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M;5 SC\*M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC!SN \W'0?=KZ HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OQV_:\_Y2\?#O_L8/"W_H^"OV)K\=OVO/^4O'P[_[&#PM_P"C
MX* /V)HHHH _'7_@ES_RD"^)G_8,UC_TXV]?L57XZ_\ !+G_ )2!?$S_ +!F
ML?\ IQMZ_8J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K\=OVO/^4O'P[_[&#PM_P"CX*_8FOQV
M_:\_Y2\?#O\ [&#PM_Z/@H _8FBBB@#\=?\ @ES_ ,I OB9_V#-8_P#3C;U^
MQ5?C+_P30\1Z3X?_ &]/B3>ZIJEGIMF^G:NB7%Y<)%&S'4+<@!F(!) )_"OU
MO_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/
M@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H
M<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\
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M-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\
MBZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6
MSX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\
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MR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\
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M/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\
MH<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_
M /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#
M_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC
M_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!
M_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR
M\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^
M#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\
MXN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .K
MHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X
M6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_
M *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#
M_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T
M@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+
MH_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/
M@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H
M<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\
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M-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\
MBZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6
MSX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\
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MR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\
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M/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\
MH<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_
M /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#
M_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC
M_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!
M_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR
M\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^
M#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\
MXN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .K
MHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X
M6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_
M *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#
M_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T
M@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+
MH_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/
M@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H
M<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\
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M-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\
MBZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6
MSX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\
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MR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\
M^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_
M (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^
M%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_
M .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P
M_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-
M(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#B
MZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNB
MN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;
M/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\
MH<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_
M /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#
M_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC
M_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!
M_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR
M\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^
M#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\
MXN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .K
MHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X
M6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_
M *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#
M_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T
M@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+
MH_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/
M@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H
M<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\
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M-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\
MBZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6
MSX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\
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MR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\
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M/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\
MH<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_
M /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#
M_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC
M_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!
M_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR
M\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^
M#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\
MXN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .K
MHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X
M6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_
M *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#
M_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T
M@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+
MH_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/
M@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H
M<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\
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M-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\
MBZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6
MSX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\
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MR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\
M^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_
M (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^
M%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_
M .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P
M_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-
M(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#B
MZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNB
MN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;
M/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\
MH<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_
M /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#
M_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC
M_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!
M_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR
M\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^
M#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\
MXN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .K
MHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X
M6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_
M *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#
M_P#X-(/_ (NC_A;/@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T
M@_\ BZ/^%L^!_P#H<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+
MH_X6SX'_ .AR\/\ _@T@_P#BZ .KHKE/^%L^!_\ H<O#_P#X-(/_ (NC_A;/
M@?\ Z'+P_P#^#2#_ .+H ZNBN4_X6SX'_P"AR\/_ /@T@_\ BZ/^%L^!_P#H
M<O#_ /X-(/\ XN@#JZ*Y3_A;/@?_ *'+P_\ ^#2#_P"+H_X6SX'_ .AR\/\
M_@T@_P#BZ .KK\=OVO/^4O'P[_[&#PM_Z/@K]7O^%L^!_P#H<O#_ /X-(/\
MXNOR4_:EUK3_ !!_P5K^'-YI=_:ZE:-XA\+JMQ9S++&2)X 0&4D<4 ?LM111
M0!_/9^SU^RC_ ,-0?M)>,OA__P )3_PC7]G+?WW]H_V?]K\SRKI(MOE^;'C/
MF9SN.,8P<YKZQ_X<A_\ 5:/_ "U?_NVN._X)D_\ )_GQ+_[!VL?^G"WK]>*V
MC%-:F4I-/0_+C_AR'_U6C_RU?_NVC_AR'_U6C_RU?_NVOU'HJN5$<S/RX_X<
MA_\ 5:/_ "U?_NVC_AR'_P!5H_\ +5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_[
MMH_X<A_]5H_\M7_[MK]1Z*.5!S,_+C_AR'_U6C_RU?\ [MH_X<A_]5H_\M7_
M .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\ AR'_ -5H_P#+5_\ NVOU
M'HHY4',S\N/^'(?_ %6C_P M7_[MH_X<A_\ 5:/_ "U?_NVOU'HHY4',S\N/
M^'(?_5:/_+5_^[:/^'(?_5:/_+5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_ .[:
M/^'(?_5:/_+5_P#NVOU'HHY4',S\N/\ AR'_ -5H_P#+5_\ NVC_ (<A_P#5
M:/\ RU?_ +MK]1Z*.5!S,_+C_AR'_P!5H_\ +5_^[:/^'(?_ %6C_P M7_[M
MK]1Z*.5!S,_+C_AR'_U6C_RU?_NVC_AR'_U6C_RU?_NVOU'HHY4',S\N/^'(
M?_5:/_+5_P#NVC_AR'_U6C_RU?\ [MK]1Z*.5!S,_+C_ (<A_P#5:/\ RU?_
M +MH_P"'(?\ U6C_ ,M7_P"[:_4>BCE0<S/RX_X<A_\ 5:/_ "U?_NVC_AR'
M_P!5H_\ +5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_[MH_X<A_]5H_\M7_[MK]1
MZ*.5!S,_+C_AR'_U6C_RU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'
M(?\ U6C_ ,M7_P"[:/\ AR'_ -5H_P#+5_\ NVOU'HHY4',S\N/^'(?_ %6C
M_P M7_[MH_X<A_\ 5:/_ "U?_NVOU'HHY4',S\N/^'(?_5:/_+5_^[:/^'(?
M_5:/_+5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_ .[:/^'(?_5:/_+5_P#NVOU'
MHHY4',S\N/\ AR'_ -5H_P#+5_\ NVC_ (<A_P#5:/\ RU?_ +MK]1Z*.5!S
M,_+C_AR'_P!5H_\ +5_^[:/^'(?_ %6C_P M7_[MK]1Z*.5!S,_+C_AR'_U6
MC_RU?_NVC_AR'_U6C_RU?_NVOU'HHY4',S\N/^'(?_5:/_+5_P#NVC_AR'_U
M6C_RU?\ [MK]1Z*.5!S,_+C_ (<A_P#5:/\ RU?_ +MH_P"'(?\ U6C_ ,M7
M_P"[:_4>BCE0<S/RX_X<A_\ 5:/_ "U?_NVC_AR'_P!5H_\ +5_^[:_4>BCE
M0<S/RX_X<A_]5H_\M7_[MH_X<A_]5H_\M7_[MK]1Z*.5!S,_+C_AR'_U6C_R
MU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\
MAR'_ -5H_P#+5_\ NVOU'HHY4',S\N/^'(?_ %6C_P M7_[MH_X<A_\ 5:/_
M "U?_NVOU'HHY4',S\N/^'(?_5:/_+5_^[:/^'(?_5:/_+5_^[:_4>BCE0<S
M/RX_X<A_]5H_\M7_ .[:/^'(?_5:/_+5_P#NVOU'HHY4',S\N/\ AR'_ -5H
M_P#+5_\ NVC_ (<A_P#5:/\ RU?_ +MK]1Z*.5!S,_+C_AR'_P!5H_\ +5_^
M[:/^'(?_ %6C_P M7_[MK]1Z*.5!S,_+C_AR'_U6C_RU?_NVC_AR'_U6C_RU
M?_NVOU'HHY4',S\N/^'(?_5:/_+5_P#NVC_AR'_U6C_RU?\ [MK]1Z*.5!S,
M_+C_ (<A_P#5:/\ RU?_ +MH_P"'(?\ U6C_ ,M7_P"[:_4>BCE0<S/RX_X<
MA_\ 5:/_ "U?_NVC_AR'_P!5H_\ +5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_[
MMH_X<A_]5H_\M7_[MK]1Z*.5!S,_+C_AR'_U6C_RU?\ [MH_X<A_]5H_\M7_
M .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\ AR'_ -5H_P#+5_\ NVOU
M'HHY4',S\N/^'(?_ %6C_P M7_[MH_X<A_\ 5:/_ "U?_NVOU'HHY4',S\N/
M^'(?_5:/_+5_^[:/^'(?_5:/_+5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_ .[:
M/^'(?_5:/_+5_P#NVOU'HHY4',S\N/\ AR'_ -5H_P#+5_\ NVC_ (<A_P#5
M:/\ RU?_ +MK]1Z*.5!S,_+C_AR'_P!5H_\ +5_^[:/^'(?_ %6C_P M7_[M
MK]1Z*.5!S,_+C_AR'_U6C_RU?_NVC_AR'_U6C_RU?_NVOU'HHY4',S\N/^'(
M?_5:/_+5_P#NVC_AR'_U6C_RU?\ [MK]1Z*.5!S,_+C_ (<A_P#5:/\ RU?_
M +MH_P"'(?\ U6C_ ,M7_P"[:_4>BCE0<S/RX_X<A_\ 5:/_ "U?_NVC_AR'
M_P!5H_\ +5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_[MH_X<A_]5H_\M7_[MK]1
MZ*.5!S,_+C_AR'_U6C_RU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'
M(?\ U6C_ ,M7_P"[:/\ AR'_ -5H_P#+5_\ NVOU'HHY4',S\N/^'(?_ %6C
M_P M7_[MH_X<A_\ 5:/_ "U?_NVOU'HHY4',S\N/^'(?_5:/_+5_^[:/^'(?
M_5:/_+5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_ .[:/^'(?_5:/_+5_P#NVOU'
MHHY4',S\N/\ AR'_ -5H_P#+5_\ NVC_ (<A_P#5:/\ RU?_ +MK]1Z*.5!S
M,_+C_AR'_P!5H_\ +5_^[:/^'(?_ %6C_P M7_[MK]1Z*.5!S,_+C_AR'_U6
MC_RU?_NVC_AR'_U6C_RU?_NVOU'HHY4',S\N/^'(?_5:/_+5_P#NVC_AR'_U
M6C_RU?\ [MK]1Z*.5!S,_+C_ (<A_P#5:/\ RU?_ +MH_P"'(?\ U6C_ ,M7
M_P"[:_4>BCE0<S/RX_X<A_\ 5:/_ "U?_NVC_AR'_P!5H_\ +5_^[:_4>BCE
M0<S/RX_X<A_]5H_\M7_[MH_X<A_]5H_\M7_[MK]1Z*.5!S,_+C_AR'_U6C_R
MU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\
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MU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\
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MU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\
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MU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\
MAR'_ -5H_P#+5_\ NVOU'HHY4',S\N/^'(?_ %6C_P M7_[MH_X<A_\ 5:/_
M "U?_NVOU'HHY4',S\N/^'(?_5:/_+5_^[:/^'(?_5:/_+5_^[:_4>BCE0<S
M/RX_X<A_]5H_\M7_ .[:/^'(?_5:/_+5_P#NVOU'HHY4',S\N/\ AR'_ -5H
M_P#+5_\ NVC_ (<A_P#5:/\ RU?_ +MK]1Z*.5!S,_+C_AR'_P!5H_\ +5_^
M[:/^'(?_ %6C_P M7_[MK]1Z*.5!S,_+C_AR'_U6C_RU?_NVC_AR'_U6C_RU
M?_NVOU'HHY4',S\N/^'(?_5:/_+5_P#NVC_AR'_U6C_RU?\ [MK]1Z*.5!S,
M_+C_ (<A_P#5:/\ RU?_ +MH_P"'(?\ U6C_ ,M7_P"[:_4>BCE0<S/RX_X<
MA_\ 5:/_ "U?_NVC_AR'_P!5H_\ +5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_[
MMH_X<A_]5H_\M7_[MK]1Z*.5!S,_+C_AR'_U6C_RU?\ [MH_X<A_]5H_\M7_
M .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\ AR'_ -5H_P#+5_\ NVOU
M'HHY4',S\N/^'(?_ %6C_P M7_[MH_X<A_\ 5:/_ "U?_NVOU'HHY4',S\N/
M^'(?_5:/_+5_^[:/^'(?_5:/_+5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_ .[:
M/^'(?_5:/_+5_P#NVOU'HHY4',S\N/\ AR'_ -5H_P#+5_\ NVC_ (<A_P#5
M:/\ RU?_ +MK]1Z*.5!S,_+C_AR'_P!5H_\ +5_^[:/^'(?_ %6C_P M7_[M
MK]1Z*.5!S,_+C_AR'_U6C_RU?_NVC_AR'_U6C_RU?_NVOU'HHY4',S\N/^'(
M?_5:/_+5_P#NVC_AR'_U6C_RU?\ [MK]1Z*.5!S,_+C_ (<A_P#5:/\ RU?_
M +MH_P"'(?\ U6C_ ,M7_P"[:_4>BCE0<S/RX_X<A_\ 5:/_ "U?_NVC_AR'
M_P!5H_\ +5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_[MH_X<A_]5H_\M7_[MK]1
MZ*.5!S,_+C_AR'_U6C_RU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'
M(?\ U6C_ ,M7_P"[:/\ AR'_ -5H_P#+5_\ NVOU'HHY4',S\N/^'(?_ %6C
M_P M7_[MH_X<A_\ 5:/_ "U?_NVOU'HHY4',S\N/^'(?_5:/_+5_^[:/^'(?
M_5:/_+5_^[:_4>BCE0<S/RX_X<A_]5H_\M7_ .[:/^'(?_5:/_+5_P#NVOU'
MHHY4',S\N/\ AR'_ -5H_P#+5_\ NVC_ (<A_P#5:/\ RU?_ +MK]1Z*.5!S
M,_+C_AR'_P!5H_\ +5_^[:/^'(?_ %6C_P M7_[MK]1Z*.5!S,_+C_AR'_U6
MC_RU?_NVC_AR'_U6C_RU?_NVOU'HHY4',S\N/^'(?_5:/_+5_P#NVC_AR'_U
M6C_RU?\ [MK]1Z*.5!S,_+C_ (<A_P#5:/\ RU?_ +MH_P"'(?\ U6C_ ,M7
M_P"[:_4>BCE0<S/RX_X<A_\ 5:/_ "U?_NVC_AR'_P!5H_\ +5_^[:_4>BCE
M0<S/RX_X<A_]5H_\M7_[MH_X<A_]5H_\M7_[MK]1Z*.5!S,_+C_AR'_U6C_R
MU?\ [MH_X<A_]5H_\M7_ .[:_4>BCE0<S/RX_P"'(?\ U6C_ ,M7_P"[:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_(G]J[_E+A\.O^QA\+_^CX*_7:OR)_:N_P"4N'PZ
M_P"QA\+_ /H^"LY[&D-S]D:***P-S\;/^"9/_)_GQ+_[!VL?^G"WK]>*_(?_
M ()D_P#)_GQ+_P"P=K'_ *<+>OUXK>&QA/<****T,PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***Q[WQEH&F^(++0;O7--M=<O4,MK
MIDUW&ES.@."R1$[F /<"@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#@?>R<85O:OV@OV8O'W[-/[)^HZMX"^+GCC5-?\ #.KG79[A]7N(5EL"%62
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MVPK[XHQVTVI_"/XF7#?VQ!;J#+;798R28' +J[22IG 97D3JNZE^$FC^+_\
M@HI^TUH?QB\0:5/X=^#G@FYW>'K&Y^_>S1N&'LQ,B(TC#*@1K&-Q!89:_,U_
M(_2NBBBM3(**** .<^(WCS2OA?X#U_Q;K<P@TK1;*6]N&S@E44G:OJS'"@=R
M0*_/K_@F7^V=K?Q7^+OQ \)^-;]YKWQ+<S>(M'660LD+#B:UBSSL$81E4< 0
MR'J:Z#_@J!\0=6^(FO> /V;_  :3+K_BV]@O-2"D[4@$A6!7Q_#O5YFS]T0*
M>AKE_P!N[]GP?LNZ/\'/C#\,;+[/)\.FM=)O]GRF>!6S#+-CKO=I8Y&ZM]H4
M=!6;;O?L:)*VO4_3"BN;^&_C[2_BEX!\/^+M$E\W2M:LHKZ D@LJNH.QL=&4
MY4CL015/XO?%70/@E\.==\:^)K@V^CZ3 9I @!DE;("1(">7=BJ@>K#) YJR
M#L**_,_P3X;_ &C_ /@HA'-XQU'QW=?!KX4W$CIIFF:.TGFW<8)!.$:-I1E<
M&25@NX$HF*ZN\_8+^.7P1CD\1?!WX^:UK&JVH$B^'?$6[[->XP64LTKQ$G&!
MNC'7[Z]:5_(KE\R;QY_RF*^''_8J2_\ I-?U]_U^3OP-^.6H_'[_ (*:?#;6
M]>T&3PUXHTW0[S1=;TQ@0L-[!;7PEV DD*=P.#R"2,G&X_I?\9/BUH'P-^&N
MN^-_$TS0Z1I,'FNL8S)*Y(6.)!W9W95';)YP,FE'JPET1V=%?F/X)\*_M)_\
M%$%G\7ZIX[NO@]\*KF20:7I^DE_,NHPQ7&Q'C:9>"#)*X!891,<#?\3?L(_'
MWX#V<OB?X,?'/7?$>I6F)F\.:NS(MWCJ!OE>&1CCA9$7C^+-'-Y!R^9^C-?G
MM^T)_P I<O@1_P!BTO\ Z'JE>X?L/?MA1?M3>#M1M-9L5T+X@^'76#6M+561
M3DD+-&K<A258,IR488/!4GP_]H3_ )2Y? C_ +%I?_0]4H;ND"T9^A-%9GB;
MQ)IO@WP[J>O:S=QV&DZ;;27=W=2G"Q1(I9F/T -?G+X=\0?M _\ !2#7-2U?
MPOXLN_@O\&+2Y>UM9[,NM[>E<9)\ME:5NF[]XL:YVC>0Q+;L)*Y^EM%?GSJO
M_!.7XK?#K36UCX7?M$>*/^$GMD\Q;+599$MKQP/NL1*RJ#V#HXZ9]:]4_8E_
M:T\1_%[5/$OPS^*.D+X?^+7A, WT*JL:WL.X*950$A64LF[;\I$B,O#84OW"
MW8^LJ*^,OVZOBIX^O?B5\,/@5\.-?/@_5_',DLE_XAC)$UM:ID%8R,$$A9&)
M4JQ**H8;C7&7/["?QS^">JV/B?X/_'35=>UG[1&+_2?%LCFTNT9L.[Y=U;&2
M2I7=C<5<-@$N%C] **R-4U^W\(^$[K6O$E[;6=KIMDUWJ-XH9(8UC3=*X!)(
M4 ,<9)QZU^>FF_$SX_\ _!1#Q1JH^&VNS?![X+65Q)9'7HU/VZ](QR"I60N0
M02B.B*&PSL<9&[ E<_2*BO@E?^"9OC?1;62]\/\ [3/CJQ\2GYC>O),(I6&>
M&5;@-@].6;OP>E=?^RG\3_CWX2^+6H?!WXV:#=>)/(M3>:9X\TVU+6LD0SA9
MY555(;&%) D###!MVX%^X6['V/17D'[57[1^C?LN?"'4?&>J0B_N]ZVFFZ8)
M C7ET^=J9[* &=CSA4; )P#\?>"_V7_VB_VO--@\;_%?XO:K\/-(U15NK'PK
MH*R1[(&P5W1+(BQ'&TC?YC\_-@YHOT!+J?I!17YR^-/V8OVC/V1]/;QE\(_B
MQK'Q'TK3\S7WA/7P\NZ%02Q2-I&63C.0GEO_ '<FOKS]E?\ :,TC]J+X/Z;X
MUTR#[!<L[6FHZ:SAS9W28WIGNI#*ZGNKKD Y $PMU/7J*_,W]J+]JSQ?\ /V
M_)ULKO7_ !%I1\/PP:=X-MKZ;['=:A/$4AS &VD^8RDD*6...2*[^S_8=^,?
MQXLU\2?&?XX>(-$UF]!F3PSX5<Q66FAAE8^&"%ESAL*>GWV^]1S=A\O<^\Z*
M_./PKXX^*W[!G[1_@[X=^/\ QE>?$;X5>-KC[)I>L:HS/<V4I=4'S.Q9=CR1
M;U+%2C[EP<K7V1^T;\&]>^-_@BQT+P]\1==^&5[;ZBEZ^K>'Y)$GFC6*5# Q
M22,["9%8\XS&O'<%Q6/E3]A[_D^W]JK_ +"1_P#2J:OO^OQW_9K_ &7?&/CW
M]ISXX>%--^.'B_PKJ?AV\\J\\0Z;/,MWK!\^1=\Y6=6)RI;YF;EC7UM^UY\2
M?'?[,_[/_P -_A[X4\47.L^/_$U_!X;A\6ZLQ-QS@/<,SE_WC%D7<22 S$<@
M$3%Z%-:GVE17Y[ZO_P $]/C-X#L$\6^ /VA_$FI?$6V0320ZQ-(+74)!@M&2
MTCC:<<"574X ; Y'W1\/H_$T7@?0T\92Z?/XK%I&-3DTM&6V-QM^?RPQSMS^
M?H.@I$'044450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OR)_:N_Y2X?#K_L8?"__H^"OUVK\B?VKO\ E+A\
M.O\ L8?"_P#Z/@K.>QI#<_9&BBBL#<_&S_@F3_R?Y\2_^P=K'_IPMZ_7BOR'
M_P""9/\ R?Y\2_\ L':Q_P"G"WK]>*WAL83W"BBBM#,**** "BBB@ HHHH *
M*** "BBB@#X.^-/Q(\6Z5_P5+^$GA.R\4:U9^%K[1$ENM#M]0F2QN'Q?_-)
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MQ)"X)5XW7/#HX92,XRO!(P:$[@U8^&/V]-'E^.W[;7P6^"&LZO?V?@K4=/\
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M9T\,ZI\1]?U#7_%6N(=6F?46!>VBE ,,(&!C$81B",AG>O=Z "BBBF(^%_\
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MEXD*II&C[&D6-6?8LLB+\S[GRJ(""Q#<@*<^(Z+^R+^UM\7K-?$/CS]H?5/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!^:O[;GP_T#XJ?\%(_@EX4\46']
MIZ!JFA1PW=IYTD/FH)[UL;XV5ARHZ$=*^AU_X)C?LT*0?^%:]/77=3/_ +<U
MXS^TU_RE6_9]_P"P.G_HV^K]":A):EMNR.+^&'P7\"_!?27TWP/X5TSPU:R8
M,OV& +),1T,DAR\A'JQ)KX;_ ."QVGC5M#^#EBREEN=<N(2H."0RQ#^M?HQ7
MY[?\%</^:%_]C+)_[1HEL$=S]!;6VBL[>*W@C6&")!''&@PJJ!@ #L *^!/V
MB/\ E*]\ /\ L -_/4*^_P"O@#]HC_E*]\ /^P W\]0IL(E'_@LQ:/J'PI^&
M]K']^?Q&T2_5H' _G7Z :'H]KX=T73])L(_)L;&WCM8(Q_#&BA5'X "O@W_@
MKY_R(?PG_P"QK7_T4U??]"W8GLCX9_X+$6J7'[*>F2,,M!XHM'3CN8+E?Y,:
M^J?@#X?MO"OP+^'ND6D:QV]GX?L(55>^+=,GW).23W)KY<_X+!?\FG6G_8RV
M?_HJXK[!^'__ "(?AO\ [!MM_P"BEI?:8=#YO_X*D(K?L3^.2R@E9].*DCH?
MMT R/P)_.O6?V3;I[S]EWX1RR'+GPGI8)]<6D8S^E>3_ /!4;_DR7QW_ -=M
M._\ 2^"O4OV0_P#DU?X1?]BIIG_I-'3^T'V3Y,_X)IVD/BK]HK]IKQEJJB7Q
M.NNBTW/]^WAEN;IG0>@)AC'_ &R%?H?7YJ_&"'Q)_P $]_VO-7^,ECI%UK?P
M@\>2$:]'9)EK.XD<.Y/10_FEI(RV PDD3(/S5]D>$?VQ/@EXU\/QZQI_Q2\+
M0VC('=-1U2&RFB!_YZ13,KIZ<@4HZ:,<NY0_;?\ "^G^+OV2_BI:ZE'$\5MH
M-UJ$1E4';-;H9HR/0[HP ?>O&OV+_P#E%S8_]@#Q%_Z5WU>7_MQ?MC0_'KX?
M^+/AA\$8Y?%5G;:=+J?BOQ-;J4L[/3[<&5XXY#C<7*!2P^4@[5W%CM]0_8O_
M .47-C_V /$7_I7?4KZCV1F?\$=M&@L/V6]5ODA5;B^\2W3R2XY=4A@11GT&
M&X]SZU]OZII=IKFEWFG7\"75C>0O;W$$@RLD;J592/0@D?C7QG_P2)_Y-&3_
M +#][_**OM:JCL3+<_/3]@/5KO\ 9O\ VBOBC^S3KMPQLX[I];\,RS''G1E5
M+*#W9X#$^!P##-WIO[2^?VNOV\/ 7P6@S=>#/ J?V[XE53F.23".8W]1M,$.
M>H-Q)Z5H?\%.?!VJ_#77?AS^T=X1BVZ[X.U"*SU+;D":U9R8A(0/N;FDB;U%
MP!72?\$O?ACJ4/P[\3_&/Q4#-XN^)&I2Z@\\BX86HD<K@?PAY&E? X*^7Z"I
M_NE?WC[9Z<"BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^%?^17T?_KSA_P#0!7P]_P %FO\ DU_PO_V.-K_Z17U?</A7_D5]'_Z\X?\
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MK9;/3--MH[2UMX_NQ11J%11[  "M"OA;]D7_ (* >'H_#MI\-/C9?_\ "O\
MXD>&T73;F;Q"#:P7@C&U7>5_ECDVA=P<J&)W*2#A?</BI^W+\$OA+X>GU/4/
MB!HNLSJA:'2] O(K^[G;&54)$QVY[,Y5?>JNB;,^;O%WA?3_  [_ ,%CO EU
M8QQ1RZSX:FU"[$2A<S?9+V'+>I*P(<^]3_\ !8B^O;GX8?#;PZEP;72]6\2C
M[7+V!2(JF?8>:[8_V1Z"O%/@%XQ\;_$K_@J'X,\:>.M$F\.77B/3+O4-+TF<
M_/;:=]ANH[=2#R"5C+'(&XL6P PK[J_;J_9OF_:<^ .I>'-,9$\2Z?.FJZ.T
MC;5:YC5E\ICV#H\B9/ 9E)Z5&Z96S5SW70-"L/"^AZ?H^EVL=EIFGV\=K;6T
M*A4BB10JJ .@  %7Z^(/V4_^"AWA74O#=MX&^,NI+\/OB7H(&G7_ /PD :VA
MNVC&WS3(_P L<F -ZR%?F.5R#@>J_%K_ (* ? WX4>&;C4SX]T?Q5>K&6MM+
M\,WL=_/</V3,3%(_J[*,>O -W1-F?.FAZ6GP]_X+%7UMH*K;67B?0I+G4[>W
M 5 S6GF.6 [M+;I(3W9R>]7/VA/^4N7P(_[%I?\ T/5*U_V _A=XR^)'Q4\9
M?M-_$BQ;2]5\51FUT'3) P,-F=G[P!N0FR...,GEE#MC#*3D?M"?\I<O@1_V
M+2_^AZI4]"^IZ=_P54\076A_L:^)8+4NHU*^L;*9T."(_/60Y]B8PI]=V.E>
M.? .R_;+\(_!7P5IG@;0/AL/"*:5!-ICS2,9)894$HD<^:,N^\NW Y8\"OM3
M]I#X,VO[07P1\6> KJ5;9M6M,6URPR(+E&$D,A[X$B)G')&1WKX[_8S_ &T+
M'X+:2OP)^/$C>!O%?A/_ $"RU#4UV6L]JH'E(\@X4JOW7/R.@0AL]6]Q+8ZW
M^V/V]_\ H!?#/_OM_P#X[7(_#7]G3]I#5/VT?"/QH^(.C^%+ 6D+6.J-H-YL
M$\!@EB#M&68NX$BCKTC3CBOJ#Q_^VU\#OASH,NJ:A\3/#NH*L?F1VFBZA%?W
M,V<;0D<+,><C!.!W) !(\A_8U^-?Q=_:<^+7BWXC7D<WAKX(M#]BT/1;RWC,
MEU*AP)EDQNX^<NP)7<RH-VPD&EPUL=O^VA^R7>_M%:7X=\0>$==_X17XE^$I
MS=:)JNYDC))5C'(R@LOS(K*P!VD'@AC7E'PC_;X\5_#?QMI_PR_::\*2>"O$
M=PX@L_%42!=/OCD*'?!* $D9EC8H"W*Q@&O=/BM^VG\-_@G\9-(^'OC.ZO="
MGU&Q-ZNM75JRZ?&2V%C:7N3ALL 57@,02<?,/_!3+X_?"OXM?!?3/ /A#6]*
M^(7CK5M6M#I$'AZ=+YK9M^&8O&2%9P3&$SN)D'& 2!]T"[,]=_X*H^([[P_^
MQQXDCL7DC_M*]L[&=XS@B)I@[ GT.P*?7=BO9OV5?"NF>#/V;?AEI>D)$MFG
MAZQFWPH%6:22%9))<#N[NS'W:LCXB?L_O\8/V4?^%6>([S&J7&@VEG)J#G>4
MOH4C9)B1G(\V,$XZC([U\J?LC?MC)^S=;)\!/V@8YO!NN^&R;72M:NHV:TN+
M3<?*5G .% R$E V%  2I7YC9ZBW6A^BU%>4ZS^UA\%]!T<ZI=_%;P=]BVEE:
MWUNWG:3!P=B1NS.1Z*":\C_9]_;8U?\ ::^.VK:1X&\#RW'PETRW*S^,+]GM
MY#<C)&Q"I#!\J!&<.%R[$?<JKHFS/ /^"J?]N^+OV@O@#X-T:VL[RZEGDGLK
M/5'*V=U=2W$*)'-@C*DQ*IZ<2$ C)KU#^V/V]_\ H!?#/_OM_P#X[72?\%&_
MV>?$?Q8\ ^'/&_@**27X@> +[^U=.AMT#2W$649TC7'S2*T44BKSG8R@$L*O
M_LW_ /!1;X6?&3PG8KXD\1Z;X$\9Q*L.H:3KEPMI&9\89H))"%="P.!G<.A'
M0F.I?30XS^V/V]_^@%\,_P#OM_\ X[5K_@GM^S;\4_@!XN^*%]X]T[1]-T_Q
M5-!?06VCW8DA@G62<LB)_ F)@!R>$49.*Z[]H#_@HU\(O@WX<N6T3Q'I_C_Q
M2ZLECH_A^Y6Z1Y<<>;-&2D:@D9Y+=<*2#CJ/V)9/C#J7P=&M_&>_,VOZQ=R7
MUEITMJD$UA:/\R1R!0#DDL0K9**54G((#TN+6Q\Q^-?#%MXH_P""R'A47<*S
MP6&C)J&QQD;X[.8QM]5D*,/=17Z.U\ 7G_*8NQ_[%0_^DKU]_P!./44NA^?7
M_!82;[#X$^%&H(H^T6OB?=&W<?NBV/S5?RK]!:_/;_@LE_R2_P"&?_8R_P#M
M!J_0FA;L'LCX _8>_P"3[?VJO^PD?_2J:OH_]KS]F'3OVJ/A6WAR:_;1M<L+
M@:AH^JH,_9KE5(&X#DHP8@X.1PPY4"OG#]A[_D^W]JK_ +"1_P#2J:OI3]H'
M]KCP/^S3X@\'Z;XT&I6UMXCFDB&IP6;26MFJ ?/*_P!2!M3<P&6( QF5:VH]
M;Z'S#X+_ &T/BI^RCKVG>!OVGO#-Q<:.SBUL/B%I:F:*<#@-*0,2\<DC;* ,
MM&Q.:^_]+U2TUO3+34=/N8KVPO(4N+>Y@</'+&ZAE=6'!4@@@CJ#7Q7^W;^U
M?\#_ !!^R[XMT2V\8:!XTU37+/R-+TW2;N.\F2Y)!CF<(3Y7EG#Y?:?EP,DX
MKW3]B[PCKO@/]ECX:Z'XD2:'6;72D,T%QQ)"'9G2)AV*(R+CMMQVIK>P/:Y[
M51115D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(#'U+9ZDU;_X+':<=8^&?PQL!(L)NO$WD>8W1=T++D^PS7C/P#^*7B;XV?\
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M[,'(49,>V6>.0CD+(#T5B(Z7-.MC[SJ"^L;;5+&XLKR".ZM+B-H9H)D#)(C
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MZB6PH[G=^#_^":G[-^J>$M$O;KX<^;<W-C!-+)_;FI#<[1J6.!<X')/2M?\
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M_@FO_P F2_#/_KC>_P#I?<5XS_P1R_Y(W\1/^QKD_P#2>&I70?<]P_X*+?\
M)EOQ/_Z\[?\ ]*X:U/V#?^3/?A5_V!T_]#:LO_@HM_R9;\3_ /KSM_\ TKAK
M4_8-_P"3/?A5_P!@=/\ T-JK[0?9/E#XD^$;/QE_P6.\&VVH6T=U:6>F0ZB8
MY!D>9!9S21-]5E6-OPK]*J_/;6/^4R>A_P#8M-_Z0S5^A-*/4)=#X"_X*^%=
M/^'GPJUA 1>6/BR/RG'! ,+N?UC7\J^[?$6@6'BOP_J>B:K;K=Z9J5M)9W5N
M_26*1"CJ?8J2/QKX0_X+&_\ )&_AW_V-<?\ Z3S5]_T^K$]D?GY_P3IU^_\
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MY> P!QD3U8WLCZ9K\\?V7[.+X8?\%1/COX(T(>3X<U'2QJLEK#Q''<-]DG!
M' "M=SJ!CC=BOI#X^?MP?"CX!^%;K4+[Q1IVNZSY9-GH.CW<=Q=7,F/E!"$^
M4A/5WP  <9. ?%/^"<'PA\7ZEKWCO]H/XB6K6/B7Q^Y.GVDB%&BLFD$A;:W*
MHQ6)4!YV0J>0P-#W0ELSE/@;I<?Q3_X*M?%W7?$,:7<OA&P:'2H)QG[.R^1
MDB ]/D:4_67/!K]%*_.K]J:QU_\ 8S_;!T_]H_2=+N=8\ >)((]+\56]F,O;
ML52,DC@ ,(H9$).#(C*2NY2?L?P#^TW\*OB;H,&K^'O'V@7=K(JLT<E_'#/"
M2,[9(G(=&]F H78'W)OVD/ >E_$OX#>/?#NKP0SVEWHUT5,XRL4J1L\4H]"C
MJC@^JBOGK_@DKXHU#Q%^R)9VU]))+'H^LWFGVK2'.(?W<P /H&F<#TQCM6#^
MV[^VYH-YX/O/A+\(;^/QY\1?%J-I"KH#BYCLXY04D_>(2#*5+*%4_+DLQ7:
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M_8RY?R[>WC<\,ID;=G^(H"N55C1)Z!%.Y]W^ /\ DR/PW_V3RV_]-JU\W?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%>4?$3]I3PA\,_C)\/\
MX;:M.RZ]XR,PM2I79;[1B,R9.1YL@,:8SE@:]7I#"BBBF(**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***^;_ !A^U/JOAO\ ;>\#_ R+
M0[.;2?$&CR:G+JSRN)XF6*\DVJOW2,VJCG^\:0SZ0HHHIB"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO%)02*"%;@CD!F_.NDL[.'3[."UMXUAMX$6*.->BJHP /H!4U%(#GO'OP_\
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M '+_  Y^%_A7X1^'!H/@[0[7P_H_G-<?8[,$)YC8W-R3R<#\JZBBBF!\ ?\
M!1K7[_XW?%+X6?LT>&[IH[GQ!?QZKKLL)!,%JN[9N&>=J+/,5/\ SSB/<5]W
M>'?#]AX3\/Z9HFE6RV>EZ;:Q6=I;I]V*&- B*/8* /PKSSP]^S3X*\.?'/7/
MBY##?77C;5[?[)-=7ETTL<46(UVQ(>$^6)%X[9'<UZI4KN-OH%%%%42%%%%
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M_P"";_[.&L:K)J,_PQM([AVWE+74;VWAS[11S*@'L%Q7K.A_ GX>^&/A_?\
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M6&<@@9! (Z"O?:** "BBBF(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BN)^-'Q4T_X(_"_7_'&JVMQ>Z=HT2SSP6N/-9#(J';D
M@9&[.,]JVO!'C;1/B/X2TKQ-X<U"'5=#U2!;BUNX3E70_J"#D%3R""#@BD,W
M***\8_:N_::TS]E'X:VGC'5M%N]=MKC4XM,%M9RK&X9XY7#9;C $1'XB@#V>
MBJ6AZHNN:+I^HHC1)>6\=PJ,<E0ZA@#^=7:8@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHKX_'[:7C+_AO#_A1I\ @>&ON?VI\_VK;]
MF\[[5G/E^3N^7'7'.=WR4KCM<^P****8@HHKYP_9T_:FU7XV?';XS> [W0[/
M3;3P)J)LK:\MY7:2Z43S1;G!X!Q$#QZFD,^CZ*^$_'G[7W[3WA'4_$4D/[.J
MW'A_2YKADU)[B0*]M&S8F.#T*+NKC/AO_P %#/VBOB_X>;7?!GP M?$.D+.U
ML;RSNI2@D4 LO)'(#+^=+F0^5GZ/T5\J_'']K+QO\#?V2]"^)^N>"+6Q\87=
MU#:WWAV\F=4M6D:08W#G.$4_\"J+]A7]M]OVM(?%6G:WHEKX9\4:')'(;"WE
M9A-;.-N\!_FRKJ5;L-Z>M%U>P6=KGU?17EG[3GQXT[]FWX+>(/'5_&EU-9QB
M*QL7?;]KNW.V*+/7&>6(Y"JQ[5X+^PG^W9XA_:U\8>*=%UOPII_AU='L8KM'
MLYI'9R\FW!#]!CFG=7L%G:Y]FT444R0HHHH **** "BBB@ HHHH **** "BB
MB@ K\B?VKO\ E+A\.O\ L8?"_P#Z/@K]=J_(G]J[_E+A\.O^QA\+_P#H^"LY
M[&D-S]D:***P-S\;/^"9/_)_GQ+_ .P=K'_IPMZ_7BOR'_X)D_\ )_GQ+_[!
MVL?^G"WK]>*WAL83W"BBBM#,**** "BBB@ HHHH **** ([JVAO;>6WN(DGM
MYD,<D4JAE=2,%2#P01Q@U\G^/O\ @ES\ /'>KS:DGAR^\,SS2&26/0;YH(6)
M[")@Z(/9 HKZTHI6ON.[1YE\"_V;_A[^SCH,^E> _#\>E+<D-=WDCM-<W3 <
M&25B6('.%&%&3@#)KTVBB@#Q'XX_L8?"']H:\_M'QAX2AEUK 7^V-/D>TNV
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M&,,Q!'7-?6U%*R8[M%?3M.M-'T^VL+"UALK&UB6&"VMXQ'%%&H 5$4#"J
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M#J58!E(P0>AKY@^(_P#P38^ 7Q*UR75[GP>VB7TS%YCH-V]G%*3W,2GRU/\
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M,RJK9XVJ68'JHKSSPE_P5K^'%WK]KIGC3PEXI^'ZW1'EWVHVHE@53C#/M/F
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MG^ZPR/T-359 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6?P9;:3;Z0^HHNJ1Z@TKR_9IO+&8S& -W7[W'O7V31>X6L%%?'G[77[>M_\
MLQ_&KPEX$M?!UOK\6N65O=M?37[0-"9+F2':$$;9P(\YR.N*^PZ+A8**\-_;
M&_:/N?V6?@Z?&]KH47B*4:A!8_8YKDP+B0,=VX*W3;TQWK;_ &6/C;/^T9\!
M_#'Q#N=)CT.;6/M6ZPBG,RQ>5=30##E5SD1;NG?%%];!;2YZO1535KXZ9I5[
M>!/,-O"\H0G&[:I.,_A7R9^PU^W=?_M@>(/%6FWG@^W\,+HMK!<+)!?M<F7S
M'9<$&-<8V^_6BX6ZGU]117QYXV_;UO\ PC^VM8? A/!UO<VEU>V-H=;:_99%
M%Q!'*6\KRR/EWXQNYQ1>P6N?8=%%?,7[<O[8UY^Q_P"'_"NI6?A>#Q.VM74]
MNT<]XUL(O+16R"$;.=WMTHV#<^G:*Y3X2^-G^)GPJ\&>+Y;1;"3Q!HMEJS6B
M/O$)G@24H&P-P7?C.!G'2JGQN^(DGPC^$/C#QI#8KJ4N@Z7/J"V;R&-9C&A;
M86 .,XZX- ';45\V_L/_ +7%W^UYX*\1:]=^&H?#+Z5J"V*P0WAN!(#&K[B2
MBXZXQ7TE0&P45\>?"G]O6_\ B1^V)XA^",G@ZWL+72KW4K1=96_9WD%J7 8Q
M>6 -VWINXSWK[#HO<+6"BOC;]N#]OR__ &0_&OAW0;3P9;>)DU73VOFGFU!K
M<QD2,FT 1MGIG-?9-%PL%%>._M:?'JX_9I^!^L>/K;1H]>FL)K:(6,MP8%?S
M9ECSO"MC&[/3M47[(O[05Q^TY\%-/\>7.BQZ!+=75Q;FQAN#.J^5(4SO*KG.
M,]*+ZV"VESV>BBOCS]BK]O6__:R^('BCPW=^#K?PVFC67VM;B&_:X,I\T1[2
MIC7'7.<FBX6/L.BBOC;XP?M^7_PO_; \.?!2+P9;:A:ZMJ&E6+:P^H-&\8O)
M(U+"+RR#MWYQNYQVHO8$KGV3117SE^V]^UC=_LB_#_0?$EIX;A\3/J6J?V>;
M>:[-N(QY4DF_<$;/W,8QWH#<^C:*X/X$?$N7XR?!WPAXWFL%TN77=/COFLXY
M3(L)8?=#$#./7 K6^)_C!_A[\-?%OBF.U6]DT/2+O4UM6?8)C#"\@0M@X!VX
MS@XS0!TU%?,7[#7[8UY^V!X?\5:E>>%X/##:+=06ZQP7C7(E\Q&;))1<8V^_
M6OIVC<-@HKXV\'_M^7_BC]MJ?X"MX,MK>TBU"^L?[<74&:0BWMI9PWE>7CYC
M%MQNXSFOLFB]PM8**^1_VZ/VZ+[]CW5?"%G9^$+?Q.-=AN96>>_:V\GRFC
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M+/X,MM)M](?4475(]0:5Y?LTWEC,9C &[K][CWK[)HO<+6"BOCS]KK]O6_\
MV8_C5X2\"6O@ZWU^+7+*WNVOIK]H&A,ES)#M""-LX$><Y'7%?8=%PL%%>&_M
MC?M'W/[+/P=/C>UT*+Q%*-0@L?L<UR8%Q(&.[<%;IMZ8[UM_LL?&V?\ :,^
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MBVXW<9S7V31>X6L%%?(_[='[=%]^Q[JOA"SL_"%OXG&NPW,K//?M;>3Y31@
M 1MG/F>W2OJCP[JAUSP_IFI-&(6O+6*X,8.0N] V,]\9HOT"QH45Y=^T[\9I
MOV>_@7XI^(-OI4>MS:*D#K823&%9?,N(XN7"MC'F9Z'I7/?L<_M'W/[4WP='
MC>ZT*+P[*=0GL?L<-R9UQ&%.[<57KNZ8[47Z!;2Y[E1113$%%%% !1110 44
M44 %%%% !1110 4444 %%%% 'SU_P4$_Y,U^*7_8-7_T?'57_@G3_P F6_##
M_KSN/_2N:NT_:R^&NM?&#]G7QQX-\.I#)K6KV2P6JW$HCC+"5&Y8].%-0?L@
M?##7/@S^S?X)\%^)(X(M<TFVEBN4MI1+&&:>1QAAU^5Q4_:*Z#/VJOV8?#?[
M5'PQN?#.MJMIJ<&Z?2-85-TMA<8P&']Y&P Z=&'H0I'Y.?M+?'+QWI?P$D_9
MU^+-C<_\)KX/U^UN+#5G)=;RP2"=%W.>7QYD923^)#AL,IW?N17S'^W-^QCI
M7[5W@,260@T[Q]I,;-I&IR#"RCJ;:8@9,;'H?X&.1P6#*2OL.+[GM&EZ2=>^
M#-IIBKN:]T!+8+G&=]N%Q^M?)7_!'[6HI?V;M?T"5Q'JNB^)KF.YM&P)(E>*
M$J2.P+"0<]T;TK[4\)Z=-H_A71K"X"BXM;*&"0*<C<J!3@_45\/_ !=_8S^*
M_P (_C3K'Q;_ &:==L[*ZUQVEUGPEJ#*D%Q(S;FV!QY;*S%FVL4*$ML;#8 ^
MXEM8^]:_/S]CORO%W_!17]I3Q5IQ%SIEG&-+-U&=R>89HUP#WR;23'^[577K
MS_@H!\7--/AFY\,^$_AG:7B>1<:]8WD E5",,=RW-PZ$C/S1H&'8BOIO]D/]
ME;1?V4?AF= LKHZOKNH2B[UC6'38UU-C "CDB-!D*"3U8]6-&['LCUSQ9X7T
MWQQX7U?P]K-LMYI.JVDME=P-T>*1"K#\B:_)[P'^TUK/[#/PM^.WP,UNYF_X
M2K0;J1?"%RP*EUN2$,J]E549+I1W+N*_7>OD[]H_]AW3/CK^TM\+_B-(L"Z=
MI+E/$5N[8:\BAS+: +CYLR91\G.PC^[1)/H$6NIT'_!/WX GX ?LWZ#8WUOY
M7B77!_;6L,ZD2":504B;/(,<81"/[P<]Z\V_X*[>"+WQ7^RG%J5E$\H\/:[:
MZC<A%)Q T<L!./0-.ASV -?;54=<T/3_ !-HM]I&K6<.HZ7?0/;75I<('CFC
M<%61@>H()%.VEA7UN<C\"_BII/QJ^$?A;QGHL\<UIJEC'*Z(P)@F"@2PMCHR
M.&4CU7TKO*_/)OV0_C[^R#XLU/5/V;=?LO$_@O4)OM$O@GQ',HV/Q\H+LBMQ
MQYBR1.0%#;L9K>O;C]NOXS6Y\/WFB>#_ (,Z=<+Y=UKEI=)<700C#^5LGG*G
M!.,!&!_C'6E?NAV\SB?BU\2-)\<_\%=/A5IFDSQW7_"-6;:7>2Q$,!<^3>2N
MF1_=$J*1V8,.HK[N^-7Q@\/? ?X::WXV\37'DZ9ID._RU(\RXE/$<,8/5W;
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M@0CIU)/6C5M!HDS[&HHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\B?VKO\ E+A\.O\ L8?"_P#Z/@K]=J_(G]J[_E+A\.O^QA\+
M_P#H^"LY[&D-S]D:***P-S\;/^"9/_)_GQ+_ .P=K'_IPMZ_7BOR'_X)D_\
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M (R _P""@WP0^$<?^D:3X= UK5(QRN2?M$B/]8;:(#/_ #VXZU]^>,O%VE>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UG0=,
M\16JVNK:=::I;*XD$-Y LR!@" VU@1G!//N:GT_3K32;.*SL;6&RM(AMCM[>
M,1QH.N H&!5BB@!DT,=S#)#-&LL4BE'C=0592,$$'J"*SM#\*Z)X9\_^Q]'L
M-)\_;YOV&U2'S-N=N[:!G&3C/J:U** "L<^#M ;6O[8.AZ:=6W;_ +?]DC\_
M=C&?,QNSCCKTK8HH *R]<\+:+XF6$:QI%AJPAR8A?6R3;,XSMW XS@=/05J4
M4 ,AACMH8X88UBBC4(D:* JJ!@  = !46H:=::M9RV=]:PWMI*-LEO<1B2-Q
MUP5(P:L44 4-%\/Z7X;M6MM)TVSTNV9S(T-E D*%B "Q"@#. !GV%7Z** ,?
M3_!V@:3J<FI6.AZ;9ZC)N+W=O:1I*VXY;+@9.3UYYK8HHH R-6\'Z#KUY%>:
MGHFG:C=P@+'<7=I'+(@!) #,"0 23QZUKT44 4M8T/3O$%G]DU33[74K7<'\
MB\A65-PZ':P(S3]+TJRT.QBLM.L[>PLXL^7;VL2QQIDDG"J !DDGZDU:HH 1
ME6165E#*PP5(R"/2LK1/".A>&9)7T?1=.TIY0%D:QM(X2X'0$J!FM:B@ K(F
M\'Z#<ZTNKS:)ITNK*RL+][2,S@J, ^81NR  !SVK7HH *S-;\,Z/XFCBCUC2
M;'54B):-;ZV28(3U(# XK3HH BM;6"PM8;:VACM[:%%CBAB4*B*!@*H'
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MKFTCDE3:<KAB"1@\CGBMBB@ JAK.@Z9XBM5M=6TZTU2V5Q((;R!9D# $!MK
MC.">?<U?HH KZ?IUII-G%9V-K#96D0VQV]O&(XT'7 4# J6:&.YADAFC66*1
M2CQNH*LI&""#U!%/HH R]#\*Z)X9\_\ L?1[#2?/V^;]AM4A\S;G;NV@9QDX
MSZFM2BB@#'/@[0&UK^V#H>FG5MV_[?\ 9(_/W8QGS,;LXXZ]*V*** ,O7/"V
MB^)EA&L:18:L(<F(7ULDVS.,[=P.,X'3T%:,,,=M#'##&L44:A$C10%50,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ9%YP =S9XSS72T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%?'?\ P4._:/\ B/\  /\ X5E9
M?#>73TU3Q1J,]@Z7]LLJNP\D1 %B OS2')KS>Z^*'_!0'P3;_;+_ .&GA?Q-
M9P?O9EMC!)*R]T5(KI7)]-JD\]^E3S%<I^AE%?-W[&_[9VF?M3Z7K.G7NC2^
M$O'GA]_+U;0;AF.T9*^8A90<;@596&Y&X.<@GZ1I[BV"BBBF(**** "BBB@
MHHHH ***\<_;#^(&O_"S]FCQ[XK\+W_]EZ_I=BLUI=^3'-Y3F5%SLD5E/#'J
M#UI#/8Z*\C_9)\=ZY\3OV;OA_P"*?$M]_:6O:IIJW%Y=^3'%YLA9AG9&JJ.@
MX  KUR@ HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***^2/VEOVZM-^ O[2GPS^'CFUDTO4WW^);F0_-8Q3'R[9@<X7#YD?/.
MP#^\#2O8:5SZWHHHIB"BBB@ HKYP_P""A'Q.\3_!_P#9;\1^*/!^K2:)KUK=
M620WL4:.R*]Q&CC#J1RI(Z=Z]7^!>O7_ (J^"7P]UK5;EKS5-2\/:?>7=PP
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MGL:0W/V1HHHK W/QL_X)D_\ )_GQ+_[!VL?^G"WK]>*_(?\ X)D_\G^?$O\
M[!VL?^G"WK]>*WAL83W"BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#X _X*E?\CY^S7_V-;?^C;2OO'7-=T[PSH]YJVKW]OI>EV<337-Y>2K%
M%"@&2S,Q  'J:_/G_@KIHC>)M3^ FCI=R6#ZAK]Q:"ZB&7A,C6J;UY'(SGJ.
ME9/B[_@CKJ'B2S._XYZMJ-TG*#5]+:=#@' S]IRO)Z\XR>*SUN[&FEE<7]BV
M_B^,_P#P43^,OQ4\'02)X!%G)9_;A&4CNI7:W5" 1G,AMY)L'! QD G%?H_J
MFJ6FB:;=ZCJ%S%96%I$\]Q<SN$CBC4%F=F/   ))/I7YN?L]_%/Q[^P+\4O#
M7P*^+.E:*? ^O3%=$\4:):K&'F=E4/(RJID^8HC^8OF+N4EF7&?2_P#@KA\1
M-6\-?L]Z/X3T9I$N/&&LQV$YC."\"*9#&#_M2"(>X##O0G9 U=G-^(?^"AWQ
M-^-_C/4_#7[,?PR7Q=:Z<VV?Q'K*E8'^; 959XDB!ZKYC[F&3L&#5/Q!^UG^
MU[^S]&WB#XK?!W1=7\&0E3=W6@R#? IZL7BGF" ="9$QG'(SS]I_ ?X,Z%\
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M$A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?D3^U=_REP^'7_8P^%__ $?!7Z[5^1/[5W_*7#X=?]C#X7_]'P5G
M/8TAN?LC1116!N?C9_P3)_Y/\^)?_8.UC_TX6]?KQ7Y#_P#!,G_D_P ^)?\
MV#M8_P#3A;U^O%;PV,)[A1116AF%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI[GY:?\ #[36_P#HD]A_X.W_ /C%'_#[36_^B3V'_@[?_P",5^I?_"I_ _\
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M2>P_\';_ /QBC_A]IK?_ $2>P_\ !V__ ,8K]2_^%3^!_P#H3?#_ /X*X/\
MXBC_ (5/X'_Z$WP__P""N#_XBCF8<J/RT_X?::W_ -$GL/\ P=O_ /&*/^'V
MFM_]$GL/_!V__P 8K]2_^%3^!_\ H3?#_P#X*X/_ (BC_A4_@?\ Z$WP_P#^
M"N#_ .(HYF'*C\M/^'VFM_\ 1)[#_P ';_\ QBC_ (?::W_T2>P_\';_ /QB
MOU+_ .%3^!_^A-\/_P#@K@_^(H_X5/X'_P"A-\/_ /@K@_\ B*.9ARH_+3_A
M]IK?_1)[#_P=O_\ &*/^'VFM_P#1)[#_ ,';_P#QBOU+_P"%3^!_^A-\/_\
M@K@_^(H_X5/X'_Z$WP__ ."N#_XBCF8<J/RT_P"'VFM_]$GL/_!V_P#\8H_X
M?::W_P!$GL/_  =O_P#&*_4O_A4_@?\ Z$WP_P#^"N#_ .(H_P"%3^!_^A-\
M/_\ @K@_^(HYF'*C\M/^'VFM_P#1)[#_ ,';_P#QBC_A]IK?_1)[#_P=O_\
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M]IK?_1)[#_P=O_\ &*_4O_A4_@?_ *$WP_\ ^"N#_P"(H_X5/X'_ .A-\/\
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M_H3?#_\ X*X/_B*.9ARH_+3_ (?::W_T2>P_\';_ /QBC_A]IK?_ $2>P_\
M!V__ ,8K]2_^%3^!_P#H3?#_ /X*X/\ XBC_ (5/X'_Z$WP__P""N#_XBCF8
M<J/RT_X?::W_ -$GL/\ P=O_ /&*/^'VFM_]$GL/_!V__P 8K]2_^%3^!_\
MH3?#_P#X*X/_ (BC_A4_@?\ Z$WP_P#^"N#_ .(HYF'*C\M/^'VFM_\ 1)[#
M_P ';_\ QBC_ (?::W_T2>P_\';_ /QBOU+_ .%3^!_^A-\/_P#@K@_^(H_X
M5/X'_P"A-\/_ /@K@_\ B*.9ARH_+3_A]IK?_1)[#_P=O_\ &*/^'VFM_P#1
M)[#_ ,';_P#QBOU+_P"%3^!_^A-\/_\ @K@_^(H_X5/X'_Z$WP__ ."N#_XB
MCF8<J/RT_P"'VFM_]$GL/_!V_P#\8H_X?::W_P!$GL/_  =O_P#&*_4O_A4_
M@?\ Z$WP_P#^"N#_ .(H_P"%3^!_^A-\/_\ @K@_^(HYF'*C\M/^'VFM_P#1
M)[#_ ,';_P#QBC_A]IK?_1)[#_P=O_\ &*_4O_A4_@?_ *$WP_\ ^"N#_P"(
MH_X5/X'_ .A-\/\ _@K@_P#B*.9ARH_+3_A]IK?_ $2>P_\ !V__ ,8H_P"'
MVFM_]$GL/_!V_P#\8K]2_P#A4_@?_H3?#_\ X*X/_B*/^%3^!_\ H3?#_P#X
M*X/_ (BCF8<J/RT_X?::W_T2>P_\';__ !BC_A]IK?\ T2>P_P#!V_\ \8K]
M2_\ A4_@?_H3?#__ (*X/_B*/^%3^!_^A-\/_P#@K@_^(HYF'*C\M/\ A]IK
M?_1)[#_P=O\ _&*/^'VFM_\ 1)[#_P ';_\ QBOU+_X5/X'_ .A-\/\ _@K@
M_P#B*/\ A4_@?_H3?#__ (*X/_B*.9ARH_+3_A]IK?\ T2>P_P#!V_\ \8H_
MX?::W_T2>P_\';__ !BOU+_X5/X'_P"A-\/_ /@K@_\ B*/^%3^!_P#H3?#_
M /X*X/\ XBCF8<J/RT_X?::W_P!$GL/_  =O_P#&*/\ A]IK?_1)[#_P=O\
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M^%3^!_\ H3?#_P#X*X/_ (BCF8<J/RT_X?::W_T2>P_\';__ !BC_A]IK?\
MT2>P_P#!V_\ \8K]2_\ A4_@?_H3?#__ (*X/_B*/^%3^!_^A-\/_P#@K@_^
M(HYF'*C\M/\ A]IK?_1)[#_P=O\ _&*/^'VFM_\ 1)[#_P ';_\ QBOU+_X5
M/X'_ .A-\/\ _@K@_P#B*/\ A4_@?_H3?#__ (*X/_B*.9ARH_+3_A]IK?\
MT2>P_P#!V_\ \8H_X?::W_T2>P_\';__ !BOU+_X5/X'_P"A-\/_ /@K@_\
MB*/^%3^!_P#H3?#_ /X*X/\ XBCF8<J/RT_X?::W_P!$GL/_  =O_P#&*/\
MA]IK?_1)[#_P=O\ _&*_4O\ X5/X'_Z$WP__ ."N#_XBC_A4_@?_ *$WP_\
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M?#__ (*X/_B*/^%3^!_^A-\/_P#@K@_^(HYF'*C\M/\ A]IK?_1)[#_P=O\
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M!_\ H3?#_P#X*X/_ (BC_A4_@?\ Z$WP_P#^"N#_ .(HYF'*C\M/^'VFM_\
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M_P#X*X/_ (BCF8<J/RT_X?::W_T2>P_\';__ !BC_A]IK?\ T2>P_P#!V_\
M\8K]2_\ A4_@?_H3?#__ (*X/_B*/^%3^!_^A-\/_P#@K@_^(HYF'*C\M/\
MA]IK?_1)[#_P=O\ _&*/^'VFM_\ 1)[#_P ';_\ QBOU+_X5/X'_ .A-\/\
M_@K@_P#B*/\ A4_@?_H3?#__ (*X/_B*.9ARH_+3_A]IK?\ T2>P_P#!V_\
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M /&*/^'VFM_]$GL/_!V__P 8K]2_^%3^!_\ H3?#_P#X*X/_ (BC_A4_@?\
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M/^%3^!_^A-\/_P#@K@_^(HYF'*C\M/\ A]IK?_1)[#_P=O\ _&*/^'VFM_\
M1)[#_P ';_\ QBOU+_X5/X'_ .A-\/\ _@K@_P#B*/\ A4_@?_H3?#__ (*X
M/_B*.9ARH_+3_A]IK?\ T2>P_P#!V_\ \8H_X?::W_T2>P_\';__ !BOU+_X
M5/X'_P"A-\/_ /@K@_\ B*/^%3^!_P#H3?#_ /X*X/\ XBCF8<J/RT_X?::W
M_P!$GL/_  =O_P#&*/\ A]IK?_1)[#_P=O\ _&*_4O\ X5/X'_Z$WP__ ."N
M#_XBC_A4_@?_ *$WP_\ ^"N#_P"(HYF'*C\M/^'VFM_]$GL/_!V__P 8H_X?
M::W_ -$GL/\ P=O_ /&*_4O_ (5/X'_Z$WP__P""N#_XBC_A4_@?_H3?#_\
MX*X/_B*.9ARH_+3_ (?::W_T2>P_\';_ /QBC_A]IK?_ $2>P_\ !V__ ,8K
M]2_^%3^!_P#H3?#_ /X*X/\ XBC_ (5/X'_Z$WP__P""N#_XBCF8<J/RT_X?
M::W_ -$GL/\ P=O_ /&*/^'VFM_]$GL/_!V__P 8K]2_^%3^!_\ H3?#_P#X
M*X/_ (BC_A4_@?\ Z$WP_P#^"N#_ .(HYF'*C\M/^'VFM_\ 1)[#_P ';_\
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M=O\ _&*/^'VFM_\ 1)[#_P ';_\ QBOU+_X5/X'_ .A-\/\ _@K@_P#B*/\
MA4_@?_H3?#__ (*X/_B*.9ARH_+3_A]IK?\ T2>P_P#!V_\ \8H_X?::W_T2
M>P_\';__ !BOU+_X5/X'_P"A-\/_ /@K@_\ B*/^%3^!_P#H3?#_ /X*X/\
MXBCF8<J/RT_X?::W_P!$GL/_  =O_P#&*/\ A]IK?_1)[#_P=O\ _&*_4O\
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M'VFM_P#1)[#_ ,';_P#QBC_A]IK?_1)[#_P=O_\ &*_4O_A4_@?_ *$WP_\
M^"N#_P"(H_X5/X'_ .A-\/\ _@K@_P#B*.9ARH_+3_A]IK?_ $2>P_\ !V__
M ,8H_P"'VFM_]$GL/_!V_P#\8K]2_P#A4_@?_H3?#_\ X*X/_B*/^%3^!_\
MH3?#_P#X*X/_ (BCF8<J/RT_X?::W_T2>P_\';__ !BC_A]IK?\ T2>P_P#!
MV_\ \8K]2_\ A4_@?_H3?#__ (*X/_B*/^%3^!_^A-\/_P#@K@_^(HYF'*C\
MM/\ A]IK?_1)[#_P=O\ _&*/^'VFM_\ 1)[#_P ';_\ QBOU+_X5/X'_ .A-
M\/\ _@K@_P#B*/\ A4_@?_H3?#__ (*X/_B*.9ARH_+3_A]IK?\ T2>P_P#!
MV_\ \8H_X?::W_T2>P_\';__ !BOU+_X5/X'_P"A-\/_ /@K@_\ B*/^%3^!
M_P#H3?#_ /X*X/\ XBCF8<J/RT_X?::W_P!$GL/_  =O_P#&*/\ A]IK?_1)
M[#_P=O\ _&*_4O\ X5/X'_Z$WP__ ."N#_XBC_A4_@?_ *$WP_\ ^"N#_P"(
MHYF'*C\M/^'VFM_]$GL/_!V__P 8H_X?::W_ -$GL/\ P=O_ /&*_4O_ (5/
MX'_Z$WP__P""N#_XBC_A4_@?_H3?#_\ X*X/_B*.9ARH_+3_ (?::W_T2>P_
M\';_ /QBC_A]IK?_ $2>P_\ !V__ ,8K]2_^%3^!_P#H3?#_ /X*X/\ XBC_
M (5/X'_Z$WP__P""N#_XBCF8<J/RT_X?::W_ -$GL/\ P=O_ /&*/^'VFM_]
M$GL/_!V__P 8K]2_^%3^!_\ H3?#_P#X*X/_ (BC_A4_@?\ Z$WP_P#^"N#_
M .(HYF'*C\M/^'VFM_\ 1)[#_P ';_\ QBC_ (?::W_T2>P_\';_ /QBOU+_
M .%3^!_^A-\/_P#@K@_^(H_X5/X'_P"A-\/_ /@K@_\ B*.9ARH_+3_A]IK?
M_1)[#_P=O_\ &*/^'VFM_P#1)[#_ ,';_P#QBOU+_P"%3^!_^A-\/_\ @K@_
M^(H_X5/X'_Z$WP__ ."N#_XBCF8<J/RT_P"'VFM_]$GL/_!V_P#\8H_X?::W
M_P!$GL/_  =O_P#&*_4O_A4_@?\ Z$WP_P#^"N#_ .(H_P"%3^!_^A-\/_\
M@K@_^(HYF'*C\M/^'VFM_P#1)[#_ ,';_P#QBC_A]IK?_1)[#_P=O_\ &*_4
MO_A4_@?_ *$WP_\ ^"N#_P"(H_X5/X'_ .A-\/\ _@K@_P#B*.9ARH_+3_A]
MIK?_ $2>P_\ !V__ ,8H_P"'VFM_]$GL/_!V_P#\8K]2_P#A4_@?_H3?#_\
MX*X/_B*/^%3^!_\ H3?#_P#X*X/_ (BCF8<J/RT_X?::W_T2>P_\';__ !BC
M_A]IK?\ T2>P_P#!V_\ \8K]2_\ A4_@?_H3?#__ (*X/_B*/^%3^!_^A-\/
M_P#@K@_^(HYF'*C\M/\ A]IK?_1)[#_P=O\ _&*/^'VFM_\ 1)[#_P ';_\
MQBOU+_X5/X'_ .A-\/\ _@K@_P#B*/\ A4_@?_H3?#__ (*X/_B*.9ARH_+3
M_A]IK?\ T2>P_P#!V_\ \8H_X?::W_T2>P_\';__ !BOU+_X5/X'_P"A-\/_
M /@K@_\ B*/^%3^!_P#H3?#_ /X*X/\ XBCF8<J/RT_X?::W_P!$GL/_  =O
M_P#&*/\ A]IK?_1)[#_P=O\ _&*_4O\ X5/X'_Z$WP__ ."N#_XBC_A4_@?_
M *$WP_\ ^"N#_P"(HYF'*C\M/^'VFM_]$GL/_!V__P 8H_X?::W_ -$GL/\
MP=O_ /&*_4O_ (5/X'_Z$WP__P""N#_XBC_A4_@?_H3?#_\ X*X/_B*.9ARH
M_+3_ (?::W_T2>P_\';_ /QBC_A]IK?_ $2>P_\ !V__ ,8K]2_^%3^!_P#H
M3?#_ /X*X/\ XBC_ (5/X'_Z$WP__P""N#_XBCF8<J/RT_X?::W_ -$GL/\
MP=O_ /&*/^'VFM_]$GL/_!V__P 8K]2_^%3^!_\ H3?#_P#X*X/_ (BC_A4_
M@?\ Z$WP_P#^"N#_ .(HYF'*C\M/^'VFM_\ 1)[#_P ';_\ QBC_ (?::W_T
M2>P_\';_ /QBOU+_ .%3^!_^A-\/_P#@K@_^(H_X5/X'_P"A-\/_ /@K@_\
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MJ/RT_P"'VFM_]$GL/_!V_P#\8H_X?::W_P!$GL/_  =O_P#&*_4O_A4_@?\
MZ$WP_P#^"N#_ .(H_P"%3^!_^A-\/_\ @K@_^(HYF'*C\M/^'VFM_P#1)[#_
M ,';_P#QBC_A]IK?_1)[#_P=O_\ &*_4O_A4_@?_ *$WP_\ ^"N#_P"(H_X5
M/X'_ .A-\/\ _@K@_P#B*.9ARH_+3_A]IK?_ $2>P_\ !V__ ,8H_P"'VFM_
M]$GL/_!V_P#\8K]2_P#A4_@?_H3?#_\ X*X/_B*/^%3^!_\ H3?#_P#X*X/_
M (BCF8<J/RT_X?::W_T2>P_\';__ !BC_A]IK?\ T2>P_P#!V_\ \8K]2_\
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M_P#@K@_^(H_X5/X'_P"A-\/_ /@K@_\ B*.9ARH_+3_A]IK?_1)[#_P=O_\
M&*/^'VFM_P#1)[#_ ,';_P#QBOU+_P"%3^!_^A-\/_\ @K@_^(H_X5/X'_Z$
MWP__ ."N#_XBCF8<J/RT_P"'VFM_]$GL/_!V_P#\8H_X?::W_P!$GL/_  =O
M_P#&*_4O_A4_@?\ Z$WP_P#^"N#_ .(H_P"%3^!_^A-\/_\ @K@_^(HYF'*C
M\M/^'VFM_P#1)[#_ ,';_P#QBC_A]IK?_1)[#_P=O_\ &*_4O_A4_@?_ *$W
MP_\ ^"N#_P"(H_X5/X'_ .A-\/\ _@K@_P#B*.9ARH_+3_A]IK?_ $2>P_\
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M2>P_\';_ /QBC_A]IK?_ $2>P_\ !V__ ,8K]2_^%3^!_P#H3?#_ /X*X/\
MXBC_ (5/X'_Z$WP__P""N#_XBCF8<J/RT_X?::W_ -$GL/\ P=O_ /&*/^'V
MFM_]$GL/_!V__P 8K]2_^%3^!_\ H3?#_P#X*X/_ (BC_A4_@?\ Z$WP_P#^
M"N#_ .(HYF'*C\M/^'VFM_\ 1)[#_P ';_\ QBC_ (?::W_T2>P_\';_ /QB
MOU+_ .%3^!_^A-\/_P#@K@_^(H_X5/X'_P"A-\/_ /@K@_\ B*.9ARH_+3_A
M]IK?_1)[#_P=O_\ &*/^'VFM_P#1)[#_ ,';_P#QBOU+_P"%3^!_^A-\/_\
M@K@_^(H_X5/X'_Z$WP__ ."N#_XBCF8<J/RT_P"'VFM_]$GL/_!V_P#\8H_X
M?::W_P!$GL/_  =O_P#&*_4O_A4_@?\ Z$WP_P#^"N#_ .(H_P"%3^!_^A-\
M/_\ @K@_^(HYF'*C\M/^'VFM_P#1)[#_ ,';_P#QBC_A]IK?_1)[#_P=O_\
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M]IK?_1)[#_P=O_\ &*_4O_A4_@?_ *$WP_\ ^"N#_P"(H_X5/X'_ .A-\/\
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M_H3?#_\ X*X/_B*.9ARH_+3_ (?::W_T2>P_\';_ /QBC_A]IK?_ $2>P_\
M!V__ ,8K]2_^%3^!_P#H3?#_ /X*X/\ XBC_ (5/X'_Z$WP__P""N#_XBCF8
M<J/RT_X?::W_ -$GL/\ P=O_ /&*/^'VFM_]$GL/_!V__P 8K]2_^%3^!_\
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M /X*X/\ XBCF8<J/RT_X?::W_P!$GL/_  =O_P#&*/\ A]IK?_1)[#_P=O\
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M^%3^!_\ H3?#_P#X*X/_ (BCF8<J/RT_X?::W_T2>P_\';__ !BC_A]IK?\
MT2>P_P#!V_\ \8K]2_\ A4_@?_H3?#__ (*X/_B*/^%3^!_^A-\/_P#@K@_^
M(HYF'*C\M/\ A]IK?_1)[#_P=O\ _&*^?;/]H*X_:<_X*"_"KQY<Z+'H$MUX
MJ\/VYL8;@SJOE7<"9WE5SG&>E?N;_P *G\#_ /0F^'__  5P?_$5^2G[4NBZ
M?X?_ ."M?PYL]+L+73;1?$/A=EM[.%8HP3/ 20J@#FDY-[@HI;'[+4445)1^
M.O\ P2Y_Y2!?$S_L&:Q_Z<;>OV*K\=?^"7/_ "D"^)G_ &#-8_\ 3C;U^Q5
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7X[?M>?\I>/AW_V,'A;_P!'P5^Q-?CM^UY_REX^'?\
MV,'A;_T?!0!^Q-%%% 'XZ_\ !+G_ )2!?$S_ +!FL?\ IQMZ_8JOQU_X)<_\
MI OB9_V#-8_].-O7[%4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHJ.>>.UADFFD6*&-2[R2,%55 R22>@
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MQCX,OFN;"9C%<6TP"W%G. "T,R G:XR#P2""""00:^,?VBO^4P/P#_[%E?\
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MRA;R_CQE7"&9-JL,$84KR,2,.: /OFBOB;]GO]NGQE)\:(/@M^T#X*M_ 7Q
MO%SI=_8L?L.H$[MJC+N 6VL%='968%<*V ?H']I+Q3\6O"/@:QO/@UX,TWQQ
MXG?4HXKG3]4NTMHX[0Q2EY0SS1 L)%B7&XG#GCC( /#_ -D_]H#Q[\2_VN?V
MA?!7B37O[2\,^%;XPZ-8_8[>+[*GVB1,;TC5W^50/G9NE?9%?C/^S+\0OVDM
M&_:B^.FI>"/A;H6O^.KZ\+>)M'N]2AB@TZ3SY#MB=KE XWEAP[]/QK[_ /C;
M^UIK7[-O[-?AWQAX[\*(?B7K'DV$/A/3I@\;:BX),8D0R?(H!.5+9X4<MF@#
MZ9HK\[-7_:<_;9^%6DQ>.?''P8\.:IX,2,7&H:;HKD7EI"<$DA;B5T('))1P
MHSNQCC[Q^'GC#_A8'@;0O$G]DZAH7]JV<=W_ &;JT7E75OO7.R1,G##TH Z*
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "OQV_:\_Y2\?#O_L8/"W_ */@K]B:_';]KS_E+Q\._P#L8/"W
M_H^"@#]B:*** /QU_P""7/\ RD"^)G_8,UC_ -.-O7[%5^.O_!+G_E(%\3/^
MP9K'_IQMZ_8J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XGXW_$!_
MA1\&_''C.*.&6XT'1;S4H(K@$QR2Q0L\:-@@X9@HX(Z]17;5\L_\%.?%7_"*
M_L3_ !#9'VSZ@EKIT?.,^;=1!Q_W[\S\J /;?@?\6M)^.OPG\,>.]$8?8-:L
MUN/*W;C!+]V6%C_>2170^ZUW-?EU_P $L/B-KOP1^(6I? 'QSFT.N:?;>*?#
MOF,=I::V2:2)">NZ(AL#@-!*.IK]1: "O$_V??VE]+_: \9_%;2]'6%]-\&Z
MVFDV]W$23=+Y0WR'G&/.295(X*JI[US/_!0']HI?V<_V<==U.RG\OQ1K0.C:
M(B-B07$JD-,N.?W:;W!Z;@@_BKY!_P""1.BZW\'OCM\7_ACXEA^Q:Z=)T[4K
MBS)R8F3G:?\ : O5!]_7K0!^J%%%?#_QI_X*4C3_ (FS_#3X(> [SXO^,;=F
MCNI[)V^Q6[KPP!16,H4\,V41?[QYP ?<%%?GI?\ [;O[5/POM/[>^(G[-2R>
M%HANN9M#GD\Z",#+2-M>?: .?F51Q@D=1];_ +.?[2G@C]J#P&GBCP7?/)'&
M_DWNG70"7=C+C.R5 3C(Y# E6'0\' !ZI16;XC\1Z7X0T'4-;UN_M]+TC3X'
MN;N]NG"10QJ,LS,>@ %?!>I?\%*?B!\8O%%_I/[.'P8O_'FFV$ICF\0ZL'BM
MG(]%!01@CE?,E#$'E!0!^@U?('PI_:*\<^*?^"C?Q7^$NHZE#+X'T#P^M_I]
MBMI&LD<Q&GY8RA=[#_29>"<?,/05Y]8_\%$OBK\'=7LU_:(^!M]X-\-7<ZP'
MQ-HN^:WMF;H&7+J_J0L@; .%8\5B?LR^(],\7_\ !6OXTZWHM]!J>D:AX,AN
M;6\MG#QS1LFD%64CJ"#0!Z=^W;XN_:@\-^._A_#\!]+DO=#N-_\ :#6UE#<A
M[CS  ER9%/E0[""&!7DODC:#7V1:F8VT1N BW&P>8(R2H;'.,]LU\[_M6_M8
MW?[-_C?X1:!;>&X==3QUK#:7)/+=F$V8$MLF\ (V\_Z03@D?=]Z^BY)$AC:2
M1E1%!9F8X  ZDF@!U%?"WQ"_X*:G7O'=[X)^ 'PZU+XQZU9\W&I6I9+", X9
ME*J6=,_+O)123P6&,XFH?M@_M??#VU_MOQE^S/:WN@0KYEPNA7;/<*G)+'RY
M)RH !))3CJ<4 ?H)7Q=\<?&'[4VG?MI>#-)\":4T_P (9C9_;)5LHI+1H2_^
MEM<3LN^*10&VA6' 3 )8@^R_LM?M;>!_VLO!]QK'A26:SU"P98]2T6_"K=6;
ML#M) )#(V#M<<'!'!! Y[XF?M8W?@#]L+X<_!./PW#>VOBS3C?/K#791[8@W
M/RB+80W_ ![CG</O>U 'T;17SE^VE^UC=_LG^'O!VI6GAN'Q&VO:P-+:.:[-
MN(04+;P0C9/'3BO.OB1^WUXE\2^.M5\%?L[?#.Y^+>IZ2YAU'7S+Y6DVTHX\
ML2<+)SW,B X.W<.: /M*BO@"Q_X*(_$_X*^-=+TC]I3X/-X#T/59O(@\1Z-*
M9[:!NAW8>19 .IV2;@O(1J^^K6ZAOK6&YMI4N+>9%DCEC8,KJ1D,".H(.<T
M2T5\Q?M;_MY>$?V6[FR\/0Z;<^-OB#J(4VGAG3)-K@,<(TSA6*!C]U0K,W9<
M<UXJG[7'[9DELVLC]F2V&B@>:;1I)1>^7C.W89=^[_MEGVH _0>BOF/]E/\
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MP^^@6^DVW@361I<%Y;WAG%^AEN4$I&T!>+<' )^_UXH ^BZ*^%/%'_!4;2O
M/Q9^*O@S7_"+/-X5N/L&BV^FW9EO-=O&E$:0K'L^3.2Q;+8 X#$A3Z1^S'\:
M/VB?B?X^O(?B9\(=/^'O@W["UU;7;7#FZ,A8".(J7;+8+%LJF-O09 (!]1T5
M\Q?M;_MY>$?V6[FR\/0Z;<^-OB#J(4VGAG3)-K@,<(TSA6*!C]U0K,W9<<UX
MJG[7'[9DELVLC]F2V&B@>:;1I)1>^7C.W89=^[_MEGVH _0>BOF/]E/]O#PE
M^TQJM[X5O-)O? 7Q&T]6-WX7UAOWAV_?\ERJE]O\2LJL.NW )KZ<H ***^6?
MB+^W%8?"[]K*/X4^(=-LM,\,1Z!)KMYXHN;TJ;=4AED*^5LYR8PHPV26  )P
M" ?4U%?G[+_P4)^,OQFOKBX_9_\ @)>^)O"D,[P1>(M>9HHKLK][: R(F#V\
MQCTR%/%+X=_X*7>,/A;XRT_PY^TA\(K[X<17\FR'Q#8+))9CD<E#NWJN?F:.
M1R/[E 'Z T54TG5K+7M+L]3TV[AO]/O(4N+:ZMW#QS1NH9'5AP5((((Z@U^?
M_AW_ (*Q#7-,\2:=!\.IM5^($>M?V+X>\+:/=M<3:D1OWS2'R\QHNT= Q);
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M\P:?^V?^U?\ $ZW76?A]^S3%;^')D\ZUEU^[9)9X2,JZEW@SD9/RJ<Y&">I
M/T$HKX/\#_\ !2[5?!OCW3_!7[1'PPU#X3:E?N([;6]S/I\A)"[FW#B,'@R(
M\BC/.T FOK/XV>-O$W@3X5:QXC\$>%&\>^(K80-9:%!/Y9NP\T:.0X!QMC=W
MZ<[* /G[3OVF?&]S_P %(-4^##SV7_"$6^BK?)"+4>?YIM8Y,^9G.-S'BOKZ
MOQ@T_P"/'Q@B_P""B>I^-X_@I=2?$.31A;R>!_MW[R.'[-&OF^9L_NA6QC^*
MOT=TK]J#4_!W[-.L_%;XQ>"[CX=76EM*)= \[SYY?G5(%0D+EI695&< 9R2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(?\ @(]*^E_V.?ACIOPC_9E^'>@:?;);NVCV]]>LH.9KN>-99Y&)Y)+N<9Z
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M7P.T?XP_LK^+=0N[16UOPG9RZ[IMXJCS(O)0O,F>NQXE<%>F0IZJ*XK]B?\
MY15V/_8O^(__ $KOZUO^"G7[2VA?"3]GSQ'X+@OH;KQKXNL9-.MM+B8/+%:2
M K<7$B@Y5!%YB@GJQ&,@,1D_L3_\HJ['_L7_ !'_ .E=_0!Q?_!%7P#I^E_
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M3-$TJV6STO3;6*SM+>/[L4,:!$4>P4 ?A6C110 4444 %%%% !1110 4444
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ML_V_/B!\?;.SGM_ 7A^S;1-%NIHROGR&-8EQGN8_.E8=5\Z,'K5_]HK_ )3
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MC/XO?#?PKXC^'D*WWC+P+K*:[9Z:V";I5&65 >&<,L;!3]X*P') /EG["O\
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M^"A3?\)S^V-^RGX$'SQ)K7]J740YWQ&ZM\Y_X!;2_F: -'_@I1\%=0\'^#O
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MXN\7>)KQ+=],T2W@>>QC<[8Y)%; ^9B/E)'RAF)  W?1UYJ%AHEO"UW<V]A
MTD=O$9I%C4N[!8XUR0,L2% ')) % 'R%^R#_ ,%!/!7Q/T_2? 'C7/P]^*&F
MQIIMSHVL1FUBN9XP$/DLP 5B0/W+;7!. &QFOL:&&.WB2**-8HT&%1   /0
M5\\_M??L?_#3]HSP-K5]XFTVUTOQ)9V$DEIXJA BN+4QH67S7'^LB&.4?( )
MQM.".0_X)<?%;Q-\6/V3=*N_%-S-J%]I.H7&D0W]RQ:6YMXPC1LS'[Q42&/)
MY/EC.3DD ^N*_-S]M_3[C]I[]N[X0? "ZNYH?!MI;?VWJ\,3E/-;;-)("1W\
MF (C?PF=O6OTCK\XOVX+JY_9E_;D^#_[0EQ:S3^#;BW_ +"UF6)"_D-MFC=B
M!W,,^]%[FW:@#]#M!T'3?"VBV.CZ/8V^F:58PK;VUG:QB.*&-1A551P !7.?
M%_X2^&_CC\.]9\&>*[%+[2-3@:)LJ"\#X(2:,D';(A.Y6[$>F171Z#KVF^*=
M%L=8T>^M]3TJ^A6XMKRUD$D4T;#*LK#@@BL+XI?%#PW\&? >K^,/%>HQZ9HF
MF0M-+)(1N<@?+'&/XG8\*HY)(% 'Y_\ _!'/PE<> /$W[0_AB[;?=:+K%CIL
MS%=N7A>^C8XR<<J>*Y']JWX/Z?\ '?\ X*Q^!/!NL+YFC7>EVES?1'.)8+>.
MXN'B."" XBV9'(WYKLO^"/?C*X^(GBS]HOQ7=QB&ZUW6K+5)8P<A7GDOI6&>
M^"QK<\41JW_!9SPB64$KX3D*^Q^R70_D30!^@MC8VVEV-O96=O%:6=O&L,-O
M"@2.-% "JJC@    #IBOST_X*Y6$7A&X^!_Q.L MMXBT+Q.EO%=H/G*<7"@X
MZA7@R >F]L=37Z)5^>O_  6>_P"2+_#C_L;8_P#TFFH ^A?V_/C!J/P1_91\
M<^(M&F:VUJ6"/3;&XC.&ADN)%B,BGLR(SL#ZJ*YG_@F_^SKHGP/_ &;O#&K1
M6D;^*?%MA#K6JZBRYE83()(8,GD)&C*-O3=O;^*NG_;Z^$.H_&W]E#QWX<T:
M%KG6H[>/4;*WC&6FDMY%F,:CNSJCJ!ZL*YC_ ()O_M$Z+\;OV;O#.D1W<:>*
MO"-C#HNJZ:S8E00H(X9MIY*O&JG=TW;U[4 ?5=?DU^V!^SKH?P;_ ."B'P \
M4^&K--,TOQGXKTVXGL8(PD,5Y#?VPF:,#@!Q+&Q']XL>^!^LM?E+^V9^T-H7
MQ<_X*$_L\^#_  Y>PZG8^"_%>G1W=[;MNC:]GU"U,L:L.&"+#$"1T8NO\- '
MZM4444 ?F5_P6,TF[U[Q]^S=IEA?R:5?7NIZE;6]_$2'MI'ETU5E4@@Y4D,,
M$'CK70?\.Z_VB_\ H[_QA_X&:C_\F55_X*P?\EH_94_[&"\_]*=,K]'Z /SJ
M_P"'=?[1?_1W_C#_ ,#-1_\ DRJ'_!$^-H?AS\4HW<R.NNP*SGJQ$)YK])*_
M.#_@BS_R(/Q7_P"Q@B_]%&@#R/\ :H^._@77?^"DBI\8+B>X^&GPZB2&QTNV
MM3<+<W?DQRL'0'O,^6SPRVZJ1S7U*O\ P5W_ &>$4*NH:^J@8 &CO@?K7D/B
M*ZTW]E'_ (*G:EK7C.*&/P+\4=.$5KJ-XBM;V]PYA!+LPPNV>$J3_"EPK'CF
MOT=7PKH3J&71].92,@BUCP?TH _,?]M;]N']FO\ :B^!6M>&Q-K#^*+6-KS0
M+V;2&5H+M1D+OS\J2 >6W;#9ZJ"/K3]@OXWW/Q*_8R\*>+/$5R;C4-(L[BRU
M"XZLXM&=%=B>KM$D;$]R2:Z?]J#XW?#G]E?X9W/BSQ)I.GW-PS>3IVCPQ1)<
M:A.?X$RIP .6;!"@=R0#WGP]U;3?BI\(]+U6+0+OPWIGB33!.=*O88X;B&.:
M/HZH2H8J<^O(R >  ?"/_!+GX>I\<?&'Q$_:5\;Q)JOBO4=<FL=+-Q\XL0$1
MY'C!Z866.%".56-@.#7Z35^;O_!,/QVOP&\;?$7]FCQO,FF>*-.UN:_T@W'R
M+?J8T1UC)ZY2*.9!U99'/\-?I%0!^=?_  6(_9WT/Q%\'8?BU9V:6OB;P]<P
M6M[=0Q@&[LYG6)1*>I*2-'M;L&8=QCW_ /YQM_\ =)O_ '#UX7_P6&_:"T/P
MQ\#A\*[:]AN?$_B:ZMYKFRC?+6UE#(LWF2 ?=+2)$%!Z@.1]VO=/^<;?_=)O
M_</0!RG_  2?_P"3)?"'_7[J/_I7+7*_\%DO^31[/_L9K+_T5<5U7_!)_P#Y
M,E\(?]?NH_\ I7+7*_\ !9+_ )-'L_\ L9K+_P!%7% 'U_\ ";_DE?@W_L"V
M7_HA*_,GP'\$=&^-G_!7CXE+XAM8K_2/#;/KKV5PF^.XE1+:*)6'<!YEDP>#
MY>#P:_3;X3?\DK\&_P#8%LO_ $0E?$'[+/\ RE._:/\ ^P8O_H=I0!^A5?G;
M^V'81?#W_@I%^S3XRTH+9ZEX@G&CWTD8P9D\T0$MZDQW93/HJ^@K]$J_/7_@
MH%_R>S^R'_V,"_\ I;9T =K_ ,%8_B]K'PY_9IA\/^'Y)8=4\::FFBM) Q60
M6Q1GF5<?W]J1D?W9&KW_ /9E_9\\/?LT_"/1?!NA6T:SPPK)J-^$ EOKHC,D
MKL.3\Q(4'.U0JCI7SQ_P5L^$NK^/_P!F^S\3:#%+-J7@O4TU>1(1N86I1DE<
M#_8)C<^BHQ[5]#?LQ_M">'_VE_A#HGC'1+J![F:!(]3L(V^>QO H\V)USD -
MDJ3]Y2I'6@#U>O._!W[/?P[^'_Q(\1^/?#WA6QTOQ9XA4+J.HP!@91D%MJYV
MIN8!FV@;V&6R>:]$KSKP;^T-\.OB%\1_$7@/P[XKL=5\5^'U#ZAI]NQ)C7(#
M%6QM?:S!6V$[6(#8/% 'Q#^V_I]Q^T]^W=\(/@!=7<T/@VTMO[;U>&)RGFMM
MFDD!([^3 $1OX3.WK7Z*:#H.F^%M%L='T>QM],TJQA6WMK.UC$<4,:C"JJC@
M "OSQ_;@NKG]F7]N3X/_ +0EQ:S3^#;BW_L+698D+^0VV:-V('<PS[T7N;=J
M_0[0=>TWQ3HMCK&CWUOJ>E7T*W%M>6L@DBFC895E8<$$4 <Y\7_A+X;^./P[
MUGP9XKL4OM(U.!HFRH+P/@A)HR0=LB$[E;L1Z9%? O\ P1S\)7'@#Q-^T/X8
MNVWW6BZQ8Z;,Q7;EX7OHV.,G'*GBOT ^*7Q0\-_!GP'J_C#Q7J,>F:)ID+32
MR2$;G('RQQC^)V/"J.22!7P'_P $>_&5Q\1/%G[1?BN[C$-UKNM66J2Q@Y"O
M/)?2L,]\%C0!R_[,_P -].\<?\%:_C#J^IP)<+X8FO\ 4[19 & N6EBA1L'^
MZLLC ]F"GM7ZBZMJ<&BZ5>ZA<MLMK2%[B5O154L3^0-?GI^QBJG_ (*5_M.M
MM&X"4!L<@&ZCR/T'Y5^@^O:/!XBT/4=*N2PMKZVDM92AP=KJ5./?!- 'XT?L
M9_M@?"GPC\7_ (A?&;XT7-]>?$;7KPC3OLNG-<1V%NP^<H<X4D;(E[JD6,X<
MU]H_\/>?V>?^@CX@_P#!._\ C7E'_!+O6M+^%OB?XD?LZ^/+2S@\;:+K4U]8
MB]A3_3(]D<<BPEADC$:3*/XDE+#@''Z+?\(GH?\ T!M/_P# 6/\ PH _'G]M
M;]LCX2>//B-\._B]\'KC4+7XG>&]10W4ESIS6T=]:J"5$K9^<J5\O'4I*P/"
M@#]C]%U:#7M'L-3M6W6M[;QW,3>J.H93^1%?.7QR_:F^&_P5^+G@?X;)X4'B
M[Q=XFO$MWTS1+>!Y[&-SMCDD5L#YF(^4D?*&8D #=],1QK%&J(H1%&%51@ >
M@H =7Y1_M:?!&S_:&_X*K>#_  1JAE71;S1K6XU$PG#&W@CGF=,]M_EB//;>
M#VK]7*_*O]JCXVV'[/G_  5<\'^,=89DT.'1K6SU&103Y=O.D\328')V%P^!
MDG9@4 ?J/HVC6'AW2;32]*LK?3M-M(EAM[2UB$<4,:C 55 P !V%<I\:O@[X
M;^/7PUUKP5XJLTN]+U*%D$A4&2VEP=D\1/W9$)R#^!X)%==I>J66N:;:ZCIU
MW!?V%U&LT%U:R"2*6-AE65@2&!'((KD/C7\9/#7P#^&VL^-?%=ZEIIFG0EEC
MW 274N#L@B!^\[G@#\3@ D 'R!_P21\;ZZG@7XD?"C7[MKRX^'>N_8H'8Y\J
M*5IE,2]]HEMYF&>F_'0 #R?_ ()$_#?3M4^-WQM\<7<"2ZCI%TNFV#L ?*$\
MT[S,/1L0QKD=F8=S7K7_  23\"ZY_P (#\1?BQX@MC:7?Q%UPWL,9! DAB:9
MO-&>=IEN)@,]DSWYY_\ X) *H;X]-M&X^)HP6QR0//P/U/YT ?:/[17Q+E^#
MGP)\=^-;9%EO-%TBXNK5&&5,X0B(,/[N\KGVS7RG_P $GO@3IVC_  ;;XQ:R
MC:KX[\;W-S/)JE\ \\5NL\D>U6.2#(Z/(S9^;<F?NBOJW]HCX:S?&'X%^._!
M=LZQWFM:/<VEJ[G"B<H?*+>V\+GVS7R]_P $I?C=8Z]\$3\)M7/]E>._ ES<
MV=SI-W^[N'@:=W$@4\G8[O$P'W2BYQN&0#[EK\Q_V[/"5K^R3^UA\)?CSX+B
M_LA-=U,V/B*RM$$<%Q@H)&(&!NFA>3.>-T2O]XDU^G%?FK^WAXFM_P!J;]JS
MX0? 3PC(-6;1=5_M+Q+<VI\R.S7*;U8C@-'"LI8'^*1%R&R* /4_^"M/Q<U3
MX<_LPKH6B2R0ZAXQU./19)(CAQ;%'DF4'_;V+&1W61J]]_9?_9YT#]F?X/Z'
MX.T:UA6[B@275+]%&^^O"H,LK-U(W9"@_=4*.U>"?\%:/A+JOQ&_9?&MZ)%)
M/J'@_4X]:DCA&7-L$>.9@/\ 8WK(?18VKWO]EW]H;0?VF/@]H?C'1KJ%KN6!
M(M5L48;[&\"@2Q,N<@;LE2?O*5/>@#U6ZM8;ZUFMKF&.XMID:.6&50R.I&"K
M \$$'!!K\I/"?[/^D_L[_P#!8CP3HWA^'[+X>UBUO]<L+3;A;9)M.OE>)/\
M862.0*.RX'.,G]7+BXBM8))YY$AAC4N\DC!550,DDGH .]?E;H/Q^T?]H3_@
ML5X%U/PY<)?>'M#LK[0K*^C.4NA%IU^\DJ^JF660*PX954]Z /8O^"SRD_LG
MZ*0,X\669/\ X#7=?;OA%@_A/164AE-E 01T/[M:^4O^"L'@V[\7?L9^(;BS
MB,SZ)?V>J2(HRWEK)Y3L/]U9BQ]E->Z_LQ_$S2/BY\ _ WB;1KN*ZM[G2;>.
M98V!,%PD:I-$P[,CAE(]O>@#:^-W_)%_'W_8OZA_Z325\O\ _!(;_DS;3O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !115?4-0M=)L9[V^N8;*SMT,DUQ<2"..- ,EF8G
M  '<T 6**^:/%_\ P4B_9Q\%WTME>?$ZPOKF,=-'M+F_C;Z2P1O&?^^JW_AS
M^W7\!/BMJ2:=X<^)NCRWTAQ';Z@)=/>4YQM07*1[S[+DT >\4451US6[#PUH
MNH:OJMW#I^EZ?;R7=W=W#!8X(8U+.[$]%5023Z"@"]12*P=0RD,I&01T-+0
M4451T_7+#5;S4K6SO(;FYTV<6MY%&P+6\IB24(X[$QRQMCT<4 7J*** "BLG
M_A+-&_X2O_A&?[3M?^$A^Q?VE_9GF#S_ +-YGE^=LZ[-_P N?7BM:@ HHHH
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M!<5ZVI1>']*MM+6\>,1M,(8EC#E03M)VYQDXS76T4 >6?M#?LT^!/VGO!?\
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MH002*[NB@#\[5_X)9_$&RTR;PCIW[3GBJT^'$J>6=",$Q AZ&':+H1[2.N%
M/=#BOLWX!_ 7PG^S=\-;#P3X.M9(=,MF::6XN&#W%W,V-\TK #<YP!P  %4
M  "O1:* "N:^)'P[T#XL^!M9\(>*+!-2T'5K<V]U;MQE3R&4]596 96'(*@C
MI72T4 ?G-;?\$O\ XH_#&:]TWX2?M(>(/"GA*[G,G]ER">)X%/!.Z&95>3&/
MF"1YXZ8%>@_ W_@EMX'\"^+%\9?$KQ#J/QA\8!UF%QKJD6JR#&&:)G=I6'_3
M1V7@?*#7VQ10!\W?M=_L-^#OVLM/TFXN[N7PKXMTEU%GXBT^!7F6$')A=<KO
M3/S+R"C<@X+!O9?A9X6U[P3X#TG0O$GBB3QGJMC%Y#ZY/:"VFN5'W3(H9@7
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MKHAT2S\+6EB!!Y9BN$W^;OSG_2"QRI)(R222:^E759%964,K#!5AD$>E.HH
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MEX?TFRTO3+6*QTZR@2VMK6!0L<,2*%1% Z    >U7** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **R_$WBC2?!>AW.LZ
M[J-OI.E6VWS[RZ<)%$&8*"S'@#<P&3QS6FK!E!!R#R"* %HHKD?B=\6O!_P9
M\/1:[XW\06?AO2);A;1+N]8A&F9694X!Y(1C^!H ZZBH;.\AU"S@NK:19K>>
M-98Y%Z,K#((^H-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%>'_\-E_"W_AHK_A2G]LS_P#";_<V?96^R^=Y7F^1YO3S-G/IGY<[
MOEH ]PHHHH ***\T^&_[17@;XL^/?&O@WPUJ4UYK_@ZY^R:Q;R6DD2PR>8\>
M%=E"O\T;C*D]* /2Z*^3M?\ ^"HG[//AG7=2T?4/%=_%?Z?<R6EQ&NC73!9(
MV*, 1'@X(/(JA_P]@_9M_P"AOU#_ ,$EW_\ &Z /L"BO&?$7[7?PR\+? [2/
MBYJ.LW$7@;59$CM+Y;&9I'9V=5S$%WCE&ZCM6I\ _P!ICX??M,:'J>K?#_66
MU:UTVY%K=+-;26\D;E0RDI( =I&<-C!*L.QH ]2HKG_'_CS1/AAX+UKQ9XDO
M1I^A:/;/=W=R5+;(U&3A0"6)X  &22 *\S^ 7[8WPM_::UC5=,\ :U<ZI>:9
M MS=)/836X5&;:"#(H!Y["@#VRBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K\=OVO/\ E+Q\._\ L8/"W_H^"OV)K\=OVO/^4O'P[_[&#PM_Z/@H _8F
MBBB@#\=?^"7/_*0+XF?]@S6/_3C;U^Q5?CK_ ,$N?^4@7Q,_[!FL?^G&WK]B
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYO\<?LEWGCC]M+P/\<;
MKQ+"NF>%]+;3X?#YM&+R,4N@)/-WX&'N0WW?X ,U](44 %?/OQ\_8U\)_'_X
MQ_#+Q_K++'=>$+EGN;;R0PU.!29(87.>%2;#=""KR*1\V1]!44 %?-_[8W[)
MEY^T^WP]N],\2P^&=4\(:L=3AN)[0W D!V$H '7'S1(<^U?2%% !7Q#\9/\
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MU#C#+'&A/'S5]_T4 5=+TNST/3;33M.M8;&PM(D@M[6WC$<4,:@*J(HX50
M . !7SM^QI^R/=_LJ_\ "P/M7B6'Q%_PE&J+J*>39FW^S@;_ )#EVW??Z\=*
M^DZ* "ODO]IS_@GKX=^.'C*+X@^$/$NH?"[XG0D-_;^B@A;A@,!I45D828^7
MS$<''4-@8^M** /SVN/V-?VOO%%J="U[]IV.V\/.#&]QIL4HO&3/<JD3'(SD
M&7VS7T?^RK^QIX$_9-T*ZB\/)-JWB/4% U+Q%J(4W5SR#L7'$<>X9V#O@L6(
M!KWJB@!DT*7$3Q2HLD3J59'&0P/!!'<5\(?$#_@F;J/A7X@7OCC]GCXE7WPD
MU6\):XT55=K!R3G:I0Y6/.3Y;I(H)^7: !7WE10!\!?\,&_'SXP*FE?&W]HF
M\U/PEN!N=%\-0F'[:F?N.^R-<?[R2#@<=QZ+X=_X)^:'\/\ ]J+X:_$SP;?6
M?A_PMX,T232$\-QVC/+<,\5XC3-.7Y8F[#$LI)*GGGCZXHH IZQI-EX@TF]T
MS4K6*^TZ]A>VN;6=0T<L;J5=&!Z@@D$>]? FH?\ !-7X@_!_Q1J6I_LZ?&F^
M\!:3J$OG2>'M3\R2WC;(Q\XW"0#& 7C+ #!9LFOT'HH _/K1_P#@FCXX^*_C
M#3=<_:,^,=]\0[#3G$D7A^P\R.V<Y)8%R5"*> ?+C5B.-RX%??NGZ?;:386U
MC96\=K9VT2PPP0J%2.-0 JJ!P    /:K%% 'BO[3W[)/@+]K#PG#I/B^TE@U
M"SW-IVMV)5+NR9L9"L00R-@;D8$'&>" 1\PZ7^Q7^UA\-;6+1/ W[3,=SX=A
MPL(URU=I8D'15#K/@ <8#@<#@=OT(HH ^&/ 7_!,^3Q'XYL_&G[0'Q(U3XR:
MO9L6MM*NM\>GQ<@A2K,2R9&?+41H3P589S]R11)#&D<:+'&@"JBC 4#H /2G
MT4 ?-EE^R/=VG[;]_P#'P^)86M+K2QIPT/[&?,4BW2+?YN_'\&<;>]=1^UE^
MRWHG[67PUC\*ZOJ^H:#<6=T+_3]1L')\BX5656>(D+*N&/&0?1EYKVNB@#\Z
MKS]@']I'QKI)\$^,_P!I2;4/AVQ6.>*&*5[RZ@!&8Y-V"00,8>1U]CTK[B^#
MOPC\.? OX;Z)X(\*6K6NBZ3#Y4?F$-+*Q)9Y9& &YW8EB< 9/  P*[.B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *.NZY8>&=$U#6-5NX[#2]/MY+NZN
MICA(8D4L[L>P"@D_2ORIA7XC_P#!6WXK:JD>JWG@G]GWP[=J@C1</=,,$ C[
MLERR_-\V4A5EX)/[SZI_X*J^,+OPC^QAXKCLY##)K%U9Z8[KG/EO,'<#_>6-
ME/LQKOOV#?A[9?#;]D7X7Z?90"%K[1H-8N3_ !/-=*+ARQ[D>8%]@H':@#-^
M'?\ P3N_9]^'.FP6MO\ #C2]=FC'SWGB)/[0EE/'+"7*#H.%4#VY-<]\7O\
M@F+\!/BEH\\-GX2B\%:L8RL&I^'6-OY38X+0Y\IQD#.5SUP1G-?6%% 'Q?\
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M ^KZ*P_ OB1O&/@CP]K[P"U?5=.M[YH%;<(S+$K[0<#.-V,X[5R/[2'Q<F^
M_P #_%OCZ#3$UB;0[47*V,DQB6;,BI@N <?>ST/2@#TJBOG?]AS]JJ[_ &OO
MA/JWC&\\.P^&9;'6YM(%I!=FX#A(+>7?N*+@GSR,8_AZ\U]$4 %%?%W[._\
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MF^/'P/\ "7CZ?3$T>;7+4W+6,<QE6'$C)@.0,_=ST'6NN\=>)&\'>"/$.OI
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M1>"K;4;75M1TFQ;67U!HWC%Y)&A81>60=GF9QNYQVK[1H **^;/VZ/VN+O\
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M&3_@H-J'PK_;(\-_!"+P5;:C:ZMJ.DV+:R^H-&\8O)(T+"+RR#L\S.-W..U
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M%\>/B]XY_:1\?2G4=6R-(TZX="H:<Q(LTB#L$A$<8QD?O''45T7[ W_*0/\
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M=9T.\'RS1\-&XQNCD0\HZYY4C(X[$&@#L**** "BBB@ HHHH **** "BBB@
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M0WL"3(& (#;6!&<$\^YJ?3M-M-'LHK.PM8;*TA&V.WMXQ'&@ZX"@8'X59HH
MCG@CNH9(9HUEAD4H\<BAE92,$$'J"*S="\)Z'X7\_P#L;1M/TCS]OF_8;6.#
MS-N=N[:!G&3C/3)K6HH *QCX,\/MK?\ ;)T+33J^[?\ VA]CC^T;L8SYF-V<
M<=>E;-% !65KGA31/%"PC6='T_5Q#DQ"^M4F\O.,[=P.,X'3T%:M% $<$$=K
M#'##&L4,:A$CC4*JJ!@  = !46HZ;::Q92V=_:PWMI,-LEO<1B2-QUP5(P?Q
MJS10!GZ)X>TKPU:O:Z1IEGI5L[F1H;&W2%"Y !8A0!G  S["M"BB@#&T_P &
M>'])U274K'0M-LM1EW&2\M[...9]QRV7 R<GD\\ULT44 8^K^#= \07L5YJF
MAZ;J5W"H6.XO+2.61 "2 &8$@ DGCN:V*** *.L:%IOB*S^R:KIUKJ=IN#^1
M>0+*FX=#M8$9I^EZ38Z'816.FV5OI]E%GR[:UB6*-,DDX50 ,DD_4FK=% #7
M59%964,K#!5AD$>E9.A^#]!\,22R:-HFFZ2\P"R-8VD<)<#H"5 S^-;%% !6
M/-X-T"YUI=8FT/39=75E8:@]I&;@%0 I$A&[(  '/:MBB@ K+USPOHWB>.*/
M6=(L=62$EHUOK9)@A/4@,#C\*U** (;2T@T^UAM;6&.VMH46.*&% J1H!@*H
M'     %)?6-MJ5G-:7EO%=VLRE)8)T#HZGJ&4\$>QJ>B@#-T/PSI'AF&2'1]
M*L=)AD;>\=C;)"K-C&2% R<5I444 8]KX-T"QUB35K;0]-M]5D9F>^BM(UG8
MM]XEP-Q)[\\UL444 8VN>#/#_B::.;6-"TW5IHUV))?6<<S*N<X!8' S6S11
M0!3U;1M/UZQ>RU.QMM1LW(+6]W"LL;$'()5@0<&DTC1=/\/V2V>EV%KIMHI+
M+;V<*Q1@GDD*H YJ[10 5CZ+X-T#PW<2SZ1H>FZ5/*NV22RM(X6<9S@E0"1F
MMBB@ K&O/!GA_4-8CU:ZT+3;G58V1TOIK.-YU9<%2'(W C QSQBMFB@ K-US
MPWI'B:WC@UC2[+58(VWI'?6Z3*K8QD!@<'!//O6E10!7L;"UTNSAM+*VAM+2
M%=D<$"!$11T"J. /I3[JUAOK:6WN(8[BWF0QR0RJ&1U(P5(/!!'&#4M% &7H
M?A?1O#$<L>C:18Z2DQ#2+8VR0AR.A(4#/XUJ444 8T/@SP_;ZV=9BT+38M7+
M,YU!+.,7&Y@0Q\S&[)!(//()K9HHH R-<\(:#XH:%M9T33M6:$$1-?6D<Q0'
M&0NX'&<#IZ5JQQI#&L<:JB* JJHP !T %.HH JZII=EK=C+9:C9V]_9RX$EO
M=1+)&^"",JP(/(!_"H]'T+3?#MG]DTK3K73+3<7\BS@6)-QZG:H S5ZB@ K&
MTGP9X?\ #]]+>Z7H6FZ;>RJ4DN+2SCBD=202"R@$@D _4"MFB@ K&U+P9X?U
MK4HM1U#0M-OM0BVB.ZN;..25-IRN'8$C!Y'/%;-% !6?K7A_2_$EHMKJ^FV>
MJ6JN)!#>P),@8 @-M8$9P3S[FM"B@"MIVFVFCV45G86L-E:0C;';V\8CC0=<
M!0,#\*EG@CNH9(9HUEAD4H\<BAE92,$$'J"*DHH R="\)Z'X7\_^QM&T_2//
MV^;]AM8X/,VYV[MH&<9.,],FM:BB@#&/@SP^VM_VR="TTZONW_VA]CC^T;L8
MSYF-V<<=>E;-%% &5KGA31/%"PC6='T_5Q#DQ"^M4F\O.,[=P.,X'3T%:,$$
M=K#'##&L4,:A$CC4*JJ!@  = !4E% %;4=-M-8LI;._M8;VTF&V2WN(Q)&XZ
MX*D8/XU!HGA[2O#5J]KI&F6>E6SN9&AL;=(4+D %B% &< #/L*T** "L;3_!
MGA_2=4EU*QT+3;+49=QDO+>SCCF?<<MEP,G)Y//-;-% !6/J_@W0/$%[%>:I
MH>FZE=PJ%CN+RTCED0 D@!F!( ))X[FMBB@ JCK&A:;XBL_LFJZ=:ZG:;@_D
M7D"RIN'0[6!&:O44 5-+TFQT.PBL=-LK?3[*+/EVUK$L4:9))PJ@ 9))^I-6
M759%964,K#!5AD$>E.HH Q]#\'Z#X8DEDT;1--TEY@%D:QM(X2X'0$J!G\:V
M*** ,>;P;H%SK2ZQ-H>FRZNK*PU![2,W *@!2)"-V0  .>U;%%% &7KGA?1O
M$\<4>LZ18ZLD)+1K?6R3!">I 8''X5>M+2#3[6&UM88[:VA18XH84"I&@& J
M@<     5-10!!?6-MJ5G-:7EO%=VLRE)8)T#HZGJ&4\$>QJIH?AG2/#,,D.C
MZ58Z3#(V]X[&V2%6;&,D*!DXK2HH *Q[7P;H%CK$FK6VAZ;;ZK(S,]]%:1K.
MQ;[Q+@;B3WYYK8HH *QM<\&>'_$TT<VL:%INK31KL22^LXYF5<YP"P.!FMFB
M@ JGJVC:?KUB]EJ=C;:C9N06M[N%98V(.02K @X-7** *6D:+I_A^R6STNPM
M=-M%)9;>SA6*,$\DA5 '-7:** ,?1?!N@>&[B6?2-#TW2IY5VR265I'"SC.<
M$J 2,UL444 8UYX,\/ZAK$>K76A:;<ZK&R.E]-9QO.K+@J0Y&X$8&.>,5LT4
M4 9NN>&](\36\<&L:79:K!&V]([ZW295;&,@,#@X)Y]ZM6-A:Z79PVEE;0VE
MI"NR."! B(HZ!5' 'TJQ10!%=6L-];2V]Q#'<6\R&.2&50R.I&"I!X((XP:H
M:'X7T;PQ'+'HVD6.DI,0TBV-LD(<CH2% S^-:E% !6-#X,\/V^MG68M"TV+5
MRS.=02SC%QN8$,?,QNR02#SR":V:* "LC7/"&@^*&A;6=$T[5FA!$37UI',4
M!QD+N!QG Z>E:]% #8XTAC6.-51% 5548  Z "J^J:79:W8RV6HV=O?V<N!)
M;W42R1O@@C*L"#R ?PJU10!1T?0M-\.V?V32M.M=,M-Q?R+.!8DW'J=J@#-7
MJ** ,;2?!GA_P_?2WNEZ%INFWLJE)+BTLXXI'4D$@LH!() /U K9HHH QM2\
M&>']:U*+4=0T+3;[4(MHCNKFSCDE3:<KAV!(P>1SQ6S110!GZUX?TOQ):+:Z
MOIMGJEJKB00WL"3(& (#;6!&<$\^YJ?3M-M-'LHK.PM8;*TA&V.WMXQ'&@ZX
M"@8'X59HH CG@CNH9(9HUEAD4H\<BAE92,$$'J"*S="\)Z'X7\_^QM&T_2//
MV^;]AM8X/,VYV[MH&<9.,],FM:B@ K&/@SP^VM_VR="TTZONW_VA]CC^T;L8
MSYF-V<<=>E;-% !65KGA31/%"PC6='T_5Q#DQ"^M4F\O.,[=P.,X'3T%:M%
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M5 )&:V** "L:\\&>']0UB/5KK0M-N=5C9'2^FLXWG5EP5(<C<",#'/&*V:*
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MY:Z?]KOXC>%/AI^SKX\OO%]W:Q6%WH]W8PV=RPW7TTL+HD"*?O,Q(&!T&2<
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MV,"6UM:VZ!(X8D4*B*HZ    >U6;BWBO+>6">))X)5*21R*&5U(P00>"".U
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M/VI$VD]QBZE'T8T ?H#K&L6/AW2;W5-3NX;#3;*%[FYNKAPD<,2*6=V8\
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M$[_VG?&'[4?P[\7:WXRBTR*\TK77TVW&F6[0H8A#&XW!G;+9<\YKZOK\]?\
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MR_;RU#X8^/[;X3?"'PJ?B)\6[H+YEDJ/);:<&4,OFJA!=MI#$;E5%(9F'2N
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M4H?_ $ET^O=?^"D/_)DOQ2_Z\K?_ -*X* / OV ]0_:@_P"$ ^$\']F>#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9FL>&='\1+MU72;'4UP%VWELDHP#D#Y@>_-6=/TN
MSTFW\BQM(+*#.?+MXUC7. ,X QT _*K5% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_';]KS_E+Q\._^Q@\+?\
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M2=*TD1B"=S+#*WG%U9F):!<MNW'<Q))YKZ+H _.K_@C?_P BM\9/^QF7_P!
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MW^'_ .SGX9.A^ O#MOHUO)@W-SS)=7;#.&FF;+.1DX!.%R0H XH ^,_VS_\
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MSP,P#' PQ4C(5@07&6'Z*?LR_P#)MOPH_P"Q2TG_ -(XJ^1_^"Q7P/TCQ5\
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MN)$*G!9#@;XR1E7(7<,' KTFDSGD<BEH **** "BBB@ HHHH **** "BBB@
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MX9^#O@G3/"7A#28=&T'3TV06T.3R3EG9CRSL<DL222>:ZFBB@ HHHH ****
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MW/L%!/X5?KR_]I3X,WO[0/P?UGP%:>*)O",.L;(KR_M[47$C0!@SQ %UP'P
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M7Q,_[!FL?^G&WK]BJ_'7_@ES_P I OB9_P!@S6/_ $XV]?L50 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5^.W[7G_*7CX=_]C!X6_\ 1\%?L37X[?M>?\I>/AW_ -C!X6_]'P4
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M+:+X_3X2_#+1/&=M<:P)-4DU+48K<VUQM.(U#W,>X8SR,_6ONK]IS]JKQ=\
M_$'P+TB+0=*GN_'6HKI^KQW1=C9MOM5<0E'P2#._)W#Y1^,IWCJ4U9Z'U#;>
M<+>(7!1I]@\PQ@A2V.<9[9J2JNJ:I::)IMWJ.H7,5E86D3SW%S.X2.*-069V
M8\   DD^E? 7B#_@H9\3_CAXRU3PW^S)\,U\6VFG-MG\1:RI6%_FP&56DB2,
M'G;YC[B,G8,&K;L2E<_0>BOSM\0?M:?M=_L^1/X@^*_P=T75_!D)3[7>:#*
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M\'BY(-2TF[P+FPG^W:<=C@'E3R5<<, >A# ?JS0GJP>B05\:?\%$/VE?B3\
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M@D$$_IM1'J$N@5POQH^-GA'X > [SQ=XSU-=.TJW.Q%4;IKF4@E884_C=L'
MZ  DD $CNJ_+GQ_H\W[?_P#P4/O?!&HW-PWPP^'*R1W5K#(0DK0NJ3CKP\LY
M$98<^7%QR*&[ E<W+']KW]JO]K*:>;X&> +3P=X0#M'%X@U1(Y7)7(/[V?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\B?VKO\ E+A\.O\ L8?"_P#Z/@K]=J_(G]J[_E+A\.O^QA\+
M_P#H^"LY[&D-S]D:***P-S\;/^"9/_)_GQ+_ .P=K'_IPMZ_7BOR'_X)D_\
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M8:-H]E#INE6$"6UK9VZ!(X8U "JH'0 "O@_]N)0W[=G[*H(!']I@\^UW#7Z
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MA:R32;W1;Q]ES.EN@C%PBM@ME5&\#E&#9 &TE_:%T/KBOS'_ &K/@]I'P_\
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M$SE)9I-Q'9DAAB]1O?!&:_16SL[?3;."TM(([6UMXUBA@A0(D:*,*JJ.
M .F*_/;]MTWO[-7[9'PJ_:)^PSWGA%XO[#UQH$+F E94+'W:&8L@SRUN1QFO
MOOPOXJT?QMX?L==T#4K76-'OHA-;7UG*)(I4/<,/R]B"*A;LM[(POB]\*= ^
M-WPYUOP7XFM1<Z3JD!B8@#?"_5)8R>CHV&!]1Z5\>_\ !(_QGK$GPS\>_#G6
M)GGD\$:X;>W+G_51S%]T0'8"6&9O^VAKZG_:(^/WAG]G'X9:IXN\27L,1AB8
M6-@T@$U_<8^2&)<Y8DXR1]T98\"OG/\ X)4_"[7/"OP6\0>.?$L#VVK>/=5;
M5HXY%*EK4 ^7(0>1O=YF'JI0CK1U#[)QW[0G_*7+X$?]BTO_ *'JE?H37Y[?
MM"?\I<O@1_V+2_\ H>J5^A--=0ET"O@#_@IQ_P ED_97_P"QK?\ ]*+"OO\
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MI^*]!T>TF_MU[:'5-/LY%Q*TT+++Y.T9^=E#Q@?WF%)[.PUNKE;]@7X'Z/\
M!+]FCPA'96:Q:QK]A;ZUJUTX'FRSS1*X1C_=C5@@'08)ZL2?HNOE?_@GA^T?
MHOQJ^ OA_0'NX[;QGX3LHM)U3296"SA8%$<<X4G)1E"Y;'#[E[#/U)<7$5I;
MRSSR)#!$I>221@JHH&223T '>A;:">^I^;_Q'\.6_P"RS_P4^^'>M>%(VT_0
MOB4GV75-/BPL+SS2&*3:.P\S[/-C^]NQP<5I_P#!:&%KCX0_#R)!EW\0.JCW
M-NXK/A\2Q?MI_P#!2/PSJGA,_P!H_#WX6V_F7&M0_-!/<*SLIC?HP>8QJO\
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MW"E1Z1E;F-?]EAG.,U^B6O>(-,\*Z+>:OK.H6VE:59Q&:YO;R58H84'5F9B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBH[BXBM+>6>>1(8(E+R22,%5% R22>@ [T 245\P?$+_@I1^S]\.]2
M;3YO&HUV\C<I(N@VLEY&F._FJ/+89'\+&LCP?_P5,_9[\67T%I-XFOO#TLQ
M5M8TV6.,$]F= ZK]20/>INBN5GUM16;X=\2Z1XPT6TUC0M4L]9TF[3S+>^L)
MUGAE7U5U)!'T-:542%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/[6_BL:+L\L8@N3-LQ]W_C\X]/O=/RK[UHI<J'S,^=/V:/V%?AW^S3J$VNV
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MJ_=GT[1116AF8_C#P=HGQ \,ZCX=\1Z9;ZSHFH1&&ZLKI-T<JGU]"#@@CD$
M@@BOB"X_X)AZ_P##W6+VY^"OQU\3_#G2[R0O+I#>9+'S_MQRQ[L=!N0MC^+U
M^]Z*5DQIM'QO\,_^"<&EVOC2Q\8_&#X@:[\:O$-BP>TCUPNME P((_=/)(7
M(X4L$/=#V]5_9V_9;M?V??''Q4\1VWB&;6G\>:O_ &M);R6HA%F?-N)-BD,=
MX_T@C) ^[[U[G12LAW9X1J/[*MKJ'[7.E_'4^(IDN['2VTP:+]D!C<&.2/?Y
MN_(/[S.-O:O=Z**8CPC]KK]E6U_:P\(>']!N_$4WAM-(U1=36>&T%P9"(W38
M077 ^?.?:O=Z** /DO\ :(_X)T^#OC-XT/CKPOKVI?"_Q\S^;)K6A#Y)I?\
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MR3FO-;K_ ()K_$SX@1IIGQ*_:8\5>)?#*E?,TN%)OWX'J99W0'T+(_7\_O\
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M[)_P:\+ZU8:QI'PQ\+Z=JEA.ES:WEMID22PRH0RNK 9!! (/M7S%_P %FO\
MDU_PO_V.-K_Z17U:OPK_ &X/CAXX^)'AKP_KG[,GB?PQH^I7\5K=ZS=6U\L5
ME$S -*Q>U50%'/+ >]97_!9K_DU_PO\ ]CC:_P#I%?4W:SL"O=7/N'PK_P B
MOH__ %YP_P#H JI\0/\ D0_$G_8-N?\ T4U6_"O_ "*^C_\ 7G#_ .@"JGQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZX=!)8R>1$<\C;%MR.S.]=%_P25_Y,^T[_L,WW_H:TUN#V/LRBBBM#(****
M"BBB@ HHHH **** "BBB@ HHHH **** "OR)_:N_Y2X?#K_L8?"__H^"OUVK
M\B?VKO\ E+A\.O\ L8?"_P#Z/@K.>QI#<_9&BBBL#<_&S_@F3_R?Y\2_^P=K
M'_IPMZ_7BOR'_P""9/\ R?Y\2_\ L':Q_P"G"WK]>*WAL83W"BBBM#,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BOR8_9A^!?B#_@H1?>/_BEXO^*?B;0]0MM7:QTV+1Y=J6P\L. H)^6-
M5=%"J%/!)))K]5/"^CR>'?#.DZ5->2ZC+8VD-J]Y/GS)V1 ID;)/+$9/)ZU*
M=RFK&G117PO_ ,%,_B+XK\!>(O@1%X9\3ZSX=CU+Q!)#>II.H2VHNHP]L DH
MC8;U^9N&R/F/K3;LKB2NS[HHHKX8_P"":OC+7_%?C;]H:+6]<U+6(K'Q.L-H
MFH7<DZVZ>;=#;&')V#Y1P,#@>E%PL?<]%%%,04444 %%%% !1110 45^1W[.
M<O[5'[5UQXTNO"WQQET.UT'4OLCQ:G*X+;RY7;LB;@!<<U[!??"/]OKX=VLF
MJ:9\5/#GC5+,972?W;S72CG;^_M$&3C'^M!YX-1S>1?+YGZ(T5\Q?L/_ +8W
M_#4?AK6=.\0:2GASXA>&Y%@UC2T#(C9)42QHYWJ-RLK(Q)0@ DY%?3M4G<G8
M****8@HHHH **** "BBB@ HHHH **^&/^"M'C+7_  7\)? -SX?US4M"N)O$
M\<,LVF7<EN\B?9Y3M8H02,@'!XXK[GI#MI<****8@HKX8^/GC+7]-_X*>_ S
M0;37-2M="O-#:2YTR&[D2VG;-_\ ,\0.UC\J\D?PCTKW7]L[X/\ C3XY? ?5
M?"G@+Q"OAW7I[B&7S))W@CN85;YX'D0%E4@YX')0 \$TKE6/<J*\H_99^&OB
MSX1? GPOX4\;^(3XG\2V$4@N;[S7F W2,Z1+(_S.J*RH">R\ # KU>@04444
MQ!1110 4444 %%%% !17Y,?LP_ OQ!_P4(OO'_Q2\7_%/Q-H>H6VKM8Z;%H\
MNU+8>6' 4$_+&JNBA5"G@DDDU^JGA?1Y/#OAG2=*FO)=1EL;2&U>\GSYD[(@
M4R-DGEB,GD]:E.Y35C3HHKXG^ /QB\:>)O\ @HM\:O ^J>(KR]\):/I;36&D
MRL##;N)+,;E&,YQ(_?\ B-.XC[8HHHIB"BBB@ HHHH **^8O^"E'B+5?"O['
M/C;4]$U.\T?4H9M/$=Y87#P3)NO8%;:Z$$9!(.#T)KU/]F74+K5OV;OA1?7U
MS->WMUX3TF:>YN)#))+(UG$6=F/+,2223R2:5];#MI<]*HHHIB"BBB@ HHHH
M **** "BBB@ HHHH ***^-O#7[*WQATO]N[4_BM=_$+SOAY,\LBZ;]MF,LL+
M0%([1K?:(PD;MD-D_<#?>)PAGV31113$%%%% '$?&3XQ>&_@1X!O?&'BN>:#
M2+62&$BUA,TTDDDBQHJ(.6.6S@=@3VKIK[7[+2?#\^MZG*-+T^VM6O+F6\PG
MV>-4WN7]-H!SZ8-?+7[7DY\??M%?LX?"LKYEA>:]/XHU&/LR:?"9(E8=U8F0
M'Z"OJ^^L;;4K.:UO+>*[M9E*203H'1U/4,IX(^M(9YY\'_VC_AO\?)-5C\ >
M*;?Q(^EB)KP00S1^2)-VS/F(N<['Z9Z5M_%KXI:+\%OA[J_C/Q$MV=$TI4>Z
M:Q@,TJJSJFX(.2 6&?09/:OG;]FW2K+0_P!NC]J6RTZSM["SBA\,>7;VL2QQ
MIG3R3A5  R23]2:^BOC!X3@\>?"?QGX;N4\R'5M'N[)EQG_60LH(]P3D>XI=
M!]3H=$UFS\1:+8:MITZW6GW]O'=6TZ?=DC=0R,/8@@_C5VOG/_@G?XIF\7?L
M9_#&\N)/,FM[&73^>RV]Q+ @_P"^(UKZ,IB"BBBF(**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _.O_@IQ_P G&?LK_P#8??\
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M=G)->6'AS3Y);FYBA9I;F3YI9Y%C7))9RY"#)&0HSBODG]@OX9>*_BI^T/\
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M>QO.@P2#AXF/&*_0JFMA/<****HD**** "BBB@ HHHH **** "BBB@ HHHH
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MMDYRL00$?WB_K4];%=+GTY1116AF%%%% !1110 4444 %%%% !1110 4444
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M3S1LPW1^C]?GC^S-Y'B+_@JM\?-;T(!M%M-(>QN9HN4^U![)'4GU,L$Y_P"
M&F>)OV^?BY^T/8S>%O@'\'?$5AJ%\/(?Q/K2!([$$8+#CRD;KAGDXQPI-?1_
M[%_[*-G^RK\-[BPN;U=:\8:U,+W7=7&2)I@#MC0M\Q1-S8+<L6=CC=@'Q/0-
MEJ:7[9_P%C_:,_9Y\3^%(HA)K4<7]HZ.V!E;V$%HU!/3>-T9/82&OCO2?V]Y
M=/\ ^"<-U++>M%\3[$_\(0D3,5N1,4*I=8^\&6W#-N/66,@]<5^FE?G!J_\
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M%I"L2 GJ=J@#-7:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;#[?/53M./-S@]*]%L?VX/C;IEE;V=G^QKXIM;2WC6&&"'4I$2-% "JJBQP
M   !TQ2;U&EI<Y;Q/XR_;-_9&LW\4^+;O0OC5X$M!YNI+91K'<VL7\3Y6&.1
M<?WMLJJ.2 .GVI\#_C5X:_:"^&ND^-O"MP\NEWZD-#,NV:VE4XDAD7LRGCC(
M(P02""?E>X_;F^.-U!)#-^QSXKFAD4H\<FIRLK*1@@@V/((K$_X)>^$_B!\/
M?$OQ8TGQ%X!U[P%X0U2[CU?1=-U:)_+M6+R*\22,BAV\LP*3@9$0.!0GJ#6F
MI]_T445H9GYV?\$>_P#D%_&C_L/P_P#H,U??7BSQEH/@/1+C6/$FLV.A:5;J
M7EO-0N%AC4 9/+$<^W6OQ'^ '[$\O[4W@3XPZ[HFISP>,?#NH[=,TYM@MKTL
M9':-R1E68+A6R "1GCD=_P#L$_L;_!;]HZSU6S\8:EXHL/B!X=G9-4\+FZBM
MXWC#E1(H\KS-H/R,NX,K#DX9:RBW:QJTMSW'_@G???\ "V/VR/V@/BMH%M)#
MX*OGDM;>9D,:SR2W*R(V"/O%(6=AU7S1GK7V#^U)^TUX:_97^&,_BO7T>]N9
M9/LNF:5"VV2^N2I8(#@[% !+.00H'0DJI[CX:_#'PM\'_"-GX8\':+;:#H=K
MDQVMLIY8]7=B2SN>[,23W-?FS^WOXQUC7OV_OAUHUIX,O_B79^$]-AU*+P=:
M2E/MEP6EF=O]7)QA("XV'*Q$' .:KX43\3.^\,6O[<_[1EBGBF'Q1X?^#V@W
M9\VRTBXM56X:(C*L5,$LF,?\]'4GJ%P13=:^.W[4_P"Q9=VNI_&2TTOXK?#1
MYT@NM>T.-([BS#$ $E8X\'GI(A5FPHD!(-=E_P -W?';_HSWQ=_X-)?_ )!K
M&\9_M@?&+Q]X2UCPUK7[&GBR\TG5K22RNH6U.4[HW4JW6QX.#P>Q -+3N/7L
M?;O@;QMHWQ(\'Z/XH\.WJZCHFK6R7=I<H"-\;#(R#R".A4\@@@\BO@?Q9_P4
M2U_X._M/_&/PSXF9O$6BZ/'':^%O#5C:(EQ=WTC0;(_-5"V,/(23GT )V@^C
M?\$L?#?Q!\!_ G6?"?C[P]K'AY]-UF272X=7MGA/V:6-&98]P&5$HE;ZR&O(
MO@C\,M*\=?\ !6/XNZQJ]K%>)X8B.HV<<O(6[*VT<<FWOM5Y"/1MIZ@4-O05
ME=G66/@_]NSXT0Q>(I_&_AGX2V%TGFV_A[[.IG@4G*B0>1*P.W&0TF1T*J<@
M94?[57[0G[&GBK2M-_:,TJT\9> K^86T?C/085W0MSC)14#$ 9V21H[ $J6P
M0?T4KS[]H'X8Z5\8O@OXP\(ZS#'+::CITRH\@'[F95+12@GHR.%8'VIV\POW
M.TT/6[#Q+HUCJ^E7D.H:9?0)<VMW;N&CFB=0R.I'4$$$?6OE7_@G#^T)XW_:
M)^&_C'5_'.I0ZE?:;K[V%M)#:QVX6$0QL 0B@$Y8\GFL/_@D?XSOO%?[)265
M[*\JZ!KMWI=LTC$D1;(;@#)[ W# >@ %<G_P1WS#\)_B5:N-L\/BN3>OI^XB
M'\U-%[V"UKGW_7R1;_M">-Y/^"CEU\)&U*$^!X] %^MC]EC\SSO(5]WFXWXR
M3QG%?6]?G_9G_C<7??\ 8J#_ -)4IL2$_P""R,BP_!?X>NYVHOBJ-B3V MIJ
MTY/VAOC]^U]K6HQ_L]6FG>!OAQ93O:CQWXD@W2:BZDAC;Q/&^%X(QY;$<;F0
MG:,C_@LS#]J^!_@*'>L?F>*%3>YPJYMIADGL*^YO '@?2?AIX)T/PKH5NMKI
M&CVD=G;1J /E10-QQU8G))[DD]Z74?1'Q%XE\#_MP_!6W?Q+I/Q#T/XNVEJO
MF7/AZ73D2:95Y(C01(S'&>$D#'H%8XKZ#_9'_:W\/?M6>"[F]L[5]"\4Z2ZP
M:SX?N'W26LASAE. 6C8AL$@$%6! (Y]YK\[-0TV#X(_\%>M"AT!!::?\0M!D
MNM3M8!A#(\=P6;:.YFLDD)/=V/>C8/B-3]HC_E*]\ /^P W\]0KZ1_;4^*'B
M'X,_LQ^-_&7A6[CL=?TN.V:UN)84F5"]W#&V48%3\KL.1WKYN_:(_P"4KWP
M_P"P W\]0KV;_@I1_P F2_$S_KC9?^E]O1W'V/4/V:_&NK?$?X ?#[Q3KLZW
M.LZQHMK>WDR1K&KRO&&8A5  Y/05\S_&K]N'QSXR^+%[\(_V;_"T/B[Q+I\A
MAU?Q)>+OL-/8':VWY@OR-P9'.W<I54?@UU'ACQY??#/_ ()A:5XFTR5K?4]/
M^'\3VDRCF*9K<)&X_P!UF!_"H/\ @EC\,M+\$_LGZ%K]O;Q?VUXJFN-0U&\'
MS/+LGDBA0MZ*B [>S._<FCR%YG%K\!_VZ;BW.H2_'SPO%JOWQ91V4?D<#@$_
M8@O89^0CKU[Z7P/_ &ROB7X)^,VF_!O]HWPS;Z+X@U7]WHOB;34Q:Z@Y.%#!
M<H0YX#IMVG:K(N21]Q55N-+L[J^M;R>T@FO+3?\ 9[B2)6DAW##;&(RN1P<=
M13L*Y:HHK*\6:TWAOPKK.KI&)GL+*:Z$9Z.4C9L?CBJ)/C[]JC]N;Q)X?^)D
M?P:^!?AU?&GQ-D^2\N"GFV^G$@';M! 9U!W,SD)'QNR=P7CU^"G[?$UI_:S?
M&?PM%J)D\T:5LCV@==O%ELZ\;>F.]2?\$A_!L.K?#WQW\5M6"W_C#Q)K\]M<
M:E(=TIA58Y6&>V^65V;UVIGH*_0*H6NK+?NZ'P_^S3^W-XN_X6POP8_:"\.Q
M^#_B!(PCTW4HT\JVU%B2%0C)3<^#LDC8HY^4!6P&^B/VCM#^,&O>#]/@^"_B
M'0?#?B-+]7N[GQ!&7A>U\MP44"&7YMYC/W1P#SV/S+_P5X^'MC>? W0OB%:H
M+3Q1X8UBW6VU*%MDRP2D@H".N)!$X_NE3C&3G[*^%?B:X\:_##PAXANT$=UJ
MVCV=_*H& 'E@21ACMRQH78'W1^3'_!.SPK^TEKWPP\2S?!;QEX1\-Z"FL%+V
MW\0PL\LESY$9W*1;2_+L*#J.0>.]?L)I,=Y'I=FFH21S7ZPH+B2+[C2;1N*\
M#@G/85\ _P#!%W_D@_CC_L93_P"DL%?H31'8);A7Y[?LR_\ *5;]H+_L#O\
M^C;&OT)K\]OV9?\ E*M^T%_V!W_]&V-$N@EU/3O^"C/[1GC/]G'P;X$U3P=J
MD&E/J6NBSOI9[6.<&#RRQ&'4XZ=1S7&-\;/VA_VQM2U"X^ S:9\./A=:S/:P
M>,?$$ >YU9D.UV@C:.3:F>!\@Q@Y<-E%Y[_@L] UU\)/AU"O#2>(609]3;N*
M^\_ W@W3/AWX,T/POHL M]*T>RBL;:,=HXT"@GU)QDGN231JVQ[(^ /&WQ4_
M:H_8<OM/\3_$O7-+^+_PQN+M+>^FL[=(;BSW' ((B0HQP,;M\9/RY4L#7Z#^
M%O$NG>,_#.D^(-(N%N]*U6TBOK2X7I)#(@=&_%6!KR']N32;;6OV1?BO;W4:
MRQ)H4]R%8 C?%B5#]0R*?PKD_P!@GQ++;_L(> =7G#W#V.E7A"DY++!<3JJC
M_@* "A:.P;JYR/[4W[<6O>%?B5;_  <^"7AQ?&_Q3N,+<LR[[73=RYVL P#.
M%(9BS*B C<3R!QL/P3_;SNK5=8?XU^%K34W_ 'W]DO!&8T_Z9DBR*9QQW'^U
MWJ#_ ()%>%8O$7@WXB?%W6"M_P",O$GB">TN+Z3#2+&JQSN >J[Y9V+#OY<9
M["OT%H6NH/W=#\FOVKOVKO'&H?LZ_$#X,?'/PNOACXEK]AN--U"RC/V'6H4O
M869HR,J&"JS;E.T[6&$9=I_1/]E7_DU_X/\ _8G:/_Z10U\^_P#!6;X8Z5XN
M_96O_%5Q;1'6/"EY;7%I='AUCGGCMY8P?[K>8C$>L:U[;\ =:;PW^QK\.-72
M,3/8> =-NA&>CE-.C;'XXH6X/8\0_:H_;F\2>'_B9'\&O@7X=7QI\39/DO+@
MIYMOIQ(!V[00&=0=S,Y"1\;LG<%X]?@I^WQ-:?VLWQG\+1:B9/-&E;(]H'7;
MQ9;.O&WICO4G_!(?P;#JWP]\=_%;5@M_XP\2:_/;7&I2'=*856.5AGMOEE=F
M]=J9Z"OT"H6NK!^[H?#_ .S3^W-XN_X6POP8_:"\.Q^#_B!(PCTW4HT\JVU%
MB2%0C)3<^#LDC8HY^4!6P&^C_P!J'QUK'PQ_9Z\?^*_#]PEKK6D:3-=VDTD2
MR*DBC@E6!!^A%?+W_!7CX>V-Y\#="^(5J@M/%'AC6+=;;4H6V3+!*2"@(ZXD
M$3C^Z5.,9.?6?VC/$UQXU_X)[^*/$-V@CNM6\$1W\J@8 >6W21ACMRQH[H--
M&?/7PM_;>^-/[17@'PKX*^$VF6.M?$PV37/BOQAJL"P:;H^Z:18E"!=K2% A
MX5NAPCD,4V/&7@G]N/X-:+/XUM_B?H/Q'33HVNK[PZNG1CSHQEG$:"",L !G
M",C]E'8^E_\ !*_P-IWA/]COPSJ=I"J7_B*ZO-1OI<<NZW$D"#/H(X4X]2Q[
MU]=T)70-V>AXY^R?^TAI?[4WP=T_QII]K_9MX)7LM2T[?O\ LMT@4L@; RI5
MT=3Z.,\YKFOVQOVP-+_99\,Z;#;::_B7QWK[F#0] AW9E;*J9)-H)" LH"CY
MG8A5_B9?!O\ @EC$FB^./VD?#MJ/*TS2_%2+;0KPB#S;N/A>WRQ(/P'I7BWQ
M*^)WB>X_X*=>+O%&E?#35?B_-X*@2TTS0;*=H_L.V&-#/Q%+\HEEF8#:,/*K
M9! I7T'RZGLFA_#S]O+XK647B#4OB1X<^&R72[XM!^S1^; IY =5MY,<=FE9
MAT(!IEG^UA\>OV0?&&D:/^TKI5AXD\#ZI/\ 9H?'6@1#]R^.K+&B!@ ,[&C1
MR S+OV[:ZG_AN[X[?]&>^+O_  :2_P#R#7GOQ^_:(^,7[0'PA\2^ ]6_9!\6
M6T.K6QCAO#?2RFTG!W13A?L0R4<*<9&0",C-'HQ^J/T2F\0:?#X??7/M<;Z4
MMJ;W[5&P9#"$W[P1U&WG-?GIX+\=_M8_MK6^L>._AOXOT7X5^ $NY;71+&\M
MT:6\",1OD?R96)Z*S9"[@0J'!-?0_P"PMH/BF;]D+P[X3^).BZEINJ6<%UH\
M]GJT+0S-:;W6(8.#M$+*@/HE?,'@GQS\2_\ @EYJ-[X1\9>&;OQQ\#+C4'FT
MSQ+I:@S6/F')##[H8]XG*@MN*.1D%LE'U-^R-XR^/>J2>)_#?QP\+6EK=Z'(
MD=IXHLV1(M6W9)*QH-K #!WJ%'(4H&#5ROA3]H3QOJG_  4<\9_"2YU*%_ ^
MFZ!'?VUB+6,2+,8+1R3*%WD9FDX)QS[5]"_"7XP>$?CEX,M?%/@K6H=;T:<E
M/,C!5XI!C='(C ,CC(RK '!!Z$&OC+P'_P IBOB/_P!BI%_Z36%'8.Y]2?M-
M_M+>%OV6_AM/XK\2,UU-(_V?3M)MW GOYR,A%ST4#EG/"CU)"GY'\+77[;W[
M4%G'XLTW7="^#/A:Z7SM.T^XME\Z:(_<<AH992".[E >"JX(IO[1VCP?'3_@
MJ)\)_ 'B%/M/A70=).I'3YAF*:4)/<-E3PP<PVZL.A6,BOT5Z<"C=A\)^?=Q
M\:OVHOV-[NTU'XU6NF_%;X:22B*]\0>'8@+G3%) #OMBBXYZ.F&.%\P$C/HG
M[!G[3WB7]I#QM\;O[4UF#6?#6AZS%'X=DAM$@Q9R2W6PDA0S92.+[_/'N:^L
M?$&@Z=XJT/4-&U>SBU#2M0MY+6ZM)UW)-$ZE71AZ$$BOS]_X)0^$8_A_\0?V
MD_"\+;X=$\06VF(Q;=E89;Z,'/?A>M&J8:-,]7\= 2?\%//AH)P5CC\!7K6[
M$\-*9Y@P ]0G-?75?(G[1C#PC^W9^S1XHG&RPU%-7\/RS>DCP?N$/^\\O'T-
M?7=-=1/H?*/P!_Y/V_:I_P"N/A?_ --QKZNZ\&O&/AK\$-5\$_M)?&3XC75_
M9SZ7XVCT=+.UAW^?!]DM?)D\S*A?F;D;2>.N*ZGX_>/(?A?\$?'7BJ:7RO[*
MT:ZN(SG!,HC81J/=G*J/<BA:('N>"?\ !+,C_AD?2Q$<V8UC4A:CTB^T-@?G
MGI7US7A/[#/P]G^%_P"R;\-=#NH_*O#I@U"=&&&5[EVN2K>Z^;M/^[7NU"V!
M[A1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G?^TE_P 9>_M[
M>!?@S;G[5X+\!I_;?B15.8Y)?D=HVP>1M-O#ZJ9Y/0U^B'3@444DAMA1113$
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'Q"^/WPGF\:>//#=CX;@U"]D;1(K02*\]EG*2.KD\<[588WA=V ""?.?A/\
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MDNV. 0N6P*\C\;?\$E/@WX@UZ35O#VH>)O TTC%C:Z-?(UNN<Y"B5'=>>P?
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M9F*X&,D8OC'_ (),_"#6]:N-2\-ZOXJ\"_:&W26.BZ@IMNY^5949QR>F_ Z
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MT(R#<61LC#GBN5_:)_85^$W[3%Y_:?B;2+C3?$6T(==T.5;:[=1@ 295DDP
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?D3^U=_P I</AU_P!C#X7_ /1\%?KM
M7Y$_M7?\I</AU_V,/A?_ -'P5G/8TAN?LC1116!N?C9_P3)_Y/\ /B7_ -@[
M6/\ TX6]?KQ7Y#_\$R?^3_/B7_V#M8_].%O7Z\5O#8PGN%%%%:&84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A_PY
M_99TKX<_M&>//B[;:Y>7FH^+;<6\^FRQ((;< Q'*L.3_ *H=?4U[A12&%%%%
M,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7X[?M>?\I>/AW_ -C!X6_]'P5^Q-?CM^UY_P I>/AW_P!C!X6_
M]'P4 ?L31110!^.O_!+G_E(%\3/^P9K'_IQMZ_8JOQU_X)<_\I OB9_V#-8_
M].-O7[%4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSI/PH^%,,\EOI_B+7H-]]K.QBK2(K12;4)QT5<88;V(*@ _0"BOS=TO]I?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5^.W[7G_*7CX=_P#8P>%O_1\%?L37X[?M
M>?\ *7CX=_\ 8P>%O_1\% '[$T444 ?CK_P2Y_Y2!?$S_L&:Q_Z<;>OV*K\=
M?^"7/_*0+XF?]@S6/_3C;U^Q5 !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'2OBA^R+\1(M2M8YKC1-,FUZQF?AH)[6-I=RGL2@=/<.1WKRS]B?_E%78_\
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M(*-Z6Q((/S1;LG.*_2GQMX[\._#?P[=:]XIUNQT#1[5=TMYJ$ZQ1K[9)Y)[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI6L5Y%%=Q^7,J2('4.O\+8(R.QXK4H **** "BBB@ HHHH **\3\=?M5>'_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7!4L=TDBQH HY)+,.G;)Z"@#KZ*C@GCNH8YH9%EAD4.DD;!E92,@@CJ"*DH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO$_VL
M/VJO#_[(_@32_%/B/2-3UFSU#4ETR.'2Q'YBNT4D@8[V4;<1$=<Y(KVR@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEDKW4ZO<^7<R2R2_.% SF9\?+QQUKTVB@#S+]GG]GOPO^S+\/1X,\(2:A+I
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M/@K\(="^ OPQT3P'X:>[DT31UE2V:^E$DQ$DKRMN8*H/S2-V'&*S?CI^SMX
M_:/\+)H/C[0(=8M86,EM<*S17-JY'WHI5(9<\9&=K8&0:])HH ^ %_X(P?"
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M ()Q?!S]H;Q!/XCU#3[_ ,+^*)V\R;5_#DZV\D\G9Y$9'C9L]6VACW;I7%>
M?^"2OP9\+Z];ZMXCOO$OQ!FMR#%:^(;Y#:C!R,I&B%AGJK,5/<5]L44 >.3?
MLI>!7^/WAWXO0QWMEXET'3/[(L+.TD2.PCM_*EB"^2$XPLS 88 87CBO8Z**
M /ECX_\ _!-GX,?M!:]<^(;[3;[PKXEN7,MQJGAN=;=KB3KODC9'C9B>2P4,
M>[=ZX3P1_P $A?@QX?\ $$.K^(]3\4>/)8F!6UUJ_1;=@.@81(CMSV+X/0CK
MG[BHH I:+HNG^'-)L]+TJRM]-TRSB6"VL[2)8XH8U&%1%4 * . !7EOC#]ES
MP;XV_:$\*?&749=47Q=X;LA8620W"K:F,&<_.A0DG_29.0P_A].?7Z* "OG+
M]HO]@+X/_M-:H=9\2Z/=:5XD8!9-<T&=;:ZE4  "3<K1R$  !G0L   <<5]&
MT4 ?!.@?\$;_ (16FLVU[K_BCQCXIMK< +8WE[%'$R@YVLR1!]OLK+UZU]M>
M"_ _A_X<^&K+P]X7T>ST'1+--D%C8PB.-!W.!U)/))Y))))-;E% '@_[2O[%
M'PN_:JCMYO&.EW%MK=M'Y,&NZ3*(+U(^3L+%65U!)(#JV"3C&3GS3X(_\$MO
MA!\&_&EAXLN+C7?&^MZ>ZR63>(KF.2"VD0@QR+&D:Y9<#&\L <$ $ C[#HH
M*\!_:(_8;^$?[3ET-1\7:!);>(%01C7='E^S7A4# #M@K)CC'F*V,8&!Q7OU
M% 'P18_\$<?A6LZIJ?CCQ[JVF1L"FGRZA;K&0#PK$0<C''R[3Z8KZZ^#GP)\
M!_ #PS_8'@'PW:>'M/9M\WD[GFN'_O2RN2\A]-Q.!P,#BN]HH ;)&LL;(ZAT
M8896&01Z&OC3XK?\$H?@E\1O$4VO:2FM> -3E?S67PS=)%;;R>6$4B.$X[1E
M /3U^S:* /C'X1_\$H?@K\,_$\?B#51K'C_4HI/-CC\2SQRVP?LS0I&HD/\
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MK'_IQMZ_8J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW0?B&WP@O3>7W_"<W'B6VT#0M/@D3R)5N)4>>25"A8A%B'S!E W#.<BO1_\
M@EQ_R8G\,O\ N)_^G2[KZ;U#0=,U:\T^\OM.M+R[TZ4SV4]Q LDEM(5*%XV(
MRC%69<K@X)'0T 7Z\/\ CA^VI\&_V=M9BT;QOXQ@L=;D02?V79V\MW<1J0"&
MD6)6\L$$$;\9'(S7N%?F9^PCH?P\\7?M(?'JP^*^EZ7JWQCD\277DVOB.%+C
M=9AV#"U64$$@CG;SY?EX^7- 'W3\%/VD/AO^T1I,VH?#_P 56>OK;X^T6RAH
MKFWST\R&0*ZCL&(P<'!->E5XI\/_ -C?X3_"OXQ7WQ*\)>%X?#^OW=D;(V]@
MWE642L07>.!<*C, H.WC X )8GVN@ K\=_"/[6<OPG_X*D_$77-0N63P9KNO
MOX5UB9L^3$(B+>WF)Z#RW@SG^YYN*_86:9+>&265Q''&I9F8X  &237Y _LQ
M?LX?\->_L@_M :P+8/XHUKQ;)J>C32 !OMEO$9E3)[2"[DB)Z#S">U '[ T5
M\L_\$X_VA'^/'[..E0ZK.[^+_"I&AZQ'/Q,6C&(96!YR\87)/5TD]*ZC]N/]
MHJ/]F;]G?Q#XG@F5/$-VO]F:)&V,M>2J0KX[B-0\A]?+QWH _/W]K#]JZ3QE
M_P %&OAQ!IMVTG@_X>>);'3#)$28WN'N$%Z^?7"M$/\ K@2.IK]@*_&GX_?L
MK7/P'_X)P^"_$-[#)%X^NO%5KXBUFYE!,T7GP3+'"Q/(*9ASG^,R>M?L!X1\
M01>+/"FBZW!@0ZE90WJ;>FV2-7'Z-0 OBCQ5HW@G0;S6_$&J6>BZ/9IYES?7
M\RPPQ+ZL[$ ?_7KYCU3_ (*F?LV:7J;V9\>2W6QMK7%KH]Y)$#GG#"+Y@/5<
MCTS7SU\1=/U/_@H[^VMKGPVGU.^T_P""_P ,G9-5@M7\O[;>H[1-S@_.\@D1
M6.0(X9"N&<Y^W?#?[)?P6\)Z%%H^G?"KPBMC''Y1%SHT%Q)*N,?O))%9Y#CN
MY)- '0?"?XX> OCEH;ZMX#\5:=XFLHR!+]CE_>P$]!+$P#QD^CJ#7<U^9_[8
MO[.,7[$>MZ/^T9\"X7\-0Z7>Q6WB/PY;R-]BN+:615X4YVQNVV-DZ O&R!2N
M:^^;7XP>';GX+Q_%#SW3PJ^A#Q%YK* ZVOD>?R,_>"=O7B@";XH?&+P3\%?#
M_P#;?CGQ-I_AG322J2WTNUI6'58T&6D;_94$U\_:7_P5,_9LU35([(>/)K7S
M&V+<76CWD<.<X&6,7R@^K8 [XKYM_93^ MW_ ,%"O'>M_'_XWF?4_"ZWTEEX
M;\*^<ZVHCC/(.,?N4)"X4CS)%D+]"&^[M4_91^"^L:+_ &5=?"CP:]B$V+&F
MAVT;(,8RK*@93[@@T ?'/_!8SQ+I/C#]E'P!K6A:G::QI%[XIAEMKZQF6:&9
M#9W?S*ZD@CZ>E?HY7X??\%&OV9]8_91L]/\ #GA?5KZZ^#'B+4_[6LM+O9?.
M.FZE%&Z/&K'G:8Y>&ZL!AMQC#']8?VP)?$$/[+OQ1?PMYPUQ?#]V8#;DB4+Y
M9\PH1SO$>\C'.<8H X/QC_P4H_9V\#^*IO#^H?$*&XO;>7R9YM-L;F[MXFSR
M/.BC9&QWV%L8(ZC%>^^!_'OAWXF>&;/Q%X5UJRU_1+Q=T-]83"2-O49'1AT*
MG!!X(!KXR_X)W_"W]G_XH?LHZ%:6?A/PQXEUCR/+\31ZI8PW-ZMZ2=WF%U+J
MO>,C "XQSFOIG]G_ /9I\"?LRZ#K&C^ ]/GL++5+]]0N%N+EIVW$ *BEN0B*
M JCDXZDG)H ]#U[Q!IGA71[O5]:U&UTG2K.,RW%]?3+##"@ZL[L0%'N37S!K
M'_!4C]FW1=6EL'\>R79C;8]Q9Z3=S0YSSAQ%A@/5<CTS7SG\4+?7_P#@H]^V
M9KOPK75[O2/@O\.)BNK_ &%]K7ERC>6^>JF1I5D1"00J1NP&20?MWPK^R%\$
M_!OAV/1-.^%GA-K!$V,+[28;N648QF2256=S[L30!J>%/VDOAEXY^&^K>/=
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M^E_^"@7[3%U^S!^SWJ&N:,Z+XKU:==)T9F4,(IG5F:8J>OEQH[#((W; 1@T
M=?\ &O\ ;#^#_P"SW="R\<>-;+3=5*AAI=NCW5V >A:*)69 >Q8 'M7+?#/_
M (*(? #XL:_#HFB^/[:VU6X<1P6^K6LUB)F) "H\J*A8DX"[LD]!7EW['O\
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M5^QK^UIJ?[,7B[5IM7\&ZU%)J/A"]N6R4!#R)M_N+(L<RLG3SH_E'SDGL_\
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M^+/[1W_"P/\ A:.@6^A_V-_9_P#9WD:7-9>;YWVGS<^8QW8\J/ITSSU%?95
M!17PK=_M;?&>']OY?A.GANV/PT.II:_VG_9$YD\HV@E+?:-VS[Y(SCVK[JH
M**^._P#@HA^TQ\5OV<[/P))\+]!M]<DU>2]74!/IDU[Y8B$'EX\MAMSYC]>N
M/:OJ3X>ZQ?>(O /AK5=3B$&I7VF6UU=1*A0)*\2LX"GD88G@]* .@HKRW]J#
MX@>)/A9\ _&?BOPA9)J'B72[19K*UDMWN%D<R(N#&A#-PQX!KSG]@'X[?$/]
MH3X.:SXB^)6D0Z+KMKKTVGPV\%A+9AK=;>WD5MDC$D[Y9!NSCC':@#Z8HHKX
M5_9G_:V^,_Q/_:\\5_#[Q;X;MK#P1I\FIK:7T>D3P.X@GV0YF9BK97G@<]J
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M[6WQGA_;^7X3IX;MC\-#J:6O]I_V1.9/*-H)2WVC=L^^2,X]J /NJBBOCO\
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M('.>*^XZ "BOA7_@H-^UM\9_V=_'WA?2OAEX;MM;TV_TQKJZEGTB>\*2B5E
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M4?VJ?@!_PO?_ ()Q^$&L;;S_ !'X7\,Z;KNG;5R[B.S3SXAW.Z(OA1U94]*
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M+G_E(%\3/^P9K'_IQMZ_8JOQU_X)<_\ *0+XF?\ 8,UC_P!.-O7[%4 %%%%
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M55/-YP%PN% "Y/UG_P %-/A_XD^)G[)VMZ%X3T.^\1:S+J%E(ECIT#33,JS
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MWP;MO"O["7C/X=^#9KN_L]/\(75KIK3RK+--&D+.J;E #%@-HP!G(KYFTWX
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M]=^$OBSQ!\6/BOKL?BSXP>)01<7*'?%I\3;2T:' !<[54E0%55"(-N2WU[0
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M]HQOV(O#7QY^#WQ N ]Y\.3/J_A])OE^W12,JI$OH)9)K:11UQ<N3PM>T_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M??-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?CM^UY_P I>/AW_P!C!X6_]'P5^Q-?CM^UY_REX^'?_8P>%O\ T?!0!^Q-
M%%% 'XZ_\$N?^4@7Q,_[!FL?^G&WK]BJ_'7_ ()<_P#*0+XF?]@S6/\ TXV]
M?L50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^>7_!5Z>.U\
M<?LTS32+%#'XK=WDD8*JJ);0DDGH *^OO&_[3WPE^'.C7>IZ_P#$7PU906T1
ME:)=3AEG< 'B.)&+R,<'"JI)Q7QE_P %??#]KXLUK]GO1+TR"RU+Q%<64YB;
M:_ER-:HVTX.#ACCBNEU;_@C#\#[VS>.RUOQGIUQU29=0MY!G'&Y6M^1[ @\=
M: .)_8)AU/\ :(_;:^+7[1-CI5SH_@:ZADTO3VN$V-=2'R$48!P2(H [@$A6
MD49/6OT2\:^--%^'?A+5O$WB*_BTO1-*MWNKN[F/RQQJ,GW)/0 <DD <FOS:
M\+^)OBC_ ,$R_C9X(\ >+O%$WCSX&^)IOL6F74T6V33F+JIVAB3&8VD4E Q1
MD8E0&R%]#_X+(>*M5M/@3X/\(Z;+Y$7BCQ#'!=-NVK(D2%UC;_9\PQO]8Q0!
MQ]C^TY^U'^V]KFIGX!:98_#;X=6<S01>)M=B3S+DA@,-(T<HW8P2D*-LZ%SD
M9N>)]/\ V]OV<K6;Q7+XIT#XQ:':!9+S1[6U668QCEF$8@AEXY'[IV/(.TXX
M^^OAG\/-&^$WP_T'P?X>M$LM'T:T2TMXHQCA1\S'U9F)8D\DL2>373T >%_L
MB_M:>&/VN/ARVOZ+$VEZS8NMOK&B32!Y+*8C(((QOC;#;7P,[2" 5(&C^U/^
MU!X6_91^&4_BOQ'NO+J9C;Z9I$#A9K^XP2$!/W4'5GP=H[$E5/Q[\/\ 0XO@
M'_P5ZU?PSX9B6P\.>.M%EOKC3X#^Z1S UPS;>BGSK>0CT$I P#2_M&:/'\?/
M^"JGPL^'WB.)+SPCX=TG^TCITQS%-((YKAB5_BW-';JPZ%8^>,T )X3NOV[?
MVI+6'Q=I>OZ#\&?"UX3+8:;=VP2:2$@;'VM!-*P(/5R@/+!0",U=:_:$_:T_
M8?O[#4?C79:;\5?AQ-,L5UK>BH@DM-S8XD6*(JW/ FCVL2%#@]/TOK%\:>#M
M'^(7A/5_#7B"QCU+1=5MI+2[M91\LD;C!'L>X(Y! (Y% %3X;_$70/BUX%T7
MQ?X7OTU+0=7MQ<6MPO!(.058?PLK JRGD,I!Z5\+7_Q@_:0_;%^+WC[1_@CX
MFTGX;?#SP7J$FD/K%];I+-J-RA*M@F.4XRI8!0@",NXL3BG?\$@=6U/1=!^,
M?PWN[EKJQ\(>(PEJQ;<%,AFCD"G^Z6M@V!QER>]<_P")+'XK?\$V?C!XY\9^
M'O"TGQ#^!/BS4&U;4+>S.+C2979F8G )39N(W$%'4(&96P0 >Z_LJ^)/VH?#
M_P 3-2^'_P ;-"T[Q+H-K9?:K;Q]IKI%$YSM6+"H@E)(/!C1UP2V0RFO+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.0^+WQ,TKX-?#'Q-XWUMPFFZ'8R7DBEMIE8#Y(E/]YW*H/=A7Y9_L]_L;ZK^
MV%^SU\9_BYXMCCG\>^.+F:X\,W$BX\J2"4R.4)^ZDLB_9_\ 92,XZBNT_P""
MR/Q\ENI/#'P2T1IIY9RFN:XMHID?8"PMX=HZ]'E*G^[$>]:?P_\ ^"K'@[X:
M>!]"\*:'\$_%]MI&C645C:QAX\[(U"@GY>6.,D]R2>] 'MG_  2V_:!D^,/[
M.MOX:U>9CXK\#.NC7D,PQ*;8 _99&!Y^XK1G/.86)ZU]D5^*/P(_:TT?P'_P
M4"N/'FF:!JG@KP#\0;G[%J^F:DH AEGVDS@@;<+<8D)QD+)(._/[-^)M8_X1
M[PWJVJ^69OL-I+<^6,Y;8A;''KB@#X\_:H_;M\0>&_BA!\%O@5X:C\=?%2X(
M2ZF<>9::82,E6 8 NJG<Q9E2,8W$G*CC+?X'_M^W%JNLO\;_  I;:HW[XZ1)
M;QF)/^F9(L2F<<<9&?XN]0_\$=_!UOK7P_\ B#\6M6(U#QGXD\0SVMSJ$H#2
M")5CF< ]07EF=F]=J>@K]#Z /R$_:_\ VM/'6L?LZ>-_@O\ '3PD/"GQ-AEL
M;K3]0LXV^PZU EW&6>/&5!"J6RK%6PPPC+M/Z8?LR_\ )MOPH_[%+2?_ $CB
MKYD_X+ ?##2O%G[*\WBV>VB_MGPIJ%O+;79XD$-Q*D$L0]0Q>-B/6,&OIO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X[?M>?\
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M 4444 %?CM^UY_REX^'?_8P>%O\ T?!7[$U^.W[7G_*7CX=_]C!X6_\ 1\%
M'[$T444 ?CK_ ,$N?^4@7Q,_[!FL?^G&WK]BJ_'7_@ES_P I OB9_P!@S6/_
M $XV]?L50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5^.W[7G_*7CX=_]C!X6_\ 1\%?L37X[?M>
M?\I>/AW_ -C!X6_]'P4 ?L31110!_.O\%?CY\1?@9^T#XN\6_#_2(-6\2WGV
MVUN+6:PENE6*2Y5W/EHP889$&2>,X[U])?\ #SW]K#_H0]._\)B\_P#CE/\
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MG_QROU[HH]F'M#\A/^'GO[6'_0AZ=_X3%Y_\<KQ/0?B]XT^.7[??PH\5^/\
M38M*\27'BOP_#+;0V<EJH1+N%4/EN2PR.^>:_>>OR)_:N_Y2X?#K_L8?"_\
MZ/@J91Y5<J,KL_9&BBBLS0_&S_@F3_R?Y\2_^P=K'_IPMZ_7BOR'_P""9/\
MR?Y\2_\ L':Q_P"G"WK]>*WAL83W"BBBM#,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_(G]J[_E+A\.O^QA\+_^CX*_7:OR)_:N_P"4N'PZ
M_P"QA\+_ /H^"LY[&D-S]D:***P-S\;/^"9/_)_GQ+_[!VL?^G"WK]>*_(?_
M ()D_P#)_GQ+_P"P=K'_ *<+>OUXK>&QA/<****T,PHHHH **** "N1^)OQ;
M\'_!G08-:\;>(+/PYI4]RMG%=7K$(TS([A!@'DK&Y_X":ZZO@K_@LU_R:_X7
M_P"QQM?_ $BOJENRN4M78]Z_X;R_9^_Z*KH/_?Q__B:]%^'WQM^'_P 6&E3P
M;XTT+Q-+"N^6#3-0BFEC7U9%;<H]R*\.\&_\$]_V>M2\(:'=W/PSL);FXL8)
M99#>70+,T:DGB7N37SM^V]^PQX4_9]^'K_&?X+27_@3Q%X5NH;J6"TO99(WC
M>18R\9D9F1U:13@-M*[QMY%*[W'HS])]2U"#2=.NKZY8I;6T332L 20J@DG
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MUB]CM8-[9VKOD8+DX.!GM6M:W4%_:PW-M-'<6TR+)%-$P9'4C(92."""""*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MILNH^$O$NC^*-/AE,$EWHM_%>1)( &*%XV8!L,IP3G##UK?H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *R-5\7:+H>MZ+H^H:I:V>J:T\L6G6<T
M@62[:.,R2",?Q;4!8^@K7K\7_P!L[]H;QG\2/VIM4^('@!+BZ\,?!NXMH(KZ
M+YK>&7[0$DE?'59I@8^,[DC':ID[%15S]H**Y3X4_$C2?B_\./#GC30WWZ7K
M5E'>1*QRT>X?-&W^TC!E/NIKJZH0457U#4+72;&>]OKF&SL[=#)-<7$@2.-0
M,EF8\  =S7D4G[9GP+CU@Z8WQ9\)BZS@G^U(C%G.,>;G9U_VO>D!V/Q?^+_A
MCX%^!+WQAXPO9-/T&S>*.:>*!YF#2.$3Y$!)RS#M70>%?$MAXS\+Z/X@TJ5I
M]+U:SAO[25D*%X94#HQ4\@E6'!Y%?*7_  5 U*SUC]A_Q/>V%U!?64]UISQ7
M%M()(Y%-W'@JP)!'N*]Z_9K_ .3<_A7_ -BII7_I'%2OK8.AZ/17/^#?B%X5
M^(MG<7GA3Q+H_B>TMI?(GGT:_BNXXI  =C-&Q"M@@X//(KH*H05YO\4_VA/!
M'P9\4>"O#_BK4IK'5/&%X;#1XH[62833!X4*LR*0@W3Q<M@<^QKIT^(OA23Q
MD_A!/$^C-XLCB\Y]!74(C?+'M#;S!NWA=I!SC&"#7Q#_ ,%*/^3C/V0_^QKE
M_P#2S2ZEO0I*[/O^O/[;X]>!+SXQ7?PKAUW?X]M;07TVD_8YQMA*JX;S3'Y1
M^5U. ^>>E=9XG\5:)X)T.YUKQ%K%AH&C6NWS]1U2Z2VMXMS!%WR.0JY9E49/
M)8#J:_.+P_\ &CX?0_\ !5GQ+XND\=^&H_"DWAE((]=;5[<6+R?9[<;!/OV%
MLJPP#G(/I0W8$KGZ8T5C>%/&?A_QYHL>L>&==TWQ%I,C,B7^DWD=U S*<,!)
M&2I(/!YXK@&_:R^#$?BG_A'&^*'A4:QO,1M_[4BP) <;"^[:'SQMSG/:F(]8
MHI%8.H92&4C((Z&EIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;Z95V0,_(*(L(8C^'<.-S*R?KS\0/^1#\2?]@VY_]%-7QK_P1SLDM?V5]7F
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M1D<B$5^B%%M6%]$?G_\ M#*$_P""KG[/ZJ JC0&  Z#G4*_0"O@']J)1I/\
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MS^S%!^T]X;NKKXB7%UJ7PS\(WTD6E^'(Y6A@N=1F57GEE9"&.R/R1C/.]>0
MP;]3_C5_R1OQY_V +_\ ])Y*^5?^"0-J+?\ 9+GD&,S^([R0X'_3.!?_ &6F
MUJA)Z,]XU:S^'/[$_P "?%FN:!X?M]!\-:3'+JDMC9LV;FY;:B)N8L=SOY<8
MSP,CH!7QE^SG^RKK'[=E[_PO/]H#5+[4-&U"60:!X5M9W@@6V5\9RIW1PY#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS?:X0 SGWD4I)_VTKB?^"EWQOF^$O[.-]HVD22'Q3XTE_L'3X8,F78X_TAU
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M9?!]J_@>V\.K>1:/Y\_EK,8(&W[M^_.78_>QS7ZK5\ >&_\ E,5XJ_[%1/\
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M0 4444 <)\>O%ESX#^!OQ"\264GE7VD>'M0OK=P,XECMY'0_]] 5\E?\$>?
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M3?AM\-_''C7Q;<)FVTD6448W=,.T4DK#!Q]U&'/6OG'Q]\&_C/)^U?\ L_\
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ME$2[[7EMH.T<'D^AK[YHHMI8+ZW./^,D,EU\(?'$,,;2RR:%?(D:*2S,;=P
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M41R[ 87@=Z^[Z*=M+"YM;A7RG_P4]T>_UW]CKQ59Z;97&H7;W=@5M[6)I9&
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M\1OAS\;K?]HOX"0"^\3JGEZ_X:5=W]H1A0K,L8(\P,JJ'C!#;E5TRW(K:/\
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M;6>+'6K-K<RXR89.&BE [E)%1Q[J*^5O^"7_ (K\5^'O!?BKX->-]+O;#5O
M^H2QV,]Q!(L<]JTKAUC=EPX24,00>5E3' K[?HHMK<=]+'YU_%[X+_%/]BWX
M\:Y\9_@GHC^,/!'B)VG\2>#[=6+QL6+NRH@)V[B[)(BL8]S@J4SNZ&S_ ."P
MWPMDL!#=>"O&\'B3/DMH\=G;R'SNFP.9@2-W&2@;_9K[SIGDQ^=YNQ?-V[=^
M!NQG.,^E*W8+]S\D?VQ-*^.W[5?PIU+XF^*/"M]X$\$Z#) OASP3Y4DU_?23
M3+&]S,F PPA;!91@8"K@L[?I=^SI;367[/GPPM[B)X+B'POI<<D4JE61A:1
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MWP/^/GQN^.FD?''XUZQ>^";32U8:/X0TV9[9Q&Q!,<D0)\N%L#>KDR2;0&P
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MIIDDDOA;Q(+:1K6> Y?R?-P5"LOSH"?E.^,G(5:^\J*JW45^@4444R0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH I:SH>G>(M/EL-6T^UU2QEXDM;R%9HG^JL"#7!V/[,_P@TVZ6ZL_A3X(
MM+E3D30>';-''XB/->DT4AC8T6-%1%"(HP%48 'H*=113$%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9UGX=TG3]2
MN=1M=+L[;4+KB>[AMT267G/SN!EN0.IK1HHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M?@)_T2'P?_X*8O\ "CG8<B/C'_A]7X*_Z)OKW_@;!_A1_P /J_!7_1-]>_\
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M?_X*8O\ "C_ABGX"?]$A\'_^"F+_  HYV'(CXQ_X?5^"O^B;Z]_X&P?X4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD>#?VKOA/X^\,^*O$6C^,[,Z%X6N/LNL:A?0S64-I)_=+3HF[/0;<@G ')%
M'K-%?)=M_P %3OV;KCQ%_97_  G$\2;MBZA)I-V+4MN(QN\O('?<0%P<YZX^
MG!XPT%O"W_"3#6M/_P"$<^S?;?[7^U)]D\C;N\WS<[=F.=V<8H V**^2M5_X
M*G?LXZ3XB.DMXUN+I5D\M]0M=*N9+52,<[PF6'/501Q],_37@SQKH/Q$\,V'
MB+PSJUIKFAWR>9;7UE*)(I%S@X([@@@@\@@@\B@#;HHHH *XSQ1\8/"G@WX@
M>$/!.K:I':^(_%9N1I5H1DS>1'ODR>B\<#/WCP,FNR9@BEF(50,DGH*_#+]I
M?XB?$']I#XX>/OC_ .!0Q\(_"F]L;73;Z-C^[B2X(BE0#[^Z7?,W]U)%SQ0!
M^YU%<'\"?BYIGQV^$/A7QYI.U;76K)+AH5;=Y$P^66$GU2170_[M=Y0 45YY
M\$_V@/ 7[17AN\U_X>Z]_P )!I-G=FQGN/L=Q;;)@B.4VS1HQ^61#D#'/7K7
MH= !6'XZ\76?P_\ !/B'Q3J,4\VGZ'IUQJ=S':JK2O'#$TCA Q +$*< D#..
M17+6?[0OP_U#XTW_ ,);?7_,^(-C:B\N-'^QW V0F-) WG&/RC\LB' <GGID
M&O'_ -MS]J[X6?"SX>^._AUXH\4_V9XQUSPE??V?IO\ 9]U-YWGP3PP_O(XF
MC7=(I7YF&,9.!S0!Z[^SW\>- _:4^%NF^/?#-GJ5CH]_+-%%!JT4<=P#%(T;
M;EC=UQE3C#'CTKF_B9^U5X?^%_Q\\ ?"B_TC4[O6?&2;[2]MA']G@^9E_>98
M-U0] >M?(/\ P36_;,^#OPY_9[\$_#;Q%XP_L_QK/J=Q;QZ9_9EY+F2XNV\D
M>:D+1_-O7G=@9YQ70?M>?\I,?V9/^N)_]'34 ?H517@'QM_;N^"G[/\ K$FB
M^*O&,+:]%Q+I.EPO>7$)QG$@C!6,]/E<@\CC%;7P)_; ^$W[2$L]MX%\66^H
M:I ADETNYC>VNU0=6$4@!=1D99<@9&30![+117 _%[X\_#_X"Z(FJ^/O%6G^
M&[23/DK<N6FG(ZB*% 9)".^U3B@#OJ*^0M%_X*M?LXZQK L&\77VG*S!%O+W
M2+E("3[A"5';+ #GTYKZG\*^+-%\<:#::WX=U:RUS1[Q-]O?:?.LT,J^JNI(
M/]* -:BO.OBO^T+\/_@?JGA;3?&VO_V+>^)[IK/28OL=Q/\ :9@T:E<Q1L$Y
MECY<J/FZ\''G'Q8_X*"_ WX,>.#X1\0^+S)KL4@BNK?2[*:\%HQ_AE:-2 P/
M!098=UH PO'O[?GA[P'^U]H7P(G\+ZC=76HR6MK+KD<F$@N+E5:%1%LRZ8=-
MT@8;<G@[37U37BVN>/O@FO[2'A7PSJUMI+_&74--:[T9[G0I&OA:[)G.VZ,.
M(OE@F^5G4\$8^;!H?%O]N;X(_ OQI<>$O''C;^Q/$%O%'-)9_P!DWUQM1UW(
M=\4#J<CT- 'O%%?*O_#T;]F+_HIG_E U3_Y&KUKX'_M,?#C]I"UU6Z^'6OR^
M(;72WCCNYSIEW:QH[@E5#3Q(&.%)(7) (SC(R >H45S'Q$^)WA/X2>&YO$'C
M+Q#I_AO1XCM-UJ$PC5F[(HZNQQPJ@D]A7S,O_!5_]F]M8^P_\);J @W;1J!T
M6Z\CKC/W-^._W.GOQ0!]@45Y7K_[4GPK\-_"4?$V[\9V,W@3S4@_MG3TDO8Q
M([!0A6%7<-D@$%<COBM?QI\=O _P]^$Z?$OQ!K?]G^"7M[:Z75/LD\F8K@H(
M6\I$,GS&1.-N1GG&#0!S&C_M3^%-:_::USX&0:?K*>+=(TY=3GO)((A8-&T<
M+@(XE,A;$Z<&,#(;GIF']KC]IK3_ -DWX0R>.+_1;GQ"S7L6GVVGV\OD^9-(
M'8;Y-K>6H6-SNVGG QDU^>_A#]L?X/Z7_P %-/&_Q8NO%_E> -2\/1V-KJ_]
MF7A\R806:%/)$/FCYHI!DH!\O7D9^_?%'[0?P,^('[.=Y\1?$6H:?X@^$<L@
M@N+K4]%N+B!W$XA -L\)D.)2 #Y?!YZ<T =M\ _C#I_Q^^#_ (8^(&EV5QIM
MGKEL9EL[K_60LKM&ZDX^8!T;#8^88/>N_KGOAYJ7AW6? 7AS4O"$=O%X4OM.
MM[O25L[8VT/V22-7A*1%5,8*,IVE01G! K"^+WQY^'_P%T1-5\?>*M/\-VDF
M?)6Y<M-.1U$4* R2$=]JG% '?45\A:+_ ,%6OV<=8U@6#>+K[3E9@BWE[I%R
MD!)]PA*CME@!SZ<U]3^%?%FB^.-!M-;\.ZM9:YH]XF^WOM/G6:&5?574D'^E
M &M17#_&+XU^#/@'X//BGQYK/]A:"+A+7[7]EFN/WKYVKLA1VYVGG&.*Y_XK
M_M5?"OX(^%]+U_QEXPL](L]5MUN=/A9))+J[C90P:.!5,A'(R2H )&2* /6*
M*^9OA7_P4<^ ?Q>\30>'](\9C3]7N9/*MH-9M)+-;AB<*J2.-FXG&%+!CD #
M/%?3- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-KMK&XM0955690)XT9@ Z\@$9R,Y!KO: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N,\6_&#PIX'\=>#O!^LZI'9^(/%LMQ%I-JP_US0Q^9)D]%
M&, 9ZLP Y-=EG')X%?AQ^U1\0/'W[3GQT^(7QJ\!%V\(_"*:S@T_4('_ -7&
MER1'/'C[Y:423$_PQ[<]* /W(HKSS]GWXQ:=\?O@SX4\>Z8$CBUBR66:W1MW
MV>X&4FBS_L2*Z^^,]Z]#H **YOX@?$CPO\*?#-QXA\8:]8>'-%M^'O-0F$:;
MCG"KGEF.#A5R3V!KYD?_ (*O?LWKK/V$>+K]H,X_M!=%NO(ZX_N;_?[O2@#W
M']H_X]:1^S3\)]3\?:[I]]JFFV$L$3VVG[/.8RRK&I&]E'!8$\UU_@#QA;?$
M+P)X;\4V4,MM9ZYIMMJ<,,^/,C2:)9%5L$C< P!P<9KX[_X*/_$CPO\ %;_@
MG]XF\1>#]>L?$6BW%[IXCO+"82)N%W%E6[JP[JP!'<5],?LR_P#)MOPH_P"Q
M2TG_ -(XJ /2Z*\\^"_[0'@+]H31=2U;X?Z]_;^GZ==FQNIOL=Q;>7,%5BF)
MHT)X93D CGK7H= !7B?Q]_:J\/\ [/?COX8>%M9TC4]2O/'^I-IEC-8B/R[=
MUEMX]TNY@=N;I#\H)PK>U=/#^T+\/[CXTS_"6/7]WQ!@M?MDFC_8[@;83&LF
M[SO+\H_*RG&_//3-?'7_  4T_P"3DOV._P#L;9?_ $LTN@#]"J\;L?VI_"FH
M?M-:A\#(]/UE?%MCIPU.2\:"+[ 8S'&^ _F^9NQ(O!C R#S7<_%+XI>&/@OX
M$U/QEXRU/^QO#>F^5]KO?L\L_E^9*D2?)$K.<O(@X4XSD\ FORXT/]L?X/V?
M_!33Q#\6)O%^SP!=>'EL8=7_ +,O#NF$$"%/)$/FCYD89*8XZ]* /URHKA/A
MK\<O WQ=^'9\=^%O$$-]X17SM^JW$4MG%&(B1*SB=4*JN#EB ,#.<5X5)_P5
M'_9PC\5_V'_PG,C#S/*.IKIER;,-G&/,\OD9_C V\9W8YH ^L**H:'KVF^*-
M'L]6T>_MM4TN\B6:VO;.5989HR,AD=20P/J*OT %%%% !1110 4444 %%%%
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MXW&Z8&'.%9Y,9GAZ#?CS$/#@_P /Z56%_;:K8VU[97$5W9W,:S07$#AXY8V
M*LK#@@@@@CJ#7FO[2'[._A7]IKX7ZCX/\46JD2*9+#4%4&>PN0/DFC/8@]1T
M9<@\&ODS_@CO\4-<\0_"OQO\/]9NFU"+P3J<<5C=%RZK!.)/W*-W17@D8>@E
MQTQ0!%X!_P"4S?Q*_P"Q2A_])=/KS3_@K1?>)=/_ &GO@9-X-D>'Q9]G,>DR
M1@%UNFNE6(J"",[V&,CK7I?@'_E,W\2O^Q2A_P#273ZH?MW6Z77_  4(_952
M0;E%_;N/JM\C#]0* /HS]G;]A?X:_ WPO +_ $+3_&7C6Y'GZOXHURV6[N;N
MY;F1D,H;RT+$\+@G +%FR3\U?\%-OV?M ^#7A?PY\>OACIEIX*\:>&M;MC<3
M:/ MO%<QN2%=XT 4N) BDX&Y9'#;N!7Z15\?_P#!6#_DR7Q?_P!?NG?^E<5
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M (;DT/5_AGX9-BT?EHUGID5K-".<>5+$JO&1D_=(ZU\5?L_7/B+]@3]L^W^
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M1F@#\TM7\ :9^Q;_ ,%+OAQ_P@L7]B^"/B9:/8WVAVYQ DQ+)MC4\*@E^SR
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M'+8/VSX%_93^#WPWT6#3-!^&WAFVACA$+33:9%/<3+_TUFD5GD)]68U\<_\
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M1J.0Q!]W^!O[ WP7^!OABUTZU\&:7XFU5!NN-=\0V45Y=S2$8)!=2(U]$0
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M-N(W$CI[=^P9^T5<?M-?LWZ%XGU-M_B.RD?2-9<*%$EW"JDR # &^-XI"
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MLLQR!GYCZU[5_P %,O#6D>$?V!_'.F:%I5CHNFQW&GLEGI]ND$*EM0@+$(@
M&223QWKSSP#_ ,IF_B5_V*4/_I+I]>J_\%5/^3'/'W_7;3?_ $OMZ .V^$?Q
M$T[X2_L'^ O&>K<Z?H7P\TR_E0'!D\O3HF"+_M,0%'NPKY _8V_9@G_;8UR_
M_:+^/32>([?4[R2/0/#SR$60ABD93E,Y\E'#(D>0"4=GW;N?:_B1X<OO%7_!
M).QL-.1I+E?AII%WM7J4@M+::0#U^2-N*[;_ ()K^+-)\5?L8_#L:4\>=-MY
M=.O(4ZQ7$<S[PWNP97^D@H ]#\1_LD_!;Q5X=;0]0^%GA+^SC$T2+;:/!;R0
MJ1@F*2-5>,_[2$'WKX2\&Z;K?_!,W]LGP[X'M]5NM2^"/Q*N5BLX[Z0,;2X9
MDBWD\ 21.\09@ &BD7.64;?U'K\YO^"J$UOXR^+_ .SAX!TO;<>*KK7_ +0B
M(?G@ADFMXU8^BLRL<_\ 3$GM0!W7_!87_DS]_P#L8+'^4M9W[#O['6C>+O F
MA_&/XR6$/CWQ[XDL8;FRBUR%9[73-/\ +"VL<<#9CR8@C9*_+D!<$,6T?^"P
MO_)G[_\ 8P6/\I:^KO@S:I8_!_P-;1#$<.A6,:_06Z ?RH \"_;:_8Y^'OQ6
M^ _BZZL?">DZ/XMTC39]2TO5=-LH[>?S88S((F9%!='";"#G&[(Y -:W_!.7
MXL:E\8?V1O!>JZU<R7FL6 FTFZN93EI?(D*1L3W/E>5DGDG)->V_%G_DE?C+
M_L"WO_HAZ^2_^"/7_)GZ?]C!??RBH ^WZ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _++_
M (*'_$/4?A/_ ,%#O@WXMTGPU=>,=1TKP]'-#H=D[)-=L;B]78I5'(.&)X0]
M*[^U_P""F_QAU3S(]/\ V/\ QK<SJI.(KB\DV^A(&G9QG'I4'[4/_*63]GC_
M + R?^C;^OT5H _-CP+\ OCI^VA^T-X3^*/QVT"+P%X&\)RK<Z3X68D2RNKA
MPOEEBZ[G1#(\FTL$557'W8/^"V=U/9^#?A)<6KM'=0ZO=R1/']Y7$<14CWSB
MOTNK\YO^"Q%NMY:_ R!_N2^(Y4;Z$0B@#Z*_9E_8Q\"?"'X6Z-;:[X6TKQ'X
MVNXX[_7=;UBTCO+JXOV(DD/F2*2%23[H&/NACEB2?!/VCO\ E+9^SW_V+[?S
MU&OT*K\]?VCO^4MG[/?_ &+[?SU&@"A_P6LNY=/^$?PUNH3MFA\1M(C$9PPM
MW(X^HKVC]DW]BGPEX+\$67B[X@:+9^./BIXD1=6US6_$%NMW)'<38D,40D!"
M!"<%@ 6()SC"CR#_ (+,6J7WPU^%5M(,QS>*1&WT,+ _SK]$* /S%_X*=?!3
MP[^SF/AY\=_ACI%EX.\4:7XAAM+B/285MK>XS')+&[Q)A<CR&1L ;UE(;.*]
MH_8X_93T/QAX5M?C;\7-,L_'7Q+\=1+K3S:Q MQ;Z=;3+N@@@B<%4Q$R=LKG
M:, <X_\ P62_Y-'L_P#L9K/_ -$W%?8'PILQIWPM\'6B@ 0:-9Q *21\L"#C
M\J /A7_@J)^S3X.\%_!^'XQ>!M$LO!GC7PKJEG/_ &AH<"VAF1YEC4LJ *9%
MD:)@^-PVD=.GW1\)/&3?$;X4^"_%CH(WU[1;+5"B]%,\"2X_\?KYV_X*J?\
M)CGC[_KMIO\ Z7V]>J_L>'/[*'P>S_T*6E_^DL= 'Q/\1K76?^"D'[9FO?#%
M]6O-+^"OPUE8:HEC)M-]=HQC;)Y4NTBR(A.0L<4C##,0?N+PQ^RC\&O!_AU-
M#TSX8>%4TT1^4T=SI,-R\J\?ZR256:0G Y<D\"OCK_@FIJ,/@/\ :@_:;^'6
MLL(?$LNMG4(/,X>Z@BN+E7<>HQ/"XP.1*37Z-T ?F?\ M_?L86/P5\ ^)OBU
M\$HF\(,]A-IGBGP_8$+8W>FW"&&5TAZ*5+*2H^7C> K)EO4?V)_^45=C_P!B
M_P"(_P#TKOZ]I_;J\3Z5X3_9!^+%WJ[1BWN- N=/B$G\5Q<(880!Z^9(A_#/
M:O%OV)_^45=C_P!B_P"(_P#TKOZ /FO_ ()(_LR:+\7M-UGQ]X\L8_$NA^';
MMM+\/Z/J2B:SAN759;F8PL"K-AH ,@C))(RJD?<W[7O[+.A_%_\ 9?\ %?@?
MPUH.GZ5?Q;M9TBWTZU2!/[0CRX(5 !NE&^,MC.)":\H_X(Z6ZP_LAR.O6;Q'
M>NWUV0K_ "45]R4 ?+?_  3A^/[?'G]F?1#J,[2^)_#)_L+55E/[QFB4>5*W
M?YXMF2>K*_I7'?\ !5#XQ7OA'X'Z?\-_#F^X\8?$B^31;6UA(\QK;<OG8_WR
M\4.#U$S>E>9^'6_X8I_X*87VBG_0_AU\8XQ-;#[L,%^[L54 <9%P70 <*ETG
MI5GX1+_PV1_P4@\5?$.7_2_ 7PHB&E:.>L4UX"Z+(.<',GVB4,.R0Y[4 ?:/
M[.GP;L?@!\$_"/@*QV.-'L5CN9XQ@3W+9>>7_@4K.P'8$#M7H]%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'R=_P %+OVAS\!?V:]5M=.G:+Q3
MXLW:)I@B.)(U=?\ 2)ACD;8R0".0\B5J?L6?LJ:9\'_V3++P-XDTJ.74/$UG
M)=>)K:8<R27,>UX&_P!R+;'CU5B.M?&_Q1\&:E_P4X_;>\2^'M(\22Z'\/?A
MU9M9Q:Q;P^<!.'VNT:[E!:697PV<&.W!ZXSZA_PZ2UO_ *.-\8?^ [__ "30
M!G_\$[/$&H_LT_M&?$W]F#Q/<-Y"W<FK>')YS@W "J3M]3);^7+@<*8I>YK]
M(Y)$AC:21E1%!9F8X  ZDFOQ[_:;_8C\9?L2VOAKX\>'/B%J7CW4?#>KVS7;
M:I;%'MXBV$9F\URT3.1$R\?ZX>IK]2?#/C'3OCQ\$K7Q#X:NL6/B?16EM)=W
M,32Q$;6]&1B5([%2* /SP^$_@>X_X*C?M&>*O'_CJYO#\%_!UX=/T/08I6B2
M[;.5#%3P60+)*P(;]Y&H.T<??UO^R_\ !ZUT%=$3X6^#CI2J%^ROH=LZG&<$
MY0DGDG<><DG-?)/_  1G\1V<7P+\:^"IE^R>)=!\2S37]DXQ(J2PQ(C,/7=!
M*GMY=?H)0!^/W_!2+]D3_AF'P?J'B3X77%UI?PV\77,-EXC\-&;S+>WN$D$U
MM)$&R0A9&'7*$[0=K[1^FW[,O_)MOPH_[%+2?_2.*OGO_@KAXETS1?V--;T^
M^:/[;K&IV%I8*Q^;S5G6=B![1PR#\?>OH3]F7_DVWX4?]BEI/_I'%0!\@?\
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MM961P#D@/@DXR?<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO/#8MU5>I+VNT ?G7R?_ ,$;=4BO/V3=0M%9?.L?$UY#)'_$N8H'&1_P+]*
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M^ >A7WAOX#_#G1M6M7L]2L/#6FV=W:S#YHI4M8T=&'J&!!^E?'/CO]C7XO\
M[-?Q2UGXC?LM:KI[:7K$AN-5^'NJLJ6LS@E@L0)5"F6;:-\;)DA7*D@?>'B;
MP_:>+/#NJ:)?^9]AU*UEM)_)D,;A)%*L58<JV#P1R#@U^<'A7QY\>?\ @G#K
MVK^&_%OA;6_C)\'IKE[K3_$=@TD]U9*Q_C8[MG ^:*3:NXDH^"<@';6_[2'[
M;OB)AI%A^SSH6D:HWR/J6HW9%I'U^89N%!QUX9NG0]*^6?VQ/V7_ !9X!O\
MX9>*/B9XQ?QO\8_'?B>*WG:W.+6TMXPBBW@3"[@'E3) 51\H"CEF^J9O^"RO
MPCO+,+H7@[QWK&L2*WE:<-/MD.X= [+<-@'U4-]*H_!OX4_%?]L']H[P]\;_
M (R^&I/ G@SP@QE\*^#KP.MP9LATF=6"L,.$<NP4LT<8"[0: /OG7=#L/$VB
M:AH^JVD=_I>H6\EI=6LPRDT3J5=&'<%20?K7YQVGP9_:"_X)X^,-8N?@]HK?
M%SX-ZI<M=OX8+,U[9L0/NJN7WA5"^9&'#@#>@(6OTJHH ^!9OV[/VB?B%;_V
M/X"_94\2:-XAF!C&H>*'FBL;9^ =QD@@5L$_Q2+TZ>GCFI?L,_&'PU^TY\#_
M (C>)+B^^(?BO4/$L.K^,=7LE4V6F)'<6_E1KD*=JQB3D #"@*H"\_J[10!\
M:_\ !6S_ ),M\0?]A/3_ /T>*\6^$?P^_:!_8S\">&_$OPCTQ?B[\+O$>EV>
ML7W@ZYEVW^FW,MO&\S6Y')5FZ; _7YHR1O/NO_!5;1=0\0?L=Z]9Z7876I7;
M:E8,MO:0M+(0)P20J@GBOH+X!V\MG\"OAS!/$\,\7AO34DCD4JR,+6,$$'H0
M>U 'QKKG[>W[17CBS;1/ /[*OBK0_$DP\K^T/$45Q]EM'*CKO@A3/S @O(HZ
M$@@UZ%^Q3^Q9K?PE\4:Y\6OBSK">*?C#XC#&XN%;S(]/1\%T1L ,[ *I*@*J
MJ$3Y<EOL2B@#R?\ :>_9S\/?M1_"74O!'B!FM3(RW-AJ4:!I+&Z0$),HR,\,
MRE<C*LPR,@CXS\"_%[]K#]C/3(/ _C#X17WQK\*Z6!;Z7KWAQY9;@6Z\*&:.
M.1BJJ.!+&C#H6(Q7Z244 ?F_XT^._P"UE^UQIDW@SP#\&]1^#.AZD#;W_B3Q
M))+#.L##DQO)%$5#*<'RHY'Y^5AUKZ\_92_9E\/_ +*?PEL_!VB2&^NV<W>J
M:K(FQ[ZZ8 ,^,G:H"A57)PJCDDDGV2B@#X>_97^#/C;P9^WC^T!XQUOPW>Z;
MX8UWS/[,U.90(KK-PC#8<^@)K[AHHH _/[X]?LD_%3X(_';4?CM^S4]M=7^K
M%Y/$/@VZ91'>,S!Y60,5#J[#>5W*ZODH3NVJDG_!17XYQV_]F_\ #(7C3_A(
M\E<8O#;;0<>8,6>2NX@?>QSG=7Z!44 ?GO\ !O\ 93^+W[2'QJT?XR?M-?9]
M.M="<2^'_ ML5,4#!@RM(@9@B!@K$,S2.54.0JA3^A%%% !7PK_P4>^"OCGX
MK_%3]G34?"/AJ^UZQ\/ZU<W&J3VB@K:1M/8,K/DC@B*0_P# #7W510 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M39V:@N(ECF#/R1P"R_G7U)X)LYM/\&:!:W,;0W$&GV\4D;=598U!!^A%;5%
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M_P#3C;U^Q5?CK_P2Y_Y2!?$S_L&:Q_Z<;>OV*H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_';]
MKS_E+Q\._P#L8/"W_H^"OV)K\=OVO/\ E+Q\._\ L8/"W_H^"@#]B:*** /Q
MU_X)<_\ *0+XF?\ 8,UC_P!.-O7[%5^.O_!+G_E(%\3/^P9K'_IQMZ_8J@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\
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M1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\
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MROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\
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M3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\
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M^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\
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M1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\
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MROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\
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M3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\
M14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_
M $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA
M_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?M
MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W
M[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR
M-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\
M,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'
M_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY
M1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^
M.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N_
M_CE'_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[
MO_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +
M^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\
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M1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\
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MROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\
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M3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\
M14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_
M $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA
M_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?M
MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W
M[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR
M-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\
M,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'
M_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY
M1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^
M.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N_
M_CE'_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[
MO_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +
M^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\
M"_N__CE'_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_
M  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'
M_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GX
MA_\ "_N__CE'_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI
M^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_H
MJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_
MZ*GXA_\ "_N__CE'_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\
M/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]
MO#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&
M_;P_Z*GXA_\ "_N__CE'_#(W[>'_ $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&
M1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\
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MROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\
M\<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_ $5/Q#_X7]W_
M /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=
M_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?
MW?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_ $5/Q#_X
M7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_
M^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$
M/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_ $5/
MQ#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%
M3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\
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M^[_^.4?\,C?MX?\ 14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\
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M1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=_P#QROULHHY$'.S\D_\
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MROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?W?\
M\<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_ $5/Q#_X7]W_
M /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_^%_=
M_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$/_A?
MW?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_ $5/Q#_X
M7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%3\0_
M^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\ 14_$
M/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_ $5/
MQ#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA_P!%
M3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.4?\,C?MX?\
M14_$/_A?W?\ \<K];**.1!SL_)/_ (9&_;P_Z*GXA_\ "_N__CE'_#(W[>'_
M $5/Q#_X7]W_ /'*_6RBCD0<[/R3_P"&1OV\/^BI^(?_  O[O_XY1_PR-^WA
M_P!%3\0_^%_=_P#QROULHHY$'.S\D_\ AD;]O#_HJ?B'_P +^[_^.5X3I/@C
MXC_#W_@H!\*=&^*VLW6O>,8_%?A]Y[V\U-]0D:-KN Q@S.23A<<9XK]XJ_(G
M]J[_ )2X?#K_ +&'PO\ ^CX*F44D5&3;/V1HHHK(U/QL_P""9/\ R?Y\2_\
ML':Q_P"G"WK]>*_(?_@F3_R?Y\2_^P=K'_IPMZ_7BMX;&$]PHHHK0S"BBB@
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M =U1113$%%%% !1110 4444 %%%% !1110 445674K1KUK-;J$W:C+6XD'F
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M)Y.:_1*OR[_X)Z_L,^#?B?\ !_P3\4M1\4>,+'6[?59+E=/T_4(8[ M;79V
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MXBNH;275(6\2W,=TT=P(Q''C9'&/+!VL01V/-?._P+_X)R^&?VFO@UH_Q/\
MB+X_\4ZUXZ\50?VB=4M;V-DMLD[(\21L6*XPPR #E5VX!IW8K(_3"BO$_P!D
M[X0_$#X)_#V[\->/O'O_  GS6]ZXTFZ:-O,M[( "-'=_F9CR<$L$SM#$ 5[9
M3$?.'_!1;_DRWXG_ /7G;_\ I7#7R9^S/_P2R^%'QF^ W@KQMK7B#QE:ZKK5
M@MU<0V%[:) K%F&$#VK,!QW8U]9_\%%O^3+?B?\ ]>=O_P"E<->/_L@_MQ?
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M%K5G$Y6">Y@M;PF8(/E&X,AXX)Y7Y2*7-W'R]C])OC__ ,D'^)'_ &+6I?\
MI+)7SA_P25_Y,^T[_L,WW_H:UL?MP?L>>%?C5H_B'XC:OXB\4Z;J^@>%KB*W
ML=)OHHK*40+/.IE1H69B6D(;##*@#CK7R]_P3M_8?\'?&#X1^'_B3JOB?Q?I
MVL6>MR,ECI>H0Q63>1*K)N1H68Y(^;YN?:C6X].4_56H+S4+;3H1+=W,-K$3
MM#S.$7/ID]Z^7?V\OVNK_P#9R\+Z+X=\&V8U;XF^+)#:Z/:^7YOV<;E0S&/^
M-BSJJ*>&;.<A2I\3\'?\$K]1^*UO%XG_ &@OB5XCU[Q?=CS9;/3+M&2T##/E
M>;*C@X[B-548PN0 2[]$3;JS]$H9H[B))8G66)P&5T.0P/0@]Q3Z_,;XF?L?
M_%#]A'3)_B3\!?'VKZSX<TD&ZUGPOJY$GF0*07=HT"QRJ%SN(5'5065O3[F_
M9F^/VC_M+_!_1O'.D1?9#<[H+VP9P[6=TG$D1/<<AE/&593@9Q0GT!KJ>IU#
M:WEO>J[6\\<ZHQ1C$X8*PZJ<=#[5^,?[)>B_$K]H+X@?$/X0Z'XJOO"_@Z]U
M675?$^MVTC-=?98Y&C2TB8GY?,9SD=PI)R%*M]>>+O\ @F1X*\"_L^_$C0OA
MY<ZY<>*-4@AOK"ZU*\5YDN+4,T<49C2, 2[G1L@_ZS_9 "4FQ\J74^YJ*^8?
M^"=?QZ;XZ?LV:*=1G,OB;PV?[#U19#^\9HE'E2L.OSQ;,D]65_2O5/VD/C)9
M_ 'X(^+?'-UY;2:79L;2&0\3W3_)!']#(R9QT&3VJKZ7)MK8]*HKY _X)C_"
MW5_"/P#?QMXGNKJ]\3^/+HZS/+=R%G%MEOLXY./F#/+QVF'I7U_0M@84444Q
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y$_M7?\I</AU_V,/A?
M_P!'P5^NU?D3^U=_REP^'7_8P^%__1\%9SV-(;G[(T445@;GXV?\$R?^3_/B
M7_V#M8_].%O7Z\5^0_\ P3)_Y/\ /B7_ -@[6/\ TX6]?KQ6\-C">X4445H9
MA1110 4444 %%%% !7R!^W+^PKI7[0&CS^,_!\:Z#\5]+07%I?VI,7]HF/E8
MI2O23@!)>JD*"=O3S?XJ?M(_%#]B_P#:PU34OB9=:GXN^"?BTJFFW<$*A=+V
MY94C10%$D>65UX:5 KY)7:.^^+'_  50^"/@_P $WE]X3\0/XT\1O!FQTJUL
MKF$/(>%\V26-5103DCEL X!-1=/1EI-:HU_^"</[4&K?M'?!N[MO%+-)XQ\*
MW":=J%PR[6NHRF89G'9SM=6_VD)XW8'D?[-=H-9_X*J?'K4-9/F:M8::Z622
M\E8=UI&KKZ8B"+]'-=E_P2L^!/B3X7_";Q%XO\6VLEAK?CB]CO1:W$92=;>,
M/Y;R*0-I=I96 _NLI[X&+^VA\(?'/P9^.VC?M/\ PITM]=O+*%;;Q3H4*DO<
MVRIY9EP,DJ8@J-M!*&.-\$!B%K9,>EVD?>U<1\<M)T_7O@MX]T[5MO\ 9MSH
M-]%<,XR%C-N^6_ <_A7@_P /?^"GGP!\;>'8;_4/%C>$]0V9GTO6+282Q-C)
M >-&1QG."K9..@Z5X;^TC^V3??M>1S? []G33;[Q#-KH^SZSXFD@>WMH+,G$
MBC> RHPX>1P/ERJABXQ7,B>5GI7_  2(NKZX_9'$=V6,$&OWL=INZ"+;$QQ[
M>8TGXYKF/^"/\;6/PW^*6F28\VT\62!^><^2B]/^ &OKK]GOX,:9^S[\'?#/
M@+2I?M,.DV^V:Z*[3<SNQ>:4C)QN=F(&3@$#/%?!VG?$*\_X)L_M6>/X/%NB
M7L_P?^(=^=3L-7L(2ZV<I9WV@?Q%/-9'3.[:J. >AG:URM[GZ:U\ :;FX_X+
M%:MY8W?9_"B^9[9M8O\ XI?SKU7Q3_P4Z_9X\.^'9M3M?&SZ].J;HM-TW3KG
M[1,2,A0)(T53_OLH'UXKR_\ X)^^$?%OQ@^-OQ&_::\9:.^B1^*(AI^@6<X.
MXVN8_G7(&56."",28^<^81CNWK:PDFKMGU[\?_\ D@_Q(_[%K4O_ $EDKYP_
MX)*_\F?:=_V&;[_T-:^C_C__ ,D'^)'_ &+6I?\ I+)7SA_P25_Y,^T[_L,W
MW_H:T^H?9/,?V_-%@\0_MV?LQ:?=1K+:S7UMYL;C*NHOXV*GV(&/QK]&J_/;
M]MS_ )2 _LN_]?D7_I8M?H30MV#V1\B?\%5H4D_8O\4LRAFCOM/9#Z'[5&,_
MD3^=>\_LZW+WG[/OPQN)3F27POI<C'W-I$37A/\ P52_Y,M\6_\ 7YI__I7'
M7N/[-?\ R;G\*_\ L5-*_P#2.*C[0NAZ/6#X\\:Z5\-_!>N>*=;N!:Z3H]G+
M>W,A[(BEB!ZDXP!W) K>K\_O^"HWQ(U;QE=>!/V=?!V9_$?C2]@N+]$8X2W$
MNV%7QT4R*TC$]!;YZ&FW9"2NSYR_9STO]IWXF?$[Q/\ M(?#_P &Z%K%[XDN
M+JUBN_$%Q'L@CW*I2W5I4.U%180_/",OK7T'XNF_;O\ '7A76/#FL_#[P!=Z
M3JUI+8W<#3P_/%(A1A_Q]<'!/-?<'PI^&VD?!_X;^'?!>A1^7I>BV:6D1( :
M0@?/(V/XG8LY]V-=74J)7-Y'YN?\$O/&WB+X,_$#QQ^S?\0+<Z7KM@YU?3K>
M64. Q1#/$C D,&1HYEV\8\TU]H_M5?\ )K_Q@_[$[6/_ $BFKY'_ ."F'@;4
M_A+XZ^'?[3'A"'_B;^&KZ&QU>-<A9H2Q\IG(Z*VZ2!CU(EC':OIOXW>-=*^)
M'[%?Q$\4Z)<"ZTG6/ 6IWMM(.Z/82L ?0C.".Q!%"TT!]&>;?\$K?^3+?"7_
M %^:A_Z5R5Y#J&GI??\ !9S3I717^RZ$9UW=C_9KIG_Q^O7O^"5O_)EOA+_K
M\U#_ -*Y*\N_YS)_]RU_[8TNB'U9^A-? '[ _P#R>A^UK_V'V_\ 2V[K[_KX
M _8'_P"3T/VM?^P^W_I;=U3W1*V93_9\5-?_ ."L'QPOM88MJ>G:.T=A%)SL
MC'V*,,OH?+QT[2-7Z%U\&?MI? [QY\,?CAHO[3?PCT]M;UG38UA\1Z#&I9[N
MW2/RS(%&2RF("-@HW+L1P#@D=_\ "W_@I]\"?B!HMO-J_B-_!&L;0+C2];MY
M!Y3X^8+,BF-ER#@Y!/&5!.*2TT8WKJCZTK)\77%Y:^$]:GTX%M0CLIWMP.ID
M$;%/UQ7Q?\;_ /@IYX6>U'A3X%6MY\2_B'JG^CV'V.PF^S6\A'WR&4-*P'(5
M1MX.Y@!@_6OP>G\;77PS\.S?$6#3K7QK):JVIP:5GR(Y3_",D_,!C=@E=V[;
MQBJO<5FCXY_X(VV.G+^SCXHU"$*^KW7B>9+V8\R$+;VYC4GJ0-[D>[M7WO7Y
MEZG'XJ_X)@?'[Q'XDM]"O?$GP!\9W(FN/[/4%M*F+L57!X5X]S*NXA94*C=N
M7Y?IZS_X*0?LZWF@C53\1[6WCV;FM9K*Y%RIQDKY7E[B>W&1GH34IV5F.2N[
MHYK_ (*K:58:A^QCXIN+S;]IL;[3[BRW#)\XW4<9QZ'RY)?PS7I?@#_DR/PW
M_P!D\MO_ $VK7YX_MV?M"^+OVO/A7J.O>$/#U]HGP0\)W<,DFKZHAADUJ^DD
M$""-><K'YCG:"<9RY#%%'Z'> /\ DR/PW_V3RV_]-JTKW86LD?/W_!&_18+'
M]F/7M06-?M5]XGN/,DQ\Q5+>W55/L#O/_ C7WC7P_P#\$??^33KO_L9;S_T5
M;U]P54=A2W/@+]F^3[-_P52_:$M8P$ADT5)F49Y8&QY_-V_.OOVO@#]G?_E*
M]\?_ /L +_/3Z^_Z(@PK\U]&\*Z+XP_X+%?$?3]>T>PUNP_L.&3[+J5LEQ%N
M&FV&&VN",C)YQWK]**_.OP'_ ,IG/B/_ -@"+_TVV%*70(]3[7_X4!\+_P#H
MF_A'_P $5K_\;KYT_P""AGP>\!>&?V.?B+J>C^"/#FDZE;PV9AO+'2;>&:/-
M[;J=KJ@(R"1P>A-?9%?,W_!2C_DR7XF?]<;+_P!+[>F]@6Z'?LD:E=Z-^P-X
M,U"P0R7UKX6FGMU'4R*LC*/S KX0_P"">GPN_:$\3_";7-9^#?Q2\.^#-*FU
ME[?4++4=-BN+A[A(8R&+O;2G;LD7 #8SNXR3G]"_V#>?V/?A6#_T!D_]#:OC
MZ/4/$?\ P2U^/GB6YN-!O]=^ 'C*Z^T0S:> QTR8ME5P> Z!F3:Q7S4"$-E"
MHE]&4NJ/7/\ A2W[<_\ T<#X1_\ !';?_(->??&?]AG]JG]H3P_9:+\0/C%X
M/U_3K*Z%Y;Q_V8MNT<H1DW!X;1&QM8Y7.#P2,@8^B?\ AY+^SB-$_M3_ (63
M;^5T\C^SKS[1GT\KR=WXXQ[XKP7PS\>_BC^WC^T!X7E^%SZ]\//@WX3O/M.I
MZXQ$4NIL#\T3#YD8LORK%\P4.SOGY5!H&IZ;_P %-I-:TW]A?7()91+=-+ID
M&IS0D[6'GQ[B"1G:9 O7'6O</V4M/TS2_P!F7X5V^CI&NG_\(SI\B>6  S/;
MH[L?]IG9F/N371?&3X6Z7\;/A;XF\#:R6CT_6[-[5ID&6A?@QRJ.Y1PK@'NH
MKX$_9W_:@UO]@N^/P/\ C_IM]9:#8S2'P]XMM8'GMVMF?.,*-SQ9)8%=SINV
M,HP-KV=Q;JQ^EU?G[^WMI5A#^VO^R;J4>W^U+C74MY\#YO)CO;5HLGTW2S8_
M&O8?&7_!2S]GSPEH+ZC#XX7Q!/LW0Z=H]I-+<2GG"X955#Q_&RU\)>./$WQ*
M^*7[;'[/_P 3/'^@R>$M,\1^(K.'PWH%PS>?:V$%Y#AY%*@@R-,6W$ MR<!=
MF230XIW/J/\ X+'?\FKZ-_V-=I_Z37=?:_A7_D5]'_Z\X?\ T 5\4?\ !8[_
M )-7T;_L:[3_ -)KNOM?PK_R*^C_ /7G#_Z *:W9/1'P5^UC_P I./V<O^O.
M/_T?<U]P?%;_ ))?XP_[ UY_Z(>OA_\ :Q_Y2<?LY?\ 7G'_ .C[FON#XK?\
MDO\ &'_8&O/_ $0])=1OH?&__!&_18+']F/7M06-?M5]XGN/,DQ\Q5+>W55/
ML#O/_ C7WC7P_P#\$??^33KO_L9;S_T5;U]P4X["EN? 7[-\GV;_ (*I?M"6
ML8"0R:*DS*,\L#8\_F[?G7W[7P!^SO\ \I7OC_\ ]@!?YZ?7W_1$&%?E)_P2
MG_9S^&OQH^%OC34/''@[3?$M[9ZREO;S7J,6CC,"L5&".,DFOU;K\Z_^"+'_
M "1OX@?]A^/_ -)TI/=#6S/K_P ._LH_!KPEJ$%_I/PN\)V=]!@Q7*Z1 TD9
M'1E9E)#>XYKU7IP***HD_.G]C[3TF_X*:?M&WK(I>"&ZB5CU&^[@)Q_WQ7WM
M\0KJ^L? /B6YTPL-2ATRYDM2GWO-$3%,>^[%?"W[''_*1W]I?_MI_P"E25^A
M/7@U,=BI;GPC_P $<]*L+;]F/7-0@*R:A>>);@7<F/F&R" (A/H =P_WS7W=
M7YE+<>(_^"6WQT\1WDFA7NO_ +/GC*[%PMQIZ!GTF8L=J8)P&0,4VL0)4"$-
MN0J/IN/_ (*3?LZ2:&-3_P"%C0(NS>;5M/N_M .,[?+\K.>W'&>]"=E9A)-N
MZ//_ /@KSI.GWW[)HN[O:+NQUZSELV(^8R,LB,H/^XSG_@/M5/\ ;>U76V_X
M)CVEQ.\HOKK2= &IOD[OF>W+[C[R;0?7..]>6:]K7B/_ (*H?&3P_IVDZ+J&
M@?L^^$[W[5?:C?)L?4YAP5&#C>RY154GRU=W8Y94K]!/B]\*-(^,7PG\1^ M
M4'V?2]8L6L]\2C-N< QR*O RCJC =,J*6]PVL<W^R7INF:3^R_\ "BWT=56P
M/AC3YE*C&YY+='D8CLS.S,?<FO6:_,W]G7]IS7/V!]0?X'_'W3+VS\/64TC>
M'O%=I T]NUNSEB/E&YXB26!7+H6*,O V_27C#_@I7^SWX3T%]1B\<IK\VS=%
MIVCV<TMQ*>R@,JJIX_C9:::L)IGB7_!0C2["']L[]DK4HRO]J7'B.WMY\#YO
M)CU&S:+)]-TLWZU[Y_P4:LWOOV*_B='']Y;2VE/T2\@<_HIK\_?B9X@^)/Q2
M_;'_ &>/BGX]T-_"FE>)O%>GVWAKP_<,?M%K86U_;$/(I P9&N"V2 6Y. NS
M/ZQ?&3X=6_Q<^%/B[P7<NL,>NZ9<6 F89$3NA"28[[6VM_P&DM;E/2QPG[$U
MR+K]DGX3.,<>'K6/@Y^ZFW^E>V5^:O[(/[:&G_LL:*?@3\>[2]\&:MX9FDAL
M-6DM9)K>:!I&=5;8I;&6.R1049",E=N3Z5\?_P#@J+\--!\%W>G?"S4[CQUX
M\U*(VNEP:?8S"*"=_E21S(B[R"<B- Q8@ [0<TU)6%RNY@?\$C\S:!\9KE1^
MYE\5G8WK\C'^3#\ZI_L^*FO_ /!6#XX7VL,6U/3M':.PBDYV1C[%&&7T/EXZ
M=I&KVW_@G7^S[JO[/?[.=EI_B*W-IXFUR\DUG4;9^7MVD5$CB8_WECC3<.S,
MP]SY5^VE\#O'GPQ^.&B_M-_"/3VUO6=-C6'Q'H,:EGN[=(_+,@49+*8@(V"C
M<NQ' ."0NB'U9]YT5\E_"W_@I]\"?B!HMO-J_B-_!&L;0+C2];MY!Y3X^8+,
MBF-ER#@Y!/&5!.*XWXW_ /!3SPL]J/"GP*M;SXE_$/5/]'L/L=A-]FMY"/OD
M,H:5@.0JC;P=S #!KF1/*S[FK\]OVL?^4G'[.7_7G'_Z/N:^V/@]/XVNOAGX
M=F^(L&G6OC62U5M3@TK/D1RG^$9)^8#&[!*[MVWC%?$_[6/_ "DX_9R_Z\X_
M_1]S2EL..Y]Z^*/#.F>-/#>J:!K5FE_I&J6LEG=VLF=LL4BE74XY&03R.:_/
M6Z^$OQ^_X)XW%_JGPMN&^*WP9662[N?"][G[981DY9E ^8$#K)%D'EGBXS7V
MS^T%\6+OX'_"37_&=EX7U#QA<:9$)!I>F\.PR 78X)6-1EF8*Q !.*\-TK_@
MJ1\ -0\ GQ%/XFN;'4(X \GAZ6PF-Z)=N?*7"^6YSQN#[?4BAV!7/8_V;/VB
M_#'[3WPRM?&/A@R0)YAMK[3[C'G65RH!:)L<'AE8,."&!X.0/5*^&?\ @E;X
M1UD>#_B7\1;[26\/Z1XZ\0-J&DZ9C"1VZM*=R# ^3,I0'N(L],9^YJ:V$]SY
MP_X*+?\ )EOQ/_Z\[?\ ]*X:^*]1_8#TCXP?L'_#[QSX T6.U^)-GI?V^YBM
MP3_;2;COC92<&4!04QUY4@[@1]J?\%%O^3+?B?\ ]>=O_P"E<-:G[!O_ "9[
M\*O^P.G_ *&U)J[*3LCRO_@G-XN^$'Q:^'Z:QX>\ >%_"?Q(T54M=<AT_3(H
MIT?!59HVV[Q'( W&>&#*<X!/V?7YR?MD?"#Q'^R3\9+;]IWX2VN=/>;9XNT.
M/(BD61@'E( _U<IQN/\ !)M?G)V_<OP9^+_ASX[?#C1O&OA:Z^TZ5J46[8V!
M+;R#AX9 #\KHV01^(R""6NPGW1^5_P"RCX-^.7Q,^.?QXU_X4^/]$\">(!KL
MG]M+J]A'<RRB6YN74)YEO+M4.CYQMY"YS@8^IO\ A2W[<_\ T<#X1_\ !';?
M_(->?_'KP]XQ_8/_ &I-5^/7A+0[GQ'\+O%N[_A*=,LS@VTSG<[MP=N9!YJR
M$8W.\9*[@3] Z%_P4L_9UUOP^-5?X@1Z61&'EL;[3[I;F(D9*;%C;>1T_=EA
MGH34*VS*=]T>(_%/]D#]KSXU>"KWPEXT^-?@[6_#]XT;S6C:1%"2R.'0AX[-
M74AE'*L,C(/!(KU[XT>#O$OPE_X)N^(O"=W>P7^N:%X-_LJ>ZLF?RWAC18G*
ME@&QY(/4>M>'?$3]J[QY^W%\0-)^&_[.9UKPWX:LK^.ZUOQX5>VVQHV5VXY2
M/@L$;#RD*I55#9_0G4O#%IKGA*Z\.ZP7U>PO+%M/O#=;=US&\9CDW[0!E@3G
M  Y. *I6Z$NZW/GW_@FW9Z7:_L7_  Y;2E41SPW4MPRC!>X^U3"4MZD,I7Z*
M*^F:_,KP+XR^('_!+GQ/J_A+Q;X=U7QM\"K^]:[TOQ#IRB273@QY##A58_+N
MC8H"P+H3D@^SWW_!6KX!V^E)<VMWXAU&\<?+IMOI+"?=G 7+L$R?9C0FK68-
M-NZ.#_X+ 6^G-X9^#\\BK_:R>)62W;'S>244R@'TW+#^0KWG_@HU9O??L5_$
MZ./[RVEM*?HEY Y_137YS_MEZW\6/C=K'@+XJ>.=!E\$^&+[5X])\+>%;MV^
MTB$D2273A@N"Y"#<0"P"X&U06_7CXR?#JW^+GPI\7>"[EUACUW3+BP$S#(B=
MT(23'?:VUO\ @-+>X]K'"?L37(NOV2?A,XQQX>M8^#G[J;?Z5[97YJ_L@_MH
M:?\ LL:*?@3\>[2]\&:MX9FDAL-6DM9)K>:!I&=5;8I;&6.R1049",E=N3Z5
M\?\ _@J+\--!\%W>G?"S4[CQUX\U*(VNEP:?8S"*"=_E21S(B[R"<B- Q8@
M[0<TU)6%RNY@?\$C\S:!\9KE1^YE\5G8WK\C'^3#\Z/ ?_*8KXC_ /8J1?\
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MX6\,ZC#9Z+XRU];#689+6.5IX3=V<>U68$H=LT@RI!Y]A7UO1< HHK\X9O\
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MOP,^+7@OPQ\,M2AMQJ^E/<O:MI\-R\THE<#;O4G.U<!1U/O7T-^P_P#M%/\
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MHIB/,/%'[+OP@\::M+JFN?#/PKJ>I3$M+=SZ3"99"3DEVVY8^YR:[#P9\/\
MPQ\.=+_LWPIX=TOPWI^<FVTFSCMHV/J0@&3[GFM^BD,*SO$/AO2/%VD7&E:[
MI5EK6EW VS6.H6Z3P2#T9'!4CZBM&BF(\FTC]DOX*Z#J4.H6'PJ\(V]["V^*
M9='@)C8'(9<KP0>A'2O6%4(H50%4#  Z"EHI#(;RS@U"SGM;J".YM9T:*6"9
M Z2(PPRLIX(()!!ZYJEX=\+Z-X0TU=.T+2;'1-/5BXM=.MDMX@QZG8@ R?7%
M:=%,1C:IX+\/ZYK%AJVI:%INH:KIYW6=]=6<<L]L0<@QNREDYYX(YK9HHH S
MO$'AO2?%FER:;KFEV6LZ=(59[/4+=)X6(.02C@@X(!'':K5C8VVEV5O9V=O%
M:6EO&L,-O @2.)% "JJC@    #@ 5/10 5AR>!?#<OBB/Q*_A[2G\11KM35V
MLHC=J-I3 FV[P-I*]>A(K<HH **** *6M:'IWB32Y]-U?3[75-.N %FL[V%9
MH9 "" R,"#R >1VJM9^$="T_PVWAZUT73[;0&BD@.E0VL:6IC?.]#$!MVMN;
M(Q@[CGK6M10!G>'_  WI/A/2X]-T/2[+1M.C+,EGI]ND$*DG)(1  ,DDGCO5
M?_A"_#__  DW_"1_V%IO_"0[/*_M;['']KV8V[?-V[\8XQGI6S10 5CZ1X-T
M#P_JFHZEI>AZ;INHZD_F7MY9VD<4UTV2=TKJ 7.68Y8GDGUK8HH *\W\8?LU
M_"CX@:H^I^(_AQX7UG4G),E[=:5"TTA/]Y]NYOQ)KTBBD,Y'P%\(? _PMAEB
M\'>$-#\,++_K3I.GQ6[2?[[(H+=NI/05UU%%,"&\LX-0M9K6Z@CN;:9#'+#,
M@='4C!5E/!!'8UY6/V1_@DNI_P!H?\*F\&_:M_F;O[$M]N[UV[-OZ5ZU12 Q
M]2\':!K6@C0]0T/3;_1%"J--N;2.2V 4@J/+8%>"!CCC%78=)L;?2TTR*SMX
MM-CA%LEFD2B%8@NT1A,8"[>-N,8XJW13$97AOPGHG@W3S8:!HVGZ'8ES*;73
M;5+>(N0 6VH ,D <^PK5HHH Q[/P;H&F^(+S7K30]-M==O$\NYU.&TC2YG7Y
M?E>4#<P^5>"?X1Z5L444 %8L/@GP[;^)I_$D6@Z9'XAG3RY=62SC%W(NT+M:
M7;O(VJHP3T4#M6U10 51US0=,\3:7/IFL:=::MIMP )K.^@6:&3!##<C @X(
M!Y'4"KU% %32='L/#^FV^G:78V^FZ?;KLAM;2)8HHE]%10 ![ 4_4-.M-7L9
MK*^M8;VSG4I+;W$8DCD4]0RD8(]C5BB@#R%OV0/@>U\;P_"7P<9S)YI/]BP;
M=V<_=V[<>V,5ZII>E66AZ?!8:;9V^GV-NNR&UM8EBBC7T55  'L*M44AA6+X
MN\$^'O'VCR:3XFT+3?$.ER'+6>J6D=S$3Z[7!&>>M;5%,1YEX4_9C^$?@;5H
M]4T#X:>%=*U*(@QWEOI, EC([H^W*GZ8KM=7\&Z!X@U33M2U30]-U+4=-?S+
M*\O+2.6:U;(.Z)V!*'*J<J1R!Z5L44AF3XE\(Z%XTT];#Q!HNGZ[8K()EMM2
MM8[B,. 0&"N",@,1GKR:U(XUAC5$5410%55&  .@ IU%,1C:AX+\/ZOKUEK=
M]H6FWNM6(VVNHW%G')<6XR3B.0KN7DGH1U-:MQ;Q7=O+!/$DT$JE)(Y%#*ZD
M8((/4$=JDHH RO#?A/1/!NGFPT#1M/T.Q+F4VNFVJ6\1<@ MM0 9( Y]A6K1
M10!CV?@W0--\07FO6FAZ;:Z[>)Y=SJ<-I&ES.OR_*\H&YA\J\$_PCTK8HHH
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M@WJ&NMK-S\+/!]QJ;OYC7$FB6[%G_O$%,$]\D9SSUKU*BD,;'&D,:1QHL<:
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MO'7@J:WN8]2LEV3SVYFC3:SK@YC9ED1L_+M<#[U>IK^TM?\ _#!?_"Y2L?\
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M]8_X*4?\F2_$S_KC9?\ I?;UC?\ !,'X:Z=X!_9%\+:A;VZ)J?B1IM5O[C:
MTA,K)$,]<+$B8'J6/>C6]@TM<]S^#/B[Q;XD^$VD>(?B/H-IX+\130/<7^FQ
MW!:.U4$X+LWW#L 8J2=N<$\&OD_QQ_P4MU3Q?XSO_"?[/GPRU'XJ7EB2MQK6
MV062GD!E5%R4)!P[O&"1P""#6K_P5@^)>L>%_@+HW@W097@U#QQJZ:7*R-M+
M6RKNDC!'(WN8E/JI<'K7T?\ L[_ ?P]^SG\*]&\&^'[:-!;1*U[>*H$E[=$#
MS)G/4DGIG[JA5' %&NR#2UV?)\?[?WQG^$-TEU\<O@%J&A>%MZ)/KV@;Y([3
M<< MEG1NN,>8I^IXKU3PI^W1I7Q _:A\*?#/PM86>M^%_$.A'6K;Q-#=L&P(
MI7,9A*<$&(J0Q!4Y! (Q7T_J.G6FL6%Q8W]K#>V5S&T4]M<1B2.5&&&5E(PP
M(X(-?EM\'_@5IW[/?_!6:T\-:(KQZ!<V%YJ>G0L/]3#-:2DQ ]U1PZ@^BC/.
M:'=!HSZ2_;J^,_Q3\&^'?%WA;PO\([CQ9X.U#PI=?VAXICO/+2Q\R.=)LIM.
M?+C ?J,[L5\]?\$]?CS\8?"OP?\ !'A3P]\$[KQ+X+DU62*3Q8E]L1(Y;L^<
M^S8?]7N;OSMK[]_:4_Y-S^*G_8J:K_Z1RUX=_P $K?\ DRWPE_U^:A_Z5R4=
M1_9.P\6?M577AG]M+P5\"E\.PW%IXATB34VUHW962 K%=R;!%LPP_P!% SN'
MWSZ<^Y^*O%>C^!O#>HZ_K^HV^D:-I\+7%U>W3A(XD'4D_H!U)( Y-?"OQ4_Y
M3%_!S_L5)_\ TEU6JO\ P4TU75/BG\5_@K\ -/OIM.T[Q5J*7FK2PC),9F$4
M;8S\PC N'VG@D(?X:+[BML/U#_@I7X_^+6O7MC^S]\%=3\:Z99R>5)KFI1R^
M26[ I'A8\CD;Y=Q!SM&"*72_^"EWCKX4>(+#3OV@_@OJG@?3[Z3RXM<TZ.7R
M0<\XCD!$@ P3LD+ #(4Y K[B^'?P\\/?"GP;I?A;PMI<&D:)IT*PP6\"!<X&
M"[$?>=CRS'EB22<FHOB9\-?#OQ>\$:KX3\5:;%JFBZE"T,L4B@E"00)$)!VN
MI.58<@@$46?<+KL:OAGQ-I/C/P_I^NZ%J%OJNCZA"MQ:WMJX>.:-AD,I%?-_
MC#]N#3?A[^U-K?PP\2Z?9Z/X8T?0CK=UXGN+QLHHB5]GE;.22P4 $DD@ $G%
M>-_\$O\ 7-8^'/C[XS_ 35;V34;+P=JLDVES2 C"><\4I )^57Q#(%' +N>K
M5YE\?/@[IWQT_P""M&D^%=:C$^AO9VE[?P-G$T,%H9C$<=G**AY'#&B[L%E?
M4]DG_;F^.?Q9:34_@C\ ;K6?" =EMM<\12F'[<H.-\:;XP!]'?H>AR!WG[-/
M[>"_%3XC3_"_XC>#;SX8_$V)6:'3+TL8;T!2Y$99596V L%.0R@E6/2OJ^UM
M8+"UAMK:&.WMH46.*&)0J(H& J@<     5^?_P#P4ZL8/!GQ5_9X^).GHMOK
MVG^(UM'N%'S30K+#*B-ZJ")!CTE;UH=UJ&CT/T%HHHJR HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\]OVFO^
M4JW[/O\ V!T_]&WU?H37Y@?\%!-$\9>(_P#@H)\'M-^'VL6WA_QG<>'XUTS4
MKPD102?:+TEF_=R<;0P^X>M=_;?LX_MRW<,L=_\ M ^'+8-\O^BHSG!ZG/V)
M"#]/SJ+ZLT:T1S'_  5(_LQ/CY^SXWA_RQ\1_P"TUV_9_P#7F#[3!]FWXYQY
MOF[?^VE?2_[97[7$_P"RG#X%FC\/V^N1>(]2>QFDN;TVRVJJ$)DSL;/#GKCI
M7%_LX?\ !/*T^&/Q)'Q.^)'C.^^*'Q$4^9!>WV\0VLF-N\;W9I'"\*6("@\*
M" 1Y%_P6ALY-0\(?">UBQYL^K7429Z9:.(#^=+5)L-&TCO-:_;M^*GQ,\3W?
M_"@?@Y+XZ\$Z?=BSE\3ZDSPPWKA@K^0,KA03][+'!W,JCBO5_'7[5FI^!?VK
M/AI\&;CPS:SMXLTL7USJD=\W^B28N-R(AC&]<V_#$J3NZ"O:/AE\/]+^%/P]
M\/>#]%A6'3-%LHK*$*H4ML4 NV/XF.6)[EB>]?$W[1'_ "E>^ '_ & &_GJ%
M/5"5F>[_ +97[55U^RKX?\(ZE:^'8?$)UW5QIC1S79MQ""A;>"$;/3IQ7FGQ
M _;X\5>*O&>K>%?V>OA?=_%272)3;W_B)G:/2XYAP41A@/SCYBZ@X)4,OS5P
M'_!:16D^#OP^55+,VON H&23]G?BOM/X"_"'2?@7\)/#7@O1[2&VBTVSC2X>
M)0#<7&T>=,Y ^9G?))^@Z "C5NP:6N?,7P=_X*&:VWQ:TWX8_'+X<W/PP\3Z
MJ8XM.O,N;6YE<E5!#\JK-\JNK.-W!(QFNA^,W[=&K6/Q"U+X=?!+X>7WQ9\8
M:4VS5KFW+)IVFR9(,<D@'S.""#ED4'C<6!4<#_P60\.6\_[/_A/Q+''Y>L:/
MXEBCM[Q/EDBCE@F+A6ZC+Q0GCN@KZ(_8K^$NF?!_]F[P5I]G;JFHZEIT&KZK
M==9+F\N(UDD=VZM@ML!/\***-;V#2USY\\%?\%%O&?@7XEZ3X-_:'^%TGPX_
MMB016>N6Q?[*&+;<L&+!DR5!=)#MR"1@Y'WIUY%?'G_!5WPS8:W^QSK^H74*
MR76CZA8W=I(5!,;M<) V#VRDSBO?OV<?$$WBO]GOX9:S<N9;J_\ #.FW,[GJ
M9&M8R_\ X\336]A/:Y@?M-?M6>!OV5O",6K^++F2>_O-RZ=HMD UU>NN,[02
M J+D;G8X&1U) /R[8_ML?M4>-K7^W_"G[-1C\,N!)$FH/,;B6,GJA8Q%\CH5
MC([\BL#]FOPK;_M@?MV?%CXG>,8UU;0_ 5Z-+T#3K@;H%822QP/L.0=JPR2$
M?\])@W:OTEI:R'I$^*_"/_!2C3-0\+^-M/\ %W@N_P# /Q4\,Z-=ZJOA/7':
M)-0\B!I2L4K(&!(4G:4SMY7> 2/8O@C^T?<_%S]E&#XPS:%%IES)I^I7W]DI
M<F1 ;6:>,+YA4'YO(!SMXW=\5YQ_P4O_ &>]$^+G[.?B'Q,UG''XI\(VCZK9
M:C'&/-,$8+3P,W4QE-S8SPRJ?4'"_8O_ .47-C_V /$7_I7?4:WL&EKG*>%_
M^"I5[\0/AYI$?A'X;3>)?BSK%W<16OA/2[EYX[:WCV_Z3/($! ))PN!PI)91
M@GH/%W[:7QN^"_P1L_B!\3/@WI^FJ->_LF]L[34G26& J"EP$VR#:6#H#OP3
MMZ C/&?\$8_AGIVF_"7QAX\>%7UG5-6.E),R@M';01QOM4]1N>9LCOY:>@K[
M?^-7PMTWXU_"GQ1X'U8 6>M6+VWF$9\F3K%*/='"./=10KM7&[)V.E\/:]8>
M*M TW6M*N%O-,U*VCO+6X3[LL4BAT8>Q4@_C6'\6/B1IGPA^&OB7QIK!_P")
M?HEC+>2)G!D*K\L:G^\[;5'NPKY-_P""7/Q4U*X^'OB;X-^*B8/%WPXU"2Q,
M$A^8VC2. !GEO+E61,] IB]:Q?\ @I9XIU+XJ>*_AE^S=X7N"NK>,-1BOM6:
M/GR+-'(0N.Z@K+,>_P#HP]:=]+DVUL?27[)/QPU[]HKX-V/CS7/#$/A1=2N)
MA8V<-TUQYENC;!*247&YUD &.B@YYKV:LCPAX5TWP+X5T?PYHUN+72=)M(K&
MTA'\$4:!%'N< <UKTQ!1113$%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>.3:"?\ EH/X:^?/^">+ZC\!_P!J3XS_ +/$M_<7^@:;NUG2VN?O1@/"N<=
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MV>?A'J7Q&@L6V2Z]=I*EJ3SR$4#:IQ\K22(3_=%/L?\ @H5\4?A)J5L/C_\
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M9T<J6&H:?=QSVY &2?,0E< <]:?X;\6:)XRT\W^@:SI^N6(<Q&ZTVZ2XB#@
ME=R$C(!''N*8&K12,ZQJS,0JJ,EB< #UKRW5OVJO@SH6K-IFH?%7P=:7ZML>
M&36[8&-LXP_SX0^S8I >IT51T77M-\2Z9!J.D:A:ZKI\Z[HKNRG6:*0>JNI(
M(^AJU<7$5I;RSSR)#!$I>221@JHH&223T '>F(DHK'T'QEH'BK29-4T77--U
MC3(F99+VPNXYX4*@%@70E00"">>,UQ$'[47P=NM>_L6+XI>#Y-4W^6+9=<MB
MQ?.-@^?!;/&T<^U(9Z?12*P8 @Y!Y!%+3$%%<;X[^-'@#X7R1Q^+_&WA_P ,
M32)YD<.K:G#;2R+ZJCL&;\ :7P/\9? /Q,;9X2\:^'_$LH7>T.DZG#<R*.,E
MD1B1U'4=Z0SL:*@OKZVTNRN+R\N(K2TMXVFFN)W"1Q(H)9F8\   DD\ "J?A
MWQ1HWB_35U'0M6L=;T]F*"ZTZY2XB+#J-Z$C(],TQ&G116+-XV\.VWB:#PY-
MKVF1>(;A/,ATE[R,7<BX+;EB+;R,*QR!T4^E 'D/[8GQC\1_"3X=Z%;^"6M1
MXY\5>(+'P]HOVN+S8UEFDR[LF>5"(PSV+ UZ_KUUJ^B^$;ZXTRQ/B+7;:S9K
M:T,B6_VRX"?*I9B%C#-C)Z $]>E?,'QSD/B__@H!^SWX9F)>QT/3=6\12PD?
M*TC1-%$WU5XP1Z<^M?7%24?-_P"S!^T1X_\ BG\2_B7X%^(O@_2_"&O^#4TY
MY8-,O3=*_P!KC>5<ODKP@0\'^(@]*] _:=\2>+?!?P"\;^(_ \]O;^)=%TZ3
M4K=KJ 31LD.))5*'J3$L@'N17D/P!_Y/V_:I_P"N/A?_ --QKZ=\1:2FO^']
M3TN0*8[VUEMF##(PZ%3G\Z%L#W.<^"OQ$B^+GPC\'>,X56,:YI5O?/&O2.1X
MP9$_X"^Y?PKM*^5O^"8>KMJG[%O@:&4L9["6_LY-W4;;V9@/P5E'X5]4TUL)
M[A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#K<?C[5TU.*UCM#";(+-=2;&8NV\_P"E 9 'W/?AVV%?<\(_X*'?\G:?L?\
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M_O$RI" >HF;TKZD_9[^$%C\!?@SX3\"V&QUTBR6.XFC&!/<-EYY?^!2,[<]
M0.U3;4J^AZ'1116AF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC1$_:2T]M$'[O[9-9>;?>7C&[S'A,F['_37KSG-)76@W9ZE/_@KQ\=]%\,_
M]/AC!>Q3^)?$EU;SSV4;Y>WLX9!+YC@?=W21QJH/7#D?=KZV_9K_ .3<_A7_
M -BII7_I'%7R_K/_  2VT*^^#_BG1G\876N_$OQ)+;R7_COQ! US-B.9)&2.
M,OE%;8 <NS'C+$  ?8/PP\'O\/?AKX2\+272WLFAZ1::8UTJ;!,884C+A<G
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MR3]55QOP?^$_A[X'_#G1/!/A>V:WT?2H?*C,A!DE8DL\LA &7=B6)P!D\ #
MKLJ:V$]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6BE8)Y!Y&I:=OW/8W:@>9$WJ.0RGNK*>.@]7Z\&OEOX0_L8WOP!_:,\1>-_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTLWG 8$DJ% J_/)-)D$D%8ASBOK*BBD.X4444Q!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5^1/[5W_ "EP^'7_ &,/A?\ ]'P5^NU?D3^U=_REP^'7_8P^
M%_\ T?!6<]C2&Y^R-%%%8&Y^-G_!,G_D_P ^)?\ V#M8_P#3A;U^O%?D/_P3
M)_Y/\^)?_8.UC_TX6]?KQ6\-C">X4445H9A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D3^U=_REP^'
M7_8P^%__ $?!7Z[5^1/[5W_*7#X=?]C#X7_]'P5G/8TAN?LC1116!N?C9_P3
M)_Y/\^)?_8.UC_TX6]?KQ7Y#_P#!,G_D_P ^)?\ V#M8_P#3A;U^O%;PV,)[
MA1116AF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\
M#D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\
M_@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_
M $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P" 4]?K
M_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]% 'Y ?\.0_
M''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4OP__ . 4
M]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\
M/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\ ^ 4]?K_1
M0!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]
M%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\
M.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_
M /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!
M_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP
M_P#^ 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\
M<?\ 12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3
MU^O]% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_P
MY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\
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MD/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\
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M 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\<?\
M12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]
M% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<
M?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T
M?\.0_''_ $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP_
M_P" 4]?K_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]%
M'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4
MOP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY
M#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\
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M_''_ $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P"
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M!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\
M#D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\
M_@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_
M $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P" 4]?K
M_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]% 'Y ?\.0_
M''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4OP__ . 4
M]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\
M/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\ ^ 4]?K_1
M0!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]
M%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\
M.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_
M /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!
M_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP
M_P#^ 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\
M<?\ 12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3
MU^O]% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_P
MY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\
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MD/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\
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M 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\<?\
M12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]
M% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<
M?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T
M?\.0_''_ $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP_
M_P" 4]?K_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]%
M'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4
MOP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY
M#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\
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M_''_ $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P"
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M!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\
M#D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\
M_@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_
M $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P" 4]?K
M_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]% 'Y ?\.0_
M''_12_#_ /X!3T?\.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4OP__ . 4
M]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\
M/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\ ^ 4]?K_1
M0!^0'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]
M%+\/_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\
M.0_''_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_
M /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!
M_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\ ^ 4]?K_10!^0'_#D/QQ_T4OP
M_P#^ 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]%+\/_P#@%/1_PY#\
M<?\ 12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_''_12_#__ (!3
MU^O]% 'Y ?\ #D/QQ_T4OP__ . 4]'_#D/QQ_P!%+\/_ /@%/7Z_T4 ?D!_P
MY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\
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MD/QQ_P!%+\/_ /@%/7Z_T4 ?D!_PY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\
M@%/7Z_T4 ?D!_P .0_''_12_#_\ X!3T?\.0_''_ $4OP_\ ^ 4]?K_10!^0
M'_#D/QQ_T4OP_P#^ 4]'_#D/QQ_T4OP__P" 4]?K_10!^0'_  Y#\<?]%+\/
M_P#@%/1_PY#\<?\ 12_#_P#X!3U^O]% 'Y ?\.0_''_12_#_ /X!3T?\.0_'
M'_12_#__ (!3U^O]% 'Y ?\ #D/QQ_T4OP__ . 4]>!Z;^SWJ/[,'_!0+X4^
M M4U:UUN[M?%?A^X:\LXV2-A+=P.  W/&:_?NOQV_:\_Y2\?#O\ [&#PM_Z/
M@H _8FBBB@#\=?\ @ES_ ,I OB9_V#-8_P#3C;U^Q5?CK_P2Y_Y2!?$S_L&:
MQ_Z<;>OV*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDQ @CDD PK2$C ]QG&1D ]KHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC=YJQF)?]1+PS@_+TY&0#T6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BN%\&?''P-\0O&WB?PAX>\00ZGXC\,R>5J]A'%(K6C;BF&+*%
M/S*1\I/2NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,MM#8FC3(R1TSUKUZ@ HJAKNOZ9X7TJ?5-9U&TTC3+< S7E].L,,>2%&YV(
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M?$%K]ITO4+74K;./.LYEE3\U)% %ZBBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^U8:7X<^)?A/6]39RB65CK-O)/(1C[B!]S#D<@$5Z17QM\1?^"3W[/\ XO\
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M;(X8P#APV-Q&R-U;=@.-H /M*N.\>?&3P%\+5C/C'QIH'A8R*6C36-2AMGD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?!+2/&UI!'8ZB6:SU73HWW"TO(\;U!Z[6!5USSM=<\YKY=_X)^_\GL_M>?\
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M )LYQC9OW=>.E=9G/(Y%?"\?_!&_X"KH1L6N?%KWA'_(4_M2,3@X[+Y/E_\
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M?%K_ ();_P#"M(3XX_9L\5:YX.\<Z7NGBTV>_+PW:C)\E)"-RL>F)"Z-PK
MEJ^@_P!A+]J=_P!J3X/M?:U%%8^.=!N#IOB"PC0Q[9AG9*$/*B103CLRNO\
M#0!](5SOB+XC>$_!]U%;:]XHT;1+F4@1PZCJ$-N[D]  [ G.#7QW^W5^TUX[
M;XE>&OV>/@E+Y/Q&\3(KW^K1/AM,MF#'"L ?+;8KR,^-R1@%1N8$5/ 7_!(#
MX46>CM/\0-7\0>._%5V#)?:G)?M;QF9A\S1JOS'GG,C.2>3Z4 ?=%CJ5IJEC
M%>V5U#=V<J[X[B"0/&Z^H8'!%+9:A:ZE"9;2YANH@=I>&0.N?3([\U^:_P 4
M_P!EGQO_ ,$^M,U/XD_!#Q+JOB'X?0Q$>)O ^M2^;OMF!5YXV10/D#9W;0Z
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M9/B=X:\$:9X/\466H:[>I8P7%V+;RHV8\%MLI./H#71?\%"/VMM?^!FD>'/
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MU\!-6OOLM]HM\V9;-F&?F  1)2 Q25 H8H5=1\N0#]5Z;)(L4;.[!$499F.
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M7XF?\%7/&VNZSJGB/4_ '[/FE7C6=GI=@=D^I,,'!'*O(!M9G?<J%@J*?F(
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M_P!.EW7FG[<7[2WQ"\2?&#1/V;/@?.UEXVUB-)-9UV-RC:="Z[PBNN3%B/\
M>/(!N"L@3YFH ^T?$/Q,\(>$;Y+/7?%6B:+>2$!+?4-1A@D;/3"NP)S6YI^H
M6NK6<-Y8W,-Y:3+NCN+>021N/56!P1]*^#_ _P#P1U^%%GHOF>.==\2>,O%%
MTF^]U(7HMHC,>6:- I;KWD=\]>^!Y%\7/V??B)_P3%U.+XJ?!OQ/J/B/X8K<
MQIKOA?6)-^Q7(7=+L4(R$X42A5>,LH^8$D@'ZJT5QWP@^*6B_&KX8^'/'/A^
M1GTC6[-;J)9,;XCR'B?'&Y'#(V.,J:_//7O%'Q*_X*>?&?Q+X1\&^);KP-\
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MZD!@<$@94J<<T >H4444 8OC7QAI7P]\(:UXFURY6ST?2+.6^NYV_@BC4LQ
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MUB>'?B1X2\874EKH/BG1=;N8]V^'3M0AN'7&,Y",2,9&?K7YM_"/]GKX@?\
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M\Z ,[_@L_9#4OA?\+K1CA;CQ/Y1/^] P_K7Z(0PQV\,<42+'%&H5$48"@#
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MK\1OVB?VG]1_:?\ BAH$WA*P@LVL/"FA72,LJ1,C1AP' ;8L;R_,0OF/,S*
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M\$O_ (P3?%'X;6=SKOP,UZX1/$'AM6+?V=EL 9.< %CY4IZ$^6_4%^@^!O\
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M<&@#VS2[JSOM,M+G3Y(I;":%)+>2 @QM&5!4KCC:1C&.U6J_,?X3?M<_$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]BS]BWQ+^RUXU\?^(==\?6_C.;Q?Y4UWY>G&U<W"22.92=[ Y,TG  ZUYO\
M%3_@JKX?\21_\(E^S]X>UCXC^/M4W6]A*NG216T#$8$QC<"23;G.TJJX!+,
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M/^"K+7R_L2>-/L9<1?:M/%ULS_JOMD77';=LZUYA_P %GO\ DB_PX_[&V/\
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M< ?F:XCQ+_P5SU/XD++H?P'^$'B+Q-XFFXCDU2W\T0 \!VM[9G+?C(H'<G%
M!_P5#OHOBU\??@!\&-)S>:Q<ZI]OOH%P5BAFECC1F],)'<,?10#WJ?\ X+*V
M"ZKI/P3LG562Y\03PLK="&6$8/MS7>?L._L8^+O"GCO4_CG\;[[^V?BOK2LU
MM;22"4Z6DB[7+$?*)2A\L*GRQIE1UPO'?\%?O^:#?]C-)_[1H _1/IP.!7Y\
M?M0QMIW_  52_9QU%B!'<:4UJN[IN#W@/X_O1^E?H17Q9_P4B^!OC3Q5IW@+
MXM_#.S.H>.?AOJ!U!+&&+S);JW+1N=JCF0HT0/ECEE>3'. 0#[3KX;_X+%7"
M0_LA(C'YI?$5DB_79,W\E-,^'?\ P5\^"VN>&X)?&0UCP5XCB CO=,ET^6Y1
M91][RY(P<KG^^%;U'>O%?B=\4=7_ ."JGQ6\(?#_ ,!>'-4T_P"#OAW5$U/7
M_$&I1"/S2H*] 2%/EM(L:;B[&4LP4*< 'UG^TY;ZE;_\$\?%L%D&2\C\$QK*
M%SD1B"/SAQ_TS#TO_!-)M,;]B7X9MI2JD7V>Z$^  3.+N82DX[[@>O;%?1^J
M:+8ZSHMWI%Y:QSZ9=6[VDUJR_(\3*59"/0J2,5^:V@0_%G_@EOXLUZQM?"FH
M_$_]GS5+QK^"XTXM)=Z/D88O@81@NT-N CDVJ0R,6% 'Z;U^=?\ P60DT\>%
M?@XDBJ=5;Q.Q@; R(1&OF@>VXP_D*Z!?^"R'PBU2&&#0?"'CS6]<N?DM]*AT
MVW\QWP<*2L[>G\(8^U?'/[:.G?&3XH:[X ^+7Q5TM/!<6LZS#I'AKP4Q8S6=
MJ")&EESRKLQ0'< S'JJ*J @'[=4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>5?M8_\ )K/QD_[$S6?_ $AFKU6O*OVL?^36?C)_
MV)FL_P#I#-0!\[?\$M?A_P"%]>_8S\)WNI^&](U&\>\U -<7=C%+(P%W( "S
M*2<"KW[<7["/PR^('P8\5>)?#WAG3/"'C30-.FU6RU+1;9+03&",R&*94 5P
MRH5#$;E.T@X!!^6/V(_^"F?PO_9K_9WT+P%XFT'Q=?:Q87%W++/I-G:R6Y$L
M[R+M:2Y1LX89RHY]:[+XN?M^^,_VTO#&I_"O]GWX9^('DU^)[+4-<U/RXS!:
M, LJG8S1Q!E;:7>3@,0 2P( /IK_ ()Z_&_7?CQ^R'IVL>)IFO-<TQKG1KB^
MD^]=>2H*2L>[&-T#'NRL>]>5_P#!%3_DUGQ3_P!CG=?^D-C7TO\ LS_ *W_9
MG_9TT?P%%=C4+NRM9IKZ\486:ZE+/*RC^Z&.U<\[57/.:^:/^"*G_)K/BG_L
M<[K_ -(;&@#&_P""0]NAUC]H*ZU!V;Q3)XDB345E_P!8 &N2"V><F1INO<5^
MC%?F]\?_ (<_$']AS]I36/V@_ACH,WBSX?\ B;>_B[P[:@[H'8[Y92%!*J7S
M*)<$(S.K85AGU+0?^"N'[.^K:#'?WFMZSHMXRY;2[O1YGG4\\;H@\9Z?W^X]
M\ '9?\%++73KK]B7XF#4F5(TM[62%CC/G"[A,8'N6P/H37 ^#OMW_#HJX_M#
M?Y__  K>^V^9G/E?9YO*_#R]F/;%>(>.OB!XY_X*M^,M(\%^"M!U7P=\"=+O
M5NM9\0ZC&$DO&3^$8RA< D)$K-@L'?  "_;/[4'A_3_"7[%_Q-T/2;9;/2M,
M\$7UE:6Z?=BACLW1$'L%4#\* .&_X)<?\F)_#+_N)_\ ITNZ\1_8\MTF_P""
MG7[2MQJSL==CAF2T6;[QM3<P\C/. BVX'L17MW_!+C_DQ/X9?]Q/_P!.EW7E
MW[:?P%^(/PN^.FD?M/?!;3Y-:UZRB6W\2^'84+O?VZH(_,"+\T@,05'5?F7R
MXW49!( /ONO-_P!I2UTZ^_9W^)\&KLJ:9)X9U(7#MCY4^RR9;GN.H]P*^:_
MO_!7?X$>(-!2X\2W.L^"]91=MQI=YILMSMD&-P22%6#+G."P0\<J*\;^-7[4
MOC#_ (*)7#?!KX!^'=4L_"%Y,B>(O&&JP^3$L ;.TX)\N,X#8)\R3&T*!NR
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MYK':<Q ,:^D?VO/VB/$'[,_P]L/%NC^ ;[QSI\=\BZP]I*$73[,<O,PY;)Z
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MC<0"K>?L4_M-ZA9SVEU^U=>W%M/&T4L,FC;E=&&&4CS>002*]D_8;_95U/\
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M[Q__ ,%;O@)X;\/R7'AG4]4\<ZRR8M]*T_3+BV+R'[JO)/&@49QDKO/H&Z4
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M:?%?Q#^W=\ /B/\ %NQ70-5\7:Y;2:9X:^82:380W"+%$X(RK$R,Q4_-EB6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH J:;I-CHML+?3[*WL;<=(;:)8T& !T4 = !^%6Z** "BBB@ HHHH ****
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M.DV.F+(+.RM[028WB")4W8Z9P.>IJW10!7L=/M=-B,5G;0VD1;<4@C" GIG
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M=V[[9IVCV]O-D@ G>B YP .O85UEC8V^FV5O9VD*6]K;QK%%#&,*B* %4#L
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MZ%(Y29'?(!Y'WN_I78>/O#LGC#P+XCT&&9;>;5--N;%)I 2J-+$R!B!V!;-
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MCXN7WBO3=3T[6)-2>/3;>WD6:/[3/YBY8\':.#0!]O445\4?MG?L"Z_^T_\
M';P=X]TOQ5INB6FAV-O:26=Y!(\DICNI9B05X (D Y[B@#[7HHKP']MO]FW4
MOVJO@FW@?2M8M="NSJ5O??:KR-I$VQA\KA><G=^E 'OU%>/_ +(_P0OOV<?V
M>_"GP[U+4[?6+W1OM?F7MJC)')YUW-.,!N1@2@?4&O5-9L6U31[ZS5@C7$$D
M(9N@+*1G]: +E%?%O[ ?[!FO_L=^)/%^I:SXITWQ"FMVD%O''8P21F,QNS$G
M=USNK[2H **^*/'G[ NO^+OV[-.^/4/BK3;?2+6^L+LZ0\$AN&%O;QQ, P^7
M)*$CZU]KT %%?*/[?G[&NL_MB>&_"&FZ-XBL?#SZ)=SW$DE]"\@D$B*H V],
M;?UKW[X-^!Y_AE\(? _@^ZN8[VY\/:%8Z3+<PJ525X+=(BZ@\@$H2,^M '84
M5P?QX^'-S\7O@OXU\%6=Y%I]UK^E7&G174ZEDB:1"H9@.2!GM7C/[ _[(>L?
ML?\ @7Q+H.L>(+'Q!-JVI+?)-8PO&L:B)4VD-WR,T ?45%%?%'P@_8%U_P"&
MO[;'B7XX7/BK3;S2M5OM4NTTJ*"19T%TSE06/RY7=S]* /M>BBOB+]OC_@G]
MX@_; \=>&M>T?Q7IOA^'2=-:Q>&^MY)&D8RL^X%>@P<4 ?;M%%>)_MC? +4/
MVFO@)K7@#3-5MM%O+^>UF6\NXV>-1%,DA!"\\A<?C0![917AO[&7[/>H_LP?
M G3? 6J:M:ZW=VMW<W#7EG&R1L)9"X #<\9KW*@ HKXH_84_8%U_]DGXC>+/
M$FK^*M-U^#6K'[)'!9021M&?.$F26ZC Q7VO0 45\1?&K_@G]X@^*7[:GAGX
MVVOBO3;'2M)U+2+Y]*FMY&GD6SDC=E##Y06V''IFOMV@ HKYC_;U_9+U?]K[
MX<^'O#>CZ]9>'Y],U;^T7GOHGD5U\F2/: O?+@_A7K7[/?PSNO@S\$_!G@>]
MO8=1N]!TV*QDNH%*I*RCEE!Y ^M 'H5%<K\5_!\WQ$^%OC'PK;W$=I<:YHUY
MID=Q*"4B::!XPY Y(!;/'I7SW^P'^QKK/['?AOQ?INL^(K'Q"^MW<%Q')8PO
M&(Q&C*0=W7.[]* /JZBBOB+P7_P3^\0>%_V\;CX^2^*]-GTB74M0OAHZ6\@N
M MQ:S0*N_P"[D&4$^P- 'V[117QG^W_^PGKW[8VL>#+S1O%&G>'ET&"ZAE6^
M@DD,IE:(@KMZ8\L]?6@#[,HK-\,Z4^A>&]*TV1UE>SM(K=I%& Q1 I(_*O-_
MVKO@O>_M#?L_^+?A[IVHV^D7FM1VZ1WETC/''Y=S%,<A>3D1D?C0!ZU17@/[
M$G[-NI?LJ_!-? ^JZQ:Z[=C4KB^^U6<;1IMD"87#<Y&W]:]^H **^(OV-/\
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M_:<\,VSLL.B:1I>O10_+Y^VR0*&/_36W,T63P/+3N:^U_P#@H!^SWXH_::^
M+>#/"$FGQ:N=5MKW=J4[11>7&'W?,JL<_,.U;GC[]G!?BA^Q['\(M<-NNI#P
MU::>ERI+1P7]O"GE2AL9VB6-2> 2N1WH ^*M:\26'_!1;_@H9X7TW2)O[5^$
MOP[M1J$DRY\F[961W;!_YZ3&&+'=(6(KK?V!O^4@?[5G_83N_P#TXR5[?_P3
MM_8\OOV2?ACK-OXD>QN?&>O7WG7T^GR-)$D$8*P1*S*I.-TCG@<RD=JI?LM_
MLJ^-/@[^U5\<?B)KTNEOH'C.\GGTQ;.X:2<*]V\H\Q2@"G:PZ$\T ?7M%%%
M!1110 4444 %%%% !1110 4444 %%%% !7X[?M>?\I>/AW_V,'A;_P!'P5^Q
M-?CM^UY_REX^'?\ V,'A;_T?!0!^Q-%%% 'XZ_\ !+G_ )2!?$S_ +!FL?\
MIQMZ_8JOQU_X)<_\I OB9_V#-8_].-O7[%4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZC)') !H [VO+OVAOVD? _[,/@=?%'CB_EM[6:86UK9VD?FW5W*03LC3(S@
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MH,^U>J?&[Q)XT^&_PWFOOA=X!M_&^OQSHD>BK>16*+&V=\N6P&P<?*,$Y]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA+]G/4/'EWX91A)XNUJ35I]Z!?LZ'[ELF/\ EG&S2E<\_O".U 'L%?GK9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=#(%'_3-DBER>BQR>M?5O[/?QBT_X^?!CPGX\T[8L>L62RSPH<B"X7Y)XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<M\/_BGX.^*VFS:AX,\4Z/XILH7\N:;2+V.Y6)_[K["=I[X...:ZF@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K,U#Q-I.DZMI6EWNI6MIJ6JO)
M'86DTRK+=-&AD<1J3EBJ L<= ,UIU^*W[;W[3WC#QM^UQ<>./ "7%YX8^#%S
M! EY$-UM'.9PDTDA'\,TO[CC[R1CU- '[4T5R_PO^(FD?%OX>>'O&6@R^=I&
MMV4=[;D_>4,,E&]&4Y4CL5(KJ* "BH[BXBL[>6>>5(((E+R22,%5% R22>
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M6WB)(_-;2!>1F[5,!MQAW;\8(.<=#7P?_P %-/\ DY+]CO\ [&V7_P!+-+H
M_0JN%M_CCX&NOBU=?#&+Q!"_CNVM1>S:-Y4GF)"55@^[;LQM=3][/-=5KWB'
M2O"NDSZIK>IV>CZ9;[?.O;^=((8]S!5W.Y"C+, ,GDD#O7YO>'?BCX,B_P""
MNGBCQ(_B[0D\.R>%TA35FU*$6C/]FMQL$N[86R",9SP: /TQHK,\.^*-&\8:
M6FI:#JUCK>G.S*MYIUREQ"S X(#H2"0>O-<6W[2/PGC\5?\ ",M\3/"2^(/,
M,1TTZW;>>) <>65WY#Y_@^][4 >CT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7X[?M>?\ *7CX=_\ 8P>%
MO_1\%?L37X[?M>?\I>/AW_V,'A;_ -'P4 ?L31110!^.O_!+G_E(%\3/^P9K
M'_IQMZ_8JOQU_P""7/\ RD"^)G_8,UC_ -.-O7[%4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ? W[:'P8^+/PO^/&D?M)_!H7WB>_L[5;'7?"S/+<F6V "D10@DF)E
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MU>M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=A9+=Y3[0TA6-R2'\J )L/S))V)(]/7]G/\ ;_10J_'OP>J@8 #O@?\ E-H
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MU^/.@?M*?"31?'GAU)+>TOU9)[.<@RVEPAVR1,1UP1P>ZE3@9Q7I= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^.W[7G_ "EX^'?_ &,'A;_T?!7[$U^.W[7G_*7CX=_]C!X6_P#1\% '[$T4
M44 ?CK_P2Y_Y2!?$S_L&:Q_Z<;>OV*K\=?\ @ES_ ,I OB9_V#-8_P#3C;U^
MQ5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 56L]-M-/\S[+:PVWF'<_DQA-Q]3@<U9HH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\=OVO/^4O'P[_
M .Q@\+?^CX*_8FOQV_:\_P"4O'P[_P"Q@\+?^CX* /V)HHHH _'7_@ES_P I
M OB9_P!@S6/_ $XV]?L57XZ_\$N?^4@7Q,_[!FL?^G&WK]BJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OQV_:\_P"4O'P[_P"Q@\+?^CX*_8FOQV_:\_Y2\?#O_L8/"W_H^"@#
M]B:*** /YW/@A^ROJO[37[0OB_P%IFN6>BW>GB^O6O+N)WC=8KE(BH"\Y)D!
M_"OIC_ARIXV_Z*1H'_@%/5?_ ()D_P#)_GQ+_P"P=K'_ *<+>OUXK6,4UJ92
MDTS\C_\ ARIXV_Z*1H'_ (!3T?\ #E3QM_T4C0/_  "GK]<**OD1'.S\C_\
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M1!SL_(__ (<J>-O^BD:!_P" 4]'_  Y4\;?]%(T#_P  IZ_7"BCD0<[/R/\
M^'*GC;_HI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_
M (!3T?\ #E3QM_T4C0/_  "GK]<**.1!SL_(_P#X<J>-O^BD:!_X!3T?\.5/
M&W_12- _\ IZ_7"BCD0<[/R/_P"'*GC;_HI&@?\ @%/1_P .5/&W_12- _\
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MI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_ (!3T?\
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MIXV_Z*1H'_@%/1_PY4\;?]%(T#_P"GK]<**.1!SL_(__ (<J>-O^BD:!_P"
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M<J>-O^BD:!_X!3T?\.5/&W_12- _\ IZ_7"BCD0<[/R/_P"'*GC;_HI&@?\
M@%/1_P .5/&W_12- _\  *>OUPHHY$'.S\C_ /ARIXV_Z*1H'_@%/1_PY4\;
M?]%(T#_P"GK]<**.1!SL_(__ (<J>-O^BD:!_P" 4]'_  Y4\;?]%(T#_P
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M"BCD0<[/R/\ ^'*GC;_HI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\
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M1!SL_(__ (<J>-O^BD:!_P" 4]'_  Y4\;?]%(T#_P  IZ_7"BCD0<[/R/\
M^'*GC;_HI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_
M (!3T?\ #E3QM_T4C0/_  "GK]<**.1!SL_(_P#X<J>-O^BD:!_X!3T?\.5/
M&W_12- _\ IZ_7"BCD0<[/R/_P"'*GC;_HI&@?\ @%/1_P .5/&W_12- _\
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MI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_ (!3T?\
M#E3QM_T4C0/_  "GK]<**.1!SL_(_P#X<J>-O^BD:!_X!3T?\.5/&W_12- _
M\ IZ_7"BCD0<[/R/_P"'*GC;_HI&@?\ @%/1_P .5/&W_12- _\  *>OUPHH
MY$'.S\C_ /ARIXV_Z*1H'_@%/1_PY4\;?]%(T#_P"GK]<**.1!SL_(__ (<J
M>-O^BD:!_P" 4]'_  Y4\;?]%(T#_P  IZ_7"BCD0<[/R/\ ^'*GC;_HI&@?
M^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_ (!3T?\ #E3Q
MM_T4C0/_  "GK]<**.1!SL_(_P#X<J>-O^BD:!_X!3T?\.5/&W_12- _\ IZ
M_7"BCD0<[/R/_P"'*GC;_HI&@?\ @%/1_P .5/&W_12- _\  *>OUPHHY$'.
MS\C_ /ARIXV_Z*1H'_@%/1_PY4\;?]%(T#_P"GK]<**.1!SL_(__ (<J>-O^
MBD:!_P" 4]'_  Y4\;?]%(T#_P  IZ_7"BCD0<[/R/\ ^'*GC;_HI&@?^ 4]
M'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_ (!3T?\ #E3QM_T4
MC0/_  "GK]<**.1!SL_(_P#X<J>-O^BD:!_X!3T?\.5/&W_12- _\ IZ_7"B
MCD0<[/R/_P"'*GC;_HI&@?\ @%/1_P .5/&W_12- _\  *>OUPHHY$'.S\C_
M /ARIXV_Z*1H'_@%/1_PY4\;?]%(T#_P"GK]<**.1!SL_(__ (<J>-O^BD:!
M_P" 4]'_  Y4\;?]%(T#_P  IZ_7"BCD0<[/R/\ ^'*GC;_HI&@?^ 4]'_#E
M3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_ (!3T?\ #E3QM_T4C0/_
M  "GK]<**.1!SL_(_P#X<J>-O^BD:!_X!3T?\.5/&W_12- _\ IZ_7"BCD0<
M[/R/_P"'*GC;_HI&@?\ @%/1_P .5/&W_12- _\  *>OUPHHY$'.S\C_ /AR
MIXV_Z*1H'_@%/1_PY4\;?]%(T#_P"GK]<**.1!SL_(__ (<J>-O^BD:!_P"
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M<J>-O^BD:!_X!3T?\.5/&W_12- _\ IZ_7"BCD0<[/R/_P"'*GC;_HI&@?\
M@%/1_P .5/&W_12- _\  *>OUPHHY$'.S\C_ /ARIXV_Z*1H'_@%/1_PY4\;
M?]%(T#_P"GK]<**.1!SL_(__ (<J>-O^BD:!_P" 4]'_  Y4\;?]%(T#_P
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M"BCD0<[/R/\ ^'*GC;_HI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\
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M1!SL_(__ (<J>-O^BD:!_P" 4]'_  Y4\;?]%(T#_P  IZ_7"BCD0<[/R/\
M^'*GC;_HI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_
M (!3T?\ #E3QM_T4C0/_  "GK]<**.1!SL_(_P#X<J>-O^BD:!_X!3T?\.5/
M&W_12- _\ IZ_7"BCD0<[/R/_P"'*GC;_HI&@?\ @%/1_P .5/&W_12- _\
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MI&@?^ 4]'_#E3QM_T4C0/_ *>OUPHHY$'.S\C_\ ARIXV_Z*1H'_ (!3T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"JJ("S,3T"@FD,ZVBN>^'_Q"\._%3PAIWBGPGJT&MZ!J"%[:]M\A7 8JP(8
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M= ":LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8UKV>@ HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;4/&GA_2->LM$OM=TVRUJ^&ZUTZXO(X[BX&2,QQEMS<@] >AK9K\]OVL?\
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M]%:QL>. TC $\C\ZP_ WQX^&_P 3;O[)X2\>^&_$=[M+&TTW5(9IP!W,:MN
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MQTUO4K+P1/<2?\([X-T^0PQ>0#@.#_"G5=P'F2;=VY1MR-] 2ZL^X]*_:?\
M@]KFHM8:?\5/!E[>*5 AAUZU8MGIMQ)\W_ <X/%>EQR+(BNC!T89#*<@CU%?
M+FI?\$Q_V<K_ $(Z;'X!:R;;A+ZVU6\^T(W/S;FE()Y/# CVX%<W^R[^S/\
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MLQXH^!-[??#?Q_I;&ZL5M]1G:VGD&3LWNS/"Q/ 96VCH5P<CU?\ 8)_:>O\
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MC=_=7I7)?&']A'Q#^R7I]W\5OV</%NMV%[HL?VK4_#-_,+B*\MD^:0+@#S
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M&Z.XMY!)&X]0P."/I7YG? ;X&^'OV_OC-\8?&GQ>U74=5DT'6Y-&TSPO!>M
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M\*OB_P#9-3_X3/[,FI>;]N;R/.RRY\O&,8[5X_\ ME?$+Q;\-?\ @I-H^H^
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MXE?$+1_A1X!U_P 8:_/]GT?1;22\N&7&XA1PBCNS'"J.Y8"OSJ^$OP"\<_\
M!2BZD^*GQD\2ZEH7PXDN94\/^$M(DV(T:,5+J6!55# J9"I>0JW**%IMB2ZG
MZ,>'_B/X3\67CVFB>*-%UFZ0L&@T_4(9W!7[P*HQ/'>NBKX?\8?\$C?@]J.D
M@^$M0\0^#-?@4-:ZI;WQN0LHZ.Z/R?HC)T&".[OV*?C]X]\-_%;Q'^SM\:K]
M=0\:Z''Y^BZU(Y=]4M@NX@N0#(=A616/S%=X;E#1?N%NQ]O44451)^6/@?X6
MV/[>G[=WQ>_X6A?7MUX;\"74VG:?X?BN&A#Q1W+P(N5(9$_=,[[<,6D'S>OI
M7QT_X)>:?X?;2_&'[.5Y=>!?'.DW<<L-K-J<S6\BD@,RRR%W1E!)()967<I'
M(JC^U3\"?B3^S5\>+S]I+X)VO]K6MX&?Q1X;1&?>I \Z0QJ<R1.5#MM^9'&_
MD9V_3/[*O[9'@;]J[PVUQH,QTOQ):1AM1\.WD@-Q;] 70\>;%DX#@=QN"DXK
M.RV9I=[H]<\/7&HZ-X1TC_A+M1TYM;6VB2_N[4&"VDN-HWF,.<A2P. 3G%;B
MNLBJRD,K#(8'((]:\M_:@^"]M^T%\"?%W@>94^U:A:%["5\?NKN,B2!\]AO5
M0?52P[UX_P#\$S_C-<_$W]G.U\/:RTB>*? ]P?#^H0SG]Z(X_P#CW9AU&$_=
M\]3"U7UL1;2Y]9,P4$DX Y)-"L'4,I#*1D$=#7R]_P %&OCPWP/_ &:M9CTZ
M=H_$WB@_V%I:Q']XIE4^=(N.1MB#X8=':/UJC_P34^.4OQ>_9QL-'U9W7Q5X
M+D_L'489AME\N,?Z.[*>1F,;#GDM"]*^MAVTN?6'3DUY=\=OA#X$_:4^%]]X
M6\6W(FT%IHY_MEC=I'):S)]UTD(*AL,1\P((8C'->;_\%#_CHWP/_9GU^33Y
MBGB3Q%_Q(M*6,_O!),"))% YRD0D((Z-L]:\0^+/P*3]G?\ X)-^(O"DL(BU
ME[*RU#5SCEKV:^MFD4^NP;8@>XC%#?0$C[1^"OPG\+_!'X:Z/X/\&Q-'X?L%
M=H&DF\YY"[L[NS_Q%F8GCCG    K8U;X@^%M U:'2]4\2Z/INIS8$5E=W\44
MSY&1M1F#'CT%?-/A#XA:I\*?^"9>B>+=$0-K&E> X)[1BH81R^0JK(0>H4G<
M1_LUXE^S/_P3K^%OQ\^ .B^/?&^M:YXI\8^+(6U&\UR'5"'@E9F#1J"&#,I&
MUS)N)96Z#@%^B"W5GZ15D>)/%^@^#K1;K7];T[0[9CA9M2NX[="?0,Y [UY7
M^RC\ M?_ &<_A_=^%=9\?7_CFSCO&;2_ML006%H.$A7)9CQR1NVCHH SGXP^
M WP-\/?M_?&;XP^-/B]JNHZK)H.MR:-IGA>"]:!=/M@7",0IW ?+@;2 725F
MW$\%PL?ICIVI6FL645Y874-[:3#='<6\@DC<>H8'!'TJS7RW^S;^Q"W[+WQ4
MUC5/"?Q!UI_AY?VO'@^]"RH+HD RM)TPH P557.<,Q PWU)3$%%%>+_MA?'J
M#]G']G_Q-XO$BC5O*^PZ1&<'S+V4%8N#U"_-(1_=C:@#\Y_VZOVL/$M]^U]8
M:SX*2>ZT/X.W$8EF@),+7#RHEUYC#HKDK;$'^ZWK7ZP?#_QQI?Q+\#Z#XKT2
M;S])UJRBOK9SC=LD0, P[,,X([$$=J^*_P!A7]CO3[S]COQ'#XWM6DUGXJ6[
M7=]/.-T\5LP)M&R?XP3]H!/\4@STJE_P2X^(VK>#9_'G[._C$^1XC\%WTT]C
M&[$[[<R;9E3/5%D*R CJ+C/05"O?7J6]M.A^@-%%?FKXP\9_$C_@HY\</$G@
M#P%XDN/!?P2\+S?9]6UJS)#ZFP8J0"I'F;RK[(R0@1=[Y.U:MNQ*5S]!1\3O
M!S:P-)'BS0SJI.!8_P!I0^?UV_<W;NO'3K6_=WEO80F:YGCMH@<&29PJ_F:^
M,K3_ ()'? .#0182V_B*YO-FTZH^JE9\XQN"A1'UY^YBODO]M_P#\4?V4_@_
M<?#*_P#$=QX_^$'B&Z@;1=2U,G[9H]Q"XD^S,>1M9 V!]T[25"893-VMQV3V
M/V%CD6:-71E=& 964Y!!Z$&DFF2WB>65UCC12S.YP% Y))["O//@GJ5KHW[.
MW@+4+ZXCM+*U\*V$\]Q*VU(XUM(V9F/8  DGVKX*\/:#XZ_X*H?$'7]7U3Q'
MJ7@[]G_0K\V=CIEA\DNILO.6!^7S=C*S.X81[U55)W&G<5C]%-+^*7@S7-3_
M +-TWQ=H.H:CN"_9+74H99<D9 V*Q.3]*Z>OB?6O^"1?P)O]"^QZ>/$6CZBJ
MG9JD.I^9+O[,R.I0@$= J]3R.".5_9O^*'Q#_93_ &C+;]G?XM^(&\3>'-8A
MW^#_ !-=%B[\D1PEF)(#;638Q)1PJJ2K T7?4++H??EW>6]A"9KF>.VB!P9)
MG"K^9IMQJ%K9V+WL]S##9HGFM<22!8U3&=Q8G &.]?(O_!5[_DS77_\ L)6'
M_H\5XM^SU^SYXJ_;N^'WAGQ/\6M;U+1/A7I5E!I?ASP;H\YA6\6WC$+7<[XY
MR\9P<;CSM*KC<7UL%M+GZ&^'?'_ACQ?<3P:%XDTC6IX"1+'IU]%<-'@@'<$8
MXP2.OJ*WJ_/7]H;_ ()G^$?AYX!U'Q[\$[W6O!GCGPO;OJEH(=1EE6Y$2EW0
M,Q+I(5!VE6P3P1SD?2W[$_QWNOVB_P!G+POXNU0QG7MLEAJGE@ -<PL49\
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M4L(7Z37<AV0)CN-[*3Z*&/:G?2XK:V/2[;4;2\EFBM[J&>2$[9$CD#%#R,,
M>.AZ^E6*^1/^"9/P5N?AG^SZGBK6U=_%GCR?^W;Z>?\ UIA;/V=6/?*LTO/>
M=J^NZ$#"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB(@'U\TQUXC^Q?\ \HN;'_L >(O_ $KOJ\0_:,^)WQ6_;P^%?BJY\+^%=1\
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M*X#9;:NS'W1]ZUXO^VC)IT/[)OQ:;5&5;8^&[Q4+$ ><8B(!]?-,=> ^'_\
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M_P""F_[/-S';326T>FL'F6,E$^>[ZG&!7UG^T%XL\<^!_A+KVM?#GPQ%XO\
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MJ6>:VFA@FU(F.22,JK_Z5-T)'/X5[7^U]^T5X\_9OA\,>(M"^'K^,O ZSO\
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M_8P^%_\ T?!7Z[5^1/[5W_*7#X=?]C#X7_\ 1\%9SV-(;G[(T445@;GXV?\
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M%O)?@F>.RMF\LY+?,"\J$$'M!&:^H/VI_@C;_M#? ?Q9X(D6/[;>6IETZ:3
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M0TEII3K%D?=+O9 L/?"D?\"-?H97P!^S!_RE!_:*_P"P:O\ Z':5]_T1%(^
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M_P#7G;_^E<-?1]?.'_!1;_DRWXG_ /7G;_\ I7#0]AQW1J?L&_\ )GOPJ_[
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M< 5\B7B_\,C_ /!2JWN1_HG@7XSP&-^T2:IO'/NQF*G_ +?37UI^S/\ " _
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M. RM93 J>A'EM7Q9_P $<Y&?]E75PQR%\57:K[#[-:G^9-?:OBK_ )%?6/\
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MI/1ACAXR0<./Q"GBNN_:%^),_P '_@;XY\:6B0R7VBZ1<7=HEP"8VN A$0<
M@E2Y7(!!([U5^I/D>A45Q'P3^*^E?'#X5>&?'.BL/L.LV:W'E;MQ@D^[+$Q_
MO(X=#[K7;T %%'3DUX5^S#^TY8?M):I\3FTL0MI/AOQ"=,TZXBY-S:B%,3$Y
MYWRK.RG ^0H.H)(![K1113$%%?*#_MTZ2O[<J_ _%J-&^P_9#J39W_VP0)1"
M&SMV>7^[QC/FG%?5]*]QVL%%%%,04444 %%%% !1110 4444 %%%% !1110
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M)[NSAGDV#"[F0,<#TR:U*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$;PS\4?$EWJ\VA6,8%E=00QFVG\XHX/EHO(Q@@^E%];!;2Y^B%%%%42%%%%
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M\):%X<>1=KMI.FPVI89S@F-1D9KIZ* *[:?:R7B7;6T+7:#:LYC!D4<\!L9
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M8 '04O7@T44 -C18T5$4(BC 51@ >@IES:PWD#0W$,<\+?>CD4,IYSR#4M%
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MG;'7CKQ7QW^T1\8O^'CWC[PU\%_A'!?7O@6QU*+4_$OBUK=X84C4,HV!P"%
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M:C^"[>"=+UBUT2Z.HP7OVJ\C9TVQA\KA><G=^E 'O-%>1_LG_!6]_9V_9_\
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M/U[X<_MH>(_C7<^*-.O-+U2^U.[32XH)%G071<J"Q^7*[N?I7V?0@"BOBO\
M;N_8(U_]KCQQX;UW2/%.FZ!%I6G-9/#>P22,[&5GW KVP<5]J4 %%>,?M??
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M>YVD9#>2F7P1T.W!J'X9_M0?"?XQWRV'@[Q]HNMZBPW+81W(CN6 &25A?:Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW/U#^UU^S%-^U;X%TWPE)XQN?">D07HO;M+6S$[7A52(U8EUPJEF;'.3M/\
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MBC+,S'@  $DGIBOS^_8!OH_B]^U]^T3\6]+5G\-7-PNEV%V5(6X4R9#+_P
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MJ*5+;0[,V[GZIU#]@G]G[4M".DR?"S0H[;;M\VWC>*X'7GSU829Y_O>E=/\
MLH:SI6O?LR_"V[T0H=-_X1NPA18SD1M' D<B$^JNC*?=37JU-)6$VSX\_9O_
M &-O''[+/QTU+_A$/&ZWGP1U&W::;P_J[/+=Q7)!VB( ! 00N9<@LIVLK%0P
M^PZ**:5A-W"OS7_X*^^((?"/CS]G/7+F.2:WTS4M1O9(XL;V6.73G(7/&2%[
MU^E%?G7_ ,%4O^2R?LM_]A^[_P#2C3:4MBH[FG9_\%D/AWJ3,EG\/?&EVZC)
M6&*V<@>IQ+7F?Q$U+XQ?\%/O%?ASPW9>!=0^'/P>TV\6^NM3U9'5IF"E6D#L
MH$CA'94C0$ N2S8.5_4VBE9O=A=+9'P]_P %8-+MM#_8QM=.LX_*L[/6-/MX
M8\YVHB2*H_  5E?L:_L2^$OB)\(='^)'QCTM?'?B_P 56,-Q#_:KLT-CI_EA
M;6*)%( _<A&SC*Y &,$GH/\ @KM_R:,__8?LOY2U].? >U6Q^!WP[MDQMA\.
M:=&,# P+:,=/PHM[P7]T\$_;Q_:%N_V6?@OX>\,_#RS2W\7^(I%T/P]:VT0;
M[)%&JJSQQX(9E#11HO\ >D4\XP>1_9U_X)?^!?#WA^+7OC!:R?$+X@ZF%N[]
MM1NI6M[65AN>,!7_ 'S9.&DD+;B,@*.O*_\ !0A(-%_;&_9;U[6_D\.)JZ1M
M-(<1QR)>6[%F] -\9.>H4^AK]#:-WJ&RT/B?]H+_ ()=_#;QIX>GU/X8V1^'
M7CJRS<V%UIUQ*+::51E(W0N1&"P&)(]I4G.& VUN_P#!.W]IKQ#\:O!/B#P;
M\0!)'\2/ ]T-/U(W"[9KB/+(LD@_YZJ\<B/CNJL>6KZ[K\\?V+5@US_@HG^T
MKKFALLF@0^9:S21'*-<M=)DY[Y:&X.>_-&ST#=:FA^V_\5/&_P :OCKH/[+O
MPRU!]%EU*%;GQ1K$1(:*V9#(8B1@A!%AV (\PR(F0"P;U_X9_P#!-WX#?#OP
MW%IMQX+M?%=\8MESJFO%IYIF(P6"YV1^P0#'J3S7B?P2N(/#/_!7'XQ66LD1
M:AK&A?\ $L>3_EL-EE+L3U/EQL?I$PK]"Z%KJP;MHCX!_:$_8C7]GBTN?C)^
MSHUWX7\0Z!"UQJ/AB.>2>SU2S',R;78MG;EBF2"%^4*X!-G_ ((R_P#)K_BC
M_L<;K_TBL:^X?%6H:=I/A?6+[6'2/2+6SFFO'D.%6%4)D)]MH-?#_P#P1G(/
M[,/BDJ-J_P#"976 3G'^A6-%K,+WB5/ ?_*8KXC_ /8J1?\ I-85]_U\ Z&H
MT/\ X+%>(3(_EG6/":F,-_'MMH.!_P!^&/X&OOZFA2/@#_@JU_R%/V?_ /L:
M_P#V:"OLKXU?%72_@A\*O$_CK609+'1+-[DPJVUIY.%CB4]B[LB ^K"OC3_@
MJ@?MOC#]G'2HL&ZO/%3>4N>3B2U7I]9%_.O1O^"J>GW]]^QGXH:R5GBM[VPF
MN@HS^Y%P@R?8,R'\*7<?8\3_ &<OV4=4_;;ND^.G[0E_?:K8ZE+(V@>$XIF@
MM8[/=\I.T[EB)SM12I;:'9FW<_5.H?L$_L_:EH1TF3X6:%';;=OFV\;Q7 Z\
M^>K"3//][TKI_P!E#6=*U[]F7X6W>B%#IO\ PC=A"BQG(C:.!(Y$)]5=&4^Z
MFO5J:2L)MGQY^S?^QMXX_99^.FI?\(AXW6\^".HV[33>']79Y;N*Y(.T1  (
M""%S+D%E.UE8J&'HO[6G[/\ \._B-\//&?B[Q+X2T_6/$NE>&+U++4KE6,L"
MQ0S2QA2#_"[LP]S7OU<%\?\ _D@_Q(_[%K4O_262BV@7=SXC_P""9/[-'PO^
M(G[..D>+?$O@K3-8\20ZS<^7J5RC&5?+=3'R#_">E2?M%Z-X<^+7_!2WP3X'
M^+,W_%#6WA\3Z'I=U,T5K?WLA;Y6((Y=U*XS\Q@C3G.T^D_\$E?^3/M._P"P
MS??^AK7L7[3W[)?@?]JKPO;Z=XGAFLM6L=S:;KEAA;JS8]0"1AT) RAX.,C!
MP1-O=*O[QQ?B3_@G5\'-2\=^&/%OA[2;KP'JVB7R7A/A>X:S2Z"\B-@/N#./
MFCVM@D9YR/IZOSK\+?%OXS_L&?$SPGX$^,.LQ_$+X4^(+H:?I?B]BQN;)B0J
MB0L2V%R"T;E_E)*.=A6OT4JE8EW"BBBJ)"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1I2JAO+C51C)'WOXS\'Z3\0/">L>&M=M$OM'U:UDL[NW?H\;J5.#V/.01R"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.)-,93E"JFX)Q_VS>']*])_:3_8-N_&7Q!E^+'P=\6W'PW^*>-\TD3LMGJ+
M ?O-H)1F  8X=&Q\R$DM4[I,K9M'6_ ?]A?PQ^S?\7]7\6^!_$FNZ=X<U"S\
MAO"#W!ELQ+G_ %C.Q+. /NAOF4EOG(.T>;_\%$OV4_A;J7PA^*'Q;N/"_F?$
M);&&8:Q_:%T/G3R8$/DB7RN(U5?N=L]>:Z']D?\ :X\8>,?B1K7P7^,V@Q>'
M?BIHL!G2>W 6#4X5"Y=0"5W[6#@H2K*6("[<5W'_  4$_P"3-?BE_P!@U?\
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MX;N=!\!Z#%H&E7%T][+#'+)*7E8 %B\C,QX50 3@ 8%=W115D!1113$%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=P #M4L#^D.I^'=*UJ2-]1TRSOWC(*-=6Z2%2#D$;@<8/-7888[>)(HD6*)
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M113V%N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5^1/[5W_ "EP^'7_ &,/A?\ ]'P5^NU?D3^U=_REP^'7_8P^
M%_\ T?!6<]C2&Y^R-%%%8&Y^-G_!,G_D_P ^)?\ V#M8_P#3A;U^O%?D/_P3
M)_Y/\^)?_8.UC_TX6]?KQ6\-C">X4445H9A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
M?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP_
M_P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D
M/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@
M%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'
M_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4O
MP_\ ^ 4]'_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#
M\<?]%+\/_P#@%/7Z_P!% 'Y ?\.0_''_ $4OP_\ ^ 4]'_#D/QQ_T4OP_P#^
M 4]?K_10!^0'_#D/QQ_T4OP__P" 4]'_  Y#\<?]%+\/_P#@%/7Z_P!% 'Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=B"3KL<QLVUO8\USGQ4_:*^&WP1U30M.\=>+]/\ #5YK<ACL([PM^\P0"S$
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M(8VDD941069F.  .I)K+\)_\BKHW_7E#_P"BUJK\0O\ D0?$W_8,N?\ T4U
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M;>8B2,$SM22/S8WWIM$@W*5&,C]5: "O.?$G[1'PW\'_ !0T;X<ZSXML-/\
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M!VM)(N&+#()]"\2?\$E= \&J/$/P2^(7BCP'XZLU5K*XNKX26KLO.V0QQK(
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MJC?\!KX__8J_:T3X?_L4^-H_'&Z/Q+\'/.TF]L;A\2NJEELXCZ$R VP_ZY4
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M1?!?1O'.F1"SN9BUKJ6G[]QL[Q,>9'GN.5=3U*NI.#Q7RC^UM^T/\2_CI^T
MO[-/P'OVT2_@3?XF\41R-&;9=H9T6503'&@= S+\[2,$&,'=3_X(]PC3_P#A
M?&G:=*9?#-KXDB73B#E3_KU)';E%A_2D_P""5]LEY\:_VH=5U-VD\4-XC2*Y
M\[_6(K7-ZS]>?F<'/^X* -71?^",/PH.CG_A)/&'C'6_$$RAKG4H+JW@4RX^
M9TC:%R 3DX=G/O7F.O6GQ5_X)1^.-"U"+Q'?_$3]G[5KL64MC>%C-IY(SA5/
MRQ2A0Q4H0DFQ@RJ<8_5*OG'_ (**:?IVI?L6_%)-3*K!'IT<\;-CB9)XFAQG
MN9 @_&@#WC3?%6D:MX5M?$EIJ$$N@W-FNH1:AOQ$UNR"02Y/\.P[L^E?F8NM
M?%+_ (*I_$OQ!9:!XBOOAY^SWH5P;22:U#+-JC8R Z@CS9&&UMC'9$K)D,Q^
M?UCX=7VN#_@CW/.'E_M%? VI(C DL+<&=5P1R ( /H!7H'_!+6STJU_8C\!/
MIBQ^9<27\MZR@!VN/MDRDOCN%5 ,_P *K0!YW=_\$:O@PNF0KI?B'QGI6KP8
M>+5(]0@9_, &&*^2!@$9^7:?>OBW]O;4_C!\)_ VD? OXJ:F?&MA9:I%KGAK
MQDV[S+JT2&>%X)"V2SJ94)#,67IN960C]QZ_.W_@MEI^G2?L_>"+Z4J-5A\3
MK#;C W&)[6<R_AF.+/X4 ?HE1110!\F?M_?M>:I^SIX7T+POX&M!JOQ2\8S?
M9-&MEB$QMP65#-Y?\;EW5(U(PS$DY"E3X]\/?^"3L'CZW'BK]H+QYXB\7^.=
M042W-O9WX$-L3SY1E=6:3 P/EV*.0H( --^*4,6J?\%DOAC!KX#6EOX;,NEQ
MS'Y"ZP7KJ1GC(E$A&/XE'>OT6H _.7QA^PYXY_8MM[GXD?LW^-M:O[?2T:\U
M?P3X@D%Q#J5NOS.J"-$5V"@X4KOQG;(&P#6_X)"^,E^(GC;]I'Q6MJ;)==UZ
MTU06K/O,(GEOI-F[ SC=C.!G%?I'7YY?\$L]/T_2/C%^U78Z05.E6OBN."S*
MXP85N-06/&.,;0* /)_VS?BAXF^$?_!331]:\%Z,NO\ B^Y\-P:5I%C(?E:Z
MNDF@B8CN%:0-C@'&"0.:]T\/_P#!*_0_B%$?$OQX\<^)/B#X_P!07S+R:WO1
M!:6K-SY4*[2VU22!RJX PBCBN5\>:/#J_P#P6?\  7VB)9H[7PXUR%< @,MG
M=[&QZAB"/< U^C= 'Y?3>%O$/_!+[]I'X?6.A^*=3UWX&^/+[^SKG3=6D#_V
M=,756?( 567S4D#JJEU616!VAJ_1_P"(?CS2/A?X%U[Q=K]Q]FT;1;.6^NI
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M 8HD3 '\J3_@JIJ:_$[XQ? 3X-:1NO=:O]6%_=6L?_+..61(8F8YX&%N2<]
MN>E3_P#!9C3UU;1_@I8NH9+G7YX2K="&6$8_6@#8^'O_  3FMOVD-#LOB?\
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ML_[1\!_":T.,3^()8N3@?-$!_6OT8M+6&PM8;:WC6&WA18XXT& J@8 'L *
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M6O;6X&JW:3*$6&1AM"QK@YKR/_@K;_R-/[.7_8S2_P#H=I7W!\;O^2+^/O\
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MX!\9^,?!GBNT4M8ZJM\DJI+U5W541^.GR.E?47[)]CI>G_LP_"B'1EC&G?\
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MWVG,I/8_:HQD?@3^=>]?LTR--^SE\*I'.YW\*:4S'U)LXJ /2**** "BBB@
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MX:91D1^,;1F]A]BO1_,B@#[F\)_\BKHW_7E#_P"BUJK\0O\ D0?$W_8,N?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ),<^&'_ %QOO_2^YKQ7_@G[_P GL_M>?]C W_I;>5[5_P $R_\ DQSX8?\
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M,DNDSMCN>!*JC@Y F1<'YERH!^HU%?,'Q(_X*-_!7X?7W@RSMM?D\777BB2
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M&#M:21<,6'!/H7B3_@DKH'@U1XA^"7Q"\4> _'5FJM97%U?"2U=EYVR&.-9
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MGPO%YUEJWF!CJMJ IR6P-[!'C=7^\Z,2P#(Q-#_AF/\ ;)_Z.=T__P $L?\
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M^$?_  4X75?!.C)KWC+4/#]MHVC6<I 0W=U$88F;/!"ELX) ..2!DU[UH/\
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MSPMI/B/0;V/4=%U6UCO+.[BSMEB=0RM@\C@]#@CH>: ->BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^=?\ @H=_R9;\5?\
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MV'<F)4D [O:$GK7Z,03QW4,<T,BRPR*'22-@RLI&001U!%>3_M7? NU_:-^
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MGDE94B52S,YP !U)/I0!\S^"?V^/A_XD_9/N/C9?7"64&G0^1J6C)(#/%J(
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MNK_85_Y,_P#A)_V+]O\ RKVO5-+LM;L9;+4;.WO[.7 DM[J)9(WP01E6!!Y
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M::+IMII]A;QVEC:0I!!;PKM2*-5"JJCL   ![55L_"NBZ=JUQJMIH]A:ZI<
MB:]AMD2:4$@D,X&XY(!Y/85J4 %?FC^V=87'[&_[:GP__:(T>"2'PGXEE&D^
M*4@4E2VT+*2H[O"%D4=Y+9B>M?I=5#6=!TSQ%9_9-6TZTU.UW!_(O(%F3<.A
MVL",\GGWH ^;?V[OV8?^&N?@A9?\(O>PIXMT:0:QX=O5E"QSDIS%YF<*LB[2
M'[,B'.,UY!\ O^"H6A>'[%/ W[0]IJ?P]^(>C!;2]O;S3Y7@O64 "5EC4M$[
M=3\OEG[RL <#[[MK:&SMXK>WB2"")!''%&H544# 4 <  =JY7QY\'_ OQ3CC
M3QCX-T'Q2(UVQMK&FPW+1CG[C.I*]3T(ZT ?*_Q0_P""HWP]6%/#_P &K74?
MBW\0=1S!INFZ9IUPD"RD<-(SHK,H')$8;H02G)'SU_P3K\(^,?!/_!1GXJZ9
M\0;N*^\;/X3GO]7FA<.OVBYN-.N67(&/E\[;\ORY7Y>,5^EW@/X0>!?A9'*G
M@WP;H/A42@+*='TV&U:7&/OLB@L>!R<UNV_AW2;76+C5X=+LX=6N$\N:^CMT
M6>1>/E:0#<1\J\$_PCTH _/O_@LA_P BM\&_^QF;_P! 6OT5K-UGPWI'B-85
MU;2[+5%A;?$MY;I,(V]5W X/N*TJ /A7_@LE_P FCV?_ &,UE_Z*N*^ROA[_
M ,B#X9_[!EM_Z*6M'6=!TSQ'9BTU;3K35+4,'$%Y LR;AG!VL",\GGWJ['&D
M,:QQJJ(H"JJC  '0 4 ?)G_!53_DQSQ]_P!=M-_]+[>O5?V._P#DU#X/?]BE
MI?\ Z2QUZIJVCV&O6,EEJ=E;ZC9R8+V]W$LL;8((RK @X(!_"IK.SM].M(;6
MT@CM;6%!'%#"@1$4# 55'  '84 ?GW_P3]_Y/9_:\_[&!O\ TMO*/$W_ "F;
M\)_]BD__ *2W-??.G^'=)TF^O+VQTNSLKR\;?<W%O;I').V2<NP&6.23SZFA
MO#NDR:TFL-I=FVK(GEK?FW0SJN"-HDQN P3QGO0!HU^>O_!9[_DB_P ./^QM
MC_\ 2::OT*K.UKP[I/B2&.'5]+L]4AC?S$CO;=)E1L8W ,#@X)YH ^</^"FG
M_)CGQ/\ ^N-C_P"E]M6?\+?BAJ_P:_X)T^ O&&A^$K[QOJ6F>$[&6/1]/.'<
M>6H9V."=BC+-M5C@=.I'U-JFEV6MV,MEJ-G;W]G+@26]U$LD;X((RK @\@'\
M*?8V-MIMG#:6=O%:6L*A(H($"(BCH%4< >PH ^.-*_X*U?L_7WP_;7[K6]2T
M_68X=[^&I--F>\,NTGRT=5\ELD$!BX'3.W.*P_\ @E7X#UZU\*_$[XF:OHS^
M&]/^(6OG4]*TEP5\JV5I6#JN!A"9RJG W",$#!!/U%>?LU_"34?$A\077PQ\
M'W.MLV]K^70[9I6;(.\L4Y;C[QY]Z]'50J@ 8 X % 'YU_\ !6W_ )&G]G+_
M +&:7_T.TK[@^-W_ "1?Q]_V+^H?^DTE='J_AO2/$#6S:II=EJ36S;X&O+=)
M3$W'*[@=IX'(]!5Z>".ZADAFC66&12CQR*&5E(P00>H(H ^)/^"/7_)GZ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _.K]J'_E+)^SQ_V!D_\ 1M_7Z*UFW7AO2+[5K?5;
MG2[*XU.V7;!>RVZ--$.>%<C<HY/0]S6E0 5^=?\ P5^_YH-_V,TG_M&OT4K-
MUCPWI'B+[/\ VKI=EJ?V=M\/VRW27RV]5W X/ Y'I0!I5^>O[1W_ "EL_9[_
M .Q?;^>HU^A59USX=TF\U>WU6XTNSGU2W79#?26Z-/$O/"N1N4?,W0]SZT ?
M W_!8S_D0?A'_P!C:O\ Z*:OT*K.UGP[I/B*.&/5M+L]32%_,C6\MTF"-_>4
M,#@^XK1H ^%?^"R7_)H]G_V,UE_Z*N*^ROA[_P B#X9_[!EM_P"BEK1UG0=,
M\1V8M-6TZTU2U#!Q!>0+,FX9P=K C/)Y]ZNQQI#&L<:JB* JJHP !T % 'R9
M_P %5/\ DQSQ]_UVTW_TOMZ]5_8[_P"34/@]_P!BEI?_ *2QUZIJVCV&O6,E
MEJ=E;ZC9R8+V]W$LL;8((RK @X(!_"IK.SM].M(;6T@CM;6%!'%#"@1$4# 5
M5'  '84 ?G/^TY\-O'_[&O[3%W^TI\,=%F\3>#];0KXP\/V^<INVF60X!(1F
M42B0 [) V[Y6P?9_"'_!5#]G/Q-X=34KWQG/X;N=FZ;3-4TNY-Q$<=/W4;H_
M3^!F_6OK;KP>17E^L?LL_!KQ#K!U74_A3X,O]09BSW%QH-J[2$C!+Y3YS_O9
MH ^ ?VMOVHO$_P"VW\+?&GA[X.:#J%I\*O#UC/J_B;QCJT)MX[U;5#.MI"I!
M/S,B''WR=N0B EO</V)_^45=C_V+_B/_ -*[^OLVU\-Z18Z&-%MM+LK?1Q$8
M!I\5NBVXC(P4\L#;M.3QC%26.A:;IFDC2[/3K6TTP*R"S@@5(=K$EAL Q@DG
M/'.30!\7?\$>O^3/T_[&"^_E%7V_5'1]"TWP[9_9-*TZUTRTW%_(LX%B3<>I
MVJ ,U>H ^ O^"L7@"]\/^%? WQY\+W$6G>+O .K0 W#$ R6\DH,8(/W]DP7Y
M.ZS2D\5V7_!+CX,WW@;X#W/C_P 1AYO&/Q'O&UZ]N9Q^]:W8L;?=Z[@\DV?^
MF_M7F_[?%]<?M._M0?"G]FC2)Y#I<5RNO^*7A/\ JH@I(4G^%E@\UAG@FXB[
MU^A=A8V^EV-M96<$=M:6T:PPPQ+M2-% "J!V   H L4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &#X\\;:3\-_!6N>*M=N/LNCZ-92WUU+U
M(CC4L0!W8XP!W) K\_O^"9/@G5?C=\5OB7^T_P",;5OM^N7TMAH2RG<(8R1Y
MI3(^ZB"&!6'9917Z+:EIMGK%C+9W]I!?6<PQ);W,8DC<9S@J00>0.M-TO2;+
M0[&*RTZSM]/LHL^7;VL2QQIDDG"J !DDGZF@"W7._$3P'I/Q0\!Z_P"$==A\
M_2-:LI;&Y0<-L=2I93V89R#V(!KHJ* /SH_X)A^.-6^#_P 0?B3^S%XRNLZK
MX9OIK[1F;A982P\X)GHK!HIU7KB60]JB_:8^'/CW]C/]IB]_:3^&>AR^*/!N
MN1E/&'A^W!W1[MIDD. 2$9D67S #L<-N^5L']"/^$7T;^W/[:_LBQ_MC&W^T
M/LR?:,;=N/,QN^[QUZ<5I]>#R* /DKPC_P %3OV<O$WA]-2O/&D_ARYV;YM-
MU32[G[1$?3]U&Z.>/X&:OF']KW]JKQ/^VI\*/&>@?![P_J%K\*?#]I)JGB;Q
MAJL1MX[U;=?-2UA!!/+*C8^^2%R$0$M^@>L?LL_!KQ#K!U74_A3X,O\ 4&8L
M]Q<:#:NTA(P2^4^<_P"]FN_M_#>D6NAC18-+LH=&$9A&GQVZ+;B,]4\L#;MY
MZ8Q0!\X_\$R_^3'/AA_UQOO_ $ON:^=OVA+GQ)^P;^VI?_'JU\/W6O?"KQO;
M1V>OIIZ9>SF(C#GG@.7B652Q <O(F5ZU^C^EZ79:)8Q66G6=O86<61';VL2Q
MQIDDG"J !R2?QJ6ZM8;ZVEM[F&.XMY5*212J&1U/!!!X(/I0!\EW'_!5?]FV
M'PV=47QK=SW(BWC28]%O/M1?&?+YC$>[MDOMS_%7BW[)]OXK_;0_;(N?VE-;
MT&Y\/^ /#ME)IGA:"]&6G)62,;>S;?-GD=AD!W506VDC[+C_ &3?@G%J@U%/
MA%X'6\'(D'AZTP#G=N \O ;/\6,^]>IP01VL,<,,:Q0QJ$2.-0JJH&  !T %
M 'P)_P %J_\ DUGPM_V.=K_Z0WU?=/A/_D5=&_Z\H?\ T6M3:WX>TKQ+:I:Z
MOIEGJMLCB18;ZW29 X! 8!@1G!(S[FKR*L:JJJ%51@*HP /2@#\]_P!J;_E*
M=^SA_P!@QO\ T.[K["_:(^*FK_!7X/\ B#QCH?A"^\<:CID0D32-/;:[+N :
M1C@L$1<LVU6.!TQDCM[KP[I-]JMMJ=SI=G<:E;#;!>2VZ--$.>%<C*]3T/<U
MHT ?&.F_\%:OV?;KP =?N=;U*RUA80S>&FTR9[PR[<^6KA?)/((W&0+TSC(%
M8W_!*GP#KUCX)^(WQ(UG1V\.VGQ!U]M4TS2FR!';!I&5U4@80F5E4_Q+&"!@
M@GZ>N_V:OA)J'B1O$-S\,?"%QK;-O:_ET.V:5F_OEBG+<?>//O7I"J%4 # '
M  H 6ODW_@IY\'-?^-'[*6K67AJUFU'5=%OH-;%C;Y,EQ'$LBR*JC[S!)6<+
MU.S R< _65% 'PC^SC_P5*^"E]\(=!L_'&NR>"?$VD6$-G?6-QI]Q+'(T2!#
M)"T,;@JV,A#AADC! R?-?V@/VZ-6_;'L]2^#'[/7@*Z\7QZU$+;4]?UBQ'V>
M"%C]]8W!6( @$33;2I7Y5W;6'W'XP_94^#GC_7)=9\0_#'PMJFK32&::^FTJ
M'SIW(P6E<*#(?][/;TKN/!_@7PW\/='72O"V@:9X<TQ3N%GI5G';19QC.U !
MGCK0!^0'A7X4^(_^"5'QT\*^,_'WAO2_'O@W5[=;23Q!I]NSR:5.PS*("^-D
MJ_-@L!YL>X J=P7]@?!?C31/B)X5TOQ+X;U*#6-"U.!;BTO;9LI*A_4$'((.
M"""" 015_5M&T_7K%[+4[&VU&S<@M;W<*RQL0<@E6!!P:32-%T_P_9+9Z786
MNFVBDLMO9PK%&">20J@#F@"[7YU?\%3?B)J_Q(\1?#[]FGP5(9?$'BV^@O-4
M5"=J0;R($DQ_!N5YF_NB!#T-?HK66WA?1FUQ=:.D6)UA1M&H&V3[0!MVX$F-
MWW21UZ'% &7\+_AUH_PC^'?A[P9H$/DZ1HEE'90 @;F"C!=O5F.68]RQ-=11
M10!^='_!4'X?ZM\)_&WP\_:=\&)Y>L^%[V"QU=5.!+"7/DL^/X3ND@?N1,@Z
M"OI3XW?#7PU^WC^RDMGIE\L-IXALH-8T349%R;6Y"[XBZCIU:-QU 9QUKWG4
MM+LM:L9;+4+2"_LY0!);W,2R1O@@C*L"#R ?PHTW2[+1;&*RT^T@L+.($1V]
MM$L<:9))PJ@ <DG\: /SF_9S_;YN?V9;.U^#'[3&D:IX4UOP[$MG8>(_LKW,
M%U:I\L>\1@LX"@*LL8<.!\V&!+>O?$;_ (*H?!+PWIHA\&ZC?_$KQ1<D16&A
MZ'I]PK3S,<(IDDC4 $\?+O;T4\9^H_&GPZ\*?$C3TL/%GAG1_$]DAW+;ZQ81
M7<:GU"R*0#P.?:L;P%\!_AO\+;HW7@_P%X;\,WC*5:[TO2X8)V4YX,BJ&(Y/
M!/>@#\OOV?\ 3OB3_P /4/!/B#XKV\6G^+_%&EWFM/ID9_Y!]N]C=1P6[#^$
MI'"HVY) QN.[=7Z)?M@?LY6?[4GP*UOP1--'9ZF2M]I-[*"5M[V,'RV/^RP9
MXV/)"R,1SBO69/#NDS:U%K#Z79OJT2>7'?M;H9T7!&T28W 8)XSW-:- 'YR?
ML]_\%#_^% Z?;_"/]IC2M6\'^*O#L2V<.O-9O<P7EN@VQNXC#.QVA0)(PZN!
MN)!SGT;XL?\ !6'X+>$M%DC\#WE[\2?%,V(K+2=,L9X(WE;&P/++&O!)_P"6
M8=L\8KZR\:?#CPG\2+!+'Q;X8T;Q19H<K;ZS817<:GU"R*0#P.GI6%X$_9]^
M&/PPOA>^$OA]X9\.7^"OVS3=*@AGP>H\Q5W8]LT ?,G_  3]_9O\::/XF\8?
M'KXO1-!\2O'&?*T^5-KZ=9LRN593]QFV1 1]42)0>2RCA?VBO^4P/P#_ .Q9
M7_T/5:_16LVX\-Z1>:Q;ZM<:793ZK;KLAOI+=&GC7GA7(W ?,W /\1]: .9^
M-_PGTOXZ?"7Q3X"UEC'8:Y9-;&95W&"3(:*8#N4D5' ]5%?G]^SE^UUJ_P"P
MC(?@7^T3I6I:?I^DR2#0?%MK"]S;2VA.50 +NDB!)VLFYEW!&1=G'Z<UB^*_
M!?A[QYI3:9XFT'3/$6FL<M9ZM9QW4)/J4D4C]* /E3X@?\%7OV>_"'A^:\T?
MQ+=^,M3\K?;Z7I>FW$;R,?NAI)HT1/?)W 9^4G .7^Q+!\;?C%\5/%/QR^)-
MUJGA#PIK%LMGH'@5IG6'R004G>)@,!5W8<@-(TCMA4V@_1WA3]F;X1^!=675
M/#_PR\):/J:/YD=[::+;I-&W^PX3*_12*]+H ^7_ -HS]N?2_P!E_P"+_A[P
M[XU\':U:^!]6LVD_X32!/-@2YW<1+&H)8*HRW(<;E(0CD_,G[=G[8/@']K#X
M=:7\%O@V+GXA^+/$VIVC1RV]A-!%9!'#[LS(IW'@$@;50R%F&,5^DWB;PKHG
MC31YM)\0Z/I^O:5/Q+8ZG:I<P2?[R."I_$5S_@'X)_#[X5R32^#?!'A_PO-,
MI66;2=,AMI)%)R59T4,1D#@G' ]* .<\2? '3?'G[,X^$/B&=IK.7P];Z-+>
M*-[++%$BI.N<999(UD&>I49KX5^ _P"U'XK_ .">%[_PI3X_Z%J$GA.SE?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\=OVO/\
ME+Q\._\ L8/"W_H^"OV)K\=OVO/^4O'P[_[&#PM_Z/@H _8FBBB@#\=?^"7/
M_*0+XF?]@S6/_3C;U^Q5?CK_ ,$N?^4@7Q,_[!FL?^G&WK]BJ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\&+7XUW/[0'BV/X./J2>.Q]M-ZVG3Q13?9_M*^;EI"%(\SR\X/7%?2']B_\
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M %<[\1/'FD_"[P)KWB[797BT?1;*6^N6C4,Y1%+%5!(RQQ@#(R2!715\F_\
M!1K4I]8^&/@GX:VKNDGQ$\7Z9H$YC.&6V,HDD8'_ 'DC!]B:3V&M6?27P_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !17YY?MS^/OB_<_MB?#?X7_  S\?W7@Q?$>B(_#[;?S_/NL
MR/A6;[L2C@=A5B#]EO\ ;7L&>6W_ &B=)EFVD*MPTKH3[AK9@/K@XJ>;R+Y?
M,_06BOS[^$O[7WQC^!OQVT3X0_M*65C<C7F6+2?%UBD<:2.S;$+&,+&\9;"?
M<1T)!8$'-?H)33N2U8***^//C)^R/\4/'_[9O@SXJ:+\08],\':2UH\^FO<3
M+/"D3@S011JIC=9@#DL1]XY!  ("/L.BBBF(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**^'O^"CO[:VI_LUZG\/] \)W$;:]<7\>LZI!D9;3HGQY#9' G8.NX<@1-ZU
M]C>!_&.F?$+P;HGB?19_M.DZQ9Q7UK)W,<B!ER.QP<$=B"*5];#MI<VZ***8
M@HHKR/\ :ZU2]T3]E_XI7^G7<]A?6WAZ\E@NK61HY8G$3$,K*05(]12&>N45
M\Z?\$\]>U/Q-^QS\.M3UC4;O5M2N(;PS7E].TTTF+VX4;G8DG  ')Z 5]%T
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MN(8V8K&, #"@< 5]OTD[C>@4444Q!1110 4444 %%%% !1110 4444 %%%%
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M>$#BWM4W2SRO!<)'$O8%G91D\#.3P*_13X4_\DO\'_\ 8&L__1"5^?\ \9_
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M_BC;#%7P,[2" 5('M]?G+\.]%B^!G_!6S7O#7AN);'P]XTT:2]N-/@SY4;F
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M?^(- B5;S2U8X\QE$<>5!/\ $I!X'F*2!78?\$[OVDO&'[16J?&"X\1^(O\
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MZ[9:L=.TV23YFM8Y))U8*,\;8H88P>NW<,\G/Z,4+WM0^'0_/KX:_ML?%3X
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M7_)K_AC_ +'&U_\ 2*^H=[.XE:ZL?</A7_D5]'_Z\X?_ $ 54^('_(A^)/\
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M ,% OB!H7[1'[2'P.^&/P^OH/$7B/2]7::]OM,E66.T\R2 E!(I*Y1(7D?\
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M?I&G0+;:?86\=K;0(,+'$BA44>P  _"O@[]HC_E*]\ /^P W\]0I["6IW?\
MP4F_:$\;?L\^"? 6J>"]?_X1]]0U[[+?S&S@N=]N(V8KB6-\=,Y4 UQ4/Q)_
M:6_;2N+S6?A#J.G_  D^%$=P\&G:UJL.Z_U=48HTJJ8W*KG) 4( 05WL0<9/
M_!9ZW>[^$GPZ@C&9)?$+(H]S;N!7WKX*\)V'@/P?H?AO2XEATW2+*&QMT50H
M$<:!%X'L*-6V&R/@'3_VB/C]^Q;\5O"WAO\ : U73O''P]\23+:6WBBT5$-D
MV0&8N(XV.S>&=9%)*Y*,=I%==K'QN^/'[7WBC6;']GVZTSP/\-M(N7LW\=ZM
M&)'U69#\WV92C_N\XY"YQR7&=E)_P6,T^*Z_99T>X95\VU\46KHV.1FWN5(_
M7]*^G_V9?!MG\/\ ]GGX<Z#8PI!%::#9[PB@;Y6B5Y7..[2,['W8TNMAZ6N?
M$FO?%_\ :8_8-\4:#J7Q=UZS^*7PKU2\6RN=2MD!GLV;)R&\M'$FT,P5MZ,$
M*@J>1^D-G>0:A9P75M*L]M/&LL4J'*NK#((]B"*^4O\ @J9:Q7'[%/C222-7
M>"YTZ2)C_"QO85R/^ LP_&O8?V5]0DU7]F7X37<S,TTGA32R[,<EF^R1@G\2
M,_C5+1V$]5<\E_;$_;8?X$ZMI7P_\ Z$?&_Q;UP+]CT>-&DCM5;[KRJA#,S8
M.V,$< LQ48W>2V?P+_;J\96JZYJGQHT+PKJ;J9(M%C1/+A) PDGDVS)QSR#)
MTZG-4O\ @GSI,/Q6_:T_:(^*NN@7FO:?JQTS3O.&YK6&26=> >5(BMXHP?[N
M\=":_1.DO>U#X=#\Y/%G[9'QT_9I\,^*?!OQQTVVM/$=UHMZ_A/XA:-;I):7
M5\D#-$CIL\LL7V]43!*[H]K;A[U^S'\9_&7Q"_8+M?B-X@UC^T/&3Z1K-TVI
M?988\R07%TD+>6B"/Y5BC&-N#MYSDYW/V_/AMIGQ+_9,^(<.HVT4TVCZ9-KE
ME-)PT$]LC2[E/8E%=/<.1WKR[]B__E%S8_\ 8 \1?^E=]1JG8-+'@_[.W[7O
M[2'[4_@N'X?^"-2M6\<1S37FO>/-5LH(;?3;,E5@ACCBBV&1B'Y*%L9QT++Z
M9\:(?VHOV6_V9W\8W'Q:7Q?KNBZZL^HPIIEM- ^E/M15+20>;N$F"Q!&%D.#
M\F3;_P""-OA6STS]G'Q'KB0@:AJOB*6.6;'+10P1"-<]P&>4_P# S7W!XN\*
MZ;XZ\*ZQX=UFW%UI.K6DMC=PM_'%(A1A]<$TDKH;=F9?PI^(VE_%[X;^&_&>
MC-NTW6[&.\B4G)C+#YHV_P!I&W*?=37+?M0_&JW_ &??@3XM\;RLANK"T*6$
M3_\ +6[D.R!<=QO92?\ 9#'M7RM_P37\5ZE\)?&WQ,_9K\4W!;4_"E_+?Z.\
MGR^?:LP\S8#_  G?%,HZD3N>U4OVX+J;]J#]JSX7_LY:9,[Z)83+K_BEH6X1
M I8(Q!^5E@WX][I*=]!6U/I']B'6OB1XL_9X\/>)_BEKKZYXC\0!M3AWV=O;
M?9[-P/(3;#&BG<@$F2,_O<=J]YJ*UM8;&UAMK:)(+>%%CCBC4*J*!@* .@ %
M2U1(4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/6M8LO#NCW^JZ
ME<)::=8P275S<2'"Q1(I9W/L%!/X5<KX._X*T_']_ ?P>L?AKHT[_P#"1>,Y
M-MQ'!S(FGQL-XP.?WC[4 _B42BDW97&E=V/'_P!F_P"#,/\ P4,^*WQK^+_C
MBRD3PW?PS:#X=289-K(T86.1!TWP0B,^A>8GUKU7_@EG\3=6\.VOC;]G[QAF
MW\3^![Z:2TAD;.ZV,I69$SU5)3N!Z$3KC@5Y5^SM_P %%O"7[/?P;\->!-,^
M$/BR9=+M\7-TI13=7+$O-*1MS\SEB <X&T=J\:^(W[8^G+^V)X4^//A?P5KG
MA3RO*M_$%G?8VWZ8,3E2 !N: A<'C=$C>M972LS6S>A^VU?*/[8G[;,OP+UO
M2OAY\/\ 0?\ A-OBUK@7['I**TD5HK?<>54(9F;!(C!7@%F*C&[ZBT?6+/Q!
MI%CJFG7$=YI]]!'<VUQ$<I+$ZAD=3W!!!_&OSX_X)\Z3#\5OVM/VB/BKKH^V
M:[8:L=,T[SAN:UADEF4@ \J5BMXHP>H7>.A-:/LC-=V7K/X%_MU>,K5=<U3X
MT:%X6U-U+Q:+&B>7$3C"2>5;,G'/.9.G4Y-<1\:/VG?B]\+OA5\0/A+^T9H%
MN;S7O#]];:!XWT:+_0]0F\DXB<(H7+$XR%0J2NY,-O'Z>5\]?M^?#72_B9^R
M;\0X=1MHII]&TR;7+*:3AH)[:-I=RGL2BNGN'([TFM-!IZZF7_P37_Y,E^&?
M_7&]_P#2^XKF?V1?CUX[^)_[3G[1'A/Q-KO]I^'_  GJYM=&L_L<$7V6/[3<
M)MWQQJS_ "QH,N6/'N:Z;_@FO_R9+\,_^N-[_P"E]Q7B_P"P6WD_ML?M90N"
MLCZXT@!'\/VRZY_\>%'8.Y^@-?''[0O[0'CWP/\ MU?!7X>:)KWV+P?XBMDD
MU/3?L=O)]H8RSJ3YCQF1>$7[K#I7V/7Y[_M8*6_X*=?LY  D_8D/'M/<TY;"
MB:?_  6:_P"37_"__8XVO_I%?5]BZA9:[J7P@N;3POJ$.D^)KC0FBTO4+B,/
M';7;6Y$,K*58,JN58@J00.AZ5\=?\%FO^37_  O_ -CC:_\ I%?5]P^%?^17
MT?\ Z\X?_0!1U8=$?D7\:/A_^T;IW[:?PDTCQ+\3]#U7XEW=F6T+Q!;Z=$EM
M8Q[I_EDC%LJL<B3JC?>'IQ]\^#M?^*7[-WP,\>^+_COXQT_X@7>D1OJ%HVCV
MD=K^Y6, 0?+#$-S2< D'&X<UX?\ M/\ _*4']G7_ +!K?^AW=?9OQD^&=E\9
MOA7XI\$:C.]K::Y82V1N(U#-"S#Y) #U*L%;'?%)+<IO8^%_!&C_ +:'[27@
MVS^*>C_$_0O MIJ@-YHOAA;=1%]G).S>?)DR&'(\PN2""=O 'UE^RGXP^+?B
M_P"'<[?&3PG;>%_%%C>/9B2VE4K?QIQY_EJ6" G(X8AL;E 4BOD#X5?M*?$7
M_@G['IGPN^._A.[U#P%:2&UT3QOHZ&:-8,G:A[.H'.TE947C:PVU^AG@GQMH
M7Q&\*Z;XD\,ZI;ZUH>HQ":UO;5LI(O3Z@@@@J0"""" 011$4C;HHKG_B!X\T
M3X7^"M9\6>([Q;#1-(MFNKJX89(51T [L3@!1R20!UJR#\]%\2S?\$]?VYO%
MM_XGA9/A/\5[AKU=9CC8K9W!D>3Y@,\1232*RCGRY5<=-M4FUS5/^"DW[8/A
M+6?#=C<67P<^&-XMP-9N8C&U[-YD<K*H(R&E,,0"=5C7>VTL%K,TWP'\3?\
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M2L*83[K.<C-GQ'X?_;D_9IT]_%,?C'2?C#H-F!)>Z,L)N+@QCEFV&*.4@?\
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M0HHS]Y6PN=S1E0<>C_MS_LW^.OB%K'@CXJ_":[CC^)'@:1Y+:QF*JM]"Q#%
M6(7<"&&UB RR.,@XS'^S?_P4.T#XH>*8OA[\1=$NOAA\45D%JVDZFCI;W4_]
MV)G 9';M')C.0%9R:?74730^L8[XV^EK>:B(K I#YMR&E!CAPN7RY !"\_-Q
MP,\5\$^(/VS/C%^U#X_U3P=^S#H-I:Z!ILK07GQ UR'= K#@/&&#(JGJJE)'
M8$'8H!KU;_@ISX\U#P'^Q[XM.FRM!<:Q+;Z0\JC)$,S_ +T>P:-73_@5>A?L
M:_#+2?A/^S+\/M'TJUA@:XTBVU*^DAY^T7<\2232%NK99L GHJJ!P *?6PEH
MKGSBO[/_ .W#X?M7U2P^/?A_5M6*AI--NK56MWVX^1&>U(&1GG:G/<=1W'[*
MO[8WC#Q=\3K_ .#?QJ\)#P=\4+. W%M):QM]EU&)02S#!95.T9#*Q1_FQM("
MGZ_JN-/M1?M?"VA%ZT0A-SY8\PQ@DA-W7;DDXZ9)HL%SB/CM\;/#G[/?PQU?
MQQXHED73;!5"00 &:YF8[8X8QW9C^ &2< $U\2>%?$W[97[8UL/%/AG5=(^"
MOP_O#OT^.= US<PD'#JQB>1^/X_W2MG*BLO_ (*T:QJWB;XH?!+X>Z=I=UXA
M@N;B749?#\$IB&IR&2.../=V;:LR@]1YI]:])M?VN/VE;*WBM[?]DV\@MX4$
M<<46J[510,!0!%@ #C%2WK8I+2YQGB[Q5^V/^QM:CQ/XFU32OC9\/[5@;];>
M'%U;0CJ[,L221\#._P#>HO5AZ_;GP/\ C5X:_:"^&ND^-O"MP\NEWZD-#,NV
M:VE4XDAD7LRGCC((P02""?E>;]KS]I>YADAF_9/O98I%*/&^JY5E(P008N01
M6=_P3!^'?Q(^%6K?%/2O%G@?5/!'A75+R'5-&T^]</%;.6E62-6_B/E^0I8@
M9$0--;@UIJ4_VA/VY]>_9V_;6O\ 0_$&MS2_#2S\."\7P_;6,#2W-X\+>4BR
M^7Y@+2;>K[1R3Q5NW\*?MH_M%6:^)I/&6B_!'1;L>;8>&X8#)>1QG#(9V\MF
M#$8SEP>N8TZ5P_Q2\"V/Q _X+#>#[+4[=;FQLM-M]4>-NA>WM998B?82K&<=
M\8K]+J2UN#TL? _PE_:;^,GP!_: T#X-_M$/8Z];^)G6'0/&&GQ!%EE9]B(Q
M5$#@N5C(**Z%E+95LU]2?M&^&/BMXL\$6-I\'_&.G>"?$R:BDMQJ&IVB7$<E
MH(I0\05XI0&+M$V=H.$//.#\G?\ !7ADT?P[\'/$,8*:CIOB?,$Z??0%%<X/
M^]$AZ]A7Z"TUU0GT9^._[-?P_P#VC=8_:<^.&G>"OB?H>@^.+&\V^)-8NM.B
MEAU&3SY!NC1K9P@WACPB=:^U?VDOV@_'W[+?[._@NQN9;+QG\9?$,\.AVUTD
M*I;37C#YY_+ C&!E0% 4;G7(QD5YG^P]_P GV_M5?]A(_P#I5-7MO[=/[,VL
M?M(?#+2QX3U)=*\;^&-076-%FD;8DDJ@@Q%_X"?E8-T#(N< DA+;0;>NIX5J
MOPW_ &Z?ACIR^-K7XD:+\0M0C03W_A#[,FV0=6CB7R8U;'.?+:-CC"[N ?NC
MP#JVN:[X)T/4?$VC)X=\075I'+?:5'<"X6UF*@M'Y@ #8/<?KUKX\^"/_!1:
M32?%%K\-OVAO#EQ\,_'L>R#^T[F(II]ZQ.T2$](@Q_C!:(\G>HP*^X58, 0<
M@\@BJ7D3*_46BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%=O^31G_ .P_9?REKZ9^ '_)!_AO_P!BUIO_ *2QUR/[7?[-O_#57PC/@?\
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M5I_$_P"#_AWXO?"_4/A_XACN)/#M]##!,EO,8Y2L4B2)AQT^:-:=MQ7V./\
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M:Q'!>9P#\IKM?!?_  27^"?AO7(]5UNY\3>-ID8-]GUW44\@[3\N1#'&S#&
M0S$''3'%?9&DZ18Z!I=IINF6=OI^G6D2P6]I:QB.*&-1A415 "@ 8 %&KW#1
M;'P5_P %$O"/B?X0_&+X;?M-^$=.;4U\*[=/UVVB^4BV+N S$=%=)YXF;'R[
MDZCI]>_!/X_>!_V@_"-MX@\%:[;ZG#)&K3V>\+=6;'K'-%G<C Y'/!ZJ2"">
M]O+.#4+.>UNH([FUG1HI8)D#I(C##*RG@@@D$'KFOCSQ]_P2E^"?B_Q!+K.C
M-X@\"7<C%S#X;ODCMP3UVI+&^P'GY4*@9Z8XHU3T'H]SUW]IG]K+P5^S/X3N
M;K6+^"_\431D:5X9MI UY>S$?(-@RR1DXS(1@=LDA3\@_P#!'^\UK4O'/[15
MWXDBD@\13ZCILNI13(4=+II=1,RLI^Z0Y;([5]*? G_@GG\'/@'X@C\0Z9I5
M[XD\20N9(-7\2W"W4T#YSO151(U?/1]FX=CUKT;X1_LX^#?@CXL\=^(O#$%Y
M%J7C2]74-6:YN3*C2B2:0% 1\@W7$G'N/2E9WN%U:QZA7-?$OP+9_$[X=^)O
M".H,4LM=TVXTZ60#)198V3>!ZC=D>X%=+15D'YS?L#_M"1_LXWVK?LW?&.YB
M\*:YH=_*=$OK^01VEQ%*QD,0D.% 9F:2-B<.)=O! !_0[4-8L-)TV74;Z]M[
M/3X4\V2[N)5CB1/[Q<G 'OFO,OCW^RW\-OVE-+@M?'/A^.^NK92MKJENYAO+
M8$Y(25>=N?X6RO.<9KYRTW_@D#\'+6ZA^V>(_'&JZ7"^^/2[K4X!!WR#L@5N
MY^Z5/N:C5:%Z/4^7_P#@I;^U1I_[0&M^'?#_ (%\[5O 7A?556^\0PH3:76I
M2JPCCC?&"$CCFPV?GW.1E5#']%?VX/\ DT;XL?\ 8 N/Y5'XS_8I^$OC/X7:
M%\/&\._V-X4T6_74[6STB8P,;A8VCWR/RTC%7.68DGC)XKU'XC> =)^*?@76
M_".NI+)H^L6K6ETL$AC<QMUPW8^]%GJ%UH>)_P#!.G_DRWX8?]>=Q_Z5S5]'
MUR7PH^&&A_!GX>Z-X+\-QSQ:'I,;16R7,IED"L[.<L>OS.:ZVJ6Q+W/@#_@F
M/_R63]JC_L:T_P#2B_K!_:D;6/V,OVV](_:$M]-GU#X?^*[9-(\1_9%^:%MB
M(P(]2(89ES@,T;KQUK[-^#O[./@WX%Z_XTUGPM!>17OBZ]&H:H;JY,JM*'E?
M* CY1F9^/IZ5WOB;PSI/C+0;[1->TVUU?1[Z,PW-C>Q"6*9#V93P?\14VT*O
MJ9?P[^)WA7XM>&;;Q!X/UZQ\0:1<*&6XLI0VTD9VNOWD8=U8!AW KP;]LK]K
M[1/@YX1U#PAX7NE\1?%G7(FT_2/#^EGS[B":0;!-*JYV!=VY5."Y  XW,O#>
M(O\ @DC\&-2UR;4=$U7Q?X/29OGL]&U./R0I.2JF6)W';JQ''2O7/@#^PY\)
M/V<&DN_"^A27>NR1&%M=U>47-X$(*L$; 6/()!\M5SG!R*>HM#P?_@C+_P F
MO^*/^QQNO_2*QK[UKS+]G_\ 9W\'_LS^#;SPQX)AO(-*N[]]2E6]N#._G-''
M&2&(X&V)./K7IM"T5@>K"OSH_P""1GC+P_X;^$?Q @U?7=-TJ>3Q3(Z1WMW'
M"S+]GB&0&(R,@\^U?HO7QM/_ ,$F_@!<322OI^O;Y&+'&K/U)SZ4.][H%;J?
M1>K_ +0'PO\ #\<KZG\1_"=@L0!?[3K=LA4'ID%^^1CUS7Q)^UY^WQ;?%S3Y
M_@O^S]%=>-/%'B7?IEWJMC WDQP.I61(&.-Q*E@TN-B)N8,>J^J67_!)[]GJ
MUE+RZ)K-XI7'ES:Q, /?Y"IS^/>OH#X2?L[_  V^!-M)%X$\':9X=>1!%+=0
M1%[J5 <[7G<M(XR,X9B,TM6/1'/_ +(O[/=O^S)\"]"\%+-'=ZFA>\U2\A7"
MSW<F"Y'JJ@+&I/)6-<U\M_\ !(__ )KI_P!C+'_[6K]":\L^!G[-G@O]G?\
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MC25D32M$L+?3;197WN(88UC0,W<[5&3WH2=[L3:M9'PA_P $H/\ D9_VB/\
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MO!?AN.>+0])C:*V2YE,L@5G9SECU^9S3ZW%TL=;7P!_P3'_Y+)^U1_V-:?\
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M2W9@0[1*B(JLP)&X@L!D;N3GZ8H7<'V/SV_X(_\ _(L?&#_L95_] :C]L?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/;
M]IK_ )2K?L^_]@=/_1M]7Z$UY9XP_9L\%^.?C5X6^*FJ07C^+?#=N+:PDBN2
MD*H&E;YH\88YF?\ 3TKU.DBFPK\]O^"N'_-"_P#L99/_ &C7Z$UY9\<_V;/!
M?[1'_"-_\)A!>3?\(_>&^L?L=R8<2';G=@?,/E'%)ZH%HSU.O@#]HC_E*]\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\N5ACC9AC PS$''3'%/4-#B/V&=(U_\ :4_:;\>?M.:[IDVD^'YXFT?PS;7
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M?'R/XPM!>?\ ":1V7]GK+]I/D>5L*8\O&,X)YKU"A S\]O\ @LE_R2_X9_\
M8R_^T&K]":\L^/W[-G@O]I31M'TOQK!>3VNE7GVZV%G<F B3:5R2!R,'I7J=
M'4+Z'P!^P]_R?;^U5_V$C_Z535]>_$;]H#X??"/Q-X9T#Q?XHL="U7Q%*T6G
MPW3%0Y4<L[8VQKDA0SD L0!S5'X<_LX^#?A9\2O&OCK08+R/7_%\WGZH\]R9
M(V;>S_(N/EY8U+\=_P!G7P'^TAX470?'.C+J$,+&2UO(6\JZM'/5HI1RN<#(
MY5L#(.!0DT@TN>/?\%)K;X=7W[*OB:Z\9G3VODMB_AR>0J;DWQQY0MS]XY.-
M^WC9N)X%=W^P^VNM^R5\+CXD:5]4_L:/F<$/Y&YOL^<\_P"I\JO'_ ?_  28
M^"7@WQ)::M?3^)/%\=FX:WTW7KV)[4 9(#)%#&7&XEMI.T]"#SG[/CC6&-41
M51% 5548  Z "A7O=@]K(=1115$A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 '7@U^6_B)?$G_!+O\ :8UCQ/9Z/=:Q\"/&
M]R&GCLT'^A.2[K$O0+)$7?8&P)(R1G<"4_4BLWQ)X:TGQAH=WHVNZ9::SI-X
MGEW%C?0+-#*OHR,""*EJY2=CEOA1\=/ 7QPT.+5?!'BC3]?MW7<T5O,!/#TX
MEA.'C/(X8#K70^+?&GA_P#HTNK^)=;T_P_I<7W[S4KI+>(>VYR!GVKX_\;_\
M$C_@IXDU;^TM!NO$G@F;?O$&D7ZO"I)SD"9'=?;#@#TK,\._\$?_ (3VVI07
MWB;Q/XN\6O%@&WNKV.&&0#.5;9'YF.?X7&.:->P].YT/@/\ X*!77QT_::T[
MP'\)O![>+/ MM&QUSQ/<%[;R 3@31[A@1K@@*XW2$X7:%RS/^"G/P5\2>./A
MSX7^(O@J%Y_%GPZU ZM%'"FZ4V_R/(Z#^)D>&)]O]U7[\'ZD^&OPI\(_!WPS
M#X>\%^'[+P[I$1S]GLX\%VZ;W<Y:1O\ :8DG'6NKHMIJ*^NAXA^R[^UKX)_:
M@\$V.I:+J5K:>(UA']I^'9)@+JTE &_"G!>//W9 ,$=<$$#IOCI^T-X&_9W\
M(76O^,];M[!8XRUMIZNK7=Z_:.&+.6)/&?NCJQ !->,_&+_@F5\$OC!XBFUX
MZ=J7@[5[B0S3W'A>Y2V660G)<Q/&\:DGDE%4D\]>:R/AO_P2H^"'@77HM9U6
M/7/'5[&PD\OQ)>));F0?Q&.*- XS_#(6'KFE[P_=.2_X)P^!_$WC_P >?$G]
MI'Q?8'2[GQS*UOHUHX^9;+S S,"0"8_W<$:DX+"$MT()^Y]8TBS\0:1?:7J-
MM'>:??026US;RC*2Q.I5T8=P02/QJQ;V\5I;Q001)#!$H2..-0JHH&  !T '
M:I*I*Q+=S\1]0^&OQ'TWXH7?[%UM<3CPK?>,4U:*^929?L'EEO-_NF/R0LQ7
MH)(SWS7[3>&O#NG>$/#NEZ%I%LEEI6F6L=G:6\8^6**-0B*/H !6%+\)O"TW
MQ6@^([Z7&WB^'2FT5-0R<BU,GF;<=,[L_-UPS#H:Z^DE8;=SXP_X*<_!7Q)X
MX^'/A?XB^"H7G\6?#K4#JT4<*;I3;_(\CH/XF1X8GV_W5?OP?8/V7?VM?!/[
M4'@FQU+1=2M;3Q&L(_M/P[),!=6DH WX4X+QY^[(!@CK@@@>WU\H?&+_ ()E
M?!+XP>(IM>.G:EX.U>XD,T]QX7N4MEED)R7,3QO&I)Y)15)//7FC6]T&EK,]
MF^.G[0W@;]G?PA=:_P",];M[!8XRUMIZNK7=Z_:.&+.6)/&?NCJQ !-?*O\
MP3A\#^)O'_CSXD_M(^+[ Z7<^.96M]&M''S+9>8&9@2 3'^[@C4G!80ENA!/
M6_#?_@E1\$/ NO1:SJL>N>.KV-A)Y?B2\22W,@_B,<4:!QG^&0L/7-?85O;Q
M6EO%!!$D,$2A(XXU"JB@8  '0 =J-6]0T2T*^L:19^(-(OM+U&VCO-/OH)+:
MYMY1E)8G4JZ,.X()'XU^*>H?#7XCZ;\4+O\ 8NMKB<>%;[QBFK17S*3+]@\L
MMYO]TQ^2%F*]!)&>^:_;BN0E^$WA:;XK0?$=]+C;Q?#I3:*FH9.1:F3S-N.F
M=V?FZX9AT-#5P3L;OAKP[IWA#P[I>A:1;)9:5IEK'9VEO&/EBBC4(BCZ  5\
MC_\ !3GX'^(OB1\*- \;>#(9)_%OP_OSJ]O%;KNF:W(4S&,=V5HH9,=Q&<9.
M!7V513:NK"3L[G@O[*/[8'@O]J+P387>G:E:6/BY(5&J>'9)0MQ;R@?.44\R
M1$Y*NN1@X.""!WOQC^.G@CX">%+CQ!XVU^UT>TC0M% [@W%TP_@AB^](Q)'
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M (5/X'_Z$WP__P""N#_XBCF8<J/S(_X?>?\ 5%__ "ZO_N*C_A]Y_P!47_\
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M (5/X'_Z$WP__P""N#_XBCF8<J/S(_X?>?\ 5%__ "ZO_N*C_A]Y_P!47_\
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M (5/X'_Z$WP__P""N#_XBCF8<J/S(_X?>?\ 5%__ "ZO_N*C_A]Y_P!47_\
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M (5/X'_Z$WP__P""N#_XBCF8<J/S(_X?>?\ 5%__ "ZO_N*C_A]Y_P!47_\
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M (5/X'_Z$WP__P""N#_XBCF8<J/S(_X?>?\ 5%__ "ZO_N*C_A]Y_P!47_\
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M (5/X'_Z$WP__P""N#_XBCF8<J/S(_X?>?\ 5%__ "ZO_N*C_A]Y_P!47_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%>1_"_\ :=\'_%SXJ^/?A]H<6IIKW@N?R-3:[MU2 MYC1_NF#DL,H>H%>N4
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M;V^9$.&&R:]1N,]<8K]%?C=_R1?Q]_V+^H?^DTE?+_\ P2&_Y,VT[_L-7_\
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M^4O'P[_[&#PM_P"CX*_8FOQV_:\_Y2\?#O\ [&#PM_Z/@H _8FBBB@#\=?\
M@ES_ ,I OB9_V#-8_P#3C;U^Q5?CK_P2Y_Y2!?$S_L&:Q_Z<;>OV*H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%$::OK&J>)+=+S[/+* _DQ1R JFS(&X#=D'!"[5 ![!\$?VM/A-^T5-/;^
M?&-IK.H6\0FFT^2*6VND7H3Y4JJS '@LH(&1SR,Z'QJ_:8^&/[.]E;W'Q!\7
MV/A][D;K>T8/-=3+G&Y((E:1ESP6V[0>I%?!?_!2KX%^'/V7;SX=_'OX4:19
M^"_$&F^((K.YM-)B%O:SDQR2HYB3"KD0R1N% #K+@YKVC]D?]DW0OB9X;MOC
MC\:=)L_'WQ&\;QKJZQZU +BSTRTE&ZW@AMY,H,1E#E@2O"KC!+ 'M'P3_;8^
M#'[0FM'1?!7C6WO=<VEUTN\@EL[B0 $DQK*J^9@ D[-Q &3BO<J_.+_@IO\
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MRR+6/^W=^TI-^R[^SWJOBC31&WB.^F32M&$BAE2ZD5CYC*>H1$D?'0E0#P:
M.I^-'[6GPD_9[E6W\>>-M/T;4&3>NFQA[F[*GH3#$K.H/9F '7G@UQWPS_X*
M'?L__%?7(=%T7X@VMMJL[A(;;5[:>P\UB0 JR3(J%B3@*&W$]J\;_8Z_X)V^
M%[7PK9_$7XUZ8OQ!^)7B-5U.[C\1$W4-GY@W"-XW^667!&]I V&^5< 9;W#X
ML?L%_ SXN^'KO3;[X?:-H-U,@6/5O#ME%87<# 85E>-0&QZ.&7 P10!\[^/O
M^4S?PU_[%*;_ -)=0K]"J_'W]G/P9XY^&/\ P5*\$>!O'>K2Z]=>&-,O=,TO
M4YN6N=-%C=R6S$\D_+(5P22NW;GY:^]OV]_VEI_V7?V>]3\1Z68_^$HU&=-*
MT82*&5+B168RE3U$<:2-R""P4'@T =9\:OVNOA%^SW,+;QUXWL-)U)EWKID*
MO=7A!&03#"K.H/9F 'O7&?#O_@HQ^SW\3M:BTG2_B':V6HS.$BAUBVGL%D)P
M %DF18\DG &[)/:O'?V/?^"<'A;3?#-M\0/C5I@\>_$GQ"O]HWEOKQ^TV]F9
M3OVM&V1+,<@NS[@#D*!@EO8_C9_P3V^"'QH\,W6GMX)TKPEJC)BVUKPW9164
M\#@85BL:A9!V*N#D=,'! !](JP900<@\@BOSK_:*_P"4P/P#_P"Q97_T/5:N
M_P#!.KXM>-/AM\4_&?[+WQ-O&OM8\*H9]!O9&+%[5=I,08\E#')%+&#RJEEZ
M!0*7[17_ "F!^ ?_ &+*_P#H>JT ?HK7FGQD_:4^&/[/UM!-\0/&6G^'&N%+
MPVLI>6YE4'!9((U:1E!XR%Q3?VE/C59_L[_ [Q;\0+R'[5_8]KNM[8GB>XD=
M8H$..0#(Z D=!D]J^,OV(_V)]-^-6@Q_'KX]Q/X]\7^+F.H6=AJ^6M8+9N(I
M'BP%<LO**<QK&8\+GH >\>$?^"F7[./C+58].@^(D.FW,C;4;5K"YLX3[F62
M,1J/]YA7TY:7<%_:PW-K-'<VTR"2*:%@R.I&0RD<$$=Q7BOQ$_8G^"'Q,\+S
M:'J/PU\.Z=$T1BAO-%TV&QNK;C ,4L2@C'! .5XY!'%?+7['.L^(_P!D/]J_
M6?V7?$VLW>O>%-4M6U;P=>7"\Q@(\K(!_"K+',& ^7S("5 WF@#[N^(WQ,\*
M_"/PI=>)?&6NV?AW0[; DO+V3:I8YPBCJ[G!PJ@L<<"O'/AC_P %!O@'\7O%
MD?AOP]X^M_[6F?R[:+4K6>Q6Z;. (WF15+'LN0QR,"OG3_@I+/HS?M-?LZ6G
MQ,9T^#KW5P^H>8S"U:Y#(/WV.-H!BR3_  -)VS7T=\3/V&?@+\<O#NFK/X)T
M;3X8VBN;35/"L,5C*\8(8*)85 >-ER,'/#94@X8 'T/7"_%CXY^ /@;HRZIX
M\\6:;X9M7!,2WDW[Z?'411+F20C/1%)K+^/?Q:TG]FGX$^(O&=S")+3P_8!;
M2S>0_OYCB.WAW')^9V12>2 2><5\6_L?_L8_\-(QQ?M _M#23>,M=\2$WFDZ
M#>2$V5O9L<Q,T>>5()*19V*A!()/R@'NVE?\%0OV:M6U)K-/B)]F.<)/=:1?
M11/]&:'C_@6*^D/"'C30/B!H%MKGAG6K#7]'N1F&^TVX2>%\=0&4D9'<=1WK
M@M4_9.^"NL:$VCW/PH\&_P!G$8$4.AVT13KRC(@96Y/S*0>3S7D'[/?[#-[^
MR_\ 'S6=?\ >-9K'X5:M:YNO!M[&URYN>0NR4L-JIP5D.Y\$H<_>H ^MJ\$^
M+O[=GP-^!^M7&C>*O'UE%K=NVR;3=/AFO9XFXRL@A1A&P!SARIKS+_@I=^T5
MXB^$?PW\.^!O <EQ%\0?B%>G2M-FL^)H(@T:RM&>TC-+%&IZCS&8$%16M^S7
M_P $W_A/\$_"=A_PD7AK2_'GC.1$EU'6-=MEO(_/QEA!'("J(&)P=N\\$G/0
M [KX0_MS? [XY:Q#H_A/Q]8SZU,=L6FW\,ME/*W]V-9D3S#@=$+5[Q7RA^TI
M_P $XOA1\<O"]S_87A_3? /C"%3)8ZUH-HEJOF@?*L\<8"R(3C)QO&.&['+_
M .":W[0GB+XL?#?Q'X'\>2W$_P 0?AWJ']D:G<77S231EI%B9V_BD4PRQL>I
M\M6))8T ?1+?''P-'\6D^&+>((1X[>U^VKHWE2>88=I;?NV[,;03][->9?%;
M_@H#\!O@WX@GT+Q#X^M7UJW<QSV6EVTU\T+#JKM"C(C \%2P8>E?!_[9FF^-
MO$G_  4ZL_"_P_U:30O$7B31;71_[3A!WVMM+"_VB52.1MA$AR.0 <$'!'WY
M\(/V&_@M\'?"MKI%CX"T76[M$ N=8UVPBO;RZ? W.TDBMM!(SL7"CL* .T^#
M/[17PW_:$TNXO_A]XML?$<5L0+B&(/%<09) ,D,BK(@.#@E0#@XS5_XO?&SP
M1\!O#=MK_CW7X?#NCW-VMC%=3Q22!IV1W5,1JQR5C<],?+7Y\_M>?"W1OV(O
MVG/@[\8?AC9Q^%=(UK5O[*U[1=/416CQEDWA(Q\JB2)I/E&%5HD8#/-?H]XV
M^'OA7XE:5%IGB[PSH_BK389A<QV>MV$5Y"DH5E$@216 8*[C=C.&([F@#\NO
MV2/VL/A-\/?VP/VBO%_B'QE:Z9X<\37YETB_DMYV6[7[1*^5"QEA\K _,!UK
M].+/XM>#K[X:P_$!?$-C#X+FM!?KK5U)Y%OY!Z.3)MV@\=<') K\[OV,O@G\
M._%'[;'[3>A:UX"\,:OHFD:B4T[3;_1[>>VLE^TRKB&-D*QC  PH' %=S_P5
M;TJT\(_!?X4Z'!IYT;X50^*+>#7+/1(?(BAM54E(UCC  7:)2!C&Y4QSB@#V
MKPS_ ,%)_P!G3Q9XLC\/V7Q&MXKJ5Q'%=7UE<VEJ[$@8\Z6-47D]6(''!Z5]
M,QR)-&LD;*Z, RLIR"#T(-?.FJ?LA_LZ_'CX16-EI7@SPS)X;O+13INN>&[>
M&&YC3'RR17*+N)R!D,6!(PX/(KVWX?\ @72/AEX)T3PIH,,D&C:/:1V=I'-*
MTKB-!@9=B23]: .@HHHH **** "BBB@ HHHH **** "BBB@ K\X/VXO^4D'[
M+W_7:U_]+C7Z/U^<'[<7_*2#]E[_ *[6O_I<: /I[]LW]D30/VMOAF^DW)BT
MWQ9IH:?0];*_-;3$<QN1R8GP P[8# 945XO^P7^UYK^H:]>? 'XTB72OBQX;
MW6UK<7[?/JL,:YVENCS*F&# GS4PXR0Q/W37R/\ MZ?L8G]H30;/QIX(D_L7
MXO>&0+C2=1MY/)>[6,[UMV<8PP;F-R?E;C(#$@ \B\&_\II/'?\ V+,?_I#9
MU:_X*R>(-5\6WGP6^"NEW,UM#XZU]5O3#U95E@BA4^HWW#/@\9C4]J\+_8%^
M*?BCXR?\%&M3\2>-;'^SO%A\-2V&IP^48F^T6T-O;NS1D#8S&+++T!) P.*^
MAO\ @J]X'U_3-'^%OQJ\-637]Y\-];6\NHD!.V%I(9$E; ^XLMNBD]O-STS@
M ^T_AK\.= ^$?@71O"'ABQ33M$TFW6VMX5 R0!R[G'S.QRS,>223WK7U[0=.
M\4Z+?:/J]E!J6EWT+6]U9W*!XYHV&&5@>H(-<M\%_C+X7^/7P[TKQEX1U"._
MTN^B5F0.#+:RX!>&50?DD4G!!^HR""=SQMXWT'X;^%=2\2^)M4MM%T/3H3/<
MWMVX1$4?S). %'))  )(% 'Y[_\ !/FSNOV>_P!M#XY?L_V]S<3>%K:(ZWIL
M5R=S1;6@V'_>:"ZC#-_%Y*GCI74_\%0O .K^!;KX>_M(>#H,^(_ 6H0PZCM&
M!-9-)E/,(YV"1FC(_NW+>E8O_!.FVU7X\?M,_&G]I*[TZ;3M"ULG1-%^T#!E
MB#Q$X[$I';6ZLPXW,P'0X^]O'W@C2?B5X)UWPIKMN+K1]9LY;&ZB/4QR*5)!
M[,,Y![$ ]J ,#3OC=X5U#X(Q?%87ZQ^$7T;^W&N6(RD B\QE(_OC!4KUW#'6
MOC__ ()E^#]5^*GBGXE?M->+;=EUGQKJ$UEHZ2-N\BQ20;PA[J&CCA4]<6Q]
M:^,CXM^)ND^#=0_8;2*>36YO&RV46I#/E_V<S^84V]1$9-ESN_N,X/%?M-\-
M?A_I7PJ^'_A[P?H<7DZ3HEC%8VXP 65% WMCJS'+$]R2: /A_P#X*Q^(M8\4
M'X-?!32+UK%/B!X@6&]D7G*I+!%"K#NOF7&_'K$M?;_PV^'/A_X2^!M'\(^%
M]/CTS0]*MUM[>",<X Y=C_$['+,QY)))ZU\7_P#!63X?^(%\)?#?XP^&+5KO
M4?AOK/VZ>-5+;(7>%Q,P'.U);>('T$A/0$U]:_ GXY>%?VAOAOI?C+PE?QW5
ME=QKY]MO!FLIL O!,H^ZZD_B,$9!!(!W-_86VJV-Q97MO%=V=Q&T4UO.@>.1
M&&&5E/!!!((-?EO^R#\&;#X _P#!53XB^"](21-%M-"N;BP60[BD$_V2=$![
MA/,V9//R<U^G?BCQ3H_@GP_?Z[K^I6NCZ/81&:ZOKR41Q1(.I9CTK\N?V+?C
M5%^T)_P5$\?^.[2*2#2]1T*ZCT])5*M]EA-K#$Q!Z%EC#$=BQH ^D_\ @J'\
M#;SXE? -/&GAU9(_&7P]N/[=L)[<?O?(4J;@*>VU46;ZP =Z]M_9@^/.G_M!
M? 'PO\0%E@@EN[/&IQAMJ6MW%\MPIS]U0RL1G^$J>]>K75K#?6LUM<Q)/;S(
MT<D4BAE=2,%2#U!!QBOQ4^)'C3QG^P_K/QT_9O\ #UG>W>G>.9X)/"DL+$M;
MPW3A'" \LTD)^SDCGS(010!]-_L?PR?M>?MJ?$7]H>_1IO"?A=SX>\)"3.S(
M0KYB@]/W3O(0>C7G'2O0?^"MGQ6U+X;_ +*,^FZ3.]O=>*]4AT2:2,X86S1R
M2S >S"(1GVD->]?LJ_ VU_9S^ OA/P-"L;7EC:B749T _?WDGSSOGN-Y*C_9
M51VKQ[_@J1\$]4^-'[*FI#0[62^U?PU?1:]%:PJ6DFCC22.95 ZD1RN^._EX
M'.* /9/V7_@+HO[.'P6\.>#-)M8HKBWMDEU.Z1</>7C*#-*QZG+9 !/RJ%4<
M 5ZMUX/(KP/]BW]IW0OVG/@KHFKVE_"WB>QM8K77M-WCSK>Z5=K.5SGRY"I9
M&Z$'&<JP'N]Y>6^G6<]U=SQVMK C22SS.$2- ,EF8\  <DF@#\KO$WP+T?X'
M_P#!7SX<#P]:BQT;Q,LFNQVL:@102R07<<R(!T7?$7V]!YF!P *_2CXM_"OP
M]\;/AUKG@KQ3:"\T75K<P2J,!XVZI*A[.C!64]BHK\Q9OVAM*_:*_P""MGPW
MU/PY,+OPQH?FZ)I]ZGW+L1V]T\LR^JF25PI'554]Z^\/VS/VIM)_90^#M[XD
MN/*N_$=[NL]"TMSS<W1'#, <^6@^9SZ87.66@#\R]2\>?&[X3QZU^Q!9:A9W
M=[J6M0Z9I?B%[L1-%IMP"YAZG:DBNCD$EE5I8P&W+M_6']G/X!^'?V:_A+HW
M@;PY&&ALT\R[O60+)?73 >;._NQ' R=JA5'"BOSXT'_@F7XI^(W[-^L_$'Q+
MJ5\G[1.N78\3V=Q-<-&\##<Z6C\@)))NW%N/+<1KP$;=]7?L"_M:-^TE\-[C
M2?$P^P?$_P *L+#7]/F3RI)64E!<A.VXJ0XP-KAA@ KD ^I:^!O^"T5E=W7[
M*V@30;C;V_BRUDN%4<!3:W:AB?3<RCZL*^^:\M_:>^"-K^T5\"O%O@&XDCMY
MM4M<V=S+G;!=1L)()#CG:)%7=CJI8=Z -WX)75E??!GP%<Z:5.G3:!826VPY
M'E&WC*8/?C%=K7YO_P#!.O\ :XC^&L#_ +.?QDD;PEXQ\-7+V.DSZL_EQSQ[
MB1:LYX#+G]VV=KHR!3PN[](* "BLOQ/XIT?P5H-[K>OZI9Z+H]E&9;F^OIEA
MAB4=V9B *\+_ &9_VV?"7[5'C3QIHOA'1=:73?#KKY6O7-MBSOD. "&ZQN6W
M%489*#=P<JH!\Q:3,MG_ ,%L-:&IX!NM#5=+WG&2-+A+;?7[D_Z^E?I+7P!_
MP4K^"OBSP[XJ\&_M*_#>%Y_$_@;8NJ6T:EC)9([.LNT?>5?,E23OY<F> A-?
M3?[,?[5/@C]J;P';:[X7U"*/5(XE_M/0II!]JT^7 W*R\%DS]V0#:P]#D  ]
MDHHKY/\ VY_VXO#_ .S3X,OM"T*^@U;XJ:G#Y&EZ-;_O7M6?Y1<3 9VA<Y5#
MR[  #&X@ \&_X)^,-4_X* _M2ZEIW.D?VA>HS(,H\C:BY5L].=DI'KFOT/\
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M^)__ &,P_P#1"U^BM 'Q1^U5^Q!XNU[XMVOQN^!'B6'P=\3X55+RUGPEKJ0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'YU?M0_\I9/V>/\ L#)_Z-OZ_16OA;]HCX4>
M,O$7_!2SX&^,M,\,ZI?^%-*TI(K_ %BWMF>UMG\R].UY ,*<.G7^\/6ONF@
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MU1R<*K$^P->D?LM:#J/A;]FOX6Z-K%E/INJV'AG3[:ZL[E"DL$J6Z*Z,IY#
M@@CVH ^-/^"9M]#X*_:8_:=\ ZNPA\3/KGVZ-9/OW,,5S<J[CV'GPL/42YK]
M'*^)/VQ_V,_&&O?$[3/CO\"M1CT7XL:6%^UV,CJD>K*J[%.Y_D#^7^[97^1T
MP"5*_-S6C?\ !1SXN>'[7^R?&G[+?C5_%,($;G1;>X-M</TR@,+%0>V&D^M
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M4)5L)Y!;:F0\D ;RV8&.,Y()RB^@K[IH **** "BBB@ HHHH **** "BBB@
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M\-:YXFU35?#^BW<J:;IMW<M)!9@73*!&A.%^48X[4 ?=-%%% !1110 4444
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MR?\ !28^-/'UK\+?C1X2G^&7Q(D86\37$;P6=W,?NILE^>%WXV EU8]&R5!
M/N6BBB@ HKXA_P""D/[;VH_LMS> =%\)S0R>)+[4(]5U&V=5;=ID3X:)L@[?
M/?*AAR!&^,'!K[#\$^,=+^(7@_1?$^AW*W>D:Q9Q7UI,O\4<B!ESZ'!Y'8Y%
M &W117YS?MAZA>?LZ_\ !0GX(?$^UN[B'0O%C+HVK0&0^22K+;R2,.G$5Q"P
M'K#F@#]&:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BO@7_@II\;?BK\-?'_ ,%?
M#'PO\7-X5N_%MS=6,K&*)XI)3+:1PLY:-R%4S-G:,X)X/%8G_#.O_!0'_HOG
M@_\ [^/_ /*V@#]%:*^$?A?\"?VW-%^(_AC4/&/QJ\+:QX3M=2MYM6T^V=C+
M<VJR*98U_P! 3YF0,!\R]>HZUTW_  5.^-GC?X#?L^^']?\  6OS>'=8N?%%
MO8RW4$4<A:!K2[=DQ(K#!:-#TS\M 'V116=X=N9;SP_I=Q,_F32VL4CL>[%
M2?SJOXTOI],\':[>6TABN;>PGEBD !*NL;$'GT(% &S17R!_P2[^-'C3X[?L
M[:KXA\=Z]-XAUF'Q'<V274T4<;+"MO;,J815& SN>F>:^OZ "BOD7_@I1^UA
MJ'[+_P &;$>%[R.T\<>(;P6^FR,BR>1#&5>>;8P(8 ;(^1UF![5[W\!/B]IO
MQZ^#WA7Q[I6$MM:LEG>$'/D3 E)HC[I(KK[[<T =_1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YV_
M'K2[O]L#_@H9X)^&K6DTWP[^&T7]L:T[Q'[/<W/R.T9)&UP3]FA(SD S8[U^
MB5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB&.9-V Y#+D8)'Z>UE^)O#&D>-/#]_H>O:;:ZOH]_$8+JQO(A)%,AZJRG@T
M8?PM^*_A#XX>";3Q/X-UFUU_0KQ=HEA/*-CYHY$/S(XSRK $9Z<UU_3@<"OR
MH^.'P#^('_!-'QO)\8/@E?W&I_#"ZN$36_#%XS2I;(6X27J6BR2$F^_&6 ).
M26_1OX%_&;0/V@/A7H'CSPV[_P!F:M"7\F;'FV\JL5DB<#^)75AZ' (X(H [
MVBBB@ K\Y?\ @K-=0V/Q*_9CN;F:.WMX?$=Q)+-*P5$436!+,3P  ,DFOT:K
M\VO^"OV@VOBCQE^SAHM^&:QU'7+RSG$;;6,<DEBC8/8X)YH ^Y?^&A/A9_T4
MOP?_ .#ZU_\ CE;?A;XF>#_'-U-;>&_%>A^(+F%/,EATO48;EXUSC<P1B0,\
M9-?)_P#PZ&_9Y_Z!WB#_ ,'#_P"%>M?LZ_L2_#+]ESQ!JNM>!;74H+[4K46=
MP;Z^:=3&'#C (X.0.: .&_;._;JB_9WU32_ G@C0F\<_%G6@OV/185>1+97.
M$>54^9V8_=B7!(!)*C&[QVS^'/\ P4,\:6B^()OB3X3\'3LHFA\/R0V^Z+('
M[MMMI*I(_P!N1N>]9_\ P3ET6+XT?M5?M ?&7Q)"M[KMEJYT[2GF^8V<<CS*
MP4'H5ABAB4]=NX=S7Z34 ?GO\)_V\OB7\&_BY8?"O]J3P[:Z#<Z@WEZ;XRLX
MQ%:SDD!6DV_NVC).#(FW82 Z#YBOZ$5\G?\ !3WX4:3\2OV1?%VH7EK&^K>&
M(UUC3;L\/ R.HE /H\1=2O0G:>JBN;\+_'CQ&O\ P2K7XB?:ICXFM_"$]K'?
M$GS1-&[VB3YZEQM$F>Y&: .6^-G[>GQ!^(GQ>N_A%^S%X:@\4ZY8N8M4\4W2
M"2TM6#;7*9(C"(>#+(2&.0JMP3D7'PQ_X*&^&;4Z]%\4/"7B6[ \R705BM@9
M,#A!NLXT!/\ LNOUKT__ ()3_"G2? /[)/A_7[>UC77/%DDVHZC=CEY LTD<
M"9_NK&H..S.Y[FOL:@#X_P#V,_V[Y?CKXDU+X:_$?P__ ,('\7=)#>=I4B/%
M'>JBYD:))/F1U'S&,EOE^968;MOU7XJ\4Z3X(\-ZEK^O:A#I6C:;;O=7=Y<-
MMCAC499C^'8<GH*_.[_@J3HD7PC^,?P/^-_AR(6/B:WU@6%]/!PUW'&4>)6
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M&_PGHMNEGI%IX;N)[2VC/RPQ3W&FW"QK[*)0H'8"@#]-Z*** /SU_P""?O\
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M _/*3]H3]J7]CB^L;[X_:7I?Q+^&\\PAO/%'A>%1/INY@ [!(HAMYZ/$NXD
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M8OV@/^"M/Q'UCQ/"M]9?#RP$>CVLW*031-#%$P4^C27$H]'8$=J +6B^'_\
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M_P#X/K7_ ..5^97P._94\!?M3?MM?M-6'CNWOKBWTC7[J>U%C=F AGO9U;)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX-_9OOO&-WX3EU227Q5>K?W_ /:-PLH$@,A'E[47:/WK<'/:@#U^OSU\??\
M*9OX:_\ 8I3?^DNH5^A5>1ZM^S%X/UC]HW1OC9<2ZF/&.DV#:;;QI<*+0Q%)
M4.Z/9DMB=^=WI0!\Z_\ !4WX0^)]:\'>!_B]X(@:X\2?#+4CJC1QIN<6VZ.0
MS;?XA%)!&Q']UG/0&OH']F/]JKP1^U)X$L];\,ZE!'JPA4ZGH,DH^U6$V!N5
MEX+)G.V0#:P]#D#V1E#*01D'@@U\;_%O_@E;\'?B-XHF\2Z#+K7PYUJ9S*[>
M&+A(K=I#G+B)U;8>>D90<=.<T ?17QH^.W@C]G_P;=>)/&^NVVD64*,T4#.#
M<7;CI'#%G=(Y/8=.I( )'YO_ /!.7XA:Y\6/^"BWQ7\9>(=-GT?4-<\+7-^E
MC<*5>"VDNM.:V7D#(\@Q8;'S#![U],_"O_@EK\(_ ?BB'Q)XENM<^)NM0,'B
M;Q5<K-;HPYSY2J _.3B0L.>F>:]J\*_LP^#O!W[0WBGXS:?)J7_"7>(]/&FW
MD<MPIM!$!;@;(P@*G_18N=Q_B]> #URBBB@#\Z_V"]5LM+_;8_:Z-Y>6]H'\
M0,%,\JINQ>W><9/-?=NK?%#P;H*EM3\6Z%IRA=Q:[U*&(;<XS\S#C-?+OQ#_
M ."4OP6^)OCSQ#XNUBZ\4KJNNW\^I7:VVHQ)$)97+OM4PDA<L<#)K#M?^".?
MP"M[A9))?%ERBYS%+JJ!6X[[8@?R/:@!G[67_!3?P9X$T.[\*?"+48?B#\2=
M1Q9V+:.AN[2UD?Y0_F)E9I!GY8XRV6QNQT/;?\$X?V6-2_9I^#-S<>*!_P 5
MSXKN%U/5E8[GME"XBMV;^)EW.S'^](PYQD^A_ _]BWX.?L\W4-_X-\&6EOK4
M:E1K-\S7=X,C#%9)"?+R#@[-H([5[?0!^=?[&'_*2C]I[_MK_P"E4=?HI7D'
MPX_9<\&_"WXS>-OB=HTNJ-XD\7;O[16ZN%>W&7#GRT" KRHZDUZ_0!^:_P"Q
M'\0M%_99_:B^-OP3\<WT?AZ35]>.I^'[S47$4-VC%RB[S\H:2)H67GDAE^]@
M']%O$7B32?".BW>L:YJ5IH^E6B&2XO;Z9888E'=G8@ ?6O)/VD/V._AC^U/8
M6Z>-M&D_M2UC,5IKFFR^1?6ZDYVA\%77))"R*R@DD#)KYMTW_@C7\,5O;?\
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MGCS6_#$NIR7GC2_&I:F+^X65!*'F?]V B[5S._!)[>E 'SC_ ,%DO^31[/\
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MX^\?Z#+JCZ[XUN6NM36\N%DA#M*\I\I0@*C<[=2>,5Z_0!YI^TU_R;;\5_\
ML4M6_P#2.6OGO_@E5X@TO3_V*_"4-UJ5G;3+>:@3'-.BL,W<F.":^M?&OA.R
M\>^#=>\,ZF95TW6K"XTVY,#!9!%-&T;[20<-M8X.#S7Q?_PYM^ G_/YXP_\
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M[$D5\X7N?V\/^"E4=K\E_P#"_P"$8)?^*&XN8W&?8F2Y4#T:.V]Z_2W5M/\
M[6TJ\LA<W%D;F%X?M-JP6:+<I&]"00&&<@X/(%>4?LU_LJ>!?V5/#^KZ3X)B
MOG&K70N[R\U.=9KB5E7:BEPJ_*OS$#'5V/>@#V*N7^*'PZT?XN?#OQ#X,U^'
MSM(UNRDLIP -RAA@.OHRG#*>Q4&NHHH _/#_ ()9_$+5_AWK/Q"_9K\:2+#X
MA\&WTUUIB-P);<R8G5,]4WLDJ]R+@GH*_0^O%M<_9,\$ZU^T9I7QM2;5M+\;
MV,"V[-87*);7:!&C_?1E"7S&^P\CA5Q@C->TT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?.O[=.M_&G0?@[87/P)CO)?&3:S"DZ
MV5E;W3_8S%,9/DG1E WB+D#/3U-=Y^S/J'CO5/@3X/NOB:LR>/);0G5EN((H
M)!+YCXRD0"+\NW[H KTZB@#!\?3:O;^!?$<N@!CKT>FW+:>(T5V^T")C%A6!
M!._;P1@]Z^7?^"??B;]I+Q%_PGO_  T)#J$7D_8/[#^W:;:6F<_:?M&W[/&F
M[I!G=G'&,9-?8%% !7Q#=>+/VJ%_;Q72HH-2_P"%"_VDBF3^RK+[/]G^R@M^
M_P#+\['G9YW9SQTK[>HH *^1?^"@7B3]HWP[9^!S^SY#J$LTTE[_ &U]ATZT
MN\*!!Y&[[1&VWDR_=QGG/05]=44 8/@&;5[CP+X<EU\,->DTVV;4!(BHWV@Q
M*9<JH !W[N ,#M7'_M,:AX[TOX$^,+KX9+,_CR*T!TE;>"*>0R^8F<)*"C?+
MN^\"*].HH ^;_P!@_7/C;X@^$.KW'QZCO(O&"Z[-':+?65O:/]A%O;E,) BJ
M1YAGY(SU&< 5](444 ?$/[-_BS]JC4_VLO%&G_$F#4D^$D<FI?V:]QI5E#"5
M6?%KB6.,2']WTRQSWR:^WJ** /BC]L[Q5^U)HGQV\'6OP7@U*3P)+8V[:LUG
MI=E<QB<W4HER\T;.I\H1\*0,<CG-?:]%% '@/[;>L_%_0_@FUS\$([J3QO\
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M]W!KZNHH X_X-W7B2]^$/@>X\9+(OC";0K&36EFC2-Q?&W0W&Y$ 53YF_(4
M#H!BJ?QXO/%VG_!?QK<^ EE;QI%I5P^CK!#'*YN@A\O:D@*L=V.&!%=Y10!\
MN_L#^(/CWX@\"^)9?C]%?1:]'J2KIPOK"VM&^S^4I.%@101OSR1FOJ*BB@#X
MH^$'BK]J2\_;8\2Z9XP@U)?@C'?:HNG/+I=E'!Y"L_V3$R1B4C&W!+9/?-?:
M]%% 'Q%^WQXL_:H\/^.O#47P!@U*709--9M1-CI5E=K]H\U@,M/&Q!V8X!Q7
MV[110!XG^V-JOQ2T7X":U=_!M+F3Q\L]J+-;2UAN9-AF02X2960_)NZCCM4/
M[&6K?%;6_@3IMU\:([J/QXUW<BX6\M(+:3RA(?*RD*J@^7'09/>O<J* "OBC
M]A3Q5^U)K_Q&\60_'>#4HO#<=CNTLWNEV5JIG\X#AH(U9CLSPQ(K[7HH *^(
MOC5XL_:HL?VU/#.F>"8-2;X*2:EI"ZB\.E64L MVDC^VYF>,R@;2^2&R.V*^
MW:* "OF/]O77OCMX?^'/AZ;X!Q7LOB1]6V7XL;&VNV^R^3(>5G1E WA.0,U]
M.44 >>_L]WOC+4?@GX,N?B&LR>-Y=-B;5UGACA<7&/GW)& BGV4 5L?%>X\0
M6?PM\8S^$Q(WBJ+1KQ])$4:R.;P0.8,*X*L?,V\,"#WXKJJ* /E']@/Q%^T)
MXA\-^+W_ &@(KZ+4H[N :5]NT^UM"8BC>9@6Z*&^;;][)KZNHHH ^(O!?BS]
MJB?]O&XTK6X-2'P%&I:@L<CZ59+;_9Q:S&V_?K'YV/.$6#NR3@'()K[=HHH
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M:DT3X[>#K7X+P:E)X$EL;=M6:STNRN8Q.;J42Y>:-G4^4(^%(&.1SFOM>B@
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MP[I_V/4/%^J?VOJLF<[Y]BK\O'"Y#OCGYI9#WP #N:\J_:F^#9_: _9]\;^
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MQ_Z<;>OV*K\=?^"7/_*0+XF?]@S6/_3C;U^Q5 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8'COP'X?\ B=X1U/PQXITJWUO0=2B\FZL;I<I(N00?4,"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%0W=Y;Z? 9KJ>.VA7@R3.%49Z<FGQ2I-&DD;K)&X#*ZG(8'H0?2@!]%%% !1
M15:ZU*TL9(8[BZAMY)CMB260*9#QPH)Y/(Z>HH LT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !15+3=:T_6?M/]GW]K??9I3!/]FF63RI!U1L$[6&1P>>:N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X[?M>?\I>/AW_V,
M'A;_ -'P5^Q-?CM^UY_REX^'?_8P>%O_ $?!0!^Q-%%% 'XZ_P#!+G_E(%\3
M/^P9K'_IQMZ_8JOQU_X)<_\ *0+XF?\ 8,UC_P!.-O7[%4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<^(VO?$J\NKY[E-0UR60_9XB $AC1Y)-H'S,2#\S,3@< >RT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?F)^W!_P %!=1^$?[97@30O#]],_AC
MP5,LGB6TM9#MOWN% EA8 X8Q0,"N>DCG/*BOO;]H;XRZ;^S]\&?%?C[4U66+
M1[,R0V[''VBX8A((O^!R,BY[ D]J_/?]D/\ 8GD^/_[)_P 4O&?CB(7'CKXH
M/-=Z5J5Y_K(/+D,L4^<942W(9FQ]Z-4QP: /U#TO5+36M,M-1L+B.[L;N%+B
MWN(CE)8W4,K*>X(((^M6J^'/^"4GQNO?&'P;U/X7^)1);>+_ (=73:;+:W)_
M??9"[",$'O$ZR0D#A0D?K7W'0 45\!?M&_M=?$WXL_'*Z^ 7[-D5NNO6.Y=?
M\73[3%8;2%E5"RLJ+&6"M)AF+G:B[@"V=#_P3=^.4UNNKW/[6OBZ/Q6Q$C&$
MWC6ZG'*!_M88K[[0,<;: /3O^"L'_)DOB_\ Z_=._P#2N*O=?V9?^3;?A1_V
M*6D_^D<5?E]^V5\:?C1\._@?XG^!GQ[M8=;U+46M;SPUXUTY5\K4HH+J-I$E
MP%&X+SDJK@@;@V]6K]0?V9?^3;?A1_V*6D_^D<5 'I=%?#__  2B^*GC#XK_
M  G\>7_C+Q+J?B:\M/$TEM;SZG<M,\40@B8(I8\+DDX]Z^X* "OSU_X*:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%$S/(?90: /D_0XVD_X+1>(&49">%U9O8?8H!_,BK'_!33_DY+]CO_L;9?\
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M/"FN>+/#\.LZKX5NC>Z-<RRR(;.8O$Y=0C $[H8C\P(^0>]=U10 5PMO\#O
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MQ,1R&P1PP/(8<@\@BN'_ &;/V:?!W[+/P['A'P='=/;27#7EW?:A(LES=SL
MI=RJJO"JJA5   Z9))]7H ^19/\ @E/^S9)JOVS_ (0J\6+.39+K5X(>H/\
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M[,5T?L)17X]_\+5_X*/?\^^O_P#A.:3_ /&*/^%J_P#!1[_GWU__ ,)S2?\
MXQ19A='["45^/?\ PM7_ (*/?\^^O_\ A.:3_P#&*/\ A:O_  4>_P"??7__
M  G-)_\ C%%F%T?L)17X]_\ "U?^"CW_ #[Z_P#^$YI/_P 8H_X6K_P4>_Y]
M]?\ _"<TG_XQ19A='["45^/?_"U?^"CW_/OK_P#X3FD__&*/^%J_\%'O^??7
M_P#PG-)_^,46871^PE%?CW_PM7_@H]_S[Z__ .$YI/\ \8H_X6K_ ,%'O^??
M7_\ PG-)_P#C%%F%T?L)17X]_P#"U?\ @H]_S[Z__P"$YI/_ ,8H_P"%J_\
M!1[_ )]]?_\ "<TG_P",46871^PE%?CW_P +5_X*/?\ /OK_ /X3FD__ !BC
M_A:O_!1[_GWU_P#\)S2?_C%%F%T?L)17X]_\+5_X*/?\^^O_ /A.:3_\8H_X
M6K_P4>_Y]]?_ /"<TG_XQ19A='["45^/?_"U?^"CW_/OK_\ X3FD_P#QBC_A
M:O\ P4>_Y]]?_P#"<TG_ .,46871^PE%?CW_ ,+5_P""CW_/OK__ (3FD_\
MQBC_ (6K_P %'O\ GWU__P )S2?_ (Q19A='["45^/?_  M7_@H]_P ^^O\
M_A.:3_\ &*/^%J_\%'O^??7_ /PG-)_^,46871^PE%?CW_PM7_@H]_S[Z_\
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M?\^^O_\ A.:3_P#&*/\ A:O_  4>_P"??7__  G-)_\ C%%F%T?L)17X]_\
M"U?^"CW_ #[Z_P#^$YI/_P 8H_X6K_P4>_Y]]?\ _"<TG_XQ19A='["45^/?
M_"U?^"CW_/OK_P#X3FD__&*/^%J_\%'O^??7_P#PG-)_^,46871^PE%?CW_P
MM7_@H]_S[Z__ .$YI/\ \8H_X6K_ ,%'O^??7_\ PG-)_P#C%%F%T?L)17X]
M_P#"U?\ @H]_S[Z__P"$YI/_ ,8H_P"%J_\ !1[_ )]]?_\ "<TG_P",4687
M1^PE%?CW_P +5_X*/?\ /OK_ /X3FD__ !BC_A:O_!1[_GWU_P#\)S2?_C%%
MF%T?L)17X]_\+5_X*/?\^^O_ /A.:3_\8H_X6K_P4>_Y]]?_ /"<TG_XQ19A
M='["45^/?_"U?^"CW_/OK_\ X3FD_P#QBC_A:O\ P4>_Y]]?_P#"<TG_ .,4
M6871^PE%?CW_ ,+5_P""CW_/OK__ (3FD_\ QBC_ (6K_P %'O\ GWU__P )
MS2?_ (Q19A='["45^/?_  M7_@H]_P ^^O\ _A.:3_\ &*/^%J_\%'O^??7_
M /PG-)_^,46871^PE%?CW_PM7_@H]_S[Z_\ ^$YI/_QBC_A:O_!1[_GWU_\
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M /A.:3_\8H_X6K_P4>_Y]]?_ /"<TG_XQ19A='["45^/?_"U?^"CW_/OK_\
MX3FD_P#QBC_A:O\ P4>_Y]]?_P#"<TG_ .,46871^PE%?CW_ ,+5_P""CW_/
MOK__ (3FD_\ QBC_ (6K_P %'O\ GWU__P )S2?_ (Q19A='["45^/?_  M7
M_@H]_P ^^O\ _A.:3_\ &*/^%J_\%'O^??7_ /PG-)_^,46871^PE%?CW_PM
M7_@H]_S[Z_\ ^$YI/_QBC_A:O_!1[_GWU_\ \)S2?_C%%F%T?L)17X]_\+5_
MX*/?\^^O_P#A.:3_ /&*/^%J_P#!1[_GWU__ ,)S2?\ XQ19A='["45^/?\
MPM7_ (*/?\^^O_\ A.:3_P#&*/\ A:O_  4>_P"??7__  G-)_\ C%%F%T?L
M)17X]_\ "U?^"CW_ #[Z_P#^$YI/_P 8H_X6K_P4>_Y]]?\ _"<TG_XQ19A=
M'["45^/?_"U?^"CW_/OK_P#X3FD__&*/^%J_\%'O^??7_P#PG-)_^,46871^
MPE%?CW_PM7_@H]_S[Z__ .$YI/\ \8H_X6K_ ,%'O^??7_\ PG-)_P#C%%F%
MT?L)17X]_P#"U?\ @H]_S[Z__P"$YI/_ ,8H_P"%J_\ !1[_ )]]?_\ "<TG
M_P",46871^PE%?CW_P +5_X*/?\ /OK_ /X3FD__ !BC_A:O_!1[_GWU_P#\
M)S2?_C%%F%T?L)17X]_\+5_X*/?\^^O_ /A.:3_\8H_X6K_P4>_Y]]?_ /"<
MTG_XQ19A='["45^/?_"U?^"CW_/OK_\ X3FD_P#QBC_A:O\ P4>_Y]]?_P#"
M<TG_ .,46871^PE%?CW_ ,+5_P""CW_/OK__ (3FD_\ QBC_ (6K_P %'O\
MGWU__P )S2?_ (Q19A='["45^/?_  M7_@H]_P ^^O\ _A.:3_\ &*/^%J_\
M%'O^??7_ /PG-)_^,46871^PE%?CW_PM7_@H]_S[Z_\ ^$YI/_QBC_A:O_!1
M[_GWU_\ \)S2?_C%%F%T?L)17X]_\+5_X*/?\^^O_P#A.:3_ /&*/^%J_P#!
M1[_GWU__ ,)S2?\ XQ19A='["45^/?\ PM7_ (*/?\^^O_\ A.:3_P#&*/\
MA:O_  4>_P"??7__  G-)_\ C%%F%T?L)17X]_\ "U?^"CW_ #[Z_P#^$YI/
M_P 8H_X6K_P4>_Y]]?\ _"<TG_XQ19A='["45^/?_"U?^"CW_/OK_P#X3FD_
M_&*/^%J_\%'O^??7_P#PG-)_^,46871^PE%?CW_PM7_@H]_S[Z__ .$YI/\
M\8H_X6K_ ,%'O^??7_\ PG-)_P#C%%F%T?L)17X]_P#"U?\ @H]_S[Z__P"$
MYI/_ ,8H_P"%J_\ !1[_ )]]?_\ "<TG_P",46871^PE%?CW_P +5_X*/?\
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M%%F%T?L)17X]_P#"U?\ @H]_S[Z__P"$YI/_ ,8H_P"%J_\ !1[_ )]]?_\
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M"45^/?\ PM7_ (*/?\^^O_\ A.:3_P#&*/\ A:O_  4>_P"??7__  G-)_\
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M_P %'O\ GWU__P )S2?_ (Q19A='["45^/?_  M7_@H]_P ^^O\ _A.:3_\
M&*/^%J_\%'O^??7_ /PG-)_^,46871^PE%?CW_PM7_@H]_S[Z_\ ^$YI/_QB
MC_A:O_!1[_GWU_\ \)S2?_C%%F%T?L)17X]_\+5_X*/?\^^O_P#A.:3_ /&*
M/^%J_P#!1[_GWU__ ,)S2?\ XQ19A='["45^/?\ PM7_ (*/?\^^O_\ A.:3
M_P#&*/\ A:O_  4>_P"??7__  G-)_\ C%%F%T?L)17X]_\ "U?^"CW_ #[Z
M_P#^$YI/_P 8H_X6K_P4>_Y]]?\ _"<TG_XQ19A='["45^/?_"U?^"CW_/OK
M_P#X3FD__&*/^%J_\%'O^??7_P#PG-)_^,46871^PE%?CW_PM7_@H]_S[Z__
M .$YI/\ \8H_X6K_ ,%'O^??7_\ PG-)_P#C%%F%T?L)17X]_P#"U?\ @H]_
MS[Z__P"$YI/_ ,8H_P"%J_\ !1[_ )]]?_\ "<TG_P",46871^PE%?CW_P +
M5_X*/?\ /OK_ /X3FD__ !BC_A:O_!1[_GWU_P#\)S2?_C%%F%T?L)17X]_\
M+5_X*/?\^^O_ /A.:3_\8H_X6K_P4>_Y]]?_ /"<TG_XQ19A='["45^/?_"U
M?^"CW_/OK_\ X3FD_P#QBC_A:O\ P4>_Y]]?_P#"<TG_ .,46871^PE%?CW_
M ,+5_P""CW_/OK__ (3FD_\ QBC_ (6K_P %'O\ GWU__P )S2?_ (Q19A='
M["45^/?_  M7_@H]_P ^^O\ _A.:3_\ &*/^%J_\%'O^??7_ /PG-)_^,468
M71^PE%?CW_PM7_@H]_S[Z_\ ^$YI/_QBC_A:O_!1[_GWU_\ \)S2?_C%%F%T
M?L)17X]_\+5_X*/?\^^O_P#A.:3_ /&*/^%J_P#!1[_GWU__ ,)S2?\ XQ19
MA='["45^/?\ PM7_ (*/?\^^O_\ A.:3_P#&*/\ A:O_  4>_P"??7__  G-
M)_\ C%%F%T?L)17X]_\ "U?^"CW_ #[Z_P#^$YI/_P 8H_X6K_P4>_Y]]?\
M_"<TG_XQ19A='["45^/?_"U?^"CW_/OK_P#X3FD__&*/^%J_\%'O^??7_P#P
MG-)_^,46871^PE%?CW_PM7_@H]_S[Z__ .$YI/\ \8H_X6K_ ,%'O^??7_\
MPG-)_P#C%%F%T?L)17X]_P#"U?\ @H]_S[Z__P"$YI/_ ,8H_P"%J_\ !1[_
M )]]?_\ "<TG_P",46871^PE%?CW_P +5_X*/?\ /OK_ /X3FD__ !BC_A:O
M_!1[_GWU_P#\)S2?_C%%F%T?L)17X]_\+5_X*/?\^^O_ /A.:3_\8H_X6K_P
M4>_Y]]?_ /"<TG_XQ19A='["45^/?_"U?^"CW_/OK_\ X3FD_P#QBC_A:O\
MP4>_Y]]?_P#"<TG_ .,46871^PE%?CW_ ,+5_P""CW_/OK__ (3FD_\ QBC_
M (6K_P %'O\ GWU__P )S2?_ (Q19A='["45^/?_  M7_@H]_P ^^O\ _A.:
M3_\ &*/^%J_\%'O^??7_ /PG-)_^,46871^PE%?CW_PM7_@H]_S[Z_\ ^$YI
M/_QBC_A:O_!1[_GWU_\ \)S2?_C%%F%T?L)17X]_\+5_X*/?\^^O_P#A.:3_
M /&*/^%J_P#!1[_GWU__ ,)S2?\ XQ19A='["45^/?\ PM7_ (*/?\^^O_\
MA.:3_P#&*/\ A:O_  4>_P"??7__  G-)_\ C%%F%T?L)17X]_\ "U?^"CW_
M #[Z_P#^$YI/_P 8H_X6K_P4>_Y]]?\ _"<TG_XQ19A='["45^/?_"U?^"CW
M_/OK_P#X3FD__&*/^%J_\%'O^??7_P#PG-)_^,46871^PE%?CW_PM7_@H]_S
M[Z__ .$YI/\ \8H_X6K_ ,%'O^??7_\ PG-)_P#C%%F%T?L)17X]_P#"U?\
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M%F%T?L)17X]_\+5_X*/?\^^O_P#A.:3_ /&*/^%J_P#!1[_GWU__ ,)S2?\
MXQ19A='["45^/?\ PM7_ (*/?\^^O_\ A.:3_P#&*/\ A:O_  4>_P"??7__
M  G-)_\ C%%F%T?L)17X]_\ "U?^"CW_ #[Z_P#^$YI/_P 8H_X6K_P4>_Y]
M]?\ _"<TG_XQ19A='["45^/?_"U?^"CW_/OK_P#X3FD__&*/^%J_\%'O^??7
M_P#PG-)_^,46871^PE%?CW_PM7_@H]_S[Z__ .$YI/\ \8H_X6K_ ,%'O^??
M7_\ PG-)_P#C%%F%T?L)17X]_P#"U?\ @H]_S[Z__P"$YI/_ ,8H_P"%J_\
M!1[_ )]]?_\ "<TG_P",46871^PE%?CW_P +5_X*/?\ /OK_ /X3FD__ !BC
M_A:O_!1[_GWU_P#\)S2?_C%%F%T?L)17X]_\+5_X*/?\^^O_ /A.:3_\8H_X
M6K_P4>_Y]]?_ /"<TG_XQ19A='["45^/?_"U?^"CW_/OK_\ X3FD_P#QBC_A
M:O\ P4>_Y]]?_P#"<TG_ .,46871^PE%?CW_ ,+5_P""CW_/OK__ (3FD_\
MQBC_ (6K_P %'O\ GWU__P )S2?_ (Q19A='["45^/?_  M7_@H]_P ^^O\
M_A.:3_\ &*/^%J_\%'O^??7_ /PG-)_^,46871^PE%?CW_PM7_@H]_S[Z_\
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M?\^^O_\ A.:3_P#&*/\ A:O_  4>_P"??7__  G-)_\ C%%F%T?L)17X]_\
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M /PG-)_^,46871^PE%?CW_PM7_@H]_S[Z_\ ^$YI/_QBC_A:O_!1[_GWU_\
M\)S2?_C%%F%T?L)7X[?M>?\ *7CX=_\ 8P>%O_1\%2_\+5_X*/?\^^O_ /A.
M:3_\8KP?2]:^*NO?\% /A3>?&9;E/';>*_#ZW N[2"VD\H7< BRD*J@^7'0<
M]Z+,+G[^4444AGXV?\$R?^3_ #XE_P#8.UC_ -.%O7Z\5^0__!,G_D_SXE_]
M@[6/_3A;U^O%;PV,)[A1116AF%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5^1/[5W_ "EP^'7_ &,/A?\
M]'P5^NU?D3^U=_REP^'7_8P^%_\ T?!6<]C2&Y^R-%%%8&Y^-G_!,G_D_P ^
M)?\ V#M8_P#3A;U^O%?D/_P3)_Y/\^)?_8.UC_TX6]?KQ6\-C">X4445H9A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;3:;9:3)9SW&E>2S2E[5]R)#(& 1'Q\PQQESSNP!B1]=T444Q!1110 4444
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M2W.K:E>:I<KXNN8UFO9WF<*+.R(4%B3C))Q[FE?6P[:7/N:BBBF(***_//\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.J6[2J#Y<]O&9HV4]FRFWC^\1WI..F@U+74YO_@FO_R9+\,_^N-[_P"E]Q7
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_(G]J[_E+A\.O^QA\+_\
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MVO-OACX%^/\ XC_;R\+?&'Q%\('\!Z=<0-IVO&PU""6&>,P21B60>86./W'
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MD\+RZKX.OY!>6@47^CWJB.[LV;IO4$AE.#AU)4X(SD$#D?\ @HM_R9;\3_\
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M8HS1LP#893@G.&'K7OG_  ZM_9S_ .A2O_\ P=7?_P <KY<\<?L]^"/V</\
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M%'+/@X&!@D@'Y5\+?#S]L[]IZQ7Q1K_Q'A^"^AWV);+1-/MVBN8XSR"44"0
M\?ZV7=R> *7X]:9#\8O^"JWPK\'>(%^T>'/#VD?VE#8S<QRS*D]QNVG@Y>.
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MX^V;_*\G&4;;LVR^F=_M7SAX#_Y3%?$?_L5(O_2:PK[_ *:!]#\</V _A/\
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M^U/\'+?PZ=<?XH^$?[,$7G><NLP,Q7T"!MQ;MM W9XQGBOB_X/\ BH_MN?\
M!1"#XI:!8W(^&_P[TPV-IJ%Q$8A=2E9@AP>0S//)(%X(2)-P!.*]O7_@EI^S
MDNI?:O\ A#+QHMV?L9UJ\\KKG'^MW8[?>[5]*^"/ ?AWX:^'+;0/"NB6/A_1
MK;/E66GP+%&">K8'5B>2QY)ZFC5[CNEL?%'_  6:_P"37_"__8XVO_I%?5]P
M^%?^17T?_KSA_P#0!7/?%KX+^"_CIX<MM!\=Z##XATBWNUOHK6:62,+,J.BO
ME&4Y"R..N/FKL;6WCL[>*WA79#$@1%'90, ?E1UN*^ECX$_:?_Y2@_LZ_P#8
M-;_T.[K[ ^.WQL\._L\_#/5/''B@7CZ58&-#%8P^;-*[L%1%&0!DD<L0!ZU/
MXB^"?@CQ;\1M!\>ZOH$-[XNT*/RM-U1I9 ]NN6. H8*>7?J#UKK-8T;3_$6E
M7>F:K8V^I:;=QM#<6=Y$LL,R$8*NC A@1V(H"^QY##^UW\#?$?PYN/$LOQ$\
M,S>'9+4M<V]U>1><$9>8I+9CYF\@D>65R<X .:^<_P#@DOI-Q_PB7Q8\1:;9
M7.E^ M;\3O+X=L[@8"1)O#%?7"M#&2.,Q$9X./3KS_@F+^SG>^(#JC^!7C#,
M7:QAU6[CMBQQSL$F0/\ 9! YZ5],>'_#VE^$]%LM'T73[;2=*LHQ#;65G$L4
M4*#HJJHP!1K?4+JUD:%?'7_!5WPCK/BK]D749-'AFN$TG5+74KZ.%=Q-J@D1
MV(_NJ9$<GL$)Z U]BU%=6L-]:S6US#'<6\R&.2&50R.I&"K \$$'&#3>JL):
M,^=OV7?VK/A+XY^!OA66P\6:%X??2]*M[2\T?4+Z*UEL&BB5&4H[ ^6"/E<?
M*1CG.0/GG]O/]L+X4?%;P9<?"+P=HT?QE\7ZO*L5A_9 ::WL+GD)-%-'DRRC
M/"Q$J06#-C*GV3QC_P $O?V?/&&M3ZG_ ,(I=:)+.[220Z/J$L$!8_W8R2J#
M_90*.>E>M?!7]EGX6_L]Q/\ \(+X0LM(O)%V2ZC(6N+N0=P9I"S@'KM!"^U3
MKL5IN?DW\'/AY:?LF?M(>$1^U'X0N[C2KJPB_L6^N[@7=CI[@KM+J-RR+"3M
M:,'$9(;:P*FOVTL[RWU"S@NK2:.YM9XUEAFA<.DB,,JRL."""""*Y+XJ?!OP
M5\;O#L>A>.?#MIXCTN.9;B.&ZW QR $!D=2&4X)'!&02#Q6GX!\ Z%\,/"=A
MX9\,V3:;H=@I2ULS/),(5))VJ9&9@N2<#.!VII6$W<Z"OA+_ (*I?&+4+/P/
MX:^"_A-GN/%WQ O8H)+6#_6?8Q(%5..1YLVQ1ZJDH-?=M>>ZI^S_ /#[6_BM
M8?$K4/#5O>>-[!%CM=6FEE9H5"LH"H6V# =L?+P3GKS3>J!:,3]G[X.:;\ ?
M@[X7\":7MDBTFT"3W"C'VBX8EYI3_O2,QQV! [5Z'110(_.']OWP_J'[,O[2
MWPY_:8\-VA:Q>Y32_$<,(QYI",F6]Y+??&">%:%#U(KZ,_;,^!T'[87[,,EE
MX7NK>\U%E@\0>'KK?B*X<1DJNX]!)%(Z@G !92>!7MOQ&^&WAGXM^$;WPOXO
MTB'7-!O"AGLYRRJQ1PZG*D,"&4'((JSX)\$Z+\.?"FF^&O#MD--T338O)M+0
M2/((DR2%#.2V!DXR>.G2E;<=]CY#_8]_;]\,>)/"]EX!^+&IIX$^)WA]!IMZ
MGB%OLD=ZT0V>9YDA 64A1O1R"6)*Y!P/=/BI^V#\'_@_X?GU77O'>CS,B%HM
M/TR[CN[RX.,A8XHV).<CDX49&2!S3_C3^R+\)/V@KI;WQMX-L]1U15"C4[=W
MM;LJ,8#2Q,K. !@!L@9.,5Q_PU_X)W_ 3X6ZU!J^F>!X=0U.!@\,^M7,MZ(V
M!R&6.1C&&!Q@[<C Q1J/0^(_@'\0O%WQ<_X*B>#/'/BS1;CPZGB#3+N]T73;
MK[\6F?8;J.W..HW"-GR<;BQ8#:PK[@_;W_9QN_VE_P!GW4-#T8*?%&E7":OI
M"LP42SQJRM"6/3?&[J,D#=L).!7JM[\$_!&H_%:P^)=SH$,OCBPMC9VVL&60
M21PE74H%#;",2R#E<_-7<4E'2S$WK='QE^R/_P % _"7CGPK:>$?BCJT/@3X
MG:*O]GZE;>(6^QI=R1C:9%>3 5SM^:-B&#YP",5ZY\7OVU/@Y\&?#5QJNK>.
M-)U.=$+0:5HMW%>7ERV,A5C1CC.1\SE5&>2*O?&C]D#X1?M 7@O_ !KX,L]0
MU8*%_M2V>2UNR!T#2Q,K. . 'R!VKBOA]_P3B_9_^'.L0ZI9^!8]5OH6#1/K
M5U+>QH020?*=C&3TY*GH/>GJ/W3Q[]@?X?>+OC!\9O&O[3_C[39-(D\11&R\
M.:;-G*6AV#S0" =HCCCC5N-^9&Q@@G/_ &A/^4N7P(_[%I?_ $/5*_0>-%C1
M410B*,!5& !Z"N'UWX'^!O$WQ1T7XC:GX?AN_&NC6_V6PU9I9 \$69#M"A@I
M_P!=+U4_>/M2MH'-J9'[3GP5@_:$^!?BWP)+(EO<:G:YL[B3[L-U&PDA<]PN
M]%#8YVEAWKY._8A_;0TCX=>&X/@?\;;M/ /C;P?G2[>XULBWM9[6, 1(TQ.Q
M&5<*"Q"N@0JS%C7Z!5Y;\9_V8/A?^T%#&/'?A"QUJZB3RXK\;H+N)>P6:,J^
M >=I)7/:FUU0D^C*WC_]K3X._#/09=6USXC>'5A2/S4M[/4(KJYG'&/*AC9G
M?.1T&.<D@<UXI^Q_^T)\5?VHOB]XO\:BQ_X1_P"!<,(LM&L=0M%^TW4ZG_6I
M(,')RQ?ED7Y$7)#-6YX9_P""8?[._AG5DU >"I=4DCD\R.'4]2N)X5/& 8]X
M5P,='##GG/%?4=C8VVEV4%G96\5I:6Z+%#;P($CC0# 55'  '  HUZAIT/%_
MB)^V3\+_ (3_ !FTWX:^+=;;0=7OK'[<-0OH_*T^(%B$22=B K-M8@GY1MP6
M!(!^8O\ @J5\6_AA\0/@CIG@[1=5TKQGX_U#5+5M#MM#GCO)[<EP'?,9;:'4
M^6%SEV9< [21]C_&7]GGX=_M Z1#IWCWPO9Z_'!G[/<2;HKBWSU\N9"KJ#QD
M X.!D'%<+\'?V$/@G\"_$L?B+PQX/3^WH2WD:AJ5U+=O;Y/6,2,51AT#!=V,
M\\FAW>@U9:ESXG? &[^-O[)/_"LO$=X%U^YT&T@?4)OG\O488XV65B,DCSH_
MFQR5+#O7S+^QC^V=9?!?28O@1\>7?P+XL\*M]@L=2U;*6MQ; _ND>7[J[5X2
M0XC:,(0V>OZ&UYU\7OV=_AO\>K&*V\>^$-/\1>2NR&XF5H[F%<YVI/&5D09.
M<!@*+=4)/HQ^L_M#_"WP_HYU74/B-X5M=/"EA<-K%N5;!P0N'^8YXP,G->+?
M G]N)OVD?CWJWACP'X-N]4^&^F6I-QXTG=K=5N!D@"-EY5^ JY#\%B  <0Z3
M_P $M_V=-+U);MO!MU?!6#K;W>KW31# Z8$@R,\X)/Y<5]+^#_!>@?#WP_:Z
M%X9T:QT#1[88AL=.MUAB3/4[5 &2>2>I/)HU#0^4O^"DOP$\1_$3P/X7^(O@
M*"2?QW\.[_\ M6TA@CWRS0!D=PBX^=T>**0+W"N "6 /7?LW_M^?"SX[>$;"
M6]\3:7X2\6B-([_0M9NDM7$^/F\@R,!*A(."I+ 8W!3Q7TS7S]\6/V"?@;\9
MM9GUC7_ ]O#K,[%YK_2IY;*25CG+.(F"NQ/.YE))'7K19WN@NK69E_M _P#!
M0#X1_ SPW=30>)M.\8^)2K+9Z#H-XEU+)+CY1*\9985R1DMSC[JL>*U?V)]>
M^,'B[X/CQ%\8W@BUC5[N2\TZQ6R%M/:V;\HLH&.>3M4C<%"[B23A/A#^P7\$
M/@GKUOKOASP7%)KEN0T&HZI<RWDD+ ?>19&*(W4[E4'GK7T#1KU#3H?G_>J&
M_P""QE@2 2OA4D>W^BO7Z 5P[?!/P1)\5D^);:!"?'"6WV-=8\V3S!#M*[-N
M[9C:2/NYKN*%H#9^>W_!9+_DE_PS_P"QE_\ :#5^A-<+\6/@=X&^.6FZ=8>.
M?#\/B"TT^X^U6L4TLD8BEP5W#8RD\$]:[JCJ%]+'P!^P]_R?;^U5_P!A(_\
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M<^'.J? >QL+N?3M0^(<M_;MX>BM662]56<><PV_,(FCR.?E+&/J0,?3OQ_\
MV4?AI^TQ8VT7CG0%N[ZU0QVNK6DA@O(%))VK(OWER2=CAER2<9KS?X+_ /!-
MCX*?!'Q=:^)M.TO4?$&LV<GG6<WB"Z6X6UD#95TC5$3<O&UF!(P"#GFD[O0:
MLM3W[X66^KV?PQ\(0>('>37XM'LTU!Y,[FN1 @E)SSG?NKJ**BNK9+RUFMY"
MPCE1HVV,5.",'!'0U9!\!?\ !*AO^$NU[]H+XB-^\/B/Q3\LQYSAIYS@_P#;
MTOZ5]*_ME? ./]I#]GWQ+X1BC0ZTL8O]'D?'R7L66C&3T#C=&3V61JZCX&_
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M/K9T?4?"UY<2>;<1^';M;>"5L@D^4Z.B9Z$(%')/7FEJD/1L\7^&DWAC7_\
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MM)+'0-+61;6WDF>9D#R-(V7<EC\SL>3WKJZ%L#"BBBF(**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \CT
M']F#P=H/[0&M?&3S=3U'QGJEK]C+WURKV]K%M1<0QA!L^6,+G)X+?WC7KE%%
M(84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% ''?&#XHZ7\%?AMKGC;6X;FXTG1XEFN8[-
M0TNPR*A*@D D;LXSVK:\(^+='\>>&=,\0^']0AU71=2@6YM+RW;*2QL,@CT/
M8@\@@@X(KQ'_ (*"?\F:_%+_ +!J_P#H^.OS_P#V&_VCO%G['T'@VR^(B2M\
M&/'Z/=:7J@)DCTR<2M'(P..!O7]Y'V#+(N>0T.5G8M1NC]A:\@_:B_:6T+]E
M7X=VOC#Q#I>H:O8W&HQZ:L&F"/S0[QR.&.]E&,1'OGD5ZU:W4-]:PW-M-'<6
M\R"2.:)@R.I&0RD<$$'.17PS_P %CO\ DU?1O^QKM/\ TFNZ;T0EN?;^BZI'
MK>CV&HQ(T<5Y!'<(KXW .H8 X[\U<KDO#NL0>'?A/I>JW0<VMCHD5U*(QEMB
M0!FP.YP#6%^S_P#'[PQ^TI\/QXQ\)1W\>DF[DL]NI0K%+YB;=WRJS#'S#O3$
M>E445Y)X*_:=\'^/?CMXM^$NF1:FOBGPS;FZOGGMU6V*!HE^1PY).9DZJ.]
M'K=%>06/[47@VZ_:'N_@O<1:GIGC.&U-Y!]MMU2UO8]BR?N) Y+G86;H/]6X
MZKBO7Z "BO)?VB?VG/!G[,6@Z/J?B\ZA/_:]Y]ALK+2K<3W,S[2Q(0LORCY0
M3GJZC'->JVLS7%K#*T,ENTB!C#+C>A(SM;!(R.G!(H EHKYQ_:!_;_\ @_\
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MP'_P4L^-'Q2T-M9\(_LV7_B32EF:W-YIM[/-$)% +)N6WQD!AQ[BON7XU?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJNO%7[42_MT+I<4&I?\ "BO[113)_9=GY'V?[*"W[[R_.QYN>=V<\=*^U:*
M05\F_M\>(_VA_#]GX)/P"BOY9I9+S^V?L.G6MWA0(?(W>>C;>3+]W&><]!7U
ME10]01A> YM6N/ _AV77@PUU].MVOPZ*C?:#$IERJ@ '?NX QZ5R/[25]XYT
MSX&^+KKX:K,_CF.U!TI;>".:0R^8F<)("C?+N^\#7I=% 'SK^PQK?QIU[X2Z
MM<?'6.\B\7+KDT=J+VRM[5_L0M[<IA($52/,,W)&>HS@"OHJBB@#XJ_9U\5?
MM1:E^U9XGL/B-!J2?"B-]2_LUKC2[.&(JLV+7$L<8D/R=,MSWS7VK110M /C
M#]L;Q1^T[HOQP\(6OP;AU&3P-+8V[:LUIIEG<QB8W,@DR\T;.I\H1\*0.XYK
M[/HHH \&_;2UCXN:'\%VN?@I'=2>-?[1@4+9VD%R_P!G(?S/DF5EQ]WG&:W?
MV3]2^(VK_L_^%KOXM)<1_$&3[5_::W5M%;R#%W,(<QQ*J#]R(N@&1@GDFO7*
M*.MPZ6*FL-<II-ZUGG[6(',. "=^T[>#QUQ7R#^P;XH_:9\0>(O%J?'N'48M
M.CM8#I7V[3+.T!E+MYF#!&I;Y=OWLU]DT4 %?&'CKQ1^T[;_ +<>GZ7H4.HG
MX&-?6*SR)IEF\'DFWC-Q^^:,S >87R0V1T'%?9]% (*^6/V\O$'Q_P##_AWP
MD_P$BOI=1DNIQJOV&PM;LB((OEY$Z,%^;=]W%?4]%#!'(_!^Y\1WGPE\$W'C
M 2+XNET.QDUD2QI&XO3;H9]R( JGS-^0H '0#%5/CI>>++#X-^,[GP(LK>,H
MM*N'TA88DE<W00^7M1P58[L<,"*[FB@#YD_81U[X[:_X'\22_'F*]BUV/457
M3Q>V-M:-]G\I2<+ B@C?GDC-?3=%% ,^,/A)XH_:=O/VT/$>F^+H=17X*QWV
MIKI[RZ99QP>2I?[)B9(Q*1C;@ELGOFOL^BBA: ?%?[=WBK]J+0/''AN+X#0:
ME+H4FG,VH&RTNSNU^T>:P&6GC8@[,< XK[4HHH \8_:^U3XGZ-\"=9NO@^ES
M)X\6>V%FMK:PW$FPS()<),K(?DW=1QVJ']CK5OBGK7P-TZZ^,B7,?CEKJY%P
MMW:PVTGE"0^5E(55!\N.@Y[U[;11UN'2P5\8?L.^*/VG=>^(GBN'XYPZC%X=
MCL=VEF\TRSM5,WG <-!&K,=F>"2*^SZ* "OBOXS>*OVHK']LSPUIO@R#4F^#
M$FHZ2NHO#I=G)#]G:2/[9F9XS*!M+Y(;([8K[4HH>H(*^:OV[->^.6@?#O0)
MO@1%>2^(GU79?"RL;:Z;[+Y,AY6=&4#>$Y S7TK10!P'P!O/&&H?!?P=<_$!
M94\:RZ=$VK+/#'"XN,?/E(P$4^R@"M?XJ7&OVGPQ\7S^%0[>*(]'O'TD11K(
MQO! Y@PK@JQ\S;PP(/?BNHHH ^6/V#?$'Q_\0>'?%K_'N*^BU&.Z@&E?;K"U
MM"8BC>9@0(H;YMOWLU]3T44(&?%?@WQ5^U%-^W1<:7K4&I#X%#4;]8Y'TNS6
M#[.+68V_[]8_.QYHBP=V2>#P37VI110@9\>?MZ^)OVE?#^K>#E^ <.H2VDL%
MT=7^PZ;:78#AH_*W&>-BO!D^[C/>OK+PW)>R>'=+?4@PU%K6(W.Y0I\W8-^0
M.!\V>E:-% 'E/[4VH_$+2?@+XKN_A6D[^/HT@_LM;:WBGD+&XB$F$E5D;]T9
M.H/KUQ7.?L6ZQ\7-<^"ZW/QKCNH_&O\ :,ZE;RT@MG^S@)Y?R0JJX^]SC->\
MT4=;ATL%?%?['GBK]J+6OCYXKM/C'!J4?@"/3KMM,:[TNSMHS<"Z@$.'AC5V
M/DF7@D@C)/(%?:E% !7Q5^T]XJ_:BTO]ISPO8_"^#4G^&$B6']I-;:79SQ!C
M<,+C,DL;2#]WMS@C'48-?:M%#!.P5\]_MP:U\9-!^$%C<? V.[E\8-K$*3K9
MV=O=/]C,4Q?Y)T90-XBYQGIZFOH2B@#S3]FV^\<ZG\#?"-U\2EF3QS):DZJM
MQ!'#()?,?&4C 1?EV_= KKO'DVK6_@?Q%+H(8ZZFG7#6 1%=OM B8Q85@03O
MV\$8]:W:* /D?]@7Q)^T9X@_X3K_ (7_  ZA%Y/V#^Q/MVG6EIG/VC[1M\A%
MW=(,[LXXQU-?7%%%"T!ZGQ5=>*OVHE_;H72XH-2_X45_:**9/[+L_(^S_906
M_?>7YV/-SSNSGCI7VK110!\F_M\>(_VA_#]GX)/P"BOY9I9+S^V?L.G6MWA0
M(?(W>>C;>3+]W&><]!7TKX#FU:X\#^'9=>##77TZW:_#HJ-]H,2F7*J  =^[
M@#'I6[10!YI^TE?>.=,^!OBZZ^&JS/XYCM0=*6W@CFD,OF)G"2 HWR[OO UP
M'[#&M_&G7OA+JUQ\=8[R+Q<NN31VHO;*WM7^Q"WMRF$@15(\PS<D9ZC. *^B
MJ*.MPZ6"OBK]G7Q5^U%J7[5GB>P^(T&I)\*(WU+^S6N-+LX8BJS8M<2QQB0_
M)TRW/?-?:M% !7QA^V-XH_:=T7XX>$+7X-PZC)X&EL;=M6:TTRSN8Q,;F029
M>:-G4^4(^%('<<U]GT4/4%H%>#?MI:Q\7-#^"[7/P4CNI/&O]HP*%L[2"Y?[
M.0_F?),K+C[O.,U[S10!Y'^R?J7Q&U?]G_PM=_%I+B/X@R?:O[36ZMHK>08N
MYA#F.)50?N1%T R,$\DUZCK#7*:3>M9Y^UB!S#@ G?M.W@\=<5;HH ^-OV#?
M%'[3/B#Q%XM3X]PZC%IT=K =*^W:99V@,I=O,P8(U+?+M^]FOLFBBA: ]3XP
M\=>*/VG;?]N/3]+T*'43\#&OK%9Y$TRS>#R3;QFX_?-&9@/,+Y(;(Z#BOL^B
MB@#Y8_;R\0?'_P /^'?"3_ 2*^EU&2ZG&J_8;"UNR(@B^7D3HP7YMWW<5[S\
M'[GQ'>?"7P3<>,!(OBZ70[&361+&D;B]-NAGW(@"J?,WY"@ = ,5UU%'6X=#
MAOCI>>++#X-^,[GP(LK>,HM*N'TA88DE<W00^7M1P58[L<,"*\=_81U[X[:_
MX'\22_'F*]BUV/4573Q>V-M:-]G\I2<+ B@C?GDC-?3=% 7TL%?&'PD\4?M.
MWG[:'B/3?%T.HK\%8[[4UT]Y=,LXX/)4O]DQ,D8E(QMP2V3WS7V?10 5\5_M
MW>*OVHM \<>&XO@-!J4NA2:<S:@;+2[.[7[1YK 9:>-B#LQP#BOM2BAZ@M K
MQC]K[5/B?HWP)UFZ^#Z7,GCQ9[86:VMK#<2;#,@EPDRLA^3=U'':O9Z* /$O
MV.M6^*>M? W3KKXR)<Q^.6NKD7"W=K#;2>4)#Y64A54'RXZ#GO7MM%% 'QA^
MP[XH_:=U[XB>*X?CG#J,7AV.QW:6;S3+.U4S><!PT$:LQV9X)(K[/HHH6@,^
M*_C-XJ_:BL?VS/#6F^#(-2;X,2:CI*ZB\.EV<D/V=I(_MF9GC,H&TODALCMB
MOM2BB@#YJ_;LU[XY:!\.] F^!$5Y+XB?5=E\+*QMKIOLODR'E9T90-X3D#->
MK? &\\8:A\%_!US\0%E3QK+IT3:LL\,<+BXQ\^4C 13[* *[^BCK<#E_BI<:
M_:?#'Q?/X5#MXHCT>\?21%&LC&\$#F#"N"K'S-O# @]^*\ _8-\0?'_Q!X=\
M6O\ 'N*^BU&.Z@&E?;K"UM"8BC>9@0(H;YMOWLU]3T4!T"OBOP;XJ_:BF_;H
MN-+UJ#4A\"AJ-^L<CZ79K!]G%K,;?]^L?G8\T18.[)/!X)K[4HH *^//V]?$
MW[2OA_5O!R_ .'4);26"Z.K_ &'3;2[ <-'Y6XSQL5X,GW<9[U]AT4/4%H9W
MAN2]D\.Z6^I!AJ+6L1N=RA3YNP;\@<#YL]*\Z_:FU'XA:3\!?%=W\*TG?Q]&
MD']EK;6\4\A8W$0DPDJLC?NC)U!]>N*]6HH \&_8MUCXN:Y\%UN?C7'=1^-?
M[1G4K>6D%L_V<!/+^2%57'WN<9KWFBB@#XK_ &//%7[46M?'SQ7:?&.#4H_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6&1P-ZO@ 8%%^C"W5'F'_!8+_DTZT_[&6S_]%7%?6_PI_P"27^#_ /L#6?\
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M2WO_ !!:G4]=^/OCO4/&S(7_ +7:<M"DI4 D1LY?;VP)!Q@<8K3_ &)?C?\
M$7PW\:O&?[.GQ>U1O$'B/P[!]MTC7Y6+27EL"A(>0_-)E)8Y%+98 2!B=H +
M]PMV/N&BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZQ]"V?JRBAZ@G8R?".GSZ3X4T6QN5"7-M90PRJ"" RQJ",CKR*^%?BA^R/\
M&7X _&S7OBM^S5?6-Y:^()#/J_@O4'6.*60MO8*'94="Q=A\\;IN*J2&(K]
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M%K>X_P#0%_*OO^O@#QY_RF*^''_8J2_^DU_52)CU/O\ HHHJB0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ _\
M@JMK/B:WOO@EHGAOQ5JWA1]=UNXL)KK2[J6$X<VR*S!'7?MWD@$^O(S6=/\
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M/B3)\)]$/Q:BTV+QSL87JZ6P,> 3L+;?D\PKC=L^7/3BO1:8@HHHIB"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"/WRG^&NM\-_MT?'7PCX=TS0](_8]\5V6E:;;1V=I;1V>H[8HHU"HH_T3H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^1/[5W_*7#X=?
M]C#X7_\ 1\%?KM7Y$_M7?\I</AU_V,/A?_T?!6<]C2&Y^R-%%%8&Y^-G_!,G
M_D_SXE_]@[6/_3A;U^O%?D/_ ,$R?^3_ #XE_P#8.UC_ -.%O7Z\5O#8PGN%
M%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GGQ?_9]^'WQ\M],
MM_'WAJ#Q'#ICR/:+/-+'Y3.%#D>6ZYR%7KZ5YO;_ /!/#]G6WF25/A?II93D
M"2YN77\092#^-?1=%*R'=G/^!_A[X8^&>AIHWA/0--\.:4K&06>F6R01ECU8
MA0,D^IYKH***8CQSXT?L@_"/]H"[%]XU\&6>H:J%"C5+=WM;L@= TL3*S@=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<I\3OA7X6^,GA27PSXRTE=;T*:5)I+*2:2-79#E22C*3
M@\XSC('I75T4#,GPEX3TCP)X9TSP]H%A%I>BZ9;I:VEG #LBC48 &>3]222>
M22:UJ**!!7G_ (#^ ?@'X8^,/$/BGPMX<AT77/$#M)JES;S2[;EFD,A9HRY0
M'<S$848W'& 37H%%(9SWCSX>>&?BAX;N- \6Z%8^(=&GY>SOX1(F[!PRYY5A
MDX88([&OF[_AUK^SG_:WVW_A#+OR]V[['_;-WY/7./\ 6;L=L;NE?65%%D%V
M><:A^SE\--3^%S?#B7P;IL7@AG21M%M4:WA9U8.')C*L6W*"6)R<<YKM_#^@
MV'A70=-T72K9;/2]-MHK.TMU)(BAC0(B DDD!5 Y.>*T** .'^+'P1\"?'/0
M4T?QWX8L?$EC&2T/VI")8"< F*52'C)P,E&!.*\*T7_@E[^SKHVK1WW_  A=
MQ?>6X=+>]U6ZDA!'JOF?,/9L@_3BOJVBBR"[*&@Z#IOA?1[/2=&T^UTK2[.,
M0VUE90K%#"@Z*B* %'L*Y;X@?!/P1\5->\+:UXJT"'6-4\+W)O-'N)99$-I,
M7C<NH5@"=T,1^8$?+]:[BB@ KA[?X)^"+7XK7/Q+BT"%/'%S;"SEUCS9/,:$
M*J[-N[9C"*/NYXKN** ,/QMX&\/_ !(\-WGA_P 4:-9Z]HMVNV:ROH1)&WH<
M'H0>0PY!Y!!KYWT;_@F7^SKHGB1-8C\"&Y:.02Q65YJ5U-:HP;(S&TA#CMM?
M<I Z5]2446079':VT-E;Q6]O$D%O"@CCBB4*J*!@* .  .,"I***8@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_';]KS_E
M+Q\._P#L8/"W_H^"OV)K\=OVO/\ E+Q\._\ L8/"W_H^"@#]B:*** /QU_X)
M<_\ *0+XF?\ 8,UC_P!.-O7[%5^.O_!+G_E(%\3/^P9K'_IQMZ_8J@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HK\Y?^"IW[:&N?!/Q-X \&>!]4:SUVVNX?$>JM!(5S#&_[BVDQ
MU21@[.IZJB=FK[O^%/Q(TGXP?#;PWXUT-]VEZY8Q7L*L06CW+\T;8_B1MRGW
M4T =71110 445XI^VM_R:/\ %[_L6;[_ -%-0![717R__P $R_\ DQSX8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?CM^UY_
MREX^'?\ V,'A;_T?!7[$U^.W[7G_ "EX^'?_ &,'A;_T?!0!^Q-%%% 'XZ_\
M$N?^4@7Q,_[!FL?^G&WK]BJ_'7_@ES_RD"^)G_8,UC_TXV]?L50 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU+PMXCU;0(I]8G_M!-*N6A-U"BQ-Y;8(R/O<'UKZS^#W[//PX^ .FS6/P_\
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MLHWOB'PG\;O&?BOQ)X9UK^V;JYO+V94DTUMJ- 86E<%8V"R')((,O SBM_\
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M5+']I#P=^T3J?P(\2_"VZT22"VU&>^L[N.VU)0638\LL$85WA9XNIRH7^[R
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MI-)URQEL;GRSAU5U*[E/9E)!![$"@#\\?A=^R_\ M$_M0?#C2OBYK/[2FO\
MA/7M>B_M+2M&TKSTL;:%L^6"L4\:IN7&0J' ^\7)(K[%_9*LOC;I?PYN-/\
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M900<@\@B@!:**S?$GB+3O"/AW5-=U>Y2RTK3+66]N[F3[L4,:%W<^P52?PH
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M0O[\V=]"S,!_$P@5CZYSU-7_ /@LMJ=_<?"GX;>%X;@VFFZWXE NY>BY2(A
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M;XM^$L#4[ (8TNHMVWSD0DE2&*AQDK\Z,IPV%X7_ (67_P % ?\ HD_PO_\
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MJ/X/Z5XYT2%K)IF:VO\ 3I'#O9728\R(L.HP593QE74D G ^;_\ A97_  4
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M_$K^)OBAXFO8/#=OXJU*(+(SG&^Y*.9!O)9%&XMC>6YQ7$_L*_\ )^W[6/\
MV$S_ .E<U?1G[:7[+4?[5GPGCT*SU0:#XITF[74]#U5BP6&Y52-KE?F",#@E
M<E2%8 [<$ ^:=5_8=_:?^&^F)XP\$_M*:[XL\<P(LUQH>L2S?8KQQR8E,\TD
M; <JHDC /JG;[R^';^)Y/ NA-XUCT^+Q8UG&=4CTHL;5;C:-XC+<[<U\*?#7
M]O+XB_LZ^)-/^'G[57A.ZTAF9;:R\>V,6^TN@. \Q3*/QR7B^89&Z,')K]!;
M"_MM5L;:]LKB*[L[F-9H+B!P\<L; %65AP00001U!H L4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%<E\7=0NM(^$_C6^LIY+6\
MM=$O9X)XF*O'(L#LK*>Q! (/M7RA_P $XOV\(/VDO"J>#/&-W'#\3-(@R9&P
MHUBW4 >>@_YZK_RT4?[XX)" 'VY117SQ_P %!/&6N_#_ /8_^(?B#PUJUWH>
MMV<5F;;4+&4Q31%KV!&VL.1E68?0F@#Z'HKQS]CKQ+JOC']EWX9:WKFH7&K:
MO?:)!/=7MW(9)9I".69CR2?6O8Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "DW , 2 3T%+7Q9^T9^P_P"//C%^UYX"^*VC?$&/2?#N
MAR6;W%A-)*+FU$$N]Q:J%,9\T==Q7!)R''% 'VG1110 445\#>!?$6K3?\%@
MOB+H[ZG>/I,7A6*2.P:X<P(WV:P.X1YV@Y)YQW- 'WS17QG\9O\ @F/X3^-'
MQ.\0>-K_ .(7C/2;O6)Q/)9:=<PK!$0BKA 8R0/ESR>]?$7[#/[%^E_M2WGQ
M-A\0>._%FDKX6U.*QMCIMVF958S E]ZMS^Z'3'4T ?M317Q+\=/@/9?LO?\
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MQU_X)<_\I OB9_V#-8_].-O7[%4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG2;.&QM+=>D<,2!$7\%44 :U%%% !1110 4444 %%%% !1110 4444 %%%%
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MX(2)-P!.VO=$_P""4W[-B:I]K_X0J\:+=N^QMK=YY/7./];NQV^]VKZ;\#>
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M?VAM'AT[X@>%;/Q!';Y^SW$FZ*YM\]?+FC*N@/&0&P<#(.*X+X,_L#? _P"
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MJ=K*)K7^U;Z>[B@8#@K%(Y1B#R"X8@\@C KZ<H **** "BBB@ HHHH ****
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MTM+>*'5-6UZ'3KZ11AIE@N[5H6/J0)I%SUQM'0#'Z6.JR*RLH96&"K#((]*
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M/&T@ 'TQ17FWQP_:*^'O[.?AV/6?'_B.WT2"<LMM;[6EN;I@,E8HD!9NV3C
MR,D9KY1A_P""S'P9DO\ #>%_'4>D>9Y/]J-IUL8P^>X%QG&WYO[W^S0!][T5
M\]>)OV\/A#H'P.B^+%IK<WB/PFUY%I\G]CPA[J"=P2$EA=D:,@*>&P<$$9!!
MKW+PSX@MO%GAO2M;LA(+/4K2*]@$J[7\N1 Z[ADX.&&>: -.BO$/VBOVROA7
M^R]%#'XVUXC6+B/S8-#TV/[1?2IR ^P$!%)! 9RH)! )P:^>=(_X++?!B\U"
M%-0\->-]%TZX;$&I76G6[Q$#AF8).S<'CY ] 'WK17*?#'XJ>$OC+X1M?$_@
MK7K3Q#H=P2J75HQ^5AC*.I 9'&1E6 89&17._M#?M">%_P!F7X>GQGXOCU"7
M2!=Q66W38%EE\R3=M^5F48^4]Z /3:*^=OCC^WK\(OV?]&T>Z\2ZM=7.J:M9
M1W]IH&EP">_:&10R,Z;@D>00!O=<G.,X./-/AS_P5F^#'C3Q9;>']<M/$?P_
MN+IPL%YXELXX[4Y.%WO'(YCR?XF 0=VH ^U**;'(DT:R1LKHP#*RG((/0@US
M?Q&^)GA;X1^%;OQ+XQUVS\/:':X\R\O9-J[CT51U=CV502>PH Z:BOA/6/\
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MJ/8  ?A5N@ HHHH **** "BBB@ HHHH **** "BBB@ K\=OVO/\ E+Q\._\
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M+O!N@^/M!N-%\2Z-8Z]I%P,2V.HVZ3Q/P1DJP(SR>>HK\C_B1^SE_P ,S?\
M!17X(>'=%O;R;P!J&O6NJZ#87,S2+IQDN56XMT+$G 9$;/4AUR2P)/[$U^9'
M[8GQ3TCQC_P4M_9[\*:7=1WEQX5U2U34&BY$-Q/<(_E$]R$2,GTWXZY  /I#
M_@I!^T5J7[.G[-M]?>'KAK7Q3K]TFBZ;<Q_?MF=7>29?]I8T<*>S,A[5%^P_
M^Q#X7_9S\ Z3K.LZ3;ZK\4=1A6[U76KZ,2SVLKC<8(6;.P)G:S+R[ DG&T+Y
ME_P6.\*:C?? 'PGXKL8&N8O#/B.&XNTP2J12(Z!V]O,\I/\ MI7VK\-_B!H_
MQ5\ Z!XOT"Y6ZTC6K..\MY%8'"LN2C8Z,IRK#LRD'D4 4?BE\'?!GQJ\+W?A
M[QKX=L=?TRX0H5N8QYD?HT<@^:-AV92"*_+3]G_X+:O^SW_P57\(^ K_ %:X
MUG2=+L;_ /L&XNG+,NFR65W)%'[%6>13CC<&(P#7Z^U^;FM?$32/'W_!9[P9
M;:1-'<#PYH-SHEU-"05:X6SO9I!D=2OGA#Z%".U #/\ @MI<26?PU^%\\+F.
M:+7)W1QU#"$$'\Z^H/V/?V5-%_9Z\!VFH7]JNJ?$S6HA>^(_$=[B:\FNI</+
M$)3\PC5CC QN(W'))-?-O_!9B%;GP?\ !^%\[)/$CH<=<&-17Z,4 ?(W_!3?
MX&^'_BA^R[XL\076G0?\)-X6M?[4T[5%C'GQ+&P,L>X<E&C+_*3C.UL9 KU+
M]C3XA7WQ3_9:^&GB;4YI+G4[K1XHKJXE8L\TT),+R,3U+-&6/N:C_;6_Y-'^
M+W_8LWW_ **:N*_X)E_\F.?##_KC??\ I?<T >*_\$8?^2+_ !'_ .QMD_\
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ME?/"'T*$=J^X_P!H3_D@7Q+_ .Q9U/\ ])9* /FK_@D-_P F;:=_V&K_ /\
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M\%_\$5/^36?%/_8YW7_I#8U]Z:M_R"KW_KB__H)KX+_X(J?\FL^*?^QSNO\
MTAL: .4_X)X_$+PC\%/C1\9/AO\ $B2U\._%O4?%$\T>IZH!%_:D+$%8HY6X
MY<F55S^\$ZE=V./N_0?@7\/_  O\1]4\?:1X1TO3O&&J0"VO-6MX DLJ YZ#
MY02<;F #-M7<3M&.'_:6_8S^&7[5&EA/%VCFWUR&/R[3Q#II$-] .2%WX(D0
M$GY'#*,DC!.:^=?V0/'?Q$^ /[46L_LQ>/O$3^-]&CTPZIX:URX)-PD*@,L3
M%B3LV!QM).QH\*2I& #UW_@II_R8Y\3_ /KC8_\ I?;5VO[%/_)H_P (?^Q9
ML?\ T4M<5_P4T_Y,<^)__7&Q_P#2^VKM?V*?^31_A#_V+-C_ .BEH ^8/@1_
MRF*^//\ V*2?^@Z17F/_  54T7Q!XG_:]^"6A^%;Z73/$.KV"Z;9WD+E&A>>
M[>+=N!!& YR01@9KT[X$?\IBOCS_ -BDG_H.D5'^V)"MQ_P4N_9C5^@C#_BL
M\K#]10!]A_ /]GGP3^S?X%L_#'@S2(;.*.-1=Z@T:F[OY .99Y ,NQ.>.BYP
MH  %?'O_  5O^&=EX;\$^$?C=X<ABTCQYX9UVU0ZI;($EFB;<T>\C&XI)''M
MST#..]?H;7Q5_P %>?\ DS;4?^PU8?\ H;4 ?0OQ(^.%G\/_ -G/5_BI+;AX
M+30/[8AM2<B21X@T41([,[(N??-?''_!/+]E6R^+.FW/[1?QAMHO&?C/Q9=R
MW>G0ZK&)8+6%79!-Y1^7<Q4[ 1A$5-N,\>Y_&SP#J'Q._P""=%_X=TJ)I]2G
M\$V5Q;PH2&E>"&&<(N.I;RMH'<G%5?\ @F+\5-(^)'[(?@ZQL;J)]4\-1-H^
MI6B\/ Z.QC)'H\11@W0DL.H( !]/ZQH&F>(='GTG5=-M-3TNX3RIK&\@66"1
M/[K(P*D>Q%?CE_P4$_9;M/V;_C-\/+KP;)<67PZ\3ZTEW'H(E9K;3]022)93
M&I)VJZ,A'^XPZ*H'[.5^8?\ P5S^*6DWOQ&^"_P^L[J.XU>RU9=7U"%.6MT=
MXHX Q[%OWIV]<*IZ$4 ?IY1110!\X?\ !1;7I/#?[%/Q4NXFVM)I\5F3G'RS
MW,,##\I#2_\ !.O08O#G[%GPLMHE($NG27C9')::XEF)_.3\L5@?\%2(9)OV
M%_B1Y9/RG3690,[E&I6O\NOX5W/[#-PEU^R!\(WC554>'K9"%Z95=I/UR#0!
M\=?\%>UUJ3XO_LWKX;>./Q$VH78TUYL;%NOM%CY);((QOVYSQ72?V-_P48_Z
M#O@__OBQ_P#C55?^"HW_ "<E^RA_V,$G_I9I]?H_0!\+?"C2OV[(?B5X9?QW
MK/A>;P:NH0G5X[5+,2M:[AY@7;$&SMST.:R?^"U?_)K/A;_L<[7_ -(;ZOO^
MO@[_ (+-:3-J/[)NDW$<;NEAXJL[F5E'"J;>ZBR?;=*H^I% 'VWX3_Y%71O^
MO*'_ -%K65\6?^25^,O^P+>_^B'J+X.>(K+Q=\)/!>M:=<?:K'4-%L[F&;^\
MK0H03[\\CL<U0_: \2:?X/\ @;X_UG5;A+6PM-"O7DD<X'^I<!1ZDDA0.Y(%
M 'R3_P $8?\ DU#6_P#L;;S_ -);2N?^"O\ RF2^-7_8LK_Z)TNNW_X(]^'[
MC1OV/8KN:+RX]6U^^O86Y^= (X"?^^H&''I7$?!7_E,E\:O^Q97_ -$Z70!^
MBM%%% 'YO0J-"_X+73>6/+_MG0,R<$;]NF#\_P#CW'Y>U?I#7YQJIUK_ (+5
M.5'F?V/X=RV,'9NTX=?3_7C\_>OT<H **** "BBB@ HHHH **** "BBB@#YU
M_;IUOXTZ#\';"Y^!,=Y+XR;684G6RLK>Z?[&8IC)\DZ,H&\1<@9Z>IKO/V9]
M0\=ZI\"?!]U\35F3QY+:$ZLMQ!%!()?,?&4B 1?EV_= %>G44 8/CZ;5[?P+
MXCET ,=>CTVY;3Q&BNWV@1,8L*P()W[>",'O7R[_ ,$^_$W[27B+_A/?^&A(
M=0B\G[!_8?V[3;2TSG[3]HV_9XTW=(,[LXXQC)K[ HH *^(;KQ9^U0O[>*Z5
M%!J7_"A?[213)_95E]G^S_906_?^7YV/.SSNSGCI7V]10 5\B_\ !0+Q)^T;
MX=L_ Y_9\AU"6::2]_MK[#IUI=X4"#R-WVB-MO)E^[C/.>@KZZHH P? ,VKW
M'@7PY+KX8:])IMLVH"1%1OM!B4RY50 #OW< 8':N/_:8U#QWI?P)\877PR69
M_'D5H#I*V\$4\AE\Q,X24%&^7=]X$5Z=10!\W_L'ZY\;?$'PAU>X^/4=Y%XP
M779H[1;ZRM[1_L(M[<IA($52/,,_)&>HS@"OI"BB@#XA_9O\6?M4:G^UEXHT
M_P"),&I)\)(Y-2_LU[C2K*&$JL^+7$L<8D/[OIECGODU]O444 ?%'[9WBK]J
M31/CMX.M?@O!J4G@26QMVU9K/2[*YC$YNI1+EYHV=3Y0CX4@8Y'.:^UZ** /
M ?VV]9^+^A_!-KGX(1W4GC?^TK=0MG9P73_9R'\SY)U9,?=YQFM[]D?4_B3K
M'[/?A2\^+J7$?Q#D^U_VHMU;0V\@Q=S"',<*JB_N1%T R,$\DU[!10!3UEKE
M-'OFLLF\6"0P[0"=^T[>#P><5\<_L!^*?VG_ !#XD\7I^T!#J46FQVD!TK[=
MIEG: REV\S!MXU+?+M^]D5]I44 %?%'CSQ5^U);_ +=FG:5H,&I'X#M?6"W$
MB:79/;^0;>,W&9VC,P'F%\D-D=!Q7VO10 5\H_M^>(OVA/#WAOP@_P"S_%?2
MZE)=SC5?L.GVMV1$$7R\BX1@OS;ONX-?5U% ''_!NZ\27OPA\#W'C)9%\83:
M%8R:TLT:1N+XVZ&XW(@"J?,WY"@ = ,53^/%YXNT_P""_C6Y\!+*WC2+2KA]
M'6"&.5S=!#Y>U) 58[L<,"*[RB@#Y=_8'\0?'OQ!X%\2R_'Z*^BUZ/4E73A?
M6%M:-]G\I2<+ B@C?GDC-?45%% 'Q1\(/%7[4EY^VQXETSQA!J2_!&.^U1=.
M>72[*.#R%9_LF)DC$I&-N"6R>^:^UZ** /B+]OCQ9^U1X?\ '7AJ+X P:E+H
M,FFLVHFQTJRNU^T>:P&6GC8@[,< XK[=HHH \3_;&U7XI:+\!-:N_@VES)X^
M6>U%FMI:PW,FPS()<),K(?DW=1QVJ']C+5OBMK?P)TVZ^-$=U'X\:[N1<+>6
MD%M)Y0D/E92%50?+CH,GO7N5% !7Q1^PIXJ_:DU_XC>+(?CO!J47AN.QW:6;
MW2[*U4S^<!PT$:LQV9X8D5]KT4 %?$7QJ\6?M46/[:GAG3/!,&I-\%)-2TA=
M1>'2K*6 6[21_;<S/&90-I?)#9';%?;M% !7S'^WKKWQV\/_  Y\/3? .*]E
M\2/JVR_%C8VUVWV7R9#RLZ,H&\)R!FOIRB@#SW]GN]\9:C\$_!ES\0UF3QO+
MIL3:NL\,<+BXQ\^Y(P$4^R@"MCXKW'B"S^%OC&?PF)&\51:->/I(BC61S>"!
MS!A7!5CYFWA@0>_%=510!\H_L!^(OVA/$/AOQ>_[0$5]%J4=W -*^W:?:VA,
M11O,P+=%#?-M^]DU]7444 ?$7@OQ9^U1/^WC<:5K<&I#X"C4M06.1]*LEM_L
MXM9C;?OUC\['G"+!W9)P#D$U]NT44 ?&?[?_ (H_:;\.ZQX,7]GZ'49;.6"Z
M.K_8=,L[L!PT7D[C<1L5X,GW<9[U]=>&9+Z7PWI3ZF&&I-:1&ZW*%/FE!OR!
MP/FSTXK2HH \E_:NU+XB:3^S_P"+;OX3I<2?$&..W_LM;6WBN)"QN8A)B.56
M1OW1D^\#Z]<5S?[$FL_%_7/@FMS\;X[J/QO_ &E<*5O+."U?[. GE_) JIC[
MW.,U[]10 5\1?L:>+/VJ-:_:!\66GQG@U*/X?1Z;=MI;7>E65M&;@7< AQ)#
M&KL?),W#$@C)/(%?;M% !7Q#^U)XL_:HTG]J+PK8_"R#4G^%LD>G_P!IM;:5
M93Q!C<,+G,LL;2#]WMS@C'48-?;U% !7SK^W3K?QIT'X.V%S\"8[R7QDVLPI
M.ME96]T_V,Q3&3Y)T90-XBY ST]37T510!YC^S/J'CO5/@3X/NOB:LR>/);0
MG5EN((H)!+YCXRD0"+\NW[H KL/'TVKV_@7Q'+H 8Z]'IMRVGB-%=OM B8Q8
M5@03OV\$8/>MZB@#X_\ ^"??B;]I+Q%_PGO_  T)#J$7D_8/[#^W:;:6F<_:
M?M&W[/&F[I!G=G'&,9-?8%%% 'Q#=>+/VJ%_;Q72HH-2_P"%"_VDBF3^RK+[
M/]G^R@M^_P#+\['G9YW9SQTK[>HHH ^1?^"@7B3]HWP[9^!S^SY#J$LTTE[_
M &U]ATZTN\*!!Y&[[1&VWDR_=QGG/05].> 9M7N/ OAR77PPUZ33;9M0$B*C
M?:#$IERJ@ '?NX P.U;U% 'F/[3&H>.]+^!/C"Z^&2S/X\BM =)6W@BGD,OF
M)G"2@HWR[OO BO/?V#]<^-OB#X0ZO<?'J.\B\8+KLT=HM]96]H_V$6]N4PD"
M*I'F&?DC/49P!7TA10 5\0_LW^+/VJ-3_:R\4:?\28-23X21R:E_9KW&E64,
M)59\6N)8XQ(?W?3+'/?)K[>HH *^*/VSO%7[4FB?';P=:_!>#4I/ DMC;MJS
M6>EV5S&)S=2B7+S1LZGRA'PI QR.<U]KT4 %> _MMZS\7]#^";7/P0CNI/&_
M]I6ZA;.S@NG^SD/YGR3JR8^[SC->_44 >/\ [(^I_$G6/V>_"EY\74N(_B')
M]K_M1;JVAMY!B[F$.8X55%_<B+H!D8)Y)KU366N4T>^:RR;Q8)##M )W[3MX
M/!YQ5RB@#XM_8#\4_M/^(?$GB]/V@(=2BTV.T@.E?;M,L[0&4NWF8-O&I;Y=
MOWLBOM*BB@#XH\>>*OVI+?\ ;LT[2M!@U(_ =KZP6XD32[)[?R#;QFXS.T9F
M \PODALCH.*^UZ** /E']OSQ%^T)X>\-^$'_ &?XKZ74I+N<:K]AT^UNR(@B
M^7D7",%^;=]W!KW[X-W7B2]^$/@>X\9+(OC";0K&36EFC2-Q?&W0W&Y$ 53Y
MF_(4 #H!BNPHH X/X\7GB[3_ (+^-;GP$LK>-(M*N'T=8(8Y7-T$/E[4D!5C
MNQPP(KQG]@?Q!\>_$'@7Q++\?HKZ+7H]25=.%]86UHWV?RE)PL"*"-^>2,U]
M144 %?%'P@\5?M27G[;'B73/&$&I+\$8[[5%TYY=+LHX/(5G^R8F2,2D8VX)
M;)[YK[7HH *^(OV^/%G[5'A_QUX:B^ ,&I2Z#)IK-J)L=*LKM?M'FL!EIXV(
M.S' .*^W:* "O$_VQM5^*6B_ 36KOX-I<R>/EGM19K:6L-S)L,R"7"3*R'Y-
MW4<=J]LHH \-_8RU;XK:W\"=-NOC1'=1^/&N[D7"WEI!;2>4)#Y64A54'RXZ
M#)[U[E110!\4?L*>*OVI-?\ B-XLA^.\&I1>&X['=I9O=+LK53/YP'#01JS'
M9GAB17VO110!\1?&KQ9^U18_MJ>&=,\$P:DWP4DU+2%U%X=*LI8!;M)']MS,
M\9E VE\D-D=L5]NT44 ?,?[>NO?';P_\.?#TWP#BO9?$CZMLOQ8V-M=M]E\F
M0\K.C*!O"<@9KUK]GN]\9:C\$_!ES\0UF3QO+IL3:NL\,<+BXQ\^Y(P$4^R@
M"O0J* .5^*]QX@L_A;XQG\)B1O%46C7CZ2(HUD<W@@<P85P58^9MX8$'OQ7S
MW^P'XB_:$\0^&_%[_M 17T6I1W< TK[=I]K:$Q%&\S MT4-\VW[V37U=10 5
M\1>"_%G[5$_[>-QI6MP:D/@*-2U!8Y'TJR6W^SBUF-M^_6/SL><(L'=DG .0
M37V[10 5\9_M_P#BC]IOP[K'@Q?V?H=1ELY8+HZO]ATRSNP'#1>3N-Q&Q7@R
M?=QGO7V910!F^&9+Z7PWI3ZF&&I-:1&ZW*%/FE!OR!P/FSTXKS?]J[4OB)I/
M[/\ XMN_A.EQ)\08X[?^RUM;>*XD+&YB$F(Y59&_=&3[P/KUQ7K5% '@/[$F
ML_%_7/@FMS\;X[J/QO\ VE<*5O+."U?[. GE_) JIC[W.,U[]110!\1?L:>+
M/VJ-:_:!\66GQG@U*/X?1Z;=MI;7>E65M&;@7< AQ)#&KL?),W#$@C)/(%?;
MM%% 'Q#^U)XL_:HTG]J+PK8_"R#4G^%LD>G_ -IM;:593Q!C<,+G,LL;2#]W
MMS@C'48-?;U%% 'SK^W3K?QIT'X.V%S\"8[R7QDVLPI.ME96]T_V,Q3&3Y)T
M90-XBY ST]37>?LSZAX[U3X$^#[KXFK,GCR6T)U9;B"*"02^8^,I$ B_+M^Z
M *].HH P?'TVKV_@7Q'+H 8Z]'IMRVGB-%=OM B8Q85@03OV\$8/>OEW_@GW
MXF_:2\1?\)[_ ,-"0ZA%Y/V#^P_MVFVEIG/VG[1M^SQINZ09W9QQC&37V!10
M 5\0W7BS]JA?V\5TJ*#4O^%"_P!I(ID_LJR^S_9_LH+?O_+\['G9YW9SQTK[
M>HH *^1?^"@7B3]HWP[9^!S^SY#J$LTTE[_;7V'3K2[PH$'D;OM$;;>3+]W&
M><]!7UU10!@^ 9M7N/ OAR77PPUZ33;9M0$B*C?:#$IERJ@ '?NX P.U<?\
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M  4&_9P\=_'[7O@U<^"],AU&'PWK<E[J337<4'E1%K<@C>PW<1OP,]*^QZ*
M"OCC_@GS^SAX[^ .O?&6Y\::9#IT/B36X[W36ANXI_-B#7!).QCMXD3@XZU]
MCT4 %?('BW]G7QSJW_!2?P5\7[;387\":9X?DL+F^-W&)%F,%V@41%MY&Z:/
MD#'/M7U_10 4444 >'?M7?LB^"_VMO!,>C^)4>PU>RW/I6O6J@W%D[8SP>'C
M; W(>N!@J0&'R5H=I^W3^R?;CP_INEZ1\;_"%I^ZLKNXE\VXBB  1>98YQCC
MAA(!@@-C!K])J* /SDU;XV_MZ_%99-&\.?"/1_AR)2 ^LW002P*>X:XF9#[X
MB9NF,5ZG^R/_ ,$^+;X,^+I_B;\2O$#?$3XM7C-,VISL\D%D[+AVB+_-)(02
M/,8# X55Y)^R** .9^*&AW?B;X:^+='T^,2W^H:1=VEO&S!0TDD+HH)/ R2.
M37@G_!.?X%^,/V>?V=5\)^.+"+3=;&KW5WY,-S'.OEN$VG<A(_A/&:^H:* *
MNJ264=C,-1:W6R=3'+]J*B-E;@JV[@@YQ@]<U\!^(?V$?BA\"/&FI>-/V5/B
M!;:)I>JGSKGP=K$GF63Y/_+(E71@,_+O 91D"0YQ7VS\6/A?H/QH^'.O^"?$
MUNUSHFLVQMYU0@.G(9)$)!PZ,%93@X*BO@+X?S?M/?\ !/>WG\('P'-\<_A/
M:RN^EWFBLPO+2(L6("(LDB#YBQ1D90<[7QF@#J5\/?M_?$R-M#U76O!GPWT^
M1##<:S8^6]R4QAFCV&4AR#D$>7@C@K7B/B+]F'P]\!?V[OV:O V@7]YXD\3R
MW!\0Z_K=\Q-U?R><\AE<$MM4+;287). 268DL?<+W_@HY\7O%%NMAX(_96\:
M2ZY,%1)=6BN!:P,<C+[8%RN<<LZ#D\C'/8_L>?LH^/M+^*.M?'CX[:A!J'Q2
MUB!K6STN$I)%HUN0%(5E)0,5&P*A(52V68NV #ZU\9>#]&^('A75?#?B'3X=
M5T35+=[6[L[@926-A@CV/<$<@@$8(K\]=+_9S_:?_8=UZ_A^!-U9?%'X8W<[
M3Q^&=<F19[0L>>&>/#<_>B?#XRT8P*_2.B@#X NO&/[<GQ^@_P"$>M/!6@?!
M'2KI?+N_$4UR)+N-#PWD@2.P;&X@B,$'&'7K69\%_P#@GGK_ .S[^VI\/O%O
MAZ*36/!&EZ+.NL^(KZ]C^TW>I2P7222F$N6 +21  9 &,EB&8_HE10!\<?\
M!2#]G#QW^T5H/PWMO VF0ZE-HNMM>WJS7<5OLB*J,C>PW<CH*^QZ** /,OVF
MO!&K_$K]GOXB>%= @6ZUK6-$NK*SA>18U>5XRJ@LQ ')ZDUS/[$/PM\1?!7]
MESP-X+\66D=CX@TN*Z6ZMXIDF5"]W-(N'0E3\KJ>#WKW.B@#XI_8#^ OQ._9
M;^!OQ(L]?\,0W/BB\U>?4])TJ'48&6[_ -'C6-6E#;8P77!).0.<&OGCX0_
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M.P*G<A([=,U],T4 %?('_!,G]G7QS^S5\%_$GAWQ]IL.EZK>^()+^&*"[CN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;]H_0OV6?@_J?C?6XS>RHPM=.TU'V/?7;@F.(-@[1A69FP<*C$ G /Q#\/\
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M^I% 'G7[!/[4_C_Q7\0O&GP+^,JQS?$;PBK2QZG&J@WMNCJC[]H"LP\R)E<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'[6"4SS]P#MLH ](_P""L'_)DOB__K]T[_TKBKW7]F7_ )-M^%'_ &*6D_\
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MYL87RZ4P,> 3L+;?D\PKC=L^3/W>*](H **** "BBB@ HHHH **** "BBB@
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MR=4T?Y]AG(7$EN&_A+@*5/'SQID@$F@#ZE15C5550JJ,!5& !Z4ZOA_]E_\
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M:QIR_P"AWUR8WCWAQ\KY=H #SO,#,,@;J^G?^"AW_)EOQ5_[!B_^CXJ +7[
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MJ^2N<#(++%;Q[L$J&F8 G'%K_@II_P G)?L=_P#8VR_^EFET ?H57YZ^&?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nvax-20221231_g2.jpg
<TEXT>
begin 644 nvax-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9]#;X# 2(  A$! Q$!_\0
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MO_QVC_AK:R_Y^/$?_?:__':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_P#OM?\
MX[1_PUM9?\_'B/\ [[7_ ..U\NT4?V9A^S^\/K-0^HO^&MK+_GX\1_\ ?:__
M !VC_AK:R_Y^/$?_ 'VO_P =KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_[[7_X
M[1_PUM9?\_'B/_OM?_CM?+M%']F8?L_O#ZS4/J+_ (:VLO\ GX\1_P#?:_\
MQVC_ (:VLO\ GX\1_P#?:_\ QVOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?
M_CM'_#6UE_S\>(_^^U_^.U\NT4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_ /':
M/^&MK+_GX\1_]]K_ /':^7:*/[,P_9_>'UFH?47_  UM9?\ /QXC_P"^U_\
MCM'_  UM9?\ /QXC_P"^U_\ CM?+M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_?:_
M_':/^&MK+_GX\1_]]K_\=KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_ .^U_P#C
MM'_#6UE_S\>(_P#OM?\ X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_P!]K_\
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MUE_S\>(_^^U_^.U\NT4?V9A^S^\/K-0^HO\ AK:R_P"?CQ'_ -]K_P#':/\
MAK:R_P"?CQ'_ -]K_P#':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\
M-;67_/QXC_[[7_X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_WVO\ \=H_X:VL
MO^?CQ'_WVO\ \=KY=HH_LS#]G]X?6:A]1?\ #6UE_P _'B/_ +[7_P".T?\
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M/_OM?_CM?+M%']F8?L_O#ZS4/J+_ (:VLO\ GX\1_P#?:_\ QVC_ (:VLO\
MGX\1_P#?:_\ QVOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\
M>(_^^U_^.U\NT4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_ /':/^&MK+_GX\1_
M]]K_ /':^7:*/[,P_9_>'UFH?47_  UM9?\ /QXC_P"^U_\ CM'_  UM9?\
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M_?:__':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_P#OM?\ X[1_PUM9?\_'B/\
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MM?\ X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_P!]K_\ ':/^&MK+_GX\1_\
M?:__ !VOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_
M^.U\NT4?V9A^S^\/K-0^HO\ AK:R_P"?CQ'_ -]K_P#':/\ AK:R_P"?CQ'_
M -]K_P#':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[
M7_X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_WVO\ \=H_X:VLO^?CQ'_WVO\
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M[7R[11_9F'[/[P^LU#ZB_P"&MK+_ )^/$?\ WVO_ ,=H_P"&MK+_ )^/$?\
MWVO_ ,=KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_[[7_X[1_PUM9?\_'B/_OM?
M_CM?+M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_?:_P#QVC_AK:R_Y^/$?_?:_P#Q
MVOEVBC^S,/V?WA]9J'U%_P -;67_ #\>(_\ OM?_ ([1_P -;67_ #\>(_\
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M=KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_ .^U_P#CM'_#6UE_S\>(_P#OM?\
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MM?+M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_ 'VO_P =H_X:VLO^?CQ'_P!]K_\
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M']F8?L_O#ZS4/J+_ (:VLO\ GX\1_P#?:_\ QVC_ (:VLO\ GX\1_P#?:_\
MQVOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_^.U\N
MT4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_ /':/^&MK+_GX\1_]]K_ /':^7:*
M/[,P_9_>'UFH?47_  UM9?\ /QXC_P"^U_\ CM'_  UM9?\ /QXC_P"^U_\
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M.5/1C14J1I1YYNR)C[TN1;_U_F?*E%?:-Q_P2>^,$,99-<\&SL/X([^Z!/\
MWU; ?K7@7QB_9?\ B7\!U2;QCX8N+'3I'\N/4[=UN+5SG@>9&2%)[*^UCSQQ
M6,,50F^6,U<U=*HE>QY715C3["XU6_MK*TB:>ZN95AAB7J[L0%4>Y)%?:OC[
M_@EKXK\$_"6^\51>+K+5==T^R-[=Z%%9,B!47=(L<Y<[V !QF-=V.U76KT\.
ME*J[)DTX2JRY(*[/B*BBBMR HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/3&,"OERL*->GB$Y4W=+0TG3E3LI+<****W,PHHHH **** "BOI;]D']C/\
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MMQOQ]X],^U8>WINJZ%_>2O;RT_S12BW#VBVO;\_\F>>T445N2%%%% !1110
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ML)(4&,*>A)SCBO *FG5A67-3=T5*,H:204445J0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%>R?LX_LL>+/VG[[7+7PMJ&C6$FCQQ2SG6)I8PPD+!=GEQ/D_(<YQVKW%O\
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M%%%%;&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]BI+_P"B*\VKB'4P5.52*D[M:WZ:=+;V5SJ5/DQ?N:75]/E^3O;MT/Q1\#^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_:VAW+R1Q77]I6<.YD8JPVR3*PPP(Y%?<'_!7/\ Y)?X$_[#,O\ Z(->I_\
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MGSEIG['7Q?UCX<KX\L_"/G>%&L'U,:A_:5FO^C*I9G\LS!^%4G&W/'2H+_\
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MD8(![5N?\%!OBI\:O$7PPT?3_&'PRA^''A.XU%%ED77;;4Y+RX5':-,Q$%$
M5VY4Y*CYAT*>,O\ E+3IW_81M/\ TWK7K/\ P5K_ .2$^%/^QDC_ /26XKB4
MER812BGHM^FW_#Z]3OE?V]:SMHOR?^1\(?#O]C+XQ?%?P?8>*?"O@_\ M30;
M[S/L]W_:=G#OV.T;?)),K##(PY Z>E4/A[^R7\7/BI'=2^&?!%]?VUM*\#W4
MDD5M SJQ5E265U20AE(.PG&*_4__ ()V_P#)G_@3ZWW_ *6SUY[\9O\ @I;X
M-^#7Q$F\%Z-X4N/$EOI,_P!CU"\M;I+:*W92 Z0IL;S"G(()097 />NRKC*\
M<54PU**=FTOD]W_2.:%&#I*K)V/S9^*W[/?Q%^"#P#QMX4O=#BN#MBNF*36[
MMR=HFC9DW8!.W=G SBO8?^"??Q!^)?@OXI:Q;?#KPI#XX-YI_G:GHDU_%8EX
M8W 65)I" K*TH'1LAVX[C]4=>L?#'[27P+F1H_MOAOQ1I GA,R .@D3=&^#G
M:Z-@CT9:_.+_ ()11F']H[Q%&WWE\-7"G'M=6U50Q4L1"M3JQLXIW[;/]4%2
MC&*A4@]&U^AS/_!0SQY\4?&7COPY'\1?!T/@2UM[.232M(BU*&_)5F EE>:(
MX))11@A<!1QU)^7_  ]X;U?Q=JT&E:'I=YK.ISDB*ST^W>>:3 R=J*"3Q[5]
MS?\ !6:SFU#XO^ +6VC::XGTIHHXU&2S-<$ #W)-?8'P'^"O@C]C'X)S:EJC
MVMG>P68O/$/B"9=TDC@9**<9V*3M1%ZGL68DXX?%PP^!C5<;7<DDO)OO?Y^;
M-:]*53$^RB[NT?Q2[?@?F;9?\$^_C_?V<=S%\/9EC==P6;4[*)\>Z/,&!]B,
MUY/\1_A'XS^$.K+IWC+PWJ'A^Z?/E?;(2(YL8R8Y!E) ,C)4D#-?H9XA_P""
MNWARSUXP:+\/-2U/2 V#>WFI):S$9ZB$1R#Z9<?A7:?%C]M#]GCXK?L_74OB
M:6758-25X!X9\A3JL$X'#J,E8BN<K+NV]@2<K5?6L;"TYTO=\M_S_0A4J,GR
M<^OX?U\S\D:]4^%_[+?Q5^,VG'4?"'@N_P!4TWHM]*T=K;R8)!"23,BN000=
MI..]=O\ L-_ 73?C_P#'J#3]5A>7POI,+ZI>P.<F:-658X688^\S+GU56QBO
MTY_:/_:H\$_LF^'=+M[ZRDO=1NHBFF:#IBI'^[08W,3\L48X7."?13@XZL7B
MW0<:=.-YR_K]&84:7M7+72.Y^2WQ"_9.^+?PKCM9?$_@B_T^VN)5A2ZC>*XM
MU=F"JKRQ.R(2S #<1G-:'Q#_ &,?C'\*?"-]XH\4^#_[+T*QV?:+K^T[.;9O
M=47Y(YF8Y9@. >M??'P5_P""FG@KXP^*;7PGXJ\*3>$Y-5E%I;2RW:WUI*S\
M*DI,:%-Q( ^5ASR17I7_  4,_P"31/'7TL__ $KAKBJ8W%490A5@DV_P;6VN
MZ_RT.FC0I5IM1EI^/7\.WS/&?^"1O_)+?'7_ &&8_P#T0M?'G[?_ /R=[\0_
M^N]K_P"D<%?8?_!(W_DEOCK_ +#,?_HA:^//V_\ _D[WXA_]=[7_ -(X*N/_
M "-9_P"'_P"0,:?^Y?\ ;S_.1\]T445[ARA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]5?\$S?^3L-%_P"P
M?>_^B37W-^W=^U9XL_9?L_!DWA;3M&U ZS)=)<#5X9I-HB$179Y<J8SYASG/
M05\,_P#!,W_D[#1?^P?>_P#HDU^IGQ@_9[^'_P >H=+C\=Z!_;D>EM(UH/ME
MQ;^49 N__4R)G.Q>N>E?/9G*,<31E45XJ.OWR.O+[6K>K^_DC8X_]D3]HMOV
MI/A1<Z_J&B1:3>VMY)IE[;1N9()6$:/N3=R%*R#Y3G&#R>M?G1X3\#V/PW_X
M*0:=X<TQ!'IUCXO46T2CB.)FWH@]E#!?PK]%/&GQ:^#O[&?PY;3K:32]&BM8
MVDL_#>F2*UW=2$<'9DL=Q !E?CU-?F!^S_XVOOB5^V[X2\5:D%6^UCQ0M[*B
MG*H7<ML'LH( ]@*6 CSXN56C&U.UOGI_P?2X8V\<#*%1WEK]UG_P/4^ZO^"I
M^FW>L? CPU8V%K->WMQXFMXH;:WC,DDKF"<!54#))/0"OA&S_8'^/E]I":E'
M\.[M;=X_,"37MI%-C&<&%I1(#_LE<^U?L%\9OB7X9^#?@.^\:^*EW6&CXDB$
M<2R3-,V8U2(''SMO*YR.&.2!FO /V9_^"AV@?M#?$@^#)_"USX7U"Y223397
MO5N4N@BEF5L(AC?8"P W#Y3STSRX.M7IT9*A"]M6_E_3.S$*$G!U'96M^+_S
ML?D5KFA:EX9U:ZTO5]/NM+U.U?RY[.\A:*6)O1D8 @_6F:5I-]KVI6VGZ;9W
M&H7]RXC@M;6)I997/15502Q/H!7Z._\ !6[X>Z9'H_@KQO#!'#JS74FDW$JJ
M T\90R1[CWV%7Q_OFO1_^";/[.^D_#_X1V/Q"U"SCE\5>)(VFCNIERUK9[B$
M1">F\#>2,9W*#]VO7IYA%X9XB:U3M;S_ .&U\CAJ47&JJ<'OKZ+^OOTV/A.Q
M_8!^/VHZ;'?1?#RY2&1 X6?4+.&4 C/,;S!P?8C-<SX/_9*^+OCKQ-K/A[2?
M!%[_ &UHZ1R7ME?RPV4D2.6",//=-RL4;!7(.*^^?BQ_P56\(>"?%MUHWA;P
MI=>,[>SF:&?4S?K9P.RG!,/[N0R+G(W$*#CC(P3]!_LX?M*>#/VFM NM<\.1
M26>JV.VWO]/O447-MNR5Y4D-&Q!((/.#D @BN5XS%QA[5TUR_P!6OK_D:NC2
M4O9\WO?U<_%?XJ?"'Q;\$_$Z^'O&FD_V-K#6Z70MOM,,_P"[8L%;=$[+R5;C
M.>*Z/X6_LM_%3XTZ:^H^#O!E[JNFJ2HO9)(K6!R"00DDSHKD$<[2<=Z][_X*
M;1VLW[6FDQW[F*Q?1[%9W'58S-+N/Y9K])/'B^(O ?P8>+X/^'M)U35M/M(8
M](TFY?RK5H@5&!AD!PF2!N7)[UI+'SAA85FES2;7DK/^OQ(]BI5W23T23^_^
MOR[GXL?%3]FOXF_!.WBN?&GA"^T>RE.U;P-'<6^X]%,L3,@8]@2":\SK]-_B
M9_P406Q^#&N^&O'7PYFTSXGSHVGS>&]5M'%A)&ZD&Y._DQ=?W>22<88C+#YZ
M_P""=O[-^E_'7XI7^K>)+5;WPSX9CCN);*09CNKAV/E1N,?,@".S#OM4'()K
MKH8BJX3G7C91ZK9^GX==W;<SJQA'EY+W?1[_ -?IKL>3_#7]D_XN?%W2UU/P
MKX'U"_TU@#'>7#1VD,H/>-YV17'NI-7O'G[&GQI^&NDR:IKW@#48K",%I9[&
M2&^6)0,EG\AWVJ!_$V![U^M'QU_:"U#X+_9M,\-_"OQA\0-1: .D>@:5-]A@
M7. KW"QL < _*BM@#G&1GG_@G^U=XC^)'B*#1?%?P2\=> )[EBL-]=:9<7%B
M#C@2S&&,QY]2NWU(KS_K^(J)SIP7+YO7\U^1T>PIT[*H]?+^F?B?17W3_P %
M./V:M)^&_B#2OB'X9LH]/TS7IVM=2LX%"11WFTNLB*.!YBA\@<;D)ZL:^%J]
M;#8B.)IJI'3_ #.>M2=&7+N/@D6&:-VC6958,8Y,[6 /0X(.#[$&OT<_9)_;
M]\=_$[XP>"_AS=^'/"6D^'+A9+55TFSN8I((XK=V18]UPR@#RU'*GBOS@KZ%
M_P""?_\ R=W\/O\ KM=?^DDU:UJ4*L&IJ]DW\[,P4G!\T=S[,_X*W?\ )&?!
MO_8?_P#;>6ORNK]4?^"MW_)&?!O_ &'_ /VWEK\KJ\G*?X,O7]$=V+^*/I^K
M"BBBO;.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _0K_ ()!_P#(R_$S_KTL?_0YJ]/_ &SO
MVZ/&W[-GQDT_POH.BZ!J>D2Z5!J$K:C#.9R[RRHRJZ2JH&(UQE3U/6O,/^"0
M?_(R_$S_ *]+'_T.:OM?XI?LK_"OXR>*K?Q-XT\+)K6L6]NEJEQ)?7,2B)&9
ME4I'*J$9=NH.<\U\SC)4X8Q2JJ\;?YG?ATY4IJ.]_P#(7P3X@TC]JS]G.TU'
M4](^S:7XKTN2.YT^5M_E,2R,%; SAE)5L \ X!K\YO\ @EW;FT_:FOX"=QBT
M.\3=ZXEA%?9_[3'[6GP__9I^&MUX=\+WFEW'BB.U-CI6@:4R,EC\H57E5.(D
M0$$*<%L8 ZD?%?\ P2Q8O^T]=,Q+,= NR2>_[R&C"Q]W$5(1M!IV_P#)OR74
MJO[M*E3J.\KK\U?[_P!#U[_@JAX/USQW\0OA9HWAW2+W6]5GM+[R[.P@:61O
MGAR<*. .Y/ [U\LZU^P;\>?#^C3:I=?#N\>UB3S&6SN[6YFQ[0Q2M(3[!2:_
M5K]IC]HSPI^S)X5@\3:Y8MJ6KWA:ST^QMMJSW!'S,N\_<C'!8\XR."2!7,_L
ME?MG:-^U0NLVD6A3^&==TM$FEL9+D7,<D+$J'20*A.",$%1C<O)SQEA<1B*6
M&M2A=1O=OS;?EM?S+K0@ZJE4=KVM]UOS/Q1EB>&1XY$:.1"59&&"I'4$>M;/
M@_P3X@^(6N0Z-X9T:^UW59N4M+"!I7QD L0!PHR,L>!W-?5O_!4;X=Z;X1_:
M L-7TRWCMO\ A(M,6[NHXA@-<+(T;/CIEE"9]2">IK[T_9J^#'A?]DWX$1W6
MH?9["_%B-3\1ZQ,/F+A-[J6Z[(P2JJ/0G&6.?6>/C'"K$M;Z6\UO\E_EW.:6
M'DJ_L8^OR=OQU/S&OOV ?C[IVFR7TOP\N7AC0N5@U"SFEP!GB-)BY/L!FN?^
M'7['_P 7_BMI^HWOAKP7<7<.G7KZ==K=7=M9RP7"*K-&T<\B." Z]N_UK[;U
MS_@KIX7L_%!M=+\ :GJ6@+)M.I37Z03LN>66#8P/L#(#ZXK["^"_Q5\*_&SP
M/;>,?"+[['46)G62(1SQS* K1S 9^=0%'4@@*02,&N:6,Q=*FZE2FK=/+UU_
MR+]E1<N12U_K8_!CQEX/U?X?^*-3\.:_:?8-9TV8V]U;>8DGER#J-R$J?J"1
M7JO@?]BGXV?$708-:T/P#>RZ;<*'AFO+BWLC(IY#*L\B,5(Y# 8(Z5ZT=#T#
MQ)_P4\N].\310SZ1-XIFWPW/^KDD$;-"C \$&0(-IX.<=Z_0_P#:8\<?%;X>
M^%]-U3X6^#M/\9213L=4L[DN9T@"Y'DQHZEV)R.-Q'&$;)QI4QTXT:,DES32
M?DMOZ\O.X?5U[>I36T;^KW_R^9^+/Q,^#OC7X.:LFF^,_#=]X?NI 3$;E 8I
M@,9,<BDH^,C.TG&:XX9/ Y-??/[8_P"W;X?^+OP9M/!5GX0FM?$MXP?6+?6[
M<A]$FC?!2(D M(2#\^!A&P1DE5U/^"7W[,^D>)(;WXJ^)+)+]K*[-GHEM<(&
MC25 &DN<'JP+!5/\)#'KM(ZJ6(G&C*KB(VY>W7T^?^>QC5IP4HQIN[?X?TM?
MP/F3P?\ L0_''QUI,6IZ5\/-0%G+RC:A/!8LP]0D\B,0>QQ@]JYWXG_LQ_%+
MX-V?VSQ?X+U'2K#C=?($N;9,G #2PLZ*23P"037ZO_&S]K#Q'\-_$4^B^$_@
MCX[\?SVS!9KZVTRXM[$G'(BF$,ADQZA=OH36[\$_CQ=?'2VOM%\6?";Q9X&N
MFMF,UMXCTB4Z?<QGY619WC56.#RKJN0>,X./._M#$N/M5!<OKK^?Z'1["G%\
MDV[_ -?UN?AG17TC^WC^SO9_L^_&9H=#B:+PQKL)U#3XCTMSN(E@![A6P1Z*
MZCG&:^;J]JA6CB*:J0V?]/\ $Y*M-TIN#/N'_@E+\,['Q1\7/$7BR^A6=O#=
ME&MHKC.R>X+*)![A(Y!_P.O9O^"@'[;'C'X*^-;#P-X!G@TJ_%FE]?:M+;QW
M$@WLP2*-) R#A222I)W#&,'/Y<5K>$_"FK^.?$FG:!H-A-J>KZA,L%M:P+EI
M'/\ (#J2>  2< 5SUL&L17C5F]%T_KSU'3JJC"22U?7ML?L;^P;^TGKO[2'P
MOU*[\3V\(UW1KP6<]W;1^7'=*R!E?;T5NH(7C@' SBOS(_;2\&Z;X!_:?\?:
M1I$:0Z>+U;J.&/[L9FB29E [ -(V!V&*_4KX(?#KP[^Q#^S;.WB'4(4-E&^J
M:W?K]V6Y8 ;(\\MT2-!U8@<9;%?CI\5OB#>_%;XD>(_%^H+LNM8O9+HQYSY:
MD_)&#W"J%7\*\["QC+'5)T%[B5O*^G^3?_#G2^:.$2J[M_Y_DFD<I1117T!P
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'ZZ?\$K/^3:;W_L/W7_HN&O,_BO_ ,%+?&GPF^/_
M (F\*77AC0=5\,:/J3VG[E9X;UXQCGS#(R;O^V>#[5Z9_P $K/\ DVF]_P"P
M_=?^BX:]?UC]D7X,7OCR[\=ZMX-L[KQ!<7!O)[R_O)Y(6EZEC"\AB[=-N*^8
MQ,Z5/,)2KQO&RT\[1]/,[\.I2PG+#25W^<O^ 8'[<7@W2OB5^RGXMN;N &33
MK$:U8RNHWPR1C?QZ$H60^S&OF?\ X(__ 'OBK]-,_P#;JNC_ ."A'[97A3_A
M7.H_#7P7J]KK^L:N!#J-YI\JRV]G;A@63S%RK2,5V[03M&[.#@'G/^"/_P![
MXJ_33/\ VZIX6$XX'$R:M%VM_P"!1U_)?(TK-<]*+=VM_P"OO^\\[_;K^$OC
M'XO_ +8^LZ5X-\.WWB"]73K$R"UC_=P@Q<&20X2,'!P6('%>(?$#]C/XS_##
MP_-KGB+P'>VVE0 M-<6EQ!>"%0,EG$$CE% '+, !ZU^GW[5'[9GA3]E6\MK'
M^PF\0^*]607;6%M,ML/*'[L232[6(SM*K\K$[#T KM_V:/VB]$_:>^'3^)-+
ML)M,E@N&LK[3;IA(890JL0'  ="KC#8&><@5%#%8BCAHRIP]R/5^O]+J56A3
MG6M-ZNVGHOZ9^$-=C\-/@_XT^,6K/IO@SPW?^(+J/'FFUC_=0YS@R2-A(P<'
M&YAG'%>L_M#_  -@B_;4UGX<^&(4LK?5=9MHK2-$^2W%TL<A 4=$0R-P.BK7
MZHR2?#O]BSX%AVC_ +*\,Z-$JMY,8>YO;AL#..-\LC=R0!ZA1QZU;'1IT(54
MM9[+[O\ /YG(L/)UI45TW?Y??^!^37BK]AGXZ^#='FU/4OAY?-:0C<_]GW-O
M>R >OEP2.^/7CBHO!?[$OQI^(7A&P\3^'_!GV_0[^(S6]T=4LHMZ@D$['F5A
MRIX(!XK[,TC_ (*Z^&+GQ-]FU'X?:I8Z 7VKJ,.H1S7 7/#-!L4#W D/MFOM
M_P -ZYHWB?P9::SX>F@N-%U&V-Y:S6Z[4D60%]V,#!)8DYYR3GFN&OCL7AZ?
M/4II=NWSUW^[J:PHTJE10C+^M-OZ?0_GJAL;BYO4LX89)[J201)#$I=W<G 5
M0.I)XP*]YTG]@?X]ZUI4.HV_P[NX[>5!(JW5[:6\P!'>*2574^Q4&O2_^"8N
MAZ#K'[3FI3:M%#/J%CIEQ<Z6DP!VS>:BLZ@_Q!&?'H"3VX^Y_P!I;XT?%[X,
M^)-)U/PK\.;?QM\/E@#:K+9F1]1CDW'(55/RJ%VG=L<=<E>#79BL7.C.%*FE
M>2O=[=?\C.%%2E4[1=O/^M3\:/&/@G7_ (>Z]/HOB71[W0]5A^_:7T+1/CG#
M 'JIQPPR#V-9FG:;=ZQ?6]C86LU[>W#B*&WMXS))(Y. JJ!DDGL*^N/V]_VO
MO"_[1C>']&\*:,K:?IF+I];OK?R[LR.GS6Z#JL:Y&[KN901PH+?5O_!.']FK
M2/A[\*]/^(NJ627/BSQ#";B">5 S6=F<[%CXR"Z_,Q')# =N=/K4J>']M7C9
M[6[_ .1G.FG45.D[W_#^OS/A/1_V!?CYKFG0WMM\.[J.&50ZK>7UI;2@'^]'
M+,KJ?8@&O-_B;\#_ ![\&[M+?QGX5U'0/,;;'/<1[H)6QG"3*3&YQV5C7ZJ>
M/OVUO&6A:_+9>%?V=?B)XGT^%VC.H76F75BLF#C=&GV:0E3U&[:?4"O3/!OB
MC1_VIOAOJ^D>+_ASXB\.6\RB"^T7Q;I,EMNW#(>&1E ?!'#+AE(!PORD^?\
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M:#8H'J0)&/IFN?Z]7KR?U:%XKO\ \.ON+5&-.*E6=K]OZ9]&_LF_\FC> /\
ML7U_]!:OPTK^AG1]2T;6O <6I>'7MY=$O;(W5I):*%B>.12X90!QG=G\:_GF
MK/+I.>)Q$VK7MIVUD%6*AAZ44[VZ_*(4445] <04444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ]QX=NI9;G3+12\LL,JJ#(B#EV0H.!SAF/:ORX\"_"OQ;\2O%$?AWPUX?O\
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MMDG(XX'1!D DDEC@CRGX _'KQ)^SM\0;;Q3X==)3M\B\L)R?)O("06C?'3D
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M&*_7#]F/PK??"/\ 9<\(Z7KT/]FW^FZ2]S>12GF!F+RLK>A4-@CL0:XW3O\
M@H]\ ;VQBGF\97&GRNH9K6XT>\,B'^Z2D3+GZ,1[U\Q?MB?\%'-+^('@W4?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUS:OYRVDC=(9\?ZM^G^R<X#$@@?:_P#P2'_Y$GXB_P#80M/_ $6]>4?M>?\
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M5+]8W;\O^"=6%C2HU6W+5I>EM?Q_X!+_ ,$C?^26^.O^PS'_ .B%KX\_;_\
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M445ZYQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@N8_X@7;S5;Z%7QG_9/I7@G[9_\ P4,\/_$3P'J'@#X:Q74]AJ2B'4-;N83
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M4JCFKK9?/9:_,\,HHHKVCSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]=/\ @E9_R;3>_P#8
M?NO_ $7#7YW_ +8W_)T7Q+_[#,W]*^L_V ?VLOA3\$_@?<^'_&GBK^QM7?5Y
M[I;?^SKN?,;)$%;=%$R\E6XSGBOC/]I3QAI'Q ^/7CCQ'H%W]OT;4M3DN+6Y
M\IX_,C.,':X##Z$ UX\:<_[3E4L^7EWZ?9.NG)+!<C>O-M\Y'FE?HY_P1_\
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M(/S['Q)(P_NE5'N>AY52=E'ZM[WJ[?U\S7F3=_:67R_K\#X3_:D^/R?M)_%
M^,4\/?\ "-,UC#9O9_;?M6XQEOGW^6G4,!C;_#UYKR&K.I:E<ZQJ5U?WDIGN
M[J5YYI6 !=V)9FX]235:OJ*-.-&"A%61YM23G)R;N?8_[,O_  3UM_VD/A3:
M>,H?B,-#DDN9K6;3QHOVGR7C; R_VA,Y4JWW1C=7S1\7?AEJGP=^)&O^#]72
M076EW3PK,\?EBXBS^[F49.%==K#D]>M>\?L,_MC+^S7KU]HWB*&>\\$ZQ*LL
MYMQNEL9P-OGJO\2E<!EZX52.1M;]&K[XS_LV_%>TT[5]:\3_  [ULPJ)+5O$
M4MH+B#OQ'<8DC/M@&O-Q%;$8:OS6YJ;_  _K7?=&M&,*E-Q>D_Z_KU.:_P""
M<^K>+]8_9ETF;Q:]S,$NYH]*FO&9I9+$;?+)+<E0WF*O^RJXXQ7Y7_M.0Z;;
M?M$?$B+20!8+K]X$5<8!\UMP&.P;=CVK]&?VG/\ @HUX(\ ^%[[1/AKJ<'B?
MQ7+&T$-Y9)NL;#( \SS"-LA /RJFX9'S$8P?R>NKJ:^NIKFYE>>XF=I))9&+
M,[$Y+$GJ23G-98.-2KB9XJ4>5-6]=M?PWZMFU3EHX=4+W=[^F_\ GMY$5%%%
M>X< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4JJ78*H+,QP !R:2O3OV:;KP;IGQO\*:GX_U1=)\+:;="^N9FMY9
M][1#?''LB1V.Z0(#QC&>:>F[V)DVEIN?L1^S7\.]/_9T_9R\.Z5J]Q;:3]AL
M?M^L7=W,L<44T@\R9G=L *I.W)[(*PM:UO\ 96\2:I<ZGJU_\'M4U*Z?S)[R
M]FTJ::5C_$[L26/N37S+^W=^W!X"^)7P5;P?\.?$3:U=:M=QKJ+"RN;;RK5#
MOQF6-,EG"# SP&SUK\X*^9HX.IBISKU;Q;?]?+I\CTY3C0IQIPUT_KY]?F?T
M#?#/QC\.M:T[^QOA[KGA>_L-,0?\2_PS=VTD5JC$X_=PDA 3N[#)S7X[?MR?
M"'_A3O[1WB6QMXO*TG57_MBP]/+F)+*/0+()% ]%%'[$?QXL_P!G_P".VGZU
MK5TUIX9OH)-/U618WDV1, RR;$!8[9%0\ G&['6O<O\ @HA\</@W^T!X3\-Z
MGX+\6KJGBK1[EX3;?V;=P&6UE&6^>2%5RKHA )Z,U:1P\\'BH2C>49:-]KO_
M #L[]KBC5C6I3IRLK:KY+_AU;T/MS]F&6'QM^R#X&M[:52MQX:33RRG[KK&8
M6'U#*?RK\9IO@[XU@^(A\"-X:U'_ (2P7'V8:6(&\TMG&X<<IWW_ '<<YQS7
MTE^Q/^W</V>=-E\'^+K&ZU3P=+.T]M/9X:XL';[X",0'C8_,0"""6(SG%?<?
M_#QC]G[[/YG_  G,F_&?)_L:^W?3_4XS^-5*-;!XJI5A#F4_\V^GJ_4SA)5:
M$:4G9Q_K\;+T.D_:!5/ /['7C&SGE2$V/A.33PV<CS#;B%0">N6('XU^=O\
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M<94#N6P!WQ7WY^R[_P %.].TOP_8^&?BW'=B>T188/$UI$9_-0# ^TQCY]P
M WH&W9Y Y)]U\5?\%+?@7H.CS7>F^(+[Q+>*/DL+#2[B*1S_ +TZ1H!ZG=^!
MZ5A1^L9>Y4O9\R;NFOZ9<G#$Q3ORM'J?P$^'>H?"?]G7PQX3U:19-4TW23'=
M;&W*LC!G9 >X4L5S[5^#-?L/X7_X*/\ P:\0> K6Y\0^)TT'Q!=6K&YTF/3K
MZ<6TASB/S5@VO@8&X<'KQTK\>*WP$:WUBO.M&SE;TO>5[&=3V<:%*%-Z+[]E
MN%%%%>X<84444 %%%% !1110 4444 %?K+_P29_Y-S\1_P#8UW/_ *1V=?DU
M7ZR_\$F?^3<_$?\ V-=S_P"D=G7E9G_N[]4=6&_B'YP_M*?\G&?%3_L:]5_]
M+):\XKT?]I3_ ).,^*G_ &->J_\ I9+7G%>C3^"/H<\OB84445H2%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_AT/X:_Z*)JW_@OB_P#BZ/\ AT/X:_Z*)JW_ (+XO_BZ_-+^V]1_Y_[K_O\
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M]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\
MHHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^
M"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO
M4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^
MBB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ
M/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/
MX:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G
M]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\T
MO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_?@@]I3_D_$_2W_AT
M/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[;U'_ )_[K_O\W^-'
M]MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_
MX=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']MZC_S_P!U_P!_F_QH
M^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\
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MK_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\
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M:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\
M/_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_
M **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_
M?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[
M;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK
M_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']M
MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=
M#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_
MY_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_
M-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X
M=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C
M1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ
M/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\
M:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_
M .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM
M_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\
MO\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+
M_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?Y
MO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_
MX+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_
MY/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?
M^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_
M (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\
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M/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\
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MO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\
M?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^
M"^+_ .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/
MQ/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\
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MZ_-+^V]1_P"?^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\
MAT/X:_Z*)JW_ (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-
M_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\
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M]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\
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M^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\
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MK_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\
M@OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']MZC_S_P!U
M_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:
MM_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_Y_?@@]I3
M_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_-+^V]1_Y
M_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X=#^&O^BB
M:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\
M/_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_
M **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_
M?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[
M;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK
M_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']M
MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=
M#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_
MY_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_
M-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X
M=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C
M1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ
M/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\
M:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_
M .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM
M_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\
MO\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+
M_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?Y
MO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_
MX+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_
MY/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?
M^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_
M (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\
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M/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\
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MO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\
M?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^
M"^+_ .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/
MQ/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\
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MZ_-+^V]1_P"?^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\
MAT/X:_Z*)JW_ (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-
M_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\
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M]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\
MHHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^
M"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO
M4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^
MBB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ
M/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/
MX:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G
M]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\T
MO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_?@@]I3_D_$_2W_AT
M/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[;U'_ )_[K_O\W^-'
M]MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_
MX=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']MZC_S_P!U_P!_F_QH
M^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\
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MK_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\
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M:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\
M/_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_
M **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_
M?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[
M;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK
M_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']M
MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=
M#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_
MY_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_
M-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X
M=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C
M1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ
M/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\
M:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_
M .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM
M_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\
MO\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+
M_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?Y
MO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_
MX+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_
MY/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?
M^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_
M (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\
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MA(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV6.01Y7<%*D^C&NRCB:>$PM)I.TF_P 'J_Q"HI5\1.#W2C^*LOR/PQHK]O\
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M@>X(/>L*O8C)3BI1=TSDE%Q;C+=!1115$A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /( (!KYN_X*??$#X3^+O$.F6/A\)JGQ#T]S!J&J:;(OV>*$9_<3, ?,D#=
M#\GS G^&NY9A"I6C2I)RON^W]==C%8>7+*4]+?U_PW],^V_V<?\ DS[P/_V*
MD/\ Z(KX\_X)!_\ (R_$S_KTL?\ T.:OL/\ 9Q_Y,^\#_P#8J0_^B*^//^"0
M?_(R_$S_ *]+'_T.:O*A_$QGR_.1;_W?#_+_ -M.3_X*+?\ )Z/A?_KPTS_T
MHDK[R_;0\<:E\._V9/'>M:1<26FI+:);0W$+%7B,TJ1%U(Y! <D$=#BO@W_@
MHM_R>CX7_P"O#3/_ $HDK[/_ ."AG_)HGCKZ6?\ Z5PUG42EA,+%[.4E_P"3
M1-Z'^_U'_=A_[<?DQ^SCKUWX=^/WP\U"TGD@G37K-"\9PQ1YE1U^C*S*?4$U
M^J?_  4I_P"32?$O_7Y8_P#I2E?DU\$O^2S> ?\ L/V'_I3'7ZR_\%*?^32?
M$O\ U^6/_I2E>AFG\3#_ .)?^E1.;";U?\/Z2,;_ ()<_P#)KJ?]AJ\_E'7A
MG[(NDV.H_P#!1[XJ7%W&CSV,NLW%H6&2LAO$C)'OLD<?0FO<_P#@ES_R:ZG_
M &&KS^4=?!NI_&;4?@%^V]XP\9Z=%]I%GXFU%+JSW;1<V[SNLD>>Q(.0>S!3
MVIJ+GCJT%NX-?>DB*6F O:]IW^Z4CZ4_X*V>//$FG?\ "%>$[:YGM/#&H0S7
METD3%4NYD=0J/CJ$!#;>F7!Z@8_..RO;C3;R"[M)Y;6Z@=98IX7*/&X.0RL.
M001D$5^Y30_"']M[X6V[2K9^*M$9EE$8D,=WI\^.AVD/#(.A'1A_>4\^:^#_
M /@F'\%_"OB"/5+B/7?$:1N'33]8O8VM@0<C*Q1HS#V9B".H-<^"Q4,'!T:R
M:DF_G_P>GHD=->#Q%ITW=6_K_,_*KXE?&+QI\8=2M[_QGXCOO$%Q;QB*#[4X
MV1+@#Y$4!5)P,D#+$9.37ZL_\$Q=,LK']E?3KBV15N+S4[R:Z9>ID$GEC/\
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MWO\ A;YGL'BCX2_L:>,/$.H:UKOB+PCJ6L7TS375U<^/93)(Y/)/^F<>F.@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7ZR_\ !)G_ )-S\1_]C7<_
M^D=G7Y-5^LO_  29_P"3<_$?_8UW/_I'9UY69_[N_5'5AOXA^??[1O@GQ%=?
MM"?%">#0=3FAD\4ZHZ21V<C*RF[E(((7D$=Z\[_X0+Q-_P!"YJW_ ( R_P#Q
M-?NSJ'P)\-ZE?W-W*]\LEQ*TK!)E !8DG'R].:K_ /#/GA?_ )Z:A_W^7_XF
MO,CFTXQ4>3;S.EX6+=^8_"[_ (0+Q-_T+FK?^ ,O_P 31_P@7B;_ *%S5O\
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M +_+_P#$T?VO/^3\0^J1_F/PN_X0+Q-_T+FK?^ ,O_Q-'_"!>)O^A<U;_P
M9?\ XFOW1_X9\\+_ //34/\ O\O_ ,31_P ,^>%_^>FH?]_E_P#B:/[7G_)^
M(?5(_P Q^%W_  @7B;_H7-6_\ 9?_B:/^$"\3?\ 0N:M_P" ,O\ \37[H_\
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M_P#$T?VO/^3\0^J1_F/PN_X0+Q-_T+FK?^ ,O_Q-'_"!>)O^A<U;_P  9?\
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M_P#Q-'_"!>)O^A<U;_P!E_\ B:_='_AGSPO_ ,]-0_[_ "__ !-'_#/GA?\
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M/^&?/"__ #TU#_O\O_Q-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_P#$T?\
M"!>)O^A<U;_P!E_^)K]T?^&?/"__ #TU#_O\O_Q-'_#/GA?_ )Z:A_W^7_XF
MC^UY_P GXA]4C_,?A=_P@7B;_H7-6_\  &7_ .)H_P"$"\3?]"YJW_@#+_\
M$U^Z/_#/GA?_ )Z:A_W^7_XFC_AGSPO_ ,]-0_[_ "__ !-']KS_ )/Q#ZI'
M^8_"[_A O$W_ $+FK?\ @#+_ /$T?\(%XF_Z%S5O_ &7_P")K]T?^&?/"_\
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M/Q#ZI'^8_"[_ (0+Q-_T+FK?^ ,O_P 31_P@7B;_ *%S5O\ P!E_^)K]T?\
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MGA?_ )Z:A_W^7_XFC_AGSPO_ ,]-0_[_ "__ !-']KS_ )/Q#ZI'^8_"[_A
MO$W_ $+FK?\ @#+_ /$T?\(%XF_Z%S5O_ &7_P")K]T?^&?/"_\ STU#_O\
M+_\ $T?\,^>%_P#GIJ'_ '^7_P")H_M>?\GXA]4C_,?A=_P@7B;_ *%S5O\
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M $+FK?\ @#+_ /$T?\(%XF_Z%S5O_ &7_P")K]T?^&?/"_\ STU#_O\ +_\
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M\O\ \31_PSYX7_YZ:A_W^7_XFC^UY_R?B'U2/\Q^%W_"!>)O^A<U;_P!E_\
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M:_#'QC?;C;>$]<N-OWO*TV9L9]<+7[D_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\
MSTU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\ \31_P@7B
M;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 31_PSYX7_ .>FH?\ ?Y?_
M (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X R_\
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M_$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;_P  9?\
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M (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\ STU#_O\
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M_/34/^_R_P#Q-']KS_D_$/JD?YC\+O\ A O$W_0N:M_X R__ !-'_"!>)O\
MH7-6_P# &7_XFOW1_P"&?/"__/34/^_R_P#Q-'_#/GA?_GIJ'_?Y?_B:/[7G
M_)^(?5(_S'X7?\(%XF_Z%S5O_ &7_P")H_X0+Q-_T+FK?^ ,O_Q-?NC_ ,,^
M>%_^>FH?]_E_^)H_X9\\+_\ /34/^_R__$T?VO/^3\0^J1_F/PN_X0+Q-_T+
MFK?^ ,O_ ,31_P (%XF_Z%S5O_ &7_XFOW1_X9\\+_\ /34/^_R__$T?\,^>
M%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;_P  9?\ XFC_ (0+
MQ-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\ STU#_O\ +_\
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M ,O_ ,31_P (%XF_Z%S5O_ &7_XFOW1_X9\\+_\ /34/^_R__$T?\,^>%_\
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MJW_@#+_\31_P@7B;_H7-6_\  &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\
M#/GA?_GIJ'_?Y?\ XFC^UY_R?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A
MO$W_ $+FK?\ @#+_ /$U^Z/_  SYX7_YZ:A_W^7_ .)H_P"&?/"__/34/^_R
M_P#Q-']KS_D_$/JD?YC\+O\ A O$W_0N:M_X R__ !-'_"!>)O\ H7-6_P#
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M^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\ STU#_O\ +_\ $T?VO/\
MD_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\ \31_P@7B;_H7-6_\ 9?_ (FOW1_X
M9\\+_P#/34/^_P O_P 31_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W
M_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\
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M34/^_P O_P 31_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\
MH7-6_P# &7_XFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC
M_AGSPO\ \]-0_P"_R_\ Q-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_\31_P
M@7B;_H7-6_\  &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?
MY?\ XFC^UY_R?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A O$W_ $+FK?\
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M_H7-6_\  &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?Y?\
MXFC^UY_R?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A O$W_ $+FK?\ @#+_
M /$U^Z/_  SYX7_YZ:A_W^7_ .)H_P"&?/"__/34/^_R_P#Q-']KS_D_$/JD
M?YC\+O\ A O$W_0N:M_X R__ !-'_"!>)O\ H7-6_P# &7_XFOW1_P"&?/"_
M_/34/^_R_P#Q-'_#/GA?_GIJ'_?Y?_B:/[7G_)^(?5(_S'X7?\(%XF_Z%S5O
M_ &7_P")H_X0+Q-_T+FK?^ ,O_Q-?NC_ ,,^>%_^>FH?]_E_^)H_X9\\+_\
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M_P 31_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P#
M&7_XFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\
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M\Q^%W_"!>)O^A<U;_P  9?\ XFC_ (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\
MGIJ'_?Y?_B:/^&?/"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\
M0N:M_P" ,O\ \31_P@7B;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 3
M1_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_X
MFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\ \]-0
M_P"_R_\ Q-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_\31_P@7B;_H7-6_\
M &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?Y?\ XFC^UY_R
M?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A O$W_ $+FK?\ @#+_ /$U^Z/_
M  SYX7_YZ:A_W^7_ .)H_P"&?/"__/34/^_R_P#Q-']KS_D_$/JD?YC\+O\
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M_B:/^&?/"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P"
M,O\ \31_P@7B;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 31_PSYX7_
M .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W
M_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\ \]-0_P"_R_\
MQ-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_\31_P@7B;_H7-6_\  &7_ .)K
M]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?Y?\ XFC^UY_R?B'U2/\
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M^&?/"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\
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MJ1_F/PN_X0+Q-_T+FK?^ ,O_ ,31_P (%XF_Z%S5O_ &7_XFOW1_X9\\+_\
M/34/^_R__$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;
M_P  9?\ XFC_ (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/
M"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\ \31_
MP@7B;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 31_PSYX7_ .>FH?\
M?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X
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M^_R__$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;_P
M9?\ XFC_ (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\
MSTU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\ \31_P@7B
M;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 31_PSYX7_ .>FH?\ ?Y?_
M (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X R_\
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M_$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;_P  9?\
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M (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\ STU#_O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 44F:* #-'-%+0!"\FSKQ3?M ]:G90PP1D52N=/8Y:
M%L'^ZW2@"RLP-/#9K":ZEM7VS(4/KV-7(+Y6[T :=%01SAN]2JV: '44E+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7FWQJ_P"//2/^N[?R%>DUYM\:O^//2/\ KNW\A0!Z31110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC;1]1PW\B#ZM2_E/KC_AYQ\4O^@!X1_\ [K_ .2:/^'G'Q2_Z 'A'_P#NO\
MY)KY'VT;:/J.&_D0?5J7\I]<?\/./BE_T /"/_@'=?\ R31_P\X^*7_0 \(_
M^ =U_P#)-?(^VC;1]1PW\B#ZM2_E/KC_ (><?%+_ * 'A'_P#NO_ ))H_P"'
MG'Q2_P"@!X1_\ [K_P"2:^1]M&VCZCAOY$'U:E_*?7'_  \X^*7_ $ /"/\
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M:/\ AYQ\4O\ H >$?_ .Z_\ DFOD?;1MH^HX;^1!]6I?RGUQ_P /./BE_P!
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M(^VC;1]1PW\B#ZM2_E/KC_AYQ\4O^@!X1_\  .Z_^2:/^'G'Q2_Z 'A'_P
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M'Q2_Z 'A'_P#NO\ Y)KY'VT;:/J.&_D0?5J7\I]<?\/./BE_T /"/_@'=?\
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M_P#)-'_#SCXI?] #PC_X!W7_ ,DU\C[:-M'U'#?R(/JU+^4^N/\ AYQ\4O\
MH >$?_ .Z_\ DFC_ (><?%+_ * 'A'_P#NO_ ))KY'VT;:/J.&_D0?5J7\I]
M<?\ #SCXI?\ 0 \(_P#@'=?_ "31_P /./BE_P! #PC_ . =U_\ )-?(^VC;
M1]1PW\B#ZM2_E/KC_AYQ\4O^@!X1_P# .Z_^2:/^'G'Q2_Z 'A'_ , [K_Y)
MKY'VT;:/J.&_D0?5J7\I]<?\/./BE_T /"/_ (!W7_R31_P\X^*7_0 \(_\
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MR/MHVT?4<-_(@^K4OY3ZX_X><?%+_H >$?\ P#NO_DFC_AYQ\4O^@!X1_P#
M.Z_^2:^1]M&VCZCAOY$'U:E_*?7'_#SCXI?] #PC_P" =U_\DT?\/./BE_T
M/"/_ (!W7_R37R/MHVT?4<-_(@^K4OY3ZX_X><?%+_H >$?_  #NO_DFC_AY
MQ\4O^@!X1_\  .Z_^2:^1]M&VCZCAOY$'U:E_*?7'_#SCXI?] #PC_X!W7_R
M31_P\X^*7_0 \(_^ =U_\DU\C[:-M'U'#?R(/JU+^4^N/^'G'Q2_Z 'A'_P#
MNO\ Y)H_X><?%+_H >$?_ .Z_P#DFOD?;1MH^HX;^1!]6I?RGUQ_P\X^*7_0
M \(_^ =U_P#)-'_#SCXI?] #PC_X!W7_ ,DU\C[:-M'U'#?R(/JU+^4^N/\
MAYQ\4O\ H >$?_ .Z_\ DFC_ (><?%+_ * 'A'_P#NO_ ))KY'VT;:/J.&_D
M0?5J7\I]<?\ #SCXI?\ 0 \(_P#@'=?_ "31_P /./BE_P! #PC_ . =U_\
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M1_P\X^*7_0 \(_\ @'=?_)-?(^VC;1]1PW\B#ZM2_E/KC_AYQ\4O^@!X1_\
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M:^1]M&VCZCAOY$'U:E_*?7'_  \X^*7_ $ /"/\ X!W7_P DT?\ #SCXI?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(QQ2U%(V* )*6BB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z*
M&;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]
MJ-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^
MU/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B
M@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;
M?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-
MOM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/
MHH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!
MFWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:
MC;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM
M3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH
M 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FW
MVHV^U/HH 9M]J-OM3Z* &;?:C;[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:C;
M[4^B@!FWVHV^U/HH 9M]J-OM3Z* &;?:OTN_X)H?\D)UW_L9)_\ TEM:_-2O
MTL_X)H_\D)UW_L9)_P#TEM:\;-O]V?JCS\=_!/K2BBBOB#YP**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD^;OVZ?@D<#\)?A'H7PS^&NF^&+;2K94^RHM^'C5S=3%1YC2'^/)SUR,8 X
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M]0N]1GU)'8U\_?%;]CCXD_"/29M=OK.RUC2;?]Y/=:3,9E@7/WG1U5MOJ=I
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M$OQ)9:S#J*-#K5S>W%W<0Q1PI(\*DRJP5P&4@-CYCD'I73:)^T5^TW<> _\
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M"MAIG[7'P+T^U^*/@35=)F:1#J6A:M#=Z<RW47_+2,YC=HSG<"#CG!Y4UK^
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MYLWJU*%##RH49<SENST&BBBOFSQ0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!*IWGW35RJ=Y]TT 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "O@
M_P#::_Y+?XD_[=O_ $FBK[PKX/\ VFO^2W^)/^W;_P!)HJ^[X-_W^?\ @?\
MZ5$_'_%#_D34O^OL?_2)GYX>,O\ D>/$/_81N/\ T:U+8CI1XR_Y'CQ!_P!A
M&X_]&M2V/:NJ7\67J_S/W;*?]QH?X(_DC9A7BK2KQ5>WZ597I79$]Y!M%&T4
MM%4,3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH
M3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-
MHI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:*
M $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VB
MC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6
MB@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-
MHHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVB
MEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH
M3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-
MHI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:*
M $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VB
MC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6
MB@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-
MHHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVB
MEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH
M3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-
MHI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:*
M $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VB
MC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6
MB@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*_2?\ X)K?\D+UW_L8
MY_\ TEM:_-FOTG_X)K_\D+UW_L8Y_P#TEM:\7-_]U?JCSL?_  3ZQHHHKX8^
M;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"Z:L?\.P?^JE?^4'_[IKK6:8/^?\'_ )&_URA_-^#_ ,CX4HK[K_X=@?\
M52O_ "@__=-'_#L#_JI7_E!_^Z:K^U,'_/\ @_\ (/KM#^;\&?"E%?=?_#L#
M_JI7_E!_^Z:/^'8'_52O_*#_ /=-']J8/^?\'_D'UVA_-^#/A2BONO\ X=@?
M]5*_\H/_ -TT?\.P/^JE?^4'_P"Z:/[4P?\ /^#_ ,@^NT/YOP9\*45]U_\
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M:'\WX,^%**^Z_P#AV!_U4K_R@_\ W31_P[ _ZJ5_Y0?_ +IH_M3!_P _X/\
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M#_JI7_E!_P#NFC^U,'_/^#_R#Z[0_F_!GPI17W7_ ,.P/^JE?^4'_P"Z:/\
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M=@?]5*_\H/\ ]TT?\.P/^JE?^4'_ .Z:/[4P?\_X/_(/KM#^;\&?"E%?=?\
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M31_:F#_G_!_Y!]=H?S?@SX4HK[K_ .'8'_52O_*#_P#=-'_#L#_JI7_E!_\
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M_P#=-']J8/\ G_!_Y!]=H?S?@SX4HK[K_P"'8'_52O\ R@__ '31_P .P/\
MJI7_ )0?_NFC^U,'_/\ @_\ (/KM#^;\&?"E%?=?_#L#_JI7_E!_^Z:/^'8'
M_52O_*#_ /=-']J8/^?\'_D'UVA_-^#/A2BONO\ X=@?]5*_\H/_ -TT?\.P
M/^JE?^4'_P"Z:/[4P?\ /^#_ ,@^NT/YOP9\*45]U_\ #L#_ *J5_P"4'_[I
MH_X=@?\ 52O_ "@__=-']J8/^?\ !_Y!]=H?S?@SX4HK[K_X=@?]5*_\H/\
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M/_W31_P[ _ZJ5_Y0?_NFC^U,'_/^#_R#Z[0_F_!GPI7Z3?\ !-G_ )(9KO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU+24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $!+/_R'_P#'* L>P45X_P#VY\6O^@)9_P#D/_XY1_;GQ:_Z EG_ .0__CE
M6/8**\?_ +<^+7_0$L__ "'_ /'*/[<^+7_0$L__ "'_ /'* L>P45X__;GQ
M:_Z EG_Y#_\ CE']N?%K_H"6?_D/_P".4!8]@HKQ_P#MSXM?] 2S_P#(?_QR
MC^W/BU_T!+/_ ,A__'* L>P45X__ &Y\6O\ H"6?_D/_ ..4?VY\6O\ H"6?
M_D/_ ..4!8]@HKQ_^W/BU_T!+/\ \A__ !RC^W/BU_T!+/\ \A__ !R@+'L%
M%>/_ -N?%K_H"6?_ )#_ /CE']N?%K_H"6?_ )#_ /CE 6/8**\?_MSXM?\
M0$L__(?_ ,<H_MSXM?\ 0$L__(?_ ,<H"Q[!17C_ /;GQ:_Z EG_ .0__CE'
M]N?%K_H"6?\ Y#_^.4!8]@HKQ_\ MSXM?] 2S_\ (?\ \<H_MSXM?] 2S_\
M(?\ \<H"Q[!17C_]N?%K_H"6?_D/_P".4?VY\6O^@)9_^0__ (Y0%CV"BO'_
M .W/BU_T!+/_ ,A__'*/[<^+7_0$L_\ R'_\<H"Q[!17C_\ ;GQ:_P"@)9_^
M0_\ XY1_;GQ:_P"@)9_^0_\ XY0%CV"BO'_[<^+7_0$L_P#R'_\ '*/[<^+7
M_0$L_P#R'_\ '* L>P45X_\ VY\6O^@)9_\ D/\ ^.4?VY\6O^@)9_\ D/\
M^.4!8]@HKQ_^W/BU_P! 2S_\A_\ QRC^W/BU_P! 2S_\A_\ QR@+'L%%>/\
M]N?%K_H"6?\ Y#_^.4?VY\6O^@)9_P#D/_XY0%CV"BO'_P"W/BU_T!+/_P A
M_P#QRC^W/BU_T!+/_P A_P#QR@+'L%%>/_VY\6O^@)9_^0__ (Y1_;GQ:_Z
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M*\?_ +<^+7_0$L__ "'_ /'*/[<^+7_0$L__ "'_ /'* L>P45X__;GQ:_Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(@\QQ[<22$>I-?HY^U)\'Y/C5\(-4T6RB676[<K>Z;N*KF=,_)N) &]2RY)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\V^-7_ !YZ1_UW;^0KTFO-
MOC5_QYZ1_P!=V_D* /2:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_X;P^!G_0\?^4F^_P#C%?D9M]J-OM1_8]#^9_A_D'U"GW9^N?\ PWA\#/\
MH>/_ "DWW_QBC_AO#X&?]#Q_Y2;[_P",5^1FWVHV^U']CT/YG^'^0?4*?=GZ
MY_\ #>'P,_Z'C_RDWW_QBC_AO#X&?]#Q_P"4F^_^,5^1FWVHV^U']CT/YG^'
M^0?4*?=GZY_\-X? S_H>/_*3??\ QBC_ (;P^!G_ $/'_E)OO_C%?D9M]J-O
MM1_8]#^9_A_D'U"GW9^N?_#>'P,_Z'C_ ,I-]_\ &*/^&\/@9_T/'_E)OO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$SQ)\5_@^^M^*M2_M35!J4]N)_(BA_=JJ%1MC55_B/.,\U[M7Y[?L-_M)?\
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M-2ES.*\M-_/\K[&E.,?JM6\+M/?33_AGVW/N2BOF7]HG]M+_ (4'\0$\,?\
M"'?V[NLH[O[5_:GV?[[,-NWR7Z;>N>]8GC/_ (**>#_#NF:=_96BW'B#5Y[6
M*>YMH;D1VUJ[H&:(SE"792<$JF..N<@<4,%B*D8SA"Z>W]=/F8K!8B7+:.ZN
MOZ^9]:UXA^U]\9M:^"/PI&K^'X8SJMY>I8Q7,T?F);;E=B^T\$X3 !XR><XP
M>-^#/[?'A/XG>(;70M9TJ?PEJ5Y((K5Y;@7%M(YX5#)M4JQ/ RN/?I7HW[5'
MBK1?!OP5UG4O$'AB'Q?I0DAAETJ>?R!)OD50PD"L5*DY! SQP11]7J8>M"%:
M&[6G?7:^Q5&E*GB(PJPOY?UH>5_L/_M(>+?C/+XAT;Q;)'J5SIT4=S%J4<"0
ML59BI1U0!>V00!WSFOJ^OF#]ASX@>$O&6B^)[/PEX A\#6UA+ TH347OGN6D
M#X+2.@;Y=G )/WN,5B^+?V_X?"/Q6U'P=<^"T^SV6JG3I-4DUGRU"B3892GD
M'  YQN[=:Z\5AIUL7*G0I\K2O;3RUWMU"I0G5K5/90LETTTT_IZ>A]<T5\?>
M/O\ @I%X5T#5I+/PQX;N_%%O&Q5KV:Y%E$_O&"CL1[L%^E>F? ']KSPG\>+Q
MM)AMY]!\1JAD_LV[8.)5 RQBD&-V.X(4]\8!-<DL#B8T_:N#M_73<SJ86M2A
MSSC9'NM%5=3U.TT73[F_O[F*RLK:-I9KB=PD<: 9+,QX  KY'\=?\%)/"VAZ
MI):^&?#-YXF@C8J;R>Y%E&^.Z H[$?[P4^U8T</5Q$N6E&Y%'#U:_P##C<^P
MJ*^3O!__  40\&^(M%U5]2TBXT'6[6SFN;:RN+@/;WCHA985G"_*S$8&Y .1
MC)XK=_9P_;*_X:"\=7?AS_A$/[!\BPDOOM/]I_:=VV2--NWR4QGS,YSVZ<UO
M+ 8F*DY0^'5[?T_D5/"UJ<7.4;)'TI1117 <H4444 %%%% !1110 4E+30?F
MH 7'K12T4 %%%% !1110 4444 %%%% !1110 5X5\:?V-?AQ\:!)=76F?V'K
M;8QJNE*(I#]P?.N-K_*F!D<9->ZT5M3K5*,N:F[,EQ3:?5??]Y^1?QN_8@^(
M7P9AN=2AMU\4>'H5WOJ&G*=\2@+DR1'E1EL9&?NDG KY^63G!X(]:_<WXI_\
MDQ\7_P#8'O/_ $0]?E'\8?#>F'PK?ZO]DC34(3&1.@VDYD53NQUX)ZU]_E,:
MF886I7;2</QTN>%B^+UE.:X7*\5!S5>R4E:Z;ERJZT35WNK-=F>)JU/&#5.&
M8-5M&S6J=S].3';:-M/ %&T55AC-M&VG[11M%%@&;:-M/VBC:*+ ,VT;:?M%
M&T46 9MHVT_:*-HHL S;1MI^T4;118!FVC;3]HHVBBP#-M&VG[11M%%@&;:-
MM/VBC:*+ ,VT;:?M%&T46 9MHVT_:*-HHL S;1MI^T4;118!FVC;3]HHVBBP
M#-M&VG[11M%%@&;:-M/VBC:*+ ,VT;:?M%&T46 9MHVT_:*-HHL S;1MI^T4
M;118!FVC;3]HHVBBP#-M&VG[11M%%@&;:-M/VBC:*+ ?O31117YF?'A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"";]K?2?&C6)X XL8]&D6Y;^'+2Q; ??()'T-;_P#P4R_Y'/P3_P!@^?\
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MG]B3P-KWPMTGQ%XTLI];U/6K=;N.(74L$5M$XS&%\ME+,5()+$CG&..?'/\
M@HE_R<!#_P!@:V_]#EK] /@K_P D=\#_ /8$L_\ T0E8U*U2CEM+V;LV_P#,
MUQM:I2HT(P=KKIY)?YGY6?M$?#2W^#'QDUSPWIEQ-)96;QS6DLC?O%1T6102
M,<KNQGVS7W5^V%?3:G^QVUY<-OGN(M-ED;U9GC)/YFOE7]OS_DX[5/\ KQM/
M_18KZB_:R_Y,M@_Z]M*_]"BK2M.52CA)3=WS1_-'34ES5L+-[M/\D<#_ ,$Q
M_P#CR^('_72R_E-7R[^T!9RZE^T3XWM(%WSW&O7$4:^K-*0!^9KZB_X)C_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ2H-^ZM;??\ YF,ZU2I&,)/1;'S=^TE^QW_PT)XVL/$'_"7?V!]ET]+'[/\
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M5G559R]Y:=//_,\K_9Q^!O\ PS_X%N?#G]M_V]YU\]Y]I^R?9L;D1=NW>_\
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M>LG_ (*G?!K_ (1W^TQ:^)VN1.(3I7V"$704@GS<F;RRG&.'+9(^7'->3_\
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MM-&TU)MHVT ?NY1117Y<?%A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X1^W)
M_P FM^-?^W+_ -+K>O=Z\)_;C_Y-;\:_]N7_ *76]=6$_P!XI_XE^9O0_BP]
M5^9^3>TT;33J*_23ZX;M-&TTZB@!NTT;33J* &[31M-.HH ;M-&TTZB@!NTT
M;33J* &[31M-.HH ;M-&TTZB@!NTT;33J* &[31M-.HH ;M-&TTZB@!NTT;3
M3J* &[31M-.HH ;M-&TTZB@!NTT;33J* &[37Z4?\$U?^2%Z[_V,D_\ Z2VM
M?FS7Z3_\$U_^2%Z[_P!C'/\ ^DMK7BYO_NK]4>=COX)]8T445\,?-A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM%6XQCKYX_>9]]V:_-GXN^%I_P!FG]H2[M/#U]+G1;N&]L)V;YPC*LBHQ'7
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M)XXXSZ+\-_V1_AOX5^']GH^I>%-,UN_EMU^VZA?VZRSR2LOSE'/S1C/0(1C
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MB:SM&"<GZ)7?X'<45Y?\/?VB/"7C[9!]J_LC46S_ *)?,%S]X_*_0_*N3Z9
MKU"M,1A:^$G[.O!Q?F88',,)F5)5\'44X]T_S[/R>H4445RGH!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;6OS:K])O^";'_)#-=_[&.?_ -);6O$SC_=7ZH\_'_P3ZPHHHKX4^:"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/!/IDD<<F' #*2Z."IVJ>G45I_!?X*>'_@3X4ET#P\]Y/;37+74MQ?NCS.[
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MS%6K8=4VJ7,Y/K=Z'DO[>5C;Z;^S-<VEG;Q6MI!>6<44$"!$C0-@*JC@  8
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M3C-/_P"P?=?^@5^F^N:3#KVBW^F7#.D%[;R6TC1D!@KJ5)!((S@^E>)?!_\
M8T\%?!3QI#XGT/5->NK^*&2!8]0N('BVN,$D)"IS^-<]+'QE]8E5WFK+[FO\
MCECB4Z%2,_BD[GO5%%%>$>8?+G_!17_D@EK_ -AJW_\ 1<M?.W[(G[57A3X
M>$=>TS7].UB]N;Z]6YB;388G0*(PN&+RJ0<CL#7W?\:/@SHOQT\(Q^'=>NK^
MTLDNDNQ)ITB))O4, ,NCC'S'MZ5X;_P[:^&?_0<\6?\ @7:__(]>[@L3AH8:
M="O?WG?3Y?Y'MT:^&>'C1K7T9\B?M.?'@_M'>/\ 3[[3M'ET^SM(!96=N[>9
M/,2Y.6"\9)8 *,].IS7US\8/!MY\/_\ @G]+H&H#;?V>G6*W"9SLD:[B=E_
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M6)K2W:3/^K01AAM#$+ECCWKW2NC,L?'%1A"GMN_7_@?J:8_%1Q,UR?"OS?\
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M-2\1R1G<D>LW2O&#[I&B*WT8$>U=<L9@:C]K-23[7_X/^1<L1@W>=I7?2_\
MP3LOV>;CP1XP\(VWC/PIX M/!;7RM"2NEP6LLB@@G:\8^>,L.#QG;TK\]/VK
MO^3J/%O_ &$+?_T5%7ZPV]O%:01P01I##&H1(XU"JJ@8  '0 5\^_$+]A_P+
M\2?'^H^+]3U;Q%!J5],D\D5I<P+"&554!0T+'&%'4FN+ XRG1Q;K3NHV:[]5
M_D<V#Q,*+J.IU^9]!0?ZF/\ W1_*OR<^-?\ R=UK_P#V,J?^C5K]9578H4=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\)_;B_Y-=\:_\ ;E_Z76]>[5X3^W%_R:[XU_[<O_2ZWKKPG^\4_P#$OS-Z
M'\6'JOS/R?HHHK]*/K@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OTF_X)L_\ )#-=_P"QCG_]);6O
MS9K])O\ @FS_ ,D,UW_L8Y__ $EM:\3./]U?JCS\?_!/K"BBBOA3YH**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;XU?\>>D?]=V_
MD*])KS;XU?\ 'GI'_7=OY"@#TFBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^&7_ $3KPG_X([7_ .-UW=%'MJG\S^\/:3[G"?\ "A?AE_T3KPG_ .".U_\
MC='_  H7X9?]$Z\)_P#@CM?_ (W7=T4>VJ?S/[P]I/N<)_PH7X9?]$Z\)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M( +E4 !;"J,]< >E:U%*52<E:3;$Y2>C84445F2%%%% !1110 4444 %%%%
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MO_B* LSL7A#54FLPV>*YG_A='@S_ *#(_P# :;_XBD/QF\&'_F,C_P !IO\
MXB@+,TKS1UD!^6N=U'PZK9^6K;_&/P8W_,9_\EIO_B*JS?%KP8__ #&!_P"
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M@R/_  &F_P#B* LSMZ*XC_A='@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\
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M#/\ H,C_ ,!IO_B*/^%T>#/^@R/_  &F_P#B* LSMZ*XC_A='@S_ *#(_P#
M:;_XBC_A='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\ P&F_^(H_X71X
M,_Z#(_\  :;_ .(H"S.WHKB/^%T>#/\ H,C_ ,!IO_B*/^%T>#/^@R/_  &F
M_P#B* LSMZ*XC_A='@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\ XB@+,[>B
MN(_X71X,_P"@R/\ P&F_^(H_X71X,_Z#(_\  :;_ .(H"S.WHKB/^%T>#/\
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M='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\ P&F_^(H_X71X,_Z#(_\
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M'@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\
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M@R/_  &F_P#B* LSMZ*XC_A='@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\
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M#/\ H,C_ ,!IO_B*/^%T>#/^@R/_  &F_P#B* LSMZ*XC_A='@S_ *#(_P#
M:;_XBC_A='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\ P&F_^(H_X71X
M,_Z#(_\  :;_ .(H"S.WHKB/^%T>#/\ H,C_ ,!IO_B*/^%T>#/^@R/_  &F
M_P#B* LSMZ*XC_A='@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\ XB@+,[>B
MN(_X71X,_P"@R/\ P&F_^(H_X71X,_Z#(_\  :;_ .(H"S.WHKB/^%T>#/\
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M='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\ P&F_^(H_X71X,_Z#(_\
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M'@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\
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M@R/_  &F_P#B* LSMZ*XC_A='@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\
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M#/\ H,C_ ,!IO_B*/^%T>#/^@R/_  &F_P#B* LSMZ*XC_A='@S_ *#(_P#
M:;_XBC_A='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\ P&F_^(H_X71X
M,_Z#(_\  :;_ .(H"S.WHKB/^%T>#/\ H,C_ ,!IO_B*/^%T>#/^@R/_  &F
M_P#B* LSMZ*XC_A='@S_ *#(_P# :;_XBC_A='@S_H,C_P !IO\ XB@+,[>B
MN(_X71X,_P"@R/\ P&F_^(H_X71X,_Z#(_\  :;_ .(H"S.WHKB/^%T>#/\
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M='@S_H,C_P !IO\ XB@+,[>BN(_X71X,_P"@R/\ P&F_^(H_X71X,_Z#(_\
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M_P!\G_&C_A5_A3_H!6G_ 'R?\:ZFB@#EO^%7^%/^@%:?]\G_ !H_X5?X4_Z
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M_P!\G_&C_A5_A3_H!6G_ 'R?\:ZFB@#EO^%7^%/^@%:?]\G_ !H_X5?X4_Z
M5I_WR?\ &NIHH Y;_A5_A3_H!6G_ 'R?\:/^%7^%/^@%:?\ ?)_QKJ:* .6_
MX5?X4_Z 5I_WR?\ &C_A5_A3_H!6G_?)_P :ZFB@#EO^%7^%/^@%:?\ ?)_Q
MH_X5?X4_Z 5I_P!\G_&NIHH Y;_A5_A3_H!6G_?)_P :/^%7^%/^@%:?]\G_
M !KJ:* .6_X5?X4_Z 5I_P!\G_&C_A5_A3_H!6G_ 'R?\:ZFB@#EO^%7^%/^
M@%:?]\G_ !H_X5?X4_Z 5I_WR?\ &NIHH Y;_A5_A3_H!6G_ 'R?\:/^%7^%
M/^@%:?\ ?)_QKJ:* .6_X5?X4_Z 5I_WR?\ &C_A5_A3_H!6G_?)_P :ZFB@
M#EO^%7^%/^@%:?\ ?)_QK@_BMX)T+1;73&L=,@MFDF97,8QD8'%>RUYM\:O^
M//2/^N[?R% '0?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?
M\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\
MOD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\
M0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-%
M '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"
MM/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\
M*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_X
MUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"
MG_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?
M\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\
MOD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\
M"K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_
M (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"
MM/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '
M+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/
M^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"
MG_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU
M-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\
M0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\
M"K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_
M (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\
M*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_X
MT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/
M^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?
M\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\
MOD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\
M0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-%
M '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"
MM/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\
M*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_X
MUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"
MG_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?
M\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\
MOD_XUU-% '+?\*N\*?\ 0"M/^^3_ (TA^%OA/_H!6G_?)_QKJJ* .1;X5>%/
M^@%:?]\G_&J\GPE\*-_S K3_ +Y/^-=K37X&>OTH%<X-OA%X5_Z =K_WR?\
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M\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\
MOD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\
M0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-%
M '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"
MM/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\
M*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_X
MUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"
MG_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?
M\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\
MOD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\
M"K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_
M (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"
MM/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '
M+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/
M^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"
MG_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU
M-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\
M0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\
M"K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_
M (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\
M*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_X
MT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/
M^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?
M\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\
MOD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\
M0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-%
M '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"
MM/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\
M*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_X
MUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"
MG_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?
M\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\
MOD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\
M"K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_
M (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"
MM/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '
M+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/
M^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"
MG_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU
M-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\
M0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\
M"K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_
M (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\
M*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_X
MT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/
M^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?
M\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\
MOD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\
M0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-%
M '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"
MM/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\
M*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_X
MUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"
MG_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?
M\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\
MOD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\
M"K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_
M (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"
MM/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '
M+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/
M^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"
MG_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU
M-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\
M0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\
M"K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_
M (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\
M*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_X
MT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/
M^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?
M\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\
MOD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\
M0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-%
M '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"
MM/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\
M*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_X
MUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"
MG_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?
M\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\
MOD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\
M"K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_
M (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"
MM/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '
M+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/
M^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"
MG_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU
M-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\
M0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\
M"K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_
M (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\
M*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_X
MT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/
M^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?
M\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\
MOD_XT?\ "K_"G_0"M/\ OD_XUU-% '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\
M0"M/^^3_ (UU-% '+?\ "K_"G_0"M/\ OD_XT?\ "K_"G_0"M/\ OD_XUU-%
M '+?\*O\*?\ 0"M/^^3_ (T?\*O\*?\ 0"M/^^3_ (UU-% '+?\ "K_"G_0"
MM/\ OD_XUM:/H=AX?M3;:=:QV=N7+F.,8!8@ G]!^57Z*!!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5YM\:O\ CSTC_KNW\A7I->;?&K_CSTC_ *[M_(4
M>DT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44GTH^M !]*/K2
MT4 %%%% $4ULDW48/JOX?X5F7%I<V_*?OE_V>O;M^)_*MBB@1@6^J X!.#6A
M#>!N]2W>FV]YS(F&_O+P>W^ K)FTR[LCF,_:$]ASV[?G^5,#;64&I-U<_;:H
M#@$X/O6E#>!N](9?HJ)90:D#4 +1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF/X8J8NEEV+G[*O4^&+D[2UM:+M:]]D]7TN?7B_M)>&O^?'5O^_,7_QRG?\
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M0\-?\^.K?]^8O_CE?.NRC91_KYG?\T?_  $/]5LL[/[SZ*_X:0\-?\^.K?\
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M5O\ OS%_\<KYUV4;*/\ 7S._YH_^ A_JMEG9_>?17_#2'AK_ )\=6_[\Q?\
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M* /2:*** .5^*'_(AZM_N)_Z,6N"^ __ "%=5_ZXI_Z%7>_%#_D0]6_W$_\
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MD^51\K<K/J*CI9=2IT:5:--6ZQO?SW1FZ/K&M_"W7Q;W<<B0D@RVK-E)$/\
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M+,QP !W)KER3A_"9O@OK^*JR=63=VG\+3_/KKT:-\SS6OEU=87#P2@DNF_\
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M:.4.8AV4;*FVT;:.4.8AV4;*FVT;:.4.8AV4;*FVT;:.4.8^N? W_(D^'_\
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MI>3VNEWES RQXDAMW=3A #R!79_$W2[R_P# 5A;VMI/<W"R0EHH8V9AA&!R
M,UZ%17G1X<I1CC(^T?\ M#N]M-6]/O.IYO4?U?W%^ZV\]$OT/-_@KI-]I6GZ
MFM[9W%FSRH56XB9"PP>F17)?%+P[JVH>-+R>UTN\N8&6/$D-N[J<( >0*]UH
MHQ7#E+%9=2RZ51I4W>]E=Z-?J.EG%2EC9XU05Y*UON_R,J32(M7\,KIUVC".
M:V6-UQ@J=H_4'^5>':K\.O$OA?4"]G!<7"J?W5U8;BQ'T7YE/^>:^AJ*Z<WR
M'#9NXU)MQG':2W,<#FM; .2BDXRW3/G6T\#>*_%-^INK:\#' :YU$LNT?\"Y
M/T%>Z^&?#\'AC1;?3X"66,9:0CEV/)/YUJT491D.&RARJ0;E.6\GOZ#S#-JV
M/BJ<DHQ71'EWQ&^%4VL7DFJ:/M-S)S-;,0N\_P!Y3TSZ@_6N#CTSQMIR_988
M-;AB7CRX?-V?^.\5]&T5YN,X3PN)KRQ%&I*DY;\NS_K[O(Z\-GU>A25&I%32
MVN>,> ?AKKJZM'J-]--I42G<VV3$TOL<'@'OG\J]#^(UK/?>"]3@MH9+B=U7
M;'$I9F^=3P!7245ZV'R/#X3 5,!1;M---MW?O*U^QPXC,ZV)Q,,342O%JR6V
MCN>2_!71=1TK4M2:]L+JS5X5"M<0L@)W=!D5V'Q0L[C4/!.H06L$ES.QCVQP
MH78XD4G 'M7544Z&3TZ&5O*U-N+4E?K[S;_4FMF,ZV-6-<;--.WH>5?!C2K_
M $7^V)+^PNK12D97SH'4MC=G (Y/TKBO%ECXC\4:[<ZA+HFI*KG;$AM9/D0?
M='3_ "2:^BJ*\G$<,0Q&!HX!UFH4[]%JVWOZ7=CT*>=RIXJIB_9IRE9>EO\
M,^<+:U\;6<"06\.OP0H,+'&LZJOT Z5Z[\,XM1N/"DL6N+=/.\SJRWX8N4(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*,'3E6S#-J<%=N,DOG<BO-4\!@IRV4DSA_@/_P AK4_^O=?_ $(5W/Q;/_%
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MGZUWOQL\68$6@VS\G$MUM/XJG]?RKGOAOXRT3P;'<S7EO>37\QV[H8T*J@[
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M?^/&W_ZYK_(5/4%C_P >-O\ ]<U_D*GK]OE\3/SB7Q,****DD**** "BBB@
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MTWKN&"/8^XJ[79&2G%2B[IF$HN$G&2LT%%%%42%%<7X\^(W_  A-U:P_V?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$HV_DH&:[NBN2>3Y?4J^WG0BY=[(Z(9CBZ</9QJM+U&QQK#&J(JHBC:JJ,
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MQV=M+<3-LAB0R.V"<*!DGCVKY\^$?_(^Z=_NR_\ HMJ]U\3?\BWJW_7I+_Z
M:^ER;.*^8Y9/&U8I2CS;7MHK]6_S/$S3+Z6!Q<*%-MII;[ZMKLBEHOCS0O$-
M\+33[[[1<%2P3R9%X'7EE KR7XV?\CF/^O6/^;5'\&/^1VC_ .N$G]*D^-G_
M ".8_P"O6/\ FU?&9MF5;->'8XFNDI>TMI>VE^[9]'@L%3P&;^QI-M<E]?\
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M2U;>R7=FQ145K=0WT"S6\T=Q"V=LD3!E.#@X(]ZEI;:,I-25T%%%%(84444
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M-IHL S::-II^TT;318!FTT;33]IHVFBP#-IHVFG[31M-%@&;31M-/VFC::+
M,VFC::?M-&TT6 9M-&TT_::-IHL S::-II^TT;318!FTT;33]IHVFBP#-IHV
MFG[31M-%@&;31M-/VFC::+ ,VFC::?M-&TT6 9M-&TT_::-IHL S::-II^TT
M;318!FTT;33]IHVFBP#-IHVFG[31M-%@&;31M-/VFC::+ ,VFC::?M-&TT6
M9M-&TT_::-IHL S::-II^TT;318!FTT;33]IHVFBP#-IHVFG[31M-%@&;31M
M-/VFC::+ ,VFC::?M-&TT6 9M-&TT_::-IHL S::-II^TT;318!FTT;33]IH
MVFBP#-IHVFG[31M-%@&;31M-/VFC::+ ?4O@W_D4-#_Z\8/_ $6M;%8_@[_D
M4=#_ .O&#_T6M;%?UA@_]VI?X5^1^#XC^-/U?YA11178<X4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO,^9IQ]I-0O:_<\"\=:M+XL\973VZM<#?]GMTC4L65>!@#KDY/XT^WMO&]G
MD,$6OP0H,+'&LZJH] !TKL?AG\-M4TCQ$+_5[06\=NA,0,B/N<\?PD]!G]*]
M>K\GRSAG$9A">.Q=2=*I.3=K6>_6^N]_E8^]QN<T<&X8;#PC4C%+7<^6=:T_
M689/M6K6U\DDIQYU[&X+D#IN;KP*]\^&FO?V_P"$;21VW3P#[/+]5Z'\1BIO
MB#X;?Q1X7N;2% ]TI$L ) RX[9/J,C\:Y7X4>&O$/A74+N+4+ PV-P@._P Z
M-MKCIP&)Y!/Z5Z659;B<BSAT8J4Z56.LK.R>KU:^:_[>.3&8VCFF7.4FHU(/
M17W7E\OR/.(YCX5\?>;=(2+.^+.,<E0W4?AR*^BK#5K/5+-;JTN8I[<C/F(P
M('U]/QKD/B!\,HO%S?;;21;74E7:6<?)*!T#8Z'W_P CS/\ X5#XH\[9]ACV
MYQYGVB/;]>N?TKEPG]J<-5:N&I89UJ<I7BU?\;)]+7NEZFU9X+.J5.I4K*G.
M*L[_ /!:_ O_ !D\266N:S:064JSK:(RO,G*EB1P#WQC]:],^',?G?#[3(_[
MT+K^;-7F6K?!G6[**U%G&NH2LI,Y21$1#G@#<03]:]:\"Z9<Z/X3TZSO(_)N
M84(=-P;!W$]02.]=F0T,=/-<57QU)P<X]M.FB>SLC#-*F%CEU&CA:BEROOKU
MUMZGA?P_U"+0?&UA-=L(8T=HG9^ N5*Y/XFO<?'&LVFF^$]1EEG11-;O'%\P
M)=F4@ >O6N*\>?"&?4M0FU'1FCWS'?+:R';\QZE3TY]#^?:N0M_A#XHFF"/8
MQP*?^6DDZ%1_WR2?TKQ\-_:^2X>ME<<*ZBDW:2O;56OHFO/5JW4[Z_U#-*E/
M&3KJ#BE=.U]-;:_\$O?!&V:;Q=+*!E8K9R3Z9*BF?&S_ )',?]>L?\VKU+P'
MX'@\%Z>Z;Q/>38,TV,#CHH]A^M<7\4/ NN>(O$PN].L?M%OY")O\Z->03D89
M@>]=&/R?%8;AVGA%!RJ<UVHJ]KW[=M+F6'S&A6SB5?F2@HV3>GYG77/_ "2E
M_P#L#_\ M&O-_@A_R-T__7JW_H2UZI/I-T_P_;31%F].F_9_*W#_ %GE;<9S
MCKWSBN(^%?@?6_#?B*6ZU&R^SP-;L@;S4;YB5.,*Q/8U[6.PM>>>X*M&FW&,
M=79V6^[V1P86O2C@<7!S2;>BNM?3N=OXTT_0]6LH+/6Y8X1-)LMW+A7#D?PG
M_'CIFO(/&WPVO?!*KJ%O=?:+,2 +*OR21MVR/ZC]*[SXE_#>]\574=_8W0:9
M$V&UG;"X'=#V/L?SKBA\-?&FJ+#:7?F+:QGY/M%X'C3W"ACC\!7D<0T:V,KU
M(/ R<].2I'_VZVGWZK;3<[,HJ4\/2A)8I*/VHR_3_@'HOPI\477B;P^_VU_-
MN;63RC*>KK@$$^_^%+\7YEC\!WJGK(\2CZ[P?Z&M;P7X4A\'Z*EE&_G2LQDE
MEQC<Q]/;@"N(^.VLJECI^EJV9)'^T..X4 JOYDG_ +YKZ+,ZE7!\/2CC)7J<
MBB_5Z?-]_O/(PT:>)S>+PR]SFNO1:E?X"1M_Q.9/X?W2_C\U>NUY[\$]*:Q\
M+2W3J0UW,67/]U1@?KFO0J]3AZC*AE6'A+?EO]^OZG+G515,PJR7>WW)(***
M*^A/$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M]VO,/VAM+O-8^$^O6
MMC;2WETXA9884+.P6>-FP!UP 3^%>H-5"\3*FNG#5GAJ\*Z5W%I_<[G#CL+'
M'82KA).RJ1E&_;F37ZGY^^"OBEXH^&]T?[)U&6!%.'LYAOB)&X8*'I@LQ[<U
M]-?#W]K+P_XBV6WB*+^P;PY_?9+VY^\>O5> HYZEJL_$SX5:#XQ#S7=DL5[C
MB\M\)+^)_B_'-?-7C#X0ZMX:D>2V_P")E:#D-&N) /=?\,U^D_6LEX@TQ"]E
M5?7;\=G\]>Q^#O+^*N#'S8*7M\.NEFTE_AWC_P!NNW<^_P"UNH;Z!9K>:.XA
M;.V2)@RG!P<$>]2U^=G@GXI^)_AU<9T?49(8NC6DWSPGANJ'T+$\=Z^F_A[^
MUEX?\1;+;Q%%_8-X<_OLE[<_>/7JO 4<]2U?/9APQC,'>=']Y#RW^[_*Y]MD
MGB!E>:6I8E^QJ=I?"_27^=OF>\45%:W4-] LUO-'<0MG;)$P93@X."/>I:^/
MVT9^GIJ2N@HHHI#"BBB@ HKDO'7Q4\,_#FW+ZUJ4<4Y&4LXOGGD^B#G'N<#W
MKYD^(G[6?B#Q%YMIX<B_L"Q;CS\A[IQ_O=$_X#R/[U>]E^28W,K.E&T?YGHO
M^#\CX[.N+,JR)..(J<U3^2.LOGT7S:/IOQU\5/#/PYMR^M:E'%.1E+.+YYY/
MH@YQ[G ]Z^9/B)^UGX@\1>;:>'(O[ L6X\_(>Z<?[W1/^ \C^]7AEU=3WUQ)
M<7,TEQ/(VYY96+,Q]23R352XNHK5<R.%]!W-?H^%X?RW*:;Q.,DI<N[E917R
M>GWW/PG,^-\ZX@J_4\MBX*6BC"[F_FM?_ 4OF6[JZGOKB2XN9I+B>1MSRRL6
M9CZDGDFL_4F7[*R%@&;&!W/(K/N-9EF.V!?+7^\>319VCRR;GRQ/4GFOS?BS
MQ&R^6$K9=ET?:<\90<MHI--.W5_@O-GZ%P7X5YI''8?-LUG[+V<XS4/BDW%J
M2YND;VUU;\D;V@QG<O%>DZ&ORK7%Z'8D,IQ7H&CP%5'%?R5BY)G]F4$=#:#Y
M15M>E06Z_**M#I7@RW/50VBGT5(QE%/HH 913Z* &44^B@!E%/HH 913Z* &
M44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^
MB@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!
ME%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/
MHH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH
M913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913
MZ* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z*
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MZ7?0KZ?8PZ78P6ENNR&%!&@]@,58HHKZ%))61Y+;D[O<****8@HHHH ****
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M #_E]R#_ %IK?\^E][/E[_A#]>_Z FH_^ DG^%'_  A^O?\ 0$U'_P !)/\
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M #_E]R#_ %IK?\^E][/E[_A#]>_Z FH_^ DG^%'_  A^O?\ 0$U'_P !)/\
M"OJ&BC_4/#?\_P"7W(/]::W_ #Z7WL^7O^$/U[_H":C_ . DG^%'_"'Z]_T!
M-1_\!)/\*^H:*/\ 4/#?\_Y?<@_UIK?\^E][/E[_ (0_7O\ H":C_P" DG^%
M'_"'Z]_T!-1_\!)/\*^H:*/]0\-_S_E]R#_6FM_SZ7WL^7O^$/U[_H":C_X"
M2?X4?\(?KW_0$U'_ ,!)/\*^H:*/]0\-_P _Y?<@_P!::W_/I?>SY>_X0_7O
M^@)J/_@))_A1_P (?KW_ $!-1_\  23_  KZAHH_U#PW_/\ E]R#_6FM_P ^
ME][/E[_A#]>_Z FH_P#@))_A1_PA^O?] 34?_ 23_"OJ&BC_ %#PW_/^7W(/
M]::W_/I?>SY>_P"$/U[_ * FH_\ @))_A1_PA^O?] 34?_ 23_"OJ&BC_4/#
M?\_Y?<@_UIK?\^E][/E[_A#]>_Z FH_^ DG^%'_"'Z]_T!-1_P# 23_"OJ&B
MC_4/#?\ /^7W(/\ 6FM_SZ7WL^7O^$/U[_H":C_X"2?X4?\ "'Z]_P! 34?_
M  $D_P *^H:*/]0\-_S_ )?<@_UIK?\ /I?>S+\*PR6_A?1XI4:*6.SA5T<$
M,I" $$=C6I117Z72IJE3C371)?<?%U)>TFY]PHHHK4@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-OC5_Q
MYZ1_UW;^0KTFO-OC5_QYZ1_UW;^0H ])HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_O])_\ $5Z_10%SR#_A7_Q(_P"AOC_[_2?_ !%'_"O_ (D?]#?'_P!_I/\
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M_P#?Z3_XBO7Z* N>0?\ "O\ XD?]#?'_ -_I/_B*/^%?_$C_ *&^/_O])_\
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MR#_A7_Q(_P"AOC_[_2?_ !%'_"O_ (D?]#?'_P!_I/\ XBO7Z* N>0?\*_\
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M^%?_ !(_Z&^/_O\ 2?\ Q%'_  K_ .)'_0WQ_P#?Z3_XBO7Z* N>0?\ "O\
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MAOC_ ._TG_Q%>OT4!<\@_P"%?_$C_H;X_P#O])_\11_PK_XD?]#?'_W^D_\
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MTG_Q%'_"O_B1_P!#?'_W^D_^(KU^B@+GD'_"O_B1_P!#?'_W^D_^(H_X5_\
M$C_H;X_^_P!)_P#$5Z_10%SR#_A7_P 2/^AOC_[_ $G_ ,11_P *_P#B1_T-
M\?\ W^D_^(KU^B@+GD'_  K_ .)'_0WQ_P#?Z3_XBC_A7_Q(_P"AOC_[_2?_
M !%>OT4!<\@_X5_\2/\ H;X_^_TG_P 11_PK_P")'_0WQ_\ ?Z3_ .(KU^B@
M+GD'_"O_ (D?]#?'_P!_I/\ XBC_ (5_\2/^AOC_ ._TG_Q%>OT4!<\@_P"%
M?_$C_H;X_P#O])_\11_PK_XD?]#?'_W^D_\ B*]?HH"YY!_PK_XD?]#?'_W^
MD_\ B*/^%?\ Q(_Z&^/_ +_2?_$5Z_10%SR#_A7_ ,2/^AOC_P"_TG_Q%'_"
MO_B1_P!#?'_W^D_^(KU^B@+GD'_"O_B1_P!#?'_W^D_^(H_X5_\ $C_H;X_^
M_P!)_P#$5Z_10%SR#_A7_P 2/^AOC_[_ $G_ ,11_P *_P#B1_T-\?\ W^D_
M^(KU^B@+GD'_  K_ .)'_0WQ_P#?Z3_XBC_A7_Q(_P"AOC_[_2?_ !%>OT4!
M<\@_X5_\2/\ H;X_^_TG_P 11_PK_P")'_0WQ_\ ?Z3_ .(KU^B@+GD'_"O_
M (D?]#?'_P!_I/\ XBC_ (5_\2/^AOC_ ._TG_Q%>OT4!<\@_P"%?_$C_H;X
M_P#O])_\11_PK_XD?]#?'_W^D_\ B*]?HH"YY!_PK_XD?]#?'_W^D_\ B*/^
M%?\ Q(_Z&^/_ +_2?_$5Z_10%SR#_A7_ ,2/^AOC_P"_TG_Q%'_"O_B1_P!#
M?'_W^D_^(KU^B@+GD'_"O_B1_P!#?'_W^D_^(H_X5_\ $C_H;X_^_P!)_P#$
M5Z_10%SR#_A7_P 2/^AOC_[_ $G_ ,11_P *_P#B1_T-\?\ W^D_^(KU^B@+
MGD'_  K_ .)'_0WQ_P#?Z3_XBC_A7_Q(_P"AOC_[_2?_ !%>OT4!<\@_X5_\
M2/\ H;X_^_TG_P 11_PK_P")'_0WQ_\ ?Z3_ .(KU^B@+GCY^'OQ'_Z&^/\
M[_2?_$5&WPZ^(QZ^+HO^_P!)_P#$5[)10%SQ*;X:_$5NOBR(_P#;:3_XBL^?
MX6_$)NOBJ(_]M9/_ (BO>V45&T8]* N?/4GPG^('_0T0_P#?V3_XBB/X3_$
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M^_TG_P 11_PK_P")'_0WQ_\ ?Z3_ .(KU^B@+GD'_"O_ (D?]#?'_P!_I/\
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M_P"AOC_[_2?_ !%>OT4!<\@_X5_\2/\ H;X_^_TG_P 11_PK_P")'_0WQ_\
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M;X_^_P!)_P#$5Z_10%SR#_A7_P 2/^AOC_[_ $G_ ,11_P *_P#B1_T-\?\
MW^D_^(KU^B@+GD'_  K_ .)'_0WQ_P#?Z3_XBC_A7_Q(_P"AOC_[_2?_ !%>
MOT4!<\@_X5_\2/\ H;X_^_TG_P 11_PK_P")'_0WQ_\ ?Z3_ .(KU^B@+GD'
M_"O_ (D?]#?'_P!_I/\ XBC_ (5_\2/^AOC_ ._TG_Q%>OT4!<\@_P"%?_$C
M_H;X_P#O])_\11_PK_XD?]#?'_W^D_\ B*]?HH"YY!_PK_XD?]#?'_W^D_\
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M])_\11_PK_XD?]#?'_W^D_\ B*]?HH"YY!_PK_XD?]#?'_W^D_\ B*/^%?\
MQ(_Z&^/_ +_2?_$5Z_10%SR#_A7_ ,2/^AOC_P"_TG_Q%'_"O_B1_P!#?'_W
M^D_^(KU^B@+GD'_"O_B1_P!#?'_W^D_^(H_X5_\ $C_H;X_^_P!)_P#$5Z_1
M0%SR#_A7_P 2/^AOC_[_ $G_ ,11_P *_P#B1_T-\?\ W^D_^(KU^B@+GD'_
M  K_ .)'_0WQ_P#?Z3_XBC_A7_Q(_P"AOC_[_2?_ !%>OT4!<\@_X5_\2/\
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MAOC_ ._TG_Q%>OT4!<\@_P"%?_$C_H;X_P#O])_\11_PK_XD?]#?'_W^D_\
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MTG_Q%'_"O_B1_P!#?'_W^D_^(KU^B@+GD'_"O_B1_P!#?'_W^D_^(H_X5_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH_L;,/\ GRP_UHR7_H)B?1M%?.7_  W5X"_Z!'B/_P !K?\ ^/T?\-U> O\
MH$>(_P#P&M__ (_1_8V8?\^6'^M&2_\ 03$^C:*^<O\ ANKP%_T"/$?_ (#6
M_P#\?H_X;J\!?] CQ'_X#6__ ,?H_L;,/^?+#_6C)?\ H)B?1M%?.7_#=7@+
M_H$>(_\ P&M__C]'_#=7@+_H$>(__ :W_P#C]']C9A_SY8?ZT9+_ -!,3Z-H
MKYR_X;J\!?\ 0(\1_P#@-;__ !^C_ANKP%_T"/$?_@-;_P#Q^C^QLP_Y\L/]
M:,E_Z"8GT;17SE_PW5X"_P"@1XC_ / :W_\ C]'_  W5X"_Z!'B/_P !K?\
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MZT9+_P!!,3Z-HKYR_P"&ZO 7_0(\1_\ @-;_ /Q^C_ANKP%_T"/$?_@-;_\
MQ^C^QLP_Y\L/]:,E_P"@F)]&T5\Y?\-U> O^@1XC_P# :W_^/T?\-U> O^@1
MXC_\!K?_ ./T?V-F'_/EA_K1DO\ T$Q/HVBOG+_ANKP%_P! CQ'_ . UO_\
M'Z/^&ZO 7_0(\1_^ UO_ /'Z/[&S#_GRP_UHR7_H)B?1M%?.7_#=7@+_ *!'
MB/\ \!K?_P"/T?\ #=7@+_H$>(__  &M_P#X_1_8V8?\^6'^M&2_]!,3Z-HK
MYR_X;J\!?] CQ'_X#6__ ,?H_P"&ZO 7_0(\1_\ @-;_ /Q^C^QLP_Y\L/\
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M;,/^?+#_ %HR7_H)B?1M%?.7_#=7@+_H$>(__ :W_P#C]'_#=7@+_H$>(_\
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M UO_ /'Z/[&S#_GRP_UHR7_H)B?1M%?.7_#=7@+_ *!'B/\ \!K?_P"/T?\
M#=7@+_H$>(__  &M_P#X_1_8V8?\^6'^M&2_]!,3Z-HKYR_X;J\!?] CQ'_X
M#6__ ,?H_P"&ZO 7_0(\1_\ @-;_ /Q^C^QLP_Y\L/\ 6C)?^@F)]&T5\Y?\
M-U> O^@1XC_\!K?_ ./T?\-U> O^@1XC_P# :W_^/T?V-F'_ #Y8?ZT9+_T$
MQ/HVBOG+_ANKP%_T"/$?_@-;_P#Q^C_ANKP%_P! CQ'_ . UO_\ 'Z/[&S#_
M )\L/]:,E_Z"8GT;17SE_P -U> O^@1XC_\  :W_ /C]'_#=7@+_ *!'B/\
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MA_SY8?ZT9+_T$Q/HVBOG+_ANKP%_T"/$?_@-;_\ Q^C_ (;J\!?] CQ'_P"
MUO\ _'Z/[&S#_GRP_P!:,E_Z"8GT;17SE_PW5X"_Z!'B/_P&M_\ X_1_PW5X
M"_Z!'B/_ ,!K?_X_1_8V8?\ /EA_K1DO_03$^C:*^<O^&ZO 7_0(\1_^ UO_
M /'Z/^&ZO 7_ $"/$?\ X#6__P ?H_L;,/\ GRP_UHR7_H)B?1M%?.7_  W5
MX"_Z!'B/_P !K?\ ^/T?\-U> O\ H$>(_P#P&M__ (_1_8V8?\^6'^M&2_\
M03$^C:*^<O\ ANKP%_T"/$?_ (#6_P#\?H_X;J\!?] CQ'_X#6__ ,?H_L;,
M/^?+#_6C)?\ H)B?1M%?.7_#=7@+_H$>(_\ P&M__C]'_#=7@+_H$>(__ :W
M_P#C]']C9A_SY8?ZT9+_ -!,3Z-HKYR_X;J\!?\ 0(\1_P#@-;__ !^C_ANK
MP%_T"/$?_@-;_P#Q^C^QLP_Y\L/]:,E_Z"8GT;17SE_PW5X"_P"@1XC_ / :
MW_\ C]'_  W5X"_Z!'B/_P !K?\ ^/T?V-F'_/EA_K1DO_03$^C:*^<O^&ZO
M 7_0(\1_^ UO_P#'Z/\ ANKP%_T"/$?_ (#6_P#\?H_L;,/^?+#_ %HR7_H)
MB?1M%?.7_#=7@+_H$>(__ :W_P#C]'_#=7@+_H$>(_\ P&M__C]']C9A_P ^
M6'^M&2_]!,3Z-HKYR_X;J\!?] CQ'_X#6_\ \?H_X;J\!?\ 0(\1_P#@-;__
M !^C^QLP_P"?+#_6C)?^@F)]&T5\Y?\ #=7@+_H$>(__  &M_P#X_1_PW5X"
M_P"@1XC_ / :W_\ C]']C9A_SY8?ZT9+_P!!,3Z-HKYR_P"&ZO 7_0(\1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>;?&K_CSTC_KNW\A7I->;?&K_CSTC_KNW\A0!Z31110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNHS@M:D+ #Z>8>OU4$>]<C8_MK6DERJWGA.:"WSS)!?"5P/93&H/YUE_!O\
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MZ7T]R;59)88A$&!(R2)"<<>E=WX]\;V/P[\,76NZE%<3VENR*R6JJTAW,%&
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M?QZGJ_S/[AR__<Z/^&/Y(****YCO"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)8;&UL+67+4<6E?O_6OR/Q_CZK#'Y-A\PPK]I1C43=M5;57^_P!WU9]P !0
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M9_,^"_A=_P E_P!)_P"PN_\ Z$U?3O[4?_)%]9_ZZV__ *.2OF+X7?\ )?\
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MA\LLN?W<?YC<?9<=Z/V@_B#/\4/B(FEZ7ON;"QE^QV<4>3Y\I8!F [DM@#V
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MP$F*[U W-T/\1]:]2CC(T94[QNHQLUW=^:_WG/4IN:J6=FWIY65E^#=SX/\
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M8PIQ=E)2U>XU&;GSR?V7'[S\]_VN &^*W[)P(R/L^G_^C[:NY_X*W?\ )+O
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M]/N-5NMPFO?)1I'E?<S'):-2<L>O4U]R1QK#&J(H1%&U548  Z "L+Q=\/\
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M1?\ MVAYGI2_=KM-+7Y17':3]X5VFEK\J\5]!A3X/,&;UNORCBK 7CI45NO
MJQBO;CL?)2>HS;[4;?:I**HBY'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E%
M 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]J
MDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-
MOM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]O
MM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y
M'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E%
M 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]J
MDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-
MOM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]O
MM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y
M'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E%
M 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]J
MDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-OM4E% 7(]OM1M]JDHH"Y'M]J-
MOM4E% 7(]OM1M]JDHH"Y^D?PG_Y);X._[ UG_P"B$KJJY7X4_P#)+?!W_8&L
M_P#T0E=57\XXK^/4]7^9_<^7_P"YT?\ #'\D%%%%<QWA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5Y]\7O@WI7Q8TE8[AOL>JVX/V6^1<E,_P +
M#^)3Z=NU>@T5T4,15PM15J,K26S.3%X2ACJ$L-B8*4):-/\ K[GNGJCX3U;X
M$?$GP!J1GL-/O)VC.([[1)6=B/8)AQ^(%5IO!OQ:\:,EE?6'BF_0GA-4,ZQC
M\92%'YU]ZT5]G'BW$63G1@Y+K9GY9/PWP*DXT<34A3>\;K_+\TSYM^#_ .RG
M_8U[;ZSXP>*XN(6$D.EPMNC5AR#*W1L'^$<<<DCBO=?&G@W3/'WAZYT;5H3+
M:S#.Y3AXV'1U/8BMVBOF<9FF+QM=8BK/WEM;2WH?>97D&791A)8/#4_<E\5]
M7+I[W?TV\CXO\6_LD^,-)O9/[$^SZ[9%OW;+,L,H'^TKD#/T)I/"O[)'C+6+
MI/[9-KH-H&^=GE6>7'^RJ$@_BPK[1HKWO];,R]GR>[?O;7\[?@?'OPWR)U_;
M6G;^7F]W\N;_ ,F,#P/X)TKX>^';?1M(A,=K%\S.YR\KGJ[GNQ_H ,  5\Q?
M%WX#^.O%'Q0UO5],T/[3I]Q.KQ3?:X$W (H)PS@CD'J*^O**\? 9OB<OQ$\3
M"TI25GS7>[OT:['T^<<-8'.<#3RZK>%.#32A96LFDM4U:S[!7R/XX^!/CC6/
MC!?ZW::)YVERZFMPD_VN!<QA@<[2^[MTQFOKBBLLMS.ME<Y5**3<E;6_Z-'1
MGF18;/Z,*&*E)*$E)<K2=TFNJ>FH5\CW7P)\<R?&C^WET/.E?VXMY]H^UP?Z
MH3AMVW?NZ<XQGVKZXHHR_,ZV6N;HI/F5G>_Z-!G>0X;/J=.GB922A+F7*TM?
M.Z>AXO\ M.?#WQ!\0_#^C6WA_3_[0GM[II)5\Z./:I3 .789Y]*\;M?V2?%=
MWX56\8166N+,ZOIMS,A5X\#:R2(6 /7@^G45]F45WX/B#&8'#QPU"R2=]M?1
MZVM\CR,TX-RS.,;+'8OF<I1Y;722MLUI>_SMY'P[I/[*OQ"U"^6&YTZVTN'/
M-Q<WD;(/PC9F_2OJCX2?"73/A/H+6=HYN[^X(>[OG7:TK#H .RC)P,]SZUW5
M%3F.?XW,H>RJM*/9:7];ML>1\&Y5D-7ZQATY5.DI--KTLDEZVOYGRW^T/\%O
M&7CKXC2:IH>C?;;$VL48E^U0Q_,,Y&'<']*],^)W@?6_$/P'A\.Z?9?:-96V
MLXS;>:B_-&8]XW,P7C:>_;BO6**REG.(E##P<5:BTX[ZV[Z^72QUQX8P<*V-
MKJ<KXJ+C+5:)IKW?=T>O6YX+^R[\,?$OPZ;Q&?$.F_V?]K%OY'[^*7?M\S=]
MQCC&X=?6NP_:#\(:OXX^&]QI6B6GVV_>XB=8?,2/*JV2<N0/UKTJBL:V:5JV
M.6822YTT[:VTM;K?IW.C"</X7!Y1+)J<I.FU*-VUS6G>^MK==-/O/#_V7_AO
MXB^'>G^((O$.G?V>]U+"T(\^.7<%#@_<8XZCK5OXX?L\VWQ.D_M;3)X].U]4
M",T@/E7"CH'QR"/[P!XX(Z8]EHJI9OBGC7CX/EF^VVR5K._8BCPWE]/*HY-4
MBYT5?XM]6W>Z2LTWHU8^%_\ AEOXB_;/(_L>'RMV/M/VV'R_KC=NQ_P&M?Q1
M^R;XNTBVTU=)A77;J1&:\:&>***%LC:B^8RLW&><?@._VC17N/B[,7*,K1TZ
M6>OKK?[K'R4?#7(XPG"\VY;/F5XZWT]VWEJGH<7\&_#VH>%/AGH6DZK;_9=0
MM8F66'>K[29&(Y4D'@CH:^>O"GP)\<Z;\8K'7+G0_+TN/5_M33_:X#B/S"V[
M:'W=.V,U]<T5XV'SC$8:=>I"*O5O>]^M]M?/K<^HQO#.#QU#"8>I*26'Y>6S
M5WRI)<WNN^VMK'DO[2?@;6_'_@BTT_0;+[?=QWJS-'YJ1X4(P)R[ =2*B_9G
M\!Z[\/?!NI6.OV/V"ZFOVF2/SHY,IY:+G*,1U4_E7K]%8+,ZRP+R^RY+WOK?
M\[?@=<\APT\WCG+E+VD8\MKKEMKTM>^O<\(^-7[,\/CS4)M<T"XBT_69>9X9
M\B&X/][(!*M^!!]NM>&?\,N_$;[5Y7]B1>7NQY_VV#9]?O[L?A7W517JX/B;
M'X*DJ,6I);<RO;[FOQ/GLVX$R?-L0\544H3EJ^1I7?=IIZOK:U]]SP7X+_LQ
M0^!M3AUSQ%<0ZEJT)W6UO "8(&_ODD NP[<  \\G!'8?M!^$-7\<?#>XTK1+
M3[;?O<1.L/F)'E5;).7('ZUZ517F5,VQ5;%QQM5\THM-=M.EET/?P_#N7X/+
M:F5X:/)3J)IM?$^96;N[ZVVZ+M8\/_9?^&_B+X=Z?X@B\0Z=_9[W4L+0CSXY
M=P4.#]QCCJ.M;W[1O@O6?'GP^33-"L_MUZ+V.8Q>:D?RA7!.78#N.]>I44JF
M:5JF._M!I<]T[:VTT[WZ=PH9!A</E#R6$I>R<91O=<UI-MZVM?730\:_9D^'
M^O\ P]\,ZO:>(+#[!<7%X)8T\Z.3<NP#.48@<CO7LM%%<N,Q4\=7EB*B2<NV
MWZGHY7EU+*<'3P-!MQ@K*]K[WULDNO8*YCXF>$5\=>!=8T0JIEN8#Y);'$J_
M,A_[Z KIZ*YJ=25&<:D'9IW7R.ZM2AB*<J-17C)--=T]&?%O@/\ 9C\9MXRT
MAM>T1;71DN%DNI&NH)!Y:G<5VJY)W8V\#O7VE117K9GFV(S:<9UTER[)7M^+
M9\UP_P -X+ANG4IX1R?.TVY--Z;+1+3?[RGK&D6FOZ7=:=?P+<V=U&8I8GZ,
MIKY)\>_LC>(M,U"67PN\6L:>QS'#+*L4\?L=V%;ZY'TK["HI9=FV*RN3>'>C
MW3U3_KR-<\X=R_B"G&&-B[QVDM)+Y_HTT?&7@_\ 9)\6ZK>!M>$.B62'+J)D
MFFD]D"$J,],D\9S@]*U_@?\  OQQX/\ BAHNKZOHGV33[<R^;-]K@?;NB=1P
MKDGDCH*^MJ*]:MQ3CZ\*E.:CRS5MGINM-?/K<^8P_A[D^%J4*U)S4J4N:]U[
MS332E[MK*W2V[\K8/C?P5IGQ \.W.C:M%YEM,,JZ\/&XZ.I[$5\G>*OV1_&&
MDW4G]C-:Z[:9_=E95@EQ_M*Y"@_1C7V?17FY=G6+RN\:#]U]'JCZ'/.%\MX@
MY98R+YXZ*47:5NW5->J=NF[/B+0?V4?'NJ72QWMI:Z-#GYIKFZ23CO@1EB3]
M<?6OJGX5_"S2_A3X?.G6#-<W$S"2ZO)!AIG QT_A4<X7MGJ223VE%:YCGV-S
M.'LZK2CV6B^>[_$Y,CX/RK(:GM\-%RJ;<TG=KTLDEZVN>2?&OX V/Q4":A:3
MIIFO1)L$[+F.91T63'/'9AR/0U\YZA^RW\1;.X:.'2(+Y!TFM[V$*?\ OME/
MZ5]ST5K@.(L=E]-48-2BME)7M]S3,<YX)RC.ZSQ-:,H5'NX-*_JFFOG:Y\E?
M#W]D'5KN^AN?%MS#86"$,UE:R>9-)_LEA\JCW!)^G6O<_C%X,N]>^$VH>'O#
MUBLD_EPQ6UJCK&H5'7@%B  %'<]J]"HKFQ6=XS&8BGB*K3Y&FETT=_ZUN=V7
M<*Y9E>#K8/"Q:]K%QE*]Y---;VLK7TTM?H>!?LO?"_Q-\.KKQ$_B'3/[/6[2
MW$)\^*7=M,F[[C'&-PZ^M<)XX^!/CC6/C!?ZW::)YVERZFMPD_VN!<QA@<[2
M^[MTQFOKBBNB'$&*ABZF-48\TU9Z.W3;7R[G#4X,R^IEE'*G.?LZ4N=.\>:^
MN_NVM[SZ(*^1[KX$^.9/C1_;RZ'G2O[<6\^T?:X/]4)PV[;OW=.<8S[5]<45
MY^7YG6RUS=%)\RL[W_1H]K.\APV?4Z=/$RDE"7,N5I:^=T]#(\5^%=-\::#=
M:/JT'VBRN%PRYP5(Y#*>Q!Y!KY+\8?LB^+-)O)#H,EOKED3^[!E6&8#T8.0O
MXAOP%?9=%:Y;G&+RNZH/W7T>J_KT,,\X9R[B!1^N1?-':2=I)=NJ:]4_S/B+
M0?V4?'NJ7:QWUI:Z-!GYIKFZ23CO@1ELGZX^M?5WPO\ AKI_PM\,)I%A))<L
MS>;<7,O660@ G'11P, ?J<D]?16V99[C,SBJ=9I1[)67ZO\ $Y,CX0RO(*CK
M89.4]N:3NTO*R27W7/EGXM?LS^*KSQ;=^(?#>H'57N)OM CGN/*N87SD!7.%
M('8Y!  ';-<]IO[-?Q(\<:Q#)XLO)+2%,*]UJ%\+N4)Z(%9OR) K['HKKI<3
M8ZE25)*+:5E*VJ7Y?@>=B> \HQ6)GB)N:4WS2BI>ZWOKI??LUY6,[P]H5IX8
MT.PTFQ0I:6<*P1!CDX48R3W)ZGW-:-%%?*RDYR<I.[9^A4Z<:4%3@K)*R79(
M****DT"BBB@ HHHH **** "BBB@ HHHH *\V^-7_ !YZ1_UW;^0KTFO-OC5_
MQYZ1_P!=V_D* /2:*** "OGSXT_LOQ^++Z?7/"[PV6I3$O<6,ORQ3MW93_"Q
M[]B?3G/T'17H8''XC+ZOML/*S_!^3/'S7*<'G6&>%QL.:/XI]T^C_P"&>A\%
M1> _BQX%D>VL-.\2V 8Y8:2TK(Q]<PD@U-IWP5^)OQ"U!9;[3M1#DA6O-=E:
M/8/4^8=Y'^Z#7W?17U;XNQ%N:-&"GWL_Z_$_.%X;8*ZA/%5727V;K_*WX(\Q
M^#7P,TOX3VKW'F_VCKEPFR>]9=H5>#LC'9<@<GDX[=!U'Q"^'ND_$KP[+I.K
M1$H3OAG3_6028X=3_3H17345\E4QV)K8CZU.;Y][_P"1^DX?*<%A<'_9]*DE
M2M;EW3OO>^]^K9\/^*OV;O'O@;4C<Z3!)JT$3;H;W2W(E'I\F=X;Z9'O65-X
M6^+GBQ1I]Y9>++V%N/*U$W B_$R$*/QK[UHKZN'%F)Y5[6E&4EL[?U^%C\ZJ
M^'& YW]6Q%2G3EO%/3\?UN?-/P;_ &59-)O[;6O&1ADEA820Z3&P=0PZ&5AP
M<'^$9!XR3R*^EJ**^9Q^8XC,JOM<1*_9=%Z'WN39'@<AP_U?!0LGNWJV_-_T
MET05\9_$;]F?QC+XXUB;0-%%YI$UPTUO(+N!.&^8KM9P1@DCIVK[,HK;+,UK
MY54E4H)/F5FG>WX-'-GW#V#XBH0H8MM*+NG&R>UK:IZ/TZ(Y+X4>#?\ A ?A
M_HVBNBI<PPA[G:0?WS?,_(ZX8D?0"NLI:*\RM5E7J2JSWDVW\SW<+AJ>#H0P
MU%6C!)+T2LCY'\!_ GQQHOQ?T_6[S1/)TN+46G>?[7 V$+,<[0Y;N.,9KW;X
M]>%=4\:?#'4])T:U^V:A,\)CA\Q(\A958\L0.@/>O0J*]C$YSB,5B*6)G%<U
M.UK7MH[ZZ_Y'S>!X9P>7X/$X&E*3C7YN:[5US+E=O=2VVNF?!_\ PS+\2O\
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MJ^I\Z_M.?"?Q5\0O$6CW7A_2O[0@M[5HY&^T11[6+DXP[@GCTKJ&T+QIX=^
M.F^']%TII/$IMOLDB+<PK]G!+;FW%PI..!@GD^U>Q45K_:]9X>CAI0BXTW=7
M3UWWUVU\C#_5S#1QV)S&G4G&I7CRNS6BLE>/NZ/1:NY\'_\ #,OQ*_Z%O_R>
MMO\ XY1_PS+\2O\ H6__ ">MO_CE?>%%>_\ ZY8_^2'W2_\ DCXK_B%^3?\
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M%%% !1110 4444 -;[M0Q?\ 'P?]W_"IF^[4,7_'P?\ =_PH L4444 %%%%
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M=M-&TT!<;MHVT[::-IH"XW;1MIVTT;30%QNVC;3MIHVF@+GZ/_"G_DE_@_\
M[ UG_P"B$KJ:Y;X5?\DO\'_]@:S_ /1"5U-?S?BO]XJ>K_,_NK+_ /<Z/^&/
MY(****Y3T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\V^-7_'GI'_7=OY"O2:\V^-7_'GI'_7=OY"@#TFB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'R1MP=!5BH85X%6 *]N)\I)ZC:*=MHVU1F-HIVVC;0 VBG;:-M #:*=MHVT
M-HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0
M VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M
M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHV
MT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC
M;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:
M-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=M
MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIV
MVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG;:-M #:*=MHVT -HIVVC;0 VBG
M;:-M #:*=MHVT -HIVVC;0 VBG;:-M 'Z-_"O_DE_@__ + ]G_Z(2NIKEOA7
M_P DO\'_ /8'L_\ T0E=37\VXK_>*GJ_S/[NR[_<J/\ AC^2"BBBN4] ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O-OC5_QYZ1_P!=V_D*])KS;XU?\>>D?]=V_D* /2:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** $/2JMS'N4U;J.1<T <AK5CYBMQ7E/C3P/9:[$T=Y:
MI.!]UB/F7Z'J*]UN[02 \5S>I:*),_+6E.I.E)3INS75&-:C3Q%-TJT5*+W3
M5T_DSX\\4?"&ZT]GDTR0W$?7R9.''T/0_I69X1^)7BSX7WK)IM[-:!?OV=P"
MT1X;&4/NQ/'?FOJ?5?#(;/R_I7">)? -KJL31W5LLH[$C##Z'J*^VP?%%3D]
MAF,%5@_2_P#D_P 'YGY/F?A_1]K]<R2J\/56RN^7Y-:Q_%>1U7P]_:R\/^(M
MEMXBB_L&\.?WV2]N?O'KU7@*.>I:O<[6ZAOH%FMYH[B%L[9(F#*<'!P1[U\#
M>)/A'=V+/)IS^?'U\F3AQ]#T/Z5G^$?B5XL^%]ZR:;>S6@7[]G< M$>&QE#[
ML3QWYKKJ9'@,TBZN4U;/^5_U=?BCS*/%V<\.U%AN(\.Y1V52-M?N]V7_ )*^
MZ/T.HKP?X>_M9>'_ !%LMO$47]@WAS^^R7MS]X]>J\!1SU+5Z-XP^+_A+P/I
MZW6I:Q;L7!,5O:L)I9><?*JGID$9.![U\?6RO&X>LJ$Z3YGMI>_I;<_3\+Q%
ME6,PSQ='$1Y%NV[6]4[-?KT.RKDO'7Q4\,_#FW+ZUJ4<4Y&4LXOGGD^B#G'N
M<#WKYD^(G[6?B#Q%YMIX<B_L"P;CS\A[EQ_O=$_X#R/[U>&75U/?7$EQ<S27
M$\C;GEE8LS'U)/)-?89=PC5J6GC9<J[+?YO9?B?F.=^)F'H7HY3#VDOYI:1^
M2W?SM\SW/XB?M9^(/$7FVGAR+^P+!N//R'N7'^]T3_@/(_O5X9=74]]<27%S
M-)<3R-N>65BS,?4D\DU/8Z3<WY!C3"?WVX%=/IGA6*$AG'G2>K#C\J^FJYAE
M/#\'2HI<W:.K^;_S?R/@</DO$G&=58G%2:I])3TBO\,>OR5N[/,-<\8Z;H.Y
M)IO-N!_RPA^9OQ]/QKS[6O'VJ:UNC@/V&V/&V(_,1[M_ABOKBRT5FQ\M=)IO
MAPMCY:^6K<7U:NBI67^+_@'Z'A?#/#X:TGB.:7=P_)<Q\#0V99LGD]:UK/33
MQQ7Z(:5X6Z?)^E=CI/AD+@[:Y(\2*/\ RY_\F_\ M3TI\"2G_P Q7_DG_P!N
M?G#IUCMQQ72V4&T#BOTGTW1A&!\M=%:VHC4<5W4^+E3_ .8?_P F_P#M3R*W
MAI*MOC?_ "G_ /;GYE1K@5+7Z?QKBI*Z?]=?^H?_ ,F_^U.!^%-_^8[_ ,I_
M_;GY>45^H=%/_7;_ *A__)O_ +47_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_
M /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG
M_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0_
M_DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I
M_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/
M_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I_
M_;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#
M_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?
M_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_
M /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG
M_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0_
M_DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I
M_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/
M_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I_
M_;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#
M_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?
M_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_
M /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG
M_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0_
M_DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I
M_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/
M_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I_
M_;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#
M_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?
M_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_
M /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG
M_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0_
M_DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I
M_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/
M_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I_
M_;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#
M_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?
M_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_
M /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG
M_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0_
M_DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I
M_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/
M_P"3?_:A_P 0H_ZCO_*?_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I_
M_;GY>45^H=%'^NW_ %#_ /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#
M_P#DW_VH?\0H_P"H[_RG_P#;GY>45^H=%'^NW_4/_P"3?_:A_P 0H_ZCO_*?
M_P!N?EY17ZAT4?Z[?]0__DW_ -J'_$*/^H[_ ,I__;GY>45^H=%'^NW_ %#_
M /DW_P!J'_$*/^H[_P I_P#VY^7E%?J'11_KM_U#_P#DW_VH?\0H_P"H[_RG
M_P#;G+?"O_DF'A#_ + ]G_Z(2NIHHK\UJS]I4E.V[;/WC#T?J]&%&]^5)?<K
M!11161T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5YM\:O^//2/^N[?R%>DUYM\:O\ CSTC_KNW\A0!Z311
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0NO^?F;_ +[-']H77_/S-_WV:/['?_/S\/\ @A];7\OXG[L_\-':+_T#+_\
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MF_[[-']CO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\ %4?\-':+_P! R_\
M_'/_ (JOPF_M"Z_Y^9O^^S1_:%U_S\S?]]FC^QW_ ,_/P_X(?6U_+^)^[/\
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M)^[/_#1VB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\ Q5?A-_:%U_S\S?\
M?9H_M"Z_Y^9O^^S1_8[_ .?GX?\ !#ZVOY?Q/W9_X:.T7_H&7_\ XY_\51_P
MT=HO_0,O_P#QS_XJOPF_M"Z_Y^9O^^S1_:%U_P _,W_?9H_L=_\ /S\/^"'U
MM?R_B?NS_P -':+_ - R_P#_ !S_ .*H_P"&CM%_Z!E__P".?_%5^$W]H77_
M #\S?]]FC^T+K_GYF_[[-']CO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\
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ML=_\_/P_X(?6U_+^)^[/_#1VB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\
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M.T7_ *!E_P#^.?\ Q5?A-_:%U_S\S?\ ?9H_M"Z_Y^9O^^S1_8[_ .?GX?\
M!#ZVOY?Q/W9_X:.T7_H&7_\ XY_\51_PT=HO_0,O_P#QS_XJOPF_M"Z_Y^9O
M^^S1_:%U_P _,W_?9H_L=_\ /S\/^"'UM?R_B?NS_P -':+_ - R_P#_ !S_
M .*H_P"&CM%_Z!E__P".?_%5^$W]H77_ #\S?]]FC^T+K_GYF_[[-']CO_GY
M^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\ %4?\-':+_P! R_\ _'/_ (JOPF_M
M"Z_Y^9O^^S1_:%U_S\S?]]FC^QW_ ,_/P_X(?6U_+^)^[/\ PT=HO_0,O_\
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MYF_[[-']H77_ #\S?]]FC^QW_P _/P_X(?6U_+^)^[/_  T=HO\ T#+_ /\
M'/\ XJC_ (:.T7_H&7__ (Y_\57X3?VA=?\ /S-_WV:/[0NO^?F;_OLT?V._
M^?GX?\$/K:_E_$_=G_AH[1?^@9?_ /CG_P 51_PT=HO_ $#+_P#\<_\ BJ_"
M;^T+K_GYF_[[-']H77_/S-_WV:/['?\ S\_#_@A];7\OXG[L_P##1VB_] R_
M_P#'/_BJ/^&CM%_Z!E__ ..?_%5^$W]H77_/S-_WV:/[0NO^?F;_ +[-']CO
M_GY^'_!#ZVOY?Q/W9_X:.T7_ *!E_P#^.?\ Q5'_  T=HO\ T#+_ /\ '/\
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M_!#ZVOY?Q/W9_P"&CM%_Z!E__P".?_%4?\-':+_T#+__ ,<_^*K\)O[0NO\
MGYF_[[-']H77_/S-_P!]FC^QW_S\_#_@A];7\OXG[L_\-':+_P! R_\ _'/_
M (JC_AH[1?\ H&7_ /XY_P#%5^$W]H77_/S-_P!]FC^T+K_GYF_[[-']CO\
MY^?A_P $/K:_E_$_=G_AH[1?^@9?_P#CG_Q5'_#1VB_] R__ /'/_BJ_";^T
M+K_GYF_[[-']H77_ #\S?]]FC^QW_P _/P_X(?6U_+^)^[/_  T=HO\ T#+_
M /\ '/\ XJC_ (:.T7_H&7__ (Y_\57X3?VA=?\ /S-_WV:/[0NO^?F;_OLT
M?V._^?GX?\$/K:_E_$_=G_AH[1?^@9?_ /CG_P 51_PT=HO_ $#+_P#\<_\
MBJ_";^T+K_GYF_[[-']H77_/S-_WV:/['?\ S\_#_@A];7\OXG[L_P##1VB_
M] R__P#'/_BJ/^&CM%_Z!E__ ..?_%5^$W]H77_/S-_WV:/[0NO^?F;_ +[-
M']CO_GY^'_!#ZVOY?Q/W9_X:.T7_ *!E_P#^.?\ Q5'_  T=HO\ T#+_ /\
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M #\S?]]FC^T+K_GYF_[[-']CO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\
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ML=_\_/P_X(?6U_+^)^[/_#1VB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\
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M.T7_ *!E_P#^.?\ Q5?A-_:%U_S\S?\ ?9H_M"Z_Y^9O^^S1_8[_ .?GX?\
M!#ZVOY?Q/W9_X:.T7_H&7_\ XY_\51_PT=HO_0,O_P#QS_XJOPF_M"Z_Y^9O
M^^S1_:%U_P _,W_?9H_L=_\ /S\/^"'UM?R_B?NS_P -':+_ - R_P#_ !S_
M .*H_P"&CM%_Z!E__P".?_%5^$W]H77_ #\S?]]FC^T+K_GYF_[[-']CO_GY
M^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\ %4?\-':+_P! R_\ _'/_ (JOPF_M
M"Z_Y^9O^^S1_:%U_S\S?]]FC^QW_ ,_/P_X(?6U_+^)^[/\ PT=HO_0,O_\
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M_";^T+K_ )^9O^^S1_:%U_S\S?\ ?9H_L=_\_/P_X(?6U_+^)^[/_#1VB_\
M0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\ Q5?A-_:%U_S\S?\ ?9H_M"Z_Y^9O
M^^S1_8[_ .?GX?\ !#ZVOY?Q/W9_X:.T7_H&7_\ XY_\51_PT=HO_0,O_P#Q
MS_XJOPF_M"Z_Y^9O^^S1_:%U_P _,W_?9H_L=_\ /S\/^"'UM?R_B?NS_P -
M':+_ - R_P#_ !S_ .*H_P"&CM%_Z!E__P".?_%5^$W]H77_ #\S?]]FC^T+
MK_GYF_[[-']CO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\ %4?\-':+_P!
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M:%U_S\S?]]FC^T+K_GYF_P"^S1_8[_Y^?A_P0^MK^7\3]V?^&CM%_P"@9?\
M_CG_ ,51_P -':+_ - R_P#_ !S_ .*K\)O[0NO^?F;_ +[-']H77_/S-_WV
M:/['?_/S\/\ @A];7\OXG[L_\-':+_T#+_\ \<_^*H_X:.T7_H&7_P#XY_\
M%5^$W]H77_/S-_WV:/[0NO\ GYF_[[-']CO_ )^?A_P0^MK^7\3]V?\ AH[1
M?^@9?_\ CG_Q5'_#1VB_] R__P#'/_BJ_";^T+K_ )^9O^^S1_:%U_S\S?\
M?9H_L=_\_/P_X(?6U_+^)^[/_#1VB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^
M.?\ Q5?A-_:%U_S\S?\ ?9H_M"Z_Y^9O^^S1_8[_ .?GX?\ !#ZVOY?Q/W9_
MX:.T7_H&7_\ XY_\51_PT=HO_0,O_P#QS_XJOPF_M"Z_Y^9O^^S1_:%U_P _
M,W_?9H_L=_\ /S\/^"'UM?R_B?NS_P -':+_ - R_P#_ !S_ .*H_P"&CM%_
MZ!E__P".?_%5^$W]H77_ #\S?]]FC^T+K_GYF_[[-']CO_GY^'_!#ZVOY?Q/
MW9_X:.T7_H&7_P#XY_\ %4?\-':+_P! R_\ _'/_ (JOPF_M"Z_Y^9O^^S1_
M:%U_S\S?]]FC^QW_ ,_/P_X(?6U_+^)^[/\ PT=HO_0,O_\ QS_XJC_AH[1?
M^@9?_P#CG_Q5?A-_:%U_S\S?]]FC^T+K_GYF_P"^S1_8[_Y^?A_P0^MK^7\3
M]V?^&CM%_P"@9?\ _CG_ ,51_P -':+_ - R_P#_ !S_ .*K\)O[0NO^?F;_
M +[-']H77_/S-_WV:/['?_/S\/\ @A];7\OXG[L_\-':+_T#+_\ \<_^*H_X
M:.T7_H&7_P#XY_\ %5^$W]H77_/S-_WV:/[0NO\ GYF_[[-']CO_ )^?A_P0
M^MK^7\3]V?\ AH[1?^@9?_\ CG_Q5'_#1VB_] R__P#'/_BJ_";^T+K_ )^9
MO^^S1_:%U_S\S?\ ?9H_L=_\_/P_X(?6U_+^)^[/_#1VB_\ 0,O_ /QS_P"*
MH_X:.T7_ *!E_P#^.?\ Q5?A-_:%U_S\S?\ ?9H_M"Z_Y^9O^^S1_8[_ .?G
MX?\ !#ZVOY?Q/W9_X:.T7_H&7_\ XY_\51_PT=HO_0,O_P#QS_XJOPF_M"Z_
MY^9O^^S1_:%U_P _,W_?9H_L=_\ /S\/^"'UM?R_B?NS_P -':+_ - R_P#_
M !S_ .*H_P"&CM%_Z!E__P".?_%5^$W]H77_ #\S?]]FC^T+K_GYF_[[-']C
MO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\ %4?\-':+_P! R_\ _'/_ (JO
MPF_M"Z_Y^9O^^S1_:%U_S\S?]]FC^QW_ ,_/P_X(?6U_+^)^[/\ PT=HO_0,
MO_\ QS_XJC_AH[1?^@9?_P#CG_Q5?A-_:%U_S\S?]]FC^T+K_GYF_P"^S1_8
M[_Y^?A_P0^MK^7\3]V?^&CM%_P"@9?\ _CG_ ,51_P -':+_ - R_P#_ !S_
M .*K\)O[0NO^?F;_ +[-']H77_/S-_WV:/['?_/S\/\ @A];7\OXG[L_\-':
M+_T#+_\ \<_^*H_X:.T7_H&7_P#XY_\ %5^$W]H77_/S-_WV:/[0NO\ GYF_
M[[-']CO_ )^?A_P0^MK^7\3]V?\ AH[1?^@9?_\ CG_Q5'_#1VB_] R__P#'
M/_BJ_";^T+K_ )^9O^^S1_:%U_S\S?\ ?9H_L=_\_/P_X(?6U_+^)^[/_#1V
MB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\ Q5?A-_:%U_S\S?\ ?9H_M"Z_
MY^9O^^S1_8[_ .?GX?\ !#ZVOY?Q/W9_X:.T7_H&7_\ XY_\51_PT=HO_0,O
M_P#QS_XJOPF_M"Z_Y^9O^^S1_:%U_P _,W_?9H_L=_\ /S\/^"'UM?R_B?NS
M_P -':+_ - R_P#_ !S_ .*H_P"&CM%_Z!E__P".?_%5^$W]H77_ #\S?]]F
MC^T+K_GYF_[[-']CO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\ %4?\-':+
M_P! R_\ _'/_ (JOPF_M"Z_Y^9O^^S1_:%U_S\S?]]FC^QW_ ,_/P_X(?6U_
M+^)^[/\ PT=HO_0,O_\ QS_XJC_AH[1?^@9?_P#CG_Q5?A-_:%U_S\S?]]FC
M^T+K_GYF_P"^S1_8[_Y^?A_P0^MK^7\3]V?^&CM%_P"@9?\ _CG_ ,51_P -
M':+_ - R_P#_ !S_ .*K\)O[0NO^?F;_ +[-']H77_/S-_WV:/['?_/S\/\
M@A];7\OXG[L_\-':+_T#+_\ \<_^*H_X:.T7_H&7_P#XY_\ %5^$W]H77_/S
M-_WV:/[0NO\ GYF_[[-']CO_ )^?A_P0^MK^7\3]V?\ AH[1?^@9?_\ CG_Q
M5'_#1VB_] R__P#'/_BJ_";^T+K_ )^9O^^S1_:%U_S\S?\ ?9H_L=_\_/P_
MX(?6U_+^)^[/_#1VB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\ Q5?A-_:%
MU_S\S?\ ?9H_M"Z_Y^9O^^S1_8[_ .?GX?\ !#ZVOY?Q/W9_X:.T7_H&7_\
MXY_\51_PT=HO_0,O_P#QS_XJOPF_M"Z_Y^9O^^S1_:%U_P _,W_?9H_L=_\
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MY_\ %5^$W]H77_/S-_WV:/[0NO\ GYF_[[-']CO_ )^?A_P0^MK^7\3]V?\
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M\-':+_T#+_\ \<_^*H_X:.T7_H&7_P#XY_\ %5^$W]H77_/S-_WV:/[0NO\
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M7_/S-_WV:/[0NO\ GYF_[[-']CO_ )^?A_P0^MK^7\3]V?\ AH[1?^@9?_\
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M0NO^?F;_ +[-']H77_/S-_WV:/['?_/S\/\ @A];7\OXG[L_\-':+_T#+_\
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MF_[[-']CO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\ %4?\-':+_P! R_\
M_'/_ (JOPF_M"Z_Y^9O^^S1_:%U_S\S?]]FC^QW_ ,_/P_X(?6U_+^)^[/\
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M)^[/_#1VB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\ Q5?A-_:%U_S\S?\
M?9H_M"Z_Y^9O^^S1_8[_ .?GX?\ !#ZVOY?Q/W9_X:.T7_H&7_\ XY_\51_P
MT=HO_0,O_P#QS_XJOPF_M"Z_Y^9O^^S1_:%U_P _,W_?9H_L=_\ /S\/^"'U
MM?R_B?NS_P -':+_ - R_P#_ !S_ .*H_P"&CM%_Z!E__P".?_%5^$W]H77_
M #\S?]]FC^T+K_GYF_[[-']CO_GY^'_!#ZVOY?Q/W9_X:.T7_H&7_P#XY_\
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ML=_\_/P_X(?6U_+^)^[/_#1VB_\ 0,O_ /QS_P"*H_X:.T7_ *!E_P#^.?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7ZR_\ !)G_ )-S\1_]C7<_
M^D=G7Y-5^LO_  29_P"3<_$?_8UW/_I'9UY69_[N_5'5AOXA^</[2G_)QGQ4
M_P"QKU7_ -+):\XKT?\ :4_Y.,^*G_8UZK_Z62UYQ7HT_@CZ'/+XF%?M'^S'
M\!?A?KG[.OP\U35OAUX1U"_N-#MI[F]O=#M9)96,8+.[M&22>I)-?BY7[L?L
MM1/<?LI_#J*,;G?PW;*H]280!7E9M*4,-S1WO^C-\*E*ND]K/\T8FD_"K]F7
MXL1W.F:#X?\ AIKTGEGS8_#R61G1>F=UOAUZ]017Y\?MZ_L>6'[.6L:7X@\*
M-.W@W696@6VN',CV-P!N$6\\LC*"5)R?D8$G@GM_V4?V#/C-X+^.GA7Q1XCT
MJ'PGI6C7:W<UPVHP3R3* 08D6"1_O [3NP,$]>A]N_X*R>(;"S^!_AK1998_
M[3O==2X@AR-_EQ0RB1P/0&1!_P "%<-_JV(IJC5YE)ZK?^OST['93_?1G&I&
MR2;3\[-_HOO/RDHKZ+_9 _8YUC]J#7+JZFNWT3P=ILBQWVIJ@:21S@^1"#QO
MVG)8Y"@@D'(!_1/2O^";OP#T_2X;6X\)76ISH@5KZZU>[660X^\PCD1,_10/
M:O9Q&,I89\L]7V1Y].G*KK'8_&&BOUT\-_\ !+_X4Z)X]U"_OH+KQ#X6NK4B
M#2+^\FCDL[CS =R2PNA="F1A\D8'+9X^3/VR/@'X$^%/[4'@+PEX6T+^R_#V
MJ06+W=G]LGF\PR7<D;G?)(SC*J!P1C''-11Q]*O4C2A>\OZU+G1G3ISJ2VCK
MZ[;??UL?'U%?L-XY_P"":'P<\00Z1!H&AS>&!'?I-?W-OJ-U-+-;!'S"@FD=
M5+.8_FVY !Q7/:U^QC^SY8?'3PEX%A\$L\E[HU]JEW&=9O?N1O#'$Q_?9!+/
M)T('R'@]L5FE&5K)WU[=%?OZFCPLUK=6_P W;_+[SV;XU_\ )F/B[_L29_\
MTC-?AI7]#^M>"=%\1>"[SPGJ%E]H\/W=DVG36?FNN^W*;"F]6##Y>,@Y]Z_/
M0?LG?"K_ (;V/PY_X1;_ (HS_A&O[0_LW^T;O_7_ -_S/-\S\-V/:O.P.*A3
MJU+I^]=_<F_R+J4I1H0B_LV7WVC^9^==%?KMXT_X)@_"CQ%XJT&XT>WNO"N@
M6B2G4+&QNYYYK]R4\L>9.\GEJH#YVC)W=L UTFM?\$V/@-JFCS6=KX8O-(N7
M3:NH6FK7331G^\!+(\9/U0BO0_M6A9.SU_KN9_59WL?C+17K'[3G[/\ J7[-
MOQ4N_"=[=?VC:-$MYI]^$V?:+=R0"5R<,&5E(SU7/0BO:?V.?V [[]H'2T\6
M^++ZZT#P6SLELMJH%WJ!4X+1E@52,'(W$-D@@#O7H+$4G2]O?W?Z_$PG3E"?
MLVM3X^HK]I;?_@G+^S_#:K$_@B6=P,&>36;X.?<[9@N?PKYE_:H_X)E6_A/P
MS?\ BOX57-]>QV2M/=>';QO.D\H<DVS@ L5'.QLL1G#$X4\$<TP\I6=UYO8Z
M/JM1K3<_/2BOJS_@G?\ !'P5\=/BCXBTCQQHO]MZ=::0;J&'[5/;[9/.C7=F
M)T)X8C!..:^VK/\ X)G_  ;7QUJ6K76B3MX?:&*&RT&/4;H11L!F29Y3)YK,
MQ( 4.% 7H<\=.(QE/#24)WU5_P _\C"G3E53<>CM^7^9^/-%>S?$GX7V'C/]
MJ#7O ?PFT:3["VK/INFV7GO,!Y?R2N9'+'9N21]Q)POTK] ?A#_P2W^&OA?1
M('\>27?C/6Y$!G5+J2TLXFZD1B(K(<=-S-SC.U<XISQE*G2C5EIS*Z74?LI>
MT=):M;]C\F**_8[QC_P3,^!_B+2GMM)T?4?"MWU2\T_4YYF!]UN&D4CUX!]Q
M7YE_M)_LW>)/V9_'7]@ZXRWUC<JTVFZM A6*\B!P3@_==<C<F3C(Y(()SH8^
MCB)<D='YESP\X1YMT>2T5])_L>?L8ZM^T]JEUJ%Y>2:'X+TZ417>H1H&FGDP
M"880>-VT@ECD+N'#9Q7Z&:;_ ,$W?@%8Z;%:S>$;K4)T0*U[<ZQ=B5SC[Q"2
MJF?HH'M5XC&TL,^6>K[(SITI5=8['S!_P2'_ .1Z^(G_ &#;7_T:]<5_P5:_
MY.4TS_L6[7_T?<U]R_LY?L=:5^S-\2/%.K^&]6N+SP]K=E%$EE?8:>UD20M@
M.  Z$-QD C'.[.:^&O\ @JU_R<IIG_8MVO\ Z/N:\J%:&(QT)PVM^C.F-.5*
ME54NZ_\ ;3XTJQIVG76L:A:V%C;R7=[=2K!!;PJ6>21B JJ!U))  ]ZKU]C_
M /!+GX9VOC3X_7?B"^A6>#PQI[74*MR!<R,(XVQ[*92/0@&OH935.+G+9)O[
MC@=]EN]/OT/I/]EW_@FSX6\#:39^(/BA:0^)O$TBB7^R)CNL++(^ZR])G'.2
MV4YP%.-Q]DUC]K[]G[X1SQ^'CXST/31;_NEL]#M)+B&';QL/V:-D3'3!(Q7S
MQ_P5)_:*U?PG:Z3\,/#][)8?VM:&^UB:%MKR6Y9DC@!'(5BDA;U"J.A8'\R*
M^?HT:F8+VU>5H]$OZ_X<]*?+A;0BKR[G[F:EX)^!7[77AZ>Y6U\.>,X@ C:A
MIS(+VV)Y ,B8EC/?:V,]P:_,#]LW]D=_V7?%5@;'6(]7\-:QYC6!GD1;R+9C
M<DB#&X#</WBC![A3@'QOX9_$[Q+\(?%]EXF\*:I-I6JVIX>,_)*F1F.1>CH<
M<J>/Q -2?%+XJ>)?C+XTOO%/BO47U'5;HXR>(X8QG;%&O1$7/ 'J2<DDGKHX
M.IAZJ=.?N=4_Z_$RE752#52.O0_:#]H__DS_ ,<?]BI+_P"B*\1_X)8?\(3_
M ,*0U+^SOL7_  F'VZ7^VMVW[3Y>?W&<_-Y6SI_#N\SOFO;OVC_^3/\ QQ_V
M*DO_ *(KXW_X)X_LL?"_XZ?"77]9\<>&/[;U*UUI[2&?^T+JWVQ""%@NV*5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_67_ (),_P#)N?B/_L:[G_TCLZ_)JOUE_P""3/\
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M;(XV[/.4#!VN &#+]UCC.17FJ$IY7!Q6TIW_ / G;[M?O-YRC'&^]U2_*/\
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M>7"TC?<#G(W8)R0!C=N'Z!?M)?\ !,WPYX_T_2KGX7G3?!6J:?;+:-97"/\
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M]KSZUXC^('Q%UK5&8O\ :KW5K:1U.<X7-K\H!Z!< =@*]_\ A#\+1\(?"_\
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M67_@DS_R;GXC_P"QKN?_ $CLZ_)JOUE_X),_\FY^(_\ L:[G_P!([.O*S/\
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M8^Y8FN<\)_M<?%[P3XHUKQ'I?C>]_MO6$CCO;R^AAO7D1"Q1!YZ.$52[850
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MU[I^Q'^RO\(_VEO"]\-8\1^)M+\<:5.7N+'3KVVB1H"1Y<\2O S8!^5OF.&
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M=T4-Q)M@B.,92%0$0X[JHS7#T5:HTHRYE%7]".>5K7T"BBBMB HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K]9?\ @DS_ ,FY^(_^QKN?_2.SK\FJ_67_ (),_P#)N?B/_L:[G_TC
MLZ\K,_\ =WZHZL-_$/@S]HCX3^.-2_: ^)MW:>#?$%U:W'B?4Y89X=+G=)$:
M[E*LK!,$$$$$=<UY]_PIKX@?]"-XD_\ !1<?_$5_0517FQS:48J/)MYG0\*F
M[W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\ @HN/_B*_H*HJO[7E
M_)^(OJJ[G\^O_"FOB!_T(WB3_P %%Q_\11_PIKX@?]"-XD_\%%Q_\17]!5%'
M]KR_D_$/JJ[G\^O_  IKX@?]"-XD_P#!1<?_ !%'_"FOB!_T(WB3_P %%Q_\
M17]!5%']KR_D_$/JJ[G\^O\ PIKX@?\ 0C>)/_!1<?\ Q%'_  IKX@?]"-XD
M_P#!1<?_ !%?T%44?VO+^3\0^JKN?SZ_\*:^('_0C>)/_!1<?_$4?\*:^('_
M $(WB3_P47'_ ,17]!5%']KR_D_$/JJ[G\^O_"FOB!_T(WB3_P %%Q_\11_P
MIKX@?]"-XD_\%%Q_\17]!5%']KR_D_$/JJ[G\^O_  IKX@?]"-XD_P#!1<?_
M !%'_"FOB!_T(WB3_P %%Q_\17]!5%']KR_D_$/JJ[G\^O\ PIKX@?\ 0C>)
M/_!1<?\ Q%'_  IKX@?]"-XD_P#!1<?_ !%?T%44?VO+^3\0^JKN?SZ_\*:^
M('_0C>)/_!1<?_$4?\*:^('_ $(WB3_P47'_ ,17]!5%']KR_D_$/JJ[G\^O
M_"FOB!_T(WB3_P %%Q_\11_PIKX@?]"-XD_\%%Q_\17]!5%']KR_D_$/JJ[G
M\^O_  IKX@?]"-XD_P#!1<?_ !%'_"FOB!_T(WB3_P %%Q_\17]!5%']KR_D
M_$/JJ[G\^O\ PIKX@?\ 0C>)/_!1<?\ Q%'_  IKX@?]"-XD_P#!1<?_ !%?
MT%44?VO+^3\0^JKN?SZ_\*:^('_0C>)/_!1<?_$4?\*:^('_ $(WB3_P47'_
M ,17]!5%']KR_D_$/JJ[G\^O_"FOB!_T(WB3_P %%Q_\11_PIKX@?]"-XD_\
M%%Q_\17]!5%']KR_D_$/JJ[G\^O_  IKX@?]"-XD_P#!1<?_ !%'_"FOB!_T
M(WB3_P %%Q_\17]!5%']KR_D_$/JJ[G\^O\ PIKX@?\ 0C>)/_!1<?\ Q%'_
M  IKX@?]"-XD_P#!1<?_ !%?T%44?VO+^3\0^JKN?SZ_\*:^('_0C>)/_!1<
M?_$4?\*:^('_ $(WB3_P47'_ ,17]!5%']KR_D_$/JJ[G\^O_"FOB!_T(WB3
M_P %%Q_\11_PIKX@?]"-XD_\%%Q_\17]!5%']KR_D_$/JJ[G\^O_  IKX@?]
M"-XD_P#!1<?_ !%'_"FOB!_T(WB3_P %%Q_\17]!5%']KR_D_$/JJ[G\^O\
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M"-XD_P#!1<?_ !%'_"FOB!_T(WB3_P %%Q_\17]!5%']KR_D_$/JJ[G\^O\
MPIKX@?\ 0C>)/_!1<?\ Q%20_!'XBW)(A\ ^*)2HR0FC7)P/P2OZ!JYGQMXR
M/@^&SD%H+O[1(4QYFS;@=>AH_M>?\GXA]57<_!O_ (4U\0/^A&\2?^"BX_\
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M4U\0/^A&\2?^"BX_^(K^@JBC^UY?R?B'U5=S^?7_ (4U\0/^A&\2?^"BX_\
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M4U\0/^A&\2?^"BX_^(K^@JBC^UY?R?B'U5=S^?7_ (4U\0/^A&\2?^"BX_\
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M4U\0/^A&\2?^"BX_^(K^@JBC^UY?R?B'U5=S^?7_ (4U\0/^A&\2?^"BX_\
MB*/^%-?$#_H1O$G_ (*+C_XBOZ"J*/[7E_)^(?55W/Y]?^%-?$#_ *$;Q)_X
M*+C_ .(H_P"%-?$#_H1O$G_@HN/_ (BOZ"J*/[7E_)^(?55W/Y]?^%-?$#_H
M1O$G_@HN/_B*L6OP)^)5]N-M\//%5P%^]Y6B7+8^N$K^@*BE_:\_Y/Q#ZJNY
M_/K_ ,*:^('_ $(WB3_P47'_ ,11_P *:^('_0C>)/\ P47'_P 17]!5%/\
MM>7\GXA]57<_GU_X4U\0/^A&\2?^"BX_^(H_X4U\0/\ H1O$G_@HN/\ XBOZ
M"J*/[7E_)^(?55W/Y]?^%-?$#_H1O$G_ (*+C_XBC_A37Q _Z$;Q)_X*+C_X
MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MBOZ"J*/[7E_)^(?55W/Y]?\ A37Q _Z$;Q)_X*+C_P"(H_X4U\0/^A&\2?\
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MQ:8L:QL[*,%SN;W. /Y 5RXG,)8BG[-QL:TZ"IRYKCZ***\DZ@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KS;XU?\>>D?]=V_D*])KS;XU?\>>D?]=V_D* /2:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDW4 +2;J,'O
M4-Y#+-#BWE6"7((9DWC&>01D=1GO36XF[*]B7<*-PK!EUB?3\#4K?[-T'VB,
M[X"?E'WL97EL?,!G'&:LQZDD@#*P8'D$'K52BX[D0J1GHGK^/W&MFEJE'=!N
M]6%E#5!H2T4FZEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\V^-7_'GI'_ %W;^0KTFO-OC5_QYZ1_
MUW;^0H ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M)FC![
MT4 &#WHI:* "BBB@ K!N_"-N6\S3Y#ILF1E(US$?NC[G0<+CY<=23FMZBJC)
MQV,YTXU/B7]>IYSXC\32^ =+EO\ 7;6Z%G"!ON--M)KT')4<)$C/U;'*]CVK
MRV']OCX(J</XV*D<$'2;[_XQ7TQ7@_QL_8O^&WQL$MU=Z9_86N-C&K:2JQ2'
M[@^=<;7^5-HR.,FNVA]5D[5[KS6WW6;.>7MZ?P>\O/?_ "?X?,S(_P!OKX%]
M_'&/^X1??_&*G7]OCX$_]#U_Y2+_ /\ C%? WQL_80^)'P@\V]L[/_A+]"3G
M[;I4;&5!\@^>'EA\SX&W=]TGBOG0-M)!&".H-?1T\HP=:/-";:]5_D<OUR=[
M6U^9^P__  WQ\"/^AZ_\I%__ /&*/^&^/@1_T/7_ )2+_P#^,5^/BL*=Q6_]
MA8;^:7WK_(/K<^R/V!_X;X^!'_0]?^4B_P#_ (Q1_P -\? C_H>O_*1?_P#Q
MBOQ_V^U&WVI_V%AOYI?>O\@^MS[(_8#_ (;X^!'_ $/7_E(O_P#XQ1_PWQ\"
M/^AZ_P#*1?\ _P 8K\?]OM1M]J/["PW\TOO7^0?6Y]D?L!_PWQ\"/^AZ_P#*
M1?\ _P 8H_X;X^!'_0]?^4B__P#C%?C_ +?:C;[4?V%AOYI?>O\ (/K<^R/V
M _X;X^!'_0]?^4B__P#C%'_#?'P(_P"AZ_\ *1?_ /QBOQ_V^U&WVH_L+#?S
M2^]?Y!];GV1^P'_#?'P(_P"AZ_\ *1?_ /QBC_AOCX$?]#U_Y2+_ /\ C%?C
M_M]J-OM1_86&_FE]Z_R#ZW/LC]@/^&^/@1_T/7_E(O\ _P",4?\ #?'P(_Z'
MK_RD7_\ \8K\?]OM1M]J/["PW\TOO7^0?6Y]D?L!_P -\? C_H>O_*1?_P#Q
MBC_AOCX$?]#U_P"4B_\ _C%?C_M]J-OM1_86&_FE]Z_R#ZW/LC]@/^&^/@1_
MT/7_ )2+_P#^,4?\-\? C_H>O_*1?_\ QBOQ_P!OM1M]J/["PW\TOO7^0?6Y
M]D?L!_PWQ\"/^AZ_\I%__P#&*/\ AOCX$?\ 0]?^4B__ /C%?C_M]J-OM1_8
M6&_FE]Z_R#ZW/LC]@/\ AOCX$?\ 0]?^4B__ /C%'_#?'P(_Z'K_ ,I%_P#_
M !BOQ_V^U&WVH_L+#?S2^]?Y!];GV1^P'_#?'P(_Z'K_ ,I%_P#_ !BC_AOC
MX$?]#U_Y2+__ .,5^/\ M]J-OM1_86&_FE]Z_P @^MS[(_8#_AOCX$?]#U_Y
M2+__ .,4?\-\? C_ *'K_P I%_\ _&*_'_;[4;?:C^PL-_-+[U_D'UN?9'[
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M^PL-_-+[U_D'UN?9'[ ?\-\? C_H>O\ RD7_ /\ &*/^&^/@1_T/7_E(O_\
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MC^PL-_-+[U_D'UN?9'[ ?\-\? C_ *'K_P I%_\ _&*/^&^/@1_T/7_E(O\
M_P",5^/^WVHV^U']A8;^:7WK_(/K<^R/V _X;X^!'_0]?^4B_P#_ (Q1_P -
M\? C_H>O_*1?_P#QBOQ_V^U&WVH_L+#?S2^]?Y!];GV1^P'_  WQ\"/^AZ_\
MI%__ /&*/^&^/@1_T/7_ )2+_P#^,5^/^WVHV^U']A8;^:7WK_(/K<^R/V _
MX;X^!'_0]?\ E(O_ /XQ1_PWQ\"/^AZ_\I%__P#&*_'_ &^U&WVH_L+#?S2^
M]?Y!];GV1^P'_#?'P(_Z'K_RD7__ ,8H_P"&^/@1_P!#U_Y2+_\ ^,5^/^WV
MHV^U']A8;^:7WK_(/K<^R/V _P"&^/@1_P!#U_Y2+_\ ^,4?\-\? C_H>O\
MRD7_ /\ &*_'_;[4;?:C^PL-_-+[U_D'UN?9'[ ?\-\? C_H>O\ RD7_ /\
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M/["PW\TOO7^0?6Y]D?L!_P -\? C_H>O_*1?_P#QBC_AOCX$?]#U_P"4B_\
M_C%?C_M]J-OM1_86&_FE]Z_R#ZW/LC]@/^&^/@1_T/7_ )2+_P#^,4?\-\?
MC_H>O_*1?_\ QBOQ_P!OM1M]J/["PW\TOO7^0?6Y]D?L!_PWQ\"/^AZ_\I%_
M_P#&*/\ AOCX$?\ 0]?^4B__ /C%?C_M]J-OM1_86&_FE]Z_R#ZW/LC]@/\
MAOCX$?\ 0]?^4B__ /C%'_#?'P(_Z'K_ ,I%_P#_ !BOQ_V^U&WVH_L+#?S2
M^]?Y!];GV1^P'_#?'P(_Z'K_ ,I%_P#_ !BC_AOCX$?]#U_Y2+__ .,5^/\
MM]J-OM1_86&_FE]Z_P @^MS[(_8#_AOCX$?]#U_Y2+__ .,4?\-\? C_ *'K
M_P I%_\ _&*_'_;[4;?:C^PL-_-+[U_D'UN?9'[ ?\-\? C_ *'K_P I%_\
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M?^4B_P#_ (Q7X_[?:C;[4?V%AOYI?>O\@^MS[(_8#_AOCX$?]#U_Y2+_ /\
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M2+__ .,4?\-\? C_ *'K_P I%_\ _&*_'_;[4;?:C^PL-_-+[U_D'UN?9'[
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M^PL-_-+[U_D'UN?9'[ ?\-\? C_H>O\ RD7_ /\ &*/^&^/@1_T/7_E(O_\
MXQ7X_P"WVHV^U']A8;^:7WK_ "#ZW/LC]@/^&^/@1_T/7_E(O_\ XQ7J'PN^
M+OA+XT>'[C6_!NK?VQIEO=-9R3_9IH-LRHCE=LJ*Q^61#D#'/7@U^%^WVK]0
M?^"7O'P!U_\ [&:X_P#26TKS<PRNCA*#JP;O?K;_ "-Z.(E4GRL^P****^7.
M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;XU?\
M'GI'_7=OY"O2:\V^-7_'GI'_ %W;^0H ])HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF\:>'O!5O;W'B'7=,T&"XE$$,NIWD=LLLAZ(I=@"Q]!S3L[VZBOI<V:*0$,
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M[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!P7?_)_Y'WC1117S904444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK07/PL\)W2W$*R#^W+^%LJ65LBV4CKA@"Y]0%_O5PK$XC,*U.E1]VW;9>?\
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MT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M-
M";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 F
MVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MH
MVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M
M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[
M31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT
M;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&T
MT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M-
M";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 F
MVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MH
MVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M
M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[
M31M- ";:-M+M-&TT )MHVTNTT;30 FVC;2[31M- ";:-M+M-&TT )MHVTNTT
M;30 FVC;2[31M- ";:_3;_@F/_R077O^QEN/_26UK\RMIK]-O^"9'_)!=>_[
M&6X_]);6OG\\_P!S?JCKPO\ $/KJBBBOSD]H**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_&VI:QX:GTJQU"2[DAM;JX:<HP< *&@5<_,.K"MH8J@L;7J.2M**MYZ&=O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :WW:AB_X^#_N_P"%3-]VH8O^/@_[O^% '#^'_@)X
M$\+_ !0U?XB:9H7V?QEJT;17FIM=SR&16*%@(VD,:_ZM/NJ.F.YJ'Q!^SO\
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MT?\ TXCY<LQTK<M.@K$L^HK=LQTJZ)^KR+\?2I*;&*EKTT8#**?15 ,HI]%
M#**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**
M?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10
M RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RB
MGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4
M ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,H
MI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]%
M #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #*
M*?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?1
M0 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 RBGT4 ,HI]% #**?10 R
MBGT4 ,HI]% #*_37_@F3_P D&U[_ +&6X_\ 26UK\S:_3/\ X)E_\D'U[_L9
M;C_TEM:^>SW_ '-^J.O"_P 0^N****_.#V@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% #:*=M%&T4 -HIVT4;10 VBG;11M% #:*=M%&T4 -HIVT4;10 VBG;11M%
M#:*=M%&T4 -HIVT4;10 VBG;11M% #:*=M%&T4 -HIVT4;10 VBG;11M% #:
M*=M%&T4 -HIVT4;10 VBG;11M% #:*=M%&T4 -HIVT4;10 VBG;11M% #:*=
MM%&T4 -HIVT4;10 VBG;11M% #:*=M%&T4 -HIVT4;10 VBG;11M% #:*=M%
M&T4 -HIVT4;10 VBG;11M% #:*=M%&T4 -HIVT4;10 VBG;11M% #:*=M%&T
M4 -HIVT4;10 VBG;11M% #:*=M%&T4 -HIVT4;10 VBG;11M% #:*=M%&T4
M-HIVT4;10 VBG;11M% #:_3/_@F7_P D'U[_ +&6X_\ 26UK\SMHK],?^"9G
M_)!]>_[&6X_]);6OGL]_W-^J.S"_Q#ZXHHHK\W/:"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OTQ_X)F_\D'U[_L9;
MC_TEM:_,ZOTQ_P""9O\ R0?7O^QEN/\ TEM:^>S[_<GZH[,)_%/K>BBBOS8]
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;XU?\
M'GI'_7=OY"O2:\V^-7_'GI'_ %W;^0H ])HHHH **** "BBB@ HHHH ****
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M -$W\(_^"*U_^-T?\* ^%_\ T3?PC_X(K7_XW7>T4>WJ_P [^]ARQ['!?\*
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MH#X7_P#1-_"/_@BM?_C==[11[>K_ #O[V'+'L<%_PH#X7_\ 1-_"/_@BM?\
MXW1_PH#X7_\ 1-_"/_@BM?\ XW7>T4>WJ_SO[V'+'L<%_P * ^%__1-_"/\
MX(K7_P"-T?\ "@/A?_T3?PC_ ."*U_\ C==[11[>K_._O8<L>QP7_"@/A?\
M]$W\(_\ @BM?_C='_"@/A?\ ]$W\(_\ @BM?_C==[11[>K_._O8<L>QP7_"@
M/A?_ -$W\(_^"*U_^-T?\* ^%_\ T3?PC_X(K7_XW7>T4>WJ_P [^]ARQ['!
M?\* ^%__ $3?PC_X(K7_ .-T?\* ^%__ $3?PC_X(K7_ .-UWM%'MZO\[^]A
MRQ['!?\ "@/A?_T3?PC_ ."*U_\ C='_  H#X7_]$W\(_P#@BM?_ (W7>T4>
MWJ_SO[V'+'L<%_PH#X7_ /1-_"/_ ((K7_XW1_PH#X7_ /1-_"/_ ((K7_XW
M7>T4>WJ_SO[V'+'L<%_PH#X7_P#1-_"/_@BM?_C='_"@/A?_ -$W\(_^"*U_
M^-UWM%'MZO\ ._O8<L>QP7_"@/A?_P!$W\(_^"*U_P#C='_"@/A?_P!$W\(_
M^"*U_P#C==[11[>K_._O8<L>QP7_  H#X7_]$W\(_P#@BM?_ (W1_P * ^%_
M_1-_"/\ X(K7_P"-UWM%'MZO\[^]ARQ['!?\* ^%_P#T3?PC_P""*U_^-T?\
M* ^%_P#T3?PC_P""*U_^-UWM%'MZO\[^]ARQ['!?\* ^%_\ T3?PC_X(K7_X
MW1_PH#X7_P#1-_"/_@BM?_C==[11[>K_ #O[V'+'L<%_PH#X7_\ 1-_"/_@B
MM?\ XW1_PH#X7_\ 1-_"/_@BM?\ XW7>T4>WJ_SO[V'+'L<%_P * ^%__1-_
M"/\ X(K7_P"-T?\ "@/A?_T3?PC_ ."*U_\ C==[11[>K_._O8<L>QP7_"@/
MA?\ ]$W\(_\ @BM?_C='_"@/A?\ ]$W\(_\ @BM?_C==[11[>K_._O8<L>QP
M7_"@/A?_ -$W\(_^"*U_^-T?\* ^%_\ T3?PC_X(K7_XW7>T4>WJ_P [^]AR
MQ['!?\* ^%__ $3?PC_X(K7_ .-T?\* ^%__ $3?PC_X(K7_ .-UWM%'MZO\
M[^]ARQ['!?\ "@/A?_T3?PC_ ."*U_\ C='_  H#X7_]$W\(_P#@BM?_ (W7
M>T4>WJ_SO[V'+'L<%_PH#X7_ /1-_"/_ ((K7_XW1_PH#X7_ /1-_"/_ ((K
M7_XW7>T4>WJ_SO[V'+'L<%_PH#X7_P#1-_"/_@BM?_C='_"@/A?_ -$W\(_^
M"*U_^-UWM%'MZO\ ._O8<L>QP7_"@/A?_P!$W\(_^"*U_P#C='_"@/A?_P!$
MW\(_^"*U_P#C==[11[>K_._O8<L>QP7_  H#X7_]$W\(_P#@BM?_ (W1_P *
M ^%__1-_"/\ X(K7_P"-UWM%'MZO\[^]ARQ['!?\* ^%_P#T3?PC_P""*U_^
M-T?\* ^%_P#T3?PC_P""*U_^-UWM%'MZO\[^]ARQ['!?\* ^%_\ T3?PC_X(
MK7_XW1_PH#X7_P#1-_"/_@BM?_C==[11[>K_ #O[V'+'L<%_PH#X7_\ 1-_"
M/_@BM?\ XW1_PH#X7_\ 1-_"/_@BM?\ XW7>T4>WJ_SO[V'+'L<%_P * ^%_
M_1-_"/\ X(K7_P"-T?\ "@/A?_T3?PC_ ."*U_\ C==[11[>K_._O8<L>QP7
M_"@/A?\ ]$W\(_\ @BM?_C='_"@/A?\ ]$W\(_\ @BM?_C==[11[>K_._O8<
ML>QP7_"@/A?_ -$W\(_^"*U_^-T?\* ^%_\ T3?PC_X(K7_XW7>T4>WJ_P [
M^]ARQ['!?\* ^%__ $3?PC_X(K7_ .-T?\* ^%__ $3?PC_X(K7_ .-UWM%'
MMZO\[^]ARQ['!?\ "@/A?_T3?PC_ ."*U_\ C='_  H#X7_]$W\(_P#@BM?_
M (W7>T4>WJ_SO[V'+'L<%_PH#X7_ /1-_"/_ ((K7_XW1_PH#X7_ /1-_"/_
M ((K7_XW7>T4>WJ_SO[V'+'L<%_PH#X7_P#1-_"/_@BM?_C='_"@/A?_ -$W
M\(_^"*U_^-UWM%'MZO\ ._O8<L>QP7_"@/A?_P!$W\(_^"*U_P#C='_"@/A?
M_P!$W\(_^"*U_P#C==[11[>K_._O8<L>QP7_  H#X7_]$W\(_P#@BM?_ (W1
M_P * ^%__1-_"/\ X(K7_P"-UWM%'MZO\[^]ARQ['!?\* ^%_P#T3?PC_P""
M*U_^-T?\* ^%_P#T3?PC_P""*U_^-UWM%'MZO\[^]ARQ['!?\* ^%_\ T3?P
MC_X(K7_XW1_PH#X7_P#1-_"/_@BM?_C==[11[>K_ #O[V'+'L<%_PH#X7_\
M1-_"/_@BM?\ XW1_PH#X7_\ 1-_"/_@BM?\ XW7>T4>WJ_SO[V'+'L<%_P *
M ^%__1-_"/\ X(K7_P"-T?\ "@/A?_T3?PC_ ."*U_\ C==[11[>K_._O8<L
M>QP7_"@/A?\ ]$W\(_\ @BM?_C='_"@/A?\ ]$W\(_\ @BM?_C==[11[>K_.
M_O8<L>QP7_"@/A?_ -$W\(_^"*U_^-T?\* ^%_\ T3?PC_X(K7_XW7>T4>WJ
M_P [^]ARQ['!?\* ^%__ $3?PC_X(K7_ .-T?\* ^%__ $3?PC_X(K7_ .-U
MWM%'MZO\[^]ARQ['!?\ "@/A?_T3?PC_ ."*U_\ C='_  H#X7_]$W\(_P#@
MBM?_ (W7>T4>WJ_SO[V'+'L<%_PH#X7_ /1-_"/_ ((K7_XW1_PH#X7_ /1-
M_"/_ ((K7_XW7>T4>WJ_SO[V'+'L<%_PH#X7_P#1-_"/_@BM?_C='_"@/A?_
M -$W\(_^"*U_^-UWM%'MZO\ ._O8<L>QP7_"@/A?_P!$W\(_^"*U_P#C='_"
M@/A?_P!$W\(_^"*U_P#C==[11[>K_._O8<L>QP7_  H#X7_]$W\(_P#@BM?_
M (W1_P * ^%__1-_"/\ X(K7_P"-UWM%'MZO\[^]ARQ['!?\* ^%_P#T3?PC
M_P""*U_^-T?\* ^%_P#T3?PC_P""*U_^-UWM%'MZO\[^]ARQ['!?\* ^%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2_\ QRC_ (;R\2?]!CPU^2__ !RCV<^P<R[GWS17P-_PWEXD_P"@QX:_)?\
MXY1_PWEXD_Z#'AK\E_\ CE'LY]@YEW/OFBO@;_AO+Q)_T&/#7Y+_ /'*/^&\
MO$G_ $&/#7Y+_P#'*/9S[!S+N??-%? W_#>7B3_H,>&OR7_XY1_PWEXD_P"@
MQX:_)?\ XY1[.?8.9=S[YHKX&_X;R\2?]!CPU^2__'*/^&\O$G_08\-?DO\
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MDO\ \<H_X;R\2?\ 08\-?DO_ ,<H]G/L',NY]\UYM\:O^//2/^N[?R%?)_\
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M!3PU_P!\+_\ '*.279AIW/T-HK\\O^'@'B[_ *"GAK_OA?\ XY1_P\ \7?\
M04\-?]\+_P#'*.279AIW/T-HK\\O^'@'B[_H*>&O^^%_^.4?\/ /%W_04\-?
M]\+_ /'*.279AIW/T-HK\\O^'@'B[_H*>&O^^%_^.4?\/ /%W_04\-?]\+_\
M<HY)=F&G<_0VBOSR_P"'@'B[_H*>&O\ OA?_ (Y1_P / /%W_04\-?\ ?"__
M !RCDEV8:=S]#:*_/+_AX!XN_P"@IX:_[X7_ ..4?\/ /%W_ $%/#7_?"_\
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MR_X> >+O^@IX:_[X7_XY1_P\ \7?]!3PU_WPO_QRCDEV8:=S]#:*_/+_ (>
M>+O^@IX:_P"^%_\ CE'_  \ \7?]!3PU_P!\+_\ '*.279AIW/T-HK\\O^'@
M'B[_ *"GAK_OA?\ XY1_P\ \7?\ 04\-?]\+_P#'*.279AIW/T-HK\\O^'@'
MB[_H*>&O^^%_^.4?\/ /%W_04\-?]\+_ /'*.279AIW/T-HK\\O^'@'B[_H*
M>&O^^%_^.4?\/ /%W_04\-?]\+_\<HY)=F&G<_0VBOSR_P"'@'B[_H*>&O\
MOA?_ (Y1_P / /%W_04\-?\ ?"__ !RCDEV8:=S]#:*_/+_AX!XN_P"@IX:_
M[X7_ ..4?\/ /%W_ $%/#7_?"_\ QRCDEV8:=S]#:*_/+_AX!XN_Z"GAK_OA
M?_CE'_#P#Q=_T%/#7_?"_P#QRCDEV8:=S]#:*_/+_AX!XN_Z"GAK_OA?_CE'
M_#P#Q=_T%/#7_?"__'*.279AIW/T-HK\\O\ AX!XN_Z"GAK_ +X7_P".4?\
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MX7_XY3Y)=F&G<_0VBOSR_P"'@'B[_H*>&O\ OA?_ (Y1_P / /%W_04\-?\
M?"__ !RCDEV8:=S]#::5S7YZ?\/ /%W_ $%/#7_?"_\ QRC_ (> >+O^@IX:
M_P"^%_\ CE')+LPT[GZ#O"&JI-9AL\5\!_\ #P#Q=_T%/#7_ 'PO_P <I/\
MAO[Q;_T%/#7_ 'PO_P <HY)=F&G<^Z+S1UD!^6N=U'PZK9^6OC5OV^?%C?\
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M'@'B[_H*>&O^^%_^.4<DNS#3N?H;17YY?\/ /%W_ $%/#7_?"_\ QRC_ (>
M>+O^@IX:_P"^%_\ CE')+LPT[GZ&T5^>7_#P#Q=_T%/#7_?"_P#QRC_AX!XN
M_P"@IX:_[X7_ ..4<DNS#3N?H;17YY?\/ /%W_04\-?]\+_\<H_X> >+O^@I
MX:_[X7_XY1R2[,-.Y^AM%?GE_P / /%W_04\-?\ ?"__ !RC_AX!XN_Z"GAK
M_OA?_CE')+LPT[GZ&T5^>7_#P#Q=_P!!3PU_WPO_ ,<H_P"'@'B[_H*>&O\
MOA?_ (Y1R2[,-.Y^AM%?GE_P\ \7?]!3PU_WPO\ \<H_X> >+O\ H*>&O^^%
M_P#CE')+LPT[GZ&T5^>7_#P#Q=_T%/#7_?"__'*/^'@'B[_H*>&O^^%_^.4<
MDNS#3N?H;17YY?\ #P#Q=_T%/#7_ 'PO_P <H_X> >+O^@IX:_[X7_XY1R2[
M,-.Y^AM%?GE_P\ \7?\ 04\-?]\+_P#'*/\ AX!XN_Z"GAK_ +X7_P".4<DN
MS#3N?H;17YY?\/ /%W_04\-?]\+_ /'*/^'@'B[_ *"GAK_OA?\ XY1R2[,-
M.Y^AM%?GE_P\ \7?]!3PU_WPO_QRC_AX!XN_Z"GAK_OA?_CE')+LPT[GZ&T5
M^>7_  \ \7?]!3PU_P!\+_\ '*/^'@'B[_H*>&O^^%_^.4<DNS#3N?H;17YY
M?\/ /%W_ $%/#7_?"_\ QRC_ (> >+O^@IX:_P"^%_\ CE')+LPT[GZ&T5^>
M7_#P#Q=_T%/#7_?"_P#QRC_AX!XN_P"@IX:_[X7_ ..4<DNS#3N?H;17YY?\
M/ /%W_04\-?]\+_\<H_X> >+O^@IX:_[X7_XY1R2[,-.Y^AM%?GE_P / /%W
M_04\-?\ ?"__ !RC_AX!XN_Z"GAK_OA?_CE')+LPT[GZ&T5^>7_#P#Q=_P!!
M3PU_WPO_ ,<H_P"'@'B[_H*>&O\ OA?_ (Y1R2[,-.Y^AM%?GE_P\ \7?]!3
MPU_WPO\ \<H_X> >+O\ H*>&O^^%_P#CE')+LPT[GZ&T5^>7_#P#Q=_T%/#7
M_?"__'*/^'@'B[_H*>&O^^%_^.4<DNS#3N?H;17YY?\ #P#Q=_T%/#7_ 'PO
M_P <H_X> >+O^@IX:_[X7_XY1R2[,-.Y^AM%?GE_P\ \7?\ 04\-?]\+_P#'
M*/\ AX!XN_Z"GAK_ +X7_P".4<DNS#3N?H;17YY?\/ /%W_04\-?]\+_ /'*
M/^'@'B[_ *"GAK_OA?\ XY1R2[,-.Y^AM%?GE_P\ \7?]!3PU_WPO_QRC_AX
M!XN_Z"GAK_OA?_CE')+LPT[GZ&T5^>7_  \ \7?]!3PU_P!\+_\ '*/^'@'B
M[_H*>&O^^%_^.4<DNS#3N?H;17YY?\/ /%W_ $%/#7_?"_\ QRC_ (> >+O^
M@IX:_P"^%_\ CE')+LPT[GZ&T5^>7_#P#Q=_T%/#7_?"_P#QRC_AX!XN_P"@
MIX:_[X7_ ..4<DNS#3N?H;17YY?\/ /%W_04\-?]\+_\<H_X> >+O^@IX:_[
MX7_XY1R2[,-.Y^AM%?GE_P / /%W_04\-?\ ?"__ !RC_AX!XN_Z"GAK_OA?
M_CE')+LPT[GZ&T5^>7_#P#Q=_P!!3PU_WPO_ ,<H_P"'@'B[_H*>&O\ OA?_
M (Y1R2[,-.Y^AM%?GE_P\ \7?]!3PU_WPO\ \<H_X> >+O\ H*>&O^^%_P#C
ME')+LPT[GZ&T5^>7_#P#Q=_T%/#7_?"__'*/^'@'B[_H*>&O^^%_^.4<DNS#
M3N?H;17YY?\ #P#Q=_T%/#7_ 'PO_P <H_X> >+O^@IX:_[X7_XY1R2[,-.Y
M^AM%?GE_P\ \7?\ 04\-?]\+_P#'*/\ AX!XN_Z"GAK_ +X7_P".4<DNS#3N
M?H;17YY?\/ /%W_04\-?]\+_ /'*/^'@'B[_ *"GAK_OA?\ XY1R2[,-.Y^A
MM%?GE_P\ \7?]!3PU_WPO_QRC_AX!XN_Z"GAK_OA?_CE')+LPT[GZ&T5^>7_
M  \ \7?]!3PU_P!\+_\ '*/^'@'B[_H*>&O^^%_^.4<DNS#3N?H;17YY?\/
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MH_X> >+O^@IX:_[X7_XY1R2[,-.Y^AM%?GE_P\ \7?\ 04\-?]\+_P#'*/\
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ME_P\ \7?]!3PU_WPO_QRC_AX!XN_Z"GAK_OA?_CE')+LPT[GZ&T5^>7_  \
M\7?]!3PU_P!\+_\ '*/^'@'B[_H*>&O^^%_^.4<DNS#3N?H;17YY?\/ /%W_
M $%/#7_?"_\ QRC_ (> >+O^@IX:_P"^%_\ CE')+LPT[GZ&T5^>7_#P#Q=_
MT%/#7_?"_P#QRC_AX!XN_P"@IX:_[X7_ ..4<DNS#3N?H;17YY?\/ /%W_04
M\-?]\+_\<H_X> >+O^@IX:_[X7_XY1R2[,-.Y^AM%?GE_P / /%W_04\-?\
M?"__ !RC_AX!XN_Z"GAK_OA?_CE')+LPT[GZ&T5^>7_#P#Q=_P!!3PU_WPO_
M ,<H_P"'@'B[_H*>&O\ OA?_ (Y1R2[,-.Y^AM%?GE_P\ \7?]!3PU_WPO\
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M.4<DNS#3N?H;17YY?\/ /%W_ $%/#7_?"_\ QRC_ (> >+O^@IX:_P"^%_\
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M5^>7_#P#Q=_T%/#7_?"__'*/^'@'B[_H*>&O^^%_^.4<DNS#3N?H;17YY?\
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M@\0\32]HU;<VQ%%47%)[J_XM?H%%%%=IR!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7ZR_P#!)G_DW/Q'_P!C7<_^D=G7Y-5^LO\
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MW+?[I/\ S_ N>*?V@/@7^S3)!X5OM=T/PD\8P-'TFR9S!D C?%;1MY>00?F
MSG-8_P 0_@'\&/VR/ [ZQ8+I=[<7*D6OBK0M@N8I .!(R\OC/,<G3/13@C\9
M_'7]M_\ ":Z]_P )+YW_  D/VZ;^T?M&?,^T;SYF[/?=FOO+_@D2NN?V_P#$
M)E,__"-_9K8/G/E?:M[;<=MVS?G';;GM53P"A0==5'S)7OT_S].YC+$.G55-
M1TO:W_ _-=CY^^&.I:[^Q#^UU:VNOMY::7>_V?J;IGR[FPFP#*OJ-C)*!ZJ
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MH-4\1_#>#38-)\2M%<RMHLBFRE:,,H>-4^53R00N!E>F<Y_.SX[?&*;X%?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME0P"H5_;*5]+?E=W^1H\1>FZ=M_\]#Z8_P""?/QJ_P"%0?M":5;7EP8="\2
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MT?PSJ]TPAM?-N)+O4)F<A-D E=Y "6 .W"@'+$#FOQ/HKD66J,GR5&HO=?\
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MT0^JH">Y-=!\%_V3?A3^RS'>^(=)CDCO8[9UN?$.OWBM)%!U;+82.->.2%'
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M17MI65CB;N[A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK^+/BAXR\>PQQ>)O%NN^(HHVW)'JVI372J?4"1C@UO\ _#.WQ'_Z%.]_-/\
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M_0%C_P"_TO\ \579T4!=G&?\*=\'?] 6/_O]+_\ %4?\*=\'?] 6/_O]+_\
M%5V=% 79QG_"G?!W_0%C_P"_TO\ \51_PIWP=_T!8_\ O]+_ /%5V=% 79QG
M_"G?!W_0%C_[_2__ !5'_"G?!W_0%C_[_2__ !5=G10%V<9_PIWP=_T!8_\
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M 6/_ +_2_P#Q5'_"G?!W_0%C_P"_TO\ \579T4!=G&?\*=\'?] 6/_O]+_\
M%4?\*=\'?] 6/_O]+_\ %5V=% 79QG_"G?!W_0%C_P"_TO\ \51_PIWP=_T!
M8_\ O]+_ /%5V=% 79QG_"G?!W_0%C_[_2__ !5'_"G?!W_0%C_[_2__ !5=
MG10%V<9_PIWP=_T!8_\ O]+_ /%4?\*=\'?] 6/_ +_2_P#Q5=G10%V<9_PI
MWP=_T!8_^_TO_P 51_PIWP=_T!8_^_TO_P 579T4!=G&?\*=\'?] 6/_ +_2
M_P#Q5'_"G?!W_0%C_P"_TO\ \579T4!=G&?\*=\'?] 6/_O]+_\ %5YM\:O
M^A^%K+2'TNP6T>:=DD*N[;A@<<DU[Y7D'[17_(.T'_KZ;^0I#6YUG_"G?!W_
M $!8_P#O]+_\51_PIWP=_P! 6/\ [_2__%5V=%,5V<9_PIWP=_T!8_\ O]+_
M /%4?\*=\'?] 6/_ +_2_P#Q5=G10%V<9_PIWP=_T!8_^_TO_P 51_PIWP=_
MT!8_^_TO_P 579T4!=G&?\*=\'?] 6/_ +_2_P#Q5'_"G?!W_0%C_P"_TO\
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M?] 6/_O]+_\ %4?\*=\'?] 6/_O]+_\ %5V=% 79QG_"G?!W_0%C_P"_TO\
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M*=\'?] 6/_O]+_\ %5V=% 79QG_"G?!W_0%C_P"_TO\ \51_PIWP=_T!8_\
MO]+_ /%5V=% 79QG_"G?!W_0%C_[_2__ !5'_"G?!W_0%C_[_2__ !5=G10%
MV<9_PIWP=_T!8_\ O]+_ /%4?\*=\'?] 6/_ +_2_P#Q5=G10%V<9_PIWP=_
MT!8_^_TO_P 51_PIWP=_T!8_^_TO_P 579T4!=G&?\*=\'?] 6/_ +_2_P#Q
M5'_"G?!W_0%C_P"_TO\ \579T4!=G&?\*=\'?] 6/_O]+_\ %4?\*=\'?] 6
M/_O]+_\ %5V=% 79QG_"G?!W_0%C_P"_TO\ \51_PIWP=_T!8_\ O]+_ /%5
MV=% 79QG_"G?!W_0%C_[_2__ !5'_"G?!W_0%C_[_2__ !5=G10%V<9_PIWP
M=_T!8_\ O]+_ /%4?\*=\'?] 6/_ +_2_P#Q5=G10%V<9_PIWP=_T!8_^_TO
M_P 51_PIWP=_T!8_^_TO_P 579T4!=G&?\*=\'?] 6/_ +_2_P#Q5'_"G?!W
M_0%C_P"_TO\ \579T4!=G&?\*=\'?] 6/_O]+_\ %4?\*=\'?] 6/_O]+_\
M%5V=% 79QG_"G?!W_0%C_P"_TO\ \51_PIWP=_T!8_\ O]+_ /%5V=% 79QG
M_"G?!W_0%C_[_2__ !5'_"G?!W_0%C_[_2__ !5=G10%V<9_PIWP=_T!8_\
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M (JC_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z
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M_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\
MW^E_^*KLZ* NSC/^%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+L
MXS_A3O@[_H"Q_P#?Z7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?
M_?Z7_P"*H_X4[X._Z L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.
M^#O^@+'_ -_I?_BJ[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_
M (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_^*KLZ* NSC/^
M%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+LXS_A3O@[_H"Q_P#?
MZ7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?_?Z7_P"*H_X4[X._
MZ L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.^#O^@+'_ -_I?_BJ
M[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X
M._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_^*KLZ* NSC/^%.^#O^@+'_W^E_\
MBJ/^%.^#O^@+'_W^E_\ BJ[.B@+LXS_A3O@[_H"Q_P#?Z7_XJC_A3O@[_H"Q
M_P#?Z7_XJNSHH"[.,_X4[X._Z L?_?Z7_P"*H_X4[X._Z L?_?Z7_P"*KLZ*
M NSC/^%.^#O^@+'_ -_I?_BJ/^%.^#O^@+'_ -_I?_BJ[.B@+LXS_A3O@[_H
M"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_
MX4[X._Z L?\ W^E_^*KLZ* NSC/^%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^
ME_\ BJ[.B@+LXS_A3O@[_H"Q_P#?Z7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.
M,_X4[X._Z L?_?Z7_P"*H_X4[X._Z L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_
M -_I?_BJ/^%.^#O^@+'_ -_I?_BJ[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O
M@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_
M^*KLZ* NSC/^%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+LXS_A
M3O@[_H"Q_P#?Z7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?_?Z7
M_P"*H_X4[X._Z L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.^#O^
M@+'_ -_I?_BJ[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_ (JN
MSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_^*KLZ* NSC/^%.^#
MO^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+LXS_A3O@[_H"Q_P#?Z7_X
MJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?_?Z7_P"*H_X4[X._Z L?
M_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.^#O^@+'_ -_I?_BJ[.B@
M+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z
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M._Z L?\ W^E_^*KLZ* NSC/^%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\
MBJ[.B@+LXS_A3O@[_H"Q_P#?Z7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4
M[X._Z L?_?Z7_P"*H_X4[X._Z L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I
M?_BJ/^%.^#O^@+'_ -_I?_BJ[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H
M"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_^*KL
MZ* NSC/^%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+LXS_A3O@[
M_H"Q_P#?Z7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?_?Z7_P"*
MH_X4[X._Z L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.^#O^@+'_
M -_I?_BJ[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_ (JNSHH"
M[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_^*KLZ* NSC/^%.^#O^@+
M'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+LXS_A3O@[_H"Q_P#?Z7_XJC_A
M3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?_?Z7_P"*H_X4[X._Z L?_?Z7
M_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.^#O^@+'_ -_I?_BJ[.B@+LXS
M_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\
MW^E_^*H_X4[X._Z L?\ W^E_^*KLZ* NSC/^%.^#O^@+'_W^E_\ BJ/^%.^#
MO^@+'_W^E_\ BJ[.B@+LXS_A3O@[_H"Q_P#?Z7_XJC_A3O@[_H"Q_P#?Z7_X
MJNSHH"[.,_X4[X._Z L?_?Z7_P"*H_X4[X._Z L?_?Z7_P"*KLZ* NSC/^%.
M^#O^@+'_ -_I?_BJ/^%.^#O^@+'_ -_I?_BJ[.B@+LXS_A3O@[_H"Q_]_I?_
M (JC_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z
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M_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\
MW^E_^*KLZ* NSC/^%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+L
MXS_A3O@[_H"Q_P#?Z7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?
M_?Z7_P"*H_X4[X._Z L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.
M^#O^@+'_ -_I?_BJ[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_
M (JNSHH"[.,_X4[X._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_^*KLZ* NSC/^
M%.^#O^@+'_W^E_\ BJ/^%.^#O^@+'_W^E_\ BJ[.B@+LXS_A3O@[_H"Q_P#?
MZ7_XJC_A3O@[_H"Q_P#?Z7_XJNSHH"[.,_X4[X._Z L?_?Z7_P"*H_X4[X._
MZ L?_?Z7_P"*KLZ* NSC/^%.^#O^@+'_ -_I?_BJ/^%.^#O^@+'_ -_I?_BJ
M[.B@+LXS_A3O@[_H"Q_]_I?_ (JC_A3O@[_H"Q_]_I?_ (JNSHH"[.,_X4[X
M._Z L?\ W^E_^*H_X4[X._Z L?\ W^E_^*KLZ* NSC/^%.^#O^@+'_W^E_\
MBJZ'0?#FG>%[)K32[86ENSF0HK,WS$ $\D]@*TJ*!!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5Y!^T5_R#M!_Z^F_D*]?KR#]HK_D':#_U]-_(4F-;GK]%
M%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"4VT_^-5\]_K5@OY)_<O\ Y(^U7AYFK_Y>T_OE_P#('Z5T5^; _:\^+?\
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M'.;?\_*?WR_^0/TFHK\V?^&N_BW_ -#9_P"4VT_^-4?\-=_%O_H;/_*;:?\
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MN7_R0?\ $.<V_P"?E/[Y?_('Z345^;/_  UW\6_^AL_\IMI_\:H_X:[^+?\
MT-G_ )3;3_XU1_K9@?Y)_<O_ )(/^(<YM_S\I_?+_P"0/TFHK\V?^&N_BW_T
M-G_E-M/_ (U1_P -=_%O_H;/_*;:?_&J/];,#_)/[E_\D'_$.<V_Y^4_OE_\
M@?I-17YL_P##7?Q;_P"AL_\ *;:?_&J/^&N_BW_T-G_E-M/_ (U1_K9@?Y)_
M<O\ Y(/^(<YM_P _*?WR_P#D#])J*_-G_AKOXM_]#9_Y3;3_ .-4?\-=_%O_
M *&S_P IMI_\:H_ULP/\D_N7_P D'_$.<V_Y^4_OE_\ ('Z34445]H?E@444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5Y!^T5_R#M!_P"OIOY"O7Z\@_:*_P"0=H/_ %]-_(4F-;GK]%%%,1%=74-C
M;2W%Q+';V\*&2265@J(H&2Q)X  [FN:_X6QX(_Z''P__ .#2#_XNI/B=_P D
MW\5?]@JZ_P#135^?_P -OASJ7Q2\1G1=*GM;>Z\EI]]X[*FU2 1E58YY':OF
M,SS6O@\3##4*?.Y*_P"?^1]YP_P_A<VPM;%8JLZ<:;UTZ6W/T1T?Q9H?B)BN
ME:SI^IL!DBSNDE(_[Y)K5K\\_B)\'O%GP5N-/OK^2%5DD_T?4--G8A9!SC)"
MLK8Y'';VK[ _9[^(US\2?AO;W^H,)-2M)6M+F0<>8R@$/CU*LN??-;9=FSQ=
M6>'KT^2I%7MY?TU^9&=<-T\OPD,PP5=5:,G:_9_KMY69UGB[Q_X=\!VJ7&OZ
MM;Z:C_<61B7?UVH,LWX"LCPI\;/!'C:^6RT?Q#;7%VQPD$JO [GT42*I8_3-
M?$NI7&J?&[XO>3<WBP76J7I@B:<G9;QY.U /0 <#N?<UW7C3]D;Q7X8O-/.@
MW2^(8YY5C,L4?V=X&ZAF!8@*/[P/'I7CT\\QV)O7P^'YJ2=O[W3S\UT^9]%+
MA/*<)"&'S#%N&(G&ZVY5]Z_]N5^B/M&\O+?3[6:ZNIX[:VA0R2S3.$1% R69
MCP !W-9&C^//#7B&\%II7B+2=3NRI;R+.]BE?:.IVJQ.*@\*^&[ZS\#VNB^(
M]0&NW?V8V]U<,N!*"""#W/!QD\G&3UKX8T.YN/@C\;HQ,S :3J)AF.<;X"=I
M/XHV?Q%>UC\RG@:U&,H^Y-V;ZK].OX,^9R7(:.<1Q5.%7]Y35XV6DM^^N]OO
M1^A=4]6UBPT&Q>]U.^MM.LT(#7%W*L4:DG RS$ 9/%6HY%FC5T8.C ,K*<@@
M]#7S!^VKXS\JST3PM"^&E8W]RH/\(RD8^A.\_P# 179F6-67X:5=J[6R[L\;
M)<LEF^/IX-.REN^R6K_KN?16A^,-!\322IH^MZ=JSQ -(MC=QS% >A(4G%:]
M>&_LB>#/^$=^&K:M-'MNM9F,V2.?)3*H/SWM_P "KW*NG"U)UJ$*E16DU>WJ
M89KA:."QM7#4)<T8.UWU:W_&YCZYXQT#PS)%'K&MZ;I,DH+1I?7<<)<#J0&(
MR*NZ5J]CKMC'>Z;>V^H6<F0EQ:RK+&V#@X920<$$5XE^V!X+_M[X=0ZU#'NN
MM&G#L0.?)DPKC_OK8?P-<W^Q7XS^T:7K7A>9\O;N+ZW4G^!L+(![!@I_X$:\
MN.8R69/ U(V35XOOU_S^X]R.1TZV1O-J$VY0E:4>VO3[T_O/IRL+5_'GAGP_
M>&SU3Q%I.FW8 8V]Y?112 'H=K,#@UM33);Q/+(P2-%+,S'  '))K\][Z2X^
M.'QN;86VZQJ(1#U,=N#@'_@,:Y_"C,\QG@YTJ-&/-.H[)/\ KNT3P[D<,XE6
MG7FX4Z4;MK^NR;^1^@MI=P7]K%<VTT=S;3()(YH6#(ZD9# C@@CN*FJ*UM8K
M&UAMX$$<,*+&B+T50, ?E4M>\?(RM=\NP4444""BBB@ HHHH **** "LKQ-X
MITGP;H\VJ:U?1:?818#32YZGH !RQ/H 36K7DW[2/POU7XH>";:UT5U:_LKD
M7*VTCA%G&UE(!/ ;GC/'6N+&U:U'#SJ4(\TELCTLMHX?$XNG1Q4^2FWJ^R_K
MKTW.[\'>.]!\?Z:U_P"']2BU*V1MCL@961O1E8!A^(K>KPC]E[X.Z]\,[76;
MWQ JVES?^7&EDDJR%%3<=S%25R=W&":]WJL'4JUL/"I7CRR:U7;^M_+8US;#
M87"8VI0P=3VE-;2[Z=UH[/2ZW"BBBNL\@**** "BBDSCD\"@#,\3>)+#PAH-
M[K&J3"WL;.,R2/W]@!W). !W)%>4?!W]I)?BUXNGT5/#QTM([9[@7#7OFDA6
M48V^6N,[O7M7F/Q4\5:E^T9\2+7P/X7E/]@64I:>Z&3&[+P\S?[*YVJ.Y/N,
M0?LTZ/#X>_:&\3Z5;LS6]C'>6L;.<L52=5!/O@5\A'-*^(S"E&CI1;DK_P S
M2NVO):6MO^7Z?1X>PN&RBO5QBOB>3G2NUR1V5TNK[/[C[ HHHKZ\_, HHHH
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M;*L;#1L- %?91LJQL-&PT 5]E&RK&PT;#0!7V4;*L;#1L- %?91LJQL-&PT
M5]E&RK&PT;#0!7V4;*L;#1L- %?91LJQL-&PT 5]E&RK&PT;#0!7V4;*L;#1
ML- %?91LJQL-&PT 5]E&RK&PT;#0!7V4;*L;#1L- %?91LJQL-&PT 5]E&RK
M&PT;#0!7V4;*L;#1L- %?91LJQL-&PT 5]E&RK&PT;#0!7V4;*L;#1L- 'Z\
MT445_11_$84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;:-M 'ZV4445_1!_$@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M)_[1/QP\;>!?B9=:3H>M?8=/2WA=8?LD$F&9<DY="?UKSBW_ &I_B7#(&?7X
M[A1_!)8VX!_[Y0']:N_M;?\ )9KW_KTM_P#T"OI./XF?#M?AK8VNMZ_HM[;+
MIT4<]E]HCGD)$8!7RU);=^&0:_,X_6<5B<4_K;IJ$G9-NV\O/1*W9G[M?!9?
ME>!G_9T:\JD5>T5?9:_"[MW[KU,7X ?M%_\ "T;F31=9MH;+7HT,L;6^1%<(
M.N 22K#KC//)&,8K4_:)^-$OPG\/VL.FI'+KFHEEMS*-RPHN-TA'<\@ 'C/K
MC!^6?V=X9KCXW>'#8HX5;B1R.I6(1OG/X<5[+^VIX-O;RST3Q+;QM+:V8>UN
MMHSY>X@HQ]B=PSZE?6N^.98NMDDL0OC3M?K;37\;7^9Y>+R++<-Q/0PS5J51
M<W+TO[UEZ-I:?+8\4'Q#^*NI6\WB&/6/$TMC&Y,EW TPM$(Z@A?W8^F*^C/V
M:?CIK?Q(>YT;7+-[JZM8O,&K01;489QME X5CV(ZX/'&3S/[,/QVTN/1K/P/
MKWE63Q[H[*Y? BG#,3Y;]@V6.#T/3KU^CO#GA72/"-BUEHVGP:;:M(TK1VZ;
M068Y)/K_ $  ' %=>386=X8FEB7.#7O)]_T_/U3.?BG'T*:JY?B<"H33_=R5
ME[O?1+[MN]FCYZ_::^)GC[X9>+[(Z+KAM-%U"VWQ1FS@<)(APZ[F0D]5;D_Q
M5[+\&_'#?$/X<Z/K,KJ]Y)'Y5UM '[Y#M8X'3.-V/]H5Q_[5G@S_ (2GX5W-
M[$FZ[T>07J8'/E_=D'TVG=_P"O-?V*_&GE7>M^%IY,+*!?VRD_Q#"R ?AL/X
M&M,/7JX7.*F%JS;C45XW=[==.RW7W'#/"8;,N%XXJA3BJM!VDTDFUYVWT:=W
MV9]4WEU%8VLUS<.(H(4:21VZ*H&23^ KX\\&?'KXB_$;XJ66DZ=K9M-,OKXE
M8%LK=O)M@Q8C)C).$!Y)KVG]J;QI_P (G\*;VVBDV7FKN+&/'78>9#]-H(_X
M$*\L_8K\%^?J.M>*9DRMNHL;8G^\V&D/X#:/^!&C&5ZN(S6CA*,VHQUE9V\[
M/\%\PR/"8?!Y'BLUQ5.,F_=AS)/7:ZOYO_R5GUG1117UQ^9A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>0?M%?\@[0?\ KZ;^0KU^
MO(/VBO\ D':#_P!?3?R%)C6YZ_1113$<S\3O^2;^*O\ L%77_HIJ^1?V//\
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ML_%+XZ6<D-U=7NI:5;(T\TAB6WM$" MERBJK'@X')]*O?LE?\EGL/^O6X_\
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M_OLK+R2]0HHHKVSY **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/45:KXU_;:T7XF_#N/1?C)\._%>NBVT41/K?ALW\[V$L2_\ +8V^[85P=L@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M36LW9>F_^2^1U\8RAEN$PF247=07-+S>J3^;YG\T%%%%?8GY2%%%% !1110
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M4UR5,70HU(TJDTI2V7<]/"Y;C,;3G6P]-RC#>W3J>TT445UGF!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS^""YFO/?_)?>?J_#\O[*X>QF:0_B2?(GVV6GSE?Y(^HXXX-/M%1 EO;0)@
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M=)U6=]]\J&VNCW,J<%O^!##?\"KO:^9OV(M4:70?%&G%OE@N8;A5S_?5E/\
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MS.%$<@+;5!.,D<^]<O\ 9];#Y5B*E;6K4LVOG^>K;_X!V5\XPF)SK 8/!O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#\9H_X8L\;_P#04\/_ /@1/_\ &:^TJ*/]6LO[/[P_U[SG^:/_ ("?%O\
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M[2HH_P!6LO[/[P_U[SG^:/\ X"?%O_#%GC?_ *"GA_\ \")__C-'_#%GC?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >4ZIX<^)TVI7;VFO6
MD=HTSM"A895"QVC_ %?IBJO_  C/Q6_Z&&S_ .^A_P#&Z]@HH'<\?_X1GXK?
M]##9_P#?0_\ C='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\
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M]##9_P#?0_\ C='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\
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MBM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\ ?0_^-T?\(S\5O^AAL_\
MOH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&?BM_T,-G_P!]#_XW7L%%
M 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^^A_\;KV"B@+GC_\ PC/Q
M6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/'_\ A&?BM_T,-G_WT/\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
M?0_^-T?\(S\5O^AAL_\ OH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&
M?BM_T,-G_P!]#_XW7L%% 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^
M^A_\;KV"B@+GC_\ PC/Q6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/
M'_\ A&?BM_T,-G_WT/\ XW1_PC/Q6_Z&&S_[Z'_QNO8** N>/_\ ",_%;_H8
M;/\ [Z'_ ,;H_P"$9^*W_0PV?_?0_P#C=>P44!<\?_X1GXK?]##9_P#?0_\
MC='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\ OH?_ !NC_A&?
MBM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\ ?0_^-T?\(S\5O^AAL_\
MOH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&?BM_T,-G_P!]#_XW7L%%
M 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^^A_\;KV"B@+GC_\ PC/Q
M6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/'_\ A&?BM_T,-G_WT/\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
M?0_^-T?\(S\5O^AAL_\ OH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&
M?BM_T,-G_P!]#_XW7L%% 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^
M^A_\;KV"B@+GC_\ PC/Q6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/
M'_\ A&?BM_T,-G_WT/\ XW1_PC/Q6_Z&&S_[Z'_QNO8** N>/_\ ",_%;_H8
M;/\ [Z'_ ,;H_P"$9^*W_0PV?_?0_P#C=>P44!<\?_X1GXK?]##9_P#?0_\
MC='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\ OH?_ !NC_A&?
MBM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\ ?0_^-T?\(S\5O^AAL_\
MOH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&?BM_T,-G_P!]#_XW7L%%
M 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^^A_\;KV"B@+GC_\ PC/Q
M6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/'_\ A&?BM_T,-G_WT/\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
M?0_^-T?\(S\5O^AAL_\ OH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&
M?BM_T,-G_P!]#_XW7L%% 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^
M^A_\;KV"B@+GC_\ PC/Q6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/
M'_\ A&?BM_T,-G_WT/\ XW1_PC/Q6_Z&&S_[Z'_QNO8** N>/_\ ",_%;_H8
M;/\ [Z'_ ,;H_P"$9^*W_0PV?_?0_P#C=>P44!<\?_X1GXK?]##9_P#?0_\
MC='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\ OH?_ !NC_A&?
MBM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\ ?0_^-T?\(S\5O^AAL_\
MOH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&?BM_T,-G_P!]#_XW7L%%
M 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^^A_\;KV"B@+GC_\ PC/Q
M6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/'_\ A&?BM_T,-G_WT/\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
M?0_^-T?\(S\5O^AAL_\ OH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&
M?BM_T,-G_P!]#_XW7L%% 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^
M^A_\;KV"B@+GC_\ PC/Q6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/
M'_\ A&?BM_T,-G_WT/\ XW1_PC/Q6_Z&&S_[Z'_QNO8** N>/_\ ",_%;_H8
M;/\ [Z'_ ,;H_P"$9^*W_0PV?_?0_P#C=>P44!<\?_X1GXK?]##9_P#?0_\
MC='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\ OH?_ !NC_A&?
MBM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\ ?0_^-T?\(S\5O^AAL_\
MOH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&?BM_T,-G_P!]#_XW7L%%
M 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^^A_\;KV"B@+GC_\ PC/Q
M6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/'_\ A&?BM_T,-G_WT/\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
M?0_^-T?\(S\5O^AAL_\ OH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&
M?BM_T,-G_P!]#_XW7L%% 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^
M^A_\;KV"B@+GC_\ PC/Q6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/
M'_\ A&?BM_T,-G_WT/\ XW1_PC/Q6_Z&&S_[Z'_QNO8** N>/_\ ",_%;_H8
M;/\ [Z'_ ,;H_P"$9^*W_0PV?_?0_P#C=>P44!<\?_X1GXK?]##9_P#?0_\
MC='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\ OH?_ !NC_A&?
MBM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\ ?0_^-T?\(S\5O^AAL_\
MOH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&?BM_T,-G_P!]#_XW7L%%
M 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^^A_\;KV"B@+GC_\ PC/Q
M6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/'_\ A&?BM_T,-G_WT/\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
M?0_^-T?\(S\5O^AAL_\ OH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&
M?BM_T,-G_P!]#_XW7L%% 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^
M^A_\;KV"B@+GC_\ PC/Q6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/
M'_\ A&?BM_T,-G_WT/\ XW1_PC/Q6_Z&&S_[Z'_QNO8** N>/_\ ",_%;_H8
M;/\ [Z'_ ,;H_P"$9^*W_0PV?_?0_P#C=>P44!<\?_X1GXK?]##9_P#?0_\
MC='_  C/Q6_Z&&S_ .^A_P#&Z]@HH"YX_P#\(S\5O^AAL_\ OH?_ !NC_A&?
MBM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\ ?0_^-T?\(S\5O^AAL_\
MOH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&?BM_T,-G_P!]#_XW7L%%
M 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^^A_\;KV"B@+GC_\ PC/Q
M6_Z&&S_[Z'_QNC_A&?BM_P!##9_]]#_XW7L%% 7/'_\ A&?BM_T,-G_WT/\
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MO^AAL_\ OH?_ !NC_A&?BM_T,-G_ -]#_P"-U[!10%SQ_P#X1GXK?]##9_\
M?0_^-T?\(S\5O^AAL_\ OH?_ !NO8** N>/_ /",_%;_ *&&S_[Z'_QNC_A&
M?BM_T,-G_P!]#_XW7L%% 7/'_P#A&?BM_P!##9_]]#_XW1_PC/Q6_P"AAL_^
M^A_\;KV"B@+GC_\ PC/Q6_Z&&S_[Z'_QNN^\#6.OZ?HSQ^([R*^O_.9EDBZ"
M/ P/NCG.>W>NBHH"X4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(/VBO^0=
MH/\ U]-_(5Z_7D'[17_(.T'_ *^F_D*3&MSU^BBBF(**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **3-% !FD9MHR>!3J* (6E% E%-ELUD^Z?
M+/MT[=OH*S;C[19\NFY?[R\CM_4TQ&NL@-.S6-;ZDK=ZOQ70;O2&6Z*C60&G
MYH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O(/VBO\ D':#_P!?3?R%>OUY!^T5_P @[0?^OIOY"DQK
M<]?HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,T4 &:*6B@ HHHH
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MR^*__0U?^4ZT_P#C5>3[!1L%']FX+_GS'_P%?Y!_;V:_]!=3_P #E_F>L?\
M#67Q7_Z&K_RG6G_QJC_AK+XK_P#0U?\ E.M/_C5>3[!1L%']FX+_ )\Q_P#
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M_C5>3[!1L%']FX+_ )\Q_P# 5_D']O9K_P!!=3_P.7^9ZQ_PUE\5_P#H:O\
MRG6G_P :H_X:R^*__0U?^4ZT_P#C5>3[!1L%']FX+_GS'_P%?Y!_;V:_]!=3
M_P #E_F>L?\ #67Q7_Z&K_RG6G_QJC_AK+XK_P#0U?\ E.M/_C5>3[!1L%']
MFX+_ )\Q_P# 5_D']O9K_P!!=3_P.7^9ZQ_PUE\5_P#H:O\ RG6G_P :H_X:
MR^*__0U?^4ZT_P#C5>3[!1L%']FX+_GS'_P%?Y!_;V:_]!=3_P #E_F>L?\
M#67Q7_Z&K_RG6G_QJC_AK+XK_P#0U?\ E.M/_C5>3[!1L%']FX+_ )\Q_P#
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M_C5>3[!1L%']FX+_ )\Q_P# 5_D']O9K_P!!=3_P.7^9ZQ_PUE\5_P#H:O\
MRG6G_P :H_X:R^*__0U?^4ZT_P#C5>3[!1L%']FX+_GS'_P%?Y!_;V:_]!=3
M_P #E_F>L?\ #67Q7_Z&K_RG6G_QJC_AK+XK_P#0U?\ E.M/_C5>3[!1L%']
MFX+_ )\Q_P# 5_D']O9K_P!!=3_P.7^9ZQ_PUE\5_P#H:O\ RG6G_P :H_X:
MR^*__0U?^4ZT_P#C5>3[!1L%']FX+_GS'_P%?Y!_;V:_]!=3_P #E_F?KA11
M17X2?V"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>0?M%?\ (.T'_KZ;^0KU^O(/VBO^0=H/_7TW\A28UN>OT444
MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7D'[17_ "#M!_Z^F_D*]?KR#]HK_D':#_U]
M-_(4F-;GK]%%%,1POQS_ .21>*O^O)OYBOGS]C'_ )'C7/\ L'?^U4KZ#^.?
M_)(O%7_7DW\Q7SY^QC_R/&N?]@[_ -JI7WF6?\B'%^O^1^0\1?\ )6Y7Z/\
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M7Y=F>(E'"5M8I;73:Y?)WZZVYD['U!%X1T\>#8O#,T?GZ:EDMBRMU:,($_/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>DV6G6J;+:TA2")?154*/T%7***^<E)R;D]V?:PA&G%0@K):(****184444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KR#]HK_D':#_ -?3?R%>OUY!^T5_R#M!_P"OIOY"
MDQK<]?HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** &M]VJ<UY!8L\US-';PJ.9
M)6"J,D=2:N-]VO)_VEHVD^#GB$*I8X@.%&>!<1DG\JZL)16)Q%.@W;FDE?U=
MCSLQQ3P."KXM1YG3C*5N_*F[?.QZU17P?\/?VB/%O@'9!]J_M?3ES_HE\Q;'
MWC\K]1\S9/K@"OJ#X>_M$>$O'VR#[5_9&HMG_1+Y@N?O'Y7Z'Y5R?3(%>[F/
M#N-R^\N7GAW7ZK=?EYGR&2<;Y5G5J?/[.J_LRTOZ/9_@_(]0HHHKY@_0 HHH
MH **** "BBB@ HHHH **R_$7BC2?".GM?:SJ%OIUJO\ RTG<#)]%'5C[#)KY
MS^(G[87^ML_!UE_L_P!I7R_JD?\ 5O\ OFO6P.58O,96P\+KOLOO_IGS>;\1
M9;D<.;&U4I=(K63^7ZNR\SVSXQZO8Z3\,?$XO;N&U-QIEU!")I IDD:)@J+G
MJ22.!7YI^/O^13OO^V?_ *,6NT\1>*-6\7:@U]K.H7&HW3?\M)W)P/11T4>P
MXKBO'Q'_  BEZ"<$F,#W_>+7Z[E>4O*<'4A*?,Y:OML?S1Q#Q*N),SH584^2
M,&DKN[>M[OHO37U/.M)ZBNUTH?**XW25^85VNE+P*ZL*CSLP9OV_058 J"#H
M*L5[L3Y*>XFVC;2T55C,3;1MI:*+ )MHVTM%%@$VT;:6BBP";:-M+118!-M&
MVEHHL FVC;2T46 3;1MI:*+ )MHVTM%%@$VT;:6BBP";:-M+118!-M&VEHHL
M FVC;2T46 3;1MI:*+ )MHVTM%%@$VT;:6BBP";:-M+118!-M&VEHHL FVC;
M2T46 3;1MI:*+ ?J-1117\QG]^A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8U\:_P#04T'_ ,")_P#XS1_;N6?\_P!!_JAG_P#T"2_KYG@U%>\_\,:^-?\
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M ,,:^-?^@IH/_@1/_P#&:/\ AC7QK_T%-!_\")__ (S1_;N6?\_T'^J&?_\
M0)+^OF>#45[S_P ,:^-?^@IH/_@1/_\ &:/^&-?&O_04T'_P(G_^,T?V[EG_
M #_0?ZH9_P#] DOZ^9X-17O/_#&OC7_H*:#_ .!$_P#\9H_X8U\:_P#04T'_
M ,")_P#XS1_;N6?\_P!!_JAG_P#T"2_KYGV51117\_G]H!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!;/_ (*T9]7D6,QN.R^GB,PI>RJN]XZKKIH]5=:V>H4445YA[X4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGXH_&\_^L<0<11R"59TJ$8<SMHYZ7^?H[I6;LSYUO/"OQ(^"<D>I/!J.@H6
M^T6TZR0D]E<HS*<^C=:^HOV?_C5_PM31Y[745CAU^Q4&81\+/&>!*H[<\$=
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M/FZE*)IOL*GSV &W&\?<7GD\>YQ5G7_A/\0_ <1UR_TJ^LA&=[7UO<+(T?\
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MX9_Y]M2_[\I_\71_PT1X9_Y]M2_[\I_\77H/]@Z9_P! ZT_[\+_A1_8.F?\
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MY]_PT1X9_P"?;4O^_*?_ !='_#1'AG_GVU+_ +\I_P#%UZ#_ &#IG_0.M/\
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ME_2NKTWPV%Q\OZ5TUKHRICY:U;>Q"]J ,>ST98\?+6Q!8JN.*N1PA>U3*N*
M(4@"]JF"TM+0 E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;E)W2N_YK=;_ )? UO\ '#XE:':C1AKU]#L'EB*X@1IU]MSH7_6NC^%O[/\
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M,QJ3H*UH:K;;[37W1//_ (@6-WI?P/U^TO[]]4O8=&F2:\D0(96$9RV!P/\
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M_KZ;^0I,:W/7Z***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y!^T5_R#M!_Z^F_D*]?KR#]HK_D':#_ -?3?R%)
MC6YZ_1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !124<GI0 4<FC;2T
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MU^,O\R?]=L^_Z"/_ "6'_P B?6W_  W]_P!2'_Y6/_M%'_#?W_4A_P#E8_\
MM%?).PT;#1_J]EO_ #Z_&7^8?Z[9]_T$?^2P_P#D3ZV_X;^_ZD/_ ,K'_P!H
MH_X;^_ZD/_RL?_:*^2=AHV&C_5[+?^?7XR_S#_7;/O\ H(_\EA_\B?6W_#?W
M_4A_^5C_ .T4?\-_?]2'_P"5C_[17R3L-&PT?ZO9;_SZ_&7^8?Z[9]_T$?\
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M $$?^2P_^1/K;_AO[_J0_P#RL?\ VBC_ (;^_P"I#_\ *Q_]HKY)V&C8:/\
M5[+?^?7XR_S#_7;/O^@C_P EA_\ (GUM_P -_?\ 4A_^5C_[11_PW]_U(?\
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M_E8_^T5\D[#1L-'^KV6_\^OQE_F'^NV??]!'_DL/_D3]<:***_&C^I0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MR#]HK_D':#_U]-_(5Z_7D'[17_(.T'_KZ;^0I,:W/7Z***8@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^Q]JT445X9]8%%%% !1110 4444 %%%% !1110 C5%&W[T_2I&Z5%'_KS]*
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M_P"B'K\R?'3^7X5O6]/+_P#1BU^FOQ2.?AAXO(Y']CWG_HAZ_,7XA''A"_\
M^V?_ *,6OTWA/_<L1_70_GWQ(US7 KR_]N1P.FW1;'-=/8R;@*XK2W.5KL--
MZ"OJ,/)L_/L;!1-N(9%2[:; ORBIPO%>LD?-2>I'M%&T5+MHVU5B>8BVBC:*
MEVT;:+!S$6T4;14NVC;18.8BVBC:*EVT;:+!S$6T4;14NVC;18.8BVBC:*EV
MT;:+!S$6T4;14NVC;18.8BVBC:*EVT;:+!S$6T4;14NVC;18.8BVBC:*EVT;
M:+!S$6T4;14NVC;18.8BVBC:*EVT;:+!S$6T4;14NVC;18.8BVBC:*EVT;:+
M!S$6T4;14NVC;18.8BVBC:*EVT;:+!S$6T4;14NVC;18.8BVBC:*EVT;:+!S
M$6T4;14NVC;18.8BVBC:*EVT;:+!S'ZLT445_-I_=H4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,=Y;Z?;?:$M)0"DCE@H+#NHR>/7&:^S=0T'3=6TUM.O;"WNK%EV&WEB5DQZ
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M *425X_^VI_R&O"W_7O/_P"A)7L'[-?_ "1/PU_NS_\ I1)58[_DF\-_C_\
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M=(WY)^FO_MKE_P" H^C/VMO&7]@_#^'1X9-MSJ\VQ@IP?)3#-^!.T?B:Y_\
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M0927M[L$NQ4[AOVD!<H"*H?M< -\5OV3@1D?9]/_ /1]M7<_\%;O^27>!/\
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M=-IH^0/C'\?M1^+=I:6 TY-)TV"3SC LQE:23! );:O !.!CO7TC^S/X%O?
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M$8S"4<=AYX7$1O":::\G_6A\#_#OXH>)?@7XBO;1K5C%YFR]TF[RF6'\0/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>0?
MM%?\@[0?^OIOY"O7Z\@_:*_Y!V@_]?3?R%)C6YZ_1113$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAKW_ (+)_P#XFC_A5?C7_H4->_\ !9/_ /$T?6L/_P _%]Z#^S\;_P ^9?\
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M"AKW_@LG_P#B:/\ A5?C7_H4->_\%D__ ,31]:P__/Q?>@_L_&_\^9?^ O\
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M*&O?^"R?_P")H_X57XU_Z%#7O_!9/_\ $T?6L/\ \_%]Z#^S\;_SYE_X"_\
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MWH/[/QO_ #YE_P" O_(Y;:*-HKJ?^%5^-?\ H4->_P#!9/\ _$T?\*K\:_\
M0H:]_P""R?\ ^)H^M8?_ )^+[T']GXW_ )\R_P# 7_D?HW1117\V']WA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7D'[17_(.T'_ *^F_D*]?KR#]HK_ )!V@_\ 7TW\A28UN>OT444Q!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG]Y^79OX?X#&3^LY=)X>JM4X_#?TZ?\ ;K7HS/\ A[^V%]RU\7V7K_I]BO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% $374*L098P1P06%)]K@_Y[1_]]"OEGQ-^QIJ^N^)
M-6U*/Q)91QWEW-<*C6[Y4.Y8 \]>:S/^&']:_P"AGL/_  '?_&@#ZY^UP?\
M/:/_ +Z%'VN#_GM'_P!]"OD;_AA_6O\ H9[#_P !W_QH_P"&']:_Z&>P_P#
M=_\ &@#ZY^UP?\]H_P#OH4?:X/\ GM'_ -]"OD;_ (8?UK_H9[#_ ,!W_P :
M/^&']:_Z&>P_\!W_ ,: /KG[7!_SVC_[Z%'VN#_GM'_WT*^1O^&']:_Z&>P_
M\!W_ ,:/^&']:_Z&>P_\!W_QH ^N?M<'_/:/_OH4?:X/^>T?_?0KY&_X8?UK
M_H9[#_P'?_&C_AA_6O\ H9[#_P !W_QH ^N?M<'_ #VC_P"^A1]K@_Y[1_\
M?0KY&_X8?UK_ *&>P_\  =_\:/\ AA_6O^AGL/\ P'?_ !H ^N?M<'_/:/\
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MGL/_  '?_&C_ (8?UK_H9[#_ ,!W_P : /KG[7!_SVC_ .^A1]K@_P">T?\
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MI^A;94;_ $ENC#T%>1_\,/ZU_P!#/8?^ [_XTV3]B#70!L\2Z>QSSNAD'^-
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M_OH5\C?\,/ZU_P!#/8?^ [_XT?\ ##^M?]#/8?\ @._^- 'US]K@_P">T?\
MWT*/M<'_ #VC_P"^A7R-_P ,/ZU_T,]A_P" [_XT?\,/ZU_T,]A_X#O_ (T
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M .- 'US]K@_Y[1_]]"C[7!_SVC_[Z%?(W_##^M?]#/8?^ [_ .-'_##^M?\
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M]#/8?^ [_P"- 'US]K@_Y[1_]]"C[7!_SVC_ .^A7R-_PP_K7_0SV'_@._\
MC1_PP_K7_0SV'_@._P#C0!]<_:X/^>T?_?0H^UP?\]H_^^A7R-_PP_K7_0SV
M'_@._P#C1_PP_K7_ $,]A_X#O_C0!]<_:X/^>T?_ 'T*/M<'_/:/_OH5\C?\
M,/ZU_P!#/8?^ [_XT?\ ##^M?]#/8?\ @._^- 'US]K@_P">T?\ WT*/M<'_
M #VC_P"^A7R-_P ,/ZU_T,]A_P" [_XT?\,/ZU_T,]A_X#O_ (T ?7/VN#_G
MM'_WT*/M<'_/:/\ [Z%?(W_##^M?]#/8?^ [_P"-'_##^M?]#/8?^ [_ .-
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MH4?:X/\ GM'_ -]"OD;_ (8?UK_H9[#_ ,!W_P :/^&']:_Z&>P_\!W_ ,:
M/KG[7!_SVC_[Z%'VN#_GM'_WT*^1O^&']:_Z&>P_\!W_ ,:/^&']:_Z&>P_\
M!W_QH ^N?M<'_/:/_OH4?:X/^>T?_?0KY&_X8?UK_H9[#_P'?_&C_AA_6O\
MH9[#_P !W_QH ^N?M<'_ #VC_P"^A1]K@_Y[1_\ ?0KY&_X8?UK_ *&>P_\
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M9[#_ ,!W_P : /KG[7!_SVC_ .^A1]K@_P">T?\ WT*^1O\ AA_6O^AGL/\
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MKG[7!_SVC_[Z%'VN#_GM'_WT*^1O^&']:_Z&>P_\!W_QH_X8?UK_ *&>P_\
M =_\: /KG[7!_P ]H_\ OH4?:X/^>T?_ 'T*^1O^&']:_P"AGL/_  '?_&C_
M (8?UK_H9[#_ ,!W_P : /KG[7!_SVC_ .^A1]K@_P">T?\ WT*^1O\ AA_6
MO^AGL/\ P'?_ !H_X8?UK_H9[#_P'?\ QH ^N?M<'_/:/_OH4?:X/^>T?_?0
MKY&_X8?UK_H9[#_P'?\ QH_X8?UK_H9[#_P'?_&@#ZY^UP?\]H_^^A1]K@_Y
M[1_]]"OD;_AA_6O^AGL/_ =_\:/^&']:_P"AGL/_  '?_&@#ZY^UP?\ /:/_
M +Z%'VN#_GM'_P!]"OD;_AA_6O\ H9[#_P !W_QH_P"&']:_Z&>P_P# =_\
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M_&C_ (8?UK_H9[#_ ,!W_P : /KG[7!_SVC_ .^A1]K@_P">T?\ WT*^1O\
MAA_6O^AGL/\ P'?_ !H_X8?UK_H9[#_P'?\ QH ^N?M<'_/:/_OH4?:X/^>T
M?_?0KY&_X8?UK_H9[#_P'?\ QH_X8?UK_H9[#_P'?_&@#ZY^UP?\]H_^^A1]
MK@_Y[1_]]"OD;_AA_6O^AGL/_ =_\:/^&']:_P"AGL/_  '?_&@#ZY^UP?\
M/:/_ +Z%'VN#_GM'_P!]"OD;_AA_6O\ H9[#_P !W_QH_P"&']:_Z&>P_P#
M=_\ &@#ZY^UP?\]H_P#OH4?:X/\ GM'_ -]"OD;_ (8?UK_H9[#_ ,!W_P :
M/^&']:_Z&>P_\!W_ ,: /KG[7!_SVC_[Z%'VN#_GM'_WT*^1O^&']:_Z&>P_
M\!W_ ,:/^&']:_Z&>P_\!W_QH ^N?M<'_/:/_OH4?:X/^>T?_?0KY&_X8?UK
M_H9[#_P'?_&C_AA_6O\ H9[#_P !W_QH ^N?M<'_ #VC_P"^A1]K@_Y[1_\
M?0KY&_X8?UK_ *&>P_\  =_\:/\ AA_6O^AGL/\ P'?_ !H ^N?M<'_/:/\
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MGL/_  '?_&C_ (8?UK_H9[#_ ,!W_P : /KG[7!_SVC_ .^A1]K@_P">T?\
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MA1]K@_Y[1_\ ?0KY&_X8?UK_ *&>P_\  =_\:/\ AA_6O^AGL/\ P'?_ !H
M^N?M<'_/:/\ [Z%'VN#_ )[1_P#?0KY&_P"&']:_Z&>P_P# =_\ &C_AA_6O
M^AGL/_ =_P#&@#ZY^UP?\]H_^^A1]K@_Y[1_]]"OD;_AA_6O^AGL/_ =_P#&
MC_AA_6O^AGL/_ =_\: /KG[7!_SVC_[Z%'VN#_GM'_WT*^1O^&']:_Z&>P_\
M!W_QH_X8?UK_ *&>P_\  =_\: /KG[7!_P ]H_\ OH4?:X/^>T?_ 'T*^1O^
M&']:_P"AGL/_  '?_&C_ (8?UK_H9[#_ ,!W_P : /KG[7!_SVC_ .^A1]K@
M_P">T?\ WT*^1O\ AA_6O^AGL/\ P'?_ !H_X8?UK_H9[#_P'?\ QH ^N?M<
M'_/:/_OH4?:X/^>T?_?0KY&_X8?UK_H9[#_P'?\ QH_X8?UK_H9[#_P'?_&@
M#ZY^UP?\]H_^^A1]K@_Y[1_]]"OD;_AA_6O^AGL/_ =_\:/^&']:_P"AGL/_
M  '?_&@#ZY^UP?\ /:/_ +Z%'VN#_GM'_P!]"OD;_AA_6O\ H9[#_P !W_QH
M_P"&']:_Z&>P_P# =_\ &@#ZY^UP?\]H_P#OH4?:X/\ GM'_ -]"OD;_ (8?
MUK_H9[#_ ,!W_P :/^&']:_Z&>P_\!W_ ,: /KG[7!_SVC_[Z%'VN#_GM'_W
MT*^1O^&']:_Z&>P_\!W_ ,:/^&']:_Z&>P_\!W_QH ^N?M<'_/:/_OH4?:X/
M^>T?_?0KY&_X8?UK_H9[#_P'?_&C_AA_6O\ H9[#_P !W_QH ^N?M<'_ #VC
M_P"^A1]K@_Y[1_\ ?0KY&_X8?UK_ *&>P_\  =_\:/\ AA_6O^AGL/\ P'?_
M !H ^N?M<'_/:/\ [Z%'VN#_ )[1_P#?0KY&_P"&']:_Z&>P_P# =_\ &C_A
MA_6O^AGL/_ =_P#&@#ZY^UP?\]H_^^A1]K@_Y[1_]]"OD;_AA_6O^AGL/_ =
M_P#&C_AA_6O^AGL/_ =_\: /KG[7!_SVC_[Z%'VN#_GM'_WT*^1O^&']:_Z&
M>P_\!W_QH_X8?UK_ *&>P_\  =_\: /KG[7!_P ]H_\ OH4?:X/^>T?_ 'T*
M^1O^&']:_P"AGL/_  '?_&C_ (8?UK_H9[#_ ,!W_P : /KG[7!_SVC_ .^A
M1]K@_P">T?\ WT*^1O\ AA_6O^AGL/\ P'?_ !H_X8?UK_H9[#_P'?\ QH ^
MN?M<'_/:/_OH4?:X/^>T?_?0KY&_X8?UK_H9[#_P'?\ QH_X8?UK_H9[#_P'
M?_&@#ZY^UP?\]H_^^A1]K@_Y[1_]]"OD;_AA_6O^AGL/_ =_\:/^&']:_P"A
MGL/_  '?_&@#ZY^UP?\ /:/_ +Z%'VN#_GM'_P!]"OD;_AA_6O\ H9[#_P !
MW_QH_P"&']:_Z&>P_P# =_\ &@#ZY^UP?\]H_P#OH5(KK(H96#+Z@Y%?(7_#
M#^M?]#/8?^ [_P"->]_ OX7W/PD\&SZ+=7T6H2R7CW7FPH54!D1<8/\ N?K0
M!Z)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !24M% #&CS4+VX;M5FB@"@UF/2A;,>
ME7MM&V@"NEN%[5,L>*?10 F*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>nvax-20221231_g3.jpg
<TEXT>
begin 644 nvax-20221231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/X<UE[>&RG\5Z;+-/#IT=TENB0I<"X2*&66&.-")T98@0V0#]0J*_)7X4_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)CE;,>0!(B\T ?>?Q<^,WPC^ 7@2]^*'QP^)N@^$?#FG+NO=<\2:K%9VL/7
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M*758DNHC<V\;S.D:2-;^<$+, 'V\'H>_HH _$[X[?L(ZA_P4+_X*O:!^U/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD,I'!!'((H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \H_;G_Y-'\>_P#8!?\ ]#6NZ^%W_),_#O\
MV K3_P!$I7"_MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE* -VBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGOBU\*_
MGQR^%WB+X,_%#0(M5\.>*M%N=)US3IQ\MQ:W$312H?3*L<$<@X(Y%=#10!\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /@'_@Y _Y,4\'?]G >"/\ TZ)7JO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOGO_ (*<_MY^&_\
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M/VY_^31_'O\ V 7_ /0UKNOA=_R3/P[_ -@*T_\ 1*5PO[<__)H_CW_L O\
M^AK7=?"[_DF?AW_L!6G_ *)2@#=HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KR#]O#]L[X5_\$_\ ]E7Q;^U3\79F?3_#
M=AFQTN&0"XU>_D.RUL8!SF2:4J@X(4%G/RJQ'K]?FCX3_P"-U/\ P5 ;XCS_
M .G?LS?LG>)7M_#2'YK/QQ\04'[R\'\,UMIZL AY!D8,I9)G4 'KW_!&_P#8
MQ^*GP<^'OBC]L[]L.%;C]H'X_P"HQ^(OB))+&<Z%:;?] T&$-DQQ6L!52G9R
M5)81H:^T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\X/V'_\ C5]_P51\>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G!^S5_P :L_\
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MX(__  RU.X'PI^'SV/BO]JO7M/F94N(PXFTWPN)%(Q)<.BS2@'*HH*G="Z$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPREW(KRCP]9"5T& S>0F2!V&: .AHHHH **** "BBB@ HHHH **** "BBB@
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MS,!VG0)/D?+ND=5)V&OJ^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?G!^U'_QJU_X*]>#_P!N#3_]"^#_
M .U ]GX!^,H7Y;;2O%,2L-%UB3H$$J![9W.%4"61B6<5^C]>1_MW_L?_  ]_
M;U_9'\<_LF_$Q533_&&B/;6]_P"7N?3KU2)+6\0?WX9TBE [[,'@FO&/^"*?
M[8'Q"_:3_95NOA#^T<S0?&GX':[-X#^+5E/)NEEO[/\ =PZADX,B74"I*)0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** /*/VY_^31_'O_8!?_T-:[KX7?\
M),_#O_8"M/\ T2E<+^W/_P FC^/?^P"__H:UW7PN_P"29^'?^P%:?^B4H W:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)KKWVOXA?#+RO"_C?SI=TUSY48^QW[9Y/GVX7<Y^]-%/Z4 ??]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?G%_P %,(9?^";'_!0;X:?\
M%@_#,36_@+Q4;;X:_M+10KB*/3;B55TK790. ;6?9$\ARQC\J)?OFOT;AFAN
M(4N+>59(W4,CHV0P/(((ZBN+_:2_9^^&_P"U7\ _%_[.'Q>T@7OAOQIH%QI6
MK0C&]8Y4*B2,D';(C;9$;JKHK#D5\F_\$,_V@?B1)\(_%W_!.;]IO5S/\7/V
M8=<3PEK5Q-D/K>A%"VC:L@8[C'-:!5R26/E!FP9!0!]T4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!Y1^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I_P"B
M4KA?VY_^31_'O_8!?_T-:[KX7?\ ),_#O_8"M/\ T2E &[1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6<:27/A_6?%MK'J4:.@=&-F',^&5E8'9R&!'45U_[-O[37P+_:^^#FF_'_\
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M^"3G[1^O27?Q%_9EU=-'TK4;KY7\0>#YQYFC:B@/4" K RKGRPD(8[F-??%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 44U98G=HTD4LAPZ@\J<9Y].*=0 4444 %%%% !1110!Y1^W/\
M\FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y-'\>_P#8!?\ ]#6N
MZ^%W_),_#O\ V K3_P!$I0!NT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9$N]1CM[;2-,LX?FMWB@?S \3>;++!)(V3*0M;X[?L(ZA_P4+_X*O:!^U/\
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M2_A3]OSXJ?%30YO"%]^U+K=U;_"O3O$41ANK.QM+J:[LKZ]A&7MUGNA:L87
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M@?%+]KO_ (*;>"]2\+:;<2RZQ\+? ?P=MH+35 T,B+&=1GD^U1!'=9!M!W%
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MN%_;G_Y-'\>_]@%__0UKNOA=_P DS\._]@*T_P#1*4 ;M%%% !1110 4444
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MP%\>?A3X;^-GPLU^+5/#?BS1+;5M#U"'I/:W$2RQMCL=K#*GD'(/(KR']O\
M_8$MOV\O!^C: G[47Q3^%M]H#W;66I?#3Q&MDMZ+B-8Y(;Z!XW2]MRJD&%L
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M:G_P<D?M,'_1/#'[/?[,NBS_ 'O[0O+GQEXBM<_W?*VZ?)@=<XR<8XK]!:*
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MW17D?P(_;Z_8A_:?$*?L]?M;_#KQC<3XV6&@^+[2XNU)[-;K)YJ'V90:]<H
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MI^+'Q:FOOB_X6TN30K72;'PYHZ&YOUB-RMI:!@LT8):-MWR-@\XH _:?QO\
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M7^TC,EQ\5?VS_@C^SSI$K!CIGPI\"3>)M3$6>8I9]598ED/0O#P.HYK]!**
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M_#7]LG]FSP7^U%\(;_S_  ]XVT"#4[$,X+V[.,2V\F.!+%*)(G'9XV':O0R
M1@C(/4&OSA_X)_D_\$QO^"FWQ#_X)6ZV3:?#+XM&[^)7[.3/Q#9R,<ZUH$78
M>2X-Q'$/NQ*SGYI: /T>HHHH ***\_\ VJOA3\1_CI^SCXT^#/PD^,'_  K_
M ,0^*?#]QI>G^-%T8Z@^D>>OER3QP"> M*(V?8?,78Y5^=NT@'\H7_!R+_P4
MB_X>(?\ !1S7O^$*U[[7\/?AEYOA?P1Y,NZ&Y\J0_;+]<<'S[@-M<?>AB@]*
M^ *_?[_B!C_ZRB_^83_^_5'_ ! Q_P#647_S"?\ ]^J /@#_ (-NO^"D7_#N
M_P#X*.:#_P )KKWV3X>_$WRO"_C?SI=L-MYL@^QW[9X'D7!7<Y^[#+/ZU_7[
M7X _\0,?_647_P PG_\ ?JOV^_95^%/Q'^!?[./@OX,_%OXP?\+ \0^%O#]O
MI>H>-&T8Z>^K^0OEQSR0&><K*8U3>?,;>X9^-VT 'H%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1^W/\ \FC^/?\ L O_
M .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y-'\>_P#8!?\ ]#6NZ^%W_),_#O\
MV K3_P!$I0!NT444 %%%% !1110 4444 %%%% !1110 445Y[\8/VMOV5?V>
MXWE^/7[2W@#P4(URX\5^,++3R/PGE4D^W>@#T*BOASXA?\''7_!'WP/JW_"+
M^'_VJO\ A-];8D6^B_#SPKJ6M37!']Q[:W:$]O\ EH.M<^?^"W7Q\^*G[O\
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M>([+X3_\%FOV2==^ ^JW,ZVMC\4-$236O NL2GA3'?0!WLF?@B&8,47F1TH
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M^$*U[[7\/?AEYOA?P1Y,NZ&Y\J0_;+]<<'S[@-M<?>AB@]*_>?\ X.%OVY/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU'Q)J+&&T5$/#^7EYRIX80%<Y84 ?+W[*WQ:\%?\%OO^"JUM^V1\/KB]U/\
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MW,:#"H@11EI#7Z/T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%5]7U?2?#^DW6O:]JEO8V-C;O<7M[>3K%%;Q(I9Y'=B BJH)+$@
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MWP2^.?C#]GG6_"WQ8UKQ#X$U@Z9XC/A/X9WNI6UO<[ ^SS800<JP(Z5]OU\
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M _2VW_X.2/\ @GS_ &WI.B:WX)^-&C?VSK%KIEE>Z[\);^SMOM-Q*L42-+*
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M_@A9I/P7\8W_ ,</^"17[2_B/]FCQA=S&YO_  OI(_M+P7K<O]VZT><F./(
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M^TGK-MKGB;]K+6K^[^(4F@(R6VCV<OGBTLK%Y5WNUL;B207#HADDVL8U"A:
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MG_@C9_P3._;;^)EU\9?VHOV4='\5^*;VUAMKK6Y]5O[:>2*) D:DVUQ'PJ@
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M,.F06T@\;> ?@])JN@7GG0I+M@NTG'F,A<1N-@VR97G!-><_\1)?_!/;2O\
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M#S_XI_M%>%_A'^SC?_M,^(O!OBJ[TG3M BU:?0](T%[G5S&ZHPA6T4[FF&\
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MQ%UKXM_%G]B;P;K_ (E\1:C+?ZWK6I0S23WEQ(Q9Y';S.I)Z#@#    %8/\
MPX(_X(V_](]OA_\ ^ <W_P <KZ_HH ^0/^'!'_!&W_I'M\/_ /P#F_\ CE3:
M;_P09_X(^Z/J-OJ^D?L">!;6[M9DFM;FWMYTDAD4AE=6$N58$ @CD$5]<T4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M73/"?CBPOI=2NL;+:TC$$KG=+,T<8.,#?D\ U\M_ 7_@C7XE^/'_  1R\<^
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MO0_Z%\'/VRO(\/>*L?+;:/\ $&T0_8+D]D^W0EH< 9>7S)'.%%?HY0 4444
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M71_'6B?\%%?$"WNBZI;W]HW_  KBWXEAD61#S>D?>4=0:_<H9QS110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP+_@I=^PT_\
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MPV_X+K^&/A+XUL?@5_P5H_9P\2?LQ^-KN7[/8Z[XA;[?X.UJ0?Q6FM0 PKD
ML5EVK&" TA-?=_AKQ-X;\9Z!9^*_!_B"QU;2]0MUGL-2TV[2>WN8F&5DCD0E
M74CD,"0: +U%%% !1110 4444 %%%% !1110 5\"?\%D?C]\4OC'XK\(_P#!
M'']D#Q))9?$OXXVLDOCOQ'9Y9O!7@=&V:AJ+X/RR3J'MH02-Q+J"KM&3]4?M
MK?M>?"7]A#]F#Q?^U5\:]1,.A^$]+:X-M&X$VH7+$);V<(/66:5DC7L"^3@
MD?.__!&K]D/XM>"_"_BS_@H-^V9IP/Q\_:$NXM:\4V\R'/A?1@H_LW0(0WS1
MI!!L,B\-OPK[C"K$ ^J/V=_@#\+?V6/@=X6_9U^"GAN/2?"W@_1H=-T:Q3!*
MQ1CEW; WR.Q9W<\N[LQY)KLZ** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\&_X*7_L1^'/^"A/[%_C/]F/5KU=/U34[(7GA
M#70Q5]'UNV/G6-XCK\R;)E4,5PQC:10?FKWFO(/VX/VX/@9_P3X^!DG[0W[0
MT^L)X>36+33 -"TE[VY>YN7*1(L2'+988XH \X_X(]_MN>(_VWOV-=.UWXN6
M3:;\5/ 6IW'@SXPZ%.H6:Q\1:>1#<,Z#A1, DX X'FE03L-?4U?A3+_P6>_9
M6_9 _P""MM_^V7\+/AS\7-/^$?QW\.PZ5\8M&U;X87U@]MXGM%8:;JEI'*JK
M/)-%N@>-#O.992'8@5]L?\1('["G_1'OV@/_  R6J?\ Q- 'W]17P#_Q$@?L
M*?\ 1'OV@/\ PR6J?_$U[_\ L$_\%*/V;O\ @H[HGBO6_P!GF+Q1!_PA6L1:
M9XALO%GAR73+FWN9(O-5/*E^;[O)R!B@#W^BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \H_;G_Y-'\>_P#8!?\ ]#6NZ^%W
M_),_#O\ V K3_P!$I7"_MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE*
M-VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNPW;1A5 'J] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^'+7Q581P@1276D"_CCO-V<F22"\BB88 Q:(>2S4 >L5\ _\$?O^3Z_V]/\
MLX"T_P#37'7W]7P#_P $?O\ D^O]O3_LX"T_]-<= 'W]1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >4?MS_ /)H_CW_ + +
M_P#H:UW7PN_Y)GX=_P"P%:?^B4KA?VY_^31_'O\ V 7_ /0UKNOA=_R3/P[_
M -@*T_\ 1*4 ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_@G1^U3^WO\ \$XOVJ_VL1\5OV</$O[2_A6P^+EO;?%+XF_#2P@@UZTO8K%
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MV\2I&GQ]\#JB(N H&IH  !T% 'Z T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %? /_!R!_R8IX._[. \$?\ IT2O
MOZO /^"E'[!.B?\ !1W]FY/V>=;^*^L>"O(\4:;KMEXAT*UBFN;>YLI?-B*K
M+\OWL'/;% 'O]%? /_#G[]NO_I/3^T!_X*=+_P#B*/\ AS]^W7_TGI_: _\
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M*J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .+H_P"%3_\ !7+_ *.T^%G_ (0<O_Q=?4U% 'RS_P *G_X*Y?\ 1VGPL_\
M"#E_^+H_X5/_ ,%<O^CM/A9_X0<O_P 77U-10!\L_P#"I_\ @KE_T=I\+/\
MP@Y?_BZ/^%3_ /!7+_H[3X6?^$'+_P#%U]344 ?+/_"I_P#@KE_T=I\+/_"#
ME_\ BZ/^%3_\%<O^CM/A9_X0<O\ \77U-10!\L_\*G_X*Y?]':?"S_P@Y?\
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M_BZ/^%3_ /!7+_H[3X6?^$'+_P#%U]344 ?+/_"I_P#@KE_T=I\+/_"#E_\
MBZ/^%3_\%<O^CM/A9_X0<O\ \77U-10!\L_\*G_X*Y?]':?"S_P@Y?\ XNC_
M (5/_P %<O\ H[3X6?\ A!R__%U]344 ?+/_  J?_@KE_P!':?"S_P (.7_X
MNC_A4_\ P5R_Z.T^%G_A!R__ !=?4U% 'RS_ ,*G_P""N7_1VGPL_P#"#E_^
M+H_X5/\ \%<O^CM/A9_X0<O_ ,77U-10!\L_\*G_ ."N7_1VGPL_\(.7_P"+
MH_X5/_P5R_Z.T^%G_A!R_P#Q=?4U% 'RS_PJ?_@KE_T=I\+/_"#E_P#BZ/\
MA4__  5R_P"CM/A9_P"$'+_\77U-10!\L_\ "I_^"N7_ $=I\+/_  @Y?_BZ
M/^%3_P#!7+_H[3X6?^$'+_\ %U]344 ?E]\7O^"!WBSX^?$O6?C'\8_#G[/'
MB'Q1XAO#=:UK6H?#FZ::[F( +N1, 3@#MVKF_P#B&P\/_P#1*OV;/_#;W?\
M\?K]9:* /R:_XAL/#_\ T2K]FS_PV]W_ /'ZN>'O^#<^#PGK]CXI\.?#O]G"
MSU#3+R*[L+N'X;W8>":-PZ.O[[J& (^E?JS10!\L_P#"I_\ @KE_T=I\+/\
MP@Y?_BZ/^%3_ /!7+_H[3X6?^$'+_P#%U]344 ?+/_"I_P#@KE_T=I\+/_"#
ME_\ BZ/^%3_\%<O^CM/A9_X0<O\ \77U-10!\L_\*G_X*Y?]':?"S_P@Y?\
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M_BZ/^%3_ /!7+_H[3X6?^$'+_P#%U]344 ?+/_"I_P#@KE_T=I\+/_"#E_\
MBZ/^%3_\%<O^CM/A9_X0<O\ \77U-10!\L_\*G_X*Y?]':?"S_P@Y?\ XNC_
M (5/_P %<O\ H[3X6?\ A!R__%U]344 ?+/_  J?_@KE_P!':?"S_P (.7_X
MNC_A4_\ P5R_Z.T^%G_A!R__ !=?4U% 'RS_ ,*G_P""N7_1VGPL_P#"#E_^
M+H_X5/\ \%<O^CM/A9_X0<O_ ,77U-10!\L_\*G_ ."N7_1VGPL_\(.7_P"+
MH_X5/_P5R_Z.T^%G_A!R_P#Q=?4U% 'RS_PJ?_@KE_T=I\+/_"#E_P#BZ/\
MA4__  5R_P"CM/A9_P"$'+_\77U-10!\L_\ "I_^"N7_ $=I\+/_  @Y?_BZ
M/^%3_P#!7+_H[3X6?^$'+_\ %U]344 ?+/\ PJ?_ (*Y?]':?"S_ ,(.7_XN
MC_A4_P#P5R_Z.T^%G_A!R_\ Q=?4U% 'RS_PJ?\ X*Y?]':?"S_P@Y?_ (NC
M_A4__!7+_H[3X6?^$'+_ /%U]344 ?+/_"I_^"N7_1VGPL_\(.7_ .+H_P"%
M3_\ !7+_ *.T^%G_ (0<O_Q=?4U% 'RS_P *G_X*Y?\ 1VGPL_\ "#E_^+H_
MX5/_ ,%<O^CM/A9_X0<O_P 77U-10!\L_P#"I_\ @KE_T=I\+/\ P@Y?_BZ/
M^%3_ /!7+_H[3X6?^$'+_P#%U]344 ?+/_"I_P#@KE_T=I\+/_"#E_\ BZ/^
M%3_\%<O^CM/A9_X0<O\ \77U-10!\L_\*G_X*Y?]':?"S_P@Y?\ XNC_ (5/
M_P %<O\ H[3X6?\ A!R__%U]344 ?+/_  J?_@KE_P!':?"S_P (.7_XNC_A
M4_\ P5R_Z.T^%G_A!R__ !=?4U% 'RS_ ,*G_P""N7_1VGPL_P#"#E_^+H_X
M5/\ \%<O^CM/A9_X0<O_ ,77U-10!\L_\*G_ ."N7_1VGPL_\(.7_P"+H_X5
M/_P5R_Z.T^%G_A!R_P#Q=?4U% 'RS_PJ?_@KE_T=I\+/_"#E_P#BZ/\ A4__
M  5R_P"CM/A9_P"$'+_\77U-10!\L_\ "I_^"N7_ $=I\+/_  @Y?_BZ/^%3
M_P#!7+_H[3X6?^$'+_\ %U]344 ?+/\ PJ?_ (*Y?]':?"S_ ,(.7_XNC_A4
M_P#P5R_Z.T^%G_A!R_\ Q=?4U% 'RS_PJ?\ X*Y?]':?"S_P@Y?_ (NC_A4_
M_!7+_H[3X6?^$'+_ /%U]344 ?+/_"I_^"N7_1VGPL_\(.7_ .+H_P"%3_\
M!7+_ *.T^%G_ (0<O_Q=?4U% 'RS_P *G_X*Y?\ 1VGPL_\ "#E_^+H_X5/_
M ,%<O^CM/A9_X0<O_P 77U-10!\L_P#"I_\ @KE_T=I\+/\ P@Y?_BZ/^%3_
M /!7+_H[3X6?^$'+_P#%U]344 ?+/_"I_P#@KE_T=I\+/_"#E_\ BZ/^%3_\
M%<O^CM/A9_X0<O\ \77U-10!\L_\*G_X*Y?]':?"S_P@Y?\ XNC_ (5/_P %
M<O\ H[3X6?\ A!R__%U]344 ?+/_  J?_@KE_P!':?"S_P (.7_XNC_A4_\
MP5R_Z.T^%G_A!R__ !=?4U% 'RS_ ,*G_P""N7_1VGPL_P#"#E_^+H_X5/\
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M'I\WBW1;1+<7@N"[B76+F[83/Y+I)+;3>?(0B()2 ?T.4444 %%%% !1110
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M/['^-=RLK-)XQ_M*71Q]KU)R2UY/%/J<LZ2R%I%(P#M)4_O?0 4444 %%%%
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M)J$=LDHO[:$7,AQYDCW45E+&9,RJTC$,4)% '[9T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'Y5_P#!=O\ 9R_:9_:2_P""A'[%?Q0_9_\ V<?&
M'BWP_P# SXI-K_Q#U;3-,"16EJVIZ'<8B\YD-RXBL)V(B##[HSN) ]X_X+-?
M'3]N/3?V?-*^$W[!7['GC;XCWWCW]WXNU31-031I-(T,X\^".>X EM[RX0M$
MK",O ID?Y)!$:^W** /RT^&7CG_@I_\ &;]@'XF?LTZU_P $VA^SOIUUHOA[
MX;?"CPEX:NEU![.TU2Y>QU35I)H^((+&R=9@Q4?,KLS,Q&/K;]I3]I'XG_L'
MWOPH^&/P5_8!\<?$OX:3VK:/KVM?#F6.YN_!UO;1P168_L[;YEW&RE@S*Z>6
ML)/SL50_2M% 'P;_ ,$__P#@GE9?"?\ X*5_M!?\%+-$^&5WX \,_%#1].T[
MPUX-N;)8+NZ=4AGU'5)[2(M]F,US$I2)L3,3,[HAD4'QC]CW]GS]I7P=_P '
M*_Q]_;G\8_LW^-=+^%/Q(^'D'A[PIXNN]&(CGO(TT",&2$$SP1L=/N,/)&H4
M!2^T'(_5FB@#YP_8>^''CVY^-?Q^_:F^*OA#4-%U3Q[\2!HWAJSU.U:&5/#.
MA0"PL'"/\P2>X.HWJ$XW)?*P !KXS?X!?M)3_P#!SA#^WFG[-OC?_A4(^&?_
M  CA\:-H;"/[6;$KN^S$_:1'YA\O=Y77YON?/7ZMT4 ?,?\ P5Z\,?&[XI_L
M1ZU^SA^S_P"&M8O==^+>M:9X'O-2TFT:5=#TG4;I(=3U&X*C]W#%8?:LN> S
MH.20#]$^"_!_ASX>^#M)\ >#M+CL=(T/3(-/TJRA&$M[:&-8XHU]E15 ^E:=
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 97C7Q5!X*\,W?B2?1M3U'[-$62QT?3I+JYG?'RHD<8)R3@9.%&<L0,FOS&_
MX-9_V9OVF/V"/V&OB!\"_P!K3]GSQ7X/\23_ !*OO$VGV=WIXF2^L7TS3K<>
M5+ SQF7S+60>4S*YRI (R1^IU% 'XS:I^U1_P7 N_P!K_P 8?M-:#_P0VU34
M_$6H02>'?A?X@\8^-;40^#M 9P0BVD)(\V:0"XNI%EW2%4B#".%!7Z ? +X<
M?%#7_P!NSXV?M/\ Q%\(:BL6A>'M$^'OPV?4;;[*=3L[6W.IZC?0@@ 1W-_?
M+!YGW3_9JXX45],T4 ?ES^V9;?&__@MM_P $_?$W[(7Q>_X)A>/?A7\7)=?L
MTT2?QK!#<:)X?FCO(B^K6^M*$6:);;S5=(H_-DWM$B2*?,KN/^"X/[*'Q7\:
M?\$4=0_X)]_LO_#7Q-X_\5'1?"^CZ#;Z?89,UOIE]8223SSN5AC)BM&.TON9
MF& 1DC]#J* /S^E^#_QJ^)/_  2/_9P_8-OO@WXHT[4-;MO O@;XP6=]I$D9
MT/2--L[>XUHRR<QF&:*PDLEE5F1VOD4$MD#U3_@MAX#^(WQB_P""9/Q9^ ?P
M7^&NN>*_%WC3PL^F^'M$T.P,AEE,T.2\AQ%"JKELR.N0I"[CQ7U;10!^8WPP
M_94_;A\0?\&T_P#PPY\)_#>O?#_XYZ9\-AHPTO5G^PRF5;\RSVL5T&\D_:;0
M2PK(LFU3<+O9,''@TW_!+#Q/\>OVBOV"_BE^S3^R=XG^$GB[X*:=HB_'[Q-K
M7AM]&@AMM)CL-MF9'"KJMS*T-U"DUMYR-'/^^<* J?ME10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y5_\ !=O]G+]I
MG]I+_@H1^Q7\4/V?_P!G'QAXM\/_  ,^*3:_\0]6TS3 D5I:MJ>AW&(O.9#<
MN(K"=B(@P^Z,[B0/U4HH ^(_^"S7QT_;CTW]GS2OA-^P5^QYXV^(]]X]_=^+
MM4T34$T:32-#.//@CGN );>\N$+1*PC+P*9'^201&O$/AEXY_P""G_QF_8!^
M)G[-.M?\$VA^SOIUUHOA[X;?"CPEX:NEU![.TU2Y>QU35I)H^((+&R=9@Q4?
M,KLS,Q&/U+HH ^:OVE/VD?B?^P?>_"CX8_!7]@'QQ\2_AI/:MH^O:U\.98[F
M[\'6]M'!%9C^SMOF7<;*6#,KIY:PD_.Q5#Y%_P $_P#_ ()Y67PG_P""E?[0
M7_!2S1/AE=^ /#/Q0T?3M.\->#;FR6"[NG5(9]1U2>TB+?9C-<Q*4B;$S$S.
MZ(9%!^\J* /RF_8]_9\_:5\'?\'*_P ??VY_&/[-_C72_A3\2/AY!X>\*>+K
MO1B(Y[R-- C!DA!,\$;'3[C#R1J% 4OM!R/LK]A[X<>/;GXU_'[]J;XJ^$-0
MT75/'OQ(&C>&K+4[9H94\,Z% +"P<(_S!)[@ZC>H3C<E\K 8-?1]% 'Y2/\
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M&D]JVCZ]K7PYECN;OP=;VT<$5F/[.V^9=QLI8,RNGEK"3\[%4/TK10!\&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV![6VMYK6!&#Q2:FL<]Q&]N@G)U2#"M)&HH _1.BOP__ &)/C5\1_#__  <
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M  6,_9=_8J^,D_P-^*_P\^+&I:O;Z?!>/=>$/AI?:I9&.8$J!/"I4L,<KU%
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M?LG:[XUL-!M(;I&EET8R3!H%AAF+3:=<((VDBCC>6U9H\961E*@'Z"?M)?\
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M (+#^&C\3O%/V/X<>)XC\/X6\37A/AP0ZIXA$0LF,N;956*)<1E0515.0 *
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M</\ #VZM-,NUFPW]JFQ9(WWYX/GX.<^] 'SUX"_X*SM^U=^U)XU_9@_X)X?
MJT^)R_#&9+?XA_$3Q%XR.@^&M/O&=T6RMKB*SO9[V?,4P^2 1?NB?,P0Q[SX
M=?ML?%VZ_;!TC]BSX[_LDZCX0US5_!FI^);'Q?I/B>+5O#E_;6<]G"\-K<F&
MWN))PUXGF1S6T!C&QAYBR*:_.W_@RN;2M&_8S^-/@+5+%K/Q=I'QA)\06-W&
M8[FWB;3K:.%)48;E(E@O!@\AE<=0:^M?@W_P5VT;X\_\%5_$_P#P2_N/V3?L
MGCKX=:9<WFM>+;GQ-#-8P:>R6;R-:M]G$SM(MU;?NRL>XC#%0N: /NBBOP<_
MX)@_L=^,/^"D?[17[=7[-_Q2_;)^,OA3P-X$^/8M_"VF^!_'4MM+:F'5=86*
M/S)Q+B"*&!46$83+[R"\4+)W,WQ6^(G[:G_!0C_@H+X8^//BK7XM'_9_^$5W
MIOPET>#7+FU3P]-';3N-9MQ$ZXO7>W6877,@60*&" +0!^U5%?SZ_'+XE?MD
M_MH_\&UWPK_X*:K\2_%*_%3X,^))5\0ZS9ZQ<P#Q9H%OJ<ED[7D4+JMUM(MG
MD=]Q(M[HD_O&JWXZ_;=\>?!/_@IY\"_^"J-CX3\3WOP$_:>\*ZAI_ASX:-?7
MD@BU=;".T^6U=S#%-<7SQ>6R(H>&61P,LS4 ?N%^T)^TO\'?V7O#.C>*?C'X
MKBTV'Q'XMTKPSH%OD&?4-4U"ZCMK:WA0D%VW2;VQ]V..1SPA->!?M)_\%4D_
M9M_X*:?![_@G1KGP(?4A\9+&6YT?QG:^)@@L?*$_F+-:-;9)!AP"LIR'SQC%
M?G+_ ,%W/V0?!?PA^*7_  3A^$'B"\U35+N;XHV>@>*K\^)=0(U!VO\ 26NI
MDW3YADDEN)V\V/;*%,:[]L483K/^"J7P%\#VO_!?7]A/]G[P[J'B#1_#T?A7
M4;&.33/$UXFH);!KLM&M\TK72LZ[D,JR"4!R4=&"L #]J*^1?^"PG_!4?5?^
M"2GP"TO]I35_V?8O'?AN]\1V^AW4-IXN_L^]M[J>*XE1A&UI*CQ;;<@MYBL&
M=1L(RP^6_P#@VK\?>/K;]H/]M[]EW4/'^OZMX,^%?QZGL/ FFZ_K=QJ#Z5:M
M?:M 84FN7>0J4LH,@L<L&8_,[$M_X/)O^42.E_\ 98=&_P#2/4* /8?B+_P7
M6M?V7_BO\%? W[;G[*=]X%\/?'FU@D\$>//#GC"'7-.ADE%N?*O%:WMIH"GV
MNW\QA&X'F94N%8K] 7_[8WQ@M/\ @HS9?L2P_L7>-)O!5UX";7Y?C@C-_8L%
MV'91I[#R=F\[0/\ 7"3<X_<E/WE?C;_P5MA\;_L8:I^Q7^W?^VOK.G_M!_"W
M1M$L+;0/A?/8C06\/7BV=E=&YB:WD9;\LL,9(N!L)MHT8%9#CZ;U+XI^,M#_
M .#J_3/#O@_Q-XD/A?5_V>I?$,W@Y-5N$M+N]:SG(D-H6\M9F$: G;G<,]<T
M ?KM7!?%?]I?X._!;XB^ /A+X\\5Q6_B3XG:_-I'@W1HR&GO9H;26[GDV9R(
MHXH3ODZ*SQKUD4'\ /#G[6'[1?Q2_P""$'QE_P""P/B+XS^)+/X^Z=^TI;-X
M<\76.MW$;:+8B72XAH]O#O\ +2P"7=QNM2ICDW#S%<@$>O?M=^$?"G[6W_!>
MS]@SQM\7_#.J6\OQ;^!5MKGB[2;?Q)J%J;>XDTO4)?)@:*=7LU1E4%8#&&(9
MF#,[E@#]WJ*_%7QKXZ_:-_;K_P""JO[6_P"PAX3MIKF7X8?".WT#X&:3??$.
MZT=/"5RUK!_Q44>Q9)+B\6ZEM7^TG]ZL3*@<JY!V_B9^T3^U&W_!3/\ 8>_X
M)>_\%#?B!9W>D:K\,+W4/BJ=!UF5=,\:^)5AU6RM(KJ5!$;A5FL()?((5&N+
MH!D.$  /NO\ X*Z?\%*C_P $IOV6X?VJ=0^"A\<Z4OB.VTG4--M_$8TZ>$W
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ME? O[6_BWP;'<^.OASI&JZ=X4U8G!MH=06)+C(Q\[!(V5"3\@GFP/G->D44
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MZ_:GU26WDU?3M/\ L/@W3K@@B_UNX!CM(MO\2J^99 .?*AD/:OH^O#_VWO\
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M  1>_;0\)Z!8^%?#'_!=/X\6&FZ99Q6FGV-IHFE)%;01H$CC11'A550  .
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MGL_M%:M^UM\%-<\5?"?XC>)(5B\6>(_AOJ<-LGB$*VY6O[&ZAN+*ZD!+$3/
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MGVLL8TB60U^A*(D:".- JJ,*JC  ]*6B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595126704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVAVAX,&#160;INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2816046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">21 Firstfield Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">268-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,010,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,173,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Documents incorporated by reference: Portions of the Registrant&#8217;s Definitive Proxy Statement to be filed no later than 120 days after the fiscal year ended December&#160;31, 2022 in connection with the Registrant&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent indicated herein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001000694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442677828224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591513248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,981,872,000<span></span>
</td>
<td class="nump">$ 1,146,290,000<span></span>
</td>
<td class="nump">$ 475,598,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">902,639,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,235,278,000<span></span>
</td>
<td class="nump">2,534,508,000<span></span>
</td>
<td class="nump">747,027,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">488,691,000<span></span>
</td>
<td class="nump">298,358,000<span></span>
</td>
<td class="nump">145,290,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">2,626,608,000<span></span>
</td>
<td class="nump">2,832,866,000<span></span>
</td>
<td class="nump">892,317,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(644,736,000)<span></span>
</td>
<td class="num">(1,686,576,000)<span></span>
</td>
<td class="num">(416,719,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(19,880,000)<span></span>
</td>
<td class="num">(21,127,000)<span></span>
</td>
<td class="num">(15,145,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">10,969,000<span></span>
</td>
<td class="num">(6,833,000)<span></span>
</td>
<td class="nump">13,605,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(653,647,000)<span></span>
</td>
<td class="num">(1,714,536,000)<span></span>
</td>
<td class="num">(418,259,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">4,292,000<span></span>
</td>
<td class="nump">29,215,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (657,939,000)<span></span>
</td>
<td class="num">$ (1,743,751,000)<span></span>
</td>
<td class="num">$ (418,259,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="num">$ (8.42)<span></span>
</td>
<td class="num">$ (23.44)<span></span>
</td>
<td class="num">$ (7.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="num">$ (8.42)<span></span>
</td>
<td class="num">$ (23.44)<span></span>
</td>
<td class="num">$ (7.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">78,183<span></span>
</td>
<td class="nump">74,400<span></span>
</td>
<td class="nump">57,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">78,183<span></span>
</td>
<td class="nump">74,400<span></span>
</td>
<td class="nump">57,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,554,961,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">382,921,000<span></span>
</td>
<td class="nump">948,709,000<span></span>
</td>
<td class="nump">453,210,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember', window );">Royalties and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 43,990,000<span></span>
</td>
<td class="nump">$ 197,581,000<span></span>
</td>
<td class="nump">$ 22,388,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442677822112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (657,939)<span></span>
</td>
<td class="num">$ (1,743,751)<span></span>
</td>
<td class="num">$ (418,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(5,024)<span></span>
</td>
<td class="num">(8,368)<span></span>
</td>
<td class="nump">19,523<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(5,024)<span></span>
</td>
<td class="num">(8,377)<span></span>
</td>
<td class="nump">19,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (662,963)<span></span>
</td>
<td class="num">$ (1,752,128)<span></span>
</td>
<td class="num">$ (398,727)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591880064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,336,883,000<span></span>
</td>
<td class="nump">$ 1,515,116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">10,303,000<span></span>
</td>
<td class="nump">11,490,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">82,375,000<span></span>
</td>
<td class="nump">454,993,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">36,683,000<span></span>
</td>
<td class="nump">8,872,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">237,147,000<span></span>
</td>
<td class="nump">164,648,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,703,391,000<span></span>
</td>
<td class="nump">2,155,119,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">294,247,000<span></span>
</td>
<td class="nump">225,741,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseRightOfUseAsset', window );">Total non-current ROU assets</a></td>
<td class="nump">106,241,000<span></span>
</td>
<td class="nump">40,123,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">126,331,000<span></span>
</td>
<td class="nump">131,479,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">28,469,000<span></span>
</td>
<td class="nump">24,291,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,258,679,000<span></span>
</td>
<td class="nump">2,576,753,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">216,517,000<span></span>
</td>
<td class="nump">127,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">591,158,000<span></span>
</td>
<td class="nump">673,731,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">370,137,000<span></span>
</td>
<td class="nump">1,422,944,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">27,196,000<span></span>
</td>
<td class="nump">130,533,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">324,881,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">930,055,000<span></span>
</td>
<td class="nump">36,061,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,459,944,000<span></span>
</td>
<td class="nump">2,390,319,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">179,414,000<span></span>
</td>
<td class="nump">172,528,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">166,466,000<span></span>
</td>
<td class="nump">323,458,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of finance lease liabilities</a></td>
<td class="nump">31,238,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">55,695,000<span></span>
</td>
<td class="nump">42,121,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,892,757,000<span></span>
</td>
<td class="nump">2,928,426,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 2,000,000 shares authorized at December&#160;31, 2022 and 2021; no shares issued and outstanding at December&#160;31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 600,000,000 shares authorized at December&#160;31, 2022 and 2021; and 86,806,554 shares issued and 86,039,923 shares outstanding at December&#160;31, 2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December&#160;31, 2021</a></td>
<td class="nump">868,000<span></span>
</td>
<td class="nump">764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,737,979,000<span></span>
</td>
<td class="nump">3,351,967,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,275,889,000)<span></span>
</td>
<td class="num">(3,617,950,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 766,631 shares, cost basis at December&#160;31, 2022 and 591,980 shares, cost basis at December&#160;31, 2021</a></td>
<td class="num">(90,659,000)<span></span>
</td>
<td class="num">(85,101,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,377,000)<span></span>
</td>
<td class="num">(1,353,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="num">(634,078,000)<span></span>
</td>
<td class="num">(351,673,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 2,258,679,000<span></span>
</td>
<td class="nump">$ 2,576,753,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595096800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">86,806,554<span></span>
</td>
<td class="nump">76,433,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">86,039,923<span></span>
</td>
<td class="nump">75,841,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">766,631<span></span>
</td>
<td class="nump">591,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594727104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance beginning (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,399,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2019</a></td>
<td class="num">$ (186,017)<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 1,260,551<span></span>
</td>
<td class="num">$ (1,431,801)<span></span>
</td>
<td class="num">$ (2,583)<span></span>
</td>
<td class="num">$ (12,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease', window );">Preferred stock beneficial conversion feature</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,139<span></span>
</td>
<td class="num">(24,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock</a></td>
<td class="nump">199,822<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">199,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">128,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,168,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="nump">5,246<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">44,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,393,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">878,850<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">878,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">19,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(418,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,350,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Dec. 31, 2020</a></td>
<td class="nump">627,209<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">2,535,476<span></span>
</td>
<td class="num">(1,874,199)<span></span>
</td>
<td class="num">(41,806)<span></span>
</td>
<td class="nump">7,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">183,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,503,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="nump">24,761<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">68,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,578,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">564,859<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">564,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(8,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,743,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,743,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,433,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Dec. 31, 2021</a></td>
<td class="num">(351,673)<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">3,351,967<span></span>
</td>
<td class="num">(3,617,950)<span></span>
</td>
<td class="num">(85,101)<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">131,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="num">(639)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,672,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">249,230<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">249,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(5,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(657,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(657,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,806,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Dec. 31, 2022</a></td>
<td class="num">$ (634,078)<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 3,737,979<span></span>
</td>
<td class="num">$ (4,275,889)<span></span>
</td>
<td class="num">$ (90,659)<span></span>
</td>
<td class="num">$ (6,377)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation Stock Issued Under Incentive Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Stock Issued Under Incentive Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595118544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="nump">$ 7,216<span></span>
</td>
<td class="nump">$ 7,292<span></span>
</td>
<td class="nump">$ 11,416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587152064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (657,939)<span></span>
</td>
<td class="num">$ (1,743,751)<span></span>
</td>
<td class="num">$ (418,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">29,054<span></span>
</td>
<td class="nump">12,661<span></span>
</td>
<td class="nump">4,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_OperatingAndFinanceLeaseWriteOff', window );">Right-of-use assets expensed, net of credits received</a></td>
<td class="nump">18,104<span></span>
</td>
<td class="nump">144,433<span></span>
</td>
<td class="nump">245,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">130,300<span></span>
</td>
<td class="nump">183,626<span></span>
</td>
<td class="nump">128,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProvisionForExcessAndObsoleteInventory', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">447,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="num">(21,903)<span></span>
</td>
<td class="num">(7,641)<span></span>
</td>
<td class="num">(15,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(477,801)<span></span>
</td>
<td class="num">(8,872)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Accounts receivable, prepaid expenses, and other assets</a></td>
<td class="nump">249,166<span></span>
</td>
<td class="num">(183,393)<span></span>
</td>
<td class="num">(422,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other liabilities</a></td>
<td class="nump">913,399<span></span>
</td>
<td class="nump">600,326<span></span>
</td>
<td class="nump">163,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,045,914)<span></span>
</td>
<td class="nump">1,325,557<span></span>
</td>
<td class="nump">271,545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(415,937)<span></span>
</td>
<td class="nump">322,946<span></span>
</td>
<td class="num">(42,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Capital expenditures</a></td>
<td class="num">(89,056)<span></span>
</td>
<td class="num">(54,501)<span></span>
</td>
<td class="num">(54,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Internal-use software</a></td>
<td class="num">(3,929)<span></span>
</td>
<td class="num">(2,985)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Novavax CZ, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(165,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,167)<span></span>
</td>
<td class="num">(363,202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,807<span></span>
</td>
<td class="nump">205,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(92,985)<span></span>
</td>
<td class="nump">100,154<span></span>
</td>
<td class="num">(377,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from sale of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">199,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">249,230<span></span>
</td>
<td class="nump">564,859<span></span>
</td>
<td class="nump">875,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="nump">175,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payments of costs related to issuance of convertible notes</a></td>
<td class="num">(5,258)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NetProceedsFromTheExerciseOfStockBasedAwards', window );">Net proceeds from the exercise of stock-based awards</a></td>
<td class="num">(639)<span></span>
</td>
<td class="nump">24,761<span></span>
</td>
<td class="nump">5,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease payments</a></td>
<td class="num">(93,595)<span></span>
</td>
<td class="num">(127,907)<span></span>
</td>
<td class="num">(96,065)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">324,988<span></span>
</td>
<td class="nump">461,713<span></span>
</td>
<td class="nump">984,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">4,520<span></span>
</td>
<td class="num">(5,292)<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(179,414)<span></span>
</td>
<td class="nump">879,521<span></span>
</td>
<td class="nump">566,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of year</a></td>
<td class="nump">1,528,259<span></span>
</td>
<td class="nump">648,738<span></span>
</td>
<td class="nump">82,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">1,348,845<span></span>
</td>
<td class="nump">1,528,259<span></span>
</td>
<td class="nump">648,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled', window );">Sale of common stock under the Sales Agreement not settled at year-end</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">17,665<span></span>
</td>
<td class="nump">10,338<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset', window );">Right-of-use assets from new lease agreements</a></td>
<td class="nump">91,855<span></span>
</td>
<td class="nump">179,210<span></span>
</td>
<td class="nump">247,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash interest payments, net of amounts capitalized</a></td>
<td class="nump">18,035<span></span>
</td>
<td class="nump">19,428<span></span>
</td>
<td class="nump">13,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 17,980<span></span>
</td>
<td class="nump">$ 12,606<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NetProceedsFromTheExerciseOfStockBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From The Exercise Of Stock-Based Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NetProceedsFromTheExerciseOfStockBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_OperatingAndFinanceLeaseWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and Finance Lease, Write-off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_OperatingAndFinanceLeaseWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from issuance or sale of equity not settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProvisionForExcessAndObsoleteInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Excess And Obsolete Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProvisionForExcessAndObsoleteInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592937200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text">Organization<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The Company&#8217;s COVID-19 vaccine NVX-CoV2373 (&#8220;Nuvaxovid&#8482;,&#8221; &#8220;Covovax&#8482;,&#8221; &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221;); influenza vaccine candidate; COVID-19-Influenza Combination (&#8220;CIC&#8221;) vaccine candidate; and additional vaccine candidates, including for Omicron subvariants and bivalent formulations with prototype vaccine (&#8220;NVX-CoV2373&#8221;), are genetically engineered nanostructures of conformationally correct recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or other vaccine approaches. NVX-CoV2373 and the Company&#8217;s other vaccine candidates incorporate the Company's proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response. The Company has announced data from its ongoing PREVENT-19 study supporting the use of NVX-CoV2373 for homologous boosting in adults and adolescents aged 12 through 17. Additional findings in Phase 3 COVID-19 Omicron (study 311) trial showed utility of the prototype vaccine as a heterologous booster, inducing broad immune responses against contemporary Omicron variants.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for NVX-CoV2373 for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commenced commercial shipments of NVX-CoV2373 doses under the name &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221; and the brand name &#8220;Nuvaxovid&#8482;&#8221; in 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442593049232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. At December 31, 2022, the Company had $1.3 billion in cash and cash equivalents and restricted cash, of which $236.2 million was raised in December 2022 through concurrent sales of common stock and issuance of the Company&#8217;s convertible senior unsecured notes that will mature on December 15, 2027 (see Notes 11 and 13). On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on the Company&#8217;s convertible senior unsecured notes that matured on&#160;February&#160;1, 2023. During 2022, the Company incurred a net loss of $657.9 million and had net cash flows used in operating activities of $415.9&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company&#8217;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration. The Company&#8217;s 2023 revenue depends on its ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. In February 2023, in connection with the execution of Modification 17 to the USG Agreement (as defined in Note 3), the U.S. government indicated to the Company that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as the Company&#8217;s management had previously expected, then the Company may not receive all of the remaining $416&#160;million in funding that was previously anticipated pursuant to the USG Agreement. On January 24, 2023, Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;) filed a demand for arbitration with the International Court of Arbitration regarding an alleged material breach by the Company of the Company&#8217;s advance purchase agreement with Gavi (&#8220;the Gavi APA&#8221;). The outcome of that arbitration is inherently uncertain, and it is possible the Company could be required to refund all or a portion of the remaining advance payments of $697.4&#160;million (see Note 3 and Note 18). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the significance of these uncertainties, substantial doubt exists regarding the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to fund Company operations is dependent upon revenue related to vaccine sales for its products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters, including whether, when, and how the dispute with Gavi is resolved; and management&#8217;s plans, which include resolving the dispute with Gavi and may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of NVX-CoV2373 and the Company&#8217;s other vaccine candidates, including an influenza vaccine candidate, CIC vaccine candidate, or a COVID-19 variant strain-containing monovalent or bivalent formulation, remains uncertain. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, revenue recognition, inventory, research and development expenses, stock-based compensation, useful lives of long-lived assets, leases, and income taxes. Actual results could differ materially from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), or are contributions subject to the guidance in ASC Topic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities &#8211; Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 958-605&#8221;). The Company recognizes revenue from arrangements within the scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are associated with the Company&#8217;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of NVX-CoV2373.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of NVX-CoV2373 to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#8220;EAC&#8221;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#8217;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#8217;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other funding agreements currently include funding from CEPI in the form of a grant (&#8220;CEPI Grant Funding&#8221;) and one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Under the Company&#8217;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of NVX-CoV2373. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#8217;s Gavi APA prior to its termination), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 730&#8221;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#8217;s policy of presenting such amounts as revenue. In reaching this determination, the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#8217;s core operations. The Company will record revenue as it performs the contractual research and development services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#8217;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#8220;Inventory.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#8220;CROs&#8221;), CMOs, and contract development and manufacturing organizations (&#8220;CDMOs&#8221;); and other expenses associated with the Company&#8217;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#8217;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The Company had advertising costs of $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock awards (&#8220;RSUs&#8221;), and purchases under the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcx_287a37ee-2b5f-45a2-a262-d63f80394c20">one</span> to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#8217;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements. As of December&#160;31, 2022 and 2021, the restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. The Company evaluates outstanding receivables to assess collectability, with consideration given to economic conditions, the aging of receivables, and customer-specific risks.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#8217;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenue<br/>&#160;for Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Accounts Receivable as of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gavi, the Vaccine Alliance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SK bioscience, Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Amounts represent less than 10%</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and Department of Defense.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently depends exclusively on a single supplier for co-formulation, filling, and finishing NVX-CoV2373. The loss of this supplier could prevent or delay the Company&#8217;s delivery of customer orders.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred. The estimated useful lives of property and equipment are described below:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#8217;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#8217;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#8220;ROU&#8221;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#8217;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#8220;short-term&#8221; leases), the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#8217;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company calculates the estimated fair value of a long-lived asset or asset group using the income approach. Impairment losses are recognized when the sum of expected future cash flows is less than the asset&#8217;s or asset group&#8217;s carrying value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development of recombinant vaccines, it operates as a single operating segment and has one reporting unit. The Company primarily utilizes the market approach and, if considered necessary, the income approach to determine if it has an impairment of its goodwill. The market approach is based on market value of invested capital. To ensure that the Company&#8217;s capital stock is the appropriate measurement of fair value, the Company considers factors such as its trading volume, diversity of investors, and analyst coverage. If considered necessary, the income approach is used to corroborate the results of the market approach. Goodwill impairment may exist if the carrying value of the reporting unit exceeds its estimated fair value. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#8217;s goodwill over its implied fair value, should such a circumstance arise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October 1, 2022 and 2021, the fair value of the Company&#8217;s single reporting unit was substantially higher than its carrying value, resulting in no impairment to goodwill as of October 1, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company recognized $4.3 million and $29.2 million, respectively, primarily in income tax expense related to foreign withholding tax on royalties. During the year ended December&#160;31, 2020, the Company recognized no income tax expense.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period, primarily convertible notes, stock options, SARs, and unvested RSUs. As of December&#160;31, 2022, the Company's 2027 Notes and 2023 Notes (see Note 11) would have been convertible into approximately 16.4 million shares of the Company's common stock assuming the common stock price is equal to or greater than $12.50 and $136.20, respectively. These shares, after giving effect to the add back of interest expense and unamortized discounts and debt issuance costs on the Notes and any shares due to the Company upon settlement of its capped call transactions, are excluded from the computation, as their effect is antidilutive under the if-converted method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#8217;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income (loss) was $(6.4) million and $(1.4) million at December&#160;31, 2022 and 2021, respectively. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were $(2.5)&#160;million, $(5.3)&#160;million, and $9.6&#160;million for the years ended December&#160;31, 2022, 2021, and 2020 respectively, which are reflected in Other income (expense).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business as one operating segment: the development of recombinant vaccines. The Company does not operate separate lines of business with respect to its vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management has evaluated the effect of the guidance and its implementation will not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#8217;s consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592800128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract', window );"><strong>Grants, U.S. Government Contract and Joint Venture [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable included $53.8 million and $419.7 million related to amounts that were billed to customers and $28.6 million and $35.3 million related to amounts which had not yet been billed to customers as of December&#160;31, 2022 and 2021, respectively. During the years ended December&#160;31, 2022 and 2021, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,432,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,239,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092,829)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended December&#160;31, 2022 and there was no bad debt expense in the years ended December&#160;31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Amount is comprised of $0.4&#160;billion, $1.4&#160;billion, and $0.3&#160;billion current Deferred revenue and $179.4&#160;million, $172.5&#160;million, and no non-current Deferred revenue as of December&#160;31, 2022, 2021, and 2020 respectively.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Deductions from Deferred revenue include the following: $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) at issue in the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below. In the fourth quarter of 2022, the Company recognized revenue of $41.9&#160;million related to a change in estimate attributed to changes in constraint of variable consideration.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $3&#160;billion as of December&#160;31, 2022, which excludes amounts related to the Company&#8217;s APA (&#8220;the Gavi APA&#8221;) with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;) and the reduction in doses related to the Amended and Restated UK Supply Agreement, as defined below. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 vaccine under certain of the Company&#8217;s APAs. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than one year.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gavi APA and a separate purchase agreement between Gavi and Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;), 1.1 billion doses of NVX-CoV2373 were to be made available to countries participating in the COVAX Facility. The Company expected to manufacture and distribute 350&#160;million doses of NVX-CoV2373 to countries participating under the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the balance of the 1.1 billion doses of NVX-CoV2373 for low- and middle-income countries participating in the COVAX Facility. The Company expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under the Company's funding agreement with CEPI, with initial doses supplied by SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under a supply agreement. The Company expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, the Company could provide additional doses of NVX-CoV2373, to the extent available from CEPI funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, the Company received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in the first quarter of 2022 related to the Company&#8217;s achieving EUL for NVX-CoV2373 by the WHO (the &#8220;Advance Payment Amount&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#8217;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that it could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. Under the terms of the APA, the Company agreed to manufacture the vaccine in facilities located in the European Union and ensure continued efficacy of the vaccine against variants of the SARS-CoV-2 virus. Pursuant to the terms of the APA, the Company is prohibited from supplying NVX-CoV2373 to any third party if such delivery would impede or limit the fulfillment of the Company&#8217;s obligations to the European Commission under the APA, except with respect to the Company&#8217;s obligations under the Gavi APA. In 2022, the Company was notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, the Company finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022 and are expected to be delivered in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373 and made an </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment to the Company. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#8220;Conditional Doses&#8221;) of NVX-CoV2373, with the number of Conditional Doses contingent on, and subject to reduction based on, the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority does not purchase the Conditional Doses or the number of such Conditional Doses is reduced below 15&#160;million doses of NVX-CoV2373, the Company would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not yet made a supportive recommendation with respect to NVX-CoV2373, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, the Company&#8217;s timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation of the Company to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement, which is reflected in Other current liabilities, with the remaining upfront payment balance of $112.5&#160;million reflected in current Deferred revenue.</span></div><div style="margin-bottom:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Government</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a Project Agreement (the &#8220;Project Agreement&#8221;) with Advanced Technology International, Inc. (&#8220;ATI&#8221;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed. Operation Warp Speed was a partnership among components of the U.S. Department of Health and Human Services and the U.S. Department of Defense working to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The Project Agreement relates to the Base Agreement the Company entered into with ATI in June 2020 (the &#8220;Base Agreement,&#8221; together with the Project Agreement, the &#8220;USG Agreement&#8221;). The original USG Agreement required the Company to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of NVX-CoV2373, and to manufacture and deliver to the U.S. government 100&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to the Company for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the U.S. government&#8217;s interest. If the Project Agreement is terminated prior to completion, the Company is entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. In July 2022, the Company entered into a modification to the USG Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373 and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100&#160;million doses of NVX-CoV2373 contemplated by the original USG Agreement (inclusive of the initial batch of </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 3&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The 3&#160;million initial doses were delivered in July 2022. The performance period under the Project Agreement extends through 2023 to cover clinical trial activities, subject to early termination by the U.S. government or extension by mutual agreement of the parties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the USG Agreement, the Company was originally entitled to funding of up to $1.75&#160;billion to support certain activities related to the development of NVX-CoV2373 and the manufacture and delivery of the vaccine candidate to the U.S. government. In subsequent modifications, the Company's USG Agreement was amended to increase the contract funding and ceiling to $1.8&#160;billion, which allows the Company to make expenditures or incur obligations of up to $1.8&#160;billion for support of the USG Agreement. As of December&#160;31, 2022, the Company had recognized $1.4&#160;billion in revenue related to the USG Agreement since the inception of the contract, leaving $0.4&#160;billion remaining to spend.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Department of Defense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a letter contract that was later amended in January 2021 (the &#8220;DoD Contract&#8221;) with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (&#8220;JPEO-CRBND-EB&#8221;), under which JPEO-CRBND-EB agreed to provide funding of up to $45.7&#160;million to the Company to support the manufacture of NVX-CoV2373. The Company is authorized to make expenditures or incur obligations up to the full amount of the funding.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the DoD Contract, the Company originally expected to deliver 10&#160;million doses of NVX-CoV2373 to the DoD. The 10&#160;million doses of NVX-CoV2373 could be used in Phase 2/3 clinical trials or under an EUA, if approved by the FDA. Pursuant to the DoD Contract, after NVX-CoV2373 is approved by the FDA, the DoD is entitled to most-favored customer status for a period of five years from the award of the DoD Contract, meaning that the Company cannot give any comparable commercial client in the United States more favorable pricing than the DoD under similar transactional circumstances. In July 2022, the Company modified its existing agreement with the DoD and delivered 0.2&#160;million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining 9.8&#160;million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding. The term of the DoD Contract expired in December 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into a restated funding agreement which was amended in November 2020 with CEPI, under which CEPI agreed to provide funding of up to $399.5&#160;million to the Company to support the development of NVX-CoV2373. The agreement provides up to $257.0&#160;million in CEPI Grant Funding and up to $142.5&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans in order to prepay certain manufacturing activities and are not subject to restrictive or financial covenants. As of December&#160;31, 2022 and 2021, the Company had recognized total revenue related to CEPI of $358.6&#160;million, with the unused amounts primarily related to CEPI Forgivable Loan Funding. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the CMO network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#8217;s Gavi APA prior to its termination), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, the Company recognized $9.0&#160;million and $178.6&#160;million, respectively, in revenue related to sales-based royalties, which is reflected in Royalties and other revenue. For the years ended December&#160;31, 2022 and 2020, the Company recognized $20.0&#160;million upon the sale of NVX-CoV2373 in Japan and $20.0&#160;million related to a development milestone payment, respectively.</span></div>Collaboration and License Agreements<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serum Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company's Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#8217;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company granted to SIIPL (i) an exclusive license in India during the agreement and (ii) a non-exclusive license (a) during the &#8220;Pandemic Period&#8221; (as declared by the WHO) in all countries other than specified countries designated by the World Bank as upper-middle or high-income countries, with respect to which the Company retains rights, and (b) after the Pandemic Period, in only those countries designated as low or middle-income by the World Bank. Following the Pandemic Period, the Company may notify SIIPL of any bona fide opportunities for the Company to license NVX-CoV2373 to a third party in such low and middle-income countries and SIIPL would have an opportunity to match or improve such third-party terms, failing which, the Company would have the discretion to remove one or more non-exclusive countries from SIIPL&#8217;s license. The Company also has a supply agreement with SIIPL and SLS under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. In May and August 2022, the Company expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s), its quadrivalent influenza vaccine candidate, and its CIC vaccine candidate, so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, a quadrivalent influenza vaccine, and CIC vaccine, and supply such vaccines to the Company. In March 2020, the Company granted SIIPL a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21, a malaria candidate developed by the Jenner Institute, University of Oxford.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of NVX-CoV2373. In February 2023, MHLW cancelled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the years ended December&#160;31, 2022 and 2020, the Company recognized $20.0&#160;million upon the sale of NVX-CoV2373 in Japan and $20.0&#160;million related to a development and commercial milestone payment, respectively, which are included in Royalties and other revenue on the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SK bioscience, Co., Ltd.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of South Korea, Thailand, and Vietnam. SK bioscience finalized an APA with the Korean government to supply 40&#160;million doses of NVX-CoV2373 to the Republic of Korea beginning in 2021. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. The companies also signed an agreement to manufacture and supply NVX-CoV2373 in a prefilled syringe.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Fujifilm Settlement Agreement&#8221;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#8220;Fujifilm CSA&#8221;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#8220;Fujifilm MSA&#8221;) by and between the Company and Fujifilm. The Fujifilm MSA </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Fujifilm CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to NVX-CoV2373 under the associated statements of work.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Fujifilm Settlement Agreement, the Company is responsible for payment of up to $185.0&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT under the Fujifilm CSA, of which (i) $47.8&#160;million, constituting the initial reservation fee under the Fujifilm CSA, was credited against the Settlement Payment on September 30, 2022 and (ii) the remaining balance is to be paid in four equal quarterly installments of $34.3&#160;million each beginning March 31, 2023. As of December&#160;31, 2022, the remaining payment of $137.2&#160;million was reflected in Accrued expenses. Under the Fujifilm Settlement Agreement, Fujifilm is required to use commercially reasonable efforts to mitigate the losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the Fujifilm CSA, and the final two quarterly installments will be mitigated by any replacement revenue achieved by Fujifilm between July 1, 2023 and December 31, 2023. The Settlement Payment is less than amounts previously recognized as embedded lease expense and reflected in Research and development expense from FDBT manufacturing activity under the Fujifilm CSA prior to the Fujifilm Settlement Agreement and accordingly, during the year ended December&#160;31, 2022, the Company recorded a benefit of $98.3&#160;million as Research and development expense (see Note 10).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except with respect to certain limited activities agreed upon by the parties, the Fujifilm MSA terminated with respect to all activities in FDBU and FDBT on October 21, 2022 and the impact of the termination was determined in accordance with the provisions of the Fujifilm MSA. The terms and conditions of the Fujifilm MSA and Fujifilm CSA will remain in full force and effect with respect to the ongoing activities at FDBK. In addition, the Company and Fujifilm mutually released all claims relating to (i) the cancellation of batches to be manufactured at FDBT under the Fujifilm MSA or Fujifilm CSA, (ii) FDBT facility idle time in 2022, (iii) failure to complete product performance qualification testing of batches manufactured by Fujifilm by December 2021, and (iv) any obligation by Fujifilm to reserve capacity or manufacture batches at FDBT for the benefit of the Company under the Fujifilm MSA or Fujifilm CSA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and, as a result, significant costs may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_GrantsUSGovernmentContractAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592803360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Revenue<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable included $53.8 million and $419.7 million related to amounts that were billed to customers and $28.6 million and $35.3 million related to amounts which had not yet been billed to customers as of December&#160;31, 2022 and 2021, respectively. During the years ended December&#160;31, 2022 and 2021, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,432,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,239,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092,829)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended December&#160;31, 2022 and there was no bad debt expense in the years ended December&#160;31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Amount is comprised of $0.4&#160;billion, $1.4&#160;billion, and $0.3&#160;billion current Deferred revenue and $179.4&#160;million, $172.5&#160;million, and no non-current Deferred revenue as of December&#160;31, 2022, 2021, and 2020 respectively.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Deductions from Deferred revenue include the following: $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) at issue in the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below. In the fourth quarter of 2022, the Company recognized revenue of $41.9&#160;million related to a change in estimate attributed to changes in constraint of variable consideration.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $3&#160;billion as of December&#160;31, 2022, which excludes amounts related to the Company&#8217;s APA (&#8220;the Gavi APA&#8221;) with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;) and the reduction in doses related to the Amended and Restated UK Supply Agreement, as defined below. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 vaccine under certain of the Company&#8217;s APAs. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than one year.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gavi APA and a separate purchase agreement between Gavi and Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;), 1.1 billion doses of NVX-CoV2373 were to be made available to countries participating in the COVAX Facility. The Company expected to manufacture and distribute 350&#160;million doses of NVX-CoV2373 to countries participating under the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the balance of the 1.1 billion doses of NVX-CoV2373 for low- and middle-income countries participating in the COVAX Facility. The Company expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under the Company's funding agreement with CEPI, with initial doses supplied by SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under a supply agreement. The Company expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, the Company could provide additional doses of NVX-CoV2373, to the extent available from CEPI funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, the Company received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in the first quarter of 2022 related to the Company&#8217;s achieving EUL for NVX-CoV2373 by the WHO (the &#8220;Advance Payment Amount&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#8217;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that it could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. Under the terms of the APA, the Company agreed to manufacture the vaccine in facilities located in the European Union and ensure continued efficacy of the vaccine against variants of the SARS-CoV-2 virus. Pursuant to the terms of the APA, the Company is prohibited from supplying NVX-CoV2373 to any third party if such delivery would impede or limit the fulfillment of the Company&#8217;s obligations to the European Commission under the APA, except with respect to the Company&#8217;s obligations under the Gavi APA. In 2022, the Company was notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, the Company finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022 and are expected to be delivered in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373 and made an </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment to the Company. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#8220;Conditional Doses&#8221;) of NVX-CoV2373, with the number of Conditional Doses contingent on, and subject to reduction based on, the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority does not purchase the Conditional Doses or the number of such Conditional Doses is reduced below 15&#160;million doses of NVX-CoV2373, the Company would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not yet made a supportive recommendation with respect to NVX-CoV2373, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, the Company&#8217;s timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation of the Company to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement, which is reflected in Other current liabilities, with the remaining upfront payment balance of $112.5&#160;million reflected in current Deferred revenue.</span></div><div style="margin-bottom:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Government</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a Project Agreement (the &#8220;Project Agreement&#8221;) with Advanced Technology International, Inc. (&#8220;ATI&#8221;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed. Operation Warp Speed was a partnership among components of the U.S. Department of Health and Human Services and the U.S. Department of Defense working to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The Project Agreement relates to the Base Agreement the Company entered into with ATI in June 2020 (the &#8220;Base Agreement,&#8221; together with the Project Agreement, the &#8220;USG Agreement&#8221;). The original USG Agreement required the Company to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of NVX-CoV2373, and to manufacture and deliver to the U.S. government 100&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to the Company for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the U.S. government&#8217;s interest. If the Project Agreement is terminated prior to completion, the Company is entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. In July 2022, the Company entered into a modification to the USG Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373 and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100&#160;million doses of NVX-CoV2373 contemplated by the original USG Agreement (inclusive of the initial batch of </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 3&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The 3&#160;million initial doses were delivered in July 2022. The performance period under the Project Agreement extends through 2023 to cover clinical trial activities, subject to early termination by the U.S. government or extension by mutual agreement of the parties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the USG Agreement, the Company was originally entitled to funding of up to $1.75&#160;billion to support certain activities related to the development of NVX-CoV2373 and the manufacture and delivery of the vaccine candidate to the U.S. government. In subsequent modifications, the Company's USG Agreement was amended to increase the contract funding and ceiling to $1.8&#160;billion, which allows the Company to make expenditures or incur obligations of up to $1.8&#160;billion for support of the USG Agreement. As of December&#160;31, 2022, the Company had recognized $1.4&#160;billion in revenue related to the USG Agreement since the inception of the contract, leaving $0.4&#160;billion remaining to spend.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Department of Defense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a letter contract that was later amended in January 2021 (the &#8220;DoD Contract&#8221;) with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (&#8220;JPEO-CRBND-EB&#8221;), under which JPEO-CRBND-EB agreed to provide funding of up to $45.7&#160;million to the Company to support the manufacture of NVX-CoV2373. The Company is authorized to make expenditures or incur obligations up to the full amount of the funding.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the DoD Contract, the Company originally expected to deliver 10&#160;million doses of NVX-CoV2373 to the DoD. The 10&#160;million doses of NVX-CoV2373 could be used in Phase 2/3 clinical trials or under an EUA, if approved by the FDA. Pursuant to the DoD Contract, after NVX-CoV2373 is approved by the FDA, the DoD is entitled to most-favored customer status for a period of five years from the award of the DoD Contract, meaning that the Company cannot give any comparable commercial client in the United States more favorable pricing than the DoD under similar transactional circumstances. In July 2022, the Company modified its existing agreement with the DoD and delivered 0.2&#160;million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining 9.8&#160;million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding. The term of the DoD Contract expired in December 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into a restated funding agreement which was amended in November 2020 with CEPI, under which CEPI agreed to provide funding of up to $399.5&#160;million to the Company to support the development of NVX-CoV2373. The agreement provides up to $257.0&#160;million in CEPI Grant Funding and up to $142.5&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans in order to prepay certain manufacturing activities and are not subject to restrictive or financial covenants. As of December&#160;31, 2022 and 2021, the Company had recognized total revenue related to CEPI of $358.6&#160;million, with the unused amounts primarily related to CEPI Forgivable Loan Funding. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the CMO network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#8217;s Gavi APA prior to its termination), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, the Company recognized $9.0&#160;million and $178.6&#160;million, respectively, in revenue related to sales-based royalties, which is reflected in Royalties and other revenue. For the years ended December&#160;31, 2022 and 2020, the Company recognized $20.0&#160;million upon the sale of NVX-CoV2373 in Japan and $20.0&#160;million related to a development milestone payment, respectively.</span></div>Collaboration and License Agreements<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serum Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company's Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#8217;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company granted to SIIPL (i) an exclusive license in India during the agreement and (ii) a non-exclusive license (a) during the &#8220;Pandemic Period&#8221; (as declared by the WHO) in all countries other than specified countries designated by the World Bank as upper-middle or high-income countries, with respect to which the Company retains rights, and (b) after the Pandemic Period, in only those countries designated as low or middle-income by the World Bank. Following the Pandemic Period, the Company may notify SIIPL of any bona fide opportunities for the Company to license NVX-CoV2373 to a third party in such low and middle-income countries and SIIPL would have an opportunity to match or improve such third-party terms, failing which, the Company would have the discretion to remove one or more non-exclusive countries from SIIPL&#8217;s license. The Company also has a supply agreement with SIIPL and SLS under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. In May and August 2022, the Company expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s), its quadrivalent influenza vaccine candidate, and its CIC vaccine candidate, so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, a quadrivalent influenza vaccine, and CIC vaccine, and supply such vaccines to the Company. In March 2020, the Company granted SIIPL a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21, a malaria candidate developed by the Jenner Institute, University of Oxford.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of NVX-CoV2373. In February 2023, MHLW cancelled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the years ended December&#160;31, 2022 and 2020, the Company recognized $20.0&#160;million upon the sale of NVX-CoV2373 in Japan and $20.0&#160;million related to a development and commercial milestone payment, respectively, which are included in Royalties and other revenue on the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SK bioscience, Co., Ltd.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of South Korea, Thailand, and Vietnam. SK bioscience finalized an APA with the Korean government to supply 40&#160;million doses of NVX-CoV2373 to the Republic of Korea beginning in 2021. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. The companies also signed an agreement to manufacture and supply NVX-CoV2373 in a prefilled syringe.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Fujifilm Settlement Agreement&#8221;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#8220;Fujifilm CSA&#8221;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#8220;Fujifilm MSA&#8221;) by and between the Company and Fujifilm. The Fujifilm MSA </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Fujifilm CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to NVX-CoV2373 under the associated statements of work.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Fujifilm Settlement Agreement, the Company is responsible for payment of up to $185.0&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT under the Fujifilm CSA, of which (i) $47.8&#160;million, constituting the initial reservation fee under the Fujifilm CSA, was credited against the Settlement Payment on September 30, 2022 and (ii) the remaining balance is to be paid in four equal quarterly installments of $34.3&#160;million each beginning March 31, 2023. As of December&#160;31, 2022, the remaining payment of $137.2&#160;million was reflected in Accrued expenses. Under the Fujifilm Settlement Agreement, Fujifilm is required to use commercially reasonable efforts to mitigate the losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the Fujifilm CSA, and the final two quarterly installments will be mitigated by any replacement revenue achieved by Fujifilm between July 1, 2023 and December 31, 2023. The Settlement Payment is less than amounts previously recognized as embedded lease expense and reflected in Research and development expense from FDBT manufacturing activity under the Fujifilm CSA prior to the Fujifilm Settlement Agreement and accordingly, during the year ended December&#160;31, 2022, the Company recorded a benefit of $98.3&#160;million as Research and development expense (see Note 10).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except with respect to certain limited activities agreed upon by the parties, the Fujifilm MSA terminated with respect to all activities in FDBU and FDBT on October 21, 2022 and the impact of the termination was determined in accordance with the provisions of the Fujifilm MSA. The terms and conditions of the Fujifilm MSA and Fujifilm CSA will remain in full force and effect with respect to the ongoing activities at FDBK. In addition, the Company and Fujifilm mutually released all claims relating to (i) the cancellation of batches to be manufactured at FDBT under the Fujifilm MSA or Fujifilm CSA, (ii) FDBT facility idle time in 2022, (iii) failure to complete product performance qualification testing of batches manufactured by Fujifilm by December 2021, and (iv) any obligation by Fujifilm to reserve capacity or manufacture batches at FDBT for the benefit of the Company under the Fujifilm MSA or Fujifilm CSA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and, as a result, significant costs may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592830816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, and Restricted Cash<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2022 and 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442593023376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the estimated fair value of the Company&#8217;s financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as Cash and cash equivalents as of December&#160;31, 2022 and 2021, on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#8217;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics.&#160;Pricing of the Company&#8217;s convertible notes has been estimated using observable inputs, including the price of the Company&#8217;s common stock, implied volatility, interest rates, and credit spreads.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company did not have any transfers between Levels.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount in the Company&#8217;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592994976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,683&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of Cost of sales in the consolidated statements of operations. For the year ended December&#160;31, 2022, inventory write-downs were $447.6&#160;million and losses on firm purchase commitments were $155.9&#160;million. There were no inventory write-downs or losses on firm purchase commitments during 2021 or 2020. Inventory </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reserves for write-downs are relieved when the inventory is disposed of through scrap or sale. Activity in the reserve for excess and obsolete inventory was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Cost of sales, including impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other additions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592803360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amounts of goodwill was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592880128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Novavax CZ<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisition of Novavax CZ</a></td>
<td class="text">Acquisition of Novavax CZ<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 27, 2020 (the &#8220;Acquisition Date&#8221;), the Company entered into a Share Purchase Agreement (the &#8220;Deed&#8221;) by and among Novavax AB, the Company&#8217;s wholly-owned Swedish subsidiary (the &#8220;Buyer&#8221;), and De Bilt Holdings B.V., Poonawalla Science Park B.V., and Bilthoven Biologicals B.V. and, solely as guarantors, each of Serum International B.V. and the Company. Pursuant to the terms and conditions of the Deed, the Buyer acquired all the issued and outstanding shares of Novavax CZ (formerly, Praha Vaccines a.s.), a vaccine manufacturing company (the &#8220;Acquisition&#8221;). The assets of Novavax CZ acquired as part of the Acquisition include a biologics manufacturing facility and associated assets in Bohumil, Czech Republic and will be used by the Company to expand its manufacturing capacity.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allocation of Purchase Price to Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has accounted for the Acquisition as a business combination using the acquisition method of accounting, with the Company as the acquirer. The acquisition method requires the Company to record the assets acquired and liabilities assumed at fair value. The amount by which the purchase price exceeds the fair value of net assets acquired is recorded as goodwill. The Company completed the appraisal process necessary to assess the fair values of the assets acquired and liabilities assumed to determine the amount of goodwill to be recognized as of the Acquisition Date. The final determination of the fair value of all assets and liabilities was completed in 2020 and is presented in the table below.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes the final allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">May 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(813)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchase price, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">165,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the assets acquired and liabilities assumed was determined using market and cost valuation methodologies. The fair value measurements were based on significant unobservable inputs that were developed by the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company using publicly available information, market participant assumptions, and cost and development assumptions. Because of the use of significant unobservable inputs, the fair value measurements represent a Level 3 measurement as defined in ASC 820. The market approach is a valuation technique that uses prices and other relevant information generated by market transactions involving identical or comparable assets, liabilities, or a group of assets or liabilities. The cost approach estimates value by determining the current cost of replacing an asset with another of equivalent utility. The cost to replace a given asset reflects the estimated reproduction or replacement cost for the property, less an allowance for loss in value due to depreciation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost approach was the primary approach used to value fixed assets, including the real property. Fixed assets are depreciated on a straight-line basis over their expected remaining useful lives, ranging from four years to 25 years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded $70.7&#160;million in goodwill related to the Acquisition representing the purchase price that was in excess of the fair value of the assets acquired and liabilities assumed. The goodwill generated from the Acquisition is not expected to be deductible for U.S. federal income tax purposes. The goodwill recognized is attributable to intangible assets that do not qualify for separate recognition, such as the assembled workforce of Novavax CZ.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current assets and current liabilities were recorded at their contractual or historical acquisition amounts, which approximate their fair value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impact to Financial Results for the Year Ended December 31, 2020</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of operations from Novavax CZ have been included in the consolidated financial statements since the Acquisition Date. As a result, the consolidated financial results for the year ended December 31, 2020 does not reflect a full twelve months of Novavax CZ results. From the Acquisition Date through December 31, 2020, Novavax CZ did not recognize any revenue and recorded a net loss from operations of $11.3&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company incurred approximately $2.7&#160;million of costs related to the Acquisition in the year ended December 31, 2020, which are included within general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supplemental Pro Forma Financial Information (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unaudited pro forma financial information below gives effect to the Acquisition as if it had occurred as of January 1, 2019. The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved had the Acquisition been consummated as of that time. The unaudited pro forma financial information combines the historical results of operations of the Company and Novavax CZ and reflects the application of certain pro forma adjustments (in thousands, except per share amounts):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">475,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pro forma adjustments include the recognition of depreciation expense based on the Acquisition Date fair value and remaining useful lives of Novavax CZ fixed assets (net of historical depreciation expense) and the elimination of costs related to the Acquisition, which are non-recurring in nature.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592823856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CDMOs to manufacture NVX-CoV2373, as well as operating leases for its research and development and manufacturing facilities, corporate headquarters and offices, and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2022, the Company recognized ROU assets and a corresponding long-term operating lease liability on the remeasurement of modified supply agreements. During the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2021, for leases that were previously determined to represent short-term embedded leases, modifications did not result in a change in lease classification.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, of $18.6&#160;million and $144.4&#160;million, respectively, for its finance leases and long-term operating leases embedded in CMO and CDMO manufacturing supply agreements. The Company expensed the ROU assets since they related to research and development activities for the development of NVX-CoV2373 for which the Company did not have an alternative future use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company entered into and extended various facility lease agreements related to research and development facilities and office space. During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease that have not been recognized in the ROU asset. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December&#160;31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes had occurred. As of December 31, 2022 and 2021, the Company had incurred $49.0&#160;million and $36.4&#160;million, respectively, related to tenant improvement costs to be recognized as a ROU asset. The Company anticipates that it will incur additional tenant improvement costs, net of a landlord contribution of $9.8&#160;million, through 2023 to bring the remainder of the building to the condition necessary for its intended use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, facility leases, excluding the 700QO lease, have expirations that range from approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDE_cc59319b-f346-4179-ace9-8b072a6d76f3">three</span> to nine years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,384</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,123</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,857</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,241</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,123</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,867</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,983</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,196</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,533</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,516</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,116</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,238</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,116</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,386&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CDMOs to manufacture NVX-CoV2373, as well as operating leases for its research and development and manufacturing facilities, corporate headquarters and offices, and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2022, the Company recognized ROU assets and a corresponding long-term operating lease liability on the remeasurement of modified supply agreements. During the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2021, for leases that were previously determined to represent short-term embedded leases, modifications did not result in a change in lease classification.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, of $18.6&#160;million and $144.4&#160;million, respectively, for its finance leases and long-term operating leases embedded in CMO and CDMO manufacturing supply agreements. The Company expensed the ROU assets since they related to research and development activities for the development of NVX-CoV2373 for which the Company did not have an alternative future use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company entered into and extended various facility lease agreements related to research and development facilities and office space. During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease that have not been recognized in the ROU asset. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December&#160;31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes had occurred. As of December 31, 2022 and 2021, the Company had incurred $49.0&#160;million and $36.4&#160;million, respectively, related to tenant improvement costs to be recognized as a ROU asset. The Company anticipates that it will incur additional tenant improvement costs, net of a landlord contribution of $9.8&#160;million, through 2023 to bring the remainder of the building to the condition necessary for its intended use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, facility leases, excluding the 700QO lease, have expirations that range from approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDE_cc59319b-f346-4179-ace9-8b072a6d76f3">three</span> to nine years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,384</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,123</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,857</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,241</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,123</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,867</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,983</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,196</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,533</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,516</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,116</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,238</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,116</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,386&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592819728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current convertible notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2027 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company issued $175.3 million aggregate principal amount of convertible senior unsecured notes that will mature on December 15, 2027 (the &#8220;2027 Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2027 Notes were issued in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and pursuant to an indenture dated December 20, 2022 (the &#8220;2027 Indenture&#8221;) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Concurrently with the issuance of the 2027 Notes, the Company completed a public offering of shares of its common stock (see Note 13). The Company received $166.4 million in net proceeds from the issuance of the 2027 Notes after deducting the initial purchasers&#8217; fees and the Company&#8217;s offering expenses. The 2027 Notes bear cash interest at a rate of 5.00% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding September 15, 2027, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2027 Notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2027 Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate for the 2027 Notes on each such trading day; (3) if the Company calls such 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2027 Notes called (or deemed called) for redemption; and (4) upon the occurrence of specified corporate events as set forth in the 2027 Indenture. On or after September 15, 2027, until the close of business on the business day immediately preceding the maturity date (December 15, 2027), holders of the 2027 Notes may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing conditions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of the Company&#8217;s common stock, or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s election, in the manner and subject to the terms and conditions provided in the 2027 Indenture.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion rate for the 2027 Notes will initially be 80.0000 shares of the Company&#8217;s common stock per $1,000 principal amount of 2027 Notes, which is equivalent to an initial conversion price of $12.50 per share of common stock. The initial conversion price of the 2027 Notes represents a conversion premium of 25% of the public offering price in the Company&#8217;s concurrent common stock offering that closed on December 20, 2022 (see Note 13). The conversion rate for the 2027 Notes is subject to adjustment under certain circumstances in accordance with the terms of the 2027 Indenture. In addition, following certain corporate events that occur prior to the maturity date of the 2027 Notes or if the Company delivers a notice of redemption in respect of the 2027 Notes, the Company will, under certain circumstances, increase the conversion rate of the 2027 Notes for a holder who elects to convert its 2027 Notes (or any portion thereof) in connection with such a corporate event or convert its 2027 Notes called (or deemed called) for redemption during the related redemption period (as defined in the 2027 Indenture), as the case may be.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes prior to December 22, 2025. The Company may redeem for cash all or any portion of the 2027 Notes, at its option, on or after December 22, 2025, if the last reported sale price of the common stock has been at least 130% of the conversion price for the 2027 Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, to, but excluding, the redemption date. If the Company redeems less than all the outstanding 2027 Notes, at least $50&#160;million aggregate principal amount of 2027 Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for the 2027 Notes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a Fundamental Change (as defined in the 2027 Indenture), holders may require, subject to certain conditions and exceptions as set forth in the 2027 Indenture, the Company to repurchase for cash all or any portion of their 2027 Notes at a Fundamental Change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the Fundamental Change repurchase date. If a holder of the 2027 Notes converted upon a Make-Whole Fundamental Change (as described in the 2027 Indenture), they may be eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 20.0000 shares per $1,000 principal amount of 2027 Notes (subject to other adjustments as described in the 2027 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the 2027 Notes, the Company determined that the scope exceptions provided under ASC 815-40,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 815-40&#8221;) apply to all but one of the conversion features embedded in the 2027 Notes. This remaining conversion feature, which is associated with a Fundamental Change of the Company, was determined to have a de minimis value as of December 31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchasers&#8217; fees and the Company&#8217;s issuance costs related to the 2027 Notes totaled $8.8 million, which were recorded as a reduction to the 2027 Notes on the consolidated balance sheet. The $8.8 million of debt issuance costs is being amortized and recognized as additional interest expense over the five-year contractual term of the 2027 Notes using an effective interest rate of 6.2%.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company issued $325 million&#160;aggregate principal amount of convertible senior unsecured notes that matured on&#160;February&#160;1, 2023&#160;(the &#8220;2023 Notes&#8221;).&#160;The 2023 Notes were senior unsecured debt obligations and were issued at par. The Company repaid the outstanding principal amount of $325 million together with accrued but unpaid interest on the maturity date. The repayment was funded by the issuance of the 2027 Notes and the concurrent common stock offering, as well as cash on hand.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes were issued pursuant to an indenture dated January&#160;29, 2016 (the &#8220;2023 Indenture&#8221;) between the Company and the trustee.&#160;The Company received $315.0 million in net proceeds from the offering after deducting underwriting fees and offering expenses. The 2023 Notes bore cash interest at a rate of 3.75%, payable on&#160;February&#160;1&#160;and&#160;August&#160;1&#160;of each year. The 2023 Notes were not redeemable prior to maturity and were convertible into shares of&#160;the Company&#8217;s&#160;common stock. As a result of the Company&#8217;s one-for-twenty reverse stock split in 2019 and pursuant to Section&#160;14.04(a)&#160;of the 2023 Indenture, the 2023 Notes were initially convertible into approximately 2,385,800 shares of the Company&#8217;s common stock based on the initial conversion rate of 7.3411 shares of the Company&#8217;s common stock per&#160;$1,000&#160;principal amount of the 2023 Notes. This represents an initial conversion price of approximately $136.20&#160;per share of the Company&#8217;s common stock,&#160;representing an approximate 22.5% conversion premium based on the last reported sale price of the Company&#8217;s common stock of $111.20 per share on January&#160;25, 2016. In addition, the holders of the 2023 Notes may have required the Company to repurchase the 2023 </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes at par value plus accrued and unpaid interest following the occurrence of a Fundamental Change (as described in the 2023 Indenture). If a holder of the 2023 Notes converted upon a Make-Whole Adjustment Event (as described in the 2023 Indenture), they may have been eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 8.9928 shares per $1,000 principal amount of 2023 Notes (subject to other adjustments as described in the 2023 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes are accounted for in accordance with ASC 470-20,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 470-20&#8221;) and ASC 815-40.&#160;Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded) the instrument (or embedded feature) must be both (1)&#160;indexed to the issuer&#8217;s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company&#8217;s analysis, it was determined the 2023 Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20,&#160;the proceeds received from the issuance of the convertible debt were recorded as a liability on the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes,&#160;the Company&#160;also paid $38.5 million, including expenses, to enter into privately negotiated capped call transactions with certain financial institutions (the &#8220;capped call transactions&#8221;). The capped call transactions expired by their terms on January 27, 2023. The capped call transactions were generally expected to reduce the potential dilution upon conversion of the 2023 Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, was greater than the strike price of the capped call transactions, which initially corresponded to the conversion price of the 2023 Notes, and was subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2023 Notes. The cap price of the capped call transactions was initially $194.60 per share, which represented a premium of approximately 75% based on the last reported sale price of the Company&#8217;s common stock of $111.20 per share on January&#160;25, 2016, and was subject to certain adjustments under the terms of the capped call transactions. If, however, the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, exceeded the cap price, there would nevertheless have been dilution upon conversion of the 2023 Notes to the extent that such market price exceeded the cap price. The Company evaluated the capped call transactions under ASC 815-10,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8211; Overall</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and determined that they should be accounted for as a separate transaction and that the capped call transactions would be classified as an equity instrument.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $10.0 million of debt issuance costs in 2016 relating to the issuance of the 2023 Notes, which were recorded as a reduction to the 2023 Notes on the consolidated balance sheet. The $10.0 million of debt issuance costs was amortized and recognized as additional interest expense over the seven-year contractual term of the 2023 Notes on a straight-line basis, which approximated the effective interest rate method. The Company also incurred $0.9 million of expenses related to the capped call transactions, which were recorded as a reduction to additional paid-in-capital.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592732864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text">Preferred StockIn June 2020, the Company entered into a redeemable Series A Convertible Preferred Stock Subscription Agreement, pursuant to which the Company agreed to issue and sell in a private placement 438,885 shares of its newly designated redeemable Series A Convertible Preferred Stock, par value $0.01 per share (&#8220;Preferred Stock&#8221;), at a purchase price of $455.70 per share, for total gross proceeds of $200.0&#160;million. During the fourth quarter of 2020, all outstanding shares of Preferred Stock were converted and the Company issued 4,388,850 shares of common stock, par value $0.01 per share, and reclassified $199.8 million from Preferred stock to Additional paid-in capital. The Company recognized a beneficial conversion feature of approximately $24.1 million at the time of issuance of the Preferred Stock that was recorded in Additional paid-in capital and Accumulated deficit as the Preferred Stock issuance was contingently redeemable and convertible at any time at the option of the holder.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592204704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; EquityIn December 2022, the Company completed a public offering of 7,475,000 shares of its common stock, including 975,000 shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $10.00 per share resulting in net proceeds, net of offering costs of $4.9 million, of approximately $70 million. The Company completed this public offering concurrent with the issuance of the 2027 Notes (see Note 11).In June 2021, the Company entered into an At Market Issuance Sales Agreement (the "June 2021 Sales Agreement"), which allows it to issue and sell up to $500&#160;million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales Agreement. As of December&#160;31, 2022, the remaining balance available under the June 2021 Sales Agreement was approximately $318&#160;million. During the years ended December&#160;31, 2022, 2021, and 2020, the Company sold 2.2 million, 2.6 million, and 32.4 million, respectively, of shares of its common stock resulting in net proceeds of approximately $179&#160;million, $565&#160;million, and $877&#160;million, respectively, under its various At Market Issuance Sales Agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592859520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to 14.8 million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of 2.4 million shares approved for issuance under the 2015 Plan at the Company&#8217;s 2022 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;4, 2025. As of December&#160;31, 2022, there were 3.8 million shares available for issuance under the 2015 Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, SARs, and RSUs. In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of 10 years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company&#8217;s common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTc0_7315172c-cfb4-43c1-b403-98d1230d238a">one</span> to four years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation capitalized and included in inventory as of December&#160;31, 2022 was $1.7 million. There was no stock-based compensation capitalized and included in inventory as of December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $171 million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of 1.1 years and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option and SARs holders exercised their stock options and SARs on December&#160;31, 2022. This amount is subject to change based on changes to the closing price of the Company&#8217;s common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the years ending December&#160;31, 2022, 2021, and 2020 was $21.4 million, $453.8 million, and $187.3 million, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2005 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,951)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,892,161&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2015 Plan was estimated at the date of grant or the date upon which the 2015 Plan was approved by the Company&#8217;s stockholders for certain stock options granted in 2020 and 2019 using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average Black-Scholes fair value of stock<br/>options and SARs granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$55.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$158.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80.48</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%-1.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-1.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-140.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7%-142.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0%-152.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-7.6</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2015 Plan and 2005 Plan as of December&#160;31, 2022 was approximately $3 million and 7.1 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2015 Plan and 2005 Plan as of December&#160;31, 2022 was approximately $2 million and 6.6 years, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the year ended December&#160;31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505,009)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of 1.1 million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase 5% on each anniversary of its adoption up to a maximum of 1.65 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). At December&#160;31, 2022, there were 0.7 million shares available for issuance under the ESPP.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of Black-Scholes fair values of ESPP<br/>shares granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23.59-$79.74</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$83.47-$238.85</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.57-$92.67</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%-3.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%-0.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-2.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0%-142.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9%-159.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6%-189.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592929888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract', window );"><strong>Payment for Pension and Other Postretirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text">Employee Benefits<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution 401(k)&#160;retirement plan, pursuant to which employees may elect to contribute up to 100% of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code of 1986, as amended. The Company matches 100% of the first 3% of the participants&#8217; deferral, and 50% on the next 2% of the participants&#8217; deferral, up to a potential 4% Company match. The Company&#8217;s matching contributions to the 401(k)&#160;plan vest immediately. Under its 401(k)&#160;plan, the Company has recorded expense of $6.0 million, $3.4 million, and $0.9 million in 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries have pension plans under local tax and labor laws and are obligated to make contributions to the plan. Contributions and other expenses related to this plan were $2.4 million, $1.7 million, and $1.0 million in 2022, 2021, and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592865632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">251,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, approximately $170.0 million and $164.0&#160;million, respectively, of net assets used in operations were located in the Czech Republic. Depreciation expense was approximately $29.1 million, $12.5 million, and $4.3 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits and compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">577,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">673,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds to customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liability related to Gavi (see Note 3 and Note 18)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442596728096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income (loss) from operations before income tax provision (benefit) by jurisdiction for the years ended December&#160;31 are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(712,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,633,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(455,253)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(653,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,714,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(418,259)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the current income tax provision (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, the Company recognized $4.3&#160;million, $29.2&#160;million, and no federal, state, and foreign current income tax expense. The foreign income tax expense is primarily related to foreign withholding tax on royalties. The Company recognized no deferred income tax expense during the years listed above due to a full valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the provision for income tax to the amount computed by applying the U.S. federal statutory tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has available federal, state, and foreign net operating losses of $2.0&#160;billion, $0.9&#160;billion, and $29.1&#160;million, respectively, that may be applied against future taxable income in the respective jurisdiction. The federal net operating losses of $2.0&#160;billion can be carried forward indefinitely, although limited to 80% of annual taxable income. State net operating losses of $0.4&#160;billion have various expiration dates between 2028 and 2042. The remaining state net operating losses of $0.5&#160;billion can be carried forward indefinitely. Approximately $15.1&#160;million of the foreign net operating losses will begin to expire in 2024 through 2027. The remaining $14.0&#160;million of foreign net operating losses can be carried forward indefinitely. The Company also has research tax credits of $46.0&#160;million that will begin to expire in 2030 through 2052. Utilization of the domestic net operating loss carryforwards and research tax credits may be subject to an annual limitation due to potential ownership changes of the Company. As of December&#160;31, 2022, the Company does not expect such limitation, if any, to impact the use of these domestic net operating losses and research tax credits.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and in various states, as well as in foreign jurisdictions such as Sweden and the Czech Republic. The Company has U.S. federal and state net operating losses and credit carryforwards that are subject to examination from 2002 through 2022. The returns in Sweden are subject to examination from 2016 through 2022 and the returns for the Czech Republic are subject to examination from 2019 through 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">479,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">845,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Original discount interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,056,799&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,027,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,020,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,015,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,983&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,676)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,983)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realization of its deferred tax assets, including its history of significant losses in every year since inception and, in accordance with U.S GAAP, has fully reserved the net deferred tax asset. The Company concluded that realization of its net deferred tax assets is not more-likely-than-not to be realized as of December&#160;31, 2022 and 2021. The valuation allowance increased by $4.8 million and $510.5 million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets, weighing positive and negative evidence to assess the recoverability. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including its cumulative losses over the three years ended December&#160;31, 2022 and the substantial doubt about the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued, and positive evidence, including its regulatory authorizations for and commercial sales of NVX-CoV2373. After assessing both the negative and positive evidence, the Company concluded that it should maintain the valuation allowance on its net operating losses, credits, and its other deferred tax assets as of December&#160;31, 2022. The release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, the Company's level of profitability, revenue growth, clinical program progression, and expectations regarding future profitability. The Company's total net deferred tax asset balance subject to the valuation allowance was $1.1&#160;billion and $1.0&#160;billion as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of an income tax position when it is more likely than not, based on the technical merits, that the income tax position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2022, 2021, and 2020 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions for tax positions of prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2022 and 2021, the Company had no accruals for interest or penalties related to income tax matters. The total amount of unrecognized tax benefits that, if recognized, could affect the effective tax rate was $5.2 million and $11.2&#160;million as of December&#160;31, 2022 and 2021, respectively. However, the Company maintains a full valuation allowance as of December&#160;31, 2022 and 2021 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact. As of December&#160;31, 2022, the Company does not expect a significant change in the recorded unrecognized tax benefits reserve balance during the next twelve months. The unrecognized tax benefits are presented in the financial statements as a reduction to the deferred tax assets for all periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592872928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitment and Contingencies<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sothinathan Sinnathurai v. Novavax, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the NVX-CoV2373&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Sinnathurai Action was filed, seven derivative lawsuits were filed: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Robert E. Meyer v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shui Shing Yung v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">William Kirst, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:22-cv-00024-TDC (the &#8220;Kirst Action&#8221;), (iv) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amy Snyder v. Stanley C. Erck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charles R. Blackburn, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diego J. Mesa v. Stanley C. Erck, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Mesa Action&#8221;), and (vii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sean Acosta v. Stanley C. Erck, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Acosta Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. On December 6, 2022, the parties to the Kirst Action filed a stipulated schedule pursuant to which the plaintiffs were expected to file an amended complaint on December 22, 2022, and either (i) the parties would file a stipulated stay of the Kirst Action or (ii) the defendants would file a motion to stay the case by January 23, 2023. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On February 24, 2023, the Court entered an order staying the Kirst Action until a final judgment in the Second Consolidated Derivative Action. The Company takes no position on whether the broader stay entered by the Court in the Kirst Action is likely to be modified to align with the parties&#8217; stipulation.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, the court entered an order granting the parties&#8217; request to set a briefing schedule in connection with a motion to stay that defendants intended to file. Pursuant to the order, defendants filed a motion to stay on January 18, 2023. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted Defendants&#8217; motion to stay.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta action. The financial impact of this claim, as well as the claims discussed above, is not estimable.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2021, a Company stockholder named Thomas Golubinski filed a derivative complaint against members of the Company&#8217;s board of directors and members of senior management in the Delaware Court, captioned Thomas Golubinski v. Richard H. Douglas, et al., No. 2021-0172-JRS. The Company is deemed a nominal defendant. Golubinski challenged equity awards made in April 2020 and in June 2020 on the ground that they were &#8220;spring-loaded,&#8221; that is, made at a time when such board members or members of senior management allegedly possessed undisclosed positive material information concerning the Company. The complaint asserted claims for breach of fiduciary duty, waste, and unjust enrichment. The plaintiff sought an award of damages to the Company, an order rescinding both awards or requiring disgorgement, and an award of attorneys&#8217; fees incurred in connection with the litigation. On May 10, 2021, the defendants moved to dismiss the complaint in its entirety. On June 17, 2021, the Company&#8217;s stockholders voted FOR ratification of the April 2020 awards and ratification of the June 2020 awards. Details of the ratification proposals are set forth in the Company&#8217;s Definitive Proxy Statement filed on May 3, 2021. The results of the vote were disclosed in the Company&#8217;s Current Report on Form 8-K filed on June 24, 2021. Thereafter, the plaintiff stipulated that, as a result of the outcome of the June 17, 2021 vote, the plaintiff no longer intends to pursue the lawsuit or any claim arising from the April 2020 and June 2020 awards. On August 23, 2021, the plaintiff filed a motion seeking an award of attorneys&#8217; fees and expenses for $1.5&#160;million, to which the defendants filed an opposition. On October 18, 2022, the Delaware Court denied the plaintiff&#8217;s fee application in its entirety. Under a prior Delaware Court order, the case was automatically dismissed with prejudice upon denial of the plaintiff&#8217;s fee application. On November 14, 2022, Golubinski filed a Notice of Appeal in the Supreme Court of the State of Delaware. The plaintiff / appellant filed his opening appellate brief on December 30, 2022. The Company filed its responsive brief on January 30, 2023 and the appellant filed his reply brief on February 14, 2023. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2022, Par Sterile Products, LLC (&#8220;Par&#8221;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (the &#8220;Par MSA&#8221;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. The parties are engaged in discovery and arbitration is scheduled for July 2023. While the Company maintains that no breach of the Par MSA has occurred and intends to vigorously defend the matter, if the final resolution of the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matter is adverse to the Company, it could have a material impact on the Company&#8217;s financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December 31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#8217;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that the Company could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on the Company's financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements in the normal course of business with CMOs and CDMOs supplying the Company with production capabilities, and with vendors for preclinical studies, clinical trials, and other goods or services. A number of these arrangements are within the scope of lease accounting (see Note 10). Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Company is contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses. The exact amount of such obligations are dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. As of December&#160;31, 2022, most of these agreements were active ongoing arrangements and the Company expects to receive value from these arrangements in the future. The Company recognizes fees related to obligations for terminated contracts where such fees are reasonably estimable. The Company did not accrue obligations that were not reasonably estimable. As of December&#160;31, 2022, the Company had no non-cancelable purchase commitments with a remaining term of more than one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592803360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2023, the Board of Directors of the Company approved the appointment of John C. Jacobs, as President and Chief Executive Officer and a member of the Board, effective as of January 23, 2023. Mr. Jacobs succeeded Stanley C. Erck, who provided the Board with notice on January 5, 2023 of his decision to retire as President and Chief Executive Officer and as a member of the Board, in each case effective as of January 23, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on claims stemming from the Gavi APA. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that it could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi (see Note 3 and Note 18).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on the 2023 Notes, due February 1, 2023 and the indenture governing the 2023 Notes was subsequently satisfied and discharged in accordance with its terms. The Company&#8217;s related &#8220;capped call transactions&#8221; expired by their terms on January 27, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591945424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. At December 31, 2022, the Company had $1.3 billion in cash and cash equivalents and restricted cash, of which $236.2 million was raised in December 2022 through concurrent sales of common stock and issuance of the Company&#8217;s convertible senior unsecured notes that will mature on December 15, 2027 (see Notes 11 and 13). On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on the Company&#8217;s convertible senior unsecured notes that matured on&#160;February&#160;1, 2023. During 2022, the Company incurred a net loss of $657.9 million and had net cash flows used in operating activities of $415.9&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company&#8217;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration. The Company&#8217;s 2023 revenue depends on its ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. In February 2023, in connection with the execution of Modification 17 to the USG Agreement (as defined in Note 3), the U.S. government indicated to the Company that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as the Company&#8217;s management had previously expected, then the Company may not receive all of the remaining $416&#160;million in funding that was previously anticipated pursuant to the USG Agreement. On January 24, 2023, Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;) filed a demand for arbitration with the International Court of Arbitration regarding an alleged material breach by the Company of the Company&#8217;s advance purchase agreement with Gavi (&#8220;the Gavi APA&#8221;). The outcome of that arbitration is inherently uncertain, and it is possible the Company could be required to refund all or a portion of the remaining advance payments of $697.4&#160;million (see Note 3 and Note 18). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the significance of these uncertainties, substantial doubt exists regarding the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to fund Company operations is dependent upon revenue related to vaccine sales for its products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters, including whether, when, and how the dispute with Gavi is resolved; and management&#8217;s plans, which include resolving the dispute with Gavi and may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of NVX-CoV2373 and the Company&#8217;s other vaccine candidates, including an influenza vaccine candidate, CIC vaccine candidate, or a COVID-19 variant strain-containing monovalent or bivalent formulation, remains uncertain. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, revenue recognition, inventory, research and development expenses, stock-based compensation, useful lives of long-lived assets, leases, and income taxes. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), or are contributions subject to the guidance in ASC Topic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities &#8211; Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 958-605&#8221;). The Company recognizes revenue from arrangements within the scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are associated with the Company&#8217;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of NVX-CoV2373.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of NVX-CoV2373 to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#8220;EAC&#8221;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#8217;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#8217;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other funding agreements currently include funding from CEPI in the form of a grant (&#8220;CEPI Grant Funding&#8221;) and one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Under the Company&#8217;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of NVX-CoV2373. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#8217;s Gavi APA prior to its termination), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 730&#8221;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#8217;s policy of presenting such amounts as revenue. In reaching this determination, the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#8217;s core operations. The Company will record revenue as it performs the contractual research and development services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#8217;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#8220;Inventory.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#8220;CROs&#8221;), CMOs, and contract development and manufacturing organizations (&#8220;CDMOs&#8221;); and other expenses associated with the Company&#8217;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#8217;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The Company had advertising costs of $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock awards (&#8220;RSUs&#8221;), and purchases under the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcx_287a37ee-2b5f-45a2-a262-d63f80394c20">one</span> to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#8217;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashThe Company&#8217;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. The Company evaluates outstanding receivables to assess collectability, with consideration given to economic conditions, the aging of receivables, and customer-specific risks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#8217;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div>The Company currently depends exclusively on a single supplier for co-formulation, filling, and finishing NVX-CoV2373. The loss of this supplier could prevent or delay the Company&#8217;s delivery of customer orders.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases Accounting</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#8217;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#8217;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#8220;ROU&#8221;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#8217;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#8220;short-term&#8221; leases), the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#8217;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company calculates the estimated fair value of a long-lived asset or asset group using the income approach. Impairment losses are recognized when the sum of expected future cash flows is less than the asset&#8217;s or asset group&#8217;s carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development of recombinant vaccines, it operates as a single operating segment and has one reporting unit. The Company primarily utilizes the market approach and, if considered necessary, the income approach to determine if it has an impairment of its goodwill. The market approach is based on market value of invested capital. To ensure that the Company&#8217;s capital stock is the appropriate measurement of fair value, the Company considers factors such as its trading volume, diversity of investors, and analyst coverage. If considered necessary, the income approach is used to corroborate the results of the market approach. Goodwill impairment may exist if the carrying value of the reporting unit exceeds its estimated fair value. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#8217;s goodwill over its implied fair value, should such a circumstance arise.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance </span></div>in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per ShareBasic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period, primarily convertible notes, stock options, SARs, and unvested RSUs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Foreign CurrencyThe accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#8217;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business as one operating segment: the development of recombinant vaccines. The Company does not operate separate lines of business with respect to its vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management has evaluated the effect of the guidance and its implementation will not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#8217;s consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592813680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenue<br/>&#160;for Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Accounts Receivable as of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gavi, the Vaccine Alliance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SK bioscience, Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Amounts represent less than 10%</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and Department of Defense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">The estimated useful lives of property and equipment are described below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">251,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591438784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract', window );"><strong>Grants, U.S. Government Contract and Joint Venture [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock', window );">Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue</a></td>
<td class="text">During the years ended December&#160;31, 2022 and 2021, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,432,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,239,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092,829)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended December&#160;31, 2022 and there was no bad debt expense in the years ended December&#160;31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Amount is comprised of $0.4&#160;billion, $1.4&#160;billion, and $0.3&#160;billion current Deferred revenue and $179.4&#160;million, $172.5&#160;million, and no non-current Deferred revenue as of December&#160;31, 2022, 2021, and 2020 respectively.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Deductions from Deferred revenue include the following: $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) at issue in the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below. In the fourth quarter of 2022, the Company recognized revenue of $41.9&#160;million related to a change in estimate attributed to changes in constraint of variable consideration.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Product Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Grant Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_GrantsUSGovernmentContractAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592880128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2022 and 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592744960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the estimated fair value of the Company&#8217;s financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as Cash and cash equivalents as of December&#160;31, 2022 and 2021, on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591650928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,683&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfInventoryReserveTableTextBlock', window );">Schedule of Inventory Reserve</a></td>
<td class="text">Activity in the reserve for excess and obsolete inventory was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Cost of sales, including impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other additions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfInventoryReserveTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfInventoryReserveTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594126528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amounts of goodwill was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442597053792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Novavax CZ (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes the final allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">May 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(813)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchase price, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">165,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Business Acquisition, Pro Forma Information</a></td>
<td class="text">The unaudited pro forma financial information combines the historical results of operations of the Company and Novavax CZ and reflects the application of certain pro forma adjustments (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">475,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442588541264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,384</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,123</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,857</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,241</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,123</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,867</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,983</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,196</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,533</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,516</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,116</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,238</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,116</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock', window );">Schedule of Supplemental Cash Flow Information of Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,386&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of balance sheet information related to lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information of lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442588539744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Convertible Notes Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current convertible notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595124176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option and Appreciation Rights Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2005 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,951)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,892,161&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Estimation of Fair Value of Stock</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2015 Plan was estimated at the date of grant or the date upon which the 2015 Plan was approved by the Company&#8217;s stockholders for certain stock options granted in 2020 and 2019 using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average Black-Scholes fair value of stock<br/>options and SARs granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$55.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$158.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80.48</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%-1.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-1.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-140.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7%-142.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0%-152.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-7.6</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of Black-Scholes fair values of ESPP<br/>shares granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23.59-$79.74</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$83.47-$238.85</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.57-$92.67</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%-3.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%-0.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-2.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0%-142.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9%-159.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6%-189.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the year ended December&#160;31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505,009)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation, Restricted Stock Awards, Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442596647168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">The estimated useful lives of property and equipment are described below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">251,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits and compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">577,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">673,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following at December&#160;31 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds to customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liability related to Gavi (see Note 3 and Note 18)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594731840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income (loss) from operations before income tax provision (benefit) by jurisdiction for the years ended December&#160;31 are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(712,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,633,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(455,253)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(653,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,714,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(418,259)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Current Income Tax Provision (Benefit)</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the current income tax provision (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Tax Rate Differences</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the provision for income tax to the amount computed by applying the U.S. federal statutory tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">479,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">845,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Original discount interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,056,799&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,027,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,020,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,015,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,983&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,676)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,983)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text">A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2022, 2021, and 2020 is as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions for tax positions of prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587679904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348,845,000<span></span>
</td>
<td class="nump">$ 1,348,845,000<span></span>
</td>
<td class="nump">$ 1,528,259,000<span></span>
</td>
<td class="nump">$ 648,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(657,939,000)<span></span>
</td>
<td class="num">(1,743,751,000)<span></span>
</td>
<td class="num">(418,259,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415,937,000)<span></span>
</td>
<td class="nump">322,946,000<span></span>
</td>
<td class="num">(42,541,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000,000<span></span>
</td>
<td class="nump">819,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,000,000<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,292,000<span></span>
</td>
<td class="nump">29,215,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,400,000)<span></span>
</td>
<td class="num">(6,400,000)<span></span>
</td>
<td class="num">(1,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax', window );">Foreign currency transaction (losses) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,500,000)<span></span>
</td>
<td class="num">$ (5,300,000)<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,400,000<span></span>
</td>
<td class="nump">$ 697,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government Contract | USG Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining', window );">Research and development arrangement, contract to perform for others, contract remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,000,000<span></span>
</td>
<td class="nump">$ 416,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsFromIssuanceCommonStockAndDebt', window );">Sale of common stock and issuance debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued for debt converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued for debt converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.20<span></span>
</td>
<td class="nump">$ 136.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023 | Unsecured Debt | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProceedsFromIssuanceCommonStockAndDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance Common Stock and Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProceedsFromIssuanceCommonStockAndDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Contract Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442588414832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration Risk (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | European Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | Government of Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | Government of Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | CEPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | SK bioscience, Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | European Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | Government of Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | Gavi, the Vaccine Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_EuropeanCommissionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_EuropeanCommissionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_GovernmentOfAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_GovernmentOfAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_GovernmentOfCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_GovernmentOfCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_SKBioscienceCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_SKBioscienceCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_GovernmentOfIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_GovernmentOfIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_GaviVaccineAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_GaviVaccineAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595133904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442583911824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>dose</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>dose</div>
</th>
<th class="th">
<div>Nov. 18, 2022 </div>
<div>dose</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>dose</div>
</th>
<th class="th">
<div>Oct. 22, 2020 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed contracts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,800<span></span>
</td>
<td class="nump">$ 419,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled contracts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600<span></span>
</td>
<td class="nump">35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,551<span></span>
</td>
<td class="nump">1,595,472<span></span>
</td>
<td class="nump">$ 273,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,981,872<span></span>
</td>
<td class="nump">1,146,290<span></span>
</td>
<td class="nump">475,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember', window );">Sales-Based Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">178,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember', window );">Gavi Advance Purchase Agreement SIIPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Remaining performance obligation, variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember', window );">Joint Committee on Vaccination and Immunization (JCVI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption', window );">Additional purchase option, number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesCancelled', window );">Number of doses, cancelled | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidate', window );">Number of doses | dose</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember', window );">USG Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidate', window );">Number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling', window );">Research and development arrangement, contract ceiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember', window );">USG Agreement | Government Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenueFromContractWithCustomerCommitment', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining', window );">Research and development arrangement, contract to perform for others, contract remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_DoDContractMember', window );">DoD Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption', window );">Additional purchase option, number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidate', window );">Number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod', window );">Performance obligation, customer status, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_DoDContractMember', window );">DoD Contract | Government Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenueFromContractWithCustomerCommitment', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember', window );">Coalition for Epidemic Preparedness Innovations ("CEPI")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding', window );">Contract to perform for others funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant', window );">Contract to perform for others grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans', window );">Contract to perform for others forgivable no interest term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CEPIGrantFundingMember', window );">CEPI Grant Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenueFromContractWithCustomerCommitment', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,600<span></span>
</td>
<td class="nump">$ 358,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember', window );">Takeda Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation to be satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesOfVaccineCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses Of Vaccine Candidate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesOfVaccineCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses Of Vaccine Candidate, Additional Purchase Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number of Doses, Cancelled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfVaccineDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Vaccine Doses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfVaccineDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Contract Ceiling</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Contract Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement Contract To Perform For Others Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement Contract To Perform For Others Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RevenueFromContractWithCustomerCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RevenueFromContractWithCustomerCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Customer Status, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_DoDContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_DoDContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CEPIGrantFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CEPIGrantFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587052080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,993,000<span></span>
</td>
<td class="nump">$ 262,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768,457,000<span></span>
</td>
<td class="nump">2,432,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,127,240,000)<span></span>
</td>
<td class="num">(2,239,287,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, ending balance</a></td>
<td class="nump">$ 96,210,000<span></span>
</td>
<td class="nump">96,210,000<span></span>
</td>
<td class="nump">454,993,000<span></span>
</td>
<td class="nump">$ 262,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Allowance for doubtful accounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,835,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts, end balance</a></td>
<td class="num">(13,835,000)<span></span>
</td>
<td class="num">(13,835,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,595,472,000<span></span>
</td>
<td class="nump">273,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,908,000<span></span>
</td>
<td class="nump">1,598,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,092,829,000)<span></span>
</td>
<td class="num">(275,908,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">549,551,000<span></span>
</td>
<td class="nump">549,551,000<span></span>
</td>
<td class="nump">1,595,472,000<span></span>
</td>
<td class="nump">273,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,835,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">370,137,000<span></span>
</td>
<td class="nump">370,137,000<span></span>
</td>
<td class="nump">1,422,944,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">179,414,000<span></span>
</td>
<td class="nump">179,414,000<span></span>
</td>
<td class="nump">172,528,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">549,551,000<span></span>
</td>
<td class="nump">549,551,000<span></span>
</td>
<td class="nump">$ 1,595,472,000<span></span>
</td>
<td class="nump">$ 273,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="nump">819,000,000<span></span>
</td>
<td class="nump">819,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount', window );">Revenue, performance obligation satisfied at previous quarter</a></td>
<td class="nump">41,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nvax_RevenueMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">273,800,000<span></span>
</td>
<td class="nump">273,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">273,800,000<span></span>
</td>
<td class="nump">273,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="nump">697,400,000<span></span>
</td>
<td class="nump">697,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember', window );">Joint Committee on Vaccination and Immunization (JCVI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">112,500,000<span></span>
</td>
<td class="nump">112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">112,500,000<span></span>
</td>
<td class="nump">112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="nump">$ 112,500,000<span></span>
</td>
<td class="nump">$ 112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableAllowanceForCreditLossAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableAllowanceForCreditLossDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableAllowanceForCreditLossDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredRevenueIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredRevenueIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation Satisfied at Point in Time, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nvax_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nvax_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594982704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Product Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,981,872<span></span>
</td>
<td class="nump">$ 1,146,290<span></span>
</td>
<td class="nump">$ 475,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,554,961<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">194,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">823,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 536,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nvax_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nvax_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587294272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Grant Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,981,872<span></span>
</td>
<td class="nump">$ 1,146,290<span></span>
</td>
<td class="nump">$ 475,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">382,921<span></span>
</td>
<td class="nump">948,709<span></span>
</td>
<td class="nump">453,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | USG Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">380,996<span></span>
</td>
<td class="nump">788,953<span></span>
</td>
<td class="nump">204,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | U.S. DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">21,683<span></span>
</td>
<td class="nump">12,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | CEPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">135,445<span></span>
</td>
<td class="nump">223,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | Other grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,628<span></span>
</td>
<td class="nump">$ 12,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USDepartmentOfDefenseDoDContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USDepartmentOfDefenseDoDContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_OtherGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_OtherGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587214032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>dose</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,235,278<span></span>
</td>
<td class="nump">$ 2,534,508<span></span>
</td>
<td class="nump">$ 747,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember', window );">Takeda Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment recognized</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SKBioscienceAgreementMember', window );">SK Bioscience Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementInitialReservationFee', window );">Initial reservation fee</a></td>
<td class="nump">$ 47,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfQuarterlyInstallmentPayments', window );">Number of quarterly installment payments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementQuarterlyInstallmentAmount', window );">Settlement agreement, quarterly installment amount</a></td>
<td class="nump">$ 34,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">98,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="nump">$ 137,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfQuarterlyInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Quarterly Installment Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfQuarterlyInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementAgreementInitialReservationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Agreement, Initial Reservation Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementAgreementInitialReservationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementAgreementQuarterlyInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Agreement, Quarterly Installment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementAgreementQuarterlyInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SKBioscienceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SKBioscienceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442597088560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,336,883<span></span>
</td>
<td class="nump">$ 1,515,116<span></span>
</td>
<td class="nump">$ 553,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash current</a></td>
<td class="nump">10,303<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
<td class="nump">93,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash non-current</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 1,348,845<span></span>
</td>
<td class="nump">$ 1,528,259<span></span>
</td>
<td class="nump">$ 648,738<span></span>
</td>
<td class="nump">$ 82,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594449952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 398,834<span></span>
</td>
<td class="nump">$ 361,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | 3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">398,834<span></span>
</td>
<td class="nump">361,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">400,536<span></span>
</td>
<td class="nump">1,056,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">494,900<span></span>
</td>
<td class="nump">447,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | 3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">322,111<span></span>
</td>
<td class="nump">447,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">172,789<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">296,000<span></span>
</td>
<td class="nump">266,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">790,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">104,536<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | 3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591943088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 13,912<span></span>
</td>
<td class="nump">$ 8,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Semi-finished goods</a></td>
<td class="nump">21,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 36,683<span></span>
</td>
<td class="nump">$ 8,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587892496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveChargedToCostsOfSales', window );">Inventory write-down</a></td>
<td class="nump">$ 447,597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Firm purchase commitment loss</a></td>
<td class="nump">155,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventory</a></td>
<td class="num">$ (79,214,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveChargedToCostsOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve, Charged to Costs of sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveChargedToCostsOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4578-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587182432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory Reserves (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveRollForward', window );"><strong>Inventory Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Balance at January 1, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveChargedToCostsOfSales', window );">Charged to Cost of sales, including impairments</a></td>
<td class="nump">447,597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveOtherAdditions', window );">Other additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Deductions</a></td>
<td class="num">(79,214,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 368,383,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveChargedToCostsOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve, Charged to Costs of sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveChargedToCostsOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveOtherAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve, Other Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveOtherAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442592152176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 131,479<span></span>
</td>
<td class="nump">$ 135,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(5,148)<span></span>
</td>
<td class="num">(3,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 126,331<span></span>
</td>
<td class="nump">$ 131,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595063824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Novavax CZ - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 126,331<span></span>
</td>
<td class="nump">$ 131,479<span></span>
</td>
<td class="nump">$ 135,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember', window );">Novavax CZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(813)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Purchase price, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587165968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Novavax CZ - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,379<span></span>
</td>
<td class="nump">$ 126,331<span></span>
</td>
<td class="nump">$ 131,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember', window );">Novavax CZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 70,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Loss on acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business combination, acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember', window );">Novavax CZ | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember', window );">Novavax CZ | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nvax_NovavaxCZFormerlyPrahaVaccinesASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595100816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Novavax CZ - Schedule of Business Acquisition, Pro Forma Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue | $</a></td>
<td class="nump">$ 475,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (419,896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Basic net loss per share (in usd per share) | $ / shares</a></td>
<td class="num">$ (7.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Diluted net loss per share (in usd per share) | $ / shares</a></td>
<td class="num">$ (7.04)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442583850368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,384<span></span>
</td>
<td class="nump">$ 40,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_CMOAndCMDAgreementsMember', window );">CMO and CMD Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability', window );">Lease liability and right of use assets recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
<td class="nump">144,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_A700QuinceOrchardRoadAgreementMember', window );">700 Quince Orchard Road Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_FacilityNumberOfSquareFeet', window );">Facility, number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Payments for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 36,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_A700QuinceOrchardRoadAgreementMember', window );">700 Quince Orchard Road Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Payments for tenant improvements</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember', window );">Facility Lease Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember', window );">Facility Lease Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_FacilityNumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_FacilityNumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nvax_CMOAndCMDAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nvax_CMOAndCMDAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nvax_A700QuinceOrchardRoadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nvax_A700QuinceOrchardRoadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595073056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets, operating, net</a></td>
<td class="nump">$ 36,384<span></span>
</td>
<td class="nump">$ 40,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Total non-current ROU assets<span></span>
</td>
<td class="text">Total non-current ROU assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">ROU assets, finance, net</a></td>
<td class="nump">$ 69,857<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total non-current ROU assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseRightOfUseAsset', window );">Total non-current ROU assets</a></td>
<td class="nump">$ 106,241<span></span>
</td>
<td class="nump">40,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">$ 16,867<span></span>
</td>
<td class="nump">$ 30,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">$ 27,196<span></span>
</td>
<td class="nump">$ 130,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseLiabilityCurrent', window );">Total current lease liabilities</a></td>
<td class="nump">44,063<span></span>
</td>
<td class="nump">161,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">$ 50,085<span></span>
</td>
<td class="nump">$ 39,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of finance lease liabilities</a></td>
<td class="nump">$ 31,238<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">$ 81,323<span></span>
</td>
<td class="nump">$ 39,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (years):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587327232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 6,903<span></span>
</td>
<td class="nump">$ 37,027<span></span>
</td>
<td class="nump">$ 2,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">94,726<span></span>
</td>
<td class="nump">468,210<span></span>
</td>
<td class="nump">66,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">6,836<span></span>
</td>
<td class="nump">116,435<span></span>
</td>
<td class="nump">4,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">ROU assets expensed</a></td>
<td class="nump">7,759<span></span>
</td>
<td class="nump">112,528<span></span>
</td>
<td class="nump">242,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">7,241<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease expense</a></td>
<td class="nump">$ 9,231<span></span>
</td>
<td class="nump">$ 119,769<span></span>
</td>
<td class="nump">$ 245,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587826512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Cash Flow Information of Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="nump">$ 190,158<span></span>
</td>
<td class="nump">$ 203,991<span></span>
</td>
<td class="nump">$ 63,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows used in finance leases</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">7,241<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows used in finance leases</a></td>
<td class="nump">93,595<span></span>
</td>
<td class="nump">127,907<span></span>
</td>
<td class="nump">96,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">30,675<span></span>
</td>
<td class="nump">66,682<span></span>
</td>
<td class="nump">5,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">ROU assets obtained in exchange for finance lease obligations</a></td>
<td class="nump">$ 73,240<span></span>
</td>
<td class="nump">$ 112,528<span></span>
</td>
<td class="nump">$ 242,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Operating and Financing Activities Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587393392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 47,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">24,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">10,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">10,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">10,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">46,562<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">149,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(24,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total current lease liabilities</a></td>
<td class="nump">$ 125,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587418272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">$ (119)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="nump">324,881<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(8,784)<span></span>
</td>
<td class="num">(1,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Total non-current convertible notes payable</a></td>
<td class="nump">166,466<span></span>
</td>
<td class="nump">323,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DebtInstrumentFaceAmountCurrent', window );">Debt Instrument, Face Amount, Current</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 175,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConvertibleNotesPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConvertibleNotesPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConvertibleNotesPayableNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes Payable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConvertibleNotesPayableNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DebtInstrumentFaceAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DebtInstrumentFaceAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594723056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Coupon interest</a></td>
<td class="nump">$ 12,542<span></span>
</td>
<td class="nump">$ 12,188<span></span>
</td>
<td class="nump">$ 12,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense on convertible notes payable</a></td>
<td class="nump">$ 14,039<span></span>
</td>
<td class="nump">$ 13,612<span></span>
</td>
<td class="nump">$ 13,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442584582784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">2023 Notes | Call Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConversionPremiumPercentage', window );">Conversion premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PaymentForCappedCallTransactions', window );">Payment for capped call transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DebtCapPrice', window );">Debt cap price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,250,000<span></span>
</td>
<td class="nump">$ 175,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Net proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConversionPremiumPercentage', window );">Conversion premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage', window );">Repurchase percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued for debt converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of principal amount redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes, Make-Whole Fundamental Change | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Net proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0073411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.20<span></span>
</td>
<td class="nump">$ 136.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConversionPremiumPercentage', window );">Conversion premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued for debt converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="nump">2,385,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2023 Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2023 Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0089928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConversionPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the rate of premium based on the last reported sales price of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConversionPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConvertibleDebtConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible debt conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConvertibleDebtConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DebtCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a debt . A payment or receipt is triggered if the market rate exceeds the cap rate on the debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DebtCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Of Principal Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PaymentForCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment which is made for entering into privately negotiated capped call transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PaymentForCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442583807120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued (in usd per share)</a></td>
<td class="nump">$ 455.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from sale of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Reclassification from preferred stock to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">438,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from sale of preferred stock</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (shares issued)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options and employee stock purchase plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442583827584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,230<span></span>
</td>
<td class="nump">$ 564,859<span></span>
</td>
<td class="nump">$ 878,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,672,398<span></span>
</td>
<td class="nump">2,578,967<span></span>
</td>
<td class="nump">32,393,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="nump">7,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_UnderwriterMember', window );">Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember', window );">June 2021 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShelfRegistrationStatementRemainingUnissuedCapital', window );">Shelf registration statement remaining unissued capital</a></td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember', window );">June 2021 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">32,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="nump">$ 565,000<span></span>
</td>
<td class="nump">$ 877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShelfRegistrationStatementRemainingUnissuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement Remaining Unissued Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShelfRegistrationStatementRemainingUnissuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442583853120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options and stock appreciation rights exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="nump">453,800,000<span></span>
</td>
<td class="nump">$ 187,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock options and stock appreciation rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term of stock options and stock appreciation rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock options and stock appreciation rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term of stock options and stock appreciation rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Proposal to increase authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease', window );">Percentage increase of shares each anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_MaximumContributionOfEmployeesAsPayrollDeductions', window );">Maximum contribution of employees as payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PercentageOfMarketPriceForStockPurchase', window );">Percentage of market price for stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Proposal to increase authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, terms of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent', window );">Minimum grant price, percent of common stock fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_MaximumContributionOfEmployeesAsPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum contribution of employees as payroll deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_MaximumContributionOfEmployeesAsPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PercentageOfMarketPriceForStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of market price for stock purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PercentageOfMarketPriceForStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594690128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 130,300<span></span>
</td>
<td class="nump">$ 183,626<span></span>
</td>
<td class="nump">$ 128,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">66,565<span></span>
</td>
<td class="nump">86,928<span></span>
</td>
<td class="nump">55,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 62,703<span></span>
</td>
<td class="nump">$ 96,698<span></span>
</td>
<td class="nump">$ 72,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594404224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">3,635,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">633,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(134,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(81,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">4,053,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at end of year (in shares) | shares</a></td>
<td class="nump">2,892,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 42.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">65.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">15.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">90.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">46.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 39.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember', window );">2005 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">68,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">63,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at end of year (in shares) | shares</a></td>
<td class="nump">63,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 109.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">31.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">121.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">112.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 112.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587249376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Black-Scholes fair value (in usd per share)</a></td>
<td class="nump">$ 55.32<span></span>
</td>
<td class="nump">$ 158.02<span></span>
</td>
<td class="nump">$ 80.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">120.50%<span></span>
</td>
<td class="nump">124.70%<span></span>
</td>
<td class="nump">116.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">140.10%<span></span>
</td>
<td class="nump">142.00%<span></span>
</td>
<td class="nump">152.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">103.00%<span></span>
</td>
<td class="nump">114.90%<span></span>
</td>
<td class="nump">66.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">142.90%<span></span>
</td>
<td class="nump">159.40%<span></span>
</td>
<td class="nump">189.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Black-Scholes fair value (in usd per share)</a></td>
<td class="nump">$ 23.59<span></span>
</td>
<td class="nump">$ 83.47<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Black-Scholes fair value (in usd per share)</a></td>
<td class="nump">$ 79.74<span></span>
</td>
<td class="nump">$ 238.85<span></span>
</td>
<td class="nump">$ 92.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442583902688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested beginning of year (in shares) | shares</a></td>
<td class="nump">819,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">1,882,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="num">(505,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="num">(163,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at end of year (in shares) | shares</a></td>
<td class="nump">2,034,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Per Share Weighted-Average Grant-Date Fair Value (in usd per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at beginning of year (in shares) | $ / shares</a></td>
<td class="nump">$ 116.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in usd per share) | $ / shares</a></td>
<td class="nump">48.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in usd per share) | $ / shares</a></td>
<td class="nump">89.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">99.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at end of year (in shares) | $ / shares</a></td>
<td class="nump">$ 61.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442588391936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution, percentage of compensation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percent of match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan | Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_FirstThreePercentOfParticipantsDeferralMemberMember', window );">First Three Percent Of Participants Deferral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percent of match</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_NextTwoPercentOfParticipantsDeferralMemberMember', window );">Next Two Percent Of Participants Deferral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percent of match</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_FirstThreePercentOfParticipantsDeferralMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollectiveBargainingArrangementAxis=nvax_FirstThreePercentOfParticipantsDeferralMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_NextTwoPercentOfParticipantsDeferralMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollectiveBargainingArrangementAxis=nvax_NextTwoPercentOfParticipantsDeferralMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587299920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Prepaid expenses</a></td>
<td class="nump">$ 160,773<span></span>
</td>
<td class="nump">$ 120,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">76,374<span></span>
</td>
<td class="nump">44,619<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 237,147<span></span>
</td>
<td class="nump">$ 164,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587864240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 341,539<span></span>
</td>
<td class="nump">$ 251,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(47,292)<span></span>
</td>
<td class="num">(25,799)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">294,247<span></span>
</td>
<td class="nump">225,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">101,342<span></span>
</td>
<td class="nump">83,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">134,809<span></span>
</td>
<td class="nump">119,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">18,895<span></span>
</td>
<td class="nump">10,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nvax_ComputerSoftwareAndHardwareMemberMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">4,927<span></span>
</td>
<td class="nump">2,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 81,566<span></span>
</td>
<td class="nump">$ 35,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nvax_ComputerSoftwareAndHardwareMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nvax_ComputerSoftwareAndHardwareMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442586861648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 294,247<span></span>
</td>
<td class="nump">$ 225,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">29,100<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CZ', window );">Czech Republic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="nump">$ 164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CZ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CZ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587845360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee benefits and compensation</a></td>
<td class="nump">$ 52,569<span></span>
</td>
<td class="nump">$ 38,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentAccruals', window );">Research and development accruals</a></td>
<td class="nump">468,214<span></span>
</td>
<td class="nump">577,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">70,375<span></span>
</td>
<td class="nump">58,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 591,158<span></span>
</td>
<td class="nump">$ 673,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442595081744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refunds to customers</a></td>
<td class="nump">$ 210,362<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements', window );">Other current liability related to Gavi (see Note 3 and Note 18)</a></td>
<td class="nump">697,384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">22,309<span></span>
</td>
<td class="nump">36,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 930,055<span></span>
</td>
<td class="nump">$ 36,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Liability Related To Advance Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442677790544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (712,183)<span></span>
</td>
<td class="num">$ (1,633,016)<span></span>
</td>
<td class="num">$ (455,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">58,536<span></span>
</td>
<td class="num">(81,520)<span></span>
</td>
<td class="nump">36,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (653,647)<span></span>
</td>
<td class="num">$ (1,714,536)<span></span>
</td>
<td class="num">$ (418,259)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587894032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Current Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Domestic</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">29,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense</a></td>
<td class="nump">$ 4,292<span></span>
</td>
<td class="nump">$ 29,215<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442588624400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Federal, state, and foreign current income tax expense</a></td>
<td class="nump">$ 4,292<span></span>
</td>
<td class="nump">$ 29,215<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, deferred tax asset, amount increase</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">510,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">1,056,799<span></span>
</td>
<td class="nump">1,027,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | No Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | No Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nvax_SubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nvax_SubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nvax_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nvax_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587232288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Rate Differences (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development and other tax credits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Non-cash stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations', window );">U.S. taxation of foreign operations</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax expense</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(30.00%)<span></span>
</td>
<td class="num">(31.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442594908320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal and state net operating loss carryforward</a></td>
<td class="nump">$ 479,134<span></span>
</td>
<td class="nump">$ 845,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforward</a></td>
<td class="nump">5,752<span></span>
</td>
<td class="nump">25,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credits</a></td>
<td class="nump">45,560<span></span>
</td>
<td class="nump">44,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredTaxAssetLeasingLiability', window );">Lease liability</a></td>
<td class="nump">27,625<span></span>
</td>
<td class="nump">52,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">195,049<span></span>
</td>
<td class="nump">20,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserve</a></td>
<td class="nump">213,076<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Non-cash stock-based compensation</a></td>
<td class="nump">27,599<span></span>
</td>
<td class="nump">24,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredTaxAssetsOriginalDiscountInterest', window );">Original discount interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research costs</a></td>
<td class="nump">49,309<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">13,695<span></span>
</td>
<td class="nump">11,801<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">1,056,799<span></span>
</td>
<td class="nump">1,027,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,020,123)<span></span>
</td>
<td class="num">(1,015,333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">36,676<span></span>
</td>
<td class="nump">11,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU assets</a></td>
<td class="num">(23,330)<span></span>
</td>
<td class="num">(10,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(11,587)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(1,055)<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(704)<span></span>
</td>
<td class="num">(878)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(36,676)<span></span>
</td>
<td class="num">(11,983)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredTaxAssetLeasingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Leasing Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredTaxAssetLeasingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredTaxAssetsOriginalDiscountInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from original discount interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredTaxAssetsOriginalDiscountInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591604752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tac Benefits Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits balance at January 1,</a></td>
<td class="nump">$ 11,154<span></span>
</td>
<td class="nump">$ 8,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions of current year</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">4,158<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior year</a></td>
<td class="num">(8,027)<span></span>
</td>
<td class="num">(1,770)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements of tax positions of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits balance at December 31,</a></td>
<td class="nump">$ 5,194<span></span>
</td>
<td class="nump">$ 11,154<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442587250528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> dose in Millions</strong></div></th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>defendant</div>
</th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 18, 2022 </div>
<div>dose</div>
</th>
<th class="th">
<div>Oct. 22, 2020 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LossContingencyPeriodToAnswer', window );">Period to answer</a></td>
<td class="text">14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LossContingencyPeriodToAnswer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Period To Answer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LossContingencyPeriodToAnswer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfVaccineDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Vaccine Doses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfVaccineDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140442591650800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023 | Unsecured Debt | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 325.0<span></span>
</td>
<td class="nump">$ 325.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>nvax-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nvax="http://www.novavax.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nvax-20221231.xsd" xlink:type="simple"/>
    <context id="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f9e1a5633fe44b2a624b7f0a93d8984_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id41865db09024993a1347220d7542819_I20230221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="i39643791632e4e05a291fb0194ec9876_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if63b56ea82ae477cbdd1dde33c7982bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9e6887961a304cfc83b8882d4e95843b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i229e45ac7dd0484582dd508d0b410d09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d2c1b3a8f554776b7ead7f9e8afc0be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i608ca42330f04ed38d4a29292e36a8e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb291a2235b342fb88d2412401c2825b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0dfc6b235bc64239a4750cc827d5e7be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42323458487a4a9c9100db83bbdf3ed4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55917cb303ae4006ae29b944e6cc0a9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba985ece231344b9884ac0673bdf1f76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib77bd7520a4c413d82a3ee385fdabe20_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i276434eedddc41439edb0c1b98cc9b7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i478e92d6d04344fbaa0f10b3ab1efcba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0c9aba10dd1499b9921e8f2fab79047_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee35c23efdb64a64bc904783db535a83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab79f65652ef4787919164353ded1194_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i939e909e3aee442cbe4c2ed5be1acf17_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i284adc6f56cd47bb8227b04aeb8caefc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if69381417968421ab3aaeea9e7e8a831_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d79e2b326344dec97c2c4f1db0400d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia79ae4732ce047b39cee388e3a7d5c42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic862fa293ea94c52be0807c27252da1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia042d64a00eb47ce9cb332d9341b3343_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75a1a3f2ee4448078a0f2e6954fd5e5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f41fed49045497fbd18a61509fff1d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75daa84e516a43879509c48930e444f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i504579d4ccfc4230b080c69863a85566_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife9d9bbf7294424fa7bb5a43026e8d23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47b104e574784fa7a1222f8870276e6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i000db304d0ac493c91874d53eda30c3f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaecfb76823254dd19a4cf6ad1affdba6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4138df8c406d48159527133860ea5188_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice8277fc63064ac59b415265922b2955_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i112cd4ea48f64fb4818bddbc7fbde54b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1a2fe6a8df24324964c4a66ca6b445a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8e7bd4e1044a4bfdab99267a4bec8cec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i461a71f67b2f48c69763adc332e28e74_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5dd03da035b34b17a46b6f7abfe523e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5673a51c537945239d7bb0e47db6afeb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ff09caaa96e4bde871b650ce7a243eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i643826e193814924924520e0e7696755_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e0508fe92d74026bf85072a53f8d173_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4cb3b3ae8c2e49b6af7301fcc04bfce2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63a2de06fc1f42a69276ce8a6224e6a0_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i673cb8037c324c8994caf3306884a92e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i807e3711af3b41989b73d47de7c77b65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5778a549b12c4102a30a2bd1229fd57e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id78b588331a244138048f135d4c38cb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0708fc22c9854f0abba5629785850b62_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0df39d26bc0a425688c0db2d06381f38_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iacf56722506e4a18bd6e4b8223b6c740_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfAustraliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d86c3d5bfd54e03b15f74461ed5ae3a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8171acc620e44403a1acf786d872dcea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfIsraelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd7831a5ea8c46faaaeebc166d30480f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GaviVaccineAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae09a72a1ca3430c9be92032270e60ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i229f36f7f6ec4f50a926d184ce91f415_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ac0cbe72c504988bee96db8bb6544d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia39f087502cf47ae90d1570eb534945f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d52b1aaa828491996f21dccbd34a922_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1404a3a6dc674929bfd21739b3442b4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie8db9b8a25904abfbbb2438880a81408_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:SKBioscienceCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b3c9b3cf2a747ce9a1576cadc4c0a46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d166751ab7a4c9c8c0655ff4da76514_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6203e4280b4a484f87366338bb51639b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic60027bdd04f4daa9e2d29cfb0744509_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40a83ca620bd452aa6f58f72d2c85402_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="icee78a963bab4b348f7582b0b78785d0_D20221001-20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="i7a081a82e367415892816cf19c0e6996_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42c53c7f16bb4d359be44c56e5a93d6d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32856f664ee8488999df14d37a8f364c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i926dd27a465e4fdabe3cf710647081f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nvax:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d102737a020478786d531e426d6e856_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46f5b877ba2042818de76d2a409905c8_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3abf6a1aebd248e584d82ca7df7e3fdf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6cd3d6a52163444b8ea692da78a4faf2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0523638414324ebda053032feb1642dc_I20221118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-18</instant>
        </period>
    </context>
    <context id="i39195769279040f9977e693d668d82a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5faf20068a344883a9f4f4c476b0ac54_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2706507e51524857a9ceffe04bbdfb19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8ad425a20a9414db980cc6c772611e4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibce1a3a4c4ef4e1d9f74c1e95e55e00c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec87e45039154115be91b56e82452836_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice1626d37f2e4ef59d96daaad71fdbaa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i368f367746e142668e6ba704011b5fc7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36fc052561f64f5bb389212acc6492e1_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i47baf28a107749f3b2ca7dc5b1b71532_I20201022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2020-10-22</instant>
        </period>
    </context>
    <context id="i23178b856de1448ab841c7dd1fda4737_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="id54b75d90c0445109878eb06ca06d922_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i67162008d7604923adbbc7b516cc27be_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i82199a3134c04ef69869eff76a4bd2cd_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i9414495645c244dfa1f4271692735ef3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14ec0fb5211549e2a256737805e4fce0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ce0f3c1c39d4e28b5fe4043d6dc2ca5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2124dc03e6334482915d316bc6b47f65_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7742e770d4074f7c8483f51032cb198a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2f39444854c467997b14a3f794dc641_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8a790ed695ae48a7825f7db0794a528b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95983058bd8d4c6b889991a78b44a3a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0953f31b29d64b1c9efe84ff12aaf7c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18d17441b7514d62aa6a4fb48ea6ec16_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb17db81cb4940059e2590656125cced_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8565eb181066484ab573f2f33ad705ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i269b7fbf10f045c7b3eac59a9ee5c87d_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="id7ac470da9ab41d39a8dd4ac58dde5eb_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ib28b320707a54cf7a261c50f50d34c04_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ia1458600dca343ad97871d021c6be059_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7be0462e374b44418c24eeac2316d566_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:DoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:DoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if04cb8aedaa04ea296920d2dafe47b45_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:DoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i67595162b2e74d70acbd1d2e3fc54a75_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09f8465b2a5e4bfaa5c2543aadab3967_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e260c6f907f4344bad6fb4ab2321f9c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3000e1e12c2e4499ac858cd2ed3830ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide4a1afee8bf4db08da83fe10dcf1648_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c853e8a4a7c4a54a237437e58933a8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1883dba2c86c4273926e697f5ab58bae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i96b9e55b23e44271b0b5d401791eb27a_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SKBioscienceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="iea6179b85088426c91dd56a7ba42e5c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c0e43b772f0435c86af0d81656bac70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6b7bd92fbd1475a82a5bfebeefa798f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifb61b7126be74d498e8a47c4f03eac57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i557fbd904011405793bff18a21cabb26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70ac59f74cd740e6a0cadeca61d87f18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8ac89c6ba624c228f64bcba1891a2a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if07eb648508740f8a5d7ef32fc803047_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8240c1c9049f42469bde4e3f3fddf4b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ebb77a8ee864fc78eb779a17c09226a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia828d2bd46af4b7f8e4984cb14c9cafb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b47a43081534cda81d9835ec8a79235_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47d72f7b153e4e8695661560c4fd46bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id90676cb023842e180c00be05cf71a12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74a7cf53ca85450590f17011e1295e6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e0b6732392440598653904929954c98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47f14050837d4c869dde5769d325bd7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50ad0f304ef5468ab90dfce6c1651bcc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaac7cacc849b46c798d58117b7ff11d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23496a29b22d4426a67a18543af66bbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6271729b2154949abe04c08bdafe9ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07ef3865c980492c8ddf20d9b5a9b4a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if419a9b5d1bc45b68cd3c42755335735_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id07aa9a3ff734e88b8adaa9f439f1d27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8047cd560f6c44c382b2c1bf052d612c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c022c32626a40f9ba08a783a679df34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia128e17147ae46ebbeef34e5ce29d598_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8099f1e2bbdd4ec0970e209f1e0b270e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ff83caef02b40f599cc74bcae40ff09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32cd12d82fc44bc780022e28d26cb8eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie83da57994934aae8def1bf0f382f5a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa7a2181db6a41c9b9b4919cafe3b1cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13a45c212dfe4e53b8afb7e0ff8967f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee8898a306024e42bfe586c67dd2d69f_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i89587ae04de147c793c1b9499301a5d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice2056ca33214fd9bb1ee8b7c7c6cca8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ca80f7d1ad642bd978daca477579b19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a506862b80548d28dfcb14cd9a57994_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ed14e6e12f045e6896127906a812d89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i016b678121634f2ea331a88b589a7be0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03e9156a13034488a05b42b0e99c2e6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0d108ce57a04b59a033717ce6e1e081_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia37923a559ac460cba463e92ab69d61b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8296c755f9446a59e2ee459a7b97bab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4056500d5930405896706052920574c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3ca7c3c6b834b43b446ee1616686ee3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if74110891d1c4616a0230ee664e7675b_I20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-27</instant>
        </period>
    </context>
    <context id="i6803c5d4d38740009777ad5eadf70727_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="iabda6dd0b85b41c5810ef5d88e33f6fb_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i98d86903b18c4a31908d43850afb1f79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvax:NovavaxCZFormerlyPrahaVaccinesASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18de67b571ba458cbba0933459b5975b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94ada334c1e14256b42648cab21c02f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i201ad52388df4bebacf2bd74f56acfeb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3094b6244ecc489b96c2559b7639a6b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i988682eb3b024cb688a6d71ca0cb108b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bb89a63509c49b0b7381f32ace08d03_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7bd187e980034898b9aecf0c85fa92f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0e0cb7900fe42bb90900d51daf494af_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="icfdf9690d60e4029a3ede7f1d4df8c62_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i728c18080ef8448fb44592281f48f9b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied7dd9ef2652406e95d1ff0060ae1b04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i864f59e306a74cabbced7a3c1435512b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96a1add754d840f5946967a65b3f474e_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3956f36cdac340c886e2cbf2ea354b9f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i502585dd7e734b158fdf6a98bb9e12e1_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i5ce452e9ba0b4f91b8ca4a6aa27cddc8_D20230201-20230201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ied73af9ac932401ebc59933f068a2e4e_I20160125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-25</instant>
        </period>
    </context>
    <context id="ic0ba24ef23674233a4a49398d78fe3b3_I20160125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-25</instant>
        </period>
    </context>
    <context id="i3e30c16b247446e89dea1ad6f8e71d44_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i34bddce3a1514a0991451e1b87ccd098_I20160125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-25</instant>
        </period>
    </context>
    <context id="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i3fac9c0e3d6c4c58ae8c9f4c1844fb75_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i8013133caa644857a213ff7c25f0f454_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i9a4f8a31db8143ffb528be60155adb66_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id6d0cb0853434fa2bfca424a22521ff9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6504e467cdf4ac9b1c7bb041d0d169a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb6c34ca0e6943a985fccfb3c3cd5034_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib3f4681005a149c69af0c9d36cd0c591_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic32ab2b881af4e00801939f78ec7d4d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72a45e70dfcc4ed3a06e5a1a0ad85788_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id09da20d245547229c7e424719065312_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifcb69e18ef584de69947a34bda69992f_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id52295e266c04be6958801ee220a81e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i708fc4297d3e486b988a67ddb519f244_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i909d287d453b483eadef68a6db51c7ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c38f0119d96422898c0a8bea2f47c2c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied0bd77787a54028835f2babf0a109d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71a915c3d5094ab9a4f33e9377b263ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5424c76f0f34f9abaf1051fa5d32862_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2f0a3575acd74594903fd3f69ea74c2c_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i0015ac21e2114e919dcd6b418ca0470e_I20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="i52570d4cefef4923bc04161998db7004_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i0d4411c1dfac48628e521c4e1c62d82c_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i833db54db4e5410a82b51d91507bc240_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id75773c016ce41a0a9271d81feb47a62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82b8e8541d10484db42a6e56bf4c319c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a884616d8f240c899d1ffded053d84f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i04e4f42ca7be4b18b06d0cb5a65f7f4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i06256858a63a4f5e993fc634c6256da8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8deb5c81e1314ef6b0780d4f3a49ed98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i78e81e12c2c645c891cd0ba8714b475c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idba79020bba2422ea08fa0e1bc48a3eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic57598acb9d345a0b294ceda6cce94ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07ae9fcb872440ec9e5ebfc077767156_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7d25ca75ae343a48d6da2c1441b845e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if37d9719b2524f6f8329cdee51688933_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i46bf6d3912154f1792ce922416ae63c1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1266c70d6883487eb69de02a5cefcaa5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i057ba2750d5b46caa17fd59064a93243_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc3b6eafa7a2453eb9dc3916a75c7c1e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1af17faf5cc45288e504b60fca3980a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i482ffe6e8ec14375b57c416c028deaec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73561b8b32cf4435ac835a50e53a576a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4b07f0a42caf41428f69609a0b2b9990_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i546bbc59bac14443b9fa7278f44f39a7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i43cd1de147754aae88ac59750e8413d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4741524c2007402199ab8e23ba7c57fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3daeefe63f648a9aefa23c5a54e474f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e434d4808f2454da2b021293904e61e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idde6dd916c874f429e3cc8fe6d0eabed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icacf535e608c4110bfafdf3621b23f38_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:FirstThreePercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8ab394f5b23492db52ba56a7cdec054_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:NextTwoPercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i07d0939ce4574bbca25cbd25ca1caa0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b46d3bb09db4518ba0e5b40ba4c579a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieaae667010054892bbaeaa0a48298ea5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0fe342175f5492284e7a2703432374a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i306c59f27cd9488b966d7683b0b6d3e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie51d31dc3a62493c90d13cac0e14c304_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id751e3e489e44cc4a6c2e3c2d4ff8264_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f4ccb5e7cb74f8d88f8a5fed001536d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccc1be450e664236a03f3377873ae30b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b0be8a4005f4b659c8142d8168d50eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i261ee1ff33254ce5ae3c71c1734f2118_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98a2c21af45f4bb8b5b57fb18fbb2a36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i134cfe86255d47f58e6942ddfddc42ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i003cbd6d8fc147008d115dcbabd4f866_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0296343bcc7a45f7af04732eca6371c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie850cc1078634b628fb807996bac48ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibba48e8ed9c64a64bc36603e29727b1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie09d6c3cc8dd494997ad5e9e0699ba04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18d589697b3448ef979612d981bcfa9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:SubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idccedc0b914042e9b04e606a7f40b047_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ed100b1f229497699cf3a210f953003_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:SubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0dadba2600544eb092b5aec9b95db726_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b5882daa660420c9f6624c60e06285f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idbdf580566214e4581e43117da7df104_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="i38dbeaf8546447cc8d0775f85d2579d5_D20210823-20210823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>nvax:reporting_unit</measure>
    </unit>
    <unit id="segment">
        <measure>nvax:segment</measure>
    </unit>
    <unit id="dose">
        <measure>nvax:dose</measure>
    </unit>
    <unit id="installment">
        <measure>nvax:installment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="day">
        <measure>nvax:day</measure>
    </unit>
    <unit id="defendant">
        <measure>nvax:defendant</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl8zLTEtMS0xLTcwMjAw_10cf82f1-a889-4bda-b99e-67223f31514a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl81LTEtMS0xLTcwMjAw_8706ead1-856a-4b21-a451-89faea8b7f29">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl82LTEtMS0xLTcwMjAw_0c617957-3ad7-45a1-b772-79a352bbb1f1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl80L2ZyYWc6ZWY1Mzg4ZjE0ZmRhNDIxMGIyMGIxYjkwNjQ2YjA0NDkvdGFibGU6NTk1YzdlODJkYmVhNGUzMzgzNDBkODEyNzBmMDVhYjYvdGFibGVyYW5nZTo1OTVjN2U4MmRiZWE0ZTMzODM0MGQ4MTI3MGYwNWFiNl83LTEtMS0xLTcwMjAw_de46bf8f-f5a8-49d9-9730-40484e89b322">0001000694</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i5778a549b12c4102a30a2bd1229fd57e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcx_287a37ee-2b5f-45a2-a262-d63f80394c20">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="icfdf9690d60e4029a3ede7f1d4df8c62_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDE_cc59319b-f346-4179-ace9-8b072a6d76f3">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4">http://www.novavax.com/20221231#LeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1">http://www.novavax.com/20221231#LeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134">http://www.novavax.com/20221231#LeaseRightOfUseAsset</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3">http://www.novavax.com/20221231#LeaseRightOfUseAsset</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <nvax:ConvertibleDebtConversionRate
      contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzExNTQ0ODcyMDkzMTQy_5f742c75-cbeb-4029-9948-e4253a87db5f"
      unitRef="usdPerShare">0.08</nvax:ConvertibleDebtConversionRate>
    <nvax:ConvertibleDebtConversionRate
      contextRef="i3fac9c0e3d6c4c58ae8c9f4c1844fb75_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzExNTQ0ODcyMDkzNjU0_86489c66-a737-4423-b870-09a24872df43"
      unitRef="usd">0.02</nvax:ConvertibleDebtConversionRate>
    <nvax:ConvertibleDebtConversionRate
      contextRef="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzMxMA_711981ca-b695-4ce4-b225-5273ad619031"
      unitRef="usdPerShare">0.0073411</nvax:ConvertibleDebtConversionRate>
    <nvax:ConvertibleDebtConversionRate
      contextRef="i8013133caa644857a213ff7c25f0f454_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzQ4MA_b86eb62e-7810-4cb1-906d-5dbf72aede1c"
      unitRef="usd">0.0089928</nvax:ConvertibleDebtConversionRate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTcvZnJhZzoxYmVjZGY0YzRjMjQ0MGJjYTY3NDA4NmE2NzJiYzc4NS90ZXh0cmVnaW9uOjFiZWNkZjRjNGMyNDQwYmNhNjc0MDg2YTY3MmJjNzg1XzEzMDU_44088c8d-e2ff-4934-a440-4d094879ad8b"
      unitRef="number">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i52570d4cefef4923bc04161998db7004_D20150601-20150630"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTc0_7315172c-cfb4-43c1-b403-98d1230d238a">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTE3_90c9eda9-1235-4bcd-ad0a-30ed86e3d16c">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6OTAwMGQyYjgyNzI0NGZlODk5MDZkOWEzMjRkZjkwYzIvdGFibGVyYW5nZTo5MDAwZDJiODI3MjQ0ZmU4OTkwNmQ5YTMyNGRmOTBjMl8wLTAtMS0xLTcwMjAw_bfe1397c-8e7c-433c-a738-4042507eb123">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xNDg0MzQwNjk3ODU5NQ_d240afd7-5867-4ee3-a93d-a171e66a42f7">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xNDg0MzQwNjk3ODU5NQ_fe42eb2b-b13e-43fb-9b72-9466aab8189f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6OGVmN2ExOTkxNTRhNDMzZWIwNTc3YWEyZmQ2YjQ4NTAvdGFibGVyYW5nZTo4ZWY3YTE5OTE1NGE0MzNlYjA1NzdhYTJmZDZiNDg1MF8wLTAtMS0xLTcwMjAw_c3e7e783-ba96-4983-a48b-6a1ed2fb4bd3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTE4_017344fd-064f-49e1-9c1b-85745c728257">000-26770</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTA5_832dacd2-ef35-4681-8f7e-6a46662af4ec">NOVAVAX,&#160;INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV8wLTAtMS0xLTcwMjAw_83071cc0-6081-42c5-960b-6d5c99926293">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV8wLTMtMS0xLTcwMjAw_b3d36fbf-53c1-410b-b848-1b6380b94401">22-2816046</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV8zLTAtMS0xLTcwMjAw_39c7ce9d-98b4-4317-8871-a3f595e6850f">21 Firstfield Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV80LTAtMS0xLTcwMjAw_ede7d80e-4411-456c-acbc-e21f48e9520c">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV80LTEtMS0xLTcwMjAw_d0e85a61-0355-4ccd-98c0-de96d6c8af71">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6NzgwMjcxNWI5ZmM4NDhjOWIyMDQ2NjkzZjNiMzA1YjUvdGFibGVyYW5nZTo3ODAyNzE1YjlmYzg0OGM5YjIwNDY2OTNmM2IzMDViNV80LTMtMS0xLTcwMjAw_1ad5b140-4881-45ed-a22a-a5158d131f30">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zMjU_82932bf4-8068-486d-9a5c-fb0cbc59cb7d">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEw_7750ee8f-7559-4309-94c2-e72c5a162744">268-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6ODU2ZDQ1M2ZhMjRlNDBiNWFlNWYzNjVhNzA1MGFhZTcvdGFibGVyYW5nZTo4NTZkNDUzZmEyNGU0MGI1YWU1ZjM2NWE3MDUwYWFlN18xLTAtMS0xLTcwMjAw_f6d97bc4-8b80-4dc5-acd1-825c14364125">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6ODU2ZDQ1M2ZhMjRlNDBiNWFlNWYzNjVhNzA1MGFhZTcvdGFibGVyYW5nZTo4NTZkNDUzZmEyNGU0MGI1YWU1ZjM2NWE3MDUwYWFlN18xLTEtMS0xLTcwMjAw_60916ad0-9319-4470-be34-9bf177fab6a1">NVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6ODU2ZDQ1M2ZhMjRlNDBiNWFlNWYzNjVhNzA1MGFhZTcvdGFibGVyYW5nZTo4NTZkNDUzZmEyNGU0MGI1YWU1ZjM2NWE3MDUwYWFlN18xLTItMS0xLTcwMjAw_559ada54-9256-4749-9946-a9a45f25b2c4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEx_7b1bed60-a714-40b4-b06f-5d6e580c773a">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEy_5f48a4f5-60ed-4845-bf8a-8efa5d795d68">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTE1_ab5d7184-afd7-4805-8407-c54208a48e03">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTA3_b21bd43c-882c-4c76-a0e3-51b130e5bcd8">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6MGIwOWIyNTQ4NzgwNDdiMDkyNzE4Nzk3YjY5YWYxZGQvdGFibGVyYW5nZTowYjA5YjI1NDg3ODA0N2IwOTI3MTg3OTdiNjlhZjFkZF8wLTAtMS0xLTcwMjAw_9860821b-f478-4518-a6d0-f74fee465d94">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6MGIwOWIyNTQ4NzgwNDdiMDkyNzE4Nzk3YjY5YWYxZGQvdGFibGVyYW5nZTowYjA5YjI1NDg3ODA0N2IwOTI3MTg3OTdiNjlhZjFkZF8yLTMtMS0xLTcwMjAw_02bd667d-75ee-4a3c-b71b-4856224acd7f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGFibGU6MGIwOWIyNTQ4NzgwNDdiMDkyNzE4Nzk3YjY5YWYxZGQvdGFibGVyYW5nZTowYjA5YjI1NDg3ODA0N2IwOTI3MTg3OTdiNjlhZjFkZF80LTEtMS0xLTcwMjAw_3870c2af-6c02-43b6-b69b-ed8764efe9ca">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xMTU0NDg3MjA5NTg2MA_449f9ed3-34b5-4613-9a5e-c690cdae42aa">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTEz_1315f2c4-d28a-4997-99d4-95350399d9ac">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i4f9e1a5633fe44b2a624b7f0a93d8984_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8xNDg0MzQwNjk3ODUzNQ_aed480bb-606b-4483-a34c-000709329367"
      unitRef="usd">4010000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id41865db09024993a1347220d7542819_I20230221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zMTA4_863079b4-2dcf-44c0-b1dc-ae5be72759fb"
      unitRef="shares">86173245</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xL2ZyYWc6NWQ1NmYwZjE3NGY0NDU2NDkyZDc5NjJjMmEwM2NhZDkvdGV4dHJlZ2lvbjo1ZDU2ZjBmMTc0ZjQ0NTY0OTJkNzk2MmMyYTAzY2FkOV8zNTA4_119c9cf8-45ee-4284-a757-308716d56c3f">Documents incorporated by reference: Portions of the Registrant&#x2019;s Definitive Proxy Statement to be filed no later than 120 days after the fiscal year ended December&#160;31, 2022 in connection with the Registrant&#x2019;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent indicated herein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTIvZnJhZzpkNmE5MzU0MzlhNmM0NGE1OThhZTgzMTgwMjFmNmY5My90YWJsZTo4NjA5MjBjNWY2NjU0OTY2YmQ4Y2I1OTM2OGFjNTVlMS90YWJsZXJhbmdlOjg2MDkyMGM1ZjY2NTQ5NjZiZDhjYjU5MzY4YWM1NWUxXzAtMC0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplOTJiNTdiZmU5Yjk0ZDYwOTBiODlhNGRlMDVhNjg1Zl83MQ_4d1393d9-1bc5-482d-b316-dbb4b6fe0f44">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODc_033d45d9-9287-4e66-bc57-98ff79892c0d">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODg_30981a92-b8d7-4144-bb9a-95b64c2ca1da">Tysons, Virginia</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODk_5c8ecd2e-b45d-4362-a34e-f8b7b83d4725">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTUvZnJhZzplOTEwYzA4NzMzMjg0NzYwYjU1NDc0YjQyNTVmZmNmYS90ZXh0cmVnaW9uOmU5MTBjMDg3MzMyODQ3NjBiNTU0NzRiNDI1NWZmY2ZhXzc0ODY_400caa96-3a51-47df-8cbf-0bfdbbf11ebe">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:Revenues
      contextRef="i39643791632e4e05a291fb0194ec9876_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzMtMS0xLTEtNzAyMDA_fcc6d592-859f-41a6-a99a-11444413ebaf"
      unitRef="usd">1554961000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if63b56ea82ae477cbdd1dde33c7982bf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzMtMy0xLTEtNzAyMDA_0a664a45-cd3a-4925-ac58-28764b4cc3fc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e6887961a304cfc83b8882d4e95843b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzMtNS0xLTEtNzAyMDA_31cf2d41-b8e4-4538-aa7c-ef95fb7cedb3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i229e45ac7dd0484582dd508d0b410d09_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzQtMS0xLTEtNzAyMDA_38eee527-c4da-4b59-b052-6fb454311d2d"
      unitRef="usd">382921000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d2c1b3a8f554776b7ead7f9e8afc0be_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzQtMy0xLTEtNzAyMDA_76cee181-b6f2-49cd-a06b-ec6ffbcd61f9"
      unitRef="usd">948709000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i608ca42330f04ed38d4a29292e36a8e2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzQtNS0xLTEtNzAyMDA_2373da09-6d59-4c58-a8c1-2df9c4e05d50"
      unitRef="usd">453210000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb291a2235b342fb88d2412401c2825b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMS0xLTEtOTY2OTA_4d21a157-596f-4c44-a387-5e68f3424e28"
      unitRef="usd">43990000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0dfc6b235bc64239a4750cc827d5e7be_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMy0xLTEtOTY2NzQ_f96ddc88-7b38-4807-918a-a6e3527e213e"
      unitRef="usd">197581000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42323458487a4a9c9100db83bbdf3ed4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtNS0xLTEtOTY2NzQ_e2203802-eb0d-47d6-bb19-e21efa0b76d2"
      unitRef="usd">22388000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMS0xLTEtNzAyMDA_532359a7-bcde-4d1f-9a8d-61ee065942d0"
      unitRef="usd">1981872000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtMy0xLTEtNzAyMDA_9c5dd588-5e3f-40b3-979d-2b6b29cce22f"
      unitRef="usd">1146290000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzUtNS0xLTEtNzAyMDA_00a2908f-a5a4-489a-81de-026e5dfaf5e3"
      unitRef="usd">475598000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzktMS0xLTEtOTk0Njg_e3f2c51a-c344-4d4d-b367-af8392deed9c"
      unitRef="usd">902639000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzktMy0xLTEtOTk0NzU_1bd4de17-7029-4068-ba43-e73610690184"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzktNS0xLTEtOTk0ODI_01ba8a70-94b1-4053-b2d8-92275d3dc863"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzgtMS0xLTEtNzAyMDA_12bf16b3-99a3-4eb4-9ba8-c72a4b57ee4b"
      unitRef="usd">1235278000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzgtMy0xLTEtNzAyMDA_28df42ea-e820-46a5-8306-73b78bfe7ed7"
      unitRef="usd">2534508000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzgtNS0xLTEtNzAyMDA_5f2feab4-4bd1-400f-b049-526059425d01"
      unitRef="usd">747027000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEwLTEtMS0xLTcwMjAw_94bbb78e-4102-4503-8ccf-6c2983940f0e"
      unitRef="usd">488691000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEwLTMtMS0xLTcwMjAw_c0fbb8c9-e927-476e-ab75-7d4084476614"
      unitRef="usd">298358000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEwLTUtMS0xLTcwMjAw_ef07b393-e75c-4364-92f7-d281d4885da0"
      unitRef="usd">145290000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzExLTEtMS0xLTcwMjAw_bcb20372-ceb9-40b1-a021-30b27b3c9e19"
      unitRef="usd">2626608000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzExLTMtMS0xLTcwMjAw_dcb4301c-766a-4587-b2bc-571160dc5bf2"
      unitRef="usd">2832866000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzExLTUtMS0xLTcwMjAw_5dd75b39-a788-41ed-90ea-e072a1171452"
      unitRef="usd">892317000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEyLTEtMS0xLTcwMjAw_5147951e-d55c-45bb-8a90-4918477ef042"
      unitRef="usd">-644736000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEyLTMtMS0xLTcwMjAw_6c745ee5-395c-492e-9d05-1b7af5cbd6b6"
      unitRef="usd">-1686576000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzEyLTUtMS0xLTcwMjAw_663a4741-4b2e-4a5e-962d-83ec9423d6cf"
      unitRef="usd">-416719000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE1LTEtMS0xLTcwMjAw_b28dffac-1688-498b-851a-c74835e920da"
      unitRef="usd">19880000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE1LTMtMS0xLTcwMjAw_7ce6cfbe-fc58-4034-abad-625fe2169135"
      unitRef="usd">21127000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE1LTUtMS0xLTcwMjAw_964db1cc-e4e1-4643-a0c9-6a443d859149"
      unitRef="usd">15145000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE2LTEtMS0xLTcwMjAw_ec1fbd6e-9e80-4c0f-9e06-0fc59f6aea93"
      unitRef="usd">10969000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE2LTMtMS0xLTcwMjAw_199c8b92-c61f-476a-b5bd-a01eaa1ae2ac"
      unitRef="usd">-6833000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE2LTUtMS0xLTcwMjAw_af70b387-6c2b-4229-ba62-39c603edf976"
      unitRef="usd">13605000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE3LTEtMS0xLTcwMjAw_4acea058-1e3d-4283-9d8f-68e3e4db5b2e"
      unitRef="usd">-653647000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE3LTMtMS0xLTcwMjAw_52ef65b6-a759-441b-a346-a746f96ecf08"
      unitRef="usd">-1714536000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE3LTUtMS0xLTcwMjAw_c76e27a0-b54f-479b-bad8-df7fd919ba07"
      unitRef="usd">-418259000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE4LTEtMS0xLTcwMjAw_da1ca305-7dd8-4ec8-8fb4-3d98a7ead94a"
      unitRef="usd">4292000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE4LTMtMS0xLTcwMjAw_95793e84-8743-4a7a-bc6f-ee4ff55b211d"
      unitRef="usd">29215000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE4LTUtMS0xLTcwMjAw_1db3ecfa-d514-4ebf-a9ff-a271cc0e3ff2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE5LTEtMS0xLTcwMjAw_1856259a-2ef1-4ab9-9162-bfae9629d0bd"
      unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE5LTMtMS0xLTcwMjAw_e3d4fc2b-85bc-46e5-9818-00e668b4af32"
      unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzE5LTUtMS0xLTcwMjAw_3e062e01-3580-44a5-903d-a3e66ca622c4"
      unitRef="usd">-418259000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTEtMS0xLTcwMjAw_04bcb035-1bf5-4ac0-bdbb-717ccd37699c"
      unitRef="usdPerShare">-8.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTEtMS0xLTcwMjAw_d95a2c67-4af8-4c9a-96d0-ae596525c23f"
      unitRef="usdPerShare">-8.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTMtMS0xLTcwMjAw_c4182bcf-abcb-43b9-b2f5-a8b8d49c92e5"
      unitRef="usdPerShare">-23.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTMtMS0xLTcwMjAw_d0f8e238-a3da-4b1b-8f52-7bdc3177b99a"
      unitRef="usdPerShare">-23.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTUtMS0xLTcwMjAw_263d52f0-98ab-459e-bcb7-6edb54b8cb4b"
      unitRef="usdPerShare">-7.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIxLTUtMS0xLTcwMjAw_98205ac3-e696-4989-b620-ec99ba87ae2c"
      unitRef="usdPerShare">-7.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTEtMS0xLTcwMjAw_2e7b6b2f-4a3c-482c-9ab8-34c275f49af1"
      unitRef="shares">78183000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTEtMS0xLTcwMjAw_a13cb166-7553-4be7-ab26-e44a01502cc4"
      unitRef="shares">78183000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTMtMS0xLTcwMjAw_4218a06a-4e68-440c-a7e8-ba951bc77a58"
      unitRef="shares">74400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTMtMS0xLTcwMjAw_fb90b521-5431-43d2-8644-e1063e89abeb"
      unitRef="shares">74400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTUtMS0xLTcwMjAw_8f7d5c0c-f2b1-4f0d-a387-88333c6aeba7"
      unitRef="shares">57554000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTo4YTU5ZTRiNjk2Zjk0YWI2YWYzYTlmZDI0YWZkY2VjNy90YWJsZXJhbmdlOjhhNTllNGI2OTZmOTRhYjZhZjNhOWZkMjRhZmRjZWM3XzIzLTUtMS0xLTcwMjAw_ee70ea05-68c2-4471-a015-c537b0128df8"
      unitRef="shares">57554000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzItMS0xLTEtNzAyMDA_943f10b4-eefa-45de-9421-3d08efc9cbc0"
      unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzItMy0xLTEtNzAyMDA_ac9ad98d-61be-457a-b50e-5cad66f042ba"
      unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzItNS0xLTEtNzAyMDA_6dce43f2-6315-4293-a84d-e18872f18e8c"
      unitRef="usd">-418259000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzQtMS0xLTEtNzAyMDA_7dbf0a8f-27e7-452b-b257-4d19f3b4b926"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzQtMy0xLTEtNzAyMDA_5c0e2a6a-14b0-4a2e-b87b-15cd0c8143aa"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzQtNS0xLTEtNzAyMDA_d1d4a0b4-b857-4dfe-88ea-00588a475e6a"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzUtMS0xLTEtNzAyMDA_5e9013cd-0299-4f32-8312-7b9854ab3a67"
      unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzUtMy0xLTEtNzAyMDA_9185ef63-daab-48fc-8844-169d81e6be10"
      unitRef="usd">-8368000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzUtNS0xLTEtNzAyMDA_9bf2f05a-1243-4a81-81ac-2e546540dbd0"
      unitRef="usd">19523000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzYtMS0xLTEtNzAyMDA_361f114c-7367-4f55-ab59-b6a2dcb2265b"
      unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzYtMy0xLTEtNzAyMDA_60f986bc-a152-4197-a84f-248a88184483"
      unitRef="usd">-8377000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzYtNS0xLTEtNzAyMDA_14bf129b-26a1-471c-8bde-6999e17947da"
      unitRef="usd">19532000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzctMS0xLTEtNzAyMDA_1027c8ca-038c-45eb-bfb9-ad01a3fd898c"
      unitRef="usd">-662963000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzctMy0xLTEtNzAyMDA_7617a853-615c-4639-895d-25631d8dd31c"
      unitRef="usd">-1752128000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjEvZnJhZzo1NzJiYWJlMGViNWM0ZDc5OTBlYTA0YTE1NjRhNDIwZi90YWJsZTpjYThlMWM3ZTBjN2M0MTc0YTNlNGNkZjMxNmI2NTk5Yy90YWJsZXJhbmdlOmNhOGUxYzdlMGM3YzQxNzRhM2U0Y2RmMzE2YjY1OTljXzctNS0xLTEtNzAyMDA_72c0fe25-d73a-46be-bf47-627fe743134e"
      unitRef="usd">-398727000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQtMS0xLTEtNzAyMDA_67f60d10-3792-48ce-87bf-71885014b1db"
      unitRef="usd">1336883000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQtMy0xLTEtNzAyMDA_85cf10cd-4176-4bc7-bd72-f93e155072b9"
      unitRef="usd">1515116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzYtMS0xLTEtNzAyMDA_7da308f5-8363-4888-975e-2291da6dab8a"
      unitRef="usd">10303000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzYtMy0xLTEtNzAyMDA_ee894795-dd6a-47fa-830a-6d2c4d7fa234"
      unitRef="usd">11490000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMS0xLTEtNzAyMDA_573efe11-4dbb-45f7-a6c4-d837aa0835a7"
      unitRef="usd">82375000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMy0xLTEtNzAyMDA_b5610319-4e6f-4b8e-89c5-239614d2504e"
      unitRef="usd">454993000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMS0xLTEtOTk5Mjk_04b84ee7-66d3-4bda-9f97-79b0f71c0a47"
      unitRef="usd">36683000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzctMy0xLTEtOTk5MjI_1d7a8988-70da-4be0-baae-c2b2a3cf79f4"
      unitRef="usd">8872000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzgtMS0xLTEtNzAyMDA_24eadd4e-73a1-4665-b222-07b532691043"
      unitRef="usd">237147000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzgtMy0xLTEtNzAyMDA_3677b5f8-4ed5-4ee6-8692-0b70a98b2890"
      unitRef="usd">164648000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzktMS0xLTEtNzAyMDA_66c9260a-34a9-4aad-8cd3-7a6a53e342b7"
      unitRef="usd">1703391000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzktMy0xLTEtNzAyMDA_273d8ed9-3731-490a-be30-2eebcff1ebcb"
      unitRef="usd">2155119000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEwLTEtMS0xLTcwMjAw_55aa55d4-0469-4e81-b990-7e96f775d6f3"
      unitRef="usd">294247000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEwLTMtMS0xLTcwMjAw_29dfdbbe-882a-4fa5-bcf2-202afde62c59"
      unitRef="usd">225741000</us-gaap:PropertyPlantAndEquipmentNet>
    <nvax:LeaseRightOfUseAsset
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzExLTEtMS0xLTk5OTc1_859973ee-9751-4f58-81a3-64d42a11731f"
      unitRef="usd">106241000</nvax:LeaseRightOfUseAsset>
    <nvax:LeaseRightOfUseAsset
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzExLTMtMS0xLTk5OTc1_a09e4df4-82ca-4c8b-8d63-a3685a65072c"
      unitRef="usd">40123000</nvax:LeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEyLTEtMS0xLTcwMjAw_0e295127-5c0b-42c6-9797-ba3d8d2fd1b9"
      unitRef="usd">126331000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEyLTMtMS0xLTcwMjAw_bb3b2a07-7a82-4ab0-9569-faa657013e95"
      unitRef="usd">131479000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEzLTEtMS0xLTcwMjAw_8c2deb53-e371-4f8c-99f0-8dabcfce4ecd"
      unitRef="usd">28469000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzEzLTMtMS0xLTcwMjAw_b4bea2ef-c761-4402-a003-a33ad677a150"
      unitRef="usd">24291000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE0LTEtMS0xLTcwMjAw_0fa0792b-e3b5-43d8-8402-e9efd09f3d5b"
      unitRef="usd">2258679000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE0LTMtMS0xLTcwMjAw_e5b691d3-59c6-40f6-86d0-bbba59acb565"
      unitRef="usd">2576753000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE3LTEtMS0xLTcwMjAw_e41a84c4-4ff4-47e3-962e-3b9314159534"
      unitRef="usd">216517000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE3LTMtMS0xLTcwMjAw_f407249f-da52-472e-9c8f-7ebef94cfed1"
      unitRef="usd">127050000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE4LTEtMS0xLTcwMjAw_61d13b1b-64c2-45a0-a0e1-bd461cd1b350"
      unitRef="usd">591158000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE4LTMtMS0xLTcwMjAw_2bf00dff-7970-403f-8c22-30346cc89ba7"
      unitRef="usd">673731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE5LTEtMS0xLTcwMjAw_3ba02bb0-4096-4c72-b4a3-1bda0f357acb"
      unitRef="usd">370137000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzE5LTMtMS0xLTcwMjAw_4aeacd12-9434-46dd-a3ab-a3410f633830"
      unitRef="usd">1422944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIwLTEtMS0xLTcwMjAw_373e29ec-cf9d-4d3a-8564-b91695d66580"
      unitRef="usd">27196000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIwLTMtMS0xLTcwMjAw_78ee88c6-7a4c-49ed-89fe-e38ce0311edb"
      unitRef="usd">130533000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTEtMS0xLTEwMTI0NQ_c987aa58-824d-43b3-bbd5-bbaf4fb39097"
      unitRef="usd">324881000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTMtMS0xLTEwMTI1Mw_3e9caebf-c486-492d-8712-c537ba029238"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTEtMS0xLTcwMjAw_350c952b-8ced-45cd-a0a3-48cf2841fdb7"
      unitRef="usd">930055000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIxLTMtMS0xLTcwMjAw_778df95e-0889-4418-87a7-9e6246003a98"
      unitRef="usd">36061000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIyLTEtMS0xLTcwMjAw_3b0a0e44-e19f-4f52-b186-4ceaf9a691b2"
      unitRef="usd">2459944000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIyLTMtMS0xLTcwMjAw_6ecfb34e-83c1-4635-9a37-245f500cdc51"
      unitRef="usd">2390319000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIzLTEtMS0xLTcwMjAw_39f0f158-703f-4ac4-9717-0e114bc25eb3"
      unitRef="usd">179414000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzIzLTMtMS0xLTcwMjAw_ba8cce8e-8acd-40b8-be52-6ed74bcece97"
      unitRef="usd">172528000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI0LTEtMS0xLTcwMjAw_0cf93431-578b-4918-a529-903c3b3ff6a0"
      unitRef="usd">166466000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI0LTMtMS0xLTcwMjAw_1b385082-0318-43e6-84ac-dde23ef040ab"
      unitRef="usd">323458000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTEtMS0xLTEyNDI4MQ_50d90b8e-39d8-4a91-85ac-1c346515d2d2"
      unitRef="usd">31238000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTMtMS0xLTEyNDI4MQ_b8d13615-1737-41ae-aa0c-558c2e86c390"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTEtMS0xLTcwMjAw_ea954d22-9e02-40ad-9b4a-0d17f7708c0d"
      unitRef="usd">55695000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI2LTMtMS0xLTcwMjAw_5da4a467-b928-45d0-8e8d-0f59f9306f5c"
      unitRef="usd">42121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI3LTEtMS0xLTcwMjAw_ebdc7cfc-b750-4546-aff9-6ad4c35416bf"
      unitRef="usd">2892757000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI3LTMtMS0xLTcwMjAw_9218d44f-3884-4c3a-ac5f-448e97dcc3bd"
      unitRef="usd">2928426000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI5LTEtMS0xLTcwMjAw_2decc3ab-3dc2-49e7-b06b-cd5dfb795f91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzI5LTMtMS0xLTcwMjAw_f907b4a2-ac68-4fbd-8153-b22b164c8f91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMjI_4a78bce0-b47c-4625-b306-6291154b5d64"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMjI_5a488198-f1dd-4b7f-9cd4-6cb011039759"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMzY_2e1f5f6c-4d53-4d17-b70d-9f3e881b5094"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfMzY_d1c479a7-0029-48c1-9d2e-7a297bcc4ff8"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_7a2c7654-bfff-47ce-99de-9e9db5a397ec"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_82dea189-29e7-4b18-8840-9b52decddf4f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_ccc1cce5-c98b-4ce2-836d-4053b63e9aac"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZGE5YmNiODc5NzM4NDU1NTg1NjgyMGFmNzhjNmZmNzhfNzE_daaf177c-378a-4d3e-a7f9-29c9606fdaff"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTEtMS0xLTcwMjAw_3e0e3335-6d8f-4a47-b521-b3bb863058cd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzMxLTMtMS0xLTcwMjAw_22cc859d-0093-44d1-bbad-463127002538"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTg_59ffc122-f25b-4092-8a45-41dbc09ed109"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTg_844490c9-e0be-478c-b7d2-e9898426dbf0"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMzI_81384262-5bc8-4789-a14e-21f3a40618e6"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMzI_be60f325-3b17-4adf-8d26-67abd098010a"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfNzE_4a9e7a5e-00cf-4cf5-9c94-2b593a6ffaab"
      unitRef="shares">86806554</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfOTI_8f73ab06-19b1-42f0-9272-7b5cfe12f439"
      unitRef="shares">86039923</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTI0_f60448ba-5f41-4303-9638-86e54287a737"
      unitRef="shares">76433151</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTAtMS0xLTcwMjAwL3RleHRyZWdpb246MTMyZjAzOGUyYmU3NGZjZmIyYzlkNjNjYTU0ZDdiYjJfMTQ1_28b8f7a7-5395-422c-8b6e-0c1177675508"
      unitRef="shares">75841171</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTEtMS0xLTcwMjAw_5aa8c578-ff40-4288-a239-0262579efd5c"
      unitRef="usd">868000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM0LTMtMS0xLTcwMjAw_bd320b7d-80ab-4ec0-8dc0-0b9402ab66d9"
      unitRef="usd">764000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM1LTEtMS0xLTcwMjAw_f95ef58f-db0a-4a5e-ad6d-f0be9620c21f"
      unitRef="usd">3737979000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM1LTMtMS0xLTcwMjAw_73f63a81-1b4d-48b8-9f0e-5d4d8ce4408f"
      unitRef="usd">3351967000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM2LTEtMS0xLTcwMjAw_80da236f-07a0-45df-83b0-57b70fd8add3"
      unitRef="usd">-4275889000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM2LTMtMS0xLTcwMjAw_d3562459-dad3-4bca-bbb8-71b10ed42698"
      unitRef="usd">-3617950000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZDU4ODVkYjBiNzE2NDBiNGE5ZmUyNmM1MDIzNjFhZDFfMjA_c670c571-b357-4a14-a52a-72e9be97b5e9"
      unitRef="shares">766631</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZDU4ODVkYjBiNzE2NDBiNGE5ZmUyNmM1MDIzNjFhZDFfNTI_46a7e3a6-001f-4095-91fc-ccb92165cad1"
      unitRef="shares">591980</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTEtMS0xLTcwMjAw_21ac5b7f-9ee3-4068-9bdd-298945d95f0e"
      unitRef="usd">90659000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM3LTMtMS0xLTcwMjAw_b2eb464f-fc5b-438d-9c7a-ef96ea262816"
      unitRef="usd">85101000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM4LTEtMS0xLTcwMjAw_3cb4877f-a5cd-4232-90e4-2b2d5b9a634f"
      unitRef="usd">-6377000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM4LTMtMS0xLTcwMjAw_d3095558-7613-4648-a9a7-b6c3fcfee23e"
      unitRef="usd">-1353000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM5LTEtMS0xLTcwMjAw_e69c1775-a4fa-4b6e-87c0-5b738380f76e"
      unitRef="usd">-634078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzM5LTMtMS0xLTcwMjAw_73be1edd-372d-4fde-bdd1-1579f3b771ac"
      unitRef="usd">-351673000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQwLTEtMS0xLTcwMjAw_c1f81a16-eb60-4113-95e4-ed750c806c10"
      unitRef="usd">2258679000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMTgvZnJhZzowZmUwYTNiMTk4MTM0YjM3ODA5ZjYwM2ZlYWJmYTliMi90YWJsZTo4Yzk1OWM3ZGVlNzI0MTM1ODg3ZmU1NGVkZjA0MmNkYi90YWJsZXJhbmdlOjhjOTU5YzdkZWU3MjQxMzU4ODdmZTU0ZWRmMDQyY2RiXzQwLTMtMS0xLTcwMjAw_c7193a8a-6789-43a2-9df1-28e84bd9fa3f"
      unitRef="usd">2576753000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ib77bd7520a4c413d82a3ee385fdabe20_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMS0xLTEtNzAyMDA_6cedb5dc-51ed-4525-970e-7e6ce39273f8"
      unitRef="shares">32399352</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib77bd7520a4c413d82a3ee385fdabe20_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMy0xLTEtNzAyMDA_06ddff85-9b7d-4c5f-86e5-516ba86f86fc"
      unitRef="usd">324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i276434eedddc41439edb0c1b98cc9b7b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItNS0xLTEtNzAyMDA_fcabcceb-bba9-4ce5-948b-f553da095090"
      unitRef="usd">1260551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i478e92d6d04344fbaa0f10b3ab1efcba_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItNy0xLTEtNzAyMDA_2ab1045d-2716-4069-93fa-47257e8e03f0"
      unitRef="usd">-1431801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0c9aba10dd1499b9921e8f2fab79047_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItOS0xLTEtNzAyMDA_3b5038e7-1d2a-4538-97e9-4bb1ce92310b"
      unitRef="usd">-2583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee35c23efdb64a64bc904783db535a83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMTEtMS0xLTcwMjAw_cb14cacd-d8d4-45da-ad9a-68b94633ed3a"
      unitRef="usd">-12508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab79f65652ef4787919164353ded1194_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzItMTMtMS0xLTcwMjAw_7ff6923a-7f8d-4edd-b690-fe6a786d2152"
      unitRef="usd">-186017000</us-gaap:StockholdersEquity>
    <nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease
      contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtNS0xLTEtOTcxMDM_d78ab371-1839-4aae-bc1f-223a3b165ae3"
      unitRef="usd">24139000</nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease>
    <nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease
      contextRef="i939e909e3aee442cbe4c2ed5be1acf17_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtNy0xLTEtOTcxMDM_26886e79-f84d-4e63-8c31-fe9cff532db8"
      unitRef="usd">-24139000</nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease>
    <nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMTMtMS0xLTk3MTAz_ecec973e-24e8-4bbb-a75b-667f8c1653eb"
      unitRef="usd">0</nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMS0xLTEtNzAyMDA_d18e8e98-5387-4d09-9934-a97d92770437"
      unitRef="shares">4388850</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMy0xLTEtNzAyMDA_7ce0c106-3e5e-486e-ac57-6ece64ab2d61"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtNS0xLTEtNzAyMDA_1b562ae5-630c-4d6d-a7fb-f74963e584ce"
      unitRef="usd">199778000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzMtMTMtMS0xLTcwMjAw_f2fcf2b7-c761-4a6a-a0ec-37709b28cb7a"
      unitRef="usd">199822000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzQtNS0xLTEtNzAyMDA_4517eadb-3eae-415c-9a65-e521edb586bd"
      unitRef="usd">128035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzQtMTMtMS0xLTcwMjAw_f863876c-54f8-43e6-94db-cb846728b4e7"
      unitRef="usd">128035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtMS0xLTEtNzAyMDA_e789c29a-2b75-4532-8481-a4d0bcb9e3cc"
      unitRef="shares">2168725</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtMy0xLTEtNzAyMDA_21a1160a-d4de-4279-936e-944ee025daf9"
      unitRef="usd">22000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtNS0xLTEtNzAyMDA_1fe92393-cf1c-43c5-9490-4f8f82563d27"
      unitRef="usd">44447000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i284adc6f56cd47bb8227b04aeb8caefc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtOS0xLTEtNzAyMDA_fc775698-688a-4d33-bdbd-e0005cc56ae0"
      unitRef="usd">-39223000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzUtMTMtMS0xLTcwMjAw_43a9189c-0cad-4141-a72f-0b886a28b8d9"
      unitRef="usd">5246000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMC0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxNjEzYzQ1ZmJmMTg0OGI3YmJkMGEwYTc2N2JlYmQxNl8xNDg0MzQwNjk3NTA0NQ_cc2f33e8-dbd0-4815-b973-82188e43a7be"
      unitRef="usd">11416000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMS0xLTEtNzAyMDA_fbaa56ec-8fbc-459c-ab89-035d7cc9665b"
      unitRef="shares">32393438</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibed783b854b841ada4d05e200071f5fa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMy0xLTEtNzAyMDA_e3ef6974-5c05-4d15-bdd6-98accbf45d5a"
      unitRef="usd">324000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6beb9cf500744018afb3bfc0034ace38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtNS0xLTEtNzAyMDA_8b379e62-01d9-4542-aa73-7bb1ae3c5af5"
      unitRef="usd">878526000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzYtMTMtMS0xLTcwMjAw_19792b5b-7003-427b-8b0f-e9df9896234a"
      unitRef="usd">878850000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if69381417968421ab3aaeea9e7e8a831_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzctMTEtMS0xLTcwMjAw_a45711e9-1c1e-4b99-b10b-345812a846c6"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzctMTMtMS0xLTcwMjAw_98f43434-fc82-47ed-8e3f-ed7b34dd1801"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if69381417968421ab3aaeea9e7e8a831_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzgtMTEtMS0xLTcwMjAw_6a17cf05-3344-45c7-bb09-08fcffd36a71"
      unitRef="usd">19523000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzgtMTMtMS0xLTcwMjAw_1995a41d-fbf8-4691-b830-537bfe211ece"
      unitRef="usd">19523000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i939e909e3aee442cbe4c2ed5be1acf17_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzktNy0xLTEtNzAyMDA_8dcd56a8-797f-4695-afca-fb828755bdf2"
      unitRef="usd">-418259000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzktMTMtMS0xLTcwMjAw_acbd9260-4b44-4b9c-8f1c-747f52e20e0e"
      unitRef="usd">-418259000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i8d79e2b326344dec97c2c4f1db0400d9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTEtMS0xLTcwMjAw_84636cd4-f722-404e-9031-e0e5f788be09"
      unitRef="shares">71350365</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i8d79e2b326344dec97c2c4f1db0400d9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTMtMS0xLTcwMjAw_28d5e646-366b-4736-a945-6cb3a93c2e6a"
      unitRef="usd">714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia79ae4732ce047b39cee388e3a7d5c42_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTUtMS0xLTcwMjAw_a512e63d-f470-4874-b208-b41bdb3a7083"
      unitRef="usd">2535476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic862fa293ea94c52be0807c27252da1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTctMS0xLTcwMjAw_209c0f8e-5446-4680-9c69-8a3dea3e87a7"
      unitRef="usd">-1874199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia042d64a00eb47ce9cb332d9341b3343_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTktMS0xLTcwMjAw_a84addc4-0343-4904-a936-670c9731e207"
      unitRef="usd">-41806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75a1a3f2ee4448078a0f2e6954fd5e5f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTExLTEtMS03MDIwMA_4f920ab7-9af4-4ae7-ad2b-033a9806a7c2"
      unitRef="usd">7024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEwLTEzLTEtMS03MDIwMA_e3691661-361b-4a25-8a88-e9178fd83354"
      unitRef="usd">627209000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i75daa84e516a43879509c48930e444f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzExLTUtMS0xLTcwMjAw_56b11a48-dae8-4e41-9e2b-766395f50417"
      unitRef="usd">183626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzExLTEzLTEtMS03MDIwMA_9f60e659-f40a-4430-b681-9694c4adf702"
      unitRef="usd">183626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTEtMS0xLTcwMjAw_ad11e148-15f5-4e5c-ac70-b461de82fbc7"
      unitRef="shares">2503819</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTMtMS0xLTcwMjAw_a8330647-a9a2-4711-a386-d9c42a1833a5"
      unitRef="usd">24000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i75daa84e516a43879509c48930e444f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTUtMS0xLTcwMjAw_858423ea-2615-47db-9477-28b6212aceda"
      unitRef="usd">68032000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ife9d9bbf7294424fa7bb5a43026e8d23_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTktMS0xLTcwMjAw_1412aef0-831c-4485-8926-e0f8f9a3de66"
      unitRef="usd">-43295000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEyLTEzLTEtMS03MDIwMA_53bf0f7f-665a-4dee-b37b-5d30eddd41d6"
      unitRef="usd">24761000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTAtMS0xLTcwMjAwL3RleHRyZWdpb246NDE5NzMxZGI2ODM4NGMzZGFjM2E0Y2RlNTliMGMzOGRfMTQ4NDM0MDY5NzUwNDM_c006f6f7-856f-447b-b5b9-8aaf264c7323"
      unitRef="usd">7292000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTEtMS0xLTcwMjAw_a1db9e91-728b-4012-a660-998eb3c9a4b7"
      unitRef="shares">2578967</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i504579d4ccfc4230b080c69863a85566_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTMtMS0xLTcwMjAw_eef5c376-f604-4777-8c6c-cbd19c5fff8e"
      unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i75daa84e516a43879509c48930e444f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTUtMS0xLTcwMjAw_bb52f8da-361d-4e62-8b65-98cdaac665ef"
      unitRef="usd">564833000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzEzLTEzLTEtMS03MDIwMA_9cf1095f-02f6-4a90-891f-5d16e8a6af38"
      unitRef="usd">564859000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i47b104e574784fa7a1222f8870276e6a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE0LTExLTEtMS03MDIwMA_92740c36-e2b6-455e-8cc9-047f92b5eb68"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE0LTEzLTEtMS03MDIwMA_4a3fee2a-de68-4899-a876-a49f0bf5e0ce"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i47b104e574784fa7a1222f8870276e6a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE1LTExLTEtMS03MDIwMA_fa412264-c121-4245-8ba4-e67ea9db5c8f"
      unitRef="usd">-8368000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE1LTEzLTEtMS03MDIwMA_e2c3f24a-7d6c-4b1b-8545-1e30a36bc929"
      unitRef="usd">-8368000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i000db304d0ac493c91874d53eda30c3f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE2LTctMS0xLTcwMjAw_8b148efe-0bee-42af-b39d-60ae04ffa603"
      unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE2LTEzLTEtMS03MDIwMA_5c29e5a1-5a63-4be3-afe9-9659a1d65433"
      unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="iaecfb76823254dd19a4cf6ad1affdba6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTEtMS0xLTcwMjAw_60692afc-c535-47c8-9806-d01eafade209"
      unitRef="shares">76433151</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="iaecfb76823254dd19a4cf6ad1affdba6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTMtMS0xLTcwMjAw_86460e9f-73c3-4ebb-8ded-1858c85d5384"
      unitRef="usd">764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4138df8c406d48159527133860ea5188_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTUtMS0xLTcwMjAw_6d50c417-70be-41ab-969c-7b3b1058ff3c"
      unitRef="usd">3351967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice8277fc63064ac59b415265922b2955_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTctMS0xLTcwMjAw_4caf7f56-2308-4b90-82af-9e856b31f275"
      unitRef="usd">-3617950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i112cd4ea48f64fb4818bddbc7fbde54b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTktMS0xLTcwMjAw_930b60c8-2be6-4a02-98b9-da3d98ab5e6f"
      unitRef="usd">-85101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1a2fe6a8df24324964c4a66ca6b445a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTExLTEtMS03MDIwMA_ecec22fa-b133-415c-839c-2856aadb60d6"
      unitRef="usd">-1353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzE5LTEzLTEtMS03MDIwMA_22a34020-82f6-4a8a-ae2f-7a010092835a"
      unitRef="usd">-351673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIwLTUtMS0xLTcwMjAw_0a237d52-7a92-4936-943f-1a415d07d826"
      unitRef="usd">131967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIwLTEzLTEtMS03MDIwMA_a9315305-8872-4ee3-86dd-33119bed5792"
      unitRef="usd">131967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTEtMS0xLTcwMjAw_40b7675e-a643-4739-8912-2e202805d7bc"
      unitRef="shares">701005</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTMtMS0xLTcwMjAw_e7e7e957-0746-40d4-bd73-88eefebb6388"
      unitRef="usd">7000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTUtMS0xLTcwMjAw_22be9607-e626-4797-8ed5-451c6a0a141d"
      unitRef="usd">4912000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i8e7bd4e1044a4bfdab99267a4bec8cec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTktMS0xLTcwMjAw_8851971b-6544-4d6a-b9a0-75261a1b09e1"
      unitRef="usd">-5558000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIxLTEzLTEtMS03MDIwMA_9fe697ef-b638-411e-abe5-edeb06581e3e"
      unitRef="usd">-639000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTAtMS0xLTcwMjAwL3RleHRyZWdpb246ZDNkZjg4OTJmMzQyNDI5MWEwNTVmZTFjNGNjNDRlNDNfMTQ4NDM0MDY5NzUwMzU_3d1711d9-40a2-4370-bc2b-239aa4aa6abf"
      unitRef="usd">7216000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTEtMS0xLTcwMjAw_cfa195dd-7d0b-4e13-bd3d-c540775a5bb3"
      unitRef="shares">9672398</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic2d2a8fbdbbb480c95c63561ffa102ef_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTMtMS0xLTcwMjAw_cb277b56-7640-4e36-95fe-b2419d6a6c5f"
      unitRef="usd">97000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7ad1370cd0724afe8bebb24862499521_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTUtMS0xLTcwMjAw_0acd9f34-4f30-419c-9a66-7c6009acea96"
      unitRef="usd">249133000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzIyLTEzLTEtMS03MDIwMA_587dc7e8-6429-4f3d-91b4-a532020e5cb9"
      unitRef="usd">249230000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i461a71f67b2f48c69763adc332e28e74_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI0LTExLTEtMS03MDIwMA_e4ee5c38-958b-4ae7-b536-878ee7ca5735"
      unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI0LTEzLTEtMS03MDIwMA_418de912-2636-4bd1-8c54-0307e300f591"
      unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i5dd03da035b34b17a46b6f7abfe523e2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI1LTctMS0xLTcwMjAw_dc5261f1-ed45-4e1a-aa64-9c9ba64dac76"
      unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI1LTEzLTEtMS03MDIwMA_ab3b3a73-1613-415b-8c14-7a803849748a"
      unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i5673a51c537945239d7bb0e47db6afeb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTEtMS0xLTcwMjAw_2b5010d6-a60f-4fa3-8be5-2810204d7d85"
      unitRef="shares">86806554</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5673a51c537945239d7bb0e47db6afeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTMtMS0xLTcwMjAw_d7d8923e-974b-4501-a910-90d8a08bff4a"
      unitRef="usd">868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ff09caaa96e4bde871b650ce7a243eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTUtMS0xLTcwMjAw_ea0992b3-4234-4048-9523-b17a338bc22a"
      unitRef="usd">3737979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i643826e193814924924520e0e7696755_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTctMS0xLTcwMjAw_84073351-e41e-4ade-8a5d-bee86aed306a"
      unitRef="usd">-4275889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e0508fe92d74026bf85072a53f8d173_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTktMS0xLTcwMjAw_f6273ee5-4a2d-472d-9207-d969cb81f87d"
      unitRef="usd">-90659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cb3b3ae8c2e49b6af7301fcc04bfce2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTExLTEtMS03MDIwMA_2d013f0b-1646-4582-b5e8-1bc8ed8015f9"
      unitRef="usd">-6377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjQvZnJhZzpjOGJmZDE4NjRjM2Y0Mzg5ODcyN2M2YWY3MTRmN2UwMS90YWJsZTpiNWI0NGJlOWMyZDE0MzcxOTBjMGNmMDcwMjVmNDQ3NC90YWJsZXJhbmdlOmI1YjQ0YmU5YzJkMTQzNzE5MGMwY2YwNzAyNWY0NDc0XzI2LTEzLTEtMS03MDIwMA_a21a9f6c-db5f-4be8-afd6-2973905dd2b5"
      unitRef="usd">-634078000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMtMS0xLTEtNzAyMDA_ff599ee3-5dff-4433-b2a2-2ba01827e5ae"
      unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMtMy0xLTEtNzAyMDA_2fec0502-9678-47c3-8113-3e9264aa556d"
      unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMtNS0xLTEtNzAyMDA_217877e7-2672-440a-a2f9-5389df890e54"
      unitRef="usd">-418259000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzUtMS0xLTEtNzAyMDA_a9ce4cce-845b-411a-b13f-0eb6ee9253e6"
      unitRef="usd">29054000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzUtMy0xLTEtNzAyMDA_86a6a8ec-4352-4c03-8cfd-f377552c316b"
      unitRef="usd">12661000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzUtNS0xLTEtNzAyMDA_332307a8-b371-4fcb-82b6-d2a318ba5d63"
      unitRef="usd">4885000</us-gaap:DepreciationAndAmortization>
    <nvax:OperatingAndFinanceLeaseWriteOff
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzctMS0xLTEtNzAyMDA_34aff6a7-b90d-4843-80a1-ca7c0df214c5"
      unitRef="usd">18104000</nvax:OperatingAndFinanceLeaseWriteOff>
    <nvax:OperatingAndFinanceLeaseWriteOff
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzctMy0xLTEtNzAyMDA_70d952ed-cdaf-45a3-9050-1c9be27383b4"
      unitRef="usd">144433000</nvax:OperatingAndFinanceLeaseWriteOff>
    <nvax:OperatingAndFinanceLeaseWriteOff
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzctNS0xLTEtNzAyMDA_28dca50c-30ac-434f-9dc3-f392fdb51c04"
      unitRef="usd">245861000</nvax:OperatingAndFinanceLeaseWriteOff>
    <us-gaap:ShareBasedCompensation
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMS0xLTEtNzAyMDA_cb2dd159-44e9-4946-ad7f-e464879e529f"
      unitRef="usd">130300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMy0xLTEtNzAyMDA_5f0f1455-d759-4fa8-afd4-f897c134f944"
      unitRef="usd">183626000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtNS0xLTEtNzAyMDA_d9df1eee-a1ae-4111-ad39-822509225c22"
      unitRef="usd">128035000</us-gaap:ShareBasedCompensation>
    <nvax:ProvisionForExcessAndObsoleteInventory
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMS0xLTEtMTAxMjc1_92425b3f-f8e5-47c1-9de7-622e6601c645"
      unitRef="usd">447597000</nvax:ProvisionForExcessAndObsoleteInventory>
    <nvax:ProvisionForExcessAndObsoleteInventory
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtMy0xLTEtMTAxMjgy_fbe74f28-59bc-46d5-83d0-a2dd1087d9ec"
      unitRef="usd">0</nvax:ProvisionForExcessAndObsoleteInventory>
    <nvax:ProvisionForExcessAndObsoleteInventory
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzgtNS0xLTEtMTAxMjg5_dc87e68d-97a2-45c5-9af2-8ed894290fa8"
      unitRef="usd">0</nvax:ProvisionForExcessAndObsoleteInventory>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzktMS0xLTEtNzAyMDA_911cf833-f5de-420f-ae85-17de0cd63858"
      unitRef="usd">21903000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzktMy0xLTEtNzAyMDA_180b78e1-ee43-4809-9ec0-e15c66188dcf"
      unitRef="usd">7641000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzktNS0xLTEtNzAyMDA_c8df6a82-284c-491d-8c8f-13e19826fbbd"
      unitRef="usd">15080000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTEtMS0xLTExNDI1Mg_49384831-7d3a-4b73-8940-3b947f23b046"
      unitRef="usd">477801000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTMtMS0xLTExNDQ5NQ_c04ce03a-8ff2-4156-bdbf-af19ebf8c8ec"
      unitRef="usd">8872000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTUtMS0xLTExNDQ5NQ_f40ee7b4-f71c-40e0-9565-5f2cf6461c3d"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTEtMS0xLTcwMjAw_5adcff76-07fb-4981-868f-0de0f1eed6c1"
      unitRef="usd">-249166000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTMtMS0xLTcwMjAw_ebc5a76b-8a7a-4d35-8636-1f859b092b94"
      unitRef="usd">183393000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzExLTUtMS0xLTcwMjAw_18c0abda-032b-46e0-8551-6dbda459ca9e"
      unitRef="usd">422689000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEyLTEtMS0xLTcwMjAw_bc6c6cb0-b3c7-4a29-9fb2-b0857352447f"
      unitRef="usd">913399000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEyLTMtMS0xLTcwMjAw_fe38a5af-8ea1-47cc-af25-1e7faed9d3a3"
      unitRef="usd">600326000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEyLTUtMS0xLTcwMjAw_ae2552a5-6334-42b0-b5a2-97f2e99e7c47"
      unitRef="usd">163161000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEzLTEtMS0xLTcwMjAw_62225873-3158-4168-9de4-c425368f2907"
      unitRef="usd">-1045914000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEzLTMtMS0xLTcwMjAw_791aa00d-a96b-4751-8bdc-b9ad328ddb50"
      unitRef="usd">1325557000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzEzLTUtMS0xLTcwMjAw_0889cec6-306a-45e0-ac3f-8369402b1152"
      unitRef="usd">271545000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE0LTEtMS0xLTcwMjAw_c59325dd-a0a3-4d69-b45d-ecda32e61afd"
      unitRef="usd">-415937000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE0LTMtMS0xLTcwMjAw_1ce161dc-d709-480b-a82c-cc3ab813afec"
      unitRef="usd">322946000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE0LTUtMS0xLTcwMjAw_ea5c53a6-b6a9-45de-a2ec-d3e4e7cf9ee5"
      unitRef="usd">-42541000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForCapitalImprovements
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE2LTEtMS0xLTcwMjAw_f733f189-ea1f-4584-b857-5b3055e88dad"
      unitRef="usd">89056000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE2LTMtMS0xLTcwMjAw_bf3cc4c4-4c04-4b07-be05-4110ef53a09f"
      unitRef="usd">54501000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE2LTUtMS0xLTcwMjAw_265ddacf-b8b2-4998-adf6-2cdd9a89cfdd"
      unitRef="usd">54473000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForSoftware
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTEtMS0xLTEwMTMwNw_8ddffb9b-98c2-43c3-857b-e5c0448c882e"
      unitRef="usd">3929000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTMtMS0xLTEwMTMxNw_8c4dd714-0419-4c81-be93-2a535453d7bc"
      unitRef="usd">2985000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTUtMS0xLTEwMTMyNA_a998e350-be17-4c58-82be-e5752a70a641"
      unitRef="usd">149000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTEtMS0xLTcwMjAw_b6a94713-74eb-478a-a71f-c310dbfd0ec7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTMtMS0xLTcwMjAw_96a6d384-061d-4de2-9a58-8c5a380fbd27"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE3LTUtMS0xLTcwMjAw_2bb24980-d104-419b-8bb0-67798726a163"
      unitRef="usd">165516000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE5LTEtMS0xLTcwMjAw_26e4c205-aa3e-4f88-8801-c862c0f84577"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE5LTMtMS0xLTcwMjAw_41d163f4-aaee-40b3-b7be-72d26b8f620f"
      unitRef="usd">2167000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzE5LTUtMS0xLTcwMjAw_e9b2798f-45a2-4f55-bb4c-fa7a52ceb8d9"
      unitRef="usd">363202000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIwLTEtMS0xLTcwMjAw_f9b56228-cbf6-4a59-901f-203994fdea5d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIwLTMtMS0xLTcwMjAw_10d43bf3-a147-4393-b647-0085a14b4936"
      unitRef="usd">159807000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIwLTUtMS0xLTcwMjAw_ba7e2f6b-3689-41cd-ae69-913ba6fdef53"
      unitRef="usd">205562000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIxLTEtMS0xLTcwMjAw_8afbf2b8-41c1-4b65-9652-8383ebd2cf6d"
      unitRef="usd">-92985000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIxLTMtMS0xLTcwMjAw_613f9b69-5704-4e4f-98e1-554793c7219f"
      unitRef="usd">100154000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIxLTUtMS0xLTcwMjAw_bed595e4-bdfd-4dbd-b363-7f263024e650"
      unitRef="usd">-377778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIzLTEtMS0xLTcwMjAw_266dcc52-556d-4294-9883-e10a2f0cf524"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIzLTMtMS0xLTcwMjAw_50a796b8-3625-4838-a4df-71fc4c4abf0b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzIzLTUtMS0xLTcwMjAw_cf55bbb6-71a5-4602-b678-02cd43714a7a"
      unitRef="usd">199822000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI0LTEtMS0xLTcwMjAw_8c8f2ccb-0947-4e87-8185-f53007a2f90a"
      unitRef="usd">249230000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI0LTMtMS0xLTcwMjAw_7a38c485-ffa9-47f2-a91f-fa17d7807d67"
      unitRef="usd">564859000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI0LTUtMS0xLTcwMjAw_9266b922-5b57-47d1-b9e3-5c2c4c07c251"
      unitRef="usd">875623000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTEtMS0xLTEwNjA0NQ_39fcfbd8-af3c-459b-af76-9d11cc91e9e1"
      unitRef="usd">175250000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTMtMS0xLTEwNjA0NQ_a87b28a6-f070-43cc-8bb1-1e3ea8b873ea"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTUtMS0xLTEwNjA0NQ_b5d13fdb-0cb4-4af5-a987-34a896380d4b"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTEtMS0xLTEwNjA0OQ_1351afdd-0ace-4b5e-a6a9-9860f9388bc2"
      unitRef="usd">5258000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTMtMS0xLTEwNjA0OQ_ae13867a-6258-4280-81fd-63bb89e57e6f"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTUtMS0xLTEwNjA0OQ_529b22aa-ecc3-45f6-9ff5-1f4d0843a97f"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTEtMS0xLTcwMjAw_ce226fee-74c8-4888-b1d6-0f99d1005fea"
      unitRef="usd">-639000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTMtMS0xLTcwMjAw_fa911ce5-0084-407f-8c70-6d1b98063d45"
      unitRef="usd">24761000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI1LTUtMS0xLTcwMjAw_f06c5dfa-5ca5-4324-a25f-acd61c89994f"
      unitRef="usd">5382000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTEtMS0xLTcwMjAw_e3cf1ce3-bba5-4870-8acd-fab00b30760a"
      unitRef="usd">93595000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTMtMS0xLTcwMjAw_338e02f3-a327-4b38-b871-ee4b2703d3d9"
      unitRef="usd">127907000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI2LTUtMS0xLTcwMjAw_2294d8b4-f5be-4e41-b266-677809186b4b"
      unitRef="usd">96065000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI3LTEtMS0xLTcwMjAw_0fe4b1dd-15a8-420a-8531-5bd36ef8df33"
      unitRef="usd">324988000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI3LTMtMS0xLTcwMjAw_1005559b-0f5c-4545-80ca-33f3b6810a62"
      unitRef="usd">461713000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI3LTUtMS0xLTcwMjAw_288aac7c-8add-4ea9-a663-2c7d2508759e"
      unitRef="usd">984762000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI4LTEtMS0xLTcwMjAw_0e99e2f1-9753-4aca-a02a-a8c584490a8a"
      unitRef="usd">4520000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI4LTMtMS0xLTcwMjAw_9e93b933-5391-4e20-a91a-1efae7c10902"
      unitRef="usd">-5292000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI4LTUtMS0xLTcwMjAw_8965892f-cb13-4cde-a4fc-2c9c6f694f48"
      unitRef="usd">2115000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI5LTEtMS0xLTcwMjAw_23f68080-83db-4f1d-9624-215790c51ea9"
      unitRef="usd">-179414000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI5LTMtMS0xLTcwMjAw_c8824ea0-ee7a-44d3-80d1-095431d54ea4"
      unitRef="usd">879521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzI5LTUtMS0xLTcwMjAw_8981c42c-f3ca-4eb3-aa3c-4e92294fb65f"
      unitRef="usd">566558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMwLTEtMS0xLTcwMjAw_7b98862b-0511-4b5e-b9a2-8fd591a98b76"
      unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMwLTMtMS0xLTcwMjAw_ac43094e-6550-4112-9136-9016d9adcb0c"
      unitRef="usd">648738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iab79f65652ef4787919164353ded1194_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMwLTUtMS0xLTcwMjAw_160743ad-2d63-49f7-999b-f71a02cf0c69"
      unitRef="usd">82180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMxLTEtMS0xLTcwMjAw_ecd49807-a28d-42a8-bddc-ab138e15f0fc"
      unitRef="usd">1348845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMxLTMtMS0xLTcwMjAw_4322b060-7671-4bda-8e30-8817ff651a6d"
      unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMxLTUtMS0xLTcwMjAw_bbbc6f13-af4e-4a42-99c8-58e073c00c2e"
      unitRef="usd">648738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMzLTEtMS0xLTcwMjAw_04d6de7c-2d1c-4372-985b-64c1a47ad565"
      unitRef="usd">0</nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled>
    <nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMzLTMtMS0xLTcwMjAw_13e7115f-1bbe-402c-9025-bef2ec6b0956"
      unitRef="usd">0</nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled>
    <nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzMzLTUtMS0xLTcwMjAw_f855b6cb-d25c-4b4b-8efa-05c646631f52"
      unitRef="usd">3227000</nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM0LTEtMS0xLTcwMjAw_d88a0ecd-e1b6-4e7b-bd40-25bbb1d42ecf"
      unitRef="usd">17665000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM0LTMtMS0xLTcwMjAw_526f959e-8efa-4091-a234-5725672e49b7"
      unitRef="usd">10338000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM0LTUtMS0xLTcwMjAw_e7308425-6ef9-417c-9d9a-f8a882e3a930"
      unitRef="usd">9255000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM1LTEtMS0xLTcwMjAw_63d5b79e-4687-4dda-9593-985d2ae4af46"
      unitRef="usd">91855000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM1LTMtMS0xLTcwMjAw_6eaa6119-d9bf-4572-bb78-9f6da2b424aa"
      unitRef="usd">179210000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM1LTUtMS0xLTcwMjAw_c91afee8-067e-448c-9a10-1152fd0d43ba"
      unitRef="usd">247599000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <us-gaap:InterestPaidNet
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM3LTEtMS0xLTcwMjAw_b91007c7-9984-48e0-9d1a-93f20e6d3f4a"
      unitRef="usd">18035000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM3LTMtMS0xLTcwMjAw_09aaa123-c1ce-4034-ab0b-b590df858b51"
      unitRef="usd">19428000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM3LTUtMS0xLTcwMjAw_3ca4a886-cdef-4918-8a4a-83a201c19b7d"
      unitRef="usd">13705000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM4LTEtMS0xLTcwMjAw_d60d9375-1fc0-4a55-8446-3c937f38aea9"
      unitRef="usd">17980000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM4LTMtMS0xLTcwMjAw_bbb447b4-f595-40d1-8805-e41b65939483"
      unitRef="usd">12606000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMjcvZnJhZzplNTNkMzhmNjViMDY0M2I0OGJhZDNlN2Y4NDA3NjRiNS90YWJsZTo5ODk5M2IyNjY2MGQ0NTQzOTFjNjc0ZjUzM2U3Nzg4OS90YWJsZXJhbmdlOjk4OTkzYjI2NjYwZDQ1NDM5MWM2NzRmNTMzZTc3ODg5XzM4LTUtMS0xLTcwMjAw_a54dc54b-8048-4762-ba03-955f76ba982f"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:NatureOfOperations
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzMvZnJhZzoxN2Y5YWMzMjZlOWQ0Y2Q4YjgzY2Y0NTJlNzYwMzhjZC90ZXh0cmVnaW9uOjE3ZjlhYzMyNmU5ZDRjZDhiODNjZjQ1MmU3NjAzOGNkXzIxNjE_1cb32208-4a7f-4c69-9022-028b94142a49">Organization&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novavax, Inc. (&#x201c;Novavax,&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The Company&#x2019;s COVID-19 vaccine NVX-CoV2373 (&#x201c;Nuvaxovid&#x2122;,&#x201d; &#x201c;Covovax&#x2122;,&#x201d; &#x201c;Novavax COVID-19 Vaccine, Adjuvanted&#x201d;); influenza vaccine candidate; COVID-19-Influenza Combination (&#x201c;CIC&#x201d;) vaccine candidate; and additional vaccine candidates, including for Omicron subvariants and bivalent formulations with prototype vaccine (&#x201c;NVX-CoV2373&#x201d;), are genetically engineered nanostructures of conformationally correct recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or other vaccine approaches. NVX-CoV2373 and the Company&#x2019;s other vaccine candidates incorporate the Company's proprietary Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response. The Company has announced data from its ongoing PREVENT-19 study supporting the use of NVX-CoV2373 for homologous boosting in adults and adolescents aged 12 through 17. Additional findings in Phase 3 COVID-19 Omicron (study 311) trial showed utility of the prototype vaccine as a heterologous booster, inducing broad immune responses against contemporary Omicron variants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#x201c;EUA&#x201d;) from multiple regulatory authorities globally for NVX-CoV2373 for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commenced commercial shipments of NVX-CoV2373 doses under the name &#x201c;Novavax COVID-19 Vaccine, Adjuvanted&#x201d; and the brand name &#x201c;Nuvaxovid&#x2122;&#x201d; in 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzA3_da6c4a64-7718-4101-9253-ba6244c8fecd">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. At December 31, 2022, the Company had $1.3 billion in cash and cash equivalents and restricted cash, of which $236.2 million was raised in December 2022 through concurrent sales of common stock and issuance of the Company&#x2019;s convertible senior unsecured notes that will mature on December 15, 2027 (see Notes 11 and 13). On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on the Company&#x2019;s convertible senior unsecured notes that matured on&#160;February&#160;1, 2023. During 2022, the Company incurred a net loss of $657.9 million and had net cash flows used in operating activities of $415.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company&#x2019;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration. The Company&#x2019;s 2023 revenue depends on its ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. In February 2023, in connection with the execution of Modification 17 to the USG Agreement (as defined in Note 3), the U.S. government indicated to the Company that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as the Company&#x2019;s management had previously expected, then the Company may not receive all of the remaining $416&#160;million in funding that was previously anticipated pursuant to the USG Agreement. On January 24, 2023, Gavi, the Vaccine Alliance (&#x201c;Gavi&#x201d;) filed a demand for arbitration with the International Court of Arbitration regarding an alleged material breach by the Company of the Company&#x2019;s advance purchase agreement with Gavi (&#x201c;the Gavi APA&#x201d;). The outcome of that arbitration is inherently uncertain, and it is possible the Company could be required to refund all or a portion of the remaining advance payments of $697.4&#160;million (see Note 3 and Note 18). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that, given the significance of these uncertainties, substantial doubt exists regarding the Company&#x2019;s ability to continue as a going concern through one year from the date that these financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to fund Company operations is dependent upon revenue related to vaccine sales for its products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters, including whether, when, and how the dispute with Gavi is resolved; and management&#x2019;s plans, which include resolving the dispute with Gavi and may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of NVX-CoV2373 and the Company&#x2019;s other vaccine candidates, including an influenza vaccine candidate, CIC vaccine candidate, or a COVID-19 variant strain-containing monovalent or bivalent formulation, remains uncertain. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, revenue recognition, inventory, research and development expenses, stock-based compensation, useful lives of long-lived assets, leases, and income taxes. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), or are contributions subject to the guidance in ASC Topic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities &#x2013; Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 958-605&#x201d;). The Company recognizes revenue from arrangements within the scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are associated with the Company&#x2019;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#x201c;APAs&#x201d;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of NVX-CoV2373.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of NVX-CoV2373 to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#x201c;EAC&#x201d;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#x2019;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#x2019;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s other funding agreements currently include funding from CEPI in the form of a grant (&#x201c;CEPI Grant Funding&#x201d;) and one or more forgivable no interest term loans (&#x201c;CEPI Forgivable Loan Funding&#x201d;). Under the Company&#x2019;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of NVX-CoV2373. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the contract manufacturing organization (&#x201c;CMO&#x201d;) network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#x2019;s Gavi APA prior to its termination), and such sales cover the Company&#x2019;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 730&#x201d;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#x2019;s policy of presenting such amounts as revenue. In reaching this determination, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#x2019;s core operations. The Company will record revenue as it performs the contractual research and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalties and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#x2019;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#x2019;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#x201c;Inventory.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#x201c;CROs&#x201d;), CMOs, and contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;); and other expenses associated with the Company&#x2019;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#x2019;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. The Company had advertising costs of $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#x201c;SARs&#x201d;), and restricted stock awards (&#x201c;RSUs&#x201d;), and purchases under the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcx_287a37ee-2b5f-45a2-a262-d63f80394c20"&gt;one&lt;/span&gt; to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#x2019;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements. As of December&#160;31, 2022 and 2021, the restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. The Company evaluates outstanding receivables to assess collectability, with consideration given to economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#x2019;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Revenue&lt;br/&gt;&#160;for Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Accounts Receivable as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;European Commission&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gavi, the Vaccine Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CEPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SK bioscience, Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Amounts represent less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and Department of Defense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently depends exclusively on a single supplier for co-formulation, filling, and finishing NVX-CoV2373. The loss of this supplier could prevent or delay the Company&#x2019;s delivery of customer orders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred. The estimated useful lives of property and equipment are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining term of the lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#x2019;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#x2019;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#x201c;ROU&#x201d;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#x2019;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#x201c;short-term&#x201d; leases), the Company has elected to apply the practical expedient in ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#x2019;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company calculates the estimated fair value of a long-lived asset or asset group using the income approach. Impairment losses are recognized when the sum of expected future cash flows is less than the asset&#x2019;s or asset group&#x2019;s carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development of recombinant vaccines, it operates as a single operating segment and has one reporting unit. The Company primarily utilizes the market approach and, if considered necessary, the income approach to determine if it has an impairment of its goodwill. The market approach is based on market value of invested capital. To ensure that the Company&#x2019;s capital stock is the appropriate measurement of fair value, the Company considers factors such as its trading volume, diversity of investors, and analyst coverage. If considered necessary, the income approach is used to corroborate the results of the market approach. Goodwill impairment may exist if the carrying value of the reporting unit exceeds its estimated fair value. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#x2019;s goodwill over its implied fair value, should such a circumstance arise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At October 1, 2022 and 2021, the fair value of the Company&#x2019;s single reporting unit was substantially higher than its carrying value, resulting in no impairment to goodwill as of October 1, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the Company recognized $4.3 million and $29.2 million, respectively, primarily in income tax expense related to foreign withholding tax on royalties. During the year ended December&#160;31, 2020, the Company recognized no income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period, primarily convertible notes, stock options, SARs, and unvested RSUs. As of December&#160;31, 2022, the Company's 2027 Notes and 2023 Notes (see Note 11) would have been convertible into approximately 16.4 million shares of the Company's common stock assuming the common stock price is equal to or greater than $12.50 and $136.20, respectively. These shares, after giving effect to the add back of interest expense and unamortized discounts and debt issuance costs on the Notes and any shares due to the Company upon settlement of its capped call transactions, are excluded from the computation, as their effect is antidilutive under the if-converted method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#x2019;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income (loss) was $(6.4) million and $(1.4) million at December&#160;31, 2022 and 2021, respectively. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were $(2.5)&#160;million, $(5.3)&#160;million, and $9.6&#160;million for the years ended December&#160;31, 2022, 2021, and 2020 respectively, which are reflected in Other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its business as one operating segment: the development of recombinant vaccines. The Company does not operate separate lines of business with respect to its vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management has evaluated the effect of the guidance and its implementation will not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg3_11ea9253-8db8-4b98-bab2-1f5d50cfa02c">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <nvax:LiquidityAndGoingConcernPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjE4MDE4_491900af-b3ba-499d-85ed-511feae0a857">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. At December 31, 2022, the Company had $1.3 billion in cash and cash equivalents and restricted cash, of which $236.2 million was raised in December 2022 through concurrent sales of common stock and issuance of the Company&#x2019;s convertible senior unsecured notes that will mature on December 15, 2027 (see Notes 11 and 13). On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on the Company&#x2019;s convertible senior unsecured notes that matured on&#160;February&#160;1, 2023. During 2022, the Company incurred a net loss of $657.9 million and had net cash flows used in operating activities of $415.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company&#x2019;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration. The Company&#x2019;s 2023 revenue depends on its ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 for the fall 2023 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. In February 2023, in connection with the execution of Modification 17 to the USG Agreement (as defined in Note 3), the U.S. government indicated to the Company that the award may not be extended past its current period of performance. If the USG Agreement is not amended, as the Company&#x2019;s management had previously expected, then the Company may not receive all of the remaining $416&#160;million in funding that was previously anticipated pursuant to the USG Agreement. On January 24, 2023, Gavi, the Vaccine Alliance (&#x201c;Gavi&#x201d;) filed a demand for arbitration with the International Court of Arbitration regarding an alleged material breach by the Company of the Company&#x2019;s advance purchase agreement with Gavi (&#x201c;the Gavi APA&#x201d;). The outcome of that arbitration is inherently uncertain, and it is possible the Company could be required to refund all or a portion of the remaining advance payments of $697.4&#160;million (see Note 3 and Note 18). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that, given the significance of these uncertainties, substantial doubt exists regarding the Company&#x2019;s ability to continue as a going concern through one year from the date that these financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to fund Company operations is dependent upon revenue related to vaccine sales for its products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters, including whether, when, and how the dispute with Gavi is resolved; and management&#x2019;s plans, which include resolving the dispute with Gavi and may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of NVX-CoV2373 and the Company&#x2019;s other vaccine candidates, including an influenza vaccine candidate, CIC vaccine candidate, or a COVID-19 variant strain-containing monovalent or bivalent formulation, remains uncertain. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.&lt;/span&gt;&lt;/div&gt;</nvax:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MTExNDQ_328df23e-405b-4106-98fd-c19a2c44d3d4"
      unitRef="usd">1300000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nvax:ProceedsFromIssuanceCommonStockAndDebt
      contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDAyNjE_e70e10f6-b1e7-4974-a19d-12686b2057c4"
      unitRef="usd">236200000</nvax:ProceedsFromIssuanceCommonStockAndDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i63a2de06fc1f42a69276ce8a6224e6a0_D20230131-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDA0NTQ_3fdb8611-4041-4504-b91b-325c3df443c4"
      unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MTExNTM_45749e6e-fb6f-4bb3-94ea-0ee0d7a95205"
      unitRef="usd">-657900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDA1NzU_a7cd5577-b003-4f86-b5c7-fcc2e24d64fe"
      unitRef="usd">-415900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining
      contextRef="i673cb8037c324c8994caf3306884a92e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MjA3OTc_885de22a-675c-49dc-9f3c-2a9fcec2aa75"
      unitRef="usd">416000000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjM0MDYzNjY_8f556068-c6cf-4287-82bf-ab17568f8af7"
      unitRef="usd">697400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg4_597f753c-d62f-4bb9-aac1-03f6f1038a21">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODQ4_b6ad244d-7833-4fca-9dfc-2938704deef7">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, revenue recognition, inventory, research and development expenses, stock-based compensation, useful lives of long-lived assets, leases, and income taxes. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODQ5_88550cb5-93df-4ce5-b463-936892113da9">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), or are contributions subject to the guidance in ASC Topic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities &#x2013; Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 958-605&#x201d;). The Company recognizes revenue from arrangements within the scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are associated with the Company&#x2019;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#x201c;APAs&#x201d;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of NVX-CoV2373.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of NVX-CoV2373 to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#x201c;EAC&#x201d;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#x2019;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#x2019;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s other funding agreements currently include funding from CEPI in the form of a grant (&#x201c;CEPI Grant Funding&#x201d;) and one or more forgivable no interest term loans (&#x201c;CEPI Forgivable Loan Funding&#x201d;). Under the Company&#x2019;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of NVX-CoV2373. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the contract manufacturing organization (&#x201c;CMO&#x201d;) network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#x2019;s Gavi APA prior to its termination), and such sales cover the Company&#x2019;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 730&#x201d;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#x2019;s policy of presenting such amounts as revenue. In reaching this determination, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#x2019;s core operations. The Company will record revenue as it performs the contractual research and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalties and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#x2019;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUw_5d07722c-ce4c-416d-a97f-98652a0a09dc">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#x2019;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#x201c;Inventory.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUx_ca885670-d026-419b-983a-6ee030f8400a">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#x201c;CROs&#x201d;), CMOs, and contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;); and other expenses associated with the Company&#x2019;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nvax:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUy_43f4e593-d055-48f3-bac3-13291e250405">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#x2019;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.&lt;/span&gt;&lt;/div&gt;</nvax:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcw_df8c70e7-5f64-422a-a9cf-2e16757cee02">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. The Company had advertising costs of $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzM4NjI_7cbc6131-b6e0-4b0e-b992-0269ef0ec810"
      unitRef="usd">84000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzM4NzA_0c9e2e90-5b12-4af8-8f1a-adf893862c43"
      unitRef="usd">8900000</us-gaap:AdvertisingExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMTc1ODUz_36d1fd3f-e5c0-49af-b4a3-ca672504091d">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#x201c;SARs&#x201d;), and restricted stock awards (&#x201c;RSUs&#x201d;), and purchases under the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTcx_287a37ee-2b5f-45a2-a262-d63f80394c20"&gt;one&lt;/span&gt; to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#x2019;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="id78b588331a244138048f135d4c38cb8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTgy_a6808dab-ad8d-4770-85ac-7cfb3cf3eaf0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk1_2f38f38b-9e98-4e90-ac72-c2f93bd0f9dd">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzEy_8271be5a-1074-4a35-9578-a083e68dbc4c">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzAy_b86b9289-42f1-4022-b5f1-b6ccb403e3d3">Restricted CashThe Company&#x2019;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk4_972fb959-9216-4bd3-ac4f-9624844aebfb">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. The Company evaluates outstanding receivables to assess collectability, with consideration given to economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk3_852ea386-105a-48f2-8b7a-e11eabcdb577">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#x2019;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company currently depends exclusively on a single supplier for co-formulation, filling, and finishing NVX-CoV2373. The loss of this supplier could prevent or delay the Company&#x2019;s delivery of customer orders.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzA4_27a8d811-40af-49ef-90c7-80ef852cb3cb">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Revenue&lt;br/&gt;&#160;for Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Accounts Receivable as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;European Commission&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gavi, the Vaccine Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CEPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SK bioscience, Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Amounts represent less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and Department of Defense.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0708fc22c9854f0abba5629785850b62_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItMS0xLTEtMTExMjgz_45265c30-7946-47fa-9b79-c7469ddefb74"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0df39d26bc0a425688c0db2d06381f38_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItNy0xLTEtMTExMzAx_c7a77984-2d06-4a6f-87e3-67459c72f185"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iacf56722506e4a18bd6e4b8223b6c740_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzMtMS0xLTEtMTExNDEz_1b1abf98-e173-4bd8-bce4-0e78f1480d20"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d86c3d5bfd54e03b15f74461ed5ae3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzQtMS0xLTEtMTE4ODUy_c239047b-2350-4322-9725-d373ec387788"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8171acc620e44403a1acf786d872dcea_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzQtNy0xLTEtMTE4NDI3_0d877880-5e8e-4dbf-bad5-bc3e3f933615"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idd7831a5ea8c46faaaeebc166d30480f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzUtOS0xLTEtMTE4Mzgz_602df0e2-7951-4a29-a4f7-7b15788ee93a"
      unitRef="number">0.77</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iae09a72a1ca3430c9be92032270e60ab_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItMS0xLTEtNzAyMDA_0c45d528-6a99-44a8-8d53-8db73aa2d591"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i229f36f7f6ec4f50a926d184ce91f415_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItMy0xLTEtNzAyMDA_49431de5-6e92-4852-b54c-b9fb162f2da0"
      unitRef="number">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3ac0cbe72c504988bee96db8bb6544d7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItNS0xLTEtNzAyMDA_aef1320f-b77c-47ef-986e-45d76c03a4db"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia39f087502cf47ae90d1570eb534945f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzItNy0xLTEtNzAyMDA_062b9f8e-e9a2-410b-b289-0d87870634a1"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9d52b1aaa828491996f21dccbd34a922_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzMtMy0xLTEtNzAyMDA_5cdd01ef-b4f4-4ec0-90c4-7d98197574e8"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1404a3a6dc674929bfd21739b3442b4c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzMtNS0xLTEtNzAyMDA_f0eb1211-53d3-4e4a-a5a1-39379d4a87b2"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie8db9b8a25904abfbbb2438880a81408_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTozZGFlOGQ3ZjU0ODg0OWE0OGI3NzRmMWU4YTM2ODhmZC90YWJsZXJhbmdlOjNkYWU4ZDdmNTQ4ODQ5YTQ4Yjc3NGYxZThhMzY4OGZkXzUtMy0xLTEtNzAyMDA_76431849-6bd5-48e2-8076-d92dafcf44de"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg5_92070919-0e12-4228-8808-3463fde4d786">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjkw_0bb3c4cf-235e-47ea-97b0-62daa42281d6">Property and EquipmentProperty and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjg1_3f4eaa90-32d1-433b-9b92-673d8ba7c49d">The estimated useful lives of property and equipment are described below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining term of the lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is comprised of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;341,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;251,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7b3c9b3cf2a747ce9a1576cadc4c0a46_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzEtMS0xLTEtNzAyMDA_80e39476-f932-420a-8e01-b1a092001cec">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9d166751ab7a4c9c8c0655ff4da76514_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiYWVjYzg5YjI1ZjQ0ZjViYjk1Mjg5Mjc4NWUzZWIwNl80_68cc1687-f80a-439d-9ae0-eb0454352400">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6203e4280b4a484f87366338bb51639b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiYWVjYzg5YjI1ZjQ0ZjViYjk1Mjg5Mjc4NWUzZWIwNl85_a1406bf0-f5ae-4daa-8ea4-60abaa3d2bf5">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic60027bdd04f4daa9e2d29cfb0744509_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90YWJsZTo2M2U3MWJmYTg1Y2I0ZmVhYjZkMzcxYTIzNTk4N2JiYi90YWJsZXJhbmdlOjYzZTcxYmZhODVjYjRmZWFiNmQzNzFhMjM1OTg3YmJiXzMtMS0xLTEtNzAyMDA_5806bed1-2e3f-4621-8cfa-0e73b38bd75f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzAz_3a987e41-fc8b-46a1-ba20-90842f3e9a29">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#x2019;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#x2019;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#x201c;ROU&#x201d;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#x2019;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#x201c;short-term&#x201d; leases), the Company has elected to apply the practical expedient in ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#x2019;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjkx_0cd7fbbf-b9ef-487e-9c1a-90d0e08fdcef">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company calculates the estimated fair value of a long-lived asset or asset group using the income approach. Impairment losses are recognized when the sum of expected future cash flows is less than the asset&#x2019;s or asset group&#x2019;s carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzA0_70df8c20-87b1-43b0-bf88-983e765a2146">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development of recombinant vaccines, it operates as a single operating segment and has one reporting unit. The Company primarily utilizes the market approach and, if considered necessary, the income approach to determine if it has an impairment of its goodwill. The market approach is based on market value of invested capital. To ensure that the Company&#x2019;s capital stock is the appropriate measurement of fair value, the Company considers factors such as its trading volume, diversity of investors, and analyst coverage. If considered necessary, the income approach is used to corroborate the results of the market approach. Goodwill impairment may exist if the carrying value of the reporting unit exceeds its estimated fair value. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#x2019;s goodwill over its implied fair value, should such a circumstance arise.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMTk5_5ce377e5-7b16-461b-87c1-3842359acef2"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i40a83ca620bd452aa6f58f72d2c85402_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMjA5_056e6ea1-9ea3-40bb-b955-413672ab3be4"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icee78a963bab4b348f7582b0b78785d0_D20221001-20221001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMjA5_f471d1ed-95e3-4931-8602-9ea540f61fcd"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzEz_0c0870d0-a1d8-48f3-9490-15f16f6adc7c">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance &lt;/span&gt;&lt;/div&gt;in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDYyMDg3_e9268816-9b18-439d-b491-790e47e89a81"
      unitRef="usd">4300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDYyMDk2_a92bdca8-fef6-4e1f-8e02-469a12a3a015"
      unitRef="usd">29200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDY0MDY1_5e85bdb4-9786-4c5e-9fdf-18a0abad04e0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjkz_88daf1da-ae6f-4acf-a82e-cdd0264a4e35">Net Loss per ShareBasic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period, primarily convertible notes, stock options, SARs, and unvested RSUs.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i7a081a82e367415892816cf19c0e6996_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzIwNTQ_1ab69c7a-7f02-4306-aa2a-26a3bd23e4a8"
      unitRef="shares">16400000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i42c53c7f16bb4d359be44c56e5a93d6d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxOTkwMjMzNzIwNTQ_e8c97b0c-b83e-4b1a-8a3d-6adc070ab118"
      unitRef="shares">16400000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg1NjM1_08ca07ae-4d21-4b13-b6b5-def4a1e1322b"
      unitRef="usdPerShare">12.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg5MDE2_ea0846b5-19dc-4003-bc50-1c2ded5bf7ad"
      unitRef="usdPerShare">136.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2MzAw_796123fe-66c8-4de8-8a6a-c0ef984a3762">Foreign CurrencyThe accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#x2019;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg1MTQ3_c738f9de-699d-4cd7-8c10-e28cf30726e1"
      unitRef="usd">-6400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzE0ODQzNDA3MDg5MDIz_6411a1ca-fedc-4795-8e0c-4000d7eaf604"
      unitRef="usd">-1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzU0OTc1NTgyNTU0MTM_26956e1a-5170-42ca-9e74-5d4db873a39d"
      unitRef="usd">-2500000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzU0OTc1NTgyNTU0MTg_3707efa0-ad83-4c89-8adb-3440089933d9"
      unitRef="usd">-5300000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzIxNDQwNDc2ODY4MDE2_772c07ae-51bc-45bd-9505-37594233c6c2"
      unitRef="usd">9600000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjky_103cc875-25b3-499b-8e56-1e84e3a9e576">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its business as one operating segment: the development of recombinant vaccines. The Company does not operate separate lines of business with respect to its vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzExNTQ0ODcyMjExMjIw_b091fd9b-918e-4210-adac-1b6f1b01addc"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzYvZnJhZzpjOTc2YzJhY2U4ZjA0ODliYmI0ZTljYmRmOGFlYzljZi90ZXh0cmVnaW9uOmM5NzZjMmFjZThmMDQ4OWJiYjRlOWNiZGY4YWVjOWNmXzM2Mjk5_45a77ee4-c1a5-4a50-aa61-1377dbe0fc39">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management has evaluated the effect of the guidance and its implementation will not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIwNzQ3_b1d2e63c-22dc-4c05-92d1-c6f577207ca8">Revenue&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accounts receivable included $53.8 million and $419.7 million related to amounts that were billed to customers and $28.6 million and $35.3 million related to amounts which had not yet been billed to customers as of December&#160;31, 2022 and 2021, respectively. During the years ended December&#160;31, 2022 and 2021, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,127,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,432,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,239,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for doubtful accounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,092,829)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended December&#160;31, 2022 and there was no bad debt expense in the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Amount is comprised of $0.4&#160;billion, $1.4&#160;billion, and $0.3&#160;billion current Deferred revenue and $179.4&#160;million, $172.5&#160;million, and no non-current Deferred revenue as of December&#160;31, 2022, 2021, and 2020 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;Deductions from Deferred revenue include the following: $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) at issue in the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below. In the fourth quarter of 2022, the Company recognized revenue of $41.9&#160;million related to a change in estimate attributed to changes in constraint of variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $3&#160;billion as of December&#160;31, 2022, which excludes amounts related to the Company&#x2019;s APA (&#x201c;the Gavi APA&#x201d;) with Gavi, the Vaccine Alliance (&#x201c;Gavi&#x201d;) and the reduction in doses related to the Amended and Restated UK Supply Agreement, as defined below. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#x2019;s APAs may require the Company to refund portions of upfront payments or result in reduced future payments, which could adversely impact the Company&#x2019;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 vaccine under certain of the Company&#x2019;s APAs. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Gavi APA and a separate purchase agreement between Gavi and Serum Institute of India Pvt. Ltd. (&#x201c;SIIPL&#x201d;), 1.1 billion doses of NVX-CoV2373 were to be made available to countries participating in the COVAX Facility. The Company expected to manufacture and distribute 350&#160;million doses of NVX-CoV2373 to countries participating under the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the balance of the 1.1 billion doses of NVX-CoV2373 for low- and middle-income countries participating in the COVAX Facility. The Company expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under the Company's funding agreement with CEPI, with initial doses supplied by SIIPL and Serum Life Sciences Limited (&#x201c;SLS&#x201d;) under a supply agreement. The Company expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, the Company could provide additional doses of NVX-CoV2373, to the extent available from CEPI funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, the Company received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in the first quarter of 2022 related to the Company&#x2019;s achieving EUL for NVX-CoV2373 by the WHO (the &#x201c;Advance Payment Amount&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#x2019;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#x2019;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the Company&#x2019;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#x2019;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that it could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue by the Company&#x2019;s customer&#x2019;s geographic location was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;North America&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rest of the world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an APA with the European Commission (&#x201c;EC&#x201d;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. Under the terms of the APA, the Company agreed to manufacture the vaccine in facilities located in the European Union and ensure continued efficacy of the vaccine against variants of the SARS-CoV-2 virus. Pursuant to the terms of the APA, the Company is prohibited from supplying NVX-CoV2373 to any third party if such delivery would impede or limit the fulfillment of the Company&#x2019;s obligations to the European Commission under the APA, except with respect to the Company&#x2019;s obligations under the Gavi APA. In 2022, the Company was notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, the Company finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022 and are expected to be delivered in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#x201c;Amended and Restated UK Supply Agreement&#x201d;) with The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#x201c;Authority&#x201d;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#x201c;Original UK Supply Agreement&#x201d;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373 and made an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upfront payment to the Company. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#x201c;Conditional Doses&#x201d;) of NVX-CoV2373, with the number of Conditional Doses contingent on, and subject to reduction based on, the Company&#x2019;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#x201c;JCVI&#x201d;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority does not purchase the Conditional Doses or the number of such Conditional Doses is reduced below 15&#160;million doses of NVX-CoV2373, the Company would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of November 30, 2022, the JCVI had not yet made a supportive recommendation with respect to NVX-CoV2373, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, the Company&#x2019;s timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation of the Company to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement, which is reflected in Other current liabilities, with the remaining upfront payment balance of $112.5&#160;million reflected in current Deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized grant revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;USG Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. DoD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;CEPI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other grant revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a Project Agreement (the &#x201c;Project Agreement&#x201d;) with Advanced Technology International, Inc. (&#x201c;ATI&#x201d;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed. Operation Warp Speed was a partnership among components of the U.S. Department of Health and Human Services and the U.S. Department of Defense working to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The Project Agreement relates to the Base Agreement the Company entered into with ATI in June 2020 (the &#x201c;Base Agreement,&#x201d; together with the Project Agreement, the &#x201c;USG Agreement&#x201d;). The original USG Agreement required the Company to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of NVX-CoV2373, and to manufacture and deliver to the U.S. government 100&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to the Company for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the U.S. government&#x2019;s interest. If the Project Agreement is terminated prior to completion, the Company is entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. In July 2022, the Company entered into a modification to the USG Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373 and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100&#160;million doses of NVX-CoV2373 contemplated by the original USG Agreement (inclusive of the initial batch of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately 3&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The 3&#160;million initial doses were delivered in July 2022. The performance period under the Project Agreement extends through 2023 to cover clinical trial activities, subject to early termination by the U.S. government or extension by mutual agreement of the parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the USG Agreement, the Company was originally entitled to funding of up to $1.75&#160;billion to support certain activities related to the development of NVX-CoV2373 and the manufacture and delivery of the vaccine candidate to the U.S. government. In subsequent modifications, the Company's USG Agreement was amended to increase the contract funding and ceiling to $1.8&#160;billion, which allows the Company to make expenditures or incur obligations of up to $1.8&#160;billion for support of the USG Agreement. As of December&#160;31, 2022, the Company had recognized $1.4&#160;billion in revenue related to the USG Agreement since the inception of the contract, leaving $0.4&#160;billion remaining to spend.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Department of Defense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a letter contract that was later amended in January 2021 (the &#x201c;DoD Contract&#x201d;) with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (&#x201c;JPEO-CRBND-EB&#x201d;), under which JPEO-CRBND-EB agreed to provide funding of up to $45.7&#160;million to the Company to support the manufacture of NVX-CoV2373. The Company is authorized to make expenditures or incur obligations up to the full amount of the funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the DoD Contract, the Company originally expected to deliver 10&#160;million doses of NVX-CoV2373 to the DoD. The 10&#160;million doses of NVX-CoV2373 could be used in Phase 2/3 clinical trials or under an EUA, if approved by the FDA. Pursuant to the DoD Contract, after NVX-CoV2373 is approved by the FDA, the DoD is entitled to most-favored customer status for a period of five years from the award of the DoD Contract, meaning that the Company cannot give any comparable commercial client in the United States more favorable pricing than the DoD under similar transactional circumstances. In July 2022, the Company modified its existing agreement with the DoD and delivered 0.2&#160;million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining 9.8&#160;million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding. The term of the DoD Contract expired in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company entered into a restated funding agreement which was amended in November 2020 with CEPI, under which CEPI agreed to provide funding of up to $399.5&#160;million to the Company to support the development of NVX-CoV2373. The agreement provides up to $257.0&#160;million in CEPI Grant Funding and up to $142.5&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans in order to prepay certain manufacturing activities and are not subject to restrictive or financial covenants. As of December&#160;31, 2022 and 2021, the Company had recognized total revenue related to CEPI of $358.6&#160;million, with the unused amounts primarily related to CEPI Forgivable Loan Funding. Payments received under the CEPI Forgivable Loan Funding are only repayable if NVX-CoV2373 manufactured by the CMO network funded by CEPI is sold to one or more third parties (which would have previously included, but is not limited to, any sales under the Company&#x2019;s Gavi APA prior to its termination), and such sales cover the Company&#x2019;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022 and 2021, the Company recognized $9.0&#160;million and $178.6&#160;million, respectively, in revenue related to sales-based royalties, which is reflected in Royalties and other revenue. For the years ended December&#160;31, 2022 and 2020, the Company recognized $20.0&#160;million upon the sale of NVX-CoV2373 in Japan and $20.0&#160;million related to a development milestone payment, respectively.&lt;/span&gt;&lt;/div&gt;Collaboration and License Agreements&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Serum Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company's Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#x2019;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#x2019;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company granted to SIIPL (i) an exclusive license in India during the agreement and (ii) a non-exclusive license (a) during the &#x201c;Pandemic Period&#x201d; (as declared by the WHO) in all countries other than specified countries designated by the World Bank as upper-middle or high-income countries, with respect to which the Company retains rights, and (b) after the Pandemic Period, in only those countries designated as low or middle-income by the World Bank. Following the Pandemic Period, the Company may notify SIIPL of any bona fide opportunities for the Company to license NVX-CoV2373 to a third party in such low and middle-income countries and SIIPL would have an opportunity to match or improve such third-party terms, failing which, the Company would have the discretion to remove one or more non-exclusive countries from SIIPL&#x2019;s license. The Company also has a supply agreement with SIIPL and SLS under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#x2122; adjuvant supplied by the Company. In May and August 2022, the Company expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s), its quadrivalent influenza vaccine candidate, and its CIC vaccine candidate, so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, a quadrivalent influenza vaccine, and CIC vaccine, and supply such vaccines to the Company. In March 2020, the Company granted SIIPL a non-exclusive license for the use of Matrix-M&#x2122; adjuvant supplied by the Company to develop, manufacture, and commercialize R21, a malaria candidate developed by the Jenner Institute, University of Oxford.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases Matrix-M&#x2122; adjuvant from the Company to manufacture doses of NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373. In September 2021, Takeda finalized an agreement with the Government of Japan&#x2019;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of NVX-CoV2373. In February 2023, MHLW cancelled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the years ended December&#160;31, 2022 and 2020, the Company recognized $20.0&#160;million upon the sale of NVX-CoV2373 in Japan and $20.0&#160;million related to a development and commercial milestone payment, respectively, which are included in Royalties and other revenue on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SK bioscience, Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#x201c;SK bioscience&#x201d;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of South Korea, Thailand, and Vietnam. SK bioscience finalized an APA with the Korean government to supply 40&#160;million doses of NVX-CoV2373 to the Republic of Korea beginning in 2021. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#x2019;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. The companies also signed an agreement to manufacture and supply NVX-CoV2373 in a prefilled syringe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#x201c;FDBK&#x201d;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#x201c;FDBT&#x201d;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#x201c;FDBU&#x201d; and together with FDBK and FDBT, &#x201c;Fujifilm&#x201d;) entered into a Confidential Settlement Agreement and Release (the &#x201c;Fujifilm Settlement Agreement&#x201d;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#x201c;Fujifilm CSA&#x201d;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#x201c;Fujifilm MSA&#x201d;) by and between the Company and Fujifilm. The Fujifilm MSA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Fujifilm CSA established the general terms and conditions applicable to Fujifilm&#x2019;s manufacturing and supply activities related to NVX-CoV2373 under the associated statements of work.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Fujifilm Settlement Agreement, the Company is responsible for payment of up to $185.0&#160;million (the &#x201c;Settlement Payment&#x201d;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT under the Fujifilm CSA, of which (i) $47.8&#160;million, constituting the initial reservation fee under the Fujifilm CSA, was credited against the Settlement Payment on September 30, 2022 and (ii) the remaining balance is to be paid in four equal quarterly installments of $34.3&#160;million each beginning March 31, 2023. As of December&#160;31, 2022, the remaining payment of $137.2&#160;million was reflected in Accrued expenses. Under the Fujifilm Settlement Agreement, Fujifilm is required to use commercially reasonable efforts to mitigate the losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the Fujifilm CSA, and the final two quarterly installments will be mitigated by any replacement revenue achieved by Fujifilm between July 1, 2023 and December 31, 2023. The Settlement Payment is less than amounts previously recognized as embedded lease expense and reflected in Research and development expense from FDBT manufacturing activity under the Fujifilm CSA prior to the Fujifilm Settlement Agreement and accordingly, during the year ended December&#160;31, 2022, the Company recorded a benefit of $98.3&#160;million as Research and development expense (see Note 10).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except with respect to certain limited activities agreed upon by the parties, the Fujifilm MSA terminated with respect to all activities in FDBU and FDBT on October 21, 2022 and the impact of the termination was determined in accordance with the provisions of the Fujifilm MSA. The terms and conditions of the Fujifilm MSA and Fujifilm CSA will remain in full force and effect with respect to the ongoing activities at FDBK. In addition, the Company and Fujifilm mutually released all claims relating to (i) the cancellation of batches to be manufactured at FDBT under the Fujifilm MSA or Fujifilm CSA, (ii) FDBT facility idle time in 2022, (iii) failure to complete product performance qualification testing of batches manufactured by Fujifilm by December 2021, and (iv) any obligation by Fujifilm to reserve capacity or manufacture batches at FDBT for the benefit of the Company under the Fujifilm MSA or Fujifilm CSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and, as a result, significant costs may be incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BilledContractReceivables
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzM1Mw_30dc2164-0fd6-4f46-b1e3-8d6f5e819a6e"
      unitRef="usd">53800000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzM2MA_21a6ad58-63a6-4a6c-9733-d6cd8b897f09"
      unitRef="usd">419700000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY4NzQ_844effbc-53b2-4955-915d-68881c503c30"
      unitRef="usd">28600000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY4ODA_f43f2716-5aec-44a7-b8c9-9d56919201c7"
      unitRef="usd">35300000</us-gaap:UnbilledContractsReceivable>
    <nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIwNzQ2_075ffd7b-2d57-44c9-86a1-297b77f88834">During the years ended December&#160;31, 2022 and 2021, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,127,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,432,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,239,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for doubtful accounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,092,829)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended December&#160;31, 2022 and there was no bad debt expense in the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Amount is comprised of $0.4&#160;billion, $1.4&#160;billion, and $0.3&#160;billion current Deferred revenue and $179.4&#160;million, $172.5&#160;million, and no non-current Deferred revenue as of December&#160;31, 2022, 2021, and 2020 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;Deductions from Deferred revenue include the following: $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) at issue in the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below. In the fourth quarter of 2022, the Company recognized revenue of $41.9&#160;million related to a change in estimate attributed to changes in constraint of variable consideration.&lt;/span&gt;&lt;/div&gt;</nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock>
    <us-gaap:AccountsReceivableGross
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItMS0xLTEtMTE3OTky_e9bdc4f9-0481-45c2-9cc7-45e6dbcf6cde"
      unitRef="usd">454993000</us-gaap:AccountsReceivableGross>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItMy0xLTEtMTE3OTky_6c6aa1b3-8c75-44db-b86b-8048769eed41"
      unitRef="usd">1768457000</nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItNS0xLTEtMTE3OTky_5301900e-2a2a-414a-9492-a339e42adf1c"
      unitRef="usd">2127240000</nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions>
    <us-gaap:AccountsReceivableGross
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzItNy0xLTEtMTE3OTky_756b20d1-1e38-4616-b8ad-7734d4bbd176"
      unitRef="usd">96210000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtMS0xLTEtMTE3OTg1_bab79258-b0a8-420b-97c2-015c9d1bcb08"
      unitRef="usd">262012000</us-gaap:AccountsReceivableGross>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtMy0xLTEtMTE3OTg1_a18b0e94-774a-47a5-8c51-7cc62fbe2c7d"
      unitRef="usd">2432268000</nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtNS0xLTEtMTE3OTg1_79f07618-3832-4f64-abad-f632d438ba64"
      unitRef="usd">2239287000</nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions>
    <us-gaap:AccountsReceivableGross
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzMtNy0xLTEtMTE3OTg1_e228758d-024f-4308-a94b-dcdd39052c33"
      unitRef="usd">454993000</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtMS0xLTEtMTE4MTky_672e8f2a-726c-4040-bc6d-4e63acdbb6f8"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtMy0xLTEtMTE4MTkyL3RleHRyZWdpb246Zjc5YzYyMDQzYWYzNGVmYWEzYWQyYTliNjk3YWVhZThfMjE5OTAyMzI1NTU1OA_6e3380df-b12b-4e25-a298-bad335ebec1b"
      unitRef="usd">13835000</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtNS0xLTEtMTE4MTky_2ed45e3f-835e-4f96-816f-4989a8e483f1"
      unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzUtNy0xLTEtMTE4MTky_38e04477-9162-44f3-8c92-2599bb8cb364"
      unitRef="usd">13835000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMS0xLTEtMTE4MTky_f2e9073a-6b05-4bdb-8151-2281667bb15b"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMy0xLTEtMTE4MTky_a9eb8fb8-80c4-4f8b-ae9e-04bdab1e2c40"
      unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNS0xLTEtMTE4MTky_4b0f48e4-b0f3-4eec-a2e0-d563eb5c9dd2"
      unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNy0xLTEtMTE4MTky_4537ffcf-be10-40c9-806d-e6ef9c319c9f"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtMi0xLTEtNzAyMDA_75ea6427-cef4-41db-ac2c-91f1a6dfcc12"
      unitRef="usd">1595472000</us-gaap:ContractWithCustomerLiability>
    <nvax:ContractWithCustomerLiabilityAdditions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtNC0xLTEtNzAyMDA_d247d655-1dcb-4554-8d94-7c97a443e0ce"
      unitRef="usd">46908000</nvax:ContractWithCustomerLiabilityAdditions>
    <nvax:ContractWithCustomerLiabilityDeductions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtNi0xLTEtNzAyMDAvdGV4dHJlZ2lvbjowNWJmMzBkYzllYTQ0NzJkOGFhYjcxZTE2ODU4ZTk4Ml8yNzQ4Nzc5MDY5NDQ2_eca4ed9a-9401-4e48-9c15-dff0c13defdf"
      unitRef="usd">1092829000</nvax:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzQtOC0xLTEtNzAyMDA_404c4235-9c3f-4258-b713-5b1f1e01ef8c"
      unitRef="usd">549551000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMS0xLTEtMTE4MDEz_a1f05211-352c-448d-be03-06e6244ada92"
      unitRef="usd">273228000</us-gaap:ContractWithCustomerLiability>
    <nvax:ContractWithCustomerLiabilityAdditions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtMy0xLTEtMTE4MDEz_caffa725-ce42-43a1-9b8f-a49af5341720"
      unitRef="usd">1598152000</nvax:ContractWithCustomerLiabilityAdditions>
    <nvax:ContractWithCustomerLiabilityDeductions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNS0xLTEtMTE4MDEz_5b1acca1-26f9-4880-be82-de1f882192e2"
      unitRef="usd">275908000</nvax:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTowNGIwMzVlOTVlYTY0MzdlOGMzNThlOTc2NDFjN2NiNS90YWJsZXJhbmdlOjA0YjAzNWU5NWVhNjQzN2U4YzM1OGU5NzY0MWM3Y2I1XzYtNy0xLTEtMTE4MDEz_120739e5-44d4-4183-b225-8e55c65b7dee"
      unitRef="usd">1595472000</us-gaap:ContractWithCustomerLiability>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU0MjM_b9940843-4ad8-4b48-b9a8-91a8c6f64ff0"
      unitRef="usd">13800000</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU2MzI_07427bd5-65ca-4492-9fc2-f9f0249cbe7b"
      unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU2MzI_46ec886f-c4f8-45b5-bb7a-ad3a35ef0775"
      unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5NTI_37016902-3ddc-45b4-869e-3ecfaabcdb86"
      unitRef="usd">400000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5NDc_a7fba182-5397-4c12-b8cd-ec5a85fd4ecc"
      unitRef="usd">1400000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMDc0Mjg_2acb582e-554b-408d-8c51-60acd2e3d59a"
      unitRef="usd">300000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5Njk_70e2414d-5d9e-487e-9fe0-66ff3f1350f8"
      unitRef="usd">179400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyNzY5ODQ_e2fdaf76-c6d2-4a51-a492-157fe16f3b56"
      unitRef="usd">172500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMDc0NDQ_6cb71919-d3ac-4392-a110-ae71853510c9"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i926dd27a465e4fdabe3cf710647081f8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxNDY1Mzk_0d4543a6-91ed-4957-a019-74f89f0e0688"
      unitRef="usd">273800000</us-gaap:ContractWithCustomerLiability>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTAzMjE_d9b07708-0aa1-4064-8f50-a9786ebda584"
      unitRef="usd">819000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTAzMzk_8f556068-c6cf-4287-82bf-ab17568f8af7"
      unitRef="usd">697400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i7d102737a020478786d531e426d6e856_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTA0OTY_0190c551-b3f4-4ccc-ba54-43e59458a385"
      unitRef="usd">112500000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:RevenuePerformanceObligationSatisfiedAtPointInTimeAmount
      contextRef="i46f5b877ba2042818de76d2a409905c8_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDI1NjQ_cf75ed8a-08df-4de1-9621-45b5b8db21e2"
      unitRef="usd">41900000</nvax:RevenuePerformanceObligationSatisfiedAtPointInTimeAmount>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i3abf6a1aebd248e584d82ca7df7e3fdf_I20221231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzEwNjU_7bbc1fd6-5d88-42b0-beb5-f62c84b351bb"
      unitRef="usd">3000000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i3abf6a1aebd248e584d82ca7df7e3fdf_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzE1NDI_026c8455-3295-43d3-b9ca-b3f6313e3263">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i6cd3d6a52163444b8ea692da78a4faf2_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODE3MDM_95baee15-5e43-4ac6-a82a-c57cbefd26a3"
      unitRef="dose">1100000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i0523638414324ebda053032feb1642dc_I20221118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODE4NTM_de75fba7-dfc1-47d2-81c2-2c433a3d7710"
      unitRef="dose">350000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i6cd3d6a52163444b8ea692da78a4faf2_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODIwNDI_95baee15-5e43-4ac6-a82a-c57cbefd26a3"
      unitRef="dose">1100000000</nvax:NumberOfDosesToBeDistributed>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i39195769279040f9977e693d668d82a1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODI5NTA_c814f9fb-b891-4a0c-9777-48de3e9461ea"
      unitRef="usd">350000000</us-gaap:ContractWithCustomerLiability>
    <nvax:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="i5faf20068a344883a9f4f4c476b0ac54_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMyODMwMzU_1686d733-764c-4cc5-88cd-ea89882389cf"
      unitRef="usd">350000000</nvax:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i0523638414324ebda053032feb1642dc_I20221118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTQ2MTg_de75fba7-dfc1-47d2-81c2-2c433a3d7710"
      unitRef="dose">350000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i0523638414324ebda053032feb1642dc_I20221118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTQ3NzQ_7e71e3b9-d280-4b67-80c0-708e81d4dfa1"
      unitRef="dose">2000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDQyNTA_8f556068-c6cf-4287-82bf-ab17568f8af7"
      unitRef="usd">697400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzExNTQ0ODcyMTc4NjA1_c801c4fd-cfc6-4c6b-b570-9bd5066bfce0">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue by the Company&#x2019;s customer&#x2019;s geographic location was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;North America&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rest of the world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i2706507e51524857a9ceffe04bbdfb19_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzEtMS0xLTEtMTE1Njgy_48be2fe4-a9aa-49d8-9ad0-95723087e732"
      unitRef="usd">194480000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8ad425a20a9414db980cc6c772611e4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzItMS0xLTEtMTE1Njgy_938c3452-1b3e-4f9a-b712-a851b8c60b62"
      unitRef="usd">823542000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibce1a3a4c4ef4e1d9f74c1e95e55e00c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzMtMS0xLTEtMTE1Njgy_c31d3773-23ac-4211-9b93-5996b0eb213b"
      unitRef="usd">536939000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39643791632e4e05a291fb0194ec9876_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTplY2JlZmRlOWJjNGI0ZGE1YWIwYmZiMzIyMTQ4MGU2Mi90YWJsZXJhbmdlOmVjYmVmZGU5YmM0YjRkYTVhYjBiZmIzMjIxNDgwZTYyXzQtMS0xLTEtMTE1OTUz_96a243e2-40fd-42e1-8d69-2385f05cb06c"
      unitRef="usd">1554961000</us-gaap:Revenues>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="iec87e45039154115be91b56e82452836_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc2Njk_7ac7295e-79c8-46b1-9d0e-a1000f2d5742"
      unitRef="dose">20000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="ice1626d37f2e4ef59d96daaad71fdbaa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc2ODM_d6e5400d-cf7f-4b2a-b680-09128a3cb2a5"
      unitRef="dose">100000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i368f367746e142668e6ba704011b5fc7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc3NzA_038e92e8-ecbe-411a-8ebb-40fe3bc07b13"
      unitRef="dose">100000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption
      contextRef="i368f367746e142668e6ba704011b5fc7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDc4MDk_0f487956-7d11-4f27-9b51-485f5b8d24bf"
      unitRef="dose">200000000</nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption>
    <nvax:PurchaseAgreementNumberOfDosesCancelled
      contextRef="i368f367746e142668e6ba704011b5fc7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDg1MjM_f4b3eff9-1ffe-44aa-9e0b-c7d9334318da"
      unitRef="dose">7000000</nvax:PurchaseAgreementNumberOfDosesCancelled>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i368f367746e142668e6ba704011b5fc7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDg3MDM_7ecbc6c1-9ae9-431e-926c-7fb6998ca80a"
      unitRef="dose">63000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:NumberOfDosesOfVaccineCandidate
      contextRef="i36fc052561f64f5bb389212acc6492e1_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNjI1Mjk_dd57aa8b-78c8-4b4c-85bd-76c85667aa54"
      unitRef="dose">20000000</nvax:NumberOfDosesOfVaccineCandidate>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i47baf28a107749f3b2ca7dc5b1b71532_I20201022"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NTg_bcd11cfd-3e59-4be2-bc6f-f9c4d3a80ecc"
      unitRef="dose">60000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i23178b856de1448ab841c7dd1fda4737_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NjY_1c419937-9247-40fd-ae1c-4832a5370d0d"
      unitRef="dose">1000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="id54b75d90c0445109878eb06ca06d922_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NzA_e40f6d19-90c2-4840-8590-ceec10a5e50e"
      unitRef="dose">15000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="id54b75d90c0445109878eb06ca06d922_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5NzM_e40f6d19-90c2-4840-8590-ceec10a5e50e"
      unitRef="dose">15000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i67162008d7604923adbbc7b516cc27be_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwMjU_2d00da02-a996-482d-b3c9-8d84b77869f7"
      unitRef="usd">225000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i67162008d7604923adbbc7b516cc27be_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDU5OTU_dcbf0f83-84bc-4565-97f3-7b0229046fe8"
      unitRef="dose">44000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="id54b75d90c0445109878eb06ca06d922_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwMzc_e40f6d19-90c2-4840-8590-ceec10a5e50e"
      unitRef="dose">15000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i82199a3134c04ef69869eff76a4bd2cd_I20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwNDE_b4eef17f-6af1-420d-b96a-3eb9daa7b474"
      unitRef="dose">7500000</nvax:NumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i7d102737a020478786d531e426d6e856_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwNTU_0190c551-b3f4-4ccc-ba54-43e59458a385"
      unitRef="usd">112500000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7d102737a020478786d531e426d6e856_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwNjk_2c917a47-5d3d-4728-b7fe-71dda5fc82ce"
      unitRef="usd">112500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIwNzQ4_4b5e1f14-e758-4784-a8e5-7f575917c49e">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized grant revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;USG Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. DoD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;CEPI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other grant revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:Revenues
      contextRef="i9414495645c244dfa1f4271692735ef3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzItMS0xLTEtOTk1MjQ_379a2590-ccf1-4b98-9ac0-3926dba15b68"
      unitRef="usd">380996000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14ec0fb5211549e2a256737805e4fce0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzItMi0xLTEtNzAyMDA_1a45f277-9dd0-4150-98b2-84e38333f924"
      unitRef="usd">788953000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ce0f3c1c39d4e28b5fe4043d6dc2ca5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzItNC0xLTEtNzAyMDA_5eb3ab8e-f260-46e5-aee1-e5675c36e53b"
      unitRef="usd">204727000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2124dc03e6334482915d316bc6b47f65_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzMtMS0xLTEtOTk1MjQ_0e69b7ed-32e6-49a7-bc9f-e5955667959d"
      unitRef="usd">1925000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7742e770d4074f7c8483f51032cb198a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzMtMi0xLTEtNzAyMDA_520d795c-4f5f-4446-9a33-7702f9451a78"
      unitRef="usd">21683000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2f39444854c467997b14a3f794dc641_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzMtNC0xLTEtNzAyMDA_cc9e2f5e-8b96-46c8-a0b6-d5bf3643798c"
      unitRef="usd">12519000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a790ed695ae48a7825f7db0794a528b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzQtMS0xLTEtOTk1MjQ_162ab43c-8431-4001-a1a4-4add914b3102"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95983058bd8d4c6b889991a78b44a3a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzQtMi0xLTEtNzAyMDA_cd91fffc-fb24-464a-b3dd-03adb9f80dad"
      unitRef="usd">135445000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0953f31b29d64b1c9efe84ff12aaf7c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzQtNC0xLTEtNzAyMDA_f4e0a9f4-eac9-4a26-80bb-5d3442b36e32"
      unitRef="usd">223158000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18d17441b7514d62aa6a4fb48ea6ec16_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzUtMS0xLTEtOTk1MjQ_07c0b426-0816-44e4-8aee-b040660c985b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb17db81cb4940059e2590656125cced_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzUtMi0xLTEtNzAyMDA_b3caf261-1ae7-48a2-86e3-fde54b7bff51"
      unitRef="usd">2628000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8565eb181066484ab573f2f33ad705ba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzUtNC0xLTEtNzAyMDA_15d5e3ef-7825-49f3-95c5-4e85b139959f"
      unitRef="usd">12806000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i229e45ac7dd0484582dd508d0b410d09_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzYtMS0xLTEtOTk1MjQ_df812200-72ee-4580-a06c-4ba0f2c4db33"
      unitRef="usd">382921000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d2c1b3a8f554776b7ead7f9e8afc0be_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzYtMi0xLTEtNzAyMDA_ae2840ba-4436-4b54-987f-852ebb4b6ff5"
      unitRef="usd">948709000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i608ca42330f04ed38d4a29292e36a8e2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90YWJsZTphMjRhZjgzYzFiZTg0ZTVmOGFjZWRlOTA0YTJhYTBhOS90YWJsZXJhbmdlOmEyNGFmODNjMWJlODRlNWY4YWNlZGU5MDRhMmFhMGE5XzYtNC0xLTEtNzAyMDA_83a55efb-d00a-42be-96e7-62b03f8c4a5d"
      unitRef="usd">453210000</us-gaap:Revenues>
    <nvax:NumberOfDosesOfVaccineCandidate
      contextRef="i269b7fbf10f045c7b3eac59a9ee5c87d_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzMzNjk_fc671df1-7a61-46ce-a140-a11cf3a93ad5"
      unitRef="dose">100000000</nvax:NumberOfDosesOfVaccineCandidate>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwODI_476911bc-4657-4e81-94f8-218940d90a44"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:NumberOfDosesOfVaccineCandidate
      contextRef="i269b7fbf10f045c7b3eac59a9ee5c87d_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMDM_fc671df1-7a61-46ce-a140-a11cf3a93ad5"
      unitRef="dose">100000000</nvax:NumberOfDosesOfVaccineCandidate>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYwOTI_476911bc-4657-4e81-94f8-218940d90a44"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="iad256618a2bb464bb04fcf8c7bc04fcb_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMDc_476911bc-4657-4e81-94f8-218940d90a44"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:RevenueFromContractWithCustomerCommitment
      contextRef="id7ac470da9ab41d39a8dd4ac58dde5eb_D20200701-20200731"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzU0NTY_6efb6fc7-1827-4712-8152-ad5d26edb761"
      unitRef="usd">1750000000</nvax:RevenueFromContractWithCustomerCommitment>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling
      contextRef="ib28b320707a54cf7a261c50f50d34c04_I20200731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzU4NDM_5d2b24dc-1eac-44a7-b5c9-664495d261e0"
      unitRef="usd">1800000000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling
      contextRef="ib28b320707a54cf7a261c50f50d34c04_I20200731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNTM2MjE_5d2b24dc-1eac-44a7-b5c9-664495d261e0"
      unitRef="usd">1800000000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling>
    <nvax:RevenueFromContractWithCustomerCommitment
      contextRef="ia1458600dca343ad97871d021c6be059_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzYxMTM_501f2bbf-afa9-43c8-b98d-d8304126942f"
      unitRef="usd">1400000000</nvax:RevenueFromContractWithCustomerCommitment>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining
      contextRef="i673cb8037c324c8994caf3306884a92e_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzYyMDE_4660742b-a64f-497d-a71d-a5b3a0605fda"
      unitRef="usd">400000000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining>
    <nvax:RevenueFromContractWithCustomerCommitment
      contextRef="i7be0462e374b44418c24eeac2316d566_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzY3OTA_4e44192d-3262-4293-80b4-587d29717170"
      unitRef="usd">45700000</nvax:RevenueFromContractWithCustomerCommitment>
    <nvax:NumberOfDosesOfVaccineCandidate
      contextRef="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzcwNDE_802a0d81-9a11-47a5-83c4-0412a3dd25e4"
      unitRef="dose">10000000</nvax:NumberOfDosesOfVaccineCandidate>
    <nvax:NumberOfDosesOfVaccineCandidate
      contextRef="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzcwODE_802a0d81-9a11-47a5-83c4-0412a3dd25e4"
      unitRef="dose">10000000</nvax:NumberOfDosesOfVaccineCandidate>
    <nvax:RevenueRemainingPerformanceObligationCustomerStatusPeriod
      contextRef="icb4d7b8e24944e7bb138b0ca7a76f1f5_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzExNTQ0ODcyMTYzMzc0_31c024db-b529-4abc-9b74-6b989d230be0">P5Y</nvax:RevenueRemainingPerformanceObligationCustomerStatusPeriod>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="if04cb8aedaa04ea296920d2dafe47b45_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMjE_e614077d-230e-44b8-bac1-01055b06a9c2"
      unitRef="dose">200000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption
      contextRef="if04cb8aedaa04ea296920d2dafe47b45_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDYxMzE_d1fbaf9b-fb9f-45a4-85e5-7cebadafef02"
      unitRef="dose">9800000</nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersFunding
      contextRef="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2Xzc3ODY_6a868c39-04d9-4a85-be57-aa84b60d5fea"
      unitRef="usd">399500000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersFunding>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersGrant
      contextRef="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2Xzc4ODk_5e4d4a64-8221-4e45-9380-cc180411838d"
      unitRef="usd">257000000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersGrant>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans
      contextRef="ib0ca310187c142558ede44c32574c3b6_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2Xzc5MTk_33e82be7-b94c-4d9f-80b4-23e7456de222"
      unitRef="usd">142500000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans>
    <nvax:RevenueFromContractWithCustomerCommitment
      contextRef="i67595162b2e74d70acbd1d2e3fc54a75_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDM0NDQ_214d47b8-39cc-4b39-b090-7666e3b27813"
      unitRef="usd">358600000</nvax:RevenueFromContractWithCustomerCommitment>
    <nvax:RevenueFromContractWithCustomerCommitment
      contextRef="i09f8465b2a5e4bfaa5c2543aadab3967_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzIxOTkwMjMzNDM0NDQ_c81345bf-157f-43b9-9252-4c7f6a185edb"
      unitRef="usd">358600000</nvax:RevenueFromContractWithCustomerCommitment>
    <us-gaap:Revenues
      contextRef="i6e260c6f907f4344bad6fb4ab2321f9c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMTkwNTg_a3530d3a-8d4d-4188-b97b-1c32c6b4c063"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3000e1e12c2e4499ac858cd2ed3830ce_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzEyNDI1_b8342972-143e-40af-b5f1-539452f449bf"
      unitRef="usd">178600000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ide4a1afee8bf4db08da83fe10dcf1648_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzI3NDg3NzkxMTkzOTg_33476ed6-6a9b-4ad1-b3d8-0b3e42dcb1fe"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0c853e8a4a7c4a54a237437e58933a8e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjkvZnJhZzo3NjI0NjJkY2Q0Mjc0MDgzOTk0YWMxMmNhNWQyOWFlNi90ZXh0cmVnaW9uOjc2MjQ2MmRjZDQyNzQwODM5OTRhYzEyY2E1ZDI5YWU2XzEyNTE5_17099232-e0ec-4b82-a968-0a7c0a8c506e"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i1883dba2c86c4273926e697f5ab58bae_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEyODMyNA_d2bd2aa0-346e-49e7-9f7f-bcddc1016498"
      unitRef="dose">150000000</nvax:NumberOfDosesToBeDistributed>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ide4a1afee8bf4db08da83fe10dcf1648_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8yNzQ4Nzc5MDkyMTE1_33476ed6-6a9b-4ad1-b3d8-0b3e42dcb1fe"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0c853e8a4a7c4a54a237437e58933a8e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8yNzQ4Nzc5MDkyMTYx_17099232-e0ec-4b82-a968-0a7c0a8c506e"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i96b9e55b23e44271b0b5d401791eb27a_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8yMTk5MDIzMjc5MTky_b4530183-93cf-43c9-af1c-fa59fc3cd35d"
      unitRef="dose">40000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:SettlementPayment
      contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjMyNw_7c1ea22e-f0fb-40e2-9307-1fb084025e36"
      unitRef="usd">185000000</nvax:SettlementPayment>
    <nvax:SettlementAgreementInitialReservationFee
      contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjM0Mw_21cb5641-7aa3-4669-acf9-d89bff88d56b"
      unitRef="usd">47800000</nvax:SettlementAgreementInitialReservationFee>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjM1Nw_f76627c6-6701-4dad-8481-a9b1e5d78f09"
      unitRef="installment">4</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:SettlementAgreementQuarterlyInstallmentAmount
      contextRef="iea6179b85088426c91dd56a7ba42e5c6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjM4Mg_f038cb54-01c2-409c-9093-b262aa434aa0"
      unitRef="usd">34300000</nvax:SettlementAgreementQuarterlyInstallmentAmount>
    <nvax:SettlementPayment
      contextRef="i3c0e43b772f0435c86af0d81656bac70_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV81NDk3NTU4MTcwOTk0_0fa9ffe1-277b-4cfe-ab33-2dfad8ef16d5"
      unitRef="usd">137200000</nvax:SettlementPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic6b7bd92fbd1475a82a5bfebeefa798f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgwL2ZyYWc6YjNjMjFmMzU2MjhlNGYzNzg2OTQ2OGMwNGQ4ZmFhMTEvdGV4dHJlZ2lvbjpiM2MyMWYzNTYyOGU0ZjM3ODY5NDY4YzA0ZDhmYWExMV8xMTU0NDg3MjEwMjQxMQ_939e98e4-08e1-4e47-a323-70d997c07507"
      unitRef="usd">98300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90ZXh0cmVnaW9uOjEyZDExMTQ1NTQzYjRkZTk4YWM4NzVjN2ZmZWRjY2VhXzMxNA_5aee8a65-d388-41a8-aece-09b687385736">Cash, Cash Equivalents, and Restricted Cash&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2022 and 2021</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90ZXh0cmVnaW9uOjEyZDExMTQ1NTQzYjRkZTk4YWM4NzVjN2ZmZWRjY2VhXzExNTQ0ODcyMDkzMTA3_2f75bb0f-ee4a-45f0-add1-907ba3ced180">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2022 and 2021</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzItMS0xLTEtNzIwNDI_d9e1835a-c68b-40c0-9023-4b220d0026df"
      unitRef="usd">1336883000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzItMy0xLTEtNzIwNDI_2ed5a1ae-005e-45bf-b795-a08c837dbd4d"
      unitRef="usd">1515116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzItNS0xLTEtMTEyMTU5_290bb21f-917c-4dfd-b60f-26df17d30d60"
      unitRef="usd">553398000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzMtMS0xLTEtNzIwNDI_5f55cd79-f200-4af4-a930-8d5e48cb0635"
      unitRef="usd">10303000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzMtMy0xLTEtNzIwNDI_e89bfa9f-91d4-4ffe-9c66-c3a7f3bddb96"
      unitRef="usd">11490000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzMtNS0xLTEtMTEyMTU5_93db602c-10c3-4efb-9962-301b94e26d8f"
      unitRef="usd">93880000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzQtMS0xLTEtNzIwNDI_123166cb-aca8-4692-ae38-f197200cfae8"
      unitRef="usd">1659000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzQtMy0xLTEtNzIwNDI_bdff6638-38db-455b-a3ec-4d2096a749fa"
      unitRef="usd">1653000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzQtNS0xLTEtMTEyMTU5_6a4b6ad2-75dd-4554-9635-49cca9c61120"
      unitRef="usd">1460000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzUtMS0xLTEtNzIwNDI_e13e4d53-de7f-460c-8a99-025b7f4a068f"
      unitRef="usd">1348845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzUtMy0xLTEtNzIwNDI_fe8ba67e-02f8-4205-868d-368192145cd2"
      unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xMzkvZnJhZzoxMmQxMTE0NTU0M2I0ZGU5OGFjODc1YzdmZmVkY2NlYS90YWJsZTozMTMwM2FkM2I2ZTM0MjY1YTk4M2IzNTdiMWQ3ZGRiNS90YWJsZXJhbmdlOjMxMzAzYWQzYjZlMzQyNjVhOTgzYjM1N2IxZDdkZGI1XzUtNS0xLTEtMTEyMTY3_df7638d9-fece-4a45-ab74-2f7e5151e8ef"
      unitRef="usd">648738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90ZXh0cmVnaW9uOjhkYjQ0YzFlNDBiMTQ5ODFhNDZmMDQzM2NmMjVlYmI0XzEzMDA_473631fb-312d-460b-ac16-253496fd712a">Fair Value Measurements&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the estimated fair value of the Company&#x2019;s financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;All investments are classified as Cash and cash equivalents as of December&#160;31, 2022 and 2021, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#x2019;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics.&#160;Pricing of the Company&#x2019;s convertible notes has been estimated using observable inputs, including the price of the Company&#x2019;s common stock, implied volatility, interest rates, and credit spreads.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the Company did not have any transfers between Levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount in the Company&#x2019;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90ZXh0cmVnaW9uOjhkYjQ0YzFlNDBiMTQ5ODFhNDZmMDQzM2NmMjVlYmI0XzEyOTk_11a7ce7b-d8d3-40cb-9786-1fc4bc5ae8bd">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the estimated fair value of the Company&#x2019;s financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;All investments are classified as Cash and cash equivalents as of December&#160;31, 2022 and 2021, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifb61b7126be74d498e8a47c4f03eac57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItMS0xLTEtNzAyMDA_738f14a8-d9bf-4d33-873e-065ff1b90f9a"
      unitRef="usd">398834000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i557fbd904011405793bff18a21cabb26_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItMy0xLTEtNzAyMDA_bebe4039-a6e8-428f-8982-ae4e17f4b3f0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i70ac59f74cd740e6a0cadeca61d87f18_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItNS0xLTEtNzAyMDA_9122e9fc-b468-4c6d-88da-f8a098b1b833"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia8ac89c6ba624c228f64bcba1891a2a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItNy0xLTEtNzAyMDA_8b92b068-7a02-43be-bed5-1406103de3f2"
      unitRef="usd">361822000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if07eb648508740f8a5d7ef32fc803047_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItOS0xLTEtNzAyMDA_7427b4b1-dab6-4749-bfb8-b83b2cf6c1d6"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8240c1c9049f42469bde4e3f3fddf4b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzItMTEtMS0xLTcwMjAw_5441bb26-d92e-4b7a-87b8-eebe682ae7bd"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9ebb77a8ee864fc78eb779a17c09226a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtMS0xLTEtNzAyMDA_d8cf0867-2fca-425b-b8a0-e0fcd3fa6ff7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia828d2bd46af4b7f8e4984cb14c9cafb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtMy0xLTEtNzAyMDA_7febdc2e-f2d7-4d9b-aa76-17093715cfc6"
      unitRef="usd">296000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3b47a43081534cda81d9835ec8a79235_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtNS0xLTEtNzAyMDA_bf4223b8-46ec-4198-a1ff-7cc41516d5a6"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i47d72f7b153e4e8695661560c4fd46bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtNy0xLTEtNzAyMDA_2b895ff7-3168-4444-8f58-5fc3daa5f3e9"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id90676cb023842e180c00be05cf71a12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtOS0xLTEtNzAyMDA_5d1efb9f-53fc-4108-b22b-f8d08ac7e9ef"
      unitRef="usd">266250000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i74a7cf53ca85450590f17011e1295e6d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzMtMTEtMS0xLTcwMjAw_ada27edc-ec67-494e-8c55-d08379e7cc5c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0e0b6732392440598653904929954c98_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtMS0xLTEtNzAyMDA_2c154c02-7d31-4de5-aff7-837a93a1a322"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i47f14050837d4c869dde5769d325bd7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtMy0xLTEtNzAyMDA_8d453fd4-c508-4a2c-98ac-12c5fd2c0fd5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i50ad0f304ef5468ab90dfce6c1651bcc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtNS0xLTEtNzAyMDA_bb466daf-633a-4126-84ac-14d5b80cc0e4"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iaac7cacc849b46c798d58117b7ff11d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtNy0xLTEtNzAyMDA_47370b90-5061-487d-9fe7-7c9f771ce835"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i23496a29b22d4426a67a18543af66bbc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtOS0xLTEtNzAyMDA_868d5b92-1777-4824-afd6-74a55e777a92"
      unitRef="usd">790672000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia6271729b2154949abe04c08bdafe9ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzUtMTEtMS0xLTcwMjAw_43b39fef-693a-46f3-a5b7-505e274cb073"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i07ef3865c980492c8ddf20d9b5a9b4a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtMS0xLTEtNzAyMDA_768cdde9-0c04-4061-85aa-014548a96241"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if419a9b5d1bc45b68cd3c42755335735_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtMy0xLTEtNzAyMDA_07092e28-bfdc-4eb1-bea0-aeacd1e5809b"
      unitRef="usd">104536000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id07aa9a3ff734e88b8adaa9f439f1d27_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtNS0xLTEtNzAyMDA_b1ae265f-c494-4228-b3db-38c4a745dc01"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8047cd560f6c44c382b2c1bf052d612c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtNy0xLTEtNzAyMDA_9df2e713-bf06-414e-b916-2fe12a13d6ce"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9c022c32626a40f9ba08a783a679df34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtOS0xLTEtNzAyMDA_3957c993-f921-4b66-8474-6823d2f8b21a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia128e17147ae46ebbeef34e5ce29d598_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzYtMTEtMS0xLTcwMjAw_f13515d2-3ac8-462b-a905-ab8a2558d829"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8099f1e2bbdd4ec0970e209f1e0b270e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctMS0xLTEtNzAyMDA_b68acf1a-b92e-478e-9fce-deeeaf2d0e3d"
      unitRef="usd">398834000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3ff83caef02b40f599cc74bcae40ff09_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctMy0xLTEtNzAyMDA_4afda8f6-8d59-4eff-83b6-560f08cca335"
      unitRef="usd">400536000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i32cd12d82fc44bc780022e28d26cb8eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctNS0xLTEtNzAyMDA_f2d40c34-936b-45e4-bb40-25526fd207c8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie83da57994934aae8def1bf0f382f5a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctNy0xLTEtNzAyMDA_101cb93b-50e7-477f-a21f-9bd3e8456202"
      unitRef="usd">361822000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifa7a2181db6a41c9b9b4919cafe3b1cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctOS0xLTEtNzAyMDA_45fd2803-a4fd-468f-8d8c-287bdf29dc0d"
      unitRef="usd">1056922000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i13a45c212dfe4e53b8afb7e0ff8967f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzctMTEtMS0xLTcwMjAw_cd17846f-7770-4b37-9ff2-58b060b3e074"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTAtMS0xLTEwNjA4Ni90ZXh0cmVnaW9uOjg3MmMxOWMyNjUyNjQwMzI5ZGJmODBiMDRlYzQzMjRkXzIxOTkwMjMyNTU1OTQ_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i89587ae04de147c793c1b9499301a5d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTEtMS0xLTEwNTAzOA_ff89310e-c787-477f-9183-725c55dec701"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ice2056ca33214fd9bb1ee8b7c7c6cca8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTMtMS0xLTEwNTAzOA_ed9d7447-46ea-43ba-bd45-b38e6c458000"
      unitRef="usd">322111000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i9ca80f7d1ad642bd978daca477579b19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTUtMS0xLTEwNTAzOA_65dd7962-c86a-47d7-8022-442714fa2a42"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i3a506862b80548d28dfcb14cd9a57994_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTctMS0xLTEwNTAzOA_e5c03117-19b3-441e-8397-1acd9d03c144"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i7ed14e6e12f045e6896127906a812d89_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTktMS0xLTEwNTAzOA_4767a3d1-e9d3-4999-9831-c040a3266e2a"
      unitRef="usd">447509000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i016b678121634f2ea331a88b589a7be0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzEwLTExLTEtMS0xMDUwMzg_b993730a-1b44-4ecb-9c4f-a5672c529e53"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTAtMS0xLTEwNjA4NC90ZXh0cmVnaW9uOjYwNjM1N2UwNTU0NDQ4YTBhZWIyNTUwNDZjZDk2ZTFhXzIxOTkwMjMyNTU1OTQ_33fa4bef-21c4-415d-8233-3d518d1dee7b"
      unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i03e9156a13034488a05b42b0e99c2e6a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTEtMS0xLTEwNjA4MA_e9cc824f-a0b4-442d-8225-361a5a8b7851"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ib0d108ce57a04b59a033717ce6e1e081_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTMtMS0xLTEwNjA4MA_c9190c3e-92be-4d9e-ab43-8fe728fa90f4"
      unitRef="usd">172789000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ia37923a559ac460cba463e92ab69d61b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTUtMS0xLTEwNjA4MA_d6b2e605-f634-4d5f-8d42-714ffb257473"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ib8296c755f9446a59e2ee459a7b97bab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTctMS0xLTEwNjA4MA_7a462c0a-5247-4323-843b-8b634a37b7d5"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i4056500d5930405896706052920574c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTktMS0xLTEwNjA4MA_db937b15-4f84-4089-b04c-4f35c4efd6d2"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="id3ca7c3c6b834b43b446ee1616686ee3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzExLTExLTEtMS0xMDYwODA_7e418a21-676c-453d-b3d6-c43832ab62a1"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i8099f1e2bbdd4ec0970e209f1e0b270e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktMS0xLTEtNzAyMDA_91e0a466-fb90-4132-9d19-f1f24952fe68"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i3ff83caef02b40f599cc74bcae40ff09_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktMy0xLTEtNzAyMDA_7935d931-c468-4ee4-b0f3-fb06fa69c06b"
      unitRef="usd">494900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i32cd12d82fc44bc780022e28d26cb8eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktNS0xLTEtNzAyMDA_48041c2d-e474-48ef-9c29-96dad17527cb"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ie83da57994934aae8def1bf0f382f5a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktNy0xLTEtNzAyMDA_310c40e4-e6a9-445c-8138-a1ccbfa4031e"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ifa7a2181db6a41c9b9b4919cafe3b1cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktOS0xLTEtNzAyMDA_2089e749-7ae8-4e62-92db-1b7b510f9d60"
      unitRef="usd">447509000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i13a45c212dfe4e53b8afb7e0ff8967f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDIvZnJhZzo4ZGI0NGMxZTQwYjE0OTgxYTQ2ZjA0MzNjZjI1ZWJiNC90YWJsZTphN2FjOTExYTE3ZDk0NTdiOGMwYjJlYTYyNTc0OWE5Ny90YWJsZXJhbmdlOmE3YWM5MTFhMTdkOTQ1N2I4YzBiMmVhNjI1NzQ5YTk3XzktMTEtMS0xLTcwMjAw_90538d23-504b-4901-87e5-273679509301"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5MTcyOQ_39e0c986-1284-4b58-b4a4-29862c6f35a6">Inventory&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of Cost of sales in the consolidated statements of operations. For the year ended December&#160;31, 2022, inventory write-downs were $447.6&#160;million and losses on firm purchase commitments were $155.9&#160;million. There were no inventory write-downs or losses on firm purchase commitments during 2021 or 2020. Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reserves for write-downs are relieved when the inventory is disposed of through scrap or sale. Activity in the reserve for excess and obsolete inventory was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Cost of sales, including impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5MTczMA_b42c21cb-f857-4119-887e-442504e4f87e">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8xLTEtMS0xLTcyMzUx_3453f93f-66e0-4340-8a73-5830f3dba693"
      unitRef="usd">13912000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8xLTMtMS0xLTcyMzUx_55071f01-9533-4986-812b-e3093099ee05"
      unitRef="usd">8872000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8yLTEtMS0xLTcyMzUx_eb2403e4-1bd3-4f64-a196-25b5178b9bdf"
      unitRef="usd">21410000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8yLTMtMS0xLTcyMzUx_efae9569-ef9b-44db-9935-10dfbdaec6c9"
      unitRef="usd">0</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8zLTEtMS0xLTcyMzUx_686e3c54-7a30-4249-8ca2-0f71d90d5fa0"
      unitRef="usd">1361000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl8zLTMtMS0xLTcyMzUx_7b3a6dbe-31f7-4fca-b63f-5983728b9c8c"
      unitRef="usd">0</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl81LTEtMS0xLTk2NTEy_568be4cd-2af0-4b5f-bd8b-232382f4e0c3"
      unitRef="usd">36683000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6MzVlNTNiMGI4MGUwNDc3YWJiNzNjMGVlZTJkMzExOWYvdGFibGVyYW5nZTozNWU1M2IwYjgwZTA0NzdhYmI3M2MwZWVlMmQzMTE5Zl81LTMtMS0xLTk2NTEy_ba0bc3f1-bc88-44d2-bb7a-6db0a7172f25"
      unitRef="usd">8872000</us-gaap:InventoryNet>
    <nvax:InventoryReserveChargedToCostsOfSales
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8yMTQ0MDQ3Njc0NDU2Nw_fcb939b3-fe80-4bf3-94fd-3e2a1b57850c"
      unitRef="usd">447600000</nvax:InventoryReserveChargedToCostsOfSales>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8yMTQ0MDQ3Njc0NDUyNQ_7f8e3fad-460b-44d6-8cd6-e9536bb5b098"
      unitRef="usd">155900000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_02bb9278-c56c-4dd5-b899-8e51010f69cb"
      unitRef="usd">0</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_17d3f222-5bba-46a3-8a26-83d21bfce2a2"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_8947e7dd-cc39-48fd-a6ea-c11e29aa8125"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5Mzk5Nw_b0a85781-8f15-4ca2-8f8c-6428cda0dfe6"
      unitRef="usd">0</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <nvax:ScheduleOfInventoryReserveTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGV4dHJlZ2lvbjo5YzY2ZDNlNzA3Mjg0YzcwOWFiNGI5NDRjZjZkYjY3Ml8xMTU0NDg3MjA5NDg3OA_34ec3576-5b51-4816-aeb9-a97535aa8bb4">Activity in the reserve for excess and obsolete inventory was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Cost of sales, including impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</nvax:ScheduleOfInventoryReserveTableTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8xLTEtMS0xLTExNDUyNw_11564c00-9313-4a55-9e49-39879771933b"
      unitRef="usd">0</us-gaap:InventoryValuationReserves>
    <nvax:InventoryReserveChargedToCostsOfSales
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8yLTEtMS0xLTExNDUyNw_19994269-6817-4d07-987a-91ae2b87d915"
      unitRef="usd">447597000</nvax:InventoryReserveChargedToCostsOfSales>
    <nvax:InventoryReserveOtherAdditions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8zLTEtMS0xLTEyODQ3MQ_10dd4214-3cd0-4fac-b9a4-a380239450b1"
      unitRef="usd">0</nvax:InventoryReserveOtherAdditions>
    <us-gaap:InventoryWriteDown
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl8zLTEtMS0xLTExNDUyNw_d4e9b059-cdb5-4ebf-a32c-4ec231c858c0"
      unitRef="usd">-79214000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryValuationReserves
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDk2L2ZyYWc6OWM2NmQzZTcwNzI4NGM3MDlhYjRiOTQ0Y2Y2ZGI2NzIvdGFibGU6NjQwZTRjZTViZWJkNGE4Yjk1NDNmN2NhMzU1NThmNzYvdGFibGVyYW5nZTo2NDBlNGNlNWJlYmQ0YThiOTU0M2Y3Y2EzNTU1OGY3Nl80LTEtMS0xLTExNDUyNw_b8933371-c594-464e-b62c-176da83bbfc4"
      unitRef="usd">368383000</us-gaap:InventoryValuationReserves>
    <us-gaap:GoodwillDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90ZXh0cmVnaW9uOjJiOTFjOTNhZWMyYzRkZjg4YTNjYThmYjVmNjgyOTg0XzQ5Mw_4c31a3c5-b1d1-4464-8de0-af2ee5385692">Goodwill&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amounts of goodwill was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90ZXh0cmVnaW9uOjJiOTFjOTNhZWMyYzRkZjg4YTNjYThmYjVmNjgyOTg0XzQ5Ng_e126095a-9e73-480a-94af-2beaf21f198d">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amounts of goodwill was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzMtMS0xLTEtNzAyMDA_198b969a-54ae-4aa4-9f41-c2fe8aa01152"
      unitRef="usd">131479000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzMtMy0xLTEtNzAyMDA_f8e61f67-f5ed-4e42-9ee1-a1241aad45c7"
      unitRef="usd">135379000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzUtMS0xLTEtNzAyMDA_7b14bbd2-03f3-40b7-a334-584d0ecc92d7"
      unitRef="usd">-5148000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzUtMy0xLTEtNzAyMDA_752ce8ac-4ab0-4d4a-9827-01918fdee582"
      unitRef="usd">-3900000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzYtMS0xLTEtNzAyMDA_6f6cdc9e-7826-48cb-a3a8-93fce42265a2"
      unitRef="usd">126331000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDUvZnJhZzoyYjkxYzkzYWVjMmM0ZGY4OGEzY2E4ZmI1ZjY4Mjk4NC90YWJsZTo2N2NjZTc5ZjI2ODE0MWI1YmU3ODMxYTA3MWY3MmQwNy90YWJsZXJhbmdlOjY3Y2NlNzlmMjY4MTQxYjViZTc4MzFhMDcxZjcyZDA3XzYtMy0xLTEtNzAyMDA_06e944a6-60dc-4421-9301-ef640aa14b1b"
      unitRef="usd">131479000</us-gaap:Goodwill>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzUyNjI_920a7767-f36e-49dd-9b6d-102538a38810">Acquisition of Novavax CZ&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 27, 2020 (the &#x201c;Acquisition Date&#x201d;), the Company entered into a Share Purchase Agreement (the &#x201c;Deed&#x201d;) by and among Novavax AB, the Company&#x2019;s wholly-owned Swedish subsidiary (the &#x201c;Buyer&#x201d;), and De Bilt Holdings B.V., Poonawalla Science Park B.V., and Bilthoven Biologicals B.V. and, solely as guarantors, each of Serum International B.V. and the Company. Pursuant to the terms and conditions of the Deed, the Buyer acquired all the issued and outstanding shares of Novavax CZ (formerly, Praha Vaccines a.s.), a vaccine manufacturing company (the &#x201c;Acquisition&#x201d;). The assets of Novavax CZ acquired as part of the Acquisition include a biologics manufacturing facility and associated assets in Bohumil, Czech Republic and will be used by the Company to expand its manufacturing capacity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Allocation of Purchase Price to Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has accounted for the Acquisition as a business combination using the acquisition method of accounting, with the Company as the acquirer. The acquisition method requires the Company to record the assets acquired and liabilities assumed at fair value. The amount by which the purchase price exceeds the fair value of net assets acquired is recorded as goodwill. The Company completed the appraisal process necessary to assess the fair values of the assets acquired and liabilities assumed to determine the amount of goodwill to be recognized as of the Acquisition Date. The final determination of the fair value of all assets and liabilities was completed in 2020 and is presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes the final allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;May 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;96,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;70,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchase price, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;165,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the assets acquired and liabilities assumed was determined using market and cost valuation methodologies. The fair value measurements were based on significant unobservable inputs that were developed by the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Company using publicly available information, market participant assumptions, and cost and development assumptions. Because of the use of significant unobservable inputs, the fair value measurements represent a Level 3 measurement as defined in ASC 820. The market approach is a valuation technique that uses prices and other relevant information generated by market transactions involving identical or comparable assets, liabilities, or a group of assets or liabilities. The cost approach estimates value by determining the current cost of replacing an asset with another of equivalent utility. The cost to replace a given asset reflects the estimated reproduction or replacement cost for the property, less an allowance for loss in value due to depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The cost approach was the primary approach used to value fixed assets, including the real property. Fixed assets are depreciated on a straight-line basis over their expected remaining useful lives, ranging from four years to 25 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded $70.7&#160;million in goodwill related to the Acquisition representing the purchase price that was in excess of the fair value of the assets acquired and liabilities assumed. The goodwill generated from the Acquisition is not expected to be deductible for U.S. federal income tax purposes. The goodwill recognized is attributable to intangible assets that do not qualify for separate recognition, such as the assembled workforce of Novavax CZ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current assets and current liabilities were recorded at their contractual or historical acquisition amounts, which approximate their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impact to Financial Results for the Year Ended December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The results of operations from Novavax CZ have been included in the consolidated financial statements since the Acquisition Date. As a result, the consolidated financial results for the year ended December 31, 2020 does not reflect a full twelve months of Novavax CZ results. From the Acquisition Date through December 31, 2020, Novavax CZ did not recognize any revenue and recorded a net loss from operations of $11.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company incurred approximately $2.7&#160;million of costs related to the Acquisition in the year ended December 31, 2020, which are included within general and administrative expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Supplemental Pro Forma Financial Information (Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unaudited pro forma financial information below gives effect to the Acquisition as if it had occurred as of January 1, 2019. The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved had the Acquisition been consummated as of that time. The unaudited pro forma financial information combines the historical results of operations of the Company and Novavax CZ and reflects the application of certain pro forma adjustments (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;475,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pro forma adjustments include the recognition of depreciation expense based on the Acquisition Date fair value and remaining useful lives of Novavax CZ fixed assets (net of historical depreciation expense) and the elimination of costs related to the Acquisition, which are non-recurring in nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzUyNjM_eebe5338-331b-41b0-bc31-97f9b0509b4f">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes the final allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;May 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;96,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;70,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchase price, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;165,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzEtMS0xLTEtNzAyMDA_51f839b1-ab88-4f6e-9056-76837cd400b2"
      unitRef="usd">326000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzItMS0xLTEtNzAyMDA_329fb619-57f0-43a8-a49e-3079e71b7a3c"
      unitRef="usd">96739000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:Goodwill
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzMtMS0xLTEtNzAyMDA_c2204ef6-f01b-4f11-ba02-7d47a11864d6"
      unitRef="usd">70662000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzQtMS0xLTEtNzAyMDA_e550866e-0602-4e73-bca4-ac885adf5d24"
      unitRef="usd">1193000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <nvax:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzUtMS0xLTEtNzAyMDA_b8c41e00-36a2-401e-b938-60ac9e877292"
      unitRef="usd">205000</nvax:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzYtMS0xLTEtNzAyMDA_f8d118fe-e52d-4f4a-a9dc-dc8bbbd29f49"
      unitRef="usd">813000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpjMjA2MmJhMDg1ODQ0OTQ5ODlhMmRiZWU0Yzg2MzJkOS90YWJsZXJhbmdlOmMyMDYyYmEwODU4NDQ5NDk4OWEyZGJlZTRjODYzMmQ5XzctMS0xLTEtNzAyMDA_7a2e3d10-8c55-492f-a146-516580c2cf77"
      unitRef="usd">165516000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6803c5d4d38740009777ad5eadf70727_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzMwMDY_16bc801c-b60e-49cb-b5e9-a3e9becae255">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iabda6dd0b85b41c5810ef5d88e33f6fb_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzMwMTI_bc7cbedd-ba0f-47d9-a409-3cba2be4854d">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Goodwill
      contextRef="if74110891d1c4616a0230ee664e7675b_I20200527"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzMwMzk_8174ac9a-3232-49c9-a8ed-9214f1102781"
      unitRef="usd">70700000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i98d86903b18c4a31908d43850afb1f79_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzQwOTM_4a467c0b-dfcb-4536-882a-7f80867723d8"
      unitRef="usd">11300000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i98d86903b18c4a31908d43850afb1f79_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzQxMzM_aeb0836e-686f-47c2-830f-c8b60bfb56fb"
      unitRef="usd">2700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90ZXh0cmVnaW9uOjI3NzMzYjI5Njk5MDRmZThhZTFiNzcwNzA0Zjc0MTEyXzUyNjE_dd891cfa-1e44-42cf-b476-c06a71c1b6fc">The unaudited pro forma financial information combines the historical results of operations of the Company and Novavax CZ and reflects the application of certain pro forma adjustments (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;475,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzItMS0xLTEtNzAyMDA_9014e6ea-9d75-4390-8eea-a3aa424a61fb"
      unitRef="usd">475598000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzMtMS0xLTEtNzAyMDA_c31ab273-025d-4737-b03f-709e699031d5"
      unitRef="usd">-419896000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzQtMS0xLTEtNzAyMDA_391228ef-3b8f-4ea5-888b-0332fc9c046b"
      unitRef="usdPerShare">-7.04</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNDgvZnJhZzoyNzczM2IyOTY5OTA0ZmU4YWUxYjc3MDcwNGY3NDExMi90YWJsZTpmMTVmMWM3YmQ2MTA0MjJmYjVlNmRlY2M3ZDFlY2FhYi90YWJsZXJhbmdlOmYxNWYxYzdiZDYxMDQyMmZiNWU2ZGVjYzdkMWVjYWFiXzQtMS0xLTEtNzAyMDA_7444f8c0-73ca-4565-91df-1b160ad5ee8c"
      unitRef="usdPerShare">-7.04</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTc_812623c1-0ebb-4a34-ab99-6b4788eb4367">Leases&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CDMOs to manufacture NVX-CoV2373, as well as operating leases for its research and development and manufacturing facilities, corporate headquarters and offices, and certain equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2022, the Company recognized ROU assets and a corresponding long-term operating lease liability on the remeasurement of modified supply agreements. During the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2021, for leases that were previously determined to represent short-term embedded leases, modifications did not result in a change in lease classification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, of $18.6&#160;million and $144.4&#160;million, respectively, for its finance leases and long-term operating leases embedded in CMO and CDMO manufacturing supply agreements. The Company expensed the ROU assets since they related to research and development activities for the development of NVX-CoV2373 for which the Company did not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, the Company entered into and extended various facility lease agreements related to research and development facilities and office space. During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease that have not been recognized in the ROU asset. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December&#160;31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes had occurred. As of December 31, 2022 and 2021, the Company had incurred $49.0&#160;million and $36.4&#160;million, respectively, related to tenant improvement costs to be recognized as a ROU asset. The Company anticipates that it will incur additional tenant improvement costs, net of a landlord contribution of $9.8&#160;million, through 2023 to bring the remainder of the building to the condition necessary for its intended use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, facility leases, excluding the 700QO lease, have expirations that range from approximately &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDE_cc59319b-f346-4179-ace9-8b072a6d76f3"&gt;three&lt;/span&gt; to nine years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 was as follows (in thousands, except weighted-average remaining lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, operating, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,384&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, finance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,241&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,867&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,983&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,196&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,533&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,516&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,238&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for the operating and short-term leases for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets expensed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the year ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTc_fbe860ed-3a12-4c57-8e0a-15284ae73d77">Leases&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CDMOs to manufacture NVX-CoV2373, as well as operating leases for its research and development and manufacturing facilities, corporate headquarters and offices, and certain equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2022, the Company recognized ROU assets and a corresponding long-term operating lease liability on the remeasurement of modified supply agreements. During the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2021, for leases that were previously determined to represent short-term embedded leases, modifications did not result in a change in lease classification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, of $18.6&#160;million and $144.4&#160;million, respectively, for its finance leases and long-term operating leases embedded in CMO and CDMO manufacturing supply agreements. The Company expensed the ROU assets since they related to research and development activities for the development of NVX-CoV2373 for which the Company did not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, the Company entered into and extended various facility lease agreements related to research and development facilities and office space. During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease that have not been recognized in the ROU asset. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December&#160;31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes had occurred. As of December 31, 2022 and 2021, the Company had incurred $49.0&#160;million and $36.4&#160;million, respectively, related to tenant improvement costs to be recognized as a ROU asset. The Company anticipates that it will incur additional tenant improvement costs, net of a landlord contribution of $9.8&#160;million, through 2023 to bring the remainder of the building to the condition necessary for its intended use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, facility leases, excluding the 700QO lease, have expirations that range from approximately &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDE_cc59319b-f346-4179-ace9-8b072a6d76f3"&gt;three&lt;/span&gt; to nine years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 was as follows (in thousands, except weighted-average remaining lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, operating, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,384&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, finance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,241&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,867&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,983&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,196&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,533&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,516&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,238&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for the operating and short-term leases for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets expensed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the year ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability
      contextRef="i18de67b571ba458cbba0933459b5975b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzIxOTkwMjMyNjMyMDY_0f16937c-be13-48fa-844d-134641a29955"
      unitRef="usd">18600000</nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability>
    <nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability
      contextRef="i94ada334c1e14256b42648cab21c02f2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzIxOTkwMjMyNjMyMDI_3dba1092-0a34-4cb0-9a88-c2cc62d751e9"
      unitRef="usd">144400000</nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability>
    <nvax:FacilityNumberOfSquareFeet
      contextRef="i201ad52388df4bebacf2bd74f56acfeb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzI0Njg_fb04c48f-1937-4115-a429-acbb3c473704"
      unitRef="sqft">170000</nvax:FacilityNumberOfSquareFeet>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i3094b6244ecc489b96c2559b7639a6b9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzI2MDc_debbf180-c92a-4c21-b184-21d234b6d9a3">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="i201ad52388df4bebacf2bd74f56acfeb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzI2OTA_f0f4e16e-1608-4177-9591-b76cee56001a"
      unitRef="usd">5800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="i988682eb3b024cb688a6d71ca0cb108b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzExNTQ0ODcyMDk2OTIw_77045a1a-1c3d-463f-bc81-f28ce0f2fe42"
      unitRef="usd">73200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i988682eb3b024cb688a6d71ca0cb108b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzExNTQ0ODcyMDk2OTIw_cd5d8066-acd5-4488-b1a2-e51c57533d54"
      unitRef="usd">73200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i9bb89a63509c49b0b7381f32ace08d03_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzE5MjQxNDUzNTAxNjQ1_e6c695af-89dd-4909-9447-54824efabe94"
      unitRef="usd">49000000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i7bd187e980034898b9aecf0c85fa92f4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzE5MjQxNDUzNTAxMTg2_cc696af1-c199-43b3-8c83-23748cde6b61"
      unitRef="usd">36400000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="if0e0cb7900fe42bb90900d51daf494af_D20230101-20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzE5MjQxNDUzNTAxNjMw_686edaa7-98b7-493c-a854-a804b850253b"
      unitRef="usd">9800000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i728c18080ef8448fb44592281f48f9b5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzMzMDc_f9093a9e-6ea0-4b80-90b7-4e0900370280">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTg_d3b392c2-d80a-491e-bc27-9e721c88acdd">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 was as follows (in thousands, except weighted-average remaining lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, operating, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_7dca23ee-ed0b-4bdc-b6e4-ed84818389d4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtMi0xLTEtNzAyMDA_fb619c5c-47c8-45c4-b1da-302cb82ebbf1"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,384&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, finance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_8128c65e-ec52-4bb2-a27b-ad8197844134"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtMi0xLTEtMTE0NTU1_ab72d956-3c25-4378-a6d6-38c118ca8ea3"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,241&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_b528353f-3ad2-477f-a72f-cadfe1b76650"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtMi0xLTEtNzAyMDA_f9c961b1-09ad-414e-a750-ec2b6f30d524"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,867&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,983&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,196&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,533&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,516&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_04e4b251-8ae6-49ba-9422-3099c8468c43"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTItMS0xLTcwMjAw_382173d1-077b-416b-bc1a-47ee0a5b864b"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,238&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtNC0xLTEtNzAyMDA_830ed373-b85c-4572-9d23-74428e71d907"
      unitRef="usd">36384000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzMtNi0xLTEtNzAyMDA_cbfdaeab-da80-47a6-b2fc-414091fc274e"
      unitRef="usd">40123000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtNC0xLTEtMTA5NjUy_971f9bf4-c2b9-4d85-9b2e-ef11c43ec8a7"
      unitRef="usd">69857000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzQtNi0xLTEtMTA5NjYw_def1351b-77ad-413e-8717-ee5476432ac9"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <nvax:LeaseRightOfUseAsset
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzUtNC0xLTEtMTE0NTU5_055b9c85-34e6-4984-89f9-cee7368c30c9"
      unitRef="usd">106241000</nvax:LeaseRightOfUseAsset>
    <nvax:LeaseRightOfUseAsset
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzUtNi0xLTEtMTE0NTU5_b97789ff-3b0b-442c-9d04-ea6bf0ce0549"
      unitRef="usd">40123000</nvax:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtNC0xLTEtNzAyMDA_0527d295-1378-4a19-8a71-7146d115463e"
      unitRef="usd">16867000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzYtNi0xLTEtNzAyMDA_58ad3fc4-47d7-44bc-9bbc-40ea9129284e"
      unitRef="usd">30983000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzctNC0xLTEtNzAyMDA_bc5da765-cf76-44c3-897d-66e7569b3e5d"
      unitRef="usd">27196000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzctNi0xLTEtNzAyMDA_97f0cd5c-e22b-4b3b-bb20-84bf0bd0b1e8"
      unitRef="usd">130533000</us-gaap:FinanceLeaseLiabilityCurrent>
    <nvax:LeaseLiabilityCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzgtNC0xLTEtNzAyMDA_521526b4-410b-4f66-90ab-b5d14d35affe"
      unitRef="usd">44063000</nvax:LeaseLiabilityCurrent>
    <nvax:LeaseLiabilityCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzgtNi0xLTEtNzAyMDA_fe8a0be4-70f0-43bc-a797-2154c960dd67"
      unitRef="usd">161516000</nvax:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTQtMS0xLTcwMjAw_1db3e104-d618-4b8c-ae9b-a57b4e6b5827"
      unitRef="usd">50085000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEwLTYtMS0xLTcwMjAw_cddfa991-5141-4f95-be9c-166cb9b754ea"
      unitRef="usd">39116000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzExLTQtMS0xLTcwMjAw_f4f463b4-2816-419f-823a-1c4d910911e9"
      unitRef="usd">31238000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzExLTYtMS0xLTcwMjAw_e89beb8c-a9d3-472f-a7c2-8b8cbeb86d20"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <nvax:LeaseLiabilityNoncurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEyLTQtMS0xLTcwMjAw_61f359f0-10cc-474e-992a-5b9c6a299408"
      unitRef="usd">81323000</nvax:LeaseLiabilityNoncurrent>
    <nvax:LeaseLiabilityNoncurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzEyLTYtMS0xLTcwMjAw_e3d7f88a-154f-4cf2-abd9-3e2aa0a82c54"
      unitRef="usd">39116000</nvax:LeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE1LTQtMS0xLTcwMjAw_d85efe00-5a10-4a47-89d5-04996593828c">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE1LTYtMS0xLTcwMjAw_0213f0e2-24ba-4a05-be28-6b0d3a936d6c">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE2LTQtMS0xLTcwMjAw_3494e916-a880-4c11-82cb-7ac7d0dbbb97">P8Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE2LTYtMS0xLTcwMjAw_3d335418-a6ce-492b-a245-98142c50b2f1">P3Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE5LTQtMS0xLTcwMjAw_d9f0f180-c91c-44f7-8326-47f8d87b0004"
      unitRef="number">0.064</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzE5LTYtMS0xLTcwMjAw_b97258a8-1256-4dbf-a1cc-a32e6b03f322"
      unitRef="number">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzIwLTQtMS0xLTcwMjAw_fbf69dd1-5916-475e-a64e-2dba3b0231df"
      unitRef="number">0.054</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo4MTczNWE1ZWNmZDY0ZDA1YWFhODE5M2Q1M2M5YzBjNi90YWJsZXJhbmdlOjgxNzM1YTVlY2ZkNjRkMDVhYWE4MTkzZDUzYzljMGM2XzIwLTYtMS0xLTcwMjAw_3e0debd4-fc78-410d-9a2f-9a966476ca26"
      unitRef="number">0.052</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTk_d55be6ae-e9f3-462c-a76d-46bab068b11c">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for the operating and short-term leases for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets expensed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzItMS0xLTEtNzAyMDA_9371e4be-4327-4e28-b7c2-5be68566d4c5"
      unitRef="usd">6903000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzItMy0xLTEtNzAyMDA_c3bffea1-91a8-4615-b790-8d443dea50b9"
      unitRef="usd">37027000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzItNS0xLTEtOTc0OTU_cf6cee46-0ecd-4bf5-81a8-9c18ea8ff340"
      unitRef="usd">2462000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzMtMS0xLTEtNzAyMDA_bec3ad99-4e8a-4097-91b6-0e55a34cf070"
      unitRef="usd">94726000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzMtMy0xLTEtNzAyMDA_b36b95ff-fe94-4fb6-9456-7d5d48f0fe4f"
      unitRef="usd">468210000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzMtNS0xLTEtOTc0OTU_0de37b0a-c8cf-4b34-9eb2-0f85f38e619b"
      unitRef="usd">66805000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzQtMS0xLTEtNzAyMDA_cdd257c5-92cc-4ce9-861b-ffc9815cb7d4"
      unitRef="usd">6836000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzQtMy0xLTEtNzAyMDA_de57a734-09ef-4175-8919-c9fd103b1d2c"
      unitRef="usd">116435000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzQtNS0xLTEtOTc0OTU_9bdef47b-8641-404c-b896-1fd839c465c5"
      unitRef="usd">4854000</us-gaap:VariableLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzYtMS0xLTEtNzAyMDA_f496a364-7646-40bd-b4fc-9ffc7e26ad3a"
      unitRef="usd">7759000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzYtMy0xLTEtNzAyMDA_0a9c1a94-c5b6-476e-8612-b0b6a52c4f5c"
      unitRef="usd">112528000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzYtNS0xLTEtOTc1MDY_b1f2176a-9792-470a-ad43-1c00e98d679d"
      unitRef="usd">242009000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzctMS0xLTEtNzAyMDA_9020deed-c334-4467-b4e2-f75efd8ec717"
      unitRef="usd">1472000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzctMy0xLTEtNzAyMDA_37ad2df2-71a9-4578-b82b-5f8bbbb784f9"
      unitRef="usd">7241000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzctNS0xLTEtOTc1MDY_3dc660e1-97f9-46c2-8597-dee97c0c1780"
      unitRef="usd">3097000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzgtMS0xLTEtNzAyMDA_9858d4cf-d8bc-4ff2-b026-db3d9548f1a8"
      unitRef="usd">9231000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzgtMy0xLTEtNzAyMDA_2f0c3053-cb18-49c7-a8a6-400b5dc2c13a"
      unitRef="usd">119769000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZToxMWI0M2FkZmEyNDU0ZGRlYjM5MGQ5Y2Q4YTI4NjQ4My90YWJsZXJhbmdlOjExYjQzYWRmYTI0NTRkZGViMzkwZDljZDhhMjg2NDgzXzgtNS0xLTEtOTk3MjA_25510f26-42dd-4ff7-9fc0-90baeb82dd9f"
      unitRef="usd">245106000</us-gaap:LeaseCost>
    <nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTU_ed31e87b-445d-48f4-808b-5d79123cca36">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the year ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzMtMS0xLTEtNzAyMDA_93dfa6b0-f0e9-4097-8302-5c04d8e3fee8"
      unitRef="usd">190158000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzMtMy0xLTEtNzAyMDA_92adb522-d152-4b3a-8d2e-2820dd4b7194"
      unitRef="usd">203991000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzMtNS0xLTEtOTc2MzE_a531b13e-3dac-4956-b06c-d7d04ad75dee"
      unitRef="usd">63634000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzQtMS0xLTEtNzAyMDA_eef80516-beab-47fa-bc00-3f85d5347c22"
      unitRef="usd">1472000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzQtMy0xLTEtNzAyMDA_57c6f77e-b3e7-4b54-b365-d7a15a63be99"
      unitRef="usd">7241000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzQtNS0xLTEtOTc2MzE_b3b9d6c2-161f-49b6-b6ab-3bb611f142f4"
      unitRef="usd">3097000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzUtMS0xLTEtNzAyMDA_20580ac7-30b4-4fd7-959d-c27e7851b05b"
      unitRef="usd">93595000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzUtMy0xLTEtNzAyMDA_90c59ea8-5586-4b11-b1c6-f35e9cc8a3ec"
      unitRef="usd">127907000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzUtNS0xLTEtOTc2MzE_c716f843-b4f5-4621-b83d-447b089063a3"
      unitRef="usd">96065000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzctMS0xLTEtNzAyMDA_7ac3b0a7-71ad-4f78-9793-2487c0b772af"
      unitRef="usd">30675000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzctMy0xLTEtNzAyMDA_02bcf4a7-7984-4105-a33e-5c4f03104083"
      unitRef="usd">66682000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzctNS0xLTEtOTc2MzE_bdab1142-397b-49e0-8df8-f69139ad4f78"
      unitRef="usd">5590000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzgtMS0xLTEtNzAyMDA_5f7a1440-7aea-4d6c-b8d8-4642f211e039"
      unitRef="usd">73240000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzgtMy0xLTEtNzAyMDA_6c2cf617-5825-415f-a887-60afcb417d55"
      unitRef="usd">112528000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTo0YzE2NzQ0MzlhYTI0NDExYTRmNDRjM2IzMGNmYTZmOS90YWJsZXJhbmdlOjRjMTY3NDQzOWFhMjQ0MTFhNGY0NGMzYjMwY2ZhNmY5XzgtNS0xLTEtOTc2MzE_560bd452-94fb-44e0-b118-f54cf04b28ae"
      unitRef="usd">242009000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90ZXh0cmVnaW9uOjZjNzI2MzRlNWVkNDQyZTFiMDNiMjIwM2ZiYzY4YjllXzQ2MTY_8bd8f6dc-3709-4d87-a1af-d697fca8cca5">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzEtMi0xLTEtNzAyMDA_32f4b63f-9165-4d5e-9c24-7ca823b799be"
      unitRef="usd">47335000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzItMi0xLTEtNzAyMDA_fba4abab-db2f-4cdf-8139-4fb8fd459b87"
      unitRef="usd">24589000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzMtMi0xLTEtNzAyMDA_e1dcfe80-b72d-4c14-8041-6f0e078b4871"
      unitRef="usd">10446000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzQtMi0xLTEtNzAyMDA_b276c1ab-ff01-4053-a3b5-e4128f19953d"
      unitRef="usd">10509000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzUtMi0xLTEtNzAyMDA_085c9c96-989e-4ca5-9447-63102cb0d00e"
      unitRef="usd">10250000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzYtMi0xLTEtNzAyMDA_a3ee6e41-c4e3-47a2-bb03-babe139504ab"
      unitRef="usd">46562000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzctMi0xLTEtNzAyMDA_1e71c4ba-a5c4-4a6e-9592-d9dafb049a2f"
      unitRef="usd">149691000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzgtMi0xLTEtNzAyMDA_77057c24-35df-4e08-82ee-5c1d3d0fe38e"
      unitRef="usd">24305000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTEvZnJhZzo2YzcyNjM0ZTVlZDQ0MmUxYjAzYjIyMDNmYmM2OGI5ZS90YWJsZTphNTFkODU3NzRkMzM0ZDY4OTgzZGFiYjM1YjgxYzNhMC90YWJsZXJhbmdlOmE1MWQ4NTc3NGQzMzRkNjg5ODNkYWJiMzViODFjM2EwXzktMi0xLTEtNzAyMDA_12c3cde7-fdb2-4f6e-ac39-c12b93178082"
      unitRef="usd">125386000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzUyMzM_c74751f9-a2cf-4afe-be42-89a8fad9a632">Long-Term Debt&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company issued $175.3 million aggregate principal amount of convertible senior unsecured notes that will mature on December 15, 2027 (the &#x201c;2027 Notes&#x201d;), unless earlier converted, redeemed, or repurchased. The 2027 Notes were issued in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and pursuant to an indenture dated December 20, 2022 (the &#x201c;2027 Indenture&#x201d;) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Concurrently with the issuance of the 2027 Notes, the Company completed a public offering of shares of its common stock (see Note 13). The Company received $166.4 million in net proceeds from the issuance of the 2027 Notes after deducting the initial purchasers&#x2019; fees and the Company&#x2019;s offering expenses. The 2027 Notes bear cash interest at a rate of 5.00% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding September 15, 2027, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company&#x2019;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2027 Notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price (as defined in the 2027 Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate for the 2027 Notes on each such trading day; (3) if the Company calls such 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2027 Notes called (or deemed called) for redemption; and (4) upon the occurrence of specified corporate events as set forth in the 2027 Indenture. On or after September 15, 2027, until the close of business on the business day immediately preceding the maturity date (December 15, 2027), holders of the 2027 Notes may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing conditions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of the Company&#x2019;s common stock, or a combination of cash and shares of the Company&#x2019;s common stock, at the Company&#x2019;s election, in the manner and subject to the terms and conditions provided in the 2027 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion rate for the 2027 Notes will initially be 80.0000 shares of the Company&#x2019;s common stock per $1,000 principal amount of 2027 Notes, which is equivalent to an initial conversion price of $12.50 per share of common stock. The initial conversion price of the 2027 Notes represents a conversion premium of 25% of the public offering price in the Company&#x2019;s concurrent common stock offering that closed on December 20, 2022 (see Note 13). The conversion rate for the 2027 Notes is subject to adjustment under certain circumstances in accordance with the terms of the 2027 Indenture. In addition, following certain corporate events that occur prior to the maturity date of the 2027 Notes or if the Company delivers a notice of redemption in respect of the 2027 Notes, the Company will, under certain circumstances, increase the conversion rate of the 2027 Notes for a holder who elects to convert its 2027 Notes (or any portion thereof) in connection with such a corporate event or convert its 2027 Notes called (or deemed called) for redemption during the related redemption period (as defined in the 2027 Indenture), as the case may be.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the 2027 Notes prior to December 22, 2025. The Company may redeem for cash all or any portion of the 2027 Notes, at its option, on or after December 22, 2025, if the last reported sale price of the common stock has been at least 130% of the conversion price for the 2027 Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, to, but excluding, the redemption date. If the Company redeems less than all the outstanding 2027 Notes, at least $50&#160;million aggregate principal amount of 2027 Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for the 2027 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a Fundamental Change (as defined in the 2027 Indenture), holders may require, subject to certain conditions and exceptions as set forth in the 2027 Indenture, the Company to repurchase for cash all or any portion of their 2027 Notes at a Fundamental Change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the Fundamental Change repurchase date. If a holder of the 2027 Notes converted upon a Make-Whole Fundamental Change (as described in the 2027 Indenture), they may be eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 20.0000 shares per $1,000 principal amount of 2027 Notes (subject to other adjustments as described in the 2027 Indenture).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for the issuance of the 2027 Notes, the Company determined that the scope exceptions provided under ASC 815-40,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 815-40&#x201d;) apply to all but one of the conversion features embedded in the 2027 Notes. This remaining conversion feature, which is associated with a Fundamental Change of the Company, was determined to have a de minimis value as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial purchasers&#x2019; fees and the Company&#x2019;s issuance costs related to the 2027 Notes totaled $8.8 million, which were recorded as a reduction to the 2027 Notes on the consolidated balance sheet. The $8.8 million of debt issuance costs is being amortized and recognized as additional interest expense over the five-year contractual term of the 2027 Notes using an effective interest rate of 6.2%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company issued $325 million&#160;aggregate principal amount of convertible senior unsecured notes that matured on&#160;February&#160;1, 2023&#160;(the &#x201c;2023 Notes&#x201d;).&#160;The 2023 Notes were senior unsecured debt obligations and were issued at par. The Company repaid the outstanding principal amount of $325 million together with accrued but unpaid interest on the maturity date. The repayment was funded by the issuance of the 2027 Notes and the concurrent common stock offering, as well as cash on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Notes were issued pursuant to an indenture dated January&#160;29, 2016 (the &#x201c;2023 Indenture&#x201d;) between the Company and the trustee.&#160;The Company received $315.0 million in net proceeds from the offering after deducting underwriting fees and offering expenses. The 2023 Notes bore cash interest at a rate of 3.75%, payable on&#160;February&#160;1&#160;and&#160;August&#160;1&#160;of each year. The 2023 Notes were not redeemable prior to maturity and were convertible into shares of&#160;the Company&#x2019;s&#160;common stock. As a result of the Company&#x2019;s one-for-twenty reverse stock split in 2019 and pursuant to Section&#160;14.04(a)&#160;of the 2023 Indenture, the 2023 Notes were initially convertible into approximately 2,385,800 shares of the Company&#x2019;s common stock based on the initial conversion rate of 7.3411 shares of the Company&#x2019;s common stock per&#160;$1,000&#160;principal amount of the 2023 Notes. This represents an initial conversion price of approximately $136.20&#160;per share of the Company&#x2019;s common stock,&#160;representing an approximate 22.5% conversion premium based on the last reported sale price of the Company&#x2019;s common stock of $111.20 per share on January&#160;25, 2016. In addition, the holders of the 2023 Notes may have required the Company to repurchase the 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notes at par value plus accrued and unpaid interest following the occurrence of a Fundamental Change (as described in the 2023 Indenture). If a holder of the 2023 Notes converted upon a Make-Whole Adjustment Event (as described in the 2023 Indenture), they may have been eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 8.9928 shares per $1,000 principal amount of 2023 Notes (subject to other adjustments as described in the 2023 Indenture).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Notes are accounted for in accordance with ASC 470-20,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 470-20&#x201d;) and ASC 815-40.&#160;Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded) the instrument (or embedded feature) must be both (1)&#160;indexed to the issuer&#x2019;s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company&#x2019;s analysis, it was determined the 2023 Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20,&#160;the proceeds received from the issuance of the convertible debt were recorded as a liability on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the 2023 Notes,&#160;the Company&#160;also paid $38.5 million, including expenses, to enter into privately negotiated capped call transactions with certain financial institutions (the &#x201c;capped call transactions&#x201d;). The capped call transactions expired by their terms on January 27, 2023. The capped call transactions were generally expected to reduce the potential dilution upon conversion of the 2023 Notes in the event that the market price per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions, was greater than the strike price of the capped call transactions, which initially corresponded to the conversion price of the 2023 Notes, and was subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2023 Notes. The cap price of the capped call transactions was initially $194.60 per share, which represented a premium of approximately 75% based on the last reported sale price of the Company&#x2019;s common stock of $111.20 per share on January&#160;25, 2016, and was subject to certain adjustments under the terms of the capped call transactions. If, however, the market price per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions, exceeded the cap price, there would nevertheless have been dilution upon conversion of the 2023 Notes to the extent that such market price exceeded the cap price. The Company evaluated the capped call transactions under ASC 815-10,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2013; Overall&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;and determined that they should be accounted for as a separate transaction and that the capped call transactions would be classified as an equity instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred approximately $10.0 million of debt issuance costs in 2016 relating to the issuance of the 2023 Notes, which were recorded as a reduction to the 2023 Notes on the consolidated balance sheet. The $10.0 million of debt issuance costs was amortized and recognized as additional interest expense over the seven-year contractual term of the 2023 Notes on a straight-line basis, which approximated the effective interest rate method. The Company also incurred $0.9 million of expenses related to the capped call transactions, which were recorded as a reduction to additional paid-in-capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTEyODgx_eb8e1000-21af-4196-845e-3be549765b1b">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzMtMC0xLTEtMTEzNTcwL3RleHRyZWdpb246MGE5YWNlMzRjMzJjNGY2NWE0OTgyZDhiZDk0YTI5YThfMjE5OTAyMzI1NTU5NA_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <nvax:DebtInstrumentFaceAmountCurrent
      contextRef="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzMtMS0xLTEtMTA4MDcz_4fb14d7d-ad5b-411f-8051-f9378387eff8"
      unitRef="usd">325000000</nvax:DebtInstrumentFaceAmountCurrent>
    <nvax:DebtInstrumentFaceAmountCurrent
      contextRef="ied7dd9ef2652406e95d1ff0060ae1b04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzMtMy0xLTEtMTA4MDcz_2ed1775e-8774-48fd-a070-0f97be662c7e"
      unitRef="usd">0</nvax:DebtInstrumentFaceAmountCurrent>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzQtMS0xLTEtMTA4MDcz_48d33fae-f752-4881-81d7-2737e3d9eea2"
      unitRef="usd">119000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzQtMy0xLTEtMTA4MDcz_ac7876bc-64b7-4495-b24d-1798af02c2ea"
      unitRef="usd">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzUtMS0xLTEtMTA4Mzcw_6d153b2c-7cb4-423c-b72d-6a31268f03a8"
      unitRef="usd">324881000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzUtMy0xLTEtMTA4Mzcw_84d8f45e-8cd2-435c-a2d8-8a818eeeacae"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzctMC0xLTEtMTEzNTY3L3RleHRyZWdpb246ODU2NjA0ZDFlZDkzNGRjMDhlZWRmYWFlZTE3YzA4NDhfMjE5OTAyMzI1NTU5Mg_33fa4bef-21c4-415d-8233-3d518d1dee7b"
      unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzctMS0xLTEtMTA4MDcz_86d5b8ad-0484-4169-bde6-ea8b47847262"
      unitRef="usd">175250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i864f59e306a74cabbced7a3c1435512b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzctMy0xLTEtMTA4MDcz_2cb7dc40-709c-42af-a344-0da3e0025b91"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzgtMC0xLTEtMTEzNTcyL3RleHRyZWdpb246OWFiYmZhMDZmMTUyNGYwNzljNWU3NzMzNDBmN2ZlMmVfMjE5OTAyMzI1NTU5NA_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia5c64b0a629a43f79fe2b97f8ef1a21d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzgtMS0xLTEtMTA4MDcz_200434e2-cb65-41cd-a844-f67e16333473"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ied7dd9ef2652406e95d1ff0060ae1b04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzgtMy0xLTEtMTA4MDcz_cc03b522-5cf0-4282-9dfc-7e8abdb2bb0f"
      unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzktMS0xLTEtMTA4MDcz_4f4d4967-20d1-476e-9841-6e359450fb2f"
      unitRef="usd">8784000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzktMy0xLTEtMTA4MDcz_a8c3168b-d11f-4c7d-8ffa-e37744c53707"
      unitRef="usd">1542000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzEwLTEtMS0xLTEwODM3Mg_f07643ae-b0b6-40a4-9c5b-6702f8a81fa2"
      unitRef="usd">166466000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZToyZWEwMDQ2Mzk4NmM0NjhkOGQ1NzZlY2I0ZTgxNmJiMC90YWJsZXJhbmdlOjJlYTAwNDYzOTg2YzQ2OGQ4ZDU3NmVjYjRlODE2YmIwXzEwLTMtMS0xLTEwODM3Mg_905cb591-6395-42fb-8c70-c1df515cdbe3"
      unitRef="usd">323458000</us-gaap:ConvertibleLongTermNotesPayable>
    <nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTEyODgy_87ffd7a1-cf53-479f-8565-6ec37d1b13d3">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzItMS0xLTEtMTA4MDcz_a53709ed-95ef-46be-be48-90a090870330"
      unitRef="usd">12542000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzItMy0xLTEtMTA4MDcz_f1aa78f1-3e66-495e-9bc7-5a13915643d9"
      unitRef="usd">12188000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzItNS0xLTEtMTA4MDcz_595ebaf2-d7a5-431b-a9e6-f196576dbf82"
      unitRef="usd">12188000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzMtMS0xLTEtMTA4MDcz_068ae510-d800-4cd1-8597-a534e4663b93"
      unitRef="usd">1497000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzMtMy0xLTEtMTA4MDcz_22205fca-a29d-4817-b52d-9e5cd8a16a75"
      unitRef="usd">1424000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzMtNS0xLTEtMTA4MDcz_22611755-79d0-4110-a168-5ef1627e26b8"
      unitRef="usd">1424000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseDebt
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzQtMS0xLTEtMTA4Mzc1_82f07895-7ff0-4f9f-a0d9-b461b8baa83e"
      unitRef="usd">14039000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzQtMy0xLTEtMTA4Mzc1_723a6a30-1b68-4b90-a4f9-f3c6d355f31e"
      unitRef="usd">13612000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90YWJsZTozMTZjMWEyZThjZDA0OGMwYTU0Njc4ZmEwZWU1YmE5OC90YWJsZXJhbmdlOjMxNmMxYTJlOGNkMDQ4YzBhNTQ2NzhmYTBlZTViYTk4XzQtNS0xLTEtMTA4Mzc1_d7e3938e-2650-4ac5-b324-80a4c57501b8"
      unitRef="usd">13612000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwODYx_349e3722-8398-4fc2-a731-78357c0ea774"
      unitRef="usd">175300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwODgx_dc93b80a-ccd6-4244-8e56-08e9b0592445"
      unitRef="usd">166400000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwODk0_33fa4bef-21c4-415d-8233-3d518d1dee7b"
      unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTI4_65e8f74f-4771-4717-b0c8-ad2c0451a960"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTIw_477d3af9-34e3-4b55-83b3-cb569aa92faf"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTM3_34cd3ddb-e410-42f2-b634-9082fd9148f6"
      unitRef="number">1.30</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i96a1add754d840f5946967a65b3f474e_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTQy_789c02b6-8d10-4994-bc90-3e0de743e5da"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i96a1add754d840f5946967a65b3f474e_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTUy_b9897d27-97d6-4aa6-9b20-ade7f790ac35"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i96a1add754d840f5946967a65b3f474e_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTYz_6eed38f7-3bb5-45af-9a8c-bf8550e0a527"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwOTEy_08ca07ae-4d21-4b13-b6b5-def4a1e1322b"
      unitRef="usdPerShare">12.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nvax:ConversionPremiumPercentage
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE1MzkzMTYyODAwOTE4_8fd03ac1-ef53-4455-99e2-e3b82d2999a9"
      unitRef="number">0.25</nvax:ConversionPremiumPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTY4_d4d316ae-9c33-4131-a70e-a219730f95af"
      unitRef="number">1.30</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTc0_19d312ef-d0b7-4b67-b826-cafb58dfe4ab"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTgy_885676be-7ba5-49e1-91e7-ce145477d448"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="id27ebdbaafdf4f4fa37e179bbdba3238_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTkw_d1fba93e-4f88-4409-bb58-4b5112a082c1"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3956f36cdac340c886e2cbf2ea354b9f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MTk2_eeef87fe-9d9c-497f-ba2c-089ddbe8b813"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <nvax:DebtInstrumentRepurchaseOfPrincipalAmountPercentage
      contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQzOTgwNDY1NDIyNjg_a1cbe598-5ebe-4536-9c23-4eaabeac2a13"
      unitRef="number">1</nvax:DebtInstrumentRepurchaseOfPrincipalAmountPercentage>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzIxOTkwMjMyNzc3NTk_b727d662-315e-4649-b7fb-26510c8eccfe"
      unitRef="usd">8800000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzIxOTkwMjMyNzc3Njk_b727d662-315e-4649-b7fb-26510c8eccfe"
      unitRef="usd">8800000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtInstrumentTerm
      contextRef="i5105b98593f0496fbfc15c46fbfd7fdd_D20221201-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNTQ0ODcyMTA0MjA4_ab33d674-57e8-4262-8c15-f6d67101658f">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i32856f664ee8488999df14d37a8f364c_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE0ODQzNDA2OTk2Mjg2_7269cd16-8ab0-4b42-a818-fd12fff81fa4"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i502585dd7e734b158fdf6a98bb9e12e1_I20161231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzc1_2d868b9d-441a-45a8-92e0-e631fdfbe0eb"
      unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i5ce452e9ba0b4f91b8ca4a6aa27cddc8_D20230201-20230201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzc1_3d5168c2-c138-4d81-bbdb-2220f8768550"
      unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i502585dd7e734b158fdf6a98bb9e12e1_I20161231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE0ODQzNDA2OTk2NDUz_2d868b9d-441a-45a8-92e0-e631fdfbe0eb"
      unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i5ce452e9ba0b4f91b8ca4a6aa27cddc8_D20230201-20230201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzE0ODQzNDA2OTk2NDUz_3d5168c2-c138-4d81-bbdb-2220f8768550"
      unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQxMw_494ca1a6-f2de-490b-8d9d-e25853714c39"
      unitRef="usd">315000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="iee8898a306024e42bfe586c67dd2d69f_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzU0OQ_9e0b499e-ad7c-42f8-a83f-13b4ce0a555f"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i6efeba3a3c864c91ac8eb1625a20985c_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzkxOQ_91a259a6-39d1-49f2-97d9-ebe1a28ce238"
      unitRef="shares">2385800</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ied73af9ac932401ebc59933f068a2e4e_I20160125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzExNDI_8faa5c17-4e4b-4798-ba84-fe8b9e7185f0"
      unitRef="usdPerShare">136.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nvax:ConversionPremiumPercentage
      contextRef="ied73af9ac932401ebc59933f068a2e4e_I20160125"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzEyMTQ_f91c07d2-b654-45b4-9588-863ae7fcbcd5"
      unitRef="number">0.225</nvax:ConversionPremiumPercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic0ba24ef23674233a4a49398d78fe3b3_I20160125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzEzMDc_b07e64ed-436b-4b84-adbb-2cbb753200df"
      unitRef="usdPerShare">111.20</us-gaap:SaleOfStockPricePerShare>
    <nvax:PaymentForCappedCallTransactions
      contextRef="i3e30c16b247446e89dea1ad6f8e71d44_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzI5Nzg_1ac2f0a0-a0db-4eb5-bffb-26a1390e7289"
      unitRef="usd">38500000</nvax:PaymentForCappedCallTransactions>
    <nvax:DebtCapPrice
      contextRef="i34bddce3a1514a0991451e1b87ccd098_I20160125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzM2OTg_cf37f42e-5e6d-43b7-adda-a75281a65474"
      unitRef="usdPerShare">194.60</nvax:DebtCapPrice>
    <nvax:ConversionPremiumPercentage
      contextRef="i34bddce3a1514a0991451e1b87ccd098_I20160125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzM3NTc_0125f0cb-3e3a-49a7-a397-c73fe2153973"
      unitRef="number">0.75</nvax:ConversionPremiumPercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic0ba24ef23674233a4a49398d78fe3b3_I20160125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzM4MzE_b07e64ed-436b-4b84-adbb-2cbb753200df"
      unitRef="usdPerShare">111.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQ1MjY_609861a7-d643-4a75-8058-e9f3b14becb2"
      unitRef="usd">10000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQ2ODY_609861a7-d643-4a75-8058-e9f3b14becb2"
      unitRef="usd">10000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtInstrumentTerm
      contextRef="i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzUyMzQ_9fc05759-1fe6-4f72-97bf-e40046dfbe87">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="i3e30c16b247446e89dea1ad6f8e71d44_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNTQvZnJhZzo1NzI0MGM4MzYzM2Q0MWZiYmNhYzVmZDhkYTUyMmYxMS90ZXh0cmVnaW9uOjU3MjQwYzgzNjMzZDQxZmJiY2FjNWZkOGRhNTIyZjExXzQ5MzE_37820b98-e730-4b43-bc83-ac0dafb4822f"
      unitRef="usd">900000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:PreferredStockTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzk2NQ_b1117366-7867-4933-a480-38f32b5f7fed">Preferred StockIn June 2020, the Company entered into a redeemable Series A Convertible Preferred Stock Subscription Agreement, pursuant to which the Company agreed to issue and sell in a private placement 438,885 shares of its newly designated redeemable Series A Convertible Preferred Stock, par value $0.01 per share (&#x201c;Preferred Stock&#x201d;), at a purchase price of $455.70 per share, for total gross proceeds of $200.0&#160;million. During the fourth quarter of 2020, all outstanding shares of Preferred Stock were converted and the Company issued 4,388,850 shares of common stock, par value $0.01 per share, and reclassified $199.8 million from Preferred stock to Additional paid-in capital. The Company recognized a beneficial conversion feature of approximately $24.1 million at the time of issuance of the Preferred Stock that was recorded in Additional paid-in capital and Accumulated deficit as the Preferred Stock issuance was contingently redeemable and convertible at any time at the option of the holder.</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9a4f8a31db8143ffb528be60155adb66_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzIyMg_f5fbd397-dbb5-47ee-a368-3f4d04e3ceb0"
      unitRef="shares">438885</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id6d0cb0853434fa2bfca424a22521ff9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzMxNQ_294fe4b4-7ead-4a99-85b4-3446972fcfd5"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie6504e467cdf4ac9b1c7bb041d0d169a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzMxNQ_81a0d369-d5ab-4c6a-96db-5f2471736f35"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ifb6c34ca0e6943a985fccfb3c3cd5034_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzM3Mg_8c0b5d94-6a01-4612-8927-16f62b775b91"
      unitRef="usdPerShare">455.70</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="ib3f4681005a149c69af0c9d36cd0c591_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzQxNA_0d48e36a-6c14-4763-a5b5-ca006cd88c39"
      unitRef="usd">200000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ic32ab2b881af4e00801939f78ec7d4d9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzUzMw_464049c2-079b-4f54-b285-c2a283507a26"
      unitRef="shares">4388850</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id6d0cb0853434fa2bfca424a22521ff9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzU3MA_294fe4b4-7ead-4a99-85b4-3446972fcfd5"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie6504e467cdf4ac9b1c7bb041d0d169a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzU3MA_81a0d369-d5ab-4c6a-96db-5f2471736f35"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <nvax:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i72a45e70dfcc4ed3a06e5a1a0ad85788_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzYwMQ_89becf98-5425-41ed-a623-83294ddf59bb"
      unitRef="usd">199800000</nvax:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease
      contextRef="i72a45e70dfcc4ed3a06e5a1a0ad85788_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjAvZnJhZzo2MWRmZmVhYjVjNzQ0ZmFjOWQxYWJjZjliZDA4YzkwMC90ZXh0cmVnaW9uOjYxZGZmZWFiNWM3NDRmYWM5ZDFhYmNmOWJkMDhjOTAwXzcyOA_4b18354d-8c1d-4835-a0dd-390371a32d9d"
      unitRef="usd">24100000</nvax:StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzYwNA_fa656432-2241-42ee-a7df-5793959a0706">Stockholders&#x2019; EquityIn December 2022, the Company completed a public offering of 7,475,000 shares of its common stock, including 975,000 shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $10.00 per share resulting in net proceeds, net of offering costs of $4.9 million, of approximately $70 million. The Company completed this public offering concurrent with the issuance of the 2027 Notes (see Note 11).In June 2021, the Company entered into an At Market Issuance Sales Agreement (the "June 2021 Sales Agreement"), which allows it to issue and sell up to $500&#160;million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales Agreement. As of December&#160;31, 2022, the remaining balance available under the June 2021 Sales Agreement was approximately $318&#160;million. During the years ended December&#160;31, 2022, 2021, and 2020, the Company sold 2.2 million, 2.6 million, and 32.4 million, respectively, of shares of its common stock resulting in net proceeds of approximately $179&#160;million, $565&#160;million, and $877&#160;million, respectively, under its various At Market Issuance Sales Agreements.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id09da20d245547229c7e424719065312_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzU4_73a331d7-eee5-4804-b257-f46601297caf"
      unitRef="shares">7475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifcb69e18ef584de69947a34bda69992f_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzcw_23957e65-4ac6-4381-abe1-480c65d8a5b8"
      unitRef="shares">975000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="id52295e266c04be6958801ee220a81e6_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzc4_b0d38b9b-b320-494a-9d07-1f5a46c8ee43"
      unitRef="usdPerShare">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifcb69e18ef584de69947a34bda69992f_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxMzkz_c1d7c2cf-c43f-4de8-bfd9-64dd5fae494e"
      unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id09da20d245547229c7e424719065312_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE1MzkzMTYyNzkxNDEx_7643f5a2-a65c-4062-bbef-fde9c92f55a6"
      unitRef="usd">70000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i708fc4297d3e486b988a67ddb519f244_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NjU3_5b4bcb71-a1ce-4fab-bebb-dc0a044ccf6c"
      unitRef="usd">500000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <nvax:ShelfRegistrationStatementRemainingUnissuedCapital
      contextRef="i909d287d453b483eadef68a6db51c7ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NjY1_26ef624b-e639-4eab-85ee-a2bcf724c26a"
      unitRef="usd">318000000</nvax:ShelfRegistrationStatementRemainingUnissuedCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4c38f0119d96422898c0a8bea2f47c2c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3Njc0_fc000a3f-8802-4548-9370-0d3323761a74"
      unitRef="shares">2200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ied0bd77787a54028835f2babf0a109d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3Njgy_0afe45df-6294-40f2-8dba-b0235fde118a"
      unitRef="shares">2600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i71a915c3d5094ab9a4f33e9377b263ee_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3Njkw_491cc527-6f0f-41c0-815e-ba379a34ade4"
      unitRef="shares">32400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4c38f0119d96422898c0a8bea2f47c2c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NzI0_faded10a-edb0-43a9-925a-333572c14805"
      unitRef="usd">179000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ied0bd77787a54028835f2babf0a109d4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NzMy_d6fbfef3-27d9-403f-9abf-77a874e09ca9"
      unitRef="usd">565000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i71a915c3d5094ab9a4f33e9377b263ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjMvZnJhZzpmZjRjZTYxZDUxOWE0ZGYxOGI2MmU2YjUyMzc3YzUwNi90ZXh0cmVnaW9uOmZmNGNlNjFkNTE5YTRkZjE4YjYyZTZiNTIzNzdjNTA2XzE0ODQzNDA2OTc3NzQw_3c546ca6-396a-4e3d-8935-e9f3350bf5cf"
      unitRef="usd">877000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTg_1f803b47-d00d-4a2e-87f0-920d4f8a8e99">Stock-Based Compensation&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Stock Incentive Plan, as amended (&#x201c;2015 Plan&#x201d;), was approved at the Company&#x2019;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Plan authorizes the issuance of up to 14.8 million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of 2.4 million shares approved for issuance under the 2015 Plan at the Company&#x2019;s 2022 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;4, 2025. As of December&#160;31, 2022, there were 3.8 million shares available for issuance under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2005 Stock Incentive Plan (&#x201c;2005 Plan&#x201d;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, SARs, and RSUs. In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of 10 years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company&#x2019;s common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTc0_7315172c-cfb4-43c1-b403-98d1230d238a"&gt;one&lt;/span&gt; to four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation capitalized and included in inventory as of December&#160;31, 2022 was $1.7 million. There was no stock-based compensation capitalized and included in inventory as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was approximately $171 million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of 1.1 years and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#x2019;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option and SARs holders exercised their stock options and SARs on December&#160;31, 2022. This amount is subject to change based on changes to the closing price of the Company&#x2019;s common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the years ending December&#160;31, 2022, 2021, and 2020 was $21.4 million, $453.8 million, and $187.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Stock Appreciation Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2005 Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,635,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,892,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2015 Plan was estimated at the date of grant or the date upon which the 2015 Plan was approved by the Company&#x2019;s stockholders for certain stock options granted in 2020 and 2019 using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average Black-Scholes fair value of stock&lt;br/&gt;options and SARs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$55.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$158.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$80.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5%-1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-1.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-140.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.0%-152.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-7.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2015 Plan and 2005 Plan as of December&#160;31, 2022 was approximately $3 million and 7.1 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2015 Plan and 2005 Plan as of December&#160;31, 2022 was approximately $2 million and 6.6 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(505,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP was approved at the Company&#x2019;s annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of 1.1 million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase 5% on each anniversary of its adoption up to a maximum of 1.65 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). At December&#160;31, 2022, there were 0.7 million shares available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range of Black-Scholes fair values of ESPP&lt;br/&gt;shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$23.59-$79.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$83.47-$238.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.57-$92.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%-3.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%-0.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0%-142.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9%-159.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6%-189.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzQwMg_9f2b78b1-05fe-49b1-baed-e9f885a8835e"
      unitRef="shares">14800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwNw_b627fee0-00d4-4818-9ad5-425182ca3cbd"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIxOTkwMjMyNjQ3MDE_fab54ff1-95c2-446a-ba65-29f4329208cd"
      unitRef="shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2f0a3575acd74594903fd3f69ea74c2c_D20150601-20150630"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTU5_ec10ace5-1471-4df3-a581-dc59a005d0ec">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent
      contextRef="i0015ac21e2114e919dcd6b418ca0470e_I20150630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAxMDA0_b68389af-1e18-4ca1-9209-de842f3d89bb"
      unitRef="number">1</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0d4411c1dfac48628e521c4e1c62d82c_D20150601-20150630"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAwOTg2_38080a9f-6ec6-4bf7-90d8-5a7ecab1d5b5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTk_064d5981-d4ac-4c2d-a910-86a8bdeabba3">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i833db54db4e5410a82b51d91507bc240_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMS0xLTEtMTAxNjMz_a1f63832-a01f-4362-b726-a59c60562d8b"
      unitRef="usd">1032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id75773c016ce41a0a9271d81feb47a62_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMy0xLTEtMTAxNjMz_d01647f1-803c-428a-9737-4305e927297d"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82b8e8541d10484db42a6e56bf4c319c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItNS0xLTEtMTAxNjMz_43189cf7-9394-4310-ac94-46d41db18f9c"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a884616d8f240c899d1ffded053d84f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMS0xLTEtNzAyMDA_d10c0461-23fe-4051-a689-7d130fef9cd4"
      unitRef="usd">66565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i04e4f42ca7be4b18b06d0cb5a65f7f4f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItMy0xLTEtNzAyMDA_b53d41a7-2d66-49f5-b849-8114893532c7"
      unitRef="usd">86928000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06256858a63a4f5e993fc634c6256da8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzItNS0xLTEtNzAyMDA_9b7f4a3f-fdad-4210-b941-0016b400331f"
      unitRef="usd">55955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8deb5c81e1314ef6b0780d4f3a49ed98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzMtMS0xLTEtNzAyMDA_eb09d510-7e78-42d0-8793-72708d0ff726"
      unitRef="usd">62703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i78e81e12c2c645c891cd0ba8714b475c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzMtMy0xLTEtNzAyMDA_e82b697f-0705-4369-a294-e21ed578d436"
      unitRef="usd">96698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idba79020bba2422ea08fa0e1bc48a3eb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzMtNS0xLTEtNzAyMDA_a24e0ae6-e001-4244-88ec-a3cfae011af5"
      unitRef="usd">72080000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzQtMS0xLTEtNzAyMDA_566911b8-c793-4767-a221-ebeeae54abe0"
      unitRef="usd">130300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzQtMy0xLTEtNzAyMDA_b7ec3988-34f4-4859-b0b2-8744606c8665"
      unitRef="usd">183626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTpmYThiZDM0M2MxM2Y0OWJhYThlMTIxM2NkNTY4YTZmOS90YWJsZXJhbmdlOmZhOGJkMzQzYzEzZjQ5YmFhOGUxMjEzY2Q1NjhhNmY5XzQtNS0xLTEtNzAyMDA_4b0df8ac-e831-4d73-817f-37446e305d58"
      unitRef="usd">128035000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIxOTkwMjMyNjQ2Nzk_cb5c8190-ba87-4c8e-91b9-aa7414d5fdfb"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIxOTkwMjMyNjQ2OTI_01a17f47-d8c2-4529-8ea9-8f6039e78bd9"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzE3MzM_7c5d5412-d808-4b27-b1dd-f40b900dad1c"
      unitRef="usd">171000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzIwMzg_1a67a6ff-313f-442f-9adf-b4345c9d1e43">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzMwMTU_19767a04-5c02-4267-8c14-67d4071122e2"
      unitRef="usd">21400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzMwMTk_2850d07f-dbc0-453a-8517-ff82a1b1163a"
      unitRef="usd">453800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzMwMjc_4a4b3b1a-ab6a-412b-9585-c7412df1920b"
      unitRef="usd">187300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMjA_2f739bff-3065-4be4-91bb-5d52909f9b6b">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2005 Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,635,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,892,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic57598acb9d345a0b294ceda6cce94ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItMS0xLTEtNzAyMDA_38b647cb-55f1-422c-a6b5-6f2c91afe3f5"
      unitRef="shares">3635837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic57598acb9d345a0b294ceda6cce94ab_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItMy0xLTEtNzAyMDA_b601e668-1a22-498a-8996-44dd56ac3a56"
      unitRef="usdPerShare">42.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i07ae9fcb872440ec9e5ebfc077767156_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItNS0xLTEtNzAyMDA_dd592270-b3ba-4042-84d3-fd7e6564921e"
      unitRef="shares">68225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i07ae9fcb872440ec9e5ebfc077767156_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzItNy0xLTEtNzAyMDA_02485e4c-228a-495d-82fd-d061b7c10cf4"
      unitRef="usdPerShare">109.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtMS0xLTEtNzAyMDA_a38ce6d8-6317-4bcc-b70c-c4f09763d663"
      unitRef="shares">633626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtMy0xLTEtNzAyMDA_7b93ac2d-9c4d-4063-86e2-87b177df7366"
      unitRef="usdPerShare">65.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtNS0xLTEtNzAyMDA_1d9bf7aa-e139-4c0d-b59c-ea370f56bdc7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzMtNy0xLTEtNzAyMDA_be22508d-6f7c-487e-a399-f1c58643e955"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtMS0xLTEtNzAyMDA_e6f97472-0a30-49c8-8940-dcb35c7d9ff0"
      unitRef="shares">134222</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtMy0xLTEtNzAyMDA_4988b74a-6998-4fcc-9c71-332260ae9275"
      unitRef="usdPerShare">15.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtNS0xLTEtNzAyMDA_0f72879d-fb92-469e-82f5-7f8aa3ee8bde"
      unitRef="shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzQtNy0xLTEtNzAyMDA_bdbf643f-14e8-4d6c-b41c-1f757eb38171"
      unitRef="usdPerShare">31.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtMS0xLTEtNzAyMDA_d44f02e4-3270-477a-98f6-ba684e28f9d4"
      unitRef="shares">81951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="if1fc831fcc074b65803a8e6b549c29ef_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtMy0xLTEtNzAyMDA_4ada0a78-486f-406f-9bf5-7df6690af555"
      unitRef="usdPerShare">90.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtNS0xLTEtNzAyMDA_53c6d8dc-90c7-48bc-873c-bb39f3fc6879"
      unitRef="shares">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iea2a80f850a047c2b97c791ae92133e0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzUtNy0xLTEtNzAyMDA_8b885f2c-9e4f-465a-a190-73d506e8d00b"
      unitRef="usdPerShare">121.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtMS0xLTEtNzAyMDA_0d188a80-3a6a-47f3-aa81-851dadeb81b1"
      unitRef="shares">4053290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtMy0xLTEtNzAyMDA_06ab6ca6-f165-449a-b733-62f6ac2127ff"
      unitRef="usdPerShare">46.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtNS0xLTEtNzAyMDA_6d8c8d71-1196-43e9-bfb8-0d3bde66fcc6"
      unitRef="shares">63725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzYtNy0xLTEtNzAyMDA_05c78405-74bc-4dd0-bf4b-d89d7cc0321a"
      unitRef="usdPerShare">112.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctMS0xLTEtNzAyMDA_535f3d79-e76c-4dec-9af5-732e79133f9b"
      unitRef="shares">2892161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie5424c76f0f34f9abaf1051fa5d32862_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctMy0xLTEtNzAyMDA_61a562f0-45df-4345-a17f-db5e40918693"
      unitRef="usdPerShare">39.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctNS0xLTEtNzAyMDA_11cf792a-c6e6-4eb1-b07f-7d2a8082aee8"
      unitRef="shares">63725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if7d25ca75ae343a48d6da2c1441b845e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTozZGJjNTlkYjY0MTM0YzFjYTM0MDIyOGJmZjE2Mzc0ZS90YWJsZXJhbmdlOjNkYmM1OWRiNjQxMzRjMWNhMzQwMjI4YmZmMTYzNzRlXzctNy0xLTEtNzAyMDA_1362b064-9bf1-4e5f-988d-ad2b7c13eeb9"
      unitRef="usdPerShare">112.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTU_965cdd3c-94d7-488b-ac1a-1194dae90d32">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2015 Plan was estimated at the date of grant or the date upon which the 2015 Plan was approved by the Company&#x2019;s stockholders for certain stock options granted in 2020 and 2019 using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average Black-Scholes fair value of stock&lt;br/&gt;options and SARs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$55.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$158.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$80.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5%-1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-1.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-140.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.0%-152.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-7.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range of Black-Scholes fair values of ESPP&lt;br/&gt;shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$23.59-$79.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$83.47-$238.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.57-$92.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%-3.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%-0.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0%-142.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9%-159.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6%-189.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzItMS0xLTEtNzAyMDA_5a8b8a95-6501-42f1-af78-0d47d6b2cf94"
      unitRef="usdPerShare">55.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzItMy0xLTEtNzAyMDA_cc31dbcc-4344-4f8c-a6c9-82d470849a59"
      unitRef="usdPerShare">158.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzItNS0xLTEtNzAyMDA_7a1fc50a-49ba-4c00-a158-80ff248f08d6"
      unitRef="usdPerShare">80.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjMjk2NGI2MzVmZjc0YWI3YjNlYjNmMTFlMzQzNDU1YV80_bc98c5d7-f478-4932-bb8d-f8ba7b54c4e2"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjMjk2NGI2MzVmZjc0YWI3YjNlYjNmMTFlMzQzNDU1YV83_f8335201-932a-400c-a7cc-0b9029b72299"
      unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo3NWFjN2NmNDk5YjA0ZmQxYWJjZjgwNmM2MGRhYTMwY180_4db9dfd8-63cc-44cf-97ad-2c7613205d4a"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo3NWFjN2NmNDk5YjA0ZmQxYWJjZjgwNmM2MGRhYTMwY183_f4a2d9b3-d7b3-4fa7-9917-381bf40f9c1a"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiMTZkYmFhNDE0N2Q0MzUzODQ0ZjYwZDU1MDk5ZjJmZF80_4ae3e7aa-9925-4d5a-980f-5349e9763e65"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpiMTZkYmFhNDE0N2Q0MzUzODQ0ZjYwZDU1MDk5ZjJmZF83_3d7ef630-e404-43c8-bc71-bdf1d9c5ef05"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzQtMS0xLTEtNzAyMDA_8256e2da-b83f-42af-a535-9e1d032cd444"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzQtMy0xLTEtNzAyMDA_7059aab0-2ac2-42a2-87bb-8f57ba8239a9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzQtNS0xLTEtNzAyMDA_3ed167c6-2917-4bb4-888e-1af0038cc6ed"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozOWQ5YjYzMDkwNjA0NTE2OGQzNzg1Nzk0MmVlN2NhZl80_9b763b93-102e-464d-8b71-ad8e9936abb7"
      unitRef="number">1.205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozOWQ5YjYzMDkwNjA0NTE2OGQzNzg1Nzk0MmVlN2NhZl83_94d4f3e0-562e-417b-a3be-eb0ba8091be5"
      unitRef="number">1.401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphNDQ2YjQ3NGI3OTc0YWZkYjRmYzZhZDViZDM1YWViNl80_dbeac9a7-fdf6-42e1-9112-defb40c7c046"
      unitRef="number">1.247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6af00ef5b1574615b4021560a46437f2_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphNDQ2YjQ3NGI3OTc0YWZkYjRmYzZhZDViZDM1YWViNl83_0b2d6024-a580-4193-8dc5-323c341d3f38"
      unitRef="number">1.420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo4ZTY5OGNhNmQ3NzI0NDBkODU0Mjg3MzZiNjUwYWFkMl80_6936c653-7a7b-453f-b6d5-62e631b1df48"
      unitRef="number">1.160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ibc80a4971464477cb548ba2e550340ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo4ZTY5OGNhNmQ3NzI0NDBkODU0Mjg3MzZiNjUwYWFkMl83_fad2094c-ed21-49ae-8f8e-2f8e1db2198e"
      unitRef="number">1.522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if37d9719b2524f6f8329cdee51688933_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjE0MGI3N2Y2MDQ0MDNjYmU0NDc5NTVhYWJlY2FjM180_e714c802-0e6e-4c99-ad0d-14e479586af8">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i46bf6d3912154f1792ce922416ae63c1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjE0MGI3N2Y2MDQ0MDNjYmU0NDc5NTVhYWJlY2FjM183_8f11790b-8006-47d1-92f6-98fe6d9f403f">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1266c70d6883487eb69de02a5cefcaa5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjM2YmRkZjQwMzk0MDk4ODJlZGM1ZjUwZGNjODBiM180_5b1b7eec-0f5a-4961-8d07-044d695a7237">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i057ba2750d5b46caa17fd59064a93243_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoxYjM2YmRkZjQwMzk0MDk4ODJlZGM1ZjUwZGNjODBiM183_310e0681-f934-485a-b3f6-3359957b0503">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifc3b6eafa7a2453eb9dc3916a75c7c1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplMDBmNjA4MjAyMzM0ZTQ5YmIxMTBkYWViZGMzNGUwNl80_3ad1b891-1ede-4e64-aae7-ab1f4549ebbc">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie1af17faf5cc45288e504b60fca3980a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo4MTkxYjgxNzk5MzQ0OGQzYmRhY2IyYTU0YjM5OGZiYy90YWJsZXJhbmdlOjgxOTFiODE3OTkzNDQ4ZDNiZGFjYjJhNTRiMzk4ZmJjXzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplMDBmNjA4MjAyMzM0ZTQ5YmIxMTBkYWViZGMzNGUwNl83_7e8debbf-afc5-46ab-8174-daa3bc5e0c45">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM3NDU_3aa2c7e2-e823-46d7-937b-0addb5c3f5bd"
      unitRef="usd">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM3NTI_585c07ea-8471-42a5-aaac-c5328b09f3f0">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM5NzQ_208ef92d-fe0f-4057-b7a4-128f841718f9"
      unitRef="usd">2000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzM5ODE_100810f6-1a2d-4ab9-b5f6-c0eb46c2d245">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzUwMTY_4fb5e061-1ecf-484d-ad03-2a04a7ee6637">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(505,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i482ffe6e8ec14375b57c416c028deaec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzEtMS0xLTEtNzAyMDA_7b882ad3-8da9-4d7c-b10a-2d4056b680fb"
      unitRef="shares">819828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i482ffe6e8ec14375b57c416c028deaec_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzEtMy0xLTEtNzAyMDA_c83754e7-35ff-4828-a451-27d448308ea6"
      unitRef="usdPerShare">116.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzItMS0xLTEtNzAyMDA_77b3543b-9d05-4f12-bd87-e4e267252974"
      unitRef="shares">1882987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzItMy0xLTEtNzAyMDA_8e588347-69b4-4f75-90fa-1be1ae5658b3"
      unitRef="usdPerShare">48.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzMtMS0xLTEtNzAyMDA_264528df-e5d9-49e5-be71-3d1a24e732a8"
      unitRef="shares">505009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzMtMy0xLTEtNzAyMDA_f2899bed-884e-438e-9e4f-cdc699428f7b"
      unitRef="usdPerShare">89.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzQtMS0xLTEtNzAyMDA_1fdb2e8e-f61d-4856-9c22-443a72bf3b8d"
      unitRef="shares">163232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9663032b8c184f709f0bde479f6125eb_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzQtMy0xLTEtNzAyMDA_64d5df84-0994-4301-b726-c333eadca1a5"
      unitRef="usdPerShare">99.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i73561b8b32cf4435ac835a50e53a576a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzUtMS0xLTEtNzAyMDA_966fe225-be4c-4bc5-857b-47dedaf89a79"
      unitRef="shares">2034574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i73561b8b32cf4435ac835a50e53a576a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo0MDdjYTQ0ZmMzODM0ZTU2ODc1NDUyMTQ3NGJkOTc4MC90YWJsZXJhbmdlOjQwN2NhNDRmYzM4MzRlNTY4NzU0NTIxNDc0YmQ5NzgwXzUtMy0xLTEtNzAyMDA_14611241-23d9-4570-8738-598ed380f4b1"
      unitRef="usdPerShare">61.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzQyNjg_8bd6ce10-3216-4a6a-9257-c23547517849"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease
      contextRef="i4b07f0a42caf41428f69609a0b2b9990_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMDk3MDU1_ddeb7b6a-6fe2-463c-b006-71e1e94e8679"
      unitRef="number">0.05</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4b07f0a42caf41428f69609a0b2b9990_I20221231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzE1MzkzMTYyNzk0MjUy_f4ebe456-90d5-459e-a2a1-8bd9c18ebe63"
      unitRef="shares">1650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nvax:MaximumContributionOfEmployeesAsPayrollDeductions
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAxMDE1_4e4ceb32-c22e-48dc-ad4e-9cbffe425f09"
      unitRef="number">0.15</nvax:MaximumContributionOfEmployeesAsPayrollDeductions>
    <nvax:PercentageOfMarketPriceForStockPurchase
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzExNTQ0ODcyMTAxMDEw_cb26f02e-7ad7-4598-a50d-46ab0620c337"
      unitRef="number">0.85</nvax:PercentageOfMarketPriceForStockPurchase>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4b07f0a42caf41428f69609a0b2b9990_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90ZXh0cmVnaW9uOjliMDgxNjdhNTlkZjQ0NDk4MjM5NjdlYmFjNGIzZmQ3XzQ3NDU_399fcaf3-13e9-45a9-9b98-d8423a5b6c1b"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i546bbc59bac14443b9fa7278f44f39a7_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo1ZjRkMGY1MDQ0OTI0N2I1YTliMzMzYWUwNmM1N2NmMF80_ce374fc6-1ddf-49bb-be38-5011bd384707"
      unitRef="usdPerShare">23.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i43cd1de147754aae88ac59750e8413d4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo1ZjRkMGY1MDQ0OTI0N2I1YTliMzMzYWUwNmM1N2NmMF83_5c166301-aa6c-4fb2-a7f8-20bbb9066c82"
      unitRef="usdPerShare">79.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4741524c2007402199ab8e23ba7c57fc_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjY2JjYjMyNWE1OTU0MGRiYjQ1NjIyOGVmNWE5MWJjYV80_ac4cc70f-be8c-44eb-b437-445bb4629cd4"
      unitRef="usdPerShare">83.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib3daeefe63f648a9aefa23c5a54e474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjY2JjYjMyNWE1OTU0MGRiYjQ1NjIyOGVmNWE5MWJjYV83_39eaebb6-ac23-45c6-bcc8-1e5e8b6566b3"
      unitRef="usdPerShare">238.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4e434d4808f2454da2b021293904e61e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo5ZWY0ZTAxNmNiY2Q0MGZlYmU1MmQ5NTQwM2E2ZDdhMF80_79da707c-36f7-4a66-82e2-c26882a5582a"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idde6dd916c874f429e3cc8fe6d0eabed_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzItNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjo5ZWY0ZTAxNmNiY2Q0MGZlYmU1MmQ5NTQwM2E2ZDdhMF83_c03c9790-87ec-4c43-a92e-a91048bb6212"
      unitRef="usdPerShare">92.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyMzU2MjgwNGQxY2U0ZTA3YTFmNGM5YWRlOGQ5MzFkY180_bfa5f52d-6cb8-4d3b-8413-60e2acd7d124"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyMzU2MjgwNGQxY2U0ZTA3YTFmNGM5YWRlOGQ5MzFkY183_f3f133cf-c745-4437-9f5f-bec57eeb5171"
      unitRef="number">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpkNGVhOTlmM2EyNTQ0Njg0YWZhNmM3M2FhN2Y5ODI0M180_167112e7-0987-483d-b0ca-2196f87f41ad"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpkNGVhOTlmM2EyNTQ0Njg0YWZhNmM3M2FhN2Y5ODI0M183_5ba66416-b33d-47d0-8448-eda8f7fb3028"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjNWUzZjg3ZmNhNWY0MGFkYWQ4NWU3ZDFiZTVmNTNlNF80_f0351990-be40-4af8-90e4-f3a630359840"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzMtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjpjNWUzZjg3ZmNhNWY0MGFkYWQ4NWU3ZDFiZTVmNTNlNF83_8fa4595f-c0c6-442a-9846-b050b9ee4467"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzQtMS0xLTEtNzAyMDA_0058f251-bbac-4a67-8042-c0bb1f1987d3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzQtMy0xLTEtNzAyMDA_dd01cdde-970e-43cf-b0d3-99c3784cd2c3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzQtNS0xLTEtNzAyMDA_af677455-2018-4f02-8df9-dd5edffd7d9b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplNDk5ZjI2ZDFmZGM0NmJlOWFlNjdiNDViZDJlOTNiNF80_71ada6f6-9f97-4dc0-bcab-d5187a365636"
      unitRef="number">1.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ifcf3b5b61f0e4df78506727fbdfeac4c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjplNDk5ZjI2ZDFmZGM0NmJlOWFlNjdiNDViZDJlOTNiNF83_cdda34fc-aaf3-47ae-9826-594d095be90c"
      unitRef="number">1.429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyNzNkMzc0YTQyZDM0NWFmOWEzNzg0MGQyYWM3OGYyYl80_175cb2b7-d5e2-4b2b-9c3a-420db5f03fb6"
      unitRef="number">1.149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="id5e123fdf6d2452988fa47520e62ad54_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyNzNkMzc0YTQyZDM0NWFmOWEzNzg0MGQyYWM3OGYyYl83_d449951f-e294-4c1d-9534-66086d25e440"
      unitRef="number">1.594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozMDg5YTVlY2M0ZDA0M2UyYTViZDkyZWEyMzNlOTk0ZF80_ca011fc1-5d57-4968-855b-0456cb835976"
      unitRef="number">0.666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i23555c6a8f5e444d97009ecd5921dfd2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzUtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjozMDg5YTVlY2M0ZDA0M2UyYTViZDkyZWEyMzNlOTk0ZF83_3daa10a5-92b9-44e7-9816-84df26896580"
      unitRef="number">1.897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i546bbc59bac14443b9fa7278f44f39a7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyY2JjYmJhYTNkZWI0ODJmYWQ3YzI3MmYyOGEwN2RjZV80_bb7d6a98-7651-4387-8588-02c72f4df1b6">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i43cd1de147754aae88ac59750e8413d4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjoyY2JjYmJhYTNkZWI0ODJmYWQ3YzI3MmYyOGEwN2RjZV83_8be7ae9c-884d-42a9-b11d-ff1f37dcaf03">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4741524c2007402199ab8e23ba7c57fc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphYjc5YzlhN2IzODA0MTkyODJjOGE3MGUyNjM2NDkxZl80_40e9e497-3f63-459b-97d3-06745347dd73">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib3daeefe63f648a9aefa23c5a54e474f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtMy0xLTEtNzAyMDAvdGV4dHJlZ2lvbjphYjc5YzlhN2IzODA0MTkyODJjOGE3MGUyNjM2NDkxZl83_c8bac955-9028-47ad-b605-80ab992cdd07">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4e434d4808f2454da2b021293904e61e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjowZDNkMjAyOTUyZDg0ZDg4OGE1ZTJkNmFkYzVjYmQxMl80_0cd9f470-32e6-4390-8143-5844d63becb4">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idde6dd916c874f429e3cc8fe6d0eabed_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzIvZnJhZzo5YjA4MTY3YTU5ZGY0NDQ5ODIzOTY3ZWJhYzRiM2ZkNy90YWJsZTo1ZGY2OGIxZDI1MDM0MjgwYmY0OWNkY2EzODIwYTNiOS90YWJsZXJhbmdlOjVkZjY4YjFkMjUwMzQyODBiZjQ5Y2RjYTM4MjBhM2I5XzYtNS0xLTEtNzAyMDAvdGV4dHJlZ2lvbjowZDNkMjAyOTUyZDg0ZDg4OGE1ZTJkNmFkYzVjYmQxMl83_f1413132-628b-4f4d-8853-0697b9935e7c">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzg3Nw_7d0801c0-d345-4196-932c-072c895e2fd9">Employee Benefits&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a defined contribution 401(k)&#160;retirement plan, pursuant to which employees may elect to contribute up to 100% of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code of 1986, as amended. The Company matches 100% of the first 3% of the participants&#x2019; deferral, and 50% on the next 2% of the participants&#x2019; deferral, up to a potential 4% Company match. The Company&#x2019;s matching contributions to the 401(k)&#160;plan vest immediately. Under its 401(k)&#160;plan, the Company has recorded expense of $6.0 million, $3.4 million, and $0.9 million in 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign subsidiaries have pension plans under local tax and labor laws and are obligated to make contributions to the plan. Contributions and other expenses related to this plan were $2.4 million, $1.7 million, and $1.0 million in 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzE2MA_078bfc31-b4c7-4a53-a8d0-b0f674bf31b2"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="icacf535e608c4110bfafdf3621b23f38_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzMxNA_cbae2c8a-886f-4a16-8678-8a0a24514592"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="icacf535e608c4110bfafdf3621b23f38_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzMzMA_5a74fb7b-59a2-402e-8300-8cbff9015f45"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ie8ab394f5b23492db52ba56a7cdec054_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzM2OA_9f7e39d6-833f-4c0b-8203-65490030bcda"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ie8ab394f5b23492db52ba56a7cdec054_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzM4Mw_fc42ecf9-d76f-4c89-9012-177b7e4061ce"
      unitRef="number">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzQzNQ_edd7b3d6-ef3a-475f-971b-de013907896b"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzU4Ng_532b1f36-803c-4fd8-808d-5a39e60b8189"
      unitRef="usd">6000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzU5MA_295012eb-3e3f-413f-9f15-549d3603c1a7"
      unitRef="usd">3400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzU5OA_32d3400a-50ba-48f5-84a6-2cb790747739"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i07d0939ce4574bbca25cbd25ca1caa0a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzgzMQ_aa3aefcb-521f-481f-b2b7-1fcf47f54b14"
      unitRef="usd">2400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0b46d3bb09db4518ba0e5b40ba4c579a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzgzNQ_40162f35-ab6f-4bae-b792-74c6871e7174"
      unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ieaae667010054892bbaeaa0a48298ea5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzUvZnJhZzo1ZmFhZDc3NTJkM2M0NDE5YjRjNjAzNmJkMGUxY2JhYy90ZXh0cmVnaW9uOjVmYWFkNzc1MmQzYzQ0MTliNGM2MDM2YmQwZTFjYmFjXzg0Mw_69ac9103-21bc-410b-b71d-1e587ec7ceae"
      unitRef="usd">1000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzU1Mw_cb99f716-ba2d-47f5-a3d2-f0e7545bc652">Other Financial Information&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is comprised of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;341,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;251,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, approximately $170.0 million and $164.0&#160;million, respectively, of net assets used in operations were located in the Czech Republic. Depreciation expense was approximately $29.1 million, $12.5 million, and $4.3 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits and compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;468,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;577,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;673,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consist of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds to customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liability related to Gavi (see Note 3 and Note 18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;930,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzU1NA_576eafc0-ab55-46b6-8fc4-92c1199792ee">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:Supplies
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzItMS0xLTEtNzAyMDA_f014a4ea-1b14-44e7-b595-0595fa711705"
      unitRef="usd">160773000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzItMy0xLTEtNzAyMDA_18f5adb8-39b8-4ab4-8321-70d5189c03b0"
      unitRef="usd">120029000</us-gaap:Supplies>
    <us-gaap:OtherAssetsCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzMtMS0xLTEtNzAyMDA_b39b9c10-50fd-493a-8978-381d152cec55"
      unitRef="usd">76374000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzMtMy0xLTEtNzAyMDA_53200372-0349-436e-8615-a58073bd93dc"
      unitRef="usd">44619000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzQtMS0xLTEtNzAyMDA_2e387e8e-e383-470c-b254-cbf776235dac"
      unitRef="usd">237147000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiY2QzYzQ1NzdmNDY0MjQ1YmU4MWM1Nzg3ODFmNGQ4MS90YWJsZXJhbmdlOmJjZDNjNDU3N2Y0NjQyNDViZTgxYzU3ODc4MWY0ZDgxXzQtMy0xLTEtNzAyMDA_473efbd6-29c0-4a37-a0cd-21663253b329"
      unitRef="usd">164648000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic0fe342175f5492284e7a2703432374a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzItMS0xLTEtNzAyMDA_a46ecbba-10d7-4599-88d7-7ba141035e44"
      unitRef="usd">101342000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i306c59f27cd9488b966d7683b0b6d3e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzItMy0xLTEtNzAyMDA_6a58b336-8eeb-40d8-a0f1-6313b567f9e8"
      unitRef="usd">83534000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie51d31dc3a62493c90d13cac0e14c304_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzMtMS0xLTEtNzAyMDA_ad782bd6-b6e1-41aa-b3f6-faa8592ec071"
      unitRef="usd">134809000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id751e3e489e44cc4a6c2e3c2d4ff8264_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzMtMy0xLTEtNzAyMDA_824042f6-1419-47e9-9995-52b8d82a0798"
      unitRef="usd">119998000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8f4ccb5e7cb74f8d88f8a5fed001536d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzQtMS0xLTEtNzAyMDA_963103a0-7438-4f55-8c11-30d854e60a52"
      unitRef="usd">18895000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iccc1be450e664236a03f3377873ae30b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzQtMy0xLTEtNzAyMDA_48d70f17-1e96-43cc-8254-1c7f2fb83198"
      unitRef="usd">10282000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b0be8a4005f4b659c8142d8168d50eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzUtMS0xLTEtNzAyMDA_192230ec-a971-419f-ae06-ca7f0da5a255"
      unitRef="usd">4927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i261ee1ff33254ce5ae3c71c1734f2118_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzUtMy0xLTEtNzAyMDA_536ba18e-e0af-41ac-976a-23941dfb7800"
      unitRef="usd">2612000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i98a2c21af45f4bb8b5b57fb18fbb2a36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzYtMS0xLTEtNzAyMDA_764abcfd-e865-404e-b5cd-23d5962db91e"
      unitRef="usd">81566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i134cfe86255d47f58e6942ddfddc42ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzYtMy0xLTEtNzAyMDA_b358863c-2f38-4a8c-8381-f27e6e1659ae"
      unitRef="usd">35114000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzctMS0xLTEtNzAyMDA_14fadaf1-f42e-4a38-837e-3bdc69b24b35"
      unitRef="usd">341539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzctMy0xLTEtNzAyMDA_c988e99b-4758-4ff5-be65-1a1d1bb8ca80"
      unitRef="usd">251540000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzgtMS0xLTEtNzAyMDA_88fc70fe-b68e-4df5-b5e4-43dfd2b8437b"
      unitRef="usd">47292000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzgtMy0xLTEtNzAyMDA_52d5d08e-4f34-4ba7-9d8e-7aafc835afe8"
      unitRef="usd">25799000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzktMS0xLTEtNzAyMDA_0b1d6405-ea73-4eba-81c7-8a8777fdf60e"
      unitRef="usd">294247000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpmMmUxN2JjMDYxN2Y0MzEwYmUxOWI2ZjAxMmU2YTFkYy90YWJsZXJhbmdlOmYyZTE3YmMwNjE3ZjQzMTBiZTE5YjZmMDEyZTZhMWRjXzktMy0xLTEtNzAyMDA_e1816db3-9572-4568-9864-2f8efc647868"
      unitRef="usd">225741000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i003cbd6d8fc147008d115dcbabd4f866_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzI5NQ_da553977-0d44-4db4-a49e-79f5490b3d65"
      unitRef="usd">170000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0296343bcc7a45f7af04732eca6371c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzExNTQ0ODcyMDkyMzAw_e5b2faad-2173-43be-9e03-51e11ced827b"
      unitRef="usd">164000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzQwNg_216f58c5-2908-4490-8acc-bd0cf1d2f24d"
      unitRef="usd">29100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzQxMA_626e018b-9141-47e4-96f7-e51f02667d90"
      unitRef="usd">12500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzQxOA_628224b3-46a4-4286-a3cc-c59fd52b747a"
      unitRef="usd">4300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzU1Ng_ff18f9c3-2cb6-4174-810f-3588ae5d9915">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits and compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;468,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;577,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;673,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzItMS0xLTEtNzAyMDA_6e4579e3-cf60-48c3-badf-0734d509ad20"
      unitRef="usd">52569000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzItMy0xLTEtNzAyMDA_d0a4619a-07e1-4356-9a50-37b84fef18fa"
      unitRef="usd">38419000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nvax:ResearchAndDevelopmentAccruals
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzMtMS0xLTEtNzAyMDA_41b26346-0d9f-427f-b694-6be37e6d5433"
      unitRef="usd">468214000</nvax:ResearchAndDevelopmentAccruals>
    <nvax:ResearchAndDevelopmentAccruals
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzMtMy0xLTEtNzAyMDA_2cc02b90-b42b-4e57-9ae3-6432d82c0a37"
      unitRef="usd">577100000</nvax:ResearchAndDevelopmentAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzQtMS0xLTEtNzAyMDA_2ed66550-4b31-4c31-b92b-cd93a8da15f3"
      unitRef="usd">70375000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzQtMy0xLTEtNzAyMDA_0474b600-c2da-498b-8907-07a500219ca4"
      unitRef="usd">58212000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzUtMS0xLTEtNzAyMDA_77d37b47-267b-4418-b7cf-bc0b4d2a923f"
      unitRef="usd">591158000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTplZjJlMDNjNTMwOTA0YmZmODFkN2M2ZGJmMTgxNmE0My90YWJsZXJhbmdlOmVmMmUwM2M1MzA5MDRiZmY4MWQ3YzZkYmYxODE2YTQzXzUtMy0xLTEtNzAyMDA_98829248-19b0-45ba-8b03-6ff98aac4846"
      unitRef="usd">673731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90ZXh0cmVnaW9uOjA0MDNmZTdiYmY4ZDQ0MjRiM2ZiYzVjNTZmY2VkMDU5XzExNTQ0ODcyMDkyNjUx_7d39cc71-cb0a-423b-9c51-a463bd8880c5">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consist of the following at December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds to customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liability related to Gavi (see Note 3 and Note 18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;930,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzItMS0xLTEtMTExNjEz_f381da22-2428-4abf-b795-ed10b8211d18"
      unitRef="usd">210362000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzItMy0xLTEtMTExNjEz_a060b082-3374-402b-a551-45433b036ce0"
      unitRef="usd">0</us-gaap:CustomerRefundLiabilityCurrent>
    <nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzMtMS0xLTEtMTIxNTA3_4bdf9a00-1541-4a3d-8adb-41c039718ce3"
      unitRef="usd">697384000</nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements>
    <nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzMtMy0xLTEtMTIxNTA3_d7c49da7-109f-46dc-a51a-7281ed1dc679"
      unitRef="usd">0</nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzQtMS0xLTEtMTExNjEz_a92b1d9b-89fc-4f04-81fc-252e20bf853b"
      unitRef="usd">22309000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzQtMy0xLTEtMTExNjEz_1e2b588f-ec29-42c9-9cf0-f695546aa866"
      unitRef="usd">36061000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzUtMS0xLTEtMTExNjEz_33831310-1772-4fdf-b05d-05a659c557bb"
      unitRef="usd">930055000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNjYvZnJhZzowNDAzZmU3YmJmOGQ0NDI0YjNmYmM1YzU2ZmNlZDA1OS90YWJsZTpiYjZiMDYxODg2ZmE0OTNhYjgxYWI1ODI5MzVkMmVlZS90YWJsZXJhbmdlOmJiNmIwNjE4ODZmYTQ5M2FiODFhYjU4MjkzNWQyZWVlXzUtMy0xLTEtMTExNjEz_1aafdf3c-f938-4663-991b-74f73369d4e8"
      unitRef="usd">36061000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjQ_6b57b039-d7b2-4bb1-9682-721cd27eefb9">Income Taxes&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income (loss) from operations before income tax provision (benefit) by jurisdiction for the years ended December&#160;31 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(712,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,633,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(455,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(653,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,714,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(418,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the current income tax provision (benefit) are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021, and 2020, the Company recognized $4.3&#160;million, $29.2&#160;million, and no federal, state, and foreign current income tax expense. The foreign income tax expense is primarily related to foreign withholding tax on royalties. The Company recognized no deferred income tax expense during the years listed above due to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the provision for income tax to the amount computed by applying the U.S. federal statutory tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxation of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company has available federal, state, and foreign net operating losses of $2.0&#160;billion, $0.9&#160;billion, and $29.1&#160;million, respectively, that may be applied against future taxable income in the respective jurisdiction. The federal net operating losses of $2.0&#160;billion can be carried forward indefinitely, although limited to 80% of annual taxable income. State net operating losses of $0.4&#160;billion have various expiration dates between 2028 and 2042. The remaining state net operating losses of $0.5&#160;billion can be carried forward indefinitely. Approximately $15.1&#160;million of the foreign net operating losses will begin to expire in 2024 through 2027. The remaining $14.0&#160;million of foreign net operating losses can be carried forward indefinitely. The Company also has research tax credits of $46.0&#160;million that will begin to expire in 2030 through 2052. Utilization of the domestic net operating loss carryforwards and research tax credits may be subject to an annual limitation due to potential ownership changes of the Company. As of December&#160;31, 2022, the Company does not expect such limitation, if any, to impact the use of these domestic net operating losses and research tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal jurisdiction and in various states, as well as in foreign jurisdictions such as Sweden and the Czech Republic. The Company has U.S. federal and state net operating losses and credit carryforwards that are subject to examination from 2002 through 2022. The returns in Sweden are subject to examination from 2016 through 2022 and the returns for the Czech Republic are subject to examination from 2019 through 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;479,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;845,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Original discount interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,056,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,027,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,020,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,015,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon the realization of its deferred tax assets, including its history of significant losses in every year since inception and, in accordance with U.S GAAP, has fully reserved the net deferred tax asset. The Company concluded that realization of its net deferred tax assets is not more-likely-than-not to be realized as of December&#160;31, 2022 and 2021. The valuation allowance increased by $4.8 million and $510.5 million for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets, weighing positive and negative evidence to assess the recoverability. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including its cumulative losses over the three years ended December&#160;31, 2022 and the substantial doubt about the Company&#x2019;s ability to continue as a going concern through one year from the date that these financial statements are issued, and positive evidence, including its regulatory authorizations for and commercial sales of NVX-CoV2373. After assessing both the negative and positive evidence, the Company concluded that it should maintain the valuation allowance on its net operating losses, credits, and its other deferred tax assets as of December&#160;31, 2022. The release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, the Company's level of profitability, revenue growth, clinical program progression, and expectations regarding future profitability. The Company's total net deferred tax asset balance subject to the valuation allowance was $1.1&#160;billion and $1.0&#160;billion as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of an income tax position when it is more likely than not, based on the technical merits, that the income tax position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2022, 2021, and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reductions for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements of tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2022 and 2021, the Company had no accruals for interest or penalties related to income tax matters. The total amount of unrecognized tax benefits that, if recognized, could affect the effective tax rate was $5.2 million and $11.2&#160;million as of December&#160;31, 2022 and 2021, respectively. However, the Company maintains a full valuation allowance as of December&#160;31, 2022 and 2021 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact. As of December&#160;31, 2022, the Company does not expect a significant change in the recorded unrecognized tax benefits reserve balance during the next twelve months. The unrecognized tax benefits are presented in the financial statements as a reduction to the deferred tax assets for all periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjM_2c9cf6f2-d60b-4760-aef5-4ab23a9b3ce2">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income (loss) from operations before income tax provision (benefit) by jurisdiction for the years ended December&#160;31 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(712,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,633,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(455,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(653,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,714,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(418,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzItMS0xLTEtNzAyMDA_2d5932fa-9c11-4882-8ced-c1d00e34327f"
      unitRef="usd">-712183000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzItMy0xLTEtNzAyMDA_22bad0b9-49a0-4e48-a7c0-b4948514501d"
      unitRef="usd">-1633016000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzItNS0xLTEtNzAyMDA_0a12645d-4d8a-4eed-866d-2a9963e4c3d1"
      unitRef="usd">-455253000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzMtMS0xLTEtNzAyMDA_8c795f3b-d2be-4819-abf9-f5c4a2817293"
      unitRef="usd">58536000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzMtMy0xLTEtNzAyMDA_0cd7cb8d-5df8-4ad6-8c09-d7350b66f075"
      unitRef="usd">-81520000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzMtNS0xLTEtNzAyMDA_7a5ef1ad-e370-4a5d-a6ce-2c28fbd2e3bd"
      unitRef="usd">36994000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzQtMS0xLTEtNzAyMDA_4225490c-7051-499a-bdef-847eaa13c201"
      unitRef="usd">-653647000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzQtMy0xLTEtNzAyMDA_1f54dc3d-d88c-4a26-a5dd-f6b6f6310195"
      unitRef="usd">-1714536000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToyZmQyODQ5YWNlMmQ0MzAxODkwMWIwNTQzZDVjMjM3ZS90YWJsZXJhbmdlOjJmZDI4NDlhY2UyZDQzMDE4OTAxYjA1NDNkNWMyMzdlXzQtNS0xLTEtNzAyMDA_8e221e3f-1b8e-441a-b1f8-152c0d0a4801"
      unitRef="usd">-418259000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzExNTQ0ODcyMTA1NzA2_5a34df0c-ef89-4fbe-b6b1-5ade16aa407a">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the current income tax provision (benefit) are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzItMS0xLTEtMTI0Njc1_a85b5b87-bb63-499c-9c61-e7690ab55411"
      unitRef="usd">1300000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzItMy0xLTEtMTI0Njc1_3d89b341-029e-449b-a479-e3ef1fc44fe4"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzItNS0xLTEtMTI0Njc1_d44875bb-2a77-491a-a385-98eaaef8a4f6"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzMtMS0xLTEtMTI0Njc1_4d1e1ab4-4778-41b6-beab-7d2df66a8613"
      unitRef="usd">503000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzMtMy0xLTEtMTI0Njc1_ac627fcb-0320-420f-aebb-d0d2d5b43b18"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzMtNS0xLTEtMTI0Njc1_2e9a4a75-5645-4709-8f8a-ea7ac0f5eb70"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzQtMS0xLTEtMTI0Njc1_636b5f7d-d07b-42b1-8e10-d0b1556229cb"
      unitRef="usd">2489000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzQtMy0xLTEtMTI0Njc1_5dbeb1a0-a4e9-4505-b69a-66d8f7e00fe7"
      unitRef="usd">29215000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzQtNS0xLTEtMTI0Njc1_60ba866b-a70f-4a08-b4f9-3c1ce8e65fca"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzUtMS0xLTEtMTI1MzA0_7b4c43b7-c441-4953-aafb-e81fe4ce2365"
      unitRef="usd">4292000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzUtMy0xLTEtMTI1MzA0_29380e39-52a1-4f84-bc16-6a95e8b5972c"
      unitRef="usd">29215000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTpkYjA3NTkxMzE3ZmM0OTU3ODdjMjcyN2QxMTRmYWRhZC90YWJsZXJhbmdlOmRiMDc1OTEzMTdmYzQ5NTc4N2MyNzI3ZDExNGZhZGFkXzUtNS0xLTEtMTI1MzA0_eed0a412-51cb-4c5a-b272-fd8cb5e56f96"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjg2MTU_395f7d4b-5cb9-4fc9-8209-f4b533ec6538"
      unitRef="usd">4300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjg2MjQ_9887b32e-6444-4326-9f93-aadc51a1fd72"
      unitRef="usd">29200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjg2MzM_d003f47a-8264-4dfb-a8c0-fe037963772f"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjI_2aa393da-c8f6-4f3b-8710-24d5fcc2d836">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the provision for income tax to the amount computed by applying the U.S. federal statutory tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxation of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzItMS0xLTEtNzAyMDA_af53646e-bc76-48f6-81dd-51eeb9e1d697"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzItMy0xLTEtNzAyMDA_e57c20e2-5e2a-48a5-b7b8-de8580cdb2ba"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzItNS0xLTEtNzAyMDA_6e2917fe-2c20-49b2-8121-b8bd56c318e6"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzMtMS0xLTEtNzAyMDA_d4100031-4ed0-4ac1-868a-5ec6bd0473c2"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzMtMy0xLTEtNzAyMDA_8d1bc9fd-9b1d-4959-9d2a-73971209d466"
      unitRef="number">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzMtNS0xLTEtNzAyMDA_8726f80b-47d0-47c8-b847-2d31b8c73ec4"
      unitRef="number">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzQtMS0xLTEtNzAyMDA_ba989de5-e2b4-4040-92c4-17c50660146b"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzQtMy0xLTEtNzAyMDA_9ce50911-b012-4483-aeca-7516e582418b"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzQtNS0xLTEtNzAyMDA_b1b6c6b3-e431-4bf0-8263-f6e8b2ba1344"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzUtMS0xLTEtNzAyMDA_119113e0-abef-4056-837b-fa6a5f6a2aed"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzUtMy0xLTEtNzAyMDA_34ce9cfb-b688-4b9c-ac7c-4c501f215d52"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzUtNS0xLTEtNzAyMDA_78a8c1de-2e30-493d-9bd9-d6f9df67dbf1"
      unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzYtMS0xLTEtNzAyMDA_e4f25502-cf48-4bf3-9d7e-32042d941d26"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzYtMy0xLTEtNzAyMDA_95ea7dfb-1bee-4af8-b503-bb82643f33d1"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzYtNS0xLTEtNzAyMDA_5048ab07-aad3-4d44-8b0d-f1145247921a"
      unitRef="number">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzctMS0xLTEtNzAyMDA_89f2eecd-cfd8-4ea7-92b0-a3c96ceb3bee"
      unitRef="number">-0.03</nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations>
    <nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzctMy0xLTEtNzAyMDA_737d5147-8c4e-4b45-b6fe-3b4649cf52c3"
      unitRef="number">0</nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations>
    <nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzctNS0xLTEtNzAyMDA_6a3ff147-c56b-432f-8fcf-e3a83f417b2e"
      unitRef="number">0</nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMS0xLTEtMTI1MTMy_4c26ac77-f4c2-4ab1-837c-72dee0a9ca23"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMy0xLTEtMTI1MTMy_d4947158-6225-47a4-afbe-7a388c5ce749"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtNS0xLTEtMTI1MTMy_f9f74d14-35e2-4f2f-af28-a4ebfd36ca18"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMS0xLTEtNzAyMDA_aa466bde-b7df-467b-8f2b-294130fce48d"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtMy0xLTEtNzAyMDA_1910e6ce-50b9-4569-959b-8d515d5f1be5"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzgtNS0xLTEtNzAyMDA_d6d74d60-86cd-4859-b44d-4cabdd76ff0a"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzktMS0xLTEtNzAyMDA_32789578-d73a-4cb7-b409-db310a6fb592"
      unitRef="number">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzktMy0xLTEtNzAyMDA_13d06c63-f814-4249-b977-e79c9be50912"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzktNS0xLTEtNzAyMDA_6c04a4e5-ee87-4701-8619-0f77fa403046"
      unitRef="number">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzEwLTEtMS0xLTcwMjAw_9c29a8e7-45b2-43b9-a854-149bf2951fdb"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzEwLTMtMS0xLTcwMjAw_0dfae5c0-6aeb-4043-9037-3c96753963f2"
      unitRef="number">-0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzEwLTUtMS0xLTcwMjAw_e36b34cd-3638-48e2-98d9-140da5d09102"
      unitRef="number">-0.31</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzExLTEtMS0xLTcwMjAw_8c6fc661-8c3b-4323-ad5d-d11b28b3b543"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzExLTMtMS0xLTcwMjAw_970e82f2-ab19-4eb5-ac0b-e5f28331683d"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo1YjhkMTllMmJhYjU0YTM5YjU4YmYyNjFkZTczNjczZi90YWJsZXJhbmdlOjViOGQxOWUyYmFiNTRhMzliNThiZjI2MWRlNzM2NzNmXzExLTUtMS0xLTcwMjAw_c41956f1-290c-45c1-914d-3ad58d28a74a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie850cc1078634b628fb807996bac48ec_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzYzNQ_d473f32a-58bc-422e-89bd-4673994a923a"
      unitRef="usd">2000000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibba48e8ed9c64a64bc36603e29727b1b_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzYzOQ_28184b81-c09a-44d7-99ce-6b805b67ceb6"
      unitRef="usd">900000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie09d6c3cc8dd494997ad5e9e0699ba04_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzY0Nw_da096268-fdac-48e3-a90d-e14a5c948e71"
      unitRef="usd">29100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie850cc1078634b628fb807996bac48ec_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzU0OTc1NTgxNDM3OTU_d473f32a-58bc-422e-89bd-4673994a923a"
      unitRef="usd">2000000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i18d589697b3448ef979612d981bcfa9b_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNjkw_d58c31f4-d2dc-4204-b7e0-cffe1f2751be"
      unitRef="usd">400000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idccedc0b914042e9b04e606a7f40b047_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNjk4_b1abdc50-39f0-4f3b-a21f-9c5884cc0714"
      unitRef="usd">500000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i4ed100b1f229497699cf3a210f953003_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNzA1_bd91149f-3d75-46a9-ada8-f6626ad67f4b"
      unitRef="usd">15100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0dadba2600544eb092b5aec9b95db726_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzExNTQ0ODcyMDk4MzUy_1b5d7f2d-ea6a-4e32-84b9-eb8e308c67f3"
      unitRef="usd">14000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i9b5882daa660420c9f6624c60e06285f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxNDQwNDc2NzUyNzE1_0c42e667-daaa-46fc-9968-78cfedcf61d4"
      unitRef="usd">46000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjA_69c4fe31-d195-4e07-a6a3-64e022671893">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;479,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;845,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Original discount interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,056,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,027,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,020,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,015,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzMtMS0xLTEtNzAyMDA_7ed2cb99-e218-451d-9a72-17f045f4708a"
      unitRef="usd">479134000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzMtMy0xLTEtNzAyMDA_2f7059b2-4075-41cd-b75c-d308b958b317"
      unitRef="usd">845731000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzQtMS0xLTEtNzAyMDA_c9f0563a-7544-4e00-b935-eed419a9f332"
      unitRef="usd">5752000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzQtMy0xLTEtNzAyMDA_1d4326e9-693c-4178-8f65-6e43f029abb7"
      unitRef="usd">25625000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzUtMS0xLTEtNzAyMDA_db4f5377-33e8-4e08-9594-983033985d67"
      unitRef="usd">45560000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzUtMy0xLTEtNzAyMDA_16d0afcc-5cda-402e-9b92-2e5df22bad4d"
      unitRef="usd">44618000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nvax:DeferredTaxAssetLeasingLiability
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzYtMS0xLTEtNzAyMDA_5436b98b-11cf-4e04-b8b1-aa8a7c5b685b"
      unitRef="usd">27625000</nvax:DeferredTaxAssetLeasingLiability>
    <nvax:DeferredTaxAssetLeasingLiability
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzYtMy0xLTEtNzAyMDA_513948d4-46fd-46e2-ad2c-fda2da59978b"
      unitRef="usd">52852000</nvax:DeferredTaxAssetLeasingLiability>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMS0xLTEtMTI1MDI1_c8db2cf6-2f00-4596-b542-6f9d199cbf24"
      unitRef="usd">195049000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMy0xLTEtMTI1MDI1_43ac6381-8aed-423f-9831-d69a79b6391a"
      unitRef="usd">20262000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMS0xLTEtNzAyMDA_13a318b6-8eb1-48d6-950e-cdb931fb13c1"
      unitRef="usd">213076000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzctMy0xLTEtNzAyMDA_a5e2e62b-8ec9-40d5-99c7-b5d6e31ffc56"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzktMS0xLTEtNzAyMDA_e7dc230a-8dbc-48c6-9f9d-3164ab6a80cb"
      unitRef="usd">27599000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzktMy0xLTEtNzAyMDA_ffb76d69-6dc5-4386-bb66-3903075aae70"
      unitRef="usd">24698000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <nvax:DeferredTaxAssetsOriginalDiscountInterest
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEwLTEtMS0xLTcwMjAw_79b65f1b-fe79-4dee-8af6-f85da9bf79ac"
      unitRef="usd">0</nvax:DeferredTaxAssetsOriginalDiscountInterest>
    <nvax:DeferredTaxAssetsOriginalDiscountInterest
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEwLTMtMS0xLTcwMjAw_b2a975af-3214-4a3f-80ec-535ba963810f"
      unitRef="usd">1729000</nvax:DeferredTaxAssetsOriginalDiscountInterest>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTEtMS0xLTEyNDk1NA_478d2b33-1a2a-4ef9-8a73-29478aed5cec"
      unitRef="usd">49309000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTMtMS0xLTEyNDk1NA_9c86da83-a6f2-4253-9881-7e13dc77063f"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTEtMS0xLTEyNTAxNg_e6ff90d5-93a9-4876-a3e0-404cda15a4b2"
      unitRef="usd">13695000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTMtMS0xLTEyNDk2Mg_c4c2315c-b94e-409d-a2d4-8bbb2e2160b0"
      unitRef="usd">11801000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTEtMS0xLTcwMjAw_3fe1b6ca-5d36-4bd2-a0de-c2def009298d"
      unitRef="usd">1056799000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzExLTMtMS0xLTcwMjAw_455a5de9-f617-4183-bfb1-07ef7e8068e8"
      unitRef="usd">1027316000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTEtMS0xLTcwMjAw_fdefc3bb-e597-47a4-8ef2-eaec6f5fd300"
      unitRef="usd">1020123000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEyLTMtMS0xLTcwMjAw_d6e2821e-750c-41ae-97bf-4732da77e883"
      unitRef="usd">1015333000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEzLTEtMS0xLTcwMjAw_7d59e095-9b70-4827-a264-c4e9413025c8"
      unitRef="usd">36676000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzEzLTMtMS0xLTcwMjAw_1082c7b8-3604-4245-8b2d-c0b6f37cbd2a"
      unitRef="usd">11983000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE1LTEtMS0xLTcwMjAw_d00989d9-d4ea-40af-a9f4-33a4ef3d1351"
      unitRef="usd">23330000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE1LTMtMS0xLTcwMjAw_b7a034f3-300b-4c2c-8be6-4cd2577bfa1b"
      unitRef="usd">10071000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTEtMS0xLTEyNTA3NQ_058338b3-ccd3-4ea2-8deb-1a6bc5d5bc63"
      unitRef="usd">11587000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTMtMS0xLTEyNTA3NQ_a8d1185c-7902-42c7-b7d7-629acaa7cc9e"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE2LTEtMS0xLTcwMjAw_4ddddd5a-5d6d-463b-9b0e-2ecb48de1c84"
      unitRef="usd">1055000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE2LTMtMS0xLTcwMjAw_ff6257d2-60ca-4150-bd8a-a0af273047c2"
      unitRef="usd">1034000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE3LTEtMS0xLTcwMjAw_287af014-1234-4461-842f-d3520ac16447"
      unitRef="usd">704000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE3LTMtMS0xLTcwMjAw_78c2587d-b41c-4402-9216-729df7858e86"
      unitRef="usd">878000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTEtMS0xLTcwMjAw_ad43c8d1-bb8f-4be9-8db1-8b9535462a87"
      unitRef="usd">36676000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE4LTMtMS0xLTcwMjAw_121ff5ab-3766-4268-9127-0094c13010f9"
      unitRef="usd">11983000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE5LTEtMS0xLTcwMjAw_d4794054-f33f-4670-919d-ad4453f6331b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZToxMWY5ZTRlZGZlMDg0MTg5ODEzOTY4Y2E1NjAwMWYwYi90YWJsZXJhbmdlOjExZjllNGVkZmUwODQxODk4MTM5NjhjYTU2MDAxZjBiXzE5LTMtMS0xLTcwMjAw_98d09eb5-0e11-4446-a547-f7fc27da9e27"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIyOTk_14b64819-f4ac-4b47-ad2d-02ac431dbaac"
      unitRef="usd">4800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIzMDY_e0e133f6-7221-4e39-8852-fde541b383d2"
      unitRef="usd">510500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjk3NzM_d80815a7-42ec-4fe3-8ef5-c4bd6f25cc99"
      unitRef="usd">1100000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzIxOTkwMjMyNjk3ODU_0b72665e-c11e-4bf1-bb9e-64530c2f47f5"
      unitRef="usd">1000000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMjE_e43d4874-088c-4ab6-9ceb-dce4831e384a">A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2022, 2021, and 2020 is as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reductions for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements of tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzItMS0xLTEtNzAyMDA_5ca7a277-b3d0-4910-95d7-481eded87f58"
      unitRef="usd">11154000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzItMy0xLTEtNzAyMDA_c7a771fa-69c4-4488-b410-04d4b9a20e15"
      unitRef="usd">8766000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iab79f65652ef4787919164353ded1194_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzItNS0xLTEtNzAyMDA_8388aff4-6115-4fcf-adcd-4544da59d9ca"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzMtMS0xLTEtNzAyMDA_d56be037-6e65-4769-a8ec-75d3b07f3741"
      unitRef="usd">1260000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzMtMy0xLTEtNzAyMDA_76fa040a-7df1-463d-8361-eda4fa3c7bd0"
      unitRef="usd">4158000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzMtNS0xLTEtNzAyMDA_01cbe1ce-fe43-478c-8006-11c0c6c0c3b3"
      unitRef="usd">1413000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzQtMS0xLTEtNzAyMDA_ec26477a-74c8-4230-b2cc-610a3e99d4ce"
      unitRef="usd">807000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzQtMy0xLTEtNzAyMDA_300e4df7-f8bf-47e9-95bf-2c9de545414f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzQtNS0xLTEtNzAyMDA_3f8c12af-ba79-461a-a512-5467f0542900"
      unitRef="usd">7353000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzUtMS0xLTEtNzAyMDA_648cbb24-3224-4581-8f29-555544bb87a3"
      unitRef="usd">8027000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzUtMy0xLTEtNzAyMDA_cc04581e-a74e-4801-b1a6-c6a354707b99"
      unitRef="usd">1770000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzUtNS0xLTEtNzAyMDA_8048b65e-da8e-40ce-b529-7044986ea6b1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzYtMS0xLTEtNzAyMDA_5c414170-d467-4cc3-b85b-08c1f6ec563d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ifc44c29d7cea45d5a28564331915cda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzYtMy0xLTEtNzAyMDA_acb0affc-772e-45a2-b3db-4036d81b1a03"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="idbdf580566214e4581e43117da7df104_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzYtNS0xLTEtNzAyMDA_36236635-4e5c-424c-9d31-a4c682ac968e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzctMS0xLTEtNzAyMDA_0ce3ca73-2d03-4225-ab65-292ff32d5d33"
      unitRef="usd">5194000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzctMy0xLTEtNzAyMDA_b7cc39ce-9e8a-461a-a93b-1d40fbefe972"
      unitRef="usd">11154000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4f41fed49045497fbd18a61509fff1d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90YWJsZTo4NDJhN2YwYjdiOGY0Njc3YjhjMzkwNTBlNjFhOTA2Yi90YWJsZXJhbmdlOjg0MmE3ZjBiN2I4ZjQ2NzdiOGMzOTA1MGU2MWE5MDZiXzctNS0xLTEtNzAyMDA_90d280ee-e180-4444-a9fe-c2d23b86c201"
      unitRef="usd">8766000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzQxMTg_ac53d425-57af-4b38-8415-5bbf84e277fa"
      unitRef="usd">5200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="iba985ece231344b9884ac0673bdf1f76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xNzgvZnJhZzo4MDdjMDc2OWIwM2E0MWJlYTgxZDY1ZDI0NDM4NjFlMS90ZXh0cmVnaW9uOjgwN2MwNzY5YjAzYTQxYmVhODFkNjVkMjQ0Mzg2MWUxXzExNTQ0ODcyMDk2Mjc3_bc471721-0133-4477-adbc-fa861daf61e5"
      unitRef="usd">11200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzY1NTA_ff072e58-b961-4ac6-bd60-aacacfeeb612">Commitment and Contingencies&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#x201c;Maryland Court&#x201d;) against the Company and certain members of senior management, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sothinathan Sinnathurai v. Novavax, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 8:21-cv-02910-TDC (the &#x201c;Sinnathurai Action&#x201d;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#x2019;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the NVX-CoV2373&#x2019;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#x2019;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#x2019; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the Sinnathurai Action was filed, seven derivative lawsuits were filed: (i) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Robert E. Meyer v. Stanley C. Erck, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 8:21-cv-02996-TDC (the &#x201c;Meyer Action&#x201d;), (ii) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shui Shing Yung v. Stanley C. Erck, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 8:21-cv-03248-TDC (the &#x201c;Yung Action&#x201d;), (iii) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;William Kirst, et al. v. Stanley C. Erck, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 8:22-cv-00024-TDC (the &#x201c;Kirst Action&#x201d;), (iv) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amy Snyder v. Stanley C. Erck&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, et al., No. 8:22-cv-01415-TDC (the &#x201c;Snyder Action&#x201d;), (v) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Charles R. Blackburn, et al. v. Stanley C. Erck, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 1:22-cv-01417-TDC (the &#x201c;Blackburn Action&#x201d;), (vi) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diego J. Mesa v. Stanley C. Erck, et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;Mesa Action&#x201d;), and (vii) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sean Acosta v. Stanley C. Erck, et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;Acosta Action&#x201d;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#x201c;Delaware Court&#x201d;). The derivative lawsuits name members of the Company&#x2019;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#x201c;First Consolidated Derivative Action&#x201d;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#x2019; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#x201c;Second Consolidated Derivative Action&#x201d;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. On December 6, 2022, the parties to the Kirst Action filed a stipulated schedule pursuant to which the plaintiffs were expected to file an amended complaint on December 22, 2022, and either (i) the parties would file a stipulated stay of the Kirst Action or (ii) the defendants would file a motion to stay the case by January 23, 2023. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#x2019;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#x2019; motion to dismiss in the Second Consolidated Derivative Action. On February 24, 2023, the Court entered an order staying the Kirst Action until a final judgment in the Second Consolidated Derivative Action. The Company takes no position on whether the broader stay entered by the Court in the Kirst Action is likely to be modified to align with the parties&#x2019; stipulation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#x2019; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, the court entered an order granting the parties&#x2019; request to set a briefing schedule in connection with a motion to stay that defendants intended to file. Pursuant to the order, defendants filed a motion to stay on January 18, 2023. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted Defendants&#x2019; motion to stay.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta action. The financial impact of this claim, as well as the claims discussed above, is not estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 26, 2021, a Company stockholder named Thomas Golubinski filed a derivative complaint against members of the Company&#x2019;s board of directors and members of senior management in the Delaware Court, captioned Thomas Golubinski v. Richard H. Douglas, et al., No. 2021-0172-JRS. The Company is deemed a nominal defendant. Golubinski challenged equity awards made in April 2020 and in June 2020 on the ground that they were &#x201c;spring-loaded,&#x201d; that is, made at a time when such board members or members of senior management allegedly possessed undisclosed positive material information concerning the Company. The complaint asserted claims for breach of fiduciary duty, waste, and unjust enrichment. The plaintiff sought an award of damages to the Company, an order rescinding both awards or requiring disgorgement, and an award of attorneys&#x2019; fees incurred in connection with the litigation. On May 10, 2021, the defendants moved to dismiss the complaint in its entirety. On June 17, 2021, the Company&#x2019;s stockholders voted FOR ratification of the April 2020 awards and ratification of the June 2020 awards. Details of the ratification proposals are set forth in the Company&#x2019;s Definitive Proxy Statement filed on May 3, 2021. The results of the vote were disclosed in the Company&#x2019;s Current Report on Form 8-K filed on June 24, 2021. Thereafter, the plaintiff stipulated that, as a result of the outcome of the June 17, 2021 vote, the plaintiff no longer intends to pursue the lawsuit or any claim arising from the April 2020 and June 2020 awards. On August 23, 2021, the plaintiff filed a motion seeking an award of attorneys&#x2019; fees and expenses for $1.5&#160;million, to which the defendants filed an opposition. On October 18, 2022, the Delaware Court denied the plaintiff&#x2019;s fee application in its entirety. Under a prior Delaware Court order, the case was automatically dismissed with prejudice upon denial of the plaintiff&#x2019;s fee application. On November 14, 2022, Golubinski filed a Notice of Appeal in the Supreme Court of the State of Delaware. The plaintiff / appellant filed his opening appellate brief on December 30, 2022. The Company filed its responsive brief on January 30, 2023 and the appellant filed his reply brief on February 14, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 29, 2022, Par Sterile Products, LLC (&#x201c;Par&#x201d;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (the &#x201c;Par MSA&#x201d;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. The parties are engaged in discovery and arbitration is scheduled for July 2023. While the Company maintains that no breach of the Par MSA has occurred and intends to vigorously defend the matter, if the final resolution of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;matter is adverse to the Company, it could have a material impact on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#x2019;s failure to procure the purchase of 350&#160;million doses of NVX-CoV2373 from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#x2019;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contends that, based on its purported termination of the Gavi APA, it is entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December 31, 2022, the remaining Gavi Advance Payment Amount of $697.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities in the consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company&#x2019;s response is currently due by March 2, 2023. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that the Company could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on the Company's financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements in the normal course of business with CMOs and CDMOs supplying the Company with production capabilities, and with vendors for preclinical studies, clinical trials, and other goods or services. A number of these arrangements are within the scope of lease accounting (see Note 10). Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Company is contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses. The exact amount of such obligations are dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. As of December&#160;31, 2022, most of these agreements were active ongoing arrangements and the Company expects to receive value from these arrangements in the future. The Company recognizes fees related to obligations for terminated contracts where such fees are reasonably estimable. The Company did not accrue obligations that were not reasonably estimable. As of December&#160;31, 2022, the Company had no non-cancelable purchase commitments with a remaining term of more than one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzQzOTgwNDY1ODY5ODU_0f86f796-7fb2-4930-b6f7-1f864f621028"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
    <nvax:LossContingencyPeriodToAnswer
      contextRef="i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzQzOTgwNDY1ODcwMDY_48cd793e-9dea-406e-9b65-4412801f30f9">P14D</nvax:LossContingencyPeriodToAnswer>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i38dbeaf8546447cc8d0775f85d2579d5_D20210823-20210823"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzg3OTYwOTMwOTgwNTY_69a009a2-5b80-485e-b5c2-df9297291beb"
      unitRef="usd">1500000</us-gaap:LossContingencyDamagesSoughtValue>
    <nvax:NumberOfDosesToBeDistributed
      contextRef="i0523638414324ebda053032feb1642dc_I20221118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzIxOTkwMjMzMTcxNTU_de75fba7-dfc1-47d2-81c2-2c433a3d7710"
      unitRef="dose">350000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i0523638414324ebda053032feb1642dc_I20221118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzIxOTkwMjMzMjc5MzI_7e71e3b9-d280-4b67-80c0-708e81d4dfa1"
      unitRef="dose">2000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="i807e3711af3b41989b73d47de7c77b65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzIxOTkwMjMzMjk1NTU_8f556068-c6cf-4287-82bf-ab17568f8af7"
      unitRef="usd">697400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:PurchaseObligation
      contextRef="i55917cb303ae4006ae29b944e6cc0a9c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODQvZnJhZzplMzM2MGZiN2Q4YmQ0N2M1YmU3NTE4OGI4NzgxZjQyZC90ZXh0cmVnaW9uOmUzMzYwZmI3ZDhiZDQ3YzViZTc1MTg4Yjg3ODFmNDJkXzY1NTI_fc9415d1-a567-4d4e-a3c5-d317f761f3e3"
      unitRef="usd">0</us-gaap:PurchaseObligation>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODcvZnJhZzo3ODBlM2I5MTdkZjE0OTNjYmNmMmVjNTQ1MjgxYmE0Yy90ZXh0cmVnaW9uOjc4MGUzYjkxN2RmMTQ5M2NiY2YyZWM1NDUyODFiYTRjXzc3NA_821decdf-6393-4601-acc8-4ccbfa5510b1">Subsequent Events&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2023, the Board of Directors of the Company approved the appointment of John C. Jacobs, as President and Chief Executive Officer and a member of the Board, effective as of January 23, 2023. Mr. Jacobs succeeded Stanley C. Erck, who provided the Board with notice on January 5, 2023 of his decision to retire as President and Chief Executive Officer and as a member of the Board, in each case effective as of January 23, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on claims stemming from the Gavi APA. Arbitration is inherently uncertain, and while the Company believes that it is entitled to retain the remaining Advance Payment Amount received from Gavi, it is possible that it could be required to refund all or a portion of the remaining Advance Payment Amount from Gavi (see Note 3 and Note 18).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2023, the Company funded the outstanding principal amount of $325.0 million on the 2023 Notes, due February 1, 2023 and the indenture governing the 2023 Notes was subsequently satisfied and discharged in accordance with its terms. The Company&#x2019;s related &#x201c;capped call transactions&#x201d; expired by their terms on January 27, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RepaymentsOfDebt
      contextRef="i63a2de06fc1f42a69276ce8a6224e6a0_D20230131-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmYjQzYjI4OTZlMzRiZTJiMWYxMmY2YzE5ZjY2N2IyL3NlYzo1ZmI0M2IyODk2ZTM0YmUyYjFmMTJmNmMxOWY2NjdiMl8xODcvZnJhZzo3ODBlM2I5MTdkZjE0OTNjYmNmMmVjNTQ1MjgxYmE0Yy90ZXh0cmVnaW9uOjc4MGUzYjkxN2RmMTQ5M2NiY2YyZWM1NDUyODFiYTRjXzIxOTkwMjMyNjY2MTA_3fdb8611-4041-4504-b91b-325c3df443c4"
      unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %J#7%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !:@UQ6KUW(O.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OITUAD=#-1?&D(+B@> O)[&ZP^4,RTN[;F];=+J(/X#$SOWSS
M#4ROH] AX7,*$1-9S#>3&WP6.F[9D2@*@*R/Z%2N2\*7YCXDIZ@\TP&BTA_J
M@,";9@,.21E%"F9@%5<BD[W10B=4%-(9;_2*CY]I6&!& P[HT%.&MFZ!R7EB
M/$U##U? #"-,+G\7T*S$I?HG=ND .R>G;-?4.([UV"VYLD,+;T^/+\NZE?69
ME-=8?F4KZ!1QRRZ37[N[^]T#D[SA7=7PBM_N>"OX1G3=^^SZP^\J[(*Q>_N/
MC2^"LH=?=R&_ %!+ P04    " !:@UQ6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M %J#7%8,'3S[UP<  ,PO   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9IK<^(X%H;_BHJ9FNJI"L&6"= ]"54$DEEVNM-LZ,EL[]9^$+8 5]L6*\FY
M_/L]L@W&*5G86Z(_-/AR7J0GDGQ>^5R_,/Y#;"F5Z#6.$G'3V4JY^]3K"7]+
M8R(NV8XF<&7->$PD'/)-3^PX)4$6%$<][#B#7DS"I#.^SLXM^/B:I3(*$[K@
M2*1Q3/C;+8W8RTW'[>Q//(:;K50G>N/K'=G0)95_[A8<CGH'E2",:2)"EB!.
MUS>=B?MIY@U50';'4TA?Q-%WI+JR8NR'.I@'-QU'M8A&U)=*@L#',YW2*%)*
MT([_%J*=PV^JP./O>_7[K//0F141=,JBO\) ;F\ZHPX*Z)JDD7QD+W^C18>N
ME)[/(I']CU[R>_O]#O)3(5E<!$,+XC#)/\EK >(H8.34!. B +\+<.M^P2L"
MO/<!5S4!_2*@GY')NY)QF!%)QM><O2"N[@8U]26#F45#]\-$_=V7DL/5$.+D
M>,J>*4<+^!.C+OIS.4,??O[UNB=!65WO^87*;:Z":U1<C+ZP1&X%NDL"&E0%
M>M"D0[OPOEVWV*@XH_XE\MP+A!V,-0V:FL/OZ>H2X3S<TX3/S.%_3Q/X=4?W
MZY7>> ?*7J;G&2G_>[(2DL-(_X^.<*[0URNHZ?])[(A/;SHPOP7ES[0S_N4G
M=^#\IJ-C4VQF2:Q"KG\@US>ICV?,3V&9D>C;VX[JL)G#7:?[AXZ/,:HM'TMB
M%3Y7!SY7S?A,DB0E$7JD.\:E#I191_)4AW=JC&H+RI)8!=3@ &K0#-2"\I %
M:J%"L&)JQ]0)I?W25+LV&>/;0K,D5H$V/$ ;&KLZ33E7S.Y#X</@^DX)-X(S
MJW6[+NYZKHZ8,; M,4MB%6*C [%1P_6*$TB.LMRF?DZ:M=8D$MI):0QK2\N2
M6(76QP.MC\8>WB4RE&\PO"**'M)X1;F.DEG#<9PN'@R'CHZ4,;0M*4MB%5*N
M4R9J3A-6CW03JBP"AM@#B;6S\(30P]>GR=/DGQ=YV^8/4QTXLT9;<K;4JNB.
M<ERW";IYXC,.4Y&H67F!EA)6,<0XFK(TD?P-/@,]3[/Z[$X+T!C4&J EM2I
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MRE'NR[R@N<AG25*4!+Z$D"/4-$V5=>U+7KY0FB7^T)%LS&U9%(!M0C#NZ@'
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MF\NI2"$<8P#W)Q*$V_J#.;_<GE</_P-02P,$%     @ 6H-<5IJ:K! U P
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M"- "9A%_(.MK5!JR))]/(I;_@W41:]L*\#/&25R"A8(8)\45/I>)J 'T[@Z
M40*,8P%F"3!SHX6RW-88<NCU*5D#*J,%FQSDN<G1P@U.Y&.<<2KN8H'CWNC^
M;G9_>S,>/D[&X')X.[P;3<#L>C)YG(&S*:0HX2'BV(?19_ %? 0J8*%897V5
MB]TEA^J7.UT6.QD[=AHCOP-,_1P8FF&TP$?'P_4F7!6>*^-&9=S(^<P=?#,.
M.1+UR %9@"N<P,3', )3PG!>7[^&<\:IJ++?;58+[FX[MSQZ%RR%/AHHXFPQ
M1%=(\3Y]T&WM:YOQ_T362(-9I<'<Q^Y-Q:E!E*( B%+SG\Y!"BD@XIS+] 1@
M!:,,@131XK&#,YR C 5O*Y_;LE-LZ>1;RO?(RM,ZFGAHJ[KK T$--]W*3?<T
M-T6Q ICQD%#\5]R0#HK55ND%OUU3)5Z(\K>A_G!<PX!5&;#>90 SEAT6;VV)
MVI2]+Z(AV*X$V^\2++X8HH22 "?+0ZKM@ZKW1314.Y5J9Z_J$8EC<<9K)?^^
M0G>.*?0#00T#;F7 /<' R57N;B74UK36.C\FLN&@5SGHG>[@N#+O;6ER;5>S
M+:N[(7X[T+&[IJE;.[*O:V]?3>UT]2?4?$G?]*"9O9YA;GAHB70LMZOKSBX3
MM4^_OM?$H^C[6$9?-FP<DJZW9-6VS<VR;XFS>GK/W:P;M=:\R,[Q&Z1+G# 0
MH84 :AU'O+-HT8P5$T[2O)^9$RZZHWP8B@8641D@[B\(X:\3V2)5+;'W#U!+
M P04    " !:@UQ6N<HAHF8)  #N2P  &    'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;+V<:W/;-A:&_PI&V]G:,U5$ +QF;<\D%,EX-K6]L;,[G4X_T!)L
M<4.1*DG9S?[Z!6E9%"Z"Q.2T^1!+-O >$._!A0\AG3V7U9=ZP5B#_ECF17T^
M6C3-ZNUD4L\6;)G6;\H5*_A?'LIJF3;\;?4XJ5<52^==I64^(9;E3I9I5HPN
MSKK?W5079^6ZR;."W52H7B^7:?7U/<O+Y_,1'KW^XE/VN&C:7TPNSE;I([ME
MS>?53<7?3;8J\VS)BCHK"U2QA_/1._PVH7Y;H2OQ[XP]USNO47LI]V7YI7US
M.3\?66V+6,YF32N1\A]/+&1YWBKQ=OR^$1UM8[85=U^_JL?=Q?.+N4]K%I;Y
M?[)YLS@?^2,T9P_I.F\^E<\?V.:"G%9O5N9U]S]ZWI2U1FBVKIMRN:G,6[#,
MBI>?Z1^;CMBI@.F>"F13@1Q;@6XJ4*D"\?94L#<5;+G"OFMP-A4<N4G.G@KN
MIH(K5;#=/16\306O,^NE=SMKIFF37IQ5Y3.JVM)<K7W1^=O5YHYD19N*MTW%
M_YKQ>LU%>'UU>_WQ<OKN+IJBVSO^X^?HZNX67<<H_/#N*HENT>45_\-U^,\/
MUQ^GT:?;'U'TK\^7=[^@DVD47X:7=Z=HC#[?3M')#Z?H!Y05Z&Y1KNNTF-=G
MDX8WL0TTF6V:\_ZE.61/<^[*)LTUU4)SM;!<+GE>WS;E[(NF]M1<^]U\GK7C
M(LW139K-Q_P2PG25Z5L2'=":S=;+=9XV;(ZF["&;98U&)#[0"WQ2J=?5U[T7
ME!S?B.MFP2K$.XC/5(MV"GEBZ+*8E4N&3CZ6=7TJRD]X_FR3B&R3B'3Q[#WQ
MWJ=Y6LP8NF>/65%DQ2,ZX7U8+]**U:<H;7A/S-X@BG]"Q,*!+BN,^NUT_+9>
MI3-V/N)74;/JB8TN_OXW[%K_T.7*BYC;B;53\=,%)30(J$/.)D^[:0$9-8(4
MBR'%$B Q(37H-C7HP-0X)AU>-)T=!\?8=RWLB0:&:CE*;,EDM0PFKN4X6"P7
MZ6+:%/N65##6%"2.3\52B4Z..):_+29TI[WM3KNK1_=T)Q^Y[=S QR[OP^[5
M:3OC=O/$HLSGK*KY_/S[.FN^HE\_E7F.^(+]G%;SWW3=;$...DBQ*:18!"D6
M0XHE0&)"*CG;5'*,(_.&[_E85?$EHFZSAX_0HENO^"HX*XLGGDGM5O&!I<VZ
M8KKL<91IUI*&I[$!0U-"#4=L3 -I%*NEQIIB,63+$B QP45WZZ)K=#'LK2H?
MT$KR=&<9UCEHE!XZ_EVEYVWJ^[XC)<44,F@$*19#BB5 8D)2>-ND\+X]*72)
MX"G>X2#PB;1?"CUE3;/EU5:KY'F^-$R-[1_J&Z18 B0F^.9O??.-OG7+^+B]
MLY[S.7BYXMOUM+TQT5GFJQU-?(LZDF7&@$.GX.-B1I Q8TBQ!$A,,#?8FAL<
M-A=E=;WF[JX+OE7C.[<9*UH4P\=H^5BER_K0C&T,,73&#M05%;N^1R0_IY!!
M(TBQ&%(L 1(3D@-;/8>QOC\]M$#%4FQTB.U*\\"FU.[<+4_O4XV2S?])-UV1
M^4*&6J@).J8!(?+]%%14T9X=3(:-]EQR8[H;6;Z@SEYH4[>:_H0*UK2_S%X+
MS,JZ.3B.S=&&#N2-FDP\*-^ R19#QHU U6)0M01*3<R7GHAA,Q(;F"_:'%$Y
MEN^I&^IP4\Y,0?1B#G'EP0V*L4#5$B@UT=*>9&$SROI<5"S-L__Q^?DQY</[
M)&_Q*>+.+M/J"VO2^YRAFLW65=9D3&\I55P(9#>-C1BZ8P-5BT#58E"UQ-BU
MHN,];,-& ',1EQ7+'@O$+:U8,?N*FBHMZCQ]>8@V_^^Z;I9\A=8Z;6MNA!QY
M50O-#1CL-B@V U6+0=62@]TK.MXS,6R&8E=\<FZ'M=92#5NRL4\<90B#<B]0
MM>C8BXA!PR90:J*M/23#9DKV^A2"%7/STREB:9T'!658)64>IHY%7?G&"S1N
M!*H6@ZHE4&IB?O2\#)N!F90?1^6$2KI<XA%+F0Q4:.9A97>FBA&'.K:G;,_4
M@F/L>S8.E/&K*<D'NN7*]U5J.<_:V3Z*/=J3+.S_A0^J,"0%"D'5IJ!J$:A:
M#*J60*F)*=7S,WP$0#N2CF*5;6&?NO+M3F@..3@5CHL:@4:-0=42*#7Q($F/
MP0@ !CM$5\PQ!A\G40D5X:NUCZ4I=PH:-@)5BT'5$B@U,4EZ&$?,,.Z;62E1
M01GABZQTPB/<%!-@J;QD:Z1<WZ(24XW,5S+8137HV*8DD#:."514T9^=XV"@
M\.O@<(8]'::2,.)X?N!ZLL.PQ\-@SX?!'A#[,\ :Z<$:,8,U %9*5/KCN+:O
MW)H3]5B6O#I/]VA1*@]M4!H&JI9 J8F.]N",F,$9 "HE*N$9*VZ"TC-0M0A4
M+0952\Q]*WK>HS-B1F?? 4N)!DKQ?;,OVPW*U4#5(E"U&%0M.=B]HN,]52-F
MJF:"I42%7&/LV=23S]V&YB"#705%9D=?10P:-X%2$XWM<1@9A,,,N!1KO8<\
MD!42#:!R;4JQ[,$4-&X$JA:#JB50:F)^]'"/F,^IF7&I/B?4LV-CZF#7DY^(
M;0HZHMVRTZH:Y6K*'C[2AG6Q%\A/T6-=2=_!\NG_1%<.4V?/DR?2TRT2_(7
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MB?H$(=<):G_.F-P$^H#ZH^;_!5!+ P04    " !:@UQ6S SCRU$)   J*P
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M<,3-NE"BB!:)9*4%<IEE.$%$N:$(## #;(1FA:B=(R*C(Q6PY)B-E=@QPRN
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MO%D$5>%6!!;Z8 !0UT5M%-J !GUG2P0%_I[CA=ZL;+G*?C@^>3X_!K[%,]W
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MIMAS7$3L-QU7NH\"UU&[" ELE>(R4GA@)%K5VC1W(:KK)DW/-Y3;@%Y'NG"
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M,BYX;6S575ESVTB2_BL(C6-&BH!HGCKZ<(0DV]VRY;;#\C$;&_M0!(HDQB#
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M7"[8LB0C09'&S( K  L)<8_%^+2=58.^@>.BVJ!6IXRA_:/ZGPY#+I9\5(+
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M/29\>KP37)&8:IZL3],5*V99@_Z]><F);"H'N'*#:H4HBL"XTZ657"5SOR9
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M;K2" \0&\#U2S_Z"$[B_^O?B?P%02P,$%     @ 6H-<5LQ3&\_V(0  (G
M !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULU5U9<]M(DOXK"(UC1HJ
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MW..)6:K#NAY*A+ Y'@MZ/+!,H@,N%VQ9FI.@2&-FP16 A92XQV%\VLZJ0=_
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MG<T/.$_N?JF*'?T5N$515<66?MQH!0>(#>![I)[[!2?P?Q;PA_\%4$L#!!0
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M*Q?1+(("-Z)1[L:TGW'GS\3+RXVB\ ]M]W:419 WY$RU8V8+*JF[5=SOXG#
M,!N^PI#M&+)@=Z<H6'DEG%C.K6G!^M<LS6^"JX&;C9/:)^766;Z5S.>67_0=
M:F?LPSQQ+,X3DWS'NNI8LU=8TPR^&NU*@M]T@<53 0G;T1N3[8U994<E7F$^
M@%$:0S;,LB/R1KUSHR!O]'_.P96D7!EJ+,+?%VMREM'PSTLN=P+'+POT%7).
MM<AQ$7$)$-H[C)9OWZ33X<<CYHY[<\?'I!_/Q5'6EPU[=/]QEQNN)W)8@-F
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M(,>"M<+>J>XC;O*9.+Y,">/?T/6VDS2 K#56U1LP15!SV7_9TZ8..X#SZ 5
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MVIZHG0'=%TK9K>(<#/MX\1M02P,$%     @ 6H-<5CJ@V@!."@  KAH  !D
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M]$H]& [+/6D%+NMH2]\.Q"\#;_TETX=N'J_AH\3/?3)_(>W#2QRV:CCA\"B
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;,5;^V_CQA'^5PC7*6Q
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MBJCT+9H]1NNW;R;OT\LS!&<#P=DY]/^3@Q\"^*S@2ZO0ZY>.P54(U[INF#H
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MN,WGF/$*HUSXA76W=CB.H&B=-_76F1C44G?_XF&KPQ.'T_05AWSKD ?>7:#
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M;>XL^QA3F7]M=5B0[9>8\$CQDO(C?82&N8>OPMY1<M<[\%NA"'"^LH@UA__
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MG-#R II?&FK2[8 #]&^QV;]02P,$%     @ 6H-<5I</A?QX"P  Z1\  !D
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M3D;"V _+]J:IMOPQ=U$U3;7AR[62B% :@/?+JFJZ&UJ@_[I_]6]02P,$%
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MBSAYWUQ#3\"[^^*8OVS9&Y2DV0S@X+$2P]O[G($Q@=QNPGXU"5OA)]M?61X
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M!\:O:V5-Q[S='[+L/&T*!-IA?+,ZKBAIE)/ E/V[&@OB:23!!79:4:)!BN[
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M>,^>X083@\M7FI0.Z2C2V#WV( *PBSPFXWT5F8"&#YU3P$Z2KU49E@WMR)]
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MK0Y?[>97[.TY93QIM8]/V'1WLY\3D*T/MNZ%B4&M3/<63[T?#@3.1R\(9+U
M%GEWBB++&Q'$?.KL!AS?)C3^B*9&:2*G# ?E/C@Z5207YO=M[O&Q11/@=DU/
M/TT#P?)A*GN(JPXB>P%BG,&=-:'R<&L*+(X!4N*S)Y7M2%UEKR+>H!S"9#R
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M7O_G?YP\/SZ=6.U3O]JG4Z._?I.U18N'=H%C5UV&*#ZVR.\8)OE][9)E7;4
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M.T<\9TOXV05J$G* =<(GLA  7K#5U<@B ; X7K:AL5)$VS%"A2' &* WD"&
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MSR%OI=,' ,*;C=)1C I^8]F.]1B22#^^.'KJ$<2+Y^0)K84^GKR$+7T,&+H
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M?GY ^F1S[1Y$8QXN";=7O(Z9:*9[[%.0L]&@MMEX<#!PXD$:NC)&4PSDH"H
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M=2<QEI%LGDW-1HN-?:HLA,8BL,LUOC29- 3X?2F$/FR,@.[M.OL?4$L#!!0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;(U6VV[;.!#]%4+=+1)
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M!I/#-W&_<[Z';K>EV]V'/GG@ULLKA6#FT%+?17(OS&Z2OU.1&6XM<IA[-ZY
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MI*A= .VOE;([QQ7H9W/V&U!+ P04    " !:@UQ6\9G00L@#  !B"   &0
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MU4+)'5'6&]&LX:2Z:"3'A2W*K5'XEF.<6;V38OOZ#E1-KF%MR,D=6U>@)XO
M(+AU"?(>Z+(#HD> (DK>2V%*3=Z( HIO 0)D-5"C3]0NZ2CB->2G)(Y\0D-*
M1_#B06KL\.*C>"CPFNN\DKI50/Z^6&NCL"W^.:2VPTH.8]FK,M<-RV'IX5W0
MH.[!6[UZ$4W#\Q&FR< T&4-?W>+5*]H*B-R0*RGN01F.92$?I %-;MBC+=(A
MTJ.PATG?E8 YZH:)QU<O,AK-SC6I;%,8VQ2%/;-<XAW4!@K+QZ#_1E9XF;G8
MDA,N\(EL-1.%GLRQB7*HUZ"&NMDE(E>M4B ,::2R=W%.XM-9^MLWVH335K1@
M(V+RDL0T]<,P1,OQHN?DDV"U!?@/F3AB7.N6B1R0H3::G$31V63POI.&57B%
MNLSY#ZF:[AA=IL3/LF@OTP<I7N??<TY/PW"$\PSCHUGJTW2?\T^%#HZ]W)^*
MS/Q9EDQ0K)\F=-++%'N$QZ1&TZF?3*=.=.PG:49&VC4=VC7]W^WZ5F#?@#;D
MS0/.#7VP2T?1#G?I  L=+.'"R2W0L()%_Y'?<5.Z%CU^"+_0S7\!4]WG[%AC
MXQ)B==L&<_,GCGC,U!:G,Z(L>S8NNMHR1Q;S'ZIPY"=G,[O2I%^[&O/OST"*
M\5HG?AB?62/VIQ%]-@Z5/-@;(36HK1N4&O%;8;II,CP=9O%%-X*>W;M!_IZI
M+1?X%8$-AH9X 3RBNN'8;8QLW$!:2X/CS9DE_I\ 91WP_4:BDGYC$PS_4%9?
M 5!+ P04    " !:@UQ6>@(CM64&  "2$   &0   'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6S%6&U/&SD0_BM6#BJ0-H[M?:> !"V]%ZE7!*75Z70?S*Z3
MK-BL<[9#X-_?C)V$ $F*^N6^Q"_K&<]XGGG&SO%<FSL[5LJ1ATG;V9/>V+GI
MT6!@J[&:2$OU5'7P9:C-1#H8FM' 3HV2M1>:M /!6#:8R*;KG1[[N4MS>JQG
MKFTZ=6F(G4TFTCR>JU;/3WJ\MYRX:D9CAQ.#T^.I'*EKY6ZFEP9&@Y66NIFH
MSC:Z(T8-3WIG_.@\Q_5^P;=&S>U:GZ GMUK?X>#W^J3'T"#5JLJA!@G-O?J@
MVA85@1G_+G3V5ENBX'I_J?V3]QU\N956?=#M]Z9VXY->T2.U&LI9ZZ[T_#>U
M\"=%?95NK?\E\[ VRWJDFEFG)PMAL&#2=*&5#XMS6!,HV!8!L1 0WNZPD;?R
MHW3R]-CH.3&X&K1AQ[OJI<&XIL.@7#L#7QN0<Z?73E=W_7/PJR8?] 1B;:4_
MKH.O\K95]O!XX& ;7#RH%BK/@TJQ1247Y+/NW-B2BZY6]7,% [!O9:18&GDN
M=FK\J"I*8AX1P838H2]>.1U[??$VI\?2J(73E_(1,.;(F3&R&RG?__OLUCH#
M@/EGD_=!=[)9-R;1D9W*2IWT($NL,O>J=_KN%YZQ]SLL3U:6)[NTGUY#4M:S
M5A$])%M#=_& ?;7)]IW:-]O^=:R\>MD]0A96VD!,B?5[W_J]J_6]5=B;-!UQ
M(%CISNJVJ:7S0M#@ 5LT'WC%>!E+I"5#W0(_6'+@!?7,RJZVAT?D+R5-P!$!
M%*C)K3(K). /QQ\&!EJ'2JT$S)(]PB,6"VC?_5((+MZO]:[ +VFJ,8$-('WO
M@9:F/NA9%J592HHL*D5!TC0JTY1< UTTW2@B(]6!N6WDQ60-F=@@1)!22":B
MG,6DS**L+$@N(E8P\E4[V?[XG,#4F$4Q8]@KXB@3&?9$ 0ZD9 =BTA5BTC<C
MYLLT,"&X<#:%"%=-,,93L25GR)"->]P$G)V;; =.""N<(&D@S$OJ]Y'"DP$0
M+!  )EV?7=G TF #F4',C<>08#PEEZT,AH<9MIB!JN1G'A$F:C-,CM8T/$GZ
M[%F<B"7?/7NKNK^8?QI_F3G ;5>C#]*1/V0W0P^6$(2(Q6E4Q#E$+1$T8R0K
M(B%2#"(K:2K(K\ KB/XL7D8W2RF \S4T+QZ4J1J$R@&/$] B#E%-2K.$',01
M8PS',:<< "^["DH;+"TX()7CEY+1(@;9* TKN> 4@/7"@]=IE$0LC2-1(@:3
MC+(<;(WRX ,7M$R()TP+H/4&8F'8K$E$12DBGG&T$[PO7FG:@>ALA>CLS8@^
MLP"I10QO\.2 /BZL:R8!V+#BDVP,^2;;V1-G;L+W[BT]E%'1_5+1<_B.%C'>
M!-HYL)L*)L$*.#;\C(2(:KP@68#83\ZF8/=\W !#O=8C(6OU/:BY??1?%[SL
M 92_M\&JL6[!"NMSHU+&P<ULB[E-%]@3\PHV*LG,(DA0\WDK@;C@J#42:A#L
M3TU3X8*)KA5>5%RP\2G)Y5,XWDS=RU0C\AX8=O1RZTW'OI?Z#-KC:4$9M 6C
M20$L9N_Z0Z.P^#@%>'7$X(ERFNSW$QKO$T;3_3X//8&]=)]\!+JI@3G(8Z/:
M>IF+^QLZWW0+J&J1G+@(JA)&^3Z,$IKC2% &(PXI!*-4P!Z^%E?H'5@T\=4-
MJ<H>DH2R?D9C:#FTG,2T[.<T(PBUB^O+2R1,K)Y@G%DO'AK(!R,[;#J@@ 9J
MC%%3;1P>_W1FIMHJ2R$O@&NK<13B\^P(O7(;$OH-V/P_('&%-S$T81L4[,J1
M/1'3M.SOY27-$T!"3).\#Y,%+8!U!$UA5 (OYUOAP6BVWX\#*/A^'Y$1X %2
M/PL/%GL( "!*!$0"#0"B!"#"-0/WXP78NP,= "_8G[UL=[!GOF+/_,WL"7<A
M!_%# T+9N^F:']P#=BK_F7O U?7-4]%_6SG_<^8G0/@2&E^;GA>Y#IGX'IP+
MH'Y9LPM>1@7<\?9\KN9L_1P"P<S\.2QIDD=%(:*R\#6^H"G?)K#8\B!E*53K
M$FLPQCG?MA[<':K&BW HE"+V!;_TA7.70YL*+X,;0XHI0#).L\U7Q\':.W&B
MS,B_AI%F9IT+3\;5[.K!?1;>F4_+PVO]LS2C!DI)JX8@RF@.%T037L!AX/34
MOSIOM8,WK.^.E00RPP7P?:BU6PYP@]7?$*?_ 5!+ P04    " !:@UQ66PBM
MA.8$  #H#   &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RM5VUOVS80
M_BL'-R@2@*LEZCU-#"1INA5(NR!IMP_#/M 2;1&51)6DXF:_?D=*5IQ6]CJ@
M'VQ3XMUS]]P;Z;.-5)]UR;F!KW75Z/-9:4Q[.I_KO.0UTZ]DRQO<64E5,X./
M:CW7K>*L<$IU-:>>%\]K)IK9XLR]NU6+,]F92C3\5H'NZIJIQTM>R<WYS)]M
M7]R)=6GLB_GBK&5K?L_-I_96X=-\1"E$S1LM9 .*K\YG%_[I96+EG< ?@F_T
MSAHLDZ64G^W#N^)\YEF'>,5S8Q$8_CSP*UY5%@C=^#)@SD:35G%WO45_Z[@C
MER73_$I6?XK"E.>S= 8%7[&N,G=R\QL?^$06+Y>5=M^P&62]&>2=-K(>E-&#
M6C3]+_LZQ.%'%.B@0)W?O2'GY1MFV.),R0TH*XUH=N&H.FUT3C0V*?=&X:Y
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M=$Y<?^E$:VN/P =NIO)U$'@Z7Q\Q]%P;@5W/"^@T7W455#@KM;7?[MKG6_O
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M6I1VN&44YY=9@/F-$+I[, ;ZSV<G_P-02P,$%     @ 6H-<5MQ!&.V4"P
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MYD(U#ZKY4"V :B%*:Z>T*64RWJR4R8"6,D$U$ZI94,V&:@Y4<Z&:!]5\J!9
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MKAE=,%D4,-\OA=#O!T4#]>[.R7]02P,$%     @ 6H-<5A"TKV3< @  I L
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MHEJ$:C&ER4G4MG/'RL[=#W7BU/3@B$%KMZAFHYJSUYZ?8+KHN!ZJ"53S42U
MM1#5(E2+*4V.C[92.U97:I^9*"7?#DZ4T#XMJEFH9J.:@VHNJGFH)E#-1[4
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ME"S)+U= 0^!9 O5^P9C<WV095$<4I_\!4$L#!!0    ( %J#7%9PF5FY]0(
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M#M1]M1!ZYW8L.2F!2<(9$K":.C/_(HV-O37X3J"6>VMD,EER_F VU_G4\4Q
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M\8AFZC4;Q2L[!Y9<Z:EBEX7^4 !A#/3]BG.UVQ@'W:='\@=02P,$%     @
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M=.K98:'_2R!,@7Z^X%QM)F:#[D^7_@%02P,$%     @ 6H-<5H_?Q)KG P
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M30J2EWF?R6;,J2Y;I<56:8DM6C<@!_LT_U5>Q4TWM@)FDQ9;I26V:-V !?N
M!<85=,/9!KA\0&I'C$#EK8T.52E@65)$R;+WG?$_T %Z ,S[-]A&Y<FAL$E+
M;-&ZH=AO?WWCENU),L/W1Y.9U0VN55ILE9;8HG4#LM_D^H/72696M\16:;%5
M6F*+U@W8?B/NFW?B/YC,S-!@:,AF5C?D5FF)+5H="_?@\#8'OM*GYM5W;UG(
M^ARWK6U/YF?Z/-K=-Z^/]:\Q7Y%"( I+)?7.1FJ@O#XIKPN2;?11\!V3DN7Z
M<@TX UXU4/>7C,G'0M5!^_^*Z7]02P,$%     @ 6H-<5N(?.0/$ @  TP8
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MD( +>!1<TX4QFO7G3);$1$H#7YLTK!@_V4D>5Y+#(Y+;(=Q)H3."#R+%],\
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M    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;+6:[V^C-AS&_Q4K.TUW4E?
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M+(LHNA71@H@8W7,2UR6I34HKLJN4D+  $A8"P1J^>&X=*-SWJDDE&<@@4%H
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MX+<$WV:FL6+SD!%%TIG@>R ,6JN9%YM,R];V2V;V?:&$_EIJGDK_ICII$GP
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M7W=)R7@A))V19-+(%Z8/)Y5JJIB388#Z8/9<#$$1]E'/PQ#DP20:=X#@4RL
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M,,/.#]( \/U<8-[:B?E ]U\B^@M02P,$%     @ 6H-<5CM'I%+5"P  \(H
M !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULM9U;;]LX H7_"N$=+#I
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M_PA5@R:&%_)$%O_)<YEWY@U(N)&*IU6PKD$:9^4O^U)UQ$Z YG0'>%6 =VK
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ML[Y./BA(Y9]=MUH)&W?#S.1\*7,6PO5 S[X2Q!8&B^^_<Z?.#UTR8<)\3%B
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M?Z42%3R)JE6I>F876QYMB+WP[,;OK<![BP+S/05 /3\4FODFL#7]OMOTZU>
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M#M#[=Q_0.Y3DZ&M,=YSD$9^;0L:K9C7#*K9E&1N^$)N-T1>:BYBCCWD$41O
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M$QD3*R\/RHZ@A3Y./U A#^>Z&0.)@"D#^7Q#J3AVU 3U%8[_'U!+ P04
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M2TI"RG(#^?TBR\3N)+]!O4MH]C]02P,$%     @ 6H-<5G/Z)/1Y P  RPL
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M*S-M@[0'S/\+(?3SPAIHY_?T.U!+ P04    " !:@UQ6>+M$G!X$  !*%P
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M%@Z387+V2+F_-VSLH/]$U8H)33@L$1B<CI!!-<.S"8RLW?Q92(/3S"U+_-Z
ML@EXOI32[ ([TKHO6/8'4$L#!!0    ( %J#7%8"(_LK_P,  .$3   9
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M$O;P04(;M/^=2WD ,\$+^%&B(.;D)(Q1WSZ$)R:X%'Q)ZXNQ/T:&,ZH.8/H
MWRI!94:; ]]/4!&::[Y#N+U.8'_O /: ,KA9\$H2ELFAK;1 DZ:=MF+&C1CO
M!3&N!Q><J86$SRS#;)/ ULYT]GB/]HR]G8P)ID?@NQ_!<SRO)Z')Z^%N#SQY
M/=S9H<;O#MNO^?S_'C8D5*8YEY4^N-]G4ZF$_@/^Z7.\80SZ&4U1.I4E27%D
MZ:HC42S1BM^_<R/G4Y];;TF6O!'9AI-!YV2PBSU.M(]2T;3/L089UDA3=9?Q
MX;'KN0-_:"_7S>B)<R/?=]QH,S#I"0S"T N?"#<TA)V&<*<&73=U561]$AI@
MM+9C. C]K;PFSZ,.!VYH;NI&^L_#_.CD).A//NJ2CW8F;TH13)O*0YMKK?2U
MQGO=#R7V:8J>NQAI3<'QEJJ>./?8#9[)3WH" W?@A2=;RNRUZER@F-==3D+*
M*Z::2M2M=HWTK.X?6^MCW6";?OA$TW3G"R+F5)?B'&>:TCDZUEF)IN,U$\7+
MN@=,N=(=I1XN]$<""A.@W\\X5X\3LT'WV1'_ U!+ P04    " !:@UQ6SZAR
MA?@"  #S"   &0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6RM5EU/VS 4
M_2M6AB:0-O+1+V!M)$HVC0<D1&%[F/9@DMO6PK$[VVF[?[]K)X22IAD/O#2V
M<\[QN=?UO1EOI'K22P!#MCD7>N(MC5E=^+Y.EY!3?2I7(/#-7*J<&IRJA:]7
M"FCF2#GWHR 8^CEEPHO';NU6Q6-9&,X$W"JBBSRGZN\4N-Q,O-![7KACBZ6Q
M"WX\7M$%S, \K&X5SOQ:)6,Y",VD( KF$^\RO$A&%N\ /QAL],Z8V$@>I7RR
MD^MLX@76$'!(C56@^%C#%7!NA=#&GTK3J[>TQ-WQL_HW%SO&\D@U7$G^DV5F
M.?'./)+!G!;<W,G-=ZCB&5B]5'+M?LFFP@8>20MM9%Z1T4'.1/FDVRH/.X1P
M>( 0582H2>@?(/0J0N^MA'Y%Z+O,E*&X/"34T'BLY(8HBT8U.W#)=&P,GPE[
M[#.C\"U#GHFO12IS(/=T"YI\)C/\6V4%!R+GY$KF*RE &.UFA5(X)B\$<JOD
MFKGS/YZ"@#DS)^0X 4,9UR<H]C!+R/'1"3DB3)#[I2PT%9D>^P9]V]W]M/(X
M+3U&!SR&$;F1PBPU^2HRR%X+^!AP'77T'/4TZE1,(#TEO? 3B8(H:C%T]79Z
MV$)/WDX/.J+IU6?8<WJ]_YXA29A.N=2% O+K\E$;A??J=UO&2\5^NZ*M-1=Z
M15.8>%A,-*@U>/''#^$P^-*6K?<42]Y)[%4F^W4F^UWJ<8)YU(:E;1DKF0/'
MM,5T'8>] (]OO9N)?5 #D70A7GD>U)X'G9YGAAH@>+,(ERGE;=9+@>'.GH.@
MUW"^CVDZ[T*\<CZLG0\[G6/AQK(LVAP/]_:*^F?G#<LMH/,H'#1L[Z,.V![5
MMD>=MN^EH1QK<UD/67GY#%X^V&(SUM 6SVCOU/OHM1'//J@MGGU4,QY_IQWD
MH!:NK6J2RD*8LD;6JW7GOG0-J[$^Q8Y>-N 7F?)SX(:J!1.:<)BC9' Z0C^J
M;+'EQ,B5:SJ/TF +<\,E?I6 L@!\/Y?2/$_L!O5W3OP/4$L#!!0    ( %J#
M7%9  LOLF@4   (H   9    >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;+5:
M76_;-A3]*X17#"V0U2+]%6>)@21LL QM431M]S#L@9%H6ZLD>B0=I\-^_*X^
M(IF1PL3&]4MBR;R'/(>\U#T63S=*?S=+*2VY3Y/,G/66UJY.^GT3+F4JS%NU
MDAE\,U<Z%18N]:)O5EJ*J A*DSX+@G$_%7'6FYT6]S[IV:E:VR3.Y"=-S#I-
MA?YQ(1.U.>O1WL.-S_%B:?,;_=GI2BSDC;1?5Y\T7/5KE"A.969BE1$MYV>]
M<WK"!T5 T>);+#=FZS/)J=PJ]3V_N([.>D$^(IG(T.80 O[=R4N9)#D2C..?
M"K17]YD';G]^0+\JR .96V'DI4K^B".[/.L=]T@DYV*=V,]J\YNL"(URO% E
MIOA+-F7;R:!'PK6Q*JV"801IG)7_Q7TEQ%8 '3\1P*H ]CA@^$3 H H8O#1@
M6 4,"V5**H4.7%@Q.]5J0W3>&M#R#X681330C[-\WF^LAF]CB+.SZRQ4J21?
MQ+TTY!=R'D5Q/A\B(==9N:KRV7G-I15Q8MY DZ\WG+Q^]8:\(G%&OBS5VH@L
M,J=]"Z/),?MAU?-%V3-[HF?*R >5V:4A[[)(1BY 'VC47-@#EPOF1>0R?$L&
M](BP@+&. 5V^/)QVA/.7AP<>-H-Z9@8%WN )/)@2<JDES >Y%%K_@-G8"!V1
M/]]#0W)M96K^ZE*]1!UVH^;;R(E9B5">]6"?,%+?R=[LYY_H./BU2S%,,(X$
MYJ@YK-4<^M!G5S*26B1'Q%AAY1&!-4M 4=@6,D@SK65F83T7N6!!>'D/&ZN1
M7?J6_8R*?O)=]6XV9%-8;G?;NK4;01LZ<EOQ=JN@;N&P'-4L1UZ6WT2R+C-6
M)+"CBRP$JK +2B 8%<2$,=("_52M2\;PL.CF6?8TWN9Y' 2/>+8;C6@P>MR,
M>T>]Y\R/:TW&7DUXBW[G9C5N,0$BX\ET^HAQ5SLV&=#Q(\K>0>U)>5)3GG@I
M?\VT#-4BB_^M:-_*3,YC:XA="@M/XG42D3B%_BV1\[DLGKU%0PW)T:7.I#W/
MK+48)JWE3&FK%?<.?4]ACFMACKW"? 9$H<,E>6)S[:+N1=QU/\4$XTA@CI+3
M6LGI09Y.4TPU,<$X$IBC)@V:,BSPKLQ<S[#4,WQF059(SLX\#EK9Z.]P5W6P
MT%QYMJI4ZM_$X<%L;!QVZN$-W75-H:)Q+#17-M;(Q@Z2I14LEJ28:!P+S96T
MJ<JIMTR=?00O#JX;'I1QMB"),L9)V&XC-&AE+#P7@XZ<1:VWL=!<I9J*F_I+
M[IN\TBX*[?<J!$/Y^UK')HH+O]^IDA=NYT6'B<:QT%PIF[*>C@Z3QTB%=R4I
M)AK'0G,E;5P!]=N"O?*X7?Q/.],8J?BOA#J$E:"-EZ!^,^%+8_(?N5G?_@T&
M@EA%WMVO8BV>3&^DPK^2&!.-8Z&Y$C>NA!X?)KU1O0DJ&L="<R5M[ GUUNO[
MI?>T75AWIC>J[\!"<W\R;8P'\QN/9]+[XW-I[8??=0VBHG$L-%?:QK0P>I"T
M9JB&!A6-8Z&YDC:&AGFK^[W2NH)T?KSJ2FM_USL+=0B;PAJ;POPVY:K\;;M3
M#]0W!*AH' O-5:VQ+&QXF(Q%M2ZH:!P+S96TL2[,_TIBKXQMOU9@4]I.6%0_
M@H7FZM3X$>;W(U7"[E)1^Q%W7G6HI@4+S56S,2UL<IA$1C4IJ&@<"\V5M#$I
MS/_N9*]$/FZ_+1MU)#*J\\!"<W5JG ?S.X\FD9^OG5'?AJ"B<2PT]^Q#8TL&
MP6%./Z#:$50TCH7F2MK8D8'_'<H^"5Q!.N]TA^W2V=_SSCJA>HS^UN&H5.I%
M<<@,J.<'(,JS1?7=^B#;>7%\Z]']"WK"R^-H#4QY.NZ#T(LX,R21<X ,WDY
M+UT>."LOK%H51[!NE;4J+3XNI8BDSAO ]W.E[,-%WD%][&_V/U!+ P04
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M!>35]X]J1[)=N5Z_8E*RK-S<$IP0KB]0Y]>,R>.._@30?(6:_0=02P,$%
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M_(39,&W@@<6!2'^6:[S:>(<\WP=839_K$&RG>"=B.\5S#4@X;^"19>%J8W'
M ZL"UCL0/QP'>BKLDR1054P;]@3C2)9A"/1BN$?3%,E."I]P?;"G)$FR+(P
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MUHHB:T61M:+(6OU/67^,X^$?QR_/M#?M\)R?+?_BN/D%4$L! A0#%     @
M6H-<5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !:@UQ6KUW(O.X    K @  $0
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M965T-"YX;6Q02P$"% ,4    " !:@UQ6J*+=_/H&  "['@  &
M    @('#'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M6H-<5IJ:K! U P  '@L  !@              ("!\R,  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %J#7%:YRB&B9@D  .Y+   8
M          " @5XG  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " !:@UQ6E=G,D;X"  #@!@  &               @('Z,   >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 6H-<5LP,X\M1"0  *BL
M !@              ("![C,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( %J#7%:3LB$^R04  #0-   9              " @74]  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 6H-<5@XP:/FE
M*0  N(8  !D              ("!=4,  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " !:@UQ6TBZV9_PA   !<   &0
M@(%1;0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %J#
M7%;,4QO/]B$  ")P   9              " @82/  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ 6H-<5N2,0@SW @  _ 8  !D
M         ("!L;$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " !:@UQ6PM5N%0$%   K#   &0              @('?M   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %J#7%;"]6_PU0,  *T(
M   9              " @1>Z  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ 6H-<5K&(DEV, @  FP4  !D              ("!([X
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !:@UQ6.J#:
M $X*  "N&@  &0              @('FP   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( %J#7%983RJ V0D  !LQ   9
M  " @6O+  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M6H-<5C3NN%;:$   FCD  !D              ("!>]4  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " !:@UQ6HAYQ/\D#  !_"   &0
M            @(&,Y@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( %J#7%82</>'! 0  )<)   9              " @8SJ  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 6H-<5I</A?QX"P
MZ1\  !D              ("!Q^X  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " !:@UQ6A]T&3+(#  !U"   &0              @(%V
M^@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %J#7%:\
M*@=XS 0  )D+   9              " @5_^  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ 6H-<5I:'R094#   \B,  !D
M     ("!8@,! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %J#7%9%KS)5[@4  ,<.   9              "
M@=A> 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 6H-<
M5J"81N,. P  ]@8  !D              ("!_60! 'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " !:@UQ6X"0]RZ0#  #/"   &0
M        @(%": $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( %J#7%85MBRS&P,  #$'   9              " @1UL 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 6H-<5O9:<=F< @  IP4
M !D              ("!;V\! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " !:@UQ6\9G00L@#  !B"   &0              @(%"<@$
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %J#7%8Z YU4
MR04  +,0   9              " @4%V 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ 6H-<5OJ8AD)Q P  K0@  !D
M ("!07P! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !:
M@UQ6>@(CM64&  "2$   &0              @('I?P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %J#7%9;"*V$Y@0  .@,   9
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M970T-"YX;6Q02P$"% ,4    " !:@UQ6$4##O> 4   B8P$ &0
M    @($8IP$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M %J#7%;9-%3TS <  %9!   9              " @2^\ 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ 6H-<5GLP942[ P  Y10  !D
M             ("!,L0! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " !:@UQ6GV1TORX$  !(&   &0              @($DR $ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( %J#7%;WKRA05P4
M *XH   9              " @8G, 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ 6H-<5G"96;GU @  E H  !D              ("!
M%](! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !:@UQ6
M8> VXGD(  "A6@  &0              @(%#U0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( %J#7%8VLF#N@@(  -L&   9
M      " @?/= 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ 6H-<5L8ZJ)33 @  A@@  !D              ("!K. ! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !:@UQ6D63!21,#  #:"@
M&0              @(&VXP$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( %J#7%;U9W#(F@(  /4&   9              " @0#G 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 6H-<5H_?Q)KG
M P  210  !D              ("!T>D! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " !:@UQ648GEOQ@$  "[&   &0
M@('O[0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( %J#
M7%;B'SD#Q (  -,&   9              " @3[R 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ 6H-<5D[E[!)?!0  ^"<  !D
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M=#8S+GAM;%!+ 0(4 Q0    ( %J#7%8P()'YZ@,  , 3   9
M  " @>P) @!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
M6H-<5C[>1;#J @  5P@  !D              ("!#0X" 'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    " !:@UQ6.T>D4M4+  #PB@  &0
M            @($N$0( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    ( %J#7%9FM%XOB04  (TK   9              " @3H= @!X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ 6H-<5L&3084G!@
M@S4  !D              ("!^B(" 'AL+W=O<FMS:&5E=',O<VAE970V."YX
M;6Q02P$"% ,4    " !:@UQ6$O1LN P'  #4-   &0              @(%8
M*0( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( %J#7%8E
M1!;SP@,  ,X1   9              " @9LP @!X;"]W;W)K<VAE971S+W-H
M965T-S N>&UL4$L! A0#%     @ 6H-<5BE<RW:+!   L14  !D
M     ("!E#0" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %J#7%8"(_LK_P,  .$3   9              "
M@4I* @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ 6H-<
M5G@SOWH( P  ,PL  !D              ("!@$X" 'AL+W=O<FMS:&5E=',O
M<VAE970W-RYX;6Q02P$"% ,4    " !:@UQ6UUKIA,P"  !3!P  &0
M        @(&_40( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0
M   ( %J#7%; H,S"R0(  '8'   9              " @<)4 @!X;"]W;W)K
M<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ 6H-<5O45O/01 P  @@@
M !D              ("!PE<" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q0
M2P$"% ,4    " !:@UQ6SZARA?@"  #S"   &0              @($*6P(
M>&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( %J#7%9  LOL
MF@4   (H   9              " @3E> @!X;"]W;W)K<VAE971S+W-H965T
M.#(N>&UL4$L! A0#%     @ 6H-<5O]R,%T !   P@\  !D
M ("!"F0" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " !:
M@UQ6P.)[:ZT$  #B$0  &0              @(%!: ( >&PO=V]R:W-H965T
M<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( %J#7%:V=_,<C0,  (X+   9
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M @!X;"]S='EL97,N>&UL4$L! A0#%     @ 6H-<5I>*NQS     $P(   L
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64$L%!@    !? %\ $!H  .*' @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>290</ContextCount>
  <ElementCount>456</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Acquisition of Novavax CZ</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionofNovavaxCZ</Role>
      <ShortName>Acquisition of Novavax CZ</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/PreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Revenue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Inventory</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Goodwill</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Acquisition of Novavax CZ (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionofNovavaxCZTables</Role>
      <ShortName>Acquisition of Novavax CZ (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/AcquisitionofNovavaxCZ</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/LongTermDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/OtherFinancialInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails</Role>
      <ShortName>Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Revenue - Schedule of Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Revenue - Schedule of Grant Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Grant Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Cash, Cash Equivalents, and Restricted Cash - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryScheduleofInventoryDetails</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Inventory - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryAdditionalInformationDetails</Role>
      <ShortName>Inventory - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Inventory - Schedule of Inventory Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails</Role>
      <ShortName>Inventory - Schedule of Inventory Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/GoodwillTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Acquisition of Novavax CZ - Schedule of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition of Novavax CZ - Schedule of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Acquisition of Novavax CZ - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails</Role>
      <ShortName>Acquisition of Novavax CZ - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Acquisition of Novavax CZ - Schedule of Business Acquisition, Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails</Role>
      <ShortName>Acquisition of Novavax CZ - Schedule of Business Acquisition, Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Leases - Schedule of Operating Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails</Role>
      <ShortName>Leases - Schedule of Operating Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Long-Term Debt - Schedule of Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Long-Term Debt - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/PreferredStockDetails</Role>
      <ShortName>Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/PreferredStock</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockholdersEquity</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/EmployeeBenefits</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Other Financial Information - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Other Financial Information - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Other Financial Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails</Role>
      <ShortName>Other Financial Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Other Financial Information - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails</Role>
      <ShortName>Other Financial Information - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails</Role>
      <ShortName>Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Income Taxes - Schedule of Components of Current Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Current Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Income Taxes - Schedule of Tax Rate Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Rate Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Income Taxes - Schedule of Unrecognized Tac Benefits Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tac Benefits Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CommitmentandContingencies</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="nvax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SubsequentEvents</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: nvax:ConvertibleDebtConversionRate, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  nvax-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="nvax-20221231.htm">nvax-20221231.htm</File>
    <File>nvax-20221231.xsd</File>
    <File>nvax-20221231_cal.xml</File>
    <File>nvax-20221231_def.xml</File>
    <File>nvax-20221231_lab.xml</File>
    <File>nvax-20221231_pre.xml</File>
    <File>nvax-20221231xex1018.htm</File>
    <File>nvax-20221231xex1020.htm</File>
    <File>nvax-20221231xex1056.htm</File>
    <File>nvax-20221231xex21.htm</File>
    <File>nvax-20221231xex231.htm</File>
    <File>nvax-20221231xex311.htm</File>
    <File>nvax-20221231xex312.htm</File>
    <File>nvax-20221231xex321.htm</File>
    <File>nvax-20221231xex322.htm</File>
    <File>nvax-20221231xex44.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nvax-20221231_g1.jpg</File>
    <File>nvax-20221231_g2.jpg</File>
    <File>nvax-20221231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1011">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nvax-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 33,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1011,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 290,
   "dts": {
    "calculationLink": {
     "local": [
      "nvax-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nvax-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nvax-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nvax-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvax-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nvax-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 716,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 12,
    "http://www.novavax.com/20221231": 4,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 20
   },
   "keyCustom": 68,
   "keyStandard": 388,
   "memberCustom": 44,
   "memberStandard": 52,
   "nsprefix": "nvax",
   "nsuri": "http://www.novavax.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.novavax.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.novavax.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.novavax.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.novavax.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Cash, Cash Equivalents, and Restricted Cash",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.novavax.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.novavax.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Goodwill",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.novavax.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Acquisition of Novavax CZ",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.novavax.com/role/AcquisitionofNovavaxCZ",
     "shortName": "Acquisition of Novavax CZ",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.novavax.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.novavax.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Long-Term Debt",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.novavax.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Preferred Stock",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.novavax.com/role/PreferredStock",
     "shortName": "Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.novavax.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.novavax.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Employee Benefits",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.novavax.com/role/EmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Other Financial Information",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.novavax.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.novavax.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Commitment and Contingencies",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.novavax.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.novavax.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "29",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.novavax.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.novavax.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.novavax.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.novavax.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Acquisition of Novavax CZ (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.novavax.com/role/AcquisitionofNovavaxCZTables",
     "shortName": "Acquisition of Novavax CZ (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.novavax.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.novavax.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.novavax.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Other Financial Information (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.novavax.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.novavax.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i0708fc22c9854f0abba5629785850b62_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i0708fc22c9854f0abba5629785850b62_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i7b3c9b3cf2a747ce9a1576cadc4c0a46_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i7b3c9b3cf2a747ce9a1576cadc4c0a46_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Revenue - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "iba985ece231344b9884ac0673bdf1f76_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
     "shortName": "Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Revenue - Schedule of Product Revenue (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
     "shortName": "Revenue - Schedule of Product Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i2706507e51524857a9ceffe04bbdfb19_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Revenue - Schedule of Grant Revenue (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
     "shortName": "Revenue - Schedule of Grant Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i9414495645c244dfa1f4271692735ef3_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Collaboration and License Agreements (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
     "shortName": "Collaboration and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i96b9e55b23e44271b0b5d401791eb27a_I20210228",
      "decimals": "INF",
      "lang": "en-US",
      "name": "nvax:NumberOfDosesToBeDistributed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Cash, Cash Equivalents, and Restricted Cash - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i4f41fed49045497fbd18a61509fff1d1_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "iee8898a306024e42bfe586c67dd2d69f_I20161231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.novavax.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i8099f1e2bbdd4ec0970e209f1e0b270e_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.novavax.com/role/InventoryScheduleofInventoryDetails",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nvax:InventoryReserveChargedToCostsOfSales",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Inventory - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
     "shortName": "Inventory - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "iba985ece231344b9884ac0673bdf1f76_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Inventory - Schedule of Inventory Reserves (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails",
     "shortName": "Inventory - Schedule of Inventory Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nvax:InventoryReserveOtherAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "iba985ece231344b9884ac0673bdf1f76_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Goodwill (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.novavax.com/role/GoodwillDetails",
     "shortName": "Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Acquisition of Novavax CZ - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisition of Novavax CZ - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "if74110891d1c4616a0230ee664e7675b_I20200527",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i4f41fed49045497fbd18a61509fff1d1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Acquisition of Novavax CZ - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
     "shortName": "Acquisition of Novavax CZ - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i98d86903b18c4a31908d43850afb1f79_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Acquisition of Novavax CZ - Schedule of Business Acquisition, Pro Forma Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails",
     "shortName": "Acquisition of Novavax CZ - Schedule of Business Acquisition, Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "ie6c26cf493804901a9d1f46d3506e9d1_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i18de67b571ba458cbba0933459b5975b_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Leases - Schedule of Operating Lease Expenses (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails",
     "shortName": "Leases - Schedule of Operating Lease Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Long-Term Debt - Schedule of Notes Payable (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
     "shortName": "Long-Term Debt - Schedule of Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Long-Term Debt - Schedule of Interest Expense (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails",
     "shortName": "Long-Term Debt - Schedule of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "iee8898a306024e42bfe586c67dd2d69f_I20161231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i67dd0e1a6a7d4d8f8413ec22787652d3_D20160101-20161231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.novavax.com/role/PreferredStockDetails",
     "shortName": "Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i72a45e70dfcc4ed3a06e5a1a0ad85788_D20201001-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nvax:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "ifb6c34ca0e6943a985fccfb3c3cd5034_I20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.novavax.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "id09da20d245547229c7e424719065312_D20221201-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "ib77bd7520a4c413d82a3ee385fdabe20_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "ib77bd7520a4c413d82a3ee385fdabe20_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "ic57598acb9d345a0b294ceda6cce94ab_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "ic57598acb9d345a0b294ceda6cce94ab_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i4b81dc44ba69425da581a9e082433cf3_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i482ffe6e8ec14375b57c416c028deaec_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i482ffe6e8ec14375b57c416c028deaec_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Employee Benefits (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.novavax.com/role/EmployeeBenefitsDetails",
     "shortName": "Employee Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Other Financial Information - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Other Financial Information - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Other Financial Information - Additional Information (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
     "shortName": "Other Financial Information - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Other Financial Information - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails",
     "shortName": "Other Financial Information - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CustomerRefundLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Other Financial Information - Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
     "shortName": "Other Financial Information - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CustomerRefundLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails",
     "shortName": "Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Income Taxes - Schedule of Components of Current Income Tax Provision (Benefit) (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails",
     "shortName": "Income Taxes - Schedule of Components of Current Income Tax Provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Income Taxes - Schedule of Tax Rate Differences (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails",
     "shortName": "Income Taxes - Schedule of Tax Rate Differences (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i55917cb303ae4006ae29b944e6cc0a9c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "iba985ece231344b9884ac0673bdf1f76_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Income Taxes - Schedule of Unrecognized Tac Benefits Rollforward (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tac Benefits Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i4f41fed49045497fbd18a61509fff1d1_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfDefendants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "defendant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Commitment and Contingencies (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.novavax.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i6ae791f028374fa2bea28d5b38f3f629_D20221212-20221212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfDefendants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "defendant",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentFaceAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i5ce452e9ba0b4f91b8ca4a6aa27cddc8_D20230201-20230201",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.novavax.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20221231.htm",
      "contextRef": "i03edd2022a524211b490c78fcdecd1fc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 96,
   "tag": {
    "country_CZ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CZECHIA",
        "terseLabel": "Czech Republic"
       }
      }
     },
     "localname": "CZ",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nvax_A700QuinceOrchardRoadAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "700 Quince Orchard Road Agreement",
        "label": "700 Quince Orchard Road Agreement [Member]",
        "terseLabel": "700 Quince Orchard Road Agreement"
       }
      }
     },
     "localname": "A700QuinceOrchardRoadAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_AccountsReceivableAllowanceForCreditLossAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Additions",
        "label": "Accounts Receivable, Allowance for Credit Loss, Additions",
        "negatedLabel": "Additions",
        "verboseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossAdditions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_AccountsReceivableAllowanceForCreditLossDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Deductions",
        "label": "Accounts Receivable, Allowance for Credit Loss, Deductions",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossDeductions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss, Additions",
        "label": "Accounts Receivable, Before Allowance For Credit Loss, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossAdditions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss, Deductions",
        "label": "Accounts Receivable, Before Allowance For Credit Loss, Deductions",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossDeductions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss",
        "label": "Accounts Receivable, Before Allowance For Credit Loss [Roll Forward]",
        "terseLabel": "Accounts receivable:"
       }
      }
     },
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossRollForward",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accrued research and development expenses.",
        "label": "Accrued Research and Development Expenses, Policy [Policy Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_AmendedAndRestatedUKSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated UK Supply Agreement",
        "label": "Amended and Restated UK Supply Agreement [Member]",
        "terseLabel": "Amended and Restated UK Supply Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedUKSupplyAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses",
        "negatedTerseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_CEPIGrantFundingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEPI Grant Funding",
        "label": "CEPI Grant Funding [Member]",
        "terseLabel": "CEPI Grant Funding"
       }
      }
     },
     "localname": "CEPIGrantFundingMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CMOAndCMDAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMO and CMD Agreements",
        "label": "CMO and CMD Agreements [Member]",
        "terseLabel": "CMO and CMD Agreements"
       }
      }
     },
     "localname": "CMOAndCMDAgreementsMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Operating and Financing Activities Lessee",
        "label": "Cash Flow Operating and Financing Activities Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowOperatingAndFinancingActivitiesLesseeAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Coalition For Epidemic Preparedness Innovations Award [Member]",
        "terseLabel": "CEPI"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationsAwardMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition For Epidemic Preparedness Innovations (CEPI) Agreement",
        "label": "Coalition For Epidemic Preparedness Innovations (CEPI) Agreement [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations (\"CEPI\")"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CoalitionForEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "CEPI"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CollaborationAgreementUpfrontPaymentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Upfront Payment Amount",
        "label": "Collaboration Agreement Upfront Payment Amount",
        "terseLabel": "Collaboration agreement upfront payment amount"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPaymentAmount",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_CollaborativeArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvax_CompensationStockIssuedUnderIncentiveProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation Stock Issued Under Incentive Program",
        "label": "Compensation Stock Issued Under Incentive Program",
        "terseLabel": "Stock issued under incentive programs"
       }
      }
     },
     "localname": "CompensationStockIssuedUnderIncentiveProgram",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ComputerSoftwareAndHardwareMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Software And Hardware Member [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerSoftwareAndHardwareMemberMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Additions",
        "label": "Contract With Customer, Liability, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Deductions",
        "label": "Contract With Customer, Liability, Deductions",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ConversionPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the rate of premium based on the last reported sales price of stock.",
        "label": "Conversion Premium Percentage",
        "terseLabel": "Conversion premium percentage"
       }
      }
     },
     "localname": "ConversionPremiumPercentage",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_ConvertibleDebtConversionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt conversion rate.",
        "label": "Convertible Debt Conversion Rate",
        "terseLabel": "Convertible debt conversion rate"
       }
      }
     },
     "localname": "ConvertibleDebtConversionRate",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvax_ConvertibleNotesPayableCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes Payable, Current",
        "label": "Convertible Notes Payable, Current [Abstract]",
        "terseLabel": "Current portion:"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrentAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_ConvertibleNotesPayableNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes Payable, Noncurrent",
        "label": "Convertible Notes Payable, Noncurrent [Abstract]",
        "terseLabel": "Non-current portion:"
       }
      }
     },
     "localname": "ConvertibleNotesPayableNoncurrentAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_DebtCapPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cap rate on a debt . A payment or receipt is triggered if the market rate exceeds the cap rate on the debt.",
        "label": "Debt Cap Price",
        "terseLabel": "Debt cap price (in usd per share)"
       }
      }
     },
     "localname": "DebtCapPrice",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvax_DebtInstrumentFaceAmountCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Face Amount, Current",
        "label": "Debt Instrument, Face Amount, Current",
        "terseLabel": "Debt Instrument, Face Amount, Current"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmountCurrent",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Of Principal Amount, Percentage",
        "label": "Debt Instrument, Repurchase Of Principal Amount, Percentage",
        "terseLabel": "Repurchase percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseOfPrincipalAmountPercentage",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_DeferredRevenueIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Increase (Decrease)",
        "label": "Deferred Revenue Increase (Decrease) [Abstract]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueIncreaseDecreaseAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_DeferredTaxAssetLeasingLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Leasing Liability",
        "label": "Deferred Tax Asset, Leasing Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetLeasingLiability",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_DeferredTaxAssetsOriginalDiscountInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from original discount interest.",
        "label": "Deferred Tax Assets, Original Discount Interest",
        "verboseLabel": "Original discount interest"
       }
      }
     },
     "localname": "DeferredTaxAssetsOriginalDiscountInterest",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_DoDContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DoD Contract",
        "label": "DoD Contract [Member]",
        "terseLabel": "DoD Contract"
       }
      }
     },
     "localname": "DoDContractMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations",
        "label": "Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations",
        "terseLabel": "U.S. taxation of foreign operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_EuropeanCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Commission",
        "label": "European Commission [Member]",
        "terseLabel": "European Commission"
       }
      }
     },
     "localname": "EuropeanCommissionMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_EuropeanCommissionsECMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Commissions (\"EC\")",
        "label": "European Commissions (\"EC\") [Member]",
        "terseLabel": "European Commissions (\"EC\")"
       }
      }
     },
     "localname": "EuropeanCommissionsECMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_FacilityLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Lease Agreement",
        "label": "Facility Lease Agreement [Member]",
        "terseLabel": "Facility Lease Agreement"
       }
      }
     },
     "localname": "FacilityLeaseAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_FacilityNumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Number of Square Feet",
        "label": "Facility Number of Square Feet",
        "terseLabel": "Facility, number of square feet"
       }
      }
     },
     "localname": "FacilityNumberOfSquareFeet",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "nvax_FirstThreePercentOfParticipantsDeferralMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Three Percent Of Participants Deferral Member [Member]",
        "terseLabel": "First Three Percent Of Participants Deferral"
       }
      }
     },
     "localname": "FirstThreePercentOfParticipantsDeferralMemberMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change",
        "label": "Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change [Member]",
        "terseLabel": "2027 Notes, Make-Whole Fundamental Change"
       }
      }
     },
     "localname": "FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_FivePointZeroConvertibleNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Zero Convertible Notes Due 2027",
        "label": "Five Point Zero Convertible Notes Due 2027 [Member]",
        "terseLabel": "5.00% Convertible notes due 2027",
        "verboseLabel": "2027 Notes"
       }
      }
     },
     "localname": "FivePointZeroConvertibleNotesDue2027Member",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gavi Advance Purchase Agreement- COVAX Facility",
        "label": "Gavi Advance Purchase Agreement- COVAX Facility [Member]",
        "terseLabel": "Gavi Advance Purchase Agreement- COVAX Facility"
       }
      }
     },
     "localname": "GaviAdvancePurchaseAgreementCOVAXFacilityMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GaviAdvancePurchaseAgreementSIIPLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gavi Advance Purchase Agreement SIIPL",
        "label": "Gavi Advance Purchase Agreement SIIPL [Member]",
        "terseLabel": "Gavi Advance Purchase Agreement SIIPL"
       }
      }
     },
     "localname": "GaviAdvancePurchaseAgreementSIIPLMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GaviVaccineAllianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gavi Vaccine Alliance",
        "label": "Gavi Vaccine Alliance [Member]",
        "terseLabel": "Gavi, the Vaccine Alliance"
       }
      }
     },
     "localname": "GaviVaccineAllianceMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GovernmentOfAustraliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government of Australia",
        "label": "Government of Australia [Member]",
        "terseLabel": "Government of Australia"
       }
      }
     },
     "localname": "GovernmentOfAustraliaMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GovernmentOfCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government of Canada",
        "label": "Government of Canada [Member]",
        "terseLabel": "Government of Canada"
       }
      }
     },
     "localname": "GovernmentOfCanadaMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GovernmentOfIsraelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government of Israel",
        "label": "Government of Israel [Member]",
        "terseLabel": "Government of Israel"
       }
      }
     },
     "localname": "GovernmentOfIsraelMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GrantsUSGovernmentContractAndJointVentureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants, U.S. Government Contract and Joint Venture [Abstract]",
        "terseLabel": "Grants, U.S. Government Contract and Joint Venture"
       }
      }
     },
     "localname": "GrantsUSGovernmentContractAndJointVentureAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest expense related to convertible notes.",
        "label": "Interest Expense Related to Convertible Notes [Table Text Block]",
        "verboseLabel": "Schedule of Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedToConvertibleNotesTableTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_InventoryReserveChargedToCostsOfSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Reserve, Charged to Costs of sales",
        "label": "Inventory Reserve, Charged to Costs of sales",
        "terseLabel": "Charged to Cost of sales, including impairments",
        "verboseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryReserveChargedToCostsOfSales",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_InventoryReserveOtherAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Reserve, Other Additions",
        "label": "Inventory Reserve, Other Additions",
        "terseLabel": "Other additions"
       }
      }
     },
     "localname": "InventoryReserveOtherAdditions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_InventoryReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Reserve",
        "label": "Inventory Reserve [Roll Forward]",
        "terseLabel": "Inventory Reserve [Roll Forward]"
       }
      }
     },
     "localname": "InventoryReserveRollForward",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Committee on Vaccination and Immunization (JCVI)",
        "label": "Joint Committee on Vaccination and Immunization (JCVI) [Member]",
        "terseLabel": "Joint Committee on Vaccination and Immunization (JCVI)"
       }
      }
     },
     "localname": "JointCommitteeOnVaccinationAndImmunizationJCVIMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_June2021SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2021 Sales Agreement",
        "label": "June 2021 Sales Agreement [Member]",
        "terseLabel": "June 2021 Sales Agreement"
       }
      }
     },
     "localname": "June2021SalesAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability, Current",
        "label": "Lease Liability, Current",
        "totalLabel": "Total current lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_LeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability, Noncurrent",
        "label": "Lease Liability, Noncurrent",
        "totalLabel": "Total non-current lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityNoncurrent",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-Of-Use Asset",
        "label": "Lease, Right-Of-Use Asset",
        "terseLabel": "Total non-current ROU assets",
        "totalLabel": "Total non-current ROU assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Going Concern",
        "label": "Liquidity and Going Concern [Policy Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_LossContingencyPeriodToAnswer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Period To Answer",
        "label": "Loss Contingency, Period To Answer",
        "terseLabel": "Period to answer"
       }
      }
     },
     "localname": "LossContingencyPeriodToAnswer",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nvax_MaximumContributionOfEmployeesAsPayrollDeductions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum contribution of employees as payroll deductions.",
        "label": "Maximum Contribution Of Employees As Payroll Deductions",
        "terseLabel": "Maximum contribution of employees as payroll deductions"
       }
      }
     },
     "localname": "MaximumContributionOfEmployeesAsPayrollDeductions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_NetProceedsFromTheExerciseOfStockBasedAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Proceeds From The Exercise Of Stock-Based Awards",
        "label": "Net Proceeds From The Exercise Of Stock-Based Awards",
        "terseLabel": "Net proceeds from the exercise of stock-based awards"
       }
      }
     },
     "localname": "NetProceedsFromTheExerciseOfStockBasedAwards",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_NextTwoPercentOfParticipantsDeferralMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Next Two Percent Of Participants Deferral Member [Member]",
        "terseLabel": "Next Two Percent Of Participants Deferral"
       }
      }
     },
     "localname": "NextTwoPercentOfParticipantsDeferralMemberMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Expiration",
        "label": "No Expiration [Member]",
        "terseLabel": "No Expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset",
        "label": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset",
        "terseLabel": "Right-of-use assets from new lease agreements"
       }
      }
     },
     "localname": "NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_NovavaxCZFormerlyPrahaVaccinesASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novavax CZ (Formerly Praha Vaccines A.S)",
        "label": "Novavax CZ (Formerly Praha Vaccines A.S) [Member]",
        "terseLabel": "Novavax CZ"
       }
      }
     },
     "localname": "NovavaxCZFormerlyPrahaVaccinesASMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_NumberOfDosesOfVaccineCandidate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Doses Of Vaccine Candidate",
        "label": "Number Of Doses Of Vaccine Candidate",
        "terseLabel": "Number of doses"
       }
      }
     },
     "localname": "NumberOfDosesOfVaccineCandidate",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Doses Of Vaccine Candidate, Additional Purchase Option",
        "label": "Number Of Doses Of Vaccine Candidate, Additional Purchase Option",
        "terseLabel": "Additional purchase option, number of doses"
       }
      }
     },
     "localname": "NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_NumberOfDosesToBeDistributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Doses, To Be Distributed",
        "label": "Number Of Doses, To Be Distributed",
        "terseLabel": "Number of doses to be distributed"
       }
      }
     },
     "localname": "NumberOfDosesToBeDistributed",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_NumberOfQuarterlyInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Quarterly Installment Payments",
        "label": "Number Of Quarterly Installment Payments",
        "terseLabel": "Number of quarterly installment payments"
       }
      }
     },
     "localname": "NumberOfQuarterlyInstallmentPayments",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_OperatingAndFinanceLeaseWriteOff": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Finance Lease, Write-off",
        "label": "Operating and Finance Lease, Write-off",
        "verboseLabel": "Right-of-use assets expensed, net of credits received"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseWriteOff",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Current Liability Related To Advance Purchase Agreements",
        "label": "Other Current Liability Related To Advance Purchase Agreements",
        "terseLabel": "Other current liability related to Gavi (see Note 3 and Note 18)"
       }
      }
     },
     "localname": "OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_OtherGrantRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Grant Revenue",
        "label": "Other Grant Revenue [Member]",
        "terseLabel": "Other grant revenue"
       }
      }
     },
     "localname": "OtherGrantRevenueMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_PaymentForCappedCallTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment which is made for entering into privately negotiated capped call transactions.",
        "label": "PaymentForCappedCallTransactions",
        "terseLabel": "Payment for capped call transactions"
       }
      }
     },
     "localname": "PaymentForCappedCallTransactions",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_PercentageOfMarketPriceForStockPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of market price for stock purchase.",
        "label": "Percentage Of Market Price For Stock Purchase",
        "terseLabel": "Percentage of market price for stock purchase"
       }
      }
     },
     "localname": "PercentageOfMarketPriceForStockPurchase",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_ProceedsFromIssuanceCommonStockAndDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance Common Stock and Debt",
        "label": "Proceeds from Issuance Common Stock and Debt",
        "terseLabel": "Sale of common stock and issuance debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceCommonStockAndDebt",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of proceeds from issuance or sale of equity not settled.",
        "label": "Proceeds From Issuance Or Sale Of Equity Not Settled",
        "terseLabel": "Sale of common stock under the Sales Agreement not settled at year-end"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNotSettled",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ProvisionForExcessAndObsoleteInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Excess And Obsolete Inventory",
        "label": "Provision For Excess And Obsolete Inventory",
        "terseLabel": "Provision for excess and obsolete inventory"
       }
      }
     },
     "localname": "ProvisionForExcessAndObsoleteInventory",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_PurchaseAgreementNumberOfDosesCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Number of Doses, Cancelled",
        "label": "Purchase Agreement, Number of Doses, Cancelled",
        "terseLabel": "Number of doses, cancelled"
       }
      }
     },
     "localname": "PurchaseAgreementNumberOfDosesCancelled",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_PurchaseAgreementNumberOfVaccineDoses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Number Of Vaccine Doses",
        "label": "Purchase Agreement, Number Of Vaccine Doses",
        "terseLabel": "Purchase agreement, number of vaccine doses"
       }
      }
     },
     "localname": "PurchaseAgreementNumberOfVaccineDoses",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_ResearchAndDevelopmentAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Accruals.",
        "label": "Research And Development Accruals",
        "terseLabel": "Research and development accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAccruals",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Contract Ceiling",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Contract Ceiling",
        "terseLabel": "Research and development arrangement, contract ceiling"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Contract Remaining",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Contract Remaining",
        "terseLabel": "Research and development arrangement, contract to perform for others, contract remaining"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans",
        "label": "Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans",
        "terseLabel": "Contract to perform for others forgivable no interest term loans"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement Contract To Perform For Others Funding",
        "label": "Research And Development Arrangement Contract To Perform For Others Funding",
        "terseLabel": "Contract to perform for others funding"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersFunding",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement Contract To Perform For Others Grant",
        "label": "Research And Development Arrangement Contract To Perform For Others Grant",
        "terseLabel": "Contract to perform for others grant"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersGrant",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_RestOfTheWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest of the World",
        "label": "Rest of the World [Member]",
        "terseLabel": "Rest of the world"
       }
      }
     },
     "localname": "RestOfTheWorldMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_RevenueFromContractWithCustomerCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer Commitment",
        "label": "Revenue From Contract With Customer Commitment",
        "terseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerCommitment",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_RevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue",
        "label": "Revenue [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_RevenuePerformanceObligationSatisfiedAtPointInTimeAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation Satisfied at Point in Time, Amount",
        "label": "Revenue, Performance Obligation Satisfied at Point in Time, Amount",
        "terseLabel": "Revenue, performance obligation satisfied at previous quarter"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSatisfiedAtPointInTimeAmount",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Customer Status, Period",
        "label": "Revenue, Remaining Performance Obligation, Customer Status, Period",
        "terseLabel": "Performance obligation, customer status, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationCustomerStatusPeriod",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Remaining performance obligation, variable consideration amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability",
        "terseLabel": "Lease liability and right of use assets recognized"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_RoyaltiesAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and Other",
        "label": "Royalties and Other [Member]",
        "terseLabel": "Royalties and other"
       }
      }
     },
     "localname": "RoyaltiesAndOtherMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_SKBioscienceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SK Bioscience Agreement",
        "label": "SK Bioscience Agreement [Member]",
        "terseLabel": "SK Bioscience Agreement"
       }
      }
     },
     "localname": "SKBioscienceAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_SKBioscienceCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SK Bioscience, Co. Ltd",
        "label": "SK Bioscience, Co. Ltd [Member]",
        "terseLabel": "SK bioscience, Co., Ltd."
       }
      }
     },
     "localname": "SKBioscienceCoLtdMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_SalesBasedRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Royalties",
        "label": "Sales-Based Royalties [Member]",
        "terseLabel": "Sales-Based Royalties"
       }
      }
     },
     "localname": "SalesBasedRoyaltiesMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of balance sheet information related to lease",
        "label": "Schedule of Balance Sheet Information Related to Lease [Table Text Block]",
        "verboseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue",
        "label": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue"
       }
      }
     },
     "localname": "ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_ScheduleOfInventoryReserveTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Inventory Reserve",
        "label": "Schedule of Inventory Reserve [Table Text Block]",
        "terseLabel": "Schedule of Inventory Reserve"
       }
      }
     },
     "localname": "ScheduleOfInventoryReserveTableTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share Based Compensation, Restricted Stock Awards, Activity",
        "label": "Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information of lease",
        "label": "Schedule of Supplemental Cash Flow information of Lease [Table Text Block]",
        "verboseLabel": "Schedule of Supplemental Cash Flow Information of Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_SettlementAgreementInitialReservationFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Agreement, Initial Reservation Fee",
        "label": "Settlement Agreement, Initial Reservation Fee",
        "terseLabel": "Initial reservation fee"
       }
      }
     },
     "localname": "SettlementAgreementInitialReservationFee",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_SettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Agreement",
        "label": "Settlement Agreement [Member]",
        "terseLabel": "Settlement Agreement"
       }
      }
     },
     "localname": "SettlementAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_SettlementAgreementQuarterlyInstallmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Agreement, Quarterly Installment Amount",
        "label": "Settlement Agreement, Quarterly Installment Amount",
        "terseLabel": "Settlement agreement, quarterly installment amount"
       }
      }
     },
     "localname": "SettlementAgreementQuarterlyInstallmentAmount",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_SettlementPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Payment",
        "label": "Settlement Payment",
        "terseLabel": "Settlement payment"
       }
      }
     },
     "localname": "SettlementPayment",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent",
        "terseLabel": "Minimum grant price, percent of common stock fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase",
        "terseLabel": "Percentage increase of shares each anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Stock Issued Under Incentive Program",
        "label": "Share-Based Compensation Stock Issued Under Incentive Program",
        "terseLabel": "Stock issued under incentive programs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationStockIssuedUnderIncentiveProgram",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvax_ShelfRegistrationStatementRemainingUnissuedCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement Remaining Unissued Capital",
        "label": "Shelf Registration Statement Remaining Unissued Capital",
        "terseLabel": "Shelf registration statement remaining unissued capital"
       }
      }
     },
     "localname": "ShelfRegistrationStatementRemainingUnissuedCapital",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease",
        "label": "Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease",
        "terseLabel": "Preferred stock beneficial conversion feature",
        "verboseLabel": "Beneficial conversion feature"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options and employee stock purchase plan",
        "label": "Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan",
        "terseLabel": "Reclassification from preferred stock to additional paid in capital"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_SubjectToExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subject to Expiration",
        "label": "Subject to Expiration [Member]",
        "terseLabel": "Subject to Expiration"
       }
      }
     },
     "localname": "SubjectToExpirationMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_TakedaArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Arrangement",
        "label": "Takeda Arrangement [Member]",
        "terseLabel": "Takeda Arrangement"
       }
      }
     },
     "localname": "TakedaArrangementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Seventy Five Convertible Notes Due 2023",
        "label": "Three Point Seventy Five Convertible Notes Due 2023 [Member]",
        "terseLabel": "3.75% Convertible notes due 2023",
        "verboseLabel": "2023 Notes"
       }
      }
     },
     "localname": "ThreePointSeventyFiveConvertibleNotesDue2023Member",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_TwoThousandFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_TwoThousandFiveStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Five Stock Incentive Plan [Member]",
        "terseLabel": "2005 Plan"
       }
      }
     },
     "localname": "TwoThousandFiveStockIncentivePlanMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_USDepartmentOfDefenseDoDContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Defense (\"DoD Contract\")",
        "label": "US Department of Defense (\"DoD Contract\") [Member]",
        "terseLabel": "U.S. DoD"
       }
      }
     },
     "localname": "USDepartmentOfDefenseDoDContractMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_USGovernmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government Agreement",
        "label": "US Government Agreement [Member]",
        "terseLabel": "USG Agreement"
       }
      }
     },
     "localname": "USGovernmentAgreementMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_USGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government",
        "label": "US Government [Member]",
        "terseLabel": "U.S. government"
       }
      }
     },
     "localname": "USGovernmentMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_UnderwriterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriter",
        "label": "Underwriter [Member]",
        "terseLabel": "Underwriter"
       }
      }
     },
     "localname": "UnderwriterMember",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term (years):"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.novavax.com/20221231",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r352",
      "r381",
      "r674",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r307",
      "r694",
      "r781",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r481",
      "r623",
      "r637",
      "r667",
      "r668",
      "r691",
      "r709",
      "r718",
      "r779",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r481",
      "r623",
      "r637",
      "r667",
      "r668",
      "r691",
      "r709",
      "r718",
      "r779",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r307",
      "r694",
      "r781",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r304",
      "r626",
      "r692",
      "r716",
      "r774",
      "r775",
      "r781",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r304",
      "r626",
      "r692",
      "r716",
      "r774",
      "r775",
      "r781",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r426",
      "r481",
      "r515",
      "r516",
      "r517",
      "r622",
      "r623",
      "r637",
      "r667",
      "r668",
      "r691",
      "r709",
      "r718",
      "r770",
      "r779",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r426",
      "r481",
      "r515",
      "r516",
      "r517",
      "r622",
      "r623",
      "r637",
      "r667",
      "r668",
      "r691",
      "r709",
      "r718",
      "r770",
      "r779",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r247",
      "r248",
      "r352",
      "r381",
      "r675",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r486",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r263",
      "r486",
      "r730",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r305",
      "r306",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r693",
      "r717",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r305",
      "r306",
      "r651",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r693",
      "r717",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r263",
      "r486",
      "r730",
      "r731",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r19",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r210",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "periodEndLabel": "Accounts receivable, ending balance",
        "periodStartLabel": "Accounts receivable, beginning balance"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r632",
      "r653"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r82",
      "r203"
     ],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r217",
      "r219",
      "r220",
      "r221",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r33",
      "r34",
      "r211",
      "r633",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r30",
      "r34",
      "r144",
      "r615",
      "r638",
      "r639",
      "r740",
      "r741",
      "r742",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r749",
      "r750",
      "r751",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r120",
      "r121",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r96",
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "verboseLabel": "Issuance of common stock, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Agency securities"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r212",
      "r311",
      "r315",
      "r316",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "negatedPeriodEndLabel": "Allowance for doubtful accounts, end balance",
        "negatedPeriodStartLabel": "Allowance for doubtful accounts, beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Allowance for doubtful accounts:"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r371",
      "r593",
      "r689",
      "r690",
      "r744"
     ],
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r699",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Government-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r166",
      "r182",
      "r206",
      "r243",
      "r289",
      "r298",
      "r302",
      "r313",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r569",
      "r571",
      "r582",
      "r715",
      "r777",
      "r778",
      "r833"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r198",
      "r216",
      "r243",
      "r313",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r569",
      "r571",
      "r582",
      "r715",
      "r777",
      "r778",
      "r833"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Billed contracts receivable"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r565",
      "r703",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r565",
      "r703",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Diluted net loss per share (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Basic net loss per share (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r563",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r563",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofBusinessAcquisitionProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Business combination, acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]",
        "terseLabel": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Loss on acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Purchase price, net of cash acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSegmentAllocationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Combination Segment Allocation [Line Items]",
        "terseLabel": "Business Combination Segment Allocation [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationSegmentAllocationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSegmentAllocationTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about goodwill in a business combination.",
        "label": "Business Combination, Segment Allocation [Table]",
        "terseLabel": "Business Combination, Segment Allocation [Table]"
       }
      }
     },
     "localname": "BusinessCombinationSegmentAllocationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CallOptionMember": {
     "auth_ref": [
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.",
        "label": "Call Option [Member]",
        "terseLabel": "Call Option"
       }
      }
     },
     "localname": "CallOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Capital expenditures included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r56",
      "r201",
      "r671"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r57",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r50",
      "r56",
      "r62"
     ],
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of year",
        "terseLabel": "Cash and cash equivalents and restricted cash",
        "totalLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r50",
      "r158"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r243",
      "r266",
      "r267",
      "r269",
      "r271",
      "r275",
      "r276",
      "r313",
      "r340",
      "r342",
      "r343",
      "r344",
      "r347",
      "r348",
      "r379",
      "r380",
      "r383",
      "r387",
      "r395",
      "r582",
      "r669",
      "r729",
      "r745",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Revenue",
        "verboseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreements",
      "http://www.novavax.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollectiveBargainingArrangementAxis": {
     "auth_ref": [
      "r709",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement collectively bargained between employer and its employees represented by union.",
        "label": "Collective-Bargaining Arrangement [Axis]",
        "terseLabel": "Collective Bargaining Arrangement [Axis]"
       }
      }
     },
     "localname": "CollectiveBargainingArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollectiveBargainingArrangementDomain": {
     "auth_ref": [
      "r709",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement collectively bargained between employer and its employees represented by union.",
        "label": "Collective-Bargaining Arrangement [Domain]",
        "terseLabel": "Collective Bargaining Arrangement [Domain]"
       }
      }
     },
     "localname": "CollectiveBargainingArrangementDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r172",
      "r188"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r333",
      "r334",
      "r655",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r749",
      "r750",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value, 600,000,000 shares authorized at December\u00a031, 2022 and 2021; and 86,806,554 shares issued and 86,039,923 shares outstanding at December\u00a031, 2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r35",
      "r224",
      "r226",
      "r233",
      "r628",
      "r634"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r155",
      "r156",
      "r307",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r68",
      "r69",
      "r155",
      "r156",
      "r307",
      "r644",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r68",
      "r69",
      "r155",
      "r156",
      "r307",
      "r654",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r179",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r68",
      "r69",
      "r155",
      "r156",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r70",
      "r155",
      "r157",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r155",
      "r156",
      "r307",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r397",
      "r398",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, ending balance",
        "periodStartLabel": "Deferred revenue, beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r397",
      "r398",
      "r402"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r397",
      "r398",
      "r402"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Milestone payment recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes payable",
        "totalLabel": "Total non-current convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Convertible notes payable",
        "totalLabel": "Convertible Notes Payable, Current"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r8",
      "r9",
      "r97",
      "r100",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion (shares issued)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r699",
      "r701",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r40",
      "r243",
      "r313",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r582",
      "r777"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r748",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r748",
      "r820"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r549",
      "r555",
      "r748"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Federal, state, and foreign current income tax expense",
        "totalLabel": "Total current income tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r748",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofCurrentIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r67",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Refunds to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r59",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Number of shares issued for debt converted (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r241",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r365",
      "r372",
      "r373",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r167",
      "r169",
      "r181",
      "r249",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r594",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r90",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible, conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of stock price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r160",
      "r162",
      "r349",
      "r594",
      "r687",
      "r688"
     ],
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount of notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r23",
      "r160",
      "r377",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r24",
      "r249",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r594",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Percentage of principal amount redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r24",
      "r97",
      "r101",
      "r102",
      "r103",
      "r159",
      "r160",
      "r162",
      "r178",
      "r249",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r594",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r161",
      "r361",
      "r376",
      "r687",
      "r688"
     ],
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "verboseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r168",
      "r180",
      "r543"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax assets",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r818"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r818"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "verboseLabel": "Foreign net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "verboseLabel": "Federal and state net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r127",
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r129",
      "r819"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "verboseLabel": "Maximum contribution, percentage of compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r54",
      "r80"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r54",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r401",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r492",
      "r521",
      "r522",
      "r524",
      "r528",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r264",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r575",
      "r576",
      "r629",
      "r635",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r575",
      "r576",
      "r629",
      "r635",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r583"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Income tax provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r245",
      "r535",
      "r557"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r816",
      "r822"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r557",
      "r816"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "verboseLabel": "Change in tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r816",
      "r822"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Foreign tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r816",
      "r822"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r816",
      "r822"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r815",
      "r816"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r816",
      "r822"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r816",
      "r822"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "verboseLabel": "Research and development and other tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Employee benefits and compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r96",
      "r196",
      "r228",
      "r229",
      "r230",
      "r250",
      "r251",
      "r252",
      "r254",
      "r260",
      "r262",
      "r274",
      "r314",
      "r396",
      "r525",
      "r526",
      "r527",
      "r551",
      "r552",
      "r574",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r615",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/PreferredStockDetails",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r577",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r150",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r363",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r578",
      "r619",
      "r620",
      "r621",
      "r687",
      "r688",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r363",
      "r429",
      "r434",
      "r578",
      "r619",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r363",
      "r429",
      "r434",
      "r578",
      "r620",
      "r687",
      "r688",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r363",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r578",
      "r621",
      "r687",
      "r688",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r363",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r619",
      "r620",
      "r621",
      "r687",
      "r688",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r598",
      "r604",
      "r714"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r600",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows used in finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "nvax_LeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "nvax_LeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r599",
      "r608"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Finance lease payments",
        "terseLabel": "Financing cash flows used in finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r595"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "nvax_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "ROU assets, finance, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r598",
      "r604",
      "r714"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "ROU assets expensed"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r611",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r610",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "verboseLabel": "Total convertible notes payable"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r785",
      "r786",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r204",
      "r323",
      "r627",
      "r685",
      "r715",
      "r759",
      "r766"
     ],
     "calculation": {
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/AcquisitionofNovavaxCZScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r329",
      "r330",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r327",
      "r328",
      "r330",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r54",
      "r324",
      "r325",
      "r329",
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/GoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentContractMember": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Formal agreement with government or its agency.",
        "label": "Government Contract [Member]",
        "terseLabel": "Government Contract"
       }
      }
     },
     "localname": "GovernmentContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r244",
      "r556"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r36",
      "r163",
      "r173",
      "r190",
      "r289",
      "r297",
      "r301",
      "r303",
      "r630",
      "r683"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r244",
      "r556"
     ],
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r245",
      "r536",
      "r541",
      "r548",
      "r553",
      "r558",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r246",
      "r261",
      "r262",
      "r288",
      "r534",
      "r554",
      "r559",
      "r636"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r227",
      "r532",
      "r533",
      "r541",
      "r542",
      "r547",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r51",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Accounts receivable, prepaid expenses, and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r161",
      "r175",
      "r231",
      "r286",
      "r592"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r42",
      "r369",
      "r378",
      "r689",
      "r690"
     ],
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense on convertible notes payable"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r44",
      "r370",
      "r689",
      "r690"
     ],
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "verboseLabel": "Coupon interest"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r237",
      "r239",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash interest payments, net of amounts capitalized"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r735"
     ],
     "calculation": {
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory.",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "terseLabel": "Firm purchase commitment loss"
       }
      }
     },
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r214",
      "r672",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r200",
      "r213",
      "r273",
      "r318",
      "r320",
      "r322",
      "r625",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r737"
     ],
     "calculation": {
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r78",
      "r738"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "periodEndLabel": "Balance at December 31, 2022",
        "periodStartLabel": "Balance at January 1, 2022"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r736"
     ],
     "calculation": {
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Semi-finished goods"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for excess and obsolete inventory",
        "verboseLabel": "Deductions"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "verboseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r164",
      "r176",
      "r191",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held.",
        "label": "Land and Land Improvements [Member]",
        "terseLabel": "Land and buildings"
       }
      }
     },
     "localname": "LandAndLandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r612",
      "r714"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total finance lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease expense:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Schedule of Operating Lease Expenses"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases Accounting"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "verboseLabel": "Operating lease expiration"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r243",
      "r313",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r570",
      "r571",
      "r572",
      "r582",
      "r682",
      "r777",
      "r833",
      "r834"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r171",
      "r186",
      "r715",
      "r747",
      "r757",
      "r827"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r199",
      "r243",
      "r313",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r570",
      "r571",
      "r572",
      "r582",
      "r715",
      "r777",
      "r833",
      "r834"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Coupon interest rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r24",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r335",
      "r336",
      "r337",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r771",
      "r772",
      "r773"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought, value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "auth_ref": [
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of defendants named in a legal action.",
        "label": "Loss Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisition of Novavax CZ"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZ"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r277",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r50",
      "r52",
      "r55"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash provided by (used in) operating activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r37",
      "r55",
      "r174",
      "r189",
      "r197",
      "r222",
      "r225",
      "r230",
      "r243",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r268",
      "r289",
      "r297",
      "r301",
      "r303",
      "r313",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r576",
      "r582",
      "r683",
      "r777"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r289",
      "r297",
      "r301",
      "r303",
      "r683"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r605",
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r829"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease obligation",
        "verboseLabel": "Total current lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "nvax_LeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "nvax_LeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r601",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used in operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r595"
     ],
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "nvax_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset, net",
        "verboseLabel": "ROU assets, operating, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r611",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r610",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r92",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r215",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r141",
      "r142",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r141",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r223",
      "r226"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r88"
     ],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCapitalImprovements": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.",
        "label": "Payments for Capital Improvements",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsForCapitalImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedTerseLabel": "Internal-use software"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Payments for tenant improvements"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Novavax CZ, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Pension and Other Postretirement Benefits [Abstract]",
        "terseLabel": "Payment for Pension and Other Postretirement Benefits [Abstract]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r426",
      "r428",
      "r434",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r473",
      "r474",
      "r475",
      "r488",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r109",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r453",
      "r456",
      "r459",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r487",
      "r701",
      "r702",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.01 par value, 2,000,000 shares authorized at December\u00a031, 2022 and 2021; no shares issued and outstanding at December\u00a031, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Net proceeds from sales of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Net proceeds from sale of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.",
        "label": "Proceeds from Issuance of Unsecured Debt",
        "terseLabel": "Net proceeds received"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r76",
      "r235",
      "r236"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales",
        "verboseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r81",
      "r202"
     ],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r83",
      "r187",
      "r631",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Payments of costs related to issuance of convertible notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r122",
      "r192",
      "r841"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r56",
      "r62",
      "r201"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash current"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r56",
      "r62",
      "r652"
     ],
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash non-current"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r104",
      "r185",
      "r641",
      "r643",
      "r715"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r196",
      "r250",
      "r251",
      "r252",
      "r254",
      "r260",
      "r262",
      "r314",
      "r525",
      "r526",
      "r527",
      "r551",
      "r552",
      "r574",
      "r638",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r785",
      "r786",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r785",
      "r786",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r109",
      "r110",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r453",
      "r456",
      "r459",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r487",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r453",
      "r456",
      "r459",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r487",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Product Revenue"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation to be satisfied"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r232",
      "r243",
      "r284",
      "r285",
      "r296",
      "r299",
      "r300",
      "r304",
      "r305",
      "r307",
      "r313",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r582",
      "r630",
      "r777"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r609",
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for finance lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r609",
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r307",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Current Income Tax Provision (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "verboseLabel": "Schedule of Convertible Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of Tax Rate Differences"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r117",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r685",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r16",
      "r17",
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMultiemployerPlansTable": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about multiemployer plan.",
        "label": "Multiemployer Plan [Table]",
        "terseLabel": "Multiemployer Plan [Table]"
       }
      }
     },
     "localname": "ScheduleOfMultiemployerPlansTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property and Equipment, Net [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/AcquisitionofNovavaxCZTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r62",
      "r165",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of Grant Revenue"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r489",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Option and Appreciation Rights Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Estimation of Fair Value of Stock"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r97",
      "r98",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r207",
      "r208",
      "r209",
      "r275",
      "r379",
      "r380",
      "r381",
      "r383",
      "r387",
      "r393",
      "r395",
      "r691",
      "r729",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r713",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r70",
      "r155",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r733",
      "r734",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedNetLabel": "Restricted stock units forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding and unvested at end of year (in shares)",
        "periodStartLabel": "Outstanding and unvested beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding and unvested at end of year (in shares)",
        "periodStartLabel": "Outstanding and unvested at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Per Share Weighted-Average Grant-Date Fair Value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "verboseLabel": "Proposal to increase authorized shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Shares exercisable at end of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Shares exercisable at end of year (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options and stock appreciation rights exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Black-Scholes fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options and stock appreciation rights outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding (in shares)",
        "periodStartLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of year (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based payment award, terms of award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options and stock appreciation rights exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term of stock options and stock appreciation rights exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term of stock options and stock appreciation rights outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance ending (in shares)",
        "periodStartLabel": "Balance beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r606",
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r243",
      "r266",
      "r267",
      "r269",
      "r271",
      "r275",
      "r276",
      "r313",
      "r340",
      "r342",
      "r343",
      "r344",
      "r347",
      "r348",
      "r379",
      "r380",
      "r383",
      "r387",
      "r395",
      "r582",
      "r669",
      "r729",
      "r745",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r29",
      "r96",
      "r196",
      "r228",
      "r229",
      "r230",
      "r250",
      "r251",
      "r252",
      "r254",
      "r260",
      "r262",
      "r274",
      "r314",
      "r396",
      "r525",
      "r526",
      "r527",
      "r551",
      "r552",
      "r574",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r615",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/PreferredStockDetails",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r274",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r28",
      "r96",
      "r97",
      "r104",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r96",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r96",
      "r104",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r29",
      "r96",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r96",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "verboseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r75",
      "r715",
      "r747",
      "r757",
      "r827"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance ending",
        "periodStartLabel": "Balance beginning",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r242",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r394",
      "r396",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r590",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r590",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r590",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r590",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r616",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/PreferredStockDetails",
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "verboseLabel": "Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r673",
      "r684",
      "r758"
     ],
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Supplies",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r5",
      "r170",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement [Domain]"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r5",
      "r170",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment [Axis]"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r309",
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax": {
     "auth_ref": [
      "r31",
      "r32",
      "r828"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.",
        "label": "Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax",
        "terseLabel": "Foreign currency transaction (losses) gain"
       }
      }
     },
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r27",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r27",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r27",
      "r106",
      "r107"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, 766,631 shares, cost basis at December\u00a031, 2022 and 591,980 shares, cost basis at December\u00a031, 2021"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled contracts receivable"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r531",
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits balance at December 31,",
        "periodStartLabel": "Unrecognized tax benefits balance at January 1,"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions of current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Settlements of tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTacBenefitsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r278",
      "r279",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, deferred tax asset, amount increase"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r607",
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r265",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r264",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "verboseLabel": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r721": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r722": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r723": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r724": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r725": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r726": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r727": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r728": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0001000694-23-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001000694-23-000005-xbrl.zip
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M=?%9$:?FN=C\_F3RX>]/)I<.@W3Z[/?4^=08CDZ[^*]'J3,\[,+IT_Z@C_0
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MUT?MLQ5ZEI7W-D40DH06$PO%EX[-8%#16Z<<=]+YI!X]^TX&XV]?@^Y'V!/
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MO4[_:Y>=_OKO9L.N7.+)U:?_7M+L!ZJFYD^2*TG=*[C_6!KRR@C\0/7A0HT
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M."10B6D*;TB$>=89E@_56XUWY@^HH$@]Q=( -29E0W!"V, 48' 1<%K(MU2
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M$)8*Z#O.N,P'56,EQ>]12^L5X>B3#8&ALBD8<J?"W:TNK+-EO95ECR9GYB,
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MBX_(7RW4_[.(XWBYV6B$N-F?%-!.$.NGC5Z/F'HV?OOGZMN-FD"F**H-SMH
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M&\NK4._J@SN"\78*@RQ$95D"#T'Q)#VXE!0)&_V#I+9K(&DW4,X7\,PJ5;9
MM)B_= ?A@B3I91:TBMF",#QJEC5+X]J527WE(E)G@6"\4O<Y*^D&KK0SC*7Q
M3GB0O'66)W+NH@E(SOMR!'CW1KKG,SU'3%%&H+0J**6XBT(AN6/$%9/(JD\M
MA#FW$&;QZM$6E4,WG[N9@5TP-[<+YE+]VJ],RP65;' HE%<*;0A<NL B6+ F
M\ZQKP)P'%#L4@<7@ !, 4PC"&R]8$@DR*AN4KK?O?JO@W8K'7B1(DL5V-G(E
MM':82HM7*;2EO^%<'^MSJ=+U!.8'\O.KZZ\V[M#!UC<703VCTCRKO>9&!(&6
M5"J#&!)/9))SU KLLM18%1S'F:WG1_UEW1"%^>R4T4& 1A4R@(Y"DVL."8+T
MQM8@?[Z 4,ZG8!:%8=%DSVQ64JD R>2@( @I>/9U:2GQ=<=XLN]5V73J#QAB
MVAJ<0G?4P>_MXE9+F90TH,B1BRC(DGH/T6D72;\FZ22+6 .97#@@YR*1Y @!
M)[\47<@J!>82.)F1LQ0S-\K50")OHEQWX"-YXY>.+:-0,A)"B0[(OXD*R,T1
MTBII43LO)3BLP:SA(F(YISH3)U, $9V)2ECIA4'C;=80M LP67S*F:]G_'\'
M$%YIB,C\C)87FN!1DRLJR>H)RP,+.BG&K><8A(4I*D+4LLGHY3T[[R9M3\B(
MIIA%0U$$0R@$IYES2ICH>4K:@ V@!.JXP*VG;H0,CD9=O,O)TEET^!U_K=LM
M#_#U1K^73CB_UHW[_<K(4,E@K<A,24UZ$C)+CAMM D3+[AO@-[[M'] M+4^W
M]Q&O[:-P?L9*C-41II<="*6G\*UXOK?3B\P$&Y(7.22NK 8G0(>, 3&#]2XO
MB3-[)]I@_NYL#J9T&Q(FE!2>\JZXMN399C8N;:I!E['GT*G>0O<(_SB]>/D_
M=$6HXO[I2_R$W:N"=W'21O_P:#0<G\%G)?>7'F9E.,31:A>&PVO[J [Z>-J"
MZB..DU!U$7NM+4F\'_>?4TQ;+T/.I7**1PA!U,#VSX(HXH$HWR-*F0;0XS:V
MR2J&!EB$A)%<Q^0L,>9^$.5[VV ]$*4##J+SY$Z $2I2.)>-"C$ =YZ# +;X
MVQ,\F)X[V2$A,XO!J!)VDD;)#G2RF*7(T3')E+T?1%E:TS,[HCBA6.21G!2?
ME5#&AX0*998YI:R"NQ]$65K3,SNB> S!6G"(SJ@<2\]):SUP&YD7PM2@GW;=
M3,_X\S\@?L2T738NK5/& YQP282D#) 6*7O(4IRL8N J^@@YW ^VW*7]J3-;
M9% 6E&2.:TDQ$#B>O),:8^GE(:2^'VRY2R-49[8HFZS(-A!9R%5QQI?U:-JP
MJ#+IFQ#OA\NRW)9H=GY+\LQ8$P,3TBF!W+'(6%DQ4W::!B[N!UN6VQ+-CBVV
MU*AD+2,XK333GF5N&2\595ZC2?>#+<MMB6;'%H8L&"N%]$(I(HLS6I9(6GBO
MR=&])WG;N[1$JX/J<%#!"-<PC&KHN>0R$<2<M$E%\ES*PFQ+_TBA0[)SWW)\
M^6Q1O?FB&2269=DR0"OC('B6<D03N=$\Q'@_^'*7UJC>? &(-D*,3OF@3+3>
M)>TXM\'FS'EZF!Y:"K[,SG\14GD#P@<ADE+"@+' 75G#E(T)]R627G9[-#N^
M@!&6V\*7LAV%\E#Z"43F0EE![.&>\&79[=$,XZ,RYTQ!$85")2J*+J4L6/)!
M QDHJ$$M;-WLT<H'[,?3VCDN67%/E-")O%JE@W$QR;*\1&LIM;TO$P!WFJ2K
M)U$2LP >9,Y6*G0N.$CT05;29Y[$/:F]O=/\7#V)0@;'QJ0-RR:6EAI.!!%Y
MR$R+9+BX)Z[*TIJ>&=:U1*)=E,)0^*-8]@%8V31"4BSD4Y;J?A!E:4W/#(,?
M+AQRRY4%5 9#6;U#-DA'%#YI_U I]T"4<]/CR1E!$4)*9?]&;QD*5CYB0=#K
M^^&C?,_T+(JC0*ZDDQ$P,Q%(_VOO8[0JT"?T+C-_/]#ZGOY?&+1$3%PD)S)Y
M=2%:Q^CJ6&H-30P.[TE=X?>4\**@A4XFT-9[Y:4"0)<P%Q\\DSN>-=P3DWF[
MFG"&:T; @N".IT">,(\^^* \+^6Z* ./]Z3VY78UX>S0XA+*9N*D##.2%RJ#
M@QPLDLURWMBL[P=:MZL)9X<6HG/>@62&"85*A(S:F6AL2B(9/Z[\X&:1T2H3
M$!LT -71M57_._L5XJM!IS_:+KN8C$Z?=S[AZJ#_":M1)W2Q/1CA<.V(7&!Q
MJVAQ,SL/WFM'41Y3"2G<B];+R ,9,2\9!YT>ZKI^+-1;>.K,LM4'/:PV$:04
M7.7D0^"EAQV1*)H8X9Y09V;II/M$'?*T',LV<4B&+$39X2%!!&4MN="!WY-(
M=&8)IOM$'0F:&6=$<$PK"H9=RN.U=LE/PJ_[X0S>(X,UPQ4/F+A"@[ST*]-H
M*'K@PGIFP)5$B[\?U+E'!FN&Y3W<!&.))MQ(E062T\/!N:"=A[+5S/V@SCTR
M6#.DCD3/M0$NF53*.6 ZD,_#T/LHL [=!+Z)5@%G#-8>5H.OHV1O81)M0=.3
ML_-Q DN<N8C: E-!>V!26FYCL5W(''^@S,)8RT6A#,C2/@ TD24JPV( 94CQ
M" C&)\-K,%NT-)2I2R05G/ F6JVS5\I V10=4>GBT'@;("R^3[,TE*G+O)EB
MVFC&DO:2T>LR_<(,T\(+5O;QJD$$M324J<OD79(1;)31!"=54#*0KD'DAAOC
MZ(5\H,R2&*89SLY;Q<G_]3QQ\F6X 0KV&*(Q"JVQ.DQW9M;"+BIE_C@:=LIV
M?ROQOT>=8>=S?_<Q;]J#3T#_KNX]'U0]K+JGKRK8A[<08_G2RO:MPC3>WT_8
M&<!D')-1)Y5D:;S)F+?60M((*5MFA3W?TE'8YJ+B53:@VBKMW2?HE+>M3K_3
M.^K-2FX7C0E?;@OYF0O?W1;R\ZF_T%,>0@*3$@M.!\6C=IQAULDYE#*;'&I*
M&SAYH,UMTL:[Y(QG,G 7%4CNF4M*.LT@!YZMK]'.6HL.[CRVVDIH;-"6!U#:
MQ1" >2DI& W:%XN_^+N&%"6P.CBB'U4=TI"=MJ%W>2_#U=;F2C^MMM8N]@M9
MRDTIO8($!%SD6+9Y-D$)HUR$('AD(HN:;$JY4$#.95-*$C;RY81TKO3&Q@ Q
MBY"LRMK02PPU4+?? 7+%,O;ZJ-./N$DQ%%1I:P#I#C?DOA,M>[$1V/"_^<L=
MP(Y&U=-RX/S+-]_YBWD5C% *8U3.!V^BT*2LK9$>3)CD@1Y(\8.!V<RJJYPS
M3F"0@0D5@W&.'&[+([ 8**Y>X+F Q45GAK5O(3@2$JF9C\H'%JQT/$L!$<FE
M9;+^OLY<->M<W!X;$G<6O6-,DCYTP0/&7#8#SN!%5O5W>^:*Z5P\H,R0]*7U
MC.6RBB%XYLO,!T^0%;FYDYT,Y3FF\KYA>J.;;X]H\,O%MB/V@8;^<\+D_!.*
M<C'"\+8I)&].(3DS"L6<LC>>)<-0,>%!8D*;>5(INVA$;0WQ<XAE6]+3E^0P
MWGB?XAO=]*>RL8MBVJUPD3OF&&:GE,M!*>V%(/-.;WQ8X-Y."X/WC=*HBX(W
M)IN2QRR,%HH9]#KQG D4!L@#JT$M^LM!_P-AWBMSG&6_VZN3B&_ZP]*1 E,Y
M_%#[^>,$*?M':8^2&;"J[(0:B3(@(U=2:RX>2FSNFJ6+0HPD+(84 ,A#4/0?
M2(O<4FA(GTDAW20(Y&*!@\"%8LC5A]@B-ZMW6.957HTAN<J7OSYWLX]+0=MK
M03$7=Q$47Z0;$YQ^D6T<DX(._'"VT1O@D)+5*KEQWQIEO+%@=)!9684/PC(O
M7LY!/G>.!TLB+%<SZEZ;+$U,$*5BT3F#(H;Q2B.M@J_!?AD+0>T'.W!'NW4(
M[32I9+12!:X=N3$&O O!(Q?(%[_'Q]QUX (&/C-L*Z(C*BVPM!@-*GL>7 0%
M!D#8F%)TT^3IU&2/7SPPY4Z9<N.'V3X*0_SO$=UMO=SRRR&X=L+M)W)O:IVO
MG?H+UME@1@K,*'*GB#YZ#M%AX$9H$,P['0N=N9G.!3PHOGHHOLNT(M5WT_F!
MZUKR%VB%R4K('J*70C&.(6KOI<S,.!"H<&)&&1?Z@4V+SJ8K9K3H 3T#,QI9
M *$P"VFL$E*2#55>>I>L*YT*Y>(3Y#ZA)5&RR$T0RI9%3LXG+(D+DQU:GI2J
MD978'$="&_V$)YAV!AO#X1%6P_7_'M%#3OY>V[P'NMW)=Y9<S.=O-"C@(@\:
M)7#-%3#ON=(<R<.V,28V:<Z^V#KA@5QWJ95*XTV&G((OFU1RV2DN,0IAG35:
M)%DCK;2@L"V 3LCD0T:&,IFHHG: +OJL(G=*Y6!UC3!>)(_R1IE+^(CO]@==
M?'[43U N -W5_5+54*?RB/E3V#$NN901P"CE=.G/7;:^BD)GEI6ND_.T2!2^
MRXS1_2*L!Y4=2)Z"XXJH&K1P 8FA6D,*QDQ7J1O)%I6G)7'721VH3K>ABYMY
M>S2('Z^2]575^43C\ZH+<28E7Q>W/B\,'>^%\]5;;Q,4.%QY56'&BL1E?,JM
MSH^P)C--R691WF$2BX$Y+954&43($910((06/.<%7A_SP(W;7IV#1C.%RMB8
MLB*W+?!H0V"*)Y:X\7 ?N;$HV.1@HE01&-*02?!.YQASD%'&I-ETA[P[T>GS
MTEREI,8X>C -7/E(?,PL^E0J$UC4GD_7?9KINL^%-F_?UR-ETA][0'[0)9?H
MA[1*O83F^AI4<^,UJ%?X]2M+(J2 (()S'+)"QLCM]])GZS"6]$0=+.,#K>Y$
M%UL!2J-EB52PPB2!&22E! P2A8=N4D)0 %[<%>A?4&:2W5P=] X'?7I[?1/(
ME,;-0*#["CIIH[\*AYT1=&]=#7!VYPT_$O,)!$M"::VL$#Y:) ?9<L^,EES4
MJ*3S+R1P'(&_.@ITA<U,PM_I?UC&VL4<@_'('6;M5"+7R2L+99H"Z*47>8G
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MX V]>%CM[G=*.K@--?.+U]J]9:TR%:/=P00.FPAZ]7@SY3O3V_T.=Z9^3QA
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MG\/W@_N=RLJ("Z78D/(JTWRJ%VQIZ"3EE!QG=GDVP+\\. A,5,5*%('MPG^
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M OE":8>%*YXE">0 MPD5HM/Z2P-3WFO6?6.*[_GFW3:^[ =[B^ :%Z16/42
M87EWY92ZS&M7GP8ME [Q2\610^@SF9^&(Q-K C8/6H4WAV]',!BOCDJ D%..
M(M6IAG/Z#*OY6[O=J6[N]V0SZ@R)@8XE )LN-HO!: Q9UQQY$7F'LBGV!H<M
M.*?34MWPHE#CHUAJC/'=5!>AAH/]K=\":R[J'4?*=R_;Y&T(NZE1;J5'EG?^
M/9#)+A%WVT4:941FH^>K^@K\G)O^X:?*=AC AM).JY@(/J)#(O 3^3'^!K]R
MK.@1"4A3KKVLGN/I=7=;S8J:3]1(@[$KC*%"RG+FCB%*SDN5]*P\<-8%,=$
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M@/WJZLI43@JM2-@ZS,AGLS-WW*([/"??T"A]\<N39B"84'*)=RB0L!+_J",
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MMZ--EQ"R*I$- T.)55;8MZM.P-8Q8Q041MJ2U(A$+KV2>#KK)7G7& FW'K2
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M6T3$ %K<-B)F/9= 3SQTO_Z!EOU@D@INO[B#TY-U-$O?ZG9]%$,>J*:H5R8
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M$-(DYMW)S$O&6"K#V9%HI]\3YA/!PZ:,&*N/-Z-&6C9^-,^&2*%1 K"2,]>
MR0C&D!)X(@<TPVAA?&/PP@BH7X8EZ TS=.9Y)A5#3GUSPVVX83K0MG']7J5\
M8M7.-#V@AB@Z]4>EFK+-SL^:2#W(+=4/&027>V\!)CFE:PE'(Q2UTFF)N():
M4-@R3K(%BV>?5C),.^Z*L-[2\MJO.B.GMAW8-D7U_DR2L\T)"$[F.)2S4=TR
M9KK.),BQU;3LPV4ZF*JN7:G5N% UEK%3&ZF1H4JSI\0/*GC9,WD?F.^<)J[S
MND!H?L\Y\;($!"<\EG/DO-<Z,&/HPE]OJ8\-7IC;U*XJ2=+26)2;==D]QM!D
M%0T:'L4)L!8'T_94%\0I[*[9+]TDEEI3$C^&_0OGF$@W#[,D8/&A/23R8KF5
M)K9[[;^;,:F);75)'82C\-D'1T.N7A],8K]UUWB[K7N.5\G#D5X@ZLR14!,8
M[ &#=UN>K?$.87"K0=6FO-&-8E["[I6I+#I.A<Q.<!DW#UE#65_C'-I_=F5.
M[Z0.2\DT"'@VDJ'7S9!UYX1:B;JX!L%FF874I2,UP"R E).4-2LAB45CT,&\
M6:T+LZKWFKTAEBSDQB-(_JR3Y_70(@EP\4!FI"'=2CT+BU-AUV#&PJAII V2
M(DAQ&?DB=<LH#>3*^R0"CSM#X2[C:,/?G%&89'Y(@5 LPT@*>/2W!&Q/CNO,
M5=Y*!9V5X#]ISCZ,1J'<KT#!UND;WQ=L;W^ON;O7_1*LO6Z_>=!_?*R]+ORP
M_?A8>YV#9O]1L?;4,9;@H_"6VNA22U\^L X;!GGJ?)\E?MCN&'Y8<47=#5GW
M8^_:>S((@241QOQV[QZR=U<B34,L^:F6I]Q6=_T#)^3M;A/RUF(N3YR0MU4K
MGHM:<1^TRD?C[D_#PX<B+6;&_<7%<JC?7V"^(GSPCF'Y[R\9O^NFK9M(/$RN
MDVOO<R4"L*:;]A2H->V[6#=MX].BUL 4EE!KV@1;0U?C>:$ K>E^,NQ:"9MT
MNZ^/M:_45G4*FXJ=K6^I'=]N[ ,W%NY_ ANZY0&/MZ7LVQN,L7O&=E<?:U=?
M>_$D\@*13;\/X/,::K;2LWPQ]=*9YU,+:BPM1-20>/$(:NU7;LJZ::YG!>BM
MV,KMZW771]J9K7KZ4/640BAKQ42?]WY:<:='1/^]RW?\O-AL.5AWF#1=YUT>
M-!_-]'WT;=I@QON==F[+2!Z!D3QR0NONO2:W*I^UQH%LTEEWVB\?'-Y9C\21
M^C@,K(<;=R[_M\S,*&D!4Y.Q_$M\5@WA9?(T96I=3;$B%[M^PO\^AB*/O=GS
M22Z]9[]#V>0PLA)N?#OAQG0V?JP&A^M2ZT&9,,]M*?7'^7NI Z\J"#!4C:>Z
M@L[S1*8$<3->3^784 J0(@K=W!HSWRHPZB[66UN !JXSQOH!F;$SQJS)*35U
MQIQ"E4"IRJM5!KGJ5%S& 5>E"U:[ZR+U*4?V.]27W,EU;ZTBN)7KKDG5%A<$
MB*4*DEI2J9:,4$T_(XDZ05I,J&(QQUQ@0O-*XF6(?4KWPG=H="$Y=H"].2C=
M8('J#$*H(:45F88(L-]<)1*@?H'EOO"K;!Z%#)M E86%X!1K>NG_EU%50\V<
ML.YA>28N]LBF3%\F/^H236]3^Z7OSD[XD@HIE_8,!N>(6\!); R$(&\37X*=
M$'^\8L]WO)?V3R5.QH7*_+M F-U 8F; PQDA*WA6>W N!'TKO ATE'.K*?A+
M*@=%K%V=T><DE'R:3Y$D&1N6EJV^9J1+NT*,1W_MQ9\08 $8!VBFG"Z(U>^8
M,+R4-BB!8[$06S95E\W$\<AR0@GE:A*Y.Z.7LN*(D*;+"Z<E4,OT?(I9R[53
M]3 ?]X8ZF9<2&9>6T'1.2FG12R^[03)<8"=Q8/WRY&4G\%$2>\#K E%3_5T0
MDU4G6LFW]*S6ZI3Q26@5=^5><B8E3<!JPHZ%!/KM"[ZO.8Q&0,R$.,*CTQL;
M_$;,4H:M1EP+7#>=!:W4&E=6$_EP/K*C1BIF.)K=(;Y,OV:FYOY5+SU=):F&
MX>RUY-'2QDI8I053./M=.!;.D+6X3+GZ-(3,\-U0M[AGB<;D98WR;B@1'/EU
MA01RL \&CVU9.%$&*G(0JVHI-VE2"!W"4$0>EEEBOCBU';*Q 4HU=Y5UOANZ
MY2G#1*WG,Y,!2_M*@A56KJJ?X("Q#$96<W&%R@K^C .MS**7;Z [7F14Q_+>
M8WU@4$P*JA&4L)V<JRN")0U2G60*C'(BE<=R]K$$\EQ"R-#9S0@UR2**EZ +
M<G8R8%WXL_OB+AD$8!LWROHZ2[@(GR>'2#/5]B4V+2"EJD%@RA-!=0S5>9<P
M\? "G5/1 =[OD7G$NV,1KD:3+'T@MY<NL\8AIG.7QX7=%N"46N[]I;O2[ HN
M+KDG>>!;)7V[]JXMZW=B=865J>-_4.'QLS/%ZLT0#F4\M[6LM$,D+Z_8D+7&
M!'$$&<FQ&9]%L_+;6MWJ :17T??(E=[DK."J2B;?J R-;/5-(,G&5\#F%[4-
MC:2B33"URVT=L1Y76M@XIIS"R)-0Z31#?XJ(&@H75XD?6[:4EXWEL2++DWA)
M,%%9'-M:J. 2&%YNM?.H49*7JQG;>J>H!0?"$^,I50X7A[.:RQ'R+VR]U@3>
M<TT=76K645WG'9 -\&I<S>\B&N.6[;QX__;=[R]>:B9ES,"QT]Z]O9D4S?U$
MC%(+<1B'0P:$(*022(@AZI$@X.<\#M-D2!#.-31+8,:>+!P$=I]C(0Y"N?+1
MW$P%J=,WLF9:G;6$%JX]\D)3).EE"H.,:^HSY:OQ&55NY1TCR:]FO"%<LN2\
M>VY+>C1F679A5C$<;F5[U$K)8W1!ZNNDKR71E>7$=K7CTRUY/BMO!P(F\B<8
M 5VICZ86SHN-P" I1F"^!.$$;@?I@E6(B!N]">5JKV4-LFX'2NIRZ1NM)]MN
MBI5^"=:9*RX'[BU$JK/2K55IGJW<J>\,X('68\HI< J_"%%'@3-[JJ@;K4"P
M.WU4A2K("5JY$X@*!;]8J%I!JB'-N?S=-@JW(,E6349_6Y.Q%G/YH4&2L<U
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M.M!*5XQ -F(S423O#2L(N74"BOPT:'5-DIHU8.R:,,.-:7QC@4 ^Y907:YD
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M-5LHP<*RP*B$JRX 7!)1@F)+WTW(ND3%W.6.(O%RKEW*;'<P309A*.K7E86
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M$POC"N*25"\LZXIQ&_O$PCP',X@FK["4PN+^TF+^;B\> _MGGF7?+8'0#2
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MQGUXW!U_ZLM-85N9%9T,Q@@T_*:Y',)*"6;DG\$YAY:N<'#%C?3:6CU./G]
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M4F3I'[CS'_71 V>,\NVFA+._.IA-L:[)^;ZYGKO))IW!DID[Y\CYQ>OVJ=0
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MON6D(<ZUR(U"9ZN$L25'NYOETYG4B+JKG9(TW]\<U#AY6[/RVO\<[VQ-H+]
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M82&10C@!&$*1#TE%F-V+B(KX]RH(+(AM396T%(29Z,+!%["2%KWX*-<8'!1
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M/^:/Y+D$]Y)])Y(WO;(C!+1"S*!80FC6[OLJ'*949=!9\1.A5^-:/SLYQ.1
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M:](W_-]2^CPGSLQ!2<I<)7=TG1G($'8"C69MO7V#$"04EAIQTA90G=R(XB3
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M]%T&1Z[@"J>3K:<7E+23I2V[&,D029QR&BUS_C@0-S(]B>06VP_"05?"B8
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MBOJC%&*BLBW59X8<4-ZC+8D->\V]O,AF%) SP<C*>BQ(&Z;U\XOS3Q:KL"#
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M7.YUL-G4U=E4<!"S"2N$!&MOL![&K<S@AN .F#2A;IJW(D6X]9OM79GM-;P
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M_UXGED_[YL#> NZ+K.ML^TH!Z*B,&PLGU-Y*X^(YD!<(G<2Y) HL+A#VA6T
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M4S6<9\^9NMJ['S$!XV0R'"QGZH<W-[_-AB!,R<10H[*[Q(QE@N G6MNET9#
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MB9-\.6L2<OKB-*'S]L("N)&5YOW1C64S*V50E,46 L#1_G\/3GE&/B."F'.
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M7X5(+V3@_?@#,W"^BKO>J$D!76:^Q9W56;.#\QF1X ]@RH&P_0+[EY034_B
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MG;T^)MD :[&,R5XTLMN:I]B1;R@^D,/XJ2$YJ^GKN8B?E\6F'F/W L67H>#
MIL6IJCQ^.ZZ3=,FR$AUQ>,I90O?13JC.R??B.F,W8C(!:X3('J@SW40:K+T
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MP.I6$KFL&,6=3)>(4+K2J]0HW$"V\'>$K&-8_6M.9F.OO)9V9[4'OW^3$D0
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MZ$/X=D]M>0.!O3.<FXC@ZX6VV$MM0;2=J6Z0'6?_^O+8[\QU7ZKN+XAPR=/
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MXPBMNCC-\&95(S6DXK<JFVA^YB_Q@_'/62T2;3YLDH:F!H^&ZW[5+LCK8[_
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M3^" U""19A$KHQHV,#U]$:&,4*L)*FAK!\99%3<3#'_%BJ?NC%>@)M 9P;_
M^#*NVH?S@7MI3X$%+HRCJD*L.MJC]#[2SR=(<-@1$";+J4\^LJ@B/$.!>>VA
M6^L"2W@@NPPJ*$ 3ZE:Z JM@=;I8:^(MO2*L;!!+N,:GH! =_:UP'Z(-L0^8
MH/M0N3B8#W*OM2'?8[T#.S[+G5$,\=+R315,=^FZ*WAD(BFPK%)L0,''5P=]
M8."M8^D(%U"G.YUUB@@G7\AKO[_3_G")^B;B<_]4' G43Z2D+^1^N.#N8]R:
M]3@OV##LW4.2L<VHPYM*+K5WUX&\;A>0*[18';B8F2W4;7,!GY:G9!GC-QC&
M"&[Q[W8.![V69\KUXP.Z%10398JU:%S7C*@X J@9Q:ZAPQ/R>#<,,!+:-M+3
MJN;J5C3;.N%XMM=F>6R;507O4XVQ#&L8$!=%&J:S8@IZ?Y+.QF7"BAPQ4M*;
M6I#'0&(0I8@+6KSQUUK6K&]7WH+.P?>"#W)G9;4S)HO/*D\S@"W6:LPX HUQ
MLBTIM+$%&0YB+G-:F.'P8ND52_-<4&&.J@R#(2P$WF"$XDJO"Q?G;%\08AT!
ME7G5:MTIZA>#XH?66N'JS*$*FWXKI#Y3PB*(G!+SZU3_;"'I'.@Y0J?KJ0RH
MP,Y* O+$R!<CJR-P#F'TWF^#%$O/G @4%1CS'P9L(.DTLMT+@8T(P=A2Z#.!
M[(#1($9_6L'03Z@62IEOO+L=,=,).H #I[1_*2>1V?ZI&?8W&[G7((-6B4U(
MJ^'03%C[>)2FBL+ "V*L1]8!!)4LOX(34J799-A4-:[GUC1OZJU1]BE-MO Q
MYCLA@RBYT [T*7J9(DCK^2%3G'?"?;A=<Q8F1^)E7W6!$F^'O2]9#@/E/>-G
ME$5+!DS"*)^+6] E#A$BCG"0TZ,C -VBY]?;R);?8,/:SA?$C)6U4KM!'!.N
MT"3HX%@>JPB"!-<<@)W;Y'(\HED\WFJF;-&2EA7\HIEC8R<$0F8.H18AQ&D;
M)DYJ\YQ9$"*;Q^G@SOO)7* /M!A^)3_.ADJ>S#SO@JZ@Z"FG'7R$L$72"PI&
MG+Q^6XO>DC/69F'Q'U-65U&A!>46(N$4'F,NXE;A?MF)=P)'BO%&+4? 70-6
M4 &'4\*Y+/QO2Q>!&OZHSGE*QH6C"9=YSL4RC85.,(!Q#$/-(&.1$M]@[PLE
MKYL9VA.*#<:)4$*$1,2VR3!-T)ZG> $'>U(3"<"!TQ]J.QKS#6$Q@GUA,I-3
M_(>S!GHQ?_+O*?5OQ=DG;8;KH'"10H)$6QP&PA^ E298N93/#1X]_10&F6UY
MEY5&A\TN-CG*:FE9@+ZL]KX2.+< _KYSB^8OS2!O1+DYJ$$(Q%AIP(J?*\;"
MLLV1=PUA4*.,G7*.%K2'SU055,@HWZ%->6EL8+[=..0SC>8N$*^[G$A08Q?<
M/(>K(PO)E5/D"P5%=LQNV#!E",J[OHA8N::XC""(.*N,D(C4Z.[$UNS0?D_M
MY49_0OB]&*_ G#%Q^96Z"A32\82W]J]V"\LI<,'V-@:%!I=*67 LB/G:3%^@
MYA"=:3+;WTTKY#,W#X:O\2TG50N,]C1E&_L5\?'8,R11,W\VA-Q$2]4?H(4_
M&]=H*-ZRTBT;AS_EQ3))55;<"D$^% GJ5CG::AQ2HHNW'RRF"4=%6Q82-838
MR)-C30EMA@H<(1K8(>/<:%L5=##M?F#[,>PD&, YK$HAE"D]]::Z%]]"5J?!
M36;TV :OE9CQJ+'" Q:AO*$%@,<0=$S2>0S8YN&LN)906MY"+ZH7.%P;3IQ:
MK"9:"*.<EPN-'B;'\J,MP.\B9B,'!.F*-)09+*?>\:#3T?GJ11VU])6<CYCK
M29#'$848$OP0?FW'T8#5OW6*SIE(S9'XG16D%S-S718G%T &H-Q'$CO3 Z%!
M NN0.;</*[_CRY/@<'<0M@()NOWFCC-0Q873X)[5@70,46-TI )G/NS8J*J?
MC84B1"]\N?@CQO"_G(&(T) Q]JO]]:UW;%+>3LI[;P/8L1)C>2;9ZVXIU--L
M#C&9T9;OU6#[F@MJ\29K!.38MW<6+D9^D1-L#(W!IW9#VP(2F_P._^2N0B>Z
M.1()<Q2FVC0 6T%M!"YBW>\-6G4^^M%%>P2_L;O;Z[>^@#-R7M']O<-^;\>O
MEGHR;O #W?UW5;KU*R=ISS4S^V3F>C=7@\)M=_ D6=)8#=_63G*: E$WOHO
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MU2 U.<YY.M/:B.LRBYD:SLO2N.43\A'JG+YV>[/D^<)CH!/ B)SLA,-7Q-L
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MG:;!FW*6!KNF+:HL:->I.6V4%5%!?7GU#'XQD4[ X%U4S8+S\S XAU\&AV&
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M)1ZJQ,.Y,BR?;EA#HX>!K3L!BRF\P>H^Q\-B"M(W53)B95=8NLA=B&0A+[O
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M?):<8 !HY(4('[#3((2Q/Z=+,US$,#L64/8+"--\8^^D]78,/X^<<.3 #_9
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MW2L:W$J6#UV @U/H,:ARN6#U#=Q0#!!XQM4+0X"T,S&$%8$*Q^Z$I 0&TA9
MIJ9H=,B-6,FWJ!@SZ\:#DWM]GVX[_[F%X2QZ!E(CRLS*)K,:N#?3BAOX.TY'
MV_!G384*.&>G)C*Z^Q*"9K7XZ5%$U-^=6G_/JN<Y#P@:-2-8A_>KP#M0TPZ.
M#XH^)D4V8W>24:GQ$3_[",Q"I5WLEZ@)!3C,S%3 42MB<E?L27;RA]RY,'-
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M 8C4]&'PYO<SC_&_OLVK MU^ HD</;*D]7="&R$*(6'*&ZQM/V6:!91I*\H
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M>+?PRN1XS\"!@SYOAHZ.9$I[.J4:A[_3@&F&_HB9NY++P_F%[ R"SA]OBY1
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M\KPNI_"4IP).E'R(3#K*[2[:CS2(Q$ >)**@*/6?L\Y/L=.3.$"/-,6[0$4
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M#E/[*_W![/T!=O>_9D22A*;G@6,549;_+:BK2<K2I]/4'>XR=4MY^8*-17G
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M5<M::R^3[4@\]&[-G_MH[.E&4_\)2E)+&H-)?=:4V@/:2V:&\:;J(-M_.G5
MI'PM^XY:1-NA43RBJJ'9T%OM5OO-;;/9;C>Q,DL'(X*?\ZO<P2[,%"X=W+>*
MFPZXT2CSTQ7.J4BJL?[*];J;T^%3-VK9L@:@C;@']8O3F\J3LZ$P9B@84S#6
MTEL-H]-J-0#&NIV.T?NWS49ZR\R4.,AJK"=%L<$$)TXXP!Q3>M"V>\<7$UT
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M^1]J<W,MBI3FM%F:DYKDL..:D\B':/1:<%S?W+::>J_=%&>[4: V'3J@+T6
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M0>K0/L4&*:FOI/ZLU%<U<+L7/9P#('HG R"=/(#(=&QJ%D16#$KN NNFEF@
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M#6CZCKIH%9H5H9D,;"(NY<.:+P=PN=FFW0?AVXKM017*;3O*&3N*<KL5B"I
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MM;&F(8,SV-]0 ?H-!/@*=*E6 %\U!,N%,8I:_ L ._%M9P0[25U5Z=P3Q)3
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M*U_O C(54S(9&2[MS65@:M[Q6@Q3FT"69SET3YNE\J3.WZI?6OS.QC)EFYO
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M).:4*">DJ8V8C9J:%J;#.UWS+DS42G,R@;62\R.(06/C<A6_A>7&;EYL9R:
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M-R^RH;28J[4VC=(%K=;"H;BP4F=,<V_')L@\4,)3W*NA9+]CH.J8X?0CT'!
MFU68LCFQ7KSXKZA>N0[(?$[ES*$ FB*5@'(95ATF4BAC85<:"4KJN!#I+" &
M%6* 8D0*2Y7?HURGMN2[<(CARA=Z@L:QQX<FBP'-#JJ$XFL3C@\)+ZDMH3*+
M1UBX#OB]YO".0#M@PMR3_&!:T.6^%L*-W]U*K$HN6,SHK;:GOQ8.(@X]_-"$
M>-_LB:2'(PPF.#1'B:?;[QFOX6C>^NZMP'X2MP[Y.4#2N2[SK@DL0/_^SOU1
M^% T5USV4_L>V]?BS'"]5;Y4YH@5;X3MPWI1A35=_!-E#1HK8!]GCI!44!;J
MPV"0F#_ 'N*FQ8WO,HZ<=UP_@>?4$"\RZQ/84+PX8HR:..OD8@!E @PM>-S,
MT@IO@$C@9?%M9J=\6*8#&.U$<F/KLS/4Y\8I51"S-(AIJ,'=E5C+LX4C7[Q<
MN%/O]%L/*1?6C7I7?_H!W4:]T>T_>1%RSZCW&JVGG'G]/!U!EDS0 <6D"N%H
M&@]X[*$#R0_NT83D9KBMG2&FLM BI?L"M-/@EN7Q_.D[4JV'*"4-F<@!-LEJ
M"USG7&N')DZA*L;&!W,C'7F?K*V]:G;J77X1K,451'8D(R:.7]!)LB[(6G()
M.3T")OVPPK$,JA%J.".@=$AZC<=0AP'Z_"),1N.+<7TP"?J1J8PF(UG6\B2X
M8&"Y(8_:I>$<J6JC^H8A&W1VWGF9GY&6"UH[<\AP9C_1090HUF@4@PV,"X1O
M'"Z3T+;$%&)?"TW4#=&^AO_/53"*D]"+IL_X3XR^9G+[ &$8/[+\EOQA0IT7
MRN^'3'[RPOBB? :]W3Z^')JN\/A7K5:WWLGO&))!>-+A+W*J3>( 5/.0"4N!
M*_/\!GJ[7>_G;E!NA99R]0*5LCJG 35NY)C4#? _8<9+0!'A%&Q] MLHN\N)
MY9.Q;DS>@R Q;8"G+#,.N2,VO7F <7GRH'@Q;C,RQ\CD>3>)&6:.1IQ;R%<1
M_&!\$CBH2IX_YKT39"3!CR.<%SOEV!6Q3PK>@_T!*!6[9L"/>O(^=$O^GNFK
M 9Q9B2^3#C%F/] ;XBG(N%4H=#01P1GNII'64<+M-AOC4V0:_K3#& PE=!^&
MM>S-,I&96[""8/N2ZUUG!-Q[;^%1I.<0G9"<XD&$+N,)B_B*Y?T35VM*H:+#
M\$0\O^7"]P__#AU= ]L68>14_"+FH0./3MB+R6*Q(R]*LT6.<>Z6EC%V3!!"
M_S9Y1(2741#.9GBF1.X*P(3X6 0^X3QQ'@=N]H0HF4YP"'F&0YZ]Y^-7P%5&
M[N@-P\SI+0A*!NS6 ;H(/:L$ 3(Q23B^MTP&/*<6R/T_$7\7"N585AR85A*;
M<BB#ALM><N9&&.X$<>]/<D!:SYV[["8_W[:6/O*E^ J/5A+/EB*GR%M?0]\[
M[*:/*DI8RSJVQRRZ\6U8\#7H*%.XBWYZ,S*U.') *>.Z'?FB@-ONI:<ZY:(2
M!8J+ST2#2H0IN<=3YB_41N!B\NMYY&5"#A!9>)2L '<&F1IF! L\^<8)4>5$
M5UH4@ J5_0'(U1@^G]$<X6>S]\IJ9EPVY@ZJE(,BD(KZ8)C<)4='Z<$;<P?>
M:/;@X:'" !FSZ[,66VD]PM)N\P6*6&7=[]AW^/F[1)W"!VOO$?59]HARSZZ.
M[K[]&K1.?YW\.OE^W3C]]>WNV_?/^NFAU8 UW)]>?1G_C5VB+ON-O_]UT[#&
M7SSS:S\^&W]NGUR]_WYR>-V$7\)S_]D\_?[>.;WZ#/>X<$X/C_73KW_#:O^^
M^=<OJW%V:/V[T6S:K;;=W^\;O>Y^BW4Z^T.KW=WO]T:C;K_7-ZR&_=OO1X$7
M1MP8^&]S/'G'YQ%KGSZ=3S=OVCP6D\G(= QMF10[DP$D=/G000<+<%2KTD&Y
M$G'U["?ID\\C-CMYFJ[_W6ST>[K9-_:'/1M.D]YJ[0^'?7._WQYV6I9AF;IM
M_O;[U7U(%M(7!_G$,9<^0Y5AI.(\4A4ZRH6.FBIT5(FUJ$HV5<FF*MG6GA&4
MJ62;KI/@WH"TMNU">O"K_);+E;;)G=-PTW:[(H67Z)U=GB6K+2@E6UC:-\;\
M<G*DS:L@2UQD3T_JF;>H]%FL<)G6@B+/7*F?JN=,ZCF?N+#+C-*$6A/CDYA<
M;9)K"M/4 "4F-U-9O ^LCJGR,=GFDI"9_4H]^AC[3BH\0._%5Y4 FXLTK *C
M(KI'^=H4K<]FKB^,793?.&%3)\V'3$K=GMD)OV) K* .3*K>#]!^UL$W.6H?
M WAJ_<&35 0MO]^S94*J2FB+JX2J6B3T$ S$K/U442W54S=P[\XRVR4 @I.2
M0W\^LKT2OM>$M)!:!D4.>?Y+2KD[9OX@R<%+=FL4()=29ZI8A\?1N;ZT?.P\
MK^B+=#.;5C-30A5B:11%5+,A5RH?(OW3L0F)/(;!3I.RA+CFZP16/$8J66Q>
MC9 L$0JWLT8(^_5ZO+4'$O:3 P9G"H8S8O)L:YP$ \UZL%2D&B.9I<%9G LS
M64Y6"&EY!1X,"L=,*X#+M#@R5 )>K2)2/@NK?WAX7[S ) XF?L@*:SZ7;GRB
M/8I"')A"4<8X 2O0DN)TNNAQ3W_-I?&$5ZY+L4_@S3Q:.KPVC\WSWY"=G"&R
MS>"';DWDK428S$<J,'6YP7X[+JD3: ?"7H2FE4FM<$(9V4BD&R).:@ +*KS#
MZBJQT'G;S%LVY!Y#*@_/+$!D2K$(689A:YJE]O@1NRD-6:HQM9@SD<D4/U'Q
M<B+:C?S[TK*'C*<?P<OZGENH@IDQ['&0]49E;!M.8>GWG28HE:PUER%J>G:
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MW5?":>,#$O!"!Q"*2<AJBP+%+*52>!F5^.M#YY*-]'V^I;J1UG4C22>,H=9
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MV<2"@N6FGV1E!WV(XIWH$*_K]>]!:8N@1#OEY#X='!]\.OQTPHUQ3@E%!-<
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M?%HBU;U\]?PO$!81=B;3F;D$'KX "IGB=SAVS.^&,77)#CG^#$ <L!T)6I7
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M_NVYLC=X&@3AT>5PK95D[<L ;H-L#&(T(!]@2#N#29.STS4-=!.67V,,N*Q
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M2#\WANVF5:Y_W7"Q$(G_\+\FG3DUP;4AW=[X+,3C+PT"*[U=7J 1!H:Q0*9
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M/=3@,^G6&&NL3]CP'+.P4>1IH@W"/2,[G6(6 C9?J*PIZF9>B':^4-[$:K1
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MS'!9F"0V^>!=Y0ZLNZ OBZI(*RNEX"9_^Z[YV^DF?_M1K.4+YF_?F(^]Z 6
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M4A$[>2&%U],P[[Q:Y\IW"%?&7CMAYU9<O]7;!85X6(Z;);;5GDT&?Z>+7Z-
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MDVS'\M3- /HK?>;5R)QJVDUM[MPT00?O]!L.BXN.>YR:@Q945*3;"8Z[9V=
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MHN!W;\1,A(I3:W?5S'T=P1C;E[F6&-O8/O /42L(A,318@R?_LVJ;NUB,YN
M/A%G#$C=75V5^51F5N:3! FFN* !EL+$_.M\F0$Q9R^ 1Q-3BV![;Y_7+TG(
M3EL9*OB?>B/X'#EIK6@?A':1G@37S^)KP955WG.]=GN,PO>"4<YS373P7IK
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M07SL A+O^:WE!P!UZ[/#G#728TK[V#Q/=^G,]([LCH(@MS&M56:4%\)0V##
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M\.,Z+=WKG<=#B:)U4RK0.B@EX]J4DANGD#RGO(^<K^=Y_C"M)L2KZXLQ6E"
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MW-X\Q"I]K P/+Z$>:(RR4^(*YMT)C!]N4.IRTAT]LR\M01^CXU8^/.UVEB'
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MGNH=TP:1[(+:QJ2.X.,-^L/?-SO?RLW*VYD\W?N=ATM9J)804:VN@J1IBL;
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MJ"\8X%1QL[/O@M\&&]ZP %BYS[W8\=I/65:*>QE\2>\*7I[]/%A7S7*=6A8
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MTG8'!:P/U?M/\*_,DU'>TWXS7ZC.)@O5[V@%8(]H!=@>$\_L%APEC_G"B4:
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M%OL9"W,6Q2,^[IF+VQP_\'=1%W,7@H_,$D&XQ<80+D@D3BOO S;Z@7#BB"@
MH+*(([[C^&&#[A^<'/O$5.(T(A%E#B(ZA6P(%EDEJ"96"E[,%3=\4]X7/QR*
M\RC54$Z)'G,)/S)IN[CI9 F;7F4=%@L!VSOPQWGI$O8.@65B$3<6A( 9A;QB
M*5(BX&>VL;6H0*)*,+QAV8#K[ZX\P;#P !O:/I-'UQ//Z!SNRYP[U[ETI?ZR
MUD)V,F,8^-RCX[)>NL&UZ\Y5*X!=F#VUTUBPA8WCA4\PD0:G-FC&R$8JB/RF
M'GOQK4S7ZL<<IBU;Y^\[S:=I+,BZ1KV&#GU9]?=_8CC)AGJQS>37VOX_A3WT
M\F&O?',+:$3 4#LMY,/-1B +YWT85IC<F4&$96 BWVV,#2\[#"X- @*C8,0X
M]O5&W/Y)&6^6A=_A*64TL[5D*@0<P4:R*O"@D^:$14^ITDH*&MB3RXNK[OQE
M%!J3QMGAL02S4!*P8X+D#'&P9I'&0J-H$G.$N^@=S5Q6]Q4:W]627[9HEO0B
M18YJ'.2](WKT-$()MCI"B4IDUU)DZ?[.2D4V6U<K)9#X+KFJ""2>4LI^T[C]
M=&R2QT()@TB*$O&D<H6L2RC"@<=E;K+3:F.KEZ-D3R:-F("=7'+1M?GD1/D4
MS4Y><X1B$P=F:2#>12YQ$?NGG3!M6A8!\]'9^R)!\PJZE@E=(ON(3&F*G0&L
M4JR@I&#(><V0]3C8Y+BF%'Q$O&GN1:YA['R6N.NA$.I#Q^H$NN54#1BB""Z9
M/8A'C8HL=O3!BA\0O8U'V<<KMWT7DV:4DY?HR.^Y#\TQBR%D'A<K*(=W.VZP
M5SIYD/= DB_I@ :JMI@.Z,]N3#'K>!%1.8!+_[L%/[RT?IQM#_6#-KY^OCBZ
M^/OT\.SOL[W;3_CHXL/9_M=/WPZ__G%V=-9J'NUL\\/;\^O&;[/Z<?CMZ/>C
MBZ.O'YI[7QML;^?SQ>'7ACC:^7 *^G6Q__6/\\;.Z=G^P?;U?V[/Z=ZG8T<(
M44Q*I+14B!L&FL$U1DPG1IU(*L4P.W]1>IL8)I9(1;G38!L$+KT7C$9A/5<;
MM0B@<YDK%;M7<6-KM."U8L5G@?]M.'!WC+9\:*EROO>/JW9QRN%I:I4B15<4
M,Q455!-M6'_!+<*=;T\QS<RL<NVO*Y?+H<JT__9)-Q9%#_6I?JCYF0<VO[$L
MILB%(>7<VUA,FRR"YD6JL';9LKX<J?ZT%B=C>=*6D> TX2PE)ZAV$4Y&(6QP
M4A8431A+AA_H;)K6X<DVIE?2Q?3#M?WC3>/D.,%9$7+T/!33T56,R#*I$4L\
M8!Z9CPZ."LYT7>L%2>5QIU&NM&G'ZU:FE^V!-H[&F#U!0NL399??$UT/,F#O
ML!:,,YXL=<E;3KFE5%"2DBF%Z1%M<M/"]*?M[G?_ZN<G^CO?V_I%VW^X[#2^
MP4E!#4\1[">DH@W@ QJ#=.X!86#R&D633[G]XWM:O:0 V>-2^9"X]<81KYS#
MG 0<B#2VVL>E[J,F%@<F#0K".L2]M,C(X)!(X+YD6R QD0UB3![!ES'.5 Q+
M(V>4?%CF42_;TV?8^;\SKY:<](Q[BZ,TG%FC1?(^.>:9#P(SOO@8F<^K31P;
M:YI8^_$BPN"8T!X[$0Q'TH(=S<%A1=I0A8A,DCJEA#,$C@DA-M7]B?>"JSP3
M&M=.NIU>;UP>^$0J)0<'E-0$8V$)-QY (6%O0IXL@[TPI+#Z8<-+JW]NYQ_+
MEC$-(.!KEW_(Y?W%7UZ)I_W#A>;3M[WM8QRXC@S0!#Q/#K:%!$]"@)4!:HIA
MG[0N"#1@<Q8$":=FS&S6=L8C4E/G*@\4^;]7MMLO6R-*0[F8$S)!UC4V36;M
MX$EV@D&$<0&!X=/L6,^H==1IP-+$(\8:$\-,4CKZ'&1\O.DQ81[=;=)^N1PV
M[^?L:F7@+A;"+[>9Q45R# !!$58&#K<D.')4@Q!22S436%DJ ;GJ3(.)NVB(
M^5B.IG/LE:GZ2J2 -;8K4_6-[.-J3-7Z,,LTKBUXBBVBJ.4B*AS YN0Q,(ME
M!+/$8ANT4+JD_L-@JY2VR ,5\L7^ES!?GGI_%J,M"S$H7AOT/NU^BUW?[,4
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MML8E%J6!=U)- :/-;-IL<@N&,Z:&D\W>3P;MX56;7N480:&ER(7A@3-!;#0
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M><X2@BW2R*5@$!A.020;0;+ "N7W5$;6GQ>D>*9U5$G("B5D;V?WV[$"%P=
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MW*^T[:;5>:C'5XLT?SB8(9>5QM[4 +8G%R<G,'@T@W\\5MQ) 2<TG,/2B=Q
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M1@?P!7"@+)>S=-IQ8%!,A)<6IS("YX1X$I+U'-P*'04EGD?B)0WZ\>?+]R!
M\<_?I3"4)PQ9YX$(+[[])_28::RQ-0G)F-M%75+(X*"1L"IZZT@03FQL9;:[
M\ER9/6TVY[(6JR1_\*<Q7.6A<R.J(?"T =WOD)A6JU-.T-Y/GT<$-Z5@%/FP
M]YW].C_&D@=ALDW!K0?<IP%90S#2TFH7HG7.LMELUJMV)2;IC@I&F>* 0>5
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M83A.-< LU77,EI4Q?7F8+>(@_RI8"48C06<(SU\ME<3]X0]?#O0K>$-S_G5
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M-__1 KA!H%F=%BSCX(/H%+0WOZ'=";%5N6B<#>XQ=5JMSD61@WNC5)^N8:Q
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M[=KF<7X.?-#>O83K-0^:/R[@F6GU,]S37O6B3L B\>!,2$$CR;(+S'U"1MF
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MH#S)I!DU/L0HB-3:L.FQG2G0Y'X-3>XIT+0'.TGN''/ T_M/X;R;M[8$ID<
MT\3XU'%@@GO8PE6@RS5:I]7-75S=K#7AN>$9O*CM?3N":[?J=+M9S1G@$6P9
M&#6*<)01<6\,L@$'1'CDR@@-OIC.)1]XO+\B>DC^N'1)!F8(^&T\$66HCX92
M3F1NU.=)*7^E_&7Y8X<Z$1 /[)#&6"*N D&&)HF,3E$&DSAF:65=WB1X7_?W
M?+Z[]C8GZ!_)GA JI5<X@/5@7*OHI D14RM\3-Y:,34B4^KS@NCSPP4;< ]5
M"M?-'5TOJODP8/.8[VS"ZY^KY !([L'G6G-G\X]&84^$(T[%Z!%.(A?F2X)T
MP IASH,TPBK*5+8GY$GV!.=T&JH$#L)Q"1)'5 K"8,FM892S4OY*^6L4]H01
M'+'4!"7#..(:A- QL">,"6- BC!XZMF>3,A?:4_>TC_QS,EHDU66<L&B,\$#
M6Y16":\\B5/C**4^+X8^_Z+<HE7=_*-=R_??A-?[57RPMROJ[2^7U;T_CG,H
M'_2Z7_N\?U&<.S$;B-.&(!(#^"=1<F1M5,@ZDKC@)CKG5];9FGF2/8G$@E>2
M;!+><T&UC@)S)S&0&68TGA['*^5OZ>2/':JH \A80C9Y@;BTX*D0Q5&PECDO
M(@;Y65E7:_(1]N010PL6N5G]6>?,MBKVQX]N_)&[RC=.SKJ-DQ[HWJ +:6XX
M>C%LBH5&/4N[L6T;)[F/>U;0'/(\AR\I(GX3'>^O.Y9V;N8A3VU_/^@MCT?_
MZN6O&C69'K1A'HV$O>EP?UDTRV]=51[L1#9V'B"$(<H[AIF-L##21FJ<X0!3
MWF-K_/1!*TB^XH#H+Z-5'_88>\SH*[F@R/+\^1-55MO<!^-BJ5>1HJ@I ^4.
M"AFF',+ PISP+ D7P+A,1.0KH$&M+!I9T%Y[T,AS[<PO9X=_':G>GS>:EPT0
M_6@&Z$5BLO?E4&CAL8H6::YR>U<K@(-8C[Q@5#ML$DLXVX )GV)P8+$*(-?+
M]KWQ$_!EK?*V6'E[*/:[8J6S1@OX8I!QQKDS6G/KL50L5\XF)0NLG$CFN0<K
M7Z 0MZ92W<5*4H+E/5H@:OW=0XIU3(8&E").B&.AD%.6(T)UTIPHHI-969\\
MOGPT6";/N:<F*!\M%T%8JH7DC!%#A ^6OV:0YY<3R^X#RP_'UE\B)L#0#\'Y
MUP0GB8@%6>'6&>0$_-/CF$-W--!,F.4D89X*ED\8Z/,K=DST:[+CXAL_-0#5
M&_[A@04%7_X:>P ]Q>EV,2FLL@_ V;O[M*_#*TY^VLNIT\MN:\S-[15W5ZA(
M;R-O2N/LJAQ=ME<_Y,F!\R=S7,(#&FJ>Q^UAAJC%W*H8I63J8XTBNQZXU0 6
M4.F=M^$1KC);^/K/?L4.9:,8 )8)1E;F2KPSWN<NF_B@L[H4AT_*V4^4PFN2
MW?_RG(V_RC?[N!MZ_H2GN4M7>O1\IWFMNIX^6F<P0AOTO!@>4YB+WA,>\A&'
M(8NU'G_#8A2K4*S'B"6BXE]#KEC\GL.\E<*O6+K!1+="#@7I/S_Y"7QB,(CR
M+WMRGNW&T K<*TETAM,/ILZ_7J!!S[U"Z<;+-S5-*<JHHR><*>&$\IQ(CZD.
MT48_W9V>95N#K?]W#A;_RPE0Q?/\Q]X.&/[NWI$]&7I3M<YPXVO#7.K'N-<+
M/@P!5S=#L[ZWBP_:U?[.9CY=V*<[FY[4-O>OJGNYD.6OXYT]SZM_CI]R[%[D
M$LO:9BYNJ7)XKE9MK\YK_7U<V_MR6=OT<-^[X(K_N/B__M9$RR#EM*8VY(H7
M:Q '+QHY@BVB 5QUZ:3&R:VL:V)6-9T<A_#$*=#/F#_RK#'/,SJ!?UTDF3O\
M_>]7V\<G[-]<(>@#H]N>!:.S&QWS>!!=FGDR;P>AX[.@- @ CPHQD;)/3S6R
M7!!$5>!<,ZRCE8-*(C592C2G"+H,W6IN!=,&AR!9[W\]U_(ABCEE%3XDBS12
M,LRHTYYHGA0V";N0,_^3)%1$]X9=)W^)A'?':Y5L<G90.#G14BG'!&<.F8 %
MXHE0Y()6*/)(I:*"&L4!"E>!<ZX:/5GR_T0TG XZKTH9?U&S_6)DF#N4?#PK
MG/:("PIZ]Q._%R+?&S+ )1TK^';8-T8#=12YS$4A:5P>":H$,CA91%PD-@HI
MM&,KZUROB<G^1N^'>\L06+R'Z W\HY>$$A>0Y_WV<8G>MV(_2Z(W>[";F!=W
M2&7.?P\)11$,XB8*Y*(BB 5B*?C"C%J]LBZP6,783,#=1"W^$]%FGH."'YGA
M37O$^8:[#\WP[@)>R?!F#GIC#"]1;8R+ 6G-(^),1V0B3\@'+XWA5">5STK,
MFGJQ9SM#W%OB4!XP@!0;RQ?,^\ D;WNTI27/FSWD34Z4(2DX&@'H0!1"KHN6
MR'A*$>?,*NH2<SJLK!/)5BF;S.%^/,\K(WGSQ//*2-Y<\;PAYIT#<I<D;^:(
M-T;R) \B),T1!DH') ^VWRDJD6>,11N\)5:LK!NS)EZ<#E.&\6:6'SA*%J^P
MV64(#C._&6Q)Z)SG//+1,RYW"J%B0A*G':,^ 0\0UFOX(7 4S HE[?3JY3*%
M\&,@YL14B$,PI"E2FB. W"/NO$!:Y)ZZ*L1@DS96Y0J_5<SXJE!\MBDP,U#2
M.0\HOC(:S1W,/S<-<18+M* P?3_)?1Y6EWF*'P*GQY@MX9(0RL&=8?G,1BB,
MM&(:":-C8!HG[LC*NB1K<G)*U*)B]"-ZY^1_9YUIG)P74GVGJ'"H?QSH/JCH
M::?7R&_YU(VY5_K/^/NH<JU0SUN?&SXROOF(=?!TYV?W?V0.&K 559O;J,+8
M6!NB6S^/NC<%6#\B<MUHCY%-<+^?;.O"7O56_G.W++-Q@NZNXO@"W/N8*;W:
M8P[$"!"OTRTV_5/1XR*_"^[)SLV]5(ZZ&<;_JR&2X\Q1;61DW$7J2"(T24],
MDE(Y>JA6UHL"ZUQ9FWL-9*S]G__8\7Y2HPKQVP(_0%-AL=(^.3 -FD?/#05>
MAYG500.1X_2E=<AS54>_U3YM=:YB'%;1_WW>]4=@NHIF)C/L'?#.M==;__S]
M]TWWE9\#3SE766<C;D^NBL&EZO?<]>4DMX1IQWB6G>M15YBC3@L$L5=IG%3^
M.C^) QM ,6&#9C3%U_OS;A<>M755L>=G1YTNW&+^OEL]:N#;GN9?)I^8$TZ2
MA",/26F!I:(JN9"B]7QZEX);K5_$S-C+P'O<21M@B/)';&M0R+HQ>M1'GCXL
M7^^7W:M:\\>A=D'Z2#!BE$C$K;3(4*&0ITQP)8C2'#Q#,F7@WW7WEX&$9"'R
MG78[_Z'0V+-.Q<7*Z5!OPVH1$,JB?2-WM@V,Y*P0YL%W7,!75H; EULI@5Q[
ML%Z@]D^=@(E5PI93;Q,G^=A7&HF-Q8XZ8PS^9?QCT$OCN4()3#_S S"^()B%
MXGX9/L?B#VMYOL!M7=: 4@.-!JI[S*J;^^0PA.B4 YG+X0G$)?/(Y6[QBD02
M#8]:YKC$E(FH%1 !0)JCC(M \KJ]8<>*?*1LPZ!55N7\-(N0K;0'@W*>#G//
M$R/$9XYN):8]4L1(M7_<A^M<%;--F_M7AXE'%WD^%,5!@$ME(K+4$@3 9SS1
M\*)D&>"F>%1C"'?+I-K<,:57B4..TLMR-D*Z^_ 0_GW+L&<[7PCP]<="1L2S
M(W#2?L!?[56W U@88CCW@[YO\/FG"/147'RAW:9WX'$X?ZIHF]5PY_GR.VE$
MVWH;O;\'S[!Y_0@E^!7@M[=Q6=W<(H<\<A\=HV!K\[1='3RR@4=DO$LI<BH2
MSJ9W*OH5LM3H9@F[QI/5+%/O* ^WK5[5=H_CV=_@O<?M3K>@\",&7TK!+2FX
M./2.RI1G@BL;5,8GC:S H6A(C"7%GN6Q"OI^*:BT8J]7]'$I_M4N5KYRFI=^
M]+<A(@U=BS-P8O(KU\@S;.QT]Y,GQ=]<!'^J:$P9AHX". Y#\WI:)/=4?NMT
M5RN-5&G!&^"W_*GBO>&\FS^7_WWW Q='<?#E(_@L'*#4Z/8 $L%1:V0?.0.J
MS5&CQBE\V;_7*AMG][2;*B[9A2_)/]["OL_RF&S,P/^TC58.$8#.%-'5TL[?
MX[L,FOP:DV#G&"(LYFBI-<@XT)^@.6468,T3M[*.I\PM'O==[&CABRYGC5[O
MW)[XVUU5L]5?FVCB-QFBL<K =;E0PC!NDS*669KR:*P08Q)XP5O%%>2GT<M:
MU&O VL1P8X$ZW4&/N-0X@<5KV%:E&T\[W2)< 5!SVNEE"K71J_3._=$ )U+N
MI#1HBPO(4GSYR!$$1(CP^+D;[75,9 1!1?EWY;PW@I<_6M8?HW_\4:>5>5<!
M-BC#6'Y#NQ-B"QS+LZ/!):^;W=F;)OT?M&.=8&N<B]DW@6-K0M)%Z5BW<#?[
MN U[9'N]>YNT$;&@7=KJN?WDUIWVDSFCZ"FMV.;U@5_8??#>D[J'4LCF<(<?
MS U[RN,^9ES3QUDS4J[9D]<,+UT'QZ_9(\DDZBYINF%BO1$5*WI=#NG8KQKN
M/&*1GI)'L,C#T1X<G'!/"I#@TCDO#"P>X9PS9Y)55.G$>6+&JC?+<U_NOA0$
MWD=W/G^Y/-C\0JJ;U3SP_:+>KN.=[[7C.MWJP^<OZGNUQLX_XVD_W\!AK7.X
MK^-J<_^BVM^]RG,+P8D5=?JU6=^K@B/[QQ$\AYC2DV=\+B(Y:'X]KGZNDSQC
M=V?O"X;U(/4]<)#[U7[]^_X%/#>I4?BYK?&ACTSQY"4B(23$C7/(Q9PSA EQ
M@6D.W@. '5#+R2IO]!QIY<P'$B+A2@EN;=3:@NPJ@:/FA 5>2FLIK?=(*SL4
MGN2B'H*LE1[QY"BR*FF0%.><P5)Z35?6%?B\DUG(\S'(LS1D#T"#XD10[BG&
MB@,E-<8Z'2ES5GFAAM,KQ@>]E-"PN-#PX(#?4UB!OYKU9O6J]GV+[.SMX^KG
MKPU8-U)KPCI\_M:&OXOJ=WC/-S!D^<#)*YS ?&F !A[!D'&FX#?A')?4^,!7
MUC5;XY,!W6<9,L>"!96.DB7)M34V)DN9%U;P")*<2FDMI?4>:66'S$0;G9/(
M^CQA4  !<]YK1**(VDDA9>XE1IE>FW)V5UJRN;=DD3,>N,8Z42YXL-0!!%##
M#.91WC/'NL2&A<6&AT<+=\3!]SH^V-NXK+5KC3K=!6PX:,%SDVJNYMC;O:C2
M+7JP&8X*ETR98,'K\HC)I')2I42:QISH(7,K?R'@!V##FIB1(0LARA , ?(,
M9HM3$QE $1BV@*-U,93"6@KK/<+*#CUFWBB3*XTBT"[/&;*&1OA!,-=@X0#V
M5M8-79.3TGK?*.R/WLNHT3M&J1N+Z:ZQ&WMGE2X(]+/"HR]\_#DTMV^:@L9F
MAEW7<+1QDQB0-WH;]OG+<)N_PBY7&R<Y[7'QT]C>%K4F&E2.H]95M;]/\[5K
MGW<OZW0_(Q@\QW:[]KDJZM^_MG8^[XIJ?_NX3L#$NF1%$C0@Z9U&/#"'<O01
M21RI]4$%0GG._9&3>7/HHPOH("^W%-!W%%!VF%@BC/F$O.(B-^-2R"21@QM>
MJ!B=((JLK+.UR1GT_WJ!=_B+CEFE17J$P@<108E32#)/-*9&ZV2Y$A1'26T0
MTZ=5EQ9I$17^X8#0<>WSMZ.=O58;^/)53MRN-7_ ]0Z.X'E9E6X?U6@]/PNN
M9HM$I )9B IAH\'ITRP@A[U%E!B9M$J<V) MTF0EW5,MTN():&F1WEU V:%P
M5DI.)'(,9).K "X?YQK%8'4"/L,PU5E )YM$EA;I?2T294((+V&;1.2<!Z,P
M-M$'82@)*=!?Q'=*B[0P"O]P9.>T6?N^WS]H_F '[=I1[7L=5S\#W?R^R^'O
M[&!S&];L6[NV5VO5<A@R82:(,3AW_<*(VZ21 1\&)69S7TUA-,?W*/P3+=+B
M"6AID=Y=0-EAYBW"@%/DL9?@(U&+0";!0&&!G8D@2C*G+DUSXF<1>5S ],W-
MQL]&B">A<M6(K1?E8\YKKNX<Q!1G6> W#9"V+D]C;H0_VLP,2'<K_5+C,@;4
MC]U.B5!/0ZC)_N@8"YVH(,B!+N3#.(4TYA0PQ^463>"L!9:K+#3(P>\/ ,T[
M'=)_9#U]H2-;ZNE"Z^E8[\,0,/$A1 3D,8]N\0EX0&#(&,^4YCY07^KI0OJ?
MI9XNLIZ.,?Y#FZ127 C8:J(13Y@B'9)! = \I!14,.ZQ>KH,R0+?.KD1::MQ
M=E7F!WRT_( 1\MSL<1G]>C;43+2M'P\NM&J;Q[ .7^C!YG;[X',5U]I_M7:^
M;[?R<]8VOS4.-N'?<!]%]$L1&ZQ,$IED%.+!8^2\=2@(HI5E4D@F5]8)9FOX
M8^<(W".D903LW864'0+AM8PGCVSN8\.5!?JKJ43"\("-<-%@#T+*Z=ID\5YY
M*K/0WFMIF19)Z1\\B.U<U?JUXVK?X_K>[M4!W$?M^W9[Y_M6O];_@:N?=Z_J
MWZMLYW/]JM[*F0)*>$>= E.4NY["KPA\7(LXQ<&)A%ERV3(1/DWI/U*N0&F9
MYE5(V6'@W!A!$HHT#UGS)" C&$=28@VRE ,!.'>G-&N3A;JE95KH>$UIF19(
MZ7]1"]*O;OX0];UOK3JMXH/-#7A^>.:]3$./KPZ^;UU5^S6@H\?XH.@E83$A
MR1,D@@"?R4B-M! .82YRGC431H%EDG(&:=6+**.E87IW&66'+%A+L!7(4&=R
MF;@"EXE(I,'QIE(;*70V3'G&>YDV,#0?(WFN@ 5K5WYKG%2NHNWV)H8_O\7S
MSZ]U'<Z;FD%OIBG0Y'X-3>XIT+0'.TGNG'+ T_M/X;R;M[8$ID< 4_V7%1]%
M1X VW.->[?C@^Q>\L_E7N_Y]E]7[7QBLT]7.YZV+&GSO0>Y?X9P*TAJ-E!0$
M<:85&$^M$:9>T03H1+);A]?$^'PS])#\/:O;4BE_2R=_[%"[J&PT'FDPA8A3
M:Y CX+:E1!)3P=N$<T>*FW#WS7R]>>A&L23VY%DMDDI]7A!]?KA>XZC>]*+>
M;QW!.L U@>CN'</W_=4$/6;5S_M7M6:5UC:/+P]RF)#C:"(W"K$D<X<9XY!1
M@2$L%1>,JQ 4>[H]>5;3HU+^ED[^V*'7@-5&@*.%J<YG4P$YB072V#ICJ ^A
M:"Q9VI/WM2?/:514ZO-BZ/,O B<7!YLU^)Z-JYV]_:N#S1\8_N.@RP36ZKC6
MWCZN][\!?]R]K&9[@GTPB:L\ZC%*\$]RRQ?"&1*:\R"9B][QI]N39_4>*N5O
MZ>2/'28"#BMA%$FJ'0)9">"IB,QGC *#PD14_K'VY)ZAX7>'A$\?&SX8I?RK
M8<U$B97G#AA^^W[VQ8">6N<L5HBH%*F7Y/?*0UJ+60PAQPLL^"+P;L<-]DHG
M'Z(/)$U/6+JKM7^#HF8U/0D[>0#7WYW>63>>-;H#C8TG,37.>IN-GF]U>N?=
MN ?7_J/5\<?OKGK[(]6#SVT?'6QZ5@-QK=(JJ-X6J./79JVYT:^UX6^?]R_!
M!3^J3PRK@GO\OGU<Z_O<4ZM?[^\"E6HU:I_A6S:K%$3^XF!ONYF'5OU?_P>K
M71RJ@#4F'J/ <CL08B0RC'J$%?7:B$A3,"O7HV_#1H8L:JSVUCK/K>'.8Z>-
M]J!%E@7@99RN5&+/V]-,5+KG\=;([-'J/ZQ(4P=8_?*:BSW :C1]LVT;)V?P
M7Z]B*P'6ZJ289'4SR++",?GM^-^#V2LW8ETY;=F3U3S.*D\(.\M3ZBZ.&O[H
MUB30MKVJQ!:8H/SB]5?&X>S.IYV1/4M+'\R[WQP\Z^V9G7F@^O!D:S"K^/:+
MO;]C=R16P_F.\W3\]=:JO$6K&X=8:9<\(\AQG[L[@@FS.F#D< +/W"5&',V)
MI5/22J</[LS#%FWES%YF48S=/%4-J$ZC-Y29P6S&P<37X<3L4R WC;-\H..N
MBM>+VN83VZI\C3]CGIW]9R<48SZ(T7*UD@?,@_R&& 9#;&_4X,P?@= ^32R]
M]4F N998>TX(=LFFD)BD\. L,3TSL1Q*7K>:;Q-\N3NOE])8O:QM''IG(Y@0
M"UQ*)I#&?!(JE4;:8@L.(>'"_$(:AZ,W%U<&\KA9>'&I1:$/P"0L>&!..22,
MI8CGH;*:8?#R\D!A@XE('$CME(9C(T&XGKAZ<M8K6*3Z?0A)M@4@<A*>*"11
M6\<,3P)D@AL:G*#."FE5-F!8_&I22 D4LY(.NK-Q:)**S 2 !\8 *(#:(4TQ
M0U( J\ ,.Q_LRKJ8BA.#>;TGL+$++ $E3/3!N[\X3)[3Z'/%GLH6 ]P/!.!
M$5'*J<BQ)!Z<B2E-81X'$Z,A]:?@CH)W 9QD3DEO*3*/$9G=?FWW$'9$.0;8
M$5/.4U<B(:.(0R%BP@P08B/=ROJ41."[3/,.^1Q*3F_P4I[(>]L!ZXV8[VU'
M+'M?E9^YW7*CW8ZA8<]BZVJMLE^,:09_=^+-@S'#HWLX AK<C3Y//0B5>)GY
M=\&1'VRY/EOI1.*1POEGIP=7])T?)^#AAD69 _[6PKG/:S\.!<OA.P:&#;,\
M4BH ^<4Z(&&9 7[J--%F95U.*?,;C0%??9(( 'YR3TU0/EHN@K!4"\D9(X8(
ML*&_*JDH16"V(B" ^5(CP()%AUC,W(; #Y.(0$!M I,@%L2JW&QW$J%N1"#3
MVZ>(092>2I^X81H#"!!K0/^Y#$Q@&>'W7R0PEV(P8S$ BLMH8!QCBP1V8*9T
M$DAS*Q'U3H&5XDHQDT^X)LNJ1F)0:9Q4,FZOYI]D(!1Y]U;!</3RP5+C9S8Y
M3Y@7OQ@!T6MC#-(%;X%;.7>]!EC8;@.N=V1_ NL;Q/N+$&@/%"/;W%8'Y*V(
M7.6%:EG7@;_9BU[Q3]L%Z^K@P6V1>=P!0W\<IQOY_)UKE3N!Q^(K.OED862J
ML_%NC;[K[*C1*SY6N8APG2>9<!6P8<9'+A1WSELJO OPPQ)O+;:E"7_3TY%^
M=??06F9C\@X)2@"_-?PH"B2!4"6NDN".\'PT^!!^/TD$7 9JY[ )C@NBG<51
M. ZHP;U0QI8F_&U% %P,H.Z2)B:0==DK=38B &V*%/=2*Q(542 "9$I1QPM,
MN+512@7[C 77ACJX:D8 KJG1T8K2A+^I&.#JQ:$TUAN"&:+$ 9DGV($8D)#'
MZN7Y1)ESQRP&]Y/Y9YGP%Z4*2+F8J0+RK5(%-D)HY%6UK>W&B3WQ#=OZ<C)0
M OCK'.8(-.LCV;^H;6[T#]K[K-[^J[WS>1=D_PNN-VOM>KM*ZOU]>M"NM0XV
M-TA.M;DK^QNXNEEK'^R%1KU=YP>;(/O-(I6GD=-B:GL'<*??CJN;^[E&CH#L
M>V=,4KE!NZ6Y03O05\L"10E');AP7@HZGB/ D_44)R>BC "A7JL ,,:3 %=4
M:!;&<P2*7(W*]394;NW#,[(%?GWUNW=+E)<.@\/DK>8R$:TU35@:>#B14GAQ
M=@'1KTFFBV_\U#B#Z_M'*-G?W7AJ&Z&R-:*O&8D&Z__G>;>;TPDV>KV8TS3&
M%OH557%S>,*<35+O3WM:/ T8I>'-CK)Y!C=6:F;6S-K&H5 RVN0QD!,A$)=.
M(EAUC@SUA!@#/"7&<4U[C"2_OP\X$M)X6T@';I<?"JDM9"%+8J_1.[L^-.ZT
M6IV+'+:U9Y7-Z&,.Y0\BKXP4):9G1YUSN+70^_>G)_C+L Y%6M]U?O=@2"VL
M1\N>]N*GT2^_AT8/_+^K3XV3XJF*#_U^]_O$Z42:=['L@Y=_OVB$LZ-/QJPI
MK'*6]; (>'CAP:O -/YU*P']SFN*PR?EO2_C-7+O:P]]+<%KDMW_\D-?^_!K
M@K'7N=G'W= O"JU_F?-O)MXZ;[U6)^S H&?[4#DJC*P^I?OE4XH@GCG)>;Y6
MJP"D;+@>4Y;^F"=>NI4C+^NNNEB=#:;:KW'1F=D,=%Q9A.7X[]=[_MO/W<V7
MG*L'?T+41P@#?HACF%EP6K"TD1IG.(_2>VR-/_PR->P[V7'F_/2TU8B]Q\5S
MV((RYT')R6F>(YWC-Z36#^W:9AT8\RZ!Z_'J]RK\[0?;V<R#,'=Y=;SDI/U7
M\V"SUJQM[K,:K>-:<_>J:(.Y]^,2K@6?\_ =]5PZ<IEG6X^/;TB8<,NC1<01
M/FCWXH01".?!,581HK!860?:N:K49&K;@)"^FE+D5Y^H'+,LARS!K02W,7!S
MUF@!A!/0BW'NC-;<>BP5<R&1I&0!;I,'&B6XO0VXC<V\(#H)&YQ&S.0IUM9Q
MI!DE2.'<I=IXS%SN947Q*J:3A]9S"FX?O*E_H9$[4R(D]WHM]&G//A6,%QJ4
M9L6X;H4FAQ'4$IYF!T\3 ] /'<"2\00C@5- W#"+M%& 5IH$(JB/7@#W4G*5
MJ<F3^2>BTW00>%5V]=A6LTNOO[,B%:7^OK+^CM$+P2C&3%&$&3>(,QF1ED0@
M*S3.FV=8\"OKG*]*\F)V,4/]7<:XU;WG+L^D=\,3$ 9;$#KG^3QE]$RE4SBS
M!?HP #\K@C:4ZN&)]]W#Y!+Q9X[XD\-.:61:11T1_#_/D\$>.2HX\BXI)2D3
MP>8>*TRM$CZ92?<BAW(&"K48X;026DMH?7ON7$+K6T/K&)GFBL7D@D34>(RX
M90I9[ .B1$I&!7.,FGP0 6R:ZP\#K?<TVKJ3)C@U=W;X:$.UX68M)^.<=GI%
M(NBGHI*C\3/^/LHB*;3JUN>&CXQO/F(=/-WYV?T?F8-NC04X;*,*XV/IQ;=^
M'G5O$CQ^1.2ZT1XCF^!^/]G6A;WJK?SG;HI4XP3=7<7Q!;CW,5-ZM<<<B%'(
MU;3%IG\J"H+RN^">[-S<2^6HFU'XOWZ=Q:U6UO>*O+-.*@J10(+ ][+CS>?N
MSX5=LMS6SBG QE7AMF[]O_/&:6Z/M5HYB6>/2!NV0CCB24J<.JZ=UY@3RZ3!
MQG/'DEO@)F-W%B:.%J;2Z!4=G[J-7@QE!F6905EF4)89E&4&Y1RNW%)E4!;*
M];]%K3;\Y\X;K7S72YQ#B9<US>CA(9.340V/$_!H2I1(@AM*-8_*4H499Y0I
M;A\?,![0I5PE>[9Q$JZIY.=NI[<<R4?M:GO_LD;_:E8WZY<Y,%'M;UW ]> :
M7^A!<P/N<9_6][:/ZU?C 8WZU<'>%ERK>E%K;K$#>,;JWA_P;+DZ]Z!=W=R"
MUP^.JM^_-J=E5EHNHW?.(H*#RO-%#-(:?E/.$DXPRW,9<^=(L@H[O2C)1^^=
M6;G4>/=!P8YAZ85)5/E@N-;.2!F4U,QA)P.+Y/$AW!+LW@SLQJ*WT@KM6&X2
M%J-#' >-+$X$@>O%G) JF:A7UC5;%>S%J4Q/4I,RR_)^':W:W!@P=L>B*<N3
M:/E4I(J"!$:"9U92;I@W.!#FK<>1<,\P+VG9O"'59-*E#4K3?,[D9"2($VN1
M8TF";%DM#(T>*P*TC/%5C><I:ZO,NIRQ,@<E2&21:P-$W'MNI:>1>1IX2II*
M7M*..53F,=JA*<><@O:"1V405]$@8XQ @CH=-+58&: =A)A58UY\:%RF8#XM
M\!5M+QYU6J'2:)]V.S^+"2_/J^*8\O0?#X]T A1R>4J74SR!^.JDK4@Q8$P$
MDZ$D%_.&1Y/Y@0;\'<PL1HHSC7*C)J0](8B!0R1XE-B*/"U$KVHC9N0&S5%4
MI]3EZ_BM]\1%+G"4DE,F+6:),:6T8C8R[$IN,8>Z/)Z0IH/"B2A$HLGS/+U'
M.N?Z$J\234XS4G +O$KUK,*W9>#B<9J8NRJ?G\5NY<AVPX7MQC)D<6]PU6$7
MM87O$8D[*8S7A-.@B=0!X,F5K&+>D&A_@E400RG#T2-K5 Y9F(1LQ!)YJQ(.
M5EB:ZT3YJJ$OKCDH Q;SJ\I4DAA) B(!9LA' 4S"*^*)8CP!F= EJ9A#59XH
M&97.DEQ A&V>I&$],DI:1)GA)"2G-,8KZW15DA=SBC)<\41.<=([ZYX/M+!Q
M4CGM=GYT8Z\,6-R+1T9;ZBFQB6=JX;033JCDB$[.4<MD22WF#8_J$]1"26Z=
M3P%%+07BF$?D1*ZZ84$828,S)*ZL:[(JI)PC)Z<,6,Q8EPGC/H$, ),,N3.Z
MCM* FQ!2"'F<82RYQ1SJ\M5X.QFAM60>T92#CU9[I)DF*%$5923@^^79#DRL
M$C*K'(QY"%B\Q&%X09[97*G[^S4D*-7];=3=3T8%>++!)M!O .A<,*M!W55$
MS 4OC:,<\ #4G8/M9K-*9'C=G*MY H"/CP&SJYPO,>#-,&#,Y'O8M6B,RS.#
M\WEC$LA%(/+$DD# )?-6YW""  S@DR.=9HP![Y9ZN5C1!CI(CNCU/E6L]^?M
M\\'0Q1!/NZ 5PU%!2Q5S^.T=F,O&S=)OWEIY^+T5\R\ 9!OM#JQ1O_C[O2!7
MXMOL\.W'!,?1.GF%4T1.:N X(>.;B!QQ!IXI=9HSE0>CJU5J)N.E_RXC$Q]!
MXV?%4TJ-GTN-'S\@H4$$G)4],9[GE"ID OQ369N\9L*F7$A"Q:HRDT[-NVC\
M!T^X>*#MQMU^)$^CC\_HN;18M7]/;/$VX]696_B?NTA5+9:(/D-$/Y[@<-B1
M(#D6*%K%$(_.(DV\0MIJI50*2>((B&[X*GUYS\S9JM$[![)**"VA=)$"?B64
MSAI*Q\AQ))K(X!@R0E'$A=3(:,D133HF+[G2,I/CS(XY^1A0>D^#S'L;8BY4
M-[N-7FY6-]Z;;K62*4U!M;-"KE;LZ6FW<PD:=!9;5Y7_?H+*8\R\"S+HY E7
M&.M B C>61=XTO*^%!TQ>Y67"ZKRSY]L_474=@^#%8(9I1 .'-S9X#BRW( [
M:W)C'^Q8D'F\GL)KD^'Y"DA<*V]PEH0G[3HUDG'FO%>6BZ1LPEPQ&KV53!$O
M[@'Z<M=GL.M;E[6]7;RSZ0&PCZ^J_8V+PR@<3=;F5L:9 #,7D8F8(4$B(3X&
M37,0DT@^108&F# 4A-5*-_9.H\^=?5M7JQD[P $?#1 _S[TO&R>5O&<%+O8J
M%[$;*ZV.+PX8BH:7L?)G/_JCRM=X"B#>\&N5V[&PT;B,RH7MO01U6 PA XL5
ME(.@.9!TKP"#0#P"2?YP,[^("2;H<?#SF'A=*9#3!7+WHO;CD!*9A/8"48,U
MXK ?X'YYCUS /I% $^4A^V!KDZRA<BU\3Q&!Y#GWU 3E(T!0$)9J(3ECQ!#A
M@^6%")"1"#P"BTH1>($(7%8W#B65$1/MD"&<Y%)YCHQ,"D5!$J92JF"*68AK
MDX6I-R+P5$L4I:?2)VZ8QB!TQ!K0?RX#$UA&^+T0 SP2 UR*P>N*P4X6 TUS
M:A#BT@(AH5HBFTL;<P>N(*A37-F5=;XV.>OWFH[ ZA:6Y"K:;J\2@46'>SCL
MZHC #J@LOFO UI[0='E^6W5O>-\]AQ78&I^0/NK/?=/+?P96<FR*K#^*X;P5
M=Q+<!?AN9[V_[55VE;)&#.[K?QO6-5J-LT;L%?W7]^#Z?P E.%XZ\=\G8 A3
M(CH9SQ#U3B).%$>:X(1RZJR-(ABP3RN5"!AQ"NM\!BOXN&;I<^!+#N7P>N(9
M"%NOT3LKVZ''LAWZV,V6[=#+=NAE._0Y6+FE:H=>//16^[35N8JQXN))3(VS
MP63./+P#K-;4Y,?E:8_^HJEPB]P>_;V2 D;"^#46:6&WN/(RC7QK'33_:E7S
MZ+:]ZL7.W@9<ZZ"]L[E]7*/ I#__!=?\<5EK;^'JQ''6MWP4=E&E55+M;XCJ
M)CP7\/#J]UU6[Q\< R>_W-G<HO6]W?ZT#NDR<J%,9,@GB1'70,N=#0EAQ7@0
MV%APCU;6!5T5\L4%+,O2(+T$O8\*>K,ZOB]![VU!;^P,/V#+)3$64"[W'V9"
M(F,%1DPYS5/,\0F[LL[T*G_YT/BW KUE2(']&GO1=OU1P5=#_!E;G<'L.9L#
M+Z!KR].#[*WIVLE/>_EIM/X;)V'S9O4WAHM?8M;L,&NR9SHGCDK&)<+!),2I
M2LA)PY%TD:DH@^",K:QSJ5?IRUL+E"W(YE>37\I!2DU^:TT>8Q\4$)<Z@Y'C
MU"$>A0+V 1Z8Y(P&30&.F0*72ZE5@F=5,%S6!#].#XN)\P,Z<>L<9WEJ@=\K
M"E2L^^1Q:>D-S1R/)ANFTQBD%.#^<,? &_+PPQE )A\,LSI8(A(P"X57F2H;
MIG]@79Y5<*/4Y3?4Y3%N@;GB3F*,/ T6<:,=T@8KA)45&';/>,N!6V0GH6R8
M_K[)(6]7!/+1X]&S7Z /@^DS;-52POEKP_EDUWFE E..*T2E E>1$XV<\@DY
MCQT/U!K*$L"Y(:M$S&JVUNS4Z,.6[I: NK2 .L-.."6@O@&@CO%CV"]J*->(
M& <.K\B-$!QF2*9DM+6>:RY7UF$[5Q5[_^K=F9X-3A;PWF3%+VSF_R!>-U2=
MRBUM>LL2@.(FAO=0YOI/K\*L-?<O#X'-&.\50=YA\$XI<\AX09#E$O!3:XW]
M@F;^#^30#^6P=2,$90E 60)0E@"4)0"ON%IE"4!9 O#T3*H$#]"KG'7 :/7@
M/F+W\0')#Y?_BI<U__6I(VIF%4[\<RAS S$<<>:K97*!&_7F02,WK]K9_ &O
M;^&=O=I1O?GCLO[]"]G9_"*J?6#2[6^M@W_&7>"_&K7VE]R\BN]L N/>VQ55
MNMT ]QD^O\^KS>-^[?ONU<'W;ZW;&?_5/6#DS:W^86*:!$LI G\GSZAQ"3EE
M!(J!8*?!!0HD=[ B>)7)61T2S4W,L,SY+S'O?2)^3\&\U+B, ?5CMU/"W5/A
M[FH,[BR6V&%-$6.*(XZI0U8(@GC.F'6821_Q"L :(!_]?5'@;AD.S*?'5*XJ
MW4'13.:NG^W/1N6W7HR56N<L5EA1&%#\2O1$(_*/FT+\UC2N2"&>%O6\&A8T
M[74VPD][XN/?YUU_9'MQXT<WQIQBO!RYQ6^$=M5;Y.[+96UO@QURL$K&8HR(
MR"VF+ M(V^ 0)QXSHXCVD:VL2Z-6F2[+!#ZPCL^D3& F.EZ2F>>K]]68>@?E
MN0E6(8)S%9 ,'L@,L4A13<!_"UXJ,S,R4]8.S.8,:'G*!]XKGE0L_3^P>MVK
M)<VH>"-(VIT,)UE#'0DF)QHGCWC"N9T;_$8%C12[I 5SN2'Z*L.S*J:>HX!1
MJ<NO4CY0ZO*;Z/)XK(1$ZH36"45/#>+4&V1\PBA)(P27UFHI5]:97,7RQ=E1
M9?G D]C%7N?,MBJ=QW*,UTM*6ZPP=SFW9J[J" IP+V']-6%]?Y*B,:;!*!.,
MB,HS:U)(R&$1$!96"N.%4 XHFF%X%8L7EWC.Q\R:N:\A*&%T"6%TIARYA-%7
MAM$)=FPM0"?S*!FF$9>2(6.(0XHGQ9@T@>>YN+-AQ_.!HH\H''AP$MA03[A9
MRSG%IYU>([_E4W&"U_@9?Q\EPQ9J=.MSP^?%-Q^Q#A[M_.S^CTPD&;X3&FRC
M"A-W$[=O_\QW7&B?2(XS1[61D7$'?A=)A";IB4E2*D</B=(KHT\==6^R6W]$
MY+K1'B.;X"D_V=:%O>JM_.=N?GCC!-U=^_%ENW=Q4GJUQ1D('\!19S <Z1/(
M>^SF=\$]V;FYE\I1-X/U?_UZBQ2X9472?2=5_LPX?W(&CIA=G[;]3YV/]T[9
ML(/#<U4ICA#([Y57+IWY<N([[;AG+S<;/=_J],Z[\U,QT_\Q,E.\NAF:U4U/
M=[Y_N:C2+5S]_E>KOO?C\F"S3@[ 9-4VJ[S6W&Y5)RIF?ES4:/6BUJ^+>G.C
M#R;GLM[^=E24NC7!3#5W<;7_@U:_[U\6,X*:NX?2 1W'S*  (H:X<P09J2E2
ME/A 58S)F0&M ,B-82-;>\N]]M1K+@3GV!O8!T]B\IYQ<-RT'2^J&2Q[!=8]
M1P[&$7VL<NHVN@^VY->7NWM[(@#K4=Z:*!W7$6O)K*;66NU-LD:NO/J0EO,V
M*-W53MH9#&8[^?&_G5[O3]OM7@%CNK#=T%MNL:L>4F]\DHFB(+%#7$F,;$PB
MYX=29HUCP%J?4YLUET,_]_(0ODX;KGQ5 )WZO5=I#'3B-T"AWK\KJ=MIWQ[C
MYR((2AR]Z<Q>5DZ[G9^-7M:)WX9]]/]=<5>5YGFWT0N-@2OPF#%-%0O?:WO#
MRK#><M2 2;I&^2N552U4#=A"W>S;%*SEZ4\+6;%6!RVO;-U1\K)XK2Q>>]/B
MM7+E'K]R>.G*_C:!O  1\\M;ZK?<HRY^>\,)TEEUX('AM^E.?_; MH%E_SEP
M%6$%=Z[I]A\%V[X.#L3>2' 7),+]3!]N$.'N7!VT=^$ZNZ+^O=:JMK.OMG$)
MU[VHPG?4]G;[!YO?FN"SL8D(=_.O-GPGKVVVCNIT_^I@<[=?W=R"9]RX!#^0
MU#9KQ[7OU:MJ/[2F#0.B01A&DT7&$X*XUA1I'T$92, X,LZH2BOKBM!5HB>'
MTTX47+Q[E4Q9%%BBXRNAXTN'JY?H./_H.-ZWGSH;L#.(&XL1CUPCJWQNXV^X
M%H0+3,+*.EF5C*UB(DM\+/%Q>?$Q2D^E3]PPC8$X$FN ,W(9F, RPN\%/N(1
M/N(2'Q</'VMC[!%;0B780L2#MH"/0!RUE %1:XQDD7L6R,HZ%V*5BD5@C\N0
M5;P-B@(WL3RETD_-V)J!%_QB^!IN4HE>LT.OR?EJVBLC$G,H4!?!]R4&69<,
M2L)S(/=$4<.*R0F"35*[LFYZOA5^83V[4O5?0_7'AZ9XV&RG Q(AY89802+M
M<4[  ;;JI$Q8B95U358%G9S']GC>4FK]_)KY&;@KI:[/HZZ/.RG*BIB(#2@R
MA4'7P5VQTD=$/=7)!1J9"T4.MS'SU!YE&0XGL[),R;,:SDMZIGM83O=X@P6:
M;S.PL(>>6Y=G70N;T#BQW:LO9['=JW5.\NUV.RUXS!]?<E)%["U*V<]"6(S)
M\9B<4I&E "F<NP8:8Y$+,2'-5;26, _BL+(N!5N57,TLK+4 XY=F<RI0 G0)
MT(OJG9< _2X />:^DR1X\"R@H+4'2D\E EH?4)).)LE %(S(Y[**\*G!NQ*B
M2X@N(?J#'OV6$/T>$#T>==$1?*7($B).QSS'%#@T21H103T.V'*=.30G>I6*
MR29Q"PC0CRB<?^6*1W\4PWDK[J1<Y]8YR:7).^E:,;8&094_!H5K\S6I[LT+
M(&]-JML#6>YOT$-A&0\)G+Z8M$$\N8B<= 0)&R*1UG*L)HIJ%[8:\A^XIT8"
M63XY SD<2<MH8MVHV=@O2A]G5L4XO1:^+&Q<L%K!A;K9LK"Q+&PL"QOG;.7*
MPL:RL+$L;"Q3T^<]HW/8?&\[PDK:UH1SM0R1A=-C\+)8;>_XLMK?8@?M*M[9
MVV<[^7N:_JI&=R^K>U_;]>]?CP[^'&_*][4!UR([>UO]ZEYHU_N[HK;G.7AO
M5[7^%W:P"=[9YX.C@\_;QW>G&<)]-#TYM%HXX;1"SDF6C^<\,EX2%)4TV#HA
M."$Y^LOP9.[6G [W*LMR2NQ['>R;P>G9"[!O'@<!+0KL78W!'@O:.,8)PM3D
MB*IQR')E4&0QD;S-*?*%FVI8 E\)? N2WUL"W]L 7VV<[P7.M1+.(6J5 KY'
M++),"V1TM#8F;7F2"P=\RU!J^,^9/8O%@-96!VYI>4H.GSI(Z;4<U&(#-D["
M_^;EGX)8)3(] 9FJDYXH#R02ZSCB2FG$B9/(1>N0"C0D*:V6)%<0XLG:Y[)\
M\,,H[VMY6+]2WI)NS$:IQ_TLZR55R3N$&<6(4YR0C< ^ @:M%KD_/-'S.'"U
M5.P9*_9K>1"E8K^)8D_X$30:RZT2".!9@,G&!FGP'E"TRGJ<1'0*SZ-B+\-I
MWDNZDBS%K-57.\,:+'QYAO6*6+0[Z3E()IU(*@"K4 Y(AB-(1X+AGXX((2DU
M/H]07N6ZG*#\@;7ZU4YG2JU^"ZT>=QU$<-$1BY'ET2 NL$!.&HND##JIB'&*
M"K3:K%+RXJ&;I5K/KUJ_VMG#H]2Z]!F>K=$3/H/$+D] =\@JG!"W6"/'DT',
M$Q]UE")Y.^NSA_)XX2GST:<4*SRU?\B+)V]^]%/DV2_0W$+]O.06WE.W51*X
MV<'][;'I7TBUOX$/E>.>,Z<0\/+<^4,P9&UR*&J2(L]3G*586>>KU-!W'_?[
MUBDX[S8WO437I477U_*/2W1]"W2]&D-7FOVAR P2U *Z)LV1\T0B:8V(V@FC
MJ)^5>US":PFO);R^4YSB4?!:ABF>C:RU<=X:8VZI02@2Q#O$O;#(4451"MH[
M$85,9G8IDG,#K8]HN;&H#1HVS[NP.K^<)+U:R4YE\1-^SYF664]7B\\-IUU7
MNM%W?IS M4/EO]_0L16O0;WD@@+$\SN5?+G<V3N^J#8!")KPM[W]0V;RP2%W
M2/@\F2IY@S3%!B7N!&/12\$T^*AK]R4=@K2VX%^K3Y*&EQ+Q4AI>0QJ:NX=&
M:^48C4ARSA%G5"*33 Y;!"^()2DHFCGUVGT!BVMQR.CQAMSA11(QA3O@91>&
M?O4P8,P25Q8 08(PA.20U1ZC%#%31C*E:%I9/^E,B$(E#:I:5L'.V;,X$(8T
M.&UZ(,*^5MD#0S-ZW^3KE4:O<MJ%'>^"A01#U(+O#I6SSO5'+AIG1T>=5BAL
M'7P.1*[;N;*MLT;L#;Y\BA4[Z8 <I0@W%:9=,XR;SE:CER]K7>=G?C7F&["5
M=-YJ57[:UGG11JYB<Q,C>^+CVMW&16_5LVLKI0A[\?.FD]U76*RO\-0GOM%J
M%#>YY$V[@#\WOQQ2:YEAP2*ODP3SQQS2BF!$>1#)>QHTDQ^F3]=&(?<W$C#J
MT'73C@LTZ;82@&CGUVT;"/N@M==YEGUW5;&GIZVKD6+LK_VS-M+Y0N7/SSK=
MJ^(;NKEF9_@U0^4K_ ;U.Y#0D9#>O!,T_*8'V%.:?I4=OA:O:=9"W6S9X:OL
M\%5V^)JSE2L[?)4=OIY2/CS@)2.F,F(=+RD3>-DYR *%^T_.,Z;/-JKWI;8]
M[L(\QG'9&'5-N-[2.V^^]N$175"G9MAMF]2;1\?5O5:KVO[KJ-[<Q_6]*C@V
M^[S>KH.3OGU\L.?[M:;O'S3&NVU_:^Q\WH5[@7MK;S=J>U^/JOT6_/^H<=#\
M @[0UU:M7Z6U?JU]NR?6J-NV38))+B-R7H%3E#TC34) @L3H3"1!FIQX3!:@
M.\)[Z-"_'F.57C,=>KE!Z87!Y1*4Y@24QJ:T1*$\Q9$B$:D%4+(".>4T"E$+
MC7UPU-D2E$I0FD]0>N'Y1@E*\P%*XW-)9*2&J%2,?\6(&T>!*5&"G'9!2,^(
MCK($I4>"TC)4F0R:6-V$V&-OM7(2SW(D?N26#B=B+$]_J[=W/.ESP/1.HXU;
M$Z)*%'T:BE8G_,W "0@7(XC'D&=J>X*TU!:8GI<N8*Z8SUD'\]%$X_UQLFS-
M,W=.8PDH[PLH8[ZB#L1YDP(RCH1<>&60"> U*F842(<)7 (MFYSD60)*"2CS
MX?"5@/*N@#(Q?U)1F31VB*O,4)37X.)QA6A@Q&FO6/1\97U.&G.^/Z LPWGB
MU]B+MNN/BN3&$'_&5N>TG1,;\[\[9T>Q6QPP^FX,C;->V8ILSKPY^..?@ZT9
M;62)DD]#R=T)/\Y9HTV( D6:NQACCI&AGB.B/%@]B0F7;F5]5L&PQ4))/!=!
M^ \/)>_AQY50,@,H&?/@C(\"&T*0 VJ,.-<,V>C!@Q-$1J$I)[J$DA)*/IH'
M-PU*?E&I5$+,(R%FW*=SQ$DO'4.1Y]"S2S@7.C&49-0YF8 P/O,)6(L%-'-P
M1E=4?KS'8]<Z)RC$< Z[G<M*AN5@O;LE*1\_\E78FM_>VIWKP2,#LCT'06'?
M;K9M6/198N73L')_PK,CP)\)BQA9%Q-X=D(BS90#<9-6)&FIC6$:'?OWQPY]
MO8")+6TL_3F(\G*OKD24]T:4,0>/<1^-3PXYJ36P+^.1]<KG;C.8)$I@EZ>>
M^9>(4B+*#!#EY<Y=B2COC"CC_IS25GL2(J*1Y5Q,EH__@T%!)A.25,$ELK+.
M2T19BN.Y[+]YVSN"ZW;\,7*V%T/1P0"4K5#")3N16R0?[I\CVXU_Y!W[\]:&
M;5WZV.O!!X8]?/Z.W5Q;6P+GTX"S/N'<19ZH$)@BL(>9BB6&@&I'Q"CF-!A.
M I4O<^X6,OI5AMD_[(E="3"O"S#CAWDB6I7;AQ$7(^(V:>0$9LBYW%F,)<;"
M5&:V##'V$F7>!&7>)1VS1)G71)EQ_T]@KJW#*C>K9(@'SI%V.*!$" <2JPPE
M=F5=E2BS%-5VQ1,7C>G.[.5UM[M1I\C.:>P6?WQ>8N;2A,EF[@:>_+27CP+/
M_7_VAONVDX:#ZG:N-ZT$RZ>!I9_P^;1)-,(>@L\7P.<#?H8,=1A9YHWTT3%@
M:M,2VI<O6%:&W^?7YYL5FI0I5C-"F3''3S$5!.$*:<_!\7,\3[!-$3'')3<^
M">K9K =)E(!3 LZKN7\EX,P7X$ST8[$LI0PX7DB7YQ<D!&0UH<BL9HD3Y6@L
M 6>YC@.+)Q[JX$,#?<MXV3N7Y WWZ,X[-AOPP3POHI$GM92P.0O8_'%W4NU>
M]>H0V+BT7BF4X#?$K2,YO],C14.,V!IOZ>R(VD>)H)5Q^KE,]7P-X"D!YHD
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MWMH1M.5M=YA-L>-5)W3WP;1WWHDK@8J$841@04#H0B,).%HQB6()+ITTH:?
M#K+P3J&S;N5ZT*)N"[0"8%F?)^D@O6G:)R$>*J#TQ225*Z36"FL#*I:LK93%
MRJ\MIN(,7%4<!,AZY3M8IZ+B?U.-GXVS25DQT<DN1SHO^NG8D3:IKZC'5*D
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MUD O_#)GX5(;X)TS='8,:.?NL*1@$\K'56949F#R2DI[O>V\']D563- M7:
M^"S0\ (>@N-;>NRB(9;3X710?J4ROC@,>_M)/]?WEAJ\H)B*8@)F/,4M9^!K
M$X>+;#IIOX*EB=$OA5.]*,X" E(ZFFHTB]PYS7!H:(9UC@P#Z.%I'^:]'(EC
M\FQH;ZB L90V&GXKM&/2$4P /AK&,"G/NSH\!VM9%%,-C %'V2S)NNG(]2E.
M!U(3/IWTL[PR_H75HG)RA\#_R@<!-EE+?O#E;_(V^^+3B&X[NV8"$U@N%-X6
ME*-?T8]J+=:,9+*>AJ1 <?O9=*"<(4]'$_C_NR0460J>RX&/80SETO8<X TJ
M12'%(>#7,LQ\64EG;N,H)37)]0!9"'YMS6!Z>)=+/1C@?_$[^@K R9FD0QQ4
M+3;<&@)+!:>R7]^V-Y.+DCV!=)UIO#KKX25P@W+P$U2V>4W^G\(98%<MO.<X
MSTPZJ<0-<>U"XSW![;B<].$A@!/H!.#W3G,^+/^+2Y>-RFG25PB$E12 ?/#<
M2HN93J8@77.WGZ.2,(B)S;Y831@!@ 9VP6;OM79-+V'Z'F+5OS*,&3]E]>[D
M]9GL*R!QX#/O7Q^<G=.#F_T3%;NQ%_"(,%\#H3.:8E7;@$@F5&C\0,H$]Z*V
MU_4+$5_)ZKXRYM*M_Q.N_^'>YQ-71'X8!II(S]- Z VF8"2:A"R@KO0-BTR
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MTFG]]]/ZQ70YZ5J^2GC$-&$Q+*WP>$ADR&G (C<2MB!%+XJ6MU@[K=]8K=]
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M"E>.@)W6::K-OLQG<N]YO#H$L?G1?V7#1)G\I0='=B37CXNRDB8,B5OJ1?F
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MKDR">[ A(R@M(P1G195.DD56S K3W/PMG]TGGW>HIF\;NSW&M\-XS85DC./
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MIB]I[SN[N+9?>5L/9R\SXE0R1EG.0@EDC-; *! 6F0<!106O[&V>/*KUU]6
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M'Y[=+W>-6'"W@UXCH?=P]G\'VZ7QK[1"#8$S"+4_9 '#@J&U.4G ) P'WKS
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M+@>T-'?7J2I1BXE_A;7[RYK&'+E]7=-:%3U<XKU+'S%?G-'NL!;LY5U&! P
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M,SM02$-;=P[Y=/81)]?O\)8R\-(Y:0-3*1"O,6@6"OB:M<W!)RN%*YU(LF:
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MY"W4G8 #LJ@S9\;R4%U2Z6Y';C3H"'8?HCWXZFU5>*<K6#/Y]V Y77MM[A.
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M%V*UT%4/%81O G^+&<_G^<!O)L.$7Q?9@3#2&JX%BP*J]^AKJ7S$FE96HH@
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M[RZ[K@NJ[S75<B.-=4NS>XRX=T>&;".OG5V8))83YU&Q6$I@'# 8G0%D;'V
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M>%\M<G*5UQ_5O^,C&3/3WM%REL*0#I@&'V2&%&EI*\<"=\W[$IR4PY>5,1P
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MN8(Q374];2[S'GRC^U1=SW#K0%=/I3[;:#I/?4\+O>V$PA%"/R4H4&>9M33
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MMXM[T@*#DYAV!XEW*#4%M7OHNW(QF]6ZO.6>M9S>R17JJ H472_-LC?@39'
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M/X71 @@R)D!E, ?IC-.MRVM/#(@=YL!I\;"/N/O'P741:6;>%B,!12U&%#R
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M'S]IM51RV7+4E;@PP$W?&11NQ\P4>.J_R^A]A2?E^[0T)/6U[A5&K"=L5#D
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M(L\#@RVDV[PZ%IKDAI;Y6MRE7KZTD4A).@0%@WLYL8#-ETA<CS]+X[AB.Y_
MS.=2"W?3X-A-0_J8R4D6RIBFJ.S#*-GKW#+N365+VOHN)S CMTIO>30T811V
M .7*#,QU"AEL=UG]?'T'R35Q.N^LUWH@JKX\R:Q#]WF+DYZ;N[1F)/<MS@LI
M Z^U@_@2'\^X22_RG!A\_-KR05DC:IEK\R8^%\0YA";(; 8C'B0RA?(L7K*V
M<+S*HC%D[YI?D[FOE$?DR*V@_OVR9AP<#6RZ&7;]*&0>@M>D3Z0[VUCJU15H
MT)PJ<^?V]BM(]#OKN!7;^<XLMCW/>0.E58Q5MO='?YNR7^DH>D^,?H,.%E"7
MAK.O.D?.9Q1KZ\,#K%T4*DZ4-Y!I+K<U5C/" S3ZK>JOHF^X<)_4K!S',SZ[
M^1U%A^%%1A!F+1%%W;4VM;P"RG!EJVNQ"H)9M^Z7BX>\8MHF\"?JX5B^AAT?
MXL'[8>R*PV;?SQV3=80A332<Z38W=<NT7JO*R4Y+1"AOQ\3=%2QB80@733OP
M=M0TN2QRSHW=I.>A#A40.LY%"J;WH"E[E[" R,[ O(7!$IUJY?F,+-DI@@2=
M[T0ZM<#X=V^&NWL"-K/ 2#[@05A1T+/V#F087$\&@IC_['GA3"YI<]VQG(KW
M>9,=?L_\Y\XW;64!HN4GHR']RUT)0%O1D =!Z3!PN*K2R6!T%V([M%.C9E&@
MMW7Z5]F1+=&,QQWV>!OGG-MS06*E,@D-Q<\<Y4;SXIO.._HYB?($>]C,#^R'
M#)?/8, >#AI@^&UV+<O91G3M4TL'ABFFUW7O?C8HY1\9X:R5E[S"T$74AE@8
MN&6X7VE!H][9[,.'E.5G#^[,2H\\8:^\Q5/ QB8I8=;++&_S%+1$_^+CGG$C
MR,3-AO%HR#(W.LU,3C%UUJS9Y_3'TU&?83)^ZY4K0K842P\DW\ C)]F H(R;
M9>QHF)"+T[P'L3UWJ<9R&E -]#!( BE6&@3 -<H[/ZW>]%-TU>OS]YM-G:2-
M3Y<[7T^-) P3$5#@"Y%EF>\:'M*>"/7F-F!"507\T@V<T<9#4H6[%;=N^CJ^
M]XF17!$]%O*4N[15"6#?M^W*@C-I97YV>,!_=G?ST/8T[,+[A"\:1^+@)=K^
MC+7W*/+J2AAOC#X7W#"9=,0F6;(241A#;#=QK!XJ*95TS(%X!%I:TT4.(K
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M6#4\0;? ZU]RB565_-* MSYYBU!@ 49N#<M6R%"<]]B7Z!M@9H=Z4L)>WS#
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M+?MJ5EDMNCE"%CGPC>$'8Q5^H*?OYLSV>!D9/,F_&BB<;L4WA%+F$81-;KQ
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M;P0W[F0F0X'406(E79B&=0XZ1]E;14M[UYIMD;Q&<<G?WMK^]71#)TH*:8B
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M_4%FC<X&NXFF\S$K\C-=NV,=]S-#,EUNLV0MF_H[C0"I$8((/G=V<!\P=A6
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M'[ZT.7^Q,*'@5O*+Q^:?Q-T8*-MSNW3K$A ^/)(P24Q='(RUOCE&DEHJ]=;
MS=:69?KDQ&]VLL\4]/*=I0=4?+?;[FIVRW.VDS9\,U>GE!MG^6K4LL][OYC@
M1XZ%")S(^L,-)DCB"/^T;=W[HUOIES)+^QO?*^TP(ZJO/*A[=(5__^52YE$[
MA;$?%XDUUPN'7C=3SY#@_S,=*[:W4K-^Q>X/74 QW(S3M+/XQ +B:'(&HH?7
M5!]4^A!YC-I\Z%I F8)7L*KIIW3RBK >NAZ<H41[ A>YY[^\V;39O-]D9GTL
MW:5?2G^^&,@ :Q65? >J,HVZZC@M@FMJ,3YXX>,,2]L8H6%JK5DCC+<1Z&O<
M6 =1NW8A@<$B(QH(SH;:-ON3,RF2EI1^D. ^G,WYCG? )8Z^%\5F8HD*O:^[
MQ=X^.AHCM=C;?^)!3""CP(P4#NB,(&#$7=)M"54U&9W9;CJ\'6IIP6U0)QM6
MM>3V9\Y?3.84UVA4^CC>$W%]N\I1-^CQ4R;O92!1F/,U1!VO="_OR_3ZA@7_
M:6L(ZQ#%> F(,UQ/!D_W@8U?5_G>N;$T=,3H><1VA%KGCB")XF)I6&;W?9"K
MPUIPQ*IYV-LGV'-U#OVK^&UQKOUK#[9SYQ8]9'2A=R%OB/G>^.+%M6B2JP_K
M5)9)@XS6.2_;\&=:[!RS):_>YB[SE@@WE\?D7A.?JT9>-;8>2 Z;)0>2(ZF
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MV]LH2ZL+_,.=E(-L1QR?P&GC^.V?7:L(X.YUR%V:"X6C*;$)S0_)8;!E+$4
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M.L=;D#7:?XPGI1!J<$,F5U1S=G_0?S^1S09VL/YJZJ8PG:("KDJ%PP[ZC*B
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MD09K!;P7-BV'"\ Z;$=C30;I5P/.U?%,TR#9%PU6OMN)5_:%NZ\<M JR@?-
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M(7P[Y5SL:CS7\LO\*N)9.8+"VOW/$A-I'5;BQ8[K)A\7ZV2R0U$+,W]P]IC
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M$\Q3M20ER6R=][.IU;_, %X\8=PVF8]?\L&.N>B+TCPOD=BP&@5607RB*2+
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M^YG5FN*7V7Y_&_TA*Q:BNC*N).]MCDQO>.H#C9D2J*5(?%P?"#>%MD9!MD"
M$Y@99@\+Y]=(]#@KWQSI%/!*C/I,0&2.N?W'S+RJ"C5<R_HY@09ZQW+(W F
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M\HERKM9_-)OB#,:7XE;^++K-4+,-7KN!23X!N,M/FE*D P=K"W]AQ V8(#$
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MTZ?9*MJDZA@:J)VXK/3V F9C8J&++&3%X9!*RO%^HA;3X.L )0;.O]F'O],
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MUX?+&ME%<:E^RJ1YP[1W:[5.+A;T+:4U:YK6-,6<PJ'-_4OT.F+C-_RGAY?
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M1R=TP)8E\?Q4@"GS."+PR82<4)#?U\R+N$&^((WS9WQ]38-A'+IRI- 5]8@
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MY" ^QW,A.L7-L [1>1O+9PFNL8I@9[N1*TL*MH2+32G\8J\!G)V#WRH,,+4
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M./_RJXZ[/?>/XYV$?1U_8@I>*+;C*LD.T[[\;:#/0:Y.Z-CRFEU;U>*=NV^
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MMTC9/FD%.HN:O2;2[4B=9)<\A"*(A7$L&OJ7/7&WB,.Y1C0]NM*-O-3U3!S
MOO[#:%"KHQX/P@D7DK*(]O6D43_OYY.&L873.[@+X#Z1<W/%T<:;>OWK.K[R
M[^G]+!*R?P_/LYU(X+-_Z#9^:*]S$*KQ-'GRZ5.NA*]:&:?ALQ=TR@?")2A*
MA%/T.$HO]/#V*&]9ZPIT3#E&I4D/7-UWD&)(^IWO^P56GW CA'GKT7>Z/Y.,
MU>4^*:08(ZACDA)J.:(VTX$Z]^Z.:P,K4 /$4",G+^;K6M#!DNOYU^:9G.,<
M.U-; @=U64GO>O;6;4LHY[/F51.K*UQ";R1*#'\^I=(EEO(+C]@6(@M1&.AL
M[6HOV1NR$ZM# R0J["A>K4^MW3SBQ64X.TE8/#W]0X$7[?0.=!?64PYS!1X+
MT%,"'TBWC .7#8BB]:.YVE>RU;<ER9X0$R.\7'R6#4F?H*A?_<DDT=PD[WG0
M!.NDS'6L>KJ4>(>36$IAM?W +R"Z&K7G<:Q^DAP$/S8-MG4E2IZD4\4HEOC^
MU\I<D@-"]UMBTDH6(9&_73[FOP6_8+[/W^3;;N?Y3+R$#];U],!&#33'YUF8
MG!.P%/1]QX!QY_+^A2&*"R,A?_[:9FJ5MCP-(-612@,X^-*]U:DJW?_J>NOQ
M);91O7 .RH6O\S\4%1!UH28??G-R'T(L7@\>3ZOC>,N[OE!.D=Z5+@ZFZ8$Q
M[09W)L2X%0H[C]]%L+ST&-2E0T;D/;H3@[NCB,(==#V:;J.75AH:Q;.N>Y$$
M:'&)+MX8]L?>?!A85Y=RX<IN/:;A==-+B&YQ^SLJFVGA:#&UOT,L^\4+.]P=
MZA^='F&03L$@\8=+VR25'4EO8L#MW7]CVI#'XI5Z)!.RX7*(W)L )<XA^?5C
MQ9PB[2]7DYW<Q2YVKK.9JX X8%UBR-5DRET:H/J;V8E<#/UT$!% = IHSX J
M!9N=D:.^ZWG\BZ_!50D[HDBFLBN0G2&)7;8Q!7Y@/ B3U"^_H'735A;9.FSP
M$M8V(?-5E.04W_#VIS%YIA/%3.' C^HGWL,WO@D(X^[7Z'6P+\J6UUR1U'+R
M?[=8+7,DVR'Q[TUJFW2&YT&ZI\ZK8+XU#8.Q\8?%R,9]#<\FQUS?;;;5Y-J[
MZ&";<T2U8[E[.@.* S^ =8W;+&BE5 YPA5M:#WYWH"'X^N("Y)->/>^@S=/K
MROW13,G]>JN:;YN\7D@6''#IKAB-'9!%VPW"'#;GES6<IQ0SSMIE/08,8@#F
M/PR,S%FTV5OVKGHVSUXYKNXL><SOB\B"H8M##G]&D04IMSP?;ET<JZUU?6@P
ME;XG""4++B+Q5XX3VAJ)>20]&H!C!<V3W,8=?7JY[%EX_T38>*#HU2J^4!YE
MU:&#$9YG=I]CMUDPK3R<X72^X#P_.7TM2],6=7\\M5WUYX21\8[>=4F\6!#B
MBR<:1KH(PK%QE^&)6^B2^+DZI!A$-S0.MZTD-)SI:78M\ZD$=+#0U<HA+RBP
MQVDWP6+VY2*!KG^@^IENR<B.2[IB!$0R.$#<<] $7F/JH]68^7=^SFC6/PI5
M_U(23_"9&Z4FA,-I@(A@&,6C%16'JMGM3DW,E=(\2H)R%9&BGNQ9H7!9<7V4
M^I^_T"G,9FN@S_0JM0!%H=@/@.>@6B0@'5I:%',(//93*YX])>6O&@@=TI&7
MV60NI14JAD;'\4<8/ )SR8R.\<RK$Y,F.\Y0?V2C^A2DW )94:8)8;PYW,,?
MO>\DNESQO?='_Z6&UN,6ZQ%@5>JV72&IMN<&2I1Z?1Z1TN:/W25E+QA6.O[A
M"'UUZ[K1>-65/4U,S$O>>Z?9;W^C9_AM?+\G;%;W2'_\S;L%B*4[HH[G(P[M
M_"9=)Z,1[JRV ZOQ2:Z#QTG6@GK"G/33;]12N^OJW58V.,=ZJTV$&F8,0-TI
M+3'#>M;T>-0B>\P2),0_W27(1:J:WNDW@D8#'5-N/G=8MOS*V&_H^$:$Y$1\
M15T\>0,#^^.O[#Z&/R(YKP2HMW#8#PI7KCZC/I*(N.F6RP+@6AN&<I\.SYA9
MB\49^[/TCI(N9W4".=Q>//4(%^'=U"Q\N[^:/SBC:Y<[,)RH =R?"W/+\DUU
M:J-G_P=H($$]DB*-D8RF,C2G+_0C>>DJ4^N8O40T$6]^D?3UAD%_NK'3+=02
M7X"&]#C0!3AKC6G<WL*(LG)'E9!2^T9$=/,0FU9#VI4W4!]NM\,"S]WL-&<[
MM_ADWX&!!CC-GZT4"ZMWW9XCR-F 2$7;@1? K[1./9P=\!.+'NV8<9'HL#A
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MZ4*()8UN1*=)FV=)N!;I"A$87TTUKYB3SG9G1^5XKF6$QHE^>S9T>-4+M3V
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M#*\1W7LL%\4)=L_WBFN'];3"#AQR^T]8!*AG',)./G^PJJ*M)\Y/0G:BV*"
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MKTPL3,63I,1K_LR0Z=%:[DN'^:/0A]^QGUV=;?DN//#Y R%541-WX1?#QZR
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M12AU4N\&)8FQ (&VDU1%!ZK1$BW^=E5EV!OLPB_CW1MZI?=2V?164KL!N*C
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MOW[]D#FL'36+7L)C,Y+SY.81W"@>A.J$O46VTT2UIV5B\2V5FH:!6.C/V7Q
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MM>2E9A-A:_.J"3'C[QN;1S=<WM:GI@9EULJA+] 6N>_%ACA#2>;6,4[JL2S
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MIN\\AMU,9BBC!1@?4)X@3N1DH>CCZV1-VY7]P?A?8UJK1[D&\V4KAD&2Q[U
M;XUNQAKXCV*\H'/0=NV!8K@#)7T$UJIS[$5)TY1J:D.*!/BT;&#=FN[2 5=
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M3IA8S8I3>/KFE#WI[]^..9'2/I6GIA+D[=*-ERR@\&G@GV!H6=@BIMYZ+88
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MK7"Z4#E.?I&=]-W6,V-8_F9HFJ9,T*,Y<T4]@QG!*Q8''6G36Y-&&:W909)
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M[)GG4?Q#EL%+?JL-" 6<L7J/K<"8#T5X>2?3I,2%_5]63X^I,K^9AD==L.-
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ML!:[I]00!+\Y]K&USKI6EB-)7^#M&0.R+L)G:1B\M-@%B4:?UN# 8L)MV6O
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M]H ]19W8G"F*D=6K(,AV-]";3>ZV#*O8.V8\X82V:?LY>>#\W U87#<E+^5
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MC9 J5WS^N*6NW9.ESW^V9BU!0L0C=BFO+(BB"W#=^;\^N,$=DBUJP%93Z/C
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MEL;%E]?>H)P7(P)0,2WG/_7ZN&FX$DODE^8L;M_G"7&$^OR@,KR4/Z4T@C
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M]&$FQ36U.$.#4>U\5[[-M1XDI-%?[[PHP49PYNA1E8%SK\"XYG_Z'XI#YU]
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MN%AX+8B[6E_.EM9Z?C/)DO5H46DZN^R?IJ^TU;VMZ>%Y7/=I_0#B&B&CL]^
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M)ON'^N25I;[;'*;+9DW2$=9N/(@@4@R=(V,>*@'_AA(!A+MUL9TH_A\;LK5
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M8EC3?O;[2!T3 ?MX]_\ XZ#_,_[++;0.:_7(2_11W'8N. %&5@=@#)!9A].
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MJ/-++(8QI58WS/^]C];_-X_=_\?H,N$0BYQA9BV$,;&:;$=:2D8HO;,H63M
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M?@/E1S]K=V'_GBU4@2=>^Z8]U/1M]4N4)RP1)4&]-'>*.- [<,2LU,^9.TE
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M*!;%FW_5I+L_@1<DUC3B22IK2_H]RT""VZK<=E,EN.O2W.4VN+EST^Z*3\_
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M>^<&C8-SJ0!L.17@2P6<+YY>(^2MKG ]H@+*,_44N\K$6;O.>*U9Z>@M7#J
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M^_JA:I-6:C8'<0X#+A!2@+>JH'48(&$VL8%M1D8R->'MT_LWQ%FZQ3,9 <
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M%G8HEA2JISW%*ZS-SMYJ&9*3T&_[>NCZFFM]]7GV7X>O_'B4CEREZ77.^?<
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MJ5WI6.$,+[-H%).;]KI<,QZ(5#D^,+WT8:3%Z*+$XJ/JCI.@OU?/6ATV553
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MW\91"O00\TKDEMI PKG<=!-]B=N7I9/76]FGN1N)D;PVT?!99[K]XJ>6FGV
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M3>F*>&5NB:G6F' 4N/NZ'E29V2]+P?1?YG3=7W_<HS+[2,<^$>\_7=]+ _#
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MR";?_9WQT%0[PU0[;['TBZ+;)[K(VYU=T3LL;V%4+/7P/TQ;CE3(9O?X*_U
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MT>T8'9UN;KGA[S,E)MMRF/VSC^+O[^*U_!UV(?3\._\W?F1ME7P;^83&Y]C
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M*=8+>SGC\BI;'Q7/G-93/K6.VJ9?2!I'MJ7G*KK6_.XX\?L_:/GX[R*A;;I
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M_)3?;]\HJ)JI 1"S?+@M3J1T+8B3;)+A="6$!DGC55B1=[[JOH2)[>5QA8;
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M(]53V^=!,80[2*ZWSN'ZYU^?YU&,:XYZO"^1VPG\DNLEVBZQ-7(G+Q+.99F
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MG.VN^Y%CL+<0HAU!W5A^"?,4(E@;X@07WF@ZG);+%TC\<#E\-=%R1V""J,T
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M.?R;A;\<C]Y^=O/VJYB2_N<8MZDU"*&Y>#8<0N=6I)P&,)=OQ]R=TA5[U,P
M*;L6Q=[M/4KNO7F_Z97V>M0CID/&TCY"O?-XR,X ]#.P=C>U4D+$R8_/4)_S
ML,$&K2%K<SYJH)>#.^6A10?0W %EP_@.S4*M&DB8-+HF#"%-[/DHLG:-N)MP
MTV%%C]"7E7;6[81%AZUJ<W!F8500D^K*[>\<)K<9(5B()Q-=_3[/#04J3E1D
M?[*J_D'?='KFEG:JS>./37;#+ENB ZNVRR<&B$>5S@TR@'"UB3YE@& V#% _
M-PC?$DA49<J#U-]D$AH[E/RXI,>&WX<!:AM'Z"]QKN2>9XUV* JR.N$A]6*E
M"?H0K$N&;3=0S+VA=9J=TOH]?Z7\W?>,[FQ*/$B3W@YXSD<2-$PY4]T@;G_S
MG,+3_72J&N:?5A)$Q3% @ @#1/U22.?JI1A3G0&A97A2 _H80O<#X&5&NC6\
MJ5=O:/T[^,[L'-=)=:D;96G?GGJ W%_$7K?L!H7!&I0([X(IAMAWX9KM?V\"
MZ*6AI)S+Q3YOKB8'E"W<&5@_&S2T]][=/5YA\>&"9B&] U6+[B[5JJ3:T(KK
M=GFW&I0])/2BQZS8"T]_.W+96.O4S8=V.K++";)L-_[=(04D,O/M,=!<ZO=]
M;1YP,I>WC+?YXQ9;VR#(I-\@1_#D@ZGU7R!DP%:^&JV0&7GTYVST,>,;^CVH
MF&S8>H.IK'^O[:CB"Y7,JM SD4N8B!7;SG@S>5-FR(^\ ]XP?RL3@EW*RX#^
MKCOIB74.5.N0!]FYQ5AKE:YZ\L!'\;30Z.U ^DCE9].3X9I7@53B85>^V.2)
M^$AMN['5VKR X\>YU\V6-VH7GVZ?,RE=!@/R8&IN/%-ZNOFOT3-GKG.D^L'J
M&[HJXS#UO3THK@W8K MTO+*$WD-$Q7E^#:MN:(F0DS.SQOK*<7'-IJP=^=@/
MO@O] B>PDPSGC<\O,T SR5UWE)).RGB/(;2EOKNZ*2D<$1CBKC?X?LLEYSM^
M2I1R.OS:T+^9G7I$T$0%WK)XQ#]@K=83E/,A@_!^P83:\ J%]\1<_<B&ATXG
M+&=W5T9#:Y?H/R"2!Z](P;YVUA&+:&&MDTYQM[RX=Q[^**NZ>N9/H)Q_O^HI
M"-)^K9<PMWR%UHQQ+[\@4+\:Z;2=AL?G#,XW+>^]8H ,:1P%K!AUNJ[W,OG?
M.,=G;QQ_2&= BP#>Z5;NLLV+G \\W'>OZ*7_V5![WK7P&7V%9E$YP "QSID3
MT70>K64>9]@Q\V5UQ1?6N5?90S,7N.*Y-K+JLK0VL=+K;+_KE3/%1@U&W%)!
MMR^+<7.<XR@V35)FK2_^,.,GHOT3-X.-]'@8?[9\QTW07"[_<]_Y(Y"+MK_N
MIRMQ)IE&<8>$IQ,:EJPO=J*J8=W.5E9A27]T))]E6M#WN#BR!L#WA7^NU6N?
M@\B'3Y'? Q.4!]0[DZ8R],&&0,"I/5<M6MJ^]R8B]:2EY.15P:1NIWZ'WIS9
M,,'/%D[[_]T WXJF<X7@\[0[H54)T1H/7&.=MSRW;K9]337S?%6A<'GNR:LT
M@S$Z"\QAF*,3Q]0RA+SE3TAU9^H16L&CE5'3DS,I&S/OS3)Z/WVTIL"\=OI?
MLD^,<>,%HK"K!!2^!'>,:DW$D&]CIHP5*W! L(/UG1^*;6->WAZ< Q<U?JT=
M;;&E<\\7E\0B[(GR2W9II?Y+K?HN% 7;3BV=;Y52(Z=,.@W;CJ)^U3R>*D9U
MN*!6!NL@%#X'U+K_.1DGXN%=6@&SD@KN\,4N")$FF(X-%R=QN\@P>(M8:EI>
ML= K4;9_U-Q\=O6HE$7,ZMJ3 )XAJAUQBL##K"F<O](27W:WOQ63J;&NX5FY
M%1E+1U_FB)CAV2,4IK^F<-V(EXJZ%2]+FZ4HAKO,=J!KP)VM)T<U%>6(\[$5
M;=7?6?M5D1H[*(E]''#*_VT8IHJC^\AS5I&9T1L9;X5;&US_)H%(@^9+4]W_
MT"M)UP2"#TMR!V!$E(5'_;AQ\ IF]H G*]7Y7</UV]F>BX?.!BN8@5(7?U(A
M'D.0IG"L;Y%L.YA&[0"32)<>6S.;K(4?BQB5Z^IBW3W^PD*:Q]5QN.B9V+&'
M/. R9@C>FHHW$#';3L0^3CF!NHF7#7OUIYU7\RW/1(;?X_@B_!,YG34RC_R.
M$A,\WV@>%R+.,>$_G[#)#@J%'C55^HGP!FP785(;&;4BCPFQ]LEL;VO5L&LI
M^;\<SJS-8* H7]0L3P^J9HAP$.SE$U8>GO!OD^!CY=I=#J<YZ'1 G?C2J:/K
M';U_.XN>:_=*+;4]8Q;9G043W+8N<=TBR-7?3#8R_EV0^7H@8#_$ !TSUO1?
MJ@34P3&%+<D_HGLMTJ_/;BCHV;9X$9^?H"JS?4@@*].*VW0=E)+:Y)"C$E/1
MQI9![%VFTL2!H/+\W-[52Z;675<<S\]<B3=&E2%+DHB:A%82F*Q**DDS%48.
MAU6'3T;*6_N;8Q^/7\Y?M@V5Q;(\3ZFV_$K=X3&[T:$&ZMT@(+WHLTB^6I(]
M]?@^^5%]8YQGVA,_\9,I%1?+1*>$0 L%^)C\<9;Q67H?JK:7<+Z$ >J$D>27
MXS\17Q^P:SN$:V./]<E_26U,]9HV=@S9$6L.CMX,*M0F(X!6T@NR(^WS;TP4
M3-S8$IIN?';)H3\\K&LJ973@;KPR8DJQKT;5;*3Q?OF73S-!N,+;?YB*@QT"
MW\;-[),OCLN)H>F"M\U,/S>0I5#+A#_#'"-HXG4;<3\,F G5#- SI"QQLCSL
MW59HH.,;_PL]ML='1%J?2OKQF]W.B>1BI@(K]=&X,<N_"^J'D2I^U8-+TBZ]
M'<\W7YBL%!>U-)Y.;7,[^//VH_I4IF\#]?@8_6KP$HH66/5OFLMWA/86P5)$
MO46+1K#A::'Z+RRFC$7]78/D_2L$")T[MM/Q0>#[["!$ Q%+=J(58'PKXYM@
MW>4H\G,21^S!_&,H05W5?/1JOYL?U]EG_DGA$SP@T\W,H_HB9X7)HMOI)53_
MD3;I^0VT5,6C<G-85>L3/SYSF^?&#5F?08Z>*JR_T@([J^["66K0:53]99LT
M!HAX-=P\H<6YP))DC]>M'22;A%VQ)9=KB 0]9,;,[LSTWLH??3W!&Z-M3&%@
M1'K1B99!L)2$]W?DYFX^5E^7U=/[SANSVZT28GXS@F-<X/EY60B[=RA&%(-_
MCSG>IC#O@Q8)@<=!>:A*I9;O-^I-(5Z.E0H7^_M_?1=_$&=O]#/JKDH:5V4(
M[66;$'T$<Z1-T3>?:252":8*"!4K32.;J;I38IM6IN<<HFMTHMP48VH^2H;J
MA7'O:3[#L-)UZ=THT19[DA7>Y"7R+!&<J)'VKC)<XMR0\4T1S]!$T=5[/'H]
MZ6KOZJL-*VQ&&:#J=,)K/'JF_W*K/Y^&CHW0QCV4;SC\9GMC_9KD>/I!QLZ?
M,!"G >]GBR-L/511DFV/*(9XNQ(2+K+<U?1V@;^&.&"O]U=RKJHVR1;NWCUI
MC-=S#T:3T\L?8PB5E'L^L&HH]DVD^;9?>3C&,:Q^N#9406U46;+XA=0?G\8@
M#C7'6VY&"4,+S,1Y.4B]P@!578'0F&Y(<ZD^%WT<BO^"!M="CZG<75^0&IXD
M]_UXR&V<>.20&_]([:0'4V./G5A79BV)1[FGSS23LZH2NF''V\[ZXGC;?B+6
MC?7?)YYO2$GY&.Z:JSSRY;%6&-ONL2!5I9XF&,&>F:>_H\&BFFFKP"*Q:6+<
MMWZF*F.U/OWAW0QYX^<I4ARIT\?1>8$I=/2$NI]Y%4DD/;+8-S0#MM$P;%(W
M4;8I<?9]B,IZ^\$10<[# GX;/+I'DY^* -S> 6N=8[5-9J7\!VG7CWRQ*"K+
ML# R/*WR1,I=D%-I_\D=6EV;(D*=5F^J#=A<H<^0Z,614+)^#%55%]OZJG7Y
MNX#@F0#)&\<LKLUY&2B:.3R&4@5V_%K!5X%9_+N'AX;Z"=0KT8/]'E:GL_3E
M-]67H*GWD ,R0C53_^XTEZKS^RKH\\C)J9$@'G7R5-$3[X9TE/HO&"!>P#],
M[\#4BG9M/2)QI#.=AJ: =[YR3D2A-7$@6#$NY>WS8^;&*C^7%6\\=E.*N4;+
M09Y%W 'D*=<TMQ=)&$>8J%ZQ^U2^.,E6T./K;;.'%6N\F_W'L9K9@B?GJJLS
M#G\A$<CY'SJ5L\WD*^,G) .\)MJ^[?!SI<S/5D!/P?8+P,./_ZV^ U3I/"8,
MT,EW[U$_9[T8H**&D,-RA/"_B02F7;H^ MWVKV$"@E,3Z#>*G4FJEZ%>UMH=
M,\)Y0UU;G!7^V[))#H-YTRI;$M$&R55'ZYD$&IV&_"%DD5'2+6V2]^TVY'[S
M"IKB=CU<B0RFH0_ 1[U%[:'<O\4KE,8(OS+-4O<&1CXI4.>_EW]C@.ZAIG?$
MA<<6S:(JBD[+Z>/3 6%0!(HJ_&0)GFQZ'#GX^%H-'B?@:RH^X4[2+:]9\ GC
MXRT7<IJK.>%Q=N;*J5Z*7%L+<6#/.1Q^)=?>1S%S5"G,+7/@NJ U@LE1[#GU
MF:AI3:M'X@Z(VU[R%'#-O.:^*\PO_&1@"'[^J,<1M2R1'9:M 5]O-NVEG7<A
M10@E4OG!R[T["W?6LVLZC*_>7LZX%VIG^S.:A6.F+?S?XB?J19)^-WC:#GN7
M%-",6C)Q/?#[EDNYF??AY?LOW,UOWG(?XM)NJJ'8366-GG]LDQGG<AL&UUC"
MM% =)R:RR;IC7#?9_/17! U3\>Y(6?HMECW[[37*>>0(3!KAL8R*:>,GQ0$3
M!])W_$HK1;=$^0)I,<47MM.^G/K.O[U>*+7F+1GD##T/];"93NA"U[P)SX0+
M(6 DI2[R!*\UF#R76:;WY/R^^(VUEZ)!9D[R<6SCZ"P,/CU7@6>I<H;#X71,
MT,Q@Z_L!\Q-'LJ_V@1M5;(;MI]#UN$1=,!?].THX1%U]075E.$#.4I[R34'&
MZ;3),WNW_)^#($3J_^!P!7R06=G+M )C(W]:S2)NIJ$K&ZE\;C1"?S="NF5H
M7-4BP/V;0G"3'L=8$AD%*$Y%/QKBI/?(<#96Q0N$E;\IO_)W25<\U^YKAFC@
MCIW!L@W 'NEV#L*#[&6 ZL/2BH&Z,*(0^>G8"PO@C:]VB6^BA+G,AW?ZA$AT
ML\9U4?NKJE%F;. W3%J(SD6<(REAH=-&3E,(I0I8>)AC\O7J5,W:C1GQ5W?N
MB1V5PJ?QA<.HPLU6-IQ )=Z\JUS:;K;[<4 KV:(D]KY/ALO9]S>?Q(8@>)E&
MU_.@\O8__X+ZG@7$T#L?H^CIQUF6%EB 3Y3+]/D%F=%:6+P$%<=+EUYOBJQ'
MEP*;NTHW)D*.1$.A???"TM^^V#MN\ NM=NR11 E5:(H<2U0O]4.RTCZUF)>&
M9YU8E53WK[A?WQ3X8E_DZ^N(W^$_W?<N1P93% %]:R)XNY_8:S;Z/E[5FVKB
M853+S=JO\Z6LNG_'Q3QTB')[ZQ8+J7?;BN+CAQ.FWJA R ,-197Q;:>!AZ?S
MCT4;'(B-L<S?0I3*]E5Q7ZG^\NA/D.@LQA<\HW2!EHT$;[:=G9+WZXG+FL%>
M2^TT(8RM]3\3&KZGK=7162@E>!II3&MXU QG8P+!)8PG1'3]\Q>_W-5"_FS4
M+UZ=Y\DY^(6?FU?M;WZ(/,8?96_$+#K?IJD69](L'OQ4QXK'V6[U2:)&^:/6
M*\Y988<WYRY*!5KO:_8A6C'A4E?:!7)!XT2;]MV9&O+0*($*7\8D3^$X$%J?
MV1O'6HP6Q[/.\C4'%1>F.7R[>?I6W\[<RD>\*+",MR<X4B0W",O0!+3(@4U*
MOM08 Q3Y$8!W"7S7B68_4F6QDG6A[ZS2]T=(O(Q?*P,4QS2![" I<"R.IYT!
MJF2JN5]Q$&+U/^L _6U)%V5^<&* ]CJC3--H64S;1. @%P,7/P"XBZEE^>9^
MSA>M,["MJ:,L;7+F-^+M[)95-BV./#>N)*_0:C507@Z/--D!R!68$-619,M9
M6Z[MD^$_\:;?,8]#PY%^ZVK*\ZZW&I+_UJ$$TH>@HL@CP.Q2^5H7A,^G37RD
MY;:.86IYVHM(J<GZ0U;+9//C?O+5LH[GQ!46CPL&WH5WF)B"GZ&)]I7)3?4M
M^9&XN-H@G1QW!BC+P,HJ4"[]4/$YS7,09/D_,EAQ.V1(!#G"%%<V$U9#SV24
MWRQ#._HK?SNAC^DM?]H0_/[*TJ%9W)0$:]D[M7A17@ ]JK**_.\84OC(]HM9
MR. NG C"GI9[X._5XR(WCK#^W+OD5^K>,J$AX6.GV%#O<6X@N%;4+9V<BE@K
M1\[@!-M$Z+,0<:I2,<J?B:\WV] 4R0ZZ<.[B0M\":>59HK@^W\=G"DH!VF\%
M"]5,LNF<V'^\5<X _9R-8!)7_:N._V5H%VH Q1?+B-8#ORAV]!]0+DW%+".>
M#8T*^"4.\$J_@N^ 2:>39<R.W\=_-V92+T\:\T0N8Z9+>_;=NF586[.<3S?*
M$T3X3CIY1JB(3UYF@.XO/E'WW/)G@'C8Z#SJ[WI0X?G<Q-=JK2];6\K :\B2
MO4(Z]ZE%9QL\N'LW 5:G'^M_Q[+6Z6MMI9 3MG?&'Z:2,M_F[G-"[;%( J66
MY:\0[#4#5-?"K(4&+T)B,8)S.* (=C1<<-+?MDOTNOZWJ3=:-29GBM_'AMFJ
MX>8KJ]K.(L<6I !;RIE-F.B#BG?CCS9JO^W4WD!GD7W&(U]K3;&_MG)[_B[=
M=P\&G+1IIPPE,!DAP!BUY*8XE-8F/Y>'NMG\%;:0<[?F7!$#5"N]:KKO]J6
M'T[G7%L*G42YS[:JV,DY@[OLL^[K;7[>.+Z<AGU4"<3 S.GCD-IK<10-*F0"
M$5QA-I7*HUX7GR<9^V2V9"C[F%)!NZ=;3)R9@<(]:C:SQ18X<!&IC1S#@2&'
M?H4 ^D=]^H?K-B%"IV5RTB"4=7OI_Q\!%H:,I]64T-X2?D./ JJ6_PFPU.Z8
MO:C*<[4/EAC8/!LT].K2D8 3B08WP6S_0>#Y2 TJ%ZFAVVGHF:G$&$*[,/RS
M=XBDD_3)OV?+_7>.O!!)4YXT=S]7'77&LE-98>DK Q0K<HS*S,[H#L3M\;HY
MF^!%$Q[#2_S0\24C"_W*^O[$],D'PVRUL)^:Y$R@SK--%GA'N;*U(#85<+U/
MQYF].)/'S/6MP'%B5Y$,=T]1(/8YR\<#E#!R!$*TF5;?-94#<N&I./: U_[P
MNN_":25%M0F^W[JGBV1K^,7G;7AR?J;0T^QU2:H=3? NFX0V!6)/U7%MG]QZ
MM,G;K8<%!?87]"'61?$<5:"TERPD3:J +=W:JQM*/CN/VN!+A0.:2R4IFBA\
MJ8LI4;TW,>1LB[378DZ%_V_]1C>?XQ\6OB>71;0_^+8&)4#N,/LE6@7UO0PH
MH?<:5=).5'W._\_,TSK;!GA6E%P[C'%'QR=6X)SX8%UW7L9/71Z>M$Z-.-VS
MJL!ZR5O<ZA@TT;Z4^T\,%E.C2?"@7'?H74I/Q$D<:,;:325$8N(09Z4R:J_K
MG_"P\'QVZK>@3@4TF4,N/54OD'J3^1.:$>K$'YCZY0O$G43:.Q_7A\V%F2'Q
M2WC#F)Y=K?L*?\]Q^-+$"\!#ZD_(SK12E)>D]I)-'$ZJ#I+TY6?):\TXQ*U,
MB[$>T$ @E\=SK659U4OS+U],;>Y.VRP7[Q($B%Z6).2GQ=2+G7=J4R:GZD4G
M1R_$N[?[R&JPA.?D2[X]UF>IXC>U7@!F%O=]6%+^:5(# 4ZQ63=D@!)#3-PN
M#X?4QUA]:6GT.<&TMV%6]8I*W'KO4_C[5/N@OO!9H6YT327U.-=[_;_DUD6'
M1YST0?RL9/R>IN:'AD>Q$8@T#V5+4+[!$;Q, YV+P@ IU5!<4#_;<7^=(NYB
MNN!<TP"&SG,>_TV74W!ULO]*\HV].5;C;P]*,D7^EI5*HMJ]V:KK:<\Q/M 9
ME4'C&R2KY<ERXNKFX>%P.+13ZUL6F?.G2N;QW-/.9N<Y!N3ICV7\P.TH(:0.
M$HNK#8NFBU*=2&]Q0FU2P!*J:IU^LFUNRNZ0O9-O8/O'Z;U+TM+S%YJJ&WC!
MZTST1W6XW?7!\-&/^PFDN#@ 3=I",='0H)V'R*K*7^<@"+\90D+<;Q-SQXF
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M(T1I.&A0-=Z"K,(X6MAG93J5(NFG:]/:U7_8GYAR2:C@5=VZDI$^J)'P\JK
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M?]N(.0Z\:M ^Z,[@'NA4<!W2['<R3V4>$/N:W=(O)OXN5J5J?NNX!85Y>4
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MVGLQ2$_BS#4"KDVPWE\5R^/"$OZ3%\J"IY7&Z:7I=O@_?,WJQ?0GT.V3U5S
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M_[8JANG'Y;?TX5T)@6B%9TA:& @%XGMP;4-,8JR"3:-Q:F= UU<K9>[D-^L
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M0]=6,>VIU#G1JWH]OAB<<4<*(08:TN*8=ZX%\DG(;B*/WZ$W%"(;L(F%]CT
MUG[^!U#X?S=D_\F;R(-81)_W[ [Y.@Z[3>[E8(7_))RAPY\^;)W]SXSQ/]W+
M5O)OWUMQ%/]10;<336:E0<MZ,ZU3@-JM9FCJ@'L1(0J-OQ=&)RGE^6"3AYM&
MTRKAN<IB6B\$Z^ =K=YT8PAE00,ML)IH ,GHW9NSZVIN^)%DEZ3M!TH_/#/
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MW59&E%Q65!I;X_O[HCOS@N?D^=:ONZ3<6WXO*2/PN*A#0)PK&@4B2"VU+PG
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MN^<J6^[@^'ZN/UZXY:LQHZ$44[V;DF4:*VKP+HAW[[CRF52!,<U1YT3 VE"
MA?$\8Y%^F.X2/HZ@4ASZ!<+08KNL9WKM7(7+@*=.,F'O(R2'^8GK]Y0;V?Y
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M>'+<5 0%B#Q\[=\_N;]@*!*C-?-?_FYC"?: 4!,*T(6 /U#8E[7G(/-D%5,
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M@9VS;%L_2_=#\SS*['H"G7V/?R_L\O.=ZY=*["NY_<CPYCOQ_+A?([RAXQ2
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MA&']$6?9N#1D. L%1?'</$IZ@5'PY10D;5TB@Z>:V^XVY_H59,O$EMKIR+U
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ME.7A]>8"?Y+/B 7V[BH1#72(STBBKA@'OEVH1ZZ5D-++J@260 ?^.4F-@2@
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MZ!2MCU56Y:-*'EG/WM_Y^K&?(%?(;ZP'2'G.(,;W1W+K#/D:Q9B:3:\ *D>
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MSSN>%X'S,NQ)\/W,K8-U+7)2KI"$ED&GX.6FT18$CBQW^]:VIAS]E8SO2=/
MB^5-;"RBOE4MF&SIW1@*$"<M>?^=I]\9J@IN<B; 7R?)(C9#H#9,DRD\Y91
M'OL,>!4U=99H2\HG*] )'-WI,V(]F2*7:3-DEBF-KC);V[\B1C-J\PL(_::
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M"TW:&0_W)<7_W*F,B@7QP2UHIR5PN]%(\;%ZZ QX63$?/SAK_*K#$V=CEF8
MO)$DP+EX^7RF[G-(2T)V-WU!D/-:*+(C<N) <4S7VU/Q\T\=^7N"PH8_IMF*
MGFDQ<>H$MQ# R^CHMFMP,7-\;IPO:5_][(/0O&Q!7N[/ AP1R1GCORN4F4Z
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M0]Y4_KU;(_).A]\;]H\/<,J1)(EV>'W\07C%ZN*S3ANJZ59T<UL*&W-J"".
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M[<L!W98,!T/6:. 6D*"[<BG?=;$>A*&S0@$X<L'D!LE%*V;&>J[&LROHL@X
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M/#D"%!/WMXX K$@NDN.22Q=5IJ.-LX;,'%]2QEHQNYHQ]>-'ZA$@=BI-GP(
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MU?.GVBJ;W%MRW-I.5=['T)+/V:IP"Z&BC+#2OO8^C?V_?Y;G/8R@)/!!G-<
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M^_!1>*]LGI5\#8\.64HV8O.ST1FR37PR?WL45R^[)YFO5$:*7Z_:'MP0("F
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M>?%TE92;>\351\D^U4K/%2D;MK@@C8GHVXLI;96I&%L:,#W3A:[CZ=Z*YCY
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M_%H/\=R+B'A>V(JG9GBJN66Z6!3XM-$]2DKP'Q<L&R@+)V<.AF$V/.MHP(C
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M"P4H=J22W\Q]?,-&.[X6'!'4B#;":3R!;&PH:'H;$LH>+UZT2Y&!!3V.'IS
MN+)-SQ.]8UU0?-033K[44[KP.OAO!8"X]H//Z6FVES';_O@+/8%P;0"99-Y-
M _C_=;4(<= A)R(N@):%+C3 #B_^.5=V.;^ $C]+_AOCS.B;.9QA3KGY2/H_
M;O3W?#!$2/T\28>L5DU(#]GJ7\YRO^VI=>F$A],E1B]%\3N3?()?A$-.,'$0
MW#:YZ((Y&&2F 4^_TH#?+\L!9/2P_ML7?EQX\VXV4(HYJL6*<'$?N[4QB@<1
M)A-E)V67/WE\KOWQXQQ[,Q^C;J)NYO:%9*A56X@FE)B'4=TSFK8ASH/7BC&1
M+0%X@\ZF_7#9Q9TM\YL9#Y>9@+1E@8SHH&,&O%.:6Q.M'RET"G>N/(H<GSN*
M.@/>\A=NJONW1;5U)::4[[C8C2"]BS_$'KFW";U2"/K7+OZ<4@USB4F8:AWL
M5&4+(RM+Q$%%P7ILN9?&*5\F,7?^!U=B$_F&CC)Q]_T-,G%I>PY[QC;=NP"M
M*E[#\"-9G X20O9.1F[.&1T_*]N?_^6'J8#$&XYD3NG@1NR-I2'FWX%<1^,F
M9\I<_]PT:1./L]TN-DP6UU1[$'!IX/B&"\XM%H._NYX!%9U%7 (9%_Q;94#<
M;$'T,L'@E.K(335+,7=;4W7%K;AC.N>&F']RFJ]LD^TI&"4!?>5W1@L-H<H&
M\ACQ=)L7X<O**W^.MCXUNG-LY\MB>0!D(X7D#080,\:\82QKF6+S0:VBJ^?C
M]L.]KZC]D.JLO?VUS.?M<QU3N\'KUW+8BM]7!."8$VK9PEI/C;>8XM[=$81H
MCF 59ZWO(.\_"@(8TY[J&>>+10%']"J#-U%N\M,2Q,2QR@+*NU96RT'L_T'=
MFX9#&;Y]P+<H6<>^,[(7DH06#"E+DE2,B*EDSU*(BAE9(TL4BB+)EF420]G&
M+DFVLC-FI(1AQC)N9GOOGN/]\OR?YSC>Y7B_O%]\&/?<<UWG=9Z_\_<[K_.Z
M;\W[3;%CC(NG=\:-GCI[OW64.G'6QXHK3"D*8>&-_5X^,-5'BV/FAFH>1'CC
M8PSJ6**?7KE B<Z,Z"6P\.R5:&)1RHOY6&UA1052RR:(F2=SDK)C0O+%PUTN
M)S@-ZEN=H=4_A6>.J0B9+3@)72EKN[1?4<B;L^!MBQ%80+^OT\8&)G?I1'Q2
MX=!F?@)- >[ON>R2^XWN=(?O>(JI?\75*(>+12^><JM].LM\#V7F-*O)M394
M]*Y;RMP)IUP!NVZ]0ZXHR^X)<9GP5D=NQ*$&FHC<78[M+7$J<H5,#P=+KH!=
M\#9L&IK["7&@TZ^@\4+>S[1QG=YI!\G@%I[)TQ^_+*WP1E=&16[3,JAV7=C]
MH$SWQMQ8S#&"7/CK+0W2YY$MF]JZU%/F8D4+_!MG^'@D5+M)07]2CP)&[C0D
M\VU3,-625@VR@;E H:6+,V!PNV&W@-+L*:MY;R191$WZISGB:^&:* HU-H]8
MZ?O7Q#N$]]5)S<F.-I%8=&8#J5@L7WBN9>./@B2!DW8FYG7J?L\%#;/D3FTR
M_#;YYBW)'N7H?GP-*H'A1>5L+V,#?+*.0N-=1&.#H,7=)]'G3Y\]*I DEM%:
M%P3TWC"%VT!R<;>'?(/NQ= <F:<2H'DOAIEP[E=OKAZ6>])W/'PGU[\3*\V9
MX794\G7; UASBSS8:Z(4+GF:>LS9LZ#0LOQJ3W@#NIS[62@0RGTK<2(."+GR
M_X LW[<CVU.15T X'0$.]#AK28PYYR7Z9A_I"*\8LJ;_N%3!P<VEN^A#J/$B
MBQ,QDP^)]_+G=?AM/U@9E3-/6N[SXWNZ#[S54WQ7MO @5VC7'02D!G:.$I+P
M-'X4$RZ.]HO@&V$=0'<B!%MD64.SHH90K(>2GF!JPO%GOG.I!G@D6O< 0F]Z
M#M*KSAD*<@+HB;$^ L4>-FG>E?_Q3VO_J:Y9@;0+V0Z?QOPWQUPO[<O1.4A\
M/<5;47+OIEOPLAN94D]*B&?IA<.LJ&FQ6V(_-K4O"6OIZ?"7%%HL,PZ7'/IZ
MGTL8)0.)'R_\KQ_'[.BRM]G 9M9JE,D<):_$ $?TE[WXB??PX96"3\^NMZ^&
M\ <9'_5S_.0B?Q?%SX#5CRJFJ.;;499F>N1>3O;+?P@2/"6BV8^XD3:)<&&6
MM>S#IC#,BGUV+[P)/?4$7O.W@%%9'=NV,Y%Z87XVRB3N;=).X!P;(+N3=![C
MZ_*[8#'(!I-L_X+P2VU5Y$!R9[[ORYBIPW M)!P?$!4"D6=5\?62QWB_-&'&
M<69];6!,GNY0;2.*._QMOP=EM3E Y6K>/2FGXNDNO=^6*N$7!=V46V\C?X8
M]B@MUB0*][V1PND,WI\;X/#.P229' #[["5H#0%O;JW/1Z5+W1MO31D^&67=
M+6(^V?+:.F?@PE4<#]$B27M;5&>5Q,5?<_?"SZ7[ZIS-_QJT$49WV,!>16I/
M%^*QX2PO\X6)+*:]*Z^MJ3%?>.D0J5,D2-HT_*>H(LGZUL5QXIW>LE"Z WJ<
M#7!>C\20\&T"<%>*QR<1@FNX9ZBAP1#U,S[LSA$."^L9*7ETT D 7O #V?D
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M)E NY$_ZG0&I%.Z.2=V6)(1,N'.WMJ;C\*_K->2X,W>F]ZJKRI]>J(ZB9^.
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M9QCO3>Y7'2Z\FA@\_?[CF\W]>^]C&.)_6.>G["'M]C.!%?]SLV1EO0 -,/2
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M;G!FZI94;:)*DH -LJ;ZAYM>#.UR\Q?UP5ZY<Y'FPH/IIG!=QJT?3?\:.KS
MEPJ/*'_.U RR),)/DU Z7;M=U<@<SXL\,]'SX;R.7']DG<]'%$0JLW@*J5X6
MH"AV&563D!:AYS5GEV@P]IU*"&'-N&<YW.<Y]>J PE5NOP)9T\!F&G(EEXCE
M";],NP,^])A[%,""^RM,AJ]J0VGJG14U/@NI7)&\\,3KZ82<N_B&)4/\83N"
MYS!+8BH\NTM!,:V=(!I2M&&D%WJ=TU?R]KL/46^?=FM/[\0^$KT+4[W&N<:=
MKMQVSZ&7UU#N5E[T:U1B?@T;Z,3*LJ8("DV<1%@R7B*0<="#"%:NU3XY%6J
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M+,D2_=?\4,<@;9\?:/M^+6;BPS_ZT?]_M;];A-H5E ^YG1#?ADW8H#[S/Q;
M,:/P/0P>?/M:H[)>H+^7FA:RN.N\OM\;1A'$$\R#&(4*3K<UJS@E\)^)*+(>
M^8B[,V8O=3%1%)09Q[O7X8"AOB#/YM1QSHUZ*%51NQ,BXD.F6K*U9]5BHB8F
MWK;^V5!C8G)&EQ3#=D--T@[8]WW-)DQ)C!(<38*TY_%395@ 7^-I(0HX?MP"
M??'1T]#4*#N/4*>W6RHK\^1TZTOCK[Z=EU&ER3._!.,JLMIL9_VLPJ '.\ _
MFVEWQMI^5,K:UGI[_JHM#1^O^L:6P.$T8V2K-ER5[-5M1>9K:58<:1:!&_OP
MK_M.21C8K;_\>3WEAJ2[4G%!::B*Q,OQ_3C297:9E&>0\A"5B*YB 8G56%YT
M>@38*M4\;]6@;W4H<U%I38ZR#$78G@<I_,:2+D/W.%(K9V?>S-*Z2'$O2 0;
MYC<K RG;>]N%7=X>7GF>]Z:G>X$:00X $-V_W>5]94XIR>[&L:"3/82CCV:C
M=),B1#E(M1T@JL)H)BH%HP<E0>:N-Y"<KC?ZCVLYW@BNNE,S]TXN7<MX4)<W
M:$54<!\7CG0)E0 5PZ@.$^R)8G/6$DNGS2NT$MTKY"_;O3QUQOQ;@1LUQG@]
M= Y[X7B^H#4^I&V0#RY!NIR+!W/['%BJ%TM*$VL\*U^^D#LQWU ^7REL%1K2
M 9X\-]S- JKM(Q%:%G,6'TL;E6[>N6KF=/[7 Z$I S<UDCW30$C*^L<6)H+M
MU7&K9Q6KLW4\UA4>>E@$KTYTW)M8B[YJ>UZ&CW:$V4L!51QJ;X*V4<+H,XH9
M5T:A=EDVGZK%US9,1&_KO\J1#35>U'<>;V)7*##4RAI-@:I-\2-S=PA VX]W
M(0_YQC$R"_:KY,^_^>C  I[YKIV0UO'@7HUV_6$BRK&QU8J;5!R>72,>)(/G
M,E&)7HU0J6?I$6)$,>$9H^,9L"=G57?VG$#(J4)J+$W)$<8"*!](0EV]>A::
MF>,Q*P))WLO>TFJ&-+//'C/[64!W*\&'UKRY5F7#/8BM7F2' NV&#^) 90-9
M949*1F8D]35&X/FGC5X;K0,NP7^6OT3L9;/HHKM3[X.ZA&(-5$C&XU_>FF!^
M5?I\@:4E'CYX3&Q&-*U!\E>: ZX2V>J ] J(:CY,#0WXT%MJ]+JPIW:]Y:@/
MO'<^YRG_1/>+U*(W82[L+[6XDD$[ZH.KP$;2;?'N9*YFY:KQ:DGPS_#'A@%5
M>I:2*(YI.;YQN1*8(F:G_Q?9NIT%B/[.8@%[#'3\<'Q_I"]?59D![?.YE?!R
MS[6Q:[A'N0TC92U2M''<B WW%V2%]8I1/J)_/!N74-IHB"1@$P[/*K^CHNVL
M*LZ)?[^BJ;+RZKGR::_;G68Z@-!EQFL#02/:>;@D&=*^G'+%2ESZ@03>CXH7
MT7#RL#ASH&P@V.W=LFN*"7 /N0<A9D*"X(5B&[GWO=YN=!1X7N7TZ]A!C1;A
M$%$N N92]@8Z&E>A7]0&F0+/V7<FP"VUBNX3K&8\GU%N:U1]+E82YE9@KIX3
MK/XC)@K8/V&.X<3_8*,@E9C41OL/[7N_W_LUY#@]\3VR-^3^J?77B4\9"Y[W
M/R$?GB:Z-D'!B"FVED]"^O%AXZ>XSE'0A7"#H4W#=\N4]"JL;U/K?O%3Q54'
M)9_OZ0A4#'_ T8-L/8$ 6$!;'N,%4<\(&3!/C>X:J&]<B)-4!8Y],\CALV0!
M_CU$J+>=5O ]G[%[CHYMSRA?3<M-^/VJ;45OV0FV 'NMSN_5,A]SF)0V*N _
M4]8C]W7X7;Y0'%,!V0K^TTD>'4PQX*4;C2'V+]=><@QWD56_H67]6<XN72OE
MLG7OL\NM=O;GV+&+38"*EI:\H@ZSU]6,+H1T[.A HF?%,7/#V=5T4Q,=3K1*
MGK6<)"2?_>C I'$\.LY B J^3"J*T7@<(6(X/.RN54.H6\A]OK[:G?[90GX^
M>YT%3,M1KE4S,,T2O_($&\FB,Y))W0Z/[0_=<^2+6I#-4\VQ+.78Z!U QA=I
MKHG:['4YV>$3YI+[''G*J>U)O)Q4S3O);OSU=Z\CSR*3$-S6B3A^.'3VU]UI
MZ\<=Y_1_/AGW 3V_*=)"/L27]JF43I#3678V6WE/TYMF]F.Y[^AQ^I7TSTGX
MJWG5'1IV2I!L' >G/,J1&#@WCOEV?B^<3+Y*@5127]%LX0;407#BXO J7,Y?
MNMZ'U[-"8:!7$?Y".ZIN(X%6M$H;__K'AE,Q5NT8[(U)NM*5CZEG)&1XY#YA
MXA"R.[WC/GZ$^X?.L8!'+$"X&A<U54VX6U<QU%]=X%$K9G@DK4(Q=,(2<S/_
MGL&OUY$0_9_LVMH=?H%:$GH7?1CKC1&&=1LFF:1562JD'7M0B'^4;IHB!>HX
MII0Q*$99;%N+S1.GGI[-U6US%1PZ^NVALM@Q9=@#"[=^W?+>$+=>3_GLY>/Y
M_* CU$/GJ5EX?>MV@^-#)9LEW%<2VH/<'C:DF_S6;^7:(W$SBH/K@ !<DP4(
M=I*+VIH\UY&/T""XT:RJ^&]KS2K+ZM#7UPGIO<>*"2_%4<' 7I0B]OQ2OE!2
ML]3.Z$-_3_*;^&0#;;KIN('6<EAX?&7E&-];- >7V&<KN2P@,GC!9J/.L<F-
MXL'(N,,"/'$2<-OQ$KB9UJ>9<Z/V5]-G+$TB;Z3)KY6;!\] AG@&N/^9K/7X
M#!D9)1J0:<X.J$Q61X95R$<?BS<U<?Y JFRYH0Q9C9[!3!748@&'JL.)HCMI
ML *TDP85?R' E57L-"@O<W0D[O6@YO/:=9XK6H!T;=!R)^A?2Y6 V+^2*ETR
M13E^HO_5=/G?WGN! WH:,0(B64-BD=4"\_5C13[W\9A#GSBJ&1(?+ SVB5I+
M[4F/!"1E#0"I2 E,D7>^T$ )A,F[03.GRG"^A5E2BD:S3(Q/&PDL3F7U&;78
M&:D\TF'^DCC;:85'4^5_X%+T3'Q*Z<'4SCEP8H931JVUR*5#DK2X4/>0B7MG
MWKV#S8XOL34 "@_B7LKC((VA\6N"/L'U:HE%'4>KRRN3S40OZ@*Z&>G65RR4
MY,>3Z)<8:40#><3(#$ =5DKT+*\G969/*:;6W!J:WY=;*ZD=A5T>_,="G?\N
M?P];9A+B6]#[$-]D]M:1T"E_,D?^]%J_$$T*MO8[SJ52UCMZQ'WC:Y0AE[!0
M/EO0Y&U#Z2+A!.ZVS0AE/)*HB5F2$?6\)?,B-$!.RET_F)AUZ^ZAG]=0V$N!
M2RR !SG[TD"*A*@+)0B!8+4.U!*RS-R,^>UQ^GG+;O?/'U^;W_)RJPLY<BBX
MB\/F;7,KVQ7-*$:,YT2D.RY6':8X#,WI2+-X;_6.4>%G>[>E)ZWTRZN<HJQQ
M_=_QK8-L.8(7(NXEZ\X]-9#/N?J)W+"6815N>'@*L8$4/)+U9TD9Y\W^>GP$
MT$JN#SF<$D5U(U\,$+9ZZPP[NM7]]DU^VET6$(K-4ML?]E"3O;ISN.ZER3![
MQ] 5D&BZ4;XC+#U ^&WYAYIWPU^\53\;=R66 <2T=:^S:ZXT$\ 3EM-^SCZY
M$?+..^PG.N##TG:,:D"01Y $[&U*W/XR?1.X G*G0]PX4XH:M7&%*D3N[D +
MJ-Q]LU'XS=U',;(,=%PE77&3.U+>3$?_\ED&\#K28,]7=N'\K!Z52K=T^T@/
MI0[.62>53393'P:G._AW7RK=RIRT(:1))*,=:;7M3-"PGM*KB:4IS=CFK,*)
MMAI*37!YPER<IL1.WYF]WK;GCPAU#3YJ%F"\@O,&X<%2OW@__+IZ4/Z.8&^)
M!Q#[3)+[.$$I;4281_8)0G/H'QWZ#B'$_V9#VP:GO#ID9$@%ZJ%A+O/"VI.C
ME;D-"CQ.19_?H>.4_QQ+ JA;>"&Z2'Q[GM X!NY&YNS<[NY$)HR+K_$[;B7P
MZ05?ZNN3CQ,/T<T*V?NC9E9LO]\HQ!TRF3I.L:)>U8[RU_S;:"&:_70*-:U8
M+;["GWAX94JR/C0B<*:I/@E0ENK*DX)*4'5=OLH$^F:7Q% 4@URZ3JO<R8GL
M&=#VDB0Z:=AP)S![D)72F)4<TML KBF_#5CZ"<T3U: :*U_5"4EAS<DJ]8?K
MVXM--O&4RU7QE!8T89PNGR%5]Q"S@EV!5 BI"!TWPW[!O22_]/^'5"6!CR!Z
MQ_(T&:5Z N11NH7F&USLG[=#PR9.Y[]]WZ/6M:%&LF,!;_*TT)_T85M3QP$,
M&J&+Z*&@CQCHP)6I*$BBYY B27K.I;NHVU/!J:VR6VOL <%KN]&=<ZPYZG6D
M#B8%MVY"CV !MYFO6$#AD/TB>@5"DX/Q48H8<0]UD:).WQV6PX*K$5->"0^[
M#[I.:C\OVC]Q-$-6.)EG]50H9@B4X"J-[F1RD-6B_>7O??^=[?$E^8IE;L*0
M<0^?V\L]W^<:HRD@1NXF9C)\5A_SJ)IQL?WZR%%L78/V8;:/'_^8S ,Z][ZG
M^PT I]VG <RO.(]S K5$K[FC^%3;2T^<(]Z[M=CDQ':93^9I/WJBLX@*9CQE
M ;>P +/O_H_?YZXZ4U%=VK^O;W74UQS&C[RL,.4^^$KO":^GSO=N3I#)SAKN
MM5.5%N&Q,K!M9 )40,_E QU$_CXP;!7^*IKBLZ"D\-E[J>>SV6?;%KWTPG3K
MR:<VW(LE:W01O[FMCC<NRG,HHO8<^ #,3GOM88/. LC;MN5'\Y5'Y7DW0#)_
M,15,'OI^DM<*>=8I@!<F9^&B;IG8V.ONUAS^WISC3?;ETD7.O)W?3@.ZV\<Y
M%W&):+:>[$!-Y;2 #KN35<:T784KG8R_C7T^YQPY7$-0)-DS0O^AZ-F2TH8[
M#C$!K5C $.^3:@9;0Q!'<]IMG7S+?:/6V?79YRLGW":K*DCP[XN0=M?A-PXI
M8,O*2J&??+ K!^;=@D<Y=>@G1]FR5)LL@L?%&ZC =*^0,(\U<B("#$?DUE=5
M5NUEM_AY%AR.'&B)XN$ZX%?(EAT&KW9D!Y6&-RAZB.!A?LT[2KH<>Q_\_*'3
MQ(S#UXR1"O-W\WLF%&5A1_*JI^!@-OC.+Q)UJ+T+?;A9=ADII6=QL_4C?NQ%
M9VP=EQACN"&K%9@M,_HA$%' KI4.K330%*<0G^L7.U(NCG<$^G5WA;T;E3GK
MS[5G)"ZS9H]TK1 NB+#Z38B=$86(CR#=&*J%HO:#7]!)Y 327<9!Q@:%S,&>
M)>A,[^0XL5EH-8J-I-DY4D]*882M\#BJ:1"4:.SMO[<[[]Z^]BR7@M3&\>8=
M!PB@G4>V:C:"R>K=0W C:OA<KC4>U,$KK][_WOOF7Y'/H6>>CWY+-X6$IK6<
ME2\6MJ#MY!$![&PN\A#SJ&F]62=X*K!C1I:4]?W3T,.)^<32KS*<E7WVWU?-
MF-6_LN/I(I4M8P;GJ) 2Z@42U<R2&A1(^53U3M5XT?9)7[KZ%W4=_Q6;/1W:
M$IP !]3AG]U])0S.D=2BR>IMYXIBZ;9OII?/"1;Q1JWV+3Q(/[%8*QO%P<]S
M\CS['TST-),WGK 6L_UE!;>GV<"OF?>;VD2#]]:,6[Y;JT+!S=3SLR(R>%1C
MV/A2$+L2Q[1"J(IB-8_)QZ;G0%THF=\0"?A5[QY*V6^GJ5')T*M',W_\W-]]
MLLY.>N0/R -&:PD#=0KM\]LYF)@P\E#5\4=)*=&R(L!HJ<^06_: 8<^Q^OW'
M.3?Z0%1%2,?@GNJQ:-(X)9.L':O'_9#(%K*)PIY^=K<MN=87C3W/+CPUM0[;
M1E&N,9XV*M 4J8+^G.TH@X)WT(MJ02Z^?\!3X+=\D9<-?H-UKRK=)?3*9Q#M
M;+ASX'!&7J,([2),'+H?1KBD7:-+7PY_)V$6Z'5\UH+_N:[3$1D>V=DH'0RJ
M:F<73*@+%7]*&H3O)AK-J4JUY?/@A^_.Y3#$]>83VKZ4R;Q\_?9!6 AC/WO%
M4J<*L1>Y05)M^Z",$9ES3CMI,R!91B]QS+M: %8>=<)>RGUB3<Y\.?6PF>S-
M _F19I-/V<\FU)X((<D(34%G2QM(ZXL.&8;Q=N$A?M22#B(H4R^0_ZC' +PQ
M:,VUV 1X .5A@KI)!?B F,9#8LN^MC#DQ9JA,3+A8%6;Q+-3"X:Z%M,OW0F:
M8]_8[KJ!)-K3>*G<E/?9@PXC'@VD[A25 PI%B1K)*GB[A>O7],P_A+H:J<%N
M]4#,V4H&+<#F3F.\]JPY+(^KQB8*Q:\;IEU9)II8M%Y!#']**7B5<20MV1Z+
MZ,.6C;</3II*Y1 /J@6MB<\4987.63D4.Y_)>&;>(I'(._\H'?;]RR/4:[;P
MXV>483WZH5,$O#\Z:I5NI!WWNF;T]NC>>:W7^.>%5[HK?3QF_]8-(..:,LX/
MF4;G_ZJ_W>/II.M-C(FY6=/)]S)XX"1#E(,=>=8[D6?C MOGMQ-Y[.=BO,D.
M/0=_+A;@<]:H;&'<^^^YC;$F2M)QSM:=)NB3U\<IS52WM[!S&QU789[*TK=5
MG5U:O=7XGD;!:OS5/G$/*IUERKP<KYMJI3@YW.*^ER*F'39[^PU;<T53BAEY
M_BS %QQ=R^2H'UL@_=$..>6<L^3?L=)\-;ZKK?\E0=JOD1HP.T(-(:VUS8BF
M_L(4?*TJ=E&]^T)+,N; 1\.^^=G<NJ[+ZB[2.^0KD3OD=>G&U+JY!J2P5:D%
MF?N:RQ6G&_Y<QWH^CE]9N2XXW;UM*RD;T;K<B9GFHSA7,TH-Q">I:FL=ZC!?
M9?_KJC:N1KYJDDDF*N%:SUR%<EXN4OV^+^7OK[^6,/2G0?<4\V9M[%%!4VU_
M&W546\E_>0Z>"7LEI-DRV6MXU7@B4W)9VT AYWP UV_K=]W\6K?O!]^8C8C)
M<D'_!@8AX5/L-9PM3#JQ?@&3I=.4$NI%N$ (QA+?DT+7QOG'33AKN?%K$56:
M0H(&?2G9QSFE6A%24&Z8[H6OPH$/LZ_%B!\+=GEK*.J;D]#;%;PHN>:J3;O$
MUAOH*G8E)[Z\Q=:N%Y![?I=\,..Z'G4+=NG96EGZ<AFRX-$3H1G*/ZJS $H9
MXZ4_UA<5HRW#63_N05JYZFH80EGRCUGA=\]MX ,[;WX)TXZ$G\SC(H'C]32E
M^UT54]Y.^_3?ZRWK.YKH)FBO)#G]TJLIP/:\3"#-&'XDGA))59]#QH\?+LQ6
M.3=_NFV<W*;H7=.7[G[TULN5;MLQ#/T@U>U0*S*F692D<2[Z=[FWUL&)DI4T
MGNR;T5))4??1E[*)2_F"EG.+[52F,EV5'!"UT.2O!3[@8W_.R57^MFF,E8BI
M\PFY^U*5R<ES=<C)Z%D]4*59JPL??J&F7+%)\-F68.WZ=,)A:ZU0Q;/GOR2'
M/E^>:KJ>!."99^CBI/ANW!Y7JEG7E'%8#>J>T3N(2LUZY(5^D53;KLL\*^9G
MN:+)<3GLX)VDEI-*W@PC1)A#[*4#%^MJ>OJ7=IDY"_"ZKB1_Y^G1.VX_[2ZA
M+S*XV:G*B*K _@OBUT8A@CQYJP,IL0PZU'S,%+LT5=/\^>L- T&9XR^^/W/.
M??,\MN7D!U._(:0;;O+!.,6,ZA0ZVV!]X,N<0VG0C2"C4,UWM1Y@45NV:/TD
M<ST0/8<)9%\]@I'. MS#K2?MF2+H"NJS@(/(-MOW:J^90<]K:6>EF(;Q_C@D
M1EIYZ>3Q?*$,Y&P13OSA8!RRPCI)@_;I:--(X[7:"\,K/VVF\XSJ%KJA/[J2
M6QMT4"/V_C0!.B>H$KTRCK?F=S:<7ZX]C?3U.RL14'.)\QP(-B)_8_48=],#
MM S6'7,0\154S=UN+;%</_""!>P?;$7^LLC_>;VNKO&[NUK[W2]OAKX?S%CO
M0C9!KW[]1T?!!.8HK@(:S0+\4'L,\V$OBH;75N3]4L W*O9[5:9E\9]J%Y*Z
M%:(D.=48Q0$ZT<Z^?VN, N+#3WJG VAVOE]A5V2/FL3\*.P7!"9$K;;.$[Q>
MU(IM:[)CJY.FP@):#9H/,_NW^$H<N[4?Z]UI62/+E'UP3WZYNBXGZ5"9D?$L
M,)WOP'T']$'(;-[V]?>T"S?@;M1 @NY@[(SR#?ZM;[\HEO?](TY =*L\OG+(
M]J2%V@_<DY)GW#<!SAP\UBZ1F;FP7[OBQ#755'.NET)WT"4&[$PXCYG:H' ]
MIGR@IN'7)(HZ!(Q:0[:U<BD\)K%/,@?7I+?B-VS>,_ 2,IF$+^RO\RCBFE4I
MEKS6N=W\C 4L?_PL(:@^#%;'_'R+-7F7+R3!R&8_560\I*(V?J&,Y,K&3!TR
M+XXHP7UZ1MDX$KD6*19(YQ$+)^B-ERP?UH]/J,KY K:KC+89#CCJ%YYC^:XC
MS4IJCZ2D-=<!<]G1ON.<L\B#R%:U@$:1N6)BR*QV%_@ 7<ER3-7@28K\&&ZU
MN#!AFEM"F)=G<^FD )C)&U)*-R;O32TB+Q)"$IB*DY-EZ?KB6ND2ZB,I:W)/
M"M,%.XU0<]+-+';MJ*ZGB2]1;FT&#?_1%[*N':J*,!"KK:ZH2C83/?VNY9KM
M5WLPN6@6%8WU!NWY0;7LVC8.*\TX*WQTH+=D@5T,*ATI2,XSL]F)K!_?V#5^
M#9)DA7P,Y1^S N/MB:?GP(+4:^@M1Y?Y!^C*]SHZI_L.U)SN>^V^;1](@C!Y
MT7C</M@V;HZ[$R3Q&R?1&,#Y\:OS<GCS%_[(!6A_2%JA!R0DD"C18W,?5>6=
MSP^5I$+,J+%X?:=V5]D*%S/CT9*\@?71%T\M19+/+)C+18\<\)O=_,?FG"E)
MX,MJ&@E#09&5HN&\X<J@%7N+W!+;1-6R[G/*6O<W]B:_?(F&?OUPG+,=XLX"
M)D%M2+9#!V@T"<X1;HQM6EPGV(^O/>5[/ GH2( >:*IT7E62>I[>D7']7TWF
MX+;ZPU1H^V&#Y$JIV.&/^"J1,T0UN?,YY=,Z \K][*48/6G6 JWVBKGU#>[A
M<=+E1J4!^J-#17>H^^=3P:>YQ'0D3?=>YN@Z+S?)#OQ!;[:K0T&-8,^'8'[$
M*%.NBC2 .WG<TS(S>^K4)[ODQ]%5@F@Y68(.T15#TT"VGH.+D$0ZB83<D!LC
M" 6X28@/$B\[SGW0O%U _OZSV_)G(;H-92MF9[?[DH"--10+X,%3R:203AD.
M]-4(&>D'$TZ:?^XE.AXYUWQ!6'WK_DA0P2QWFPZ"DRY-PD;>',$YQ!O5:/5'
MR!]3S%$;3(]\&;$2I*_\U?N__D,NM@FZS87$K-%#25L=KD>&-7OU-".*'?H]
M9$KX#>X\:[Z=Z67R'7N*:W;^YBP%H\-(8P$>$=P4<ZHK4_C;6N'8W5*,?#-V
M]&VDD<+GE%C;*I'J:V)V_'DAH#E-XL@_VY]^P?&S #<I2 RR^E"R@1K,K]->
MW#$D*=V:"-K/IT#3-:>Y% H'S/YM+02!9=PP1B[=1"G:*:H0I9#D2T5V307V
M^4\6EH^J3)B%WIX''$_PZ'!SGFPIONDNS"%3:0(@X+\@)&M0*I.S^C H&N*;
M$FY%^B#PQ''0_W2X=]>I=USS8#I7/F51;&9G\'C6+%80!NY*\V4JC#;>(@MU
M.KITO0@DI,"D'C^^I>$A_2KQ)5%>QE+W+%?*K+#R"MN1OD \V2Y=QAS [85K
MDM9QUS*<XTTLT@(6(B\,_<WHU3XN68Y2E[:^2(#XKDTTM*"K:U"WFX]J.T(2
MJKZV7R;OR[9S/B]DX!1U6CZ\;NJ>X<"8\TO:IBC'7YP2722+\&/T$6FSF^@Q
M9Z&GYK;.[ZE;(&?T\L[)N_7^+5UTM]3,/VLK&)H,581RD33Z(S[V]B?LZ*9
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MJ,H41:PTUF_PKV5W.Y8FH:?* @IF\X4FLG>ZK$HC9[,@ZT_ B6@*_QCD#R$
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M/^68I@K,/'SV^?#I(].MB9?WS8HNIO/\<#7#0R=1!&YBVEL?%B#*/ :_,6X
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M'QZ"(53B#DRFN'VKH#(%5:F[;[_8!9I=E#46-%G9!(-5V3Q0>F;E)S<,8?[
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M'#J?<SM/$;?W'N'1G+HC8%3J([SQ>1+RXGZN@01[F40UTZ) ;:DA]!&MS#J
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MTP_.@1T2SQO5K[=6M3$R$S&ISG8;IV_PL5[@_=6]E%Q>AF EUU!!7B.,! O
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M%V@2%I=%H6D;[L"?>:[1/<U9'"6Z!SW\[T''2WP(;5H)/PDIHG#"9WLZWZY
M3YZW3:QOE68%7:-1 VQ>LZ;X4#N+P$A383_)U?!=W943QV"GTM[\LW/ ,(5%
M>'7!1W^>!@TZBL(W!\0&#\3J<TP^[-15^0!V=D1Z6FO\@DVC"*)^9+FVBM8!
M4HF%P;^G[E"'45Y),3559";$&]0J(C*0"HK.9VZ,8'AP'Z@#7QE@H&=I(;M
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MKELALX4 )!%Q*NP<L,',%S/CIK*O=.M?ELXW1*M''P> V L\/[+?=FE\2%E
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M.%NF\FF[,?^L+4H.4[YG.O@Q%=[JR7-PE<E!9/XW:,SZ3W/6E*EP/HIJ]Z*
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M+LL6T<D?],I0J,J#3X4U//&6/,:<LOE9J\*WV=5)2CA4G*$J1?XN,2ZI=HL
MY?M](RG0?66 _[6047IXT(SCPW1+5K\_Q484" [!3S.H)2J_2_%9$*JK<M(R
M.+?N_]UX6F7D>'!I4DHKK'OEB]_X;?;^/3CQ!I,0+VPY>9LP!+VOGK3;>ZLK
MY8SS9D0M+QP+;H>.)1[$=1H*C.BSX5KX^2F^YG4C?@X<M'*(A$+TL^M-PX!
MN9>6=Y@O?O*+L)U,B_[>4M_&(0"KFBKJ+-5(JH^BUVG';5HLOUY\TMA U2\I
M5(XO<9KK?:-E(J4[!:GP((>?'D']J;@*K+4%.PQ GO$M.Y&:L_R_IAE?D96)
MLO$HX)/'\7<@V&'LQ'@B.L(/OF' XV@P-1,^H=FW!93(@PT1AD9ZG_4$C%M=
M!AX]!'28Z]__ +M'<N]2G6GHW&/SAY[T4@-[#0(-C7(O<3@&WK:VB_]M^-T
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ML@?^$;ZX-,R+IRK=IKIVP]V[1($M9D= W\WVQZ<*_SD]OGG%L:_;,M90F-*
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MB).,E:$;4/49@^$<]%S8<>^"(),;L1((93;&IU7>"5H![ZCIBCSKSVAVKQ4
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M#<KN@O,J$TI)6@VBY,"W_L]ES$.#68XWNM <M&7Z9!H-RD%D=7I^!MF=PEY
M,79]L8YJ/@38Y1_->K5]4Y0%'7\Z.EEZZ4+H^!>G)'NE?)-# %\6'8E>E6*&
M)7;^$-#9>I3<STPXJC/0]ES5GJTH$"8@I"_:WU85=6=S=6Y)9KWZ 0>#\XB/
M%%?+\<ZIWTZN0:C. _>45K7RH%"[.H=Y^7MUK[YNSA^8"2?>G]H^FWV.S\T7
MR1JNY F7-#Q.<>G3U5.=WLW3:%2+RN!!!]@BFO\96]B!))HA$^PM4 C#BQ2^
MY2#LI$J=V\0G_*.CCL8HN><1<YGTF;[BX]-3+8SV0P"@[0SC>WVX-E$[L:1V
M'":D>:*5N%S(^R,XX-4Y'+[W;L@GRX8"J#IU@I2]$4%5*".P%<-ND]CC6DT"
ML8@$9S$29*"0DC@X_>1KDX?K?9E,E[GG%X,>V-E!"OZ,TR-06<Q74;HHHH&,
M/0140Y.>0-V3O?+/I/BEZ(Y_7E374TQ_\<>TJ\JPQ40B)KB3LD(^((;EK0X2
MU]O;+N6+< +C75IC!;7U:XQ]"@;Z;AJ__J.!YCH$/%R,!XLPSGD> H3AGL-"
M]I2,.V.VAEDXB2/B7Z<CN1( +%J1+&H%>OUW-N<^!+;%FSE8A[@S;3VR"--B
MQDJ@K8?N&TOH>R/LM]D<7)H 28-D<<F8O1"LS1IPNK6,P4$B*9E-H=WG'3H2
M])^M-_.5G]_&_&0/#>ZL-F<28"%%@WJ$%?@1S>L0\%(;/TP%@/_V ,C:3Z**
M,?H/]KJ!,U-=BW^+SYHM66#V8YH2LZXMZ:]G?M]FOW.JT?$"((3PP(2G#/!Q
MIIS7Z^WP)(:BQ^!:(7$-\4?FLG>%JC)%YXD@E&V#5O,3D,:[D]-OJ28@C5@Y
M\!T'H-_H',V8WD;8F#6QC,D_UM3,/B!]*I4L4/H,H?T-,K+COGP(L$F=52KZ
M.]3\(5I@#2PL@9?O@Q[OPZ,32F*K&Y(W:\;X]>R>?^1^#SKW\:.QF8Q:U['=
M$4[/<OT=!A<<%ZS/3ST&NT3\^5W:"7AOU&_OP7-NHX?/Q"X=5(3-$'M/-% @
M.!VD1/&HMS#^W74%)>9+Q1:!:[:2T)Z@B)# F%91WI*#6G%"6\%Z\%,92\53
M;T]NRE8^=C:L^^,>_6>M%LZU.BG*8M13D7G!5/BGSSVNI^%%N7-._)$@;.%Q
M9L24T"M [LAD\3<\C!/5S>)NA;XUSV>],YM<&%/9&I7%'[8M2\.C,/-7X!#>
MP=J1.8>;27)WKW>DCR?'WM&1B>0XW8A. 1^#J9&HN*$/6/2)F;R*<_M7A(RO
M#GJ?V\ZXWBU565:X>D4FDI-]"<I#DZ?7H!]_\R<.=R6A^6%@HD&3XCO,^AVY
M.QB3:4&Y']4LJ8*N?E(O!H3K7>:!A8%3DP>N63V_?I(P&(?>,0O](4%9(]8:
M=6D 0,AL+9%&9WJ6GSKL+KT4[8%(%H?Q F-V+6Y.>]9D8E34U4TMJ9V:,7D+
M#R<_4C*P6X0,JJ/1(8!CL7M]BY\F1Y0;*K:J&I%+M?,IEGJ1ZIG3P<!__S 7
M]4*)L!4%9Z>I$V5Q"QE8-*==&,)T;(SE3>RK8'Y5C8J(INEMRQ],42'Q>482
M37A(U%HD)U*XEU!LS2;TPF=0<LI%3P!]8@.LKYS?_GG:<L^I?$?['KVBU80$
M)AL0+3?VRDJ':<K*YG:6G."NL[L9&[=;'YU>$7/J*4ZH&9+)TQ>G(U 9K1)4
MOK5\$7HCS83TP7J1*OV[?WYZ)G9_:<)]7FJ\Y=E>@,^3C+U*/D."D%.D:M/6
M(> 80W0-SL8X07'I$+\8\;#([LS'1J=W-I(#BL"%0)65^92_PV+8)%M G'!/
MZ,SBTNZ?B^:X0=7;6O;15>]@:=6?D'MCQCLB4K1B<&%=-\V5HH=#((#\FI;'
M@IJ_$7*-#A"Y%T_8RDF65*FQ0S[\E R)Y) [,1EI>;=BS%_)R>56'?IS4^)V
M[^\S^?_GN>7%YL_82 Z9U(+QL9NO2/K5S7WBBFZ!.ESL<AG3-BO9T0P^QC2H
M^J_G?UVY0ND@,B[Q3Y_7_/"2\Q->7HY%;N3D0=A$UIA<6D&&@VY?YS!FBUS9
M8 BDY, +8.)$GI_O2LLH 4;Y!V1)Y/RFG2NK8 =]Z0-[)K3%B!:YX*Y&%:(9
MCQF>AW<8M1E2BHW2Y4>A&LNIDT&D^B!</D8DZ]E,=VC$ID3N(N7#(4 QB7+I
M$/"HY!!P8/YQRH8JQ^@Y0&_,4JU@UTEL*3$5V5WE!$4-NJAHOG]'U^7N_K(T
MLY0!PW?-EE+A0X87I_X&))"/<0%SQ0TF6KAZ9VWO95W_\01[[I\L+KVF@]V.
M5.2-/#V1TN%/_VD1^?_20AVAUX$\OZ%F]'#*V<D5^B#^A#.-$[@QWI(IX_E[
M^G<-Z1T.Z;]<3FXYH3?628_ J4@V?7G\P)_QT3.3!(LNVSZUK$?=R:_Y+@_/
M#U^9S-K]3"@=-BZJTG^V=)88%]EZ!25W9.W/%\,ERN7!6E.7%*2GCL[0G/M"
MFS<]FLGHRA=G11G'X?5!MQ8[#P'$U+ X]W38E"$<8SCRYI>HSZ),R$I@G>CJ
MB=]A#D8BI+HIPCX<2O56;;?"?G.KU8UDLB<?N(=V3FS]\<WMUE9_O6<M"TDQ
ME6$91B+;:,($U7.!T1>0SY,[W)D6](82L3D2O5?A_7/_M)!:M/?,3EA5?>R&
M!/*>E6T^.^EX$+K#&3B5S^)U\ X)A3VPGI.]:(RJE>3!!Z@3',L((DS;(^!L
M^G;X?HWQB5\CRD:=TP-J":[?$U^KL/0M#%\;?6$@GKB_1SY#_Z""AD!C[%%)
MFS0#_MB2ZLG24:,2;6.LCJE,=OA24B1L6PV!6Q\,8[O\1-BF=[%FA6D5J85<
M1%+MM*.)>9?,KO&_+_J=_IM7Z1O9L[7J]?<'O//A>]*[9 O11OL.(U@PU2E\
MH>$04 /L17$&"4UU3![0[']E?9D%6X3_T#AKGG,*(V \TXZXU+^>2.5+BHE,
M)"[.2I 13?17X7Q("<RJ55"BU?LK+N1+E3>Y$XY*S48V6'Q16V J+5=$2@UC
M!,E"4R/QK9@AKN794JW7.<K4SSO?'__!<^G^T'6'YL >T<D.;Y60+R)WK=MT
MW;)"@XY_UR*V%G+V$C[>4J?8#" _3Q'FX=0'05$]]MXK403:A6;E3Z+<<J*$
MYZX[4MFL)Z=.SFY-)L4T(\%63&/PT%DFD^X$U=?%M4<3_;\,EDX04@HG,?17
M1J(")HI0I6^ROQ:3?5:$G3L@R(<C1K >ZG/&]!22J6WC:$H?["C._,?KZ_P-
M6DP,\ X<K;76_:<D+LT31E.B?-<P2ID4<[P[)8=8WI&O^FKDB1SI6))KN6:1
M(8DSGS6SX EO1R!>1ZSOQ@=2RY(<DH.I\[MZTZ8K2U6B2H??*^?UN]@E>S@\
M?,"GGMJHP3)K!=9B=!T"ZGH6"<%8E"!D*EP\KDNUU(O[T>=K03ZL+WI1C2^3
M4AM[PL[\W=D^)!<<RE1X"<!Z^?APC@'L>BBWT[F].[5.KM"9A2M>CL?4@A_P
MSH;XX W6-W15G]9%)E)FR5@ZFBGK'X/$*8%7:HFN#0D9]\<P^V5YMR&^8D(7
MO0'&,VMOIF8T',\+VZ0R)I'2E2 W9,1!'Z*BUF-W[=/9^GC;;T\?V.RXV>ZT
M*KE(U(S5&5%/,W[8 &M7.BQ ?=FZYT-8&VQL3BSW2D3IHK).W=PZUS2D/IJT
M_J ^VR _40D_/%U.WD73/[7)!!5W!8;S-1 Q'I-@B$,\%(/]"AN1'GVGV>>X
M<C8I!O%YM:A-B])!#0?35.F?]2\1[Z@><_ ZT5Q?6&I;__D@RIB4-"![IU/U
M?%1#^+.6-P%%9-9_(G,GF_"%:CO/Z$?S_P$*V0?Y (\;EGZ$N^<%5PXV)@??
M,4,_-1Z>ZU5;>#%WH)6(9;#"S+/Q\AV+'$$+$+;17U-^E*W<H4LWDS@?[ET3
M4$<X<DU2D'AV2BAQJJ=-,74"^OC'GZ0O%MYV9,[D"ZT1W ^P4HU#?.J7I31%
M=D0W-*DNSN'3TD"2=6DP+DC_ D9Y_,2ZI&C*\S,[@GERF8XN4+3]04!*UP.F
M;40X,S"7$+->\!<5V&^04-,Z[G4@H6=<K.3T L:N*]C9V=#EQ)P/_A*JVN-+
MYR27TD_X;#%YM8V.\ =SV,U0KBYVXYUBEZV#MS"S ]NY%P!'M(9@PSY9NR9Q
M_M<J@^ WQW/5N)WM>YZZL)\*+'CBWJ9N=,"6PJ7T#>VYF#P6/@P_0KM+.K9X
M ^&09V0J]43N=6?U?K9@S[>8)R[?F7C3M#6]\C>H/[3Q(23F/:R" NZ^MW0A
MZ_C<7(_O?#N;B'*:5\,D_>'V])U[S[2&GGX(@'X[!& @>%2B(="1<G'V<ISQ
MV";J%4/J2IGG3>W;[<*%*<_2U9[\Q/OHC3RM(EO\1:=:%/,E$/G)&<3ASEGX
M,0?(!0CG(\('L_<:RJ(8>8]46<&T ,*PLZ_1!J<C]6RB4CO:VQ+S?)U\BV+N
MBE>RY.]:,O/1#/+K\M0<:;C/+SR,?FK],]BV5^\'>]N(LR]5EV:;C2_KL.2D
M;(=I:B3XM]Q].JGVW=6V2O;LT33U/=\?_I6H/NG34(X@I6[Q[<LJ2/.Q3=5H
MGMGKL3HSY(RH9$)OV.I1G\1]<_)Q>CT*_@1,L6#,X/3@W$Q(N426RC?:<=P_
M!'A0C7TSG5I@$>MO%R9VO3GGQ#];@26<PA>SR4S!/TICD^:IAUQ[?P9!7B%'
M!;^&/#3<4OK6=[=!XLOZ1J[*">8?*S'FP?5OMS8"/;$#GVB*[ G#\=*$DY8A
MDPN6+T_)GC2>1VK/2D!6%X]2$EK!6!3_^C"@+NRN94/;!24?P1Q9&PS?L6<M
M8N2_DS$MFI6&X!ZH)"$:-T5Q:5CZRKMW*)4$+Y43O6;)YBJ/[W4\Y3,DATAG
M=3"ZT75GI@C>Q/+[I+#%N$+B^"O[\6;3VMC5.79.5J&M.:NGEOG&:C2#X**#
M:>72X8)_MAD)^KO+*8MUH@GA0L/8;]YG%TW#C$3O(6Y[.H-K+'XE][H ?-;W
M&O>*<"X;N0HH! B"^HO 9!?*!$[UB#U%=Q&<Y%C=T )90V&.10_XRNE=Y9C5
M$5RY)/7LGTWF2U3J@C^!8@Q7R'8471@44FBTI&A<R(:87FZZH"+'$^C#-:_U
MIR\$L'=.Z2OHWTLI(6X5,+_!<V2B_&MO7/#5XRFS]]ZX$PNX_6SZ0?]6.FEK
M*]3;X+5EFJ/O30U9I)B0)S]3!/+Y&IIJF[]4U>K.@JO[BY8X?BG_"GX,:R&E
MS"VU=17A(&Q,3"!\^XL)?0P@L;+4G8D)MS 3XV2"Y%[*D]/;(PXRT4]6 AMN
M[*E&MVG!$Y!<K6)+^]XG.BT%/.KM:^QEMP1RL&8WCK7/B8:K1[SQ8^XOQO'W
M:J4\/K#;S%"0=HH4EW*JRNF&$[LY\K:#=EIOS<D?]9WMDNY23R']3)G'#,>E
M+7(KT2:^;AW->PV7/5K'5F5[JE7[R&47FSDSHS['1_]$\-HYIF6&PHR_:5\(
M],12@":8\7^P]YY1347MNF@0!.F"]*Z@H#1!>@N*-!$!E5ZBTCN(]$#HO2.@
M($6J]-Y+Z"!([Z'W&DD40B DG/#M<<^X>WS[GK/O&&?O?<>X^\?\MT:RUCO?
MYWF?9ZZYWMDUBV)HT?U=8-,RM%K;%C3=1/'A3R=KP\ERO^\U>MFOT=M(@D<O
MYBYZKJ>%LBA8L.UE>D76W(@<+-CXRV!BLLT-B;&7.V'PIOMNUYG CBU7D#?Q
M'P$2GL9S&MM,'$X9:#K>KDY=ZZS<^56]ZZ77+VE=9 = />+O!UJ 8&2;J&_H
MAT7H/[O*\8JI!P<;2_,]+M:Z?_(?9F[K2_?[Z->.$UR+%?I_B)7ZM%YJ.B^G
MXZY9'*LFRS#<WI428\*LE<X->]O?=/AM:V[^$Z]?8.E->F1C/_7BGRO .@0>
MN#X6E.@ENJA=/U-/^:BO/GR:13+&3)TEE<;;@KWU;^S29CV^H'3C)=$VQME_
M5A)2(]R#)>E-S6(-[QTKMLM>V%FQKW7BYGB;Y+Q$4WLF$N-9J8.F00J!8K))
MP'<WO<L8-=),IS8[[*6V107NAR]3*([*N_!U-)"[RP[Q?_WW5!4S&@RE/UZ,
M-)"$7^H6FWF945-(1+O?;!FXN6D2">ZU^GF?\?\2.Z_PTL5Q[0IP_6Q]G W3
M5P "XZ[4652B'>,L<#'ZQQ,UY?:ZVC"\C 7W"S8M]^,9E:'YFH/Q>=*H"I_P
MPWNWCMNUM8A0:&1_*^6OLK^K]8W)VV+O $2.W\ZSEOFN3SVNX"N[ E =A)L@
M<%^+Q3XPM-5'K?53/3M6G!\#6[5A4)GH$<FC,X1P'_"VX\F/T^:ZMX&SW>HQ
M_,)?7=E,FO3ZY7Z=R/,13MM44F+C(#:8;%C&VAZR?3:4,=Q2)@0%- _;&FV*
M>;C<5'*Z/,5>NO0#\/^ZL."U"Z^+'7[*'#$O<*MI5P# =;].BDO!1H1E0RUQ
M5:H0['-Z\+,)OUR/B T19A*GI=-=<;SR);])OP9J*()+NV-XP?=KD"E%X>M(
MGD:6-IGW=>E[BR7A4=:K3?P?Y<K,V0\;L9G^ AK(J;6BD$MOA?3TYRW+Q4WV
M3#NB90:)R02#S)CF/9D)/P>&R=T\O/:7PFM_I2XSKKDD@D\79MFN8"XK&(](
M_UC=-S9KIR?'>,W7#6F8.89'7P%(H8MRO,[K$+2J0D_M8(=]-A#.:3/Z,;K1
M.4'>K?6ZV+HKE.=&H6&'J$MH([8A;8T/85EKQ/Y4 -((K&/]U6-,>H:7#3*9
M3<O'RMUS"C]SH\Y!J -LW3'$O%6+6--Z74WN%5CQS*;;=[;A#SB1E*E;XNB\
M8WY1R8-RK(2O3.M_4UXJWJ"BT-7"G="@+ 'D%HN=W9^]U-QU!XLOO34[RB\9
M 9O'UM_W%3EBE<$8#"UN.@U4W]A=KM]WYL\1WO/:T/[U_KU)UCP7-I[;&E!7
MY2X%;Z8!Q.E.1U".!!G_IO/"7_Q#H9<Q.EYIZP(XBH9)QY/P:1UWM5/BE&V,
MV(K!+ZO'Q+^AOO$^F ?12X)X 26'K8!>"^"%^$W]D#92^[5#/W_!CT,K\,I"
MJ W+G?N_$N"WN!W65+]MN??YA5_CV,L9'HM17<(- TFT8N&?^-J4^::YJC%L
M<P]N]@;&P;N,"U>^'!M#:@;Z%ZY/J@O ,:'#W?('OH^4^96ZA[SYFBK\Z,"&
MF*UD]Y[@LNS&OXA:LZCB4A#[DQ?M;:0[K%YFVB&;'C.\S)?\6V/S]JC?4+QR
M?;I1+O&W"X5C,F68)0]-(D<UBY['#0=1V,<XGATJ=R]K5>(+JQRR$7X(6>=<
M-.I9>^8EL[(S>8#J'S]T]!^^%QW!_;DQ93OQSW&_I%N4\+OZL6MI_ ';#'&P
M'YN_ O3@Z*?++H5)(A>-6K*6\[*0Y2%F1OP6MV.__4;MJW0UG\#IA\#WD;67
M+]&Z:V.,PS8-M%[!RC4SZ1.<7B%C-UYH2Q"OM2*_46P6O$4O(VFU0B"WP.\W
MU1ST7Z<]G=R=9AC9$BGK%Q.LJB)A'C!A <!_5&9 _CV5I2/I'Q,[%@IL++\"
M],8OWND%$EG@+5AH18IOL9%03>/1,5>]$"%36Q4QO%W2->L4Q?XO#M01X^)_
MC=T:SEBP; X,3]&]/TOVX>"ID1_BS3&1S!(!W XGH_;7VHF,?P!BKQ6OSUFK
MU8DU'YB%B?F<S-XQ?BY@V?28_[Q6P'N%OCIV81^6BTV$V/#'P]S6"K,WAS,9
MY&\8EY9&NYE3=F7J#R44>J:8[#+O*Y]6&6MDC2G3(W>/=/%E'C<+NBVGL]X*
M)3%&.XK9"]>7]TK"72P5;.)MW[!L5KCAB\/ _">\U ._P]LJ'"-NGH,-_9 Q
M6+">W-18>[+,V,#O:9Y7WU9B\7O&U*>+4*GE45D=WQOZ_P#F,&H%6^:$]V*@
M\ OJ2$$Y2>K([-<SP-J1MCFK)16Y8I[5)F[KW^9,QXI.?JS*+I ;"O>'D<EK
MQR%RSN)!^Q\/6\">(]9LA<HA59CO$<P#%3?MP5K(X$MYM/W&*MV 76.-C8_R
M2F%#&8:HG\E,,;3*A6K)FH0YARH]ZCP:Q8*MK@0Z4%.C2U^W(=HXF!P9#LC=
MX\C[FVG/(T:27@B)-*Z6^\FJK%_K6"\@'IA(57@]L%,/85G?GF\4>AJ/VCB@
MF*1Q=A18;ZL4YA2)=I)TO?:-9M>:YP\0/H'Y!/(?:*D,$3BZO.N\X5K1X\8O
M=P9WW#K79 (0L%HK6#>^N,CK:?D^)P<LM--D"JT4_- D$IS0.B[Q9)49+W/Z
M0^FW5^N.^VVAUM! _X?H8.<"U?*1W'RJ!MJ7[PW!PQ$;V]T-(CMXOC$Y.W*[
M!O7T*HEJ[.\ZOC;9A].\>%!+/G#O??\*WJ=?\?L+'.]\ZII_O]51%OE?'F,N
M#_G7VR/U<:13USV)$3VXMM_ DPH[.-!>.*QEKI]Z86Z @Q)QH/2@OG1!@*'4
ME2].M/NMD\')NN93#!?X\9P"!6X$1XH 17('";JI-Z3R?V[XK,%DE:7*]'YN
MVQ7/HWM/4"78+V!)S%NP2#-BM*'4MKBKQ8_;X.VR8&C_8R:(-RM YM/[O6>)
MY](8#?!'Y$H:@E9K86YC)';L\D$']1S<24#<^O[LGRZN3$:W+!"'A24/CD?*
M031SM9G^+R=\!,.T#ZKW#.A-?48I.P![Z0!3*>+J'I+)L(U@%JG>@P3&J=X,
M?LA_)-6Q6V?KHS[700&SC6I-/U/4>-?<[[D8.G (N@_IXJS_48#-J,?>T*<Y
M:!&.K#!OKG,@O:<?19L?UUF5X+;,.MDQC<C*E(A?-V7I7N-KJJ\)([WQ+78H
M\!7U]/6I(8P0<V#4%> 63NR0D^$*8)7I,3IT:.*19HA(S1E*,%$;:6X@X3#F
M%[&"]9'1+K)2!BAL&!M@9J% H#F4OV\5H0."O>DS<F64L?QFKB&ID_ESASG/
MA'#UP>1+2*NN^^$8FH^D;T0,;;7;HW ';6WKE:7<WV[N#4C1CA%9:I2D"HFY
MG,AY/Q]UX8Q2PJ;4@194U[^."U3$558<T$:WFQM\FI][8P[@VXH8M^#C.36?
MB66M/HHW05J'GJRR>8'T$:A:A\;T5Z6V@BE+E!,;B615EY&5/X\)<%-&8T=/
M$(V;C9TC3CO.Z!=UK,6,W8P"9&G&2;>'VE-TF84^>PIM0$T/MXYA0!3[E((,
M;G*5',>M5B64F=^L16/<^K[R7K@H#-!T7OM YX];5?SO"9X+(J.#3YP(K=4
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MG.IU2:C?'KA;$QHBA,V=:YY2] C&RSM;G'&K]8T#V7%NP>)IL%>)^2\N@^]
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M'54ZG_YD\Y+\YW7V>#%)Q%M,$-AG.Z%(8P3K>F]/65\GLKCX+)I-^W_V2@<
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MJD /,HX&4J-?O:/P?$3]4R;,9(VRK\"TP_PQX+-F7LH_+8-70E.>\>D2O*4
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M!*N,+AOW:4)NM]*DA.8[\\():AX(!)^9$GL?@NPO)='?U[6B5^@;D+S![HO
MVWN-;((S&;OV[VCCBG94F9GU",*\Z;= "&VM\R>@*!"*$H3E9*=^9YRM@.N"
MWH;:4J,5<?0VV8C2.B#Z;;:U&G3] 6XR' ZR&.:4',*\@B]L<ICYE1XXPSQ1
MN8CPH\JUNQO"=]K2]#U?CN^GRQ=SVD"_ %Y4>.F:!(UZ::N^UGTE?,1Z!7C@
MBRC%=>Y? ;[7@^DQRF P8A'2I?Z[7BNBY57]!I08K! GZRBL/"&PV>Q<5Z:&
MV5)-9+SAS3YLS3L4J78O=="C5;[R.38'ZK@:W2#B%8R70227XNN55"85F.=S
M/*2N]]C>)0KV.JE(4V[S<6U9-?AS7HM=.4,$9D,A>XT:9MQ)BEA\.WW+6.NV
M8;.,VS?XTKGG#;DU9EI5;:U?=!;1V0C4%2 4;Q.U< _P;),Z=P5(*AV VATO
MUJY= >""""T0PF^@)SN"6S^)(4.UHW5",*"N7>=+MDNS0(D:;/&IK&&3/!_T
M"WS+/]'KK/<U6K_3[-Y<^6O9R)-ET9T+GN3[['F1F4^[]E[$I2!X>RK1#_5[
MXV-7R*?$J,.AU'7'-. /TU9-W@[PR]ZI3ZT\CTI=9=6YSK]^B6'4Z1P3*%DI
MPO!?*L[ZWX5TR3C]EGLV];-L/YVX-'_D?C=]8BI3@8&&=1*XDN_.4I#O7#:D
MBQE,\K[@DA+I'!WRPMT19"(A+"3-@$+T#^:@SG<^9_=,9B[61]8G*_S ?G7G
MC&4I"CK^K2"QGTX5OT'=4&,(LX$\QDCIA">&U#P46*PB?@P8XXU_EQN5^^R?
M1?M_RB!D[%]Y/*7 Z04T0DK42S5,?HJ6=JXHV+PG-5YK+O^*&/!;C?Z<= VZ
MD-8+:>3L <5!.=SMO<,C3UD+T[IGHXYT?Q')51-<FO]\VX@O9%X2/OH=D*YW
M4)O[B.,@,>$0'\?59,@&HZ:&GB7OF8=(,PTWP2B'KN" #76YXR7[]=*5_PCP
M)HX1;=_%(HAJ:_&/MD@=N@+,'U%4SJH;9[?]-AQK91E9:'VB_*DB_CW^>@_<
M.! !A5HMT]H?)DI&@F6(HTN<'%KK[.2*,^2R1>7SLXXX)SLR*P>I%_11J?AT
M "T>FH&(0!J,W6,1C>3.VZ:+&9#JY4'/GC]94;5MB7$NM,Y.0!/W$2-!PN?3
MXK(!+QGT_IC\C&O5T> <?Q/=0I?R]:\^'(3QL('4CC:;KU52VW@J** SBQT8
M5MBG?F+'ON+*AH;*%C-*^G-JJ5Z-/U50=T::HS M]:9.P) 52@U5[,&^Z#"+
MYO;%[;GO@0,?E*P;[8;Q#_(6S0",9.2\?06PH:8K.3 3G1,?CN;WC0P[KBF<
M3K6*!WJZ?GVS\*&SDX=SXI&X3UCB^&4%7@P[:@#C0#607DX"+VA/&HA:X9$M
MHP?Q<<_<%CQ3[[?@&.%C"I?'?6J#%+>$1%7W](_P8'NPBZC$]6GR7P'4-BJ3
MH6N5$**3;+I+TD9T7&HN\+:7V0$3QSZ 6$-ZB^;+:IQBXB9_UE>PWR;( #<"
M^>,$(</KZ+>3T).X1_3'/^3KY*"H.]AB\2L K+33GV].[FG^?HMR?W)90P:=
MCTVR>4Z4Y-+B0MS'W2(V_<E3!,DES3!.;;57"\.R=068]+(_OG"=?[UT'C6
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M6RZRN'T?L@9)]@NG&TR!R';,'LH@%==!E)K1*8O.K5E7\6OU]I@Z=>"$BH#
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M$@T&( ,$ ,Z_C*@D?D1!05@[C=KI5^!46%=WM?WZS#.CR9DM3U_<S8CC /=
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M!XQPWZ2'WKF"=0&LAQNY ^U1FH8STCPE7DEX(*KGY>9PO>]/[2'P\$RWU#[
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MSSD.T%WEIJU!&R2*0)$B6<_),W4^1[^S X^45%8U!G9X7(Z\$'?%],Z(_Y*
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M$8UK$-ODMK[SU7Q%>EK8G/]&^<.?+\-;#058XY;U#=@SLBP\\,FM:H? :9H
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M%+=P)3\,[7LNN>Z('X<PKQPT9V?]?CC#0H7<_>X-CWUE;N;\^DUY*3_A38A
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MRPG3\:6F' )/]@\!IT- !/Z(P+A*/*BJ2=A]^^V:,\SI$>_)"W5>')JO/>6
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M2V_ZR%L]4EK37=#9<^Y6!6?OVTS9&RXF3);.$&\]3EU! T$9KRSFPER&J\O
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M\(?0^"U0/ ,)Z=.L![%U$=D('9B=1!B#EQ0OP=(^3>M[SA[[K2_"(1WB0H:
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M2R<^95=P2EERSL9TI\E7 1XS)0_$*/>O:+.+S2Z$7HFKOME..3F]VO/KU=F
MSPY-I',B-_P>P7[%',KX>Y$Z:W%0Y?N!E,R@N@;R:@XZ?J]9(F57&F5U;()N
MPSX")YA%=H)GVPS&6R!ITH22GF]HN:2:^"RM'-M30/N-ZYJ5S!?^G(*[MTT\
MCYE((\['<J1A!#>VMEN<O^U%-CI@(B34701H2ED:U']-.:\!"@ .TTA<8/PL
MF;$D3YP".P=]IX#@=,1O!-O9:$LJS,D7",^J>W264.7TOEX4R[R9<]-P=MN
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MB1*'_L?7/)HYAP!;Q/BN6B[97,Q0@),9Z7RD1VY9049_9]#GVB.-O).*VT]
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M1OZ00;*T;1I&G@+:7D=_R6071'POU2-UM%M_"HPWB%&VMSV[HX;_>%8(B8&
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MP(?UZ/]@=_][-7O%3#K1YZ0"^D,*S$2VEF?8>E)B:##4RB$W!OCG(^'34V!
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M_>;QEQ%C][J.Z7&#(U]3)K+H& EN@ME>Q\#4,LF#;)L_::>>&R-H/>8_>\:
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M]3FE.2*ZO%Z*>'4-O*2?(7!7A 04N36,FO!-:&C#%CDO&'/\9@G0UQ1?81X
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M\S)B$HB7/525;*RMH9QT_@<1!P".B(U50>HY$.8.#;GQSN_77XC;;*..4]]
M3:@#Q1(^)L%->ZT'2CY%_K#8T-00&&$Z5&9,,:,V'[/V:_VX*.#7^D(KM=CG
M/PB$>2#F&BF,T(=HN?6[!A(K8EB/QQZ':<=I>\I?']S(K_>J49"C+!JEJC?G
M&/E.]6Q_M&3C8]K$@#9/4?Q@CRKBV_5.DB_C<KG([DM!4UWEW;SXZU=:SCK$
MS"3XBO;J&W3_\*0RQ,>+!&@C8Q;+P+BM34W"KI[P6D,XIQM>5%;6S/?V[$"&
MM]1/IC?2 9;PA_G2]P\ T6B8P@'@8PCQ&B,SIZ.I&0\N4QS@#&UR ' ;"&<H
M(,^N-J^8B'NI KF&J*;!3?VJ[Q9O<Z'U"L7&&(J!MO W73GFG3H\:^PYPN%K
M*5X/4JQX^_[3=WZA'":I24/M/_/F=\X978/D0DXR(G,AEI>N"94U)>RU(:/_
M\8K54W6WFFFJM:$_=LNT3G"V5I)UDQ9^^E3J^"@7UW9OV1HC-2/:%;WPRM33
M@=L+[9XZF0P3I3D8YYB^=DY)92NX9^J2"LN5.SWS(F0BFZ%#^&',1:N(8S#(
M A-OML.]";.('TDWOC==JI33104OR4XDWP3LHTD/1E$:[G/LHTIZFFZ9W(EX
MY=I*NZD5R$7*%8OHE)>5YQ4ZOIZX"!B037[R_T5;Z/_!T4;L2JA&1\-/3NA8
ME/U4K$Z4Z'58_P+M3E)3F!RP"@_33CT.UR++DB!$Y<TIPL#"1-?L@[E'^,2;
MJP6$LH^-_'[,K)D\X$38&U/7@;T(EX)0AD0^GDK[,-$&/S$(!ZYFP&]_P,N:
MF=LZR^X%7JH_)<7T4\)9L<L56/8<)L0PHS1X/X+E\&1V,^8<"=4 CWV27LS0
M33^Y!L9-''Y1?B[-4"KR@,Z,;WK3![&$04B57K0ZK3NK?4Z,^?I8D(8CYIS$
MW1\YYN\$6LT#@:L02]N%Z(U<RFTH)RZ9RG<: F&&F JV)L<*RGLM/7#(0E3,
M=@>U;4O$536E(*^P:X3X4)B0'CQDQ+71 -,PL^^)U1DJ3N6CEET[?$Q_9#<]
M*2&ND*J<[T[S".X56P@/_+R[PW%DM-HVMO[/E83^WM+IK.+.O"KNVX-W<R7K
MR/6,>S_>6./H"W[Y@-/T,FU[E;=/Q'SI . ?]9V+6YM75+?1!D+E]6JVH)K6
MDQ,I5\E?;*V(Y?7E,_>F9VY=#GVC(5VE%DQI[.\#5794/^0%KFP"X'?@X]C:
MI=PNKRE9/"A,QPE7@HP&"ZB%?-=%ZFA^/EV+L_FM.,!\D<O[8H=QMPV+H/"C
M_?,4%8;0K:7*'0 J3$T8ZO=*R2*"K&#;3)/J@  VZ>>,W*6(@I'/<>&_%P#"
M"LNO#)W@FL=L$S-T5<B43M0WVCO$XC2<#S%9\.D L"IVEVDI]ZOYIC4CE;<U
MZUV8:+KQR2U3MS.E3.,=WS\/TYSRXB[/3$\E;=2O=O'O[/[[7E0(L1A/-6+\
M^UISFDP4^NIGYJ5&$*:KW192]S.?<*8Z5 $:.&TL\F)-WX14^6M.,S WZZG*
M8NC<BR87.H?; 4#V'.6PB,&T,CW=+<"* 7H][($F*2#IK]IL#AT\=]L74H&E
M)58RKN]IAC[(A>H]H1.,&XC$C.<3^MIJX?+$)CTC$CP%H=7"]3='/<.O.B6\
M5DJ*ZUO/'<T5A%PU(@92_1I!N+,9Y%A+=OA@2HPR8W]<3ZAROQ-OO F+T7]E
M2LHNJ&7[J=.VERR16\7_=QV7^_<6-AZ\86E..U>;!PRMIWUJLB,XD>S&]&2H
M_H1L9)2.65%US!QHZ'>J\SN,&6-9K)#Z6>GFXF]M0Q.QQZB@.EH!^KFX:9L&
M]M0S%"?9'7%BQH@T67UE3^/C^,OG-E.D9+5ZRTNUNEW(C(BX?2,2@<Q4 A]&
M5'G%Z$CA_DI!>*2_KHG K*Y<S[F7I6?AU#Q3,'JZ^7&]Y).)%'H?EF#AR6R3
MWH7+Z/0PH0M1[PP/:W-&CN=3=+,7BX]%<4]N9W>*>N!N&W8^"]<'F=(9BE08
MM+#<JLO9N0UUL2*DK5FD:STM_I;"\5[@6CA*Q="ZV[&-]=AWF33-1=_S_S=-
M#OY_,/Y+.V[\AX%2(X\Q6#-#5%NBP#H>W(H470>QZ@3Y;RK^&$^N+WO^Q*E^
MLK,\(7)@KNV9[LW3[VD9-P P9C_*6?KD/SOFA>ZYU52;3!.FXS^SW(FS_)WL
M,[&BC'#KJ;F>\@!'N4!O@[/3TG^-JI=X-&(%H<M6+!!H_KVV^Q<?<WXR'4@O
M;?/I>>HT%@, YG_^'[A67W(]11*4"*X>:,/&TL\0O;)QV.-RJ5VMS&:]NMV/
MZ2'WA1O^OC@AU;>H7[+FL8+Y[Q][.03OT@8^"7M$N%V$4Q9<O;.N=2)?HF?S
M:?>*;VDIVX5>_3/A+*<<;_ Q_3T >#$>RCJYCF!C&J/' A]LJ(M68Q?/462&
M1 ]$\?KZ"CU/2#67OEJ$,KO&6$2S;))[B,6NGG!-^.!^X7?<5^OEP1VV?HO^
M-B%*BQ.+4]2E2_NV*^I\3'VP2V0G7&X$BGU$YQSNI(RXJ,'(R!.!P<7MVW93
MR0H;OJ:\)K*9:Z[_UX?)-+=B[$^4X)''UO>5HLL.#RB5K FHVCMX')OY^2Q[
M\/,[)^ZL=WXI?[CU]VW?T;L1E?0,RCFJ9'2+C4@&:7,Q(PT"6?LUL='YVT7R
M_/8>:K"BU"VQZW<:EG^S^K^TG<'1^#_;.BPCJ?P0NM'65 :]<_P ,%0;L,\/
MT:!/82L2ZS;#G7%L3XFA$R^="9OM>Z?,/9[*NHD8"/U>K4:FLTF-HX+3Z&S4
M_:I/]EM=2($U#$+/N<IA_JL4R[$_5\00E:[,;QEZY2UTSXCV04\5!B)?FN?\
M1 0F* 84YI 63'V427!:_->OO5'6MBG;< .1M 3B;Q#!&AFAA>X 3I6I#P -
MSOVLFO]Q0QTMPZ\H-<WR)-=5?%2E&S$56S("?@J>=,%Y;11+-Q%JLWV^D).>
M7.K#GW0>]_@172PS9IT8FF*@\UPQ'&*@$F7)UJW#X\K<A7 &8ZS:L#6LK;I2
M'?:ZLVC2Y\BSXVKM/K\F9\.C#>\OGI=\[;3W.F*-M=@#0\K">0KLV8XK;U9_
MO] KD_-K>]LZ3L[)(K6_WQNPJTY,[O BG]N*WC47G85.X%B3=M$O4.?J%;83
MN2JJG\K*/I9.:3)(OE-^)]!@<'N!SAZR (H5'.\C9I%BB"[)_J+!S(DBRAIJ
MSQXN^U<9%]^^Z".!P.P FFEI7K\1'LED.<$DN.XDQ@P8UG3I*48I/D#-66_H
M3,+U;P.63FX%C\9@DRUB8\G3>5AZ/Z(6T8K Z-S[$8)CC:9P.KKRU(>]>2.<
M?-M>.-8@QWYF?V(.R\U82GK@0!'^6 ZHD7'=X(ZX'EAI[N>,&/?2V_?ICX,5
MVE--I--L8#[SH:QXVY>[RESDW)MUX]6*-Z5.CB4./S<1_+S'PL/VZ 4;"X^^
M&A/X)=4N'[K>E@E'XS9O3]@-!;"])-6-^[*??0/T-EHTNF/ FHE#NPY@6-M
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M')EH>8VR'1?JR7$+3KIR>>6,Q0G%GNT+P%(A<C09XI M^L<U3:S0_D'J#;V
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MF5EU[ZW+PIV)S//22B.+G0TG^6W8JW=:OG+\Y ?ZAFPI4&$P;G+(=!V:ER,
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M#_9((0QN%B,N3_J9_X<7@5/!%OH&\^-=46%?TCCVUZJ/_Q@0=#^8N^P;^NK
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M"'?"E9[+X*$$$OYBR^0;3B:DRRST<T07[RJDN=Q6<Y/VO)*;T46[2T^O,%!
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M>3O9YX&IU]0,.*][6+?Y3Y(U<)L25#!^U:<(T]YZ9"M#,[3F^O CTX_O&MY
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M%/YF 0J<2AQVEF!BPFN6P[NPAWQYS&3B9/@>(6EE6:JSB$?;PY V /LX0CH
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MU*C6+"70+CSY0--WPMZ].4%RE_!LX*M+_O4=E-01)9K@%B'W@U 2Y(AS38,
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M>8CDJ83!T!@KD=HI9%9CLC/0I[^8F6C[?:E/B3()8$76/I/YVF!5V#;]KAT
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MD ?V94BEVX9N2JQ )D*>M^1XG-/YG;=K=&SB8PY%@5Q<L=&^,J)*@U%X\4P
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MWD'(:M(N(W-JA&LMB6H"7R3TK^M2C2FG.QN>GL[BBJP+\"Z<Q'E+61U$>7]
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M J"!S\I;.#M*,#4,H3@TVVD/%D2HDS372F]_("[7G=^*$N\,K2"HA!"KY64
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M?:J6E=8/%"TO\4[K?_W(ENCSI4;7[HY[XLDYD"L++2M0]20C3C&!RM.S>]
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M^$EZPX:F3%[([PFI=$;)_:5Q+[3"&4X>:HZC1@3_N04!Z%%4FY46-D:B9*V
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MWKN>184KG1I.A_TF-4G)'WXV&UO7H*VJWM<FW(^?T8X[+97S%A"GO>T29EM
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M*A;2#2C!:\<H?_$D;%;IWQF)!8HR,1U!.F\]'_@ZB%?=[N9%^>2@?XN[R-T
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M.'@)72^=JW\\XG*]N.6BA/>1WO_\$P%#NXGR;62\A7(@,82TRS+_O(,*3_E
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MM<OD@*CP\9;QASA/](NFE9V[Y)HLB78"^_"QX5:P&+JWLFH?1'PULZ=>F0]
M2J>]T(=1;.4/Q(8=9\8!M&7SQ^;L:VW6R@T/>MNWY"./4&O2NP:_!,Y]MI-(
M+<DT-[,2-#$_>PDDPD9>H@O&,"TN.Q^<4?O'\JL^:CFLC_G0%3^+GJBD%I'%
M:F,-S*'-C$+^?_]^378'/)%D$/:NGS*\4D(L0W>HADLBZ^=,5XF57M.:Y/7B
MN5P[2V&7VZ5Y%;Z#7X?.?:ZK?'$WMZ28ER6Y#W!KV31)H+D;)O@$EPSG:-0>
MQ)[V^EN$" J\NNWP,TCCVXQ\NN=Z+SIU!)2:; 0=Q0@PFE$6I8 -U11H#*EL
M0R!T8_Q.N0L]\5Y*[&!G7*]31GT_N#=E''X>>7_:4+H'75>>@#&PD1@;]AJZ
M7=K8]X1/BI%WG1VYZT+ /9B':J)D&<4XGP%V(+T+)_3$# I!FEX>WC@'YJ,;
MC!Q]8_6C4?09LW^$5^C&?,IKM4#;I."L G )^O_4O&#O/=:/M4"!@ H<"*3)
MH*#DG;BMI]^Y;M<S!VDF^>BC\5[-?W5/OWFUJ9E89?C:?E@$9/\-UVB_*CQK
M.?%XV>#RTB] ER1:AQE'V90D7KL6-J"G>>C9HS/C]A*@,QRB6Z5CN=7WQ:JE
M;K_R.U%FW0N1$0-%FOB_/(+I9VA16QCO89YAIM;DC6[+9WOYW5R(3TZ$+CG1
M9.-HX\>.BGS_"WOO&=9DM*V+!E&19J1W@H""TJ2CE A($Q$4%1 A(M*EB4A/
MD"J]*""@%&DJ)2)50$)'0'HO0@I*AP0P?)#"B>OL7VO=Y]Y]SSW/7OL^AQ_C
M5YXD[S?G'&.\[S?G'(.%_:RM5WZ8VJTPQI.A5U#34KCN3M.HA>IS>^O3A.8#
M*+N;T<.9Z.C@6P+<05-<QN[)R<R_V'6$FA\.7ZE\$J:UA@Q'.$ C<KG@"O#1
M&5KD(42WE[1LG'P[8Q'5I*B0XGW\!I^Q81G]A[L!<.">8UKBN!D=J3=48Y:8
M1K @GX56=7?T!\#ZTMO; R,(*MZD5@\2 W;6 &<+INFD7#R*+(:JA$5ZQ#YY
M9=F,&N.U9Z!J"7-)K'[^>/"H,0F05(G#>G+ OU,UALB0]S @O(._\/E$LN7*
M9Z61+\IC^N8U 2WQFKX+7TQ?>%#YJ#]0+$VJ'^X;V7VT<E9!/:FFK7=5,&_J
MG8>!"HV?M=!##-UPA4-0/,??*QZ6_OG0H69:FNAO+B!?FG$]T;6D&35M\[AG
M.8/#?G,\2?@:JDZ"S*E^ Y\%KB7+ QK%:W<O_V2=*&CB8%OWN2CN8$BJW3F8
M'(760=;7(!N*)'4@NOV,#A(KH$<='19_XN I>ONNXI1A$4XKQS'(0H;VN$N4
M;(^_-W:GJ9,D^(RAACLV %'S)]\[]\IYNY=YP3NO;UH*ZS:]IO.C,MW"> +&
MT$>Y,5X7/=)')A;,=!,MOG^-O0?=:ZLGF_A"/B_%HC *E&0JA^LY<I?)L?F>
M['$:)QT(V6&K6,.51,"P#*TPB+^C9/R.&_^)/Q'>'WKDSC6^QRV(V\\WT2AB
M!B:7QQ]"-!UN4L1!P:NV N//WND3>=?_&#^/,F?N=;)@:E<WOM&NE3?$T'8(
MJF)8]T.#9\2(KP$2!AQK<:6_)+9:T]6MU')W;>Q%A:C;QXF 4X\?M7#0L:AU
M%(Q9C,/POQ="<W?V<6 RO]XAJ.OBTD8D2038QF$G,@E[:*'=*WX=%"UYX?RB
M']\K5X<_!3P,6W(\!,FQ??G*U,L95O;50Q\"7.#I0K%:'8(<@1*B&>%)CGC,
ML:J50Y"KL5OTLA5=37*DN*!=[MI5[K]WG(X74#(UZ L3S#N:)0@,T;NC2L^Q
M.[<GW3>P.T)A[SW\K_9(Q.[EQB^<W&B2(C'Z#V(6PAT;456CY+.^;L75VV55
M)OPZ Q^_7F6Q9"T .8DV.X["061?"JK)Y[U_$JX_FBR5%,FO.3E31@;S.F]6
M#,B3.J%74D].I)J4T=GQRV+==@,G!I@%#-W=\Q.9G6\]2N0=NRA*%YIW&@2R
MYZ3;MB"SEW3QPV)0CU ,4RN;86NZ]<VC6QC3?2?YAE3OW+V"+)6#REUDQ=I.
M=#>B2JX+.H7$$JL(8D2/41S!(DQY<L<WB0[UX]%E";9BW2MA/\RZ_(JQ158^
M[P $N@#&%ZS+-U(M-ZW8Y89U%+:=Q3VM'3(:?18Q4\P)V5) -$G2\U"97;#N
MLI-HV L-J%27;^D"6TC#O.)>TTOW8B/+((\<-F!RN=L6+(H20K@AIP:)84 F
M.LXTUE:]KHD0W<EJ<2>J5X[)WY'>VS-_Y1'?7#YC2HILZW8ZO7C&\Z<&M$G9
M..M$D#T$H2=?Y@%Z?O8.N(D8>*O,P4=8DVJ$W+9TI.H)6:8EOFXSNAW5;E/@
M_&H[=BTI!E&U%5.AQ476T=D[V3O>ZS)9<?/Z0\1'EL *?L46R<O*RPN?+3:,
MRJG#\W23NS32Z=)3'*R+]\BGI%1T,D48P7XSRPZWR<M_+RL('4Z]=(J^M1Q*
MB\,SQM>'!B/_F$[[=5B@SHR<97*]1]S3:3.23]+H^GS&W*MG5G9T\$<]TN,?
MU^WZ;24!9C248RWWS/E$TY=PM7$!RPG1R)3TN=1.,6F4E-:*^'.I[?#S)[U3
MZ; 0O(E ?3"89 (?G0=-"/00%-=R/6,<,)ONN*]?[R4')BVTM8\99U'XD+&'
MH">Y4PN=\^>!A"*R#R#TL3B2X&-XEV.F\9->J7YII;;<MN<TZ0MD\5F+N/M2
MW,C?S?D%00UE3^$DG-RT>><D7#+^B8N2947ZS*^&DPGPP?-T&L$5N(4:4(@$
MZ9E_QG4\<CV<X+AFX3\QCVO?N\?&"(W%/KO4PH#*%(5;59C37/QO84)\.[5^
M ;$2TA\\2 A'[VWPD-S]&3IHJ#+S^]!@)N? N[_S,;G1@;8.J/_(=8F6R=V\
M#\L"F/DW96"6M%RJ11:H(&M1DJC"_HB.!I/YZ/+I3G]9FB*/-[]VG^AGTQO
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M=>2R'((>;W#H$!RC0S _'65TB :58P^='>^ZQ-R^LQ-VF6LW-U[C7"&PT]:
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M$Y;6?^%G[P^_XV\+.3:@;'EPC=!1V0,9%^(#-TP&87-97.#*^/E2#,6C5]/
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M[%L" Q*#K-_P)HO'_*ZTN*U]W,%(,'"RR0;1J@9U8O[.?T&+=^9BG3EW09"
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M-,7M?L<+VODKK_":2O.\',!&GUHS1C X5\=-NAK U-LF#?"HQL&#\1@>TP]
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M*YTG#\W3*YF7LM7YYQMC28)>@4=3\Z.:QWMI!53'Y?39(G+^.,9SA]F7#PC
M]\:)Q">%^(8H#&=P30O\$8MNVGVEA'_C_-TPM8V"QP#RD,VM][!(C7XJV\SX
MATOB,W$%9<YB;Q+HNL5)'ZUHZM:2$\L0HL7/>'-@A'+S]]6,:<)'JF$<7D[F
M64^.4%(7M_YF$'(&ZD/C+%!<[VCQ2A]$I4&8_A;Q,H^12N)[P#%'L;1C$#8Y
MN:Z>P7:>*9J+FZV<M$&$R8B7FV'A_K?=#Y?H:5X8OM9KU=2+]4!4 )PU=ENC
MH#*Y$1PT.[!G<5'BE--*"#./BP%C9;.UCBDQ"%- 8J^UNYWLV.BY&''_M\/"
M+[CO_7H,B0T'8^=9'8Y!\29#K@TFXVY$DZ*K*GH>4=]&/THVO7A^+9W_\:98
M45^;(%R;@=$",@1Y-$F(H%+RT0O%JN$X6?N#JNFNFNWYX(3,M1.@LE=.@H]F
MSWR$YJQ76=!/-U&N^CA(C5EADY]9W[^0HX4[-']2G.*_ISM7(X%XG.XSQ(B<
M!^NY+D44 4!063/S6^VKHX5=S2MNJ*W,*YS;UB/QM<J1UH8W<"SSFPAI^@*4
M3?<9Y2+,TQRX$UP]#Z#QFI.%S;BXG8,3;RK=TZX\RAZ36GIPLU+_A!5'@7D@
MM-'Z#XDQ__<M8WQ+"M%5']SI4YE=%7+EVR=:L^K?W@R<8_$R.)3&&*REI<9,
MG_RO+?8I6K&NX]*;5ADB$N_;A^*%AT@EZ7QT?)QM\XUNY^;:J=Y E*6?3!UF
M]09[X%9+NT^?98@3JB 3OF2[=5#B'<.,*0YNH\1D&8-PWH]Z'RP'6"N3-VXY
MLNGDQQ!MZ:<#B)GMN>+W@%\==!F@>?FP<2:[5+>06S/-SI3WDU@08C_O=7Z0
M>E0L"44_/58"XSI!8B<_S3\&,81ZE^5IT?6%SM%M^ZKZBWH>SQ.=DW*8O$1V
M9[<_+VV#@T=,+W!Y( *1'6>I5L^6 _@1/_*EQZLFA^],'.1=,_RUH'FAQD)Q
MH6_MQ KHFPFWKBT*,7VTFO8T #BO%\^*]4@"B_H<<3:DE\Y]:\F>KK;QRO6/
M%^-YTWC&<.L[UR67)D9D=K2.A7 G+];+3:8,'.G2SZ<YRJ?\O,D9B'"5.A0S
M^PB'NN4@B?;<S"VQ$$_BMU>I"QC7%B@MMVBS\*@6IR?RMW4R%\S4F),P)- F
M RM?>U.O>@86'>Z>_2NT(_1TBT_TM,P5_W /7=QWI"A=:!K9H8/Q1L<ASR#$
MK(*+ :;NW(31D&,0]]>N5_I)]D:NP;Q8MU1I%@77KG"L'[A4@,A*%;RX!5PC
M_L3%0P5ZXR1,CW0G+!7Y!&?UO@&#)-.;@"*QL6OA\J1 \:<1I?S?!49Q;WIY
MNK@?;5N?.'@(!2&^8SXOU%+"?;A)P\ODDLAG!>M\9FU@8E7Q%C/[XVJ3H-(@
MHY?W+^#GJLFNJ+PU;N""=>K6X:;CLHQ'9?_)H1<X-LQ>GW/7:;V.)%3G5U^R
MQ83&5U?R0^!><-%GS7BJS%7XA3.KKKW_R"98'69-C%-B3+8[/C?]0F@PUH G
M?1BA\L-]#$^\"B V^B]UE'EKU_;JLM;BWV7T'8,^)$T0K;K G%1SX![E(7T8
MR=8:7C%(B)3II*N,K1)Q"2H"K;,M[,D;3C*\O31'?5MOV;*^?N<LBB84!2;>
MKOAZ"?/8:EIR1NM>92_!2_:=$6<GR[C2B^OIAH-:>JDWS.T"']-8"Y,4C=27
MN('SO=1LJVDHO:>1D<B2V2CT-A#C#M\B^]UH60P=[HNDG?N$QJS;;)9^9J.N
M,?Y4Y%T#OP(T$84(V[D?ANT^39[,FEB)=$NZ(I,K&W#[Q!=)?!]Z)((ZSS@U
M:;V?-$8N ,X2(?K2>W<;QUD*RC<?]/]SH^_)4I"(5)SW*4CGQL8-1RX=1OJ-
M_N[#YRTI )A'/C:<<]@0NM=CY\9B1WB8L9CA4DM4I9]>71+1E7$G!"3G&L$H
MA-"F6IO)>F47PKV?<VVR%PL53\[$LP5Q;4HF&:9K,JZ&<4C> $>'#J76PN*\
MOIN82O- "_D=;81&P*AC4)W:"\8IU8CA]?<74D\\9WJ_>AO]@PU@)1?>*3X&
M==QB2*)K-J8\O<&E]2\]?K=$CBZOWUQ"2+?1/S3'3(/Y&:<X8U9&4'0L&3K@
M<.3:V:8PULI'!)N0N-"7ZT?K4)P=D6&7Z*>*ZFU#J?_D_HFAL]'")1HW<SC\
M]7W3>:9[WAY(7YG]<QY]@U;R5.+6!IF9Y)'G5D4&X&*2^\:R64G\WOH2",+E
MDHGXZ_ 2XM]2GB2&JI)4&T><I]I,:'(JX(U3-[,7P,3ZE%GF*-@#L4_@<^'Z
M<UM-!OK/N<OKK0!YANNVRKTL2]+CM1J\Z\J='1;F2CK!.Z=U.\V%Z4KI/IY4
MO@"[L9#T*0P>1_;O%OPT-S-G4GG:?'+=F5+SHT:'GG;-]W<NK\T7K6V$$GUF
MD8T:1M'R03 !T&<$190 7"G3SMFQ$Q>1/A3B=C_A5YWRVX?7$Z:8O.?88@>5
M$6.VJR@&2MI]2L=B3FF4G@LQ;S7Q+Q2+P[-)5Y#6',S^D-$_!F2*'I -C 7P
MBPWIO5,83_#T1E?;A;2'DHT:R.EF-5+VURP[DW;)%E"XV;:,],?,%; DLN<I
MLL-$8Y'M0F0C'M/Y8^<CBT[!E]PK_-^*G^JY$2Z;;;^LJ<ZALX4L2=CB<Y+H
MDHA1!%>4K3VQ:E\KMV&!^5/.-PZ SNM@9G<@[29Q$L8P4B^%G3Z::_5<B?IP
M"94D&O9\.+FJ8-S?SR,\=CS)2,/DT5G_T#Y'D>7PX2MH<Q)R$T)QA%&P#O'Q
MK<:D#;-)#4> 6E$A5OJN*"N(Z]3N-7V]+K9AQ\?>)8=_>]Z%+ \I$.*C-,""
M:\')J0KVM4GD^;T^V]NAC47G!S*FHA4[D '#,VD4LB=@^GA!+,$)MMK5J'!S
MY';OKW#E1C6K6N8KEGW_O/U9?#-:3;$;LY0#X:D/8%IWT:.]TW57S2& 61:M
M DM-IF?(=/_I2;7 ?WG5!EJ#%!3>?\0L%:D;%- G()_;FJK/M(DTXI"1&J]W
M"]U;ZCP]R.SU:1$O-&U'5V8=&?JD]I#*)]:97%*:C+@BADE \F@^4=4\M;/C
MID7^?)&YX%S[M^4B]4MW$6OM_6MM*HS8OX00W; !SX+9[Z[B/=,KG>:]9QHR
MPR%9JR>R; U7'ZT"A3,FP7LGZFB9QGKW53P0-HS_T8'?6P8+,WXQ:)-?AYQ1
M-D:E\G4&3:V/G.I$T!<BK\Z_CNIQ'. (I1;7*/8HMC)6YY!+6][?0IJ0.9\J
MN;86C?*J'UD)9[@;!9!D1,N8*F2I&BH!-7?W=2<.FLK(_*-[$*GL(?Y46G^)
M$F.-6:J9K(A<PKR8'#Z4)W%D-)C +GVDUX/=<\@94]33M)A]U231FQ!^!*07
MDDX_"^3+CLO5??WR2L=23>'$<F.:QL-WY?I2KXIT#$G9).BL^I)D#H49:&Q'
MB2,XD]'<#M65N?ZE!7+CKQR_BX@Z-P4-_>RK,:LL?LG5^44:<U? 1M/:FJW\
M(C\'Z)HB?@=0DE9$]).O/[\!Y'Y#U^SZL^[*EQ5GG&_YM^T?>G\#N-X]!2Q.
MU^N%)&DB^4W)7X6PEB&RH:)Z;[OR8!-WHA[=CE]97F6.7LG=6YRM()L3<9LM
M^'<*RZ4=,$^B"09?=6MNWM'!R8P\:BJSR5T_E?5GFN>E1$I:>SKT!_+%480W
MF!TN]I"WO->WR+Z]_"O(CD<?G 4_9) ?$X94E2,MTD+',/MM;*(VS//#10@)
M6#,$3-4C]B:=O?UR(\*YNCCIZLE<N9?<_14$\!28;F5$KC\&?:(@?_O-1UI0
MI/M&$8/@4Q:\O72>:TK!:\JN3/OH;,P#Y)]KW#,X.G;K&%32^#3$<#N<=0M5
M#5MEC!F=N?8$KN550/J ?C_K=13Y;;#)+_>G1^*'M< :D;Q 9I6YI66!@QRL
M*B _W#%\:JV@U;ZPL2M P)E/JX3 ?<9*Z?/<]RF5#FV_VXZRGLK#2KVYNQ"A
M:;E%JJ!1APK>:IJJ+EL4AI[:QAV#/- _DG@G4K^F?T.F(MDW,4OO%NMP6$@"
MA+.T:11^@C!TW?LJ@\,M$,REC)4*:IH2'WXVR6#BJR'HXAG<Z!BT5 +>=</P
M0392<^@YL[@41ORZ<BW&+'(YPT)(3K"'X\BB(1<&JSUY[J\I_W;)<GK,L.5"
MVO+F]P #DD?3$A206\A# ][%R4Z? "3_Y!CV<"F@]KF["_>Y8@R5I761K$Q+
M:@-1G6@YU&O5ZS.RDNJXD->YEM#[V63WINB=P,53YY9Z;K_4$<2G&;$=^9*O
MU<7<IF7H"<S,&TD,U=&%:I/L//1_2VM(J7W./R7UT@"=BSB+Z%P\PTAA2 $?
MZ!F,^S#_4,D;D6I5^&FD/,7QI1K\2R.\^FJL^<7!S ;])^?VA#+V=S8[*.J_
MH9\78T)4.;W:SD[6SVNMTRU:8 ?>V*JWGMO=O,\%3$.E.+^9MZ_IG62X,!$Q
M"&77X]Q8//F &/!"N>YRR'RHA;/QPWQ/RG6#K?9[7[]?#OV=5G_(O>E-N6=
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MX($".D>:%3H2^[<8DQD[5+JY5[6V0V\Q(856/#P/@7WNJS8__-/]#+4YT\T
M3FAL2E<MF.WW]<SQ8U"AL0LW1:S_&,2V2'Y!*T((.-%_YG0AB3F_1SX=@QP#
MX$E.9=M\9\KV%7 :1P5//1L0$]!=WV.0,&3SUB1D/\FG@G+V&-1?094^!M7<
MN\E065X;8W"#][_I%WZ$* O9U*4=@VZ,5Q77MM3_ZRX?=_W<VD*W7<S!!R
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MKE-D(0^HWV\JS_8K> !D>_ E8O=<-/[=Q[;95L&G@?B*VJ+\20PRE8%P X_
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M4GM'Y6/5O6/. ^Z>U<(PBL_5+&S7@I(4B3=):CBI2&W;Q]IIX[5S-R\M)IX
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MV=3'\@E3[U;BA<AV'L)XA;E[3%7K)E]!:?('0-5Z!NG<TK _JV2&(M4'ZMW
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M1N8+,M%:\@K<2491[2DT*=>&TFG3N3'M[]#;ND%"Q/OPP2;%K3BLO*]3DZT
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MPOD2Y7Q_<_-:9*#/=%[$)06JO,^<=Y=Y A\?T>62 ,:CL$;9AP8\G4/$<Q[
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MSJ);H:-*U$G:3_ L77?Z'8Z,%3OK\_E;K(35*^N@8)'$(LV J+E(/;$)V!V
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M^;VG&K>N[AP^FMC/,YA!PD*2[4XIC'$/+*/J-.K9I7X<N^/"^5U;9U0G$J%
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M%\KHK__1_GN'<RQS+Q+*/Z>9#31W<'0:7FY\H [[:[]RAH [ ,K2S,$AGMC
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M1H7_9WDM6X*YK[3/'Y0==X8W(\0--(Z-AQ:BJNH7G&*-!W;<9)<X4QI'%ZP
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MFLV2A%K80/0Q9O?8S!)MY1'_.$'?6KK"&'R*7OP/J1G+U(%)4S[&L%YA ?B
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MRW,7OUJ>;"[\Q?:UC,4[9AJ5]9K)$)($[2C]&@"EM"X3YU<F?;WT3,/J-W=
MG'?3[OA+MYTM>1YC(RC",YAN/:4EZW7TT,IN/49(BX[15)>I5R@?<N0MY])?
M.*ADG0O8RDK(FWC;3Q'HQ*WJ[[*9_']]>GW(XIF.] XH"KZ??GYPT\Q6N?H"
M!!OB6?"CY#T_S^!$1V+TU&E9<AF5I2S7@'$R.]%XI99V!8@G)C7S*D+$W=#R
M:I!8O:.SC54OS;J6Q>\-'7SJ<,VIH?++Q(WD!S\@L[G(*F2\<I8A&<G*,P>A
MMM0')S _"$WIHQSW_V9+CHI83GDG\]\=6V!YD'6U%2':"2!KUL]1B<(R[=.&
M_MYQ,YI9),FL#^&&52_+?44WMVS'NUV4UA,^%;?^FF7BH"Q'2-$@UJZTE 1!
ML;69,V_Q&$'3P.)INT^GG#D;AM_I_B*?PQ[; 3V3_(<8)(1QL'2C"H;%R7)
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MBF3@=D!'4*/?%.L%]%;HJ2SK;<1H@BP4 =$[(&X:AJEM3%?7(N%W0(86;1
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M;MC/U UY99[;4%EYMN]L(.+MF_4G9OO[!MK8',>O&?>!6?IF2WW7HFS.>^^
M"IZ,=2,K(73![WCC#N]G,UR4FFH"OX3=4L./\.F[!O=#W9*51.^_X'_4PR']
M<VP4\4^_G<3L@M2*-:]%(RJ-L3A>((EP(">CS+WA04N@ZXG2[V?-)1*'K-7Y
M+0=&=*$W?VSYZ=$(8W0AU]N,3+IL"<P0X*7(M]MY?<V=K*8WA/VB9#1&';4S
MY.<R$H_DN>+U4DHJ=&P,6FY,XO:A78/W3\C';XH_K!U[F')=][:)S6.7W\K.
M P%\)4F)[3&DS"TB-9<5USFPLUEX=#4>$5D;Z*A#@3=ZJV9X4NTE\%'C!;?
M;Z[%%!I)57Q^7GO$*8X*!>01S=FN5 3CK5^86%L R9G >W/)\\%V-W.S\JK(
MS7,[(#?C(Z'1+LJZ-TK#V&8FD->LW*N5=#W>E!8VA"O%(GZTKH/6^L[O_S76
MBJFVZ$3&0B68^L8T;1C/2%1\&"\&24@2OOQ+\[73OJX*U6OW189]U?H<?K#=
M/?=PB.5,$W= /*I^6\XLGTAW)O +W"U;SK94S7UQMF[NAZ2\E\7?Z0:^1ZB?
M68'Z?_,Q&F4H?266\CH#"\W7KR1XK,5@*JGE0>DJ)S8TIMP-HZ4N=2?\L'JC
M"%:]6'*Z-!SSP;-L\7M>MM,,EI&B@AZG-L^V_R+A?GLMUGIK_V'YF:\W##_9
M]?NJ--F<[O81V^Y*:_';3F057Q68(<6;R>5/1!VV!US;QC"\^OO<Q7A=O$JM
MAHBWS_>-L67T!(@_B PW*JGGP85BO '9_E:2>H=VTP6BM]1"SO':+5*U\]?:
MAT>0,PK)><WSD<YZF_EKN2L-R.!!Z$M(#4<\4Q.F64=V;5F+D_R0<\Q3PR[^
MU@#=?7^2U%+ %?&>IW]=;QH%"C;/GVBQAN1!R9;+1268!_VQM^Q[Y824S]D[
MQ<9]V0&9UQX1,#Z'_U[^IT"$B"QO6K_+_(;DG,LT2K<A3Z=JU)]XLV76+5\:
M*JU^&0TB@^F%2@0((^X58E$S\LY_5OVLZ!P[H%-Q *N*//@ W;Y^_U;HSV*[
M>=R?<;D[#UT#;AL>>/MF%J23XM&/<.-/F)!?H9"1#I31KV\]_1;*>?-/VS36
M/:Q1N)T3^2;QR1/U$"Y "X]:::08,[EX[XNUH1)ESO^ :<U^O=Y$DFH-D5^-
M'M]8[RHZ^2O!G,W:^=74_5AV=Q5TN%G1-M3UD_VCTV\]5>\WQ$@7X)\L(Z\E
M;EZ '2AAA8"B)_K(_\7>>T8UU;W[HD% D!:1WE$0D*H@14H"(DU$5!0$A*@@
M'2)*E9 @2)4B\ **0I0B($VD24OH"$B77D*3'D@H84D*-_[O'7N<O<^^8Y]Q
MQ]AWG _GP_R6M;+F\\SG5]9<<\X,HD S+G9.C@"/QZ?936QHFI)&^%IVE]UR
MC=G:G[]9*KN;J-")<CT&Q<]=^<NES!<(G-BD$N<AA.TG=YMZ_FI7GK3PD+=*
M\%-O)?\8S_\(FL^V^7TN0]-WEP0UP]!)JIL%2*;'8"S_&)3WS88.'&:P/VIX
M'5J;)NY(>*P+WT(6#[)9LDY:E(B9PL8T6GW>.&*)+#M76S$,SXGKN7UB0/O=
M[4\NC^VNBG"H?N32'N_%$6[B)E M.$$(-X!:O%F\B!)8G^K(KI4ZGYA1:,B7
M&GRF6&;9S3;1] _&)[1P;&GD'^J]0A5U=F]M;J79GQH5/%6Z_WJA,(=QH#9B
M/8N/09.]K4<JT0@1%W5X+$;QS=0:"0-[3_*MN_73B::AN%%8$.6U>O8ZFH<0
M2#F#O0V4P@7HR.6F$NLH-=X("]"=]-KOK7*NXE#['?PM-R)Q4?V>8.LRR!Q[
MS:*^<O_Z?_9JKA-X1Y:@W**^\NNF25.8B:3R$N"YV<E-6P*F[%JV,YM!H-N@
MXK/"!]MG;X\:/(%;UF%=X$E34+P* 65,[$\6F.3L7U/Q$FJKSAKVE;YV*!IE
MU7GOGWE77ME!X8T768:>P? 796-[7=JYO$X\46QM7S[X04:!+O+Y->P9K)M*
MC,1IVNDUI#R&@(TH][?UA_%L!@RK.82F7Q&^7!4;^P?1^3QYYH+LV>NUX]G*
M?W5FD$(SMG*G/8%]X7=_G>]BPAU6>(ERM4)'<,KB+S437I?+\0S*J\8_H)O0
M2=!YF:Z>#*MM#X45"4 6UO496"=KN!7<_M"[".=$;^G==H8VNL2:I"EP877M
M52VM;?;+[U+S(*JV% 9 :A$G.AOL+9/ATCDL!.:9A78SH0RE9'P'G4E?,!DR
M4Q/[7Q26P8 ,M'46U@H%X3KG9.OKFXC0).7$2MW:9_R^WNEDK>6E%8Y=XM2C
M=1ALL.;OK/*E_S_W0/\_[?^T_Z6&O$8;Q>UF@*-AI(L W5":M,#*1O_PD&U0
M/0\@8JB)M@4458+952_A;!U9RHC7^N3JDNO_O"T7TI".XJJHY6,0Y/PQ:$+G
M[SZ>D4W(1FO"1&M().]M.Z'(__%/$2_)SVBM]39XAMR!)2A+9SVX(U2)N2.?
M6G0)Y?;VS_U\A>&;(+,716RGID?Z:/+(82@O]/$Q:*KM[B^,C(,'4AF071PN
M^CS;PA8Y3/J=)F7$<"WY=]IX5-H)C)E#+@:HH-/#+4!J_N\K85B093MXR9*[
M4:ABN-2K[!'X[ )B\GS"/5Z>E"M>C&$61B-#Z:EVN3#:J3;R+0]<56!+0P.<
MM])L28)M1B:K\($JWK.PQT7H0\#SZE'LU-6@V9?+J$J'CV.H^2]H\6I.YS^9
MU5&9Z\XIN]9B8\G%Y9_/L6)-U"=1+0H0)B!U =4*YP["=M1\N^^)U&I*W+>;
M,;[C7QL/3=^]P.@>D&[-2"XIP)Q4P7\B1'=!3R)UW'!5QZ#6+*6#Z5XYZ^D.
M;5YY\YEI^6"7!QPIGR4+IPWDG!((^H_Y:VZ\<,@+Q3\PZ5*2M1S'L <=WARM
M.0:YS*QI#CU0BX^,G\;8$T1I?/0(@%'S!6@0PGMA GX YM=\=<#Y#FT^IB1S
MIGVBFV')V$2HGZWFIC97V@*V*@F?&DIV--%LWID<L< 0.:;6R'1AYBX9$N*F
MV-T>IQG6$Z\5+ K.D/_T.MY&538M.XT>X)AZS'=J<GO@D_C3GH<54SYKYZ9Y
M1$."$V27,E>@\TG$ZJ0V5)R=\]L];UU;263P0,KK$1K(<[-\<F>^\QT90A$C
M#(15%2%'N%+A-9XY#18_MSM6_HG_X!/P^.1-!D9=FY:IP':% 4!F &^[!.C:
MYS@.$%"+8G]^;:F'L)J7?LC/(KVD&.F.F=S8GBJ<%X\*J.Z96UTO13!\7EFB
ML?,5!SL%3E+D,*XUWO0!M)BQ5WZ/:$GAW20%$7:B77[A$5Y'^QOO<T;\9K57
M\3QG5'E/21E9T<AR$HX*O71!B\9P$^&=X 0L-]:]7,AM)\=D,28*_=&VGVO)
M\RW-_X?0O416J3-.JY!'@MMS-5]3//!H1PKJ&)0")DK1.DK-CT%FSN4?H/,I
MV%W7J4!J%!R[KUZ>2_NOU,C(AH3SGL3TGE%$.[36=:NC8-;XVU1?J/=*YY+\
MALK2XX*)ETF=6./BO6G2S#'HGS!:+_;@CP M70GY:K#V(<GD!YIPS^V.Y02V
M0[%'*!<S,@G^1+[K!$V&9H4,;&T^.T17[K2)Q-YTSF@]>A ?VI=W;?P5O7[O
M8I=[$?;'(%@FBI;6Y;A$5J<_9AV%KM$KK*X?@X:U"LE7UU[H/03V.NMMVE#,
MF]D7QK:9RU)S)WM#GI_=BLF/$<]; @5*L\V5#^P \IKM"?:=-HY,U"R$V#N*
MR9+YA++*D.""4GO#(YLN(U4%T_9]_C]K[K7.TF4#'["N>BJD+. =48=N JNB
MVXY!)]?L.G9BE95+'S<0F=M#)).>%9G[N]_"&QF]@NI*J92&LBRN8WV.06)!
M-O<)*Y4$<K/ BYNE[DH),YRZ4-T[9XTEB <M+;KC,Q)_CU"58*&) ($M+WB1
MCADYD_EYU\*$K[(,2#D!6:^O'#HY.%R/?3!GLK)*.;/7.7<.4",R=DE4HMK9
MG^=OUG#YAVK/V1J&=9P>.'-1^J*SVXI#HU.?.BD)?^\8)(,E1M#:\4['(-//
MY?2$SG\6/_F+=@;87,#A+RVPHA;A"\5K7OY!XV==7E7LOONQ5EIO*GAP[GZ7
MQQ%\*3#!KSQ6H@+6;LF[EG%BTVQ,E[EH;MI4)W?B>K/$5;5PG=-&[!8,^Z[O
MZ6B"HN?F_-_<1-/2NAT-"]W70^D@]V$DW\^&K/S*U6$VB>3Y&44\.M@!SL,I
M[^"OL)M[M^A)JU/HQ:ZJH@Z54/@$Y9A0VR,>& C9? S:?2%174Z-GCX&F?ML
M[AP!C"2Z34@=I):BMB"X(_O NX?72M]9DA!WQ^F=*I$05:F.4BI:G](Q><3[
M82L^-.YB[QJBT0\O9;/F@! BNR.XB*MM$HG"*GA-0I*E-]QVQ.D^PN1C9W[V
M]JS4[L^7QN878E@GY&8:N)NUI ./0>QT5,*=0$JZU>QYT*103)XB^M^'#QJ"
M6?X!_H3_C'-Z\D/K"A,QC6DQ9<18LZSP:/@;PL$WV'-!SR-4B_^7U+<L?/.&
M,W>%Y3@?$=5Y# (NK$9F_PJRFK]7NMJ.C7E1<*07/;$E0U9O?!6Z*V1XO?D9
MG_$<UPKH(=63\ (EXH!0(VSAN!^.E"(\SW^I*3B9ACYWQ9(0G[K'D#!Q/M!G
MNE.^W-<V=PD-2'DG?L!6)L6ILU[%E/LO!J>0G'Z^4FJJ2S#;T)];#FFPF3OX
MDU'4M5@.R+!T[7 #*;BK34399@FAF=@R:.4O_N'/RATV+)%!AZIEB_QWY35]
M8!GKFU#@ LO69O#'A+L4D^K:))>5ZLR>Y0=%G=?_.#HNAO@F9[_Z5?#$Y8I"
M0^[?PZ>+W:V%H[><%M^_[L.Z5V!&MA5K.=!:LR9"79]VES,(?2]@8=#E'Q3-
M8Y#S+CV=%L6P;#IHX-D7=Z;V%AQSRX,,V\:G9%O IV;;I#,QA5%"ZL7KTJ<E
M$X)[NE:N3)WJ?+9\R4CBTQR(GGXI HZ:V@NG:I0JS$:6).\=4KBQ1N%=)*?Q
M:N8$Y&CH8DB2Z@U$QYVYV7N67W4&**SC<W\/_J%P'](LM'=HG?8#5#XX[.D]
MDT?FS^=5)C&6E2@ZJKB9WV\V=1ZZXW([^[Z(.$H3WH^AEH=!75%_KA]V'8/(
M()6]$?H0/,>AL <S)I2]7@(#BC;MH5#'H2WU!O"6EC-9.=\K@]M'V#M*Q#-<
M536XZP55KKP?RW ,ZG&%2-'UQ@D5JL;$G0S])"L\"K@EP7X,6GL/F-#)R1I+
M\<'XT8,8A1 G"$2AG- Q]=E)\TE<[MIIC1HN(KUB,G-"N7WX^JRR0M8?TD]?
M\,"<;7[B"'>2_JC"8M$'G702,,>O-[WTB49V"Z?-)9 9@]1N?34\?U >^3E[
MUL3J7$E\[MX)S&GZ7[Q *%,_Z5H2WC\80W)2[A!V(BX756?4_E*L%M-0>!W]
MW=3I[.NFJ@*?;@&0AEI#?"IZ$#NAB9XX7+@/W3_Y=WYM:>T S$W'824D)"A]
M9<D .XX$!?5LXD_W%81UW7A;<^]I$-?+=QH5,/43IR>OYL",[VPD/3@&12J1
MGQ^#AIK_U>$ '"7",92()@E1OZ#<+,&3;MC3D$M!4-A(25GD[T;4Y&N?H1[N
MU*=!WMP5U8DV6KIG5$]"Z"8R.H76+W6-]HM^NU3X;[]=:&4Y9 AMJ= ]"RR)
M ^7,A($N;!RT-@G/L!",%( T$?;F<:]V("-%F_'7[FQX@?MXP.\$OU&*!7[R
MZNBL_K[E)IS]GHY/&JEV(ZA'H<]./3DS>[G>6?C#8&IU-%I\\930E#/[N)CG
M#/2)$O3&,%VYP"(#CK2-ZU$4*6U$[.\P1K7IW 8)TKO)M^14!X%.R\AZ6.=
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M6]" +;0R%!>[?\@_)TU0Q$[7V!C4:,7ZDEYQ9D/TI<5ZKW[T+]?^>[P:H.(
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M7QV!^Q=SUXS?_EZ9:/[:-\57-#)017I?JJ@T\T*,0B\<^@05\2*J?JIOH'6
M9<;#A^;TP"S'OL*51F2^:(E(_K WUG0]SE!$U)W#7=2MHC-,_DL\B$6?)5\[
M[D),?JG;B\#8RW7[LS!Z<B]OAO%[ZDQ8NSF#PAFE3H EQ4T\ E)S)X)0%K4C
M50TBH9J6],Q-35VK,#IS)"\' C^4G^5E8*9&UA0[^3X)\>;\G=7NS3%VR"I^
MY7:4$'U@G#:5)#RWG1,DP*,I/*Y*!=%^>IH&5>F6&J:7&TSQN8'-(G$?01]
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M'4R.C@C*J.5NQ*ECD$.U!%4E&U/VQ?[T(>09%8WU%,$FH,4QR@@==-O3]8L
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MC Q2))/P4];.3/)7-QZM'^0]9?7Y $CA..3B<^F(PBLJI@X":QG><%REWFI
M1RIT6:X)P; K]=L;N"12@2K>L5YV=9)V^99)'C)<T)F;?<O:8:F+ACT:MZ;?
M^Y\E$3NWK_???Q81TY2!CQC"N2GTW.X4E.Z#BR8EOC@%;0I_#3X*I$5]=8X0
M;K.7]SK\T0/_2V G_VJ 54.[;%PZIT,N1G=7NPNT;-EO"6IYL2E>TZUQ\_M)
MFO+).=*XNQ',#N-'=%BUBOEBO&=9\'@45.FEC/.PR=LG:6)JNS_!6L\4=M-A
MSE/^,42U(J"EZR0INGRVIV13-;$UL\$OG:EP5#7#2;.;TW"K7+R@J1_.",1_
MAEL 6F@Y;M?IU,59=]67\CRZ\R8W0_4%@U15G$0/1:=Y"1[$FV-M0B']8(XC
M9K,U%<W9O 4WOYC=@6EE=L5K%Y/*_54@+''E0><\UI" OTN/45B;Z(0LU&4I
M,4N$<T2)WLI24</)!A.1\_:"#43TR7G7+M!YBZ/20P0@P9JD*1W0?W\:Z8J,
M]X>Q2=>N+YQ_7?0W=0Y:(NU'U]&^\+N7/QJ7P/"^K<?2VV<&NOQ>D[T9Z[WC
M@CUAG&E]_WZC0NEB(YE^#Y(F!O0Z0!,#EOZ/SK12^^_55!0)>C*>=DDH%(U%
M?I0X0VI^PI7_Y:.?)GD 5OUU>N<8)[4B$>>EKLW2 $ZN>SF!J4L:Z7P:-NA[
MJ==^EW*SSU0IM//'Z#D[F$_G_[EOKAIY#$RY4U]R O@\W(,V)F\4 R#*$N];
MWY!A^AKT3T_M''=X8C1)*"$EY+@NF/WV0OCL/R%!%(9]_12TN@'U,"+P(_#'
M#RI'OOSMQSN1TBM.02Y+<4@^==ASC)YO"3'P++)-UTTX+V(V67/-IKQGZ!0$
M -2BK"W[6@OG9G-U1K6Y[^3F:'*'4_X1U@_T'#O\PNYX)_A2E&GP%\I&%R&=
MI79Y,8IPW/XN@9^:;E/+Y= 2+RK^7)&C>,OU3FHJS37O __E4U"IA" B'M66
M6*JM<!"/%\9Q@2FFPA+GLVP>+_RRH,(]%Q4BV-CH6>K7Y",0/E*;TNI(1316
M_3/#?:)FRTIX%-*GR4 J4S2X,S5P(A?[<@11 ]<N?HU_'^)3]1JC=^Q3NQR>
M5EZ8%H*H([TY!3TU8K+\R*M%*BRO5+0@ZWDI&3B_JL[9P_Y:/C@%:;!Z!7PN
M?RF2-K%YE@%O2;!VGXY(VP1XVTG,$3U78B]458_MM@5VB[S@3?FTSMS0#]M7
MP'W\FG0"G:U\X#TC'L*BV3T]'-'6;1[TU^'!'^)@2[/G ;"P.>B36X,@<N[K
M 88K]4#BRCXWC/@0>-,'#VK[VMCC/M,+3,[.?F"A;GD&0GWQV';WV^H)B0'2
MR?0.N%]]/3 :<W1(R2EH=O$Z5GW<<MXMRU)_<?[70 77P1\%Q7O0B/QUP:B0
MN<HTI!L4D!B*QH7W_L1QMB]>:@-L</+7#P2MQK3H]F!\2Q<+Q*0CGCGJ\-/L
MF5?PA?0CZEEC97COX&AW)9WL\E2N]?L66M@?2HJI^,9)2 @31Y.M[F[?VCA2
MSR4S_,1M:^-8$]M$X#*C^V)M;6-*CR:5PAGWK-WNBT5QZ.)V RVC'S $X4Z4
M<#Z=!\ *VBA1_<93[@K?1(YCHY@;G9F9M DN<S(PT8!I,KTU^E5EM"8_]CBB
M[J#(P\SJU[8J,N;(P\'?_TOC[>M53"U</)#+/_@AJVE]>\WN)_."9F::$,HB
MTR?>'/?=GXT)T/<R55IB<O=_L&BA]US:33KQBN;X#Q.;Z:U$F#L,9NWFI\R;
ME<5N967=.S;X7"%";U3'\ETR"$0/F>X%"R*7/S8$Y?8(#L=2^)7Z*W]L36]#
MQ=AB%\LIJ-I&;[=I[K*_J$^_I+F.V%Z21^(TU Z*@JZH7]M \$!=[S1CXZ]Z
MO)?A66AX3#4T=3.ES">!=YYJW:U'QBR36:3A$J673C_:-($N@C[1N/K>AJ8H
M[M+@=?M"WH=* ^N56M46]*>@H"J$^Z#Q*<@I%[ALWC6<:%7( :8&XKK=5#]B
M+MC1A%V//$C>RPM[H/I-%P2O.X9V(,/;> %6[+$!UB5"VJI?YYN)[EO"[VR=
M&X&."(R?>GK[F6UA!'-K<@'6*^9A2JST 7WZ\1:C<C>7F"+*Q%C,[MC]4LU)
M8$&<<ZW/9-QZF>U<[/+5;0H5E>O+?)0XX:'(:S9&?S'S.K^9&2T3G6B8ZH35
M6E,QX*+[?;+.8RY8^5YU9'%3:W.*+M>UDGZ%:\L@VH<P.C?$-]T^Z&M_$Q2<
M!2!=ST!'O_G)DXA10]R0J?9IGX7<T]_J%PK<N^*!G*%=X>UCW! #CG&8_6X1
MH3BGC$,P2\>JUK-;/R1^)RF)5?UYFX#55FOKK-X+3L:68?8C-)4#;K-R A*/
M&Z9K+6WR"7<NO"F,3_RQT2Y_]8?*$Q8Z#3HE7/2_<7\-;L+NHY>B-;D"U RQ
ME1&')2\]:>\G]S?4AD-D[^M#TBQC(9GVE+\>%&GI[CUKMHV/QU5V>@8M=3_8
M<%L.MJF[(9HY,N#5D;: /R?L!YYGSZ&83A;\/TV'&ES&C_2QYD0>#[(AHO,4
MA%=!49[(?13,BQ-;EHB&NLG-=G9UV(HE2)NKVM1F^O]Z_;FJR4(W2]6E$1(F
MKRSII"[01ZI'.O57HN;09AEH1B.V+G2I=%U)G8._4FDC"P<]9K96?CE776@=
M"-Z>;U7[_)&UZ\0Y>XP^>VA*RD>4C[GJW+IP3=Q[]U]M,8 $G@,XQD##-:'?
M25GDJWJ>=23A 5O^B;47#BWA_ :^/I-WB:.<<]>PIF9MN[C**#M<<;CO/NOC
M&W',5IV83EUJ<3.+67IB=JL@OI>4\!*)RC4<.6(4?@QH]5DQ;5_ZB+E\079;
M9+=7@N%7]_F_$V$,WWX0!G.? Z^*@&@=K&VR'>:[U9PMCKFNN2OPBY6U8,#>
MQX #]>H^CZL=HD(N*NWMYW98YG*I*5@C330J!$S 0G!:W-?$K\7)ZAKE\X\[
MO%\QI*NKW,FX*"T_)\Q(*,^+N@D)":,H5JE\Q(A(URF(ZB%1:AV&>H]GP2)W
M>2LM@3Z#*6\X%4ZD6R(58RC^8NQI;Y?\>9.!3W8VEA9,3"D@$4.)G1:"LZ&]
MHC^I4/'WF'\J_DV#4^M,P/!;40X7ZN)WT\B@?[%E3;M07J0;,FJ)/D0!D$"_
MQ@X3(6U7<.*=G?@@F7(._>*R%+' C)AV>_W>%^R6R7R#,.!R5L='W17=G3*,
MH=3M>H_O+G<#?./55![ZW+.3"+H,[K9WNTH+"54;ASK!9G0[836VQ;Z8^._W
M]_O ;/OAC+D<6_%1AJ>@;9K+!EPRQ'L#0X&"H1#S%O@=(!&]%$%F_XZ#QAV!
M=SZ>_U&,\K;B%[=HN&HJ+68FRO-$(>&%Y%X=KPTK'RD2X;I+C0\%6-&5U4O=
MZL;Y,UK%'JJ.::6-21:I#@=QOG]6VYV\<J\]_FT8S*DX.J<%&=>KTA;("A0*
M_?+),<WHYC]PPQ76&5TT8I?>UP/GOSR<5"<7;=7V+=&'I0FM?'',SU[KYVI4
MXNA/FJNZ][6\;&:5LEB)G!Y]MO(]T=VG()1Y;]M5[#![?X%U[<C73NK4[Y]S
M3"'' T\1J,\EA^I0S/0N?3X\\%^JS(DE=_$:E 0@NE03ZS.XB?*T47L(I44W
M>[&P=TXW=6G[?T#8;2GO^)^<,YZ*19 2GR,VA2>?HX8[EV@W<K$FT# $,UEP
M\X';B<3KVFCD1$'=0!3]<_7N@=5,EZ=SO]^F$R9$PMI*2 U0)^M*U JZ(A'M
M8<2NA2Y5)-DH*?@JY36R\/ [S-:J+I./;PR[6\UF?!X]9%XXJ@OK]O*Z6,_Q
MXUNO\[.6A23N\T%5ZE03TX.Y]=$[T=CME>*N)78@VNQ;PZBZS>?-<1L4D#]!
M5Y30Q>_+R=Z=2FR\4'U3PNWA((7@U/GO?"\,F02S[AX*[KH\P.*+BQ\'M]R=
ME':TEZD M?O'/[,\K]'%]+&\Z<;?Y(>D*(0;(L9*%9#K0]3>7@*H%LS6U%R%
M]V7M:. 5/5SU-S?^J P_F/D27'Y[WX=B5Y8_(+A;]7'A>%/L6B6F[%T=L]48
M9L50-;)/WJ:/$RV<C+MJPM9@\B ]3;]2B)0/_2VU!(+N@):&'U36MG$29<X"
M0+VCLR7"B'+NGHHVEZB8+OR0UWMA\&.5*LM/>N#9#8=V(?,THAXIPZLUD& #
M5P=&P3%Y-?78BIRG,%V/V_O/C% A=I>PO&1-6D&CA>/\H2[#QQ0!%_8&\3.-
M>(\BLZ[#3F#>-A([,K2SIR!'N4C)%K^7>KDJ?8OB52?3^H3[1/[W^ B*QLN-
MGCHI#X*@QF[&(R"7G.+[&Y-L'\BO:]JJ)M658<70A<CS9!9 JX,35E$J&UG<
M9S^=VNU@&9?<RI6><.(X.H79=/B]!$C)=7V'=4.I#L'\&\^4>O;#?$N.)#.X
MJ@R<32HOT4*D8O3[M.>-[IZXX!$ FJ+%48)HV_@5(];'?1#EE)+F.K/S!FHI
MM.]IPDN<O&T_1?'3".SO2^\>2=W8E5U.6IL*0$G:O=."G*7Q8#T+1#Z9[B1?
MH8SV&9".GD[T)IH25.'&K8"3#,&K:<2KH=^^3R)4YT5\>AU$_ZH1DZKQ%W^M
MT3*%O;+XM^6[OQL;,T3#Q.4@U5=-M:G%8]5!M$'$=L 3UZ\/$"AKWNO;%!&J
MTHHEOR^RV>3A]3CVXI#2C_^!W'DG8EC<O*NQ/5F!M <GPP3>NBT)(EWYC\ ,
MWN=7M+%?\U'Q$WQ_(4Y)$.ID3-*MU \NV8>L-.2.;.4N*.I5YQ)'JWBP2WZ
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MCO0V0J5C7'J'A5QQV[;4XS""V.VQ(SWX#\C?YWR7=:#^=(O])$+H0MFN$>
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M8T%ZK_%'5.E'I8E2D59T6EJ'$ $B7O?9S#>4=_H(6AO0VJ5.&[E>*TD+B91
M@<R/2)^9A1(11\.M&TS%S=4YJJSFVQV5F60V<J\R$H1P'68/6&JWE0HWP-+&
MD#UU.^0MKVG#.03XJ='7?UAF_4;;I!?1R;A\J@P>+KW\?R>F^/]#'GA,2.Z
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M\:3BC);!\8?>G+TT\L*R"XG?!Q:H$AU!D4^%[ KQ,C;*N\]Q8BO1.S]Q/O>
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M[WL;+$I1^B=SXVDS&*3: ><W-3"5I2WF_IR "1W=2J_#K<BGO7YUPR7;9]D
MB1!1,1'V_O#$J?]).X!??V;I@3N$86<F+KP""X36FN.^SU>V;IZ?KZ75&RMH
M6!2.F8"KKOT_CAI95'YOG3?QK.V?MNRO::/IWS>2XT[<!Y[?!T44?YZ8H'[(
M(#CD9+*>[\<O<WW--A\SHZIL8RR??<T ]L4MZ"8LG>^\@X]#6.K3DJ<13')D
M!R](VI9EGI.0RS.(C+\KA^_N[*31TN,DFF>I;("NWK]$HD"_\/DO'6 B]"8>
M'%]_*BB7\]KC*K\=#RE72]2-@ ^'-!FA7#2UA@%@!LH%HN+R0K0+WB9R?[#^
MB/6==V" X(W+'V0B[=5-N.ULZ6]&,;" +K$^W*/^T4!G"#$3"XUYQ+'A?!Y/
MC\162KQS" @O_2JGQ,_'4=J<JGRI4;@_4LM>AEE@(^+JT/SNF&M3?5.*6Z+G
MB-672)G. [K3]Q[]DR!IAB0L<+>)X3RZ XFO^C'[Q7%!&DXNWJTU]T=F,8EE
MS-J"X,R+&G3+T?I";MPK$-ICP-L\!EP7O'64W;/ (]D>?H<7&>CCLRW_-E5Y
MSN"NY[B8>-"H_?XZ(%UV9AO]+A1Z%7EK*EC 3.Q:(_ I+$*KAR5,U&CU+O!!
MY,&C=,<0\@6I[M'#<_ _'17W4<> 8#Y(_TU3I=1R2$]E^(V&\;I1<"C4<D+!
MT?ADY;M:7[F:ZK6RQ)5JPHE6^W]R,4T+B1"^-EZ<C4'#E$[@DBR$U2M;_<28
M0/D/4>&[%5AZFM5[2F16X.&M_V@+JHW LGFR,S,Q< G"LB8L@>?.2ZL@9BUO
MYNCF#I\^J/6_//-",'>L7Y."JQJBEIH*$#=9'X>.G)IM,UTR$^LI#[+5#_8F
M5EYN#6CU>-'S4%TA8%QL*E)]K8I>$4.+A8V)!Y"OX)(S-)E*6K9*Y<SU&5Y.
MM;**.8[#+GH3<A4MZB<J:].T1MPR(:KB%B?7_Y>X2=EA;('W6Z\#]>GI\[.V
MF-[QT<  D52-0@N[W)G7,I&,XC@@GYG+AA:\18-K\>+1H(B'&GZ+M[*:]C41
MWP/",F=_/JK/:G03^I$;YH_PDOK:5)_IFM*1_#9:GV>MK.5=J=>;G]F/4HYZ
M'V:I/6WOZ^LM9N3R+'KY@@"<,!]K,H\Z!NK4>T8Q B83P>"X#HGHWH<YP0.S
M51@-MY@W@1G*&3(-I^AB^]G80/21NCS_$CKJO7GBXSI@[):ITQ1*;+PN16W>
MM+6U.96#S])4N_$]@.R.O%!2A>C4@^!V^L",,T1D=TY]1W,^- SICJX7'U#X
M<$:]7W]M;7B?OH7I?V FBH*ARY>(WECYF[T4R8F"+WM"RIRZWS9_RW*XLBR>
M,!'_TPY'GSL31R48T12M4.6%/CC]U-)TW;FWGM8_-.:5:Q34Q<3*:MX/8B,U
M1/;.1FK+_'?&KG *[)\7PG44O)O9T")DOUVX=R/,6FUZ.KU'8OR[C<_5C\RO
M:Y(5PNYLZ O<LK0*-KLQ;CBNL"] BM^2\Q4-3TI*N,[Q9Q"?TB9 ARP"[-^T
M;2RBMUAQOPBQ8\%"QMB=A-MXH7>Y 03OAE3^.YZO5Y+?)E9&T8A61T='=Z$,
M_Y/]5&3JSN3F3FY]>JU^WS3DWNE1?\'';Y/N2X24:#I&7AEUM#B9\^^<J$J]
M'_DGH%9[X?R?=4R79'7!=GCY@=D+X=I9HCON\PG5YS6UBY(#C[#Z0IG<,<MI
M@IY05IA$62BR%_/\3\^F2QZM[4B)N]<>OP9,Q)\"0,:5$S4='.0[.,2 .;T#
M$=6)^6I/B+F0PO1U0*#?VK!_Q378VII?\#P#G? 3"P:W?W<N^0$:1)$)A2QU
M($,0BPL</_,D:^M>SSF:4TO@!ZY\>ND^<]8H-MV-'&(1Z1I9F2B[E 8BAO3/
MR]=]5LT-BWS?D*<)#96O4U$^9SL=(O"Z9!3."CR*^"\X7@)^"6Z4ZED D:DB
M("J;S(K+3JP[!K;,0>LY+/?G[7Z/&?S(S_M=W:%F+5BR9GSU4(9*15"; ^)^
MY;C90G<Z!J?PFT.DY*_IR!)4#L1_)]%>O0M*E%[M@@H08_R01E_:($)]0[-&
MXB]*F]JAF2; Z_?;LI,__DS\@=$G\@:/D]U4I,6-<AP%7LVX+[(<7<D'L1#3
M<6,[%$8$R1RFC0?W;/E;(+'9*2B]KC+/D%\[3-S+=MRO^'S+SX=^31FR>I[!
M^.TP9<E<(#2D"^U*69BN:P=M9819+V!LTN=^[PP,O9KQTTEEJ(2[(CQ#=RA,
M":3+9+WIRC:!DE"#Q;2H[0Z,*JO9P_J-L/C=DS#?,/!0BEK!'3Z6O@X?822%
MV:K4[ W19I%2X-^XQ9,S.8'?X1?(TGCA^LC5@F$^3X>X@/N%#3[*34O6"<0N
M,,_/W^[R+5^_/V=R]EE*E]/CN3SU(.'Z'_-J1&8<[P"TCN$).1PU4/B5?#55
MVJ\N4PN=+;'4;WI1HY&#1NU397U#>LRJJ)%.X&(<F1/9):R*BTA+A6O.S!./
M@:7L!!YYJ%7K!*HX15X\HD:^QE"@;.MB_:G;/=]%[[^P_X[P+,D $V6--_&"
MGM7]><)NMRPC\X6, =!5@#3:VW$!1[4XMB&[]\SVRP+#0*EG=#F9*P\W9)>U
MN5I9/VUJECEK$5]A0;%G8"&4\_CK*5CO<[85@1OJ>/NWR?172]-CEU-[)#NH
MM3!J;$$M&U>,35DJ>=B(/_="-DCBMDO:6 OH\3'P_GHF_I=I [&59&P2OHP4
M(+[AFCC[!4/P#A<Z.XL75UM+UVJP<LB4K_,3\Q*I!2(*%Q$)>:>)N<7M!T]T
M+ M#WXSH,+PR1B?^M'B]J)22.MZU^*NK7$\!/Q"G!_:2LL*;QU] LWH]CA+X
MYDS0MC40CH8E\TJ-J_Z.(SF1:<?_S#V8OX #]^]$_;IW1CA)LB+'N1K;WY[E
M*74I13&[>5@I]7*BA4&M[^WD)K$T6Z(L2:J+Y&/?@Q\@/%''8(B/[1&L1&79
MG[Z;096J">=7>H<V-UNAHL]/7[S=]SX?[ '3(WY:5$QB5 E5['\$2DRF#?KP
M]IZ28YN!QLE)OLS5":;-\MUEPM>CM"#0S,+E+W!=&%/X*/WZO.#$UM2OZP[-
M?O+SYQS<%UW=8;PR:?QWDVO8'R>#Q]+B* J-?^9XDM67D@QGO2M_-F">7PT7
M_R*7")'DHD$[.U7")Q;HR>KEQX#;.I(;QE^\3I/8WM[??B^%7PBIN(OHK(;R
M4\8A'#H1) _*V/1"K4>/D)\Y2ZCV)2,$7VC4B1"31L\,L2C&R^[L8;=3MAU"
M!IN%T5@$44)Q<Q5[#+"R*I"ZU?-$6Z5YG!PL)ZNLOP]21$2#4JXC6J(_KU@P
M3)XFMEYJQBV'1@EYFV=?M+5?7$\(YJ]GEY9XJQS=Z ED!*:>"T+S>.:LQO6W
MOMO0@A<4/ ^C+_8.RICCOF30F/.VBJO\1&#_>%[F[Q"2+?RCGO11#$4P=!A*
M-*Y<URKN]N>R=?3L$,/EO?OA-DX9Y[R4[?FMNU7ZJ]'BPU*%BH>DZ4WS8T"Z
MO)HJDQ"]B$,;A#[84;%/D5[]R3;,0L>I ,R"R:C=,+@1MQG GAS[ZF%?O_'-
MK];"CZEA+H<W*ZH?>88'=^<\4;]YE,,39]<H:5(#>4A/SOJ=_7WC%\@22M4?
M.#/D;!44,]Q]8 T^[8^JTCM-U/J=-]W3\*R]S3ZU6(-5;&C-@%WP7NXIL8].
M;]T.(@))CI2N#H;:HS2R*=6"L<)GTBY-! DTXIV>/-S](%?C>/:NZR_QNZM!
M(F55FR>J%^]+TV[+^&2(*]5E*+^1EOLX -!,/'/F))TFP\TQ!H3[N,;$XA>F
M50:\!+^:]KY-$=GJO7FFJ[ION:E*K.M:A[8)#DIPF_2Y4/H29KG,0.D<=XF3
M=*JA71W,#^QU>,[^Y>U5X-"CF_(GQE/EW-IQ/UK?A4:-G--YJ7"A=7#;Q1C@
MB$F/IU8?K<7$613744H'[0!)@S+2P8'S[BTM+T+/!8<X"AV,W_FQVG3C\NT#
MVZGVJO_-CZ-0>D?Y>N=_H@$*6VCY0$ZI 7V:ZR\#YM<1;Q;)[[MUYXT,"2/A
M%@P__,G<+LLV\10IF/LXY4PHG;/S1=SV%[))A4GQKQ6GLXPL%<87_=D90MQ?
M#EA"WR!KH -)4(S!(CA&QY]SX*@@V$]^_XK+HD$$>%AK^;V<NC1EHW0'*O]G
MCA#\E-,]"@T>U8\0Z@V&L)--FYHN37M3:GH'^V\8OQW+%@^:$W2][YUZE+#/
MG#:S2OA,?$S2W%!75HPA&YR;(*O(#Q@_<R>^-^</I4E)"Y//- 3@.9:&\/OP
M<3 [-?(\X>,VZ%K_'MT'YBQ$Q4M&_GS>4RO;S_R^R'G0\1BZVS[Y1^0--0-@
M#V]HO7H7FG7]&)A]5-P'I?<ZC+R+\@] V1<:&7L,DY$X.1L5$M3;'A&/=H$F
M4G4MPINJ:X5Y.T+]-G_8W4V'O?ON9$(7P1HV&@M9?+Y0FQ6-K1]7A(F&+3'7
M\ID$.QG;M#ADB^7.Q%[^UQBV&4;6-VXV+J%GPK'HY'KT$\R/@C+R6;SA:XQQ
M/.Q<J?:U"SMZ*F><Q-CR-2WX(GMD*AR51&@W041)*/G%:@_H<#GB&"@Z4-W3
M2ULV!Q&3;DW4?9)U&E?5-35#*!R.C.QJNM?[I#?<LI9@LXKE8[NXA\J#++Y$
M[+H@62 ;*0>4[*_3B=1; $&L$!#>HR0^@6/ U%^:=D^F.EB16K6-IRN"M(_"
M3:NG=F(WS-1^[&IL^]%?^1B0Q?(U^K-P;$/YKW)"TS'PO!#^";W_'4QY[OB9
MOI',@Z*8>70O$#3_S-%BW8_H*5CG:3%^'$3:V'CA4^$;-+.:]^,?+26KZ3T>
M2C'EGS#1 62Q.T1Y*#EG- :]&5A_#(P)K)-N4MA]%0? 3,< 5F!J"S[W9N.,
M(B%BO_$%_O=G4X;LLWZ7^!]4&-V*4NFBCX3H(;S\$_58)M&+1<= [7:KV](6
MTZ_+U>.)W]:M#Y\K^OK-;3=EZ,_=(@]/I!9.H0W;Y)?3V$)_3'DC68G1IOB3
M;8K?A]6RPX6&C&9&IJ1[:5/O>^\6+J]N!N 07=#&A2Y(W!GU)WH#BZ/LMB_K
MS51(UW?-Z_1(Z4C5=\J*[,7?[HQ_G9X]!CCT>$(]"#)'SSKD%L@\G\$](>7O
M/I6 %':7?F8$\*6-TH<)1I^!S0C"<J5I9W3,2(8P.1PT@2%N_QB(IW!_"?XT
M)W =/>6+S>5+CEP;85IMV/2H#R$<L#M=%,1=>69P-LY$[/;0D-%%NF"Z$-0(
M:F:#0$-DQ&<3;N,6$F$&[SXM@SB(B=^JZN7]2=98R<86N;DEBXR3-P5<A3JS
M1+(&14 5$#?([#O%60_LT>H37QUH!1%U/?RW7T5_Q7!#/P]$3DEZ#?@>W^DN
MUV6CD0_R>I,H3;O;2CF-YJ%ZB3':&Y1$X<3[I^U#3X72=JJ/>1'F!<;F7$;>
M>-VVF;D^9IXQLHT=_,5]ZZ2.]42;Z!*4ZJ9;ZCAD#X45OUVT-'J"2-B7\X>I
ME)T>Y?B-ZQWAAEO,(A]HE658/E_Q4(/X.[F/$\X=5>JHX\NQ\^W%J(0V_>2.
MLSC'#,%O/9%GW)GT;+]CZ!T8/NEOM/Z8FX)WHT^I(C'#2QYD54A?BM^ 8WOB
M]WS<]N,[TJ%! PGQ-]88=Y^$#1D]Z&W,&1#GH#DT^[<F12\H8VB!"]0@7UY,
M2VP+*^%Z."X/FMF:.08&^L;)3PWWO/@#4Y.:"*B/2*(D:,"?BWSAJ$ *A^Y5
M:VFH)=;['K6Z!)>DO/NQGV<@U(TT(7Q\29%D)]F4419ROA]LV9&L81I'+V':
M(2)C/MLW;^'EILB_Y2R:O\TI.?C=R6-VE-Y(W((LEB!J/Z0M(I]TB!'9Z,?J
M=V+\:>TCDF%?O-8'>?V/ H(2]<T-.<X I.W$7Z#9PF6W.*JT@W3#M:N5*G)R
MWQS5G#IT^%;\02=T'4AWX%]O-7\T?%2)]DP"SR(6_5J77[W@(!P*->2X)3^)
M:6Y[=O:"..)4CW8()B4U0%\X;EDQWIF'&%A,#95$LFDA\6[?R&3SE.)274K\
M ,W;VXPK\."814C: JN>M'-$6C=5.T\G*%(U^R/W<KI?,4(?[\U%'O3!9$F:
ME$YU2-UD)JK?'P.UG81951(3)=JJ<6LMX9Z^E> ?:1^5G@XR/1WF<CM!.V+[
MM*,4KTUAO(ASZ<UQ<0SEF+,@>BV51]3,>)^Q.NH=9OD0E?QE6'0/')!>H_)Z
M5430. W]707!BMB\\>H8, EF.F)"#5!OVIPC,8V:]4X:XR3C\ X^%!5<0V9X
M@7D)$%AB*)0YU_/ A#2WG'E]D[6';M<,GD29/@;JW)";C3A%!WS;>^/PTG,.
M\C)#-RY]=39!RCN NPN<C;KH*GQH1J1IOY"]\ +=2-:]/33>/Z$.P3S3C&G4
M^D2V3J_>8Q4#S,4>;]CJG3PJT..#7>_@<>8DQF"1[-"G5VK'ZSTED;3H+(&'
MNGCH*?@(&F?NL(.Q'@$G0^L:FBM"TQSQ@F?7QWOFP^>8/?FVTSZZB>3+1KT?
M>"_B%X:- "\SD#D@6'#"!7Y)HD_C IN.G6^"CW\^NJDY^I/SK2LUK>?Y!SXF
MG]+0V1,!!]FLVFQQ'P/G'A,9CH&[0\? VJ/*AQ#<]05,=#]<9HIL@]->^G4%
M+A&J>%9[^-W'@ZG!+O!'_]^>:_;*XL= 5L+91G$>/VT"->\_[R334KF;&V)/
MUSH28N@-[G-6_JS#_/9#6>@SQW&8[COCGOGUQH"Y2VB;!UQ4E\ 7+C6DX;2Q
MT(2V$)3>-Y7+M=[9^O?']2[U<5!MO*LLLI7-_?LGU2L^M.QL$7J6D5NL5??4
M#]6*Y I[*%S5N5M;RPTL-F(,099^-[AOLI ,:H46SC,L"+,?O>W@))*LST#C
M]"2(Y@X3LT,2F:FU_N*[[&E-CP_.KSR@X?[)C6_LA1+%#S:IBHM*C8?=\D/A
M.UU:+7TUT];CP0(O,6K\&&?-M\%//5!&8BD]49J*,XAEJ30X-\P7#]I$X\-M
MSORH?>L0@>K16JGZ>-#09?#;82Y;V&Z^^3NLV>)9O3Y 0EE/;@8)J:U:3NSX
M[FWI3;+4?OLV5&W(P58QTGN2=B)GN8T5OX%%]6[=\%7YEZ"HYWO@/&XR>;LY
MF[;\I)$XBF20]H@X3&'2/0N[?%30 <!$\=;5 ?ED%3SK2K;]ZR]#H@[-D]W&
M[(&?D\O2#.Z#+)2^P?2IRNTF66@*4J,(.WE4B:OMM7?[J-)30174GR0G;E_I
MK5&;[@\X^]3@=F[G[<@(Y*W@RD SW/PKO<)R:EUU1@+?Y+]M#K-8IED_%*'9
M5_T(LR"FO(4Q$TVKB#W0YIP(Q1Y,6%.."1]_%5-DR<M%?O$'95HG1K1L5M%=
MYK/%_6"<93D6_VQYI+G4EG@F/ &"%<0YYYZ+5111HXVE\!U6+>I\4-O^6MXH
M G[H!:'RH\KP&[Z0ZT348OE<GPS=>6]"!517;<G\%87VM;#L^'*Z6XH3G];Y
MH9K74;J&L-)21)?",>#^R>"BEBL"A.EKP"I6UGN/UA4&_O+SLE5:P76F^9T,
MA-:@-WOP:00KXBP"FZO2ETXL7Z0CI.@P5CHBBF8^AOBD\G5JW)_Y:C3XS>$A
M;4H^[9;,<EL8_EDGE-E:91E\QE.81_F<Y[CM1$%#&$!9:CVQ$*F*1> LD)@W
M!P0W(L0OCU]6JA?,Y2BD?BENZ)?=J;G5ZYR%7&R1M,@\V]U3@R@Y(I7ZT%7@
M8J:R.F2(OX)+8<;$N'+?U@GKG9LO;S<^3WYQT(_]<><UC[O,PV1I(7V]#U0U
M"SH!NY%JC M)W@-S_;Y](:EPW>+;A3" O)Y\-<^8CJU^>KKS&!!$+V;".6,'
M0\L7Y;>.@1[S>'L'@=:3C1,>WMX)]-<_;6_BJG7HK3%:W%V#^Z@_ [BV3!"D
M:S#1EF/@20''W!)#+-6 -?L;P6E#<HM@A4 PCI>I,Y6>N-))>R)2+T;O FZ7
M^"+49Z/E-I[3>)55;"O]J.*=2NO0-[2?YHB2XS&0UJ$%TR3:W,^B*.$7XF!*
MP6?C3'UM;L7.>S@NRPJ<OZNY?A+N I_I4, O/*$J]7<X8]R(AL/ F?D8[X*?
MSQP55AHR?DC&CWY^7&VJ=D4TH"F*AH'*D.,@.%-4=(M>EA]%Q'8!9HXO^OFK
MWORT=T[*R,]5'UZ9A+.1K;51<U3[?F:8U./$%\>U112^J\2FA%_#"S_?M/2O
M>S6XG>\NI!\Z4RJV<1UOG%P'HOV)7Z#FRO$@9GZ)TQ(CI2%"=;ZB)Z/H']#<
MY4[5PIH7P3W)IL2[2)P9%%.,+4[L$%SG;8 RPX)+%-(KB? ?V-5$4"[7ZVHY
MDO5-<;<$-\^O/#(SD/R%,QTGB)R$!%PE*I8BZ@G%/?5L:"PM,? E-&\UC%1_
M.-.QYFJD8>?*)P56O_8X$A2-OHNF<LG/"#\0)LYJ@NQ4X(5Q+BS)JNEHG2A(
M9"XBW2I6TCYOPR="?KN/&M.%.(X'^PK+VP]8U+>/_4@:23V<=\M@2..?%Q0J
M"O@J:+.RL(DD"<+ Q&RJ./W<P827>@*I:U/!.BRSI;@<%8?QSM[<XI!4?SNT
MLUL"UE:_2D 3SP47-79#9G>P-MTH5D>SQ9W8PX96_S?W0BP_[C([T D\\15/
M_FA3GMN[^J%K\!,0$8=%8U2P-LDZ)L? *4(,7JP[9Z3)X=Y/@M:GMG'M1V?+
M,WI#F%^'H"ZCDG1<J(Y>0&1<2@.ZBHD.YFVXJGI!IBEGJ>H)R>;G:#K3LSJQ
MFC0ZN06/R$6A U-04)N4XF,8J"#TD:^'!9X+X_;Z(:IL?8Q1H2I16M@U)=7V
M\!C0JZ/Y_.7_</^__]>M#Y<;M\*H93*4&'(,N##$H/=@W"1.:.I"_2JY:!F[
M<)0LS/.G\Z$%PZ;9GV>MJ6B<*?+W%=[>41*]-_@PH!$U4_8?[/+YYZTO5[/)
MW,,#>:(9HUCU[@BI6Q&<5_'SI>):18L25H6IIJ%C:CINM(Z\;H,CO9]">!=P
M5]"SA.7.C<*+1=X\.6-=W]/8J\I5G"Z\$+GRA6=7ZU>=$0,?ZN)1ZS'@&G14
MJ<?9]>[G=+H77.GSJO<6QZ%/_$%F3^?*@U(1YE]L!F>%]46(QIN-5%9T:K)-
M8,D;\>=52AX2$MT66+Q9VXAG*]CM"GM<S]KC0?-*\/K;_M\?9"<C=6L)K$0Q
MO#<A B?<O+@3/R_^'D\?YP+[$NK]P2,CM-+(R.[5=O^,]97F<UG\_< A/-U6
M.8KMX@H[5)BJ!BY!O'T1B^[IV%$ IMZ@%=<'/?.!X*OJ<E',KO>C&$>9,$OJ
M5H,.N=E&:GLQ,L)T"2%,].@Z)T!,ZK6_'EG#4G@O^XL#/7^_$8%_)6T$Y0D7
M&2.;W54,BK@Z:E7K\CC 1<N,7^_5\W3H"9@*]288$0,=Z_3.$K\O'84/..M,
M\(W"IS#1$C75X)"/;LI#G:NK<OFX$\FN^&/@#/HVF(LR,!4"Y86XC_)M9#6>
MD3/:L,)MD;L#@_WB I]@$FO>E,C=?<JA+^%PGTD?<GV]OJ/(*T3G<U<PR_BE
M +F 0?ZG>SU Z-JCZ:?P071=5B[I%HQC3,?7B^ZA5H)[[630VL+]NK8T@0GA
M5EONX%%MI\ 1[^\+1*D=<M[H'Y]SH47\]/T.P&.LO.IE3<-+*HM:8F43$)/=
MN\#.'O^'<M7?&R1GQ- UA+OYX1)B+VB"YN"(4.E2M$GR_=Y>_#(W#U;VJCIY
M62JO\!=J!$D4FZ\O_MG!2^Q6V-GR-25FVET>E_$3$$A_]BG"EW0%/H@ 0>ZA
MB<8(K&[#A +D/?P+0?']O  LC&+SLI46N7\N[7J$]R\HA7&6!"(K'A5=@,0W
M.JO63ZQF&TQE]8]NAGP"V+FE6!]_&-S0%_XSR#3U-H6+>&'(X!Q>Y;2Q :D>
M];G2P6Y\3X"W?6*GLFY# R>\M.V6J/JA<U@)"(2^AN+L^!9QR.Z=:"]_ =V&
MEY7G4]7\K@Z<6.3<B-EPDNJ!SAS8']57;%+D*5]:1DHOG!EB;F?H?.0[[F#G
M]= _-KY#SW?S"6>RVBFY7EP^.)CHT3\OC"]J_1H:[CRNNB;6_SMH>'#;*O"U
M:^%I+?#@U"3\#F5RX?TGY&8,5I*X3()XVP\\V4<QMSU8\$(]G&8WOS=2\K%U
MM_=$9XNFJ^NWSG[0&KAS(>$SS(.HO;@@>)%C+B7<-.K0-,AWF*4B^F.R, GZ
M8/4H!]CV_GX,$,\5DU^L]AX#A\O4-%E$F-P_"4-334(5B\\$B<ACP-$'L=>!
MB10@G85=^M/2:X87.YT(LRJ;6\/PO,J7FU8/88TL#%^DF7SQ&B@4SP#H<G[G
M30U090O."AW/& Y3!='"/ST2PN[*_ZI9=D@7X-_S$!-I/'=:G'6T"2EPE 07
MVH TCH?Z=U'4\9=YP$P4/KO.4JPL<[302)&H/&G:(K N8VB,FN1%.4^^W"!H
M]U# ?X;OS*QA5&,ZLM_.=#<0&AY6QR_%JO)960D")X%;.)NH(,4X/>YQF#HV
M5V'!Z'/=S&6>!K7R>K&+AQG735S^#$0Q46TTA-\F&^%7>U'$<XH#* ZR C%@
M21,F@'/IWN53S7TP!P\60]^1\A*^_0#UO=?VW"V% 0V =L_(/"GO9)*UUDWB
M>,^'TNBZ6;5RX)5FOYK_M^G4S"D/G51#F"*8S(Y>E%DSZJN"V1\\00S>)-U0
MTM#8[##//@92;9Z&.O1!J1_(1@BTJ2\B^8FI_OPP>KS.O!&RU(EG)/-7Y)41
MV+NT![7];PL+>2P$1 !X_CS4P>OS[^D0=ON^UV'/- Q'WYEYA$;W:S$\"9K9
M9PVD\@<'QE.W6B84EJ,DI?)95DZ83W6H4Y-(UWO$S/[+*VY:1PET03JFSFXD
M-4K/%_CT DN=8L*"<'V$BV76,6">.MZ3!W[?HC:%<7YU)A[KQB<5^(0CH(N%
MOY%' SB2JFV+MJA/_#$5NNW[S@+_B3G.^.;G* VQ^5JRX=(6<Q<A*1CE;0]/
M\)D]X6NTKAVDP0]1>:K!_<M_RPT_;G@4C7"/D.GIP@2WK%,<'_'&[&7?V&BW
M>>EDK,!NM(1(F+T(T?/NI7!26?-HGZEM6PC))!0%Q8>DUKN:OJQKVH&5;%[D
MWQ7JE(@?%'"13H@J.P5\9EB8%\+[Q2V1K%L^!^="'!H<W7VUUK6?\/.#E3DT
M!:?JX0]A?^:N.1S_V>A'7";XX*VI^5[P9WAQDED>N4W]GC+L^=.4H8%WX@HI
MW>^!+%3^,7!'$9-[#-PSC]Z*J#3D3DL-$HA^1XSJOJ"T]<+#M0 D(VYQ75N9
M2E%9@0A1QYWX#K%0\ZX#2P?O>>DO=:8OK[#WE*R?GFM]]AG89!QAA860@N'C
MSMK^"<YGCO+T&$U7J+ZF++NP_D5/X%K#[0&F3K!\@^S@:,H'OI-&/^ANX7C)
M'+18P[S4<;+^)/GB,IK;*5J"4"Q!<NAWO_/KPCVTTNKKP1&3E4,+AF\\6IGO
M2EVXMS(GU!\^J")NBSS5\>LH>-S%U6 ?4U7$F#7V0Z#D,<:9G[8J0EG[%S3G
M&. Z!MR05+K?I5?WR7S)O O$L=XA2HQ@N1SZJO-PHL./Y'[2.726"_14+<27
M+9+#M.I[U0[E5,\Q(%E0>0S,S%$S_-N&YS3/J'G!C2@1L>Q&M%LV-;LZKS:V
M'Q]TY<([(Q7GK\Z.AN^-C&E/2(F'VZPY!71H$4VQZ(0SQT!T?<JC*8=6%..Z
ML?7XZ>O#'%]_^R3N\&D[5FT-71E*[^(7(=RB25N"\JT)L]0ZH*A\VB_FW@"S
M7E&(4 OG&O^@4!]T/%A6]VZ_P!QSB6+%#X'"IH:G)@)I5K>OB/V$OH  >K3$
M0 H3*[YX63VE0^E>2U:E0G252:$7G#?J=^7T]88;6$:F$)H8P%>$U\2ND7-@
M'%D+V51>J$'WI7A8X=)Z=7TI@@L8_.+<YYK\%G%:69-Q)J#+RD:3YL7C6."P
MZL^6MT^*:=#Z+W\4T\FK7Z8H!Q]PSSQY],Y,I;]B[Q,<.6#4%*))64U)"IYM
M"T&-?5Q-'T0-;J!F*: Y<T+)T?OI>R;E7@]_OEL[N!X:=<C(H1'["%BX[9FP
M636Y?PR0.1T(T4W$2=P)5I!S&&___*FGGO9MZOR<W/J7.9IT5MX\%]]U/D?U
M.@_H*P3.&H7IAL9E"S,1O;&D-ZKT[0UXGMJ51EDZ3H:&R&, +>Y^"20VE+QW
M[X@)CTJ^@(KK.#W59E;E6)F7]M9N.")$&T%G6>HN$J(AR+9Z LU+ML2]LCZB
M>K_;0AJX7CUI:[9^R\6J@=+U..&.KYO0BN4UB[RR$FMN7?U&Q(X%PU;1O^X
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M%./;#(H\E= RA[F;UEW- R=G/#(@6K^C*4PG2?;>"R>"(&RA MC)1D):G[^
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MJOZ(&X=A7?]W#O<!=-9M^(]SN+B>$68J6[YI&?OV,[5K@\8>IJPK=.9VMR5
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MHE*NJ^H/6PCTW>([QR0&Z G?H!3E_5P>+%5\DF!"3:(!2]%4%COTKN,+_<U
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MVJ+'Z#*!B"%H=&D!E+>:?,_IVX(U<>?TYPGIY%>()TFW$(R@5_(5_UE/#:5
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MA@L\"[:0!VHH0M?+;6U7; :;?[,E-IE[%[N\9_[^^M/%$F8=IKX$C9U3/\^
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M76(029UXZRDQN??P@P)$:O>7=5&>W@/8LV^LKP@\_9!02PEO7&Y[$^1,%3D
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MJ>I=_I,SL#,L])F^3?V_7?GS/; 5XQ6A)6PH0"SL4.>-%9)'"%B./&J14OS
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MK8NAS9L)2>K,3;H S:MU2.0? 8,")D= F]5Q]TQ,I,RB08%NDKCIQYBK7.P
M?4TI+:(6R!$/90XYK$7-SS_.SX.&HJ=#]?2YG_R3+4M(P^-)*HPF%<*) IW!
M*_DIT(ER5YX#SF56^L^#.5J(X?7S*KD8BI8 FVS/C''M*X^X\1_<<>)"<1\!
M4.2#@C!%36/GL@U[P3$9I41]DIA%SKC!UC['92>>$6X1<<FV*.9)#8/V'NF%
M@7 PSG36'0-.]$-''@&(N[FL@77??B5FQ#K47'8*.*WV(";C=]II0W/_E&<S
MM]+F\\:^DO\B&B^@XS/ONJ*4<(VO%^,EO\KW?K0NHII=MV9AS3^XRP8$(8X
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MPB6.']^?!PCMS[K-[W@TH0F7P=34S#]PZJG]X\:"N82K$)AD&3WV\(_7PA&
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M/L9=Y6(/X[@%D*DX)C)7?3>:G2IB190@9!*]CP#FX0/3WBG$#%>*->L'3[^
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M5U#.M9H-JB)>* N3*.L>V9"T>_^3E5A07/VI3OGVQV6K0G'NNR:$ZY0\+8%
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MW>#?<>.J[>/('QK.W#NEV&NT>EG#H7N]!.6ZY%B(6?>(#GC!6_7NF6H7)?R
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M?[QPC#]?_T_%_0_35@OTSE;Y3PW9%['9FQ:P'TFQ"B5-*6S\[<*;D!IEZHN
M#B1%J!9%DTF.TE5*[B$.I^E "#X.O^#:%2MY.\T"82J#[UQ, C-:6;YUBT9]
M.X;]/>@[PN(21M(D1Q%%VA<%8-KZI,@66D8IK'7]VW(VDX1]0FT\9$_B]$_6
MN+E7G.C1CWQ1R2YU!9CMK,0G$#%K&"=8DLQO)U.1C!=U5P_-N<ZC18\M2?'
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MOSI.YZ;*D^S2=BZAW4:V]P(XS_?FK:*;4B.:GAG\ZFB]R+12"/7"A!HZAJX
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MRX404.&CTD$$-J7!T9N62[7P/-0U64"RZ(0:/_@)FIK"JYA8?;)EG7=::&6
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M(*5+_+&6;<J[MFF1T*RLZM/3)1>^T]AEB:=979+Q>GS4>T2[7B0'4@ 0=$F
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MYD>Z18''1WC7D:96OQ:[=5TBTI[V@2[+ '5:P6].E067?JL0!_,N:Z@DI%C
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M,T BIV$6V)ZN,!<3K>F:LE/FHYFDM?XH+/EA9DB>?]GDNDOD=(LEL$L[C=
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M+&?[S.,BO]VJDX';U4GX.>?4/L1#QBN$,4UN>0\EA'/G%UY]+M)P$>4U2M=
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M5QJZHJ,>[V6FKK=@/#YJ=HV6G/;.SG"3YAXD#[-Y\H+E8L?\N9$@_$5?U-K
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M+J!-H.;E1Q*5C3L->2<(M\<;"IHI]3SGES;0?0<R"D81^HW4"P!C <]'MZ6
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M6:"J_]0=F0.8XX]2Q2[<:9_VJM(Y^R[!8XMKS9.10U/H0Y'_BSOWBWD%^>O
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M*(.SY787F*T0J]&O<NM9H+B"-8>TNC"))X^BD _//-7I#(AS>Q FTW-YIDK
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MJ,KDK0)98F+$B!J,S:_?,7V#R&B[-I',,#;7/.C?7JL.>\L\]:@%E89H8F0
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MSC$05@D?@T45-;4F(]8*6V70?NM=,1]&D7R/?VD(8@*+V(QH8[.6N/"8+$,
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M]J %14^Q_9+OL@59-WAZU-MG9*@),FB?OE>9X:)(*?H^>J'%==TIAR8&^;=
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M)P;1 Z115'^V!:&?\'XW'6X:XL,W/#$BJG,I,L=MS46(J1SBFR[^8.AU5>,
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M5WA-A#.R4^H(Q+05ZM<VC VLMVFL['Z:R)[YUX0ZC>,7J%FIIWUUD69-)IE
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M8@9!![6L9X71*$!1S=8\:4V3?)(ESY.VD*3:MA$ B,C6^9?)/U)OX>C<VZV
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M)?BZ/C:R\W"-;-F/:CBZPREPGG[HH#5$3 =;2 AG<4#QUL1C@X +KPP>ZZT
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MD'CF<!,2Z)C]Z:1VU>(,D.W703[:] QPE#KW'836+_JKX$3.58@'A\E5E6U
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M.M_MO93N_>%3I%FH#XL4?*--$*"!J*Q]_XQREN))PNZ8@ZB>I$.16NW#G*9
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M+XMMY1DCJU58EQ/C2ZT-G_FYSXE*\Y2>)E[3Y/Q^3:Q>JJ"^,GU\?2T\]#E
M+RR,_1,J6BQ43N-;2]BVOO3"K]4M([=4QM,;5Z.9+'X/L/PL8WPY6RK]G'?!
MA 9B,J\F)&&('IV0$*0F 18MP:Q<];7&(#ON'K-5MO^CDL0!<_B6Y74(G+X=
M<T4F'B*-X.G$ &#$@V2!8 ;2"9>$OGEUVXL3-/FMRS,37OR9@B/'V:,]+O$E
MJ,F T!<T=_\:SF*](,5T 5RZ\/OY5QJ(\JX,>@!'5Y;2Y^ _>;$MK?(4&U@+
MCV]'<9)=*>^H$,#W&;[\J'L_.&T^RZ.T;=K L<C91%-:KLB4N<LA-5[< :JZ
M(O<CT,Z5>JK=<<E(;41;  $A8",1#N=_+U5AJA]&73\5S'96LV+QJ4BC;<SK
MIOZ@(#P#71%VHDA\M0N4BW'-TW+'E[]NQ4?20(ZP*?T>(H:[+CX^2]C))CXR
MH*-ZTN7%C[[\V]N5ZXRA'HJ<)=(7SKXW?*X1E$7LH'SR7IA&+QXNA#IE:D%M
MZM_;;QQ_C#)H:#*] 8Y#-#PP?S-H.GE1-S"69Z?<P6Y^?5WM#<;=(PI:/1#O
ML8B>YL9Y1"HNW#&OKR-81'/];'A__OQ5C<MQEJ=8!JI/ZL^;MB6J14(]!J.@
MM=TMF5R4#"J?:[VE==2G/()]8[3@HZXVY 'O):D9QO?]XMY"YI&\QY*Z?$%8
MGTD\=!)#M LG6@)WE(5B;Y$<N[YFM(^JE.M8Q;RVO<SP-+!I\LMC[CZ1GS<&
M6!*I<PLUV/A#11% <1G3#E G" SMO2LF^6^36VM/[YQ4%/K^Y[G%W=7AF_Q)
M)UI'<Z)=_N-!QK+(O%\'#6N,H=U9S"V.><"W$W%N2N<F^O[<6&$X;\CC5'73
M4FNKL#WK!,*"4@-UB><@OP"R<2XM3(M0%BJI,Q/28F%5D*ZQC% OA:2_C)4V
MYUCM*;GR 7I;*F>N@Q+<"J;$DOF71,#$34K>H9O1S=$#BJQI<Q(=D<KHB)1
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M9O%M%.!9VU%?LMJHSL5#'6: %'_49@\W23Y^GP+(' -?4(!;GX^^]%<[(/#
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M RT(SB %Z.)UT@0S,-6\_&U,=5YWO7*X\>7!7A&%FJF*5SY5N-AL_-R1FHB
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M\1DXZ$II=Z+KN"HDGG-^P[]'.339>5MO8FY?/_0J\/V-2T$%%&L".PDC#U*
MAJ%NU'1L]V05WB_@L#1F#9FJ]80MB##HM]K_^,/9CQ=SHC[,0(C<M)B^J  8
M2PBBDWRB=CC@D<%VM<*$$5>=BFFAU.=OKUPS^B4R^E''265MX@0[T*A'5(24
MWRX>$GQM]("=P=@[OM)C9#:=:^@3_*+>*06!8&E#$4DQK <M/@^M X6;S(@O
MPWH74_L)JJ$,8T+7QFZG?L)!$TX]+;0K&7?7R[SG?)7M\8OP>]NU2<*[!#A&
MJ?NS^(I4E\D)</9*QJ>1@T'I'Z?I5@OE=4)F246W/H:-378N8HVFG-M $L'"
MZV+9B>6.Y<O<:Q8O. 0W]]\*K-./N9/&\T]4,Y*91K') =8P+FHT6!##T6T:
M?ZD6F;->^NB?;?#)+Q44@EH@_7A()3I\H5:DR'"ND/JK(Z$FCW!\2R:)*K_W
MH;6;7XP7HOQ5_JHUX#]1H![L6#8M]KK6&EHUO@QM6D.6;B+KE'JF I5?3X>J
M/[CHVZOU?459=Q*=4_N548@J80;_W@:Y30%N^J'WV]?:;*ALBP)(U1.<$%,?
M%@\='CB-_Y._LL"SL+L0@L(GFNX!@HZW:QAK3JQV0(HB(Z!7MO8J\52>_*PP
M_#/Z8!5"?G9S\GMU>'#XQ,G&22*/$MXO09FE)J^.AP*X&@=TDZ\C9 &J*(JD
MWJ6_"G0@]VG"2*?:4?6J[ Q3H=? "_<QVI:?6IW>YS=E!TUL\UYFQ:])31F(
MJ4UJ:&CA44E4.=6(^ G7X:4 M5\F*8"!7^4N\C@%^%A9B)A\!CU4\*#%_5IQ
MW^;!CF)^[;1@8S$ZV3JM"WPXJQ=(TT>)W?"GLZ60=_[\S-" ]Y:_4&]_Z)RD
M<M;CBP19HO6$#G_N]<U-34-5C2^URG//6J9JQ3%FUWH^.K,[EK15XDNHLRP-
M_P+!L_J1V';;\3B3&!6T(.AGA24WNXD6%FYFU=DMV!OEUNN>S@S46']J<L/C
M*$^%4&?K!;+@GX)\A41#,'H%PA62V"=Z-HIP(^S.HBEL/]CYTE\7=? W?9R[
M?Q8!;U%U4%=DI),:R(A=6.]<. ]&0;NY3FPCIX/5.7C4FER.:32?4S01BI._
MLN[UBA69%LC^&-8 (7+-FJ(GVEEAZCV0)Z+P!4=0W92^IFI4HD4/<DX,,6CP
M0"H[[G$.X3P>1BK1.D>P"E5JQL7&3!@9<NK"RS:"Z02J?*]$#M<*G^TZ5J-Q
M2Q]8O<18,ZSWP&9'&_?#F)03?AQ,[&M-,@K"GXO;KC+R(3B.Q7J;N;^1O]<=
M8.4R$Z%SDE2]BZ(N#Q+6N/82U]>9'=1,%L&M]$/BM,Y,&@F/GNUX,6RB:;NL
M]_08YU_EOV_2UA/DB<JX[)UQW. -JKG+Z/.^7-H1# V!=MTU?*^N>VIJO7WL
M*:_\)4\)@<[7T6H(U\6I4E-28>,I' '_-!AGC5J6[OF2AGE7E>BAP,_%U0]Q
MFYE..?6SXNGGEI<LG^=UCSKY2OSH96AI--;M@?X_Q+UG5%/1V_9YD"8U@/06
M%!"5)DU4, &1)B(6.D*4*B!%I1L20)KTHJ @13HBTGL)'13I34(-H("")"+A
M0 H3_L^LF7GGF35EK7>M^7"^L%9"SM[[ON[?=<Z][UWC'U.AC#^O;%0P_/U/
M ,_'!$ZM=P+,/Q^4,/]2X]ME[DD$SRUU(J)F%MEKZF?6"+XS,5(AW9#(%=*#
MM,J;6E9%N@>OUQ(7 *=K*>W9YO,?(KWU @55@=J[#V9Z,-'"%ETY48MG")%-
MBF\*'Z<I+SW@TG(VO>>G$%0C>DYLD$93  WF#%MM/Z)&H:(P8=3@(D_K>87"
M0/[\%19[QM8(B;?=H=C+-VJJLYNBB65H_+V1V>UV(;(:Z$YPQWV"S@95=*75
M5)E(*YMWBC&P?R=UG;^^YG/&E:4B$^Z,X:!.P7G:3P?D$^-!=UR6^-\CH%?
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M5\6CBB;H#V:^0?'Z-N&9Q.L^]W=U5V0GO3X/V!Q<S(4TR=+,IQW-EE6C1H\
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M:GV//8/8V]JIVM_&]R8O/F5<8U/V%.K\+\]05M67U%?5]S$Z]\+'.(!9BQ%
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MXD#6Q8$-'MSG8*(:EX_AI]K*YL:$R3%X].:Y="AG"Q_'X2<&IO =AS_+DIO
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M_FS-EOC9E1G0F2"/OW#7P O3I#GFCE@9-'2*X31N?&K*F^>0J!*(N<5(O[L
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M,U[Y?M$@@X!>;/HE ??NG:PSDS<<H5P]6I/@4_'XYY?+=-#3?O#J7<;<=GV
MRZ8N25<G\!G.\K.]*0>;LWR/@5-]$#_80%X$LLD^8,^E.K)GQ@1 %N=;L.$0
M880^$8ROEE 9]:SF:-S@6*^M>%F9(^_FJ))-*#,E/)4]$W'IQ((?K)RG,TD
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MIH,$3-B;WSF\/Y?M*2\IPP>/BWK)M/D@KJ@ F3%DM&;^=7(%P;2 !LY0YA0
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MELL^3FAO:^GI?4;ND@DXOIU<^1E.ZJ!6J*(F8>WJO/I%=3$(G]*** ,"12'
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M;S(!6QK;CWAL95G9=4F-V+(><E*53=(/K@ LX9;9U'$:O]7ZXH<IMW$#'GX
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M\RJ !V?&,?%M['M@:L?-5O_]D_<N#LZ:)]T(RK&]3P<-**_:^+CYZ-I[/&F
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M0JD-'12IK<8W&>C3%:R=4>5&^-F3D,GTJ+_N+75'A9<Z>(8IW 9=+4LIZ%V
M4N.,Z:!WOUYBWH[]7!'8W6U^[?0X*$#5?RR=6%UE(L]R?5!/H<_L,DA6;7\Y
MB&R%"*56(IR*7=%57MDN. B36TI--4U]7 HVKWXA^3/8V>!\C-@7IB,/ZUM(
M*.#,7@(&(40^ 7RZ:Z98VE6J5O;2Z?F+:T^,"BUDRUT'O_\OS+UY--3A'_<]
MDNQ-]MU4E+(G6\(HV9*TV6,(2;9D9\QDWTT(I9B$D"1[UK%+0O;=C!DA2V8L
MXYM9W.-W/^<Y]W/?YSSW<IX_GC^^Q_'7?+_7=7T^[]?[6C[709Q4"YQ&4:5Z
M B2B%0X9395;A$T'[MP?WMP4]!\7>C#C,P-;4&L_=GF_W^7Y,_5D'(?7NM.Y
MHL%B2\",\IPJ59G19:O4;2^$U[<KS5OIW%=?<T!LI+'&/-<4YI1V^RJ.H_1N
M^% >N1^":@6C/EFO:3W($P!B%LFGUA&0URK_O-);/<->>!6]BBS?D8(70^4T
M,@]!G4Z(4>3N4]LX.O?0(4BT0@G0_T#U(+%NTO+AMF.M7$^Q)_V]',9WL3S2
M?@GO7PM+"+II/N3N\S1N7Y9?R7&(FG\:SD[Q0 RW:@)(/.087!XP]WF*Y6WV
MO5Q42]LNZRYN>WW"_C-'UB ARY+)&?GJG576P")D-@@G65J\3J;+CR TW/WF
MC"3S%_%)_%$A'#8B!=<3+^]G?FV8&\YDE411_.@#="T@YG.P%+ZBP^,; 4C#
MN4N:>H@D?L)>[[JD9QTSQ^94&\]5I?E=\R>R&DGEOZH'Y.-?MTI2#8856X7A
M=VU8RMRU<K3LYLUI4V_:7 (WQ5\/ZED^=]\;LU?5K4P%9O]XA)3$?^;07YZ+
M?26\V/%[>PET?6?'MVU(@&@>#_4<2H;5@E%[YJR(GUK<15\B/O[XY0#7FSPS
M?^PK3MLIZFSIVJ=[1H[7IMZ+[C$ 9PBE!F:B][8J:'F6L_14*K2^W"[I._7S
M$-0BV5Y@90X(A IM>!#[30!SB@I5=WBWS-K1(^7L[+W6=$G$<)"VB?2(X-KT
MXS:9#Y\BVHZA[=B??('C,=6'H,W.18K5N+RN#H"T'$^,S3!KK+6L#__VCR=O
M+"(M+[!8I_?N'.('IDXC6=N>I,4("VQ/!3N8%7ZG^L6<G8F'6'CVW81K\ITL
MF;>'7_[HABSWC!Q#5ZQ]&]TTH, XGQBLWSBCH6N]P^68SA=DWR!-^&CRH=TO
M'M@D57>BJ[&=$K!>R0M9!J.> M>O@4YXO'F]F2K<&^@,,*4_8U(CR<3 S2BN
MB*F)SFY=D7%_5"0&O'62IGOEE]K 3VEQK<J$)004M7]S^D=B/R.QUWB(UB>T
M7H#S F'%[D$.9R*7\?:&,'#[Q?BGST6D4C7W [W*5*+&0HHG6LY/DK_1BCS+
M\?7UM R?T_4QQWV[!<MJ[^JUW3EN#3IYZ=Y"W44%1=\\19+5)HHB9HOB ]X^
M&&E5AT-K'7TF%L3M[:YK-:ETI1NU#1Z"%C[L.:V35QC(FN(@2GO?*OI'5YU8
MWME?A"WEYNJO\W!_@#=V<?A9G*K"UGX\DOV?@\_,#CF[(=;X,2UCRS71X *I
MM2S35>KXJ4=+/#98XBU('))75^ IEG^W0C 8\H!H%!-@^CW 3,R\Y1G)[HJ[
MI?$X)OX?XGK6:9<;W&K?U#X606?XR"N3&#>?64;&TB>=J%?%<,M3-96$.LD3
MRJKU&BC.$..J?PA'A?,+%37/S06\L1WH.M2FP./6\QD]MDKM$H(;(7628K',
MYY9\WZF(S/8_YC*\G,WZQ?EV9B?U'E$!U04&Y#6B-FJO!C145HUZ[1FE- K5
MUV99)Y!Y/[M)D!)IBH6UWW3DX6!B-ODMT$=D);_XI<M-'P8[5]@!;R8DF'M$
MX=<$;6S(9R\]T,,U6'^_\"7F59U%->P>([Z%@7+\T''K&3B$E)J+0_.=_Y ^
M]U0T]\-#HW/O$^^06(*+F))JS'+?+X*U<=1<!M<'NPQ3KQ+]NBY%YJ2^Q</;
MM<)W600&P93A,^M35JL*:N/LNVX$S,;DT4Q5R@34?2A5-"BR568U%)PJ[Z,.
M9%@WCG[(DC TU[W6J.KAQJ81JWTVH*(6Z:XT ^[%5F$WMG!-8F\\F]U(V5V7
M._-G[:5ELT8=E/^M;+<E.[KJW>'W#OC>8Q""WM Y!,G,4BR04\:'H#\/QC<Q
M]>8; Y\1(Q"NFLI%'1/_"C' ^8Z]LT&.X53ZS?=1/$B<S&_'>>:S*Z!TWMEK
M]5^*8YYBN!G @([5>@[,3.(-DTB<=U*.[]-/452\7@8\P</.JWGZH14*G),5
M_S)1"MJTZAJ^ #+Z8W"S IDX^+4 =_'ZF0=!QQ:]'LMR&BV#F!WW(16VP X.
M1>6W-9/I%L1P8Y[XG'P(OTS:"#M-'VV(_X@.[=KDY1LYW0NT/T')A"9S4&*L
ME8^+1WT_6QK")[<GF'CA/P53_I</+'>3,(GE<$Y<"[*KOCVGWW#TKYI(Q]ZE
M3C'CJ?V.'.H.(RKMJ"H9^/TD[2"*8? \WP.2;GZ9F?O'?IFS"X9W]GG/'H+
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M=/]>^[G1FQW>J^2G%SY\?O'_5L>AXCMZIHE^;Y&X3N^!<!Z"5@&YO9G_L?S
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MW LSCUI0)-'KGTX$26J1CL_D-INA<^:#3UX>Y$I1OSQV06=U@C RV#L['D=
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MD?HLG%)^Y%=&LN]@8S!$4T@$ __V5FO+UNV=>[6BO<_=Q7L4YC#)W.NY0#"
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MN:TF0M<$_M/'9^X(4NR9A9B1-&JL=0Y%@[ A/]LO6!.<&(#R?3"0F<SP13.
M;83P*[)6S-):DI#M=4ET$IIX";T#[8]'D7E'H-MS<!A&>(?O+P$&D$X%,QG
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M1R4=Q) $>N8@K3#!X$';FKJ&C]\#=JHY"82'.Q4*GM<_K,O>>3R5 *PJ88Q
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M^0MRU4:@;M#'?/K3>>\Z/Z$'C6);]8<[5H#=-PF])-WX*@P[B+(=#>P!M;Y
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M,3!LW70UU)1/>ZCGE>\%.;O43 .1R2J9 OMF%/$RYC%2BI8)-Y*FAH*V!3=
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MV>\<BZ,$-LIUQ%$2BBHDB4.E;*/$'69 Z-F/)ST=WDSV"8S73KT2/AECH!_
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MYGW81*N_EU:0SJ!LFO+K6UTKIL;*4H?,_)Q52()D1? P2;-ER_U12BN,=WE
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MKE[D3;%QX_\F?+BCJRS@HRS]MTCI+3C]:$$(]$H%$Y R=62 C#+;1<0+8(N
MBA%NV*B4S'KZ*_6]>(K,Z^\@2;2"FW>NKG9P&PF+AT6T\\+UI[HEN8<KM:\4
MV#UO:(A-_'J5;2')9A[W9#I34U1M8N0JQQ=10VDIDFYUK(XJ$^L5:")$L @F
MH?TX/,<<T"+T.664#(>+W3NY\ER_*I$3NC/8=0"J7:<L,\/SG#>5C3$>V&I2
MZ@:I]ZS(ME&H/MW:&/8H>DK@_5/<,U@3+1A%><B,;IXT=?H;WSJRWGBCSF5R
M5U.&VN 3D/"OP-8+8=>TM+<>_5)^UGVFO?8_7J%KKU"B .E"Q@B,G::'X_6T
MK*^?>'1'XKN+Q*:3/EB\C%-4[HOFY\^?A]2FX)>[ IU#:+*%<"^]1N%L_51G
MH<0B:>!4XB&I/YJLN;LU?Y<1NWF1"IEAC$+X=82!JI6>[=6[<&%Z=6%]W*"3
M2,2@U_G1WBEG6E!H"GB14IV_FL?C=0+N@7#$;?I?#1@L<VL0G'X]X7^\I^:C
M)ZNTYL(;YWH$-QX#R%2UX#8OOMADI223DZ)+RT6$LSU:,\E'KMSJ:6*5G1+:
ME]4#(?WM_TI\V/4XF9,-L!A1>!CG<14#U8"%=;2R#8M,$-)WIW2#2.6CG:%G
ME01M<;BDS0-AAK32J?I8O<$?7Q^6-1SJ Z,4K:YLASZ@_I<S7025*L'X3$%_
M5(K2-BFTA6=Z"535OT>YU(W9Q/OP3PL^9)F[HI(KORIW-@_,2Z^!.BL:4(J
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M<YL]Z!\3")&2:<>VB;"> U!D8&-GI1@^*VZI:VKQW+B7@FSZET1B:J-MD=Y
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M<_ &&X6XZ:WE[&!G6(C[G]_WM9R7GI6-E,JD-O +I/ZL7+\*,;X#R[!%)1Z
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MYW<H!&JZ^E=<BIG9A"$/0/T;C"DTY8(&(W/1:M4"&<B,R5#4=PK*?8AZ7.P
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MR_]_"@O]YP_P%RQP-J3' 5GON%ZEO_7ZG&G-X):ES('K=F'EV98&(,FUS0S
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M[ED%=YAD<OYJ@HG+M&3TIX4]4!;>&N7QU7]U<NM#9F7Q3M WCVWT@Y+HPZP
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M,C\Q3P#;!# [D O+&(&9HLW?GOW5M=N%&^G ?C]S_@:_L<3O 3%T107+P_*
M\3Z+_J9.4Y3SB8<T3P$RDM2*EN"ALAESKLQW>R"/G@'1IZD!G4HY>$UJ.\O!
M/?O'*Z!^&6!@K=L.SA9[-<\XQ]IKW#K]F6<HQN?W#=YZ2BV7UWDN(2J)]>\D
MYC0.W:LDLGBZ(8P<H.Q!V<+Z*4Z.3DKD:XEE6CW)=P(/M%80&R(]C[$M86IS
MJRDN+H#@FWFX3_HJ5$IS_G.SRY"%TNNM)PF#@Q<J8[_W&^<LM _N%Y?/F+[&
M\LEI#$6B-Y,>%GLUI3MH>F/TRT:>I]\;Y'D^\4,3S]>QO!;HAI\ET8;2P 0K
M(2SIIXZ3O^8O/M<\#9PY7?9:N83\R^'J)R6<!7,VOTA=7L)J.?XS*9D6RIK_
M!W1VR@T@L814@J'4"Q9M?@"R_@;D$?KZ<*2.H>7/$4ZL;'=)AT-S#58WOYG:
M (E!\'X$XNODTKZ/W0EP]8X_?_.F^\I<5G1RU%,VMSA3T .,T(:^L3>YJ4\=
MN&RQ<#;%K"U*UE3\\P^RT0]>A9AW\"]MYTYL$SHB&=%T4]J%\(1NA H2QZ[P
MLT%^8U&<Q=HTEPMWY!>\#K3(![X(7!A 5^V[3YH,8_DB:0\4*)&FX!)[%<)F
M5E:A^,#PF4?C'LA;N$XB$/^.!3]+PGSK.=$/N-%-/JR+U!D8NAW-&@B[0;[#
MQ'Y;59L9.C RP>Q^XS0?O52R%2:1.(T^:-.:NHVNDR_FQ?,.1*G$_RD?[SYB
M62VM[?+TS.]+1W8X'O_V+A?ZL0=J""VC"%HR4'27,'*ALBP0>SQT#S3C[Q\H
MU!.7-GSALOG9#]H;J:APB%LSVID%55Q4V4F$RAJ*<W*%" ^S _"T2TN7%ISV
M6^UYL^ECL@]<[U]8$4,C_N%1J@;%FV17C?AFJ%@/8 ^60;I9P-TXBMN\]*$Q
M=8ZGF?-\MNC$],[I>Z*99I;+A__Q' &"R]FGJ1R:7;A#_Y*'> Y=*=L 2K.N
MKJ\Z0^"])WKSAY.[+]<&=873O:(3W53!BH\01DL()DT7W#G+@WJLNF!%/#UY
MVW)R<'#A%[/OSO.!K2NIQ8'\#PX^>E2P"?WW<,VO<=N#X(PW$R0Z#T'G(:C?
M+</Z8X"^63*)^EA0]/V[0W*(A4.=FS#E?_HF6M,LPU.8@GC QR+D4!OJ/?(V
MH]6ZOOXK8HR:AO%.TWX8JU>7KII:0&/?)V$)-(M->6CA-<^.B>?1Y6$DV6MR
M5/N\&2:6:NNRS8059NCI;WP-_P4+W!="*7N@ ^P4.9+$TBR4 S6S)7G!Z4WV
M-LU_73>D;.'8(?TTO$]:XY8GK1FK\U-AC<6E7)_4_;:E#I"76X#;:,LWLUK%
MLJ9F-..DRQ_M01R8,-"MT!KHOXML"EE<BO^/$0[+$?]APK'E^H\33C'XWT<X
MD53S<:;L&J0.'Z=BJ%S6@SRZ3(-12^9=3 )/],YU'>\_7*FR<=$5]+E3/\>M
MTQ1T;=+YNT;DCP\#;3=DSY% A;0K"V"NEX[]T/>09*3O?H^EG-Y?-".3MZ9O
M^GW91COFWSCA.,Z$_CX70+R*5\:W9\%\]WUF1\0*(<9S]T!-7H5E/N?\S!?U
M8#>4>I+*9@PPF0%$;;'"4G6V'R(#1[*^!<'\1UA7E-(0X2G4)^3M>/J)/5 =
MW7%T]:KK5TW8^U_4)H^+_/"VE">W,%J;K;$P1SNCX\C.5K2 &_TDV: _-=>4
M\@0GE%HP^D7<C #,OFJ>2V1_^UM[61[TD$/(AMB[DE*_!XIA:GXD"PPN:*1<
M:HZ2O!6O<W.>T]!M/%/(O?7X.>G607F.[_AI2 ]$BFZ\"!,8HNRR0.OGWU.N
MYV$W7)RU9^AE<CSL\C*("!G-OT+_..R0OCWMJAMB5NK4F/[M@Z\QG.X=$R)7
M(AZVRB]N":'6G^?+"&2E-9_Z$/FC8^I?< #8QP$6&$N&^ZE$G_.[^E/-]QTN
MJ7;T7<T42<J?+;=(Z\1Z/XCP3RY-@<Y*V -E)73.R1KFD;+A(D,GDFD!SKD[
M^'2W&O?]'(63.]HAQT,KD.Y*+H3&)K*<=0LP(CF.T/=OS;K?E)OI8OF=&_SL
M:9P]UU!ZK%Q[Y+-_LIKWY?M!AB1HIYP$-@^6B<03:^?+7LPK#TY<9MX_KL%?
MI3I3))KU+_XPI52Q$,@T@_1VJ5"]\YR?-?FJM96%J^G2Z+NR:)?Z+$:3NKZ7
MK58>RX6S_T*3P\BFFG;*_H<7/KB!]J?S:$^*S.JL2F]:6L-L5-Y YE9=J;Q$
MUX.#_K]8UL8BO5OQ8GY03KI8,.6(EXW$T)L>7 N6]WYS<S_VHPS;,9H\>Z.A
MPEQX#'8I,-6;_#RKS5XX+7S7(EDSZ\OBXV%1QP,W=EZ$WS+>[ UAZ85!5GPF
M8GQLC@*!O9LT(Y8P+9.<X[A$"T7Y^UPVE1C^U&1ZY'< ;4;S;\C^FP<WGGU?
M0$G$H#+_^WXFB_+C#0?2S4??Y>+7"9/N ;2_&5_[7TIWSF??YS/69#V<+5<?
MLFD/E SUQ?"M2?'"9G8ES5QT;K7H8J8?#NF]/Z[A=H48)"&T.+ =5/3W[U2\
M1T=>]Z-KJ[?C7T]F250/'MLI.TA__&FG;BQYE$4?>=2:\0YI7VC='BCE'E.P
MK =UU#T=3U,*"" T9]9^3+1,_.Y@QAC)V>18FQ+ZPNPIP/8R@A<+YNB!K(1"
M8@_D>_.,R]!Y)=CZHES>EE'E<]H<47-S_#_V(BR7.88_$(#T@3TV5"&?^I3F
M/;X^/6,M9W'O6\+CW]/<0L'IE3?"T(.P::Y.PW.,,HS/)ONO(EU!FR5L3"-O
MS.32H:TRJWSQ!1$NIC.W!6DX]+'-%:2_0CP01H9UH7C@QD17_^X6Y/1?L,@J
M"K?[+O_K#O4LO>W^1SY@Y4>N"1[$\1%]EO&VXP@*QT&-HF"B2Q\F;SK42G^U
M/&_?DC;IPR,U],,LWS ?;<\"U(/[W5>8$RQZBPWHX*";%<+/4!0Z1RW+C#TK
MWS]9N)!^P>S)8D1M;)W7@\'*H5:EC):_U<%7R MYP6]7IZ@M;B_NQEMNJIR^
M49)D[N!]!R2U/!7''$6]QW1EX+(]Q_4=7\_="$^3X3^-*;VDM'F8K>OCV8$3
MDDU5_*GL"CT/ P%9E6Y4T^Q^ MTOI3P:@'KH;+U1G/7)'*(@9#W]%;%T[?.O
M="-#-T8-QG<6AKM&_02<8PJE$]:65N+I-O[EOKMC%X8.OGHTY8!].%++<;92
M:9RON?MA$&R_.)XITKO=G)K&R&^($KG0I(V0'=EPG_PS9 _1[*E5J.II8_Q(
MMKR03JJ/3$_IP]>J=.'%3,BC,QJM&7R_\.! 9]K%]]^6K<(OILE>57UZ[,Z.
MS_6<3$M%2]D?[:O1AI<93S !-KSP*""X! ATGC@YBI#WH?XJ7WVD24LL;\D^
M(8A-U-*.G\VU&]0R%L79C._VU94#D9<_CC>XK 6H7VFT48ML'<B5+[&;R)^.
M+ITKV.FF/MDOO ^79)0T?&PSKOP55G2<<KD?WH)/\';Q?1,T4F;FD#:;T>88
MQ-R^M!4) 63!W;-558& )5.:)3]T ZHX^%Z$5)AE!8AV"7[/2<?<?[OL+KK,
M,=O!Q9QU.\1XU:$:7O5I@;MV(B12B7W>&WG,!*1[=]C%7[KC@<X2-\1P2B9N
M8.<W\[#U(EH0K@14DS'4E^3<PM.5</%?GC4N%_E,RY\/O^OQ/M3E2_#J'_IQ
M<C>JFERZN!EKR 5< 1\)E^BF%DF-$/12M0:M!J?[=F3ON)FSUM. /I__N];Z
M6-N&@LE5T8V -V;I-[R,!J3Y8]Z!.8]:G/C&A8(?84DA;MI%X,)LC^&AJ>J_
MYSW2G FLU+Y5V\"]0''#C"O#9,*24[":<HW(%8O@!AR(/6Y:E -Y"7^:[1,C
MWX(BGO.N)QG^R6 .QOA_QR:BR):86(0"Y5C!9MP&W9B,MPM5OM8=EMRXE*%S
M8]GAS%<^_F?FM_2,%U& ++I+"=+#[^]V;E+?CB)-57MM@EX%N62?>^"@Z7C[
M)?W==XOS)[9!VYB9,&KVZ![(+S!!+7S(E,RL*_;MHOJ?CT<+E./8(7^SU&KY
MFD\(Z)[S7+GG_QTV7<>\>H9V#3D5R&A&8^JCI+J[=UUK\LMF7'ZUA+SV/])>
M]MKJF&VQZ.'$X@.@4/8VS!+FGQT(<4@1>C!%SBSO&O(HT-OD9Q5R'\V2\4S2
M!?:VW1R6;J3?V ,]_4(7W0/57B+N@2Q#_!B'T3)3&"\5+A8+II%7^H8^AJ@2
M)0]V_IFU(#;;^=SQ:#;I,,A72LG7F8,FC*%N%H.CH8L-R"U_0V'6)%^G]D 6
M@56_T#C_Q6[$-U@=)+F-F]L>,_ZGWE\XJ[&B)?'U-P_J-5D?[C^G:YBCL#J;
M)TB_#(X;@$W? S\[W]!'3Q^]#BB;4U2+&#A6RYMK)A$Z3'>OT4%?;XH+*$X_
M]O7S^ GL338617LSN<MI5WUUF[I;P3%%ZH7ZZA3MSN'="[_$D\X-A7%:/YF6
M>)>HEB:JTW6/@RNC@6Y%B)+I;)'\T8#VRWVDG.45;Y6RMC,I>L=NOC 1Y!B+
M&(6]AW;9X!",!J3 +T==QZ1D3EUJTKF8'Z8<AV4/.,E^ K$/W@"!3C@FS" [
MCS,EYOT<QL)S^IGG*4IQ;]EY)%(^VUT(VA+>&N@+W@[]2_?A^&8(8N)V\215
MEO!YT=W!02;5O"('7ZCC"2*TQN6>*5HK?*-/+[M)KAB4N'MW.?4)^JW^;4*[
M]J<BP4FXY;LY'E<YB[J"W0UW.K]9W!S3: *2 .6E*Y$SNG*+Q,FA<=Y+)+YQ
MQ,;708.JG(GG?\,,9I+<YPK(@8"\]F-#6?A-0*6<;@"$O-'LI\ON]E;G-KV-
M^)QT^]9Q=8O%]Z%7E[3O<I(<.8,_<U4AL!A(FRKM$EVSGM+TI'3\SNB]4Y'!
M4N4^WRYEG]9&A]SG[EOVNAFCGFGTI^"[H1!=<P3!1]<A;\?0];AF_D0)CRB=
MN+;]XGA=4Y6>L)?!D*"KZ[_O;#I HKDA!]T,)?= TYU+@0S( 43/U+_N[72,
MC2:XSX%$-%U@A7GU $6=V5G0SWP9L$8]BY%$+N9!MS)5DE!4WDGH'V(@K/;Z
MOU$M_C]_.'"ET[E8Z6+2 O\X7950>!;O\BU$ONU%E439H,5'3HCMIV@3]D,G
MCAJ#)AG'V,@:>/)E*#]=>YRE7V4HV[THOOK6)'C_2+E*$,C@ >\#,[Y#Q >J
M_0<R=#*8DK$$5-*C9VTH\3V0#U08;CRR%$ T;7)L2@E=CVVQ]+ %FS2>"QJ)
M/Q!%,P7="A?\A(  [DL&VMU2PJ,!]=9<5Q)- CS]7MB)O)5K5=4YE70J23;;
M4A/SGV,(MF5D@^,Z2UG3KL#!4VT<(>$%'MM]9ZHUA5.^T!0IGVO033+Z!Z^J
MG0]V08$04FL0[HXCX5:=!1M-D,0&R8.]&K_?]G(_L3[F\0YVTNM$8M>9Y>6W
M!A2WQ_\_,;3%8CB,>PI)F_J%HM*//1;^!N]6M(JSLI:P3!XH87ZY\%9 \OM7
MPDG':]%JGL$PV__ZMA7_/?XW#Z$C\]\[4&P%J^&D5VZ\.>?MQ7X-E/>>M1:W
ME'B7U<Q;4W[R\4_C/\5<_]+!R:%EO%K1(UXOI2)@^3DIZ53FF4Q*5TR$?GI1
M2;3BR'\!<-A=KY_WMYE$C#%02/\HJN]E04:!9\Y@9HA9I]X-C_L1/VK^]WY;
M_]=]\AS7K1%ZB"G45EY& I)Z+MQE#V3>:02IU=@_FOEO'82NHDPQN8-9*,T.
MY.^!;GUQWP-=T?I+$_JOCX7_'O]7#0@*0G:P]N^A3N$Y'D*/A*,=R#EKN.]]
M*(/)9V&*<GP!64Y/[K52-V79HR+$*@60G9I,7<!OP0K+BYCLD,^SMWN^U.HR
MZR,KDRF9NV63=WXU;9S\2 39Z:)IY2K8"ZM++XW2Q4W/ $4N22LY&_WBEC[#
M_=,@FR6WOX1-X(S*^MJ2I)3_#R#-NZKEK>K,+^'?-[$*;-O7.7'<?Q^4SMER
MO41\V@,U:/= A. F%/0G;.K"S?UJ"=+5&LY/?8H77$HKSS\H5CCW6]KS_L$_
M.;*>EM#[4ROF]/W2:XBS )YF#3=C5+09O_JR5,W1<[0]-]8[*'.;/T<@Z:#Y
M\-MCA\KZ.-2U#'_UST.%.\X R$54=V%8W\*9%JV"TQGWO N?>LYE"\D8S\\/
M5F8X2.I^XW(U1=P"S(C4,A:II5B%$0+4^P3A1P!3V0RI? :+(47\1-]VIF4[
MU<:(Y8_J+Y]EK >$YU!5&6^1WFLZ^G;D<N)& ^7P!O;N:'BPBYI\"\=FI;G^
M:,^ZT<_0XQX<F6ILNY:F\"\T,&+& =:0$+.Y-+XNTKT'.JIO.'3P8^GM9R;'
M'VL8=]Q*'?ST=DB&5P#A$* RZTC%C$(] N/)?M8^+=B4D(3( +"9HE&1*<?#
M#^ZH,]K*00.*E:J%GSA^/E+X#>O"?X"1G&B7G;H)V&34<4UDO#1YYUNX]T4!
M!6,QVJNE>)_2M-JQH#".S:,S0CE$:T%J)>M9'_6+I$I3OO?W0^(FWV%PDRUU
M%F,NIFW*%EG+V?RQW7WKE8C=1=YH!,KNIL@G?)J4)*.X0^1GD2ZY[<OIO+>]
M.;S- K.7RN]F?M93.W>"JL^?:8R.TW@!34&1[2#)>R#!TZ-,)3_,X0Y1P,0A
MQV3L79OA3>M(:0'>[/5LM9G#Z-_9!\F5YT]'0R\IK*  ><WA261M>:].\;/%
M?(U>!=F[]@F;Q)^F#R ?4%TPG/IB7D_4M6XI7<H\J@<9%S2STRC^X_5&B*K.
M^1M/U=4K0 *=\^-'6B7THK?0P!F1]4T*'XT59,<Z9(TI&.=Z\J49ET&$5-F+
M%VH5[R\._(@J5A8;'T2&3-1BG4&[>E2>YMQ-JCY@K['5-MJ1&O<Z*T5=DC0@
M5QWY'1'*_(2LD^O! T:&@G1CEK)CH)%=$.K#MCW0$_"Z#=5&3MD0^R.J7"+X
M*QS3U9Y!)3!J-:'1"DMX=CITU+$'(TR_25"2L_'\+3 C1N4N9#N0HF4O<M+2
M4?'^\UO@JI_HK_,B5 Y&2<=IW)N/%&WJ2XIP0LV5CMNC<,/?!NU5+V^QYYB(
MG@CAEE(?210[K]O? \'I,;G'" &&VP2YQ'M,;;A0:[[21LA;$X._2>YIO87Y
M([NW71>TEDP4CD>#QPXK1%.PJ:2_&=$+)RFP^! 5K<F5[C#=HA=OG6O%'!I\
MI9^![>B*>E,_P.LY%"MJ"N,#G6\/Q/L0#%EU$Z\;7<FF]>"/UJQD$VVW?N@%
MD)0^>]YFUI@MC;_4'BZ^_0D*\T&+,_(,06O0NJD8E3\&P02M=LK9K=6=C6NV
M4Z<R&472( MW\VSK8OBP!51=]?QQMO5_HZ'A_Z'A^$..U+D'.G!@','/G''C
M_-8&C5('W#NO*1:=JF_()&$BX]AOW."(5S7Z5//(8D6_ MV.\0E,;0E<9Y"]
M>Q&&XQ.>*>9U:B;W^B$^S7<$#F$6'Z@I1[+;^-&W&9E[H#L1AE#F "OHVKR)
MB7']Z1WR^E./',HBF!_ RB:*UU;$[)0^>]V-^CFAVED,'C=0N5X_63]D;=9%
MT&N5:+Y*6"#(/,W5MAT<C(PY)+/F4+6_E5>N;PTO"I<89XH 3RT#"'N@!$?K
M-T/^#Y!1U OK,IQ2%-T!;HXX;DAU5#\K(R.+D"1HKG!KH(XRN+8HLCXCU+(V
MJ9<'HSRD77:0L'"RYU$XJ^@94__<2SFT9 /4^!!*ML:G7W.I00?3G($6J%"M
M@.J3!<V6EP\>,R=%T1W?5/MPH#^;@ (7/5\E90^TMGUE#S3:7#6/](+M:.'C
M(-0SOM!=<R$$##$#$T=HP/4 " 'Y&"5%NCWY5\FT.E!?D^BJXS@X7A*SJI5U
MZI-=LXK.V9I#$K&!#NAQR$P>T[IIR9R1[&S#S.HUDLHSA4/W0)PEP%LBF 4?
MW/0()%%%8!5QNJV>HI$[^7LU3$F]]VC,Z4-E&3S95PS6-@Z#%'Y/,0_[[H'D
M3M'VU>RL"C/7-^3;+Y@0W5.%+I3B1)8!7EP//-B_]+?9^M!<TXRP36T/K2>B
M+TP@>-6_B 6!!<B! 40_DJHUM <J*W %(>(<5S;C_RHTLG[K#Z\9GK\<(-*5
MV(4?-KP!]6Q<N1=40(,0$Z)#]D#)$)X&-"_@WA>& C<,;<JL,V7>)PYIOAD@
M9E$KLM7"2C2\?QS76?O&M//9 ]69][2R("ZTE;P%S7BT+J7:]"UW R95G?/B
M8\FY"PO&&20=GGA[['/$(O$;!_5.,D CJJ2W>=.X$+V/&E]5AN-6",@TPD>M
M7'%F[;V1VER"R?L6C6R/BR^>LT\'1-\_$J&4L:Y LPB/[<HUU O$!?=H[8$$
M[BE- KY7K<Z/E6;%4P(_>N(J>&X1! J-+N@4@T=:%+ZPQ&("D"_79<!+=\NX
MG-'_6!1V1#Y6#)09UT@ONGU3>&;+>X/2^^@_L4K>3OY^WP!&>T-@++1^I1M[
M)/S*+K(6,"087.MIS+1L4$D=!#4$X84WAM4_^8[_-<[X!DY%':O/B$'RP*V)
MA2&U;WZ&VCS\*7%$X4_Z*>A"F'SL?!PB&-&#^>#"'(<=8*JREL(S<2Q!)?E(
ML/\;V!449;U*)9_ZO/\V]:D1EV<CZ'X$B*%#QB9I;(J&AUE-U4>^[A@-T;NQ
MJ:3L3OO0+9U@)M5KH5D..\!*/,X8GO,+#I?IA7+0W9QG^Z!\FV5-5DX96*KZ
M28?+>R"19UI_L48?+AZ(^K6_$)$D2YH'_ +%O"^(S$4-_A"_!^J7/S399JI6
MU5V6>F2U];&1K=IF5BS(PO0J0S4 LU@(E0I1L)_X&XB;[6UD*GC..0R@Q2=E
M!E2KHJJYW2*ETS%*H$A'^K$QYN5@ I(15,M:B#2_-:1[U<FWB+X]T&&2N%/U
M)+$K-TBL>NYU4@M(6R'T]LO8Z:D5/,F74DJ$=6(>,[4!".6'?)MMQXF&N#8E
M8K7!,:65K#!.]+%/;)]--UYU]H4E\$%-H'=0.QK()U"JXO0>Z&=9,5B%\80E
M-VBHZ15[2L-??&I&4GK;[9A#MQO]PXG)IT,=LZP:?_'1@[K2IN7"(*Y3K-2&
MS+)(<M$Y(+^"?M]&",B[1CG\R^TT33-Y55OI7&.*.CPI9PL]>%XJ)F,FEE">
MJF_'B@,V1C']3!7KO^-PS=(>OL*RFW-ULSB(UDE:O1Q/IX&!#\?&87ET'"8@
M,)FI1G8DY=#4@4ACBM;;US[./ZIXG8M0W@]&NL/CJ9P*9V/C)9P2#)**P2T^
MZ'3,8ED8:SET2,%5OQF>H6M13E>5?5F2O'2F(4IY<JFWFO2B)6WL(M]QV<?'
M4J,&/+#L'7F )47E$M!/QG:[:8U $/DU-_HC!%9.JW6OI&%P9KP)\]:@D'''
M82C93@5W=H4:QBC4U"L46+4*% 7BC4M]WLS7:CSX#,Y7<W_Y^G:B3&D]HN$7
MODXE%FZ_:/.X0W"4'ESC)R5-2:IW27/>OO;1/\FT!Z77VXQJE=I4=/_@_;$8
M;%N"T4.<14S 1#!^^-2"_BZ;F0(?C0!!$Z2"*V4=F*YN?KLU5W77>G"P[%A;
MG*5K)8]$$@L[5P'2&[.61A3M)M!.M^[)YD$UO/ 597MRY][L63!$[:B9H=UH
M--2X MV/QI52OP ,<M,2BGX6E>@HLB (U+Y9#9UJ[% D+R]<U)W,__XUO;<4
MI^:QA1VLY!L5L\OA^I-"C:8H5RWM@69D^ENH+RINWEAS* *WMC5A8B[4F:KA
MU!63NS,[XX/7C*3Z31'7$<-[H'HHB9MF#S]%;NI621"?[\NK^G5_SHH(36JA
M: OT_EBX\LWEDT4 =OE8)VWNEFB7L.$S0L:T C6.+)473$"Q(\8-E2ERJ=6"
M))YR?[#:+/[#&6DUV>9G.C^KI#]LL9T(-H*\:J#@Z4+QNT0;1IKF3K5W+N[V
MVVDV666[>&_)WE#(>QC)+H1V'2Z1=VWJ+G&LS?.5FU9>M4M/''_983$O>_V*
M^Q%NPS6Z=SHL69C_DOF5E9C3M<E3?9BCFBIINY/M2SSM?F*WR(K4>XVY0XKX
M5M/,N7/2^JF(=6_)"HX_ZE1DU@_@"!EG*58XV^WLKZXZ((OKS[8.FZ $KL-H
M:G!K\F4(N"VH&HZ8:G-:\GTH[V5ST-5)U\4LQQE\]MR/[_'2<\T,O!X71SVF
ML9P42]CD #:- 3FRHU7&3:"5(.NHKOLNZ]?]]P'O[-/QZH=A:O#$V&!V45NN
MF7K'E2(6@'+^913#G7RE:HDJN.Y>9^\D#YCZ>HOZO$'UZR='.@]]?.+>-"3^
M\(N'+P9BJ(_HA/+7P\#T1^/8GL G!;U=,[APW/DA&Z_EH'9*<R:;5[KKL/V-
M4JW10UR_)(6."_:'\ :;2 _Q)DO*IL4JG!'CY!_GAQ7N@82@?GN@%$R#8U^4
MRY+(^A=%<;.4DMH45\KRXMT+HE6B_V]L"A5=X&;%YE'PR"5 @<ECL <Z_:H$
M.3WKO0=ZW13R$D6^@DK'>?A6_6+)P?X45 _=\L1'$2^<&>BVZ(O&P1C5WR<Y
MW;]+*GQ'S591HX%RN<Y>%H*-F26K)(I?:?"MF@92;.R%6WJ3>X/Y\[YW;<P1
M#]@'_SYXW5,O&NK9)K<'DJY)VP.YV;)@K*':;X",HB>W:#,B3/9 )9,-__."
MT?^J;)T"]31&$N./W;'J[\;01/65]D"EB\7@Z8+]\N__QNMP>V"-Y9N/^PU%
MX2PT?._%0NQRB4>,Y/^C!YS^>_S?/\!?48 "(L>7 #Z&^/K([=6AC^_;*1J3
M4T=K3UA*M)=\R-99%CB/]IF +N;BZPS+CB\A)!N>COY><5Y[%/-4ARFD_A1B
MW8S>;][7Z)?;(I>,\98TVPUIJ*VCZ#<)8N7FTS6R1_(SWH-071T9'_=[2R"^
M3N9N7=[?JZIE,5[+G^\1V&G/+3=]& 2,]2".4U3H DW$S9A3Y)6D!A5^.)CR
M;.E#RTB#4[>$W%R)F2A;6$6F14UE:\P';>O^D3W08IUS&1UU$ $)O\?=6QU?
M1_ 0N:85FI;9;(1?_W&!E4+<>N282[\'E.Z!P/J,5VT<Y,VEFORP(/)4US8>
MIXM-1 >XG7]]U3$R0$:^52A+Z/]A[SW#FGK?-=$@"%($I/<H15":(@A2$BPT
M$1&5+D2:- &E1@F)TCL* @)*E"**0*0K+70$!*1(%T@ J8&$$@)I$W][SIQK
M]G^?:SZ</6=FSL6'YPNL%6[>]RGWO;+>YZFIK(HYR91-UB'N4W-4P QV/S%_
M%[^1*DSC"[L8^&O'9UW0]6N2[8UKQ%GQ[_FR@ Z3N5ML#= [K0=^X; +A5"$
M855RE\D0SJ6RNB;J2LECZ2A+0"B3735!=9U! XYRX#,3&^3=YI#Q!PT@9E+^
MNX_#02*ZUV9=3;NEQ6&#LJ\M7^#VYYV+'NM<%ER?%:8#?% 1P*.4"P&?O6BZ
M@[MGYA.KQ*P2G@@N+O:ZG+JM-3Y_"7C!QR+7^!W/JYVWIU6C(7C;.&48Z.7D
M!+1>/V/M3FVMN'6 756R3>#TT)1LS$C3T^R03N6+8$:YQMOP1#_E1DM8BVG&
M[)P/]71_5)]JPB>>$_6(1SRR7GSEV$XIDL3(8@Q")4SQ)DW,0R:16-;L@ZND
M:!D73-+%&Y2,&*_]XF/ D\E:\U8TO:$:ULO:0+R%7Q1(%0]IYV&"#X.Y']K?
M&6O@9A'K1XK(]MT7G8(+N+[CZT\]\=V$:>[42>9-NZ(2#Z+CR2&_P,:;HXHX
M;2);S;?JMU>-U&\6.HA(O0N_++6+0;(@?%,B(!(-Y[T_K<RH#^WH&<S?"<A;
MRWPYZ3!U:;70X=DC'L(I-]V R8:IOR>2P^.AXACS2#]U<(S=8F8R[?2J-U'O
M;-OEQZ&2#4.PSTJE4G?394^(R&75) ), %*,:L#R7%-*$I),8T^>F_9H A*4
MG/LB^ IS!N+&W7_YY&G(MP\\1XLC7"")32HD%%ZJ4U4"*MZ^)W]KC,+=TZ=]
MW?;MI"PD*_J/?ZF4;0A.H><;:(#QF7O4-RCT ^ $8:K#*:WC@+)9YNUEDCXG
MIV]L(JKT/4(YD;(QYWI_S SO1]PB*1+*.@]\-#N#M8__?MO^I?L#*16Z0T[]
MV,YN*>OT3?31!)N,UOV"$_K\\!Y(C7LXVONXV(Y']^/WT,^F0((Z?K1 _UO-
MDF>0#-4UM,FA^0@W\]E4ID*&OW'3 6G*I,^,,.B@ P8)UC\@G$&;W!0GQBI5
MS))J,3=[!SA70, ,53YO,7\ZX/WLO=<S>IBNGOW@9\S]V\SGOHM_7IDE*810
MLOPZ(&1655I*_#-E>#-BZ\$L.QVPSH4\$!]KILF.@E2@^32.=(*F \D:\Y:S
MPU$%_PN5YNV"?=+3XNGUY?+#[6NZRTW.KKJL79OC\_(RFRGC/+0;4Q@P]7D:
M'7#UZ7X$L7D09D26@H]EJ^+T,#AI'TB+=OOY%4?5FJH;#?J1<:]W."3YA R_
M2SVT<=9,?!:,QE<PHO\=>,>$Q@B3.7LZ8*OUFWE\+SD YD;RPZJR0!,P\FU&
M@]6]FI5?/52/99R;#3;NA;R0%%$\<_)9CQK/]8,QS!CN"=X/FQ+];G3'/'9&
MDM=$^*U<*2U?L/37EPVY:$/N2(G$EQ&)X8;'88MD&T2+06"]]UU2 !F\>F9^
M-KYNX9.[VY/WTHYVMKZZ==T1$A4N[T0MN]UE?(>8QFG]LUR4QW@_&F.9RDBJ
MV*/9$][9ABFEAB]+)^^E5-:9R4(#G<_IMKYS?_;NJ34GPU]<?Y;N,+*-B^W(
M;4'[TJOM8Z=-RK>U"WC/)AXPUTNM>Z^@>*=(Q6-$RS%G0L<B@P4EC+5:(R9K
MQ6".=X\_)EJKEOM#V1(3F1.??6O>WZ8=VV70'3B2> Z"4/C(C#OX.RG[?XF5
M7<7NM?<ISHVU ?FAL_:/LGUC7.06XNT]TY_M2]^A+OE_U!N_Q?9GB2(8@ UN
M)*1@,Z/@ !+GC1&8>="'%-Q;;]/!G]WJPR*]!D("?%R/,E_@C39?[-KM (_3
M)M!5FI$PG<)E.Z/U)V43GG9N)596&8-] 34*+OJQ$53@.TMF_&<@_OI ]%-T
MHBQA"2<^?XV?E-FE.7RUJ*=W3SFRH+][.>ELR?U@H3GNX_#(GVS8F4Q";1?X
M",+707$>DD@3\IIEU]6<5T2N__;OI[I=W)9]+H1U"TYZ8G6BWUI4*6GB*S61
M8%5^.@USW,6R@O.Q1G7BV*VC;6QNB17S8[(<!#I@*H (2R"^HKZ%F6%L2D=]
MGAYCR)(J(ZVC?LXLG>]R<UJ@<3LOQMX@6LXW@6L[9R>:AB^/%JI!42T/U?6N
MBW;*>MP]X2-S9NGU2&= M\>];,!V"DE&/D;)?LX\2=?E%-DZ=A?-UWMT=_[-
M]VZ!\]IGP)OFBN1-U$\O2B7)>MX439)#XT2QJ",D[! >QL^HINA!C64GS]N#
ME5'R'OOQ[VT6;W'"-S0M(J*I+)74@B9^+RF@V *07U?VX.; N=]OO7Y;&%[8
M=J/=2<0_,M2^Q=:/Q%NKLJXT25.3=\.<5[7@L^^\K*R#_>LB3JK=_*)]!I?^
M*E5G72J\*9::A5A@)'S$>&$!'; B8?E/JWDY*JH+)S_G8-Z*YE3VK4Z)<12N
MJVTDJ,9G7)"L&KZP;X4WM!?/#,U8R5#@2/IH0\N _T!O^: YP.NWAQ [R6<!
M^VRT8_T?>"+!_,K(Q5Q5H>^2.BD[T)AMMBW4SVQ**XF98/VWM0"<]HM!,> B
ME.MJ'HZ<A. /02B>M:W/&G4RNM'@\\_(A9(N[IV"V$MS&T ?4B6QC20SAS[>
M6^8%%*"<D8LW=#7X\NM]??9]'2.!&P.GB+<\F!>HW!?3:)P&6%:+%[G"5GY.
M1 6V;>D21(L9>&$![8(FB[O1 4-]*L6TYLU/M"%(-:IC<_)VF,J2*;YC7>;R
MSXP%'[7B?<4W7.&]@@VA7ZY'9SV3E[#[?W@(B(I&+%Z *]$!Y2;@G8Q)])7/
MVV-MX*TLM!!BO !Y8.JC#W2$#T&8=A"3=^8VT'.27D^4WH]8.,X<"'(1:X^U
M8%\QC[ R*[Y,5U*[D$U"MB"JV3HAXT"R:C.Z"ABE KN#/QASR\B<QW%>6(]]
ME" CP=;<S$&[]^X,N ';U$_-0WNFL,)[:<)#U72 6/6!YT%ROM1;<1L[]471
M"CNC+B;!J^=I,HD*+AV/9J7 7G[/,I&5=$#<9C5*'.K2(24Y$CCQSD&MGR:>
MM?GV!2Y*FLO^Q^_D=P]EY'V']-GJ2:J=3^7;S3E6X'+XF4)6U/O51\H=A;AZ
M-[FKLR.\_L>T3H8?8SEA;TD8H/"%M&GO1=,!+DE<:PFZ%EYB2;]I.<>;S]X>
MG A.9R/9CIJP?4S3XS8?'_F?]-3^/I3<>6#>!F%9RU4<*SOZ(27?MC<L2/6Q
MA)?-,YWR3L"&L>0R\S:"QK%)B+ CU-1CP,^DCE:,:%"=E^F AZL'#U)\]S3Y
M?6[[8-A%E,8M,Q[<>\1B-HF""A,Q)!Q^J>6I<%05>'RI4VC2,,GM>%0!Q'7$
MY$3G<V'Y=5@JJ\F&B48IHS*TX:U0!"36O!TY&=IY*Z(8&DUTT#%*ZL1P/8&H
MOP>WQI?KQY3)O!"CBK_C:2^%$",)>VT\4SKZ#&5NA@]I1Q[;<;#R".R#<Y+%
M"VK1A@YI:E5?.KER[92>L_KC?3>\B6625\3[U'36-.U[GSCQM^)K%M.O;]PN
M"&)Q89MI*")6D7A\R,:P(P3K<%EC=)5O*6VP<$#5V,]E'_.0>#1Z"%&'6W-D
M%&$6%&DMA" ^9SGP#';E04(GD$<%7+[QKH[%E'CO2^TTSY4<V<CD&>,!.\#V
M+$G&*IU1I8]0[I!2/JHY0"L="(I3,]-?>M=M4F$I^D/WOIOKXD27%7?LT*J!
M//PSB!:5OV]-"GK29(=1LB1^ L<F+D.LL,1,VG/8]P'G\YESZ\D1?UQMIMU]
MA_?Z7Y*O4TZ/P4#9BYGM:/;>0C4V3;.2J;QW>CD!X441;?<3Q0 $,.FL>WC5
M@!"\@Z;>T!C/_.1]M^?'\>D;W\[UJ+@DU>1VY*=>HP.>6Q?".\!;'G3 ,<2Z
M+4-%#YI"6.F %B/PPUBPAWDT[20>V"KB"S.8PW&U?"35=YPSO-UWZT:<'\O#
M\1FN'Y%O_"V"-YABR;W$,PPJ9D1BJ'_GOA1:O!U@/X+&SI#QI\PGA6F=L]3L
MIY ).3,T16"6^#K:/,.PAN_H[ATE-G :3W_:O[MPB:8&_89F<#B2PLZLH*Z!
MVV,Z@&,8"\JH"_M3R.*C4)5^6S#@>;=;*'3Z8_<911Q+XBVV%4MX,'SV?-5L
M;<SZZX^:YT:EG?6B=EB0W\4.B,#)^KF.KAC#KTA!&)":M?AD)L#;:K4EC$-X
M6KQFVG= 9$"0 (S4]1'&+3$RN!"^*U%7SCU M0T8+91XLUS)A[<.N1=]\=9T
MTE:%SQ5F@:@X9BT ,!^N@B_+FD=RK-(D1TNM]HQ_E<I5U-?"4PVD!8(H<:@(
MQ%QVT]D1&@?%F/26? Y:ME* QG?LU&5$J:-5)Y4E/H4]V^&2.M.:R.!/+XA_
M<_O"WR&4),UV!%N#TYSY) 2S38UIM^.4%+_SYF305H&UC6S0!OB)T@USB-KY
MR6? 0!Y<Z=^!V\FSK-L8= NT%Z3OX3X2&2$S?#J062*\QFBTJ8?Z4=<(@>&9
M0&.3JPLO='VR@;I;?*W- #=*)#Q<O(>H@_NU-J30V&OQ'.;/Z8#*!VE!Q:UM
M'7!E)Y37T V>;*YBKO/G=1==)HWU)!=V4844"\P44 3J;?4SR+B!JGFW*KMS
M56D>=ON]$:3#YB?;=S3>!,SF"9*D)@5*VK7PDZ]"1E11&NQL2J[)&-R@R<Z)
MUM>2(.?0;/)%M K";39)&(&_"8EC%(EF1.*?4%561PCH/69 </_&Z!0$4-Y,
M!]S%6.L$+'8W:'+9A-$!0603F'PYG@X@+LSR463K&/7;(<EK.I_+?;%MZ_%X
MP,!U &F6QFDYUZ=YBXJDR&!CX@5'U0=X"U]I<H$"6/ WA@QYZJ^*NU C(&;P
M8>"6ZRP?>-VPD5'63J-^,+SMC#7.X GYCD=P&DG\9F/:W&94D%M59KOF"1'G
MD6I;YQ?ODNQ3/_&9)#-).2FQ+@RLQ.#.,SBH&4&&UNX]2Y7V FPA2;+(R'4*
MF"Q"0MRN?684@/+2W!M3<\F25!'[?3/LR-1'RO&P3,C9?VGNN&L)^&=0_<7'
M1;019(U4UI'8]?<$OPVL:*M/T\@K@,[CE._6[Q M]N"%7MAE.L!)#TP'&,5O
M,U#+:U+>+N%>,HJ(-X.&M-U&Z?]]5H'HSB!%T%J?(F@I DP[UNM[=( L)Z:(
MFJ#M3DOM@F2 637H@.3<D]1:L =0@B*-3XFFV&)US*S6;M31 9'%<Y\JJKV+
MC#-.$6,K@B?/\O<?>=[LB[B#=D?OGX0<!Z_;#C,*MS9)$_MKE*&^6/#4FFKS
MA)2"Z54@&TBFW,S95*2V\>T493-7G^=/=/KEDVHFTLG6SWB,Z8"HS+]?1] !
M>>9X-!UP9)8.R!!<0@(;%,F^\$$Z@+,:PD1"8<!M'W?>7LY[,>VY5Z]R'[I@
M;9V4NY]NKQB1?HFKK3&L&H.<S)_;3&C0KON310"W^J\TV:0OY%B'LT;=!(\6
M)):>6'@T=V(%H@@? N)O'3?J@BL.@?CAO6.*V-E8X3%"PEOXT-'<UGZ!^_<4
MZUX%Z?IE'A74O)\AX\%6YD&D:9,8&\NR-E)*,1&WA2ZUTHZ.2-^OY;P4A\/]
MX46_CHQNE?5IP<7/H^=>TKB&&G3($LMU':\86<H#&F'1V(!^Q?.F(:"Q[@SH
M^:G;;.9O<O\T5>2T,:H!4S>&#A!H;"K>._#\\LMN1D; 6@X[<?ZN;+I5[WV^
M1SQW(#G(2F"G-Y(D#VR?Y84=(W40<\#,$$CW1ZA[1Q*_7E-7L]P7\*\O[/4>
MH'LY>UP7YY@.HB"Y:+R=WU'/;.3Z-@;!WRW 7N+I>#)Y5#P:,J/.?_E\ZLDP
M3@/^OU[O])M!JMC786#J-TU&W5!)J_PA[&)7J] FNO^(\B988GL(K8">*T14
M.PS@3-[;\1SQ'!N& ?%-Q1G;I'AHMDB0I)7-PE:[U[C<;=E,"=;]\2^ #_I@
ME\-GP8?V?X3Q7")UD74H.M1WRE7UB%B02"U!2=N^6RY[0+U\_P;FZLO%NJ53
MUF5/K7/L$"V7Z !W<<7(7'#44WMMB><:'3\22)^O7Z88A $-  &T8R0$!AE=
M)_!4-9("_D#R,TE**,U(]\H@^.K9% ,XI1:VO-_]/42)3(*4+[70 9-\F[@9
M+;Q9<F%Q%#OUD^^ =[#^LIA-EFWSNL@+/<4XO#R%WX480D*4&A5/P/0B+!KB
M(@RHY4_TUHTO]\,^W7N/VWNU@RI2>,=JP'=5S$A,Z?$[CH_Y3/K+@)TBM>C;
MQ[[K\GIZO./);I)F0$>XH^/J%NHZ/^$/)KLLLGK[3J<$:,0;=WWRP ;=2.L^
MY6]R26,8)D*-IW'!F$8R[^#]GI>4[$;U_[Z]9:*JDJ87;'+A?$HRR*P!KH';
MN<4$T:;8,HI*&.48:1C[.84/FM9R(LE_)6%ZQK,V8"(G6L_.(.Z7;4IPI[G_
M/XU$(DE@O&HS!$"Y>"#\3/>".Z;QHM&VG'W8@!)NHB"]U^048$[8Y7DSME8W
M9,Z!#>L7&03F)"%OFME?'LD_X3!AO/[Y;/3Q\+OAEYC?X^QW;K$"PW7Y\V":
M^-PL#/+XRDKALIVK-*>IUD26L[[))">?^9V1T0_OBR971S6%K$=_SMA.GXKW
M#HUMZ_I[>*HH_-BZ5X< TQ8Z'CWW&E&9DJ#Q)$@4!JA[./2FP<[J?8 W:]@U
MDY,&!PK,DXU7YU#KG_%%Q">VXLV.7%\&5>7,51PN)TP[U.W=T2WI%\@-#A>>
M;'2.!Q25>%[,/3FD6M5XY42 4RCSU+TK[<]E?0MM322VV"6L-?"?,6P1#!^Y
M"_5K/I"U8XU;:AP8QZ2:"/^ ^3ZL/[_$C/9:]_A?%PO?>.(A[#!YPN=6?ZA[
M9]V5M6RN--DM6Q/=<IDZB4\NXF=.2CVZJ<:T>C2(L?K@2%V9?!);ZP$D1A=<
MU%;HD>U09S<QT<S]/=_B6;XN\I-L6JJ)1OG?-\"04/XYGC8Z(!JD3@ FZ"IC
MOJH[(-IO#GG56@V;UJQ,_(C*5EMDFK994.B<7_7^Z?&..[0+R0.[0+C:%B+&
MEA HSG/"8WA;+B/_2*^4D2$@)3WF@8A,.2J'C<*')GJ+%4V!,<QORJAT@!MM
MLG$+_GJ[,N4A+7VW4(#I3W;F^@2^ZR[):O:X&]XQ2_AYUI#5H,^)4HR[%;?$
MZYYRGQYV9__'_=YU^,V8'3J G82X\7,GQZURJ&K*IJ14^56J=+3ZL5AVV1>"
M^@M+\8-YS[0@"4AFV%'"O+Z9>->,\!>"<J1KU9658QFL,BP=9U\04@'=ABS8
M!J#1WP9TM+XZT*?CRWC9L21./QM5C=!O3K(22=_=VG@>?-=K095\?,=%96L[
M<(\*M->3,1@N#7Q[MO_\\>JD5XI<Y]XM?XP'6*P?]4?STMB@XEATK.Z9,FAE
M&WY-&Q7EF[21%*!4<:KR=<--AROG6#:B9;:/@"YO.OQB+#>G'UZG>10M5-8D
M;X AW>D*N9C7X^/>E_8#>J4X<JK^P<6\E/I<Q;J\9^=A+G._.;'"T7X4/:S#
MV3'[0=7YK;*'?LY\!F>79$[N_5O7VA;![=R$OTWOJ3E5X!-&)09X@J];O(5Z
M<&WVVVEB3_/" _E7GU%D%5'C5<55+X4CBO8V#WWR:FNC=4*AMXPDSBO<-6!F
MTI< L(D(*O_G]\W[Q^X-M*=$-XF3ZN?6-CF@]3<<W-OV.B\$.&]UB_66_QKA
M2RQB2K]Y8=S:[-_.##UE:P,>6\D5QC=E<B>]\RQ_7:KDLUTAIV2S92*;X6PB
MFVIRNG8Y[QG']L QV@":IX&-( ,A;,90-%C3L7U0$VK11_L^!;+5'O=BOFJE
MW,C%*TN7=B_M:"LP\W3FLN'WVOVX?WM(*0P^#*(*+3M[2UXYFGUZ1\NI1?*R
M1,1WU.LR\%PZL-*GL\0/@>&HCU>;2GKS]-=<Y!8/96>:C>6^YI6P\MT^ANLF
MD"_"SB=@S);:C'6%/]A!Q?8\OPWB3KQ+#K:VYEJ/U+FX</5KS<W!-(>42(IJ
M'@7$^&\P?=RC>JH&0Z56DT.#]]*C!0 *1^.TF"72["WG@-76Z^X8O\EN&/AT
M(\J;)M4XR/='T3N)&ZNUUP7._%/P?+"6>5'U1LB:/E +T2*](=.4,X_#U9>,
M9DJ=M8YWO61]^\')B-EPGGE("&F^V5&"E(6I1_&04-?*"=QQ@6PY+A_U*]K;
M_<59'C5OB?CSG(QGL-H' Q-%+;,5 VWE&"";42!QZ)[&XF_B>^GN@! =0.%T
M<3&^N%A0'\"=)8NT?L?STI41-'=H?:E>Z(<,M7&6X-QOEKIF'2[UC@X8<!C'
MM86@"N%2% U\;2N"JP6SR>8A)"4QZ"27,6 >:1B5K(9+MDUFM8V3E\A>8631
M<EWWN48>K'RT7X,.UDQMUG90-=WJ3^=*B-%)*^YO4C^*C;X*UAH Y&^R'<F(
M5V!.)N7C0UL@8@W:@:H2)&]S@DK6VV[!=5N/'/+@US;#\7E_WL<S3=!AQ%PZ
MHC(XIX3!/RFGK*T52B0?;@0EU#YST77YT<MMQ&5^>1-9QB 5ZH3,]2E\5]<L
M]\XLTYHCU_ #?'".]KV)Y=&>T1J\<?%J29[T5ZS1P8;LMD-*+$P\'XIJ.8B)
MJO86:/BINHXT_U;QX'Z%?9V 1S?+N:,FHFP:U0Q^ 3E.$R?Y88#A.YOLT*O7
M4PSP&\@_81F=\B$V#=UBUBW^-HN_I])FZNP4WG$+-X.9&X[CT1T@)0(PB@+F
M?EE**EZ>6;-^W"M3O="QD!;*ZLST6REF$0";O=Y(N(HQCP*I0PT1G*1AHP2'
MG^ZIEUPKLHT,W VGBQ1ZH*#=40M]@4!EOJXV;2ED_DK&FN>'%2)ATF[JDZR1
M@)>@ )^)UBTV^6H#K#G7BM2Y094=GU#3RM' G*JM#26_.=OWZ6&B(KQ&HU7+
M[WA2-09(<G[KF#*OI*>ZPD%%OF&;?BZ?'8PX'R?ZJ 0GD^X%[F ;>^<&UK?Q
M:T38X(-A$)!DU=OVY>95<R7[PJ]ODG-=AX1>-J]S\JH]8O4>]/A;N>)FC\%$
M"?EM2>](LVU/$7&!%2%*FH.^YS7-_MD]FMQ)\AC$  !+*4*T,(3V QS8QGZ3
M=*6LS$)$>V+:6]@/(*-GE)4AD2SRXI'>-B[W'#6[202ZB>G/F9-T;\E^.'-\
MV-TT1T]LPF[TF*ME$%>>= -C\S)D%\8^6.B?L)LR</<1;#BSV,9W;-#(C1D
MM_P?Y;K_C+-)^S,D42PP60I(?4^!/,$[J0*[RE13=WV4?,I<R9>^756Y[>K*
M_./$%JN1+SNJ"('Q^OL(#[TT"Z$#6@-,Z(!Y@?6.0'BK!20%@:]&S.7/;F^B
MZ #,I0(Z@! /_@\NMXT:)+,;P/48/_C%B-44Q$ 30ZU'_DFC SH5&"+^[Z1<
M*3H &89@U-(^A@!,M'@@;+0N)TC:8VAX:QH'XT[0 1U X\\VIP-$\FE"*(I
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M(0!P.ONH^]?7W.$F;ZJ2V;2XND0U"&"*T%5SL9H(?'![N$%_[6-VSK$_QC'
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MQ%-YWX=.?H%OQ%)^D#X3/A,CJ8DP<2R"'79[]#2A*'JW[^Q6;^LL;]5 ZM;
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M^9X66_P8:@!-4C3J3#+D82,%S!5%8AI&&BSFV5/_K';=C"O,-57WEXFSN/Q
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M.#@GS)GD[K8(!%27I12O[X-^B;WI4OI*!^06%B4;KL)V!#%H#IH.S)0@CS/
MIDS*&)/DL'[Q[$^4.SZ\\%':**@=MN844TA5<+TC?3GV^SS5A;\;]8142KX/
M\R6UX.?;'3G'$*Y@89-";RL_SS-"3Y][= .5$G+ #8F"8[\-W (W^DI^I0Q"
M - I4U+Z7!)GAYW2##RM9,(@[.&^Z(1T-%/Y8/0C(^=CQ6@!D)P'F(T&7,M5
M(VB,C>^824U/WS/.#Y#2OVOQ.RN^.'GQ&2H*,9<*%MG5<>#I #(W./@$%9!B
MVM2JJ5'1A?QMCR4;4L@D.TVF5UV*K"VBU/V_(Y&4#,NA2!8*S[L.';N5@ZXX
M%_MN=(S7U5.6?@]K-HMYKI?YJ!BIU%Q299NE#2/QMVR+"(8I\Z)-K+#3GKG*
M&E5#V*UE15Y;NXLF<BWW+HC*W%A0T/):85 !%SI@TGO.K"'W),F%P=[O$G!]
MK_GH@-;S6+>T[CJ+WLZFP*&N;]\8"^V.;#K6%S:%@7"M-''@^],P5*D)'_52
ME5%%16/A@L>&SWGA^E:E$N]_P&]1^$F[JK@3#/FG3G+'ZN"X$<?71NV._DDK
M\;QS!-07>KP:GVZMB]M_WK+@&I&JAKC!\&2+GR!.BLZ8KB<V-*-Z,#!6=R6+
M=<G?^&X26TCPV7=/OZPP9#ZRI<XO\B_AGSE6-_P^FG5,5P?T*?#+1R#Z8N:7
M2EYP;*Q@2EG # K1XE2M2$Z)0G+#+AQOJ1ZN1O$Q!:D:]%R[PDIDM7KX])U>
ME%R>R^_\)+Q/%\Z$ 9,Y8ZU#VSWQ#TD.7V;B$(A>[PK\^M72'ZUHV*TTWBDZ
M,<C.<G:7V;T=60'$F9+!*YM82#102B,E-LV622E7<A0VL!,E4=<EL&TF7K[3
M<UZ2>]U]!]@&$A]N &)^7[@RB',I'ZJ:\L I^^3=$M)Z>:7XF1Y L-#\U;VN
M?F Y&/?<A6Q%DMI%*5E?(71&KK'6%AQOL4R^TL?KE^,BZ%2UE5AX$_H #_EW
M7T+D8TKE0")T0(N3AB(/3['=RHS2SX7Z$66?3MX+=OME-D^K1K%7-T_M?IZM
MDJ<4]LX941-,Z8#WJZ_J>#[MS326V4!=KHYH)-U>U5&^8%Z;NK'ZYTYDO.SM
M_J5Q!7D\JM\,B#7Z9P^Y":<_!^&GVB_ Q$EZ+H^(+[T(&:9K-2*7?HMR#P7*
M60SR7N2\P!W61>-XCS5%\= ZF^2C?Q4DKF;66/'INK,8NMN*\"]?"S7_^#!0
M XNNG/E,=J. 27)SC?S-LYQ-X@,8A<#O'X;+5%3&>Q\+Y/=M(X5[-+^[JCS*
MS]#E?C5#Y)O\0RLB<\$'$5SKKF,@2=HPZ"1!J/&(*+HB:%/=WJ%WA XHS?78
MNP@0_YEB!2"L0<K-<4$E,/^O!.%G3=(>$:UT@)#NF>>?;"+/%X[8U^Q_CTPM
MX'L??9VRW/-HW%&&)F2$P]$!USYC,FE'P72 _!@_'CV7@E,LH4WE"I$&Y@=8
MH"%MCY3K/2>[\1OOPG5BN?@,*W1]'LOH'!\,U*(./7Z96C,>NO$4@>LC9&*Y
M0&"2-]X($UP*C&XPG_\D&_KV2;)4_R\U[K;PNR]DG7NW>92.MCQ,%ILG&E"+
M:*RK=HC8)C%8R A(9D:CW>763PI$]K./6CG3 G5]Z)-D/\?76\&5%YF(/%/>
MQ+MC<%T[DGT''<"S6XV?;:<#6/O'M T6DF]?&DEWX3_'YMESI""\H>)+&Y_N
MWEP*18#?YF>#ISN^EYB(+YCEUO61B57>+4KI'4;EZ%SE3_WTE?!'1MTUK8=;
M(725TX>G<E/C8X,.YE.U'Z^#W?AE%X\QNZC^K9-1%IK7R3DO(KC\0SDHY$K2
M"B-/$'<(\%)WO/,^7(@B.UPFU0\1,A?1#'EX:=]$/"+][,R]T&#F[>[O@NM@
M_-T!@5F2._$20<W&1%:YV&%B9=L$R')E*_J1>3[+9%B.Y-H8V'6 =27W"#4;
M+N:I?>-1X=>?2ANNJ4>9'F3;6-FZ[:EL])&&?X^;&@3\\2.%='4V"O6;XL2)
M%80W,Z=.7A"?#_0I.LDKV%+O#Q 1/54G=6F^F/J*40N\AN"J7L"CH$O0IV&F
M#C559%\DEGKV9W5I.[.6YXS&,<&:%V57)'O+H^<AKH,W?T?U36\A)P.(48/@
M!^!(NZ*DW8]VN^_=:LJ'YQ^E/ G<G^"5?]?\P*5?4.29<0MIK 5\%.R%G.(Q
M2^ALTB!]0^ 1;4_S$I)T]/$'O1+1OSL-E_,SU 3*CJE]QW7+<E_(80227=H]
M0DP7Y-D,VV")<I!WUH?4/V.F(P43[F$!LOC.EZ;;JCVP1C14PEA?1F,5C*\
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M/A+3&)T1<PI;JDCLI+[8V6^PTW5W(:!;[*#;0<H7-Z1]AXX"U1M0KP&.)B9
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M%5NF^V?@Y1=X^^+4Y@C9I/L'0A-XG7T<*0XWOYUL$KHSP>7H*7K\ED/YH_B
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M'X>RWT[^TDHNZ3XK"9WGF=H1_G_:N?_G_=^]V9=K-IGT<-::GHW:X,T^T#S
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MX#99\PP+X/MME%>TIVX;^P(^T42<'J+N7=$W71?6L)!WSQQ46W'3AOCL%HQ
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M?#2=)SEPF&G%\*Z]^HROLS-'])FNYT_9GS\W6S-3^&.O/OHCH]9F&443]CG
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M&&S&8D'L]JZ*!+8/[Y3"45D^KNJ=>7[+YWVLD'?+DU;7)[(;5F*$#\EIA&Q
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MB!EQ\AG:I3?> 2Y_>9]HULF'KBPG)T.-F;!OA%GJ0S(5RE0FAI'2[A1"$J7
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M6]RP020?-@$J+T4-,6M,P7GG<W:JO<\,A!;]O+#-N],1<D_(.B5(F?2) $?
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M@*E]M#D[U)HB'51,RAE%@X+*AA8EQ=_" (B;C5X7RG8:=9_TMC2$&45':0:
MS-)?79.5^\O.?"VF8;/>T%] 3<:;TPKTU%P(:!XSNNBU-."DA5?^!.Z$R[.V
M175SB6O@P+I+LE(F/*'%QMR"Y=8X>-W1&F*J(=G0Q9>@I?L-^G"RXXS.Q,34
M#'C\YYV3^XHFM[1COG6%A&0<",0!MBW_!8XI:\2F>HS2.8A"#<=<RKY\>C;*
MPN^([C_M(B(<SK8UU2JZ6SJIQ+H$'S_9@:QVBP'C=?Y1LY#W\\E4$M^Z99W[
M:-H'W"1HH*[;>&:0>[/O$O8.Q,'*F,L@!"GL>/A5(%.?7]1G#V/PQO G.1_
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M+KI29:H9A7(2;K'II@V].W(M1O*H*??K@+/& >_<E4],?=L_/H]YI8-8WV(
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M64F!]>15"N#) W%'D.%"\\GVC(""+_;?^055?C47;4:[BW&O/(KGR+V$NWY
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M,3%+,B^#4\S(OYLH]..>>,IC\A#E^IK/D9JED#^V1A=8SR;Z!?U5 KTN><0
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M9]4^S/K.8H'PCI?0J_7O!-3K:DO6)UH-BM$OXE7XKM4XEMNLDM;8+B0LX84
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M''-NDH]>?'>SZE<+WL29PJV.F/7D;9M85#4#U,DS_8-]LLWM>.UP0("0Q\[
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MYQ9C>N+E3H:A),QK(3'AMQ:/X,_KAB>&2Y?6-O#'Y=?$3R]GW\I*$):I0K_
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M]A'[B'W$/F(?L8_81^PC]A'[B/_S$/^Z=^LZ _2OKRS#S++?P>W',;A",$<
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MO600C:\(HVW 1IHEY*[94,[#'/ 9O5!>]0PJV\(70:PE23\GT]M#[1CDF<.
M?R7ID4Q6Z+=??5,4;,D#D+W2=H7AI%W]Z!U,7>*53]=AJK+/KSO9(TC7%%0.
MFUF(V\\ &P3=-;9@D@NYAYC8TT@-TGGA_MK2\UQ/UJ+F1;?Q3FD3J7N\8-9[
MO2+W-9M K&L7_U>'K_*?7#I'/L7;%W60:HWC.0P#7_,]%SKS&\S[J^)@?#!7
M("7%1V-<]N;:KX@RA3OH)CH_U6($<0JN0\2F/="=*UG-T7#K>&_LO:,^*.8.
M/&E0VK$SDG#]9[.A0S)B!KOIS0 )8=:<6AF@86LCR4E3.(8!.MC/ &6) [<8
MH!N!F*W6'ZV%_W=G#8"5SNG  ,G7X ,IXNO(K82]UA4BBIK\29<6;L( %4U$
M:[]%#V%GXJXVQ=$Y'E'TG+M#M$)'5MY[Q'N< "\W_=*,^^;P4^#?FD$Y+*.[
M;&8:"!OK[*0_/4A.!N@.157&=+193'/F[KSBQ/&S/ 7OA^L-NA_8_SEN:GID
M;=[)+_ZS !U,'T>!,7?0Z6['@6"*E<D;(,Z2]'35]S6L^**%^^8/KPO+?1;C
M3YPMF(^P.N%HYADI<-&U_^='(2367E&'3AO6U5;E207!&;,T3]7ML<3*SV-5
MK./II]CN&VU 45#B)>1LG LP3?)=T'W8[(^4;9A9'VN5_K:0<W7%[R.GZDNG
M1>G2G+[B:HN(+"/PZ]K_YC]E8)8TD4>1:U=?,$"6(1PTCO_:F>1/.3F92;QM
M5%8F\7HBM\Y=CX:8>O^'0FL(.Q5\M>D3K8D!NOM9_E.>]XFQI/2SLBKOZ-FZ
M<P=)P+_SZ_]&)@"L4]R0?6Z&$@S05#L^D 8^A.B:)#2LAS/3# P(8X#<V>(Q
M6W!^%@K?WQ/+_]]D)48"B<N%;#Y6?X0B<TU M@B!T*IKH"NF_/NV;__56':;
M**Z^$6&)$%P9&*2MZDR?M!JMV+K@@U:_XWCK$7R5E!,JQ9*I5[!-IF)KH1TI
M,#<GA ),1_&QH%<4XMO)F+%,#YQ#&[2AH?,<'T&!RI^"0\52+<5'?D;TQ(@+
M608JI9\OBOR!3[Q\S:%IA0$B6D*G^X;"\O%S;A197G+:79S[[*)G(<]+B!\X
M)4]]_0OE"EP,@!+?! *6?EL2EFCM<Z&#PK-%M4]$G&1[OZ>?>:1F>-W+]O5C
MS34(T7XCK4 -D"NB*HTUJRZ<<S%*CKJ-7#\X4NG,%\*A8KU4?^0SY3O8>6\(
MM[/VATC <;_0SNAD@([XS(NEWQ,,KQA_W?B2.]9R454F)BMZ("@+RH-L]]8B
ME0-(W/BC@RD5H0L'A- #3]3!^2!? (JS66>C>/O4@_F;KY!>. .0HKL5$N08
M/)@KO'B-+!=G*EN9V<-5 1X0B4.]!#]%_/Z$3(,>AT/QZH"2;AN2Q:= :4**
MF$V.^;1SD>+^+% "\?U@EAHBC#;CF2'[%MVH\AXWZH?[IY=DQ;_O);F[2S%'
M]KE O# 4H=G=7UHLPPQ0NX/A*5@-#MN)371&Q<.MRF ^I22>[$CYW'O?FK\E
M.27KC)P^LW)C/A&?,2-#IM8A19$=O1B A_CFMUD@SXJ>2D"(,L4/9Z/?*^N?
M*/)K";9@<"LO@RI8-KQ!/P[7KLN@><S+>D_^\O_.LPQ])2GQS8^JC*>IFXX2
M-OVT9AW?KQ/ G>+>O&PX)OO\"*U;P*9#B-:01_/'F#4W84$"VYT1)RG=["*6
MLNXR&)DB[AX$U9@K"KGJ>DU?INQ,Q^,C6\(A/$Q];.MJ93M!92?,HF.A!U4K
M7]>-U)TS5*"/3XKJG)QD]>U9%;EI=C")S;K2Q-V$SJGM)=&[]J+D8EM@ \G^
M95+0]]DY]4UWJ"-BR$VLEHAL"TR,4$VU$JC+35P[85LL(CUWNG<L*]/FOF4A
MSQ JB0P&,T"XO+R)&((/7>$72AC!=P-;DOZNU%==QAH4U>OMY)'5)WM863:
MY1YKI?!AFMZP=@KTV,]ZT8K4@I#L[>8P6\N,%K&WGI DZ5;[OXW_S3(1G?-Z
M=VP'<D5]E61>41ZPRA!E$=JKV&IK A;1#V9;?OK#C)C^5'COB<^Q(4(RB!@X
MJTP>(CG$T4_X( \BCO@H+:BG['UZEW/=-%/UI([UKXL-?1Y*S]F13_BXVI99
M'X[^/>D+4ZN0O#;I1$I<ARY$:7:K-$U@32,;ZNJ"4Q_>"N8Y&+39@TJ[PKP=
MKZEV0L:,+_DEB5YMP #Q]U;08C45L/6Q+B]R/"2C:05RDK$J#C_G0 @HU1'
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MCW9F_]*;[$$2G3&[VBA.Y-2R+P/T6G=\Q^8ATP_VPYC5/C!-L)8%H)!JR-Y
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M)\7_>L\,N6]!N4G_V82WFM0]4K\8R#X[\> QXX,AAZ-5_L.3T#=RN^?.KUH
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M924'_+-NB*,;P.UJ 3EB8(^A7LL44\Q/!Q2G?3U8XWZLEP%B?5S$% CE/Z"
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M(HG6R.E5?'T5=[DG[LRV+^!H8%/I.A@I>LR2K2]4(VLTL[1PYS-;&K(=@I
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M%CF+/@ZP4T)UU]4I1G?I@D2V6+2V34*>ZRM=0YW&T ;[1A&I(]/A#KOGWYT
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MO/=^4A/'#$V7?-D4G- D97]"8'MFCK%K>Z2%MY6>F';M$/38N SD@6XVPGF
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MWTJW84=QIO*@_+C_OF$[??]AATS:8G2 N=$K@ +E+.X$SJO_P*RS%4<5T[G
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M.=_(7-+^"]H5)SQ=Z\Q]WRHCG8DN",H#W*]P"*I>R (!25,,KMT9L<8(Y V
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M7^7U1_,WG478XB&1/C2S^1//^ELG3Y3K]/1,J)?/#]X+?*;[VD#N2RY?5AP
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M;?PUFT(D=NQO<:D[1>_DD&_ ]UM#DG1UBFC=MYJO^N1>P4^61G>;[W"R06Q
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M-;)_1Y9R5), 32TX@ XU'MU[^]CQMY+3JXX%W]0@CE399R[+SD_R.C;&9K7
M1&'F\FEK&&X\V"1'NSP4D(UHLW@P@8B&Q0GI7Q0ZW042 P5@^^'C6Y0@P(F
MG:R:Q[5L)3B(U8SIP-P^=8<62$[%XH,?"=YP<1Y?;P@Q\SW9KVVJR](YA2,1
M9R?J&+$^F$/0BSHT+>2?RJZ_@.(%1.\-Z>DAV8#XN09PK(UT,=M8/2PZ<-V:
MO4A0?=3/6RC3M?N(H45T8N&%@?2_O.!.XBF<*X*A8N8SN"K7RMJ6Z-;HR[K!
M"$IO@(1"Y48;)0E;&^E4*20'Z9?T2?)LN"H:['%YNMU)N&T_J+_)@W,R[\[5
MSN>_;ET4?I #\AI!J=%.#=7 QG$=TJQ L&OJZAV$ T&7KZ_/^+6SM$6:D)'L
M&SY]UO3]CZR+RH#<UL:R*/%<6 EC:%;B0C[YV3>LIT B7ZM%@JF'K] M)Y68
MJ?-7*ZO]/HD9B&R:'D4;!>JRWARM+AY6XU4?.@0Q(W>R;XT9N79.'D9L_$F7
MX@YD&)S&3(]+[MP(QQ,%AMP[RO#6FZK35T>.G^"&R0[J_4.!U+Z+W_C8^ @+
MT,"4*\KT] VF]88( *$/2)>[/R"OD&]]J.S'+[Q.$ EY9?"%_$E'P5B&"&F-
M9EV<Y%@1I0D-,V[Z$]!TOPHF[*F>!SL,;BA9T"2\&<*+/'8VR?S9NH/]X[9"
MT;@9^<+H"W\X/("][6QJS2[DO_X31$0[8@Y4T1%0BB(SLE>*L*_1<V6X;55&
M'YQRV>P0E#=I]1O^/V8$_L21+&</)-!NRE3QHD/0 %&>==<2)XI[I#S1,45)
MIG_0.VM ^'3V.Q",#_,TM]R_MG.L#H<+7C:S4#D$"43:OD1EAURV(O*B M#-
MLD[WR4%$R$F(-N*-L-RX:7#RDCOK[NDI@V'%Z@>[H6%:0[RG-5&_LI!/SD^5
M/IA:C/DQ*2KEW7$)_AYS%'G9C:J*;KZG8S6GS&-(?S=W"))"(-?\5B\N/GSY
ML,G]?,%SX?QO7)I<5<(G%'8]<;K(,*8DS@:8DLSQU>Q?LX^W.5;NWQG=FC4;
M]-URBND_4].8KGBMY/6=JPS-DNJQ^ZG6UM<4>(0?I1@7@5 !3$ *JP(^J.-(
M$[)0:>7:W^18-@V5+P<33G6F0NF,W6U,V]A*.\H>U84Z"QN'4=K(AZ ?_6(X
MBELDTOI9QGO)D>(S#Q6MF_IWI"^=UGC569T2N:?V-U[_* )+_%1H[86I-&Y?
M#]TS?J%S*>QIOF'7CF-D40S]>DQ$Z N'WW NYCAQ[NXT95(Y-+Q)/&BD$3U?
M%]<;L*ZV<S:NMY"ER:)O]<&Q5TY+O*<@SYZ?HD?L:9<9,P5'2(9B7VV])<Z7
M^XK<_J-R,7"NHC'>P9@IF5P U@(O"7!,D^+Z,S]/FW>O#P8#H#5*9$<1M3?!
M3AR1KI=/1TDEEG/,7*&R_D"S3U'0](AEDE2'1M-0HPR:,A:Q*+'VP.5-6'']
M09HFQP#7-@:0J5: ;+S\]=V9++RN,>8L<\"B+[U%=4'Z9U#\Z#G(1_->QZ,?
MU+WPKFYWYL%Y9;;Y59PX=F>J2_<JOP,'LT=[]/AJ""\ O@$TD-E;H"+(6V1'
M7B_B9$M8[GBGNFSR0^2+RT=.%,H\4;SWD+6A^C]G0SEND[<VF&YW8WPR-%'$
M*^P1X>K3@?:S9_3P3D'^&U'?E2EJP*="Y"-Z)@.R7F\^<K?:QKP6$R;T .+6
M^/),DGO<(8A/S-GO9V5JLQ#+FK02R2=\GL@^;TA62G3">HBR"HROJ:_JP)K%
MS_](V Y>4]B&$HPW%@]!/+U,V H#I_#3(I1M7Y"GQ%YY2>ZXW:\AI1SG;_>_
MUEUMRV&__GCOU)CL%UE&V]B2,3&6##,A)].$ZBBAI \9@2<6.R,#S>Z-2"A=
MUQ#\(W-P??^4@$J8QGRY/NCO-0:7 =70$UY5O#$5%H9?CZHAW\(%9"EE^T-F
M:]VL@L_"*6]4GQ17J4C_%MV 4H\#<(H_B2^]=%W+O*F$;&P1Z;-G[_GWDB*E
M\NN?AY'9VD?<O%2V-SCE)*\>9-!$M%NR$O=_0#B!\@[V;_&M>C)1!.+%&X5W
M9'*?479T"@]!M:\IV%9TC 2T'0Y:D58>4+)<-QDMG6^L2WT@I:!T0UU+):>$
M[U>AM"'( B@B!35C)!J5@_!;$L"S3OBPTO$\V[>=F9 "XY,'!8\F7KU4V!ZF
MH($+)8Q^-.D^^AC =0BR_#H:\$ZIXQ!$92>L]JBL5EK;=PNAVJT7[B9IL,N
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M_08CAZ#_Y(J5,#AY#T%GO8O1XYZ'H$/0-1L"SGWKP,QM8Y_Y9JAH7:.&_WH
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M_1@QH)>Y ?DF+1\NY/4*,,-Y]09_M'\&\[,&TKI689^.BII"1L<XAMFY9\9
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MYPB@0LJ-53#;2[M!Z#M($M+GL-QY=O\Z1<^@RK!BT(=I$K52X;#(<CKTU[D
MO#5&&?,Q$^9SB)D5?EP ,9U[ &J[6UCN?<[7&*L%LU?J2RQ?T$%G!. U1 I+
M59F^"PUS97ZY#_.;8!Q12D&$)Y.?$O?BJ%('H":JW>2&M<N8&NS=.KGMSE4>
M>&?R4S>T^DY'#,S.2H\A%AWUO*[4DT2=P91<0]+318&4@LE142,<L/3J_7("
M<]4OC:\*H& 6 0M\_X_DPX>,=+4/1-Y/JQ>3K[V/E'"+N^R\PJKK.ITAX-$A
M?DZZXY,"RS?,/*0/(DG5Q\)X1TC[BC];?OZ1<[D$LW=RU%B@ELMS,BO((")D
MU/X(_ ,8N[8-Q=H5L20I-Z7M?K0,S>J!FA&Z$1'<H8#=%2C>>IXOPYN9^EZN
M\?%WU-SK)!"03 9(7@0K!K%+A/NJ1)WSM?YYP:=F,;%ALJ9NCB#IQY1;I"ZU
M-0C"H5887R=!E\1L@/+75-;9.CI7^><B70>"8<&B8^_#4[T7..YE*Y[\JQ$B
M'OH&Z:'DA&MM(\J;MP,3$M,(;;^.S'MMN1E.IM\XP#G/8FW81M)BY#\^SN$'
MV?5#WE4>#C(D3B/Y)+!SM%PH#M^P4OYB1?G3S'7Z/?&+/-7G%XJ$,_\-#T-2
M=7]QBV$ZH6JM4+7[G*\YT=K<S,3%<&VRICS*J3F3UJ:J?==2/8\!X9( F< X
M_V=D6]U'TA)#Z+GA.AI=E^H]23(;2RK]J:DM2Y%YPQF[3:4*8CT/COJM,WI[
M'.G5@1'QA;)211Z2N.Y:B(U4]"VVCQ^_]_[]X/@'&29^B@)SJZ[B<GCT^%I0
MBA?Q>6:GC6!J^+Y)DEKF*/;)9V&[(_9_7X2[Z>_TA]PZK$3V#I* ]K8X 03U
M[U#T#",%RR666:Y10HO]O*\;BGWN:C/D^A5 65#[$\) K\^5\Q +* %_O]SO
MGJ\!5F&ZY4B:\61-+F8+-^L10/F3/C;X4KI[)>L>M[X:X^8LV0:0;0>@)*@/
MFGM3\CAL85_"R.FR6[LF>CYX1.N=^$77&_C[8@+8X;W[17_^S,7=0>7U/KJY
MX1Y7-ILI5ON)_V_Y4>J3KK]-4TF3KZ.T\\AUTRAI'VC3 2@YD,Y7WE=\PB,-
M0U$*","]SVCXD&":\,W6B#:1O<.R.2<P2N\K&.^G/<06+%.#TC:@8@<@'^?3
M3B.7E&!;6/F\7;VWSRG+>+6=:488R8,8*#I+>ZM6O\C6GULL@ITN!2(E7X0N
M.KFLV]I.O'@2!HKG-1#M@,B.]O*R#VL_@04>(FU L0YO(K^91/JJ')NGGHVQ
M1L8V&E<R+M/2FN.IK9_:R_ERY&R %&UU&9L2(GQ(6""[,73;C392I3Z@Y?Z0
M>$IK&'YG\?-IS04'IQ7H_.>;(KJF$\^X<,IZXQ8W8896>I(>%-4-2:T9759
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M(9%Z1UK1#MSS#96/Z#G>IY:O':3\@L]W4_M\#PX/T?V:PGISJ^38[S,*+#E
M_7T<)S06=;ZXY[81Z9:C&GY=6F'66".:[9R[LX#']X"U)VQH@5^8+3:<RB)?
MGZX8Z3']"P_,L,HX#,2P0Y6+BWP\1K_.*4T8P)<09/-(ET/TA*(/':$%)7S9
MQW%9- ,XIJ:D[Y'YNUJNC7*IY?D2@N;!H!_V=V%W7K)DF$=V'!Y23#@ X=(7
M@WK;!V.$R(AXJ]PQ>^6T>K+$A;$M-BZA[/?+1OWA%R*7O3Y&YA^FM+MKM@[7
M*->M$/8U]^%I7WYE46 9-"0.?J%SJ5Z#5MVBDE!@L<4XXQ+ZZ?I]^3YA?!M]
MQ,DIO$[V;.!MWMN7;3+1P7<H7?M_^A_-\#-AH0VGFDA(9^!4&U0,WYY^F);4
M[ICM[ABG'>42QS=JQID*W;U+HX\/K6L?K*$R&>J;ZD=^0O*L' A74Z!#C"M6
M6G/G'MGD--_%NG2=[,L8J!L<5KW7%WW!0NK?8#M!GSY4JHO%B\D]K5!.J>GB
M-?_,=<9E @+*'2Q.>-SK^7%A1,P$&M9V24;"B"OR(V-T_*HG3-52?;X@N.>=
MJ1QINS 1]:9C-UIM;?<LR*K\ Q99P9XLX<D9JE/3<Q'_BM[4WW@==0X>J5X?
MA(7QC)0<U?S]*&#$!W?1+JB9_7E_K)N^%IEH!'[T-XS.L8<+6C3K@Q&+#D"]
M5PS>&'ZEQ5# A,6 \HJ'Y.+F (JV3T>9R,K+^REWYN;Y&4)\8N5046%+_<%O
M2J;1:U<88BJ=#VVL08V3D8W1&/0N=2MBX4?HP\%KE$>,@.@K#% 02H1Z8[@7
M ''Z>,8&[^C%//02S'VJ5IE8HO\UD'(UH"U;964@8EP?YF*E)ZS+],+N/5$E
M7FZNE^N1N?I""Y/T&8W%X]<\/[T!25#>L["TW#\ _2MJ\YLAJ-\/0/\UR6%,
MU/^BY#"BHO^RY#"$Y%^2'"=,HVXE2=Z>5D0]'4$*498!XN47#T M@AN+8A%'
ME;^?^'[)Q@KY0/KG42..KP7D8PK,18USITLQ:KGFN.Z3\=ZL.XNAQ'!M'.HR
M+8IZDV(!Q/<5J5@L,DM<4U+7,N'.(1,NC'T1,6O+CPD2S?T;2MM*HEP[#&+3
M)<.KR65MM(Z+!$7]&&LHT^)^=Z"LN?(P@1H3)/+^,T'D.?@<RL0_+2:)XLHX
MX!MDZ5<?K%D^OE-CC8U6C$/E66=MWW]+B[=HZ9"62O[VU5GFR-^VR&71_?8D
M$)[.M1*>M;<&?K*M?:=1)>74EYH[L[G>DQI" RM< U_U!"SRT2?U6$J$WR(E
M5;1=*JE"I-KQJ%Q;4IFC3>_/3=;SG[[_/+E++HNJEIA?>R*PRIARRO0NNA2P
MAP,S [FP] F88;UQU9GUGOV>Q0G4^+?3E^QY],5^#8O4O_D'+4 ?5[^8]8L\
M3U+.Q[.KR0$R$N0W[0]'RA>,V3)J#D!W^H:%GZ4$="ME8]3('__A@;9!!@^D
M@X'-7BLX4XQUGGZV^=UI\[0<SU"T]R_[X\VD!K:[E]@$_K'3B?3YQ?I^)2'L
MJ98P8H#R'=+NN._9V<E9L7QUD0RSI_D.X.&.-_@6 XJ(+T:@!?U$,V!N(&&[
ME(1W64Z.[6R.7K10,('7E)UYH^L<+**SN?QOIB;V,";S.P#Q=#J !QE,U*DA
MD48XN[H>:OO6ZU?46DFJ0]IG8M^_P8%3275E,-!99(#%\?4BCACKH.@L7\<K
M&RK<.9YGF5?*T@D?\O$7GC0?(CC_CTBB/&@?0W;25B' P[5U%%/_8Y5$B.T"
MXJQ_0-W2%NIZ?$ZAB-XJ7X8J[ ;#\3ZFZ*P"(U: /':D.,'O0OBJB_JIF=EP
MC]C^ =W(86'VR@4]@0:2*[Y/$,D)]X ^[4O%O6GV&YR\:E63%L3*[=;S_LS@
MYZ5>9C!"\2T##RO&V#2D7 F/[T6H(!>9&<&IPC96E,&E%*<KMQ56[QYI5PAZ
M$;0Z7%]]B)XT$<: (O$ %"26JN@48PUA,BI_<_:!;LZ=5H;-$6P2"\+4($*U
MUP2YM[*C'G P[HYQD"H-3;6BF -A]L3;]/$O&Q<61HY,S-![*QQ6HM9>[X:)
M)<S7'[7H2-FKK^M4E?N-$ILLOGE<[51SPDJ@9>6H@L97;K;1HI>V.?Q,7]$M
MH>4D/E-:,=4IC%BH+ O$B(<>@!;\_(($^F)3/U^Y;GRF46,[I3@<XOJ^+H@L
M.XM0V2QFG?V!AS/L!(9R;>W:JD.W+^.G,FFCLX[<&ES](5*/^-=J^OS3SN36
MUJXO<E5]F-XA!&_>G_7[D"M+G7]B\SM(X&>1S/!D2"KTUH I16+2?$J$4K:?
M/A:EYOTOOSOTUG?Q8UI,Q?*&9B$!55BY=#+K<?4'6X775C/Y\U&ERP6@-L.(
M Q#UHGS/^/YI!/@ U/VG_@ D7ME+HJS%]@WSPWBH,F<;S]U*55NR_MR'!;&^
M+ #M>-?Y]4/YM"%8OS<!G::XC^#>/57Y?'[-BE*NIJ$/ ]^XNS*++BB&64PK
MA3SF]-L4>Q[D7^?A4/*A+<-4O.'=$1=[\0L9^JSW]$LX^6VA2=J>)>'2/5H[
M/)L%@4\\9:/Y/\PHXUM3RZ0RGKR,<CHV*'$/7&ZZAA;P1IV?$K+ZHO:8ZZ'%
M707EWTO/WB>\V]!X)2,S=9&IRI"A9/]9@Z5A6GY0R_%K&%J*I. !:()HMV6.
MT$+,%>_FI<<CR>?"G0Y QMUZD(;#I+O_X1[":M(<G>/A >@T,Y!_ '(;]3@
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MX$XC_V'H,08GLD[4*O43<0?4__Y]:H-S4TJ.<VU$W?#7D:F 7D_G[!JV929
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M. T)?7_4G9/B@G226>VS]+* BS[R61\INC9:KS!'FY:IGG^=GW^*UO<$12K
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M&=;[-<ZS'X]1)K(05O#>5939[.7%#@JGPJF7<!<A,?NJ;V::>MI.RT]./71
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MB%O/>=F4$4+PU<N^(?CHU:+L$HUU=SM_?K"BSZQM$'E6<OQ;C$/JP-;Q"A7
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MMR)7'ZV/F.,C%PX/ G"0Y>)V$"^)"Z=.B.C*-<6K?)G8")1M':7E4=.#-OM
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MD:'QAU&D)S:/9AX3FR\%+:4R66&[TDJTBG];A_HZR;^,1(E)[A#=8S%.;ZD
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MW$N3?^%%8YUP,(8#&^?[#"*@:83NE8A(4"*FS#CH:WMZS]_JZ!9V]P+\NF[
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M@?3)K</P2QKQ9YR[1'>V+1?FUPR-DZ_M#193839&^W)M*TDQ/[:_K[KO[M(
M(DO(. PK68HD39U!G-UWO79Z;X!E#5R=GF&Q11E-XNOS#!V8B7D]Y\UWZ1F
M>075"1>$)F$Q;]TU;F,AI[H79N[\*6J.=X>Z+B4*^RE"X^YLW%0'=/-U76(D
MEI&,8'\LXC?%\(_7._Q2$!-C3JP3JP2& TKV#,LE[I9>;OL7099" &01R Y.
ME,BS.8>;"7]/E9B<73O_5')J$AK6<:\\(NQ$<?O+X"E=<J55&<!.KY>WZ#W2
MA$T_XZG.D9]10;>49M!9S6+Q%W8WR=)7=ZUA!+I5B*O&4%G+2JQ=NNZ&S-E\
M4:Y"]5#[XRT22OSVIOY&:TX0.EZ1;]/G: )T"NLPP4-/;!6SA=B_C3$:[/#B
M2J=+4IFG2,(J@#=66S;O&6UJQ,B<M@28I=<E?%\<<>!CO1)U8;./E^*R )P2
MH;)RH 0U5#SF$$Q.J?P.H5N\070E;&S&H_+\R?F(MPG\+T\8ZJLP_N5C3N<T
M>RH>9#.SA=D_3-^UV!PAHY"_-FF N:3F&\,O\31 A]!UR8D9YP1+9^[J_(,+
MG)X/A6YK^A[B=Y]@<*;L;YME,^;?0RYX;\IO@W&C8XBS37V$;T.4L/LU)T0?
MR4> F50>IC"%Q)!M<5WS-BA<>!<_)%I#P8^@"3%*"GS5YGD_[WFN#U7TV7V1
M/_B0$$@AA!4^]PW"VFCVN9VJD+C;JC8D?O$G(<G&LL%/3D.\/][!3.3F<K'?
M@OAH@0WO=TF"GN6@Y0[93W75?&DY%(QW@==1'5H@Y>PM"!ZR%;$+:UDL\*">
M7R:U<&H6XW)60+JIT>-^25O?BM4"P^UN,4T&D3U;*JLK/9KE%\'''] #I<X8
M*!XT]PW(JFA]]T$YKN\ )L(#?MWE\ZTJ<XQ0_8@/D*)S+AAL=^?)E2^_U>+"
M^V@ M_A)^N@".XTF#HQQZ!"R)059W!OD(F]! ]C/M'[4[14::B]J.2@1-"WC
M+1Q,RAMZ##DR=<.D]M8U\0[G#FQ;UZ*ZIY8""TB2Y/O$5ER<^P5B#;8SV><'
M$?XP]!IZ4_A42G?.;ZX\0##ORP^__ "\B(]*L"0J_9VK>4) +OT@4]S,6/"1
M6XU06@H-<'>$RZVX1+J7Z45\C-K?CUP^)KOG3B\U/Z:$P]UE3P4*X*X+G\!_
MC9O4S%/0NZY&2'5=BO1+;)_^?-A[CE,M[-<D:VP=Z'8WR0_6!S^[Z>-J^3/>
M7;D(&CB5$<38ECAI98-ZL2UJ+"68U*M2[/-_+&$DFHP@7\Q@W\H7[_E]5(+
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MB$ES RV17_ &>>EN!<7.LH6Q:L\C77/D.B-$(5A/D6GPMU_,3.>E9^APNE3
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MFZ7DMR=G(NW=-/64+)IS8F\.!K\W2U@:2<K,S*@C@#;^[2K>KZ'D:7%.0GN
M$6UW$_73BNV'.Z,)B*L+K\Z@)B^J/BX^T%$!]P-Y8'S."&:8J N5?73HMD_^
MC(:40M??Z(@*4MW'EUAKW]+%_74;/.D,=;R7I+2.GE2)^)*]VZK67G1]:=HM
MI?.U\N$:JCW_-9\_UC1.9XS"WTP<("F3P97#54$N[33 N?T*UDAIR_;'DVP1
MZGBA3M$8TC/^70^N,EYG\MC25QJ ?=WZ0*?2EO7CM$T2%84T2:>/I-?:K.P8
M7=9?<^=NZFN568I_D(Y/RT]L=]WIENY^-/L"29*L7> ZA) ,[WZ=@@T".:X,
MW>)F0\XRF74R[%J^YMT0\-4LVG,@9-+_5RQ4I$6+IWE0BW_M-131X=GYY^Z;
MEQD_7LD#=C5^*O^Z!9+\BDW8O1 #[%XO*D26?*VK2UZN39O4NYH0K5"F>EUO
M34^UWRXD]D%MVGR^L.EHDR\:ARFR'U5UQ(ZRS<Q2,VB [-E[IO^J@/W?]I>/
MOZ<^^\ZF( A@OI;8I$YPJL>YI>%1/],1\?O:0X'27V?8UM/29Y\>5-X-]-B(
M%(I;/<'8*9?MM-HPGJ:<DH$H U9 VII !&]*9J-ZOO,!]Z31^"L8YH?U3%]9
M!^<0N[R]WRO =\/I[%]2;!9T"6SGSN&<JI9=#,<%F(Z4(/JR=PBNDD[YMF3#
M#3W;+8/ 7I(?;%KX!#$99]8(Q"VW&Q1;.Z,]2G)^]BQ-]53=1?&E*'8[G+ZA
MT/)J'_F;]3#]IMJGPM]-EATUE,#ZP'A#DUA6CX*SWM3F()C#WEG<0"?H7%6Q
M.DD NU6'#2"=E6,FZY,5_%Q%S;^U+QR\3CQ_L:&TNQ^F#IM&G(9C#:F#LU?+
M:J)[AGS U/'2O9TET?+X6^4LG.S:G+!VN/!U&H NP.,F857%UDH%8>Z?DXQ&
M7SZ9-4BX<:;\U:TGFPF/<"R=&S[_\?0Z(O U485T"VK4YH\()EO4%T15!J2^
MGX+;S[3857VT:WYSV:RG_C(@.V8T[_5NZ_P7\5GCE%A" PV@KDZHS357*C3,
M_%'\_5"6Z.-^=W-@(NQ)H"OI$I%_=M),R@.;-]PK02HI^_0DZ*X$N0B?[A[2
MK!0R?QDG G4QI@'>EUH%?7)Z<6I7WT$@7+ @B ;P$UP61 ]!RD";TR"'+&4(
M,[&^<]T4YUU121B>P)9<%VHFGFYGCHWONW4I^$G,,M<!D*QA2X"10&ETX=*7
M@4>(D?A)?L,40P7BZ .E4NCWY.?G[$"[[@5%^PKODRTNY(LY -?QY7MJ1I,G
M35I 9>B85\O)EY6U+B89G<V,OS$587K"_V\$,!;F2X]G,C3 XNIENN!06J9V
M6P"KNS87496G/C:?Q?EDC:7-_4VS;ZAK8G!38K[[48#AL@C3J59540EUCY 6
M:BN".U "!UD8@8G@4XHH\;DR:5YN;K !^K@T!C7HC"=D9 I[1/V0YB_+M<C7
MWC;0U#+:=7\A=^Y"K*3BOK'++B1GE"Z.]T!D;D;J'0P;?#TLGP;X8@ENIE/)
MHQ9'O.$D%AL:8&48 H2WW@<Y&@$"_4<T&&7?*=$ FR-#\TV6%03U:+CXKV<2
MU'K%W[XJ#Q<$T274GW0YQ/P3%(*HV,K (GFA-201RS#"FD,5M;\!P;IC9[B2
M8[<8,'8AWX2DGI0\NZWO@E>P*(_NT-%;+: F!DJ0[A@> (6IHGHB;E[S!KIB
MJUZ7D&,0HMCU&!J@'!C"*!B:2&1_3NB.WT?^@D=/;L9':5V'HI\.BY$,,[ZM
M^]6D5&R\W+V2Z.?M^H.![_&YTTP."9 OJ#+P9A(N "NVL8Q%LA$K.FB "8O-
MS%0#323!;G&*<?K^^FX7FT1/J8;P_E1$@:H=_FM*\Q;BFI'\46]2T-._D%)X
MY(8&B.0#[1PBF$49/'.N5FY 11E[5K@>)4>NCZ+F"A$GR$\7(AJE%R#L3FB+
MT; D=Z4L2G&FZ_64M3XA^].?$U%0.:$;=0L)A]AY(QY]5SS8' \*1RX&FXW9
MCUR7_7)2R"A[0/#MA0_^@A?VD8.HMPB<Z0"K"__5:@3><'+AUAC6H-R9H-RO
MF?4;<-AS[67L@ ]K;Z>G0J7G /M3D[9Y":3_A0<8,:HKW,+Q>X=9$4N@O#L$
M068:&$"$ !D#(?BN3G,+8)AB0%'Q[@\_\,]K),U$AZ5$\,KG,YD7DV( >B=0
M-B W(\XG4 &"(?Z[S:\?!]52^98B"?5/[2Z?8O8\M7PDH5F4B9<E<R+G=,+S
M>WV>SZMOGY\6/WQ52;FVI&I%XAM2!$:#EX&;$)(5-)KP&7^UP:J5$HUUU?RT
M.JGHZ<[:_JQ7ZIG[AS@U0.Z[T6C)[\VVXB:9JL]J4#V4!D<UFX$S,X8NS=%'
M9#CC/B.![IN3=(EPNN:JH %6'U81B^:E(F4:;Q<.2+FGZ!=:3_%VR^@I'?F1
M1*F3B%,P7NKO9G9<5V2C'26CQ GW(%49->%7?FCW->$M1O!Z01ASL#_Z[U:!
MO)4SV+/33U?T=X]'3'![U$:NH3XP(L-">8/J;GOS >C1>UED0X%U&BF41)>O
MW;E01FK'/@WPQP+%T\Q-5AUMEB;?^=-X.4<793Q:8L[T0KX,"4Y 36B?Z9HP
M@*7^=^^W.3R@LJSC5>9J6C";*![H04?"*E6FG@:X75Y)[6]$;(Q-\P0-_NRM
MUVF96V2B 1RCNM@'="]$?I_#N K7][HW07YUD,:=.8<KJIH4+6D RY6@&?S%
M#AM^2B0-8 \BINKRAMPKMSPK.?GP5&/C,]^4KL<#];HBI5Z02 MJ$WP^UNO1
MF))E:M-(%5MX?5UMTK:>2)F][;XH>F/[OW;/72"7[2FC.72'[,1 IQ8/KBL&
M7KD_<T><>_+?5_VR-XK;#3$:'[['2)8MQB5WA68Y*UU5'?+\F'U$ Z3VTP M
MFLRL/ISBA=\ZX-9'LNBZ/94-]_EH(TY8+XA=IK)"L'/J?ES'@G0ERV=AD\*;
M-P\_$%:\(!IDNA\,3H768%4BQ 8#P3C^ YVF.)U8V"!2ODOYG,H]&L!VZDIV
M7UX(Y KU%[S:M^[?%U3<%R>5&^;Z[QA+SWX2%/W0_?;,G[(YY3_R!6$M?$*Z
M*VZA=&UXE<A2Y%0Z/4/\OGLO"RWM$)1GK5B&N/,\[M[ 8*R-&)LD--*,$(A/
M:7)K7L@.-=M(5MY TX7A,$1D0(#*RH47!IU$12,(KNBD-@]$AK&KQ6U>ZX;&
M >+N0&K\H5-L4T7Z884VI8ANQV.!-;IMD B_HQ/$QV,\-4-V[Y"P$165+/X>
M2._#,[\;;6/K^H.X\+U4UHRY)O9[]>5$)Q>O>5>W)SUMWV8ME9H^,H7L<@7>
M7X3[.8=0MD8/_8K6>=()90'?(0\=4(U96PX9#/J_-IYF, )>)@W5OU84D:C[
M'2]IZ;R]G$O>$[L@MG'(N87Y0KKP;PLJ47K>* 9S8G,!5_4C/:4@QUFJL#J+
M7=ZJ721!4 ?5/J<UEYO(P"CZ%B[B#0RWD<#K1NF&52+9G?WH,S?MKW+&V:*T
MP8J0)H]DQKI7#!BN@^4->FX^J3Y<B6(?)SK,3_N]"+CWY!E>*4\'K@1H(3VT
M79X&,/J?FLF^M8CPP8/)G#5S-B&Y_7Y?B<&D]IHH+7VVLS+S$H(T0).:SEO_
M+,R[U2?&1YTV?_4G=J]MI5/3/%^W=ZCO5/HC6HS"_<-_PB?0;<(71_.>*AFH
MZ,G-O'+M*;_A\)*Y]G&'UR8D1(G$CH43Q>EI"WD>RCJVW*XE9L#<SF/^P\W[
MT][Z:D=E^,WX_B?*S:=.85O7NQZ0H<6X"\7[4;O% JJ60P?)&PXF$YVAXB;^
MLJC_N.AQ2_#Y?[[E$?(#A=-#'*J Z)TYCO:B ?)\?0Z5_ENO_K6';VV/"CUQ
MGP=F@BH+R)D.'48D_GT(Y7I*XWP3\-]!X:088B%]^MH4T0#YB>A,<*[17/R7
M =G(4$YC"X[_-RX+.F['[?]/[7_HW*_)/)#,,=6&.1\(GW?G[%_H-_SMZF52
M/S([J\X[\<(IWXGUA.4'-ENMT0$:H.T+F:Z1M2^:TT-2((1L'2A'NK_.@Z<.
M CD39-TN\'18?&8M+P4$E=@P*RV#IOSCR33 #!RS1 /P?WJ.EY'XC@D6_&[2
M< "ZN%=#%6+'(H_$TVNH;/,TP/P*#1!^E^A"C?JW R&8B"+6DX>H4R/P9>HZ
ME090(0Y2:K[1  ,4-(7JCB_60D;1  A,L-BD"=6HG2+]7_TQ"/N'RD_/]I%%
M\+EF6:H,2A%5O0\\I 'H6@353U6$NZZ!=FD 'QH GD%V/&J6HL)AIS7S08MD
MHR$,T1L4AEK)<<809:-I@.C<_X2ZOJM/<J<;, 0)22)C%G0)L[DT .@ <G"(
MZHPOFD<M'\R%'',=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS
M'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=
M<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS'7,=<QUS
M_:_E0GZE >S@$_.]!'N<3!E6_ZQ]D"?+OM^(UJ ':WN/S2R3U-O[+3N["'^R
MRO^UH@%Z#4/F@,U;(B<P[8D&(KV7\=:=%CK7X0N_!^J0("&=1O&:QP7RF[;^
M"N\+'#N[E@XV)6@ ,3Z\";6S"4P#Z%]%WD3J4NA("UJ2\''T=QI@]675,M?V
M,%%DY77O_'-M3O/WH?]#M\"!;;&H$-!Y#8>"?'K'D=GFK7T[=JO7#89D9*Z\
M$A24O\R<;O"MJ'3GYII4#MZA#<$-/9LC? W768$=EFBW-1_^6S6K^WQ)O-^K
M4D)"ZJMR^K1XR;H!D1TO^V1P;O2'EA"QA/0@^[(&>&SR:M\'/3Z^<R7G"ZV\
M/GA8+8>2@4CH@BFU'[<4^6W]**Y-;'RO04_&?E(N9?QMYIDXC]E41>NA@)-9
M)2^-P3[%%XUQ2X4>7]?&>"QL<E]-B54TA7Y)O[;W\ADKXH5D\F.GHL]3.IS_
M+KV5RL75M+GS0)?&MI;;8-QCC;?=G6@ H(*3OS=:@IWOL$>"K:O8ZT?^D^ ;
MNDS\8'#-HU4/\9RH9_]G=0WK?D0+/-(_)9J[S FWW>%G\? /VZ=M[*",#7-$
M"?;2AVM#M<NO;W8IR2=&-69]&'*=$%3B-#:]E!.%QJ%"]FD @34Q(]Q6>*'+
M 58_PUIF2#_--X[-]9:AJB#ISREMKB%B Q81HP$HK8G2D"B!NMK?C%@[\A[+
MN;O2_"*&RM7_^/%C\$-7I5ICZV[B1;R$MT(Q,#Q;DO]F#>GI"*A,!C:PZ#JS
M=)BAO#&UZ_9;KO_UB,2U2:-G%55']!%]>/L_E_TY;L?M_^OM?TUI*]@"M:T-
M5 YO>ZNC2_""KZQ*X>91'J 7>F= Y49M-8Q7O=&O@JXF-DY/]K+XD7MW/N F
M%ZZ@&F1_BRV#R9P"A.<T0*@ _@8Q_&[%3B//O!Z_BT^DAU#6P%-I"D"C_MQ-
M488=<S_R13^JX=1/S/YF !UX"+P:M(\,@;MB)CH6F-7L:]Q\:TZYJN'/@;9K
M%X$ZPE^*=@<(5W#GRG UA*UAL@1RBI)A/A1*:>S]/=91D>PC]KW\0\O!F;-V
M[Y"R=N"SX/D8NP-/5"\Y+O,59YV+KH,X9FQ]E[P5 /JO+KA::H)]A+="4(L7
M<2AJPQKHZ&Q3X#Z)B]I1 Z]L+O0J=O'CX3=ZY[T:6%@BC1-KS  <RG&<?L1P
M,C,DYBV#F.3.1&?VQ6RW;I7#C(5F22<W]-I JCARJI#*3.T'G:R<DE:QQ"VW
M4;A5Y2_!.2DI>DO[[:GW&JCVM8A8!,X($@KBTU"YEC]7I ]B7D]LOUHQHOA8
MJQ4$%(>:;HS#FWA-_BPN,%%'"P)JFVV6I-C$<IV7%V:XMD&,KAO-C-21%&$@
M$8'-DGU<&GQ8&63395$1M<3[_KWD[QQM$=8']P7/F=S$%FT8$<4/-I#8:& (
M(5L1IQ*JB&"?7N$!XF]$:Y=&C=I7I;):IR@Q1&FU)0T^72^OEN&T5E_GVZ !
MD&8'GX9S)1,SE3_ZPVUB@9],P0W4#A#3\$)!%X7Y?E,-#_^Y;,/"[U+BXG_N
MW;Y0*L*D_O&.)B]Z%((S$0"%(5@#F7.@)C^IC+B26'JZA5?JO2EPK/YCY.YT
M@6]RY=W'AF1!'];Y[]57C0M9S1M2]^$#6UR2;M^3)G2/:OX>(#)&P+.0TH$-
MMGRR.6X3U<X>,3BMAR6%/?_J6/;K#Z7,-%F^9SV,Y8-OZ*5,AYMS%,0\*)0&
MJ "%;%W^H[3-'B@_*/OU5IF%\XTGEC/WV0$EY/MZ^\Q*<2)"K!<)>E[ZO[R_
MU2<L3P##1\";VVVH\?BY[;?(_=X,H]-._$L911H*K4[%$]K?BE-&G_UDN6;^
M+/;#:[U%GTX 47\^:_D=[ P-T'I/9G,?>!KJ0SXM5EG1,+@TM-G_\8*!RWDG
M\RL9G+DJ:1\4VOS3Q6US(XHV"CMFT>1*TDQ4%HM)OF2YOVP/B3*)X!F$?*,!
M<,:@"?#/4C)G=*?P25Q*_&<;HK^'TOQ*>J#YS_G?#Z4J3G\\)3XE():SC8R$
MV\8'MRT@NS#LCBJ/#B>EB[+T39GL#"KO<81/C.?!<6IHMNBP:QS9TPU4/U($
M\H'IXP",^X[&@RB*%%TEIM %PADJ!UEQ*% )BP003>[C01$R*I0*HT'7+]FS
M8QQ\$];GY5,\H[N,FQL/"#R4X+WM&'Y!&Q#Q?45-V%5? W7=,)U(9'5B\?6X
M//E.WO,G/CPI\00<YL0I<XG7[YA'^>[O':[NV)GFK/;<,-RD 2 XV +66>J
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M&OJV62PWV*5-L[6\\+V@ .^9BO=%5]G9^EP5935T[,:Z0?B;,S][.N"'_1W
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MUL+^;.4C]=]\::ST;<L])'+HQ;/.^-OE4PC.R7[EE YON79.44Z50@<6]8X
M.6H_C>-6_ON8%[]K,\C3=""RU>UC<!Y6<<T#QW-L162T:4[Q\(I]U\Z ZL@(
M!G%?^=K\EOF^F_B;)0#PE:LE&13!OJ)9AFXBVJ:U\%'11_=L&I[3>*_X\7Y<
MFI1N##B:J 9PG'Q0U7H6WJX!XZ;<(O!W-X_NUT>A4%(>&S>>!29U:=6?B3,^
M&=>H37EV12IG-Q;G\[.4Z$$RQB,M??CMCEZ\D1#4BYKQ5 YO^LK9'I;+S965
M91@;I=Z7Q=EN7;#VVO'WQ,S8K+_)B533HL*%L/M_Y4"CS9)S*$2=_>(+U2D0
MI+YU\!W9:33A"?^/)\M2Q='NO2QUY\-XLU@@,C;IL> J]AC54^_"/R[=F[MR
M+^# A]F.AC5E+Y:@]6Z_;NBEUL*CQA8%0I(#*+"'1?_^H)UL;MSR!4[9W*=,
M8]K_D49EK*$(1O'3VTA"T+J;D%3):E1OR;_5*L<H88)@12L=\&,4[#_NGE^B
M _^P U0$SA;._23LNES#($R38HP?1?CD+X..-=\J\ A<K1(5E?=<$#KMF%)K
MX2@K+/-4:XS'P#$WO_S,(YO$)9M[7V_'GK]AK&/F27+IFEB,"' =T=8J]Q3A
M_E#RI3[#:3AMZ*#V,;'#ZCK=4.DXV)7615,<3VSK!=*+NM(YE  TYXR#9?=4
M0((AM)+CH??9!:7)[#SUU6?+CB-\EA86-M>\ZALG@D-Q;IWFAY<KER<$$6'F
MN<N$^#,?D&6_VD^$'S_)LF<+GE/D6W6^,)QY<ZPVE.I-C1K]-.SM/&?)?MFI
M%UQ^?] T36VA[GT0U)\SIWM_T;2UOKFJ(>W'UK1!AFC,R?PDS:S2ORJ3 X?G
MC]^TL);,(T1W(@0H>E ;@FU< .I$;=%=[X $/6@U]YKW^%_]*\T*:-NI>!1W
M5K:H5.K2Y*^;)J^NM/-/]Y O4RSB.F_+="(%S[QRBI@*F'POY/QF<L%%?*1M
M\.I?$^9K5N@?H,M+*L9!6(S\<X0)42W8X2:_,Y^7-;.(N0^$.]03HG"]\_NC
M1C'-9F7!:#NDS5BMP[J/-=(G,[SHET[GUIV#HMF]+D\!81V@;$+VM^T_C8OW
M]K1YX51[ %0[;>RF9C_?]T:CA.'?M^T>'98X9N 3W#$'>4D[Q64QA^*'PLX(
M-+5BJ)5% T'S&]WK.2YBC1,7$QO$4P<&]8UK)M@F?LHN?\F-NZ?U$^S.$R=0
MQ^7"TXD0-' MK?3*&_-.N]!R@<\X/M3&-A)VEC34%H4G0;OV_T0GK,8JH*MJ
M-=;#B,(=X+0./V%MI)5C"[]VTIA93]#[47V"3\\EVCED)R$8TZD4G!;<_+;V
M]8B;8++1TTLJ[7]2/Q>UJ^\9%:AUS0AH^Q .?!,%\P7W=(I+U4297Y)5#;<,
M+<*%'6^T,9(X>4)9!YJ:FR[E/W1W6_=WMJ)U\V" J)?^C::<S[11@PRNTMLB
M&O<"-&P-+3D_:D=H\(]#P>*MTJ27IHU#JCXQK>>'=R;SE3!N3RJ<S(X4A93F
M7=/GN2?W(C<K3SC,9,ZL_*:% ;_>^>5/J=,(N$_XW0#5A/6FV%.-=:]ZI!YJ
M'"D[+(&P<%[$TH')'MQ85 VIK(QV>L;TB OG1&1Y[3PZ/N7J!OP$M&VI*.N4
MA;TG+<^L:TJ\ T<')N@ 3J9S776'#AP+I@/6.=T&KLD3F/ZJQ%N2!UWM^%F+
MQ3)/-X?$R4:J6_W@4+S29YG>N1%D[].#B W111Q*N4O@[0K4M#Y^^'1EW>B&
M2X1Z6YO!9:P>+IXEKAL/[_01"--)7C#G"D;>Q@^G7[$)&MSE\#KR_G&-1D+4
MK+)?SEM5C(5YLN9R0P513=L(ASH1W&'_TFZL6;]D-:39I%B,5A JW[E48GQ3
M*O \()6$81L=BVE5#S,D!")T4RI(=*!+9#3=K_Y;Y7! 9F:,5/L1-<E&JP@6
M8;'+%=)Q&I*NY1^="F'Y1+4QS?OK+;^S.^O2 [?.?_QU^;?4?\702")N5=N4
M4#H'2E")]4<="][NG-A(/VN3W&,YJJ @\:CPG(E6JM2QP[@(N?C<:'[Y[]*C
M/7>Q/O$Y8+QN.O4M%GTR.*5CWYN8OA;BC/+SXMZ.K^OT5?95]IMH3#"U:AZM
MY<JDZFV$DLG%(AX;%:X>9](,-=P"[YDJ226;2Y=:F*<Z$X<5UKVCTJ,IQJ4D
M<TLS(_T1'W^O*RP<086_M$\4Z5SVET!\^S2@3WQ&RBN]W>L63I#I&DM+5NBI
M;QCSSD]XO7OP^IO3#2)G3932.RLX&M;X+ QN)O9WP$5T)4AJIF9JEPECL?XZ
M&LHV&+.1#7FL8U;6:756J?U;6HJQTTI#81:*L?+:MROL27'WSTJCN N4G3Z]
M8K&ZX#5_C)V-R/]UT*I?='HB<6-44U$H[!K!IU.ZUH<_.,^><-'^D,!ZF2>O
MTQM]%U]SI<1?ZXZX"O8"Z#@EF)3^8:G2G8@\KFT+S>\ ZA(_BWG_EK@6L7X\
MIF.=*_'2LW@_1U6^QM.XOM'G"T$MNXPP4O8*94JR)1N'F9'DCJ31CA B:0BW
M4^<?)O:_].HI/7S?YG)/(U>*LX?!60-C>Y,E;8P+*99\-\R%5/Z^/R\XO<=V
M+,2QK6RT[F/'@Y2S0G(2SWA#Z$#5N/@([K6%%:=O8?[I]/>6KPL(6MF]I'7"
MV9J+N<@8V#E-C7KRJ2%&\KSQUS_Q3/Y^$DI<F]Q:[U;J\AVVL,Y-\9+O8OAF
M-6VYO\CDWC)%'PU^?@N_/ORR<O$'ZGYMH'.#O.@!@]L$M\X9H>"].^(R!.?&
M.266J6,CM<(5S=4KK2XG006/K2WZ*@J\;CJ5)RXZ,&XNUSEAT)U:2M$CV)06
M_%+H+?.I;7K[+O5QEO+%5$D)7R///^"?:AUP-IID<"X=:$?SJQRNJ'VY:#L8
MP%$KEVF=5!E5IVM=U(0XTB@LX_LM\/E6-I#T97;8),O1T29]/8^K11OQ$\,/
M:PL4.%82=H:4-+?YXEC=D3H1F\( /S?)H/"H@/#%I^9O$]GY47@MHE05R06W
MZB,>7-^CN=F)%IZXBI_P%.GXF#AEQW_&(L=0OO;-H_FC/?';D+<Y/-1Z7762
MH"GBQH_64RMF'J##GU[<A"@GMJEV>K=Q=ZCS\R2"O7@2X,=5WJH,^,QQYQ.5
M(ZKT[YZ\=-I \J!=6\SM:]K%7W13YZCF0BA^"Y7]%AH90M *+Q<.LZC_,/-^
M$XFW]D&$&'7RB+@['_RNF(>NPT^:*>1I'_T$KFT=.7Y 75K5*LM?P>C6Z5;A
MW+C="S^#L<7G_,8H= #5]KG6UMZQQX/A 1/0Q[4E/W05+CGK$'1?WCW6&?@)
M5OV8[9I.$B,BVRC&:4/G0">="Q9C=M?-.P7=FP1PULW)"P:0R]\ZG]G5V!J=
M]QGPNNZ]?B<W[MR+_^@="4QCVO]*^^_;\?*';$B2Z;2%U,AT<<Q^#]!XG]*E
MF9>?-/ZEKX_AYR,$7QF%;*-)EYO-Z(#>0CD=>*I,!PBJY.JB, [\= '\<9#<
MS/GT$S5E)^X# E)982T:C H C\D1I ,Y&=%4&H0FW?QE82C>^LFE;4UG ?F9
M-Q0%.O""JW-F1\%SAL2J2 =XC2@2SM)TX/UC&SK0)@PG95 'Z4!4&!Y-V1D&
M;VXQ[J<"[] -AM!"/$%_]AC'4>M/Z(#,',@:L0V*G,$_"\ZD10XXT & 4:?,
MN?_]\I!/X'_=(03)#<-%!S!F^C0Z\$\=(#8SYH? 4V*TA_B\^??!JL _'YSS
MV1=4]:&PI-.!6-04Z!\N0+FX&$D'%C^\IP/PO]Z31W:&]Y*B1R0I/=B@OP\/
MC#U 4*-R9=33 (8VG6,;B'\XG2:\_9D.; _=I /HO]XS2$6!YRGZ*TDT%WP3
M[9@B+_Q[8RE\]@B:8@;ZV_BA?XS^X6PZ<&0/"]];+H+/_/YKBFACR"W8J=UK
M=$")Y$0'#@O&HI<<1]#X0_\T._\@=M[?S_\'>:"8/?"Q_7SX_PQUP;6+%&1,
MN"7X*TSP;U.?]Z^'#F-4F?_Z5"Q2FW%/'54>,N6OJ9G8IIEWZA:#%L!<Z'\]
MZ8-_&S7:'_ZW<__&#!,Y)G),Y)C(,9%C(L=$CHD<$[G_0>2*[Y(>S_4G7]45
M'+U_3EG/8_LD3SOTS\6_CW?L%$$4JQN+=0AEKPK-=7N=MU?%VL9:V"?[+\?=
M]+_1N)E+C;G4F,@QD6,BQT2.B1P3.29R3.3^KT.N$HKOZ5:;3*A_L=N?@ [M
M&WKPT&V,"]+XGZR;S)7!7!E,Y)C(,9%C(L=$CHD<$SDF<DSDF,@QD6,BQT2.
MB1P3.29R3.28R#&18R+'1(Z)'!,Y)G),Y)C(,9%C(L=$CHD<$SDF<DSDF,@Q
MD6,BQT2.B1P3N?_+D$-;HV=30\R("+(.*8Z+K/52&!/G+63TF-=PTJP J2[A
MUTXIG:$#_UJ@0'$>?"!R-D'95$QKX$*O4G;\5^&7_+=6@+7<QDKA%Y5\U,R$
MA+/8$8W'TMZ#!OSSV:?^HY\1_>^9LQ>AE*:]@]C?F/EBFS^6&>9)!Q ZDK2F
M^BT^EF65_P0_G/+_VRP?Q $7C50LO[,I2G]KMH)]U_$,O-G!YGI++ELGT5Z@
MG;;J_XY+[H(*?KQ,^E/:"/%K) _*Q5:BU6;SLHB_]?%OHBTFY1E  -_K&L#"
M@(]I3/M/;[;_<KWR+ZLNS(B@<1B&KZM8IT0"(69\%I</_J>WMWD9_[QN#U@.
M_K?EK'PMV55V1<S\GAP&)N.NJXDP35[$[GY[H7IX^&/EF-<'_S>1CVM=$ZTG
M3!^R2CS;/@$=="]Y^3M()# (K-DJ!9L U;"W#SCM;/('@SHRH%%R8AUV4RJ\
M1[^]3[[B%\'=+=G(JEYQ"SQ;".*#+QW$@BBLG^C ? 95CB 3N8,06MI>ME_(
M]"I9'BJ52OMC$6TI;)+E]G[BJ[+&_%@W\B1X-F/_4B.QQ18[0 >(\ML^Z61Q
M?%I=(!7GE;#_P3CALC; @8+R0#CDSPT9T]CS3 HX/-1_;AG0@8@LB@4=>,?S
M H[G7J4#R1YT +^-B /O '@$C64*OF46AB7(8=GC=8]!>0J#45<;ATXJV6T(
M!UVY\&M%6.KDL4 EL2_"78_.C:,"U:^?'\'Q#2X;1@K+%>6MSI">]'0I[@/!
M1HSPN('>8P3_OS6T&O"MU\(M.N"GY5:&T:_W<31Q/X(I[:GX<4:XUD+1C//^
MWH!*(@[6(8JPZ"3VD6+XV=T>BC9N+IT*:$LR,H8@""7%Z.\-$,GU/"_07_?@
M*;6D6:W^0R?^L5=&DX83NGE1M*L@FP)*X1CHKPF!_+<)^?O?88BZA)IPHZ.4
M&-URTSWS"C!V$<2'7F+YKR+^0\,>R$O4?3]1=.]8N'WZ%M(1WO%-]RS\.^MG
M,(D]@ [TJOR]075+=^+2X.Y)M2V)_5K%W[H-=" Z*\R2(1S[_R.<^S\V0>?#
M:[SR5M1]YJ_L>D+ZPOWH (\ZJ8 .7.8Y3 =FQ<;H@-3@O]$V]H7L/FDT[#OS
MY3E3%J8L3%F8LC!E8<K"E(4I"U,6IBQ,69BR,&5ARL*4A2D+4Q:F+$Q9F+(P
M96'*PI3E?WM94!_1+IA$QE#6#^(Q5@3!F+*=2;E))V<G'<D?N&3UK] C)P[H
M-V6/IS;A #_(JR;HSAB-(Z6GS2N4UNV H)ZI15U4^CQ8H)]QO+JQ)R[O1K9<
M%\C)PH!_JR?N/_SK^'_O62C_ZGO*$+,G]=THTO8/\&H3_-1E\93_Z#T1_U]V
MK8>OEB\A#DA.BY,%<O]M8U7LS!'\H>V2ARF 9GC5E19^*TMVF#(4NW;_G%].
M])$.R1PSF"UL&%V=6O]"5S$X;;*],E_3]9'1^1"7.NUR?'Y\925-[*LO]X4+
MRM#=M%8>Z@?T?#TIA3:%WLDX1]85>'_$1L&_Q*MOYAMAF*2@/'<DB/N.A\L%
M91/G0>F,3]"T&YB%M 'PQ6VBW7QM0]JTJ]( [VM_[Y*VV>>DH9&6Y6D%)$U.
M/MCMPWL&RWDBI1W2&[NK?8.9")==BL"I.=_A55,CV<(_I6F1?*7FD]9!QP<M
MO?*\+DCFYC.6-) 8E\)8=P<TSYG5>+T[O%1\:;#N*?,0\Q#ST'_'(>I%.A!Q
MGQ&;V,?0:_<9 >F'@SWE^R3D PA_?5J7#3I#5,;0@?RZ6MP">@,S<E)H9A;I
M,&C 3S#"_,?OW?AW[%\Z=>>4?[G/["9[_N!?&UCLG+7&%+059Q''H)>*3Z;;
MPY!^02>N<^@MBUXXPL(N?'(VCI2"A5#X;#LUZQ$JI3PBRR'\Z=$5^5MNS4/8
M# WY?M^J$UL-$]QJ?D,RVG>(=_&I?B;.O9#T?2IW2;!GJD=?/O\/75)N1D75
MN:I7?1VGGGV1'&V]347!/1$"82P$Y\@/P:'F@R@)=!7TK8-5Q&VA"Z\J^/*+
ME)[]$NE.$!XK*M8/H@/<!B(7.TV319'6%L[&6)]8V#E"]-JD#RY<$V/F(^#H
MH0PQ>'#OU41S:<,:UX)W.]>S[5U5[$RUS'K3'/@EA*^\66ZN1<O@8\0^AV[O
MI<PC@^B</%^;&;D(SN@U;C^GX^TCR!H+LB@-/&_MNYUZ]I:#T>.U/ED40*V@
M QY<=&#\3T>&Y%+@J."GA>)'?:]6#F^*?'Z9_E"R^-O"98T-:%JVQJV,PJ/C
M?!XWFD?4O4.I_+/(:K6N&1#%C^10'IQB7?.]IJD[P]1+\DOM&[VOL?U]1SJK
M-D_!+ M_>^*=U(@4PF8D3+HPFB9!>JP_M":O:/:AZ+Q7H6F,H:\3U_6V9QW^
M6M$WWHT]].4OM+%V\7;?RS3BL RC?-K:"%\UT'=[<BC/[>!46:^?E^;Y2E/A
MOD\?O]P)C3@:=IM !XA_1L..$Z2W.W(.#NV$VV#,P6Z-3<.GTZS.M(&5>W[W
M(<_A6[:NK,<MOH\NCBE>6RZ_QG@1ZV6U%%YM\ C,&0 2@(JS_MCE$76PLR-%
MK8 UH3J:,HGJ_(W6IZ:^S2KEA! F/JUT^\VGO%QZ?)#/QNBEMD-^L&C'GXR%
M%CCWVX+Q#WL5TMHL/UF&DX,!UV3?<^Q"C5IGBE$&,'B8#6/%(:"VZ4/VP:Q&
M]4,UNWT5>26%F7XR9%,A+=ZE28;JJ;]MD/6VW2]#"]+,^?4#A#0NF!5,O- =
MM^N U:Y;]2FI2GY=:S&WUW ^;;+QA6J3VZI(DJ$#!X]])!QZ[Y5/T1NZ,RC]
M-D*A\I[#6A/"7/G2F5?P&B[N)YP:J&J)'*TBEPQA 3O7F\NGC_7U&5YA"V"S
M/23)9<NY?LMNNV2P6,^QEO_M&3X+QZA3C'6>OJY*AH1=(_$3+#<[ZD*,HA7\
MWTHDKG2'-CE$I<[=?=Y0ML+!7:'.^JXBCD^&,9/8QB%]'NVK67<_Z0[D-LY$
MPY3K2)&S3ER=:6^.>:;Y_8H$M7U%*U/U76'\Y66>=1,"*:'%SM=.55<_VY!^
MM6-M<+YGZU!EEM,EG/P@AF_^Q[5&@S M/)0X3D(0GN,.(;!0'=Z.NOW[ZT/"
M4F3Y#C/^DM\_T[:)&S^5LES\3@:BWH,]>";DC*E(;3G^7WBX!S2]*\5\2']]
M^W#WXN-Q04F=7@D>BW%;=OMXW W3Z;0OJVD"99XE LT(YUST>57$9#].O*"H
M9: .[9'?UG/ZVY!9O?MP".LY+9H7Y"JM'U[//];I<V*"I-\C0*S;+\=NK068
M&BCU:+^A [:G3^A5KMD".1>T=H?[_%2PF+PMATR;_M6;T5K5IO7Z:YYR2,)F
MH@HR:IIG1-NT_.N=(7]2?%6J\(-%SCBMZA-\/)9RVZ@Y=@J?Z)QM3&TLI..B
M/<G*U$;WNM)$UV,EYVF7OC(..A!@#=?$?9Y=F9NT'GV)TM?6Y:XXHW:TJ7KG
M1QR%0N)E4'"0P*9[NOH'3)*::?&C(O^XV#TA&X[R6/4C*T\E)38CV8[D^,61
M+^(4$Q5U06$R!)DX__RZQN:ALHR%*6]];05#I0:Y T8Z,84Q[2.?>PUS9]R^
MQ[VQKUDI4;9O29R.HS#XC$ZF7&=4** 7= !_XJ\21?;?:).K)X/XQ\,7(<0'
MDE5DS \3N07DSS_$5P3X^D&_N0<$@?2"<7N/ET"4ES*'RY$-R*/*)R!U3AZA
M5<>Q=0NREQF^OE-0_!C>J;QVNNDAT#JL,-QL\]7PJOO3A&\L;,F^FG>R< FS
MI><8$V^RI7'W1:EF1;Q-*:QGS-_V=]I+<DC8O1^[*HV?QA[NO@QX6)L]G7G
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M">X\G^WQZ(KVBQ90KMKJ><P 7%4O#QID;1!K?AX^Z5(A\.N:##>6Y$X,:&,
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M:Z@!47]-LN3@+3,]F/KF_?_JG-C_N3/&GH#Y,+-)Y#YZ?05R[_3*)E.QKS
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MD6SFL9RN?0&)(_P(#@9P/UK.F.2/";.KL($(KW@7X<N:L^?[1BZ?;PYAW1?
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M,C:W_[AR_,E%7DOUW4]?-]<>LHX(JK71M2$N,!ZRV'17J#T/O:7[3$#@'<.
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MS7]P\6[C04JLQJ!;O4^I5X(8V+)-9IB$4HPD$<E2M>!8]H0&-B,T \ I;^5
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M>U@W] D-/@<-X9TZB,PJ@AD=GNLZ/:_G("! S<_BW-]W760/U_;>4R4@:<E
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M>]^(V;09>DK3+GGRJQXV8GGW]NQ;E."U=SFO4O8.8Y3IY5B/4@3N2(?U&<_
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M5=CXZ2F 4/>,G1#IU5G2^=?=ZIYC&6.?Q^*EC4T[5&,;@;F4O=:]$. ;I:4
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M*6>]0Y;K["6IC=AEEQZX$NT0L;,3$AD['0:;LE]6[#KQI:=(0X*HY'A%[WD
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M<US:BRK;I+G+M<7.X3CDUCZ^.C;64Y>='3VY%<[&;HX7;V8"B!9]9]K+])D
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M_8-__A&/+MD53(/>,#^>W4+=W2J"9-U"ZA2*LYGBU8_DL<\#[-@N-9U+T#/
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MHU2*%O$0:3E*[]SX?E[C:CCPY;Q0D5RX]:L]D,O0 :SIB;M1FVH1LQZ4)82
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M6 \-5K/ONQT-6F9N]!>,E<?,ZVY5""FGI6?&ZV6KQC[I-USEG.IQMULZ;*W
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M-@:OV/;;,K^=Q(D>/VP?-J@=4SVU/]WSX%>%S+P[LAMTBL\B<H*]*I/$5U.
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MF08"[S7*WJT-@MS_H$W?_YL!>9#-"C5JGQ"I(Y OM[-TYGAIOGZ&&UE_,3S
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M8]3^;P,@=;72.#MJ13G2MW8V]H=<VK2B],-=/"OGFG'Q1$DN\X?3W)\ %1J
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M'M)^!J6/P]]_ <GJL*4K][0S8GB8!E27AL+"15Z:S)0I11)WO_E?W%QER_7
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M721A&Q41Z_[9-F93*&BZVTK%'3%CU1F+W'XF%-;9/-:ZUH'/X<-%^LVY@^$
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MS/#.!*Q^2G#'WR?4ZU71Y#+7D,L'_AK;>JK64 7..S[8#"V,[!@K*!IT3G;
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M,O9SROYFJ<KJF?_;YGGW)VOS/9O!EN'Y5#:,< '-LJY?705A!6%B104M '>
MKK^J:N4$'^L$=EXZU6L[]DXTHNRT6$>_F$LQQ^19*>SU%Z%X<R%/&]@LX0'Z
M^(A.1<!QC 3HEUC3RB;BM:!&L^B#]KV';8>WX'Q>LU$W.O::ND=_$6ZXQ^LG
MO>;L1X_+5C'>USIP;)*&1.&3H_@K9=.VJYN4!4I&-<IJJ[Z7=\LX/J39OG:5
M4O:LU+P=>$<$26'_A3BR?*CR1<@Q^4\IU;""Q[&^K@DM:Y6M!?<KR6Z;J8W\
M4/C;M$)YO8@:T[[Z/!@K/&_.\)VA16UHEJ?\-4 [.</!@%LS#0Z<YZVD"9Z1
MW%]+R!9,2!\KO45>'OUVARLKCXI*K]%%^(M;U%#130NP=CZW1D(VWZ3;ES&Y
MNYOXW.-3+W%4W)!P,DMC#SZ.N*9_"5+I?I( 0_/9) "4G018YAFV1?"; !-4
MZMX&&MLXN#FX:[TM+AO"*;6*R=T)6Y=^[O24[D[)@JV51)=+!-=)(4%AB86G
M4Z/(GK9-23,P67W2/).E*9JF0L$W_%JP@4<0%CQ- O"51HF'(;B;%]*/3K<_
MBD%O0&3!'SD\&^LUW-8&N&9(@*@"(%RM!/+HSTGJ:;T=/]R+NR!X.L92HP@
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M^#N@>RMK4<5!K9KA6+]"H*_IF>[D#BY#ECG[UHGMLB -1WRUG6V#.>A0=LU
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M^2(Y^R5L[O^0]]XU51DIE!0'&QY,X ^@"=%-71LB'YWH'638M01538<2/>!
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MCN7_6J%/>)UVFACD66"NZ3!7C:F,L_7)W+WF^*0E[Y?Y/7%]* 9,5J,!TA%
M$D60!F Q1RK3U2SP8N%4?N@ FI="C:<!/F92V6B EIA#KGD: #D$Q;&M[SUG
MEP_Z&^V1:T(28VD )0B4<*A-O=D0&'YR^=/?*&.((!K@$G#%.89* ZC_F>45
M/OC(=(?Y;]5'3HN!!IA3I3#A: #T*I 8OG\HQ)CV^._4P+\'<,*]XV^UJF01
M&B",=T^FG0: 9OVYY1"U\OVN+_W?JH\\=C 4QT<-(=( VWLPLK(?Y?+I_NM_
MJ_T;?N#@C+?'I!V3=DS:,6G_94ES0\AC<R,EJ^^D@%!#%)XG-T^JRIEP^^J
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M!SNMU'(KY!XKZ\J$R+(8T0E^ CK UP(E,CG3 .U'.$+6L.R4D_*J-,#;,1J
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M@*]BX12Q 4(QKW$I[DS*A?0<L^8 ZWO3U[ /K)U;O/&;!M-CDK9>#.$21M$
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M\!RCN5HIA;*W+L.]]JK\\=*%LYJN]&%'8P+C1ZD3M2+PBQ&^^G6Y::R\A-Z
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ML3TQ]W*3(M.RV(?TYZQ0&H]+E3L/;I E[T[N838KI[QZ+S;I*\1XS$DYGMM
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MCGLBF'RY>W[<HG/XT5% VG.#^GI@7KM:$&>%;<:,C&*^5XK!:F+R,AW D2"
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M*C)X(\D'&[YO;O#/M9$G.&A,/VC;OK9#@SLCIRTLNH6:-^07DDPN=P5IJR:
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M45#9;AE">-:B @XMKV<E,<U15_?X,Y%CS"V<2FJAUH=-V/H9F28=P#P/U?]
M@FFAJ9Z"^?AMDX[UY-GA8HIIW%"@&O5K+6CZ2M+DI4CR$?S"SJB4"Y2P,N1[
M7&G9K*YG>)EG\2S$+^M[2&G%G??7TGAYV=?!3+X)6+Z)2-44SUW"]H8-MNWG
M%BC;GJ0U;1JISC59XEA9:G:83/0!E&F%MMXG%ZOZS%<OV_B>Z)<L,C+IW05O
M>Y&RNK):1GM/#CYT$6BJTK(UE!]9V[%EY&G(1>K)S%H@=AUGBZ4#V)]5$,Z
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M)GP*>N^06T\'_,JC%A,1$AV;JI^(\+*%6!EOW%A5+Q8<@;Q$ZZ4#7K\RHOW
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M?T);Q;0B]'#GKOJL_F+!0-T^HD[I+KG?%UQ%VU2=68[6X5R5_TM==V^ &?+
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M.,U4HZ%+YS5]#>0X>0,\JV(/3GV('1<6/!$[%;'*N46MI#0_,"OQ>R31E?F
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M_$L*<%_N#1BCZT4!VG7__220GX9L,)?>0S#+4=%OF!+R;Q?!!OO[*8SWV%5
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M,D_RH)N3"(K!=[]B97,]2)\]GYH'2<C8LRJ._"!>_N+[XH2-IR>==DJ'J(R
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M8J2/4- Z+;&+W!T^,57G&)$\6W21V(-_@_G+7PZGA_= W['>V6=T,6Q(M!>
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M][2>!CV=)'^,Z%"*:>>6MSDDWH-T]6@*>O#3^\/G,]<:+-7(T[N'AV2U-94
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M. >5$>Q, >(5!<@-M3ML)]:D=54 +PK #5Y,P,^2OZ4ACRYO[ J0ST[DF6U
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MP&02)4*1LZ9X3[JPP[I/W$VD;O]C2&M%287U)3%["=7C@7OO73\>R+.GR(6
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M$7#1/ZKF'EI1CA@(H%<EY]0/2D?21K&%A.AKD>RIKOCV;R<7CJ 0#\"1:HC
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M+"*\"_2CT>CE-,3$'M5>HR!=LLK0]BI->,W+?^Z))@GRTGUU'=0V.FO_<W1
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MH]8F>;+D&\;T>;C?70$=E^81 5X$-6G#(?!^R%JL*(AM<>!MKK( =@+.=6@
MI0@:DFLR>JA0>[K'<J@ZXQ[5W5JG$*MCG4L^4YDW.D'\K/[U*U04+F5=L)F4
M@G=O8J84LH 7?71IQD<M'I]Z2RA X6NP%$LTR^EJS+2P$O41OR/VZM)KL0^
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M&S\)'4X>5_F6G$4L(X27VNS1-QH1E],MB;4OEVEJTG<<LI.D%03*[)]D1X]
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M!JVH!-#DZ3>8_8ZG>C4NYY[$.Y,/(U.GN&5.^1[W?:4GJ7'(PBTEN@]7!CO
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MJY$0/SE@7%8:9US54WI+[&H.J<G2=X_'.=D@7OUQ>U(X_7AZA:#%\OBOF#Y
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MYP#I)9T%VOE+__)6<B[?Q_U&5;"2E1XT]$,^/KKT[MI")0*#B2+T]O?Q-SS
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M;GJD@WI?!IU)/)*A:/2ARMHCP7-,1+V\(X/7M4,E+X%*I-D=_M5W#5=%6JD
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MO:KU?2-BKX.C3<20$$KLEVA" 2>:<[+<-I)#;2LE([OHQ64?:[C_!O!);42
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MWBNKF6(B4? B]GGGYJI]: 2:B00I#H>S/#K&!G>3=EZ*:I_V1F3]5I"+UV_
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M%DAMU!_BIA#][%)@;EC;?%UR_A;0:Z,K:1.SXFRXW4GT(^03G=+/XQ=-Z]-
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MER2WU6WI=*M^Q14ZH2X7OLRJ2+C\SK<F%(#J^:H >EW?.F)MTS78#B)3?7V
M ?,\5VV-/U+S8^_TAI88##CWEG= )*!-%H+]->:?)7>*/YLY2&O2 "("KL\5
M6=UU5F0*>''G@/BW$X>?JX<R(\9%'B]/L%E&N,L]4/+;VO_MTVLR@QX15Y&4
M?W_?M&+3V8G':^4"'G/GAV$'09IKUOVY1]$*Q_K%:<%Q.15I3>>!P<7L1/#M
M2> I[R"V1,OBSL%=L6Q=-A'YJNC9J-C\'6>H]+5$JH%QS^"?[O4,Q#NYRA14
M:T8X!%.-F]1H@'LW=0I1#'<,A 55#^<91F'3PAL%L[O5"F/T%CX=U]%.>\&I
MK!0,L&$E"1[Z!QVB_%H7)%:J\#_J]ML!#G#J+[=<9%O>_LO2+$)B^5A(6K#0
MVR>1&=TUKH+>HVPVEN_O+)V!(\@J^*Y,/! WGY#-_D;>IWDM26S6Y*HK*VDZ
M1JE"J93$H.R=$&=4S*3> HL.J/+$[/D ]=[/][8)/ZH%VVNEE:2-H8A@R;+.
M62HW<5^;&#LEK^BL_?AH^K,?=B)'T]>OD#RWC_)L]^DH^XG-Z9AUK>RU]V3+
M1<4*;C37LJW;#.\8[K\*%OPB]I\9N1!4KCD^:*LZ7T.G0D,#9-19]/U*G3YP
M/MN7R-$R?K4?\108 MJY8%0ZDVMOZ32QT7Y6B]$7P5+>-[B@R#8U9PSMS#S1
ME9G*X9F/Z:+41.1]<VOWN?C%((S'M\A L[T=#))?1N=JWA*KN33E!SE&A#SX
ML1)$4@QE//OL<270)Z)25F#9]):.Q; ZB'=VZ5&L<56TE^,81HI51UGB9MH_
MYFV@0\(UA#63X@<VWP&NI-*(#]G!FQ2_1JK3I.'E?<,",U,&AN!F3,]O"7M/
MC\QBV,E7BM!V<4-*C;+S[M8S F.(1K99KMT #VUF">ZWC'7@V1(8:GJ1.#CL
M&_^F<7ZFX)X^_O/C1EO5'G3Q#=P#I^,_HN>#[#!MZWOIFZ'K+\7S<-M"K4./
M_*V+M\.QLW9SWHC&B6'>9O2A(89A3.G6+);$O\G>.@X&;0,EGI F3Y$"IM97
MSTV) I\%K$*&N$+L*.?W7LVO V-)P%A7?_%C, H.]5K*JW/#5/1G]G*5V :0
M[JO>@-JWUX\OI?#82I_E>('H>+H':>TEH+)GVKP#IBC]AAO5Y,P]Y*%5&=2K
MDL_HPC<6^?S+A'OSWB1D1HEA/0W C'@:P4YD> )TH [VQH,7XCM-@=YD5!_L
M>_3R"U WS'K?QFS,?IGY30GBZVB%_!KJ@_HL#5 1\,HE7'L&.I_[/,M2JRA;
M4TAYNS8>BYKSS^)H>A97QCF0-WH-_;U@(MT$G%RSXB^*$V6U5SK7.[QOW">R
MM:Q/ \1%5W J!<L5[G!*;B*;M$<8*8[(@#S,$+4'#>GGI>;3 +#!+OA5@DH^
M;O4.JC3Y[K1.E?.>O7STRX7TM C+9MM6ELXI7MT5/\$V%*KN>0''B=H"L<W2
MC6 : )R2HCJ7@'U;&6XCFCL;N:/C"_'!;.Q!Y^R]0YJYRD-*CZ,'/!C#5!8Q
MLQEK6@QIX<&*06Q)%[4E7H=I%"ZP/AF80TX9VS::2=53FI?W!O6S%L1&/ANE
MG0+K&8;C0MF/*W6<J!Q>S3#$DM&;%],;R8-2R $W(3D=7[2C+=4<O#J/N.9#
M39U"G,4Z'?]0)@1B,MDPY$8<TT-V52ROO["X-;BF,#*FIY5<?3Q1,W>+Q^*8
M/RA[X?3//>CG'O)-4R _7#MI6DQVA : ?MY#Q,JKKBTOK6$7J%SM> 4A[MD^
MZU6Y+HU$Y[F=K;#XR USY H*E^,2\EV 2@-HT  MRY]Z:8 GVAP:H18+T\NW
M,&0'=%,/6234!E30JR#' A2!%;<]CQH#UU"8%/0^M-H!*XCS&I0PV!-B2VH:
M<]XF@O!EZ3K":ITK]D+?UKGM"B0-$#KXLTQ.+90YKBQ_M>%0LUM'$%Z<WL!*
M$)=M'Y4#2#Y*'!#]6=PRL<7Z XR_BJ!*T#.!1G;O">JK%" -4/>.!B!^]_^4
M&^QA1\VWH2#'G:FU=N#OO^3*J1>*Z3GB%BN>!J >U::K_Y2^I*\3,)1C"F!Z
MPLE" Q 2]^\'0Y8&($.4:1K 8A,Y%T$]##.E 4X;3R-(I[P1-,!A 1I@^A;B
M;[K,5 ;^06Z*6CO_O]<?N#\/4[S?2/'K0B2"B2<)SF0QNS :8$%HB@8@G_A%
M2???*""Y$\N*R#5&V.T&D78_T@"W$'@6W 31"LM-3W[U&ND:G:-WP9G^-RI
M5X4%Z3%E$16[SKR]+DNEJS0IT(S!-Z=(TP"?LH-H@#^0JOHW.@P./]+Y(Z/
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MX%"%Z-XFD'P,\1[A;(O9XM"C 8[$[Z44T@!G; @0ZAL4.=L$0?@"GLI#@VB
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M^2N.A:M9Z'=\!EO"II?W#2CGLV7X9A(K]/+OY\;8MTF5%]?6^M$MD7$2)UR
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MH'NX40*>JTD_I$8G[3A;GH-:P0[8X1 J9Y J?G:7?)5C',35/&V"+-:>R;@
MV-@'WAC:TSOB.3!CE:,7_3F'?]UB0IR77W S/Q\1-U^MH^]>O;ZJ*=ZS^2UQ
M9/5LQKAFPVJ48CO3P*4/=D=]@TL?]H84<SG<7Q!,*ZRQQSU5X)BDN#5Q@- 3
M]PL32;^-E;NV<KI*!(2NYC@JF\=?J)1DJY9ZBOJ(>0(>X>G8R8MH<F%F0C2(
M?EYH89?*H@%6X>ZZ3H<:?72F3[\^%]#G]MT.WC]1SIZ\?Y/8V#C.XWP&T:#A
ME7/;J>#^$MAVG\]T!V3=[C_[=1XH.KI;4!Y(MQY@T9H="&B]\%4.YYT^;>7*
MM8F_RC)Y6QUGB0;;F&4D-=2$(D%,$#>#"1/,"LL69KJ=AHR\CC-<'IQ3;1+=
M8UFGZ_.'DWA?;]5;(0J"-FF MSMQT)?E^C1 .2]V:^25RW</*>:*4[B2,KY\
M3SD[9=3GQO;Y^9\+GY.>!R<YBA_:"/[*$;S=HV2KK2N2%9:5.:(R['EMQE23
M6U.C+*S$Z(9R27=)7_73$>57_PT/PO-TZ(GG,,+KGYZL'.!?!W]7XOD<<Y%^
M54=ZYU)KDO:"]S9WQ&B R&DS>GSE1>V_3V*>1I*C1-D0@]$(,8@2O 6\H0!%
M[C#1 ,,Y$)\XQ+<@CF6JZHR",@W [V2X0 /H2>S4T3.C'$<:X/$WQ-:3V(A)
M>K ,ER=^S[B3D]^ID6W2(N+(WS=O<_>MU,H[?=.7H78 EA3U[\_@/X$;^B)_
M*)X5&H5.)=YSOH1JF#C9>CX0LM+A5;?]M)&%& 4=RD]XU"'^3.2^D)OBC>UR
MMSG!&7>)-5"GH%5&O\Q2C^><KPE5PVWJLRT!6(^\=/,TR;,P^_Z1+VA=Y<E5
MF:G(-^ C%M/[!MY.ZTW#3('3?CZ7-<7EU;I3/9WEQ9,[7I9?J)_G\P<%4O*L
MSY$M*GESA^I:EU^!,WUW6[7WI/QYJ16+- #I\* ^3"/'\$9+1LQ\^I8G9MFI
M]3BS:#A/N$^,K/3]&+.TI&7N-G ]I#;B,!&,1Q@34WT\7#+-?HYD)5P7N5D3
MV5>&:W(<#D-6^$Z7ND-*L\FQ0XCE=N89:"WE'0W01VRD+&O/2C[_RU_2+GR)
MK7CSB!_?<&-"DATK9^Q_6OKH=9M;>\N:;HB1XH_ZU4_]1%L0>Y++"-)&+V9+
M,#?J5UL#WIA%* U0FEM*K+3=118?M3S^P-<C-'LAZRKT!25$$N3MX<QJI!!<
M+M%XM#M5H2CU^4^2,Z0+[1E1^W[Z_ 1R^^4.$>L5LI'0X6P5W]6/^.X_GP8?
MP&RHS=  J 7$CL,<PFIBCYVL3@- 7&B A>-E- !T59<1\L9SQ_EJ2$CN KEB
M_WUJR+FMZ<T\[,^6_NCZ*DH+TY!HDW7O;)@V];M97^TX9PZ\F&)-54T-<3#S
M"=)95)]80^ZEOZ:DH<4=QH4)^JVO;W%F:4J-0XHZ+N7(KU_K.D5H>PA_6(M%
ML<5GP;^-R_5=9\<9]FSM7;!;&304F6,N:+*A0+]OK_*81KPU"4_P<#GSNL=!
M]^XNQ^L,E^@KW!]?J%GLM=[?5J:$PVR7.#W,#\6^N</!<A:Q<<8_Q-TU3X3K
M%K0EMG]M&NZL.+B\ 1:+:G9AL@ENLGH>W;31UBR(C;QC/F0:IYT=5^ZT,G_+
M'-J"*;8+37^UPWFE_'U02E-;U?B:PF119&1U=Q OAI-AR3G$I+2L%B]JWI<W
MT5E2TZM 3$H5KCM'XMJ;15C3 !QMM]X7%$[-Q=UD;+F1=?W3UK<-[^]^4K53
M_O?J$<7LF6D.4?6*JW')UYWYBR545#_<G_S*L!8YC':3RGG5--!HD*DKGON=
M#00R]RJK]MU6F@Y<L*V@Y^0WKKY>G!KEF\S:JS3/Z[$76?>/&UM'1)*9H3@1
MNT?^S(V.X.'2WS;X@QF&YE28<)S5HIP*T\&+U*M4+%6(:)?>^F4)8EU5:'=B
M8^@^=E9LX8)XSGR6BK(GIC"_2)UPQ"CAC86BY*M]6Z--<NXX^.F(>P51 J=(
M ]1?=%)*>X2ROMF5:RGAX'W?Q2R_64/3?(O,WMHQ8R84^%W&M<SZ[<>/N.QO
MJ P?_9U-/QH@)9MA_XKWYL/!$G/3.WTW>!;=L3<TC/FL.@O+)O64@A]94U;<
M#U<Z<U';E40('"&ER083.MW69375<3C)1)^ 8[9\=N?.I?@_I03339DL+H*T
M$T0#W'789AXVQ7F1+\-/^C'*>CJ0OCZ].@Q_.DV5)H<S5.Z@6%CT6 *P#CH=
M/5J95?9?-#']2..X*;QL-D-WDYVN$ZM/\KI=NKUH.V@&9NGQ"0M\BU0IC1+1
M6EX%VH3E=8@_V"\+>_U"32#[,!J/!P:N*)V"B9[MZ@@1Y-F@>M  <5&K'9&K
M=3HKQ[RU5R+PK?MZ!L@6#H+M<'.HE'!CT(>(!&HP$T.U;[[??,NR,4KI/#$+
MY&$;OZ(U\NC)^YO:"V<,STT/@-@T1'1W]<RPW^DVE>Q_FLA\C11^"NTG#-^*
MJ?WH56* 1F\:;%G8M?)<(V@'4Q6]AZZ\NU:3:'^BN-?JF>IAN,"1([G ID%#
MCWT!(@V@6LP56)+HW]P)J3'UD\]FR;F(OR\\XR>IN7]U>=@I@G!^;9RD-EF!
M+KYITG:E!>);5N=OQ-SJ)#\X%*7VM:5KY7.PM(18'<"#;]# Y:.5N"^A?DKH
M<SU_U01I?\UG5+111DFHH>^[A%Q/LKUZMIV3J6,O/#?-0!V8%+W$%9Z#FZGH
MSX@S5R^(M+-OX;N>(32VWBH[AU&';N[B;(LM<<RAP_G4#\LBH<.O?%Q5=R'<
M=RQ7U 04-R&?].N;H^8S7T='B."V5C/<]WBP0>[]%RWL-!_M?"S62-K+FU^'
M[9X2+.">-@S%3!TC.N8YJ(TX)8*+1Q#TI. .618<"#O#)=ZD'W;!^5K4'K+(
MRH45'V/W]LOJA6L3:89V@0OWJ!S@U3N*>Y2=R#3I#T' &S^U>,DS\K4MT*5A
M/&J([DM^P@]5# H\,(>R..GZ[HE%Y>Z5;:Z=0'F@_)3R.:WBN.+KU05%XVB
M=P3RE:"<[9.V%P+W.Q\DJ\X@&VI9'9T?HDY0"L$SB3\1/Y7!6PPHK]__7P"+
MH*H\ C>%4X7IWI='@GR>'(%$<\%\" P-M>S+#WI$;@U-5GP<E1A7YI6Q^E+C
MZ'&A(;S?V)+@O'IRNOY*Q&K\IJ/ZM7#%]R9-\H5 #U5%'X&^Q$48(QXMR@,[
M.;C-J&'CZ/:@+_%IQB.>)X5OK478?2-?J?%@3!803Q#OP#^'*:VOUY\T9V7
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M#>]1TU?'CX#<SX0S>2NE8][<HZ>9:,[0Q;(X^(V2<NWXMD+IX\#&#GF$\/Y
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M,0(BT6)YX7#6)="8-25,P3YB[^0"^(]5/',04V$*OW8)T&3XM_J5"WF;UVD
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M)?J2M#Y[[.YU4)?7Y1^F;V;%X4UH*'NX/..(/4QN..S=G:0YIM)!5R%RX.<
M;%+^7*%1:V>:DWSBVM!@"/$.GJO-0B_B6H*KL&'EZ/68&I5DT[/217:*@EK-
M[8Z83G %:S2XG.(;F/6(],;DC=1Q2%3-Z6'MU:;=0W4@M15[;$PC?21][8>/
M%=EFR'$D<RAZ[[4RKV3TW.]KB@:Z5Y;V0K<:-\7:JG?1^:@/D:ORX],8<4U1
M^]5(3)L#-Z>[]NB&;X] X["[ZSZSIH!X>W&1F.N;-V$&:LW(]W\F7^30GD=$
M^9OXO>WGC)+(<'OO[^8!<PE.$8#]@>K:%GZ'VX:\J8JY*%Y746LV]?&IS+S$
M3-0E<(S/$K?1[<MW./.$\2)0MYXCQ_ENQ=>EKNG/MGT*D';W==U*3:L;+-8@
M7ION^NJ<NPZ3_W['UP4(Q'*UQMMZJO]J=?%-^P0G,Y'L5PE:JJ>\,UE)67/N
M0"NKB94[;7?>$N>E'W .MBSSO/0XR]W)SQ^O1=!N4>"[LWV^/-M"5WS3+;O-
MK>V=V.7;++&=E\$6!-;Q^5G)R!#.^6\8N16[X2\U80]S(ARTKOC91E/>OOQB
MO_OFLZ<-D?WLZY+7)1;5;A;Q)+MOZ"(4UK4!I"G]R_NQO,.[ECF/R3T'0@_$
MWX8L*NY+JK% Z!Q;,8NP^B]'D@5@E2GE317PZ,A]012S_A/LB#QD= 3O[\W\
M-+"SS$2K<QA>^._^W^7_#H;<WGK9+V]:63(R1K:CAQZD'D+SGO?>%SC1\(0Q
MW=F&AQ61\)W%M"7K#4LJ\!&Q(>I4",$,4R^"@ED #KW;(6=<ME(7:B#E>A@?
MNP6P\?%5:YJT/LTRJJ+RR^V:)( .2![<0<?ES4.<UFQX6!#)WZ]:'K?U7/'(
M=.SYI%;,#^S%D.V-@T-5.D 6YIFQ+63\V297D2P25^P'*Q^G%%/Z64G!Y <!
MM3^4KY%-B:C/W^F !ZAGO\F=B["<)1>$U0F;J'G@A,C2NIY9B%P.-6RQ><8W
MI$5/DMK&RQ[M!>>WZH]$71B?KNQR03]#E*YT_H05T2XC)4<I+,6.!W\H5#N-
MQEYZ>.(I/)\"W? 8]>*=+BQ1O#FREIE"!2Y/4M# \'D^[M8>ED?%>>HKN<"@
MZ12K04J#=-[[1OVB@(8G4+S#D[H1MW2:A>[";-#-E9S?GN;E;;N*#T<:^+JE
MH05EVRS#@(/P;N!NKY)[&[$TMK,U'EOZ,_N,,J&+ @WQYWA:)D4T4^_#N-Y
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M.6?<& H\16:/O.-:4*O;!^_%0@RSQ]>P+NN>S_TO)RAQ#>PS#KSYH/GL#')
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M6R"SBL,KD=C);<V[#_=_;*"$,U1A5TGOU])![41N_\,,F2H\Q3LZ&(?2I2;
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MSB+$YLXU:?Y#N$_5)A:JWZX-4"AZ=N]NQZS?P?IGT[HU/@8,C(_6"Q(HQVS
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MCZJ\@?@K@TM^SI@*[8K)HQ!-QCD;3;'$LZ"'->F)5KU5PZY%)=8E0YWA.G2
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M=1N67>[LKU,TT3'QO&(DYP\]..)$:ZB7:DPH?!;(YX1@:Y1Q+UXU8#^'$/N
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M-],5.L PB_H5)!W0^@-\X=JPSU7(AKR.+6^'9.5]X3[K9B4?X>Q8:E$<A@Z
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M[C )Q/_5WGG'-9FM^_YU$%!I-J031Q041%0$5$HL PB(#+T3$9$2>J^)HH"
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MB?B&50ML5#TO6:==_V!Y%_<H:9*K'MXE7+7,D<ZI/F7QVL53_5"!-=%@9\'
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M(FU@UR.XH( G%!6%+$UGEYCV)R\W'TSJ]28F'A<;1W?6K)NEJK>"=\159!C
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M "K.7)D"3YR5KZ>Y1G7HE"_>-+H/Q!X;O9ZZ=:4FZ(*RY/Y2'@G[<\4BHW\
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MU/GI"<,7BCVFN@O)YO:5TY/^OR*K\XW7)W)V7?7H4<B[H3P955DIO.L8P%<
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M,?31ZOO32+ZI6?S2D^L_=\)W[X7?-SNZL_^18:A3'C[G?X[V6N9T$><H?(#
MX,&RMP2V@5Y<0&.XA\#8U,@%1K0]]?[N/%_Q%N*?6:']H\S>QW;W\J;H; >R
MB#NHSA'59MJP3H$/<: -!P(/IC*8#"$C.KPEAR-)$G>?SXQ!2\:5EU8ZQ!B9
M5ZK,BA_ZV&]9C9O/YNG%O'T)A9$;"=3V&5C!53_M8#_@ I=J N;LP.T!<T:S
MN^G7*"BT349V3U"T<ON:,5^6R+/<P!]MK9E3+8P(T)6IR1*@52R3:(X]3\M
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MQM-4=-%);6@KZTG^:@%;,<$O6,TQ]8;+H1D;]=*+>\QCA+[JI+(?$WQ7$[A
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MNEB3YG M4U,LL;W5>NC98ZV5-BT(1.@E6Y13R-V!&29!\72%I5D&K@-C^<6
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MX!M:$U;1:WX>&TQS6.\-^UI<$QDU0@MVW*R0BBH^0XO(R>B^4Z*FC5YG^?$
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MKRKR\GSUHOGH[YJJA"="0;XVMT.&2$A.&9E*) ,\</J>3=];!"0P'W'*_V1
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M3ZQ=J@S6@N[OS+\Z@^Z^>KN><))32Z:6PMY3V#)-WL#K7)87N'@1Z,I](#C
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M;<>E6G$K:"Y\:&> V?#VNKH;<R6_:/&,UX_ J< 0!;SJ+0\U[H7\R/BF7G1
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ME_OBE I# J^=65=T0VKUWMK4T93[HXU92*D@!!"\P989/O)M+T-GB4!W2:=
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M%(SMECEL7Y\W[[-;[MU0;PW+[V16XLM4I/Z.>G0%?@+%W&YFO<<=(LN:@H@
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MN8%EU@+FN%TJ%,P7>;6MO%Y _T>/&">02__]/P[Z2*9F8T40 61P'R4#>W-
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M%S7T/EXK5!08_88'3B._IQ_C?2@&TP47X^3=K!S:@KB_J[*8,AVU4(CU]6Z
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M!Q=GY3P9LC7:]0RXD(K?4Q(0@2W]O4]A?\_1%$_;RY6Z>CCM-7O6_#B12>@
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M29H[!YZF,8R;K9U;7:]ID:+"PD+,4R.7JBV[^@]YW>G9L>VC1',\X13*1;P
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MJCAP;57P$II,74$QOF&AS<I\*UM8<@^9V*Q(CB$S%UJ,S9OAM;_\ODKWW-W
M\UN>3)CZLF9L<L%60>LNN!I%="2"AZB0,0*S<W@'X7:*(G0.C((E2B>)F1,
M%%/D$4 QY>B3)D,L'<IO'_@MU^=6_&YKY]8:CJZE"?.IW*VC:S$OJ15 *VG,
MD=73Y &HP0@^K#R)D<#[A5V]5.LM4<O)J&FHN668+97?Z7?FV];[>JA=#U/A
M$U3&.%DX7$LJ,MQ'*ZCF8'),#G.AE6[8#)O_?C8N79NOS=/D^<=]\U3\,C7?
MLA6N%A ^BS=9+,[]74&)R_*=AHU=CPL%%[\&\BE^_X5T#K<*KT=R*]QMKIF8
M]$+[."\L^Z&_%8M2!2V!QNZ"1X!_J2O#:Y&&48W>M8)RZV>SY_&1X-0)M:/E
M@7KA]KI=@=MEC$8_^1UJ.:?G]^/]JJN,ZL3YT N')C,<'73+)!]%ZA7&-Z2Q
MHO@*&*XT9/3#H*UGW)GIG/0TS9+]EYQB$=E0]T>VH>D^#^6$BJ;-]2!VU$GP
MD'BA)],"S<:8L\4Y4RQ,.MY\:]_T-7+K0IIKWG/7>Q+:V87K=5./T S33;*[
MPVX9TH$ YY%QKHO@]?QE0](8D7L9C&J59S[8AMF7UFXAIG;CM-/N]"/']PSF
M3/TJZM[7W33M[0_*PU+H?UJN/H>MW B?Z)4T=@CB,%2BAX]5OWU;T6=JZ5%W
M^PPCO<-0*@Z=_>O)O:8</='8(!I;V'-:E&,^%\FR%F\JE!8D$"SXO@,-MGYF
M70V(,VC :'))Y[[7E^1>O?Q;N^;*%\GXDDMB4PE[M:A@+C<&D@!EFF,,&:Y-
MF+716X:^:=?5@+E)I9='ODL4/+XW82J=T97^I^/O&PH52.8K.,)2;ASS;Y#0
MP6PFV5;G"$Y7<RPG[^7X5/;'W#GV@*K/%883SJ/7$YOV-S@RI7'"P/T-OC7D
MQ2P]]U</,?K!3I#?JXF)+6Y+/M'O;G]#^=$?JL#'W^_5O84.?11[<"TY%;8D
M-B%HG/$,JVFS(SJMM0;Q!.Y$E6A,X[6D%WH4+= \CJ(TO:O6PNDQKTS3Z7Z7
MI0SABJ<@&(&H*==MT-#P(K4JEZ]@R"V'BGU_L&AM)/5M<A^67^X+5O!V)\TG
M63NA+J^@:L3YLLY< RB.Y67/?0/9LTI=N2'0@V=C73$1G CFT3?U^JUV)H[Z
M12C#X(@U"E7%=J<CQ2_'7J"85:Z@$M(HVL).M?RH8# ?@>("T(?["#QVQQ;'
MP3'0:57?A]D#&J+/?S;C]!W0>H('@PHRCCO:"#5\:T&!S7J^F:#P#WW4?Q](
M'FN0?@:=C;ZB*>]>?QMR*DXYLF;"OZ#@QPG535&W#^TV2P9I7#5!*D'RJC]C
M82X1;&DN5;*JL[)D&%ET-?W]JK#%8;$[0/3[0CP)#%ODRP=S\Z Z9D\\O=*.
MUDK%S, ;!E]?U,)*\W<,J-$=S'?J[;\^JG^(?U_7^,%&D;NGSF0T1OPI89=R
M>K@/(%&PIJ6-5)$[%WR=0VL=KO]S&LTT-%9S^PE<J VX<*7A]@S'?8=:0UC[
MP9T/[OQ9TT#E?A"&* BMF!J#U/Y)#5AV %;GGZB\U?4,[PD=>[$KF3S6DR[A
M';"F,^?S!=\K4LT5PZF(D1"FOS&0R=L)1'#\&VM(-?[-P<9+#_B*%_*<L_YT
MGIL( ?2EC[QDB$CL/!3>/;M777<RF:^1RSD!'R".!"-K=+)"0(?< 'GCO[0;
MUQ$,HY.D.Y[*Q8[D,FOYBEDM)#DS8?/SO2NH0%RBEN[G;9?M$XZ R2W FB_N
M&PLX>?H>"5'A$Q=3=-U.=.KF:%_D-TP36JG@J:P1'"PIHC%F/R?@Y(U$OZ2%
MSP)HO*-48.&&?CWGOS?-TJ%;<[KK. OI6N;#O2=%?M'80LS7,H @973:)<3\
M"_M:PKV 3-7:JH"+ST#S9FR*[H'^^:<.&R^\O9/B];7 ZU2L]GFSA;Q?7XUA
M:6'8S<4;2RO%^T#^D[B;R^E.=6:8%*I"=?ZT>=3Y\B\T=?^OA[AD2L C&5%N
ML. >X$\:^<U\@M<4W(?E VW6@1^].Z)-8]3TSV2TQME^C))S&]&)=]!C*X[\
M+%0%Z4D^]S#2$('F[/ CT-]1_4"*@R[RC4VJYQWT"H\&_<L5#D1^+;9A(!T:
M7XXZB6WU"F;1VT@C^4WU*ZB;>+OGG<326?<[.QVLO[>FNWV[\MOB]C495",*
MM?KLOZL^W\DQ''^]/[R65S2S:YF2S5L5K30T/^2;-_1C8N+R;56%)-?3<M_/
MK%^K>\LN)L(.A3I[7K@/^ )*;E53OE$EM: 8772FIK^JRZ3;X[V]R_L'/DEC
M:S\WW/XPM_?DJ=5I6BBQO#IL 0">HJ=HF0JH0"!6B)/05'^BG->9,2B^VU@6
M[M<R[/O6 A&;U\YT%!MFU442QETV?SOXT<U]CV>L)!8\BD;/4L&3]'&LL#+-
M)[Y[[[P/%,D\=AT! 8XM]7>VYIN";*7'K-,9R9UFXZ_:5+5-VE4/V7@Z8Y]&
M9H&+B-V.A^4AM!V$!2=;KM2;)_,MGS45_\QS2K^^H;(JR2QSTZTKI^Q<;.Z6
M_\>6DOV/OL)74.LI:_'*4*U(-50*)C?#!C=S [-:+597SV1/W\Q^^^9)*FJI
M!]:4132!6@ME/,%[]!+/4A/'@)M6>TK=9Y:WE3+I:ST"*\:]QS]5VN[F;6E7
MO7?@]%*<6.:^-Y7<(4%:@P@O@K^U##K&0;/LLQH,0XIG>X.X[M06DI)C49#L
M%]JZS^2%2;&*D(*._9+W),/N*LXI("AKD;_G!/<A%-,SAW#MU5V"%Z8QI!D=
M*.[-*/1FDT#9[]..[_9[):;;KAO,.?%V$YL<*6OXAP>F!.4 HRC/%<&UXIV/
M&]3L2/PMCA@99)U5G_@^^%9YQ6W]@8K')P8^J%?'6-JA\)4\?_XY9#&K^=NA
M2IS!W"F>)MX4>LP Y@ZYSUM'L>0#ZGNXR0^,\U)\;<5SOB]9.BS5*O>HD&]0
M&2^)F@#C&;T&/5<*M&!2,: M.<U;'$I@>EWI; /6686!4S0UUS291):4JE7G
M];M*<1@?:<ZNSY^4CC>YW9$4Y#R)M4&(>[RC,";UAP1M)LU%/8,_!S(TL2UJ
M\R0"C.'4I+T:VPI<&#8Z=V/B]1;-_ ]RA_<KC^NO455(;:I ;EU ;MT0VA#Q
M"K_KO:"A0?Y9L(56:5CQS#W*ANL9.\[6QY]./?E[&RMSE\A@TO?S):IB\=+1
M-8C^JKU&;A[PA+RHGRF2\)@Y^GKQ"DJZ)IFC-2I>@'E"#&BUC?CM:+DE5DD7
M&XD_),@'_)W3XX99BXW&JZ-?.\)ET3G--;GC, 4?DH?B9(V9PY+3/'&^C.!.
M XYW/-J5^PB*FKP.2$03@F>]=C83=I=1<H_7MW<&'VJ5J_NZM4OC[*0HP1DU
MW$D4(3(R"!LACC"FQ.F)I08ZDBOQ,8)'D1($_>C<MIV&=F%/HBM.\T[GJI4M
M,1SWZB06V?Y*KCO9>.T7:<P9EA >1IH7U"%@HL)&17"3($&@::T">V(I4M!E
MJ):;-,"7?T1##'' A'?Q5X.]QG[?[SMN"_65J*KRB_4+F.4J-VO)@XNQ#1N?
M0<K-%D&C@1;;"E8G/;B0^4F[%M'BW4WGSR3:';OM,'D[0'0*#>DILVM+X:^8
M\J,W)TDWKSB5\ ^#&8B7LC'Z&:'M4+4@%_AIPSO7?<U7[SLT9RH<5=YS NOB
M.H5I=88&A_E*M0>A]^AEY::><<,/X&)J^:_Q $3]0M8+XK]QG6OWNVN(Y.9^
MRNY6</WY_=]Q &"2%X2(P1-O24$5,=@X!:CVOTG%64<X-'"F;LY'7C5]CA<5
MZSA?47-\=0X[N$%G]=ZV?1O"#SH1:,?V8GI(-#*T4XJ9VY250-&&GH7P8F;K
M;^3I%PYO]C=H^>DC=VOOV!EOC<C9! ]8 4%%NA1E9.F7<2DD6%*1W#K,7?_E
M?G++\[7[?ZJ'$L:[=Z8/S]7^JT7&'Z';_CG/=P= \T4GO3 T=P.^@FNKU/4G
M,_<6N1D(G&71;Y[+]K7MFL9<M7<)7MSDK_&_>)Q"<<I[HR"+ZDM6O8=3(722
M9*H1YH&?\5Y;1HHZ^HZUYR>PY8_[)M$ILMP_[?L8]PJ-OHPM\.5S&?@W]&L!
M".(\=HA UI"DEUXCTE90HSV,$K8#Z'%&4 !;0VO&6[VEAA\G:7KL>YMWYLG;
M0Q<R P:JMF4^]DW=I7XFIG<\E?W\$3JN&@WM,H;7%IEU#)AB1M5^[W\'_%I\
MC'?@2+]#'Q$AG(SH^?J&SCTOK#H/T[ 5RC1K\<GA)D"5?Z:: O[N'LK3*N'8
MNU#Z2N3&.T3<2DNNR"6ZF6\R2#Z 8Y++D >L$M11SY'7$\;61_LUF/,N\B]"
M9A',Y :_7*9X6O\1)]>>]0RL;HOV6UD5\7LF[_"CR9;0TB*LP>-=B8Z"'8;Y
MRB7<V.IQ^!4LYV5P9&A'9G[#@-=799NWN 4U'HQ8>AY75?" >A%Y_6ZL? OO
M#+)4!R*-LY3RGHRBU]F]X)OW7]YLJJM,FLHQRM_Q[G="HPW^XJYOZ4L967H"
M"G"!"!D![53%Z-D6>H4!^QU8V;2"0EN=>+*"\@^TV$5EO$MX%6BX,75?A%[4
MYWF;<_G=V9AS.VXJB-Q90_GR&I.*E;>2!;%,<HJ-,=YQF-G78,F,49LZ-6QF
MF/#+?<RCM:]SP[)..>U$*@H^2C B-E5B:Q9:>L83FC%EZ!NP$7\'!Y?9X,&T
M7) _;!IS7&#T1U-_M*&Z?D#+PVS[T[Z$=1YBB4]5SCYZA2$3I) WNX55QA\#
MAYV&"98PW=T^@>^ZA\0[T5*/;BD>*C7:U:73]GUB5U'0!?KZ3-O[)X+W..>'
M_A!L0A9/';^30VV_#J0@Q,65FI4G-D0P%3S]>[<!+,Z_ME,_CI'OV?;4S=CO
MM^XQRPJFG[14]CNS10&*N%G-G*^VQ&EI(H$N1'%"(U!MS$;8Z1IOOBWH]:..
MD:4"$6WK!O\(O']TK:#Z_KQM95]@S>PF$O:)'%:<VKJ:,( 7[F+H$X;I(VI
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M'5O[62_L20KX\B4*=0FUZ@VQA40-I2X[.PNK&,47&*^@4OY[>2-F#[T6*S!
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M"C],S?ET]9XQ,:PH>'5[N=H-<7SP$&PS. T(,%H6NZ,DUDONX.N4^0JU1X&
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M_B;]?::4G6SNG<>9\L0\C#(]F]6SGHX-KD0@_ZI@G6K")P)M!??JY.D/X8<
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M>(9W!AM;@;46-.#VX]NL^5+L%<HWCJN;H!8-\ISGS8BT<.,WSZD@#;_095S
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MO<8WYW;,,N3M["B=*?V"4^,3WD)L.O#LT?#PS:!4GTU_-IKP$^Z+NL[H+17
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M:)9'.-9NOD&,U=:$48B9#GU(12*2)(SR-+!9"OJ[F1OOUY*"1M0;4 L+E+1
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M;98"B8+,J3219;]SF^A[0<&CEO1&.U(VLCHF+[4$WLX.& '.D1E"2PSV(M^
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M/P%#DTOG &@\J(_FC0_@T(F;^A>-'S>@<Z360N=!J^ZO0S10].]IQ*@K@^N
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M*-W#L<P>5SYQY,DX4F$<>_QKNU[6HMZ_&S[]_.7W-CS+1<13P1(H(H(@$HF
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M/,GC7!2P8&F],HU@$4<(*D&3E.18)2R9/<M5N11?UG2UMCQ4',M^%R9X[<6
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MDDS (HYYFL2,(N30DMA^X*F]5UO3ZSR\G?%@9SWHS'?3:7.>$ O^'PCF@5\
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MTL2KLD-[=^-C@MK:1A'A6/2@<[W@"\"[TD4H.'NGC0;)6DF@K@&\-38D?;B
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M727S'*HLS[/(*C\)4U:7)AI5'DF8B9@EL8H0+8A/ EH(5 ?3.U[VBZT;VP=
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ME )CGH?BEP?*[1S<(W8]<ZLV&C16@]IL8.T&&\,MK %/DW=$JU4$S*.YX:3
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M,H!L#+5+S'[LWHHP3[*T0/J[S(HHAIBR%!8B32 7B4KRB*3"U/1P%VD/AO
M2NW#(.SV(0R%6\]?M,;,B3U=4BW%?-@B%S3-R@620)^0UJX&_1:X.'U(ZD[W
M=%S$KLC_@/)]:V:U-C*BI]L&5^:1/HRR^BF2Y01+J)7!]LZ&7>MS<OQH]<[M
MKHXU"_;D/^H<[G)*:(YHI"347TD$,18($J1T_)'&F!8Y(KE?]M[I;L86>6QU
M:^Q<4\V7?Y3@Q1RCF"W <E\:R+>,P6F<W7CD>O1ZYH\CP9_&QH"5#%HQ"%7*
MX'0GP]8R:'7TJ)A!^]4=5\2>GN?+5REMTE]UEJ,^5YRD2N*$8"@BLRX?<PZ9
M)!+F22'R)$6%X%Z\<+:G\5%#^_*")XZ.BT0AT.GYU3]YV&R[A]0<.>NANO=%
M=$(MLYSM9]C%DDON'BUY7+RA@]+#3D;PR_/SW(XQG9O8Y*/^6MXNU'+U5.O,
M5H)B^]HP)(IS)9(4IDE*Z\*^&<]@'!<10\*4TU1NJ74!K!EA9MUN!OR.1U5<
M;GP".TZ9JSYYQ"(A!K"=N 8>E+ZI[?)HS$Z,AH]L3_#Q$4MNCP)5M0Q&,DY[
M1@TS7N7N>&VB^</QLI%\((60,'"VJH9<V<5P2B)AL-A3%PG49+> ^&&EFWQ9
MO=I/Z=_I_$5.:2R04E$,45HD$*?Z(\8HR:'^QUBH7(@B0\U98K=8^+@3IW=L
M_V1PSQ^HQD90&B,G(,^R29:@6B-B8H\& V:S+N@:O)?<!AS__F\HB_Z2H DP
MS[1=:$H)FI B\KD1^07?)\;,+>KN. X#"2 U _"U&@!K7[B8^KSO@8+I$QT,
M&D6?=_ P?&ZYLD/<_&ZYT"'DVM1X_KQ<RU)/E0Q!U85'-^O*^G&7E+$4YICK
M^#C-$2P*A2!-8BQ2PK$23GDC'GV.;:9=FP>>S4GFY>(_/6(G1Y =8MCPT/6]
M@K\U&%B+06WRIJZPRU)^9T@]PL[PT X47EZ&.% DZ8=0:\3HV-1PD:&?;WL1
MH.>MG4B:&H',Y>+C<O7A>2;DTXS?K^2S#E'$0I;E[6*Q_%'E&5F9FV91-*%1
M3E0*%<41Q*;,L_[-E&J5*4(RQ3G-/$B[BPVC(_$/][=>+-,)>"<B[QO.WHF]
M=@!H#T#C MCU >PX40E]75YM#38&7LS?]U@,]"58_ <-1O770'*!^CLU/>2G
MX!K?#SX-5S450HWLB]2]VD7V>ZO3^'[Y1&?ZA> H+B0O8)JJ&.*(Q9 *1J%)
M/Q,TYG%"8K_"K9<['=O'X$C,:FNV/8*L#0??*M-]"RNZ#(';K#\TL#U_%H)@
M>J4 6#M(O:A\G>GR#:6\VD%HU^NZ<._ ZL@FN<BH<C36E?9XZ<-WNJ@WOS6Y
M*CE;2W%;VSOE*F4QH@F4$B40JUS"@D0)+!3A)#4UPPK1+()^EGW+)OL[T&&!
MM7&COU=[Y]"#764%+XO9N@2J,?X-1'D[/!INK#NVL?Z7$?*M_-_Y I2[I\$W
M,K\;%$P&6X7#"&1^NP_>6PL =[#\7T,:N/N0!!,-OL*$CKFOIOW/R\4FL[/2
M0/GPTU@MIU1*15D<0U305(?N)(=4Y1S*+"NP5!&*5>J5 ]O:W=B"]HI-:I&G
M7V1EI.?WY@+ ;I^(<+#US.H58KN6-FI+OWRX!)]_.JP3*J'28ML[&S8]ULGQ
MHS19M[NZ:EK,C:CNU^]2QX9FY S?F4*-.4*1,AJX19(A'1[K>7_!XPRRE"(2
MDP)AY"5>=*ZCL7%';2>PAH+&4J_BEQ>Q=2./$(CU3!O=P.J@2-&.1# -BC/=
M#*PZT>[LL<[$A>N[[?C;#:E_S-;?W[WHF=R37#4UV%YOA+#KE9HC,(HI8[G1
M-A,ZRB@*2%.10BXS)56",1+N]=#<^AP;76P,\]N7=D'7;:L_,&;];_5;@X&Q
M&#0F3S85)%\GH$=$_7;Z R,[W$[_]0A[[_E[8'5IS]^EJ4'W_#U\.]SS][FU
M TU7A6GNU/ME*<N'Y:_R_<PLO[$7/<^<8B5$)G$">88,.:,(DCC*893H&2!7
M*"XRZDS.;3V-C9(K6TV*M##6@O42, G$UF /8FE%V(&@0^'6,RW7D-TI8 V=
M@(<E^%6"]^$Q\Z#@4-@-1+Q78.A'MRZXM))L:P/#4:N+'WN$ZG1#QXTGNBD4
M<;^:<7DO5W:A;TIHIG*>4Q@5BD+,"(), PJSE)(DCM)$42\QFW,=C8U$C9WV
M+(K=Q3&[-B^E ,_Z ;>[-[Z;-^?@==QI"0!:W]LB=*?VRP18,\VF1;4/$G#?
MX@(4H389SG4S[([ !6>/EN\O7=]5%/SI:5D5!+;-E3<OZ^_+E2E5-:41DDF2
MQ3!17,^#BUA")HL<%E0D)$DPP43X:7R?[6ML%%&9VIRFJ39U =V8VWVKMPUO
M-\((A&+ODV$+8$T9E:%@:VE(\>N+< 33LC[?T\#2U!==/E::OGQ+QT7VEW)F
M4OET#VRVJ.H7R$>[>3B?UTMV54DT2M-(1)3!N" QQ#EFD F40HQBS3,$YQ(Y
MK:AY]SPV<FD,!SN6ZW>DLAULC>]6E<Y]0!R7ZON N>^U^U (^R_G^Z(5:GW?
MN=]A%_Q]X3C: ?!NH,-:T__SLI#F(*N)L<J;QY6T^1!U(GTF>):0C,$L+Q#$
MA!%8%"*"%#/%F"8TGDGGM::VGL9&4\96>[X76&O!QER/]9)69!W6F$+AU3/?
MG(6JRX&/5LP\UIA"83?0&I/_X^:WM.0"1^O24FL#PRTMN?BQM[3D=$/'I253
MJ<JT=J>JQ VCA[A\>E[)[W)1;JI<;8]1"QH5&"L8TR2!.(XR2(HDAFDN]/.!
M2)JE3ES:L?^Q,>S&?+.ZLF=WDZ'D>S:XZ\ XKE7U!W??2U@AD/9?T.J&5ZAU
M+L_>AUW^Z@;-T:I8QV;\Z*Y<K:>_T9^SIY>G)BADC HB"$SC5,]ELRB%#,4Y
M1%C_ R(*4^(TESUJ>6P451OGQC['.+7SRE7>]\P8M5T!]1'/>MOVONN;=MYU
M_=OV/3]N;Y W^*P;S;MY_H)N0<8-U_'GR]P<\K'IHB?>[T_+LOPL-0D\Z'@G
M3XHLDP+!.(X9Q-R4*#<:R6E4I"S.)"ZX5XTRS_[']@;OF ^6-A6:[WW_YMIV
MO^#"=T#<@HL>8>Z9*G81KI+-3T88OQCS_V1K$I@H1/L0+M+H"%Z@2,.W]T$C
MC8[0'$8:79OIL!QE#J.^H\]VFV]:%)R2N& P1TQ!+*(<$FHTGJD0:98G>::<
MV.RHY;'QE#TYS>DS>+;[RUVWY8\1=%AFZHI+S\1B(=%V55ON7?WW6#+JBL-
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M#L?V 6],AK2RV4AY6*/M;J1/C247M-O?]CXP[)D &FM!;2YH[ 7&X&Z5E5R
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MU?OV:Q4:=D_O/M"?O\J%5#,=#V\SDVW>Y38]5:1I&L6,PD05^E,0IPFD^A,
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M72(\C[#K4F$0W'HFAETK32K,\UQNT-LUV4KH/*^6==I%R+7#BS %6T,\W]/
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MY,;G2A3 7*0@P3'D(D_T74[%IPX/,S8:7AVC+ND?$:WEO+#V2H,F4A#2)&5
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M0%1V9)!!B>BTHKLT<N;JR]N$F@7Q>B:ZGE%W:K5>?IXOS#^N66E2)) @FN0
M)R(%B*09H G,04:RI,A17.#4<3_J*<GXMIO;?2N?MEK?'=QI^C<-=9DQ.P8:
M8!9ZIJAM^&O?F<F57G6^T[-@L3'LIWVH!Z(]] ]UD>+=&HAZ0'6J@ZC/XSSR
MU_XZ+V=+O=5[*I=+*>]F?Z.<MV5S].BW3T\OL_*_Z[_^]>9OMVUF#>*8Q(5*
M09X)6'OU ,T*X^E+&>-2%06VRA/WEF!LF[%:AVBEA#'1-]2H/^=-1:(?C"HN
MF6I>TW2:0 <!OV?J],/=)Q?-:P(<,M#ZGHB!\LX"?PANV6:78'@RQ\SKP<-E
MEEVB]U8^V44/\CTZ>M5OY7SQMDK1^"8KN7C5^S_.,JA2SH!$$&N[GNI5!O$"
MQ!+G.4-QAF/L7O;W^( NG]-P-7\_-&5F([J,_DIG+W3Q%B57D7E'78^8C@*=
M8$68RJDI<R4 XBH#6"_BI@&CBC72G"GI6N<W),S]%_G= /FCY/5['<'0,-L>
MZH4 KO?SO5;(:)U,UXD9\JSO'!3!COV.#C3P"> YA?</ \_><2$OKT,[UPV6
M8P5CGG,!TD(@@ I! (L1!((H@@F+50$+MS:-QP<;VU9_):LG+QS"TY$9+D1I
M,&Y8RQG]UDMS:1M$0E/$H:'>AR1.*'V4)D[=XQFH_<\7TR/6+>=@^Z81O;R-
M8+UD%1S6.50\[?;#AXV1/:C87MSKX:O\7KI?*'\L9W+QILT2\^#GC;(O<2QE
MP40"]*XU!0C'.2 \C4&*"589)%*EL<OB=&*LL:U-*U%K0UMVPKJM5*>PM?NZ
M R'6\Z>^#=9*SH#%U!SP"$0#IT8:E!,L5-XE")M;/!S</]'7LO%CR.OIM#1F
M7OLRIVG")(SUMK4H8H (Q("(G(&$Q3 3)AR>VM=>.SK,V#C""'I5=Q-KQ8TZ
M>1V\H<=!M? Y!X&J9W(P,NX!Y.,W/HZ4@W,X"&(#>8 /(A?(P7L6AY->W.-W
M#^>J/:O!EC_V_-7^J4!Z=Z!?AD_&+OA>5QE0J1!8V^Z )J9]798+0 JB@$IX
M ;,\0WF:NB8 [0XR-C)<RQC50FH[U8CID>BS!Z?=5NE2D'JF06=\O-)XC@$0
M,'EG;XC!4W:.*7DH4>?HM7Z?^T:MJZ[15RDK4QRFG#ULM)ZN)D@FDN8J!8PK
M 1 3IEJT4$!(0K7UA!4D69>X\]V>"JP%L'KUM_-ZO@\1:WGW:U.+SS'RR1YX
M.[8(B^,P%+)56&]#ZJNHE7NS^7G PP-GK *QC?VX@U*0,QR[O.3^ -\6@F4=
M6M[NDB$7FH6R#, $)0#)C ":IA0PPE BTP3'A55'K<./']M^I)/.M;'?%F1V
M7.(/1,^$T0G6@R/FL,[!&NMM/7S@SGF'%-MOC7?P*D\;XI$NY =:F>I13R83
ML0D361/!A[?U)5_I6]V![W>Z$(TC^'96+1>U/5K5V2;?'^GL[KE.3?N;K/2Z
M?CMK<D<F.<2IPAP#CA@#*,DY(%E"0);G2BEJMB:.R<1#B>ZQF^E[(Z/E6Y1U
ME9&JSLU_F97+*GJMQ8Y^*&=1912O+$,3!W\7+(VJ,<WO0(::T0?4"D6;2F]N
MKB+V%FU>UVH>U:I?1>W1UX;V;8NSI=8_:@&XBAH(3+V:!H2 IN# TQ;*O!Q*
M[&%-UH$G8\\,'GK\8&$RCD?A)YXP(GXY'-31PRFY!1S]172\S_FYA<H6\1P7
MGJP+64X^S9;ZT]$&WJW03U_5"OCRTG02BS-!""V *O0?B$@!"(HQP J;:+ D
M)S&QL<3.CC0VHZP1MO9?;(L;-?+:[97. WR:+X+"UC-;>"-F31?6:!P@BTKR
M/S_,7_]#/Z/A"?W#FA[./WD0<K!6L*,&^QL&MO>:T>]4_:_5]<OR<;XP)00F
MDO&B@*D F2HTH>"$ AJ+'#"42:1@@N/,ZOR]-PG'1D0F,T-_0XWEMFCB?$7=
M':VLJI?ZA'IX$^[H]/9LJX68M/$;98V6=2V]6L]HK>@(#*]S<_#>%M91^?XU
M3*ES\ :SF<X.Y-LU@C[-%TOS))/ ?MN25%?D#BK3G)8H$).< I0A!C 4 K D
MD7&.6,)([G'8>'K4D9XP;@@="9/LOV)T/J]<CQW/X&Y'S %@'*JCQ!JZNDY"
M)VKXXH-VF 1K+'%RL(%[2]@HOM]>PNHNWSHPY7S1^'"^[12W6Y<^^R@KOBAK
MO\\$$\44*0@@7#* $-?V*Q<2()BK(H=(ID*X;#==!1C;;G)7:.>J+H[XV]%.
MGZCV3$2[\E[5FSZZ: [+WS8J\D6_?9U/2ZXMY#ZRHGPA#%:XQ7'X@2NV^(&S
M7ZK%\SE^;'<M7J5F4A-KT2WC3.^0%,UC0'(< Y3+#% &.4CTBYI+1AD33O&:
M^T.,C;$V)/39%AW T(Z3+D.F9];9!"7XAN>XYH'(XL  @]+!<05W/_@35UX6
ME;GJ [$15C7)"$LRG&0 FS^00K$VBV(,N))9 DDF&!$KVVB^I%.[;_S4F#Z6
MT6KD_M[O>HSMMLC3M=!^\9@'(;?C@HL1?.^HRY\6\ZJ',,M3> 2.K#PXU+L$
M4YY2^EC\Y,E[//+;?KW_:!J^U_N-.V5&T=3T<?ZQZ^G7E6R3L:0<<Y )00"*
MH0(,B@0H)"@3!,J,6\51.HPYMNW#KW^^_W.DI73(WK($]S1U] 19WVZ5^V@M
M<5.#LI8Y^N%/6NQ5^\X_>553L\35(44N/+X#Y<M9XQPHA\X-J),)=9:/&BZ[
MSDVWK50[QUO]MGPW\^FT:?[U@2X>FA[-&^[YNNZVS#,)XZP +#9],W(E $54
MFW44R9S$6"CHY*:R&'-L1+T6.5K+O'5HYE/GW 9\NSU@8$A[)O*UM, /3><]
MH0,^@;:&-B,.ND-T@&!WH^ARJV=SYHW6\5TWH?8X\&[6;4O?)I G+,M1 7A1
M,(!XKFU02"0H\@)2FHJD@-*I3;/5L&,CH[MGN=!; .-RHM5CI*;SWZOHI6I"
MH%6C4C0U.CD:HY:S8$=)X;'MF95:@>LD0'D5K1J&=?$/\]G*;#U>:<V]L[,3
M3*%Z/-L-.FRW9R<@]OH^N]WM&7#&'Z5X,;T*;5JFUGG2ZXIZV-2,50@##DV%
M0D0X8%E!0<ZADHCC/,;$K=O#)>*X?'?#M'SHM#$&QZHU\<=2:[:0>F8=J>RB
MJ;(CN*'@[YGV-G&W[1'=%EWHY[ P!*ZAPKPN$678B*X H.T%;X5XIH?_\%XN
ME].F24_#X!.4J3PGG #)6 H0,RG72D&0)C&60J%<YE8%] X_?FS[N[6 T7,C
MH8,?:Q\\"U?@19#TS4]K-+X&0,/!@7<1*@/YZAS0<7/*'57^I/]M_Z[A7&U'
M)=[RJAV_RM.!IDTP\Y])\GNE4Y/>MTYI-O]P/1/;O]BXLHG6T*2Z,/O6C[+Y
MO_[[]$74I[K\T1C9AFP;"I[H7:*0.8H!C*D)L4@S0#A2(!$R2S$2"*;%9&E_
M_#JL^$Y,.\!)KNEJ6[;B&^/9V--7C54MUVI>U>4X%^M$=7.!HZ=OV+?$TFDX
MVKGOV_]83[/Y,_JT.<T;M0B:2\R\[_QR^XX&A:B#(?JA ^)'XT!HL8@Z,)JM
M= -'0-_FNTQC*#?IL,(/ZW%]EXG9<]Z^CQ2>086<+UZDV A$:,]="4J@S' .
M8I$I@(HD!3379D"6Y4510($PS9Q""X\,-#9;H)5S,V#&,<3P&*)V:T0(G'IF
M\P,0]5"HZ1P0H:(/CPTS; SB&67W(A'/7>_C!?!-'6N+:ORD+UQ^-,3TAUSP
MLI)?-</)7\I9^?3RI'F-&VLPSBDO$,\ CU,$$(TIH DCH,"0\RSA"!=6$<N#
M23PV?FJEBQZ,[-&S$?@J>FYD-1Y%OID@K&BYB/3*\N)2V'N0]\#&1S*RV>W;
M[6)TB<YD"G]H,X6C YG"77VFJ%8\^EAO?5O5HUKWJ'MY6NW']E*XN(I&]G(,
MY'WZ_BBCITT& ,),L^RFN>8#0P/:R-;2F(.%A@GF[;M1WZ3?'%I%=),V3#.
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MJBV@"D8]QT<:F&K.JKQ/+>=O\:.2[_2/)G&HKF 6"PZA0 G(<EEO?B@@%'/
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ME N=G!]R;(RRE[6_%OKJDFAC"_#MV"8LI#T33@ TG6G''J! S&,QX*#D8P_
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MYN./GY8_"2;D[>_._R30&Y=5AJ*S F6"!1]X E.TR49BL-'^_Q__Q"P&EZP
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MQ5>N[H02M/':^<)/3(<?3,IA=8(#3H)V(_2>D?2$.,J5JY7[)!Q*(G#U"D"
M"E:"M]R!$X5S--JY$RM(;RQW&"(&G/H\7G@#L1_7%8XOZ2N+D<',F==T9,92
M_R [&&/B) BI@PI2&'>:\W'/PH<A8< 9SA8"'10FUM70:R:DS$58;H HSZ!X
M*C57*R!JR8L2TB##AJC86OHP7 PXT=E&J,-P48F->9B\FF;\^A_X;>1#"#(Z
M66,K1@R$2.Y2$B#0.FF"D;ZT2&C=6O8P1 P^Q7F*,)NAX5]_OB/$U_2%(YL%
MK3(RKZ9E-C]??=1-<@_K&73G,UJT#MI/V(D=A"H/H]LK7(&$"<:+D!9X(6]
MN>3!(R?S[] ;)3+]D;XGD[TKG.3ZK5-HJ^<_*J! H5A]X5UCG\@I=#8.2K'%
M<><0RVFW%EN+]=,^J)VB;GB 1\JP;Z]_3?;K3>.QD591)2,**&W(==5HP4>N
M(4KM6'%,*'V:+;^U8#_]@SJ%P%&R' 8,7H[GYZ_RJ!C+H[(*A*[%R,F3;Q(U
MG6B!<ZTP>?JS!0C6R_73-JA3"!PAQX&>Y<_.WKP_>_WJ^9,/+YZ__T!__OKB
MS8?W9R_/WKYX]^3#*_KN,:?[ 9_:I%7@ XD_T0.X6,#'$#Z/:E;H'%=E=JO6
M8I>@,F0'/ \6(B.OCCQ[!M[7=PW9%Y31)"_V;:L2%G&E^\TZZ[V%D^7B\BO7
MF^P[I!QK*BX_]NH#/X0XP9$U0:\.."GJ8U"G+3@A-"C)0C&TD1CN*_<_AK&;
M%/3C2+34]Z41:2#A'H^2Q7PY>CN?Y8NT/)N_Q_F7<<(G7\>+$05(4A4NH'";
M0%$, SZG %A*D#HD7>*^Q,$50FB!+730OZZ1<=_:_6+C%#W.&@IU&*!8/)GF
M#0>+Y[/S,)Z.'(6Y#DL"KPM)I+AZTM+!*]"GH*7*3AYD.PY#QET"^H%'&YW>
M!<B) NX1)9<;9L/(K[@J1M2%JTB;AJ@UM38=-02>/3B5@RJTF;S7C4^6&P3T
MCHY3%3IK)=T!0..7VE]K0WH2CK.D'$11WXC*[, Q3^+()B>5&"//NS$PMI;O
M)VKM#A;'2K9'4*SBMW>S;V&R'&,5Q]GR$\XO@2TH],X80*KZ[D<4!)<<H=M9
MKKEA(O/OQBC[%N@G9&VO_V9"'(!UN/*T*$3$5_17.DRCT9FI#!2M&U!8;]^]
M-6"=$4P*[7#O)>9)<<D5%?W8BH;^9R,!#P B[_ +3B\(Z%=IGJQ+'28!/@@Z
M &WMCN08AZ0=5T$A#VY?MO,8@-RF82#AR9$ZG344\(  ,E(\B$+N-I 9I="]
MND?.>0_!,QFMX+B_.O048/0+B-,T> \<'B3.HV'P!>=QU@@(SV:+U1G[XNMG
MG"ZVQ,'1%!&X N+'K?MT.D\G8XFR>,>EB>J@1,8#@'$?+0,Y6-I8CB8"'PQT
MSLH&^J,DG1>U#SA?=>OD)9!?;124G$MFIAAT^[IJ'XN7*P+ZM29MM+H#*L<)
M>! GS *)@$\DE.?$P63VN>ZAC7Q&TCC!3"Z .9++74>01.U2K87-$FU27+=&
MRUZ"^C4QG:"GG0(&@*9?<(KS,"%>GN3S\735@KQ655^RHQSQD9 !<EU A9@A
MA."!%^E5E$'9L&_NQU%9DOTD]1,Y=XJHEDH8 *9NRVAD.$HC'46*M2)?B:#)
MPF;ZIT_):R.3;WZ[=YN&?L;(='Z*'2WFXV$R6X9)$YB<?<8*\^G']>WGZ]EB
M,6(,K2K9@:]]AE4@442!J5;E)A>8,4&U#J=WD-&OB6GL%Y\JY@$@Y<UL.KO)
MQ0;S5_O(,^YCI,B0HD-7!Z<XB"D4R#YAXDD&N[<B_AC<?)>H?DU.8Q2U5<$
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M@NPD=0P47*\6BPOB)'!C@F$1@JB-HG21X%C=-4XYEHQ,*#OHP78/-7VGKWH
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M!-XH"]9PSUDDKT2VKBA].)6#,6NG(6A'+-JEN@:1:K\5;PLOG;((S$H&RMH
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MWQ:X:L\PDM%YCMG3:9-K2I$\%V)3@#&!#%^P5H3#[.*Q%/1[4=^?C7P4C0W
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M23='E-RWTT8Q>R889M &U=H=]2(8*-DPH90AE[3Y'* 3Z#T,FC]:CO_1-#@
MM-:1'7A9R+21)[&:D-B*D\O@/!D6E2\%G"ZFUBT9B.C)G\TE*&?KMUK?-AU$
MV&'X^]&N!]KK9 ! 6]W3UIF"*V=VO/C[,Z)AO*Q_&T45=+3:@C/!@HJQ@&<>
M 8VTTE@C4FI]7["'G,- ]:-=%;22?\-W\PT&*MSV%:+A7'B7(3-5)XM@O?A
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M SA)-TR\)'6\((LQGX;)LXO%<G9.*SS]]@O./L[#YT_C]*1*Z!:KRK/$BE+
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M%X:0M34*.%D&M+L,@T '-*"CZUSQ+/2PNN*FI5FC!10[N>?V5T$/N+EL#$F
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M^UB#N^\6G^>GN&52.*.\5 E\B F4II,X2D3PS@J1+2-?>:=!A3M3,.WLS/&
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MDBH6("8; 5'9Q#A7\NZDOX//I?9<O*@GI5W@=_>\FQ@ ?;PRW(ZH>RE\EC9
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MJR^X2-_O<<&"\]QZ T%8!0H#AYB9@*R,3SP:)7/SA@T/4C)M<D*7^&N@L@Z
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MON/AXX<^]<;10]]='SNW%NS_:73_NVM_R?8 ARV*.=,V!Q&! .M ,:/!&<G
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MS!=?UA]6M57$AW(9;_@T7R2\$8=X$\[HV[/S<#+++M68 PF1:PNJ2$\F1Q'
M<BF%VR"+/4(.11->^K]_VZ"X"RQT<'(^]+9TS==O>%+S,39M2V?1&D^.LR)6
M0JEEF!Z"LQ9$*9D7I_-X==#/4_>2LD4;X[:%OCIMI/]<)X\'PL,/[.(1.YOL
M1L QFIL<())I4B"433*RY"&F7)/\-8+G9$MP&:-.SB;G6O<TFB8%XL9'KR]5
M\AO^B8MSG/%BO"U90;9"@A)%0PB10_(Q%<E#2:,U>7F"K.X\HE8X&O"0>)"*
M.KK8'V+I5SQ[MZ 3!3?-T+B/RA<5(3&/)#CR]3QR!5H'84-1-LK639H'$]>=
M4S4% O=75Y\XO.3KTKK^B*M/7TDA;^8GYV2]S&R*S-%V EXVX\!% K)E)&AR
M-PUC06@S5F73<"J[<Y2.B,R6"GQ9$/TIK.=IAB4@KTY=T+G6KCI=)S=HX#&'
MG.J^;#X-=5<:N_.'.H#G[LKKU"UZCV&-Z]:)VP,^M84#LROQC;R2[;)7':VE
M8M80"IQ5OC8/+4#&G*L=\'11PC.F6>,M?)N"0P^M]X1YQ,UGOL%U6LV_73].
M.<,,BH1@2IT%H6AG!>T\Z&B$#Y;[P%N[5$^0,ZT7<8#>[QXUK40^<;; ZUH0
MC"L2W]GW7\/I1:H,'<">.:9 T&$+BB$#KQV"\-9)S%E:.\@!?29IX*&UI\9'
M(Z4N&TIXZLPQ_+:=Y?KJRPJQQC'OLK3-OHS*96,4 RZ< :6E!<=(5I81EYSV
M$LI!W3">RRL;2M!T"4B'ZWPYM@*F3G!^_<L'L@)?__+FBJGU-N5&%++W.&>@
MD)&<@O;@T'/@BF5?I#*8A^4T/[K$A)EIX^ARV5RP4\/CE67L?Y_7E[4/55ZK
M_-LRY"N.M@Q%NKY3K*-'3.6*U[P;1W9\CER2&Q%-U'$04H:L-F%6V_B@:2[N
MJ?'S-J1:MOM]<Y??921[9:(, :*/'%0*"9RB+:%=]EH;7L3=.1R/X.:I5::)
M"1T)+\W$.[5Q<YT>GG.0=;YX2CS51$\Z'+-DM4UL9IK307EWJ/)+KI(8P]#=
M3Y8] &"+6Z>ECY(.-%YBK(.M$+P1=#\6[FT6D:DR**?AA=5%[**L1^HB=I'<
MU.GQM_+Z T'=!6;!:+\ICXYTI=%Y*%UVWD;O0FA1"M-A7<1.*GNT+F(7^4VM
M^%MY_=))K5/2($(MX_ I0.#* .-69E4LAF&]%EY>7<3>BM];?A,K_A/)>&.>
M?$JX"*OY\N+8PU*RT(17#+7WG5'@/9>0G$=OF'=6#0J+/@. !Q>?]KEPC+O_
M<!E/#9(MW;\OUM\PS<L<\]9&]E(*&X0 DVI-,3,&HA ,0DY<^"Q5&-84XCF@
M/$; =-=% Z4N6TNX$YC4L8(IK"\]'F4RINPR%%'?N#$8<#%("+)6H15I8FSA
M/#R\^H0 ::/2!T!R@'P[R"%X^(1]?Y7SRWD=$>(<W;EU6*'4=<2@HBN8:33.
M.9TY#H'+P4]R5R1-FR'0^D8:0P]3![1^FW_Y>O:A_+Z^Z%'W(9[1/L/\;O'S
MW^EK->]HR[R=+T*M15CD#]]P1>I;?-DP?]G$[OL,C96E> LY*]I(NG8_E9+.
M\FQ$L*X.NKSC[SP2^6I"3H^/?7NB8SFIJJ8&YV4X\-?S>EQ_*)_^?4XJ>(MX
M-B.G0*DZ+3S(1/O7*0M1>1*JM58'I9U+SR:C/+-&CZ&T!C!J)-1N[L/;0/^,
MJ],/Y?5R<9&*$9"@CM:1F2 15"F*; 46@?DB,O-TSI?65<#/4]6CGW88L$;2
M2!<5G;>YV3;\GA7/4F&<@TM,$1NU,#4F!I%9AD5ZG4)K6^M!0GJTL-I@Z7"Y
M=W!$W6;BS@T^R\+2_T(&CRR#(H\#8L$,,1MKG6!H2NL.?D\2-.T4@..!Z1 ]
M= >J:].N:'):,@;(KG!0L890)-8\Y^1821KCW0R7QG#:S0(?K2_^\8"TG^P[
M@-#'\'V3PD,NPV<DE^'LW>FWU?+/B[R>64SD'4LZ5;67]9#5%GR*$=!D$ZU0
M1?#6B<M/$C1M/_DQX=1.#UV7$5R7#G\Z__;M9,->./DIG%1G]=-7K,5G5QGZ
MVP+SL^7%OSVXVJ#%XNV*$IJ+8IS:!>N%L?4\L]'1E>@W4R<]0O($R8PN!M=Z
M!%W;VH6G;WQ97!(NTR:U,H+B=..'R JPA.3H$J,QCGM5[F-Y':M^81?=[V9H
M[2+V#IV_.^Q</61]*!=QMWDX^;B\J _[N>[*]3R>D(VP/IL9%[E!KD$);B\F
M,WL=ZZ#FF% 6Q2QO76[:B/1ID=D03KL =23-=F#X;0/$#XK3!U9XR@(XUM"P
MB@F<3W7&@\U,Q%A2;!W3>(*<J<.OS8[$5B+O&ST[;)DH%?>8&?C(29B*)?!D
MYX(@-QRSSSJJUE-8FA ^[5'8#$;#X3F23J=^5GHX!I0U#UYXX+J*4 8/T04.
MW@060K:"Y?2<O_'HIT\=\3_X+&LCMV8SRYK'SK9#;6>><1F9SN"T0KK-M8(@
M+0?K=8[2.Y=4.$X(;4O1U/']D1R#@P3?P47X-#<[F8^6R1(R:"-J!W@E:/LP
M!<9&GEA(:.6X3P#[T]Z39W 8GG:"ZDC*[0#4-RV!>P(UF46AG06MZP5OHP ?
M-+E>FGLGR>/BOG7WN*?HF?JI:A3OX""A=V%5W>, A?0Q\@"Z1$_[D/9!#$;0
MMUEX;:/)R0XWJ_9"P8CO3 WMJH,DUZ]A=3WM>9:DS%)I))^@UF\&.IPC"04T
M*B:#\1Q-ZUR<9XF:^F5I;/-J3_%W<!D]R] NSFDP7.M:C^R*(L$*!DX5!BG*
M4*3$5$3KQXR&Y'=I9^T+K%UA.Y*6.P#X@Q?_#;%J98SVVD,F:9)8)=FRPC#0
MW*;H.+KL6C_"/T/2(""Z%W!8MA1]7V;7#2:R4C;4$?*RA@.521Q"\@F*Y=SK
M(JU(80_+:T<X^([AT$Y^$]I?&R;^B34JA_G5GW2<?L'?L%9+W4S O6Z#&5AR
M.1LP10A0+&OPOFB03@LO9? Z#:O4&+SDL.N+]8Z3<43<P3UT^PI^EDU.&T-'
M7WR 6 J=CKDD<DIS >[1U++]HNVX(:OG:9S&9!H3)T_:38V5U@$H;][0 [AC
M,3K44=)>5I;.:K00>-!U#(G6V1K)W:!QE'O:2HT V?PQ^XB '%%A4UM8=]AY
M,U^GVO;JMSJ/Z5)TFDG%C5%D)R8/RAFZ5NA" 5]R"!YE8':O:_6AQ88=;CTG
MBXTBU@Y.K2=/Y9L,?L15JC9FB2EI9C,D5U.'<ZK\%0/99":ME0Z;EZ?M2F,_
M5^GA"-GE$CU471W \8DS^2'N8G;:^ERG3T<ZDX750,ZN *^-$L*SPOR8 8=&
M4#S*)=H<BB.JZH44!CQ8[M<R^?_I!<9(\-^!I7&2^-$4Y"DB:$^VG.(J0+!*
M@2%81E9?PF-K3VW,)/XZ<G#&&<=L5(3,)1FI"0MX8@643,$8SG5VK9,'[U/1
M5;K^+EI^^@K<6< =7'*?OBY79]6IN.; U%ZPL7"PK(YZ29%#"$D"(ZY,U#R&
MTCI5X3X57:4O'P*1 P7< 43^"*MY;?ISS4!4"H,F*6BKR&D1@=S/9#((YT-0
MPM16%XT1<H^(KG)"#P'(8>+M !]7A%^)(_/(G8X"K""9J. L.,\$:)6LS+8(
M(UJ/(;Y'1%>9GX?@XS#Q=H"/)S+D7YW2X3C_ST8MLR"9DR5E",4I4#I(\%YI
MR-:S[+E+W@SJ^MNFKN$F:1W8*_L#8'B]PM[:Z QD[VI3?5R?738]B>1+9N,3
M,%T+S8SBX+!(*"J9P@(70;0.$SU!3@>6S2A@.D3J'0#H^OI%C\DK;NGZM36.
M3[((5B!D)EE*W&J91JG='FS5'"LOM\FMM9,XFR4"'*\+P^NP_OKV9/G7C;8#
MRS)JZX4!*X[=;V%7IL>)S\A"EG"N(TRRKW8R6O Y%$A%&U2:16%;5QNUB<]<
M3(3:RO JAO!JD;<Y>O1U.IO_.3^;X_JB?<HUSY8GJV,"80WMR4B^HS.;MO%6
M>?(KE;QK6C\VAFN?Y3LPA/93_^U97*-+OH/[['9HZK)1SDQ)5T?_6,!,?]2B
M4W#2&)"Y5M/82'?UN-DGEY1,^#!V!/T_&2?<2QD=0.HA:V_+RX?%=2^O4*7D
M4$+,M2VX1T?[LI!IF9FRY$.(Y,?L@_ X91,^@!T?<B,HJS,(?ES-27S?PLGU
M?O+69"T$2.[)U(R9UP098H9^C-9Q5TKKN.23!$T3H^P <(>II@.<#6D6_E@O
M0T;^D=3>@&.ZGNHLUFZK]35;L9PEAH*Q,0H/(+>#<,1A)MVQ5?9"T/E@D<;,
M9&M0<J0=[>4V*]\Q"48KG2TSTNC6L8V]B>WJA6=L9!ZNKJX357X)9^>KS8VS
MC1-<\CAO$"89\N'M(B([LS).\,-9*:TR%K*+JL[R(=_!% <N^,15G</2O 5C
MV^24AYK=7R'_TFYX<XZ_DOP^_X4G?^(OR\79U_7,,191(P<O72#.?0(OA(%(
M9W61)7#-VJ?E[$=K5_&271 S9#)!<V5U<+,.Y?/_Q;#Z_-=R1B=_2<P**)F8
M4DDH8L\DL$')9'2QS+6V]78DL2O[[A@0W$<U+PUY!"6<62^%4X;56NU$)@E9
M"!Z#!!9,8CS3AFN><+PSD5W9<$=#W\[J>6'X>[L\7\UBD=HX%<#Q5"=4$Y.!
M)P4<;?:\6-1FJFOXDL:N<H".A;Z=E?/2P#?_$V?<,26-92!]'3DB$X)GH@ 3
MF%!F&77SAM"[TMC54_[1P+>K<EX0^%X56O.*22N]"5&00RX8[3"9#7C'(^@<
M%0J,3#5/*MJ+T*YZ?!T#AONKZ05A<1:T,J'D )G7K)HB:]<@;R 7P4B*66><
MROCKJBG8,1"WDS(ZZ#7W)%^_+_*V8@[SSW\G^JNO3NMW,Z-28*)F!TI1^U1)
M45M41V 6N0L8@\J#)JZW0MQCA';59FDT^#51T^Y8]!=87."7.EAGS$YU,YX+
M8U:2";N9+BYB@6CKVV&MDE%H@PBM\7;($]FQ.C4=@J@6HFXX5V:BAX;9G?J[
MQD\-,W[<QX:[[%P]-_RO?06Y7'RI!6MO,)Y=IW_^NCS#-5UZM53ID!>;P1_>
M1(C[L=+HQ::N6LO/3Y;K\]5UDD6JV=.ZD'M44[^4BA(B,ZG.>DB<9Z4T;UV"
M^S EAY[<]5/?+>BSSJLE]+F*<^:XM3DE4:>B$W,617U35Z"U5]PSR;-O?6H_
M0,:T[RX-]'[WY#Y4U!VX-K=9>/7W?#W#()2O;=V]I2M'2300N"H@)3,V)LYX
MR*."I5(Q/58.4NR30-E9RMWAY-=PBF^6M0/63!C:*:;6G_@Z*BR*#"$4"T%S
M)B*JI)O7!SY&2T^8V5W'3T)F3X%/W65L\^;R<3E?G'W"/XF-[S7Z\WJY(*OS
MK+8XWMSYY*N3BN4O>!IQ-<M80D##P"?MB#U9P#MRW7/QJ3!+_$KUG#FSY]H]
MX6=?A2^/)_VIP56YV7#W/[A:/LR6W;*5T$4>&=WJK,X<-LE K.%'EZR,.L<B
M8QP$JN%K3OO"WQY,(TF[@ZNMNB-G6W?D,_V;S='-8LK)&0G%N[H1> T>TFXH
MQ:7(><RA>;G$0W3TA*+#S:"#)=TA6K;[RL8L>3 .8B'9*.5K775V$+Q/O!B2
MC6N>^/<@)1,GMQVLX6<@LX>X.P#-[XLU)O(Z<V5C>TJJRKTH",SYVH_?TDD<
M.8.4E1.L:)U4:\/Y 3+Z@LL^VEVV%74':+E][+Z?+_#=&9ZN9QP9!H81-&X2
MF!@#9PUY%R70]HIU5'3K,H%'2)DV@6Q<[WP_>4]M#-^UR+:!U.W<K:MH5TC&
M1^84H+@XBA,$*1B@CBJAR-&H,L@0'K9>3Q[5GGI=CBODJ7%S6T9O0\*+%\O+
M@6W1&ZFME2 WX^ E[; 8K %>DJ,CU:.V9A!@GEEHRL+S$;2Z'$G$'=Q.OR_"
M14>JBROVW7I]7FND+AL,2<6$TH%#V)1DN<3!JXS $Q9FK7'8/ 7F:8JFK"\?
M#UDC:./0O(//S2#VM-QFRIODC7= 5ATQI:.N@[DM:&,<RRX9KEI#[&F*IJPH
M'Q]B#;4Q]4BI1UBY'I!U)3!O2RA>)6"^UGAFYR%&;0!-L2JK9!0?-FAL\)(]
MA7K&LY4.%'4']]]CU_FLF!)THGL\NYJO4VHS!:]KGK\+3G#,7K?.?G^,EOZL
MJ4/U_J3+MJ<2N@/3S<M\FT?X<86G\_/35XM;UWMMX;?^%4F&*LO$N(0@"FW/
M.OS*>Z'!L, +$KN8QWU]W9GD_LRQ4:$YKDJ[--DNT[MNRGCF9<H,Z1Z1J1JB
M2=0$6+)&N<TN!J6\MR/:; ^1U)_1UAB(+572:PO0!S,)[_2\;9X7^<CGCY<:
M.82A<;,CC8W:<HM0N#-TK1)J7 D>F-'>)R?1-Y_;/$YVY#U11OHRG9SGVH#K
M9J=M:RUZ@0Z22!H4LP&B=>3;)"9-,+1S<FMK;BAMTT=5#T3(W9-J%*4T3(G?
M'VXWJ;\:]K[XLKGLJP&P-0G6,_+#(QVYDH26(WG1Y*I'43B@9<6'S'QL/NQS
M*&W3.Z:-X3:*4CIP)A[81C./0I;H%61#VT8QVBS."P-9"LNRC$A"'/\8F_Z]
M</P3:R=1OP![ZE7.\_IQX>1&/_%&MM23G]W:CAK.R+@V%'*7I.!D8!LRZ!5+
M$>KT1'+QM O6A8*Y=5>BXU68D#-1DI4)>$X*%(8,+G+:5IEG;;5"*\=@[B54
MF.RB]R$5)KN(NH-;Z<&4,"]ET6@SB%#/2LYK"T47@"=AG10:>6@^)&#?],JC
M5IGLI-PAZ96[2+I#M&PSPK*)=)]*#X($06*IK;%+H;LZH-<JAR!B\S+WEY)>
MN9.&AZ57[B+N#D#S4,Y?%";:XA$"EDVB>^UNF I([^C U87QYHVP7DIZY4[:
M'9!>N8NH.T#+ X5:/FT>JCE(5NB*KLG)(?D".106F1$8V+C/*'WF^A]R&1TH
MY>YP<J.&QG$5?15+T;6'8!VD%K5 <,@9QCI>3;4>I/EB2AYWTO'0DL==!#YU
M0N4.=5+9618<N0->ZUR+[5CM7A[KN6DUIL2*OW/J'*<J[?@ECCLI>,^JM%VD
M/6GL>#ACX5_XSZ^T[-OS10[;&7";UO5;EIT0]>G8 ->9SF\9$"(R!"6X*SHP
MJ>Z^VAP"L&>HF3 G92R4[(S$E@J;^J#;H[J8\Q2E=A*D-&1X)F\@!!,@$VW.
M1V5C')94-U)M]_'+<?<^^$:6?A>/9Q^^5?V\6V3\&_/G9<V4(>C^_._S^=GW
MBS\W)@?WP289R?\5J>8X%P6.HX+@@V,Y>N-]^^%Y0RB;_M6CI4$_@C8Z,/*?
MXNJ&RZQXR$X&<FQ+%"0XH2#6IQXII"(/5^B,K;,!AE$VK4$W!B9V@-V>"NH
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M(&I>I,F8<O/Y4.>;B;:7^O?/1-M'%V-'(.\OX\4T_5KHR>3+;B^,>1)<.9]
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M68RT0YO2?'KG 'R,&QP= :N'+H;'U'$'.+]5]G^U\JMD4_0>T&L!JIAJ[ZZ
M<U+S;,EK=*U3]QX@8^0CO]&Q<3=-]$A%=8"U9V7ZF$A_7*?J9$+AJ$$+[T Q
MBF=B, 981L-M<2RUK\H[FNIN.ER.Z R<6/?GC/9WE]6XM^I:OKI<?9XOIO^%
M><("67>P 6I. 2B;:HUY-J"D<P:9MKHT'[71FHG.5_7&*&QE!$T@\1)LXD>R
MQ#U12+1H3([ G:B;:TZPR;>B+;:F7CD96]]0#LC.R$?-9VXGC6#23_9P@T7C
M6YA>U&W\S7SQ=_JWJXGWTIGH/-C,*'3BM+'[+ VX*#T+69)+>O)H]$!>1CYN
M.7-K:0&07C:7^+P<XETY_/SGU^DFQW*3N3M)R;,<.(.<Z[!K'2FDJFU]M$1A
M6.UFD9I/H6I%_,C!1@>F<'((C)U*<;#0MVT@U];^.JSPJA_DNDIB>PU$\JC9
M A.4-HH2/,A<[X&B08@E,H@<"RLF>,%V2\(X!;7C=I@=R0CZQ$(O&\,A,EG_
M^"<N5]=%'7SB<Y1&2P$81:[^(P-OB'=76Z0J+5G*K<OA6](_;I_;'K:',8#0
M@1%<GQ_CXAM9]".BN%A_$?WV:_F :?YI5F.F#<?K'.MMJ4E]]=67^26M!<:A
MP<00''>T%F1+&Z42 3*S')4M7H;6OM) K(S;57=DT^@!'N=B)>_FF\KZS;*P
M_#A?U8[$/]ZOHG@W7_U?7/T0TJ1.&="\&)"*DW*4$Q!"$%!T8-HJ5@_KQK"3
M0YC9R5+<O[*E# Z1EVPKFP7ES7RQ?:E^CD]DS$Q[1TO'.D.9,0T^R PITC*B
M' O<-9^:>5(.=[(J_Y=5G1I,'9C:L5'=53"W?+L]WUB+[NULM9C.EM.T+E6?
M%&XKXYYV:5D3_JRBJ(X4J;W7*AM&"U WD<T>?.UVX\A>J%UUAYP78$V_7JZ6
MJS#+% S>$422I@B7,D1A ^W@V8'GN4#6SO&2G##]W$$^Q\QN=O/75?V0&.G%
M6 XY4K\OB'_#Z:?/=??^AHOP":_[6/PTGZW+M"_#Q4=<?!&3*%,V,B1"NZN.
M<)(0Z"5:7H0LCB./00UA1J=E<S<#>]%W_!WCZ@68WG;OKG>ZM]<@/E'9.IYH
MU3&Y9HYJ@>!S]&"\%IJ<8.2EFQO.9[G9S9!>]/7_^"AY6?:RXY+")Y:TYE$D
M2!)K6R_28?044D83,]>)\WNUZ3T9TJYL[F9A?V45C(.KL\T_V-XGDR!^+:]F
ML\L:6&['^#FGC,CD(!O.+2A+<66L\SZ0O&:3;#+"W3DN;YUN\#AQNUG#7^D%
M ZAZ;*AO2V37YCJ-EYNKL*NSR^6K);%,C[MXC?ER/>!B64\:,?D4@$LCH190
M0#"1 [TFN$JTN^XX[G;O1^\&TY=VUW\"-8T-PINV](^P^ ]<K9-TWLP7MX;W
M3E2R,4:>@"Q,D?N&&7Q)D7@*B7'RW=+=#M:/39W:[8&[ >ZEW: /II*S:M%Y
M564V+P^___.?]5=LWK1SS^<.U\;S& 'TT=A3.H^29P;9U2$FDB/MPX*"OQ)5
M<$4;;EJ',KTT]FR3_;*ID@R1%Q:+ *>*K[.G%+A2$A1-&@ZFSJ!VK2/"(1@Y
MZX:?^V#Y\8:?8\&B@[,4\L[G7_"ZY_0O6Q8W_:0P%!4"!Y(EL5(<;6=8.!0;
MA'1!Q1AV:JFT!\*?(*>7UJ"C@64^C.;Z!>&VFP)ST25O$O!H"CEK3H#W)0,B
MR<XP)H(HIX%A#VU1FJE]-S@=H(,. %5-[->RGA:Y;:$1LRJT4RC0W C:*)0#
M>DE 2E(E(;P)O+73<X^(+H%SB(+OC2L[1MH=P.4#:8((^/QJEE_C-[R8?ZT2
MVGKR6Y:D9DEQ1 C.UL:IDB(Z&00)R/#(LT^QM+ZKWH&L<<O'AX-4:XUT +*_
MXPP7X8(X>I6_3&?;>1_?\#93*045V'IRFR7+\:G.]G 1='9&R(B1V]:C W8B
M;-S*Z^& UEXK'4"MC8OZX[B,Y20%<PB>' M01M99EEQ EE:A#]ZXNS6AG=3^
M_+)7:Z83='3N)7@8$R$=&,B6,\P/,[XU_DGQ2?F,$K2LXT2,B1!3*L"(/R^K
MV%GK3.G=*!MYX.V8X+G;?+2])AMV@SGMB?PF#2'05O:5GIBFFX.TFHBP?)5H
M4YNNO@]X+K_'TT]Q.G^H,/HXH^?19PJ6.(C 4W4X.'FY*8,03+&2DM*F]=%;
M+V?TSU[O/=.],+$BC8@22A0(2D@%WD8.V="N& SAV?\U?&N(L_A],#O<\*U]
MU-^!)W)K1%"I\U\"!;/2NG4C)@L>'8.LG'=>\I#*7\.W&D/@J>%;^^BC(RQM
MPV*KC=4N>++"FH-@58:8LZKY\#J4%+-*K;W7GOJ''Z[)IX=O[2/6L3.(]A@,
MA=$)&:.'.O.!/&3-P-5UO#C+-'=).E>><Q'/>?C67FH]</C6/C+N"CK?\%&>
MDI#)Q!@A6$?!6UUG0]0.%+(U5\KKW9+/=GS@N"<Y@X"FD70[V($:I.9E)2CJ
M+Q+8NM>]#AQ\*F0HF%U&78KCS=-JCJ:ZE^/%,3VG$^O^G-%^O[3QP_SBXLU\
M4=^<I")$423U:"B84IH;4D)0Y*LP&[-,Q8:.B\MO<'+V/>#WPN-PA>6'@N-E
MF<BFB_$D^$S>NO3@/-.@2K:D#I? YE*XTIZG[KJ7W&/B3 VC(3*',Y8#8'*P
MG7Q=WV;\M@J+51?6LF[J>MW!Y>^+^7(YX3QJRUB=,UTRD%]J('!K083"A!.)
MPN+FQZ'MV3C3,0G]6LRQ4.EA;UD'3<OE)>;7EXOKCJUKMI?K-^_T-LJ3C,4K
M21*GM8#\V^0$1 P(T1N;T9#T8^MKE?VI/-,A!P-B?5A%[P]EOX'R##_5>Y$N
MEGZ2<\'IZG+QHX/7)!OE98P.F*SMNFJS2<>$ 5>TR,)AR*IUXO0 ;)SIH(-^
ME_YCH?(B[.6^QYBLP8B&@6?&@+*,5@O!%'AI1%)H,JK6HX3'"2SZ:UC0KZT<
M!Y,C XN?9WW8RHV^)ELA2"XE,S* S-:12G0")VK_$L&3*(F'W#P9OCD39QI2
M]'$Z=1PD7HA=/-Z:[M90E;J6E>U:QER1Y)*6.L::@7(1(4BK*<024F/6G/=\
MMKLCEV<:P/1A60.#JH>X_302FBBCBG524M 7:]$&;=).B@*9'(K"&4DM=.S0
M/<7:BSD_'@3AXQCD7G [GQ/G1R^,'SQ'?%) 3$M7BK! /GLD)7()+N>UAR!4
MB5+DYE5$)V3O3-W)3FUR)-B=P^[XG&CN=?)_4CK98M$VDA:=)ND4R\'Y0"(R
M.9,U*:?QY YI4P[/U!D]4[L<#GPOP30?.'E]VJ7((=HH(^3:XD@)+2%DZP%M
M4"ZS9&SS*J!3\_AB3O?/PCR'!. Y&&@C5Q]=XB)F"]HF#BJ;0$Y_<F 9\[;X
M@L6W'E'64V1Y#A<(79CC"'![(4>KC[=2O^/<!RMS8 :D% E4*@EB-@4*O<JS
M=SFFWLY3=V3M3#?&/@Y1AX#/F;;I?;5<7G[92.5W^M!T]O-R-?VR_M"\O G3
MQ7H&R+:;[8#M 0ZBXQ2- HX74!\M SQ33G#FP-0&&DHJPK)W&CS7Q@I4M(>P
MQDOA2VD98)"A#RR"B\F \J9V4#0),!=G9;(\V>8YY7^U#-@3L\.U#-A'_1U$
M.1O*Z</KRF9T0JL0B>Y<NRXH;\$YEL ;%:7AVH70.LGO%@$OI6G 7B"XVX3H
M8(UT *?#!?>#[5F^4QA;G,N\UL068^.F89X+&<$&3]$*:NM=/R=7C_,Q+KB/
M@%6S@Z-&.NX Y]==RWXDC&^+K#WC:,CY!Z-<!B5\'4R4&7@=E,F1"Q];+Z&/
M$M/YU?[@.'FL3^%12NL-?5L6G#3K]J04;L8 *HI"%DW1)W/!A%*L$\$.B;L>
M&BKTC;@#%#4BUI:+U>1#E=NF&;R(VO+LR;<6MG;%=1 P*\C6EN@Q818[-5*@
M;[V!+/KK!ZIN/?"E]$ XQ!$\7/(]P&6+<IZ$C!(Y<#*1VH93@4OUQL=;I9)(
MR'8;:K\+8,;<[(Y0UEUU'R"YD17^C^FL3LR[VD2CKU72 J*H-PM2"W L,$C1
M!Y6CSWFWAG//J/S60T=6^B$JF[>0W]B*WXQ*W!*>G<E8QR!*"BE !16!I&$
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MMJCF'0&VSQXWG#H]?NZE@AZB@RYBIK6E;TQ\:^^3@D5*03M,6,=]WM).H+!
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MP<"\P52\;'VU]10]X[:<&GIM:J:)#E#UJ*Q^N4ZM<*HXY;D%C!9!"2?!<8;
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MC#3-L]$&9&?<R*TCI ^B_W-SLN>S&J/0[YN XE$W< @?>M]G#^HB'R6($WC
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MOGFKO<=HZ60A.D+/ST+G *%W )ZKZ[B?-LT:MFUVM?$",]D3!:&A&E6"&+V
M8C/%"UHXT?R6^4%">H/-(3J^6P!\M, [0,VM,XR;:1%;=I3B,@JB/RNO0 61
MP>G,(,J 2.LUQ22M:SZ>(:F3(Z662&JIA XPM3VZN&T7-D7/G>>@4ZQC;&N!
MBF>:6")S*1F=RZV=H(?HZ.3,J"5ZCA9W!Y AD?Q$3YVN;OJ%ZZV=ER!BL@FT
M0 \JJSI87GC:WP77W#DM66O7YU%B1LY9']!_;B/_7H'T+GRYFF<0&./),0M)
M<U'SY@4$QY"64IVU53H;TWH9>H:D<3VC1HK?!4X':J$#4%T5F&_7UIHIP4**
M8"3CH'B@[3AI SEEAQ1R6"-:-Y&^34&'D#E4N?-FDNX )S6W A?3^<: G#>E
MSE@":YRD/9W7AHM$/.W%I5BM8_L<JUL$C%S/,NQN=:"<>P+)UES(6I3'Q(GS
MVA,XAP)>60<A$L23T%R7UA4I=T@8?3DY5)F/P>( R8Y=QOG;9?QW3*N/\Y__
M_#K=I/=='2@$&5+(1+NVNO:,5K6>/X)"G\A84BYZMPXRCSZB$_T?HK5Y<Q&.
M#81W]\EWR6G/%9F#UPD4XQ9BR8)^).:CM)&)9^\P'_GN<2.:9JH_4FA][ KW
MG:I?KAL5>FF*H^="89ZXX8*#$[* +CD*Z55- SE%V/++7@UJAZM>/'4H?)@F
M.L#5<XD?/FNEG >6:S*1$G4,2_0@%<J8N<,2.DR_.6UH<Z#N]\S V4,1'<#J
M<0.<%$&KMZXS'46-V:21X(+)P%-D5J'SR$Z7.S'Z_C84G!HIH ,H/7P"]:6>
M9D],\BES<M?0N+"96>"XKQ/7R;,Q.J@B6Y^T/$'.N 'U@&!JI8(.T/3/<'&Y
M4<G%Q?R/VD;E]9:0>NNR7.+JI\]A]@G?SK;\H=1""5IILZVN0CU=<D&1STG4
M!7(7ZBBRQA#;E\9Q?:T!<3>HLCH XUUNEIN1H<Q%';S24%-V03F*=>@_!X8^
M[K.+M-<WS\EXD))QQT\/"*P&@N\ /K_/%ICFGV;3_UISLG45EQ\_A]6_S2\O
M\MLO7T-:_5P*IM7T6W4J/X05DN"$C[DP" YCG:6L(-*^#[XP9EA.)>K6F^9A
ME.X$/W.&\#N!XCH=%O!@+>J6O]=38I@TDXYJV+GG$P8KL-V1J5.4T7H=8O09
M8HCK35%#D(39[#2FQ)%A:FWO Z;F7UO%]3.JF#^0/<W2]&(S;N/5575G39RZ
MI._[?NO#$PIWE*JI4E'38J]0"W#6%.+#6_IZ&8)J?:K1@.Q.4B2/1-B]?O\G
MUF<'^_8N+-]*^;NQP$RTS599$G.NP_E4SA%BB@:*R$9&PXDE-@)V'Z.WDVS,
M$4#;1(-=='S?A=MK;VEYE:(Q2<&31V(U:,7(76'!@@_(ZS4+\\9KH9O?21Q&
M:2<YGR-@]$BMG0TZW\VKCW5)'XL7N#U9GXC";9%D?=HF!&49[1I*2O Z*4Q8
M++.MVXL<2FO'1<<#(_1HS9W+?O^95/&WL,1<._,0E^M7?_Z3XH;ECQ#Q/2Y2
M[8&JO<@\9062ZP(JNGIY30X/;1]%&^5H3VG=SJ,Y$^,>+HWJ&0RFZ[&34W;A
M_O??Z.6KWL&;TH0?'<LFR&4P.3/029;:/%J#B\Q!DEX6QKA,=SLH/I++<C0I
MXYX^M<;G".HYDY5WR^2M3UR=VJRFX6(BC$K.H80H:O,+&XAG%@H$H1PW);"$
MK1O;M*![)_S:<\'O:!K='\5^@^(9?EJ/:S@IF#?#QO*_7RY7FXD0*OB@M)4@
M?/:@:M%SJ&?5Y.$[&Z6*F8UQ7'"7SIW ZEXB6(_2V-D$8%?WM#_/2*;K2X_U
MP1UG]$]=B)!8;3,J:B*W4A1V!L.8L;%8/T8(]C"U.V'4OT2,-M#>V2'UWA7Q
M_62$B76).7+&01M+^TC0-=/ :<A91^%((:ZT+GYOS,)N=PKL)8.ZM:*[=7L?
MZA ],0RQ)(HI><X9%!.%7"$9H6253&%6D/!/ N&'J-L-G2_DRNMH]1SMJ9Z^
M'?<]VPNSFR-+6Z<![/BXP7("#F'W! D"C"6=%8',2D_[N.<,8J&@/CO!M55&
MF>&Z1PW09_NZL_FO]P5^S;.+07CI% BI3.WRC.!2I! PN(3&"9E3\X;(NQ#6
M[R7_/BBY5]S07"<=[++W&'D\Y_[67? DLY1H[U!@:Q6\,LE"<(K$F6S0D4F'
MS:?$'$KKN' < #;/)8(.H<,N8I\].+V:AR,QFV"0G \AJO/A!3CGR,<A=#F4
M@4O6.KS9G\IQ$TRZ0N@A>NL3FP_FWO[(47#*"<V5 %;KEI0)$B*O%4S"\>A3
MMDJT/C;:D\1Q4TI&0&5#C8T*R?4]V5WN?L&PK 9W-8EY8FHM@# !LB[D"SD;
M(6:*_M:I,TJP4'"WG@O//6G<Q(_A<-1>S#TZA%<O;-SJB34B6>\)^D%H$E16
MX(V.P'5*)K@LBG1#+UNW21HW!V.$9>H(C?0(L+>S;R2^^>+[1%K:V86QD+SD
M=<_/X&W$VAQ'D[4DQ\W@,<4U->.F3HP J\/TT".B:NR_?6V;;7<S1XG"GZMB
MI8>3F'Z:+U<316:CF2P@'*/-7G(%L6@+3(E@DDP#M.0<@H]Q$RC&\>%.JOO^
M'+WEKXOII^DL7-3SKUI1_&,@IN#,&PJGN#.UW*_4&<;((!0K<@X2U8Y=MG9^
MY+@I$2=V_=H(OL]@]NWL_6)><SNOHB&RI-?X#2_F7VO&QP1M"EX%#B@\@A(U
MD5EEVC<B<S9'F="=8.M^DL9Q4Q]&V=#;Z:S';7Z==32Q+&LF0H3 C"?;8A8\
MRP8T4S(*G9.3K9/#'J9DY#2$,4[Q]E9 GXO;MG%"81Y+9C4/F )U1H%Z<(91
M6)6<M2EF[EO?IAW1L6*XC($1@+2_ IH-Z&L(HP=R;G) ;KWPD&KYF;(!R9/T
M!4ITA15M.'F30V/JT(2IEW3?<*1J^LF?OL?9.UQ-B %D5FN(4JA:76/ ,2S
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M(*KJA,K6I6C/$M69ZW6@]I\$U;&J&'LGO,/-]HA[_FJV_*,NM-I(%\*ZE6,
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MGKJCK I;)4NUQH_5H'K!SN;#TQ0OIYQ+/VZB1=#-;57"%N/Q! :%=YLJYS7
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M7$[?'O/I@.RDO6)D*CS6EL(_3KL#I5TGW!*"+W$'BQM=9X;K2O9<9RXLO#M
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M^.0\=(4!=4H"?M(G'*.$H/ @/%L:I>?R'UX^INAC!]T1?R;T 4XRS@J#I%[
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MH_;[N2.5,=/#[?&I'4V.R*?V*BJ:-0_L#XL%6&QL(J&$,]0O]46>T9?T0O/
M4W2CT%#LU 8C)9+]U<)+LP[M]<V!P&LWZK.3Y.6:($/A65. ?2$)Q+USXWEI
M;R#1,#LC&9&YOG[VP>UN;V__2A-;.A[!YW*MQ )8-<&>SVMU3:S'E2K+N_Z/
M6>FI6)JE+F2+O>,/OZ!9"71K8CNX!IU[N+K)[SA13^P]+-52QS+F4P3GSU<H
M%#,/%])#A5#VN*,XPOD@7HFLUM_@X,E1(%O,E8L>!18%-I*XEO$/WS/11$D
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M[7*K=2 ]BC3#2 V%:V@0..2[BRZZL_ $'2>=4WX"A4P+*GS)\3!XI%\GW?"
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MKN QD>835^ZE(V6FHVAA=TT>!P:;5=]9_S=>^;<CI_?I]IW>"\9 V!)':8^
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M:YYEU7M7C?"MJM<%!9,=A":7OP;@603>7Q5L-F(U-V@9C6!$!+#.'2'-+4R
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MH>36<11*GRU$6WWRI\T,CRD+Q?6'+]'+BX[0,2PVCRC]HI*:4?B?71497;7
M<E8E7#G(8)EOIANCN,5!VOE:];Z+'0,]K=%K1XUVIW,$P:N*\LTZ$OP12:9!
MROA)^V@CFC'I[2RJA*-DP<&FRM%^ 0>&V@MV!,Q!R'%\_3N)0R.=&["BY*O5
MK*-LEL3Y=+92VZ9SCE(Y5T7$MH*Y9M4'=M4M&U^J)8*5 !HW#*G&EVC219QF
MNRZYF7"0#KRP@U.#E2)EZ-)TT\]GTM>A'N7K=:\DT==O'X>J/9^#'4_O=#./
MS>&7U$+?J54T0X4X;IX*<:6CW'CR9Z;R?1M-!1J>O=;,/%AD"TB<EX6)VI2
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M(>6X!^SH!EA/)@:)*0OLGF&=2F*G19>NI=0%GW<.422O52IZ=6WW#+LT>DF
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M[@F@&P%4$A=M^@#6Z+OUT^.8*R]8R]"@HJ7AP,:32L7K8ZXSOT'-&3,04U!
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MSJ9JU>0O+>BC++OAHB]O_0102P,$%     @ 6H-<5CH=YZ/.!0  53L  !<
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M!P  &"4  !<   !N=F%X+3(P,C(Q,C,Q>&5X,S$Q+FAT;=U:77/;MA)][Z]
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M_7KQM;ME^!H^",:;G0_=SOM#6R&H*@.( G2:2CSZ, T8-\(# @&6D1(4.":
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M1 'CDD=223>CU+ZN6UI?'GP>5V%I/!!=*D%]'KFK!C0NS1BXMKX4B6-M$N^
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M"9:OX6-$Q1<PC$;+Y<6V9.M$@F,Y7?C(RR_LDM1RR61*QSL[([-^'YGZD%'
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M8X1[?#H4^GFG=SW]5!T*]2/]N',][1UO-8.3H9>>F&N/&B?^@W?3>E14?,5
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M\=EI9GRV[^)IZF1LW:.?.A )2;B0A(X I:A_?7<7  E2E"*WN<;RI#/-67P
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M-VK!%_Q#Q*[SN,^^,3/!4 8/!V<7*IOS?$6_AF??LAF',7+!XI1K&DV+N"S
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M,C,Q+GAS9%!+ 0(4 Q0    ( %J#7%:>^ &Y?2@  /^3 0 5
M  "  :/2! !N=F%X+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !:@UQ6
M$%Y7F&B   #B^P4 %0              @ %3^P0 ;G9A>"TR,#(R,3(S,5]D
M968N>&UL4$L! A0#%     @ 6H-<5D)X!F4WQ X !2@5 !0
M ( ![GL% &YV87@M,C R,C$R,S%?9S$N:G!G4$L! A0#%     @ 6H-<5I7N
M[>KKQ , 1ZH' !0              ( !5T 4 &YV87@M,C R,C$R,S%?9S(N
M:G!G4$L! A0#%     @ 6H-<5AJ9&4#/&P$ 1'4! !0              ( !
M= 48 &YV87@M,C R,C$R,S%?9S,N:G!G4$L! A0#%     @ 6H-<5@'SI_@U
M4P$ /_T- !4              ( !=2$9 &YV87@M,C R,C$R,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( %J#7%8=L=2ZF-,  '=Y"0 5              "  =UT
M&@!N=F%X+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " !:@UQ6_(5+UT(W
M  !J,@$ &               @ &H2!L ;G9A>"TR,#(R,3(S,7AE>#$P,3@N
M:'1M4$L! A0#%     @ 6H-<5B[FA5\L(   R*\  !@              ( !
M(( ; &YV87@M,C R,C$R,S%X97@Q,#(P+FAT;5!+ 0(4 Q0    ( %J#7%:-
M32=$20@  '$E   8              "  8*@&P!N=F%X+3(P,C(Q,C,Q>&5X
M,3 U-BYH=&U02P$"% ,4    " !:@UQ67IRSH:L"  #R"P  %@
M    @ $!J1L ;G9A>"TR,#(R,3(S,7AE>#(Q+FAT;5!+ 0(4 Q0    ( %J#
M7%8Z'>>CS@4  %4[   7              "  >"K&P!N=F%X+3(P,C(Q,C,Q
M>&5X,C,Q+FAT;5!+ 0(4 Q0    ( %J#7%8_>S8OCP<  !@E   7
M      "  >.Q&P!N=F%X+3(P,C(Q,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    (
M %J#7%8OZ*'RE <  !8E   7              "  :>Y&P!N=F%X+3(P,C(Q
M,C,Q>&5X,S$R+FAT;5!+ 0(4 Q0    ( %J#7%960#) )04   42   7
M          "  7#!&P!N=F%X+3(P,C(Q,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0
M   ( %J#7%8LG4EA.@4  "81   7              "  <K&&P!N=F%X+3(P
M,C(Q,C,Q>&5X,S(R+FAT;5!+ 0(4 Q0    ( %J#7%;NIDZ3$A(  ,E:   6
M              "  3G,&P!N=F%X+3(P,C(Q,C,Q>&5X-#0N:'1M4$L%!@
0   3 !,  P4  '_>&P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
